{"meta":{"query_hash":"7976f2dfdd68","filters":{"topic":"PARP inhibition in cancer therapy"},"cohort_total":1206,"direct_labels_cover":6,"predictions_cover":1206,"exported":1206,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7976f2dfdd68","api":"https://metacan.xera.ac/api/v1/cohort?topic=PARP+inhibition+in+cancer+therapy"},"results":[{"id":"W104860504","doi":"10.1023/a:1011910329010","title":"Analysis of ADP-ribose polymer sizes in intact cells","year":2001,"lang":"en","type":"article","venue":"Molecular and Cellular Biochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; Université Laval","funders":"National Cancer Institute","keywords":"Poly ADP ribose polymerase; DNA repair; Polymerase; DNA damage; DNA; Enzyme; Chemistry; Biology; Ribose; Cell biology; Biochemistry; Molecular biology","score_opus":0.006224565494629747,"score_gpt":0.2504189962250055,"score_spread":0.24419443073037578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W104860504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918671,0.004272949,0.00071038876,0.00025507194,0.000024267258,0.00007625589,0.000014455972,0.00001414629,0.0027653193],"genre_scores_gemma":[0.99893,0.00008363184,0.000088687055,0.00033469312,0.00003668227,0.000008754362,0.00008443809,0.000014329671,0.00041878133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907804,0.000023905803,0.00024833603,0.0002659916,0.00018754447,0.000196173],"domain_scores_gemma":[0.9994367,0.0000161803,0.00007058807,0.00031846546,0.00003842655,0.00011964634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009884921,0.00013513619,0.00033060022,0.00015898439,0.000014943255,0.0000072383273,0.00005980579,0.000121652025,0.00029179725],"category_scores_gemma":[0.0000110509,0.0001355148,0.00016811861,0.00062399724,0.00008721169,0.000014992485,0.000025118525,0.00011679596,0.0000024446215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011452262,0.00012009365,0.012689006,0.000057259964,0.00032000648,0.0001977912,0.000041792326,0.000009605061,0.9859532,0.000015006613,0.0000460176,0.0004356687],"study_design_scores_gemma":[0.000985765,0.00004035823,0.0004386975,0.00005286438,0.00039824276,0.000014321512,0.00009524959,0.00011420912,0.99746346,0.00001841441,0.00025298403,0.00012541954],"about_ca_topic_score_codex":0.000055255186,"about_ca_topic_score_gemma":0.0000012307047,"teacher_disagreement_score":0.012250308,"about_ca_system_score_codex":0.00004301939,"about_ca_system_score_gemma":0.000046719335,"threshold_uncertainty_score":0.5526133},"labels":[],"label_agreement":null},{"id":"W117351027","doi":"10.1007/978-1-61779-270-0_25","title":"Poly(ADP-Ribose) Metabolism Analysis in the Nematode Caenorhabditis elegans","year":2011,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Caenorhabditis elegans; Poly ADP ribose polymerase; Biology; DNA repair; Enzyme; Biochemistry; Transcription (linguistics); DNA damage; Polymerase; Ribose; DNA; Cell biology; Gene","score_opus":0.05054971979982283,"score_gpt":0.4349767475445138,"score_spread":0.384427027744691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W117351027","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07747594,0.0062671877,0.906082,0.0016288253,0.0003089251,0.00045574436,0.000017161296,0.000044031156,0.0077202213],"genre_scores_gemma":[0.27060732,0.00021915625,0.72177035,0.006845875,0.00014175395,0.0002456436,0.000050648847,0.000035321635,0.00008394567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99578303,0.002652914,0.0005189036,0.00046007807,0.00014009596,0.00044496104],"domain_scores_gemma":[0.9987452,0.0002457878,0.00012724685,0.0007542796,0.00005546532,0.00007199625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023198242,0.00022268375,0.0007223933,0.00074360025,0.000036452904,0.000008011228,0.00032464875,0.00025572817,0.0004402079],"category_scores_gemma":[0.000265095,0.00016331548,0.00028052807,0.0018544873,0.00023022466,0.000030747316,0.00004876224,0.00045884465,0.000013116596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056987285,0.000849542,0.10989471,0.000060848914,0.0019842675,0.0012540269,0.009413989,0.000024986684,0.7648739,0.06545019,0.00029550403,0.04532815],"study_design_scores_gemma":[0.0055444795,0.00050566334,0.20766301,0.00007034786,0.0016903789,0.00036549402,0.0010720865,0.00049885566,0.6824763,0.06460405,0.034685016,0.0008243524],"about_ca_topic_score_codex":0.001188133,"about_ca_topic_score_gemma":0.00019486285,"teacher_disagreement_score":0.19313136,"about_ca_system_score_codex":0.000069012814,"about_ca_system_score_gemma":0.00007562478,"threshold_uncertainty_score":0.6659812},"labels":[],"label_agreement":null},{"id":"W1501218729","doi":"10.1096/fasebj.28.1_supplement.1071.9","title":"Role for DNA repair signaling in coronary artery stenosis (1071.9)","year":2014,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"DNA damage; DNA repair; Apoptosis; Artery; Poly ADP ribose polymerase; Cancer research; Coronary arteries; Stenosis; Coronary artery disease; Oxidative stress; Cell biology; Internal medicine; Medicine; Biology; DNA; Biochemistry; Polymerase","score_opus":0.028049435078050897,"score_gpt":0.28409578813572817,"score_spread":0.25604635305767726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1501218729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929503,0.00040302513,0.0020354704,0.002797628,0.0002865236,0.0002983198,0.0000075317107,0.00005209824,0.0011691111],"genre_scores_gemma":[0.9945021,0.00007246193,0.0012533981,0.002697693,0.0010482336,0.00003547202,0.0000051300776,0.000027026443,0.00035845267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988629,0.00013389328,0.00034957443,0.00013674777,0.0002420716,0.00027477246],"domain_scores_gemma":[0.9991698,0.00026363,0.00013520621,0.00022824196,0.00008545783,0.000117640026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011932964,0.00011645507,0.00022610031,0.00010618572,0.00017040866,0.000024943074,0.00011748037,0.000057872097,0.00024816865],"category_scores_gemma":[0.00006755956,0.00007999487,0.00018887091,0.00010382523,0.00006217409,0.00008788354,0.000014355808,0.00033271912,0.000026499025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017403141,0.0001989909,0.027617212,0.000047185094,0.00020053511,0.00006505936,0.0014757364,0.00045257076,0.9488978,0.00036484367,0.0069066146,0.012033146],"study_design_scores_gemma":[0.030885873,0.004289747,0.13552585,0.0022508227,0.00054264173,0.008118617,0.004405703,0.014414405,0.7256197,0.025564983,0.047434468,0.00094719545],"about_ca_topic_score_codex":0.0000036545734,"about_ca_topic_score_gemma":0.0000037774737,"teacher_disagreement_score":0.2232781,"about_ca_system_score_codex":0.00014682351,"about_ca_system_score_gemma":0.00009035887,"threshold_uncertainty_score":0.32620963},"labels":[],"label_agreement":null},{"id":"W1507914722","doi":"10.1007/s00018-004-4505-1","title":"Poly-ADP-ribosylation in health and disease","year":2005,"lang":"en","type":"review","venue":"Cellular and Molecular Life Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Chromatin; Gene isoform; Subcellular localization; Poly ADP ribose polymerase; Biology; Proteases; Cell biology; Enzyme; DNA repair; DNA; Computational biology; Gene; Genetics; Biochemistry","score_opus":0.05849517282854521,"score_gpt":0.3831253735424183,"score_spread":0.3246302007138731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1507914722","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014321608,0.99677855,0.0005117829,0.0014841341,0.00009620468,0.0005920101,0.000012617554,0.00002129046,0.00036018243],"genre_scores_gemma":[0.00071357674,0.996551,0.00045516042,0.001919888,0.00013639648,0.00003955049,0.000054070628,0.000018913173,0.0001114724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982724,0.00016535923,0.00043447103,0.00052471686,0.00032653104,0.0002764993],"domain_scores_gemma":[0.9988326,0.000036580845,0.0001878444,0.00019227511,0.000018138746,0.0007325985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005520578,0.00023382562,0.0007423863,0.00031693725,0.00012218716,0.00004109854,0.00008729362,0.00009673043,0.000029699046],"category_scores_gemma":[0.000117829164,0.00018903175,0.0001152458,0.00042217295,0.0003525502,0.000074091535,0.000040770887,0.00019508929,0.0000069336024],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012886573,0.000047734822,0.00009252222,0.005795669,0.000020339105,0.00005424655,0.000103203136,9.517493e-7,0.000016827678,0.00091508374,0.00023940252,0.9927011],"study_design_scores_gemma":[0.00041951376,0.00012507488,0.000014926297,0.0066198003,0.000078388264,0.000026170055,0.000032330634,0.00007544552,0.000010791668,0.00021110014,0.992179,0.00020748991],"about_ca_topic_score_codex":0.000022093596,"about_ca_topic_score_gemma":0.0000019429788,"teacher_disagreement_score":0.9924936,"about_ca_system_score_codex":0.00007132844,"about_ca_system_score_gemma":0.0016006434,"threshold_uncertainty_score":0.7708491},"labels":[],"label_agreement":null},{"id":"W153114641","doi":"10.1007/978-3-540-72843-6_4","title":"Scaffold/Matrix Attachment Regions (S/MARs): Relevance for Disease and Therapy","year":2008,"lang":"en","type":"review","venue":"Handbook of experimental pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Biological Sciences","funders":"","keywords":"Epigenetics; Relevance (law); Disease; Computational biology; Scaffold; Histone; Mars Exploration Program; Cancer; Nuclear matrix; Scaffold/matrix attachment region; Neuroscience; Biology; Bioinformatics; Medicine; Computer science; DNA; Genetics; Astrobiology; Political science; Chromatin; Pathology; Chromatin remodeling","score_opus":0.09614867352712998,"score_gpt":0.46577246730226113,"score_spread":0.36962379377513116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W153114641","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012598552,0.99397385,0.00014406712,0.00013464628,0.0007158979,0.0044537247,0.0002123916,0.00007040602,0.0001690041],"genre_scores_gemma":[0.000102734404,0.9931787,0.0010087317,0.0007435388,0.0006652891,0.0031084835,0.00019667539,0.00011404091,0.00088178896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978087,0.00013607064,0.0007688777,0.0006513675,0.00023950687,0.00039546195],"domain_scores_gemma":[0.99838835,0.00032582175,0.0004946279,0.00033850298,0.00007866615,0.00037401976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008338015,0.00053588196,0.0018097183,0.00022199431,0.00014844206,0.000007275382,0.0001655899,0.00022664166,0.00035059763],"category_scores_gemma":[0.000008002318,0.00046266953,0.00065203576,0.00012531872,0.00053818873,0.000069873604,0.00007009901,0.0002177648,0.000016418595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074411784,0.00370111,0.00001771886,0.014685902,0.0038469154,0.00034517483,0.0007892066,0.0000014271592,0.07088071,0.00046621176,0.3295423,0.5682821],"study_design_scores_gemma":[0.006616605,0.0009165452,6.4114164e-7,0.005850322,0.0005798496,0.00025393715,0.00001371635,0.000006866567,0.033360895,0.0000310645,0.952023,0.00034650374],"about_ca_topic_score_codex":0.0000033758402,"about_ca_topic_score_gemma":7.6293084e-8,"teacher_disagreement_score":0.62248075,"about_ca_system_score_codex":0.0002997986,"about_ca_system_score_gemma":0.00049733056,"threshold_uncertainty_score":0.9997825},"labels":[],"label_agreement":null},{"id":"W1535458693","doi":"10.1046/j.1432-1033.2003.03366.x","title":"Endogenous mono‐ADP‐ribosylation mediates smooth muscle cell proliferation and migration via protein kinase N‐dependent induction of c‐<i>fos</i> expression","year":2002,"lang":"en","type":"article","venue":"European Journal of Biochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"Canadian Institutes of Health Research","keywords":"Cell biology; Signal transduction; Cell growth; ADP-ribosylation; DNA synthesis; Kinase; Intracellular; Protein kinase A; Vascular smooth muscle; Biology; Phosphorylation; Chemistry; Molecular biology; Biochemistry; DNA; Enzyme; Endocrinology; NAD+ kinase","score_opus":0.023862282309015416,"score_gpt":0.22260003619327534,"score_spread":0.19873775388425993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1535458693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486005,0.001785094,0.0014264262,0.00038866408,0.00010641896,0.00025235387,0.000008069858,0.000018029987,0.0011548765],"genre_scores_gemma":[0.9976108,0.00033943471,0.0012028686,0.000051986124,0.0005735544,0.0000049667324,0.000021205999,0.000028464225,0.00016670642],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850875,0.00015682617,0.00062510505,0.00018015053,0.00040286224,0.00012631238],"domain_scores_gemma":[0.9986171,0.000018527035,0.00075957587,0.00018174615,0.00028468223,0.0001383727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047468767,0.00015090284,0.00021119852,0.00010715579,0.000067674606,0.000022725677,0.00007091432,0.00006301461,0.00012303502],"category_scores_gemma":[0.00006868139,0.00013311527,0.00007347047,0.00011506822,0.0000627472,0.00017779783,0.00001870641,0.00025690472,0.000005859299],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018287984,0.00023453799,0.000485547,0.00015546716,0.000013333223,0.000047300473,0.00070279016,0.000026702433,0.9880941,3.1260592e-7,0.00041369456,0.009643344],"study_design_scores_gemma":[0.0022079565,0.0004686168,0.0011817481,0.0003646242,0.000042612228,0.00020089641,0.0001582396,0.00016837714,0.99466336,0.000017862687,0.00041529047,0.00011040211],"about_ca_topic_score_codex":0.0000025017303,"about_ca_topic_score_gemma":2.9000907e-7,"teacher_disagreement_score":0.0095329415,"about_ca_system_score_codex":0.00008709802,"about_ca_system_score_gemma":0.00003796029,"threshold_uncertainty_score":0.5428283},"labels":[],"label_agreement":null},{"id":"W1546873627","doi":"10.1523/jneurosci.20-21-08005.2000","title":"NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase","year":2000,"lang":"en","type":"article","venue":"Journal of Neuroscience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"U.S. Public Health Service; Medical Research Council Canada; ALS Association; Parkinson's Foundation; Heart and Stroke Foundation of Canada; National Alliance for Research on Schizophrenia and Depression; National Institute of Neurological Disorders and Stroke; Medical Research Council; American Heart Association","keywords":"Excitotoxicity; NMDA receptor; Chemistry; Poly ADP ribose polymerase; Neuroscience; Polymerase; Pharmacology; Biochemistry; Biology; Enzyme; Receptor","score_opus":0.024118161345975535,"score_gpt":0.30602693263296304,"score_spread":0.2819087712869875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1546873627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883144,0.00030987238,0.00042016472,0.008658254,0.0010185965,0.0001815436,0.00009441475,0.000032521697,0.0009702428],"genre_scores_gemma":[0.9631977,0.0008942207,0.000207497,0.031799406,0.0006777467,0.000004536967,0.0000016502665,0.00002829491,0.0031889253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997177,0.00008082525,0.00071815937,0.000349444,0.0012103652,0.0004642296],"domain_scores_gemma":[0.99834085,0.0001207952,0.00043726832,0.00035313936,0.00017381937,0.0005741167],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038096588,0.0002329776,0.0004426603,0.00021010164,0.00017738166,0.00006512904,0.00041370167,0.00009658116,0.0010966496],"category_scores_gemma":[0.000186144,0.00019191149,0.00020256094,0.0006784446,0.00037447302,0.00046504408,0.000026385473,0.00057851314,0.00007277976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044650113,0.0002583699,0.0008488178,0.0000111764475,0.0000076235087,0.00014833371,0.0001590169,0.0000052192913,0.9696794,0.0000012235997,0.024909388,0.0035249107],"study_design_scores_gemma":[0.0033453621,0.0011734044,0.020489335,0.00015211273,0.000022300088,0.0010496357,0.00003270488,0.0005033996,0.9115998,0.00002081734,0.061376497,0.00023459035],"about_ca_topic_score_codex":0.000048097245,"about_ca_topic_score_gemma":7.1184417e-7,"teacher_disagreement_score":0.058079578,"about_ca_system_score_codex":0.00013316449,"about_ca_system_score_gemma":0.00036994275,"threshold_uncertainty_score":0.9998165},"labels":[],"label_agreement":null},{"id":"W1575938215","doi":"10.1126/science.1129808","title":"Gene Expression Needs a Break to Unwind Before Carrying On","year":2006,"lang":"en","type":"letter","venue":"Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Gene; Gene expression; Computational biology; Cell biology; Biology; Genetics","score_opus":0.023932019018977086,"score_gpt":0.31135394162429225,"score_spread":0.2874219226053152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1575938215","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19990943,0.0003029905,0.00051935867,0.77003324,0.002875107,0.0012568559,0.00012720321,0.0002526885,0.024723157],"genre_scores_gemma":[0.047913156,0.0000060457105,0.0026896663,0.9302865,0.006324659,0.000102474965,0.00009024384,0.000066233166,0.012520998],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970298,0.000025389383,0.00025780257,0.00065259315,0.001432726,0.00060168654],"domain_scores_gemma":[0.9987189,0.000034056382,0.00011373833,0.00078335084,0.000173357,0.00017655565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003220449,0.00026745364,0.00031867553,0.0008311283,0.0002497593,0.00007325127,0.00043539994,0.00028919452,0.00018774798],"category_scores_gemma":[0.000040884985,0.0002176651,0.00009412335,0.0012906733,0.0003667395,0.000110582674,0.00008647785,0.00087839656,0.00026922987],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023979981,0.000017397588,0.00026106625,0.000048862705,0.0000038076091,0.0001601322,0.00040254652,0.00003438805,0.15351507,0.000004183048,0.8434541,0.002074465],"study_design_scores_gemma":[0.00059587386,0.00037085035,0.0013397057,0.0013521241,0.00001870857,0.00008636734,0.000024326315,0.000010759912,0.24768831,0.00018585226,0.7480345,0.00029266058],"about_ca_topic_score_codex":0.000041163134,"about_ca_topic_score_gemma":0.0000022696563,"teacher_disagreement_score":0.16025332,"about_ca_system_score_codex":0.00060618244,"about_ca_system_score_gemma":0.0005118964,"threshold_uncertainty_score":0.8876125},"labels":[],"label_agreement":null},{"id":"W165258051","doi":"10.1007/978-94-007-2199-9_2","title":"Niacin Status and Genomic Instability in Bone Marrow Cells; Mechanisms Favoring the Progression of Leukemogenesis","year":2011,"lang":"en","type":"article","venue":"Sub-cellular biochemistry/Subcellular biochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Niacin; Bone marrow; Apoptosis; DNA damage; Cancer research; Biology; Poly ADP ribose polymerase; Genome instability; Chromosomal translocation; Genetics; Immunology; Endocrinology; DNA","score_opus":0.01649882653366251,"score_gpt":0.23757137468764533,"score_spread":0.2210725481539828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W165258051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986644,0.010354911,0.0006455276,0.0001024533,0.00014780226,0.00075438997,0.000083383595,0.00009304443,0.0011744557],"genre_scores_gemma":[0.9958199,0.000640903,0.0026670524,0.00006808642,0.00013378046,0.00012314222,0.00017301149,0.000100113444,0.00027398884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961771,0.000110301306,0.0010644918,0.001135725,0.0006590288,0.00085339544],"domain_scores_gemma":[0.9972973,0.00006453297,0.0005048886,0.0015075675,0.00020359542,0.00042213235],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008901417,0.00063150027,0.00076804805,0.00012508048,0.00015784687,0.00003072434,0.00037496706,0.0005642387,0.0002055412],"category_scores_gemma":[0.000102872684,0.00055524183,0.00029621657,0.00053344085,0.0007416893,0.00006554897,0.00028681674,0.0006056289,0.000011235627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006185425,0.0005060794,0.006265691,0.001145481,0.00008950821,0.000107924214,0.00040964683,0.0000022129734,0.9889171,0.000028271728,0.00003817436,0.0018713588],"study_design_scores_gemma":[0.002905088,0.00015044406,0.00061455567,0.00040337772,0.00011947304,0.00009051182,0.0006844814,0.00009792174,0.99396294,0.0002845617,0.00015748038,0.0005291818],"about_ca_topic_score_codex":0.0001389219,"about_ca_topic_score_gemma":0.0000059972217,"teacher_disagreement_score":0.009714007,"about_ca_system_score_codex":0.00042741265,"about_ca_system_score_gemma":0.0005573976,"threshold_uncertainty_score":0.99968994},"labels":[],"label_agreement":null},{"id":"W1656738322","doi":"10.1002/0471143030.cb1807s21","title":"Nonisotopic Methods for Determination of Poly(<scp>ADP</scp>‐Ribose) Levels and Detection of Poly(<scp>ADP</scp>‐Ribose) Polymerase","year":2003,"lang":"en","type":"article","venue":"Current Protocols in Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Polymerase; NAD+ kinase; Ribose; Enzyme; Biochemistry; Polynucleotide; DNA repair; DNA damage; DNA; Base excision repair; Chemistry; ADP-ribosylation; Molecular biology; DNA polymerase; Biology","score_opus":0.07986506767833891,"score_gpt":0.4372161227471471,"score_spread":0.3573510550688082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1656738322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4530937,0.017066872,0.3906736,0.000113530696,0.0020388782,0.13382094,0.00041313822,0.00018068074,0.0025986617],"genre_scores_gemma":[0.8299337,0.0003691944,0.04666584,0.0002478283,0.00047043173,0.121481255,0.00012679806,0.00014030718,0.000564671],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99606,0.00086403836,0.0013383324,0.00080554513,0.00022414101,0.00070792966],"domain_scores_gemma":[0.9963292,0.001583825,0.00093871646,0.00060692115,0.00032862707,0.00021274584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015249697,0.0004775935,0.0010466061,0.0006369488,0.00011427105,0.000019549003,0.00023903167,0.0005427483,0.000033646957],"category_scores_gemma":[0.0012126457,0.00045637382,0.00024203851,0.0005712325,0.00046307454,0.00015825038,0.0000741765,0.00047508674,0.0000047719222],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010935812,0.0005882595,0.010714458,0.0013003986,0.000035004312,0.0000017165904,0.0005121709,8.8715854e-7,0.72583055,0.0005822315,0.00004252186,0.26028243],"study_design_scores_gemma":[0.0071810666,0.0019261023,0.0028463192,0.00046850814,0.00006807326,0.000031896503,0.00016408798,0.00031227325,0.92542416,0.002853736,0.058599524,0.00012425252],"about_ca_topic_score_codex":0.00003623687,"about_ca_topic_score_gemma":0.000015067441,"teacher_disagreement_score":0.37684,"about_ca_system_score_codex":0.00023069198,"about_ca_system_score_gemma":0.0003578624,"threshold_uncertainty_score":0.9997888},"labels":[],"label_agreement":null},{"id":"W1775970800","doi":"10.1096/fasebj.28.1_supplement.1080.9","title":"Improving survival with cytoprotective therapeutics administered after a myocardial infarction in the absence of reperfusion (1080.9)","year":2014,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Saint John Regional Hospital; University of Guelph","funders":"","keywords":"Medicine; Myocardial infarction; Hemin; Internal medicine; Cardiology; Population; Occlusion; Coronary occlusion; Infarction; Surgery","score_opus":0.02309667391533118,"score_gpt":0.2784106992427376,"score_spread":0.25531402532740644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1775970800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916749,0.00012322738,0.0050491346,0.0017738006,0.00021747177,0.00037257484,0.0000037562027,0.000010706518,0.0007744164],"genre_scores_gemma":[0.9978085,0.00007120988,0.00030809455,0.0012237845,0.0005022452,0.000035091623,0.0000010394799,0.000016718957,0.000033299824],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99842656,0.00043086882,0.0003040825,0.00013618474,0.0005081338,0.0001941545],"domain_scores_gemma":[0.99902,0.00017683013,0.00026145298,0.00034199565,0.00015394161,0.00004578536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015975933,0.00012849478,0.0002143154,0.00008460618,0.00013362261,0.00003466437,0.00015316461,0.00006052878,0.00004872049],"category_scores_gemma":[0.000049516344,0.000062551146,0.00011020908,0.00021806554,0.00017732332,0.00008893186,0.000020285015,0.00060329307,0.000003749716],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02038861,0.00031772532,0.058664456,0.000092005146,0.00036345396,0.00009346815,0.016703056,0.0001687384,0.8505217,0.00022918347,0.000039383318,0.05241825],"study_design_scores_gemma":[0.023143535,0.011779645,0.59680563,0.0021649173,0.000612216,0.008192484,0.01150912,0.003741591,0.3346124,0.0037743822,0.0028488163,0.00081523205],"about_ca_topic_score_codex":0.00005986101,"about_ca_topic_score_gemma":0.00003941281,"teacher_disagreement_score":0.5381412,"about_ca_system_score_codex":0.00010929705,"about_ca_system_score_gemma":0.0001456505,"threshold_uncertainty_score":0.26210418},"labels":[],"label_agreement":null},{"id":"W1819519921","doi":"10.1186/s12916-015-0454-9","title":"Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors","year":2015,"lang":"en","type":"article","venue":"BMC Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Fondation du cancer du sein du Québec","keywords":"Medicine; PARP1; Chemotherapy; PARP inhibitor; Immunohistochemistry; Ovarian cancer; Poly ADP ribose polymerase; Olaparib; Oncology; Internal medicine; Cancer; Western blot; Cancer research; Biology; Polymerase; Enzyme","score_opus":0.3590067080389577,"score_gpt":0.5087717208459763,"score_spread":0.14976501280701865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1819519921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8524739,0.011010798,0.00085183256,0.12562707,0.004487747,0.0039673364,0.00006767394,0.0000863843,0.0014272495],"genre_scores_gemma":[0.9800477,0.001830245,0.003174526,0.005460753,0.008518986,0.00055045827,0.00004835535,0.0000542564,0.0003147436],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99682164,0.0005038953,0.0016667603,0.00037875242,0.00036221003,0.00026671265],"domain_scores_gemma":[0.99649745,0.0013388629,0.0007359233,0.00085448235,0.0003264063,0.00024689714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007009003,0.00020066535,0.0010675419,0.000143851,0.000053420023,0.000004619777,0.00029730267,0.00020452823,0.00006903204],"category_scores_gemma":[0.005452389,0.00011990024,0.0002599596,0.0005896758,0.00041907665,0.00006207172,0.000033815628,0.00028813962,0.0000016036864],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042031533,0.00037897678,0.43002468,0.000302727,0.00025504053,0.0000014593357,0.004995413,0.00004916051,0.028800307,0.0024339585,0.5012792,0.02727592],"study_design_scores_gemma":[0.09160266,0.0033961067,0.5774633,0.0053102616,0.00069932203,0.000068933194,0.012955674,0.00052485237,0.051265556,0.02132639,0.23461062,0.0007762809],"about_ca_topic_score_codex":0.00014255148,"about_ca_topic_score_gemma":0.00014679396,"teacher_disagreement_score":0.2666686,"about_ca_system_score_codex":0.00032337775,"about_ca_system_score_gemma":0.00141388,"threshold_uncertainty_score":0.65274125},"labels":[],"label_agreement":null},{"id":"W1888631028","doi":"10.1186/s12885-015-1803-y","title":"Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors","year":2015,"lang":"en","type":"article","venue":"BMC Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"RAD51; Clonogenic assay; Insulin-like growth factor; Cancer research; PARP inhibitor; Growth inhibition; Homologous recombination; Biology; Ovarian cancer; Growth factor; Poly ADP ribose polymerase; Molecular biology; Cancer cell; Autocrine signalling; Chromatin immunoprecipitation; Receptor; Endocrinology; Internal medicine; Apoptosis; Cancer; Medicine; Polymerase; Gene expression; Gene; Genetics","score_opus":0.041235621281270486,"score_gpt":0.3217437157108552,"score_spread":0.2805080944295847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1888631028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899042,0.0022586556,0.00079350034,0.0018090986,0.0028401935,0.00096086814,0.0005547782,0.00014600206,0.0007326586],"genre_scores_gemma":[0.99466103,0.0008629063,0.00072139007,0.0015375814,0.0005459667,0.0003475184,0.00012100729,0.00006795473,0.0011346414],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976651,0.00015664857,0.0005902672,0.0005169856,0.0006888749,0.00038210707],"domain_scores_gemma":[0.99806654,0.00009415623,0.0003185091,0.00033927293,0.0007767993,0.00040473166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002640492,0.00029977577,0.0005180645,0.00025505378,0.0000684023,0.00002132443,0.00008715871,0.00024388211,0.00043211508],"category_scores_gemma":[0.0000916589,0.00028079946,0.00012832093,0.0005244686,0.000116434036,0.00020979755,0.000059792827,0.0002448199,0.000045910354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013864614,0.00029411918,0.011034351,0.00023022867,0.00006181405,0.000010931234,0.0016759487,0.00023812498,0.64969975,0.0000321357,0.33056206,0.0047740843],"study_design_scores_gemma":[0.0048637115,0.00046073546,0.0043418617,0.00074921455,0.00006505053,0.0000138285395,0.0002197375,0.000088052955,0.9767103,0.00026982866,0.011873709,0.00034397453],"about_ca_topic_score_codex":0.0021029164,"about_ca_topic_score_gemma":0.0002762295,"teacher_disagreement_score":0.32701054,"about_ca_system_score_codex":0.0010163889,"about_ca_system_score_gemma":0.0006082474,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W1890517770","doi":"10.1016/s0091-679x(01)66013-8","title":"Chapter 12 Identification and analysis of caspase substrates: Proteolytic Cleavage of poly(ADP-rib ose)polymerase and DNA fragmentation factor 45","year":2001,"lang":"en","type":"book-chapter","venue":"Methods in cell biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Wellcome Trust","keywords":"Poly ADP ribose polymerase; Biology; DNA fragmentation; Cleavage (geology); Apoptotic DNA fragmentation; Cleavage factor; Polymerase; Molecular biology; Caspase; Apoptosis; Cleavage and polyadenylation specificity factor; Cell biology; Biochemistry; DNA; Programmed cell death; Messenger RNA; Gene","score_opus":0.0660374730711592,"score_gpt":0.3896220289282951,"score_spread":0.3235845558571359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1890517770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8930173,0.017518187,0.038561773,0.0003427719,0.00041786858,0.002573029,0.0009928911,0.0000537571,0.0465224],"genre_scores_gemma":[0.92633456,0.00990003,0.041443117,0.00044175476,0.00017140494,0.00015239997,0.0010567848,0.00012809224,0.020371884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997832,0.0002444568,0.0009960557,0.0005851414,0.00014243578,0.00019991516],"domain_scores_gemma":[0.99808496,0.00040289664,0.00086832803,0.00044236518,0.00009998238,0.000101462756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007186818,0.00032381163,0.0010877699,0.0008947837,0.000030039802,0.000007311422,0.00008326189,0.0005360237,0.0006525135],"category_scores_gemma":[0.00005134909,0.00030525896,0.00015963631,0.00016014819,0.00048624148,0.00004882678,0.000036660094,0.0003037133,0.0000022710403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000499835,0.00009110772,0.007853424,0.00041354547,0.00073196023,0.000018417,0.0008453427,0.0000016872118,0.9076916,0.0023530237,0.0000073354786,0.079492725],"study_design_scores_gemma":[0.0021741148,0.0005760093,0.0126766935,0.0002278794,0.0015588078,0.000017715034,0.00012466202,0.00022351764,0.9764829,0.0040600887,0.001495652,0.00038191138],"about_ca_topic_score_codex":0.00018749623,"about_ca_topic_score_gemma":0.00006762428,"teacher_disagreement_score":0.079110816,"about_ca_system_score_codex":0.00008214592,"about_ca_system_score_gemma":0.000053464413,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W1906457741","doi":"10.1016/j.radonc.2015.08.003","title":"In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio","year":2015,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Deutsche Krebshilfe; Ontario Ministry of Health and Long-Term Care; Prostate Cancer Canada","keywords":"Clonogenic assay; Cancer research; In vivo; Radiation therapy; Prostate cancer; PARP inhibitor; Medicine; Cancer; Chemistry; Internal medicine; Poly ADP ribose polymerase; Biology","score_opus":0.084946706541947,"score_gpt":0.3800376252545269,"score_spread":0.29509091871257986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1906457741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979511,0.006110546,0.0009413737,0.011659993,0.00051015057,0.0010609297,0.0000046643413,0.000016258133,0.00018507289],"genre_scores_gemma":[0.9947544,0.0022805524,0.0004472503,0.002123541,0.00012002451,0.000109327564,0.0000022632753,0.00002339939,0.00013929514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983033,0.00058456836,0.0004569918,0.00021786774,0.00028523357,0.00015205053],"domain_scores_gemma":[0.99891853,0.00019343714,0.00033602212,0.0002993379,0.00020861631,0.000044048644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006541614,0.0001569028,0.00047941154,0.00016317815,0.00005581216,0.0000059789377,0.00010916608,0.00015379972,0.0000360478],"category_scores_gemma":[0.000036023255,0.00009111848,0.000046435096,0.0005736792,0.00046439943,0.0004162189,0.000010420934,0.00023589216,1.5194884e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014779192,0.0044842483,0.23394473,0.00026308713,0.0008957792,0.000021483209,0.10320254,0.0045611956,0.5925562,0.01354949,0.0023642415,0.029377813],"study_design_scores_gemma":[0.13377815,0.025592737,0.20152432,0.0015906747,0.0002795752,0.000422784,0.02620014,0.011817754,0.45957613,0.028840557,0.10923706,0.0011401178],"about_ca_topic_score_codex":0.000115837065,"about_ca_topic_score_gemma":0.0007701373,"teacher_disagreement_score":0.13298008,"about_ca_system_score_codex":0.0007953897,"about_ca_system_score_gemma":0.00042104637,"threshold_uncertainty_score":0.3715704},"labels":[],"label_agreement":null},{"id":"W1925308079","doi":"10.21037/1123","title":"Targeting ataxia-telangiectasia mutated deficient malignancies with poly ADP ribose polymerase inhibitors","year":2013,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ataxia-telangiectasia; Poly ADP ribose polymerase; Cancer research; Polymerase; DNA repair; DNA damage; Mutation; DNA; Biology; Gene; Molecular biology; Genetics","score_opus":0.06194304950215909,"score_gpt":0.3793730274704367,"score_spread":0.31742997796827765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1925308079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647336,0.013343063,0.0007921564,0.016086292,0.00017491201,0.0016969735,0.00020841356,0.00017874839,0.0027858382],"genre_scores_gemma":[0.9952772,0.00017214006,0.0011280653,0.00046500703,0.00066239166,0.0008600588,0.00023357682,0.00007035669,0.0011312013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962836,0.00017355828,0.00041559341,0.00051434245,0.0018216041,0.00079129974],"domain_scores_gemma":[0.9982011,0.00021494107,0.00007541607,0.00028428712,0.0008953811,0.00032891912],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005454814,0.00024231874,0.00029154553,0.0004254731,0.00035862706,0.00008299797,0.00015607596,0.00011545113,0.005289196],"category_scores_gemma":[0.000035367713,0.00019557543,0.00009301953,0.0011008426,0.00041610576,0.000290667,0.000021612821,0.0006019105,0.00030009996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050083557,0.00084351824,0.089956515,0.00058371655,0.0005738215,0.00025998388,0.005461455,0.0019932552,0.80958426,0.0018222273,0.06292299,0.02098988],"study_design_scores_gemma":[0.022764683,0.0025627236,0.17734253,0.0026593828,0.00020067458,0.00041327724,0.0027901446,0.005223075,0.72354347,0.0021237922,0.05844247,0.0019337684],"about_ca_topic_score_codex":0.0027534734,"about_ca_topic_score_gemma":0.00008141771,"teacher_disagreement_score":0.08738601,"about_ca_system_score_codex":0.00030721774,"about_ca_system_score_gemma":0.0010014882,"threshold_uncertainty_score":0.99562013},"labels":[],"label_agreement":null},{"id":"W1958260647","doi":"10.1002/hon.2160","title":"PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage","year":2014,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"PARP1; DNA damage; Cancer research; Biomarker; Immunohistochemistry; Poly ADP ribose polymerase; DNA repair; Biology; Real-time polymerase chain reaction; Medicine; Mantle cell lymphoma; Lymphoma; Pathology; Gene; DNA; Polymerase; Genetics","score_opus":0.030124478932331607,"score_gpt":0.3228460020073416,"score_spread":0.29272152307501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958260647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97572786,0.0006351633,0.0001868477,0.0006904491,0.000028685034,0.00029299723,0.0000048500415,0.00001651816,0.02241661],"genre_scores_gemma":[0.99873084,0.000053570908,0.00087125564,0.00016554672,0.000012050346,0.000058162663,0.000007834885,0.000007553152,0.00009317342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987635,0.00027150582,0.00042317752,0.00022419417,0.00015224951,0.00016538185],"domain_scores_gemma":[0.99829817,0.0010118148,0.00027022895,0.0002891305,0.000069405505,0.00006123919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005276814,0.00011694955,0.0004890785,0.000038510156,0.00004323726,0.0000015885681,0.00009833421,0.00023743136,0.00023041024],"category_scores_gemma":[0.000248334,0.00006957994,0.000045290224,0.00013869927,0.00043544587,0.00002812287,0.000049462076,0.00018211135,0.000003052691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010557313,0.002884115,0.39625615,0.001583247,0.00005511147,0.0001297438,0.00097187376,0.000006720579,0.578463,0.0034849271,0.0037976468,0.001810114],"study_design_scores_gemma":[0.009999303,0.0014367178,0.45256743,0.00039091718,0.000065014836,0.00035426326,0.0006006194,0.0006995248,0.52928126,0.0019133613,0.002507103,0.00018445111],"about_ca_topic_score_codex":0.000006426113,"about_ca_topic_score_gemma":0.0000024209685,"teacher_disagreement_score":0.056311294,"about_ca_system_score_codex":0.00005693084,"about_ca_system_score_gemma":0.00009806653,"threshold_uncertainty_score":0.28373876},"labels":[],"label_agreement":null},{"id":"W1959879209","doi":"10.1242/jcs.114.20.3771","title":"Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis","year":2001,"lang":"en","type":"article","venue":"Journal of Cell Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Biology; Apoptosis; DNA damage; Polymerase; Proteases; PARP1; NAD+ kinase; Caspase; DNA; DNA repair; Molecular biology; Programmed cell death; Cell biology; Biochemistry; Enzyme","score_opus":0.025648713563097832,"score_gpt":0.31880240152787265,"score_spread":0.2931536879647748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1959879209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93011916,0.0014269181,0.06048764,0.00423205,0.00044301385,0.0007653583,0.00004356411,0.000014896967,0.0024673792],"genre_scores_gemma":[0.99597615,0.00022594872,0.002932235,0.0003245243,0.00022644865,0.000019651246,0.0000027992114,0.000013080734,0.00027918382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983204,0.000031868578,0.0006712373,0.00018326053,0.0005323789,0.0002608283],"domain_scores_gemma":[0.99789023,0.00012461559,0.0008973405,0.00027593458,0.00059234205,0.00021953575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008375701,0.00011389316,0.0003114234,0.00031808717,0.00013154671,0.00001714368,0.00026073915,0.000053739157,0.00007559864],"category_scores_gemma":[0.00015641657,0.0000944269,0.00017305683,0.0008392476,0.000312213,0.00032428303,0.000017477703,0.0001463224,0.0000025214802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048705417,0.00034432497,0.0010041835,0.00006249086,0.000016319796,3.7588123e-7,0.00011307054,0.000020577278,0.98889977,0.000119563796,0.0034908673,0.0054413765],"study_design_scores_gemma":[0.0017594644,0.0014577521,0.0028270062,0.0001785652,0.00009008908,0.000055942128,0.00015959627,0.000104858795,0.98921317,0.0004701257,0.003593763,0.00008966366],"about_ca_topic_score_codex":0.000014453351,"about_ca_topic_score_gemma":4.6535348e-7,"teacher_disagreement_score":0.06585695,"about_ca_system_score_codex":0.00016440058,"about_ca_system_score_gemma":0.0005510676,"threshold_uncertainty_score":0.3850617},"labels":[],"label_agreement":null},{"id":"W1960241973","doi":"10.1093/jn/132.1.115","title":"Pharmacological Intakes of Niacin Increase Bone Marrow Poly(ADP-Ribose) and the Latency of Ethylnitrosourea-Induced Carcinogenesis in Rats","year":2002,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Guelph","funders":"","keywords":"Niacin; Leukopenia; Nicotinamide; Internal medicine; Endocrinology; Bone marrow; Weanling; Bone marrow suppression; Ethylnitrosourea; Medicine; Niacinamide; Chemotherapy; Biology; Chemistry; Biochemistry","score_opus":0.042379327827795646,"score_gpt":0.3029267980461465,"score_spread":0.26054747021835084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1960241973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829071,0.009532513,0.00001686287,0.006931633,0.000109883316,0.0002986174,0.000016322754,0.0000045707807,0.00018249283],"genre_scores_gemma":[0.99482363,0.0040467284,0.0003988646,0.0003397434,0.00035061585,0.00001308083,0.0000023812554,0.000010030888,0.000014943013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983943,0.0002876436,0.0007404024,0.00009911432,0.0003451213,0.00013342954],"domain_scores_gemma":[0.99875045,0.00023399983,0.0005537093,0.000098301716,0.0002654724,0.000098094395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006962538,0.00011408957,0.00053675217,0.00027179322,0.000029761262,0.0000056601284,0.00006876924,0.00010912073,0.00021114861],"category_scores_gemma":[0.00013770319,0.00007657936,0.00015065959,0.00028178704,0.00017418254,0.000110117195,0.000013279956,0.00031444905,0.000001051163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004143987,0.0011687306,0.0074471505,0.00016266167,0.00008425018,0.000108640874,0.0005035211,0.0000020771683,0.9825508,0.000052615556,0.0013702419,0.0024053236],"study_design_scores_gemma":[0.038338415,0.001728645,0.04829579,0.0011593644,0.00039633588,0.0012428405,0.0005895098,0.00023839803,0.90580857,0.0017359238,0.00031627208,0.00014993775],"about_ca_topic_score_codex":0.00006182135,"about_ca_topic_score_gemma":0.0000043994146,"teacher_disagreement_score":0.07674223,"about_ca_system_score_codex":0.000084632586,"about_ca_system_score_gemma":0.000036494723,"threshold_uncertainty_score":0.31228158},"labels":[],"label_agreement":null},{"id":"W1963697475","doi":"10.1074/jbc.m408435200","title":"Poly(ADP-ribose) Polymerase-1 Is a Negative Regulator of HIV-1 Transcription through Competitive Binding to TAR RNA with Tat·Positive Transcription Elongation Factor b (p-TEFb) Complex","year":2004,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"P-TEFb; RNA polymerase II; Transcription (linguistics); Transcription factor II D; Elongation factor; Transcription factor II F; Chemistry; General transcription factor; Molecular biology; Elongation; Polymerase; Transcription factor; RNA; Biology; RNA-dependent RNA polymerase; Biochemistry; Gene expression; DNA; Promoter; Gene","score_opus":0.04578155148545025,"score_gpt":0.2977837122950449,"score_spread":0.25200216080959464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963697475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805787,0.0003141549,0.012471259,0.0049482775,0.0000885809,0.00036222456,0.0005358823,0.000030756953,0.00067015144],"genre_scores_gemma":[0.99132943,0.00010324388,0.006943837,0.0009648991,0.00044761878,0.000011669054,0.00010701596,0.000023411609,0.000068850524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979744,0.00007831289,0.00079764955,0.00032348762,0.0005269949,0.00029917096],"domain_scores_gemma":[0.9982933,0.00009153156,0.000669095,0.00016095857,0.00053078413,0.00025435202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016838299,0.00031047643,0.00072044076,0.00008913444,0.00010224475,0.000020004734,0.00014272555,0.00025233722,0.0007634976],"category_scores_gemma":[0.000055530756,0.00022318406,0.0003000931,0.00038009547,0.00033232346,0.00023515538,0.000009746761,0.00046433852,0.000007069944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043291016,0.00036188963,0.00053714257,0.00007744762,0.00025339908,0.00004403,0.003217635,0.000019585374,0.9904361,0.00011512977,0.00011794892,0.0004905923],"study_design_scores_gemma":[0.0060519143,0.0020229064,0.014577941,0.0010354747,0.00010960365,0.00034886782,0.0017808902,0.0000059238837,0.9731586,0.00033298472,0.0003304628,0.00024442998],"about_ca_topic_score_codex":0.000029107821,"about_ca_topic_score_gemma":0.0000016003495,"teacher_disagreement_score":0.017277498,"about_ca_system_score_codex":0.00063163094,"about_ca_system_score_gemma":0.00019954662,"threshold_uncertainty_score":0.91011816},"labels":[],"label_agreement":null},{"id":"W1965782508","doi":"10.1021/jm901775y","title":"Optimization of Phenyl-Substituted Benzimidazole Carboxamide Poly(ADP-Ribose) Polymerase Inhibitors: Identification of (<i>S</i>)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-1<i>H</i>-benzimidazole-4-carboxamide (A-966492), a Highly Potent and Efficacious Inhibitor","year":2010,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Benzimidazole; Carboxamide; Chemistry; Poly ADP ribose polymerase; Potency; Stereochemistry; Polymerase; In vivo; Pharmacology; Enzyme; In vitro; Biochemistry; Biology","score_opus":0.0062798812641752955,"score_gpt":0.24571955461422174,"score_spread":0.23943967335004643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965782508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988298,0.0051116077,0.0017259546,0.002309258,0.0014355999,0.00048492206,0.000096015625,0.00006292141,0.0004757456],"genre_scores_gemma":[0.99334717,0.00077537965,0.0022262258,0.00025594103,0.0031242832,0.000021508567,0.000078083336,0.00009626772,0.000075149714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937631,0.00010976495,0.0030781103,0.00057790754,0.0019083337,0.00056278025],"domain_scores_gemma":[0.9934645,0.00027127808,0.0032279782,0.0007936798,0.001462046,0.0007804787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013905353,0.0006126819,0.0014568992,0.0004472359,0.00014136336,0.000042912543,0.0004246272,0.00057550194,0.00017557584],"category_scores_gemma":[0.00072570227,0.0005605497,0.0004283039,0.00071929046,0.00082444196,0.00039803347,0.00009618783,0.0014708347,0.000002205254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019294252,0.0006979534,0.0023820875,0.00087894447,0.00033761916,0.00013471516,0.0006996236,0.00079257437,0.9889883,0.000025735639,0.00067467557,0.0024583475],"study_design_scores_gemma":[0.009041116,0.0003916985,0.0024950893,0.0015792322,0.00083144766,0.001558336,0.00059814844,0.0011744796,0.9813214,0.00007760515,0.00051098724,0.00042048574],"about_ca_topic_score_codex":0.00009890263,"about_ca_topic_score_gemma":0.000005929181,"teacher_disagreement_score":0.007666924,"about_ca_system_score_codex":0.0002700591,"about_ca_system_score_gemma":0.0008973612,"threshold_uncertainty_score":0.9996846},"labels":[],"label_agreement":null},{"id":"W1966928113","doi":"10.1126/science.1072221","title":"Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor","year":2002,"lang":"en","type":"article","venue":"Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1812,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Apoptosis-inducing factor; Programmed cell death; Apoptosis; Mitochondrion; Cell biology; Caspase; Biology; Molecular biology; Polymerase; Chemistry; Biochemistry; DNA","score_opus":0.032331303389692714,"score_gpt":0.29296826533585657,"score_spread":0.26063696194616387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966928113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98947763,0.0018904918,0.00080627395,0.0012586399,0.0005482513,0.00022872379,0.000053350468,0.00005928931,0.005677326],"genre_scores_gemma":[0.9973926,0.00014840042,0.00057525,0.0005616151,0.00016487984,0.0000120251325,0.000004779742,0.000012406813,0.0011280628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998084,0.000024113764,0.00027419906,0.00036239813,0.00092417386,0.00033108037],"domain_scores_gemma":[0.99911004,0.000050125618,0.00016424384,0.000346847,0.000120876924,0.0002078555],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026600444,0.00012280201,0.00018717807,0.00018887805,0.00013398934,0.000023693274,0.00021408773,0.00005662993,0.0010762964],"category_scores_gemma":[0.00007335786,0.00010979704,0.000050697836,0.00055198255,0.0002445915,0.00027631025,0.000032330252,0.00013448067,0.00007850907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011781589,0.000113913986,0.004751786,0.000017732287,0.0000039243055,9.93506e-7,0.0007129794,0.0000019895617,0.9878082,0.000027233522,0.00088903477,0.0056604114],"study_design_scores_gemma":[0.0008534737,0.00014773692,0.0032952842,0.00004358493,0.000009669031,0.000006436454,0.000107293585,0.00036857434,0.99412996,0.000027006408,0.00089910324,0.000111909045],"about_ca_topic_score_codex":0.00006522503,"about_ca_topic_score_gemma":0.0000010547424,"teacher_disagreement_score":0.007914927,"about_ca_system_score_codex":0.00021897111,"about_ca_system_score_gemma":0.000135133,"threshold_uncertainty_score":0.99983686},"labels":[],"label_agreement":null},{"id":"W1968670575","doi":"10.1016/j.neuroscience.2007.04.062","title":"Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain","year":2007,"lang":"en","type":"article","venue":"Neuroscience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Poly ADP ribose polymerase; Biology; Molecular biology; Nicotinamide adenine dinucleotide; NAD+ kinase; Western blot; Biochemistry; Polymerase; Enzyme; Gene","score_opus":0.05791769078695933,"score_gpt":0.3260949455119533,"score_spread":0.26817725472499393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968670575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97182006,0.0006259806,0.0051153805,0.020566106,0.0005060188,0.00041066037,0.00004217728,0.000061654864,0.0008519913],"genre_scores_gemma":[0.9885894,0.000017837427,0.00012433477,0.009971653,0.000860738,0.000017530076,0.00001411331,0.000019987927,0.0003844169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997728,0.00015366379,0.00038470133,0.0005787978,0.00068941026,0.00046542264],"domain_scores_gemma":[0.99807453,0.0011701765,0.00012084859,0.00035144755,0.000036748963,0.00024624052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011644568,0.00021188227,0.00022446093,0.0003082981,0.00037015803,0.00008089006,0.00015028164,0.00011456081,0.000034590346],"category_scores_gemma":[0.00063436886,0.0001710061,0.000047192992,0.0007943154,0.00066006795,0.00027830483,0.000058887068,0.00049246236,0.000010103375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029106662,0.00009610055,0.9448658,0.000020102672,0.00000289636,0.0000882532,0.0005631024,0.0000018142013,0.045279413,0.0008212125,0.000973724,0.0069965026],"study_design_scores_gemma":[0.0019136374,0.00031480793,0.984404,0.000042992207,0.000018285204,0.00029365704,0.000071049755,0.00018048342,0.006108048,0.00050275435,0.0059829955,0.00016728243],"about_ca_topic_score_codex":0.00025782041,"about_ca_topic_score_gemma":0.00005917136,"teacher_disagreement_score":0.039538193,"about_ca_system_score_codex":0.00007000832,"about_ca_system_score_gemma":0.00014467648,"threshold_uncertainty_score":0.69734263},"labels":[],"label_agreement":null},{"id":"W1969446926","doi":"10.1007/s11064-012-0887-x","title":"PARP-1 Inhibitors DPQ and PJ-34 Negatively Modulate Proinflammatory Commitment of Human Glioblastoma Cells","year":2012,"lang":"en","type":"article","venue":"Neurochemical Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Infrastructure Canada","keywords":"Proinflammatory cytokine; Poly ADP ribose polymerase; Viability assay; DNA repair; Cell biology; Programmed cell death; Biology; Chemistry; Biochemistry; Inflammation; Apoptosis; Immunology; Enzyme; Polymerase","score_opus":0.0815772907644842,"score_gpt":0.4020421000038247,"score_spread":0.3204648092393405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969446926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953374,0.00038404128,0.0000056812664,0.0006268416,0.00008534224,0.00070520525,0.00001040705,0.00004680476,0.0027982565],"genre_scores_gemma":[0.9987104,0.000089789064,0.00013629482,0.00014179229,0.00038672995,0.00009624283,0.0000054365173,0.000042195068,0.00039115318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973255,0.00022015258,0.0004085458,0.0003379589,0.0010482653,0.0006595722],"domain_scores_gemma":[0.99836624,0.00032868717,0.00008982033,0.00039986862,0.00029302656,0.00052236684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007709564,0.00017820622,0.00033461582,0.00021963613,0.00012324101,0.000016358696,0.0001396344,0.00014007998,0.00016115505],"category_scores_gemma":[0.00019431907,0.00015926198,0.00007959926,0.0003517848,0.0006289561,0.000117863034,0.00019050078,0.0007675305,0.000045463858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043603205,0.00031708876,0.0055140303,0.00021306344,0.000026901225,0.000014493717,0.00048471312,3.3367587e-7,0.9854924,0.00023204285,0.006503056,0.0007658101],"study_design_scores_gemma":[0.0016332265,0.00069256197,0.005997847,0.00018191556,0.000012545266,0.000022520064,0.00007641311,0.00003799985,0.9867509,0.00043053276,0.0040444033,0.000119125994],"about_ca_topic_score_codex":0.000017836863,"about_ca_topic_score_gemma":9.173706e-7,"teacher_disagreement_score":0.0033729463,"about_ca_system_score_codex":0.00018097008,"about_ca_system_score_gemma":0.0000943445,"threshold_uncertainty_score":0.64945155},"labels":[],"label_agreement":null},{"id":"W1970366287","doi":"10.1053/jcrc.2000.7903","title":"Role of poly-(ADP-ribose) synthetase in lipopolysaccharide-induced vascular failure and acute lung injury in pigs","year":2000,"lang":"en","type":"article","venue":"Journal of Critical Care","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Lung; Nitrotyrosine; Vascular resistance; Bronchoalveolar lavage; Lipopolysaccharide; Pulmonary hypertension; Pulmonary compliance; Hemodynamics; Anesthesia; Internal medicine; Endocrinology; Nitric oxide; Pathology; Pharmacology; Nitric oxide synthase","score_opus":0.00934757427570542,"score_gpt":0.32141120807448237,"score_spread":0.31206363379877694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970366287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892895,0.006842265,0.000013621005,0.0032237058,0.00007983954,0.00014225271,0.000042342563,0.0000071955737,0.0003592586],"genre_scores_gemma":[0.9985782,0.00017475244,0.00048761643,0.00046605757,0.00025441602,0.0000059058953,0.0000025692345,0.0000220114,0.000008472077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983111,0.00011353663,0.00067857374,0.00016584198,0.00046690478,0.0002640226],"domain_scores_gemma":[0.9991093,0.00011801183,0.000084827574,0.0001951119,0.00026087128,0.00023184589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030029708,0.00015363221,0.000565223,0.00031512993,0.000024133611,0.000016418853,0.00010146311,0.00016105981,0.0006520151],"category_scores_gemma":[0.00019363573,0.00013607294,0.00016449195,0.00020213559,0.00012217127,0.00022601393,0.000017998487,0.00059429265,0.0000033378715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043381527,0.0012372187,0.05452184,0.0017596051,0.00031823758,0.0027687934,0.008179499,0.00001826077,0.8572983,0.0016750074,0.0005926411,0.06729243],"study_design_scores_gemma":[0.025674567,0.005898091,0.11289235,0.0076068463,0.0019705025,0.0038704367,0.01897554,0.00049958436,0.8100339,0.0070651565,0.0041226563,0.0013903804],"about_ca_topic_score_codex":0.000059514252,"about_ca_topic_score_gemma":0.000016587388,"teacher_disagreement_score":0.065902054,"about_ca_system_score_codex":0.00018753819,"about_ca_system_score_gemma":0.0001889041,"threshold_uncertainty_score":0.71391076},"labels":[],"label_agreement":null},{"id":"W1970758107","doi":"10.1586/epr.11.63","title":"Mass spectrometry-based functional proteomics of poly(ADP-ribose) polymerase-1","year":2011,"lang":"en","type":"review","venue":"Expert Review of Proteomics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Chromatin; Proteomics; Proteome; Biology; Computational biology; Cell biology; Chromatin remodeling; DNA repair; Stable isotope labeling by amino acids in cell culture; DNA damage; Polymerase; Genetics; DNA; Gene","score_opus":0.07243935755958335,"score_gpt":0.373333894773214,"score_spread":0.30089453721363063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970758107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000011119852,0.9612946,0.027470835,0.00036410292,0.00073413405,0.008081522,0.00035716407,0.00008178026,0.0016147731],"genre_scores_gemma":[5.7380737e-7,0.8017023,0.1933107,0.0010020438,0.0011404796,0.0018654646,0.00049542834,0.00018852435,0.00029446252],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943154,0.000398294,0.0029507494,0.00089028745,0.00087539066,0.0005699094],"domain_scores_gemma":[0.99430144,0.00016033933,0.0029375385,0.0017331303,0.0005582174,0.0003093273],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010165491,0.0010291304,0.0057411296,0.00067975424,0.00006733954,0.000011690594,0.00056444027,0.0006379745,0.003105064],"category_scores_gemma":[0.00035764684,0.0008270492,0.002347021,0.0011568721,0.00039157923,0.000106033796,0.000084355466,0.0009391073,0.00010600234],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005962638,0.0010442672,0.00000938272,0.6634226,0.0014743744,0.000032284137,0.00006522233,1.4410388e-7,0.0124965785,0.0014949817,0.014417542,0.30494636],"study_design_scores_gemma":[0.0012076754,0.0006696602,0.0000015139146,0.28095892,0.00095219834,0.00013848084,0.0000047755743,0.000002571416,0.020852294,0.00008529059,0.6945055,0.0006211004],"about_ca_topic_score_codex":0.000042905944,"about_ca_topic_score_gemma":5.179474e-7,"teacher_disagreement_score":0.680088,"about_ca_system_score_codex":0.00064799626,"about_ca_system_score_gemma":0.003010046,"threshold_uncertainty_score":0.999418},"labels":[],"label_agreement":null},{"id":"W1970995808","doi":"10.1074/jbc.m110.206771","title":"Identification of Macrodomain Proteins as Novel O-Acetyl-ADP-ribose Deacetylases","year":2011,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institute of General Medical Sciences; Cancer Research UK; Wellcome Trust","keywords":"NAD+ kinase; Biology; Acetylation; Biochemistry; Chromatin; Sirtuin; Nicotinamide adenine dinucleotide; Histone; SIRT2; Cell biology; Gene; Enzyme","score_opus":0.07175172486882947,"score_gpt":0.31721786714833833,"score_spread":0.24546614227950886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970995808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950337,0.00039884978,0.001354581,0.00034082905,0.00008831555,0.00014343529,0.000021770591,0.000016932294,0.0026016028],"genre_scores_gemma":[0.9961357,0.00018108239,0.0028000344,0.00015363775,0.0004067759,0.000009713858,0.0000060630346,0.0000098465525,0.00029714475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998656,0.000025800617,0.00075548614,0.00015135684,0.00025536693,0.00015599892],"domain_scores_gemma":[0.9984754,0.000051616094,0.0007996527,0.00020665237,0.00031687756,0.00014984421],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045410765,0.00012846485,0.00036225244,0.000033933648,0.000029424193,0.000006123207,0.00016623171,0.00019487382,0.0010511116],"category_scores_gemma":[0.00043451323,0.00008929101,0.00021212529,0.00012916872,0.00022006144,0.000058295132,0.00002721593,0.00028260265,0.0000121138755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008839319,0.00052812137,0.0017234893,0.00008015084,0.000071041526,0.000029784238,0.00009339727,8.299776e-7,0.99577224,0.000040191437,0.00032784473,0.00044896995],"study_design_scores_gemma":[0.0016674981,0.0005830132,0.0046033068,0.00015973295,0.00003778547,0.00083011354,0.00015207405,0.0000034323484,0.9899775,0.00063277537,0.0012615413,0.00009122423],"about_ca_topic_score_codex":0.000004105166,"about_ca_topic_score_gemma":7.336054e-8,"teacher_disagreement_score":0.005794745,"about_ca_system_score_codex":0.00008598489,"about_ca_system_score_gemma":0.00012730011,"threshold_uncertainty_score":0.9998621},"labels":[],"label_agreement":null},{"id":"W1972260679","doi":"10.1007/s10495-007-0127-z","title":"PARP-1-induced cell death through inhibition of the MEK/ERK pathway in MNNG-treated HeLa cells","year":2007,"lang":"en","type":"article","venue":"APOPTOSIS","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Wilfrid Laurier University","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; HeLa; MAPK/ERK pathway; Programmed cell death; Cell biology; Apoptosis; Cytoprotection; Signal transduction; Phosphorylation; Biology; Mitochondrion; Cell growth; PARP1; DNA damage; Cell; Molecular biology; Chemistry; Polymerase; Biochemistry; DNA","score_opus":0.031678634550325976,"score_gpt":0.28956550244507295,"score_spread":0.25788686789474696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972260679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815572,0.00013277147,0.00021900167,0.00056053966,0.00027468006,0.0006328132,0.000024695408,0.000061347535,0.016536977],"genre_scores_gemma":[0.99744725,0.00009553348,0.00065104454,0.001182902,0.0001315824,0.000044322434,0.000021261047,0.000040572257,0.00038555247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981769,0.00009320215,0.000572444,0.0003314877,0.00043305245,0.00039296303],"domain_scores_gemma":[0.9988741,0.00014079649,0.00023813554,0.00053117925,0.00012794587,0.00008779312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042240816,0.0002248901,0.00037079645,0.00013006406,0.00007296162,0.00000913196,0.00011657191,0.00021098855,0.00019292119],"category_scores_gemma":[0.000028120608,0.00016861093,0.0001776226,0.0007380004,0.00008020245,0.00011473978,0.00004271501,0.00030568492,0.000051430172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022005937,0.00036439372,0.013884604,0.000070188325,0.000028229959,0.0000084938365,0.0010186791,0.0000088689385,0.98268306,0.00026897318,0.0006673851,0.0007770683],"study_design_scores_gemma":[0.002757875,0.00020424493,0.011853845,0.0003218619,0.000039509217,0.0000058503724,0.00029452104,0.000006735153,0.98252404,0.00042353445,0.0014023707,0.0001655941],"about_ca_topic_score_codex":0.0005553278,"about_ca_topic_score_gemma":0.00006876635,"teacher_disagreement_score":0.016151426,"about_ca_system_score_codex":0.0002636053,"about_ca_system_score_gemma":0.0001049388,"threshold_uncertainty_score":0.6875754},"labels":[],"label_agreement":null},{"id":"W1973510280","doi":"10.1097/00024382-200116020-00009","title":"DOES THE ACTIVATION OF POLY (ADP-ribose) SYNTHETASE MEDIATE TISSUE INJURY IN THE SEPSIS INDUCED BY CECAL LIGATION AND PUNCTURE?","year":2001,"lang":"en","type":"article","venue":"Shock","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Sepsis; Nitrotyrosine; Bolus (digestion); Anesthesia; Medicine; Ligature; Saline; Myeloperoxidase; Pharmacology; Internal medicine; Nitric oxide; Nitric oxide synthase; Inflammation","score_opus":0.015862452661268678,"score_gpt":0.3072770465201596,"score_spread":0.2914145938588909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973510280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726199,0.00019610509,0.00016737268,0.02591166,0.00014124841,0.0004446274,0.00002844288,0.000018642222,0.00047201663],"genre_scores_gemma":[0.9972673,0.0001909979,0.00004503501,0.0020443923,0.0002557774,0.00003862716,0.000037101865,0.000012579451,0.00010819843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906504,0.00012510936,0.0002275883,0.00015792507,0.000288277,0.00013607922],"domain_scores_gemma":[0.99935687,0.00019454959,0.00010865117,0.00025537988,0.000046328256,0.000038212413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034447823,0.00011401696,0.00016522178,0.00006754597,0.00005918272,0.000014460597,0.00008640414,0.00009527984,0.00010617267],"category_scores_gemma":[0.00010679815,0.0000499608,0.000029322484,0.00027176458,0.00008197752,0.000098817785,0.000014710873,0.00020788639,0.000004732029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005701051,0.00013318959,0.004904942,0.000043691824,0.000049239727,0.0000043707964,0.004029028,0.0000024385965,0.909292,0.00016257963,0.0067106416,0.07409779],"study_design_scores_gemma":[0.0012698385,0.00024763218,0.027158577,0.00015922074,0.000051457297,0.00001529491,0.0008403976,0.00008860009,0.9442263,0.0019316544,0.023880968,0.00013003772],"about_ca_topic_score_codex":0.00017673649,"about_ca_topic_score_gemma":0.00002355966,"teacher_disagreement_score":0.073967755,"about_ca_system_score_codex":0.00005717358,"about_ca_system_score_gemma":0.000044409957,"threshold_uncertainty_score":0.20373423},"labels":[],"label_agreement":null},{"id":"W1975272351","doi":"10.1016/j.molcel.2008.08.009","title":"Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation","year":2008,"lang":"en","type":"article","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Polymerase; Biology; ADP-ribosylation; Poly ADP ribose polymerase; Biochemistry; Transferase; Enzyme; Residue (chemistry); PARP1; DNA repair; DNA; NAD+ kinase","score_opus":0.03108811992052445,"score_gpt":0.27881148983141346,"score_spread":0.247723369910889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975272351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981917,0.0005739286,0.006042414,0.0013188242,0.00010214667,0.0004789097,0.000028162696,0.000118852775,0.009419732],"genre_scores_gemma":[0.9956251,0.000099536395,0.0004442396,0.0011837754,0.000054090728,0.00008350919,0.00015497023,0.000048277623,0.0023065384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984835,0.00007799279,0.00024053126,0.00044154862,0.0004347928,0.00032165073],"domain_scores_gemma":[0.9989597,0.000026173926,0.00010499481,0.00046984502,0.00015169436,0.00028758773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010508901,0.00022248647,0.00031239656,0.00013563797,0.000116281444,0.000016925116,0.00010302173,0.00014289442,0.00018288026],"category_scores_gemma":[0.00002111351,0.000234717,0.00015332419,0.0005219394,0.000039737377,0.00009476083,0.00001930366,0.0001974651,0.00038417644],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021782996,0.00031543736,0.0018798084,0.000031460342,0.00005487445,0.000179481,0.00018876736,0.00011568951,0.98911744,0.000006792477,0.00635731,0.0015351089],"study_design_scores_gemma":[0.0017010897,0.00019581849,0.014625929,0.000025225592,0.00007049466,0.000036138816,0.000011415858,0.00018016745,0.97101253,0.000006433325,0.011903292,0.00023147732],"about_ca_topic_score_codex":0.000067885245,"about_ca_topic_score_gemma":0.000009131289,"teacher_disagreement_score":0.018104922,"about_ca_system_score_codex":0.00019283529,"about_ca_system_score_gemma":0.00011121458,"threshold_uncertainty_score":0.95714813},"labels":[],"label_agreement":null},{"id":"W1975307022","doi":"10.4161/cc.10.8.15273","title":"Synthetic lethality of PARP inhibition in cancers lacking<i>BRCA1</i>and<i>BRCA2</i>mutations","year":2011,"lang":"en","type":"article","venue":"Cell Cycle","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK; Wellcome Trust","keywords":"Synthetic lethality; PARP1; Biology; Homologous recombination; PARP inhibitor; BRCA2 Protein; Loss function; Poly ADP ribose polymerase; DNA repair; Olaparib; Mutation; Cancer research; Genetics; DNA damage; Genome instability; Gene; DNA; Germline mutation; Polymerase; Phenotype","score_opus":0.03397336297072318,"score_gpt":0.2760444127140923,"score_spread":0.24207104974336913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975307022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668216,0.0005174304,0.000287355,0.00022929409,0.00012151118,0.00030230964,0.000020999509,0.000044877503,0.031654622],"genre_scores_gemma":[0.9984326,0.00016335574,0.00076588703,0.000374005,0.000043724314,0.00005704124,0.000015380338,0.000021946302,0.00012609604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894553,0.00006580436,0.00034642688,0.0002615957,0.00017593396,0.00020467622],"domain_scores_gemma":[0.99936897,0.000060163973,0.00013077106,0.0002707126,0.00007137754,0.00009797973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002538445,0.00012230809,0.0002520222,0.00012880859,0.000040194485,0.00000485173,0.000037356458,0.000086020555,0.00042656995],"category_scores_gemma":[0.00003114068,0.00012560881,0.00005951899,0.00023723637,0.00022041006,0.00009407422,0.000020771246,0.00016669491,0.00002665309],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018068266,0.0028308535,0.16841221,0.0024290134,0.00022400366,0.00036032623,0.0565895,0.0008379345,0.7407085,0.007128145,0.0029446983,0.015728036],"study_design_scores_gemma":[0.005075932,0.0003455386,0.088660195,0.0006244868,0.00009925357,0.000059994352,0.001144133,0.0003728885,0.8926878,0.008828184,0.0017585428,0.0003430631],"about_ca_topic_score_codex":0.00088689727,"about_ca_topic_score_gemma":0.000117570984,"teacher_disagreement_score":0.15197934,"about_ca_system_score_codex":0.00019325384,"about_ca_system_score_gemma":0.000130852,"threshold_uncertainty_score":0.5122179},"labels":[],"label_agreement":null},{"id":"W1975399471","doi":"10.1042/bj20021675","title":"A proteomic approach to the identification of heterogeneous nuclear ribonucleoproteins as a new family of poly(ADP-ribose)-binding proteins","year":2003,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital Fleurimont; Centre hospitalier universitaire de Québec","funders":"","keywords":"Heterogeneous ribonucleoprotein particle; Heterogeneous nuclear ribonucleoprotein; Biology; Molecular biology; Biochemistry; Binding protein; Peptide mass fingerprinting; Ribonucleoprotein; Sequence motif; Binding site; Western blot; Chemistry; RNA-binding protein; Messenger RNA; DNA; Proteomics; RNA; Gene","score_opus":0.02578119938514952,"score_gpt":0.282238821558356,"score_spread":0.2564576221732065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975399471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990225,0.0005813906,0.005105995,0.0014839533,0.00012962807,0.0014460831,0.000017594157,0.00002556396,0.0009847794],"genre_scores_gemma":[0.98710203,0.000040837396,0.011695316,0.00045592195,0.00039795737,0.000050208102,0.000004681132,0.000044077107,0.00020894395],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978716,0.000105696905,0.0008350919,0.00026888622,0.00062294153,0.00029577658],"domain_scores_gemma":[0.99843377,0.000017157357,0.0005272542,0.00042969675,0.00020719576,0.00038493503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058739126,0.00018495148,0.000349164,0.00015806674,0.00011029171,0.000037619615,0.00027683144,0.00014499629,0.000091723225],"category_scores_gemma":[0.00044978378,0.00013699385,0.00023150048,0.00039531273,0.0001272175,0.00005974816,0.00003533974,0.00039725855,0.000044132303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042870332,0.0002832792,0.000063359745,0.000058361496,0.00009720577,0.0000056384465,0.0005467276,0.000012917128,0.99431235,0.00030144773,0.0028450547,0.0010449495],"study_design_scores_gemma":[0.0015634971,0.00037617813,0.00023707809,0.00023886393,0.00005946993,0.0012982263,0.00017710621,0.000044206838,0.9915275,0.00038313633,0.003957165,0.00013759715],"about_ca_topic_score_codex":0.000032386404,"about_ca_topic_score_gemma":1.16516894e-7,"teacher_disagreement_score":0.006589321,"about_ca_system_score_codex":0.000184366,"about_ca_system_score_gemma":0.00044369543,"threshold_uncertainty_score":0.5586447},"labels":[],"label_agreement":null},{"id":"W1975806500","doi":"10.1074/jbc.m008044200","title":"Functional Competition between Poly(ADP-ribose) Polymerase and Its 24-kDa Apoptotic Fragment in DNA Repair and Transcription","year":2001,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Polymerase; Molecular biology; Transcription (linguistics); Biology; DNA clamp; DNA; DNA polymerase; RNA polymerase II; Biochemistry; DNA polymerase II; RNA; Reverse transcriptase; Gene expression; Promoter; Gene","score_opus":0.0483947639421056,"score_gpt":0.2827109179486558,"score_spread":0.23431615400655023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975806500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238807,0.0040281857,0.00016468848,0.0029293068,0.00008745309,0.00008164592,0.0000135688315,0.000020650616,0.00028644563],"genre_scores_gemma":[0.9970335,0.001417843,0.00015777211,0.00039848642,0.0008298264,0.0000041077474,0.000029214649,0.00000633628,0.00012291412],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989715,0.000044043063,0.00044825836,0.00017534982,0.00020216519,0.0001586771],"domain_scores_gemma":[0.9994306,0.00007935402,0.00016834136,0.00006424031,0.00007157375,0.00018589101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028343164,0.00013050997,0.00031574952,0.000052366315,0.000044578064,0.000010206528,0.000033366345,0.00018362634,0.0004990092],"category_scores_gemma":[0.000053186075,0.0000986954,0.00009657719,0.00010490892,0.00009252317,0.00007453121,0.000011124806,0.00036348743,0.0000018663292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008966688,0.00017739886,0.054170255,0.00007619417,0.000058628353,0.000090419315,0.00004166817,0.0000018150041,0.94294417,0.000018941875,0.00020276566,0.0013210633],"study_design_scores_gemma":[0.0075132246,0.00093354407,0.4335302,0.0005832466,0.000098953096,0.002296161,0.00023690317,0.00005896637,0.5499042,0.00056462735,0.0040214257,0.00025850264],"about_ca_topic_score_codex":0.0000025393897,"about_ca_topic_score_gemma":2.8057505e-7,"teacher_disagreement_score":0.39303994,"about_ca_system_score_codex":0.000121325225,"about_ca_system_score_gemma":0.00004287393,"threshold_uncertainty_score":0.5463801},"labels":[],"label_agreement":null},{"id":"W1975931552","doi":"10.1016/j.canlet.2014.02.010","title":"Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Letters","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China; Public Health Agency of Canada","keywords":"Olaparib; Pancreatic cancer; PARP inhibitor; In vivo; Apoptosis; Cancer research; Pharmacology; Poly ADP ribose polymerase; Cancer; Medicine; Biology; Internal medicine; Biochemistry; Enzyme; Biotechnology","score_opus":0.04738824100464858,"score_gpt":0.34535489805288194,"score_spread":0.2979666570482334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975931552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314034,0.00089832593,0.00065303233,0.0039197006,0.00022097876,0.00042875926,0.0000695529,0.000016897406,0.00065240794],"genre_scores_gemma":[0.9972971,0.00088259124,0.00020181896,0.001235487,0.00009530315,0.00019565916,0.00001374994,0.000022248163,0.000056045883],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983529,0.00013673704,0.0006826616,0.00032505262,0.00027241893,0.00023027079],"domain_scores_gemma":[0.99890757,0.0003835545,0.00031019837,0.00027121868,0.00006256408,0.00006489042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044190927,0.00016080122,0.0006255481,0.00024784723,0.000017304288,0.0000065989684,0.000083675215,0.00009092103,0.000028240675],"category_scores_gemma":[0.0001353975,0.00015787316,0.000052850668,0.00026980552,0.0003315546,0.00016661291,0.00002320042,0.00023205907,6.0880717e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010009879,0.0009675183,0.38856867,0.0037053938,0.00036995558,0.000043488017,0.0070843324,0.033453837,0.5266073,0.005033807,0.0061937585,0.017962053],"study_design_scores_gemma":[0.060447782,0.0014363088,0.56003654,0.015532145,0.00049409474,0.00001966728,0.00056134874,0.09854951,0.25571784,0.004387692,0.0015723458,0.00124475],"about_ca_topic_score_codex":0.0018014002,"about_ca_topic_score_gemma":0.00055863964,"teacher_disagreement_score":0.27088946,"about_ca_system_score_codex":0.00029995208,"about_ca_system_score_gemma":0.00016913649,"threshold_uncertainty_score":0.6437881},"labels":[],"label_agreement":null},{"id":"W1975969421","doi":"10.1177/1933719111433885","title":"Administration of the PARP Inhibitor Pj34 Ameliorates the Impaired Vascular Function Associated With Enos-/- Mice","year":2012,"lang":"en","type":"article","venue":"Reproductive Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Enos; Medicine; Pharmacology; Internal medicine; Nitric oxide; Nitric oxide synthase","score_opus":0.03671919598438442,"score_gpt":0.2963396144273415,"score_spread":0.25962041844295713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975969421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930083,0.0010725853,0.00009027051,0.00375863,0.0005834151,0.0005699564,0.0000062916383,0.00003734417,0.0008731894],"genre_scores_gemma":[0.99877965,0.000022246104,0.00009520337,0.0002145732,0.00060807384,0.000045182504,0.000003991612,0.000008592401,0.00022250476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983124,0.0002214787,0.00021826092,0.0003499889,0.00065896084,0.00023887298],"domain_scores_gemma":[0.99878496,0.00010662508,0.0003043309,0.0004315587,0.00032184322,0.00005067642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018712044,0.00012001247,0.00017010399,0.000050704053,0.000358683,0.000024191131,0.00014353426,0.00004606335,0.000044849163],"category_scores_gemma":[0.00053685834,0.000056547295,0.000081070364,0.0011106827,0.0010562555,0.00032651992,0.00002436935,0.00014082962,0.000006965522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015137139,0.00148767,0.57699996,0.000076688644,0.00066270726,0.000002413632,0.009148518,0.00029482815,0.39817914,0.0020500028,0.00520566,0.004378706],"study_design_scores_gemma":[0.0006964365,0.0010301681,0.62392896,0.00017132574,0.00017210202,0.0000427174,0.0022381318,0.000036090052,0.36907563,0.0004970542,0.0019708418,0.00014056973],"about_ca_topic_score_codex":0.000033050906,"about_ca_topic_score_gemma":0.000017191636,"teacher_disagreement_score":0.046929013,"about_ca_system_score_codex":0.000094241244,"about_ca_system_score_gemma":0.00030175011,"threshold_uncertainty_score":0.38918176},"labels":[],"label_agreement":null},{"id":"W1976657680","doi":"10.1074/jbc.m402729200","title":"Poly(ADP-ribosyl)ation as a DNA Damage-induced Post-translational Modification Regulating Poly(ADP-ribose) Polymerase-1-Topoisomerase I Interaction","year":2004,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Topoisomerase; Polymerase; DNA damage; Enzyme; DNA repair; DNA; Chemistry; Ribose; Cell biology; Biology; Biochemistry; Molecular biology","score_opus":0.04820200388839795,"score_gpt":0.3388438699523063,"score_spread":0.29064186606390835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976657680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834504,0.00084673485,0.0016882108,0.012220591,0.00030656267,0.00020241302,0.00003203603,0.000071101415,0.0011819485],"genre_scores_gemma":[0.994898,0.000075330994,0.0016836958,0.0010535284,0.00189999,0.000013764629,0.00023374877,0.000028474476,0.000113448834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99749446,0.00008622748,0.0011006745,0.00037252496,0.00060967583,0.00033646554],"domain_scores_gemma":[0.99764025,0.00016346734,0.0009863062,0.00029298937,0.00058743666,0.00032951988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004455393,0.00031430597,0.0004970041,0.0001482181,0.00017634436,0.000055250304,0.00018950553,0.00041623952,0.0007801507],"category_scores_gemma":[0.0004433085,0.00025553047,0.00035805244,0.00033672003,0.0001313557,0.00037583412,0.00002473999,0.00078250474,0.000029848781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015442253,0.00041307815,0.0009942031,0.00004912031,0.00010952491,0.000053112002,0.00022505033,0.000049065584,0.98826444,0.00010972145,0.00005180795,0.008136668],"study_design_scores_gemma":[0.0042433487,0.00065211096,0.014750044,0.00040190184,0.000078997764,0.001540465,0.0004857872,0.00010949477,0.9755343,0.0014660754,0.00045416603,0.00028326147],"about_ca_topic_score_codex":0.000044942604,"about_ca_topic_score_gemma":0.0000011202342,"teacher_disagreement_score":0.01375584,"about_ca_system_score_codex":0.0005129514,"about_ca_system_score_gemma":0.00042469034,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W1978912495","doi":"10.1207/s15327914nc4602_02","title":"Niacin and Carcinogenesis","year":2003,"lang":"en","type":"review","venue":"Nutrition and Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Niacin; NAD+ kinase; DNA repair; Poly ADP ribose polymerase; Carcinogenesis; Biology; DNA damage; Signal transduction; Cancer; Biochemistry; Cancer research; Cell biology; Genetics; Enzyme; DNA; Polymerase","score_opus":0.10050234963367899,"score_gpt":0.41345995823242687,"score_spread":0.3129576085987479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978912495","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023332523,0.9974547,0.0000068660756,0.00026043478,0.0001912849,0.00070124096,0.00013840325,0.00003261025,0.0011911363],"genre_scores_gemma":[0.000009175657,0.996601,0.00009762862,0.0007934561,0.00036979545,0.00082081556,0.000058013044,0.000038753387,0.0012113478],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907154,0.0000609724,0.00025422813,0.00032231465,0.00013829893,0.0001526595],"domain_scores_gemma":[0.9995194,0.00002747077,0.0000993072,0.00015440851,0.00005364247,0.00014575062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007060213,0.00023014296,0.00087790715,0.00013270354,0.000060155675,0.000019849267,0.00002294835,0.00023030778,0.0005450756],"category_scores_gemma":[0.0000041042886,0.00017008276,0.0001317724,0.00016527454,0.00008063976,0.000031666616,0.000009092992,0.00018022147,0.000011129636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001428961,0.00004493873,0.000029893155,0.021935383,0.000074651136,0.00000887545,0.000014897826,3.1759226e-9,0.00000581237,0.00009840381,0.0075665284,0.9702063],"study_design_scores_gemma":[0.0012949753,0.000046807087,0.000017669901,0.015399531,0.00059578614,0.00024573173,0.000011958532,2.6851032e-7,0.000019032233,0.00006211471,0.98212075,0.00018535172],"about_ca_topic_score_codex":0.000018918967,"about_ca_topic_score_gemma":0.0000039546085,"teacher_disagreement_score":0.97455424,"about_ca_system_score_codex":0.0001451928,"about_ca_system_score_gemma":0.00015574442,"threshold_uncertainty_score":0.69357735},"labels":[],"label_agreement":null},{"id":"W1983910372","doi":"10.1158/1538-7445.am2013-623","title":"Abstract 623: The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Phosphorylation; DNA damage; Serine; DNA repair; DNA; Poly ADP ribose polymerase; Cancer cell; Cell biology; Chemistry; Molecular biology; Cancer; Biology; Cancer research; Biochemistry; Genetics; Polymerase","score_opus":0.09970882893528606,"score_gpt":0.4057869596043363,"score_spread":0.30607813066905026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983910372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981721,0.008265202,0.000012975266,0.004136922,0.0001043072,0.0012769725,0.000049736725,0.000051168274,0.0043817493],"genre_scores_gemma":[0.99371886,0.0031367894,0.000045683835,0.00011882836,0.00016791506,0.00055368576,0.000012713776,0.000023010907,0.0022224823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797827,0.00008722074,0.00034507102,0.00034013987,0.0008576379,0.00039168663],"domain_scores_gemma":[0.99840695,0.00031654403,0.00007618787,0.00046307294,0.000567409,0.00016985254],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010897329,0.0001348679,0.000243394,0.00008709957,0.00017486616,0.000043512955,0.00013470423,0.00010119944,0.003064025],"category_scores_gemma":[0.000052862106,0.00009238355,0.00008267395,0.00027336617,0.00054062845,0.0001633387,0.00004890351,0.00045864485,0.000085562395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049841106,0.0003829249,0.048771027,0.0017331734,0.00060330535,0.000032937263,0.0068664765,0.00013010894,0.8238504,0.0009680425,0.05515496,0.05652256],"study_design_scores_gemma":[0.010972854,0.0006716983,0.32106328,0.00090671325,0.00006380145,0.000046876918,0.0027023721,0.00022180569,0.6225834,0.0029310426,0.037466668,0.000369515],"about_ca_topic_score_codex":0.0040721293,"about_ca_topic_score_gemma":0.00013539096,"teacher_disagreement_score":0.27229226,"about_ca_system_score_codex":0.00021856275,"about_ca_system_score_gemma":0.00026707587,"threshold_uncertainty_score":0.9978473},"labels":[],"label_agreement":null},{"id":"W1986072777","doi":"10.1074/jbc.m010360200","title":"Nuclear Factor 1 Interferes with Sp1 Binding through a Composite Element on the Rat Poly(ADP-ribose) Polymerase Promoter to Modulate Its Activity in Vitro","year":2001,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Medical Research Council Canada","keywords":"Promoter; Molecular biology; Biology; Poly ADP ribose polymerase; Transcription factor; Transcription (linguistics); Response element; Activator (genetics); RNA polymerase II; Polymerase; Gene expression; Gene; Biochemistry","score_opus":0.05592043442531127,"score_gpt":0.3116253351554585,"score_spread":0.25570490073014723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986072777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891311,0.00011467639,0.000095082636,0.009980237,0.00006072406,0.00021640271,0.000018673758,0.000016715632,0.00036641085],"genre_scores_gemma":[0.9975246,0.000084767016,0.00028260515,0.0016351969,0.00034924774,0.000007247752,0.0000031027303,0.000015576637,0.00009763818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998799,0.00007174503,0.0003490653,0.000213864,0.00028304654,0.00028326988],"domain_scores_gemma":[0.9992396,0.00009671469,0.0002511427,0.00017962267,0.00007498317,0.00015788645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018718647,0.00020418836,0.00038168087,0.000040715615,0.00006148202,0.00003098203,0.00017224366,0.00013159195,0.0006633771],"category_scores_gemma":[0.000054384112,0.00010287202,0.00011979878,0.00018261395,0.0000724798,0.00007458332,0.000046793528,0.0006593931,0.0000130661965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008292851,0.00036819564,0.0018168053,0.000018090876,0.000072138966,0.00021496885,0.00018014784,0.000005818505,0.9873678,0.0000016912376,0.00013723143,0.0015242663],"study_design_scores_gemma":[0.0017195098,0.0009489186,0.0022200616,0.00038106553,0.000013381673,0.00037964096,0.000120991695,0.000028580831,0.9925271,0.000014645863,0.0015128701,0.00013320154],"about_ca_topic_score_codex":0.000005381441,"about_ca_topic_score_gemma":3.021092e-7,"teacher_disagreement_score":0.008393541,"about_ca_system_score_codex":0.00028559254,"about_ca_system_score_gemma":0.000041208932,"threshold_uncertainty_score":0.72635144},"labels":[],"label_agreement":null},{"id":"W1986135694","doi":"10.1139/o05-042","title":"Chromatin architecture and functions: the role(s) of poly(ADP-RIBOSE) polymerase and poly(ADPribosyl)ation of nuclear proteins","year":2005,"lang":"en","type":"review","venue":"Biochemistry and Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chromatin; Biology; Epigenetics; Histone; Poly ADP ribose polymerase; DNA repair; Cell biology; Chromatin remodeling; Polymerase; Acetylation; DNA; DNA replication; DNA damage; Histone-modifying enzymes; Genetics; Gene; Computational biology","score_opus":0.012834349102790037,"score_gpt":0.2784892706985371,"score_spread":0.26565492159574705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986135694","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01007325,0.9877231,0.00001358778,0.00026228325,0.000038840983,0.00054857513,0.00028606164,0.000019111258,0.0010351505],"genre_scores_gemma":[0.026123183,0.9724861,0.00023405178,0.00009760301,0.00046015368,0.00006390831,0.00023183563,0.000028566456,0.00027460925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876046,0.00010322024,0.00049050804,0.00038127688,0.00008582136,0.00017871357],"domain_scores_gemma":[0.9989373,0.00011423657,0.00047334994,0.00033622066,0.000041645017,0.00009723651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014626676,0.00030288793,0.00085226836,0.000074986616,0.00008260105,0.000007673476,0.000086895554,0.0005105612,0.000117590775],"category_scores_gemma":[0.00003310551,0.00020312694,0.00012957581,0.00012784537,0.00059195276,0.000014670216,0.00006652537,0.00032910943,0.0000016082564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088882305,0.00007125788,0.00002137918,0.004646483,0.00011834547,8.7450525e-7,0.000105042396,1.6857864e-8,0.16276601,0.00004201404,0.00005943599,0.83208025],"study_design_scores_gemma":[0.00079652003,0.00032614273,0.000017345215,0.0024336004,0.00048235088,0.00026647255,0.0001795401,0.0000035977225,0.09462127,0.0000627915,0.9005792,0.00023117861],"about_ca_topic_score_codex":0.00003256669,"about_ca_topic_score_gemma":8.353029e-7,"teacher_disagreement_score":0.9005197,"about_ca_system_score_codex":0.000028181685,"about_ca_system_score_gemma":0.00014672556,"threshold_uncertainty_score":0.8283276},"labels":[],"label_agreement":null},{"id":"W1989577779","doi":"10.1016/j.cancergencyto.2004.05.005","title":"Increased frequency of multiradial chromosome structures in mouse embryonic fibroblasts lacking functional Werner syndrome protein and poly(ADP-ribose) polymerase-1","year":2005,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McMaster University; Hôtel-Dieu de Québec; Hôpital Saint-François d'Assise","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Biology; Werner syndrome; Molecular biology; Poly ADP ribose polymerase; Helicase; Mutagenesis; Polymerase; Chromatid; Premature aging; Genetics; Genome instability; DNA repair; Mutation; Chromosome; DNA; Cell biology; Gene; DNA damage; RNA","score_opus":0.021492047644411167,"score_gpt":0.2739797843026271,"score_spread":0.25248773665821594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989577779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683854,0.029994277,0.00009711963,0.00055364554,0.00011005476,0.0005459427,0.00023426625,0.000023552393,0.00005577034],"genre_scores_gemma":[0.99329734,0.0024710726,0.002962466,0.0003698656,0.00050062744,0.00008940858,0.00003219222,0.000056976507,0.00022003442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983484,0.00005361601,0.00045312234,0.00043975646,0.00033898637,0.00036611845],"domain_scores_gemma":[0.9991592,0.000032630225,0.00017046681,0.00029412442,0.0001023241,0.0002412433],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009221579,0.00029027445,0.00042218907,0.00020324893,0.00007359536,0.000026149466,0.00008518838,0.00019567949,0.00026922434],"category_scores_gemma":[0.000015328988,0.0002897673,0.000062989515,0.00020159189,0.00028590145,0.000048648075,0.00005669354,0.00022132532,0.0000019120562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025914892,0.0001083571,0.1037348,0.00022752926,0.00012060143,0.000023358163,0.0002982176,0.00043479042,0.8826302,0.00014380494,0.00008754044,0.011931626],"study_design_scores_gemma":[0.0061765723,0.0005632128,0.26600215,0.00035931237,0.00009195238,0.00019850579,0.000056210592,0.0010985743,0.7231168,0.00034911354,0.0015276854,0.0004599023],"about_ca_topic_score_codex":0.0002704732,"about_ca_topic_score_gemma":0.0003076058,"teacher_disagreement_score":0.16226736,"about_ca_system_score_codex":0.00016708607,"about_ca_system_score_gemma":0.00034427716,"threshold_uncertainty_score":0.9999555},"labels":[],"label_agreement":null},{"id":"W1989991921","doi":"10.1158/1078-0432.ccr-14-2565","title":"Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <i>BRCA</i> -Mutant Ovarian Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Cyclophosphamide; Veliparib; Ovarian cancer; Fallopian tube cancer; Fallopian tube; PARP inhibitor; Oncology; Internal medicine; Cancer; Chemotherapy; Gastroenterology; Surgery; Biology","score_opus":0.2632031430878121,"score_gpt":0.5062227187434356,"score_spread":0.2430195756556235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989991921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690149,0.0062050675,0.000056690726,0.014396387,0.002752024,0.006009782,0.00029411132,0.00009731107,0.0011737554],"genre_scores_gemma":[0.94538105,0.039275438,0.0019425926,0.003183923,0.0027536543,0.0040787077,0.00007101195,0.00016965655,0.0031439562],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99062836,0.0023159685,0.0025258446,0.001240253,0.0020707613,0.001218787],"domain_scores_gemma":[0.99369276,0.00278849,0.000444074,0.00094907335,0.001008826,0.0011167765],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010760974,0.0004794291,0.002989412,0.0004140736,0.00015674089,0.00008252803,0.0005113417,0.0006267343,0.0010910043],"category_scores_gemma":[0.0030934657,0.00033849277,0.00030883474,0.0016247657,0.0022731046,0.00024141371,0.00030436562,0.0020932574,0.000013242306],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97063565,0.00079206994,0.007225938,0.00035072002,0.00045796757,0.0003915129,0.0006270572,0.00007613694,0.00058561243,0.00031000606,0.00806284,0.010484506],"study_design_scores_gemma":[0.9495453,0.0038002443,0.005454884,0.0010606844,0.00019559308,0.00004476376,0.000277008,0.00029499672,0.0012839062,0.0007751046,0.03680575,0.00046171813],"about_ca_topic_score_codex":0.054555047,"about_ca_topic_score_gemma":0.013342288,"teacher_disagreement_score":0.04121276,"about_ca_system_score_codex":0.0022384787,"about_ca_system_score_gemma":0.0136085935,"threshold_uncertainty_score":0.9999067},"labels":[],"label_agreement":null},{"id":"W1991704748","doi":"10.1080/01635580701649628","title":"Niacin Supplementation Decreases the Incidence of Alkylation-Induced Nonlymphocytic Leukemia in Long-Evans Rats","year":2008,"lang":"en","type":"article","venue":"Nutrition and Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Cancer Institute","keywords":"Niacin; Weanling; Nicotinamide; Internal medicine; Endocrinology; Cancer; Medicine; Leukemia; Biology; Biochemistry","score_opus":0.03636982476645436,"score_gpt":0.3386790121594803,"score_spread":0.302309187393026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991704748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539685,0.0021537521,0.00013118758,0.0014604976,0.000082888895,0.0004808035,0.000027718814,0.000017067829,0.000249215],"genre_scores_gemma":[0.989557,0.008937324,0.00012271713,0.0008463463,0.00012449281,0.00025664273,0.000050273968,0.000009414787,0.00009578945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919087,0.000048240763,0.00025876315,0.00015504671,0.00023037018,0.00011669155],"domain_scores_gemma":[0.99954325,0.00007707972,0.000094033465,0.00012558162,0.00010677936,0.000053277214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099275676,0.00008805975,0.00016119177,0.0000972811,0.00008929536,0.000005974056,0.000036987356,0.00005101589,0.00042282074],"category_scores_gemma":[0.000021505595,0.00006516491,0.000035535802,0.00025469728,0.00009737212,0.000113816845,0.0000074835266,0.000083250554,0.000003842506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003459509,0.0007642336,0.52433926,0.0011622299,0.00014603551,0.00012543802,0.007838964,0.00035034894,0.39360365,0.0005133748,0.018881315,0.04881565],"study_design_scores_gemma":[0.01643003,0.00033054035,0.49152893,0.0015680144,0.00006236767,0.00022742692,0.00095109595,0.0012738319,0.48178563,0.0004948247,0.005097893,0.00024940426],"about_ca_topic_score_codex":0.0011505594,"about_ca_topic_score_gemma":0.0007786581,"teacher_disagreement_score":0.088181965,"about_ca_system_score_codex":0.00061893894,"about_ca_system_score_gemma":0.00039039447,"threshold_uncertainty_score":0.46295908},"labels":[],"label_agreement":null},{"id":"W1991923395","doi":"10.4161/cc.3.3.670","title":"Defective Control of Mitotic and Post-mitotic Checkpoints in Poly(ADP-ribose) Polymerase-1-/- Fibroblasts After Mitotic Spindle Disruption","year":2004,"lang":"en","type":"article","venue":"Cell Cycle","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Université Laval","keywords":"Biology; Cell biology; G2-M DNA damage checkpoint; Mitosis; Genome instability; DNA damage; Spindle checkpoint; Poly ADP ribose polymerase; DNA repair; Mitotic catastrophe; Cell cycle checkpoint; Cancer research; Molecular biology; Genetics; Cell cycle; Spindle apparatus; Polymerase; Apoptosis; Cell; DNA; Cell division","score_opus":0.0057290774284247895,"score_gpt":0.24413681092780018,"score_spread":0.23840773349937538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991923395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993124,0.00367832,0.00044300663,0.0011859937,0.00026004823,0.000750202,0.000045375527,0.000049228896,0.00046380018],"genre_scores_gemma":[0.9983878,0.00005338764,0.00037259905,0.00063366146,0.00024752182,0.00007562785,0.000019150411,0.00005307878,0.00015716457],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982274,0.00008581078,0.0004907054,0.0004551642,0.00030813826,0.00043278234],"domain_scores_gemma":[0.99903226,0.00010091082,0.00017217791,0.00036725088,0.00010783006,0.00021954777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014935876,0.0002819639,0.0005120053,0.000264791,0.000049337348,0.000018760566,0.00007864036,0.00017421972,0.00021688812],"category_scores_gemma":[0.00005406503,0.00027639372,0.00015355772,0.00029470597,0.00022052116,0.0001816589,0.00003249975,0.00027703252,0.00009731725],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031890466,0.0013822408,0.05098888,0.000723637,0.00013060795,0.00019875412,0.0026352191,0.00040653461,0.938634,0.000056740508,0.000052393494,0.0016019735],"study_design_scores_gemma":[0.018305812,0.001247576,0.66975486,0.0010310757,0.00017002782,0.000105001665,0.00038247573,0.0002864519,0.3074964,0.0007722153,0.000045778084,0.0004023359],"about_ca_topic_score_codex":0.00033951216,"about_ca_topic_score_gemma":0.0000668649,"teacher_disagreement_score":0.63113755,"about_ca_system_score_codex":0.00031377378,"about_ca_system_score_gemma":0.00015654707,"threshold_uncertainty_score":0.9999688},"labels":[],"label_agreement":null},{"id":"W1992383407","doi":"10.1016/j.dnarep.2015.02.004","title":"Quantitative site-specific ADP-ribosylation profiling of DNA-dependent PARPs","year":2015,"lang":"en","type":"article","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of British Columbia; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Biology; ADP-ribosylation; DNA repair; DNA damage; Polymerase; Biochemistry; Histone; DNA; Enzyme; NAD+ kinase","score_opus":0.09189252791174868,"score_gpt":0.34324157397401295,"score_spread":0.25134904606226427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992383407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864269,0.0015302411,0.0013663189,0.0005263932,0.0003847849,0.0005423222,0.000039162976,0.00028017387,0.008903732],"genre_scores_gemma":[0.9868242,0.00010208254,0.011771837,0.00019455703,0.000195349,0.000052325813,0.00010688127,0.0000320475,0.00072073424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985144,0.000089094705,0.00041297806,0.00029365756,0.00049850583,0.00019137237],"domain_scores_gemma":[0.9987965,0.00008921278,0.00020154224,0.0003774662,0.00038809885,0.00014713194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054123683,0.00013954531,0.00029874506,0.00012544182,0.000036617945,0.000007611456,0.000056021447,0.00009045613,0.00015731907],"category_scores_gemma":[0.00013179524,0.00012849626,0.00013182427,0.0002207859,0.00008831227,0.000100985795,0.00002281022,0.00014363986,0.00017721887],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005218947,0.0009006789,0.07610309,0.00036117315,0.00033845156,0.00014869911,0.009345894,0.00053779373,0.84011847,0.019573737,0.04436092,0.0029921178],"study_design_scores_gemma":[0.0073527,0.0020370714,0.008861686,0.00044298917,0.00009680465,0.000064275475,0.0030869124,0.0028501851,0.91144764,0.0020393562,0.06128345,0.00043689684],"about_ca_topic_score_codex":0.000023853365,"about_ca_topic_score_gemma":0.000008489046,"teacher_disagreement_score":0.07132918,"about_ca_system_score_codex":0.0002204479,"about_ca_system_score_gemma":0.00015551869,"threshold_uncertainty_score":0.52399254},"labels":[],"label_agreement":null},{"id":"W1992476369","doi":"10.1016/s0301-472x(03)00083-3","title":"PARP-1, a determinant of cell survival in response to DNA damage","year":2003,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":391,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; DNA damage; DNA repair; Biology; Genome instability; DNA; Apoptosis; Polymerase; Cell biology; DNA replication; Cancer research; Genetics","score_opus":0.06411873971903466,"score_gpt":0.41958449373482737,"score_spread":0.3554657540157927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992476369","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009490502,0.9858976,0.000010116927,0.00003009245,0.0005536337,0.0014018031,0.00004239873,0.000026737096,0.0025471102],"genre_scores_gemma":[0.010809359,0.98467857,0.0015377436,0.0003336416,0.00007618652,0.0010996591,0.00007825365,0.00016554292,0.0012210205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969275,0.0007619696,0.0010769966,0.00055469887,0.00024905978,0.00042975918],"domain_scores_gemma":[0.99846065,0.00032366964,0.00033097397,0.0006571553,0.000031565905,0.00019600609],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044625445,0.0004454625,0.0028773472,0.0005147064,0.000024945602,0.000005800351,0.00020087458,0.00040336038,0.00061281497],"category_scores_gemma":[0.000042341264,0.00039598058,0.00036364718,0.00042480783,0.00015086611,0.000036981786,0.0000876217,0.00031316298,0.0002521071],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053166162,0.03568868,0.0012053837,0.25080115,0.0021837049,0.04053795,0.025896259,0.0000023840971,0.22898658,0.025062716,0.035984512,0.3004845],"study_design_scores_gemma":[0.0022400825,0.00086099474,0.000008320777,0.00820931,0.00008390495,0.001204204,0.00036675716,4.764841e-7,0.137947,0.0000069986254,0.8486777,0.00039427076],"about_ca_topic_score_codex":0.000013457154,"about_ca_topic_score_gemma":0.0000051016896,"teacher_disagreement_score":0.8126932,"about_ca_system_score_codex":0.0004377309,"about_ca_system_score_gemma":0.00046033692,"threshold_uncertainty_score":0.9998492},"labels":[],"label_agreement":null},{"id":"W1993344194","doi":"10.1158/1538-7445.am2012-4692","title":"Abstract 4692: ABT-888 synergizes treatment of colon cancer cell lines with irinotecan","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University; Jewish General Hospital","funders":"","keywords":"PARP1; DNA damage; Cancer research; PARP inhibitor; DNA repair; Veliparib; Olaparib; Synthetic lethality; Topoisomerase; Poly ADP ribose polymerase; Molecular biology; Cancer; Comet assay; Irinotecan; Biology; Chemistry; Colorectal cancer; Polymerase; DNA; Biochemistry; Genetics","score_opus":0.1540170921789979,"score_gpt":0.47011049998236865,"score_spread":0.31609340780337075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993344194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623565,0.02755671,0.00000809758,0.0013088556,0.00026017136,0.0007966371,0.00011479755,0.00004698074,0.0075512584],"genre_scores_gemma":[0.9775549,0.015370875,0.00015921032,0.00010279535,0.0012299494,0.0011330863,0.000016091719,0.000060642153,0.0043724533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99768513,0.00008048142,0.0002982214,0.0003209041,0.00084322674,0.0007720197],"domain_scores_gemma":[0.9983101,0.00018373632,0.00011522028,0.00047838574,0.0005420445,0.00037053874],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035309268,0.0002159026,0.00042828245,0.0001700466,0.00012500279,0.000016505717,0.00013459154,0.00012394848,0.0033466362],"category_scores_gemma":[0.000013128115,0.0001541125,0.00009203953,0.00043664555,0.00038471576,0.00015807422,0.00002546988,0.00025408468,0.00004442312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005269203,0.0025100273,0.06838428,0.0008743054,0.00045355584,0.000052091524,0.0031819888,0.00017984846,0.86440873,0.00015034029,0.012360385,0.04217525],"study_design_scores_gemma":[0.004068507,0.0016434084,0.028519738,0.00046863174,0.00006418425,0.00001008539,0.00040198315,0.000009411718,0.8849294,0.0000139089525,0.079681255,0.00018946854],"about_ca_topic_score_codex":0.0093607325,"about_ca_topic_score_gemma":0.0012310673,"teacher_disagreement_score":0.06732087,"about_ca_system_score_codex":0.0016106698,"about_ca_system_score_gemma":0.00094037084,"threshold_uncertainty_score":0.99756444},"labels":[],"label_agreement":null},{"id":"W1993972255","doi":"10.1006/excr.2001.5263","title":"Importance of Poly(ADP-Ribose) Glycohydrolase in the Control of Poly(ADP-Ribose) Metabolism","year":2001,"lang":"en","type":"review","venue":"Experimental Cell Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Biology; Polymerase; Biochemistry; Ribose; Enzyme; ADP-ribosylation; DNA repair; RNA polymerase III; DNA; Chromatin; Cytoplasm; Cell biology; NAD+ kinase","score_opus":0.126349552235156,"score_gpt":0.4686902832341981,"score_spread":0.34234073099904205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993972255","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017834387,0.9796945,0.000016852964,0.00030479478,0.0003276398,0.003777712,0.0003050349,0.000029889323,0.013760178],"genre_scores_gemma":[0.056980506,0.9383073,0.00014016869,0.00024622225,0.0011954609,0.001134285,0.000198663,0.00016716526,0.0016302238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99111617,0.0018032495,0.0020137832,0.0009780668,0.0028636542,0.0012251069],"domain_scores_gemma":[0.9956223,0.0010818786,0.0007868408,0.0018530462,0.00030697638,0.00034895504],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033536449,0.0007444739,0.0032104233,0.001151779,0.00014654236,0.00004279116,0.0012178064,0.00050689385,0.0016579889],"category_scores_gemma":[0.00013480357,0.0005349018,0.0010016147,0.0022954263,0.0010145493,0.00015066171,0.0002158032,0.0020033813,0.00012804722],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009825098,0.021492517,0.0008846101,0.05143754,0.0029399316,0.003905992,0.011480666,0.0000040361756,0.16642359,0.003307106,0.048336174,0.67996275],"study_design_scores_gemma":[0.005865684,0.0008537049,0.000030369216,0.0050643426,0.00022503974,0.0001800454,0.0009283738,0.0000120841405,0.071546495,0.000054610595,0.9147842,0.00045507684],"about_ca_topic_score_codex":0.0006703047,"about_ca_topic_score_gemma":0.000011674086,"teacher_disagreement_score":0.866448,"about_ca_system_score_codex":0.0007405549,"about_ca_system_score_gemma":0.0012981562,"threshold_uncertainty_score":0.99971026},"labels":[],"label_agreement":null},{"id":"W1994051196","doi":"10.1016/j.bbrc.2006.01.145","title":"AMP-activated protein kinase is a positive regulator of poly(ADP-ribose) polymerase","year":2006,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Regulator; Chemistry; Polymerase; Poly ADP ribose polymerase; Protein kinase A; Biochemistry; Molecular biology; Kinase; Enzyme; Biology; Gene","score_opus":0.07058538867542488,"score_gpt":0.3958783974009008,"score_spread":0.32529300872547595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994051196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973526,0.0023536622,0.00004675772,0.021559307,0.000007125569,0.0006207621,0.00019467605,0.000042953587,0.0016487617],"genre_scores_gemma":[0.9966738,0.00012765032,0.001753297,0.00016302434,0.00016836774,0.00014995509,0.00021663359,0.000019310135,0.00072794687],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983348,0.00018975153,0.0003047813,0.000295099,0.000544961,0.00033056265],"domain_scores_gemma":[0.99780995,0.00024176174,0.00006366629,0.0011461991,0.0005043391,0.00023410616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021201717,0.00014344654,0.00027403602,0.00014237614,0.00021275645,0.000024199155,0.00031335087,0.00013301118,0.00007731679],"category_scores_gemma":[0.00014968427,0.00012111519,0.00010960921,0.0007621887,0.0014246502,0.00006228855,0.00025044117,0.00050037727,0.000026193453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040247716,0.0011188028,0.000060246777,0.000049573613,0.00003797241,0.0000017390056,0.00006848604,1.37963205e-8,0.98920786,0.0050732708,0.0028075115,0.0011720274],"study_design_scores_gemma":[0.0009813679,0.00023058103,0.0014960684,0.00026909154,0.000018206347,0.0000058439746,0.00003533194,0.00015737308,0.99028695,0.0022511408,0.0041439915,0.00012404156],"about_ca_topic_score_codex":0.000984833,"about_ca_topic_score_gemma":0.0000041251315,"teacher_disagreement_score":0.023147821,"about_ca_system_score_codex":0.00010861257,"about_ca_system_score_gemma":0.00017574038,"threshold_uncertainty_score":0.5249183},"labels":[],"label_agreement":null},{"id":"W1994894991","doi":"10.1016/j.dnarep.2008.11.018","title":"Delocalization of nucleolar poly(ADP-ribose) polymerase-1 to the nucleoplasm and its novel link to cellular sensitivity to DNA damage","year":2009,"lang":"en","type":"article","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Nucleoplasm; Poly ADP ribose polymerase; Biology; Nucleolus; DNA repair; DNA damage; Cell biology; Molecular biology; NAD+ kinase; DNA; Polymerase; Genetics; Biochemistry; Enzyme; Cytoplasm","score_opus":0.016476190922330942,"score_gpt":0.2720938991567115,"score_spread":0.25561770823438057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994894991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94649225,0.00023402947,0.011327158,0.03983033,0.00020033508,0.0009833219,0.000088216235,0.0002288147,0.0006155415],"genre_scores_gemma":[0.9752237,0.000012641661,0.0020885447,0.021796448,0.00046212994,0.000016994212,0.0000238966,0.00003975131,0.00033585867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982801,0.00009789923,0.0003912301,0.0004640073,0.00042905466,0.0003376891],"domain_scores_gemma":[0.99859476,0.00008856828,0.00009372892,0.0006052926,0.00021348963,0.00040415334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005245804,0.0002345412,0.0003732802,0.00019698724,0.00013880567,0.000026496833,0.000096454605,0.00012500618,0.00006794319],"category_scores_gemma":[0.00021600489,0.00019927915,0.000115403345,0.0006451586,0.000037172475,0.00011614593,0.00006449501,0.00015896416,0.00009296385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045381152,0.00016537558,0.0003607763,0.00003726702,0.000047908412,0.000039428865,0.0016985327,0.00016496412,0.9845352,0.0008456406,0.006411976,0.00523913],"study_design_scores_gemma":[0.0016150736,0.001014908,0.028575735,0.00031419515,0.00007963391,0.00005621641,0.0001890029,0.005381777,0.8900272,0.00003180365,0.0723692,0.00034520574],"about_ca_topic_score_codex":0.00008921294,"about_ca_topic_score_gemma":0.000039670955,"teacher_disagreement_score":0.09450795,"about_ca_system_score_codex":0.00011250686,"about_ca_system_score_gemma":0.00008156408,"threshold_uncertainty_score":0.8126368},"labels":[],"label_agreement":null},{"id":"W1995005155","doi":"10.1038/nm.2387","title":"Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death","year":2011,"lang":"en","type":"article","venue":"Nature Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Excitotoxicity; NMDA receptor; Glutamate receptor; Neuroprotection; Poly ADP ribose polymerase; Small interfering RNA; Programmed cell death; Pharmacology; Cell biology; Receptor; Chemistry; Biology; Apoptosis; Biochemistry; Polymerase; Transfection; Enzyme","score_opus":0.020308551608427677,"score_gpt":0.26696936126263,"score_spread":0.2466608096542023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995005155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690419,0.010354938,0.00067691976,0.012503491,0.00041746857,0.0010429084,0.00006697175,0.00015937368,0.005736057],"genre_scores_gemma":[0.9894852,0.00009672672,0.0005027054,0.007734172,0.001069844,0.000094053474,0.000036013935,0.000066776505,0.0009144863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979606,0.00011426987,0.00034366656,0.00054567814,0.00060757675,0.00042816045],"domain_scores_gemma":[0.9984485,0.0001883192,0.00020909088,0.00076166407,0.00010241953,0.00029001175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035983877,0.00038839306,0.0005439906,0.00013014936,0.00015147892,0.000015732661,0.00029138173,0.00037400358,0.00044228346],"category_scores_gemma":[0.00012981698,0.00021696178,0.000053329735,0.00025127394,0.00028095313,0.000105397965,0.00008480537,0.0015346721,0.000008375281],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016033358,0.00010661976,0.0029918815,0.00008187073,0.00016265114,0.00008450519,0.0032433916,3.0453254e-8,0.98322374,0.00009007062,0.0049744127,0.00343752],"study_design_scores_gemma":[0.0068972474,0.0017809432,0.011647695,0.00084347447,0.00011671938,0.00012735787,0.0005932762,0.00003882547,0.97406554,0.00023735104,0.003377369,0.00027419982],"about_ca_topic_score_codex":0.000921028,"about_ca_topic_score_gemma":0.000047086214,"teacher_disagreement_score":0.02044335,"about_ca_system_score_codex":0.00010713066,"about_ca_system_score_gemma":0.000088740846,"threshold_uncertainty_score":0.88474447},"labels":[],"label_agreement":null},{"id":"W1995543194","doi":"10.1074/jbc.m114.630160","title":"Structural Basis for Lack of ADP-ribosyltransferase Activity in Poly(ADP-ribose) Polymerase-13/Zinc Finger Antiviral Protein","year":2015,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Poly ADP ribose polymerase; Zinc finger; ADP-ribosylation; Polymerase; Biology; NAD+ kinase; Structural motif; Stress granule; Homology modeling; Biochemistry; Enzyme; Gene; Messenger RNA; Transcription factor","score_opus":0.10225869377040002,"score_gpt":0.3525236118821968,"score_spread":0.25026491811179674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995543194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99610776,0.0007104742,0.0002181452,0.0020166875,0.0001135729,0.00029620682,0.0001268943,0.000015693771,0.00039454887],"genre_scores_gemma":[0.9978347,0.0000344752,0.0010144197,0.00022266993,0.00072821655,0.000017588483,0.000014162853,0.000016730772,0.00011707409],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831885,0.00008079278,0.00068651454,0.00023965663,0.00034416694,0.00032999692],"domain_scores_gemma":[0.9986766,0.00015956968,0.0004268386,0.00019573788,0.00028585634,0.00025539956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056030735,0.00023554475,0.00074005197,0.00007070248,0.000030103867,0.000011780207,0.00017981781,0.00031813903,0.00020210192],"category_scores_gemma":[0.00050413504,0.00016580931,0.00032340523,0.00020341808,0.00022495346,0.00012164037,0.00002567947,0.0005188858,0.0000013450224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048990464,0.00026426162,0.012333186,0.00015221238,0.00007295534,0.00005763269,0.000085687774,0.0000037847979,0.9790863,0.0000051452885,0.00030790665,0.0027318907],"study_design_scores_gemma":[0.0052326964,0.00095605437,0.008228795,0.00033946362,0.000034311037,0.0001463716,0.000108307795,0.000050126862,0.983988,0.00033829358,0.0003960677,0.00018154053],"about_ca_topic_score_codex":0.000023424367,"about_ca_topic_score_gemma":0.0000016341374,"teacher_disagreement_score":0.004901682,"about_ca_system_score_codex":0.00022269186,"about_ca_system_score_gemma":0.00033782425,"threshold_uncertainty_score":0.67615074},"labels":[],"label_agreement":null},{"id":"W1995944333","doi":"10.1158/1538-7445.am10-686","title":"Abstract 686: Potentiation of the cytocidal effect of streptozotocin on carcinoid neuroendocrine cells by a pharmacological inhibitor of poly(ADP-ribose) polymerase","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Streptozotocin; PARP inhibitor; Chemotherapy; Pharmacology; Medicine; Cancer; Cancer research; Polymerase; Internal medicine; Chemistry; Diabetes mellitus; Endocrinology; Enzyme; Biochemistry","score_opus":0.0315083783498445,"score_gpt":0.4015214390341645,"score_spread":0.37001306068432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995944333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994211,0.00052114343,0.0000022991685,0.0022875227,0.00057084224,0.0015848309,0.00036273984,0.000017886845,0.00044170266],"genre_scores_gemma":[0.99861574,0.00012998095,0.000009534168,0.00014464498,0.00045711914,0.0002543351,0.00001532235,0.00003390253,0.00033941187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701315,0.00036584103,0.0005246725,0.0003684978,0.0012865498,0.00044129186],"domain_scores_gemma":[0.9981838,0.0004803932,0.00028461055,0.0005116127,0.00036067405,0.00017890178],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006886773,0.00019576584,0.0004654972,0.00020867774,0.00008797348,0.000008391537,0.0003095639,0.000096232565,0.0015923566],"category_scores_gemma":[0.00017777133,0.00013171672,0.0002247342,0.000557248,0.00074355275,0.000060242637,0.0000944988,0.0011440822,0.000007568629],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030160674,0.00034089608,0.008448745,0.0003321968,0.000075949,0.000013536099,0.0000670415,0.0000124057615,0.9693599,0.000016756796,0.014274465,0.004042051],"study_design_scores_gemma":[0.0042295153,0.0015356346,0.020569276,0.00018342894,0.000049528422,0.000008239593,0.000022596654,0.00001917366,0.97261524,0.000012825543,0.0006687021,0.00008583685],"about_ca_topic_score_codex":0.0008306457,"about_ca_topic_score_gemma":0.000022979619,"teacher_disagreement_score":0.013605763,"about_ca_system_score_codex":0.00014993384,"about_ca_system_score_gemma":0.00039324362,"threshold_uncertainty_score":0.9993203},"labels":[],"label_agreement":null},{"id":"W1996604836","doi":"10.1118/1.2031008","title":"Po‐Poster ‐ 29: Radiation‐induced apoptosis of lymphocytes to predict late toxicity from radiotherapy","year":2005,"lang":"en","type":"article","venue":"Medical Physics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Radiosensitivity; Apoptosis; Radioresistance; Radiation therapy; Annexin; Toxicity; Cancer research; Comet assay; Prostate cancer; Medicine; Biology; Oncology; Internal medicine; Cancer; DNA damage; Genetics","score_opus":0.02038452302653014,"score_gpt":0.30080498592471294,"score_spread":0.2804204628981828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996604836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974993,0.0003850423,0.01160807,0.010640873,0.00051184563,0.00043253633,0.00008483439,0.0001109762,0.0012328303],"genre_scores_gemma":[0.98255754,0.00024422244,0.00071156386,0.012936137,0.0031294117,0.00004875714,0.00006911623,0.000044211687,0.00025902837],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99778014,0.00006919585,0.0004915661,0.00034175665,0.001022935,0.00029442052],"domain_scores_gemma":[0.9986565,0.00016482352,0.00014150464,0.00045368477,0.00010919234,0.00047428787],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022119225,0.0002115228,0.00051497866,0.00006510625,0.000048496146,0.000011379609,0.00019784414,0.00018906734,0.0015843272],"category_scores_gemma":[0.00012283852,0.0001869255,0.00016361315,0.0003145805,0.00010592452,0.000121317236,0.000034058074,0.00022800635,0.00010558085],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014432939,0.0014509124,0.015128622,0.00010455184,0.0005843862,0.000010228925,0.0041565765,0.00017334803,0.21413067,0.00007299832,0.037867643,0.72487676],"study_design_scores_gemma":[0.005343103,0.0003882392,0.006322758,0.0002546801,0.000058744816,0.000003194803,0.0000128282545,0.0004274762,0.9775635,0.00040688994,0.009016446,0.000202116],"about_ca_topic_score_codex":0.00009978529,"about_ca_topic_score_gemma":0.000006393407,"teacher_disagreement_score":0.76343286,"about_ca_system_score_codex":0.00038162214,"about_ca_system_score_gemma":0.0003339427,"threshold_uncertainty_score":0.9993284},"labels":[],"label_agreement":null},{"id":"W1997369842","doi":"10.1007/s11033-012-2009-x","title":"Racial and tissue-specific cancer risk associated with PARP1 (ADPRT) Val762Ala polymorphism: a meta-analysis","year":2012,"lang":"en","type":"review","venue":"Molecular Biology Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; SickKids Foundation; Mount Sinai Hospital; Ministry of the Environment, Conservation and Parks","funders":"","keywords":"Odds ratio; Internal medicine; Allele; Bonferroni correction; Biology; Oncology; Allele frequency; Gastroenterology; Meta-analysis; Genetics; Medicine; Gene","score_opus":0.11095385035493749,"score_gpt":0.4023881020540032,"score_spread":0.2914342516990657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997369842","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034315872,0.9955339,0.0014319067,0.00013057572,0.0003715949,0.0013897585,0.00032465166,0.000111537316,0.00036292916],"genre_scores_gemma":[0.0033294435,0.99187255,0.00039912495,0.00028387885,0.00027639992,0.001201528,0.001462399,0.00014071465,0.0010339844],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99527496,0.0009584901,0.0013752943,0.0013091003,0.0004038951,0.0006782383],"domain_scores_gemma":[0.9955216,0.00015682538,0.0024974635,0.00123664,0.00023263946,0.0003548211],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010865629,0.00088604935,0.0065363958,0.00060806033,0.00014616479,0.000029932986,0.00012231963,0.0010226816,0.0016138004],"category_scores_gemma":[0.000092447604,0.00059082155,0.0021176029,0.0012208143,0.0004281348,0.00004211011,0.00008245352,0.0007974601,0.000015298869],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010474289,0.0003618867,0.004140016,0.001148084,0.7386017,0.0064347945,0.0001670035,0.0000043816462,0.0002641487,0.000055297227,0.00094104855,0.24777694],"study_design_scores_gemma":[0.00026801357,0.00014355379,0.000086676446,0.00022163666,0.40734366,0.0010256387,0.0000015422531,2.455779e-7,0.00008865608,0.000050591596,0.5903435,0.00042632828],"about_ca_topic_score_codex":0.00016886806,"about_ca_topic_score_gemma":0.000065698165,"teacher_disagreement_score":0.58940244,"about_ca_system_score_codex":0.00029464802,"about_ca_system_score_gemma":0.00044048857,"threshold_uncertainty_score":0.9996543},"labels":[],"label_agreement":null},{"id":"W1997953313","doi":"10.1073/pnas.0406182101","title":"Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality","year":2004,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health","keywords":"Poly ADP ribose polymerase; Biology; Embryonic stem cell; DNA damage; Synthetic lethality; Cytotoxicity; DNA repair; Cell biology; Molecular biology; Biochemistry; Polymerase; Enzyme; DNA; In vitro; Gene","score_opus":0.044508561816254955,"score_gpt":0.33394328915146865,"score_spread":0.2894347273352137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997953313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503453,0.00007438331,0.0000120582945,0.048585996,0.000013220863,0.0004309961,0.00003836089,0.000023732007,0.00047599705],"genre_scores_gemma":[0.9922412,0.000006964705,0.004522351,0.0030096774,0.00015278652,0.000018691626,1.1176047e-7,0.0000060841176,0.000042103056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979134,0.000013373606,0.00027968176,0.00034544474,0.00123427,0.00021378891],"domain_scores_gemma":[0.9991329,0.00012118983,0.00021741472,0.000016235326,0.0003409131,0.00017139933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015440852,0.00013184354,0.0002621633,0.00022867926,0.000199763,0.000026609836,0.00023066778,0.00009710586,0.000006956036],"category_scores_gemma":[0.00087114377,0.00009532782,0.00007156446,0.0009929452,0.0006477479,0.00030939042,0.00011245672,0.00021168958,0.0000026645682],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008883531,0.000064601,0.028082294,0.00005629942,0.000019762132,5.961755e-8,0.0004725176,0.000029952862,0.9626766,0.007997188,0.00042791723,0.00008401793],"study_design_scores_gemma":[0.00038942014,0.000111537665,0.41915745,0.00018737797,0.000011667436,0.00003413573,0.00009426384,0.000006285029,0.5733041,0.0065358267,0.00009762203,0.000070301205],"about_ca_topic_score_codex":0.00018299333,"about_ca_topic_score_gemma":0.0000022340378,"teacher_disagreement_score":0.39107513,"about_ca_system_score_codex":0.00015969829,"about_ca_system_score_gemma":0.00013540484,"threshold_uncertainty_score":0.38873556},"labels":[],"label_agreement":null},{"id":"W1999855539","doi":"10.1207/s15327914nc4501_14","title":"Chronic DNA Damage and Niacin Deficiency Enhance Cell Injury and Cause Unusual Interactions in NAD and Poly(ADP-Ribose) Metabolism in Rat Bone Marrow","year":2003,"lang":"en","type":"article","venue":"Nutrition and Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Central China Normal University","keywords":"Niacin; Bone marrow; Endocrinology; Internal medicine; Weanling; NAD+ kinase; Red blood cell; Medicine; Biology; Chemistry; Biochemistry","score_opus":0.01614328915587066,"score_gpt":0.3219089153411167,"score_spread":0.30576562618524605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999855539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91859037,0.07785686,0.000028464816,0.0022644696,0.00020768498,0.0004024456,0.000054316322,0.000019605917,0.00057576835],"genre_scores_gemma":[0.9627308,0.035430875,0.0001543252,0.0008171625,0.00015282797,0.00019880048,0.000010927071,0.000017927567,0.00048630175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988958,0.000090509595,0.00027263863,0.0003655111,0.0001305537,0.00024495966],"domain_scores_gemma":[0.99958277,0.000044346132,0.00007093088,0.00012390506,0.000042203297,0.00013586633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016844939,0.00017351774,0.00029789156,0.0002705963,0.000081735576,0.000036877238,0.00002070366,0.00008182507,0.00017799049],"category_scores_gemma":[0.00001698166,0.00016402124,0.000019642444,0.00029701926,0.00017136066,0.00024259408,0.000016934637,0.00027958828,0.0000017532856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008965839,0.00081715646,0.02331178,0.0012883593,0.000033899574,0.000093986106,0.0025015636,0.0000016632263,0.9219364,0.0011825678,0.004810048,0.043126017],"study_design_scores_gemma":[0.030693805,0.0006523762,0.1110137,0.0025423877,0.00018830803,0.0003874808,0.0022313115,0.00023346923,0.54383385,0.0017487428,0.30541167,0.0010628906],"about_ca_topic_score_codex":0.0002441,"about_ca_topic_score_gemma":0.0010512742,"teacher_disagreement_score":0.37810254,"about_ca_system_score_codex":0.00018600635,"about_ca_system_score_gemma":0.00010980472,"threshold_uncertainty_score":0.66885924},"labels":[],"label_agreement":null},{"id":"W2000064534","doi":"10.1016/j.biocel.2008.09.026","title":"Regulation of poly(ADP-ribose) polymerase-1 functions by leukocyte elastase inhibitor/LEI-derived DNase II during caspase-independent apoptosis","year":2008,"lang":"en","type":"article","venue":"The International Journal of Biochemistry & Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Retina France; Fondation pour la Recherche Médicale; Fondazione Cariplo","keywords":"Poly ADP ribose polymerase; Apoptosis; Biology; Molecular biology; Caspase; Polymerase; Programmed cell death; NLRP1; PARP inhibitor; Cell biology; Enzyme; Biochemistry","score_opus":0.011859257830835239,"score_gpt":0.25501707647009236,"score_spread":0.24315781863925712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000064534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926746,0.0020954192,0.00035182337,0.003199766,0.00082872075,0.000111520385,0.00018342544,0.00001907081,0.0005356857],"genre_scores_gemma":[0.9959422,0.00047374747,0.00014863987,0.00032346067,0.0013711308,0.000008161217,0.00017366184,0.00002278539,0.001536219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998111,0.00007210277,0.00083108817,0.00023790372,0.0005188481,0.00022905374],"domain_scores_gemma":[0.9979776,0.00010286654,0.00091994536,0.00028619161,0.0005543018,0.0001591028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002414149,0.0002188271,0.00035007816,0.00016488074,0.00018472686,0.000009937271,0.00034978896,0.0001848287,0.0005744679],"category_scores_gemma":[0.00006827323,0.00017237058,0.00027907584,0.00013074835,0.00034591733,0.00008735064,0.00010136571,0.00039888217,0.000009681628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017551362,0.00034180825,0.00085351896,0.000021660902,0.00031559847,0.000030077728,0.00017146197,0.00003503673,0.9903138,0.0000043144396,0.0057405727,0.00041697297],"study_design_scores_gemma":[0.0036239533,0.0003123528,0.00070872507,0.00010874421,0.000083347804,0.0013608554,0.00020248975,0.000022294656,0.99117225,0.000028950593,0.0022361188,0.00013993788],"about_ca_topic_score_codex":0.00007442599,"about_ca_topic_score_gemma":0.0000012800817,"teacher_disagreement_score":0.003504454,"about_ca_system_score_codex":0.00039403024,"about_ca_system_score_gemma":0.0003571121,"threshold_uncertainty_score":0.7029068},"labels":[],"label_agreement":null},{"id":"W2000080307","doi":"10.1111/j.1471-4159.2009.06167.x","title":"Calpain activation is not required for AIF translocation in PARP‐1‐dependent cell death (parthanatos)","year":2009,"lang":"en","type":"article","venue":"Journal of Neurochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Calpain; Apoptosis-inducing factor; Poly ADP ribose polymerase; Programmed cell death; Cell biology; Mitochondrion; Biology; Calpastatin; Chromosomal translocation; Apoptosis; Molecular biology; Biochemistry; Polymerase; Caspase; Enzyme","score_opus":0.04233375181543475,"score_gpt":0.3254046151481332,"score_spread":0.28307086333269843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000080307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98639673,0.00016143033,0.0049319686,0.007658929,0.00009115529,0.00020251182,0.000008632335,0.000012187821,0.00053645973],"genre_scores_gemma":[0.9951489,0.00022352222,0.0007484153,0.0032830376,0.0003503462,0.000008391125,0.0000085489355,0.000014959657,0.00021385624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987339,0.00002411794,0.00055635395,0.0001651318,0.00034733748,0.00017316718],"domain_scores_gemma":[0.9990805,0.00007538679,0.00036050074,0.00016234478,0.00020689954,0.00011441173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002758727,0.00012695417,0.00026580272,0.00009829643,0.000029662835,0.000013760234,0.00009673114,0.00011207427,0.000042230367],"category_scores_gemma":[0.000084715,0.00012391829,0.00013632007,0.00012978168,0.000014423171,0.00013826284,0.0000025498132,0.0002868365,0.0000013439653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011671997,0.00017363655,0.00043648487,0.00008099487,0.0000116359115,0.00002918085,0.0002251663,0.0000712916,0.9928745,0.000005294205,0.0013714996,0.0035530876],"study_design_scores_gemma":[0.004785179,0.00037848714,0.006885726,0.00025343435,0.000029059964,0.00015568882,0.000065891676,0.00021897077,0.985614,0.00029519663,0.001219715,0.0000986786],"about_ca_topic_score_codex":0.0000014255047,"about_ca_topic_score_gemma":2.6954473e-7,"teacher_disagreement_score":0.008752198,"about_ca_system_score_codex":0.00018546257,"about_ca_system_score_gemma":0.00019347995,"threshold_uncertainty_score":0.50532407},"labels":[],"label_agreement":null},{"id":"W2000425014","doi":"10.1158/1078-0432.ccr-14-1552","title":"A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis","year":2014,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Veliparib; Medicine; Internal medicine; Gastroenterology; PARP inhibitor; Neutropenia; Ascites; Oncology; Cancer; Ovarian cancer; Leukopenia; Chemotherapy","score_opus":0.07481250261711388,"score_gpt":0.4690696051276442,"score_spread":0.3942571025105303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000425014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971828,0.00022818227,0.000021071055,0.00053036393,0.00006987463,0.001890661,0.000017704248,0.000015444073,0.00004389797],"genre_scores_gemma":[0.99871606,0.00033836308,0.00008023476,0.00011845089,0.0000667021,0.00058944797,0.000038453552,0.000030268793,0.00002202009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969952,0.000616768,0.0006723457,0.00047636783,0.0009072124,0.0003320796],"domain_scores_gemma":[0.9981309,0.00049757585,0.0002032736,0.00029924128,0.0007249495,0.00014403765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015405323,0.00015902493,0.0005396668,0.000389581,0.00008383949,0.00002150321,0.000099540426,0.000111901994,0.00004364743],"category_scores_gemma":[0.00018273415,0.00012461598,0.00002968258,0.0007726353,0.00034266512,0.00021004307,0.000027950078,0.0006195029,0.0000022602394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031426862,0.008820508,0.8866495,0.000071197486,0.00005268098,0.000008158544,0.0014298257,0.000095477626,0.00089958304,0.000007394538,0.000058978025,0.07047984],"study_design_scores_gemma":[0.09720323,0.022045514,0.87700856,0.0003601955,0.000012651813,0.0000016530818,0.0006393817,0.00094412186,0.0014811524,0.0000305303,0.00014640148,0.00012661265],"about_ca_topic_score_codex":0.0006901478,"about_ca_topic_score_gemma":0.00068944716,"teacher_disagreement_score":0.070353225,"about_ca_system_score_codex":0.00028691077,"about_ca_system_score_gemma":0.00035366116,"threshold_uncertainty_score":0.50816923},"labels":[],"label_agreement":null},{"id":"W2001182126","doi":"10.1200/jco.2007.11.2839","title":"Docetaxel Plus Cyclophosphamide in Adjuvant Breast Cancer","year":2007,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Docetaxel; Cyclophosphamide; Oncology; Adjuvant; Breast cancer; Internal medicine; Cancer; Chemotherapy","score_opus":0.14729863909111626,"score_gpt":0.5105592915120212,"score_spread":0.3632606524209049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001182126","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019973895,0.005803116,0.00009068273,0.956895,0.009700906,0.00039220884,0.00007629995,0.000019504316,0.007048371],"genre_scores_gemma":[0.00767823,0.012054038,0.0012516957,0.9338215,0.042473234,0.000018221383,0.00001884593,0.00008842388,0.002595806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914503,0.000596376,0.005790947,0.00043548195,0.0010654455,0.0006614341],"domain_scores_gemma":[0.99043375,0.0029962035,0.0048573255,0.00040669186,0.00087799045,0.00042801883],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0049499855,0.00040382394,0.004463485,0.0005769181,0.000028214487,0.000011559627,0.00041278746,0.0034435827,0.001980738],"category_scores_gemma":[0.0009448439,0.00030504283,0.0012099954,0.00035094816,0.00048326116,0.00011941724,0.00006128722,0.0122195175,0.00007642494],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006307227,0.00046000257,0.0202581,0.00012814385,0.0004940088,0.024751019,0.000050369443,0.000027416852,0.000014566908,0.0000043920086,0.8766594,0.070845366],"study_design_scores_gemma":[0.01702731,0.0025089886,0.09588387,0.0012620847,0.00039040647,0.004561514,0.000018384448,0.00001027377,0.00001857451,0.00025316825,0.8778175,0.0002479379],"about_ca_topic_score_codex":0.00018669135,"about_ca_topic_score_gemma":0.00012272823,"teacher_disagreement_score":0.07562577,"about_ca_system_score_codex":0.0022406569,"about_ca_system_score_gemma":0.009089485,"threshold_uncertainty_score":0.99994016},"labels":[],"label_agreement":null},{"id":"W2004355892","doi":"10.1016/j.humpath.2013.11.024","title":"B-lymphoblastic leukemia/lymphoma: overexpression of nuclear DNA repair protein PARP-1 correlates with antiapoptotic protein Bcl-2 and complex chromosomal abnormalities","year":2014,"lang":"en","type":"article","venue":"Human Pathology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Calgary; Calgary Laboratory Services","funders":"","keywords":"Poly ADP ribose polymerase; Biology; Cancer research; DNA repair; Molecular biology; Lymphoma; Nuclear protein; Apoptosis; Karyotype; PARP1; Genome instability; DNA damage; DNA; Genetics; Polymerase; Chromosome; Immunology; Gene; Transcription factor","score_opus":0.016481180279523302,"score_gpt":0.24973734998110414,"score_spread":0.23325616970158083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004355892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575186,0.00014555713,0.000118362936,0.00009170246,0.000052808842,0.00094037334,0.000016695294,0.00024381978,0.0026388129],"genre_scores_gemma":[0.9972363,0.000009625627,0.0015755491,0.00025279378,0.00016540897,0.000117554504,0.000041108924,0.00007036915,0.0005312882],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980118,0.0002647529,0.00052624306,0.0005015599,0.00029633215,0.000399261],"domain_scores_gemma":[0.9987853,0.000070498914,0.0003436423,0.0005289871,0.00012797065,0.00014355758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027461172,0.0003052221,0.00066058064,0.00015933052,0.00021258397,0.000015827598,0.00011306182,0.00022086562,0.0004008833],"category_scores_gemma":[0.00006324145,0.00024854392,0.00009291444,0.0001176126,0.0009283058,0.00011877819,0.000086015025,0.0001803953,0.000026408834],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010243277,0.0002505129,0.0032951178,0.0007878636,0.00006922538,0.0001359828,0.0010592705,0.000012764681,0.9827564,0.009643455,0.00065935,0.0003057487],"study_design_scores_gemma":[0.07049161,0.03002367,0.4293404,0.015268567,0.0006599292,0.010545965,0.0019251865,0.0064956513,0.40950835,0.008507016,0.014454695,0.00277898],"about_ca_topic_score_codex":0.00003456855,"about_ca_topic_score_gemma":0.000007312582,"teacher_disagreement_score":0.573248,"about_ca_system_score_codex":0.00015632458,"about_ca_system_score_gemma":0.00011609788,"threshold_uncertainty_score":0.99999666},"labels":[],"label_agreement":null},{"id":"W2005378502","doi":"10.1139/o05-044","title":"DNA break repair: refined rules of an already complicated game","year":2005,"lang":"en","type":"review","venue":"Biochemistry and Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft; Deutscher Akademischer Austauschdienst","keywords":"Poly ADP ribose polymerase; Polymerase; DNA repair; DNA; DNA damage; Computational biology; DNA polymerase; Computer science; Biology; Cell biology; Genetics; Chemistry","score_opus":0.047080993023273135,"score_gpt":0.3568744036745696,"score_spread":0.30979341065129645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005378502","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003911038,0.988557,0.000002489087,0.000049497427,0.000056839977,0.0002991192,0.0004714647,0.00011649212,0.006536078],"genre_scores_gemma":[0.0008500108,0.99331886,0.00045345942,0.00015252446,0.00045039598,0.000066753375,0.00341811,0.000034393666,0.0012555063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834365,0.00009009772,0.0006347493,0.0005912037,0.000070607304,0.00026968768],"domain_scores_gemma":[0.99862605,0.00007916116,0.00040839793,0.0006408996,0.00007579832,0.00016971445],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016118218,0.00036227732,0.0014485973,0.00006187246,0.000032161486,0.000003949356,0.00014603036,0.00082060206,0.00028654133],"category_scores_gemma":[0.000018241646,0.00029102448,0.0003171786,0.000097529955,0.00035304305,0.000012809655,0.000053018688,0.00028580768,0.000024873243],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001839958,0.0004305935,0.0000093141725,0.01865934,0.0003207852,0.000018476445,0.000016410926,2.9397581e-8,0.083492644,0.00007656953,0.0022849182,0.89450693],"study_design_scores_gemma":[0.00076057063,0.00024388936,0.0000036790539,0.0019796889,0.00042472107,0.00028970122,0.0000060065468,0.0000023258763,0.026439978,0.00002593457,0.96956736,0.00025614732],"about_ca_topic_score_codex":0.000011520078,"about_ca_topic_score_gemma":4.2602093e-7,"teacher_disagreement_score":0.9672824,"about_ca_system_score_codex":0.000072720424,"about_ca_system_score_gemma":0.00022581949,"threshold_uncertainty_score":0.99995416},"labels":[],"label_agreement":null},{"id":"W2005586545","doi":"10.1016/s0300-9084(00)01194-9","title":"PARP degradation in apoptotic Syrian hamster embryo (SHE) cells compared to HL60 cell line","year":2000,"lang":"en","type":"article","venue":"Biochimie","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Ligue Contre le Cancer; Ministry of Environment","keywords":"Poly ADP ribose polymerase; Apoptosis; Molecular biology; Biology; Antibody; HL60; Hamster; Polymerase; Cell culture; DNA damage; Cleavage (geology); Chemistry; Cell biology; Biochemistry; DNA; Immunology; Genetics","score_opus":0.02326863689617148,"score_gpt":0.28451301813664187,"score_spread":0.2612443812404704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005586545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98111683,0.00022456869,0.00033448238,0.0024907128,0.0003430021,0.0007367739,0.000031835316,0.000099268735,0.014622553],"genre_scores_gemma":[0.9825145,0.000097414864,0.0024645186,0.0041545187,0.0003753576,0.000058624377,0.000110051515,0.000040576975,0.010184438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984726,0.00006697242,0.00043802182,0.00038751937,0.00028518404,0.00034973942],"domain_scores_gemma":[0.9991832,0.000044367815,0.00006132898,0.00042756644,0.000051306826,0.00023227505],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000171572,0.00021031905,0.00033092636,0.00020117135,0.000049737646,0.000029950494,0.00011980204,0.000112041445,0.0030067898],"category_scores_gemma":[0.000010154075,0.00020183457,0.0000819035,0.00038378593,0.000042654894,0.00007300652,0.000016079755,0.00018036172,0.0015315794],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021389534,0.0012913618,0.002583664,0.00024041142,0.000055818728,0.000086533655,0.0013829179,0.0015642993,0.91161263,0.000055018445,0.060688272,0.018300094],"study_design_scores_gemma":[0.007856814,0.0005336216,0.02552966,0.00045477625,0.000060279875,0.000023892435,0.00013510039,0.00092166226,0.892829,0.000108853485,0.071022004,0.000524354],"about_ca_topic_score_codex":0.00010300303,"about_ca_topic_score_gemma":0.00006804203,"teacher_disagreement_score":0.022945996,"about_ca_system_score_codex":0.00020034827,"about_ca_system_score_gemma":0.000089585585,"threshold_uncertainty_score":0.9992458},"labels":[],"label_agreement":null},{"id":"W2006379287","doi":"10.1155/2010/151750","title":"The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Poly ADP ribose polymerase; Medicine; Ovarian cancer; Cancer research; DNA repair; Synthetic lethality; Polymerase; Cancer; Homologous recombination; PARP inhibitor; Epithelial ovarian cancer; DNA Damage Repair; Mechanism (biology); Bioinformatics; Internal medicine; DNA; Biology; Genetics","score_opus":0.023941851724949215,"score_gpt":0.3706857974250996,"score_spread":0.3467439457001504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006379287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96836156,0.005302764,0.000015514386,0.023157565,0.00047985787,0.0002018464,0.0000050175217,0.0000020376542,0.0024738428],"genre_scores_gemma":[0.9933966,0.0051197316,0.00019134524,0.0004867784,0.0007491344,0.000008164184,3.5573524e-7,0.0000053427166,0.0000425516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987406,0.00017085811,0.00064218114,0.00006082458,0.00023927582,0.00014626293],"domain_scores_gemma":[0.9988018,0.00024310547,0.00062964315,0.00013951803,0.0001453784,0.00004054829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005746418,0.00008119501,0.00038044152,0.00010895137,0.00003926333,0.0000029763094,0.000114212664,0.0000719387,0.000057215853],"category_scores_gemma":[0.000034481884,0.000040099138,0.00015305728,0.00017368594,0.000101485464,0.00003513006,0.0000033070664,0.0001662242,7.0424414e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040132585,0.0021053606,0.016361982,0.000012197231,0.00027951127,0.00013970844,0.015120443,0.00032509922,0.16783461,0.001001377,0.0023402462,0.7904662],"study_design_scores_gemma":[0.017322956,0.024194071,0.11707051,0.00032422174,0.0002995489,0.00065273815,0.005469172,0.00008411519,0.14460175,0.0054603373,0.68439215,0.00012842352],"about_ca_topic_score_codex":0.00009066304,"about_ca_topic_score_gemma":0.00009255657,"teacher_disagreement_score":0.7903378,"about_ca_system_score_codex":0.00035656395,"about_ca_system_score_gemma":0.00042702167,"threshold_uncertainty_score":0.16351955},"labels":[],"label_agreement":null},{"id":"W2006806309","doi":"10.1073/pnas.0606528103","title":"Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death","year":2006,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":717,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institutes of Health; University of Ottawa; National Institute of Neurological Disorders and Stroke; American Heart Association","keywords":"Apoptosis-inducing factor; Poly ADP ribose polymerase; Programmed cell death; Apoptosis; Cytoplasm; Cell biology; Mitochondrion; Biology; Chemistry; Polymerase; Biochemistry; Caspase; Enzyme","score_opus":0.05769557500955475,"score_gpt":0.32355043155891355,"score_spread":0.2658548565493588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006806309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762504,0.00046080645,0.00000122433,0.0068498375,0.00006853843,0.00025429405,0.00003146659,0.000035094203,0.01604834],"genre_scores_gemma":[0.9972505,0.00002728915,0.0010656246,0.00066675304,0.00057834963,0.000019357061,6.004805e-7,0.000011693694,0.00037984902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970948,0.000008017125,0.00051877653,0.000353769,0.001741108,0.00028354494],"domain_scores_gemma":[0.99881464,0.00014958414,0.000612484,0.00001633108,0.0003320032,0.000074926174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068004447,0.00017189233,0.0002887011,0.00029572714,0.00024323985,0.000026812135,0.0005294259,0.00014801223,0.0000757853],"category_scores_gemma":[0.00016692915,0.00011829343,0.00014502682,0.0008660643,0.0004924709,0.00040692824,0.000078145014,0.00026749214,0.0000050005897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028764702,0.000087428074,0.022940367,0.00006558343,0.000014210795,7.361028e-9,0.00012789997,0.0000031481227,0.97113776,0.0044766683,0.00092208857,0.00019606495],"study_design_scores_gemma":[0.0005699725,0.00008651021,0.08344974,0.00015749961,0.00002259072,0.000008540285,0.00009878747,0.0000899718,0.90889734,0.006389488,0.00011782967,0.000111730275],"about_ca_topic_score_codex":0.00006467342,"about_ca_topic_score_gemma":7.5646085e-8,"teacher_disagreement_score":0.062240437,"about_ca_system_score_codex":0.00011226183,"about_ca_system_score_gemma":0.00012246854,"threshold_uncertainty_score":0.4823866},"labels":[],"label_agreement":null},{"id":"W2009660891","doi":"10.1021/pr800810n","title":"Proteomic Investigation of Phosphorylation Sites in Poly(ADP-ribose) Polymerase-1 and Poly(ADP-ribose) Glycohydrolase","year":2008,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Phosphorylation; Poly ADP ribose polymerase; Protein phosphorylation; Biology; Serine; Biochemistry; Phosphorylation cascade; DNA damage; Polymerase; Kinase; Proteomics; Cell biology; Enzyme; Protein kinase A; DNA; Gene","score_opus":0.10344201272352482,"score_gpt":0.3800537402206966,"score_spread":0.2766117274971718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009660891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870715,0.004571115,0.00018276564,0.006334902,0.000091209746,0.0015307964,0.000016553924,0.000016910653,0.0001842362],"genre_scores_gemma":[0.9939913,0.0008517674,0.003768409,0.00011542451,0.00076551473,0.00008770558,0.0000114985205,0.0000471919,0.00036117318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956513,0.00055148645,0.0011771938,0.00032457063,0.0017465231,0.0005489118],"domain_scores_gemma":[0.9974368,0.00024083427,0.00062333693,0.0003468508,0.00091603835,0.0004361327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003090352,0.00023339887,0.0006501407,0.0016678249,0.00018825417,0.00003367512,0.00021115488,0.00023439174,0.00020054137],"category_scores_gemma":[0.0006713757,0.0002053066,0.00014298876,0.0013509935,0.00070756924,0.0005395075,0.000074062395,0.0012865842,0.000017259534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026060732,0.0002131912,0.09840178,0.00026122414,0.00007052751,0.00022423112,0.0015124063,0.0000069362313,0.8943961,0.00003917671,0.00075192226,0.0015163806],"study_design_scores_gemma":[0.0059965486,0.0019956126,0.11409018,0.0009935166,0.000022430575,0.0010307794,0.00014832034,0.0003914514,0.8735227,0.001336939,0.00028768412,0.00018385332],"about_ca_topic_score_codex":0.00032296174,"about_ca_topic_score_gemma":0.0000073831193,"teacher_disagreement_score":0.020873465,"about_ca_system_score_codex":0.0005281561,"about_ca_system_score_gemma":0.001287506,"threshold_uncertainty_score":0.83721596},"labels":[],"label_agreement":null},{"id":"W2009754997","doi":"10.1016/j.semradonc.2010.06.001","title":"Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets","year":2010,"lang":"en","type":"review","venue":"Seminars in Radiation Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Synthetic lethality; Poly ADP ribose polymerase; PTEN; DNA repair; Cancer research; DNA damage; PARP inhibitor; Medicine; Polymerase; Olaparib; Biology; DNA; Genetics; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.058787435616739596,"score_gpt":0.4350381243465812,"score_spread":0.3762506887298416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009754997","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00067507173,0.9816484,0.0043397797,0.004929219,0.001883385,0.0048313923,0.00026011158,0.00011794375,0.0013147019],"genre_scores_gemma":[0.0009670672,0.98084104,0.007951096,0.0024276616,0.0010395049,0.0040242104,0.0022099214,0.00016132784,0.00037817258],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942503,0.0009487175,0.0023030543,0.0011923924,0.00040627908,0.0008992363],"domain_scores_gemma":[0.99561536,0.0017686245,0.0015424538,0.00062436564,0.00018365172,0.00026551858],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023974474,0.0007543614,0.0031053254,0.001840142,0.00017027925,0.000032161217,0.00024280451,0.0028463188,0.0001550189],"category_scores_gemma":[0.0011365904,0.0008109493,0.00049607863,0.0009864114,0.00030841568,0.00024313094,0.00006828383,0.0017303991,0.00007451531],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003951116,0.0005042717,0.000040444877,0.0029090561,0.00007039374,0.00012117838,0.0012810205,0.000053726388,0.00011657141,0.0014753017,0.0014181774,0.99161476],"study_design_scores_gemma":[0.00535671,0.000746907,0.000029730274,0.0067098667,0.00035747854,0.0005730001,0.00006919702,0.004653259,0.00043354827,0.0018167566,0.9785349,0.0007186808],"about_ca_topic_score_codex":0.00014783989,"about_ca_topic_score_gemma":0.00031795359,"teacher_disagreement_score":0.99089605,"about_ca_system_score_codex":0.009879724,"about_ca_system_score_gemma":0.009684569,"threshold_uncertainty_score":0.9994341},"labels":[],"label_agreement":null},{"id":"W2011441939","doi":"10.1093/annonc/mdv095.7","title":"Identifying ATMic non-small cell lung cancer cell lines: Implications for designing clinical trials","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.6213517073570092,"score_gpt":0.602548487235175,"score_spread":0.01880322012183422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011441939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7771961,0.020379804,0.14662185,0.028789911,0.0035126214,0.0051443353,0.00029422477,0.0001518166,0.01790934],"genre_scores_gemma":[0.95284456,0.0061813807,0.028151417,0.007770341,0.0024310714,0.0011828202,0.00007563141,0.00007208068,0.0012907254],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972861,0.00043204633,0.0014519655,0.00035995673,0.00012361362,0.0003463522],"domain_scores_gemma":[0.9953185,0.0021245268,0.00093693426,0.00036360027,0.00096282054,0.0002936406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005346893,0.00016371011,0.0010485167,0.000097257194,0.00006371044,0.000010345876,0.00017723754,0.00031341196,0.00008900639],"category_scores_gemma":[0.0008218569,0.00015055414,0.00039206663,0.00015769481,0.00011098073,0.00008739945,0.00003909351,0.00020437971,0.000014033385],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037812376,0.0021900972,0.05714513,0.0009080767,0.00061322836,0.000013342096,0.0027213146,0.00025934487,0.27480432,0.00029182585,0.5880852,0.069186874],"study_design_scores_gemma":[0.049033638,0.010714643,0.016057368,0.0008217625,0.0017322234,0.000052073,0.0021517766,0.001806854,0.6246307,0.0059706056,0.28614053,0.00088783266],"about_ca_topic_score_codex":0.00014663722,"about_ca_topic_score_gemma":0.000063630694,"teacher_disagreement_score":0.34982637,"about_ca_system_score_codex":0.00016139972,"about_ca_system_score_gemma":0.0016325052,"threshold_uncertainty_score":0.61394197},"labels":[],"label_agreement":null},{"id":"W2013718737","doi":"10.4161/cc.29212","title":"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines","year":2014,"lang":"en","type":"article","venue":"Cell Cycle","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Alberta Innovates - Health Solutions; University of Calgary","keywords":"Olaparib; Cancer research; Biology; PARP inhibitor; Poly ADP ribose polymerase; Cancer; Cancer cell; Ovarian cancer; Molecular biology; Polymerase; Biochemistry; Enzyme; Genetics","score_opus":0.0072295530506883395,"score_gpt":0.23552803388316249,"score_spread":0.22829848083247414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013718737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627364,0.0005164025,0.001452527,0.000105629086,0.00004971723,0.00040244663,0.000006276444,0.000027774257,0.0011655657],"genre_scores_gemma":[0.9984471,0.00014369925,0.00093131344,0.00008398174,0.0000858297,0.000051915315,0.000009742236,0.000020476436,0.00022589376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992218,0.000069650676,0.00017756644,0.00021839993,0.00015523833,0.0001573638],"domain_scores_gemma":[0.9995047,0.000055329034,0.00012513892,0.00017343635,0.00006959036,0.00007184694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001777897,0.00011700154,0.00022876814,0.00005353953,0.00003098843,0.000005935541,0.000022812561,0.00007941675,0.0000644477],"category_scores_gemma":[0.000013024589,0.00009414901,0.00002289265,0.0001332136,0.00007176445,0.00007667317,0.000017294866,0.00013368305,0.0000045882516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003854086,0.00018887137,0.07508028,0.00027627303,0.000003506058,0.000006716856,0.00024006411,0.00046345664,0.9218761,0.0000035327587,0.0001225933,0.0013532013],"study_design_scores_gemma":[0.0033292517,0.00028653615,0.03174275,0.00076098414,0.000015367494,0.000010238264,0.00007327719,0.0031067715,0.9603427,0.000045883873,0.00017487865,0.0001113847],"about_ca_topic_score_codex":0.00037921907,"about_ca_topic_score_gemma":0.00021033996,"teacher_disagreement_score":0.043337535,"about_ca_system_score_codex":0.00006543168,"about_ca_system_score_gemma":0.0000458151,"threshold_uncertainty_score":0.3839285},"labels":[],"label_agreement":null},{"id":"W2014973711","doi":"10.1016/j.radonc.2011.08.013","title":"The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination","year":2011,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"Terry Fox Foundation; Ontario Ministry of Health and Long-Term Care","keywords":"Homologous recombination; Receptor tyrosine kinase; Tyrosine kinase; Cancer research; Homologous chromosome; Tyrosine-kinase inhibitor; Recombination; Cell biology; Chemistry; Receptor; Kinase; Medicine; Biology; Internal medicine; Biochemistry; Gene; Cancer","score_opus":0.020939633045099864,"score_gpt":0.2804133283281839,"score_spread":0.259473695283084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014973711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98249584,0.0072507486,0.00011420305,0.0077775624,0.00063477043,0.000923561,0.000030520067,0.000083615545,0.00068916404],"genre_scores_gemma":[0.9692071,0.01158897,0.0076803477,0.009218365,0.00075289037,0.0003209258,0.000035009925,0.00009620994,0.0011001516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980781,0.0002948932,0.0005363745,0.0004807534,0.00016126249,0.0004485834],"domain_scores_gemma":[0.9988594,0.00042130786,0.00020136734,0.00021996969,0.00009458867,0.00020336837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085087767,0.00027878254,0.0005554225,0.00016362591,0.0002475639,0.00003684759,0.00008115199,0.00020174938,0.00018394181],"category_scores_gemma":[0.00007242985,0.00022312973,0.000054898996,0.00028891148,0.00040508984,0.000108561144,0.000026492206,0.00033211903,0.000008127302],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033598866,0.00049118773,0.004001332,0.00006751737,0.00012090022,0.000106784806,0.0105511695,0.0000010916397,0.7952079,0.0005092422,0.031441595,0.15414137],"study_design_scores_gemma":[0.013338712,0.004962246,0.0042704106,0.00031302244,0.000033202956,0.00055934885,0.001751637,0.00010965328,0.6126988,0.00061045197,0.36076537,0.0005871462],"about_ca_topic_score_codex":0.00009820555,"about_ca_topic_score_gemma":0.00008430462,"teacher_disagreement_score":0.32932377,"about_ca_system_score_codex":0.0005051442,"about_ca_system_score_gemma":0.000113656555,"threshold_uncertainty_score":0.9098966},"labels":[],"label_agreement":null},{"id":"W2015264243","doi":"10.1016/j.ejmech.2015.03.067","title":"Towards small molecule inhibitors of mono-ADP-ribosyltransferases","year":2015,"lang":"en","type":"article","venue":"European Journal of Medicinal Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Structural Genomics Consortium; Cancerfonden; Svenska Forskningsrådet Formas; Vetenskapsrådet; Stiftelsen för Strategisk Forskning","keywords":"ADP-ribosylation; PARP1; Chemistry; Poly ADP ribose polymerase; Diphtheria toxin; Small molecule; Transferase; Polymerase; Biochemistry; Intracellular; DNA damage; DNA; Enzyme; Toxin; NAD+ kinase","score_opus":0.047623411694460153,"score_gpt":0.28398203375976977,"score_spread":0.2363586220653096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015264243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9510791,0.003562935,0.0012740474,0.0019216103,0.0003502146,0.0000833155,0.000009031177,0.00002365113,0.041696142],"genre_scores_gemma":[0.99634475,0.0002279474,0.00095243717,0.00045494872,0.0016886594,8.3224467e-7,0.0000071424192,0.000046997222,0.00027630365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99778104,0.00013791278,0.00090187695,0.00016289449,0.0007951881,0.00022108313],"domain_scores_gemma":[0.99797654,0.0000368832,0.0004591169,0.00025958734,0.0006558449,0.0006120502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013300579,0.00020395256,0.0005118418,0.000088361136,0.000022148995,0.000008348449,0.00024106966,0.000050734732,0.00029152448],"category_scores_gemma":[0.00026900333,0.00016481648,0.00022191621,0.00019591548,0.0002254184,0.00006168944,0.000026795231,0.0005334553,0.000011099623],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021801626,0.0004044184,0.0031052125,0.0004842601,0.0003231665,0.003489448,0.0017627801,0.000040522773,0.9431708,0.000009087687,0.02737484,0.017655306],"study_design_scores_gemma":[0.007147952,0.0013029183,0.0010057724,0.0011470466,0.00018889568,0.0028955557,0.0013888313,0.0000065205045,0.97108006,0.000032882774,0.0136440145,0.00015955773],"about_ca_topic_score_codex":0.0000066826,"about_ca_topic_score_gemma":2.1154577e-7,"teacher_disagreement_score":0.04526568,"about_ca_system_score_codex":0.00013266571,"about_ca_system_score_gemma":0.00060941617,"threshold_uncertainty_score":0.6721021},"labels":[],"label_agreement":null},{"id":"W2016807397","doi":"10.1002/dmrr.842","title":"PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes","year":2008,"lang":"en","type":"article","venue":"Diabetes/Metabolism Research and Reviews","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Poly ADP ribose polymerase; Oxidative stress; Endocrinology; Diabetic retinopathy; Diabetic nephropathy; Internal medicine; Kidney; Biology; Diabetes mellitus; Chemistry; Cell biology; Medicine; Biochemistry; Polymerase","score_opus":0.06665324421785553,"score_gpt":0.3559398213198268,"score_spread":0.2892865771019713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016807397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8917794,0.10463909,0.000008146803,0.0012409613,0.00001723446,0.0022399225,0.000010165894,0.0000052545447,0.000059826292],"genre_scores_gemma":[0.9431931,0.055882584,0.0002293895,0.00007939352,0.000064790314,0.0003612536,0.00001994218,0.000014496174,0.00015505514],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997689,0.0008172269,0.00048665883,0.00034347348,0.00032009016,0.00034354566],"domain_scores_gemma":[0.9989595,0.00038691115,0.00014729015,0.0002100918,0.000116000134,0.00018023187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025207063,0.0001780472,0.0006972412,0.0003262364,0.00013222623,0.00003135529,0.000052329327,0.00010222946,0.00002186689],"category_scores_gemma":[0.0007812831,0.00010827644,0.000036614336,0.00046617002,0.000796382,0.00023952781,0.00005662065,0.00046142738,8.814322e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004258538,0.00019548651,0.47160435,0.0016264794,0.000066482055,0.0000050097083,0.0042667105,2.9217446e-7,0.5082044,0.0015689348,0.00029368943,0.011742318],"study_design_scores_gemma":[0.011384815,0.00046934583,0.5420602,0.0032640996,0.000056974175,0.0000064489295,0.0003912267,0.0006132526,0.4251933,0.0029473035,0.013264378,0.000348661],"about_ca_topic_score_codex":0.00007535704,"about_ca_topic_score_gemma":0.000004057315,"teacher_disagreement_score":0.08301111,"about_ca_system_score_codex":0.0000316344,"about_ca_system_score_gemma":0.000066566565,"threshold_uncertainty_score":0.4415385},"labels":[],"label_agreement":null},{"id":"W2017215338","doi":"10.1093/nar/gkt134","title":"The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair","year":2013,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Biology; DNA; Phosphorylation; Cell biology; Genetics; DNA repair; DNA-binding protein; Computational biology; Molecular biology; Biophysics; Gene; Transcription factor","score_opus":0.058401109356597834,"score_gpt":0.3588384656213614,"score_spread":0.3004373562647636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017215338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822029,0.0027707971,0.00003441179,0.0034778093,0.000076004704,0.001154514,0.000018115023,0.00007968586,0.010185799],"genre_scores_gemma":[0.99324596,0.0016892565,0.00025014573,0.00006668754,0.00009671247,0.00018021338,0.000010530381,0.000025921472,0.0044345604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762946,0.00016787746,0.00037906622,0.0003327285,0.0010426037,0.00044826235],"domain_scores_gemma":[0.9981,0.0004740992,0.00006402179,0.00054992264,0.0006166809,0.00019527842],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015537527,0.00013437611,0.00023700875,0.000116209885,0.00032314993,0.000063518404,0.00015755802,0.00012647001,0.0009668993],"category_scores_gemma":[0.00013094571,0.000092007744,0.000086871936,0.00030380543,0.0007358824,0.00016614111,0.00008383849,0.00044064785,0.00018961649],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009969854,0.00081436697,0.13493194,0.0013516358,0.00089367945,0.00005385095,0.010536012,0.00002767814,0.57320815,0.0069606365,0.08732464,0.17392753],"study_design_scores_gemma":[0.02591217,0.0036691928,0.35379592,0.0008527044,0.00009984594,0.00020991871,0.009580471,0.0035724575,0.41025397,0.015140939,0.17615694,0.00075545645],"about_ca_topic_score_codex":0.0005377105,"about_ca_topic_score_gemma":0.000025605546,"teacher_disagreement_score":0.218864,"about_ca_system_score_codex":0.00014102536,"about_ca_system_score_gemma":0.00013155057,"threshold_uncertainty_score":0.99994636},"labels":[],"label_agreement":null},{"id":"W2018329608","doi":"10.1074/jbc.m708558200","title":"A Third Zinc-binding Domain of Human Poly(ADP-ribose) Polymerase-1 Coordinates DNA-dependent Enzyme Activation","year":2007,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Thomas Jefferson University","keywords":"Poly ADP ribose polymerase; Zinc finger; DNA-binding domain; DNA repair; Biology; Chromatin; Polymerase; HMG-box; Cell biology; DNA clamp; DNA; Molecular biology; Biochemistry; Chemistry; DNA-binding protein; Transcription factor; RNA; Reverse transcriptase; Gene","score_opus":0.03368635474612415,"score_gpt":0.321912345880612,"score_spread":0.2882259911344879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018329608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414605,0.0005268378,0.00068818824,0.00094047934,0.000101503225,0.00009110773,0.000015395457,0.00002450326,0.0034659568],"genre_scores_gemma":[0.9978235,0.000041685358,0.00052738003,0.00025713418,0.001005975,0.0000021699761,0.000027103139,0.000013225541,0.00030183973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981909,0.000040276263,0.000872405,0.00018591824,0.0004176512,0.00029287775],"domain_scores_gemma":[0.9983193,0.00020286298,0.00087630725,0.00017276999,0.00021089558,0.0002178162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009717858,0.00018779894,0.00051275245,0.000088921915,0.00008140762,0.000012136378,0.00017480155,0.00030930623,0.00058474625],"category_scores_gemma":[0.00016559,0.00013505529,0.0002496604,0.0001857338,0.00019017079,0.00008027035,0.000037472586,0.0005193098,0.0000033927809],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087586005,0.00028178352,0.0073923287,0.000059211237,0.000105824176,0.00009046536,0.00007946179,5.204008e-7,0.9898586,0.000050324743,0.0005855434,0.0006200352],"study_design_scores_gemma":[0.0024693925,0.0005460092,0.0051364005,0.0003001303,0.000029662238,0.0004545177,0.00046751744,6.4723235e-7,0.98902553,0.00055295974,0.000882095,0.0001351496],"about_ca_topic_score_codex":0.0000063637503,"about_ca_topic_score_gemma":2.462505e-7,"teacher_disagreement_score":0.0036774587,"about_ca_system_score_codex":0.000283015,"about_ca_system_score_gemma":0.000087667766,"threshold_uncertainty_score":0.6402561},"labels":[],"label_agreement":null},{"id":"W2020134182","doi":"10.1159/000104683","title":"Poly(ADP-Ribose) Polymerase Offers Protection against Oxidative and Alkylation Damage to the Nuclear and Mitochondrial Genomes of the Retinal Pigment Epithelium","year":2007,"lang":"en","type":"article","venue":"Ophthalmic Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Advanced Micro Devices (Canada)","funders":"Sight Research UK; Wellcome Trust; National Research Centre","keywords":"Poly ADP ribose polymerase; Biology; Oxidative stress; Mitochondrial DNA; DNA damage; Mitochondrion; Molecular biology; Oxidative phosphorylation; Retinal pigment epithelium; DNA repair; PARP inhibitor; Mitochondrial ROS; Polymerase; Cell biology; Biochemistry; Retinal; Enzyme; DNA; Gene","score_opus":0.06077394699861609,"score_gpt":0.36946880399951526,"score_spread":0.30869485700089916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020134182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98414624,0.0005495183,0.00013303987,0.010142119,0.0001816273,0.0018136163,0.00002220268,0.000013114494,0.002998531],"genre_scores_gemma":[0.99801916,0.00013517287,0.00029855536,0.00021362686,0.0004937851,0.000055936132,0.000005136388,0.00002655101,0.0007520854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793047,0.00034085373,0.0002783097,0.00032052977,0.0007816427,0.0003481819],"domain_scores_gemma":[0.99891686,0.0001932728,0.00009357408,0.00042141668,0.00021939166,0.00015546803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015187009,0.00012856397,0.00017637489,0.00021340376,0.00038331444,0.000041163,0.00015090362,0.000085399275,0.000093371935],"category_scores_gemma":[0.00019370842,0.00008061612,0.0000494037,0.00045470134,0.00044990287,0.00007862886,0.00014303702,0.00046572313,0.000012685648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022456166,0.00008352719,0.001432648,0.00006453685,0.000051051386,0.000016106393,0.003161664,0.000002982775,0.9699335,0.00019742468,0.00063443236,0.02217648],"study_design_scores_gemma":[0.004504691,0.0022503145,0.2056608,0.0006081339,0.00004226148,0.00028957776,0.00507686,0.0004392667,0.766039,0.000485441,0.014313722,0.00028993597],"about_ca_topic_score_codex":0.00024300153,"about_ca_topic_score_gemma":0.000011739502,"teacher_disagreement_score":0.20422816,"about_ca_system_score_codex":0.00019617604,"about_ca_system_score_gemma":0.00011161595,"threshold_uncertainty_score":0.32874298},"labels":[],"label_agreement":null},{"id":"W2021073550","doi":"10.1523/jneurosci.2499-14.2014","title":"Poly(ADP-Ribose) Polymerase-1 Causes Mitochondrial Damage and Neuron Death Mediated by Bnip3","year":2014,"lang":"en","type":"article","venue":"Journal of Neuroscience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; University of Manitoba; Health Sciences Centre","funders":"Research Manitoba; Heart and Stroke Foundation of Canada","keywords":"PARP1; Mitochondrial permeability transition pore; NAD+ kinase; Sirtuin 1; Poly ADP ribose polymerase; Cell biology; Programmed cell death; Biology; Nicotinamide adenine dinucleotide; Mitochondrion; Apoptosis-inducing factor; Molecular biology; Apoptosis; Polymerase; Biochemistry; Downregulation and upregulation; Caspase; Enzyme","score_opus":0.025181586470521815,"score_gpt":0.3008656184239622,"score_spread":0.2756840319534404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021073550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98695576,0.0008195061,0.0012645028,0.008195236,0.0022701656,0.00013542273,0.000022039545,0.000031382144,0.00030597456],"genre_scores_gemma":[0.98732734,0.0003994905,0.00032907096,0.010615647,0.0009426959,0.0000021943958,0.0000015325808,0.000024717696,0.00035729722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818295,0.00013688575,0.00044607607,0.00026625494,0.0006753401,0.00029248276],"domain_scores_gemma":[0.99866533,0.00021134986,0.000380785,0.00022434493,0.00012165233,0.0003965445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026092626,0.00016705878,0.00032729103,0.00018953018,0.00012975791,0.000070071,0.00021095123,0.000059691236,0.000032141783],"category_scores_gemma":[0.0006775296,0.00013248326,0.000078840996,0.00029575877,0.0002692816,0.00033855773,0.000038510378,0.0003635257,0.0000046913956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021344499,0.000092698385,0.0035653196,0.000010606272,0.000003905904,0.00008571707,0.000063781794,0.000001667145,0.9870862,0.000030678286,0.008072801,0.0007732264],"study_design_scores_gemma":[0.012357562,0.0069829673,0.22624795,0.00037602297,0.00017419306,0.0051990882,0.00006333484,0.001736152,0.47751674,0.0002501007,0.26848948,0.00060640916],"about_ca_topic_score_codex":0.000014261386,"about_ca_topic_score_gemma":0.0000011141741,"teacher_disagreement_score":0.5095694,"about_ca_system_score_codex":0.00004250187,"about_ca_system_score_gemma":0.00014987153,"threshold_uncertainty_score":0.540251},"labels":[],"label_agreement":null},{"id":"W2021253518","doi":"10.1158/1535-7163.targ-09-a115","title":"Abstract A115: Contextual synthetic lethality: Repair-deficient hypoxic tumor cells are sensitized to poly(ADP-ribose) polymerase (PARP) inhibition","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"PARP1; Poly ADP ribose polymerase; Synthetic lethality; PARP inhibitor; RAD51; Cancer research; Cancer cell; Hypoxia (environmental); Biology; DNA repair; Clonogenic assay; Homologous recombination; Molecular biology; Programmed cell death; DNA damage; Polymerase; Cell culture; Chemistry; Cancer; Apoptosis; DNA; Genetics","score_opus":0.031868384040929426,"score_gpt":0.30876111917182025,"score_spread":0.27689273513089085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021253518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646206,0.008536669,0.003585476,0.018217618,0.0008212927,0.0016837005,0.00040088574,0.0006559149,0.0014778265],"genre_scores_gemma":[0.93038225,0.0002374247,0.0010624191,0.06726926,0.00047933235,0.00012770592,0.00005574039,0.00012659574,0.00025926766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958241,0.00021301008,0.0008871914,0.0010360052,0.0010896464,0.00095003104],"domain_scores_gemma":[0.9973989,0.00008893897,0.00039292307,0.0011987424,0.00037850114,0.00054199377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044508628,0.0006665506,0.0008924375,0.0003454599,0.00022267908,0.000087511144,0.00017924767,0.00025218487,0.00037796923],"category_scores_gemma":[0.000033172564,0.00067277305,0.0005560719,0.000671489,0.00020213444,0.000107022825,0.000045082306,0.0005795353,0.0001693181],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001438131,0.0006970439,0.000080285194,0.0000859706,0.00029554314,0.0010641199,0.0006131374,0.00018921665,0.98130536,0.00024334964,0.0011164409,0.012871378],"study_design_scores_gemma":[0.004526033,0.0008234211,0.002144115,0.00083202554,0.00043295496,0.00022292766,0.00040162186,0.0002339252,0.9641599,0.00026807887,0.02512488,0.00083013164],"about_ca_topic_score_codex":0.00018457565,"about_ca_topic_score_gemma":0.000023302016,"teacher_disagreement_score":0.049051642,"about_ca_system_score_codex":0.0008257849,"about_ca_system_score_gemma":0.00039500452,"threshold_uncertainty_score":0.99957234},"labels":[],"label_agreement":null},{"id":"W2021699091","doi":"10.1016/j.molmed.2005.08.003","title":"Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy","year":2005,"lang":"en","type":"review","venue":"Trends in Molecular Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; University of Alberta; Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; DNA repair; DNA damage; Polymerase; Ribose; Cancer; PARP inhibitor; DNA Damage Repair; Cancer research; Biology; Optimism; DNA; Computational biology; Chemistry; Biochemistry; Enzyme; Genetics","score_opus":0.10704043611075453,"score_gpt":0.4363044159069052,"score_spread":0.3292639797961507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021699091","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004683958,0.98857635,0.00050793804,0.002009358,0.00035566423,0.0012787369,0.000018040271,0.000105385625,0.0071016764],"genre_scores_gemma":[0.00015802812,0.99068004,0.00352385,0.0012437261,0.0016072955,0.0009425291,0.00083006115,0.00021118658,0.0008032728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99501455,0.00045003797,0.0017491258,0.001105471,0.0009188629,0.0007619646],"domain_scores_gemma":[0.9979071,0.00010337997,0.00062395894,0.001041398,0.00009462015,0.0002295276],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011128294,0.0008845697,0.0032985932,0.0021158347,0.000053590866,0.00001755911,0.0004509522,0.00051466166,0.0013640365],"category_scores_gemma":[0.00012238679,0.0006889999,0.00038855735,0.002919459,0.00024334656,0.00008785113,0.000071003305,0.0015213877,0.000012798121],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008496824,0.00027761696,0.000039750674,0.0025304703,0.0001746912,0.0003150889,0.0006492044,0.0000292975,0.00018034465,0.000064379055,0.00145474,0.99419945],"study_design_scores_gemma":[0.0071970653,0.0002803539,0.00007104785,0.037075926,0.00038242777,0.00023873858,0.00009107355,0.00020209131,0.000039353617,0.0000400559,0.95369804,0.00068381306],"about_ca_topic_score_codex":0.00020899238,"about_ca_topic_score_gemma":0.000017294085,"teacher_disagreement_score":0.9935156,"about_ca_system_score_codex":0.0013371918,"about_ca_system_score_gemma":0.0005273735,"threshold_uncertainty_score":0.9995561},"labels":[],"label_agreement":null},{"id":"W2021897957","doi":"10.1016/j.bbrc.2005.03.135","title":"DNA vector-based RNAi approach for stable depletion of poly(ADP-ribose) polymerase-1","year":2005,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada","keywords":"RNA interference; Gene silencing; Biology; Poly ADP ribose polymerase; Polymerase; Molecular biology; Cell biology; DNA; Computational biology; Genetics; Gene; RNA","score_opus":0.12121274918728617,"score_gpt":0.4097481667440356,"score_spread":0.2885354175567494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021897957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8983314,0.010046851,0.014828457,0.06869631,0.000038650054,0.0025617972,0.00054396736,0.00017275332,0.0047797835],"genre_scores_gemma":[0.9783805,0.000291355,0.019901214,0.00024581575,0.00029966072,0.00032529017,0.00038520832,0.000019985351,0.0001509762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985213,0.00013160938,0.00028196562,0.0002712833,0.00045190557,0.00034189256],"domain_scores_gemma":[0.9978,0.0005148377,0.00005218116,0.00096852245,0.0004228064,0.0002416823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041429748,0.00012184437,0.00025668606,0.00012671645,0.0002311014,0.000022253666,0.00034812992,0.000121459496,0.000032633077],"category_scores_gemma":[0.00024679885,0.00010405364,0.00012315944,0.0004601464,0.0008163981,0.000059862105,0.00012274996,0.00036175075,0.0000075669086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041437795,0.0013434862,0.00008390534,0.00012255149,0.000034294593,9.8178624e-8,0.000038653117,0.0000010175298,0.98784107,0.003640349,0.0029665702,0.0035136298],"study_design_scores_gemma":[0.002027722,0.00039993285,0.0004583623,0.000106095315,0.000029254408,0.000002687914,0.00006909288,0.023974476,0.9591641,0.00035491373,0.013270252,0.00014311654],"about_ca_topic_score_codex":0.00008655599,"about_ca_topic_score_gemma":0.0000019172758,"teacher_disagreement_score":0.08004907,"about_ca_system_score_codex":0.00012369906,"about_ca_system_score_gemma":0.00021084493,"threshold_uncertainty_score":0.42431843},"labels":[],"label_agreement":null},{"id":"W2022309076","doi":"10.1007/s10549-012-2188-0","title":"Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Office of Science; Breast Cancer Research Foundation; Pfizer; National Cancer Institute; National Institutes of Health; Cancer Research UK; Belgian American Educational Foundation; Stand Up To Cancer; U.S. Department of Energy","keywords":"Olaparib; Synthetic lethality; Biology; DNA repair; PARP inhibitor; Homologous recombination; Cancer research; Gene; Genetics; DNA damage; Molecular biology; Poly ADP ribose polymerase; DNA; Polymerase","score_opus":0.07377723545298644,"score_gpt":0.41215573030947594,"score_spread":0.3383784948564895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022309076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905894,0.0019638934,0.000036856363,0.005488701,0.0001058283,0.0008164859,0.000704773,0.00002358358,0.00027049426],"genre_scores_gemma":[0.99664354,0.00023967621,0.00007621341,0.00016534819,0.000271597,0.00082188006,0.000035961955,0.000020871596,0.0017249223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783665,0.00018961793,0.0002945979,0.00030392673,0.0007706767,0.0006045203],"domain_scores_gemma":[0.99819624,0.00036222648,0.00007146928,0.00053278246,0.00037523053,0.00046205916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014012866,0.00018186597,0.00035988312,0.00046335245,0.00026907542,0.000066653265,0.000100647376,0.000067624795,0.0007557016],"category_scores_gemma":[0.000046011217,0.00011114965,0.00017108953,0.0011344033,0.0003620664,0.0001293928,0.000048279122,0.00014482028,0.00003395522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09567325,0.0017725215,0.8083462,0.00012414149,0.0036574386,0.000042642718,0.0021872332,0.0001465639,0.026038261,0.00012834379,0.0028064293,0.05907695],"study_design_scores_gemma":[0.0044623455,0.0012437068,0.8994439,0.00013480743,0.0002643635,0.000028172526,0.0004109532,0.00004800861,0.07731643,0.000025087527,0.016483301,0.00013892354],"about_ca_topic_score_codex":0.0024153988,"about_ca_topic_score_gemma":0.0005631603,"teacher_disagreement_score":0.0912109,"about_ca_system_score_codex":0.00075332477,"about_ca_system_score_gemma":0.0004883702,"threshold_uncertainty_score":0.82744026},"labels":[],"label_agreement":null},{"id":"W2023165782","doi":"10.1021/pr301219h","title":"Mapping PARP-1 Auto-ADP-ribosylation Sites by Liquid Chromatography–Tandem Mass Spectrometry","year":2013,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Tandem mass spectrometry; Phosphopeptide; Chemistry; Mass spectrometry; Collision-induced dissociation; Tandem; Ribose; Liquid chromatography–mass spectrometry; Chromatography; Polymerase; Peptide; Biochemistry; Enzyme","score_opus":0.06830340061477215,"score_gpt":0.37960023566018386,"score_spread":0.3112968350454117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023165782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755106,0.0029948738,0.0080205435,0.009167204,0.00011810999,0.0012888984,0.00000721375,0.000046624176,0.0028459576],"genre_scores_gemma":[0.985426,0.0008835333,0.011432532,0.00015481641,0.0010164912,0.00011246533,0.000010956158,0.0000484204,0.0009147566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959884,0.00035412432,0.00077914906,0.00024719705,0.0019785196,0.00065256126],"domain_scores_gemma":[0.9972388,0.00022466881,0.00038224718,0.00032187212,0.0014149732,0.00041744803],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030129114,0.00018180883,0.00047772814,0.0014890443,0.00020536252,0.00013429369,0.00027002537,0.00018150391,0.0030263742],"category_scores_gemma":[0.00037016987,0.00014533736,0.00024041305,0.0017262949,0.00021658593,0.0005022047,0.00004605825,0.0013804034,0.00023313503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025041963,0.00014981681,0.009872253,0.00013191733,0.00015878989,0.000046281915,0.00019607494,0.0000016959923,0.95737004,0.000033214368,0.031190647,0.00059882784],"study_design_scores_gemma":[0.0076293973,0.0073542837,0.060713124,0.0017308822,0.00004455411,0.0009913363,0.0013727888,0.00067661214,0.87537485,0.008033838,0.035542578,0.00053577503],"about_ca_topic_score_codex":0.000027195296,"about_ca_topic_score_gemma":4.5176762e-7,"teacher_disagreement_score":0.081995234,"about_ca_system_score_codex":0.0005181563,"about_ca_system_score_gemma":0.00035911982,"threshold_uncertainty_score":0.997885},"labels":[],"label_agreement":null},{"id":"W2023477758","doi":"10.1007/s10038-007-0203-9","title":"Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Human Genetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Biology; Breast cancer; Missense mutation; Genetics; Haplotype; Gene; DNA repair; Exon; Coding region; Mutation; Cancer; Genotype","score_opus":0.016895492705305215,"score_gpt":0.29635101374584943,"score_spread":0.2794555210405442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023477758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685806,0.0014705043,0.0010907758,0.00022786781,0.00005183378,0.00009108381,0.00008960484,0.0000027106903,0.00011753164],"genre_scores_gemma":[0.992833,0.0018204541,0.0050273915,0.00012236087,0.00014526836,0.0000017092738,0.0000029020243,0.000013558927,0.000033353648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887556,0.000037764403,0.0005008571,0.000112206224,0.0002855026,0.00018808234],"domain_scores_gemma":[0.9987804,0.000040016424,0.00039075725,0.00016655057,0.00040677405,0.00021548035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003040292,0.00010507671,0.0003353979,0.000831711,0.000059601913,0.000010458263,0.000079595266,0.00006423895,0.0001608122],"category_scores_gemma":[0.000010860117,0.000087119886,0.000057959547,0.0006278055,0.0001285885,0.000035419216,0.000007237939,0.00021206604,4.1783784e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006012171,0.00004414718,0.98825735,0.000018590054,0.00054662424,0.00006801081,0.00076141214,0.0034774793,0.004487095,0.00003318753,0.00006356708,0.0021824418],"study_design_scores_gemma":[0.001177667,0.00035495672,0.995623,0.000102519065,0.00087029143,0.00013770259,0.0001406916,0.00020816292,0.0010109346,0.00020100223,0.00008630415,0.00008679461],"about_ca_topic_score_codex":0.07149203,"about_ca_topic_score_gemma":0.42391634,"teacher_disagreement_score":0.35242432,"about_ca_system_score_codex":0.00025728223,"about_ca_system_score_gemma":0.00050244725,"threshold_uncertainty_score":0.934691},"labels":[],"label_agreement":null},{"id":"W2025139162","doi":"10.1016/s0027-5107(02)00188-4","title":"Niacin deficiency increases spontaneous and etoposide-induced chromosomal instability in rat bone marrow cells in vivo","year":2002,"lang":"en","type":"article","venue":"Mutation research. Fundamental and molecular mechanisms of mutagenesis","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Niacin; Genotoxicity; Poly ADP ribose polymerase; DNA damage; Bone marrow; Micronucleus test; Comet assay; Micronucleus; Sister chromatid exchange; NAD+ kinase; Chemistry; B vitamins; Biology; Endocrinology; Internal medicine; Biochemistry; Toxicity; Medicine; Immunology; DNA; Polymerase","score_opus":0.034990221326482676,"score_gpt":0.30469690955959294,"score_spread":0.2697066882331103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025139162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968227,0.0011086883,0.00022298483,0.0004307712,0.000047289403,0.0009573382,0.000044242744,0.000021871967,0.00034408752],"genre_scores_gemma":[0.9980275,0.0003304435,0.0011906481,0.00021510183,0.000010612718,0.000111888745,0.000011794819,0.000027565547,0.00007442379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750197,0.00039776243,0.0004824763,0.00050825125,0.0007067588,0.00040279783],"domain_scores_gemma":[0.99920946,0.00015719989,0.000086854896,0.00023916534,0.0001091637,0.00019813221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084559905,0.00019796238,0.0003805684,0.0005869167,0.0000971658,0.00003481945,0.000076487544,0.00013092019,0.0005139513],"category_scores_gemma":[0.0001120795,0.00020342066,0.00005929174,0.00055761734,0.00021040958,0.00011944951,0.00009410627,0.00022802803,0.000006150549],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003684109,0.0006727999,0.00082462584,0.00022235507,0.0000124370445,0.002536499,0.0006014496,0.00001764529,0.9913967,0.00044483965,0.000013880591,0.0028883528],"study_design_scores_gemma":[0.003302172,0.0010510371,0.0017982295,0.00019150859,0.000017732038,0.00070137496,0.0015207125,0.0010722785,0.9883183,0.0018073433,0.000033689656,0.00018561861],"about_ca_topic_score_codex":0.0010013968,"about_ca_topic_score_gemma":0.0002884247,"teacher_disagreement_score":0.0030784013,"about_ca_system_score_codex":0.00029177096,"about_ca_system_score_gemma":0.00008100165,"threshold_uncertainty_score":0.82952535},"labels":[],"label_agreement":null},{"id":"W2025341045","doi":"10.1016/j.exger.2011.06.005","title":"Cardiac calcium pump inactivation and nitrosylation in senescent rat myocardium are not attenuated by long-term treadmill training","year":2011,"lang":"en","type":"article","venue":"Experimental Gerontology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Phospholamban; SERCA; Ryanodine receptor; Internal medicine; Endocrinology; Calcium; Nitrotyrosine; Heart rate; Cardiac function curve; Chemistry; Medicine; Heart failure; ATPase; Nitric oxide; Nitric oxide synthase; Biochemistry; Blood pressure","score_opus":0.13338164403657157,"score_gpt":0.3489212886365668,"score_spread":0.21553964459999522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025341045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621266,0.0012661634,0.00026694412,0.0003172386,0.00032089048,0.0004943219,0.000014843446,0.00005956791,0.001047353],"genre_scores_gemma":[0.99874026,0.000037813246,0.00017165348,0.00050737854,0.00009689919,0.00016484044,0.00012988821,0.00003017816,0.00012107548],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987875,0.0001175079,0.00027081402,0.00037210275,0.0001586771,0.00029336117],"domain_scores_gemma":[0.9995129,0.000026883166,0.00012774601,0.00017854573,0.000040998377,0.00011292855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008759462,0.0002044388,0.00042713035,0.000109870176,0.000055195625,0.000008477798,0.000038326292,0.00015097577,0.00013315672],"category_scores_gemma":[0.000007434665,0.00019209753,0.000048011294,0.00010126308,0.0001451468,0.0001476959,0.000018516828,0.0001536907,0.000007897379],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017777148,0.00024981625,0.24969433,0.000017860355,0.00007211517,0.000060878752,0.0070888503,4.265955e-7,0.7393064,0.000029898609,0.00024190694,0.0014598316],"study_design_scores_gemma":[0.003243013,0.0004399026,0.30196986,0.0000616573,0.000020948197,0.000076492535,0.002181942,0.00001587044,0.6916637,0.0000035069727,0.00015984153,0.00016329],"about_ca_topic_score_codex":0.00024845416,"about_ca_topic_score_gemma":0.000041542902,"teacher_disagreement_score":0.052275535,"about_ca_system_score_codex":0.00043753907,"about_ca_system_score_gemma":0.00004558117,"threshold_uncertainty_score":0.783351},"labels":[],"label_agreement":null},{"id":"W2025577445","doi":"10.1016/j.dnarep.2005.04.015","title":"Ionizing radiations in Caenorhabditis elegans induce poly(ADP-ribosyl)ation, a conserved DNA-damage response essential for survival","year":2005,"lang":"en","type":"article","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; Biology; Caenorhabditis elegans; DNA damage; Polymerase; DNA repair; NAD+ kinase; DNA; Molecular biology; Biochemistry; Cell biology; Enzyme; Gene","score_opus":0.02809001098682897,"score_gpt":0.31764022508759715,"score_spread":0.2895502141007682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025577445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97712463,0.0004153262,0.0013800481,0.018271258,0.00047986262,0.0010483155,0.0001976147,0.00039878016,0.0006841622],"genre_scores_gemma":[0.99029475,0.00004961509,0.004197943,0.0019617465,0.00090618763,0.00036341132,0.00024238601,0.000066410386,0.0019175191],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775696,0.00032517276,0.00064279174,0.00046894382,0.0003531221,0.00045301093],"domain_scores_gemma":[0.99820817,0.00065222883,0.00018827296,0.0005151417,0.0002498485,0.00018633612],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011411359,0.0002325526,0.00039680945,0.00038408305,0.00021308611,0.000038569713,0.00011844117,0.0001949327,0.0003060439],"category_scores_gemma":[0.00076659425,0.00026145455,0.00022903841,0.0005654921,0.00012074198,0.00027411417,0.000025116153,0.00026483482,0.000053128693],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014626413,0.0017305698,0.041150484,0.00028421075,0.00053563993,0.0002546581,0.009529841,0.0003076434,0.8547744,0.0057325847,0.065468505,0.0056050126],"study_design_scores_gemma":[0.027750649,0.00095424056,0.2764763,0.0006874362,0.00022942448,0.00017801816,0.0016569935,0.0074312063,0.2914184,0.00058213307,0.3914919,0.0011432956],"about_ca_topic_score_codex":0.00023107747,"about_ca_topic_score_gemma":0.00093613315,"teacher_disagreement_score":0.56335604,"about_ca_system_score_codex":0.0005866734,"about_ca_system_score_gemma":0.000670777,"threshold_uncertainty_score":0.9999838},"labels":[],"label_agreement":null},{"id":"W2025969430","doi":"10.1016/j.bbamcr.2005.11.015","title":"Dynamic relocation of poly(ADP-ribose) glycohydrolase isoforms during radiation-induced DNA damage","year":2005,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Nucleoplasm; DNA damage; Cytoplasm; DNA repair; Fluorescence recovery after photobleaching; Gene isoform; Biology; Cell biology; DNA; Poly ADP ribose polymerase; Molecular biology; Biochemistry; Nucleolus; Gene","score_opus":0.024498622006974363,"score_gpt":0.3524104874988968,"score_spread":0.3279118654919224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025969430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825806,0.00037252496,0.00014918974,0.0066072135,0.00009767725,0.0011121234,0.000054918855,0.00011518492,0.0032330996],"genre_scores_gemma":[0.99667823,0.00042871077,0.0010525561,0.0003469029,0.00026367046,0.00012762824,0.0002545994,0.0001274788,0.00072020746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956491,0.0003782358,0.00070300925,0.00081007666,0.0015964448,0.0008631583],"domain_scores_gemma":[0.99735636,0.00015735145,0.00029499023,0.0013180419,0.00048314768,0.00039014078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000792895,0.00038179755,0.0005077836,0.0008470078,0.00025401457,0.00007485945,0.0004837324,0.0002880862,0.00013615128],"category_scores_gemma":[0.00013617032,0.00037660223,0.000302388,0.0014350429,0.00032167175,0.00029914576,0.00018393964,0.00088083517,0.00019483062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007397625,0.00069887156,0.0000061241262,0.00024262456,0.00011247799,0.000031701267,0.00057620177,0.00002100951,0.99547267,0.000100467325,0.00031578442,0.0016822922],"study_design_scores_gemma":[0.0033064627,0.00056350214,0.0030135056,0.00018668758,0.00005413807,0.000013079595,0.00009241635,0.0026886424,0.98902905,0.00013909541,0.0005751785,0.00033822324],"about_ca_topic_score_codex":0.00009153552,"about_ca_topic_score_gemma":0.000005776979,"teacher_disagreement_score":0.008420179,"about_ca_system_score_codex":0.00066001824,"about_ca_system_score_gemma":0.0006507977,"threshold_uncertainty_score":0.9998686},"labels":[],"label_agreement":null},{"id":"W2026806110","doi":"10.1074/jbc.m110.175190","title":"Double-stranded DNA Binding Domain of Poly(ADP-ribose) Polymerase-1 and Molecular Insight into the Regulation of Its Activity","year":2010,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Zinc finger; DNA; Polymerase; RNA; Binding domain; Chemistry; DNA-binding domain; Biology; Cell biology; Biochemistry; Molecular biology; Binding site; Transcription factor; Gene","score_opus":0.025123775015254993,"score_gpt":0.29623497076680416,"score_spread":0.2711111957515492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026806110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648917,0.00075956393,0.0001053985,0.0017506247,0.000074889635,0.0000899485,0.0000064623787,0.000005652527,0.0007182659],"genre_scores_gemma":[0.9990879,0.00014400289,0.00042941672,0.00006838617,0.0002312175,0.0000019641175,0.0000036653073,0.0000062393087,0.00002715678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99908286,0.00003909249,0.0004072607,0.00011743613,0.00024073607,0.000112609436],"domain_scores_gemma":[0.9989317,0.000109774446,0.000550608,0.00015477567,0.00015080578,0.00010233225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004071189,0.000114157156,0.00034156206,0.00003685792,0.000040650575,0.0000066786624,0.000105886735,0.00022286705,0.00018649081],"category_scores_gemma":[0.00009105654,0.00006578959,0.00013501149,0.00013407992,0.00027572617,0.000054132877,0.000025948666,0.00043613167,2.9851418e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014435919,0.00010409789,0.0014751075,0.0000708266,0.00006852658,0.000009496099,0.00018396118,5.1765795e-7,0.9950566,0.000039605693,0.000018234528,0.0015294249],"study_design_scores_gemma":[0.0026169475,0.00018749277,0.0070950915,0.00011559963,0.00003328336,0.00019616011,0.000057393547,0.0000061750525,0.9888415,0.00031546375,0.0004695117,0.00006537948],"about_ca_topic_score_codex":0.0000033964116,"about_ca_topic_score_gemma":3.921889e-7,"teacher_disagreement_score":0.0062151076,"about_ca_system_score_codex":0.000030953215,"about_ca_system_score_gemma":0.00007932552,"threshold_uncertainty_score":0.26828215},"labels":[],"label_agreement":null},{"id":"W2027997839","doi":"10.1007/s00216-010-3560-8","title":"Quantification of urinary AICAR concentrations as a matter of doping controls","year":2010,"lang":"en","type":"article","venue":"Analytical and Bioanalytical Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Chemistry; Urine; Chromatography; Isotope dilution; Mass spectrometry; Biochemistry","score_opus":0.018042112456983957,"score_gpt":0.31151056567344193,"score_spread":0.293468453216458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027997839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97600424,0.000114955496,0.00039663233,0.0049793553,0.000026663538,0.00012820632,0.000029444907,0.000015850044,0.018304624],"genre_scores_gemma":[0.9983202,0.000038385282,0.00028198777,0.00034771633,0.00010499994,0.0000058785045,0.000024567811,0.00000794745,0.00086828123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890125,0.000010681875,0.00045391024,0.00023643048,0.00023561362,0.00016208952],"domain_scores_gemma":[0.99908423,0.00014965142,0.000107875414,0.00027451658,0.00018814071,0.00019555952],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012814532,0.00011524133,0.0003706134,0.00003281457,0.000028807337,0.00000972425,0.000065222084,0.00015226498,0.0017091931],"category_scores_gemma":[0.00014676465,0.000093587725,0.00013612206,0.00017320554,0.0006950342,0.000039093142,0.000022178834,0.00025031515,0.000017942428],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024808358,0.00036112263,0.03862578,0.00027316087,0.00016297963,0.000009355355,0.000017987548,8.459106e-7,0.9520805,0.007663379,0.00036654796,0.00019026428],"study_design_scores_gemma":[0.0023722602,0.00021348415,0.024913264,0.00019765142,0.0005935966,0.00022905825,0.0001086375,0.006228089,0.96048325,0.001634475,0.0027954436,0.00023079061],"about_ca_topic_score_codex":0.000015559488,"about_ca_topic_score_gemma":5.095235e-7,"teacher_disagreement_score":0.022315966,"about_ca_system_score_codex":0.000013343605,"about_ca_system_score_gemma":0.000093192706,"threshold_uncertainty_score":0.9992034},"labels":[],"label_agreement":null},{"id":"W2028118139","doi":"10.1371/journal.pone.0086010","title":"Crystallographic and Biochemical Analysis of the Mouse Poly(ADP-Ribose) Glycohydrolase","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Mutant; Biochemistry; Enzyme; Chemistry; Complementation; Transferase; Ribose; Poly ADP ribose polymerase; Cell biology; Biology; Gene; Polymerase","score_opus":0.02502004827302836,"score_gpt":0.2417225487978103,"score_spread":0.21670250052478193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028118139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691516,0.0004289591,0.00010115591,0.0017973819,0.000011349919,0.00016605809,0.00003215099,0.000036652673,0.0005111574],"genre_scores_gemma":[0.99821067,0.000092969196,0.0005341131,0.0007831445,0.00009586517,0.000017561082,0.000020841162,0.000014201852,0.00023061088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904495,0.000053733616,0.00021522492,0.00019848121,0.00034467646,0.0001429316],"domain_scores_gemma":[0.99918884,0.00007393302,0.000098524244,0.0004573792,0.00007940422,0.00010193719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014869716,0.00010119489,0.00036934362,0.00022513431,0.00004041811,0.0000068403165,0.00008625419,0.000077975405,0.0001326804],"category_scores_gemma":[0.00009930438,0.000073441064,0.0001460968,0.00079121126,0.00022720489,0.000026167434,0.000037484122,0.00013232343,0.0000023711332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012723319,0.000610575,0.046604306,0.00006908921,0.0017460678,6.532721e-7,0.00009296649,0.0000016723416,0.95039564,0.000091394875,0.0001817992,0.000078590165],"study_design_scores_gemma":[0.0017298376,0.00017708533,0.025210125,0.00013310199,0.0035595007,0.0000030444498,0.000016761192,0.00239281,0.9661294,0.00020674757,0.0003145301,0.00012704536],"about_ca_topic_score_codex":0.000032308715,"about_ca_topic_score_gemma":0.0000060060365,"teacher_disagreement_score":0.02139418,"about_ca_system_score_codex":0.000022013768,"about_ca_system_score_gemma":0.000019498448,"threshold_uncertainty_score":0.29948395},"labels":[],"label_agreement":null},{"id":"W2028213565","doi":"10.1016/s0169-328x(00)00122-4","title":"Effects of transient global ischemia and kainate on poly(ADP-ribose) polymerase (PARP) gene expression and proteolytic cleavage in gerbil and rat brains","year":2000,"lang":"en","type":"article","venue":"Molecular Brain Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health","keywords":"Poly ADP ribose polymerase; Gerbil; Biology; PARP inhibitor; Kainate receptor; Ischemia; Molecular biology; Kainic acid; Excitotoxicity; Brain ischemia; Cell biology; Polymerase; Glutamate receptor; Internal medicine; Programmed cell death; Apoptosis; Biochemistry; Medicine; Gene; AMPA receptor","score_opus":0.01684730494728277,"score_gpt":0.34676397699614814,"score_spread":0.3299166720488654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028213565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861582,0.006289245,0.00014796648,0.004636941,0.000017089702,0.0015499584,0.0000145093245,0.000022107439,0.0011639752],"genre_scores_gemma":[0.9976771,0.00040646567,0.00037491426,0.001016071,0.000044177086,0.00014442763,0.000009367726,0.00003286286,0.00029462468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99739563,0.0005008115,0.0002865243,0.00059532805,0.00070739497,0.00051431725],"domain_scores_gemma":[0.9989483,0.00028563722,0.00003705797,0.00034982085,0.00005797802,0.00032120466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008604805,0.00021426722,0.00035773768,0.00022690506,0.00009648181,0.000034253324,0.00008921281,0.00016581657,0.00005293626],"category_scores_gemma":[0.00020051215,0.00019476109,0.000046005902,0.00044167176,0.00047300739,0.000064484375,0.00005952001,0.00043539304,0.000003852925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016456055,0.00022448614,0.000557015,0.0005101111,0.000025027404,0.0006267132,0.00061423145,0.0000025221,0.9717634,0.00007776005,0.0006360488,0.023317106],"study_design_scores_gemma":[0.0071160793,0.0008913335,0.0064624087,0.00081349263,0.000011543624,0.000088310735,0.000046308996,0.00016400211,0.9834046,0.00023431439,0.00060469215,0.00016293858],"about_ca_topic_score_codex":0.00012233945,"about_ca_topic_score_gemma":0.000005790088,"teacher_disagreement_score":0.023154167,"about_ca_system_score_codex":0.00012765318,"about_ca_system_score_gemma":0.0001284489,"threshold_uncertainty_score":0.7942127},"labels":[],"label_agreement":null},{"id":"W2030592870","doi":"10.1074/jbc.m610502200","title":"Poly(ADP-ribose) Polymerase 1 Is Inhibited by a Histone H2A Variant, MacroH2A, and Contributes to Silencing of the Inactive X Chromosome","year":2007,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences","keywords":"Chromatin; Biology; Molecular biology; Histone H2A; Histone; Poly ADP ribose polymerase; Polymerase; Genetics; Gene","score_opus":0.015413461391892796,"score_gpt":0.29997039483764404,"score_spread":0.2845569334457512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030592870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98635834,0.007352664,0.0005233953,0.0048992275,0.00010181865,0.00013707146,0.000102531645,0.000010209157,0.0005147165],"genre_scores_gemma":[0.9960854,0.00016384288,0.00022824979,0.0029667823,0.0003331579,0.000002569102,0.0000051066954,0.000009908171,0.00020498993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859565,0.000035956695,0.0006526088,0.0001909013,0.00026281775,0.00026205403],"domain_scores_gemma":[0.9985671,0.00023846039,0.00052169187,0.00017836987,0.0002540982,0.00024024739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005114971,0.00017354851,0.000504199,0.000049198963,0.00007056855,0.000009285875,0.00014440774,0.000232278,0.00029205283],"category_scores_gemma":[0.0003864994,0.000105078696,0.00015857452,0.00030683124,0.00028809777,0.00004244401,0.00006659705,0.0004558832,0.0000011874998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011871743,0.00017872785,0.0034896208,0.000040052695,0.00011029314,0.00007038496,0.0001689997,1.2861422e-7,0.98996437,0.000006124053,0.003644458,0.0011396842],"study_design_scores_gemma":[0.0023445222,0.00035485477,0.0066423467,0.00036322128,0.000053850945,0.00077190023,0.000285289,0.0000023779244,0.986243,0.00012722355,0.0027010855,0.0001103103],"about_ca_topic_score_codex":0.000021047103,"about_ca_topic_score_gemma":3.3033675e-7,"teacher_disagreement_score":0.009727027,"about_ca_system_score_codex":0.00031687279,"about_ca_system_score_gemma":0.00011494062,"threshold_uncertainty_score":0.42849848},"labels":[],"label_agreement":null},{"id":"W2030655272","doi":"10.1042/bj20050792","title":"Poly(ADP-ribose) glycohydrolase is a component of the FMRP-associated messenger ribonucleoparticles","year":2005,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Wilfrid Laurier University; Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Context (archaeology); Messenger RNA; Polymerase; Transcription (linguistics); Second messenger system; Enzyme; Biochemistry; Biology; Translation (biology); Chemistry; Cell biology; Gene","score_opus":0.01632000308581145,"score_gpt":0.2817322973778578,"score_spread":0.2654122942920464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030655272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715055,0.002184826,0.000024768928,0.025556877,0.0001887926,0.00013166307,0.000028273564,0.000029731398,0.0003495584],"genre_scores_gemma":[0.99526083,0.00008314562,0.00049225247,0.0032152703,0.0007743028,0.0000046365176,0.0000031721102,0.000022784074,0.00014359034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983414,0.00007787967,0.00051410485,0.00016831385,0.0005838465,0.0003144821],"domain_scores_gemma":[0.99891627,0.00006342454,0.00029081808,0.00028246513,0.00018661839,0.000260395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027218324,0.00015769336,0.000308749,0.000059849892,0.00011109166,0.000021935071,0.00019393873,0.00013090073,0.0007729461],"category_scores_gemma":[0.00011703154,0.000106414474,0.0002936279,0.00024485268,0.00021123685,0.00006466794,0.00005435009,0.00045276663,0.000041314568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003026835,0.00046045543,0.0027935721,0.000010936352,0.00014207739,0.000009750121,0.00027477587,0.0000017128046,0.950836,0.000029033437,0.0441306,0.0010084093],"study_design_scores_gemma":[0.0032389348,0.00009201157,0.009986719,0.00025058075,0.00010012951,0.0003953798,0.000038211187,0.00031516296,0.97530615,0.00017967631,0.00997375,0.00012327675],"about_ca_topic_score_codex":0.000008634002,"about_ca_topic_score_gemma":7.757342e-7,"teacher_disagreement_score":0.03415685,"about_ca_system_score_codex":0.00026000114,"about_ca_system_score_gemma":0.00013866441,"threshold_uncertainty_score":0.84632176},"labels":[],"label_agreement":null},{"id":"W2032772300","doi":"10.1016/j.yexcr.2004.08.036","title":"MIBG, an inhibitor of arginine-dependent mono(ADP-ribosyl)ation, prevents differentiation of L6 skeletal myoblasts by inhibiting expression of myogenin and p21cip1","year":2004,"lang":"en","type":"article","venue":"Experimental Cell Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Myogenin; MyoD; Biology; Skeletal muscle; Myocyte; Cellular differentiation; Cell fusion; Cell growth; Cell biology; Myogenic regulatory factors; Molecular biology; Cell; Endocrinology; Biochemistry; Myogenesis","score_opus":0.039300153015328604,"score_gpt":0.37913728195969126,"score_spread":0.3398371289443627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032772300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962733,0.0019129282,0.00030682437,0.00005521721,0.00007349347,0.0008092181,0.000060768136,0.000020364974,0.000487886],"genre_scores_gemma":[0.9982239,0.00011230673,0.0010654103,0.000011588574,0.00010546553,0.000089786765,0.00012680571,0.000043913304,0.00022082259],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99687684,0.00026320017,0.0007255706,0.000437478,0.0013474728,0.00034945484],"domain_scores_gemma":[0.9987417,0.00010370674,0.0003261419,0.0003102186,0.00030343945,0.00021478564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006649506,0.00019984422,0.00041325006,0.00032321937,0.00009958071,0.000014684751,0.00014205603,0.00014626207,0.00023590252],"category_scores_gemma":[0.00005515397,0.00019336781,0.0000896532,0.00028441558,0.00031634234,0.00025795086,0.00015665077,0.0002886665,0.00000416113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064214197,0.0016603179,0.0016880254,0.00023068929,0.000023074248,0.0000030793824,0.002959538,0.000022414588,0.9921488,0.000054424316,0.00021649759,0.0003509518],"study_design_scores_gemma":[0.0056290687,0.0019125337,0.0015856876,0.00070026465,0.000010581159,0.0000056415265,0.002245618,0.000057700836,0.9875732,0.00012484983,0.000020666921,0.00013419925],"about_ca_topic_score_codex":0.00015581503,"about_ca_topic_score_gemma":0.0000030391016,"teacher_disagreement_score":0.0049869264,"about_ca_system_score_codex":0.00024907346,"about_ca_system_score_gemma":0.00015212908,"threshold_uncertainty_score":0.78853106},"labels":[],"label_agreement":null},{"id":"W2033816200","doi":"10.1016/s1470-2045(14)71135-0","title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":544,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Université Laval; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Carboplatin; Tolerability; Internal medicine; Regimen; Ovarian cancer; Chemotherapy; Oncology; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Phases of clinical research; Urology; Cancer; Randomized controlled trial; Cisplatin; Adverse effect","score_opus":0.05582660886094198,"score_gpt":0.39046445905146526,"score_spread":0.3346378501905233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033816200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8005265,0.00028367963,0.028165802,0.13403223,0.0030143333,0.014160028,0.00024002204,0.00038743208,0.01918997],"genre_scores_gemma":[0.9655396,0.00032156947,0.0034488037,0.019811882,0.006624247,0.0034945467,0.00012605177,0.000076403994,0.0005569159],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99824333,0.00038656933,0.00038515314,0.00033599444,0.00020507103,0.00044388114],"domain_scores_gemma":[0.9977868,0.001113923,0.00033306007,0.00045458126,0.00019611978,0.00011550656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001281428,0.00023252338,0.0011043639,0.00005660988,0.00016071652,0.000016153906,0.00015857881,0.00015283229,0.0002255932],"category_scores_gemma":[0.00014443508,0.00014177457,0.00014020392,0.000159517,0.00025641607,0.000035939946,0.000010728521,0.00032570562,0.000011489171],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92692107,0.0005837316,0.000023670615,0.00004037392,0.000359983,0.000006240074,0.0010977912,0.000014615329,0.003906357,0.0021956407,0.019254502,0.045596037],"study_design_scores_gemma":[0.7619015,0.019123029,0.00007515105,0.000094537245,0.00018496731,0.00004039328,0.00006304402,0.0015497475,0.007345175,0.000861339,0.2085955,0.00016564416],"about_ca_topic_score_codex":0.00003397959,"about_ca_topic_score_gemma":0.0000995833,"teacher_disagreement_score":0.18934101,"about_ca_system_score_codex":0.00031226632,"about_ca_system_score_gemma":0.00040164823,"threshold_uncertainty_score":0.5781399},"labels":[],"label_agreement":null},{"id":"W2033937930","doi":"10.1038/onc.2009.492","title":"Activation of PARP-1 in response to bleomycin depends on the Ku antigen and protein phosphatase 5","year":2010,"lang":"en","type":"article","venue":"Oncogene","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Biology; Poly ADP ribose polymerase; Bleomycin; Phosphorylation; Molecular biology; Phosphatase; DNA damage; DNA repair; Cancer research; Cell biology; DNA; Polymerase; Biochemistry; Genetics","score_opus":0.02046704854305507,"score_gpt":0.3080478839706329,"score_spread":0.2875808354275778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033937930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98995006,0.000058709273,0.000042160515,0.008488171,0.00004899254,0.0006720483,0.000024602607,0.000012625993,0.00070260675],"genre_scores_gemma":[0.99728954,0.000015880565,0.0008011009,0.0013854232,0.00006938659,0.00011285463,0.0000085931715,0.000013711922,0.0003034973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926656,0.00007642998,0.00017667425,0.00016648207,0.00019135047,0.00012249559],"domain_scores_gemma":[0.99935675,0.00013651753,0.00006481134,0.00030762554,0.00006202358,0.000072255796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006616022,0.000085248044,0.00014274768,0.00010647391,0.000032556134,0.0000062909967,0.00005901452,0.000063611216,0.00023815717],"category_scores_gemma":[0.00031379765,0.000061101964,0.000021913056,0.00023353506,0.00004617891,0.000036481535,0.00001758713,0.00017120822,0.000018346112],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004159002,0.00009336699,0.0025848828,0.000010164586,0.000009791828,0.000008904867,0.00026095958,0.0000034491336,0.9840711,0.0003086161,0.0005906595,0.007899114],"study_design_scores_gemma":[0.001452341,0.00035521164,0.029901592,0.00013415444,0.000004039915,0.000007156161,0.0000526492,0.000012898586,0.9469676,0.00012254107,0.020927334,0.000062453306],"about_ca_topic_score_codex":0.00007898512,"about_ca_topic_score_gemma":0.00004952021,"teacher_disagreement_score":0.037103463,"about_ca_system_score_codex":0.000041393563,"about_ca_system_score_gemma":0.00010717675,"threshold_uncertainty_score":0.2607654},"labels":[],"label_agreement":null},{"id":"W2034142957","doi":"10.4161/cc.22604","title":"Predicting PARP inhibitor sensitivity and resistance","year":2012,"lang":"en","type":"letter","venue":"Cell Cycle","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Cancer Foundation; Alberta Bible College","funders":"","keywords":"Biology; PARP inhibitor; Poly ADP ribose polymerase; Sensitivity (control systems); Resistance (ecology); Cell biology; Genetics; DNA; Polymerase; Ecology","score_opus":0.016349949919959708,"score_gpt":0.25474073035109074,"score_spread":0.23839078043113104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034142957","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25381443,0.011984003,0.00023197346,0.62030244,0.0029668345,0.0014670439,0.00033547866,0.0005995867,0.10829821],"genre_scores_gemma":[0.3458264,0.000380239,0.0013052161,0.6024005,0.027208265,0.00008158149,0.00031709395,0.00020433472,0.022276403],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983067,0.0001267723,0.0002800906,0.00044446305,0.0003764414,0.00046554187],"domain_scores_gemma":[0.99890405,0.00021462736,0.00019570002,0.00046797656,0.00007863952,0.00013899576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003011359,0.0002903799,0.0004514254,0.00008655388,0.00011189109,0.000028202194,0.000043452343,0.00059957895,0.00015635569],"category_scores_gemma":[0.000032706626,0.00028828968,0.00009890052,0.00009589023,0.00015299888,0.00009288054,0.00004795578,0.001406072,0.00010196242],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070448456,0.00003590479,0.0034671545,0.0008161547,0.000036304657,0.00039301722,0.0002478802,2.8304558e-7,0.008804869,0.0000038060368,0.98588127,0.00024288626],"study_design_scores_gemma":[0.0011763801,0.000042315576,0.0017945097,0.0005784857,0.0001326911,0.000090622634,0.000023592764,0.00001862969,0.018183365,0.000091614296,0.97754306,0.00032472005],"about_ca_topic_score_codex":0.000027561615,"about_ca_topic_score_gemma":0.000014025596,"teacher_disagreement_score":0.09201195,"about_ca_system_score_codex":0.00016175176,"about_ca_system_score_gemma":0.00008113553,"threshold_uncertainty_score":0.9999569},"labels":[],"label_agreement":null},{"id":"W2034878791","doi":"10.1074/jbc.m109.077834","title":"PARP-3 Is a Mono-ADP-ribosylase That Activates PARP-1 in the Absence of DNA","year":2010,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Vetenskapsrådet; Knut och Alice Wallenbergs Stiftelse; Karolinska Institutet; Cancerfonden; Stiftelsen för Strategisk Forskning; Ontario Genomics Institute; Stiftelsen Lars Hiertas Minne; Ontario Genomics; Genome Canada; GlaxoSmithKline; Ontario Innovation Trust; Wellcome Trust; Pain Relief Foundation","keywords":"Poly ADP ribose polymerase; DNA repair; Biology; PARP inhibitor; DNA; Histone; Molecular biology; Topoisomerase; Cell biology; Genetics; Polymerase","score_opus":0.049515077744600185,"score_gpt":0.32034660720433294,"score_spread":0.27083152945973277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034878791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946955,0.00029021577,0.0000148875715,0.00331773,0.00007285662,0.000077531055,0.000009911091,0.000006510738,0.0015149015],"genre_scores_gemma":[0.9980744,0.00034832332,0.0002648197,0.00089116645,0.00034885443,0.0000060228826,0.000002809606,0.0000057691777,0.00005782588],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892366,0.00003762276,0.00043600934,0.00013727858,0.00028362393,0.00018181348],"domain_scores_gemma":[0.998819,0.00029432977,0.0004311199,0.00023794232,0.00011333929,0.0001043028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005341462,0.00013173219,0.00035578953,0.00002732832,0.000026382897,0.000010448566,0.00026945138,0.0002252443,0.0007386213],"category_scores_gemma":[0.00028865025,0.00006794338,0.00018367302,0.00014330473,0.00024978124,0.00005290287,0.000024568788,0.0008322528,0.0000037798768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040294084,0.0002300228,0.04787467,0.000036013116,0.000027946651,0.00006866915,0.00017975522,7.310756e-7,0.9489757,0.000008745791,0.001498771,0.00069606554],"study_design_scores_gemma":[0.0011556963,0.00018902971,0.02821093,0.00012617909,0.000011438474,0.0005327564,0.00032668852,0.000006712361,0.9630925,0.00093981007,0.0053278967,0.00008033457],"about_ca_topic_score_codex":0.00000398821,"about_ca_topic_score_gemma":4.7620986e-7,"teacher_disagreement_score":0.01966374,"about_ca_system_score_codex":0.000034443754,"about_ca_system_score_gemma":0.0000883237,"threshold_uncertainty_score":0.8087385},"labels":[],"label_agreement":null},{"id":"W2035067002","doi":"10.1016/j.biolcel.2003.10.003","title":"Alteration of poly(ADP‐ribose) glycohydrolase nucleocytoplasmic shuttling characteristics upon cleavage by apoptotic proteases","year":2003,"lang":"en","type":"article","venue":"Biology of the Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Biology; Subcellular localization; Nuclear export signal; Poly ADP ribose polymerase; Cytoplasm; Cell biology; Green fluorescent protein; Nuclear localization sequence; Nuclear transport; Nucleoplasm; Molecular biology; Biochemistry; Cell nucleus; Nucleolus; Polymerase; DNA","score_opus":0.012704968336590437,"score_gpt":0.2580794781017082,"score_spread":0.2453745097651178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035067002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965045,0.0007497484,0.00041825595,0.00039846762,0.00042853414,0.00048564025,0.00010510297,0.000023411398,0.0008863614],"genre_scores_gemma":[0.9986305,0.00009625801,0.00046747888,0.0003099852,0.00010164634,0.0000180323,0.000047460064,0.000019936711,0.0003086921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891126,0.00018471251,0.0004086061,0.00019892053,0.0001070139,0.00018948971],"domain_scores_gemma":[0.9990693,0.00008321405,0.00036867976,0.00035681782,0.00006691849,0.000055117936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021253356,0.00014117002,0.0003257423,0.000060972896,0.000059653106,0.0000036399229,0.00011779963,0.00013939878,0.00010822464],"category_scores_gemma":[0.000111820176,0.00010596864,0.00011195444,0.00011470293,0.00018506966,0.00003251648,0.000021086933,0.00014851178,0.000016390892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030936045,0.00022376805,0.00790245,0.00012721124,0.00003216822,0.0000011014647,0.00010453212,0.0000032870191,0.9897993,0.00018176463,0.0008863735,0.00042865286],"study_design_scores_gemma":[0.0017175257,0.00036568957,0.0010312032,0.00010767835,0.000057356654,0.000019396435,0.000021870193,0.00015121618,0.9899064,0.0002099664,0.0063173734,0.000094370225],"about_ca_topic_score_codex":0.000014749846,"about_ca_topic_score_gemma":5.501416e-7,"teacher_disagreement_score":0.0068712467,"about_ca_system_score_codex":0.00005846855,"about_ca_system_score_gemma":0.00009206089,"threshold_uncertainty_score":0.43212757},"labels":[],"label_agreement":null},{"id":"W2035386385","doi":"10.1158/1535-7163.mct-05-0128","title":"Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft","year":2005,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Temozolomide; Poly ADP ribose polymerase; Glioma; DNA repair; Pharmacology; O-6-methylguanine-DNA methyltransferase; Cancer research; PARP inhibitor; Growth inhibition; Medicine; Chemistry; Polymerase; DNA; Methyltransferase; Cell growth; Biochemistry; Methylation","score_opus":0.024224175741875877,"score_gpt":0.3031121217187833,"score_spread":0.27888794597690747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035386385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9050052,0.06859414,0.0014418982,0.020442534,0.00044346665,0.0011328303,0.00012943121,0.00042672592,0.0023837355],"genre_scores_gemma":[0.9725727,0.0014193272,0.004645849,0.019134976,0.00049680326,0.00037274466,0.000061286024,0.00015221535,0.0011441399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99624413,0.00021569966,0.0009088927,0.0008930043,0.00087022944,0.0008680292],"domain_scores_gemma":[0.9982079,0.000056259876,0.00029982376,0.0010080083,0.00018792518,0.00024005907],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041990916,0.0005253796,0.0006621109,0.0004667103,0.00018740298,0.00006777253,0.00019009112,0.0002979311,0.00032840003],"category_scores_gemma":[0.000019221045,0.0005284621,0.00039004895,0.0011504221,0.00029879794,0.00016728969,0.00005671057,0.00046466838,0.00006240904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018104549,0.0007319838,0.002122229,0.00022755342,0.00035755502,0.0008847129,0.0019519157,0.00010735516,0.9797226,0.0010588587,0.0026790106,0.008345731],"study_design_scores_gemma":[0.0053750835,0.00022578427,0.0015344372,0.001086765,0.00023055999,0.00013328054,0.00025760394,0.00028098773,0.8047727,0.00041003746,0.18503372,0.0006590856],"about_ca_topic_score_codex":0.00024272443,"about_ca_topic_score_gemma":0.00049266836,"teacher_disagreement_score":0.18235472,"about_ca_system_score_codex":0.0012116394,"about_ca_system_score_gemma":0.00046247776,"threshold_uncertainty_score":0.9997167},"labels":[],"label_agreement":null},{"id":"W2035457633","doi":"10.1016/j.molcel.2012.03.012","title":"PARP1 Parylation Promotes Silent Locus Transmission in the Nucleolus: The Suspicion Confirmed","year":2012,"lang":"en","type":"letter","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre hospitalier de l'Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Biology; Nucleolus; PARP1; Chromatin; Gene silencing; Genetics; Cell biology; CTCF; Transcription (linguistics); Transcription factor; DNA; Gene; Cytoplasm","score_opus":0.018659501817940752,"score_gpt":0.26408672831806923,"score_spread":0.2454272265001285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035457633","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022496855,0.009669288,0.0044138245,0.9464793,0.00049925543,0.00370886,0.00002102723,0.00009772356,0.012613843],"genre_scores_gemma":[0.46134323,0.00033648222,0.00015345769,0.53429896,0.0017574766,0.00038207351,0.00063841755,0.00012583987,0.00096405816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972316,0.0005734152,0.00045835786,0.00040062368,0.0008323556,0.0005036379],"domain_scores_gemma":[0.9986805,0.00016300454,0.00022077422,0.00080052926,0.00007309578,0.000062110965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057067897,0.000376365,0.00038247614,0.00012429732,0.0001062011,0.000044904908,0.0003189917,0.00062719436,0.0004874707],"category_scores_gemma":[0.000015540392,0.00021706583,0.00025074786,0.0002462495,0.00013567,0.000048250877,0.000021127289,0.001835609,0.00011603095],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002804585,0.000443534,0.00026435743,0.0009578369,0.00012459328,0.0013967382,0.0056391265,0.000034670258,0.07898179,0.00007156371,0.9004639,0.011341463],"study_design_scores_gemma":[0.0019396911,0.00018119242,0.00021175061,0.00036295885,0.00020890382,0.00005261166,0.00008061295,0.0001283655,0.0476575,0.00028477155,0.94861573,0.00027589023],"about_ca_topic_score_codex":0.000064966145,"about_ca_topic_score_gemma":0.0000018083931,"teacher_disagreement_score":0.43884635,"about_ca_system_score_codex":0.00015976737,"about_ca_system_score_gemma":0.00011948739,"threshold_uncertainty_score":0.88516873},"labels":[],"label_agreement":null},{"id":"W2035849143","doi":"10.1371/journal.pone.0015834","title":"A Key Role for Poly(ADP-Ribose) Polymerase 3 in Ectodermal Specification and Neural Crest Development","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Genomics; Hôtel-Dieu de Québec; Centre hospitalier de l'Université Laval; University of Ottawa; University of Alberta; Université Laval","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Zebrafish; Neural crest; Biology; Morpholino; Neural plate; Cell fate determination; Neurogenesis; Cell biology; Neural development; Cranial neural crest; PARP1; Genetics; Poly ADP ribose polymerase; Gene; Transcription factor; Polymerase; Embryo","score_opus":0.13101865282359781,"score_gpt":0.27165724153487397,"score_spread":0.14063858871127616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035849143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947838,0.0010885429,0.00020286339,0.0013427681,0.000033992063,0.0006103293,0.000012798799,0.000050521947,0.0018743703],"genre_scores_gemma":[0.9874909,0.000044054916,0.010932775,0.0007104293,0.0002140432,0.0002385737,0.00003866405,0.000024357347,0.00030620102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991395,0.000019443258,0.00023923167,0.00022193976,0.00017153549,0.00020836035],"domain_scores_gemma":[0.99958265,0.000031679665,0.000061087056,0.0001626632,0.000054320008,0.000107588756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009486222,0.00010973451,0.00020345209,0.000118197946,0.000049073504,0.0000092203845,0.000046280802,0.00005553445,0.0001716583],"category_scores_gemma":[0.000026250324,0.000110091525,0.00002156905,0.00009483893,0.00004320385,0.00008334369,0.000015067954,0.000096683034,0.000016119495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035960712,0.005250649,0.13219519,0.00037485544,0.00029066936,0.000035569552,0.01326972,3.5563687e-7,0.8244705,0.00086159346,0.00037023248,0.01928456],"study_design_scores_gemma":[0.0035801253,0.0002270263,0.18125694,0.00021014616,0.000047356592,0.0000116477095,0.00015765584,0.00046366098,0.81295174,0.00025112467,0.00067151606,0.00017102735],"about_ca_topic_score_codex":0.00004403899,"about_ca_topic_score_gemma":0.00003264788,"teacher_disagreement_score":0.049061753,"about_ca_system_score_codex":0.000084897256,"about_ca_system_score_gemma":0.000076960336,"threshold_uncertainty_score":0.44894022},"labels":[],"label_agreement":null},{"id":"W2037147607","doi":"10.1016/j.jmb.2005.11.028","title":"Involvement of Polynucleotide Kinase in a Poly(ADP-ribose) Polymerase-1-dependent DNA Double-strand Breaks Rejoining Pathway","year":2005,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Commissariat à l'Énergie Atomique et aux Énergies Alternatives; Ligue Contre le Cancer; Electricité de France; Fondation pour la Recherche Médicale","keywords":"DNA ligase; DNA repair; Molecular biology; Biology; DNA; Polymerase; DNA polymerase; DNA polymerase mu; Poly ADP ribose polymerase; Sticky and blunt ends; DNA damage; Recombinant DNA; DNA clamp; Biochemistry; Circular bacterial chromosome; Gene; RNA; Reverse transcriptase","score_opus":0.020730809510362606,"score_gpt":0.31044416112705386,"score_spread":0.28971335161669126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037147607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98374134,0.007839212,0.0019627362,0.005124783,0.0002747219,0.00023352749,0.000021521586,0.000011168436,0.0007909687],"genre_scores_gemma":[0.99471235,0.0002519607,0.0023520186,0.0021764021,0.00040609195,0.0000068901795,0.000011176772,0.000029723915,0.000053410866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779844,0.0001693087,0.0011147815,0.00022920138,0.0003332581,0.00035497913],"domain_scores_gemma":[0.9986036,0.00005185535,0.00067600305,0.0002858918,0.00017472841,0.00020793587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072173355,0.0002131178,0.0006593378,0.00050305534,0.000027810845,0.000008301744,0.00017714158,0.00018650778,0.00020963795],"category_scores_gemma":[0.000042189382,0.00018265872,0.0002606124,0.0002181646,0.00013784185,0.00007610769,0.000041220923,0.00044248032,0.000006066298],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021975348,0.00040778704,0.004793466,0.00003434232,0.00019269662,0.0004924001,0.0003279051,0.000055748376,0.98004854,0.0004634001,0.0001272675,0.010858895],"study_design_scores_gemma":[0.014021072,0.0014085497,0.00189,0.00035992035,0.00006967918,0.0007446425,0.000167629,0.00001983622,0.9769132,0.00023025136,0.004006569,0.00016861797],"about_ca_topic_score_codex":0.00011697786,"about_ca_topic_score_gemma":0.00004570312,"teacher_disagreement_score":0.011823537,"about_ca_system_score_codex":0.0002275687,"about_ca_system_score_gemma":0.00035127756,"threshold_uncertainty_score":0.74486065},"labels":[],"label_agreement":null},{"id":"W2038154591","doi":"10.1073/pnas.012460399","title":"Role of poly(ADP-ribose) polymerase in rapid intracellular acidification induced by alkylating DNA damage","year":2001,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Medical Research Council","keywords":"Poly ADP ribose polymerase; DNA damage; NAD+ kinase; Nicotinamide adenine dinucleotide; Polymerase; Programmed cell death; Biochemistry; Biology; Intracellular pH; Molecular biology; Chemistry; Intracellular; DNA; Enzyme; Apoptosis","score_opus":0.0419492091109603,"score_gpt":0.32231249519594835,"score_spread":0.28036328608498806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038154591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876371,0.001040778,0.0000016591698,0.006198644,0.000014120811,0.0002541215,0.000014074868,0.000011325649,0.004828177],"genre_scores_gemma":[0.9988356,0.00009478742,0.0005735588,0.00031022393,0.00009852131,0.000015468215,9.958367e-7,0.000006547317,0.00006427117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793154,0.000012169863,0.0005461036,0.00024139331,0.0010980279,0.00017074974],"domain_scores_gemma":[0.9989512,0.000094461626,0.00064844894,0.000016511342,0.00024175756,0.00004760156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001303386,0.000105061474,0.00022357436,0.00029469872,0.00008932039,0.000009843075,0.00038577293,0.00011153917,0.00006003693],"category_scores_gemma":[0.000382025,0.0000813905,0.00006571658,0.0012590048,0.00048783058,0.0003981691,0.000048124704,0.00022039657,0.0000010029324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006368286,0.00010804317,0.009512057,0.000036747024,0.000010701398,8.102739e-9,0.00040826085,0.000004649852,0.9840432,0.0029652521,0.00014731055,0.0027000972],"study_design_scores_gemma":[0.0006101116,0.000080615566,0.04266858,0.00020138663,0.0000100525085,0.000007608881,0.00053337455,0.00078393455,0.9495053,0.005311293,0.00021739955,0.00007033632],"about_ca_topic_score_codex":0.000028537657,"about_ca_topic_score_gemma":8.263577e-8,"teacher_disagreement_score":0.034537885,"about_ca_system_score_codex":0.000075952885,"about_ca_system_score_gemma":0.000068126625,"threshold_uncertainty_score":0.33190084},"labels":[],"label_agreement":null},{"id":"W2038167510","doi":"10.1074/jbc.m112.379289","title":"Crystal Structure of Human ADP-ribose Transferase ARTD15/PARP16 Reveals a Novel Putative Regulatory Domain","year":2012,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Transferase; ADP-ribosylation; PARP1; NAD+ kinase; Poly ADP ribose polymerase; Enzyme; Biology; Diphtheria toxin; DNA-binding domain; Biochemistry; DNA; DNA repair; Polymerase; Transcription factor; Chemistry; Gene; Toxin","score_opus":0.0384526401107803,"score_gpt":0.3214655787772885,"score_spread":0.2830129386665082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038167510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972244,0.00087654794,0.00050107884,0.0003468475,0.00009806415,0.000121301564,0.00015855774,0.000014295333,0.0006589254],"genre_scores_gemma":[0.99590784,0.000033050917,0.0022773338,0.00028335757,0.0013666027,0.0000025391037,0.000027729553,0.0000147659375,0.00008676487],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833584,0.000060247006,0.00078967644,0.00015532087,0.00035952084,0.00029937513],"domain_scores_gemma":[0.9985845,0.0001067368,0.0005257026,0.00019049263,0.00024630435,0.00034627545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042309164,0.00020765302,0.0006403945,0.000044242937,0.000051652,0.0000060406114,0.0001402419,0.0003213373,0.0010565727],"category_scores_gemma":[0.000115645424,0.00013911669,0.00030984706,0.0001310716,0.0003328111,0.00009713142,0.000019379671,0.00055144326,0.0000011139516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070318225,0.0003756194,0.005785985,0.00012147043,0.00014226903,0.000023995124,0.00034150266,0.0000029569892,0.9916664,0.000057043868,0.000672157,0.00010745715],"study_design_scores_gemma":[0.0033921076,0.0005071715,0.018124664,0.00025317186,0.00006330667,0.001076502,0.00036716575,6.3163185e-7,0.9736382,0.0014712319,0.0009468326,0.00015902135],"about_ca_topic_score_codex":8.905232e-7,"about_ca_topic_score_gemma":6.651275e-8,"teacher_disagreement_score":0.018028168,"about_ca_system_score_codex":0.00015466404,"about_ca_system_score_gemma":0.0000918143,"threshold_uncertainty_score":0.9998566},"labels":[],"label_agreement":null},{"id":"W2040299042","doi":"10.1021/jm100249w","title":"Structural Basis for the Interaction between Tankyrase-2 and a Potent Wnt-Signaling Inhibitor","year":2010,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Wnt signaling pathway; Chemistry; Telomere; Cell biology; Signal transduction; Computational biology; Biochemistry; DNA; Biology","score_opus":0.0286563520000064,"score_gpt":0.3280632765617665,"score_spread":0.2994069245617601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040299042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906365,0.00063000823,0.0005657184,0.007188655,0.00068357534,0.00014222458,0.000010853744,0.000009162006,0.00013328271],"genre_scores_gemma":[0.9920512,0.00005908114,0.0009064337,0.0003960362,0.006480097,0.0000071651516,0.0000042750685,0.00001651768,0.00007919958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988111,0.000012400631,0.00047603593,0.00012012845,0.00042125722,0.00015905272],"domain_scores_gemma":[0.99846464,0.00048501592,0.00041641155,0.00012809849,0.00030117258,0.0002046852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059097115,0.00013223817,0.00030078014,0.000043323253,0.00010958556,0.000022708693,0.00009981173,0.00011389691,0.00023322875],"category_scores_gemma":[0.00041998495,0.000080892365,0.0001404375,0.00007079814,0.0001483795,0.000093733375,0.000014948919,0.0008537453,5.546042e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008275837,0.00001978695,0.0055138418,0.0001866385,0.00020414336,0.000029308827,0.00031535263,0.000005577361,0.97352666,0.000004977127,0.0017093441,0.017656775],"study_design_scores_gemma":[0.004789078,0.00045558944,0.0076432466,0.00087108026,0.00064159714,0.004430534,0.0019766847,0.00022751337,0.9690564,0.00033059702,0.009420642,0.00015703938],"about_ca_topic_score_codex":0.0000050175786,"about_ca_topic_score_gemma":6.394201e-7,"teacher_disagreement_score":0.017499736,"about_ca_system_score_codex":0.00009335345,"about_ca_system_score_gemma":0.00015685934,"threshold_uncertainty_score":0.3709146},"labels":[],"label_agreement":null},{"id":"W2041515353","doi":"10.1136/jmg.2004.030049","title":"Identification and characterization of missense alterations in the BRCA1 associated RING domain (<i>BARD1</i>) gene in breast and ovarian cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Medical Genetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Cancer Institute","keywords":"Missense mutation; Biology; Ovarian cancer; Cancer research; Breast cancer; Phenotype; Mutation; Allele; Gene; Genetics; Single-strand conformation polymorphism; Cancer","score_opus":0.016898132502327416,"score_gpt":0.3102817669869104,"score_spread":0.293383634484583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041515353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972166,0.00091100024,0.0009328652,0.025758503,0.000079732614,0.00012154427,0.000013931589,0.0000017811909,0.000014624004],"genre_scores_gemma":[0.9934807,0.0048779114,0.00039686088,0.00090590277,0.000307634,0.000004820852,0.0000071742747,0.000007178577,0.000011842172],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985484,0.00013942037,0.0005981223,0.00007986372,0.0005395341,0.0000946466],"domain_scores_gemma":[0.9993458,0.000068566325,0.00029890935,0.00007860341,0.00011743997,0.0000907153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012638195,0.00006395686,0.0001890576,0.00013371253,0.000025464155,0.00001818016,0.0000649262,0.000096560434,0.0000461824],"category_scores_gemma":[0.00008637168,0.000048665846,0.000023066941,0.00018854006,0.000073394636,0.000058270514,0.000010780845,0.00023948387,2.332282e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024087081,0.00040949407,0.06288822,0.000057569236,0.00007372772,0.00007574122,0.0056761103,0.00009864145,0.8975111,0.00010344299,0.00014967805,0.03271538],"study_design_scores_gemma":[0.004439465,0.000084988234,0.9759955,0.00057312567,0.000049924212,0.00093905936,0.00022231435,0.0034343256,0.013401805,0.0001659765,0.00062226993,0.00007126567],"about_ca_topic_score_codex":0.000017842105,"about_ca_topic_score_gemma":0.00008541618,"teacher_disagreement_score":0.9131073,"about_ca_system_score_codex":0.00007885553,"about_ca_system_score_gemma":0.0001535149,"threshold_uncertainty_score":0.19845356},"labels":[],"label_agreement":null},{"id":"W2042685981","doi":"10.3389/fonc.2013.00279","title":"PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets","year":2013,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research; Université Laval; Shastri Indo-Canadian Institute","keywords":"Cancer therapy; Medicine; Magic bullet; MAGIC (telescope); Cancer; Poly ADP ribose polymerase; Cancer research; Bioinformatics; Biology; Internal medicine; Physics; Astronomy; DNA; Genetics","score_opus":0.07203980643888751,"score_gpt":0.39738659344041877,"score_spread":0.32534678700153125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042685981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013676446,0.9827454,0.000103821825,0.0011060609,0.007420837,0.003162963,0.00004947997,0.00008196045,0.0051927096],"genre_scores_gemma":[0.000020747259,0.9875504,0.0036642295,0.0015009101,0.0013078295,0.0027119375,0.00011282345,0.00017121303,0.0029599585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99553126,0.0006622943,0.0015272425,0.0009714853,0.00036366194,0.00094404904],"domain_scores_gemma":[0.9981136,0.00022490737,0.000704943,0.0006195095,0.00009750784,0.00023955699],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062116026,0.00076404086,0.0041305665,0.0013363298,0.00004851953,0.00002201997,0.0003975591,0.0014321608,0.0015159904],"category_scores_gemma":[0.00009444147,0.0006569777,0.00047659923,0.0008166658,0.00030959258,0.00010864947,0.00009812953,0.001831551,0.00019274058],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009504104,0.00026323565,0.0012202212,0.0021669718,0.00018658474,0.0003316204,0.00021559872,0.0000042473907,0.0000057424068,0.000008562551,0.18465762,0.81084454],"study_design_scores_gemma":[0.0034802202,0.00035892322,0.00006648669,0.009022854,0.00013875127,0.00010181431,0.0001267627,0.000020474423,0.000016123427,0.00024071509,0.9858783,0.0005485938],"about_ca_topic_score_codex":0.00072839257,"about_ca_topic_score_gemma":0.000113110356,"teacher_disagreement_score":0.81029594,"about_ca_system_score_codex":0.005395434,"about_ca_system_score_gemma":0.0023794747,"threshold_uncertainty_score":0.99986416},"labels":[],"label_agreement":null},{"id":"W2045601092","doi":"10.1080/01635580701268337","title":"Niacin Deficiency Alters p53 Expression and Impairs Etoposide-Induced Cell Cycle Arrest and Apoptosis in Rat Bone Marrow Cells","year":2007,"lang":"en","type":"article","venue":"Nutrition and Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Simon Fraser University","keywords":"Niacin; Bone marrow; Apoptosis; Poly ADP ribose polymerase; Endocrinology; Internal medicine; Biology; Cell cycle checkpoint; Cell cycle; Medicine; Biochemistry","score_opus":0.015406466726838701,"score_gpt":0.2911307089572571,"score_spread":0.2757242422304184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045601092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989881,0.007201858,0.00006644,0.0012487569,0.0002735813,0.00045537867,0.000016941623,0.000036181962,0.0008198563],"genre_scores_gemma":[0.98879534,0.009441271,0.00046028435,0.0009353525,0.00015036667,0.00008922981,0.000009104701,0.000019743065,0.00009932036],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988878,0.000032224805,0.00027121327,0.0003422866,0.00019099168,0.00027549395],"domain_scores_gemma":[0.99949354,0.000052863095,0.00007877285,0.00012740113,0.000042883486,0.00020455943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002334151,0.00016187389,0.00024407507,0.00018276359,0.00009457909,0.000028135586,0.000025700541,0.00012753994,0.00009775432],"category_scores_gemma":[0.000005605262,0.00014071295,0.000031156957,0.00018601817,0.00009249315,0.00013154182,0.000019307949,0.00018786742,0.0000023870791],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036100624,0.00023425472,0.0049209422,0.00031313451,0.0000031592967,0.000012775531,0.00059006887,0.0000018229322,0.9850338,0.000015021718,0.0015935207,0.006920459],"study_design_scores_gemma":[0.0075888927,0.00021450373,0.0060681873,0.0007578196,0.000024812636,0.00002233499,0.001124101,0.000059177455,0.98031217,0.00020095202,0.0034096637,0.00021737382],"about_ca_topic_score_codex":0.00019134866,"about_ca_topic_score_gemma":0.000088412344,"teacher_disagreement_score":0.0072278865,"about_ca_system_score_codex":0.00012394787,"about_ca_system_score_gemma":0.000035670055,"threshold_uncertainty_score":0.5738107},"labels":[],"label_agreement":null},{"id":"W2045677364","doi":"10.1369/jhc.2009.953380","title":"Assessment of PARP-3 Distribution in Tissues of Cynomolgous Monkeys","year":2009,"lang":"en","type":"article","venue":"Journal of Histochemistry & Cytochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Cancer Research Society","keywords":"Poly ADP ribose polymerase; Biology; DNA damage; DNA repair; PARP inhibitor; Cell biology; Molecular biology; Gene silencing; Ku80; DNA; Gene; Polymerase; Genetics; Transcription factor; DNA-binding protein","score_opus":0.011187851588380263,"score_gpt":0.3363566030897093,"score_spread":0.32516875150132907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045677364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902368,0.0016995064,0.0011316333,0.0006286489,0.000068853304,0.00015144986,0.00006228205,0.000012944662,0.0060078357],"genre_scores_gemma":[0.99673533,0.00021415083,0.0023944762,0.000054903634,0.000249661,0.0000058233095,0.00006426518,0.0000148281115,0.00026655913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740845,0.000024389363,0.0014141477,0.00021674672,0.00069370016,0.00024258612],"domain_scores_gemma":[0.99739456,0.000060392147,0.0013778919,0.00040957594,0.0005732645,0.00018431523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033206868,0.00023090446,0.0008315336,0.00007841216,0.000024040251,0.0000059427343,0.00023594202,0.00022980409,0.00020353094],"category_scores_gemma":[0.00013762528,0.00022752793,0.00030835505,0.00028107985,0.00018165636,0.00008707239,0.000019661255,0.00054519455,5.9695026e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004041548,0.00070602883,0.0047421376,0.00039442224,0.000065445536,0.00013734472,0.000076542674,0.000076707365,0.98967224,0.000024960962,0.0022067633,0.0014932479],"study_design_scores_gemma":[0.002941923,0.0004568859,0.018148128,0.001119361,0.0001036626,0.0006994875,0.00014850222,0.000051674073,0.97478724,0.00027177014,0.0011028346,0.00016855603],"about_ca_topic_score_codex":0.00000729692,"about_ca_topic_score_gemma":1.7859189e-7,"teacher_disagreement_score":0.01488503,"about_ca_system_score_codex":0.00082155305,"about_ca_system_score_gemma":0.00064058905,"threshold_uncertainty_score":0.92783195},"labels":[],"label_agreement":null},{"id":"W2046240854","doi":"10.1186/1477-5956-8-22","title":"Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry","year":2010,"lang":"en","type":"article","venue":"Proteome Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Industrielle du Québec; University of Alberta; Wilfrid Laurier University; Université Laval","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research","keywords":"Poly ADP ribose polymerase; Proteomics; Biology; DNA damage; DNA repair; Computational biology; Chemistry; Cell biology; Molecular biology; Biochemistry; DNA; Polymerase; Gene","score_opus":0.02006627637336209,"score_gpt":0.29777101722949095,"score_spread":0.27770474085612884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046240854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941144,0.000105956875,0.0013165999,0.0025714687,0.00020538832,0.0005461011,0.000010714353,0.000048313566,0.0010810822],"genre_scores_gemma":[0.978871,0.000056064422,0.020513866,0.00022075746,0.000075301454,0.000083637366,0.000008293325,0.000009065442,0.00016200425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986366,0.000028165166,0.0002721466,0.0003559085,0.00048560533,0.00022158322],"domain_scores_gemma":[0.9989991,0.000062169915,0.00020415439,0.00034182685,0.00020491876,0.0001878283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008859555,0.00010933773,0.00017764351,0.00027047584,0.00011454707,0.00004594428,0.00017736408,0.00006110337,0.00018107206],"category_scores_gemma":[0.0003791344,0.00009484656,0.000025154823,0.00092556985,0.001149957,0.00041890258,0.00003087852,0.00028947857,0.000022632872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000314117,0.000020000169,0.032969255,0.00004219751,0.00000410624,5.103894e-7,0.0002825907,1.5465227e-7,0.96512496,0.00049714674,0.00016348579,0.00086416485],"study_design_scores_gemma":[0.00049377733,0.00014654825,0.05996682,0.00005760536,0.000008387573,0.000015712178,0.000056859815,0.00012678702,0.9353311,0.0030529865,0.00064729305,0.000096136915],"about_ca_topic_score_codex":0.000017574854,"about_ca_topic_score_gemma":0.0000015729303,"teacher_disagreement_score":0.02979389,"about_ca_system_score_codex":0.000055806086,"about_ca_system_score_gemma":0.00020788016,"threshold_uncertainty_score":0.42370644},"labels":[],"label_agreement":null},{"id":"W2046461922","doi":"10.1074/jbc.m211641200","title":"Poly(ADP-ribose) Polymerase-1 Is a Positive Regulator of the p53-mediated G1 Arrest Response following Ionizing Radiation","year":2003,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Ionizing radiation; Regulator; Poly ADP ribose polymerase; Polymerase; Chemistry; Cancer research; Cell cycle checkpoint; Ribose; Molecular biology; Irradiation; Biology; Cell cycle; Biochemistry; Enzyme; Physics; Apoptosis; Gene","score_opus":0.021082656505322057,"score_gpt":0.28521983866599115,"score_spread":0.2641371821606691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046461922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917824,0.0038288978,0.000059567807,0.0034107016,0.00030189345,0.00010355233,0.000030838703,0.000012339508,0.0004697883],"genre_scores_gemma":[0.9980612,0.00009713768,0.0002635242,0.0010111389,0.00036956705,0.0000030176373,0.0000062138797,0.000012227391,0.00017597956],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840826,0.00022411939,0.00062071293,0.00016620645,0.00036857362,0.00021212846],"domain_scores_gemma":[0.99836993,0.00042552347,0.00065002596,0.00022206578,0.00016602335,0.00016640531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007664422,0.00016044856,0.00039995014,0.000042396314,0.000087440494,0.000011837489,0.00014294143,0.00024618048,0.00028569018],"category_scores_gemma":[0.0015173036,0.000098237906,0.0004207396,0.00030130183,0.00014991821,0.00005848833,0.000019263147,0.00041659086,0.000002823807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018908725,0.00012392589,0.010570918,0.000015880074,0.00014255063,0.000049443785,0.00015285955,0.0000011934336,0.985984,0.0000069117987,0.00071710884,0.0003442976],"study_design_scores_gemma":[0.0024905042,0.00023032265,0.032871842,0.0003334968,0.000061555715,0.0002985147,0.00019949592,0.0000063005223,0.9612275,0.00009987686,0.0020745893,0.00010599648],"about_ca_topic_score_codex":0.000002514535,"about_ca_topic_score_gemma":4.205135e-8,"teacher_disagreement_score":0.024756534,"about_ca_system_score_codex":0.00023380114,"about_ca_system_score_gemma":0.00032256637,"threshold_uncertainty_score":0.40060255},"labels":[],"label_agreement":null},{"id":"W2046810852","doi":"10.1016/j.jmb.2006.06.082","title":"Crystal Structure of Visfatin/Pre-B Cell Colony-enhancing Factor 1/Nicotinamide Phosphoribosyltransferase, Free and in Complex with the Anti-cancer Agent FK-866","year":2006,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Mental Health; University Health Network","keywords":"Nicotinamide phosphoribosyltransferase; Nicotinamide mononucleotide; Chemistry; Insulin receptor; NAD+ kinase; Nicotinamide; Insulin; Receptor; Internal medicine; Biochemistry; Endocrinology; Biology; Enzyme; Insulin resistance; Nicotinamide adenine dinucleotide; Medicine","score_opus":0.008942099812979977,"score_gpt":0.27676694304280697,"score_spread":0.26782484322982697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046810852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98889893,0.0026750893,0.0067080613,0.0011995911,0.00008356774,0.0002512353,0.00010946986,0.000004994993,0.000069082096],"genre_scores_gemma":[0.99775296,0.00024593543,0.0012999291,0.0005416365,0.000108029955,0.000003124686,0.0000121637395,0.000020285475,0.000015924059],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987576,0.00013879337,0.00051058934,0.00016352147,0.00020946401,0.00022004994],"domain_scores_gemma":[0.99909407,0.00007812676,0.00038393625,0.00019448473,0.00018587174,0.00006350765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014188686,0.0001709143,0.0004933822,0.00012262164,0.000038298556,0.00000848241,0.00014840641,0.000118624135,0.00015371079],"category_scores_gemma":[0.000018409244,0.00010646469,0.00009215612,0.00017168818,0.00022477868,0.00003371027,0.00002364692,0.00037685107,1.5885131e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007477978,0.000080595455,0.03213074,0.000057944835,0.0000798094,0.0000512566,0.00017167407,0.00046060828,0.96572536,0.000052966898,0.00029428364,0.00014693766],"study_design_scores_gemma":[0.004704026,0.0009694122,0.104577966,0.00012518794,0.000068334964,0.00019289258,0.000097888944,0.00002734896,0.88792425,0.00026719808,0.0009303092,0.000115181305],"about_ca_topic_score_codex":0.0001886957,"about_ca_topic_score_gemma":0.00033138294,"teacher_disagreement_score":0.07780113,"about_ca_system_score_codex":0.00009327881,"about_ca_system_score_gemma":0.00015645154,"threshold_uncertainty_score":0.43415043},"labels":[],"label_agreement":null},{"id":"W2048465335","doi":"10.1093/nar/gks798","title":"PARP activation regulates the RNA-binding protein NONO in the DNA damage response to DNA double-strand breaks","year":2012,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"Canadian Institutes of Health Research","keywords":"Biology; Poly ADP ribose polymerase; RNA; DNA; DNA repair; Molecular biology; Polymerase; DNA damage; DNA-binding protein; RNA-binding protein; Homologous recombination; Cell biology; Genetics; Transcription factor; Gene","score_opus":0.09524547749145432,"score_gpt":0.3984670524958999,"score_spread":0.3032215750044456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048465335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574606,0.00005231046,0.000031886462,0.03239663,0.00007029893,0.0026124925,0.000008754242,0.000047976668,0.007319054],"genre_scores_gemma":[0.9954667,0.000012897934,0.0001971355,0.0005444186,0.0005107297,0.00065267365,0.000013054342,0.00004933454,0.0025530686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99580497,0.001195164,0.00035184604,0.0003368832,0.0014088765,0.00090225],"domain_scores_gemma":[0.9977025,0.0008652255,0.000065961,0.0009300867,0.00021294602,0.00022332129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0096636955,0.00018878539,0.00023301765,0.000429266,0.00047079907,0.0001607763,0.0005120323,0.00017230526,0.00051886553],"category_scores_gemma":[0.0005087524,0.00011477147,0.00007619242,0.0014240256,0.00031825434,0.00041908622,0.00011370082,0.0010653188,0.0003135812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010669737,0.0002008082,0.001635019,0.000040804152,0.000028747505,0.000013214039,0.008185938,0.0000040968566,0.97068363,0.0006060236,0.004562977,0.003368977],"study_design_scores_gemma":[0.0050338553,0.00057353836,0.09361931,0.00050097017,0.000012004179,0.000041715328,0.0049505727,0.000047519865,0.8419356,0.0003123023,0.052752726,0.00021992615],"about_ca_topic_score_codex":0.00011087139,"about_ca_topic_score_gemma":0.000016632226,"teacher_disagreement_score":0.12874809,"about_ca_system_score_codex":0.00047356982,"about_ca_system_score_gemma":0.00021843187,"threshold_uncertainty_score":0.5681214},"labels":[],"label_agreement":null},{"id":"W2048470590","doi":"10.1371/journal.pone.0047978","title":"PARP-1 Modulation of mTOR Signaling in Response to a DNA Alkylating Agent","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"mTORC1; mTORC2; Poly ADP ribose polymerase; PI3K/AKT/mTOR pathway; Cell biology; Protein kinase B; Programmed cell death; Phosphorylation; AMPK; Biology; Signal transduction; NAD+ kinase; Chemistry; Cancer research; Apoptosis; Protein kinase A; Biochemistry; Polymerase; Enzyme","score_opus":0.10912958844107297,"score_gpt":0.3173272922977587,"score_spread":0.20819770385668573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048470590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978818,0.00015248984,0.00022702718,0.0010465533,0.000034566703,0.00038030103,0.0000051872225,0.00002849594,0.00024353844],"genre_scores_gemma":[0.9910364,0.0000055965543,0.008183242,0.00036853942,0.0002018523,0.000056207155,0.0000066819125,0.000017365564,0.00012411259],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990229,0.00009064524,0.00028029323,0.00010934574,0.00030942893,0.00018741055],"domain_scores_gemma":[0.9994086,0.00013522783,0.00008037187,0.00019950455,0.00006702502,0.00010925909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006223387,0.000070867536,0.00020717806,0.00015820097,0.000018028208,0.0000036861989,0.00003818866,0.000044539825,0.0002037591],"category_scores_gemma":[0.00039827937,0.00007255292,0.000029483743,0.00022343485,0.000013512748,0.00009644807,0.000020592379,0.000082422164,0.000039839342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013085301,0.0006530495,0.03501463,0.00006839779,0.00004175114,0.0000017803383,0.002083165,0.00010315605,0.96011525,0.000013119193,0.000041726882,0.0005554493],"study_design_scores_gemma":[0.001537164,0.00023988467,0.15879315,0.0010499407,0.000041325486,0.000001581725,0.00017380991,0.0010405413,0.83685607,0.00006437572,0.00009975372,0.00010242637],"about_ca_topic_score_codex":0.000014542953,"about_ca_topic_score_gemma":0.0000016781024,"teacher_disagreement_score":0.12377852,"about_ca_system_score_codex":0.00016512121,"about_ca_system_score_gemma":0.00003291145,"threshold_uncertainty_score":0.2958622},"labels":[],"label_agreement":null},{"id":"W2048567256","doi":"10.1007/s00018-009-0105-4","title":"Functional interplay between Parp-1 and SirT1 in genome integrity and chromatin-based processes","year":2009,"lang":"en","type":"article","venue":"Cellular and Molecular Life Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; University of Ottawa","funders":"Centre National de la Recherche Scientifique; Ligue Contre le Cancer; Agence Nationale de la Recherche","keywords":"Biology; Chromatin; Heterochromatin; Poly ADP ribose polymerase; Cell biology; Histone; DNA repair; DNA damage; Genetics; Histone deacetylase; Molecular biology; Chromatin immunoprecipitation; DNA; Gene; Polymerase; Gene expression","score_opus":0.02979388740760136,"score_gpt":0.3085344008920097,"score_spread":0.2787405134844083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048567256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98363024,0.0075201844,0.0051062056,0.0028960812,0.00003293684,0.00019849472,0.000005892046,0.000023084256,0.0005868538],"genre_scores_gemma":[0.99683404,0.00015984186,0.0009423447,0.0019518909,0.00006360874,0.000009190968,0.000014065548,0.000004902767,0.00002012637],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989936,0.000043391312,0.00019038367,0.00034789174,0.00024224578,0.00018254074],"domain_scores_gemma":[0.9995787,0.00006079532,0.000052259853,0.0000860366,0.000048808943,0.00017340196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038849976,0.00012660598,0.00021267938,0.00015376725,0.00010950683,0.00004660724,0.000054106502,0.0000647712,0.000027846749],"category_scores_gemma":[0.00012727569,0.0001028741,0.000021032747,0.0002967597,0.00044941908,0.00009289812,0.000018537457,0.00016807868,0.0000014676748],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022755387,0.00023901035,0.14796126,0.0005583114,0.00005254752,0.00012857972,0.0012684055,0.00006249035,0.8384793,0.00094311626,0.00024958054,0.009829887],"study_design_scores_gemma":[0.0072025047,0.0030271404,0.5000292,0.0010156617,0.00014796777,0.00012724282,0.0010371853,0.0020590485,0.47144723,0.007916438,0.0050700773,0.00092026906],"about_ca_topic_score_codex":0.000016392065,"about_ca_topic_score_gemma":0.0000037834905,"teacher_disagreement_score":0.36703202,"about_ca_system_score_codex":0.000018882747,"about_ca_system_score_gemma":0.00026140636,"threshold_uncertainty_score":0.41950843},"labels":[],"label_agreement":null},{"id":"W2049028195","doi":"10.1126/scisignal.2000902","title":"Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1–Dependent Cell Death (Parthanatos)","year":2011,"lang":"en","type":"article","venue":"Science Signaling","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":464,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Apoptosis; Programmed cell death; Polymerase; Cell biology; Biology; Molecular biology; Ribose; Cancer research; Chemistry; Biochemistry; Enzyme","score_opus":0.09824333107992472,"score_gpt":0.35178951594270047,"score_spread":0.25354618486277575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049028195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708543,0.00032388823,0.022764876,0.0013480166,0.0010262856,0.000814473,0.00012253298,0.00016028008,0.0025853915],"genre_scores_gemma":[0.97631377,0.000007841078,0.020016648,0.0027449662,0.0005488462,0.00012500757,0.0000051333272,0.00005275742,0.00018505676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99608666,0.000043979442,0.0005655443,0.001033391,0.0010564865,0.0012139347],"domain_scores_gemma":[0.9978768,0.00022140396,0.00013622345,0.0005480725,0.00034713894,0.0008703652],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010360703,0.0003354866,0.0004375185,0.0006008918,0.00083252153,0.00013840511,0.0004811878,0.00013014539,0.0011282394],"category_scores_gemma":[0.0003245543,0.0003167085,0.00018970024,0.0009022976,0.00037137585,0.00050656585,0.00010502276,0.0002912126,0.00015882897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015398071,0.0001387666,0.004212623,0.00006825768,0.000018851555,0.000009378179,0.003321041,0.0000030636863,0.9899303,0.00046016526,0.00022673554,0.0014568521],"study_design_scores_gemma":[0.001029339,0.00047507323,0.00054825825,0.00031338772,0.000059234208,0.000020624411,0.001040409,0.00021331324,0.9953231,0.0003189551,0.0002676708,0.0003905849],"about_ca_topic_score_codex":0.00013266044,"about_ca_topic_score_gemma":0.0000023538487,"teacher_disagreement_score":0.0054594874,"about_ca_system_score_codex":0.0003527793,"about_ca_system_score_gemma":0.00065442343,"threshold_uncertainty_score":0.9999285},"labels":[],"label_agreement":null},{"id":"W2049436645","doi":"10.1258/ebm.2010.009280","title":"Poly ADP-ribose polymerase-1 and health","year":2010,"lang":"en","type":"review","venue":"Experimental Biology and Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"NAD+ kinase; Poly ADP ribose polymerase; Nicotinamide adenine dinucleotide; DNA repair; Niacin; Genome instability; Biology; Chromatin; Biochemistry; Polymerase; DNA damage; Chemistry; Cell biology; Enzyme; DNA","score_opus":0.09897521991096013,"score_gpt":0.4970098726646297,"score_spread":0.39803465275366956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049436645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000092523565,0.99177,0.0000043823325,0.0050944593,0.0010192655,0.00075578695,0.00005100419,0.00006123695,0.0011513009],"genre_scores_gemma":[0.00033843625,0.99109155,0.00021313169,0.0051001124,0.0020272944,0.00014110877,0.00048941997,0.000042801308,0.000556121],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828833,0.00012214038,0.0005690885,0.00056476827,0.00010560182,0.00035008305],"domain_scores_gemma":[0.9987427,0.00009222004,0.0002719627,0.00042139905,0.000017350378,0.00045439263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031934143,0.00043948827,0.0020214834,0.00021609382,0.00014906435,0.00000428381,0.00009834484,0.00050626945,0.0006053531],"category_scores_gemma":[0.000031383675,0.00028959327,0.000103936974,0.000116350515,0.0010105813,0.000027336087,0.00009173823,0.00067669066,0.000018462128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060986855,0.00009156455,0.00003479419,0.0016054161,0.00013493284,0.000022812412,0.00039956666,5.4130585e-11,0.001353351,0.0007763633,0.0076115928,0.9879086],"study_design_scores_gemma":[0.0021787432,0.0018600567,0.000013710822,0.0063303965,0.0001512915,0.0014145712,0.00014246572,1.5068234e-7,0.00052921387,0.00004162112,0.98712033,0.00021746846],"about_ca_topic_score_codex":0.00013231699,"about_ca_topic_score_gemma":0.0000030164606,"teacher_disagreement_score":0.98769116,"about_ca_system_score_codex":0.00009450226,"about_ca_system_score_gemma":0.00025522747,"threshold_uncertainty_score":0.9999556},"labels":[],"label_agreement":null},{"id":"W2049812113","doi":"10.1002/glia.20936","title":"Astrocytic poly(ADP‐ribose) polymerase‐1 activation leads to bioenergetic depletion and inhibition of glutamate uptake capacity","year":2009,"lang":"en","type":"article","venue":"Glia","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Glutamate receptor; Biology; NAD+ kinase; Astrocyte; Biochemistry; Bioenergetics; Molecular biology; Cell biology; Polymerase; Enzyme; Receptor; Mitochondrion; Endocrinology","score_opus":0.022123358267323256,"score_gpt":0.27722970451751044,"score_spread":0.2551063462501872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049812113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99023485,0.00015856947,0.0045285965,0.004069729,0.00012574489,0.00032469715,0.0000295327,0.00008454805,0.00044371813],"genre_scores_gemma":[0.995488,0.000030224528,0.002181176,0.0018374438,0.00026613267,0.000018350793,0.000051157185,0.000016887032,0.00011062769],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879843,0.000041041643,0.00034811263,0.00027604483,0.0002954789,0.00024088696],"domain_scores_gemma":[0.99933064,0.000020760941,0.00013542113,0.00023315776,0.00011386723,0.00016613299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014401936,0.00016739767,0.00026905647,0.00022345694,0.00006915194,0.000015593978,0.00003458674,0.00010495181,0.00010073649],"category_scores_gemma":[0.000053859025,0.0001672302,0.00006002201,0.00032054214,0.000069580405,0.00014421501,0.000010767457,0.00012632138,0.00002272654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004349546,0.000095877804,0.0014541693,0.000043321805,0.000014042223,0.0000030694873,0.00024173096,0.000013720864,0.98472655,0.0005408582,0.00077007303,0.011661641],"study_design_scores_gemma":[0.0018601522,0.00075677497,0.10890205,0.00030557363,0.00004063276,0.000029364694,0.000045432145,0.00009778201,0.8865104,0.00054088153,0.00076128036,0.00014970438],"about_ca_topic_score_codex":0.00007872262,"about_ca_topic_score_gemma":0.00000636595,"teacher_disagreement_score":0.10744788,"about_ca_system_score_codex":0.00018228304,"about_ca_system_score_gemma":0.000057592457,"threshold_uncertainty_score":0.68194497},"labels":[],"label_agreement":null},{"id":"W2055443384","doi":"10.1016/j.ajpath.2010.12.004","title":"Signaling Mechanism of Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Inflammatory Diseases","year":2011,"lang":"en","type":"review","venue":"American Journal Of Pathology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Poly ADP ribose polymerase; Polymerase; Mechanism (biology); Biology; Immunology; Medicine; Cancer research; Biochemistry; Enzyme","score_opus":0.03900532691694775,"score_gpt":0.3417638665079199,"score_spread":0.30275853959097215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055443384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002909028,0.99538124,0.00053226016,0.00006620687,0.0004976702,0.00032786868,0.00008426967,0.000016157748,0.00018529233],"genre_scores_gemma":[0.0061149294,0.99127495,0.0013378814,0.00031920275,0.00077361387,0.00003013897,0.00001762809,0.00009610686,0.000035562287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99602526,0.0007875429,0.0021060945,0.00032705115,0.00033875837,0.00041526547],"domain_scores_gemma":[0.99482757,0.00032660374,0.003861516,0.00046531044,0.00021575562,0.00030327536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006211171,0.00045492267,0.0038872918,0.0012265721,0.000026728505,0.0000061366572,0.0003609669,0.00022594619,0.00032843451],"category_scores_gemma":[0.00014650906,0.00036792888,0.0009130359,0.00053666875,0.0006730995,0.00008318091,0.00005740809,0.0009095529,0.000017757238],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038409166,0.00033212706,0.00034935164,0.0027986635,0.0004668731,0.004253987,0.00048804266,5.285747e-7,0.000623551,0.0010789357,0.00012274778,0.9891011],"study_design_scores_gemma":[0.008351861,0.013645077,0.0005111635,0.09019122,0.008785608,0.047614794,0.0014433177,0.00000304747,0.0024596755,0.0033022272,0.8215661,0.002125904],"about_ca_topic_score_codex":0.000024768164,"about_ca_topic_score_gemma":0.0000011979256,"teacher_disagreement_score":0.9869752,"about_ca_system_score_codex":0.00024333509,"about_ca_system_score_gemma":0.0013824349,"threshold_uncertainty_score":0.9998773},"labels":[],"label_agreement":null},{"id":"W2056498488","doi":"10.3389/fphar.2013.00018","title":"Resistance to PARP-Inhibitors in Cancer Therapy","year":2013,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Université Laval","keywords":"Cancer therapy; Medicine; Poly ADP ribose polymerase; Cancer; Pharmacology; Cancer research; Oncology; Internal medicine; Biology; DNA; Biochemistry","score_opus":0.022013366907800487,"score_gpt":0.3454462394461926,"score_spread":0.32343287253839215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056498488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473415,0.010112711,0.00043730836,0.028045164,0.0065051373,0.0021364344,0.000012717529,0.00008345099,0.0053255633],"genre_scores_gemma":[0.9566384,0.0041864244,0.0055936724,0.024929937,0.0008120965,0.003029302,0.0000073759584,0.000056581182,0.004746237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983475,0.00013248088,0.00040630347,0.0004118094,0.00018485075,0.0005170304],"domain_scores_gemma":[0.9994284,0.000042357067,0.00007268985,0.00019153513,0.000075493335,0.00018955705],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002012631,0.00019158755,0.0004301479,0.00046972622,0.000031165317,0.000009541361,0.0001549289,0.00013732754,0.0021488885],"category_scores_gemma":[0.000014580474,0.00018612848,0.00005884252,0.0006744562,0.00010638678,0.000119430144,0.00002444263,0.0003554683,0.00009227925],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088372553,0.00018823678,0.14485577,0.000021882817,0.0000462444,0.00004930621,0.00062881655,0.00009078078,0.04841496,0.0000128247375,0.7881507,0.016656728],"study_design_scores_gemma":[0.013414436,0.0002701033,0.091835245,0.00019798768,0.000019740695,0.000006996448,0.00030292344,0.00025774288,0.12991624,0.0014129445,0.76193243,0.00043321156],"about_ca_topic_score_codex":0.00024819907,"about_ca_topic_score_gemma":0.00011589464,"teacher_disagreement_score":0.08150128,"about_ca_system_score_codex":0.0007085551,"about_ca_system_score_gemma":0.00017216186,"threshold_uncertainty_score":0.99876326},"labels":[],"label_agreement":null},{"id":"W2057879261","doi":"10.1042/bj20020669","title":"The genes pme-1 and pme-2 encode two poly(ADP-ribose) polymerases in Caenorhabditis elegans","year":2002,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Caenorhabditis elegans; Biology; Polymerase; Gene; Biochemistry; Operon; Alternative splicing; Subfamily; Enzyme; Genetics; Molecular biology; Messenger RNA","score_opus":0.020543292244166244,"score_gpt":0.28583767490402556,"score_spread":0.26529438265985933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057879261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9217865,0.06283081,0.000097450946,0.013489571,0.00036018717,0.0001424655,0.000020398897,0.000033174252,0.0012394675],"genre_scores_gemma":[0.98635644,0.008876652,0.0004892686,0.0015765545,0.0019994155,0.000014835422,0.000004553996,0.00002782134,0.00065445877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985076,0.000069007794,0.00041552458,0.0002227833,0.00036155537,0.00042353405],"domain_scores_gemma":[0.99912477,0.0001707811,0.00011878053,0.00020754176,0.00006803673,0.00031011068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020698253,0.0001844615,0.00024966124,0.00010006026,0.0002168902,0.00008412065,0.00014437799,0.000103707825,0.0004300879],"category_scores_gemma":[0.00009378266,0.00012943507,0.00010000864,0.00019676644,0.00027038623,0.00008667219,0.0000342481,0.00051412947,0.000026013737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030670047,0.0002472077,0.020012083,0.000022018896,0.00010556246,0.00033925407,0.000429066,8.9683084e-7,0.86845326,0.00015435425,0.047824766,0.06210483],"study_design_scores_gemma":[0.007257958,0.00033742195,0.0071124313,0.00042506738,0.00007449941,0.008051931,0.00033826267,0.00029314455,0.89430505,0.0007290339,0.080639444,0.0004357537],"about_ca_topic_score_codex":0.000058355774,"about_ca_topic_score_gemma":0.000013229644,"teacher_disagreement_score":0.06456997,"about_ca_system_score_codex":0.00015230988,"about_ca_system_score_gemma":0.000068542846,"threshold_uncertainty_score":0.5278209},"labels":[],"label_agreement":null},{"id":"W2059397580","doi":"10.1073/pnas.0606526103","title":"Poly(ADP-ribose) (PAR) polymer is a death signal","year":2006,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":636,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institutes of Health; National Institute of Neurological Disorders and Stroke; American Heart Association","keywords":"Poly ADP ribose polymerase; Programmed cell death; Apoptosis; Excitotoxicity; Chemistry; Cell biology; Biology; Molecular biology; Biochemistry; Polymerase; Enzyme","score_opus":0.051155919929456124,"score_gpt":0.3345953264226731,"score_spread":0.28343940649321697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059397580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9088415,0.001720209,0.000005369196,0.030304743,0.000035254416,0.00026919565,0.000044904576,0.000031795862,0.05874706],"genre_scores_gemma":[0.99463487,0.00001842247,0.0011048432,0.0024400218,0.0004328412,0.000013346834,2.391561e-7,0.0000063381,0.0013490797],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997658,0.000003970383,0.0003676582,0.0002484063,0.001531472,0.00019047348],"domain_scores_gemma":[0.99921423,0.00006446181,0.00037153138,0.000009148327,0.0002953958,0.00004521546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006490957,0.00010985169,0.00019236057,0.0001990246,0.00017249114,0.000016548844,0.00038676025,0.00009040526,0.00020492615],"category_scores_gemma":[0.00005642472,0.00007344614,0.00012174478,0.00074324507,0.0008010619,0.00027712624,0.00005474366,0.00016687463,0.000005469273],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000809851,0.00012823031,0.04312608,0.000062607825,0.000029225586,1.8701025e-8,0.0001412572,0.000003878186,0.8835341,0.054034907,0.018389117,0.00046962913],"study_design_scores_gemma":[0.0004940702,0.00007141157,0.08534056,0.00013991585,0.000020400475,0.000029415703,0.000042415708,0.00015723676,0.87802285,0.03421424,0.001391907,0.00007560568],"about_ca_topic_score_codex":0.000033760945,"about_ca_topic_score_gemma":2.9088888e-8,"teacher_disagreement_score":0.0857934,"about_ca_system_score_codex":0.00006459265,"about_ca_system_score_gemma":0.00008625415,"threshold_uncertainty_score":0.29950467},"labels":[],"label_agreement":null},{"id":"W2060550559","doi":"10.1074/jbc.m111.296475","title":"Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes","year":2011,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Mayo Foundation for Medical Education and Research","keywords":"Veliparib; Poly ADP ribose polymerase; Topoisomerase; PARP1; DNA damage; Biology; Camptothecin; PARP inhibitor; DNA repair; Olaparib; Biochemistry; Chemistry; Molecular biology; Polymerase; Cell biology; Enzyme; DNA","score_opus":0.02846856656092621,"score_gpt":0.29780684329709006,"score_spread":0.26933827673616384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060550559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775562,0.021145608,0.000108979606,0.00021534327,0.00023267607,0.00009798429,0.000043342246,0.000014875233,0.00058496644],"genre_scores_gemma":[0.9953635,0.0028459278,0.0008810952,0.00021447326,0.000568597,0.000005574434,0.0000054991924,0.000019443924,0.000095891424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803746,0.00005287856,0.0010483119,0.00025037746,0.00032173752,0.00028925386],"domain_scores_gemma":[0.9980097,0.00014321982,0.0011596598,0.00017457179,0.00022768344,0.00028520686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030453075,0.00025138023,0.0007510213,0.0000779207,0.00004596341,0.0000067128135,0.00013688799,0.00029664743,0.0004939203],"category_scores_gemma":[0.00011396697,0.0001820046,0.00023011063,0.00021490532,0.0003614147,0.00009347655,0.000044628425,0.000450585,4.994823e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096902216,0.00026348676,0.005465082,0.00017010309,0.00013083703,0.000025631098,0.00041365737,9.824342e-7,0.98923236,0.000003818133,0.0006700855,0.0026549445],"study_design_scores_gemma":[0.0018981739,0.000626117,0.0005357503,0.0008146328,0.00007189896,0.00006635354,0.00039796234,0.0000033633328,0.9950212,0.000055758417,0.0003304989,0.00017823916],"about_ca_topic_score_codex":0.000088073364,"about_ca_topic_score_gemma":7.786337e-7,"teacher_disagreement_score":0.01829968,"about_ca_system_score_codex":0.00010200304,"about_ca_system_score_gemma":0.00015901592,"threshold_uncertainty_score":0.7421932},"labels":[],"label_agreement":null},{"id":"W2062939866","doi":"10.1016/j.taap.2003.09.009","title":"In vivo erythroid recovery following paclitaxel injury: correlation between GATA-1, c-MYB, NF-E2, Epo receptor expressions, and apoptosis","year":2003,"lang":"en","type":"article","venue":"Toxicology and Applied Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research; Consejo Nacional de Investigaciones Científicas y Técnicas","keywords":"Apoptosis; In vivo; Paclitaxel; MYB; Cancer research; Pharmacology; Chemistry; Biology; Medicine; Internal medicine; Transcription factor; Chemotherapy; Genetics; Gene; Biochemistry","score_opus":0.021411127437448337,"score_gpt":0.3297218019390736,"score_spread":0.30831067450162525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062939866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894081,0.00071889267,0.0002740998,0.0020046479,0.0011007113,0.00088311615,0.000046134013,0.00006702942,0.0054972894],"genre_scores_gemma":[0.99128103,0.0008503677,0.0013827872,0.00517066,0.00029867105,0.00040224558,0.000026548061,0.00003506997,0.00055263593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980493,0.00028990186,0.0004911617,0.00055576547,0.00015111986,0.00046270422],"domain_scores_gemma":[0.9988511,0.00056325685,0.000170984,0.0001609832,0.000034140485,0.00021954249],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007043516,0.00026705518,0.0006315948,0.00026276225,0.00019645487,0.000011691209,0.000056971658,0.00048300173,0.002140809],"category_scores_gemma":[0.00007425293,0.00027001358,0.0000650138,0.00025655937,0.0002538931,0.00014911502,0.000053574426,0.0005618223,0.0000357871],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011607534,0.00022706902,0.011474912,0.000055014832,0.00019679187,0.000013301412,0.00042556462,0.000013835086,0.94263995,0.0012145805,0.040430762,0.002147496],"study_design_scores_gemma":[0.012284781,0.00085401646,0.002924192,0.00008099556,0.00035512343,0.000060678587,0.00038058966,0.000020750374,0.8371765,0.004065613,0.14129357,0.00050320616],"about_ca_topic_score_codex":0.000006525064,"about_ca_topic_score_gemma":0.0000025535498,"teacher_disagreement_score":0.10546344,"about_ca_system_score_codex":0.00018888428,"about_ca_system_score_gemma":0.00014759005,"threshold_uncertainty_score":0.9999752},"labels":[],"label_agreement":null},{"id":"W2063132598","doi":"10.3109/14756366.2015.1005011","title":"<i>In silico</i>investigation of PARP-1 catalytic domains in<i>holo</i>and<i>apo</i>states for the design of high-affinity PARP-1 inhibitors","year":2015,"lang":"en","type":"article","venue":"Journal of Enzyme Inhibition and Medicinal Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Bilim Akademisi; Türkiye Bilimsel ve Teknolojik Araştırma Kurumu","keywords":"Poly ADP ribose polymerase; In silico; Rational design; Polymerase; Computational biology; Chemistry; Drug design; Binding site; Enzyme; Stereochemistry; Biochemistry; Biophysics; Biology; Genetics","score_opus":0.035963094925733,"score_gpt":0.29080125597709916,"score_spread":0.25483816105136614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063132598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891629,0.0027882399,0.0013114495,0.006071558,0.00016079065,0.00040319972,0.00002348207,0.000006557805,0.000071799885],"genre_scores_gemma":[0.99681556,0.0009825705,0.00084538537,0.0008701364,0.00037750555,0.00002564355,0.00001965208,0.00001819349,0.00004537427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789387,0.00008145373,0.0011121662,0.00018683774,0.0005151496,0.00021053312],"domain_scores_gemma":[0.9976397,0.0006933774,0.0007974836,0.00016707368,0.00043453305,0.00026781487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019301334,0.00019280512,0.00060900627,0.00015466762,0.000034065597,0.000008743294,0.00007370543,0.00015712439,0.000016114735],"category_scores_gemma":[0.00057605276,0.00013854277,0.00008803702,0.00028579342,0.00052689953,0.00017663126,0.000022935881,0.00039559705,2.7800715e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050812317,0.00040965865,0.005793669,0.0014646696,0.00012691919,0.00012290389,0.004893094,0.0008041197,0.96471494,0.00015300613,0.01567426,0.00076151086],"study_design_scores_gemma":[0.0121233445,0.0008946301,0.001684343,0.0019055564,0.00017033094,0.0006966266,0.0022591683,0.0002836297,0.974249,0.0048878435,0.0006972943,0.00014822614],"about_ca_topic_score_codex":0.00008328071,"about_ca_topic_score_gemma":0.000006968295,"teacher_disagreement_score":0.014976964,"about_ca_system_score_codex":0.00014861261,"about_ca_system_score_gemma":0.00044316976,"threshold_uncertainty_score":0.564961},"labels":[],"label_agreement":null},{"id":"W2063299963","doi":"10.18388/abp.2009_2455","title":"Inhibition of poly(ADP-ribose) polymerase activity affects its subcellular localization and DNA strand break rejoining.","year":2009,"lang":"en","type":"article","venue":"Acta Biochimica Polonica","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; National Cancer Institute; National Academy of Sciences of Belarus","keywords":"Poly ADP ribose polymerase; Polymerase; DNA; DNA repair; Molecular biology; PARP inhibitor; Biology; DNA damage; Chemistry; Biochemistry","score_opus":0.015926135436921566,"score_gpt":0.2761435535336566,"score_spread":0.26021741809673504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063299963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805791,0.0022115195,0.00030293883,0.015021221,0.000115776944,0.0005036035,0.00007022811,0.0001143511,0.001081261],"genre_scores_gemma":[0.9974246,0.00056200795,0.00018167419,0.0013721074,0.00023198285,0.000010113748,0.00010366507,0.00003283554,0.00008099566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983355,0.0001280082,0.00036642505,0.00046145712,0.00034787937,0.00036072131],"domain_scores_gemma":[0.9988579,0.00009134345,0.00029406583,0.0004271518,0.00008965944,0.00023984184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023940536,0.00027487054,0.00047170251,0.00021887632,0.00012534,0.000024850067,0.00007644886,0.00025481137,0.00009540045],"category_scores_gemma":[0.00009303133,0.00026967435,0.00011698689,0.00036269313,0.00019652971,0.00020920172,0.000028839568,0.00023917294,0.0000070768265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010312004,0.0003392417,0.00027186266,0.000097226744,0.00005362756,0.00001868928,0.00025794507,0.0000011406042,0.99273914,0.0002036624,0.0022913977,0.0026948538],"study_design_scores_gemma":[0.0035504221,0.0011618546,0.01232898,0.00036539862,0.000114063594,0.00012422848,0.000024196925,0.00025587832,0.9804336,0.00011079372,0.0012785546,0.00025205524],"about_ca_topic_score_codex":0.000047628844,"about_ca_topic_score_gemma":0.000007660791,"teacher_disagreement_score":0.016845517,"about_ca_system_score_codex":0.000101158184,"about_ca_system_score_gemma":0.00017511014,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W2063413535","doi":"10.1242/jcs.01080","title":"Poly(ADP-ribosyl)ated chromatin domains: access granted","year":2004,"lang":"en","type":"review","venue":"Journal of Cell Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; Health Canada; Université Laval","funders":"","keywords":"Biology; Chromatin; Histone; Cell biology; Histone-modifying enzymes; Chromatin remodeling; Histone code; DNA repair; DNA; Transcription (linguistics); Genetics; Nucleosome","score_opus":0.06662653207690032,"score_gpt":0.42840348296488767,"score_spread":0.36177695088798734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063413535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021738234,0.9939707,0.0004938581,0.0002259887,0.0011576569,0.0004984972,0.000015374477,0.000030994244,0.0033895792],"genre_scores_gemma":[0.00066294544,0.9962257,0.0018259315,0.0002709724,0.00059799955,0.000009980625,0.0000052801315,0.00004416305,0.00035703622],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956512,0.00011382717,0.0015414524,0.00039606405,0.0017648714,0.0005325724],"domain_scores_gemma":[0.9957965,0.0001300775,0.0024229873,0.0005021901,0.0006360356,0.00051222317],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017691226,0.00041015388,0.0019153022,0.0010634427,0.0002099887,0.00019825572,0.0013827417,0.0002196514,0.00040771082],"category_scores_gemma":[0.00019574734,0.00027662038,0.00067979103,0.0027814787,0.00075299275,0.00066744804,0.000110518355,0.0009703716,0.00007477339],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017536177,0.0008432238,0.0000138896585,0.029607125,0.00027002758,0.0015855514,0.00043833823,0.000009309525,0.010623237,0.00012180565,0.0035698994,0.9527422],"study_design_scores_gemma":[0.0027811902,0.0007178186,0.0000376911,0.07706422,0.00076305814,0.0047011506,0.00002784891,0.000006172459,0.0060187853,0.00028730129,0.9071417,0.0004530678],"about_ca_topic_score_codex":0.000011774251,"about_ca_topic_score_gemma":9.912504e-7,"teacher_disagreement_score":0.95228916,"about_ca_system_score_codex":0.0013566106,"about_ca_system_score_gemma":0.0068229786,"threshold_uncertainty_score":0.9999686},"labels":[],"label_agreement":null},{"id":"W2064098728","doi":"10.1016/j.mrfmmm.2007.08.005","title":"Changes in poly(ADP-ribose) level modulate the kinetics of DNA strand break rejoining","year":2007,"lang":"en","type":"article","venue":"Mutation research. Fundamental and molecular mechanisms of mutagenesis","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hotel Dieu Hospital","funders":"National Cancer Institute","keywords":"Poly ADP ribose polymerase; Ribose; NAD+ kinase; DNA damage; DNA repair; DNA; Molecular biology; Polymerase; Comet assay; Chemistry; Biology; Biochemistry; Enzyme","score_opus":0.07785866689862087,"score_gpt":0.3665730970292649,"score_spread":0.288714430130644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064098728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633504,0.00080319063,0.032747507,0.001920115,0.00007182546,0.0006736394,0.000065967906,0.000014586484,0.00035273944],"genre_scores_gemma":[0.99577326,0.00015206837,0.003519839,0.00030139333,0.00003493655,0.00003245709,0.0000344113,0.0000305355,0.000121108766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99791086,0.00016346545,0.00041390862,0.0002848079,0.0008641247,0.00036281036],"domain_scores_gemma":[0.9991049,0.00016168648,0.00014169567,0.00025163687,0.00021469571,0.00012538205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001492949,0.00015097193,0.00028362995,0.00045718925,0.00007804933,0.0000179829,0.00011693493,0.00010337079,0.000096511496],"category_scores_gemma":[0.00006875147,0.0001257976,0.00007116962,0.0005036544,0.00027344815,0.000048674876,0.000074511416,0.0001808297,0.0000019140812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044751947,0.0001832586,0.00015593282,0.00014952669,0.0000663554,0.00010507353,0.00086418906,0.000027987317,0.98013926,0.0015903371,0.000014597429,0.016255995],"study_design_scores_gemma":[0.002179297,0.0009337382,0.011405669,0.00020305901,0.000031708612,0.000059918657,0.0027573593,0.00018554063,0.9788165,0.0032276532,0.000093675204,0.000105871004],"about_ca_topic_score_codex":0.000308431,"about_ca_topic_score_gemma":0.00019542634,"teacher_disagreement_score":0.032422822,"about_ca_system_score_codex":0.00010568903,"about_ca_system_score_gemma":0.000060049002,"threshold_uncertainty_score":0.51298773},"labels":[],"label_agreement":null},{"id":"W2064477709","doi":"10.1186/cc5283","title":"Insulin therapy inhibits poly(ADP-ribose)polymerase activation in endotoxin shock","year":2007,"lang":"en","type":"article","venue":"Critical Care","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Poly ADP ribose polymerase; Polymerase; Insulin; Shock (circulatory); Internal medicine; Intensive care medicine; Pharmacology; Biochemistry; Enzyme","score_opus":0.03987395667790997,"score_gpt":0.3686087071663049,"score_spread":0.3287347504883949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064477709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752782,0.005605888,0.0020813413,0.005450098,0.00039423615,0.00061552174,0.000031829182,0.00016499996,0.010377887],"genre_scores_gemma":[0.9922606,0.00007045708,0.0006184788,0.005912173,0.0008691474,0.00006164555,0.0000782046,0.000047264115,0.00008204561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980918,0.00007092111,0.00045006958,0.0004039232,0.0004530907,0.00053018925],"domain_scores_gemma":[0.99871486,0.00036671624,0.000037007216,0.00033895712,0.00025087933,0.00029158065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002579407,0.0002269758,0.00031816965,0.00027860803,0.0000824741,0.000027093874,0.000090099646,0.0002311345,0.0005772662],"category_scores_gemma":[0.00039411135,0.00021936414,0.000108987886,0.000480519,0.00018801229,0.00017304535,0.000024746321,0.000476267,0.00006477328],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034319193,0.00082196685,0.015369623,0.0003327085,0.000035087716,0.00031740294,0.004646723,0.0000018798586,0.78738296,0.006893223,0.0011996671,0.17956686],"study_design_scores_gemma":[0.005075663,0.00042209052,0.016082278,0.0002904308,0.000011238633,0.00003438424,0.00188855,0.000010712136,0.9692051,0.00063275464,0.006084718,0.00026208398],"about_ca_topic_score_codex":0.000067836336,"about_ca_topic_score_gemma":0.000025076437,"teacher_disagreement_score":0.18182217,"about_ca_system_score_codex":0.00042577955,"about_ca_system_score_gemma":0.0001720299,"threshold_uncertainty_score":0.89454097},"labels":[],"label_agreement":null},{"id":"W2064830796","doi":"10.1124/jpet.102.039768","title":"Antisense Oligonucleotides to poly(ADP-ribose) Polymerase-2 Ameliorate Colitis in Interleukin-10-Deficient Mice","year":2002,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Poly ADP ribose polymerase; Proinflammatory cytokine; PARP inhibitor; Molecular biology; Colitis; Oligonucleotide; Inflammation; Nitric oxide synthase; Interleukin; Chemistry; Biology; Pharmacology; Cytokine; Polymerase; Immunology; Cancer research; Enzyme; Biochemistry","score_opus":0.043882333187321085,"score_gpt":0.36131914757170036,"score_spread":0.31743681438437926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064830796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97369635,0.017224716,0.000025528916,0.0072233095,0.0009608952,0.00024531025,0.000012686069,0.000016407112,0.0005947983],"genre_scores_gemma":[0.9748226,0.0013982857,0.0005000794,0.022349529,0.0004905753,0.0000110189185,0.0000011911746,0.00002926919,0.00039744665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985093,0.00014327427,0.00058587576,0.00019684489,0.00022152146,0.00034320593],"domain_scores_gemma":[0.9992811,0.00008161992,0.00023111957,0.000089811234,0.000098053526,0.00021829938],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002129142,0.00021289625,0.00043989526,0.00035532546,0.00007992328,0.000024179688,0.00011172403,0.00010034705,0.0019185913],"category_scores_gemma":[0.0000036783201,0.00019379414,0.00010592788,0.0002649669,0.00019137604,0.00012643264,0.000040919786,0.00033623233,0.00004784967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027826545,0.00088808313,0.0005315347,0.000014977967,0.00021269426,0.00041161774,0.003065474,0.000013376493,0.9806632,0.000024830688,0.008004142,0.0033874384],"study_design_scores_gemma":[0.0065776464,0.0020179348,0.0008187089,0.00010552568,0.00011228692,0.0013720167,0.0011223055,0.0002423141,0.9521808,0.000019845265,0.035240453,0.00019015528],"about_ca_topic_score_codex":0.000011800748,"about_ca_topic_score_gemma":0.0000013731465,"teacher_disagreement_score":0.028482368,"about_ca_system_score_codex":0.0002805086,"about_ca_system_score_gemma":0.00005345405,"threshold_uncertainty_score":0.9989938},"labels":[],"label_agreement":null},{"id":"W2065488592","doi":"10.1139/o05-039","title":"Poly(ADP-ribosylation) and genomic stability","year":2005,"lang":"en","type":"review","venue":"Biochemistry and Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Forschungsgemeinschaft","keywords":"Chemistry; Biology; Computational biology; Genetics","score_opus":0.04438726727379407,"score_gpt":0.33598387451581146,"score_spread":0.2915966072420174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065488592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003161527,0.99173397,0.000007998974,0.00008263288,0.00007790151,0.00026901538,0.0001608836,0.00003141007,0.004474685],"genre_scores_gemma":[0.0022608405,0.9954005,0.00018123623,0.00012719708,0.0006029988,0.000046980527,0.00051142,0.000020014691,0.00084884715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988338,0.000056880093,0.0003610402,0.00050629635,0.000041442636,0.0002005788],"domain_scores_gemma":[0.9992579,0.00008625487,0.0001781314,0.00030736785,0.000028205037,0.00014209146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013779732,0.00028155252,0.000842149,0.00003465523,0.000056033383,0.000008958889,0.000060684426,0.0005890753,0.00044246082],"category_scores_gemma":[0.000016215858,0.00023087271,0.00012621564,0.000061655344,0.00027862028,0.000011934438,0.000053006752,0.00028081288,0.000020274852],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002783075,0.000044201108,0.00008958937,0.0068313824,0.000056492594,0.000002582892,0.000013083963,1.6579499e-9,0.008747216,0.000014138496,0.00013823852,0.98403525],"study_design_scores_gemma":[0.00045407357,0.000063267646,0.000012948629,0.000570832,0.00022807028,0.00012143046,0.000008673834,6.070445e-7,0.007165202,0.000023509383,0.9911417,0.00020968284],"about_ca_topic_score_codex":0.000003933139,"about_ca_topic_score_gemma":3.408631e-7,"teacher_disagreement_score":0.99100345,"about_ca_system_score_codex":0.00010699533,"about_ca_system_score_gemma":0.00022919486,"threshold_uncertainty_score":0.9414716},"labels":[],"label_agreement":null},{"id":"W2065603241","doi":"10.1093/nar/gks1337","title":"2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation","year":2012,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Transactivation; Biology; Aryl hydrocarbon receptor; Repressor; Poly ADP ribose polymerase; Aryl hydrocarbon receptor nuclear translocator; Molecular biology; Biochemistry; Aryl; Polymerase; Enzyme; Transcription factor; Gene; Chemistry","score_opus":0.061062626220752064,"score_gpt":0.3618770059318442,"score_spread":0.30081437971109215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065603241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98353493,0.0047940603,0.00080581976,0.0060095685,0.0002679941,0.0012578233,0.00018930336,0.00014051229,0.002999965],"genre_scores_gemma":[0.9947222,0.0015405582,0.00090857845,0.00060696993,0.00085409405,0.00020186116,0.00006823492,0.00013505829,0.000962452],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949417,0.00028899708,0.00085363066,0.0008238029,0.0018012833,0.0012905544],"domain_scores_gemma":[0.9969925,0.0004896498,0.0001500516,0.0010923974,0.0004177374,0.000857665],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002035196,0.00043336707,0.0007800417,0.000802114,0.00029432322,0.000055437384,0.00029702394,0.0004460739,0.0027948127],"category_scores_gemma":[0.0002283122,0.00041538352,0.00023897158,0.0011424248,0.00070464046,0.0006787515,0.000047091533,0.0012622118,0.00013078169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034324042,0.0009896918,0.017148172,0.00034983916,0.00023531362,0.000015126691,0.0066166874,0.0000010454212,0.9463178,0.00025163317,0.004084023,0.020558294],"study_design_scores_gemma":[0.0045929383,0.0008685002,0.014280155,0.0004070017,0.00007729854,0.00007940056,0.0007228788,0.00025062574,0.9678082,0.00021479289,0.010307421,0.0003907989],"about_ca_topic_score_codex":0.00041413348,"about_ca_topic_score_gemma":0.00000642159,"teacher_disagreement_score":0.02149042,"about_ca_system_score_codex":0.00034132594,"about_ca_system_score_gemma":0.0002484194,"threshold_uncertainty_score":0.9998298},"labels":[],"label_agreement":null},{"id":"W2066474732","doi":"10.1667/rrol02.1","title":"Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities Report of an NCI Workshop held September 1–3, 2010","year":2011,"lang":"en","type":"article","venue":"Radiation Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Radiation therapy; Cancer; Medicine; Resistance (ecology); Medical physics; Library science; Gerontology; Biology; Internal medicine; Computer science","score_opus":0.43208147974280015,"score_gpt":0.487009064390191,"score_spread":0.05492758464739084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066474732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9376553,0.01369304,0.000012014335,0.003641826,0.00019031827,0.0011549066,0.000021407654,0.000046180256,0.043584988],"genre_scores_gemma":[0.9566983,0.022021208,0.0009539661,0.00018103549,0.00042476977,0.00052455487,0.00007759895,0.000061124265,0.01905745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956997,0.001097372,0.0006479621,0.0004961575,0.0014888282,0.00056997465],"domain_scores_gemma":[0.9971862,0.0007485294,0.0001876302,0.00060362864,0.0010183868,0.00025566103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008424201,0.0001457848,0.00032476138,0.00114803,0.00021133566,0.0000389431,0.00016291045,0.00021785425,0.0006532336],"category_scores_gemma":[0.0006674655,0.00014444564,0.00004627935,0.0011522681,0.00046106422,0.00041963265,0.00005194856,0.0008415793,0.000008308524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010369311,0.0018992274,0.41213006,0.0011178078,0.0003660529,0.0016797727,0.03668095,0.000064624364,0.044487957,0.003970665,0.2209788,0.26625475],"study_design_scores_gemma":[0.009808896,0.0011495148,0.6453376,0.0024419148,0.000027775553,0.00014509427,0.009022423,0.0012301941,0.12369265,0.008599931,0.1977994,0.000744597],"about_ca_topic_score_codex":0.0023078541,"about_ca_topic_score_gemma":0.0012438104,"teacher_disagreement_score":0.26551017,"about_ca_system_score_codex":0.00046099263,"about_ca_system_score_gemma":0.00090579974,"threshold_uncertainty_score":0.715245},"labels":[],"label_agreement":null},{"id":"W2066493037","doi":"10.1016/j.dnarep.2008.01.001","title":"Depletion of poly(ADP-ribose) polymerase-1 reduces host cell reactivation of a UV-damaged adenovirus-encoded reporter gene in human dermal fibroblasts","year":2008,"lang":"en","type":"article","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université Laval","funders":"National Cancer Institute; RIKEN","keywords":"Biology; Poly ADP ribose polymerase; Nucleotide excision repair; Molecular biology; DNA repair; Reporter gene; DNA damage; Polymerase; Gene; DNA; Cell biology; Gene expression; Biochemistry","score_opus":0.02592825901128063,"score_gpt":0.2802963513258261,"score_spread":0.25436809231454544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066493037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965514,0.0004562771,0.00010710212,0.00035715973,0.0001034355,0.0004662151,0.000026621849,0.00013027915,0.0018015327],"genre_scores_gemma":[0.9972849,0.000071684255,0.0014849463,0.00021407189,0.00020364612,0.000044764736,0.00012894628,0.000042231837,0.0005248329],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976952,0.00013752108,0.0009801099,0.00040406134,0.000494123,0.00028894856],"domain_scores_gemma":[0.99844205,0.00006842103,0.00066671934,0.000542796,0.00018081024,0.000099186334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034027308,0.00021002784,0.00048844935,0.00039854838,0.00008555579,0.0000035836806,0.000085576976,0.00017575726,0.0001829636],"category_scores_gemma":[0.00007956053,0.00021501874,0.00019896,0.0004677735,0.00020275255,0.00019806558,0.00003060232,0.00020950912,0.0000044650715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060962915,0.0004319126,0.04405403,0.0001051726,0.000044351753,0.00011618111,0.0011941689,0.0000056086105,0.9516372,0.000009232211,0.0016341581,0.00015836643],"study_design_scores_gemma":[0.00235165,0.0003928562,0.17423217,0.00024272864,0.000025015306,0.00016172513,0.00012083163,0.000040244067,0.8220144,0.000017101229,0.0002539266,0.00014734647],"about_ca_topic_score_codex":0.0004874059,"about_ca_topic_score_gemma":0.000024337556,"teacher_disagreement_score":0.13017814,"about_ca_system_score_codex":0.00017680165,"about_ca_system_score_gemma":0.00022164466,"threshold_uncertainty_score":0.8768209},"labels":[],"label_agreement":null},{"id":"W2069169392","doi":"10.1016/j.dnarep.2006.10.027","title":"Altered DNA damage response in Caenorhabditis elegans with impaired poly(ADP-ribose) glycohydrolases genes expression","year":2006,"lang":"en","type":"article","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Biology; Caenorhabditis elegans; Molecular biology; Poly ADP ribose polymerase; Biochemistry; Gene; DNA repair; DNA damage; DNA; Polymerase; Gene expression","score_opus":0.011256400033160427,"score_gpt":0.26139117274514373,"score_spread":0.2501347727119833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069169392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468416,0.0010594554,0.00011656229,0.0016541372,0.00025603265,0.00068583095,0.00010645369,0.00064821984,0.0007891425],"genre_scores_gemma":[0.9938368,0.000035002282,0.0019080506,0.0006983253,0.0007073724,0.00018496873,0.00015771492,0.000091385395,0.0023803313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740404,0.00032201788,0.00055433996,0.0006284594,0.0005298207,0.0005613004],"domain_scores_gemma":[0.9984567,0.00021536686,0.00018697766,0.00084221934,0.00010391274,0.0001948174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041195413,0.0003553891,0.0005050194,0.0003900751,0.00012923716,0.000031083535,0.00014194545,0.00017838234,0.00030278842],"category_scores_gemma":[0.00006936789,0.00030065916,0.00017960645,0.0005530546,0.00018786962,0.00024334919,0.00004248855,0.0002532206,0.000046734534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017624935,0.00054083415,0.036393847,0.00007885768,0.000052431704,0.0013314232,0.00048389516,0.0000770474,0.91692513,0.000024362214,0.025990231,0.00047699813],"study_design_scores_gemma":[0.009083384,0.001655854,0.1755848,0.0008192283,0.00005551036,0.00048574174,0.00019887186,0.00050916313,0.75552213,0.00010527252,0.055460762,0.00051931455],"about_ca_topic_score_codex":0.000823906,"about_ca_topic_score_gemma":0.00026760407,"teacher_disagreement_score":0.16140303,"about_ca_system_score_codex":0.0003715572,"about_ca_system_score_gemma":0.00029170874,"threshold_uncertainty_score":0.99994457},"labels":[],"label_agreement":null},{"id":"W2070758111","doi":"10.1074/jbc.m706734200","title":"PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites","year":2007,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":599,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; Centre hospitalier de l'Université Laval; University of Alberta; Centre hospitalier universitaire de Québec","funders":"","keywords":"DNA damage; DNA; Kinetics; PARP1; Cell biology; Biology; Chemistry; Biophysics; Genetics; Poly ADP ribose polymerase; Physics; Polymerase","score_opus":0.10172774914764461,"score_gpt":0.35044303466399784,"score_spread":0.24871528551635325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070758111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742734,0.00047850964,0.00069324323,0.00041325172,0.00003293922,0.0002682768,0.000023416214,0.000005983671,0.00065701694],"genre_scores_gemma":[0.99396354,0.00017013108,0.0054068477,0.00015976815,0.00019485052,0.0000054957177,0.000004382825,0.0000064668757,0.00008853888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987939,0.00002028543,0.000650501,0.00012181551,0.00025988737,0.00015359726],"domain_scores_gemma":[0.9988278,0.00015500712,0.00043929723,0.0001419672,0.00023321646,0.00020271493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004644216,0.00011176834,0.0003966111,0.000038062357,0.000011976854,0.0000032847302,0.00009459586,0.0001456323,0.00017998012],"category_scores_gemma":[0.00036499478,0.00007505972,0.000101049875,0.00009418269,0.0001316866,0.000017563525,0.000043065582,0.00020266396,7.6404456e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010370616,0.00035754486,0.02016744,0.00012366862,0.000051997522,0.000045535668,0.00007318903,0.0000039884694,0.9768154,0.0000036431338,0.000111724046,0.0012087761],"study_design_scores_gemma":[0.0017478176,0.0012566526,0.024518542,0.00021544677,0.000022809585,0.000119138174,0.00019636586,0.0000024925318,0.97013754,0.000073169096,0.0016387036,0.00007134587],"about_ca_topic_score_codex":0.0000023081086,"about_ca_topic_score_gemma":8.129861e-7,"teacher_disagreement_score":0.0066779153,"about_ca_system_score_codex":0.00007461958,"about_ca_system_score_gemma":0.000029092687,"threshold_uncertainty_score":0.30608466},"labels":[],"label_agreement":null},{"id":"W2071445918","doi":"10.1073/pnas.170280397","title":"A cellular defense pathway regulating transcription through poly(ADP-ribosyl)ation in response to DNA damage","year":2000,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Poly ADP ribose polymerase; Polymerase; Transcription (linguistics); DNA damage; RNA polymerase II; Biology; Molecular biology; DNA repair; RNA polymerase I; DNA; RNA polymerase; Cell biology; Biochemistry; RNA; RNA-dependent RNA polymerase; Gene expression; Gene; Promoter","score_opus":0.052937513696997104,"score_gpt":0.3262088370988653,"score_spread":0.27327132340186816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071445918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98108494,0.00010716221,0.000007670215,0.012385619,0.000017007593,0.00039419232,0.000013897141,0.000020029178,0.0059695016],"genre_scores_gemma":[0.9951537,0.000019103374,0.0031047955,0.0012220611,0.00008712782,0.000027592434,4.6683132e-7,0.000007638796,0.00037748358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99780154,0.000027574584,0.00047401836,0.00029170033,0.0012178381,0.00018733897],"domain_scores_gemma":[0.9993971,0.0001117433,0.00022750853,0.000015826958,0.00020069805,0.000047100228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022378368,0.0001110209,0.0001961273,0.00025256135,0.00014164005,0.000020586289,0.00028231906,0.000100680336,0.00012055704],"category_scores_gemma":[0.0003736428,0.000085636675,0.000083549,0.001379377,0.00036952694,0.0006370465,0.00002004706,0.00018006138,0.000004876261],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007987012,0.00006173135,0.0010702232,0.000041496824,0.000005879091,3.1268865e-8,0.0019137773,0.00012626562,0.98950344,0.0051436825,0.00014921726,0.001185563],"study_design_scores_gemma":[0.0009437048,0.00016999773,0.072957724,0.0004705834,0.000009702197,0.0000121133135,0.00041657238,0.00070326286,0.9063992,0.016864851,0.00095145474,0.000100851765],"about_ca_topic_score_codex":0.000013794108,"about_ca_topic_score_gemma":2.0980679e-7,"teacher_disagreement_score":0.08310425,"about_ca_system_score_codex":0.00014386594,"about_ca_system_score_gemma":0.00007618771,"threshold_uncertainty_score":0.34921622},"labels":[],"label_agreement":null},{"id":"W2072550119","doi":"10.1016/j.mrfmmm.2007.05.008","title":"Niacin deficiency delays DNA excision repair and increases spontaneous and nitrosourea-induced chromosomal instability in rat bone marrow","year":2007,"lang":"en","type":"article","venue":"Mutation research. Fundamental and molecular mechanisms of mutagenesis","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Cancer Institute; Cancer Research Society","keywords":"Ethylnitrosourea; Chromatid; Micronucleus test; Sister chromatid exchange; Bone marrow; Sister chromatids; Kinetics; DNA damage; DNA repair; Biology; Chromosome instability; Molecular biology; Chemistry; Genetics; DNA; Chromosome; Toxicity; Immunology","score_opus":0.0303997804005414,"score_gpt":0.32673764159015967,"score_spread":0.29633786118961825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072550119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951661,0.0014987111,0.0019134781,0.00023470979,0.000040423252,0.00091905514,0.00002922995,0.00004556741,0.0001527303],"genre_scores_gemma":[0.99598587,0.00022355252,0.003434824,0.00019825023,0.000017969904,0.000047833168,0.0000360762,0.000030334018,0.000025314239],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99741787,0.00028949074,0.0005070835,0.00056932145,0.00079220196,0.00042406147],"domain_scores_gemma":[0.9989162,0.0002475224,0.00010587711,0.00025162863,0.00018271804,0.0002960699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020763772,0.00021341252,0.00037202472,0.00053421984,0.00018628918,0.00003549531,0.000058056474,0.00015381182,0.00007285116],"category_scores_gemma":[0.00024013387,0.00020838334,0.000070743525,0.00043774754,0.00029374578,0.00012506334,0.00013256172,0.00021879656,0.0000019693402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014579338,0.0003852655,0.002103822,0.0002370984,0.000023720468,0.0024639685,0.00042862367,0.0000022743911,0.9853582,0.00075090805,0.000006198958,0.006782025],"study_design_scores_gemma":[0.003942274,0.0020128526,0.019288719,0.00023210103,0.000045628312,0.0025489803,0.0029949928,0.00036546032,0.96375406,0.00453623,0.000037009413,0.00024169295],"about_ca_topic_score_codex":0.00061134086,"about_ca_topic_score_gemma":0.00020874657,"teacher_disagreement_score":0.021604102,"about_ca_system_score_codex":0.00022400662,"about_ca_system_score_gemma":0.00012130546,"threshold_uncertainty_score":0.84976256},"labels":[],"label_agreement":null},{"id":"W2074952360","doi":"10.1038/bjc.2012.451","title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","year":2012,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":852,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of California, San Francisco; University of Texas MD Anderson Cancer Center; U.S. Public Health Service; National Cancer Institute; U.S. Department of Health and Human Services; Science Foundation Ireland; Conquer Cancer Foundation; National Institutes of Health; Stand Up To Cancer; Entertainment Industry Foundation","keywords":"Loss of heterozygosity; Homologous recombination; Ovarian cancer; Biology; Homologous chromosome; Cancer research; Breast cancer; DNA repair; BRCA2 Protein; Genome instability; Cancer; Genetics; Oncology; Allele; DNA; Gene; Medicine; DNA damage; Mutation; Germline mutation","score_opus":0.017011516756691564,"score_gpt":0.2972541560484307,"score_spread":0.28024263929173915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074952360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98399603,0.013878999,0.00017439676,0.00019104804,0.0011594542,0.000246565,0.00021949729,0.000012168288,0.00012185402],"genre_scores_gemma":[0.98943776,0.0092923455,0.00024791874,0.00020509436,0.0006849452,0.000026398222,0.0000046532627,0.000027030565,0.000073831034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981972,0.00014602777,0.0008485314,0.00013377568,0.0003959156,0.00027856516],"domain_scores_gemma":[0.99845153,0.00005548038,0.00082322344,0.00014576041,0.00037840242,0.00014557844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006840534,0.00012298407,0.0005590813,0.00019952098,0.00002771938,0.000006652245,0.00011669422,0.00012637634,0.00062457524],"category_scores_gemma":[0.000057317156,0.00013809485,0.00024317266,0.00014974449,0.00007986455,0.00023713936,0.000024129311,0.0003479181,0.0000010772586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081549963,0.00045700735,0.9438352,0.00030378916,0.00023029823,0.00015601124,0.0004941977,0.00014243263,0.025617557,0.000017067012,0.0005279734,0.027402984],"study_design_scores_gemma":[0.005503068,0.00034879174,0.9546437,0.0022750357,0.00013187242,0.0013431372,0.000037484475,0.000014657128,0.034447752,0.00010781424,0.0010308825,0.00011580558],"about_ca_topic_score_codex":0.0031372008,"about_ca_topic_score_gemma":0.0011090692,"teacher_disagreement_score":0.027287178,"about_ca_system_score_codex":0.00056578673,"about_ca_system_score_gemma":0.00033910104,"threshold_uncertainty_score":0.6838661},"labels":[],"label_agreement":null},{"id":"W2075745805","doi":"10.1074/jbc.275.20.15504","title":"Characterization of sPARP-1","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Characterization (materials science); Materials science; Nanotechnology","score_opus":0.033637035768236824,"score_gpt":0.29313992165309843,"score_spread":0.2595028858848616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075745805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945808,0.00012289225,0.000057915044,0.00048692978,0.000031965632,0.000028075814,0.000007291569,0.0000062445383,0.0046778764],"genre_scores_gemma":[0.99795055,0.0006273605,0.00023370312,0.00025843913,0.00038195902,7.745767e-7,0.000011686,0.000003455239,0.0005320479],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993904,0.000011938103,0.00034337395,0.000057940837,0.00012395348,0.00007236186],"domain_scores_gemma":[0.9995119,0.000019915691,0.0002171497,0.000074674965,0.000104914834,0.000071474955],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000117237556,0.00005677749,0.00022106706,0.000011826869,0.00000987688,0.0000024305232,0.000056099227,0.000100965124,0.0064862026],"category_scores_gemma":[0.000034902823,0.00003704098,0.00010403094,0.00006948802,0.00006914137,0.00002733436,0.000003957306,0.0001424665,0.0000074620048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044122897,0.0001029316,0.0033736266,0.00002457439,0.000022816717,0.000017005957,0.000013509082,9.913606e-7,0.99070436,0.0000018148778,0.00011761425,0.0051795365],"study_design_scores_gemma":[0.0008333268,0.00020412079,0.021031909,0.00009599244,0.000013013931,0.00036376994,0.000007897503,0.0000033805911,0.9641521,0.00007605917,0.013179138,0.000039303362],"about_ca_topic_score_codex":2.2411315e-7,"about_ca_topic_score_gemma":4.1534167e-9,"teacher_disagreement_score":0.02655226,"about_ca_system_score_codex":0.000030490919,"about_ca_system_score_gemma":0.000039983956,"threshold_uncertainty_score":0.994422},"labels":[],"label_agreement":null},{"id":"W2077239497","doi":"10.1016/j.ceb.2006.02.013","title":"The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives","year":2006,"lang":"en","type":"review","venue":"Current Opinion in Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Wilfrid Laurier University; Université Laval","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Biology; Poly ADP ribose polymerase; Cellular metabolism; Cell biology; Computational biology; Metabolism; Biochemistry; DNA","score_opus":0.16427521110897383,"score_gpt":0.43731006358268965,"score_spread":0.27303485247371584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077239497","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011842188,0.9923125,0.000027182736,0.00019854064,0.0056942864,0.0008852263,0.00007273602,0.00003161641,0.0007660983],"genre_scores_gemma":[0.00007132286,0.9965067,0.000042459076,0.0000024627077,0.002929996,0.00016857102,0.00019811449,0.000042258343,0.00003813181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741834,0.00040004854,0.0009090768,0.0006709885,0.00017123009,0.00043030834],"domain_scores_gemma":[0.9982161,0.00046759465,0.0006397905,0.0004622752,0.000079451114,0.00013480546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000387795,0.0004820775,0.0017330495,0.00038893358,0.00007626777,0.000013179866,0.0002460518,0.00031684598,0.000031281863],"category_scores_gemma":[0.0000529489,0.00031923095,0.00035615521,0.00024046592,0.00035585958,0.00004027435,0.00012468034,0.0007602575,0.000011973937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030881558,0.0001565616,0.000023221883,0.0063654203,0.00005169616,1.4234108e-7,0.00049473153,7.19925e-8,0.00001386071,0.0039569037,0.0011766208,0.9877299],"study_design_scores_gemma":[0.001005544,0.000112546426,0.000064044376,0.009140519,0.00014174554,0.000014323009,0.0003897268,0.0000018333214,0.000032302258,0.000994133,0.98783785,0.0002654487],"about_ca_topic_score_codex":0.000024923573,"about_ca_topic_score_gemma":0.0000026966604,"teacher_disagreement_score":0.9874644,"about_ca_system_score_codex":0.00017684401,"about_ca_system_score_gemma":0.00044612793,"threshold_uncertainty_score":0.999926},"labels":[],"label_agreement":null},{"id":"W2077782535","doi":"10.1016/j.mrfmmm.2011.11.008","title":"Niacin requirements for genomic stability","year":2011,"lang":"en","type":"review","venue":"Mutation research. Fundamental and molecular mechanisms of mutagenesis","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Niacin; Poly ADP ribose polymerase; Biology; Genome instability; Telomere; Genetics; Cancer research; DNA damage; Endocrinology; DNA; Polymerase","score_opus":0.29273226076411896,"score_gpt":0.4599784019394176,"score_spread":0.16724614117529862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077782535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025891254,0.97559255,0.015184124,0.00006145895,0.00018419353,0.0053565074,0.00058517966,0.000045919438,0.0004009105],"genre_scores_gemma":[0.003821038,0.9845672,0.008735483,0.00011956672,0.000057398964,0.0016645625,0.0006091861,0.0001387106,0.00028681473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967352,0.00044209787,0.00086528884,0.00076445326,0.00069626037,0.00049669546],"domain_scores_gemma":[0.9982725,0.00018177742,0.00036431538,0.00052928616,0.00037883548,0.00027329993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016208976,0.00039433182,0.0012901213,0.0005695334,0.00018207483,0.00003675993,0.00020649089,0.0003058765,0.00045952536],"category_scores_gemma":[0.00010914979,0.00036100313,0.0005248119,0.00035074103,0.0002767907,0.00007549215,0.00016408955,0.00026807483,0.0000261456],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004977417,0.00064101524,0.0000032703804,0.038003087,0.0010057496,0.00008201711,0.00033123995,2.8530414e-7,0.06416601,0.006226201,0.00015819517,0.8888852],"study_design_scores_gemma":[0.005616345,0.004316686,0.000025004587,0.011053911,0.0022815561,0.00025856137,0.0009101652,0.000030585812,0.23147735,0.021263309,0.72170633,0.0010601814],"about_ca_topic_score_codex":0.00006330882,"about_ca_topic_score_gemma":0.000003926865,"teacher_disagreement_score":0.887825,"about_ca_system_score_codex":0.0004949497,"about_ca_system_score_gemma":0.00054777804,"threshold_uncertainty_score":0.9998842},"labels":[],"label_agreement":null},{"id":"W2078168572","doi":"10.1126/science.1221870","title":"PARP-1 Activation—Bringing the Pieces Together","year":2012,"lang":"en","type":"letter","venue":"Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"","keywords":"Poly ADP ribose polymerase; DNA; DNA repair; Chemistry; Computational biology; Cell biology; Biophysics; Biology; Biochemistry; Polymerase","score_opus":0.04749036496411589,"score_gpt":0.33231936486991337,"score_spread":0.28482899990579746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078168572","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034689917,0.0006254795,0.00050737214,0.96652377,0.0015553639,0.0003849917,0.000008255373,0.00009942579,0.026826346],"genre_scores_gemma":[0.05272824,0.000047325662,0.0004595824,0.92615116,0.009528074,0.00007645881,0.0000150951755,0.00003499497,0.010959101],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979682,0.00003440645,0.00017078852,0.0003561115,0.0009685607,0.0005019649],"domain_scores_gemma":[0.9989017,0.0001119469,0.00014533868,0.0006364761,0.00013778266,0.00006675591],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007364407,0.00016692675,0.0001776522,0.0001663685,0.00033432362,0.00008035384,0.00046188643,0.00015556824,0.00093588803],"category_scores_gemma":[0.00010194593,0.000103028484,0.0000719301,0.00060486695,0.0007614225,0.00025611455,0.00006552341,0.00095992355,0.00033703013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067993233,0.000010180038,0.0005792637,0.00003760355,0.000015064441,0.000008173446,0.00055518246,0.000002747626,0.006514298,0.0000425388,0.9878805,0.004347649],"study_design_scores_gemma":[0.00015558334,0.000018451452,0.0015482069,0.00018096037,0.000019087844,0.000041311956,0.000034942554,0.000022041517,0.012636011,0.00014430592,0.98506767,0.00013144789],"about_ca_topic_score_codex":0.000018033788,"about_ca_topic_score_gemma":6.346336e-7,"teacher_disagreement_score":0.04925925,"about_ca_system_score_codex":0.0002364304,"about_ca_system_score_gemma":0.0003792797,"threshold_uncertainty_score":0.9999774},"labels":[],"label_agreement":null},{"id":"W2078283762","doi":"10.1139/o06-083","title":"Poly(ADP-ribosyl)ation regulates heat shock factor-1 activity and the heat shock response in murine fibroblasts","year":2006,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ente Cassa di Risparmio di Firenze","keywords":"Poly ADP ribose polymerase; Heat shock factor; Heat shock; Heat shock protein; Biology; Transcription factor; Molecular biology; PARP inhibitor; Polymerase; Hsp70; Cell biology; Chemistry; DNA; Biochemistry; Gene","score_opus":0.009238253225476613,"score_gpt":0.25493138096611684,"score_spread":0.24569312774064023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078283762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911067,0.0049858554,0.00002763753,0.002693164,0.000052650114,0.0002040209,0.0000431819,0.00003136407,0.0008554509],"genre_scores_gemma":[0.9980092,0.00032823958,0.00005112235,0.00020549241,0.00019295509,0.00002670056,0.00006459197,0.000011056695,0.001110624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989829,0.00015116336,0.00021043094,0.00035622236,0.00006878879,0.00023047467],"domain_scores_gemma":[0.99934494,0.0002676051,0.000044258482,0.00024539453,0.000030096797,0.00006767838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022974478,0.00018185194,0.00027860046,0.000043983582,0.0000813172,0.000013377463,0.000052080984,0.00024950324,0.00008683416],"category_scores_gemma":[0.000036913494,0.00013132034,0.000047268994,0.0001048376,0.00039430746,0.00003238512,0.000043783362,0.0001848088,0.0000024996898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073302835,0.00007090937,0.006495653,0.00006952052,0.000011475161,0.0000049422656,0.000060246002,0.0000031681307,0.98507774,0.000017653618,0.00020937323,0.00064901257],"study_design_scores_gemma":[0.004108147,0.00020146692,0.037433185,0.00005729113,0.000012843125,0.00006189316,0.000040573734,0.00015133276,0.95589983,0.00021868975,0.001678281,0.00013646398],"about_ca_topic_score_codex":0.00021818954,"about_ca_topic_score_gemma":0.000011498189,"teacher_disagreement_score":0.030937532,"about_ca_system_score_codex":0.00007595467,"about_ca_system_score_gemma":0.000058151625,"threshold_uncertainty_score":0.5355088},"labels":[],"label_agreement":null},{"id":"W2079384610","doi":"10.1007/s11010-008-9894-2","title":"Induction of apoptosis by the inhibitors of poly(ADP-ribose)polymerase in HeLa cells","year":2008,"lang":"en","type":"article","venue":"Molecular and Cellular Biochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université Laval","keywords":"Poly ADP ribose polymerase; HeLa; Apoptosis; DNA fragmentation; Molecular biology; NAD+ kinase; Polymerase; Fragmentation (computing); Cell culture; Chemistry; Benzamide; Biology; Cell biology; Programmed cell death; Cancer research; Biochemistry; DNA; Enzyme; Genetics","score_opus":0.007255616368588156,"score_gpt":0.22317116213132915,"score_spread":0.215915545762741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079384610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99128354,0.0071257474,0.0003222842,0.0004525477,0.00006787452,0.0001419397,0.000025110621,0.000009637929,0.00057129946],"genre_scores_gemma":[0.99930847,0.000115980554,0.00007924378,0.00017079974,0.000064028376,0.000014619392,0.000048109585,0.000017640356,0.00018111852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990045,0.000038751583,0.00031543092,0.00021931002,0.00025095348,0.00017109318],"domain_scores_gemma":[0.9994191,0.000016260197,0.00013069523,0.00030176397,0.00004861114,0.00008357532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011444879,0.00013977497,0.00023395107,0.0000499566,0.000036360878,0.000002859693,0.00006993069,0.00014953948,0.000035897854],"category_scores_gemma":[0.000014511789,0.00011853582,0.000099528355,0.00023661782,0.00029978933,0.000018894558,0.000027026728,0.00017403522,9.20381e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081526545,0.00015051599,0.0007506167,0.00010283311,0.000035318684,0.0000136436975,0.00012448424,0.0000010545717,0.9973391,0.0000088017205,0.00089086115,0.0005012272],"study_design_scores_gemma":[0.0011731498,0.000071753944,0.00002737553,0.000101994876,0.000032149746,0.000043580458,0.00021074513,0.0000064685883,0.9979967,0.000018607172,0.00021407414,0.000103389975],"about_ca_topic_score_codex":0.00010203669,"about_ca_topic_score_gemma":1.5214519e-7,"teacher_disagreement_score":0.008024901,"about_ca_system_score_codex":0.000037862126,"about_ca_system_score_gemma":0.000077518496,"threshold_uncertainty_score":0.48337504},"labels":[],"label_agreement":null},{"id":"W2079891276","doi":"10.1016/j.molcel.2010.12.006","title":"PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining","year":2011,"lang":"en","type":"article","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"Biotechnology and Biological Sciences Research Council; Cancer Research UK","keywords":"DNA ligase; Biology; DNA repair protein XRCC4; Non-homologous end joining; DNA repair; Ku80; Chromatin; DNA; Molecular biology; Poly ADP ribose polymerase; Sticky and blunt ends; Genetics; Cell biology; DNA-binding protein; DNA mismatch repair; Polymerase; Gene; Transcription factor","score_opus":0.03390383084429662,"score_gpt":0.25783510827728545,"score_spread":0.22393127743298882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079891276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87909067,0.0006698149,0.017265826,0.0003914418,0.00024983313,0.0003696802,0.0000038083595,0.00010122925,0.101857714],"genre_scores_gemma":[0.98664993,0.000029156043,0.003630476,0.008296939,0.000076269294,0.00005456732,0.000008543838,0.000040398863,0.0012137475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909574,0.00004483991,0.0001659744,0.00030112622,0.00015676655,0.00023554289],"domain_scores_gemma":[0.99943936,0.000010768502,0.000047906222,0.00027129927,0.000058505786,0.00017213615],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013440374,0.00014421406,0.00017872728,0.0000947084,0.00004954842,0.000014252895,0.000050623185,0.00008935007,0.0010982774],"category_scores_gemma":[0.000009693143,0.00013707553,0.000052035775,0.0001358496,0.000040192626,0.000041482414,0.000035443427,0.00014027413,0.0002282759],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009361675,0.0001951955,0.0055786134,0.00007753171,0.000091418675,0.00047153138,0.0024971568,0.000013727278,0.97025216,0.0004015301,0.0035663387,0.015918659],"study_design_scores_gemma":[0.002972572,0.0010813861,0.006918329,0.00006968303,0.00009978691,0.000087932065,0.00016017779,0.000046423047,0.93155324,0.0007208274,0.05598604,0.0003035934],"about_ca_topic_score_codex":0.000047110196,"about_ca_topic_score_gemma":0.0000032454768,"teacher_disagreement_score":0.107559256,"about_ca_system_score_codex":0.000040236617,"about_ca_system_score_gemma":0.000037623166,"threshold_uncertainty_score":0.99981487},"labels":[],"label_agreement":null},{"id":"W2080726143","doi":"10.1016/j.cancergen.2011.09.004","title":"Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer","year":2011,"lang":"en","type":"review","venue":"Cancer Genetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital","funders":"Canadian Institutes of Health Research; Government of Ontario; Ontario Institute for Cancer Research","keywords":"PTEN; Synthetic lethality; Ovarian cancer; Epigenetics; Context (archaeology); PI3K/AKT/mTOR pathway; Biology; Targeted therapy; Precision medicine; Cancer research; Cancer; Bioinformatics; Medicine; DNA repair; Genetics; Gene; Signal transduction","score_opus":0.1138870166839916,"score_gpt":0.3953097854832502,"score_spread":0.2814227687992586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080726143","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014834203,0.9955581,0.00011405995,0.00009009341,0.00040013817,0.0019349997,0.00022509541,0.00001427966,0.00017983862],"genre_scores_gemma":[0.00048233412,0.9950861,0.0011569831,0.00017128063,0.0007010617,0.0020729424,0.00005582966,0.0000805569,0.00019292317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979805,0.00019711621,0.0008205877,0.00046398398,0.00020309692,0.00033476358],"domain_scores_gemma":[0.9987527,0.000102184276,0.00037003472,0.00056827953,0.00010264969,0.00010411278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010791854,0.00043685216,0.001243672,0.00018213583,0.00007244561,0.000020828622,0.00017950084,0.00023874315,0.0002788536],"category_scores_gemma":[0.000006848763,0.00029896587,0.00021018268,0.0003768033,0.00016011647,0.000014847888,0.000019637144,0.00019792549,0.000005466844],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021600246,0.00017600921,0.00084533537,0.0033700895,0.00025661147,0.0000180417,0.002405527,0.00008286773,0.000017615694,0.00001963749,0.00020596795,0.9925807],"study_design_scores_gemma":[0.0010088639,0.00045869706,0.0009544755,0.0044994233,0.0014533115,0.000050380306,0.000049631,0.00005024198,0.000089873836,0.000053588028,0.9910421,0.00028943078],"about_ca_topic_score_codex":0.0007214646,"about_ca_topic_score_gemma":0.00036916882,"teacher_disagreement_score":0.9922913,"about_ca_system_score_codex":0.00047837102,"about_ca_system_score_gemma":0.0008266107,"threshold_uncertainty_score":0.99994624},"labels":[],"label_agreement":null},{"id":"W2081630196","doi":"10.1074/jbc.m110.105668","title":"The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction","year":2010,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; Canadian Institutes of Health Research; National Institute of Diabetes and Digestive and Kidney Diseases; Emerald Foundation; Susan G. Komen for the Cure","keywords":"Poly ADP ribose polymerase; Chromatin; DNA; Cell biology; DNA repair; Zinc finger; Biology; Polymerase; DNA-binding domain; Chemistry; Biophysics; Molecular biology; Biochemistry; Transcription factor; Gene","score_opus":0.0257474723379425,"score_gpt":0.29983412085165323,"score_spread":0.27408664851371073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081630196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438626,0.0008913215,0.00010765895,0.0030131228,0.00026018513,0.00014916416,0.000048718037,0.000024341562,0.0011192099],"genre_scores_gemma":[0.99831593,0.00015241961,0.00021334027,0.000105582825,0.0010111668,0.000015451553,0.000006235474,0.000016833696,0.00016300974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981004,0.00014124313,0.0007640643,0.00026076898,0.00040422752,0.00032928103],"domain_scores_gemma":[0.99791867,0.00057689875,0.00079515594,0.00033677334,0.00011649644,0.00025603073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093762425,0.000252162,0.0006242547,0.00008156318,0.00022606217,0.000034870667,0.00020249459,0.00035475157,0.0005445527],"category_scores_gemma":[0.00033408552,0.00015896752,0.0002292939,0.00019039829,0.00053281453,0.000107544045,0.000052593896,0.0010679468,0.0000028508884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080648996,0.0004343788,0.011745965,0.000048754184,0.000107707325,0.00002955282,0.000056755078,5.435179e-7,0.98264825,0.000017727938,0.0003578791,0.0037460108],"study_design_scores_gemma":[0.0017653031,0.00035614328,0.09919549,0.00018301881,0.000057311874,0.0008005587,0.00039961925,0.000010091848,0.8958299,0.00031996696,0.0009171542,0.00016541053],"about_ca_topic_score_codex":0.000078639074,"about_ca_topic_score_gemma":0.000024445126,"teacher_disagreement_score":0.08744952,"about_ca_system_score_codex":0.00018858277,"about_ca_system_score_gemma":0.000146337,"threshold_uncertainty_score":0.64825076},"labels":[],"label_agreement":null},{"id":"W2081673104","doi":"10.1007/s10549-011-1375-8","title":"Biomarkers of PARP inhibitor sensitivity","year":2011,"lang":"en","type":"letter","venue":"Breast Cancer Research and Treatment","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Breast cancer; Sensitivity (control systems); Medicine; PARP inhibitor; Biomarker; Oncology; Internal medicine; Poly ADP ribose polymerase; Biology; Cancer; Genetics; DNA","score_opus":0.10794391362082746,"score_gpt":0.38517812548318286,"score_spread":0.2772342118623554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081673104","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112659514,0.008936142,0.0000118351845,0.8600612,0.0006202428,0.0034990176,0.0061358274,0.0001289581,0.0079472335],"genre_scores_gemma":[0.7941328,0.03467988,0.0006433711,0.1244339,0.019328242,0.004164225,0.0017460893,0.000536449,0.020335024],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972454,0.0002807028,0.00032143272,0.000641433,0.0008301614,0.0006808927],"domain_scores_gemma":[0.99834555,0.00020440582,0.00013366633,0.000564632,0.0005007358,0.00025099158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035122657,0.00036401945,0.00070987985,0.00043119505,0.00011605536,0.00002237099,0.0000623557,0.0004523404,0.00074403314],"category_scores_gemma":[0.000009966933,0.00027363864,0.0001767355,0.00029677115,0.0007549511,0.00005559344,0.000060563383,0.000773411,0.00003515856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041610077,0.0007091168,0.009114906,0.00069744984,0.002537695,0.002783336,0.0003019326,1.02181545e-7,0.003039777,0.000023726468,0.9049845,0.07164649],"study_design_scores_gemma":[0.0113611715,0.0039405143,0.036108322,0.0029126627,0.00046926684,0.002126779,0.00010053636,0.000008364488,0.041066986,0.00045420273,0.90077907,0.0006721509],"about_ca_topic_score_codex":0.008189018,"about_ca_topic_score_gemma":0.00020125725,"teacher_disagreement_score":0.73562735,"about_ca_system_score_codex":0.0009966881,"about_ca_system_score_gemma":0.00090726424,"threshold_uncertainty_score":0.99997157},"labels":[],"label_agreement":null},{"id":"W2083946902","doi":"10.1016/j.mam.2012.12.005","title":"Reprogramming cellular events by poly(ADP-ribose)-binding proteins","year":2012,"lang":"en","type":"review","venue":"Molecular Aspects of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Ribose; Biochemistry; Plasma protein binding; Lysine; Binding site; Poly ADP ribose polymerase; Chemistry; Amino acid; Biology; Polymerase; Enzyme","score_opus":0.04665816246617733,"score_gpt":0.3567227046326632,"score_spread":0.3100645421664859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083946902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004669046,0.98644155,0.0020596143,0.0011242662,0.00075717486,0.0033589355,0.00005811726,0.0001602201,0.005993419],"genre_scores_gemma":[0.0012071771,0.9923093,0.0015391113,0.0002680676,0.0018275427,0.00045741236,0.0011082048,0.00032542864,0.000957789],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994564,0.00033290187,0.0016593277,0.00095974724,0.0015800669,0.00090396893],"domain_scores_gemma":[0.99559635,0.000107966196,0.0013467974,0.0021443488,0.00020455828,0.00059997523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012233389,0.0009360521,0.0038096737,0.00065318804,0.00009232448,0.0000095486275,0.00061653106,0.000645357,0.00073010655],"category_scores_gemma":[0.00044885805,0.0007437007,0.0008205634,0.0009866094,0.00041315457,0.00008488354,0.00018264171,0.0010836325,0.000116142364],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007906863,0.0005469408,0.000009820545,0.034064025,0.001481149,0.0008045937,0.00017062559,6.760558e-8,0.027364753,0.00075358263,0.003835729,0.93088967],"study_design_scores_gemma":[0.0027314771,0.00075145497,8.04657e-7,0.050286807,0.0035494298,0.000500952,0.0000346239,6.5542775e-7,0.015423249,0.00017998737,0.92599964,0.0005409365],"about_ca_topic_score_codex":0.000081777325,"about_ca_topic_score_gemma":6.696128e-7,"teacher_disagreement_score":0.9303487,"about_ca_system_score_codex":0.0005320991,"about_ca_system_score_gemma":0.0004378189,"threshold_uncertainty_score":0.9995014},"labels":[],"label_agreement":null},{"id":"W2085215116","doi":"10.1038/nbt.2121","title":"Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors","year":2012,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":460,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Structural Genomics Consortium","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Olaparib; Poly ADP ribose polymerase; Polymerase; Small molecule; PARP inhibitor; Computational biology; Biology; Chemical biology; Chemistry; Biochemistry; Enzyme; Genetics","score_opus":0.008652512575361737,"score_gpt":0.2946905990793961,"score_spread":0.28603808650403434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085215116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623914,0.010690283,0.00005779223,0.0024752405,0.00015182364,0.00017579479,0.000027701111,0.00009095827,0.000091255555],"genre_scores_gemma":[0.9955381,0.00024924963,0.0034888382,0.0005540467,0.0001083169,0.000008529313,0.000031332427,0.000012291486,0.000009293964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991109,0.000016881519,0.00023409228,0.00024789738,0.00014565028,0.00024459165],"domain_scores_gemma":[0.9994188,0.00007374957,0.00010894174,0.0002480537,0.00005476572,0.0000956976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013277847,0.00014103518,0.00041781293,0.0004580704,0.000030302486,0.0000037312184,0.000053385174,0.0010846999,0.000018624578],"category_scores_gemma":[0.00017215872,0.00011618095,0.00006498091,0.0007277494,0.00038737038,0.000056270226,0.00006086767,0.00072462193,6.360027e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012454428,0.00002637524,0.17016956,0.000048729053,0.00043378887,0.000004471676,0.00007731209,3.7162346e-7,0.82105523,0.0037281387,0.00018540994,0.004146058],"study_design_scores_gemma":[0.00093546684,0.000077592755,0.06568885,0.000032256772,0.0005547783,0.000058401794,0.00014314179,0.00014528027,0.93038666,0.00023587327,0.001606722,0.00013494727],"about_ca_topic_score_codex":0.000008985678,"about_ca_topic_score_gemma":0.0000015120489,"teacher_disagreement_score":0.10933145,"about_ca_system_score_codex":0.000050404815,"about_ca_system_score_gemma":0.000022714463,"threshold_uncertainty_score":0.8366199},"labels":[],"label_agreement":null},{"id":"W2085908746","doi":"10.1038/sj.cdd.4400851","title":"Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases","year":2001,"lang":"en","type":"article","venue":"Cell Death and Differentiation","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":338,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Medical Research Council; Natural Sciences and Engineering Research Council of Canada","keywords":"Poly ADP ribose polymerase; Proteases; Caspase; Jurkat cells; Cathepsin; Cleavage (geology); Apoptosis; Molecular biology; Biology; Programmed cell death; Cytosol; Biochemistry; Polymerase; Cell biology; Enzyme; T cell; Genetics","score_opus":0.01573362775224625,"score_gpt":0.24919175660214332,"score_spread":0.23345812884989708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085908746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956779,0.00026608148,0.002702378,0.00021262343,0.00007807742,0.0006129444,0.00004321587,0.000013337871,0.0003934414],"genre_scores_gemma":[0.9992567,0.0002030993,0.000058350695,0.000059984795,0.00007566761,0.000029522947,0.00014818943,0.000011626445,0.00015686083],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991401,0.000050721723,0.0003673855,0.00014570483,0.00019402428,0.00010207553],"domain_scores_gemma":[0.9991259,0.00002472895,0.00043170986,0.00025624575,0.000109965826,0.000051444782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005665157,0.00010031542,0.00021426185,0.00008646394,0.000042567928,0.0000053748367,0.00005307178,0.00006752451,0.000054258417],"category_scores_gemma":[0.000021383566,0.000075804615,0.00007323307,0.0001743323,0.000062303974,0.00008277485,0.00001819359,0.00005343583,9.164801e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023277425,0.00021263413,0.15872234,0.00018837037,0.00001531392,1.7156174e-7,0.00016790986,3.4644086e-7,0.8376195,0.00023409736,0.0000082899915,0.0025982433],"study_design_scores_gemma":[0.0008271798,0.000088198976,0.45046273,0.00007688952,0.000054911525,0.000003703494,0.000014065265,0.000091228925,0.5482274,0.00009413716,0.000024971052,0.000034558958],"about_ca_topic_score_codex":0.00005198182,"about_ca_topic_score_gemma":0.0000015694243,"teacher_disagreement_score":0.29174036,"about_ca_system_score_codex":0.000023070115,"about_ca_system_score_gemma":0.000050976145,"threshold_uncertainty_score":0.30912226},"labels":[],"label_agreement":null},{"id":"W2085971965","doi":"10.1242/jcs.01636","title":"Mechanism of early biphasic activation of poly(ADP-ribose) polymerase-1 in response to ultraviolet B radiation","year":2005,"lang":"en","type":"article","venue":"Journal of Cell Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; Université Laval","funders":"","keywords":"Pyrimidine dimer; Poly ADP ribose polymerase; Biology; DNA damage; DNA repair; Carcinogenesis; Ultraviolet light; PARP inhibitor; Molecular biology; Polymerase; DNA; Biochemistry; Chemistry; Photochemistry","score_opus":0.015583005116485298,"score_gpt":0.308424620873799,"score_spread":0.2928416157573137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085971965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929474,0.00015514062,0.0030912983,0.0032485053,0.00013898929,0.00014237712,0.0000037120806,0.000003349527,0.0002692214],"genre_scores_gemma":[0.9964199,0.000045877336,0.0028907745,0.00038740804,0.00015055784,0.0000015726022,2.5901386e-7,0.0000065938884,0.00009704039],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982772,0.00009392232,0.0005697532,0.0001204086,0.0007698759,0.00016885866],"domain_scores_gemma":[0.99869514,0.00014964209,0.0005646005,0.00015598032,0.00028595977,0.00014868716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022417123,0.000076431235,0.00023230347,0.0008224555,0.000031149077,0.0000097509665,0.00018033385,0.000043708696,0.00006334938],"category_scores_gemma":[0.0002584469,0.00006668578,0.00006153375,0.0010469805,0.00011630261,0.00041963498,0.000010744294,0.00014696692,0.0000037446237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024833598,0.00011701444,0.00094444933,0.000009051176,0.000003193702,0.0000030535102,0.0012784706,0.000113814276,0.98717606,0.000087852124,0.00005311324,0.0077305743],"study_design_scores_gemma":[0.0017514862,0.0009787524,0.058218848,0.0002060313,0.000008268835,0.000025471843,0.00013332134,0.000085788895,0.9382118,0.00009819542,0.00022849638,0.00005355398],"about_ca_topic_score_codex":0.000032480133,"about_ca_topic_score_gemma":0.0000012884466,"teacher_disagreement_score":0.057274397,"about_ca_system_score_codex":0.00028854926,"about_ca_system_score_gemma":0.0006666696,"threshold_uncertainty_score":0.27193674},"labels":[],"label_agreement":null},{"id":"W2086038769","doi":"10.1038/nrc2812","title":"PARP inhibition: PARP1 and beyond","year":2010,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1311,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; National Institute of General Medical Sciences; Canada Research Chairs","keywords":"Limelight; PARP1; Poly ADP ribose polymerase; Polymerase; Biology; Computational biology; Enzyme; Chemistry; Biochemistry","score_opus":0.049853410910879074,"score_gpt":0.43076390228851186,"score_spread":0.3809104913776328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086038769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013855705,0.9860038,0.000008877196,0.00095018046,0.0019219238,0.0033966221,0.00028910904,0.0001150887,0.0073129707],"genre_scores_gemma":[0.000001091412,0.98513585,0.0008007568,0.0054915226,0.0038439496,0.0023332976,0.0003885119,0.00016449647,0.0018405434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964055,0.000244143,0.0012698108,0.0010359231,0.00053372025,0.00051090727],"domain_scores_gemma":[0.9972774,0.00017753564,0.00090469804,0.0010213072,0.00020662836,0.00041242407],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00068501855,0.0009371674,0.0044031343,0.00027888364,0.00013553507,0.000059439433,0.00018407169,0.0025099537,0.0019935572],"category_scores_gemma":[0.0001832365,0.00065923855,0.000999061,0.00075130194,0.00024929483,0.00013071539,0.00008468573,0.0051798173,0.00025414716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012774983,0.000037062466,0.0000047462377,0.035463773,0.00012269741,0.000035940047,0.000022387587,4.9640416e-9,0.0000052938967,0.00034441327,0.06825292,0.895698],"study_design_scores_gemma":[0.0006740798,0.000061146035,0.0000031536408,0.06694196,0.0019502217,0.0005954836,0.0000020041136,1.7078231e-7,0.0000142613435,0.00011465085,0.9290657,0.0005771345],"about_ca_topic_score_codex":0.0000065641016,"about_ca_topic_score_gemma":0.000024051997,"teacher_disagreement_score":0.89512086,"about_ca_system_score_codex":0.0004025177,"about_ca_system_score_gemma":0.0008313715,"threshold_uncertainty_score":0.99958587},"labels":[],"label_agreement":null},{"id":"W2086417409","doi":"10.4161/cc.11.5.19482","title":"Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells","year":2012,"lang":"en","type":"article","venue":"Cell Cycle","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"University of Sheffield; Research Councils UK","keywords":"Homologous recombination; Biology; Poly ADP ribose polymerase; Ribose; Homologous chromosome; DNA repair; Recombination; Replication protein A; DNA; Molecular biology; Cell biology; Biochemistry; DNA-binding protein; Enzyme; Gene; Polymerase","score_opus":0.016142351855759518,"score_gpt":0.2593866749336051,"score_spread":0.2432443230778456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086417409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617167,0.0017602615,0.0006026905,0.00039872061,0.0009221357,0.0005160431,0.00009600216,0.00011781818,0.033869646],"genre_scores_gemma":[0.995318,0.000084359104,0.0014465937,0.0009483473,0.0009538699,0.000032479795,0.000061504485,0.00006127591,0.0010935985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978406,0.00007822352,0.0005920629,0.0003429575,0.00055667805,0.00058949797],"domain_scores_gemma":[0.99850816,0.00009119228,0.00027360208,0.00058286876,0.00013328886,0.0004108746],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00039048883,0.0002541527,0.00042550635,0.00018503911,0.00008296772,0.000016510794,0.000104710525,0.00012673257,0.0020014988],"category_scores_gemma":[0.000026094689,0.00024351581,0.00020979291,0.00034835454,0.00018782743,0.00017538741,0.0000510708,0.000270498,0.0010063769],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031183768,0.0012480962,0.00086718483,0.00014443767,0.000025902638,0.000027532056,0.00065347657,0.000043097723,0.98710614,0.00020379799,0.008772198,0.0005962762],"study_design_scores_gemma":[0.0023232,0.00026392358,0.0014587495,0.00014810966,0.00007254301,0.000044342796,0.00015240852,0.00010358488,0.9666172,0.00013116618,0.028443078,0.00024167683],"about_ca_topic_score_codex":0.00003853814,"about_ca_topic_score_gemma":9.3320386e-7,"teacher_disagreement_score":0.033601288,"about_ca_system_score_codex":0.00021151343,"about_ca_system_score_gemma":0.00009884793,"threshold_uncertainty_score":0.9997715},"labels":[],"label_agreement":null},{"id":"W2087478784","doi":"10.1097/01.anes.0000299434.86640.15","title":"Inhibition of Poly(Adenosine Diphosphate–Ribose) Polymerase Attenuates Ventilator-induced Lung Injury","year":2008,"lang":"en","type":"article","venue":"Anesthesiology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Poly ADP ribose polymerase; Tidal volume; Adenosine; Lung; Pulmonary edema; Pharmacology; Mechanical ventilation; Anesthesia; Internal medicine; Polymerase; Enzyme; Respiratory system; Biochemistry; Chemistry","score_opus":0.025420495287636336,"score_gpt":0.29372828689797637,"score_spread":0.26830779161034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087478784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934339,0.004743504,0.000017196333,0.0008592609,0.00018888181,0.0003146723,0.000014063414,0.00010432875,0.00032420666],"genre_scores_gemma":[0.99630374,0.00053291366,0.00016465322,0.002295512,0.00026070085,0.000048474456,0.00008493714,0.000042928295,0.00026612115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984408,0.00010187316,0.00051886827,0.00035718692,0.00022318293,0.00035811565],"domain_scores_gemma":[0.9989646,0.00009235523,0.0002448643,0.00041289415,0.00013924752,0.00014603326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014447336,0.00022785172,0.00055848074,0.00020834347,0.000116929725,0.0000030257927,0.00008679902,0.00024839098,0.0005328892],"category_scores_gemma":[0.00004749903,0.00021029694,0.00015762016,0.00030059155,0.00029397878,0.00010142367,0.000027260063,0.00021923654,0.00008990905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014362688,0.00037847878,0.25188854,0.00008713179,0.0000994395,0.00050419016,0.00057220703,9.4894284e-7,0.7360456,0.00031404017,0.0055902433,0.0030828735],"study_design_scores_gemma":[0.0017152803,0.0010070428,0.21139674,0.00013330704,0.000057178237,0.0007956859,0.000045233013,0.0000146956645,0.78299505,0.00016434651,0.0014886789,0.00018679033],"about_ca_topic_score_codex":0.00014898005,"about_ca_topic_score_gemma":0.0000015738959,"teacher_disagreement_score":0.046949398,"about_ca_system_score_codex":0.00008328605,"about_ca_system_score_gemma":0.00016954922,"threshold_uncertainty_score":0.85756606},"labels":[],"label_agreement":null},{"id":"W2087824350","doi":"10.3389/fphar.2012.00202","title":"Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?","year":2012,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Triple-negative breast cancer; Epigenetics; Breast cancer; Cancer research; Triple negative; Component (thermodynamics); Poly ADP ribose polymerase; Medicine; Bioinformatics; Biology; Oncology; Genetics; Internal medicine; Cancer; DNA; Gene; Physics; Polymerase","score_opus":0.0456841310292869,"score_gpt":0.3630662994430856,"score_spread":0.3173821684137987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087824350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97039473,0.008287783,0.0030507606,0.008256166,0.0065153865,0.0016624322,0.00012001317,0.00004571512,0.0016670304],"genre_scores_gemma":[0.99098617,0.00046750135,0.003119294,0.0043394305,0.0003851787,0.00023494876,0.0000073082297,0.000034330486,0.00042586363],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9981441,0.0003438948,0.00044146067,0.00028963733,0.00026651306,0.000514395],"domain_scores_gemma":[0.99908483,0.00009474381,0.00019357761,0.00028452047,0.000097949785,0.00024438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047308474,0.0002006086,0.00044095007,0.00019653358,0.00009556559,0.0000056780304,0.00021344732,0.00010601669,0.00049343804],"category_scores_gemma":[0.000014768204,0.0001630127,0.0000849347,0.00046755708,0.00031281658,0.00012087224,0.000037779697,0.00031893252,0.000010365987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007277052,0.0008158231,0.20572768,0.00022511861,0.00075362064,0.000028561668,0.025077878,0.00043163964,0.15012555,0.0001661871,0.59843475,0.010936135],"study_design_scores_gemma":[0.018601373,0.0008867441,0.46709806,0.0005659923,0.0005059576,0.0000832476,0.010996987,0.00082357146,0.3654797,0.0018632178,0.13220575,0.00088939833],"about_ca_topic_score_codex":0.00018958413,"about_ca_topic_score_gemma":0.000073584124,"teacher_disagreement_score":0.466229,"about_ca_system_score_codex":0.0008232032,"about_ca_system_score_gemma":0.00021184166,"threshold_uncertainty_score":0.66474646},"labels":[],"label_agreement":null},{"id":"W2087964934","doi":"10.1158/1535-7163.pms-b13","title":"Abstract B13: ATR and PARP inhibition enhances topoisomerase I-dependent DNA damage in colon cancer cell lines","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cytotoxicity; RAD51; DNA damage; PARP inhibitor; Poly ADP ribose polymerase; DNA repair; Cancer cell; Topoisomerase; Cancer research; IC50; Chemistry; Cell culture; Synthetic lethality; Molecular biology; Cancer; DNA; Biology; Polymerase; Biochemistry; In vitro; Genetics","score_opus":0.022851423000106435,"score_gpt":0.3095930713613835,"score_spread":0.286741648361277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087964934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747129,0.01873179,0.00015968847,0.0037054385,0.00035342877,0.0010153641,0.000053518976,0.00007976305,0.0011880848],"genre_scores_gemma":[0.9796366,0.011718583,0.00023357105,0.0067318985,0.0002472821,0.00080492115,0.000032440075,0.00007493164,0.00051975204],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979614,0.000083113206,0.00050309324,0.00052919803,0.000445818,0.00047739546],"domain_scores_gemma":[0.99898875,0.000054486783,0.00020586759,0.00037641832,0.00019286027,0.00018164092],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016965832,0.00035853827,0.00043539668,0.0001311218,0.00008739048,0.000078474426,0.000106378866,0.00023901473,0.0019176579],"category_scores_gemma":[0.000005757569,0.00033936548,0.00010060038,0.0002553277,0.00015936527,0.00026382046,0.00004264676,0.0003910187,0.0000337587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019177368,0.00022677821,0.0056471406,0.00019303373,0.000101639125,0.0000779435,0.0006742805,0.00011524987,0.97784555,0.000031154166,0.00032454336,0.0145709],"study_design_scores_gemma":[0.0038437133,0.00025023223,0.025624586,0.00041373217,0.00012127385,0.000012176724,0.00035938373,0.00025741657,0.9625249,0.00047703332,0.005665051,0.0004505364],"about_ca_topic_score_codex":0.002949623,"about_ca_topic_score_gemma":0.0017348609,"teacher_disagreement_score":0.019977445,"about_ca_system_score_codex":0.00047470792,"about_ca_system_score_gemma":0.00022066821,"threshold_uncertainty_score":0.9999058},"labels":[],"label_agreement":null},{"id":"W2088538523","doi":"10.1038/nsmb.2306","title":"PARP pairs up to PARsylate","year":2012,"lang":"en","type":"letter","venue":"Nature Structural & Molecular Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Poly ADP ribose polymerase; PARP1; Polymerase; Chemistry; DNA; Biophysics; Cell biology; Biochemistry; Molecular biology; Biology","score_opus":0.011736585762755998,"score_gpt":0.35081041664367885,"score_spread":0.33907383088092286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088538523","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029230373,0.01050678,0.0005007284,0.946751,0.009264825,0.0015022659,0.00043404056,0.00029679807,0.0015131724],"genre_scores_gemma":[0.19717398,0.000043228156,0.0013110134,0.7902502,0.007004954,0.00009250495,0.002510146,0.00013259635,0.0014814098],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967748,0.00027657746,0.0004953263,0.0009443944,0.00040826743,0.001100647],"domain_scores_gemma":[0.9981727,0.00006086711,0.00024755852,0.0009837688,0.0002522225,0.00028286636],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00013865111,0.00074277364,0.0010267555,0.00034598412,0.00008941373,0.000022835104,0.00040719405,0.005024603,0.0011967849],"category_scores_gemma":[0.00011624115,0.00058445183,0.00046066055,0.00034332593,0.00021515244,0.000038735554,0.00013056239,0.00622725,0.00023027843],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020294556,0.000003704951,0.00027664276,0.00011934561,0.0004331575,0.0005501892,0.000093000424,0.0000013612754,0.0698079,0.0006591288,0.92435294,0.003499659],"study_design_scores_gemma":[0.0011202713,0.0003148455,0.0007683724,0.00011235755,0.00020542006,0.0006985801,0.0000046014634,0.0000020633697,0.024198415,0.0034232545,0.96850806,0.0006437355],"about_ca_topic_score_codex":0.00002436996,"about_ca_topic_score_gemma":0.000001999835,"teacher_disagreement_score":0.16794361,"about_ca_system_score_codex":0.0002831654,"about_ca_system_score_gemma":0.00015969948,"threshold_uncertainty_score":0.9997163},"labels":[],"label_agreement":null},{"id":"W2088549564","doi":"10.1242/jcs.128769","title":"Nonhomologous end-joining promotes resistance to DNA damage in the absence of an ADP-ribosyltransferase that signals DNA single strand breaks","year":2013,"lang":"en","type":"article","venue":"Journal of Cell Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Canadian Institutes of Health Research; Cancer Research UK","keywords":"Biology; DNA damage; Chromatin; DNA; DNA repair; Cell biology; Molecular biology; Ku80; Poly ADP ribose polymerase; Genetics; DNA-binding protein; Gene; Polymerase; Transcription factor","score_opus":0.028904141078623737,"score_gpt":0.2926823388939917,"score_spread":0.263778197815368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088549564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924314,0.00017101035,0.000739529,0.0020756242,0.00012084853,0.00040408643,0.0000061351475,0.0000072234566,0.0040441263],"genre_scores_gemma":[0.9952506,0.000029806843,0.003602407,0.0009066745,0.00009301457,0.000007979374,4.8094586e-7,0.000010347569,0.0000986996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975901,0.00013435975,0.00057006767,0.00024317359,0.0010969158,0.00036534],"domain_scores_gemma":[0.99844176,0.00024660557,0.00033156294,0.0003394039,0.0003855346,0.00025514484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023242165,0.00014533702,0.00033958376,0.00029224594,0.00011591357,0.00010619558,0.0006275662,0.000050410134,0.00026967534],"category_scores_gemma":[0.0001308036,0.00009650843,0.000077514625,0.0008182064,0.000514004,0.0009039252,0.000018261,0.00030898675,0.0000064128744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015540513,0.00027658706,0.0009067651,0.000039550367,0.0000038716234,0.00009112965,0.003591359,0.00007222702,0.9935852,0.000017993454,0.0001622924,0.0010975723],"study_design_scores_gemma":[0.00118544,0.001174259,0.03184122,0.000508382,0.000012011835,0.00020471898,0.0013846285,0.000058397833,0.96282184,0.00046934155,0.00022208804,0.000117650045],"about_ca_topic_score_codex":0.000036537356,"about_ca_topic_score_gemma":0.00006107327,"teacher_disagreement_score":0.030934453,"about_ca_system_score_codex":0.000109408604,"about_ca_system_score_gemma":0.00042564076,"threshold_uncertainty_score":0.39354998},"labels":[],"label_agreement":null},{"id":"W2088568685","doi":"10.4161/15384101.2014.948787","title":"PARP inhibitors target ATM+p53-defective gastric cancer","year":2014,"lang":"en","type":"letter","venue":"Cell Cycle","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DNA damage; Cancer research; Carcinogenesis; Genome instability; DNA repair; Synthetic lethality; Poly ADP ribose polymerase; Homologous recombination; Biology; Cancer; Cell cycle checkpoint; Cell cycle; DNA; Genetics","score_opus":0.016759409929788343,"score_gpt":0.2757411737344744,"score_spread":0.258981763804686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088568685","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02315959,0.0109477565,0.0014611562,0.74369967,0.008615003,0.0033001485,0.00056404504,0.0009940602,0.20725854],"genre_scores_gemma":[0.033515777,0.00072576624,0.00062796084,0.8899188,0.03451678,0.00081955746,0.0009060936,0.0004197447,0.038549524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695534,0.00017022269,0.00051152025,0.00087346375,0.0007007182,0.0007887536],"domain_scores_gemma":[0.9981929,0.00017260564,0.00039942295,0.0008133698,0.00021341133,0.00020830343],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001903985,0.0005967492,0.00088883785,0.00029175795,0.00013078304,0.0000402506,0.00023060435,0.0010046044,0.0049664825],"category_scores_gemma":[0.000028796643,0.00056350965,0.0004230389,0.0003861756,0.00019370555,0.00007593366,0.00005906356,0.0023253807,0.0011246133],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007009978,0.00006579038,0.0012452004,0.00040124892,0.000119391516,0.00015667256,0.00014258035,0.000053420263,0.0019787597,0.0000017374981,0.9953128,0.00045226282],"study_design_scores_gemma":[0.0021799624,0.00024213042,0.00025961807,0.0004410053,0.00020770036,0.000060090646,0.000016347263,0.00005151235,0.020736922,0.00034536785,0.9749199,0.00053945224],"about_ca_topic_score_codex":0.000248329,"about_ca_topic_score_gemma":0.000005036655,"teacher_disagreement_score":0.16870902,"about_ca_system_score_codex":0.0008051993,"about_ca_system_score_gemma":0.00038045706,"threshold_uncertainty_score":0.9999763},"labels":[],"label_agreement":null},{"id":"W2091086437","doi":"10.1038/onc.2013.311","title":"A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Oncogene","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Cancer Research UK; Institut National Du Cancer; European Commission; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"ERCC1; PARP1; Biology; Cancer research; DNA repair; DNA damage; PARP inhibitor; Molecular biology; Nucleotide excision repair; Poly ADP ribose polymerase; DNA; Polymerase; Biochemistry","score_opus":0.01720244514141314,"score_gpt":0.30067307376785646,"score_spread":0.28347062862644334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091086437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97863317,0.0063916426,0.004974397,0.003065189,0.0017743417,0.0033783526,0.00015655,0.00016215719,0.0014641777],"genre_scores_gemma":[0.97885406,0.0021660256,0.0039030337,0.0033127458,0.002250437,0.0025706894,0.00015621721,0.00013604338,0.0066507305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99743015,0.000054968375,0.0005988189,0.000702227,0.0005351392,0.0006786943],"domain_scores_gemma":[0.9983505,0.00006953792,0.0002675267,0.0005564909,0.00046976155,0.0002861532],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026096462,0.00040435055,0.00057496305,0.00018603366,0.00024048575,0.000115000985,0.00022314493,0.0002331394,0.002168899],"category_scores_gemma":[0.000017432028,0.0003544139,0.00034792087,0.00031083447,0.00013615718,0.00018812636,0.000063694744,0.00022642617,0.00027322798],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073611736,0.0005584239,0.0016452098,0.00019423255,0.00029882984,0.000028763414,0.0008720332,0.0003105526,0.8810857,0.00005631624,0.101678245,0.012535577],"study_design_scores_gemma":[0.011790389,0.0009089178,0.0025387243,0.000344589,0.00022918484,0.000040782994,0.0003669242,0.00083045656,0.9562073,0.0005164174,0.025620207,0.000606107],"about_ca_topic_score_codex":0.004144106,"about_ca_topic_score_gemma":0.00008523344,"teacher_disagreement_score":0.07605804,"about_ca_system_score_codex":0.00037066807,"about_ca_system_score_gemma":0.00047373038,"threshold_uncertainty_score":0.9998908},"labels":[],"label_agreement":null},{"id":"W2091977946","doi":"10.1158/1535-7163.pms-a02","title":"Abstract A02: PARP inhibition selectively kills RNF20-depleted cells","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Homologous recombination; Biology; DNA repair; Genome instability; Cancer cell; Molecular biology; DNA damage; Chromosome instability; Cancer research; Chromosome; Cancer; Gene; Genetics; Cell biology; DNA","score_opus":0.02606190089490515,"score_gpt":0.2985627160633738,"score_spread":0.2725008151684687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091977946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737964,0.0040146387,0.0054728333,0.0065159015,0.00066897005,0.0018540168,0.0000746418,0.00042275435,0.007179792],"genre_scores_gemma":[0.9766415,0.00097589946,0.0010570505,0.019937715,0.000299674,0.0005303785,0.000050809835,0.00014226709,0.00036470356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976054,0.00008437966,0.0004965927,0.0005697859,0.00062073127,0.0006231189],"domain_scores_gemma":[0.9984323,0.00005423288,0.00022545626,0.00055702066,0.000484287,0.00024671433],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012579662,0.00041079553,0.00045182713,0.00018485225,0.00012792305,0.00008558648,0.00011269308,0.00027065678,0.0020906539],"category_scores_gemma":[0.000008421729,0.00039381417,0.00024348132,0.00052172,0.00016034255,0.00019129968,0.000031072574,0.00049637107,0.00046930453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013863522,0.0002147307,0.0007096619,0.00007178476,0.00038962983,0.00006485296,0.00028071608,0.00008113712,0.97792,0.00014081378,0.0027020664,0.017285962],"study_design_scores_gemma":[0.003170112,0.00025444626,0.01097813,0.00024281435,0.00019328039,0.000044034554,0.000089138,0.0002504344,0.9515413,0.0020177606,0.030709343,0.00050918275],"about_ca_topic_score_codex":0.0003493073,"about_ca_topic_score_gemma":0.000017355545,"teacher_disagreement_score":0.028007276,"about_ca_system_score_codex":0.00052118197,"about_ca_system_score_gemma":0.00030294425,"threshold_uncertainty_score":0.99985135},"labels":[],"label_agreement":null},{"id":"W2093988174","doi":"10.1007/s10637-012-9886-7","title":"The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Abbott Laboratories","keywords":"PARP inhibitor; Irinotecan; Cancer research; Veliparib; Poly ADP ribose polymerase; Olaparib; Oxaliplatin; DNA damage; PARP1; Cancer; Synthetic lethality; DNA repair; Base excision repair; Colorectal cancer; Biology; Medicine; Polymerase; Internal medicine; DNA; Biochemistry","score_opus":0.03616634036575846,"score_gpt":0.31929290745368355,"score_spread":0.2831265670879251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093988174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709805,0.012070838,0.000020652758,0.012476324,0.0008654457,0.00046604118,0.00006534993,0.000060091592,0.002994742],"genre_scores_gemma":[0.98488784,0.0017447348,0.0013098492,0.0012429695,0.0029201582,0.00020360187,0.00005540506,0.0000331516,0.007602289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862176,0.00005588263,0.0003946777,0.00018089436,0.0004484414,0.00029831444],"domain_scores_gemma":[0.9987067,0.00030693843,0.00022043301,0.00025617596,0.00016291068,0.000346835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013674195,0.0001917484,0.00025015988,0.000043394764,0.00014848425,0.000015283624,0.0000855712,0.00008931734,0.0002874398],"category_scores_gemma":[0.000034822966,0.00013127236,0.000117948206,0.00017790445,0.0003259856,0.0001429176,0.000015804317,0.00008003834,0.000042887666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016818421,0.0025285599,0.108032145,0.00032531115,0.00086341123,0.000010494129,0.017086806,0.0007989014,0.543262,0.02298043,0.23985665,0.062573485],"study_design_scores_gemma":[0.0031321314,0.000395622,0.011796855,0.0001578012,0.00011432836,0.000013029314,0.0002571852,0.000094636816,0.68014324,0.0015135335,0.30218613,0.0001955128],"about_ca_topic_score_codex":0.0011859108,"about_ca_topic_score_gemma":0.00010506772,"teacher_disagreement_score":0.13688125,"about_ca_system_score_codex":0.0004252487,"about_ca_system_score_gemma":0.00078492856,"threshold_uncertainty_score":0.5353132},"labels":[],"label_agreement":null},{"id":"W2094170505","doi":"10.1073/pnas.1209507110","title":"Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Université Laval","keywords":"Xeroderma pigmentosum; Nucleotide excision repair; Poly ADP ribose polymerase; DNA repair; DNA damage; Biology; Polymerase; DNA; Molecular biology; Chemistry; Biochemistry; Cell biology","score_opus":0.04195571226413234,"score_gpt":0.32748240498435105,"score_spread":0.2855266927202187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094170505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97930306,0.0007991607,3.3355934e-7,0.010633205,0.000018111627,0.0004023565,0.000021315902,0.000012162355,0.0088103],"genre_scores_gemma":[0.9980136,0.00006693545,0.0009893049,0.00068556954,0.000082378996,0.000020285719,3.803803e-7,0.0000063110724,0.0001352304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727404,0.000021270538,0.0006292941,0.00023593528,0.0016679884,0.0001714616],"domain_scores_gemma":[0.9986423,0.00025106355,0.00066613,0.000029024883,0.0003681884,0.000043297216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015807301,0.00011137588,0.0002697573,0.0002532205,0.00010699968,0.000008377355,0.0006430008,0.000103156344,0.000078503486],"category_scores_gemma":[0.0005492559,0.00006550256,0.00014514601,0.0010849492,0.00079732685,0.0003693595,0.00007784405,0.00022283533,0.0000019556342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046891048,0.00013950784,0.0036184678,0.00004430906,0.0000135491555,1.4048321e-8,0.0005358449,0.000001905848,0.98418653,0.006778824,0.0031342108,0.0014999347],"study_design_scores_gemma":[0.000527055,0.00014787345,0.09422041,0.00033887813,0.000014895416,0.0000268363,0.0012857327,0.00032068655,0.88666105,0.016004398,0.00038751517,0.0000646768],"about_ca_topic_score_codex":0.00011979434,"about_ca_topic_score_gemma":1.6428515e-7,"teacher_disagreement_score":0.09752549,"about_ca_system_score_codex":0.00004772196,"about_ca_system_score_gemma":0.00008457757,"threshold_uncertainty_score":0.2937784},"labels":[],"label_agreement":null},{"id":"W2095061901","doi":"10.1073/pnas.1405158111","title":"Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis","year":2014,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; NAD+ kinase; Hexokinase; Glycolysis; Programmed cell death; Polymerase; Ribose; Cell biology; Bioenergetics; Biology; Enzyme; Biochemistry; Chemistry; Mitochondrion; Apoptosis","score_opus":0.03861303175714018,"score_gpt":0.3213103621072992,"score_spread":0.282697330350159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095061901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709858,0.00074885204,0.00016389233,0.012779933,0.000075142634,0.00024437899,0.00004554443,0.00003636318,0.014920121],"genre_scores_gemma":[0.99667114,0.000102618396,0.0013636795,0.0014238603,0.00026231224,0.000021139256,0.00000106807,0.0000082947345,0.00014588905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971501,0.000016432909,0.0005517055,0.00029060498,0.0018155397,0.00017560832],"domain_scores_gemma":[0.99853975,0.00012374176,0.0008066575,0.000018541221,0.00046306066,0.00004823332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010265769,0.0001291788,0.00029020212,0.00024361178,0.00014586761,0.0000115255925,0.00030085412,0.00012454134,0.000065701366],"category_scores_gemma":[0.00033112237,0.00009391582,0.00015405258,0.0009274363,0.00090615754,0.00043637483,0.000068207635,0.00014138511,0.0000014867862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013654893,0.00013594994,0.004197418,0.00010338967,0.00003994993,8.481953e-9,0.00021691197,0.000024487237,0.9075613,0.084663525,0.0014077249,0.0015127623],"study_design_scores_gemma":[0.0007892205,0.00017355297,0.0104696015,0.00028373362,0.000043109776,0.000018087323,0.00014038275,0.0003620448,0.9500857,0.036729656,0.00081557623,0.000089359004],"about_ca_topic_score_codex":0.00006143319,"about_ca_topic_score_gemma":2.2295723e-7,"teacher_disagreement_score":0.04793387,"about_ca_system_score_codex":0.000088548884,"about_ca_system_score_gemma":0.00006588505,"threshold_uncertainty_score":0.3829776},"labels":[],"label_agreement":null},{"id":"W2098122970","doi":"10.2174/156800910791208571","title":"Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent","year":2010,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Poly ADP ribose polymerase; Gene silencing; PARP inhibitor; Temozolomide; Cancer research; Biology; Chemistry; Molecular biology; Polymerase; Biochemistry; DNA; Glioma; Gene","score_opus":0.02492817481694091,"score_gpt":0.3460347325329664,"score_spread":0.3211065577160255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098122970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922184,0.001916129,0.00029503336,0.0025948763,0.00089268,0.0015822253,0.0003260765,0.00008961488,0.00008498015],"genre_scores_gemma":[0.99683374,0.00027480978,0.00085089,0.00075618905,0.0007216307,0.000461148,0.000026478625,0.000041376825,0.000033751592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716574,0.00027242742,0.0005699477,0.0008504005,0.0005064321,0.0006350256],"domain_scores_gemma":[0.99822736,0.00033227104,0.00031177857,0.00025754666,0.00023847015,0.0006325534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006357144,0.00043266892,0.0008356595,0.0003688657,0.00012340827,0.000022593995,0.0001033392,0.00013023063,0.00027100282],"category_scores_gemma":[0.00028554563,0.00041257506,0.000131353,0.0007874166,0.00017126136,0.00020941766,0.00013011959,0.00085440837,0.00001434337],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016914025,0.00080068683,0.007591046,0.00014688319,0.000060404825,0.000036111385,0.0013794091,0.000064649714,0.95239556,0.000005398167,0.0022058224,0.033622652],"study_design_scores_gemma":[0.0031589763,0.00023607023,0.041735128,0.00046868564,0.00010350189,0.000013006419,0.00011177949,0.00033058636,0.9527244,0.00003619867,0.0006872045,0.00039449002],"about_ca_topic_score_codex":0.0017553438,"about_ca_topic_score_gemma":0.00048784466,"teacher_disagreement_score":0.03414408,"about_ca_system_score_codex":0.00048100186,"about_ca_system_score_gemma":0.00036079748,"threshold_uncertainty_score":0.99983263},"labels":[],"label_agreement":null},{"id":"W2098816367","doi":"10.1016/j.ygyno.2015.11.009","title":"Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status","year":2015,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Public Health Ontario; Women's College Hospital","funders":"National Institutes of Health; Canada Research Chairs; National Cancer Institute; Cancer Care Ontario","keywords":"Medicine; Ovarian cancer; BRCA mutation; Oncology; Internal medicine; Cancer; Disease; Mutation; Serous fluid; Gynecology; Genetics; Biology; Gene","score_opus":0.050721896523145064,"score_gpt":0.34499920259877004,"score_spread":0.29427730607562497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098816367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661752,0.00016088772,0.00019416437,0.009906864,0.0016749275,0.0007691085,0.0002885268,0.00020395116,0.020626383],"genre_scores_gemma":[0.9857208,0.00009333361,0.0010676812,0.010069503,0.00044556902,0.00052251265,0.000097707736,0.000040639334,0.0019422431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772966,0.00032376,0.00038743982,0.0004768381,0.0004354028,0.00064691005],"domain_scores_gemma":[0.99810845,0.0004322238,0.00027828506,0.00028083115,0.00054019043,0.00035999893],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063325674,0.0002501197,0.00061653677,0.00013580336,0.000077679346,0.00001821387,0.000102024096,0.00044643055,0.004396207],"category_scores_gemma":[0.0005467498,0.00019440951,0.00008030039,0.0003381331,0.000267343,0.0001073876,0.000042028296,0.00040094784,0.00021959728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024194501,0.0029781687,0.86081576,0.00006941673,0.0018530056,0.0034581434,0.009546432,0.00033780016,0.004062136,0.0009996732,0.038330294,0.05335467],"study_design_scores_gemma":[0.031471185,0.009310276,0.8260287,0.00007890907,0.00041554592,0.00010009135,0.0012316563,0.00015795148,0.003062045,0.001479017,0.12609425,0.0005703756],"about_ca_topic_score_codex":0.0003622457,"about_ca_topic_score_gemma":0.001311508,"teacher_disagreement_score":0.08776396,"about_ca_system_score_codex":0.0023363063,"about_ca_system_score_gemma":0.0019678774,"threshold_uncertainty_score":0.9965139},"labels":[],"label_agreement":null},{"id":"W2099342841","doi":"10.1016/j.ygyno.2009.07.009","title":"BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide","year":2009,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; PARP inhibitor; Cancer research; Poly ADP ribose polymerase; Epithelial ovarian cancer; Ovarian cancer; Oncology; Cancer; Internal medicine; Biology; DNA; Polymerase; Genetics","score_opus":0.03393218428434309,"score_gpt":0.3599466495170423,"score_spread":0.3260144652326992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099342841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88462424,0.00038135893,0.00020424959,0.081505805,0.0031927638,0.0017811172,0.00008249602,0.00033932456,0.027888639],"genre_scores_gemma":[0.93405807,0.00018295168,0.0013138619,0.058870826,0.0025826287,0.00027852287,0.000024916455,0.00003410563,0.0026541187],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970792,0.00039118828,0.0006512164,0.00068145007,0.00035986403,0.0008370874],"domain_scores_gemma":[0.99800575,0.000508374,0.00024930012,0.00067649747,0.00022118074,0.00033890543],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000771306,0.00037439918,0.00077968626,0.00018694389,0.0004191904,0.000034076216,0.0003104171,0.00046797437,0.0021442827],"category_scores_gemma":[0.00018566864,0.00026419217,0.00020755726,0.00043003965,0.00024440893,0.000070068396,0.000087453125,0.00063259143,0.0006533532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008214435,0.0008880449,0.0012654783,0.000026791027,0.00016299386,0.0006567384,0.0015954887,0.00043344023,0.7387048,0.0028317508,0.16336644,0.089246586],"study_design_scores_gemma":[0.0070982547,0.007868944,0.08695523,0.000086804925,0.00024220062,0.0002429676,0.0005101653,0.00007881623,0.14941244,0.0035342854,0.7433508,0.0006191011],"about_ca_topic_score_codex":0.00017443238,"about_ca_topic_score_gemma":0.00064805057,"teacher_disagreement_score":0.58929235,"about_ca_system_score_codex":0.0010927933,"about_ca_system_score_gemma":0.0005538621,"threshold_uncertainty_score":0.99998105},"labels":[],"label_agreement":null},{"id":"W2103272465","doi":"10.1158/1535-7163.mct-09-0872","title":"ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Synthetic lethality; Olaparib; Poly ADP ribose polymerase; Cancer research; Mantle cell lymphoma; Biology; DNA damage; Cell culture; DNA repair; Cancer cell; Polymerase; Molecular biology; Cancer; Lymphoma; Gene; DNA; Genetics; Immunology","score_opus":0.014287442575405696,"score_gpt":0.2850526350548136,"score_spread":0.2707651924794079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103272465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97514725,0.0055354172,0.0023630175,0.006579779,0.0029168264,0.00089285517,0.00012630482,0.00027831085,0.0061602374],"genre_scores_gemma":[0.9703413,0.00032647725,0.0029705674,0.023753865,0.000910365,0.00012763524,0.000024372945,0.00017819875,0.0013671677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970256,0.000083978404,0.0005202,0.0007445688,0.0007857566,0.00083986373],"domain_scores_gemma":[0.99803436,0.000055357956,0.00017313487,0.0010064837,0.00025010933,0.0004805737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020800074,0.0005123859,0.00051117584,0.00026966986,0.00020511023,0.00007902715,0.00028249982,0.00031311868,0.0005085413],"category_scores_gemma":[0.000008024978,0.0005002079,0.0002979277,0.0006907653,0.00020930353,0.000082403465,0.00008493122,0.00042840632,0.00038190614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002643262,0.00036804707,0.0004989692,0.00005910833,0.00009391705,0.00016175314,0.00060721627,0.000028304345,0.9717165,0.0001550385,0.0015446878,0.02450213],"study_design_scores_gemma":[0.0029682314,0.0002734608,0.0005041019,0.0000801022,0.00018804823,0.00007386675,0.000120649755,0.00011289755,0.88957053,0.0001166607,0.10546989,0.00052156014],"about_ca_topic_score_codex":0.0002866544,"about_ca_topic_score_gemma":0.000049766102,"teacher_disagreement_score":0.1039252,"about_ca_system_score_codex":0.00028342623,"about_ca_system_score_gemma":0.00052807067,"threshold_uncertainty_score":0.99974495},"labels":[],"label_agreement":null},{"id":"W2108899241","doi":"10.3945/jn.109.111757","title":"Niacin Status Impacts Chromatin Structure 1–3","year":2009,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"University of Manchester","keywords":"Chromatin; Histone; NAD+ kinase; Niacin; Acetylation; Poly ADP ribose polymerase; ADP-ribosylation; Biochemistry; Chemistry; Sirtuin; Biology; Cell biology; DNA; Enzyme; Polymerase","score_opus":0.014292192021070191,"score_gpt":0.31764728297471834,"score_spread":0.30335509095364815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108899241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032044,0.002276954,0.00030302576,0.0061296634,0.00024502183,0.0001552521,0.00002172318,0.000017846143,0.0005300606],"genre_scores_gemma":[0.9910885,0.00084903056,0.0052651414,0.0016160301,0.0011393679,7.144112e-7,0.000011057099,0.000008214595,0.000021959637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903405,0.000033114964,0.00036874774,0.00006466457,0.0003337777,0.00016566637],"domain_scores_gemma":[0.9991541,0.000022053558,0.00030781387,0.00009839593,0.00023693651,0.00018068326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011165092,0.00008732223,0.00024001532,0.00018154713,0.000032148066,0.000018540186,0.000037814592,0.000075723074,0.00029981855],"category_scores_gemma":[0.000055156186,0.00007035808,0.00010854845,0.00016241406,0.00001892418,0.0001995575,0.0000019565994,0.00025412414,0.000005764307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009884686,0.0005682007,0.0007438978,0.000093976516,0.0000481108,0.00014108882,0.00025868008,0.000009451231,0.9366596,0.00009125602,0.048795126,0.011602142],"study_design_scores_gemma":[0.03140349,0.009351793,0.29110897,0.0036944482,0.00022238227,0.008036442,0.00039708597,0.0000689945,0.55198634,0.02897703,0.07439819,0.00035483792],"about_ca_topic_score_codex":0.0000014110091,"about_ca_topic_score_gemma":6.27092e-7,"teacher_disagreement_score":0.38467324,"about_ca_system_score_codex":0.0002464144,"about_ca_system_score_gemma":0.00010490861,"threshold_uncertainty_score":0.3282803},"labels":[],"label_agreement":null},{"id":"W2111045834","doi":"10.1016/j.yjmcc.2008.06.009","title":"PARP mediates structural alterations in diabetic cardiomyopathy","year":2008,"lang":"en","type":"article","venue":"Journal of Molecular and Cellular Cardiology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Diabetic cardiomyopathy; Oxidative stress; PARP inhibitor; Poly ADP ribose polymerase; Endocrinology; Internal medicine; Fibrosis; Streptozotocin; Cardiac fibrosis; Downregulation and upregulation; Diabetes mellitus; Knockout mouse; Biology; Medicine; Cardiomyopathy; Heart failure; Polymerase; Biochemistry","score_opus":0.01344038801133001,"score_gpt":0.25278343345273424,"score_spread":0.23934304544140422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111045834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842439,0.011943746,0.0023090579,0.0004694627,0.00030875314,0.000101773796,0.0000033955553,0.000005557555,0.00061434635],"genre_scores_gemma":[0.998136,0.0006896608,0.00045004726,0.00034008146,0.0003391541,0.0000049499527,0.000007931122,0.000013002653,0.000019216031],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989343,0.0001812155,0.00038808567,0.00012672003,0.00018924472,0.00018037914],"domain_scores_gemma":[0.9994508,0.000041707368,0.00012302847,0.00013701337,0.00012276598,0.0001247031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024499441,0.00011408126,0.00053669786,0.00019132487,0.000045301585,0.000005306767,0.000053479842,0.000098803575,0.000018701578],"category_scores_gemma":[0.000053641365,0.00009472156,0.00021261584,0.00011591507,0.00015359602,0.0000496024,0.000015984982,0.0002784815,0.000002169424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037230417,0.000032071603,0.18482889,0.00004980774,0.0004924968,0.01393567,0.00094308896,0.0013473829,0.79590154,0.00028533596,0.00055465533,0.0012567671],"study_design_scores_gemma":[0.021518996,0.003266123,0.25118724,0.00033827813,0.0008436257,0.078804635,0.000765283,0.00051374116,0.62681794,0.0054912684,0.009546826,0.00090604014],"about_ca_topic_score_codex":0.000004891057,"about_ca_topic_score_gemma":5.296677e-7,"teacher_disagreement_score":0.16908358,"about_ca_system_score_codex":0.000052539137,"about_ca_system_score_gemma":0.00011543449,"threshold_uncertainty_score":0.3862633},"labels":[],"label_agreement":null},{"id":"W2111365327","doi":"10.1016/j.ejca.2008.03.019","title":"Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Poly ADP ribose polymerase; Temozolomide; Melanoma; In vivo; Cancer research; Angiogenesis; PARP inhibitor; CD31; Biology; In vitro; Glioma; Polymerase; DNA; Biochemistry","score_opus":0.021716845727099417,"score_gpt":0.27290877613245507,"score_spread":0.25119193040535565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111365327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98277146,0.011935775,0.00005975697,0.0013205244,0.00014488869,0.00008167472,0.000026972759,0.000009490987,0.0036494723],"genre_scores_gemma":[0.99447376,0.003834816,0.00042661658,0.00045431996,0.00060426514,0.0000011403426,0.0000012209589,0.000029615741,0.00017427141],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985884,0.00026680887,0.0004999473,0.00013608983,0.0003390633,0.00016972923],"domain_scores_gemma":[0.9990391,0.000069054695,0.00043118687,0.00010799828,0.00020465013,0.00014797544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004767147,0.00013042944,0.00038018258,0.00020280085,0.00004606487,0.000007222291,0.00006330794,0.000023910683,0.00018834093],"category_scores_gemma":[0.00009651781,0.0001131735,0.00007700874,0.00020543399,0.00017367282,0.00018179078,0.000020436833,0.00020808162,0.00000143732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021460506,0.00027127287,0.13017602,0.000083650855,0.00013631879,0.0011957844,0.0010429752,0.000008633343,0.8515693,0.000021656117,0.004362474,0.008985878],"study_design_scores_gemma":[0.003785321,0.00047788885,0.2611804,0.000601882,0.000036247075,0.00125404,0.000114902214,0.0000067452524,0.72990394,0.00001316183,0.0025059865,0.00011945115],"about_ca_topic_score_codex":0.00035746855,"about_ca_topic_score_gemma":0.000015287596,"teacher_disagreement_score":0.1310044,"about_ca_system_score_codex":0.0000889566,"about_ca_system_score_gemma":0.00022711125,"threshold_uncertainty_score":0.46150813},"labels":[],"label_agreement":null},{"id":"W2114114329","doi":"10.1021/bi902079y","title":"Crystal Structure of the Catalytic Domain of Human PARP2 in Complex with PARP Inhibitor ABT-888","year":2010,"lang":"en","type":"article","venue":"Biochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Diamond Light Source; Wellcome Trust","keywords":"Poly ADP ribose polymerase; PARP1; NAD+ kinase; Polymerase; DNA; Chromatin; Chemistry; PARP inhibitor; Ribose; DNA repair; ADP-ribosylation; Biochemistry; DNA damage; Enzyme; Transcription (linguistics); Cell biology; Biology","score_opus":0.011701744877118374,"score_gpt":0.2735198795656024,"score_spread":0.261818134688484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114114329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978796,0.00004783389,0.0000033155106,0.0002656873,0.00005922234,0.00020082673,0.0001266869,0.00001287473,0.0014039453],"genre_scores_gemma":[0.9991053,0.0000012507488,0.00038545355,0.00008672339,0.00018411553,0.0000072055077,0.0000672227,0.000018080418,0.00014469613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990373,0.00001327361,0.00030394204,0.00019916722,0.00028754395,0.00015875437],"domain_scores_gemma":[0.99908876,0.000021433223,0.00019885415,0.000541883,0.00008362894,0.00006546623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070259484,0.00014023905,0.00026637592,0.00003169748,0.000032876786,0.000004118934,0.00015839681,0.00014461984,0.00031051785],"category_scores_gemma":[0.000021058919,0.0000951449,0.000066476685,0.00017366292,0.00045115192,0.000018935221,0.00003596245,0.00032599302,7.3531675e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012794923,0.000086258035,0.026041623,0.00024370926,0.000024723171,0.000003936603,0.00020393974,0.0000011376164,0.9722802,0.00005887203,0.0008979693,0.00002965525],"study_design_scores_gemma":[0.0021201987,0.00006922123,0.03099878,0.00018447454,0.000019843523,0.0000588946,0.00018443118,0.0000032073144,0.9656942,0.00023063016,0.00033772056,0.000098401804],"about_ca_topic_score_codex":0.000053412834,"about_ca_topic_score_gemma":0.000078061326,"teacher_disagreement_score":0.0065860287,"about_ca_system_score_codex":0.000051001887,"about_ca_system_score_gemma":0.00017614431,"threshold_uncertainty_score":0.38798964},"labels":[],"label_agreement":null},{"id":"W2114150320","doi":"10.1111/j.1529-8027.2012.00413.x","title":"PARP inhibitors attenuate chemotherapy‐induced painful neuropathy","year":2012,"lang":"en","type":"article","venue":"Journal of the Peripheral Nervous System","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Vincristine; Poly ADP ribose polymerase; Medicine; Peripheral neuropathy; Pharmacology; Allodynia; Neuropathic pain; Chemotherapy-induced peripheral neuropathy; Chemotherapy; Chemistry; Internal medicine; Hyperalgesia; Polymerase; Cyclophosphamide; Diabetes mellitus; Endocrinology; Enzyme; Biochemistry; Nociception; Receptor","score_opus":0.020012368797388123,"score_gpt":0.26537981962863844,"score_spread":0.2453674508312503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114150320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859417,0.0010799291,0.00015058026,0.0056849527,0.0048713605,0.00039282706,0.0000047723693,0.00006351323,0.0018103668],"genre_scores_gemma":[0.99119407,0.000040099905,0.00022359563,0.0025571825,0.0050307107,0.000011583962,6.391238e-7,0.00007627153,0.0008658638],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99719983,0.00039431482,0.00094487006,0.00015761143,0.0007903133,0.0005130468],"domain_scores_gemma":[0.99781406,0.000058688685,0.0009367325,0.0005169874,0.00030869275,0.00036482172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011491572,0.00028539466,0.00062938395,0.000106504696,0.00018239516,0.00004609662,0.0003197479,0.00013636987,0.00011345742],"category_scores_gemma":[0.0000624685,0.00017245083,0.0006040524,0.0003333323,0.000074362426,0.0002735798,0.00004585716,0.0005882365,0.00003617561],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026592796,0.00092493184,0.15580977,0.0008256995,0.000959777,0.0002740052,0.008850956,0.00031725012,0.7605323,0.00037154282,0.0476842,0.020790294],"study_design_scores_gemma":[0.029489014,0.004294114,0.3637756,0.007743125,0.0012190166,0.05059903,0.008796063,0.0012684214,0.24585953,0.00011820284,0.28479248,0.00204537],"about_ca_topic_score_codex":0.0000213075,"about_ca_topic_score_gemma":0.0000015522888,"teacher_disagreement_score":0.51467276,"about_ca_system_score_codex":0.00066932803,"about_ca_system_score_gemma":0.00017540395,"threshold_uncertainty_score":0.7032341},"labels":[],"label_agreement":null},{"id":"W2115028635","doi":"10.1016/j.ctrv.2010.03.006","title":"Targeting DNA repair in breast cancer: A clinical and translational update","year":2010,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"DNA repair; Synthetic lethality; Medicine; Breast cancer; Homologous recombination; Poly ADP ribose polymerase; Cancer research; DNA damage; Genome instability; BRCA2 Protein; DNA mismatch repair; Cancer; DNA; Mutation; Germline mutation; Genetics; Polymerase; Biology; Gene; Internal medicine","score_opus":0.12089813744190153,"score_gpt":0.46419491885373404,"score_spread":0.3432967814118325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115028635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036371042,0.992262,0.0000054325055,0.001446785,0.00075539335,0.003998463,0.0011898143,0.00009228378,0.00021343183],"genre_scores_gemma":[0.0000018570892,0.9899845,0.0008908445,0.0007560059,0.0018284568,0.005630337,0.00044166614,0.00010215124,0.00036417943],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99550647,0.0004756184,0.0022637467,0.0010675428,0.0002470454,0.00043958615],"domain_scores_gemma":[0.9980595,0.00015912662,0.0007901043,0.00060581736,0.00006863511,0.0003168323],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008057729,0.00080399256,0.004527322,0.00020996353,0.00007910276,0.000019602128,0.00012585483,0.0005531784,0.0014832683],"category_scores_gemma":[0.000020988537,0.0005404011,0.0013348169,0.0004296425,0.00022750825,0.00010313602,0.000023657421,0.0008100875,0.00008499038],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000604501,0.0002053855,0.0050911447,0.008192714,0.00031852874,0.000038267637,0.00003925909,2.2088639e-7,0.0000010359508,0.000020569198,0.0052396054,0.9807928],"study_design_scores_gemma":[0.002321642,0.000079196376,0.0003760303,0.03652269,0.0020961668,0.00015076138,0.0000016688521,0.000008346043,5.9129366e-7,0.00001486614,0.9580199,0.00040813014],"about_ca_topic_score_codex":0.00017982279,"about_ca_topic_score_gemma":0.00018270957,"teacher_disagreement_score":0.9803847,"about_ca_system_score_codex":0.00055785605,"about_ca_system_score_gemma":0.001443409,"threshold_uncertainty_score":0.9997048},"labels":[],"label_agreement":null},{"id":"W2116236442","doi":"10.1186/bcr3484","title":"Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer","year":2013,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Sunnybrook Health Science Centre","funders":"American Society of Clinical Oncology; AstraZeneca","keywords":"Medicine; Olaparib; Neutropenia; Tolerability; Internal medicine; Febrile neutropenia; PARP inhibitor; Metastatic breast cancer; Taxane; Oncology; Breast cancer; Regimen; Cohort; Adverse effect; Surgery; Chemotherapy; Cancer","score_opus":0.08670294013995589,"score_gpt":0.4172623707952946,"score_spread":0.3305594306553387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116236442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98149544,0.000125155,0.000040350882,0.0041608773,0.00015693586,0.009588486,0.0043761367,0.000013415315,0.000043191856],"genre_scores_gemma":[0.99011153,0.000114266964,0.0002288314,0.00006721752,0.00016132185,0.008483266,0.00008153657,0.000055936056,0.00069607695],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969284,0.0003119821,0.00064438675,0.00044338434,0.0011373905,0.000534483],"domain_scores_gemma":[0.99658054,0.00046275946,0.00038103212,0.00046039934,0.001941308,0.00017393303],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046804783,0.0002823369,0.0007546447,0.00031520205,0.00013174869,0.000025274092,0.00017594162,0.00007912173,0.001847282],"category_scores_gemma":[0.00006236486,0.00014748436,0.000117793104,0.0011226136,0.00053978583,0.00025815633,0.000031503863,0.00023973483,0.0000026290356],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8393635,0.023556823,0.060432706,0.0010684715,0.0012255497,0.000007989133,0.0031952318,0.000109398046,0.0013377233,0.00011563522,0.003002135,0.0665848],"study_design_scores_gemma":[0.76487064,0.027095398,0.18119732,0.0017132419,0.0002567155,0.000022710117,0.00080779305,0.00057308737,0.022037093,0.00028692468,0.0008001727,0.00033889362],"about_ca_topic_score_codex":0.008433552,"about_ca_topic_score_gemma":0.008981326,"teacher_disagreement_score":0.12076461,"about_ca_system_score_codex":0.0012464935,"about_ca_system_score_gemma":0.0016008553,"threshold_uncertainty_score":0.99906516},"labels":[],"label_agreement":null},{"id":"W2117964602","doi":"10.1016/s1470-2045(11)70214-5","title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; Vancouver General Hospital; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Université de Montréal; BC Cancer Agency; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Internal medicine; Tolerability; Breast cancer; Ovarian cancer; Oncology; BRCA mutation; PARP inhibitor; Clinical endpoint; Triple-negative breast cancer; Adverse effect; Response Evaluation Criteria in Solid Tumors; Cancer; Serous fluid; Phases of clinical research; Clinical trial","score_opus":0.11106092244593813,"score_gpt":0.3838345029660907,"score_spread":0.27277358052015255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117964602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882612,0.00004453457,0.00003544999,0.0014671265,0.000726463,0.008553026,0.00043224305,0.000072567884,0.0004073596],"genre_scores_gemma":[0.99524146,0.00008360401,0.0006702085,0.0013326462,0.00029971497,0.0019245067,0.00008638415,0.00006379875,0.00029765393],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99659085,0.0009409626,0.00071507384,0.0006441341,0.00037275,0.00073624623],"domain_scores_gemma":[0.99787706,0.00035956895,0.0005279848,0.0007264408,0.00028181527,0.00022711609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054896437,0.00043598266,0.0015807158,0.00016676048,0.00017256026,0.0000358586,0.0006359565,0.00016079385,0.0014142034],"category_scores_gemma":[0.000084842344,0.00023127689,0.00004221551,0.00068341586,0.00022429084,0.00017343876,0.00015735088,0.0006481685,0.000022745704],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7266828,0.03020309,0.21164231,0.00007036807,0.00084629864,0.00037496744,0.015544612,0.0000018179228,0.00022432528,0.000022490718,0.0018753612,0.012511566],"study_design_scores_gemma":[0.47375298,0.011457595,0.5127542,0.00017156325,0.00034525982,0.00003103232,0.00068874116,0.00014563525,0.00023653844,0.000026032416,0.00015210675,0.0002383171],"about_ca_topic_score_codex":0.0064090365,"about_ca_topic_score_gemma":0.011189224,"teacher_disagreement_score":0.30111188,"about_ca_system_score_codex":0.0008835015,"about_ca_system_score_gemma":0.0007893453,"threshold_uncertainty_score":0.99949867},"labels":[],"label_agreement":null},{"id":"W2118668903","doi":"10.1074/jbc.m115.694992","title":"Poly(ADP-ribosyl)ation-dependent Transient Chromatin Decondensation and Histone Displacement following Laser Microirradiation","year":2015,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Victoria; NOSM University; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Chromatin; Histone; Histone H2A; Histone H1; Nucleosome; Molecular biology; Cell biology; Chromatin remodeling; Biology; DNA; Chemistry; Biochemistry","score_opus":0.037593458590789115,"score_gpt":0.31870689513405054,"score_spread":0.28111343654326143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118668903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422437,0.0020458265,0.0009898712,0.0018072193,0.00017992995,0.00010177148,0.000007813891,0.000014157736,0.00062905496],"genre_scores_gemma":[0.9977905,0.000114464885,0.0012404295,0.00031355242,0.00030903803,0.000006010339,0.000029432735,0.000007700058,0.00018884451],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989023,0.000036975507,0.00047831915,0.00014481694,0.00030373276,0.0001338459],"domain_scores_gemma":[0.99916977,0.000051956446,0.00031367372,0.00009292012,0.00014032006,0.00023133575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048059013,0.0001195988,0.00027020602,0.000035434376,0.000039997718,0.000017249127,0.00005283948,0.00013769891,0.0001633125],"category_scores_gemma":[0.00014066155,0.00008913126,0.000114198505,0.00006573228,0.00005082231,0.00008140091,0.000010916628,0.00019249647,0.000004399745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006185455,0.00018921126,0.0097684385,0.000043193984,0.00010227747,0.00004596374,0.00032255272,0.000018723571,0.98604095,0.0000059098566,0.0013081088,0.0015361473],"study_design_scores_gemma":[0.009167932,0.00074874307,0.02420259,0.00022576185,0.00013375451,0.0006648188,0.0007940362,0.000117869655,0.9600164,0.00040783896,0.0032883354,0.00023186463],"about_ca_topic_score_codex":0.0000026839557,"about_ca_topic_score_gemma":4.79973e-7,"teacher_disagreement_score":0.026024474,"about_ca_system_score_codex":0.0004377862,"about_ca_system_score_gemma":0.00012262737,"threshold_uncertainty_score":0.3634667},"labels":[],"label_agreement":null},{"id":"W2121618450","doi":"10.1186/1742-2094-10-49","title":"Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis","year":2013,"lang":"en","type":"article","venue":"Journal of Neuroinflammation","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; St. Boniface Hospital","funders":"Canadian Institutes of Health Research; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Manitoba Health Research Council","keywords":"Neuroinflammation; Experimental autoimmune encephalomyelitis; Neurology; Medicine; Poly ADP ribose polymerase; Immunology; Neuroscience; Encephalomyelitis; Neuroimmunology; Polymerase; Multiple sclerosis; Biology; Psychiatry; Inflammation; Genetics; Immune system; Gene","score_opus":0.012694191158150838,"score_gpt":0.2643884395926547,"score_spread":0.25169424843450383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121618450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843557,0.0007666706,0.0005925869,0.0129499445,0.00046065758,0.00069861114,0.000002773596,0.00004574063,0.00012735036],"genre_scores_gemma":[0.9980764,0.00011587598,0.00048791422,0.00070472754,0.00042401341,0.000041673266,0.000007846018,0.000027571019,0.00011401455],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977301,0.0001977639,0.0010258966,0.00024844415,0.0005239316,0.00027389056],"domain_scores_gemma":[0.9986146,0.00014499588,0.00047316527,0.00020283369,0.0003573005,0.00020709816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038298313,0.00021741448,0.00042268072,0.00058658986,0.00008081803,0.000103649865,0.00009372093,0.00011270463,0.00019060992],"category_scores_gemma":[0.00040138795,0.00019531247,0.00010201152,0.000326682,0.000072797746,0.0008057806,0.00003901353,0.00038451265,0.000043172742],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007824574,0.0001193361,0.0033201813,0.000021553633,0.000017321454,0.0000988798,0.0002826978,0.000085713895,0.97996384,0.00013661275,0.00060998247,0.014561412],"study_design_scores_gemma":[0.006429745,0.0022519748,0.5900293,0.00015791603,0.000033691344,0.001161362,0.00016167438,0.0033610978,0.3943091,0.0003178755,0.0015738499,0.00021237251],"about_ca_topic_score_codex":0.000043630513,"about_ca_topic_score_gemma":0.0000032546025,"teacher_disagreement_score":0.58670914,"about_ca_system_score_codex":0.0001781512,"about_ca_system_score_gemma":0.00009728876,"threshold_uncertainty_score":0.79646116},"labels":[],"label_agreement":null},{"id":"W2122545253","doi":"10.1016/j.celrep.2014.08.036","title":"ARTD1/PARP1 Negatively Regulates Glycolysis by Inhibiting Hexokinase 1 Independent of NAD+ Depletion","year":2014,"lang":"en","type":"article","venue":"Cell Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"National Institute of General Medical Sciences; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research; University of Pittsburgh; Cancer Institute, University of Pittsburgh; National Cancer Institute; National Institutes of Health; Max-Planck-Gesellschaft","keywords":"NAD+ kinase; PARP1; Hexokinase; Glycolysis; Poly ADP ribose polymerase; Mitochondrion; Programmed cell death; Cell biology; DNA damage; Biochemistry; Enzyme; DNA repair; Biology; Chemistry; DNA; Apoptosis; Polymerase","score_opus":0.010988628865708248,"score_gpt":0.2516460291170514,"score_spread":0.24065740025134316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122545253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98161715,0.00043238723,0.0015911427,0.000308967,0.00022217132,0.00037011018,0.000006702742,0.00009279008,0.015358585],"genre_scores_gemma":[0.9964253,0.000046140947,0.00074863,0.0003392771,0.0001756788,0.000048465237,0.000085071,0.000041018124,0.002090446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978272,0.00008445935,0.00080141716,0.00044829148,0.0005632674,0.0002753765],"domain_scores_gemma":[0.9982275,0.00010333133,0.000793078,0.00045133397,0.0002445443,0.0001802505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006482799,0.00020050663,0.00043572803,0.00013866764,0.00008520554,0.000017554461,0.00004893466,0.00014437128,0.0003572814],"category_scores_gemma":[0.00021369739,0.00019440471,0.00015656896,0.0002648855,0.000118043085,0.00010207757,0.000035121586,0.00019471344,0.0000142360295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015252376,0.0002649692,0.015413729,0.0002148594,0.000056790665,0.00022082603,0.00035955632,0.000062934094,0.9673789,0.00004779026,0.012474454,0.0033526488],"study_design_scores_gemma":[0.0011207706,0.00022014057,0.0029607045,0.00024907707,0.000076312404,0.00035986537,0.00011554435,0.00014446177,0.9760119,0.0007279021,0.017825412,0.00018796092],"about_ca_topic_score_codex":0.00010376915,"about_ca_topic_score_gemma":0.000006889575,"teacher_disagreement_score":0.014808129,"about_ca_system_score_codex":0.00015292494,"about_ca_system_score_gemma":0.00010871713,"threshold_uncertainty_score":0.7927594},"labels":[],"label_agreement":null},{"id":"W2124470568","doi":"10.1158/0008-5472.can-10-2352","title":"Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Cancer Research UK; Abbott Laboratories","keywords":"PARP inhibitor; PARP1; Poly ADP ribose polymerase; Clonogenic assay; Cancer research; RAD51; Synthetic lethality; Biology; Cancer cell; DNA damage; DNA repair; In vivo; Molecular biology; Cancer; Polymerase; DNA; Genetics","score_opus":0.07678439385390248,"score_gpt":0.4114094948835611,"score_spread":0.3346251010296586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124470568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771431,0.00123677,0.000018586632,0.013290711,0.0003352785,0.0009404046,0.0001754318,0.000020503494,0.006839198],"genre_scores_gemma":[0.99476206,0.0003940443,0.000051999716,0.0022311676,0.00030836993,0.00082741614,0.0000045620313,0.000038694012,0.001381663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975846,0.00026163636,0.00027929465,0.00038354608,0.0010188309,0.00047211058],"domain_scores_gemma":[0.9980396,0.00059804204,0.000093121,0.00086091086,0.00022599565,0.00018231595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013381292,0.00015407252,0.00026801485,0.00008309939,0.00015517921,0.000015904798,0.00029603008,0.000080049205,0.014116614],"category_scores_gemma":[0.000118146854,0.00010374248,0.00011291625,0.00021514592,0.0009423313,0.000031889107,0.000053546617,0.000994044,0.000080081765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068671675,0.0003332554,0.0046378137,0.00014366317,0.000033906497,0.000013387226,0.0002489471,0.000049062128,0.98207825,0.00033639066,0.00910469,0.0023339326],"study_design_scores_gemma":[0.0017671956,0.00030067467,0.008197361,0.00029294527,0.000022074855,0.0000030464753,0.00022861826,0.00018953868,0.91393185,0.00008648985,0.07486118,0.000119049575],"about_ca_topic_score_codex":0.0034044029,"about_ca_topic_score_gemma":0.0007057317,"teacher_disagreement_score":0.06814641,"about_ca_system_score_codex":0.0005307477,"about_ca_system_score_gemma":0.000632363,"threshold_uncertainty_score":0.98678464},"labels":[],"label_agreement":null},{"id":"W2133947353","doi":"10.1517/17460441.2014.911282","title":"Advances in the approach to novel drug clinical development for breast cancer","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Drug Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Clinical trial; Drug development; Medicine; Intensive care medicine; Breast cancer; Drug; Population; Clinical research; Translational research; Cancer; Pharmacology; Pathology; Internal medicine","score_opus":0.11827331199395044,"score_gpt":0.4680147860398713,"score_spread":0.3497414740459208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133947353","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000039626248,0.9849454,0.003521158,0.0021502574,0.0030354788,0.0038527492,0.0003409399,0.000048049544,0.002101994],"genre_scores_gemma":[0.000028359136,0.9785752,0.0017701573,0.0064370707,0.0038984194,0.007899546,0.00046767047,0.00011555383,0.0008080172],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960135,0.0002900511,0.0014703695,0.0010443407,0.0006779713,0.000503748],"domain_scores_gemma":[0.99758273,0.00087874656,0.0004592269,0.0008158457,0.00007945289,0.00018401978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014080044,0.00064878527,0.0021860343,0.00027076766,0.00013030779,0.00008562442,0.0005830168,0.00023751285,0.000043040294],"category_scores_gemma":[0.00008252344,0.000393405,0.00071240077,0.00040069487,0.000108888366,0.00023003039,0.00007893601,0.00061776664,0.000064508335],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030950966,0.0010772118,0.0000122523115,0.0035827165,0.00008500251,7.2658383e-7,0.0008180991,0.000015102658,1.9296942e-7,0.00074661017,0.05984658,0.933506],"study_design_scores_gemma":[0.002011473,0.00006355137,0.00005515542,0.021211734,0.000023872472,0.000035546556,0.00020766014,0.0000101040905,0.0000034025813,0.000011547803,0.9758807,0.00048528382],"about_ca_topic_score_codex":0.000023780858,"about_ca_topic_score_gemma":0.0000145419,"teacher_disagreement_score":0.9330207,"about_ca_system_score_codex":0.00059596315,"about_ca_system_score_gemma":0.0011210504,"threshold_uncertainty_score":0.99985176},"labels":[],"label_agreement":null},{"id":"W2136466694","doi":"10.1016/j.bbamcr.2010.04.011","title":"Characterization of nuclear factors modulating the apolipoprotein D promoter during growth arrest: Implication of PARP-1, APEX-1 and ERK1/2 catalytic activities","year":2010,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Electrophoretic mobility shift assay; Gene knockdown; Molecular biology; Promoter; Nuclear protein; Poly ADP ribose polymerase; Transcription factor; Biology; Chemistry; Downregulation and upregulation; Kinase; Gene expression; Cell biology; Gene; Biochemistry; Polymerase","score_opus":0.02115612839068872,"score_gpt":0.30335451404015773,"score_spread":0.28219838564946903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136466694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968292,0.000014721388,0.000027741551,0.0014652235,0.000049072416,0.0011476341,0.000057861504,0.00003556573,0.00037299225],"genre_scores_gemma":[0.9992985,0.000072222414,0.0001854854,0.000039632672,0.00010346545,0.000073168,0.00009910869,0.000073126976,0.00005526562],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977498,0.00021705145,0.00040678855,0.00045929325,0.0007724871,0.00039457454],"domain_scores_gemma":[0.99839234,0.00012252262,0.00030452452,0.00075027015,0.0002951145,0.00013520733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045480474,0.00023198183,0.00034483068,0.00027391835,0.00019095029,0.000057223846,0.00027968612,0.00016478263,0.000023772924],"category_scores_gemma":[0.0001059381,0.00018210706,0.00012445556,0.00050277717,0.0006155163,0.0001741745,0.00017764399,0.0007043959,0.0000038550493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023336234,0.00020737204,0.000069053596,0.0004522074,0.000062661384,0.0000021099113,0.0016440673,2.9430555e-7,0.99675804,0.00032640414,0.0000061812843,0.00023826375],"study_design_scores_gemma":[0.00064163376,0.00023407285,0.026502652,0.00013467537,0.00003495175,0.000005342791,0.00017102915,0.00021673222,0.9716702,0.00021082848,0.000025363115,0.00015250091],"about_ca_topic_score_codex":0.00016538647,"about_ca_topic_score_gemma":0.0000028041238,"teacher_disagreement_score":0.026433598,"about_ca_system_score_codex":0.000059207854,"about_ca_system_score_gemma":0.00014905292,"threshold_uncertainty_score":0.742611},"labels":[],"label_agreement":null},{"id":"W2136939272","doi":"10.1107/s1399004714017660","title":"Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2","year":2014,"lang":"en","type":"article","venue":"Acta Crystallographica Section D Biological Crystallography","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Basic Energy Sciences; Office of Science; Terry Fox Research Institute; University of Toronto; Canadian Institutes of Health Research; Industrial Macromolecular Crystallography Association Collaborative Access Team; Ontario Institute for Cancer Research; U.S. Department of Energy","keywords":"Poly ADP ribose polymerase; PARP1; Polymerase; Cancer research; PARP inhibitor; Chemistry; Computational biology; Rational design; Biology; Cell biology; DNA; Biochemistry; Genetics","score_opus":0.01997997536159033,"score_gpt":0.26985443217199584,"score_spread":0.24987445681040552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136939272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99183774,0.00034578738,0.0010403998,0.0033713381,0.00039654213,0.0013129889,0.000019936417,0.00015910872,0.0015161291],"genre_scores_gemma":[0.9975489,0.00020334094,0.00037035692,0.0010725763,0.00042828958,0.00023048007,0.000088812296,0.00004007712,0.000017176802],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963087,0.00060590456,0.0011663572,0.00071980816,0.0006931851,0.0005060756],"domain_scores_gemma":[0.9970567,0.0005869212,0.00063938845,0.0010797882,0.0003666481,0.0002705319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011459191,0.00046433182,0.0008029482,0.0010273294,0.0005945259,0.000037607475,0.00063405134,0.00042697275,0.00009522301],"category_scores_gemma":[0.00021012645,0.00024652926,0.0008534015,0.0034774195,0.0017896567,0.00011212977,0.00019227734,0.0006518298,0.000001142785],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036265442,0.0003331779,0.023873536,0.000074621836,0.00030332533,0.0000030877754,0.0012113091,0.00001777729,0.9706438,0.0014750096,0.0012000683,0.0005016025],"study_design_scores_gemma":[0.00661518,0.015345912,0.27753747,0.0008296245,0.0005914834,0.00014366026,0.0067763487,0.000055721033,0.046123683,0.032941625,0.61136883,0.0016704451],"about_ca_topic_score_codex":0.00022375555,"about_ca_topic_score_gemma":0.0002538917,"teacher_disagreement_score":0.92452013,"about_ca_system_score_codex":0.000061015053,"about_ca_system_score_gemma":0.000050469087,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W2138277779","doi":"10.1158/0008-5472.can-05-1186","title":"Efficient Deletion of Normal <i>Brca2</i>-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Poly ADP ribose polymerase; Intestinal epithelium; Polymerase; Epithelium; Cancer research; Molecular biology; Biology; Ribose; Medicine; Pathology; Biochemistry; Enzyme","score_opus":0.05584133082506588,"score_gpt":0.3705531389634022,"score_spread":0.3147118081383363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138277779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97286445,0.010879797,0.0066489554,0.0069178888,0.0002520217,0.0012876054,0.00015137473,0.000094697025,0.0009031936],"genre_scores_gemma":[0.9959933,0.0006645379,0.0004681187,0.00056751154,0.0010639435,0.00047068953,0.000077416655,0.00007555181,0.0006188942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955403,0.00033051436,0.00066516147,0.0006511313,0.0019125419,0.00090032036],"domain_scores_gemma":[0.9977073,0.00010026871,0.0002117119,0.0005571766,0.0010696832,0.00035383765],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011709031,0.00029766394,0.00041422795,0.0005341679,0.00034197725,0.00006595967,0.00020337017,0.00017369083,0.00096175144],"category_scores_gemma":[0.000054355678,0.00026656027,0.00018511733,0.00094113016,0.0007170985,0.00017275664,0.00008595447,0.000848746,0.00007335953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038965112,0.0012219971,0.00008797848,0.00015044515,0.000066891684,0.000024984,0.00071400346,0.008701081,0.95226145,0.00021445096,0.0037270738,0.028933108],"study_design_scores_gemma":[0.0057147294,0.0013911914,0.00020730238,0.00039697046,0.000036149377,0.000116783405,0.00019442648,0.018789427,0.96956193,0.00014812537,0.0031404162,0.00030251898],"about_ca_topic_score_codex":0.0007924867,"about_ca_topic_score_gemma":0.000011055845,"teacher_disagreement_score":0.02863059,"about_ca_system_score_codex":0.0010033471,"about_ca_system_score_gemma":0.0010295591,"threshold_uncertainty_score":0.99997866},"labels":[],"label_agreement":null},{"id":"W2139595202","doi":"10.3747/co.22.2517","title":"Have We Given up on a Cure for Ovarian Cancer?","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Ovarian cancer; Breast cancer; Cancer; Internal medicine","score_opus":0.3762647808646073,"score_gpt":0.5165238671607065,"score_spread":0.14025908629609923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139595202","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19101638,0.05098852,0.023160595,0.5423676,0.09203,0.011834148,0.0014595704,0.0011012461,0.08604198],"genre_scores_gemma":[0.9484531,0.0055786823,0.0031884795,0.009893607,0.015103551,0.005661238,0.00046731997,0.00020247675,0.011451518],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892944,0.00006488402,0.00023088983,0.00029587,0.0001843678,0.00029455932],"domain_scores_gemma":[0.9990261,0.00011170712,0.00012082631,0.00023925686,0.0002424836,0.00025959068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021765607,0.00014853441,0.00035523743,0.00010426926,0.000047294667,0.000006619907,0.00009478651,0.0001450902,0.00026763717],"category_scores_gemma":[0.00008232952,0.00012981251,0.000099584366,0.000090243564,0.000090099915,0.000035259785,0.000021302456,0.00026241565,0.00009283733],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023835278,0.00055121724,0.0035121827,0.00011846368,0.00008268553,0.000013313181,0.0020976358,0.000021082313,0.00038805298,0.0023630043,0.76103866,0.22743018],"study_design_scores_gemma":[0.010368866,0.0018067516,0.00040850506,0.00021126136,0.00006732661,0.000026955544,0.0002603015,0.00032925207,0.0011838981,0.00242023,0.9827882,0.0001284554],"about_ca_topic_score_codex":0.000017844855,"about_ca_topic_score_gemma":0.000040440744,"teacher_disagreement_score":0.75743675,"about_ca_system_score_codex":0.0009314139,"about_ca_system_score_gemma":0.00077800953,"threshold_uncertainty_score":0.52936006},"labels":[],"label_agreement":null},{"id":"W2139596299","doi":"10.1016/j.radonc.2008.04.005","title":"A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia","year":2008,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Abbott Laboratories","keywords":"Poly ADP ribose polymerase; Cancer research; Clonogenic assay; PARP inhibitor; Radiosensitivity; Radioresistance; DNA repair; DNA damage; Cell culture; Chemistry; Radiation therapy; Tumor hypoxia; Prostate cancer; Cancer cell; Cancer; Cell; Biology; Polymerase; Medicine; Enzyme; DNA; Biochemistry; Internal medicine; Genetics","score_opus":0.03592418584567387,"score_gpt":0.31639765118842134,"score_spread":0.2804734653427475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139596299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9610924,0.022399865,0.002056832,0.010185832,0.00085787976,0.0006189648,0.000045126882,0.00021770626,0.0025254039],"genre_scores_gemma":[0.9599965,0.0071726902,0.0067178165,0.016374648,0.0040264404,0.000076831224,0.000053658387,0.0001277825,0.005453631],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977158,0.00014421661,0.00059550675,0.00063467695,0.0003014975,0.00060834136],"domain_scores_gemma":[0.99860907,0.000225486,0.00022995251,0.00044516084,0.000108733555,0.0003816172],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024086061,0.0004261781,0.0008986177,0.00028989208,0.00043418963,0.000020894104,0.00011943543,0.0004407505,0.00048696183],"category_scores_gemma":[0.000011607868,0.00037965347,0.00020697493,0.00027172387,0.00069145893,0.00012054382,0.000025797179,0.0004025819,0.000019825093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011378244,0.0010724135,0.0014403033,0.000056703553,0.00019392627,0.00043498052,0.0013817694,0.000008829975,0.9792792,0.0007671785,0.009993861,0.004233],"study_design_scores_gemma":[0.049656086,0.0082880985,0.029487275,0.00026622662,0.00024168348,0.0159501,0.00054612797,0.0002817986,0.5715943,0.00041845193,0.32184193,0.0014279591],"about_ca_topic_score_codex":0.00018695148,"about_ca_topic_score_gemma":0.00004649062,"teacher_disagreement_score":0.40768495,"about_ca_system_score_codex":0.00060938916,"about_ca_system_score_gemma":0.00043509767,"threshold_uncertainty_score":0.99986553},"labels":[],"label_agreement":null},{"id":"W2140577256","doi":"10.1096/fj.09-137695","title":"Sumoylation of poly(ADP‐ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function","year":2009,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universität Innsbruck; Universität Zürich; Turun Yliopisto; Université Laval; University of Dundee; Deutsche Forschungsgemeinschaft; Slovenská Akadémia Vied; Medizinischen Hochschule Hannover; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"PARP1; SUMO protein; Coactivator; Biology; Poly ADP ribose polymerase; Acetylation; Molecular biology; Transcription factor; Cell biology; Biochemistry; Chemistry; Polymerase; Ubiquitin; Gene","score_opus":0.029893724650510545,"score_gpt":0.28577556697205303,"score_spread":0.2558818423215425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140577256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98382586,0.0028781788,0.003977354,0.00807632,0.0002711501,0.00024040007,0.00003173062,0.000029846296,0.00066915975],"genre_scores_gemma":[0.9974199,0.0002958516,0.0001617001,0.0009827291,0.00087109953,0.0000031321722,0.000027937991,0.000013156276,0.00022452365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872345,0.00011202782,0.00039521573,0.00013779661,0.00044837446,0.00018315016],"domain_scores_gemma":[0.99922585,0.00005861375,0.0002582107,0.00013088834,0.00017320321,0.00015324104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044068598,0.00013660002,0.00019367166,0.00015945287,0.00022860405,0.000030372765,0.00005134129,0.00008843073,0.00028355556],"category_scores_gemma":[0.00004151442,0.00010151728,0.00009530551,0.00021213462,0.00008713547,0.0003258323,0.0000041657886,0.00036882045,0.0000060302755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013167663,0.0001017926,0.0009629639,0.00001200083,0.00005457021,0.0000044621697,0.0005266973,0.000028581162,0.9807878,0.0014306544,0.00030708875,0.014466622],"study_design_scores_gemma":[0.0050281985,0.0010574992,0.2023415,0.0002625165,0.0001688376,0.0010288694,0.00031417678,0.00042438155,0.78600323,0.002306399,0.00090030517,0.00016406289],"about_ca_topic_score_codex":0.000005166122,"about_ca_topic_score_gemma":0.0000014572829,"teacher_disagreement_score":0.20137854,"about_ca_system_score_codex":0.000100162964,"about_ca_system_score_gemma":0.00016205768,"threshold_uncertainty_score":0.41397548},"labels":[],"label_agreement":null},{"id":"W2142194813","doi":"10.1016/j.cell.2011.10.046","title":"Structural Basis and Sequence Rules for Substrate Recognition by Tankyrase Explain the Basis for Cherubism Disease","year":2011,"lang":"en","type":"article","venue":"Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":252,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Canada Research Chairs; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Ontario Institute for Cancer Research; University of Toronto","funders":"National Center for Research Resources; Canadian Institutes of Health Research; Terry Fox Foundation; Human Frontier Science Program; National Institutes of Health; European Molecular Biology Organization; U.S. Department of Energy","keywords":"Ankyrin repeat; Cherubism; Biology; Peptide sequence; Genetics; Ankyrin; Computational biology; Polymerase; Biochemistry; DNA; Gene","score_opus":0.10071350404643067,"score_gpt":0.2988541061465599,"score_spread":0.1981406021001292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142194813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362004,0.00095322705,0.0009240782,0.0011240027,0.00014977832,0.0010740209,0.001560066,0.000044327964,0.0005504511],"genre_scores_gemma":[0.99370825,0.00022048893,0.0029984124,0.0014564159,0.0001679212,0.0006201244,0.00031731848,0.000030446654,0.00048061172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999265,0.000028461824,0.00016786697,0.00024337335,0.00009263186,0.00020265784],"domain_scores_gemma":[0.9992749,0.00019087963,0.000083916835,0.00019466787,0.0000980486,0.00015756127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015442568,0.00013316094,0.00013692511,0.0000278128,0.00014052895,0.00001873062,0.000063955646,0.000053772008,0.00029914454],"category_scores_gemma":[0.00007028789,0.00009738351,0.00007888435,0.000046672452,0.00012468599,0.0001000311,0.000007836945,0.00007001166,0.000009129409],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01953088,0.00065607874,0.0096437065,0.0034386176,0.0004191852,0.00007082306,0.011700466,0.0000040337877,0.7017956,0.00094155344,0.12532826,0.12647083],"study_design_scores_gemma":[0.0077183796,0.00044967703,0.008107282,0.00021121708,0.00036725067,0.00001811999,0.000904448,0.00092812127,0.95062447,0.02092039,0.009312446,0.00043817324],"about_ca_topic_score_codex":0.000023544017,"about_ca_topic_score_gemma":0.0000046025248,"teacher_disagreement_score":0.24882893,"about_ca_system_score_codex":0.000049973343,"about_ca_system_score_gemma":0.00005777685,"threshold_uncertainty_score":0.39711845},"labels":[],"label_agreement":null},{"id":"W2146803828","doi":"10.1186/1471-2199-8-96","title":"Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1","year":2007,"lang":"en","type":"article","venue":"BMC Molecular Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Leibniz-Gemeinschaft; Natural Sciences and Engineering Research Council of Canada; Centre Hospitalier Universitaire de Québec","keywords":"Poly ADP ribose polymerase; Biology; Polymerase; Molecular biology; Gene expression; Gene; Posttranslational modification; Cell biology; Regulation of gene expression; Genetics; Biochemistry; Enzyme","score_opus":0.025658172520461424,"score_gpt":0.31736422697241023,"score_spread":0.2917060544519488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146803828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.759842,0.0017110833,0.23608735,0.00083731173,0.000072645045,0.0008192918,0.00009415486,0.000022877228,0.0005133291],"genre_scores_gemma":[0.9482799,0.000015358002,0.05101716,0.00020789677,0.00010479181,0.000019542047,0.0002987334,0.000026920266,0.000029699233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982882,0.00021956513,0.0007126278,0.00028381438,0.00028816052,0.0002076064],"domain_scores_gemma":[0.9984635,0.00009490216,0.0005437815,0.0005159898,0.00033390423,0.00004788681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004484005,0.00015857915,0.00034355497,0.00012789924,0.000047498233,0.0000021495953,0.00014904622,0.00022261018,0.00020408019],"category_scores_gemma":[0.00009687863,0.00012120705,0.00017060299,0.00025337978,0.0003598217,0.000053837844,0.000025262114,0.00011874537,0.0000036406916],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014564752,0.00018133994,0.0018075245,0.00008355957,0.000054978045,0.0000010210749,0.00055033417,0.000092637616,0.983347,0.011757641,0.000034199264,0.0006332721],"study_design_scores_gemma":[0.0015175976,0.0003869597,0.015247872,0.00011180239,0.000037809343,0.000015671149,0.0000866414,0.00018281539,0.9780357,0.0036095146,0.00066509465,0.00010252682],"about_ca_topic_score_codex":0.00013337148,"about_ca_topic_score_gemma":0.00000424983,"teacher_disagreement_score":0.18843794,"about_ca_system_score_codex":0.000031533335,"about_ca_system_score_gemma":0.00015000589,"threshold_uncertainty_score":0.494268},"labels":[],"label_agreement":null},{"id":"W2147619880","doi":"10.1158/1078-0432.ccr-10-1382","title":"Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Olaparib; PARP inhibitor; Ovarian cancer; Synthetic lethality; Cancer research; Carboplatin; BRCA mutation; Medicine; Cancer; Serous fluid; Serous carcinoma; In vivo; DNA repair; Biology; Internal medicine; Poly ADP ribose polymerase; Chemotherapy; Cisplatin; DNA; Genetics","score_opus":0.10164309985967723,"score_gpt":0.49531777570483054,"score_spread":0.3936746758451533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147619880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786165,0.0013935509,0.000035850568,0.014516016,0.0017491446,0.0017398468,0.0003197138,0.00015127107,0.0014781369],"genre_scores_gemma":[0.98913425,0.0019737969,0.00030188877,0.004330752,0.0018437658,0.0016551447,0.00018446836,0.00011622604,0.00045971124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99397707,0.0007211817,0.001499639,0.0011409019,0.0014378008,0.0012234036],"domain_scores_gemma":[0.99614507,0.00078434526,0.00026685788,0.00075638626,0.0012394888,0.0008078812],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027190787,0.00035841097,0.0008350736,0.00043264934,0.00023989283,0.000092309114,0.0003148884,0.00049115566,0.004001661],"category_scores_gemma":[0.0010514733,0.00033390897,0.00019130865,0.0016493996,0.0010876342,0.00026437512,0.00018118735,0.0040134597,0.00021398153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004538729,0.0014623512,0.04387299,0.00021728959,0.00012796657,0.00037076368,0.00051191094,0.000005808855,0.7817654,0.0001837962,0.13011022,0.036832757],"study_design_scores_gemma":[0.021679973,0.002557471,0.043749176,0.0011559466,0.00007324896,0.00006680326,0.00020687481,0.0002177035,0.7374649,0.001658355,0.19027601,0.00089351786],"about_ca_topic_score_codex":0.005489583,"about_ca_topic_score_gemma":0.0029023914,"teacher_disagreement_score":0.060165796,"about_ca_system_score_codex":0.00054288347,"about_ca_system_score_gemma":0.0014934336,"threshold_uncertainty_score":0.9999113},"labels":[],"label_agreement":null},{"id":"W2148191984","doi":"10.1073/pnas.1000556107","title":"Structure and identification of ADP-ribose recognition motifs of APLF and role in the DNA damage response","year":2010,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Canada Research Chairs; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Zinc finger; Ribose; DNA; Poly ADP ribose polymerase; Polynucleotide; Biochemistry; DNA repair; DNA damage; Polymerase; Biology; Binding site; Chemistry; Enzyme; Transcription factor; Gene","score_opus":0.03186758828203542,"score_gpt":0.327663995888611,"score_spread":0.2957964076065756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148191984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953414,0.00007306843,3.6098376e-7,0.004001264,0.000013923869,0.00021646988,0.00005471502,0.0000024165781,0.0002963636],"genre_scores_gemma":[0.99921125,0.00002877529,0.00056378305,0.00013245155,0.00004053566,0.000006269492,5.085306e-7,0.000002244392,0.0000142062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988337,0.000016278282,0.00031845339,0.00013774331,0.00063318294,0.00006064692],"domain_scores_gemma":[0.9990489,0.00019447353,0.00045281983,0.000012652127,0.00027437962,0.000016810796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022376028,0.000053775108,0.000119591576,0.00018377086,0.000055767625,0.000009059351,0.00020005384,0.00007298268,0.000010513363],"category_scores_gemma":[0.0008332836,0.000032987427,0.000022951821,0.00046096754,0.00097378815,0.00025221324,0.000030439873,0.00017457696,8.1834095e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017900982,0.000027705904,0.010319364,0.00006994521,0.000004675884,3.0959468e-9,0.0008821602,0.0000016547665,0.9854485,0.0024498343,0.000046228888,0.0005709414],"study_design_scores_gemma":[0.00026732704,0.00004187697,0.36590132,0.00006719969,0.000008378304,0.00000998395,0.00039939673,0.00016797792,0.59630775,0.036791682,0.000016761313,0.000020344714],"about_ca_topic_score_codex":0.000004888434,"about_ca_topic_score_gemma":2.478339e-7,"teacher_disagreement_score":0.38914073,"about_ca_system_score_codex":0.000009810211,"about_ca_system_score_gemma":0.000032630247,"threshold_uncertainty_score":0.3587963},"labels":[],"label_agreement":null},{"id":"W2149136613","doi":"10.1093/nar/gkl1148","title":"CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease","year":2007,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Northern British Columbia","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canadian Liver Foundation","keywords":"Endoribonuclease; Biology; Endonuclease; RNA; Molecular biology; Messenger RNA; Recombinant DNA; Cleavage (geology); Gene; Biochemistry; RNase P","score_opus":0.07220629953171336,"score_gpt":0.39493473109706767,"score_spread":0.3227284315653543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149136613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95386434,0.0018429995,0.00029128446,0.005161807,0.00023297705,0.000804889,0.00015222575,0.00018959353,0.03745988],"genre_scores_gemma":[0.9895522,0.00054509414,0.0014848721,0.0020758726,0.00088806066,0.000047508922,0.000078076606,0.00013019303,0.0051981425],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953447,0.00022777304,0.0005768002,0.00087316596,0.0016637719,0.0013137815],"domain_scores_gemma":[0.99686056,0.000716983,0.000089952046,0.00094510935,0.00035955466,0.0010278394],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002021737,0.00033618923,0.00050968624,0.00044836997,0.0003851117,0.00014088312,0.00037542463,0.00039807314,0.004706463],"category_scores_gemma":[0.00036869926,0.0003235947,0.00013849682,0.00078099285,0.0008227875,0.00024436225,0.00023224503,0.0014811466,0.0009559161],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040657404,0.00070486654,0.033784043,0.00020597661,0.00028291118,0.00097091036,0.0024565428,9.492849e-7,0.52668315,0.00092488783,0.3448143,0.08510571],"study_design_scores_gemma":[0.014146456,0.0020932648,0.050580725,0.00053381454,0.00010997737,0.00025301042,0.002183021,0.0005011955,0.17359044,0.0019674296,0.7531406,0.00090001896],"about_ca_topic_score_codex":0.00066477346,"about_ca_topic_score_gemma":0.00006001796,"teacher_disagreement_score":0.40832633,"about_ca_system_score_codex":0.00048614608,"about_ca_system_score_gemma":0.00020997084,"threshold_uncertainty_score":0.9999216},"labels":[],"label_agreement":null},{"id":"W2149928705","doi":"10.1042/bj20041718","title":"Regulation of the poly(ADP-ribose) polymerase-1 gene expression by the transcription factors Sp1 and Sp3 is under the influence of cell density in primary cultured cells","year":2005,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Molecular biology; Poly ADP ribose polymerase; Biology; Sp1 transcription factor; Transcription (linguistics); Transfection; Gene expression; Chloramphenicol acetyltransferase; Carcinogenesis; Promoter; RNA interference; Cell culture; Gene; Polymerase; RNA; Biochemistry; Genetics","score_opus":0.010770944803461864,"score_gpt":0.24100143169375188,"score_spread":0.23023048689029002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149928705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370235,0.002238258,0.00017786243,0.003571854,0.00006143523,0.00018970478,0.000021575268,0.000004394517,0.000032582764],"genre_scores_gemma":[0.99811,0.00029755832,0.00025847222,0.0010843648,0.00015500278,0.0000019885608,0.000005765079,0.000008978177,0.00007787077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887115,0.000104189545,0.00037009965,0.00012938304,0.00039046683,0.00013471422],"domain_scores_gemma":[0.9993325,0.000055789795,0.00025718904,0.00020915274,0.000080789,0.00006461918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020617062,0.00011794026,0.00017179875,0.000030702955,0.00009165313,0.000011724229,0.00013653238,0.00011936122,0.00004346713],"category_scores_gemma":[0.000010158286,0.00005564103,0.00009853346,0.00014264096,0.00024014476,0.00008258081,0.000022395909,0.0003325198,4.6527228e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020583876,0.00008604193,0.0027768826,0.000018074446,0.000011510711,1.9382425e-7,0.0008834977,0.000024003071,0.9928412,0.0000018470993,0.0029919066,0.00015904834],"study_design_scores_gemma":[0.001069536,0.000029527073,0.089976385,0.00013741622,0.00003122435,0.00003565913,0.00017181925,0.000014719308,0.9082125,0.000065040214,0.0002005668,0.000055595556],"about_ca_topic_score_codex":0.000024231518,"about_ca_topic_score_gemma":9.917644e-7,"teacher_disagreement_score":0.08719951,"about_ca_system_score_codex":0.00011569662,"about_ca_system_score_gemma":0.00006755825,"threshold_uncertainty_score":0.22689752},"labels":[],"label_agreement":null},{"id":"W2150645494","doi":"10.1002/jcb.21051","title":"PARP‐3 associates with polycomb group bodies and with components of the DNA damage repair machinery","year":2006,"lang":"en","type":"article","venue":"Journal of Cellular Biochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Ku70; Poly ADP ribose polymerase; Ku80; DNA ligase; Biology; DNA repair; Molecular biology; DNA damage; Gene isoform; Nuclear localization sequence; DNA; Cell biology; Polymerase; Genetics; DNA-binding protein; Nucleus; Transcription factor; Gene","score_opus":0.0058001888551916575,"score_gpt":0.21101426393902956,"score_spread":0.2052140750838379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150645494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556625,0.0024459427,0.00006109706,0.00057742,0.000046567537,0.000076950055,0.000013345605,0.000011918437,0.0012005331],"genre_scores_gemma":[0.99798816,0.000050852712,0.0008761257,0.00010990299,0.00021973267,0.0000015537253,0.00001222093,0.000019226447,0.0007222266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989109,0.00003502795,0.00035754705,0.000116785595,0.0004415371,0.00013818523],"domain_scores_gemma":[0.99891114,0.000042130527,0.0006050872,0.00022221661,0.0001506148,0.00006878099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022235421,0.00014484616,0.00032535093,0.00003565106,0.000059785336,0.0000120354825,0.000096671814,0.000074865966,0.00001896404],"category_scores_gemma":[0.0000157006,0.00008141514,0.00012267959,0.0000727807,0.00024996602,0.00004579929,0.000024204095,0.00026522973,2.2560795e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000557057,0.00018565345,0.10644172,0.00014909825,0.0001933225,0.000073240735,0.000051075865,0.000006629356,0.89111626,0.000008956833,0.0012004144,0.000016567727],"study_design_scores_gemma":[0.0029503582,0.00028323522,0.046547472,0.00073150377,0.0001849367,0.0004533023,0.00010339274,0.000021774149,0.9480426,0.00008333605,0.0004897472,0.00010834404],"about_ca_topic_score_codex":0.000031823736,"about_ca_topic_score_gemma":0.0000040368554,"teacher_disagreement_score":0.05989425,"about_ca_system_score_codex":0.000070868606,"about_ca_system_score_gemma":0.000075136435,"threshold_uncertainty_score":0.33200133},"labels":[],"label_agreement":null},{"id":"W2151209400","doi":"10.1073/pnas.1108799108","title":"Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage","year":2011,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research; National Institutes of Health; National Institute on Drug Abuse; McKnight Foundation","keywords":"Ubiquitin ligase; DNA ligase; Molecular biology; DDB1; DNA repair; Ubiquitin; Biology; Ku70; DNA damage; Cell biology; Biochemistry; Chemistry; DNA","score_opus":0.10491820627045789,"score_gpt":0.33388205523575093,"score_spread":0.22896384896529304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151209400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549218,0.00029855242,0.0000011997556,0.011271261,0.00004595068,0.00033244444,0.000041959844,0.000036692018,0.03305015],"genre_scores_gemma":[0.9944245,0.000070345464,0.0018028211,0.002466517,0.00021317367,0.000024588633,3.1568993e-7,0.000010901711,0.0009868337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709237,0.000008511925,0.00046851396,0.00037067538,0.0017999712,0.00025993746],"domain_scores_gemma":[0.99878913,0.000075246746,0.0006367212,0.000023985172,0.00037547256,0.0000994223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014730555,0.00016280496,0.00027195763,0.00026615814,0.00021395842,0.00002259182,0.000714445,0.0001319419,0.0003405846],"category_scores_gemma":[0.00023963004,0.00011159187,0.00014424836,0.00067126995,0.0012954914,0.0005193427,0.00014659642,0.00024380592,0.000009642781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020406897,0.00021158604,0.01868389,0.00016585737,0.000071808,1.12109724e-7,0.0022754131,0.0000012141312,0.94389534,0.025867525,0.008054833,0.00056832883],"study_design_scores_gemma":[0.00056982675,0.00011403531,0.08477273,0.00029774552,0.000031063686,0.00003542512,0.00032249806,0.00007732842,0.8741651,0.039037008,0.00047258672,0.00010464395],"about_ca_topic_score_codex":0.000019811292,"about_ca_topic_score_gemma":8.532053e-8,"teacher_disagreement_score":0.06973025,"about_ca_system_score_codex":0.00007968394,"about_ca_system_score_gemma":0.0000894013,"threshold_uncertainty_score":0.4773292},"labels":[],"label_agreement":null},{"id":"W2151876400","doi":"10.1158/1535-7163.mct-12-0950","title":"RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université Laval","keywords":"Olaparib; PARP inhibitor; Cancer research; DNA damage; Cancer; DNA repair; Medicine; Biology; Poly ADP ribose polymerase; Internal medicine; DNA; Polymerase","score_opus":0.02604159606197083,"score_gpt":0.29894876053579533,"score_spread":0.2729071644738245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151876400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9028069,0.007635072,0.005643385,0.07641435,0.0025196138,0.003176952,0.00024440096,0.00024227216,0.0013170916],"genre_scores_gemma":[0.92011756,0.0011624588,0.0004995365,0.0749388,0.00075060123,0.0013284616,0.000014372684,0.00012966615,0.0010585645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971171,0.00017176387,0.0004736556,0.0006610906,0.0008274348,0.000748941],"domain_scores_gemma":[0.99785835,0.0000709841,0.0002325825,0.0009088917,0.0006043159,0.00032485795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019655508,0.00046279083,0.00052169245,0.0001420435,0.00023688433,0.000115026305,0.00028263396,0.00019374004,0.00047698105],"category_scores_gemma":[0.0000097434495,0.00034036217,0.00025309742,0.00067372434,0.00018887062,0.00008692147,0.00009358105,0.0004964804,0.00046477036],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030562314,0.00022091417,0.00093256106,0.00006937018,0.00064821803,0.00007019821,0.0021776815,0.0023984753,0.950589,0.00023599483,0.02361811,0.018733827],"study_design_scores_gemma":[0.001899186,0.00021467458,0.0031979382,0.00032635118,0.00028973565,0.000026212943,0.0005101639,0.0006642608,0.79414386,0.000101660116,0.19814195,0.00048404126],"about_ca_topic_score_codex":0.0010206276,"about_ca_topic_score_gemma":0.00014853722,"teacher_disagreement_score":0.17452383,"about_ca_system_score_codex":0.0007256095,"about_ca_system_score_gemma":0.0003425025,"threshold_uncertainty_score":0.9999048},"labels":[],"label_agreement":null},{"id":"W2154132663","doi":"10.1093/nar/gks486","title":"Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress","year":2012,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Stable isotope labeling by amino acids in cell culture; Biology; Proteomics; Biochemistry; DNA damage; Poly ADP ribose polymerase; Quantitative proteomics; Proteome; Context (archaeology); DNA; Polymerase","score_opus":0.09997106233386699,"score_gpt":0.4268993499048363,"score_spread":0.3269282875709693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154132663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884399,0.00059549295,0.00023835433,0.0056609097,0.00024058338,0.0024546045,0.00007997941,0.000052448682,0.0022377349],"genre_scores_gemma":[0.989233,0.000025826394,0.008421494,0.00020582437,0.000206758,0.00023968128,0.0000065554354,0.00006285702,0.0015980041],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960831,0.0010613976,0.00044226382,0.0003070905,0.0013062346,0.00079994544],"domain_scores_gemma":[0.9975815,0.000520979,0.000108784436,0.0008180172,0.0006334623,0.0003372793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038675666,0.0001681159,0.0003099288,0.0003771161,0.0002634814,0.00002245882,0.00039800323,0.00018745859,0.0003768113],"category_scores_gemma":[0.0016880829,0.00012158724,0.00012367693,0.0014602434,0.00049658323,0.00014642236,0.00024096735,0.0009009805,0.00026526337],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061851745,0.0002820881,0.023307236,0.00009944051,0.00008665167,0.0000048957054,0.0046570394,0.000010641303,0.96176565,0.0018706872,0.00092772266,0.00080279994],"study_design_scores_gemma":[0.0016725959,0.0009671513,0.06305776,0.00042420832,0.000017524775,0.000022933174,0.0020202084,0.00017773594,0.9288275,0.0002695167,0.0023935654,0.00014930392],"about_ca_topic_score_codex":0.00004716608,"about_ca_topic_score_gemma":0.0000026742464,"teacher_disagreement_score":0.039750524,"about_ca_system_score_codex":0.00046130133,"about_ca_system_score_gemma":0.0005100655,"threshold_uncertainty_score":0.49581838},"labels":[],"label_agreement":null},{"id":"W2155244882","doi":"10.1158/1078-0432.ccr-11-2890","title":"Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase <i>In Vitro</i>","year":2012,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Veliparib; Olaparib; PARP inhibitor; Poly ADP ribose polymerase; Cancer research; Pharmacology; Medicine; Biology; Polymerase; Biochemistry; Enzyme","score_opus":0.2767273602044271,"score_gpt":0.5716575263099984,"score_spread":0.2949301661055713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155244882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95782274,0.006238724,0.000060643793,0.029504575,0.0007354037,0.0011359394,0.00013143173,0.000051881234,0.0043186564],"genre_scores_gemma":[0.99050945,0.00045072282,0.00075132033,0.0039171684,0.002690667,0.00036660052,0.000020312391,0.000057355264,0.0012364053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953362,0.00061387534,0.0011358069,0.00052500254,0.0012418773,0.0011472816],"domain_scores_gemma":[0.9965621,0.001060228,0.00012532322,0.00078261667,0.00043662477,0.001033075],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046514203,0.00020437695,0.00075747457,0.00048420942,0.00007756146,0.000017667155,0.00030300897,0.0003102723,0.0015138775],"category_scores_gemma":[0.0010255106,0.00018377442,0.00022910954,0.0015265268,0.0005522609,0.00017148802,0.00022228324,0.0015103398,0.00031919713],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014864168,0.003139958,0.3297838,0.0004038825,0.00019917899,0.00007367979,0.0015066145,0.0000048666616,0.41513324,0.0007101289,0.14453319,0.0896473],"study_design_scores_gemma":[0.008217839,0.0011052078,0.053803224,0.00073742465,0.000037421585,0.000018783834,0.00041731764,0.000016180202,0.70351535,0.00020909132,0.23155408,0.0003680741],"about_ca_topic_score_codex":0.00097115943,"about_ca_topic_score_gemma":0.00012051736,"teacher_disagreement_score":0.28838214,"about_ca_system_score_codex":0.00040058806,"about_ca_system_score_gemma":0.00086919864,"threshold_uncertainty_score":0.9993989},"labels":[],"label_agreement":null},{"id":"W2157594513","doi":"10.1093/jn/130.5.1102","title":"Niacin Deficiency in Rats Increases the Severity of Ethylnitrosourea-Induced Anemia and Leukopenia","year":2000,"lang":"en","type":"article","venue":"Journal of Nutrition","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Guelph","funders":"","keywords":"Neutrophilia; Leukopenia; Niacin; Anemia; Internal medicine; Hematocrit; Endocrinology; Bone marrow; Ethylnitrosourea; Bone marrow suppression; Medicine; Chemotherapy; Biology; Biochemistry","score_opus":0.02341158276907212,"score_gpt":0.30124627493379885,"score_spread":0.2778346921647267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157594513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956344,0.0017054958,0.000009544173,0.0018888882,0.000034994297,0.00018580823,0.000008168207,0.0000040241684,0.00052867085],"genre_scores_gemma":[0.9977343,0.0013473199,0.00035793037,0.00034830184,0.00017417694,0.00000500661,0.0000024816616,0.000006785204,0.000023692328],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990284,0.0001161219,0.00041456334,0.00007659129,0.0002612243,0.00010308475],"domain_scores_gemma":[0.9993928,0.00010504692,0.00020363934,0.000103607475,0.00013326752,0.000061642895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045480602,0.000076975855,0.00024883906,0.00012161406,0.000037593847,0.000010568379,0.00005930878,0.00006846908,0.00019061084],"category_scores_gemma":[0.000054552063,0.000054407057,0.00006380475,0.00021876552,0.000069052345,0.00014358362,0.00000558967,0.00027514232,0.0000023254927],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006834486,0.0036980247,0.04544223,0.00058628316,0.000058242014,0.00026607187,0.0015758765,0.000032317068,0.8826328,0.00011453761,0.008485068,0.050274093],"study_design_scores_gemma":[0.022524586,0.003091232,0.6890958,0.00327875,0.00020771004,0.0067429957,0.0010817195,0.000115054216,0.26254883,0.005697107,0.005311091,0.00030513317],"about_ca_topic_score_codex":0.000075257805,"about_ca_topic_score_gemma":0.00001666652,"teacher_disagreement_score":0.6436536,"about_ca_system_score_codex":0.00009057627,"about_ca_system_score_gemma":0.0000913387,"threshold_uncertainty_score":0.22186553},"labels":[],"label_agreement":null},{"id":"W2158343538","doi":"10.1158/1535-7163.mct-13-0749","title":"Glioblastoma Cells Containing Mutations in the Cohesin Component <i>STAG2</i> Are Sensitive to PARP Inhibition","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Institute for Advanced Research","keywords":"Poly ADP ribose polymerase; Mutant; Biology; Cancer research; Molecular biology; Mutation; DNA repair; DNA damage; PARP inhibitor; Cancer cell; DNA; Cancer; Gene; Genetics; Polymerase","score_opus":0.026576075252569154,"score_gpt":0.3001990841337632,"score_spread":0.27362300888119406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158343538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97249025,0.00047577167,0.005955088,0.018217763,0.00020661869,0.0018075478,0.000057612087,0.00007919456,0.00071014836],"genre_scores_gemma":[0.9438593,0.00009092923,0.00048192873,0.054611273,0.00011704574,0.0007072331,0.000027059856,0.0000543386,0.000050926756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980334,0.00025153486,0.00040116932,0.00037063158,0.0005170035,0.00042624093],"domain_scores_gemma":[0.99887717,0.00012345909,0.00015916995,0.00041234662,0.00029545132,0.00013239935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022936407,0.00027124703,0.00034257185,0.00018480224,0.00012308528,0.00007703299,0.00011344624,0.0001134364,0.00011964149],"category_scores_gemma":[0.000008852931,0.00022645306,0.00012054556,0.00059195096,0.00012288717,0.000091887174,0.00002782384,0.0003546992,0.00012211785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042790794,0.00025750182,0.0013144495,0.00004193694,0.00016437338,0.00026116116,0.0057804463,0.0018653873,0.9838523,0.0002942088,0.0010593933,0.004680936],"study_design_scores_gemma":[0.0038997992,0.0007016147,0.0130488705,0.00060800486,0.00017776807,0.00009113106,0.0046019736,0.0011642785,0.9602732,0.0005645787,0.014377666,0.00049110147],"about_ca_topic_score_codex":0.00032523138,"about_ca_topic_score_gemma":0.00015246391,"teacher_disagreement_score":0.036393512,"about_ca_system_score_codex":0.0004148885,"about_ca_system_score_gemma":0.00013356947,"threshold_uncertainty_score":0.9234488},"labels":[],"label_agreement":null},{"id":"W2158594431","doi":"10.1158/1535-7163.mct-08-0959","title":"Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"RAD51; Imatinib; Cancer research; Clonogenic assay; Gemcitabine; Imatinib mesylate; Mitomycin C; Chemistry; DNA repair; Biology; Molecular biology; Cell; Cancer; Medicine; Internal medicine; DNA; Biochemistry","score_opus":0.026343124940142452,"score_gpt":0.3143477273620954,"score_spread":0.2880046024219529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158594431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753613,0.0019000703,0.006662755,0.0020687378,0.00016499024,0.0005641723,0.00002435314,0.00008071324,0.000998103],"genre_scores_gemma":[0.98957723,0.00043397088,0.004712672,0.005081138,0.000084272884,0.000014531924,0.000024497635,0.000037036647,0.00003462859],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818957,0.0001999888,0.00043517555,0.00049005134,0.0002877216,0.00039747581],"domain_scores_gemma":[0.99915475,0.00007000365,0.0002315148,0.00029172903,0.00015635882,0.000095626696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004988251,0.0002642319,0.00043475785,0.00015486601,0.000090735295,0.00002993292,0.00005443649,0.00013044734,0.0000092802275],"category_scores_gemma":[0.00003698614,0.00028325198,0.0000756047,0.00037194503,0.00009800715,0.000102704995,0.000019385072,0.0003627632,0.0000019626787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060857227,0.00019944667,0.00018902513,0.000040537772,0.000029426528,0.00020174822,0.0006609938,0.00053146185,0.97453654,0.000026897445,0.000015571073,0.022959758],"study_design_scores_gemma":[0.0057751094,0.00028012838,0.005492164,0.00021569598,0.00007835509,0.00010326738,0.000092340735,0.012360121,0.97430825,0.00076639495,0.00019538234,0.00033277032],"about_ca_topic_score_codex":0.00008046566,"about_ca_topic_score_gemma":0.000008502494,"teacher_disagreement_score":0.022626989,"about_ca_system_score_codex":0.00045377348,"about_ca_system_score_gemma":0.00016413003,"threshold_uncertainty_score":0.999962},"labels":[],"label_agreement":null},{"id":"W2159807872","doi":"10.1136/jcp.2010.086405","title":"Melphalan as a treatment for <i>BRCA</i> -related ovarian carcinoma: can you teach an old drug new tricks?: Figure 1","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Melphalan; Olaparib; BRCA mutation; Cisplatin; Ovarian cancer; Oncology; Medicine; Chemotherapy; Ovarian carcinoma; Internal medicine; Cancer research; Drug resistance; Cancer; Biology; Genetics; Poly ADP ribose polymerase; DNA","score_opus":0.14014760722245143,"score_gpt":0.4185905294570746,"score_spread":0.2784429222346232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159807872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97997975,0.00084459945,0.00050896686,0.0117769595,0.0020191937,0.0006401219,0.000035357498,0.000043751465,0.004151289],"genre_scores_gemma":[0.98190945,0.000382982,0.0059425104,0.0038495401,0.0020945987,0.00002171867,0.000028400455,0.000055187826,0.0057156044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99630237,0.0004955951,0.0021299233,0.0003945836,0.0002757196,0.00040179407],"domain_scores_gemma":[0.9966878,0.0004653356,0.0012083488,0.00048465122,0.00033339008,0.0008204529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017914848,0.00027642032,0.0013398494,0.00021339873,0.000077047414,0.000010474835,0.00023319414,0.0004587441,0.00071368256],"category_scores_gemma":[0.0005747023,0.00020065387,0.00075864315,0.00017156058,0.00018073758,0.00011348524,0.000018398528,0.0007533952,0.00003287047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04572335,0.015251573,0.5293194,0.00012677796,0.002687047,0.015439675,0.026825937,0.00001555816,0.0067119524,0.004930582,0.11745487,0.23551326],"study_design_scores_gemma":[0.16613731,0.084996425,0.41458276,0.000420679,0.0036468962,0.020409415,0.0016792334,0.0001527897,0.0072655957,0.032277435,0.26729977,0.0011316834],"about_ca_topic_score_codex":0.00030680568,"about_ca_topic_score_gemma":0.000078314304,"teacher_disagreement_score":0.23438157,"about_ca_system_score_codex":0.0001810399,"about_ca_system_score_gemma":0.001099535,"threshold_uncertainty_score":0.8182427},"labels":[],"label_agreement":null},{"id":"W2159944012","doi":"10.1186/1477-7827-7-143","title":"Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes","year":2009,"lang":"en","type":"review","venue":"Reproductive Biology and Endocrinology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Cleveland Clinic","keywords":"Poly ADP ribose polymerase; Biology; Sperm; DNA damage; Male infertility; DNA repair; Spermatogenesis; Chromatin; Infertility; Andrology; Germ cell; Cell biology; Polymerase; Genetics; DNA; Endocrinology; Medicine; Gene","score_opus":0.04809873006235655,"score_gpt":0.3663847634216859,"score_spread":0.31828603335932937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159944012","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075471783,0.9894524,0.000012497712,0.0005872531,0.00037546974,0.0007945055,0.00010916856,0.00005130902,0.0010701976],"genre_scores_gemma":[0.010682794,0.9871544,0.0003593538,0.00013783532,0.001010082,0.00012909842,0.0002188882,0.000027923645,0.0002795758],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99631274,0.00064270105,0.0009028244,0.0014119935,0.000074774034,0.0006549633],"domain_scores_gemma":[0.9984374,0.00018979723,0.00045698948,0.00073798146,0.00007509219,0.000102742786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025491888,0.00050297263,0.0027381605,0.0005821667,0.000049459726,0.0000034563361,0.00018291881,0.00074392994,0.0002513764],"category_scores_gemma":[0.00023702615,0.00038169263,0.0003476541,0.00032532803,0.001129065,0.000039038205,0.00012238072,0.0007833685,0.000034402394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004785534,0.0003549159,0.0023314434,0.0007549948,0.00038702606,0.00016664498,0.00006379585,1.756522e-7,0.0040988172,0.0019836077,0.00012449453,0.98925555],"study_design_scores_gemma":[0.0016501131,0.0020509872,0.0016460828,0.0013710463,0.0004592558,0.007294997,0.00007480352,8.329519e-7,0.0028850983,0.0028466983,0.9792149,0.0005051617],"about_ca_topic_score_codex":0.00008126618,"about_ca_topic_score_gemma":0.0000022831057,"teacher_disagreement_score":0.9887504,"about_ca_system_score_codex":0.00010431714,"about_ca_system_score_gemma":0.0001993043,"threshold_uncertainty_score":0.9998635},"labels":[],"label_agreement":null},{"id":"W2162944731","doi":"10.2337/diabetes.52.7.1683","title":"Poly (ADP-Ribose) Polymerase Inhibition Prevents Spontaneous and Recurrent Autoimmune Diabetes in NOD Mice by Inducing Apoptosis of Islet-Infiltrating Leukocytes","year":2003,"lang":"en","type":"article","venue":"Diabetes","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; Fondation pour la Recherche Médicale; National Institutes of Health; University of Alberta","keywords":"Insulitis; Poly ADP ribose polymerase; NOD mice; Nod; Islet; Apoptosis; Nicotinamide; Beta cell; Diabetes mellitus; PARP inhibitor; Endocrinology; Medicine; Cancer research; Internal medicine; NAD+ kinase; Immunology; Biology; Polymerase; Enzyme; Biochemistry","score_opus":0.01084670831892246,"score_gpt":0.2522604792678235,"score_spread":0.24141377094890107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162944731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984976,0.013402348,0.00000773605,0.00036060406,0.00021402734,0.00046999106,0.00008219322,0.000064606844,0.0004225053],"genre_scores_gemma":[0.99836826,0.00015338697,0.0006107674,0.00046182706,0.0000780556,0.00009868013,0.00011468793,0.000047660407,0.00006669671],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777067,0.00021447628,0.0007087029,0.0004499688,0.00032027712,0.0005358804],"domain_scores_gemma":[0.9988862,0.00033325556,0.00031180013,0.00026569885,0.00007238288,0.000130652],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047181125,0.0003107667,0.0006107371,0.0002708692,0.00011110831,0.000038159444,0.00007074973,0.00017058114,0.00012664373],"category_scores_gemma":[0.00029675587,0.00032076603,0.00009469711,0.0004115435,0.00018066692,0.00021137888,0.000030953983,0.00033095165,0.000005052016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005160814,0.0003087903,0.05237166,0.00025882988,0.00007434479,0.000007845404,0.00057102315,0.0000015483329,0.93638396,0.000042579275,0.0003068826,0.009620927],"study_design_scores_gemma":[0.0025292288,0.00042598482,0.00404833,0.0014603295,0.00006181566,0.00001576695,0.000222376,0.00014438748,0.99034166,0.00016146821,0.0002945026,0.0002941364],"about_ca_topic_score_codex":0.000088790555,"about_ca_topic_score_gemma":0.000004460579,"teacher_disagreement_score":0.053957712,"about_ca_system_score_codex":0.00018989742,"about_ca_system_score_gemma":0.00011640473,"threshold_uncertainty_score":0.9999244},"labels":[],"label_agreement":null},{"id":"W2164091821","doi":"10.1124/jpet.103.051342","title":"l-Selegiline Potentiates the Cellular Poly(ADP-Ribosyl)ation Response to Ionizing Radiation","year":2003,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université Laval","keywords":"Poly ADP ribose polymerase; Polymerase; Selegiline; Ribose; DNA damage; Chemistry; Molecular biology; Ionizing radiation; Biochemistry; DNA repair; DNA; Enzyme; Pharmacology; Biology; Irradiation; Medicine; Internal medicine","score_opus":0.02997272991116482,"score_gpt":0.36372435860516716,"score_spread":0.3337516286940023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164091821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690521,0.01911439,0.0012531965,0.009201544,0.0010312847,0.0002392589,0.0000022531358,0.0000111690815,0.000094846066],"genre_scores_gemma":[0.98791486,0.00063947536,0.0008111185,0.010086036,0.00037314117,0.000009493915,0.0000017509218,0.00001685962,0.00014724127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879855,0.0003648582,0.0003592266,0.00010931343,0.00019878111,0.00016925175],"domain_scores_gemma":[0.9993529,0.00014236086,0.00021889604,0.00007542436,0.00011101011,0.00009944694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008043509,0.00012396953,0.00019925466,0.00013163916,0.00017862808,0.00001928394,0.00006717815,0.00007561007,0.00026309598],"category_scores_gemma":[0.00001614276,0.00008917262,0.000080092774,0.00015656425,0.00009075656,0.000108676795,0.000011310073,0.0002434261,0.000007716292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040821778,0.00020493542,0.0003656732,0.000004345782,0.00020284377,0.000021535014,0.0015607227,0.000044444554,0.99114656,0.0001037611,0.0009183711,0.0013446347],"study_design_scores_gemma":[0.0036603904,0.0009864408,0.0006011271,0.00001711312,0.0001407047,0.0003138316,0.0008998459,0.000118882046,0.93205416,0.00009476096,0.06102907,0.00008366754],"about_ca_topic_score_codex":0.0000010357558,"about_ca_topic_score_gemma":8.284979e-8,"teacher_disagreement_score":0.060110696,"about_ca_system_score_codex":0.0001663407,"about_ca_system_score_gemma":0.00012394325,"threshold_uncertainty_score":0.36363542},"labels":[],"label_agreement":null},{"id":"W2164550834","doi":"10.1002/emmm.201200229","title":"Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53","year":2012,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Calgary","funders":"National Cancer Institute; Leukemia and Lymphoma Society of Canada; Canadian Institutes of Health Research; Alberta Cancer Foundation; Leukemia and Lymphoma Society; AstraZeneca; Alberta Innovates; University of Calgary; Cancer Research Institute","keywords":"Olaparib; Poly ADP ribose polymerase; DNA damage; Cancer research; Mantle cell lymphoma; PARP inhibitor; DNA repair; Biology; Cytotoxicity; Chemistry; Molecular biology; Cell biology; Polymerase; DNA; Lymphoma; Immunology; In vitro; Biochemistry","score_opus":0.014312390849847218,"score_gpt":0.2863096454055635,"score_spread":0.2719972545557163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164550834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98773617,0.0025307548,0.0031034884,0.0009224152,0.000104124054,0.00045502852,0.0000050827753,0.00002557715,0.0051173624],"genre_scores_gemma":[0.9979276,0.00021017181,0.0007607647,0.00079434225,0.00012529572,0.000065851375,0.000034468314,0.000028180528,0.00005333617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854445,0.00009286247,0.00048629483,0.00023304936,0.00032173577,0.00032162754],"domain_scores_gemma":[0.9992816,0.00006703189,0.00014262875,0.00030089176,0.00004777447,0.00016011321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044492222,0.00016803911,0.00041809265,0.00034043822,0.000024690285,0.0000028375034,0.000043856562,0.00010227218,0.00014540786],"category_scores_gemma":[0.00012805343,0.00015910764,0.00003993271,0.00042320948,0.0001791892,0.000113083865,0.00003410654,0.0001495217,0.0000065027116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001306249,0.00037274326,0.0063377377,0.0001887795,0.000014405794,0.000088958346,0.0022570472,0.000028018676,0.9894654,0.00033141242,0.00006805733,0.00071677327],"study_design_scores_gemma":[0.009595869,0.00023241377,0.12074559,0.0009381661,0.000039318005,0.00005377754,0.00046323566,0.00013790683,0.86702085,0.0005223547,0.000104278406,0.00014625143],"about_ca_topic_score_codex":0.00016827503,"about_ca_topic_score_gemma":0.000024961288,"teacher_disagreement_score":0.12244461,"about_ca_system_score_codex":0.00017379936,"about_ca_system_score_gemma":0.0000638356,"threshold_uncertainty_score":0.6488221},"labels":[],"label_agreement":null},{"id":"W2164708087","doi":"10.1093/nar/gkn771","title":"Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes","year":2008,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":415,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; University of Alberta","funders":"National Institute of Neurological Disorders and Stroke; U.S. Public Health Service; Canadian Institutes of Health Research; Centre National de la Recherche Scientifique","keywords":"Proteome; Biology; Poly ADP ribose polymerase; Biochemistry; Ribose; Proteomics; Plasma protein binding; In silico; Enzyme; Computational biology; Polymerase; Gene","score_opus":0.08688888882635037,"score_gpt":0.3708946421512399,"score_spread":0.28400575332488953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164708087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865625,0.00086645887,0.00040876027,0.005284157,0.0000916041,0.0048857396,0.00014543634,0.00019762224,0.0015577156],"genre_scores_gemma":[0.9910846,0.0001743925,0.0015331225,0.00009820711,0.00037897885,0.0009040619,0.00010754268,0.00010955032,0.005609567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944533,0.0006153575,0.00097414054,0.00078664994,0.0021722808,0.0009982615],"domain_scores_gemma":[0.9970481,0.00024682478,0.00038837423,0.00085796765,0.0010657735,0.00039298655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025080678,0.00033580448,0.00068556913,0.0009496584,0.00077247265,0.000080876365,0.00040416824,0.0003461323,0.0004418182],"category_scores_gemma":[0.0014786279,0.00032292836,0.00015015257,0.0016920354,0.0013311848,0.00035994707,0.00021705001,0.0010751243,0.00017690331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006742025,0.0005473777,0.024133679,0.00034488915,0.00014871868,0.000057162088,0.0014653384,4.9431185e-7,0.96674085,0.0002793369,0.0028786275,0.002729332],"study_design_scores_gemma":[0.0044268663,0.0011829158,0.11733645,0.00088227587,0.000028570352,0.000092650895,0.0005488395,0.00022034305,0.8689693,0.0008148256,0.0051245824,0.00037235953],"about_ca_topic_score_codex":0.00045911994,"about_ca_topic_score_gemma":0.000019100495,"teacher_disagreement_score":0.097771525,"about_ca_system_score_codex":0.0006639524,"about_ca_system_score_gemma":0.0006206131,"threshold_uncertainty_score":0.9999223},"labels":[],"label_agreement":null},{"id":"W2164897814","doi":"10.1158/1535-7163.mct-09-0042","title":"Niacin status and treatment-related leukemogenesis","year":2009,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Niacin; Bone marrow; Apoptosis; Cancer research; Biology; DNA damage; Haematopoiesis; Poly ADP ribose polymerase; Leukemia; Chromosomal translocation; Cancer; Chemotherapy; Immunology; Stem cell; Endocrinology; Genetics; DNA","score_opus":0.07197418825721326,"score_gpt":0.3812024341047375,"score_spread":0.30922824584752423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164897814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028014657,0.99626434,0.000064493586,0.00025968204,0.00027291809,0.0014977808,0.00015056982,0.00015972073,0.0010503236],"genre_scores_gemma":[0.00007298453,0.99571234,0.0002793025,0.0016004745,0.00016959518,0.00036697526,0.00020653343,0.00020598904,0.001385828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973406,0.00020427453,0.0007132904,0.0007435566,0.00036839448,0.00062988553],"domain_scores_gemma":[0.9984387,0.000056052304,0.00035985743,0.00075540505,0.00009531318,0.0002946638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009067476,0.0008289817,0.0021713409,0.00030099877,0.000096902106,0.00004990341,0.0001234418,0.00060544716,0.00021686466],"category_scores_gemma":[0.000003749508,0.00066483754,0.00066812546,0.00053124875,0.00015314898,0.000039275827,0.000025244552,0.00038021937,0.000044096694],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051821822,0.00011052918,0.000018959498,0.0013343452,0.002139143,0.00013091475,0.00010567363,0.0000023031698,0.00018073343,0.00008997262,0.000049686827,0.9957859],"study_design_scores_gemma":[0.0023689133,0.00050062087,0.00001697746,0.005121206,0.0060858787,0.00016369193,0.0000083611985,0.000008853038,0.0004250694,0.0001212205,0.98460776,0.00057144533],"about_ca_topic_score_codex":0.00007485789,"about_ca_topic_score_gemma":0.000009985,"teacher_disagreement_score":0.99521446,"about_ca_system_score_codex":0.0016881437,"about_ca_system_score_gemma":0.0013574809,"threshold_uncertainty_score":0.99958026},"labels":[],"label_agreement":null},{"id":"W2165947030","doi":"10.1200/jco.2014.59.2311","title":"The Long and Winding Road","year":2014,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Olaparib; PARP inhibitor; Ovarian cancer; Oncology; Breast cancer; Prostate cancer; Internal medicine; Cancer; Cancer research; Poly ADP ribose polymerase; Polymerase; Biology","score_opus":0.20132819445398942,"score_gpt":0.5190743910872542,"score_spread":0.31774619663326475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165947030","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009074296,0.0022193806,0.00017542568,0.9773986,0.004629064,0.00015209851,0.0000014472571,0.000008106073,0.0063415836],"genre_scores_gemma":[0.00990423,0.0048556784,0.00054588483,0.934871,0.04720031,0.000003870666,0.0000034865457,0.00003787643,0.0025776553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563974,0.0008341517,0.0025598567,0.00018975197,0.00050085876,0.0002756501],"domain_scores_gemma":[0.98874545,0.0070991656,0.0033034857,0.0002708218,0.00037594957,0.00020510478],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0057768477,0.00017657307,0.0017501632,0.0001028604,0.000095397,0.000024900286,0.00022435586,0.0015434901,0.00010962502],"category_scores_gemma":[0.0028297526,0.00009823657,0.00056236127,0.00006190888,0.00056309404,0.000048459136,0.00004194331,0.006348624,0.000027948692],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006570406,0.00004681818,0.0030385226,0.000033768123,0.00036839317,0.0016367435,0.000016414695,3.200562e-7,0.0000053959943,0.000011843481,0.8625701,0.13161466],"study_design_scores_gemma":[0.004262102,0.0043020328,0.013766062,0.00031024296,0.00033910247,0.003222157,0.000009179662,0.000008801533,0.000007121104,0.000627206,0.9730543,0.00009169558],"about_ca_topic_score_codex":0.000003838521,"about_ca_topic_score_gemma":0.0000041512794,"teacher_disagreement_score":0.13152297,"about_ca_system_score_codex":0.0001780202,"about_ca_system_score_gemma":0.001242847,"threshold_uncertainty_score":0.9997527},"labels":[],"label_agreement":null},{"id":"W2165973127","doi":"10.2174/138161209787185823","title":"Niacin Status, NAD Distribution and ADP-Ribose Metabolism","year":2009,"lang":"en","type":"article","venue":"Current Pharmaceutical Design","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Niacin; NAD+ kinase; Nicotinamide; Niacinamide; Nicotinamide adenine dinucleotide; Metabolism; Biochemistry; Nicotinic agonist; Chemistry; Glycolysis; Enzyme; Biology; Pharmacology","score_opus":0.1055288611138656,"score_gpt":0.41791849452935975,"score_spread":0.31238963341549414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165973127","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2193105,0.122757815,0.6169019,0.025665889,0.005249786,0.005283808,0.0008524562,0.0012549445,0.0027229125],"genre_scores_gemma":[0.9899334,0.0060334443,0.0011737846,0.0016779448,0.000837125,0.000046790665,0.0001927695,0.000020469972,0.00008428018],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828035,0.00016748115,0.00031150447,0.00037211095,0.00036212348,0.00050644187],"domain_scores_gemma":[0.99890786,0.000106216656,0.000059940787,0.00020691314,0.00010910857,0.0006099272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003358035,0.00022730169,0.00032159017,0.00006580234,0.00010017063,0.00003796317,0.00006331145,0.000081214515,0.00030871792],"category_scores_gemma":[0.00010240589,0.00020052654,0.00008163736,0.00023953193,0.00014340282,0.00015199222,0.000018270024,0.00043468626,0.00008524842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023763578,0.0010921666,0.00084284885,0.00014926486,0.000102884485,0.000046550653,0.00022478472,0.000014359588,0.07404964,0.011228746,0.079654284,0.83021814],"study_design_scores_gemma":[0.007828445,0.0003923196,0.020208232,0.0001989175,0.000353812,0.00008434819,0.000014845008,0.0035715583,0.098797776,0.003435464,0.8647126,0.0004016876],"about_ca_topic_score_codex":8.6000495e-7,"about_ca_topic_score_gemma":2.8331396e-8,"teacher_disagreement_score":0.8298164,"about_ca_system_score_codex":0.00014638511,"about_ca_system_score_gemma":0.00012093347,"threshold_uncertainty_score":0.8177235},"labels":[],"label_agreement":null},{"id":"W2169358331","doi":"10.1098/rsob.120173","title":"SET7/9-dependent methylation of ARTD1 at K508 stimulates poly-ADP-ribose formation after oxidative stress","year":2013,"lang":"en","type":"article","venue":"Open Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universität Zürich; University of British Columbia; Universität Konstanz; Functional Genomics Center Zurich; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; School of Medicine, New York University; National Science Foundation","keywords":"Biology; Oxidative stress; Methylation; Oxidative phosphorylation; Ribose; DNA methylation; Biochemistry; Poly ADP ribose polymerase; Cell biology; DNA; Enzyme; Gene expression; Gene","score_opus":0.03291606953023398,"score_gpt":0.34927642706260487,"score_spread":0.3163603575323709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169358331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069935,0.000549105,0.0014634761,0.0018341923,0.00019106512,0.0012626571,0.00016165289,0.00002458874,0.0038138886],"genre_scores_gemma":[0.9959037,0.00007584419,0.0012781789,0.0005736331,0.000099376404,0.0002709427,0.00038131184,0.00001438588,0.0014026458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895424,0.00014516182,0.00036855452,0.00022718798,0.00010879213,0.00019609585],"domain_scores_gemma":[0.9990992,0.00010902675,0.00023318728,0.0002827381,0.00020071444,0.00007511008],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018974369,0.00013443017,0.00031798967,0.000096642834,0.000049417908,0.00001861015,0.00013580506,0.00014633428,0.006133768],"category_scores_gemma":[0.00003841288,0.00010764984,0.00005156179,0.0001009346,0.00010440788,0.000351354,0.00014650787,0.00010050739,0.00037279245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017132778,0.00027393384,0.046490327,0.00010021485,0.00022547711,0.0000057628727,0.0020189385,0.00004574657,0.9171265,0.0004582633,0.0029777465,0.02856386],"study_design_scores_gemma":[0.0036470494,0.00075493485,0.045837544,0.00013547666,0.000050492723,0.000023351975,0.000276416,0.0006001595,0.9406645,0.0022653916,0.0055365413,0.00020813038],"about_ca_topic_score_codex":0.00040592157,"about_ca_topic_score_gemma":0.00006482447,"teacher_disagreement_score":0.028355729,"about_ca_system_score_codex":0.00015193019,"about_ca_system_score_gemma":0.00003993009,"threshold_uncertainty_score":0.99477476},"labels":[],"label_agreement":null},{"id":"W2170476788","doi":"10.1158/1078-0432.ccr-10-0939","title":"Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer","year":2010,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Breast cancer; Triple-negative breast cancer; PARP inhibitor; Cancer research; Poly ADP ribose polymerase; Cancer; Synthetic lethality; Medicine; DNA repair; Targeted therapy; Polymerase; Biology; Internal medicine; DNA; Genetics","score_opus":0.4045928384629675,"score_gpt":0.609833792293307,"score_spread":0.20524095383033952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170476788","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012624562,0.96887416,0.00004055159,0.009553727,0.00402899,0.008642315,0.007859602,0.00019390185,0.0006805388],"genre_scores_gemma":[0.00008493994,0.9511156,0.0003038234,0.0022247836,0.02184813,0.016876074,0.0005973419,0.00042193045,0.0065273703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9890253,0.0017760644,0.0029417037,0.0022896172,0.0020651037,0.0019022223],"domain_scores_gemma":[0.98819286,0.0052427654,0.0009689691,0.0018107967,0.0023899772,0.0013946353],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0053802333,0.0011047226,0.004657219,0.000905507,0.00080179994,0.00022546793,0.0007963139,0.0022861667,0.009146569],"category_scores_gemma":[0.0010773274,0.00085331633,0.0026563692,0.0021005948,0.0026362918,0.00023188142,0.00023099336,0.007457322,0.0002954878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031675056,0.00073216285,0.00008932367,0.004765425,0.0008361611,0.000058759808,0.00007969396,4.921962e-8,0.000029801153,0.00010627554,0.07548891,0.9146459],"study_design_scores_gemma":[0.009848897,0.001098999,0.00017124983,0.017360514,0.0004900079,0.00011907388,0.000032747816,0.000005069485,0.00042302575,0.00043150233,0.9691887,0.0008302039],"about_ca_topic_score_codex":0.0012696406,"about_ca_topic_score_gemma":0.0002670619,"teacher_disagreement_score":0.91381574,"about_ca_system_score_codex":0.001512105,"about_ca_system_score_gemma":0.014491881,"threshold_uncertainty_score":0.99939173},"labels":[],"label_agreement":null},{"id":"W2170744774","doi":"10.1242/jcs.106963","title":"Quantitative proteomics and dynamic imaging reveal that G3BP-mediated stress granule assembly is poly(ADP-ribose)-dependent following exposure to MNNG-induced DNA alkylation","year":2012,"lang":"en","type":"article","venue":"Journal of Cell Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université Laval; Centre hospitalier de l'Université Laval; Hôtel-Dieu de Québec","funders":"Canadian Institutes of Health Research","keywords":"Biology; Stress granule; Poly ADP ribose polymerase; Interactome; DNA damage; Stable isotope labeling by amino acids in cell culture; Biochemistry; Proteomics; Cell biology; DNA; Polymerase; Gene; Translation (biology)","score_opus":0.026677948601156652,"score_gpt":0.33134157338621967,"score_spread":0.30466362478506304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170744774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918386,0.0008476658,0.0033874093,0.0022482094,0.00088637904,0.0004037309,0.000011421101,0.000016324011,0.00036028938],"genre_scores_gemma":[0.9902541,0.000050092145,0.008736661,0.00062642846,0.00021610463,0.000007237547,0.000001910188,0.00001924107,0.0000882378],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975819,0.000074949116,0.00049471366,0.0002451403,0.0011384338,0.00046485008],"domain_scores_gemma":[0.9983633,0.00011226528,0.0005391666,0.00019245387,0.00030773814,0.0004850748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019026861,0.00017531298,0.00032360796,0.00039341865,0.00022738792,0.00010314985,0.00021446584,0.00005660721,0.000017311932],"category_scores_gemma":[0.0001835846,0.00014704977,0.00010233602,0.0005379013,0.00011081344,0.0012715289,0.000053792694,0.00031919923,0.000010410296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001586404,0.000091760674,0.032073688,0.00002621745,0.000016352054,0.00002000092,0.0031605605,0.000009223954,0.9629134,0.0000063639336,0.00008184043,0.0014419354],"study_design_scores_gemma":[0.0021959012,0.0006543473,0.069756635,0.00045488318,0.00006781337,0.00014132987,0.002061955,0.0006083117,0.92369133,0.000071146074,0.000078146186,0.00021822144],"about_ca_topic_score_codex":0.0000200032,"about_ca_topic_score_gemma":0.0000050539406,"teacher_disagreement_score":0.03922211,"about_ca_system_score_codex":0.00041853436,"about_ca_system_score_gemma":0.00034445804,"threshold_uncertainty_score":0.5996515},"labels":[],"label_agreement":null},{"id":"W2171297740","doi":"10.1371/journal.pone.0021807","title":"Catalytic and Non-Catalytic Roles for the Mono-ADP-Ribosyltransferase Arr in the Mycobacterial DNA Damage Response","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Weill Cornell Medical College; McMaster University; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"DNA damage; DNA; Biology; DNA repair; Gene; Cell biology; Genetics","score_opus":0.07858628243809644,"score_gpt":0.2691139904149,"score_spread":0.19052770797680352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171297740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936263,0.00022587656,0.00014309901,0.0037606766,0.00007149036,0.0015459063,0.00010599478,0.000032823067,0.00048786015],"genre_scores_gemma":[0.99733686,0.00015142352,0.00027799013,0.0012177422,0.00030741375,0.0004667638,0.00003604847,0.000035099736,0.00017067822],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987863,0.00010721564,0.00028275556,0.00027045657,0.00026965138,0.0002836588],"domain_scores_gemma":[0.9985226,0.00068402797,0.000055659657,0.00059149,0.00006297882,0.00008325765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008696505,0.00017834181,0.0002972495,0.00009508089,0.00012223308,0.000033467837,0.00021036086,0.000082250495,0.00007058711],"category_scores_gemma":[0.00018933645,0.00011131586,0.000066241424,0.00016526348,0.00019728647,0.00010977393,0.000020549745,0.00021603853,0.000029288476],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041007362,0.0035894827,0.008601655,0.0005514547,0.00081436883,0.000112442925,0.033524036,0.0000014479159,0.9087345,0.00030616336,0.0010999847,0.0016570818],"study_design_scores_gemma":[0.012449348,0.0015435941,0.18820712,0.0007894231,0.0009831632,0.00004829269,0.0017257619,0.0006694888,0.79139644,0.0009873285,0.00078750146,0.0004125455],"about_ca_topic_score_codex":0.00007454133,"about_ca_topic_score_gemma":0.00008385986,"teacher_disagreement_score":0.17960547,"about_ca_system_score_codex":0.00006398517,"about_ca_system_score_gemma":0.00011240376,"threshold_uncertainty_score":0.4539329},"labels":[],"label_agreement":null},{"id":"W2189420219","doi":"10.1186/s12974-015-0448-8","title":"NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1","year":2015,"lang":"en","type":"article","venue":"Journal of Neuroinflammation","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Health Sciences Centre","funders":"University of California, San Francisco; U.S. Department of Veterans Affairs; Alzheimer Society; Manitoba Health Research Council; National Institutes of Health; Children's Hospital Foundation; National Institute of Neurological Disorders and Stroke; American Heart Association","keywords":"Poly ADP ribose polymerase; Tumor necrosis factor alpha; Kinase; MAPK/ERK pathway; Molecular biology; Cell biology; Biology; PARP inhibitor; NF-κB; Signal transduction; Chemistry; Enzyme; Biochemistry; Polymerase; Immunology","score_opus":0.03165809297205264,"score_gpt":0.2755626784873885,"score_spread":0.2439045855153359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2189420219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98206025,0.0032082812,0.004562701,0.009330432,0.00033238126,0.00027644105,0.000018294419,0.000042441778,0.00016878283],"genre_scores_gemma":[0.99751514,0.00018037746,0.0006185604,0.00026939143,0.00081211946,0.0000064799606,0.00006732071,0.000039893705,0.0004907345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99775666,0.00015524589,0.00083466986,0.00020905356,0.00082651066,0.00021787676],"domain_scores_gemma":[0.9981876,0.000083213396,0.0006962576,0.00017490139,0.00047955668,0.00037845076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005349883,0.00021817644,0.0003428154,0.0002858366,0.000090563975,0.00006502309,0.00008214736,0.00013029715,0.00018172065],"category_scores_gemma":[0.00012702616,0.00020117531,0.00012699992,0.00025620268,0.00009976799,0.00086310937,0.000009730219,0.00034306056,0.000009877831],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018811924,0.00015169718,0.00024444636,0.000040319926,0.000059410333,0.00010340661,0.00045942768,0.00009665611,0.9803257,0.00017848022,0.0077563683,0.008702917],"study_design_scores_gemma":[0.0066983537,0.00090888166,0.0028337156,0.00027258138,0.00011921339,0.000958146,0.00012884643,0.0015294735,0.9684327,0.0007013159,0.017213996,0.00020277828],"about_ca_topic_score_codex":0.00001892296,"about_ca_topic_score_gemma":7.4066105e-7,"teacher_disagreement_score":0.015454878,"about_ca_system_score_codex":0.00020341463,"about_ca_system_score_gemma":0.00026922356,"threshold_uncertainty_score":0.8203691},"labels":[],"label_agreement":null},{"id":"W2210184605","doi":"10.1186/s12885-015-1957-7","title":"A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients","year":2015,"lang":"en","type":"review","venue":"BMC Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Deutsche Krebshilfe; Norges Forskningsråd; Stockholms Läns Landsting; Karolinska Institutet; Canadian Institutes of Health Research; Fonds Wetenschappelijk Onderzoek; Breast Cancer Campaign; Cancerfonden; Agency for Science, Technology and Research; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research; National Cancer Institute; Kuopion Yliopistollinen Sairaala; Francis Crick Institute; Deutsches Krebsforschungszentrum; Academy of Finland; Génome Québec; McGill University; Breast Cancer Research Foundation; University of Cambridge; Dietmar Hopp Stiftung; KWF Kankerbestrijding; Cancer Research UK; Kreftforeningen; Helsingin ja Uudenmaan Sairaanhoitopiiri; Ovarian Cancer Research Fund; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Itä-Suomen Yliopisto; European Commission; Susan G. Komen for the Cure","keywords":"Medicine; Breast cancer; Hazard ratio; Oncology; Single-nucleotide polymorphism; Chemotherapy; Internal medicine; Anthracycline; Radiation therapy; Cancer; Genotype; Biology; Genetics; Gene; Confidence interval","score_opus":0.04493242607375915,"score_gpt":0.33812859975609955,"score_spread":0.2931961736823404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2210184605","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041973095,0.94710076,0.000010509477,0.00046414827,0.00050516584,0.0047305473,0.0049476544,0.00016920632,0.00009893178],"genre_scores_gemma":[0.003868361,0.9844413,0.00004331242,0.0018660254,0.000851332,0.0063937637,0.0013446828,0.000273208,0.0009180193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951817,0.00051340286,0.0010119941,0.0010709414,0.0014830353,0.0007389683],"domain_scores_gemma":[0.997364,0.00015257727,0.0009910886,0.000776067,0.00042448138,0.00029177315],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004463607,0.00093976455,0.0022487114,0.00027004737,0.00012216519,0.00006585164,0.00039874233,0.0005861323,0.0016174274],"category_scores_gemma":[0.000027130674,0.0005667981,0.00048416186,0.0010194139,0.00023434343,0.00014451971,0.000056638048,0.00079008634,0.00001566756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029098056,0.004423141,0.11017414,0.005575711,0.0029271531,0.00010380728,0.0018990308,0.0000017435148,0.000049155442,0.0000028450506,0.32159784,0.5503356],"study_design_scores_gemma":[0.023099037,0.0016615968,0.058787744,0.062069587,0.0047516706,0.000120823366,0.000062801315,0.000059611495,0.0001239099,0.000013925379,0.84699744,0.0022518542],"about_ca_topic_score_codex":0.0022057735,"about_ca_topic_score_gemma":0.0007264447,"teacher_disagreement_score":0.5480838,"about_ca_system_score_codex":0.0025438352,"about_ca_system_score_gemma":0.0018420246,"threshold_uncertainty_score":0.9996784},"labels":[],"label_agreement":null},{"id":"W2224500197","doi":"10.1200/jco.2012.30.15_suppl.5001","title":"Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Clinical endpoint; Internal medicine; Carboplatin; Urology; Maintenance therapy; Oncology; Randomization; PARP inhibitor; Randomized controlled trial; Surgery; Gastroenterology; Chemotherapy; Cisplatin","score_opus":0.12501870968713022,"score_gpt":0.4775891494285547,"score_spread":0.35257043974142444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224500197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855176,0.00096932345,0.00039847757,0.0038706937,0.0027341996,0.004649425,0.00013532849,0.000021477357,0.0017034361],"genre_scores_gemma":[0.9923612,0.00072216964,0.0020896757,0.002483563,0.001040085,0.00046460083,0.000038240636,0.000071459464,0.0007290374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99067736,0.0024620618,0.0044819973,0.0005856297,0.00090193324,0.0008910257],"domain_scores_gemma":[0.9903983,0.0030905935,0.004214016,0.00045959817,0.00091333775,0.00092416385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006448229,0.0005761161,0.005370609,0.0002273752,0.00017471114,0.00003638481,0.00034941867,0.0005264153,0.00018281458],"category_scores_gemma":[0.0019463557,0.00037471106,0.0004556436,0.00040115335,0.00046618632,0.00047229533,0.00015968672,0.0016051352,0.000012788614],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.806567,0.05635656,0.041434493,0.00002561439,0.0029328952,0.0005558006,0.0065790983,0.00005413389,0.000079715595,0.00007111912,0.01103491,0.07430863],"study_design_scores_gemma":[0.88835627,0.089004844,0.008548818,0.0005799383,0.0013126459,0.00012581155,0.0009806812,0.00044009686,0.000087756096,0.000051678853,0.010113623,0.00039781115],"about_ca_topic_score_codex":0.0010968571,"about_ca_topic_score_gemma":0.0011337699,"teacher_disagreement_score":0.08178926,"about_ca_system_score_codex":0.004406521,"about_ca_system_score_gemma":0.0039432105,"threshold_uncertainty_score":0.9998705},"labels":[],"label_agreement":null},{"id":"W2226081785","doi":"10.1158/1535-7163.mct-15-0282","title":"Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"PARP1; Olaparib; Cancer research; Veliparib; Medicine; In vivo; PARP inhibitor; Poly ADP ribose polymerase; DNA damage; Biology; DNA; Polymerase","score_opus":0.025574440247841997,"score_gpt":0.3001339648040031,"score_spread":0.2745595245561611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226081785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88615334,0.10536253,0.0008864669,0.005651495,0.000650267,0.00085045607,0.00005482586,0.00019926073,0.00019137037],"genre_scores_gemma":[0.98445326,0.0046498613,0.0011545554,0.007567817,0.0014632117,0.00027824074,0.00004603121,0.00019230833,0.00019472191],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99615777,0.00027818975,0.0007695882,0.0008692767,0.0009686375,0.00095655303],"domain_scores_gemma":[0.99793375,0.00008645508,0.00031470554,0.00078648026,0.00023858945,0.00064002274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037748567,0.0006726248,0.00083181384,0.000896739,0.00010185324,0.00009556515,0.00029992813,0.0003448438,0.0001242891],"category_scores_gemma":[0.000034176996,0.0006515891,0.00018833674,0.0016917727,0.00017008139,0.00019366718,0.00011903434,0.0007031258,0.000048127342],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017468475,0.0073783216,0.6046704,0.0010521369,0.0021026009,0.008113192,0.0074730576,0.0001990805,0.24684522,0.0034817213,0.0019511435,0.09926465],"study_design_scores_gemma":[0.1710905,0.011942968,0.2196666,0.00046303868,0.0059788725,0.0029789475,0.0012665517,0.0015764964,0.51747733,0.01694399,0.04424937,0.0063653514],"about_ca_topic_score_codex":0.0004535071,"about_ca_topic_score_gemma":0.000044766293,"teacher_disagreement_score":0.3850038,"about_ca_system_score_codex":0.0005493454,"about_ca_system_score_gemma":0.0009011314,"threshold_uncertainty_score":0.99959356},"labels":[],"label_agreement":null},{"id":"W2236834172","doi":"10.1038/srep19020","title":"Characterization of the interactions of PARP-1 with UV-damaged DNA in vivo and in vitro","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Institutes of Health; Shastri Indo-Canadian Institute","keywords":"In vivo; In vitro; DNA; DNA damage; Characterization (materials science); Computational biology; Poly ADP ribose polymerase; Biology; Cell biology; Genetics; Chemistry; Nanotechnology; Materials science; Polymerase","score_opus":0.014384160345403412,"score_gpt":0.2671720690538952,"score_spread":0.25278790870849177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2236834172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978608,0.000008630982,0.00008147426,0.0006504824,0.00068517035,0.0002588555,0.0000067880615,0.0000056718445,0.00044214376],"genre_scores_gemma":[0.9983149,0.00000541299,0.000059022914,0.000023832943,0.000012987216,0.00001803129,0.00000454198,0.000005435617,0.0015558285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999122,0.000037909176,0.00034477544,0.00020458581,0.00020702953,0.00008368873],"domain_scores_gemma":[0.9992113,0.000026897736,0.00028637465,0.0003581862,0.00009159497,0.00002560836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045555277,0.00005131249,0.00013952352,0.00016659724,0.000025627065,0.000007951431,0.000028572045,0.000020709786,0.00009783548],"category_scores_gemma":[0.00006514661,0.000027512588,0.000021408141,0.0004083719,0.0002587017,0.000118961274,0.000016120275,0.000049326434,3.9055314e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011571108,0.000055294673,0.08203782,0.00001885196,0.000004133103,0.000014937054,0.0003295709,5.0297706e-7,0.9167448,0.000004778307,0.00006993162,0.0006036123],"study_design_scores_gemma":[0.00045268703,0.000015069374,0.13628113,0.00040064182,0.000005295767,0.000083272775,0.00003754452,0.000005876954,0.8610466,0.00015383669,0.0014886694,0.000029350544],"about_ca_topic_score_codex":0.000018024608,"about_ca_topic_score_gemma":0.00007379044,"teacher_disagreement_score":0.055698242,"about_ca_system_score_codex":0.000049179413,"about_ca_system_score_gemma":0.00010626011,"threshold_uncertainty_score":0.11219307},"labels":[],"label_agreement":null},{"id":"W2255845282","doi":"10.1039/c5md00552c","title":"Continuous flow photochemistry as an enabling synthetic technology: synthesis of substituted-6(5H)-phenanthridinones for use as poly(ADP-ribose) polymerase inhibitors","year":2016,"lang":"en","type":"article","venue":"MedChemComm","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg; University of Manitoba","funders":"University of Manitoba","keywords":"Continuous flow; Intramolecular force; Polymerase; Chemistry; Poly ADP ribose polymerase; Combinatorial chemistry; Ribose; Photochemistry; Stereochemistry; Enzyme; Biochemistry; Biochemical engineering","score_opus":0.020188722937391334,"score_gpt":0.2960961910592878,"score_spread":0.2759074681218965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255845282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885138,0.0015225232,0.0012128887,0.005978124,0.00045884794,0.0011235838,0.00027189613,0.0004279665,0.000490355],"genre_scores_gemma":[0.9933799,0.00027544898,0.0039413003,0.00034104873,0.00053695246,0.0007829925,0.000032684577,0.000121262594,0.000588447],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972023,0.00006635922,0.00078782724,0.00075475784,0.00048650126,0.0007022955],"domain_scores_gemma":[0.99668896,0.0008895204,0.0003995152,0.0012839987,0.00038014364,0.00035787403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043912293,0.00048045893,0.0009347349,0.00040339862,0.00018394315,0.000034540408,0.00037567888,0.00049193273,0.0005653573],"category_scores_gemma":[0.0019160333,0.0003616863,0.00030754757,0.00046547284,0.00078715937,0.0003059158,0.00007950345,0.0002503945,0.000055189303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011466137,0.00050755666,0.0022333742,0.00019361972,0.00020676717,0.00006311429,0.00016390087,4.5687779e-7,0.9483576,0.0002523509,0.000709144,0.04616555],"study_design_scores_gemma":[0.0033813906,0.00032683555,0.000046531422,0.0018590012,0.00023050618,0.00031625392,0.0004660526,0.000041148127,0.98365206,0.0006395736,0.008597097,0.00044356467],"about_ca_topic_score_codex":0.00016491814,"about_ca_topic_score_gemma":0.000009176228,"teacher_disagreement_score":0.04572198,"about_ca_system_score_codex":0.00022645095,"about_ca_system_score_gemma":0.00038730432,"threshold_uncertainty_score":0.99988353},"labels":[],"label_agreement":null},{"id":"W2266099825","doi":"","title":"Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Cancer; Breast cancer; DNA repair; BRCA2 Protein; Biology; Ovarian cancer; Gene; Genetics; Synthetic lethality; Cancer research; Allele; Homologous recombination; Mutation; Prostate cancer; Germline mutation","score_opus":0.08739391783872785,"score_gpt":0.31216636897644845,"score_spread":0.2247724511377206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266099825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698834,0.009700249,0.01266639,0.0033716694,0.00022771406,0.0013598026,0.000026705531,0.00011677654,0.002647334],"genre_scores_gemma":[0.993804,0.0005571847,0.0017495271,0.003111938,0.00017359109,0.000266419,0.000006009737,0.000072595074,0.00025877566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837136,0.00006183443,0.000291908,0.00038496745,0.00047297784,0.00041696776],"domain_scores_gemma":[0.99880093,0.000069362715,0.00012250502,0.00075641205,0.00009888165,0.00015188355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023241472,0.0002738999,0.00036565706,0.00011007116,0.00008301656,0.0000102565955,0.00012810779,0.00009069512,0.0000532697],"category_scores_gemma":[0.0000034397597,0.00017090277,0.0002137581,0.0004623541,0.00019925556,0.000021844884,0.000011004613,0.00011562793,0.0000073664855],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01659324,0.0028374356,0.037582703,0.0005651118,0.009505501,0.0009775481,0.029077945,0.01770492,0.55014426,0.00528969,0.0005948246,0.32912683],"study_design_scores_gemma":[0.0030751943,0.003216078,0.0040775407,0.00023080023,0.0007438092,0.000088780005,0.00052533124,0.00022889761,0.84586453,0.00007682304,0.1415427,0.00032949998],"about_ca_topic_score_codex":0.00024545295,"about_ca_topic_score_gemma":0.000344685,"teacher_disagreement_score":0.32879734,"about_ca_system_score_codex":0.00090610713,"about_ca_system_score_gemma":0.00035794615,"threshold_uncertainty_score":0.6969213},"labels":[],"label_agreement":null},{"id":"W2270704840","doi":"10.1038/nm.4032","title":"Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","year":2016,"lang":"en","type":"article","venue":"Nature Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"PARP1; Olaparib; Poly ADP ribose polymerase; Cancer research; PARP inhibitor; Synthetic lethality; DNA damage; Cancer cell; Cancer; DNA repair; Biology; Medicine; Polymerase; Enzyme; Internal medicine; DNA; Biochemistry","score_opus":0.005994849007095061,"score_gpt":0.28229218965544567,"score_spread":0.2762973406483506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2270704840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738521,0.014351224,0.0005800572,0.0065078093,0.0024214152,0.00077856414,0.000012706654,0.00018437041,0.0013117401],"genre_scores_gemma":[0.99473286,0.0009315015,0.00037748076,0.0019261689,0.0016115984,0.000053884523,0.000034011584,0.000047548583,0.0002849346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975109,0.00009610106,0.00064545585,0.00045478222,0.000917522,0.00037524872],"domain_scores_gemma":[0.99741745,0.0009699201,0.0004425365,0.0005961086,0.000356042,0.000217958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005140593,0.00030905486,0.00077918766,0.0003307354,0.0000649729,0.0000037977306,0.00018453466,0.00035635498,0.00043502418],"category_scores_gemma":[0.002318259,0.00018000064,0.000118962744,0.00069233554,0.0004049441,0.00012392116,0.00003857567,0.0005340718,0.00003587153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032581872,0.00011082426,0.015910098,0.00034731164,0.0001175479,0.00007505946,0.000311107,4.2437904e-7,0.9621921,0.0002679074,0.009729458,0.01061235],"study_design_scores_gemma":[0.007902556,0.0010270687,0.022126425,0.005047561,0.00016345386,0.00004827975,0.000060898943,0.000009990393,0.94204986,0.00041300402,0.02094397,0.00020693234],"about_ca_topic_score_codex":0.000021485526,"about_ca_topic_score_gemma":0.0000035734347,"teacher_disagreement_score":0.020880757,"about_ca_system_score_codex":0.00016003488,"about_ca_system_score_gemma":0.00013202289,"threshold_uncertainty_score":0.7340213},"labels":[],"label_agreement":null},{"id":"W2280782183","doi":"10.1080/23723556.2015.1052180","title":"New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology","year":2015,"lang":"en","type":"review","venue":"Molecular & Cellular Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Intensive care medicine; Cancer research","score_opus":0.23227610739661383,"score_gpt":0.4455484157597253,"score_spread":0.21327230836311148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280782183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003528397,0.959756,0.019769944,0.0027127059,0.0015108034,0.005050015,0.00006316605,0.00013173834,0.010970338],"genre_scores_gemma":[0.000052026404,0.9778611,0.010308775,0.0036729707,0.0009630052,0.002387274,0.0007042722,0.00032588828,0.003724702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949656,0.0009012692,0.001606943,0.0010500556,0.0004970573,0.0009790767],"domain_scores_gemma":[0.99699,0.00037375288,0.00063215557,0.0009179329,0.00031480417,0.0007713354],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012498595,0.0009251319,0.0044226116,0.001079415,0.000064206004,0.00005574384,0.0005072246,0.0016834731,0.00031343964],"category_scores_gemma":[0.0000898715,0.00086303824,0.0009038936,0.000627715,0.0002021061,0.00008966396,0.0001568585,0.000999684,0.00014003435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039186204,0.00028765568,5.720498e-7,0.0032361546,0.00047378938,0.00241521,0.00050274545,0.000016183845,0.00094287324,0.0021122908,0.015044077,0.9745766],"study_design_scores_gemma":[0.004031918,0.0035571211,1.9706738e-7,0.002787029,0.0012170185,0.00046291086,0.0008516844,0.0000049683813,0.00053175166,0.0027108383,0.98314035,0.000704199],"about_ca_topic_score_codex":0.00011362815,"about_ca_topic_score_gemma":0.000089307294,"teacher_disagreement_score":0.97387236,"about_ca_system_score_codex":0.0034148535,"about_ca_system_score_gemma":0.016288923,"threshold_uncertainty_score":0.99961257},"labels":[],"label_agreement":null},{"id":"W2284327835","doi":"10.1177/0967772016629012","title":"Julian Lewis (1946–2014): A ‘serious hero’","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Biography","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medal; HERO; Gold medal; Battle; Classics; History; Art history; Art; Ancient history; Literature","score_opus":0.014049316241098973,"score_gpt":0.3164702592651122,"score_spread":0.30242094302401323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284327835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6760316,0.01042898,0.004981779,0.30145344,0.0031670716,0.00033396546,0.00003102439,0.00010711701,0.003465047],"genre_scores_gemma":[0.9738693,0.010526466,0.001579433,0.0112369275,0.0024822196,0.0000081248545,0.0000016668464,0.000038979008,0.00025683412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968132,0.00009084114,0.000730217,0.00017294828,0.0018755302,0.000317265],"domain_scores_gemma":[0.9980436,0.00016952159,0.00037911677,0.00026349834,0.0002474868,0.00089676405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00096742675,0.00016823054,0.0004786592,0.0006148776,0.00004801311,0.00001628195,0.00029861988,0.0002565943,0.0036966668],"category_scores_gemma":[0.00025469315,0.00009127521,0.00060400687,0.0005156639,0.00038437202,0.00012593734,0.00002822799,0.00042954343,0.00012493014],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012207333,0.00057039276,0.04965251,0.00005587438,0.0006909818,0.0012208614,0.00016707469,7.291275e-8,0.019487789,0.00031663734,0.670022,0.25659508],"study_design_scores_gemma":[0.010840382,0.0018353908,0.026631398,0.0018132338,0.00014129614,0.0025700873,0.00006614083,0.0000019590093,0.008634571,0.0012772876,0.9459787,0.00020952817],"about_ca_topic_score_codex":0.000013985637,"about_ca_topic_score_gemma":0.00000331258,"teacher_disagreement_score":0.29783776,"about_ca_system_score_codex":0.00006930586,"about_ca_system_score_gemma":0.00031186317,"threshold_uncertainty_score":0.9972141},"labels":[],"label_agreement":null},{"id":"W2294633761","doi":"10.1093/annonc/mdw133","title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Myriad Genetics; AstraZeneca","keywords":"Olaparib; Medicine; Internal medicine; Ovarian cancer; Oncology; PARP inhibitor; Population; BRCA mutation; Chemotherapy; Cancer","score_opus":0.03294610948529814,"score_gpt":0.38652179802397246,"score_spread":0.3535756885386743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294633761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923383,0.00065335294,0.00017364221,0.0061872727,0.00002704519,0.00044810708,0.00011187938,0.000008639471,0.000051733507],"genre_scores_gemma":[0.99672,0.001383746,0.0009382768,0.0007789257,0.000011763855,0.000064614505,0.000013221933,0.000012988804,0.00007647037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987764,0.00020231507,0.00046176816,0.00025930896,0.00014715754,0.00015306944],"domain_scores_gemma":[0.99852145,0.0005436644,0.00033287128,0.00018943689,0.00034026627,0.00007230949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046849545,0.00012114533,0.00065858924,0.0003866107,0.000023672837,0.0000018715402,0.000038207305,0.000093987794,0.00010237677],"category_scores_gemma":[0.00012219691,0.000082362145,0.000042996002,0.00051522464,0.00024087782,0.00008585193,0.000013306364,0.000066723536,2.8386717e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12519008,0.000829696,0.6876582,0.000034277295,0.0014377458,0.000021618445,0.00247802,0.000070394795,0.014251975,0.00006006682,0.0000804912,0.16788742],"study_design_scores_gemma":[0.030742662,0.00487998,0.9578866,0.0001552572,0.00017476881,0.0000025726438,0.00007722479,0.0000709407,0.0045736306,0.000061630584,0.0012805874,0.000094173236],"about_ca_topic_score_codex":0.00015839051,"about_ca_topic_score_gemma":0.00039485135,"teacher_disagreement_score":0.27022836,"about_ca_system_score_codex":0.00006744774,"about_ca_system_score_gemma":0.00016896676,"threshold_uncertainty_score":0.33586308},"labels":[],"label_agreement":null},{"id":"W2298857745","doi":"10.1042/bj20151077","title":"TCDD-inducible poly-ADP-ribose polymerase (TIPARP/PARP7) mono-ADP-ribosylates and co-activates liver X receptors","year":2016,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Liver X receptor; Poly ADP ribose polymerase; Gene knockdown; Biology; Molecular biology; PARP1; RNA polymerase II; ADP-ribosylation; Polymerase; Cell biology; Transcription factor; Gene expression; Promoter; Nuclear receptor; Gene; Biochemistry; NAD+ kinase","score_opus":0.025656982218007225,"score_gpt":0.30063353183631375,"score_spread":0.27497654961830653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298857745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801445,0.009083467,0.00033336313,0.008524194,0.00059273175,0.00023884788,0.00004741799,0.000114162714,0.0009213276],"genre_scores_gemma":[0.99005324,0.0036113693,0.001164963,0.0012520929,0.002391936,0.00002232342,0.000015309779,0.000073647425,0.0014151037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976226,0.00009980599,0.0005825826,0.00051684404,0.0005211031,0.0006570424],"domain_scores_gemma":[0.99802566,0.0002516047,0.00027830352,0.0003749562,0.00018350624,0.00088599464],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003442153,0.00038248842,0.0005149753,0.00023329013,0.00021495881,0.000088366876,0.0001940756,0.00031131494,0.0027109743],"category_scores_gemma":[0.00024726652,0.000259099,0.00021177303,0.00022520777,0.00040558376,0.00030348788,0.000066340755,0.0005579144,0.00018724136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092141965,0.00019804333,0.008157144,0.000026656151,0.00016040758,0.00009095548,0.00016531597,4.4698133e-8,0.90887326,0.000033778906,0.061437372,0.019935578],"study_design_scores_gemma":[0.0042079356,0.0003655983,0.0015697131,0.0005628031,0.00007277476,0.0017431125,0.0001011817,0.000008201453,0.95198846,0.00033154024,0.038679067,0.00036961355],"about_ca_topic_score_codex":0.000026056567,"about_ca_topic_score_gemma":4.4409657e-7,"teacher_disagreement_score":0.043115173,"about_ca_system_score_codex":0.0003177004,"about_ca_system_score_gemma":0.00022585022,"threshold_uncertainty_score":0.9999861},"labels":[],"label_agreement":null},{"id":"W2304716045","doi":"10.1517/14740338.2015.1045875","title":"Safety evaluation of olaparib for treating ovarian cancer","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Drug Safety","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Olaparib; Tolerability; Oncology; Internal medicine; Nausea; Ovarian cancer; Cancer; Adverse effect","score_opus":0.18505262006867182,"score_gpt":0.4859453302992656,"score_spread":0.30089271023059383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304716045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.055003e-7,0.9821776,0.00045475014,0.0007640028,0.0027462586,0.0047762603,0.00087454065,0.0000904991,0.008115355],"genre_scores_gemma":[0.000015924417,0.99045825,0.0011247636,0.00034196718,0.0025469738,0.0025336838,0.0022291944,0.00014946815,0.00059976254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99527967,0.0006285134,0.0015882195,0.00076051673,0.0013536487,0.00038943812],"domain_scores_gemma":[0.9961789,0.0005132541,0.0011097774,0.0008800504,0.0010815288,0.00023649083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003118448,0.00061391544,0.0025004838,0.00031475027,0.00015012528,0.000014776636,0.00023358526,0.00043417668,0.0008233047],"category_scores_gemma":[0.0003589392,0.00049452425,0.0007945582,0.00042984032,0.000092571456,0.000100487756,0.00004255364,0.00038721264,0.00003262187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068295037,0.00016654501,0.0000011607666,0.0027732446,0.00036662348,4.066887e-7,0.00066572474,0.0000430955,0.000005204514,0.0006355531,0.025465345,0.9691942],"study_design_scores_gemma":[0.0062700408,0.00020175338,0.000007786779,0.030565342,0.00031387698,0.000015271955,0.00009931024,0.0003706587,0.000056108718,0.00008340037,0.96160346,0.00041299147],"about_ca_topic_score_codex":0.00013877435,"about_ca_topic_score_gemma":0.000009538829,"teacher_disagreement_score":0.9687812,"about_ca_system_score_codex":0.0027583905,"about_ca_system_score_gemma":0.0031376537,"threshold_uncertainty_score":0.9997506},"labels":[],"label_agreement":null},{"id":"W2308659819","doi":"10.1038/bjc.2016.41","title":"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","year":2016,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development","funders":"Cancer Research UK","keywords":"PARP inhibitor; Medicine; BRCA mutation; Ovarian cancer; Tolerability; Breast cancer; Olaparib; Dosing; Cancer; Pharmacodynamics; Internal medicine; Oncology; Pharmacology; Cancer research; Adverse effect; Pharmacokinetics; Biology; Poly ADP ribose polymerase; Polymerase; Genetics","score_opus":0.01034263473245879,"score_gpt":0.3000696872213802,"score_spread":0.28972705248892144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308659819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97890526,0.015390437,0.00012557687,0.004268816,0.00057643984,0.0005031211,0.00021306479,0.000008042928,0.0000092574755],"genre_scores_gemma":[0.9960165,0.0019939572,0.00072081183,0.0004442287,0.0007220061,0.000033318713,0.0000016988911,0.000031084088,0.00003641436],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99830145,0.00012230876,0.00072763243,0.0002204843,0.00038239988,0.00024570033],"domain_scores_gemma":[0.99840426,0.00009379861,0.00083917024,0.00011071754,0.000331569,0.00022045891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002730495,0.00017529122,0.0005005713,0.00012268107,0.000087165696,0.000045117325,0.00007581405,0.000078801946,0.00006855121],"category_scores_gemma":[0.00014323786,0.00012228127,0.000075646814,0.0001980418,0.00043222852,0.00034429,0.000026846908,0.00028878584,6.854253e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02361539,0.0002839403,0.031969678,0.00014125288,0.00022589466,0.0002467998,0.0010529101,0.000020240992,0.14740203,0.000013413149,0.00008402502,0.7949444],"study_design_scores_gemma":[0.59639794,0.0021600062,0.14477693,0.049409095,0.00067904143,0.009587632,0.002314957,0.0002657317,0.19278966,0.00014260024,0.000816035,0.00066037185],"about_ca_topic_score_codex":0.001041992,"about_ca_topic_score_gemma":0.0012666392,"teacher_disagreement_score":0.79428405,"about_ca_system_score_codex":0.000270149,"about_ca_system_score_gemma":0.00055422576,"threshold_uncertainty_score":0.49864855},"labels":[],"label_agreement":null},{"id":"W2309983655","doi":"10.1007/s10637-016-0335-x","title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Veliparib; Cyclophosphamide; PARP inhibitor; Medicine; Triple-negative breast cancer; Nitrogen mustard; Internal medicine; Oncology; Breast cancer; Chemotherapy; Metastatic breast cancer; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","score_opus":0.01259685493353731,"score_gpt":0.2914200369288869,"score_spread":0.2788231819953496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309983655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97265893,0.00073961273,0.00007301426,0.02247703,0.0005316421,0.002821297,0.0005315164,0.000031249947,0.00013567678],"genre_scores_gemma":[0.9956955,0.00019905674,0.00086999085,0.0014746967,0.0005489763,0.00051291246,0.00007552395,0.000036109384,0.0005872837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974299,0.00033290728,0.0008252612,0.00040361664,0.0007252316,0.00028307902],"domain_scores_gemma":[0.9976749,0.000911526,0.0005734825,0.0002503595,0.00029891712,0.0002908262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056701625,0.00029827177,0.00087393005,0.000171404,0.000113828355,0.000013849551,0.00011099988,0.000090673304,0.00022428749],"category_scores_gemma":[0.00055320724,0.00016075105,0.00013188143,0.0004303414,0.0015159375,0.00030922613,0.000042942276,0.00020380215,0.000003375177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96259755,0.00058429304,0.0020864664,0.000021645903,0.00020101492,0.0000017666607,0.001449912,0.000004130965,0.0009028901,0.0014103673,0.0013040653,0.029435875],"study_design_scores_gemma":[0.97829515,0.0007816804,0.0049874233,0.00094717456,0.0001324503,0.000004650724,0.00004252095,0.000034169258,0.009729253,0.0044419966,0.00038099455,0.00022256598],"about_ca_topic_score_codex":0.0007425509,"about_ca_topic_score_gemma":0.000042610005,"teacher_disagreement_score":0.02921331,"about_ca_system_score_codex":0.0002033919,"about_ca_system_score_gemma":0.0010721347,"threshold_uncertainty_score":0.6555238},"labels":[],"label_agreement":null},{"id":"W2314860898","doi":"10.1158/1538-7445.am2013-617","title":"Abstract 617: High-throughput screens identify PARP inhibition as being synthetically lethal with ERCC1 deficiency in non-small cell lung cancer cell lines.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"ERCC1; Synthetic lethality; Biology; PARP inhibitor; Cancer research; DNA repair; In vivo; DNA damage; Cell culture; Poly ADP ribose polymerase; Nucleotide excision repair; DNA; Genetics","score_opus":0.04290597672587172,"score_gpt":0.3883638873514839,"score_spread":0.3454579106256122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314860898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96384823,0.003936264,0.000291335,0.003544145,0.00029033943,0.0023390497,0.00005128462,0.00009275395,0.025606586],"genre_scores_gemma":[0.9903257,0.0033076222,0.0006680945,0.0005940896,0.0007786758,0.002351196,0.000041555373,0.00013832422,0.0017947356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948908,0.00019643124,0.0007235032,0.0010737103,0.0016457345,0.0014698228],"domain_scores_gemma":[0.9970569,0.00034263794,0.00017171675,0.00076348154,0.0011639562,0.0005013197],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001176807,0.00041973966,0.00058463536,0.00045109444,0.00029441982,0.00019323618,0.00034563063,0.00033697372,0.0061261365],"category_scores_gemma":[0.00006934405,0.00036574836,0.0001229215,0.0011031531,0.0005417248,0.0005122248,0.0001503353,0.0016230396,0.00043111594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00131354,0.0012561907,0.03340572,0.0029745668,0.00009151106,0.0007169585,0.0029956584,0.0012503302,0.93519115,0.00033038342,0.015564459,0.004909499],"study_design_scores_gemma":[0.011390401,0.0010911673,0.16231832,0.006353081,0.00013616693,0.00007196076,0.0019009588,0.0008006876,0.8117675,0.0012048424,0.0017243184,0.0012405769],"about_ca_topic_score_codex":0.04322935,"about_ca_topic_score_gemma":0.0033509505,"teacher_disagreement_score":0.1289126,"about_ca_system_score_codex":0.0019725722,"about_ca_system_score_gemma":0.0016496547,"threshold_uncertainty_score":0.9998794},"labels":[],"label_agreement":null},{"id":"W2315089601","doi":"10.1158/1538-7445.am2013-1906","title":"Abstract 1906: Differential downstream effects of nicotinamide adenine dinucleotide (NAD) salvage pathway-inhibition in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Nicotinamide phosphoribosyltransferase; NAD+ kinase; Chronic lymphocytic leukemia; Nicotinamide adenine dinucleotide; Cancer research; Nicotinamide mononucleotide; CD38; Biology; Leukemia; Chemistry; Biochemistry; Enzyme; Cell biology; Immunology; CD34; Stem cell","score_opus":0.02653195952976865,"score_gpt":0.33112868026877845,"score_spread":0.3045967207390098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315089601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941038,0.0029605767,0.00003132844,0.00025747067,0.00019030973,0.0018373397,0.000042704763,0.00007218049,0.0005043113],"genre_scores_gemma":[0.99691457,0.0013112581,0.00005707875,0.00007430653,0.0004922654,0.00063908787,0.00005277317,0.00007335636,0.00038531102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996811,0.00019645663,0.00059139915,0.0006328113,0.0009083923,0.0008599594],"domain_scores_gemma":[0.99801934,0.0006440908,0.00015508533,0.00052447274,0.00031003638,0.00034700663],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039264595,0.00029819226,0.0005865448,0.0005387772,0.00012617685,0.0000596126,0.00014321515,0.00021823184,0.0012591658],"category_scores_gemma":[0.00025111914,0.00027459528,0.000113250826,0.0005798596,0.00056289794,0.00026496744,0.00013702048,0.0007546842,0.0000961592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005582444,0.00007940223,0.005241553,0.0016864947,0.00006280274,0.00013049394,0.00029096822,0.00014566313,0.96945333,0.000053563726,0.0014881075,0.020809354],"study_design_scores_gemma":[0.011426303,0.0006015954,0.18446833,0.0026712914,0.000020855368,0.000036160513,0.00008528595,0.0018883944,0.79801923,0.00026221346,0.00027179855,0.0002485686],"about_ca_topic_score_codex":0.009185573,"about_ca_topic_score_gemma":0.0010239368,"teacher_disagreement_score":0.17922677,"about_ca_system_score_codex":0.009999056,"about_ca_system_score_gemma":0.0025112259,"threshold_uncertainty_score":0.9999706},"labels":[],"label_agreement":null},{"id":"W2315097589","doi":"10.1167/iovs.11-8853","title":"Altered Expression of the Poly(ADP-Ribosyl)ation Enzymes in Uveal Melanoma and Regulation of<i>PARG</i>Gene Expression by the Transcription Factor ERM","year":2012,"lang":"en","type":"article","venue":"Investigative Ophthalmology & Visual Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Sherbrooke; Hôpital du Saint-Sacrement","funders":"Canadian Institutes of Health Research","keywords":"Transcription factor; Gene; Enzyme; Gene expression; Cancer research; Cell biology; Transcription (linguistics); Melanoma; Biology; Chemistry; Molecular biology; Genetics; Biochemistry","score_opus":0.049337414247099004,"score_gpt":0.34290578760456236,"score_spread":0.29356837335746333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315097589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972286,0.0010573582,0.000047392434,0.00060147245,0.00030901664,0.0005278928,0.000029874423,0.0000111157115,0.00018727565],"genre_scores_gemma":[0.99912035,0.000013916347,0.0005274615,0.00012513914,0.00008202308,0.000048123336,0.000011620574,0.000010834546,0.000060501927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980486,0.00038460226,0.00042359563,0.00031593977,0.0005232688,0.0003040114],"domain_scores_gemma":[0.99889517,0.00016460467,0.00038911434,0.00027273656,0.00013915764,0.00013923777],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0007274675,0.00016522176,0.00026658908,0.00013303307,0.00020341166,0.000009992291,0.00021247359,0.0001262153,0.000070189424],"category_scores_gemma":[0.00020381146,0.00010003017,0.000051761865,0.00062541274,0.002865554,0.00049901626,0.0000688898,0.00020488663,0.0000012114912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011557646,0.00009957283,0.12100375,0.000018672445,0.0000039674155,3.4642227e-7,0.003117039,0.00000404423,0.8752648,0.000114612165,0.000056473214,0.00020112412],"study_design_scores_gemma":[0.00049230346,0.00017769885,0.3869812,0.00014563683,0.000008090965,0.000047028145,0.00016588255,0.00005915923,0.61136377,0.0004856952,0.000015436597,0.00005809174],"about_ca_topic_score_codex":0.00008495385,"about_ca_topic_score_gemma":0.0000015871803,"teacher_disagreement_score":0.26597744,"about_ca_system_score_codex":0.00010439435,"about_ca_system_score_gemma":0.00017597042,"threshold_uncertainty_score":0.99984807},"labels":[],"label_agreement":null},{"id":"W2320834114","doi":"10.1158/1538-7445.am2013-4378","title":"Abstract 4378: Poly(ADP-ribose)glycohydrolase (PARG) is a novel therapeutic target in breast cancer.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Synthetic lethality; Poly ADP ribose polymerase; Cancer research; DNA repair; DNA damage; Olaparib; Cancer; PARP inhibitor; Biology; Breast cancer; Polymerase; DNA; Genetics","score_opus":0.10282170091736256,"score_gpt":0.4296681558549162,"score_spread":0.3268464549375536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320834114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91582733,0.012138171,0.00006847507,0.064499386,0.0005239581,0.0021130461,0.0006247947,0.00012911888,0.0040757293],"genre_scores_gemma":[0.9857507,0.0022577452,0.00015967031,0.0048786253,0.0013841563,0.0028641664,0.000027238922,0.00011700339,0.002560735],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9956515,0.000120327364,0.000573163,0.0008228813,0.0014281927,0.0014039228],"domain_scores_gemma":[0.99759173,0.000202758,0.00011714376,0.00082226057,0.00070998166,0.00055612536],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008590238,0.00035322874,0.0005593384,0.0006704821,0.00020441091,0.00012068576,0.00044224254,0.00026407957,0.033934098],"category_scores_gemma":[0.000032404383,0.00031496456,0.00015892569,0.0014462633,0.00047467012,0.0003875419,0.00010361198,0.0014413047,0.0008661152],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014900798,0.00085150904,0.06300498,0.00039303198,0.00028472467,0.0000735475,0.0012375588,0.00006468486,0.81806266,0.00014887487,0.08905166,0.025336713],"study_design_scores_gemma":[0.018535135,0.00046622852,0.63047266,0.002571267,0.000061296276,0.00019677305,0.00078117347,0.0018332436,0.20630695,0.0025091881,0.13498788,0.0012782246],"about_ca_topic_score_codex":0.01845172,"about_ca_topic_score_gemma":0.00029297662,"teacher_disagreement_score":0.61175567,"about_ca_system_score_codex":0.0017183982,"about_ca_system_score_gemma":0.0016272959,"threshold_uncertainty_score":0.99993026},"labels":[],"label_agreement":null},{"id":"W2322006754","doi":"10.2174/138161212802002823","title":"The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas","year":2012,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Poly ADP ribose polymerase; Ovarian cancer; Cancer research; BRCA mutation; PARP inhibitor; Polymerase; Serous fluid; Biology; Germline; Ovary; Homologous recombination; Mutation; DNA repair; Synthetic lethality; Cancer; DNA damage; Germline mutation; Genetics; DNA; Gene; Biochemistry","score_opus":0.2941309904649982,"score_gpt":0.4673214552720542,"score_spread":0.17319046480705602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322006754","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019159243,0.99541616,0.00011177431,0.00010074954,0.0007740733,0.0029164248,0.00004774145,0.0000151847535,0.00059870706],"genre_scores_gemma":[0.00424112,0.9942092,0.00005748892,0.000021048218,0.00068299676,0.0006868739,0.000037729314,0.00004221084,0.000021359674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651057,0.0011123691,0.0010920479,0.000297095,0.0005231733,0.00046473922],"domain_scores_gemma":[0.9972623,0.0014550189,0.0004135896,0.0006166885,0.00007612402,0.0001762713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009817302,0.0004292364,0.0013701391,0.00014779698,0.00006635954,0.000013213975,0.00031995046,0.00017931282,0.00009758036],"category_scores_gemma":[0.000036049605,0.0002069698,0.0006297114,0.00049485563,0.00035897776,0.000039023496,0.000023393442,0.00049773225,0.00003317153],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014704895,0.0011535168,0.00011198061,0.0025738403,0.00018070261,0.0000045056054,0.00039101456,4.0770232e-7,0.000022360242,0.00097087177,0.00027507826,0.9941687],"study_design_scores_gemma":[0.0013099954,0.00039551788,0.000027331664,0.0033898659,0.0019436529,0.000034229088,0.000041886404,0.00002846975,0.0010835422,0.0001648898,0.99141407,0.00016655536],"about_ca_topic_score_codex":0.0000059395047,"about_ca_topic_score_gemma":4.3314773e-7,"teacher_disagreement_score":0.9940021,"about_ca_system_score_codex":0.0003471052,"about_ca_system_score_gemma":0.00043725412,"threshold_uncertainty_score":0.8439984},"labels":[],"label_agreement":null},{"id":"W2323821846","doi":"10.1074/jbc.m115.707653","title":"Scabin, a Novel DNA-acting ADP-ribosyltransferase from Streptomyces scabies","year":2016,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Guelph","funders":"Institute of Infection and Immunity","keywords":"Stereochemistry; Enzyme; DNA; Chemistry; NAD+ kinase; Guanine; Crystallography; Biochemistry; Nucleotide","score_opus":0.05035971861175642,"score_gpt":0.3044211340053654,"score_spread":0.254061415393609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323821846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302226,0.00059857365,0.0015542367,0.0032255996,0.00014396003,0.00005719634,0.000089122856,0.000035907055,0.0012731653],"genre_scores_gemma":[0.9961146,0.000437942,0.0015868355,0.00041807562,0.0012408227,0.0000042383454,0.0000071807367,0.000012510778,0.00017781006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865746,0.000024727047,0.00058489665,0.0002143607,0.00028420697,0.00023435926],"domain_scores_gemma":[0.99867374,0.00035842852,0.00032541036,0.00018214103,0.00021937763,0.00024089888],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024743128,0.00018016569,0.00044948145,0.000028508335,0.00005036179,0.000017526936,0.00016355347,0.00021858852,0.0025436736],"category_scores_gemma":[0.00041179563,0.00009388974,0.00027221048,0.00009221546,0.0002149588,0.00010147832,0.000023036568,0.00028531422,0.000013513947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007001565,0.00017819996,0.015757633,0.000020326177,0.0001178602,0.000060933875,0.000035422378,4.5647667e-7,0.97615355,0.0000035530595,0.00043928163,0.00653265],"study_design_scores_gemma":[0.0035419702,0.00025216435,0.0064810356,0.0005804008,0.00004355627,0.00033031148,0.00015807925,0.0000014764262,0.9802465,0.0002799493,0.007940397,0.00014416775],"about_ca_topic_score_codex":0.000003663397,"about_ca_topic_score_gemma":2.459007e-7,"teacher_disagreement_score":0.009276597,"about_ca_system_score_codex":0.000141409,"about_ca_system_score_gemma":0.00011872048,"threshold_uncertainty_score":0.99836814},"labels":[],"label_agreement":null},{"id":"W2323840860","doi":"10.18632/oncotarget.7883","title":"Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; National Cancer Institute; Canadian Institutes of Health Research; Cancer Prevention and Research Institute of Texas; RGK Foundation","keywords":"Olaparib; Cancer research; PARP inhibitor; Medicine; Ovarian cancer; Population; PARP1; Oncology; Cancer; Internal medicine; Biology; Poly ADP ribose polymerase; Genetics","score_opus":0.01365515279082239,"score_gpt":0.29935143870327335,"score_spread":0.28569628591245094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323840860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8500671,0.0013005905,0.110711195,0.01584827,0.00077858235,0.002226466,0.00056525046,0.00046302116,0.018039517],"genre_scores_gemma":[0.9617436,0.000058543006,0.009332859,0.0011513575,0.0009401764,0.0003689989,0.00011603314,0.00007480965,0.02621363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984549,0.000064703796,0.0003705186,0.00043636787,0.00026452204,0.00040898868],"domain_scores_gemma":[0.99903077,0.00023918277,0.00020543156,0.0001430684,0.00025554886,0.00012601358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004306771,0.00018318596,0.00029539445,0.00006854857,0.00020297113,0.000021905238,0.000066402325,0.00013089112,0.00017350886],"category_scores_gemma":[0.00021448,0.00014547176,0.000121214835,0.00020783888,0.00007120803,0.00022071718,0.000018374521,0.00013697056,0.00003279845],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014595012,0.00018152938,0.016391784,0.00013678716,0.00009957299,0.0000045247198,0.00023856985,7.701961e-7,0.84913486,0.0009368713,0.12622313,0.0051920684],"study_design_scores_gemma":[0.00684828,0.000430057,0.0030655114,0.0017547249,0.00007282698,0.000046521687,0.000064752654,0.00006304212,0.79813856,0.0022161184,0.18692645,0.00037312566],"about_ca_topic_score_codex":0.000012318102,"about_ca_topic_score_gemma":0.000027031207,"teacher_disagreement_score":0.111676484,"about_ca_system_score_codex":0.0004757049,"about_ca_system_score_gemma":0.00014207413,"threshold_uncertainty_score":0.5932166},"labels":[],"label_agreement":null},{"id":"W2325021350","doi":"10.1152/ajpgi.2000.279.3.g641","title":"Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis","year":2000,"lang":"en","type":"article","venue":"American Journal of Physiology-Gastrointestinal and Liver Physiology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Proinflammatory cytokine; Poly ADP ribose polymerase; Nitrotyrosine; Inflammation; Oxidative stress; Tumor necrosis factor alpha; Cytokine; Nitric oxide synthase; Colitis; Chemistry; Intestinal permeability; Nitric oxide; Immunology; Biology; Cancer research; Molecular biology; Biochemistry; Endocrinology; Polymerase; Enzyme","score_opus":0.011126234688084794,"score_gpt":0.25175517804110314,"score_spread":0.24062894335301835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325021350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867314,0.00047883624,0.00017086677,0.00039235363,0.00002621411,0.00013990774,0.00003253825,0.000008221698,0.00007793921],"genre_scores_gemma":[0.9966008,0.00045620883,0.002361113,0.00017580019,0.00034100752,0.000007553081,0.000018696182,0.000016331114,0.000022478449],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982974,0.0002010236,0.0008221771,0.00022773247,0.00015821349,0.00029345026],"domain_scores_gemma":[0.9983939,0.00016752345,0.0008958202,0.00016378696,0.00025997407,0.00011901703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016600716,0.00020513943,0.0008794875,0.00026776065,0.000030520474,0.0000021888275,0.00008963171,0.000045925248,0.00024147429],"category_scores_gemma":[0.0000391378,0.0001775919,0.00015889223,0.00026678707,0.0011863837,0.0001455777,0.000026732612,0.00032613537,0.0000037199807],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036764862,0.00025236365,0.0010121524,0.000114683906,0.00005229168,0.0000132099385,0.00032803594,0.0014885742,0.9722583,0.00012581823,0.000038541464,0.020639515],"study_design_scores_gemma":[0.009711536,0.027088903,0.5034172,0.0030243185,0.0002134686,0.0032096796,0.000793074,0.020079872,0.4266777,0.005281848,0.000051385985,0.00045100972],"about_ca_topic_score_codex":0.000262007,"about_ca_topic_score_gemma":0.00000920901,"teacher_disagreement_score":0.5455806,"about_ca_system_score_codex":0.000096005904,"about_ca_system_score_gemma":0.00026718242,"threshold_uncertainty_score":0.7241987},"labels":[],"label_agreement":null},{"id":"W2328487159","doi":"10.1016/j.jns.2013.07.2104","title":"Investigating the role of poly-(ADP-Ribose)-polymerase as a therapeutic target in pediatric high grade glioma","year":2013,"lang":"en","type":"article","venue":"Journal of the Neurological Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Poly ADP ribose polymerase; Polymerase; Cancer research; Glioma; Medicine; Chemistry; Enzyme; Biochemistry","score_opus":0.030668437422958512,"score_gpt":0.2963935921495678,"score_spread":0.2657251547266093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328487159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95269895,0.0032090228,0.0000041333697,0.0431709,0.0003388919,0.00021235217,0.0000010715005,0.00000769308,0.00035697437],"genre_scores_gemma":[0.993021,0.000108936176,0.0003030036,0.0060929237,0.00044424532,0.000008619125,6.610312e-8,0.0000055492264,0.000015655907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978243,0.0004027651,0.0005521357,0.00016484327,0.00077439216,0.00028157388],"domain_scores_gemma":[0.9984841,0.0005163315,0.0006149349,0.00017688886,0.00008448777,0.00012330341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009538299,0.00012420656,0.00028028782,0.00014337305,0.00017233448,0.0000423331,0.00067090493,0.00007019481,0.0002505687],"category_scores_gemma":[0.00043269322,0.000051257757,0.00016086161,0.0010924496,0.00077027176,0.00017665573,0.00007734211,0.0005216671,0.00000840959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011948452,0.0003758559,0.78197503,0.000013417025,0.000024327182,0.000030675026,0.0005184049,0.000374043,0.21017598,0.0013882234,0.00047739234,0.004527163],"study_design_scores_gemma":[0.0014362488,0.002782773,0.80550945,0.00005133931,0.000060195078,0.0008179356,0.00025868096,0.0009134406,0.06432548,0.12314111,0.0005751785,0.000128156],"about_ca_topic_score_codex":0.00010987213,"about_ca_topic_score_gemma":0.0000019588506,"teacher_disagreement_score":0.1458505,"about_ca_system_score_codex":0.000020509839,"about_ca_system_score_gemma":0.00018245321,"threshold_uncertainty_score":0.28380984},"labels":[],"label_agreement":null},{"id":"W2331070389","doi":"10.1097/01.cot.0000294165.37549.61","title":"Old Drugs Taught New Tricks","year":2004,"lang":"en","type":"article","venue":"Oncology Times","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Radiation therapy; Erythropoietin; Anemia; Colorectal cancer; Pharmacology; Internal medicine","score_opus":0.020519520077396877,"score_gpt":0.3364765921975359,"score_spread":0.315957072120139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331070389","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061939873,0.0019084148,0.0019407666,0.08788111,0.0010672162,0.0005695406,0.000008794303,0.00035686826,0.8443274],"genre_scores_gemma":[0.44931203,0.000618015,0.020093717,0.036920473,0.0028265787,0.000098186094,0.000056687408,0.000079430974,0.48999488],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915713,0.000027797962,0.00020441278,0.00021926269,0.00015313702,0.00023823624],"domain_scores_gemma":[0.9993831,0.00007007334,0.00007473625,0.00024000612,0.000046120032,0.00018597083],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012213306,0.00011818753,0.00029521468,0.00010158278,0.000051984636,0.000005901021,0.00007834571,0.0001843715,0.004087696],"category_scores_gemma":[0.000033467193,0.00010414179,0.00008927331,0.00019703785,0.00010551709,0.000054386997,0.000018736591,0.00021540378,0.0013209332],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084085413,0.00061062194,0.0014314239,0.000026870752,0.00020692658,0.00029419066,0.0026405398,0.00006206279,0.010437351,0.012933968,0.84980994,0.12070526],"study_design_scores_gemma":[0.009233913,0.0007500693,0.0009054187,0.00004811612,0.000060551403,0.00020459328,0.00012028843,0.0000037965017,0.017183555,0.007879551,0.9634885,0.000121652374],"about_ca_topic_score_codex":0.00010629362,"about_ca_topic_score_gemma":0.000007852651,"teacher_disagreement_score":0.38737214,"about_ca_system_score_codex":0.00048205236,"about_ca_system_score_gemma":0.000860112,"threshold_uncertainty_score":0.99945664},"labels":[],"label_agreement":null},{"id":"W2332693961","doi":"10.1107/s0108767311092750","title":"ADP-Mg<sup>2+</sup>bound to the ATP-grasp domain of human ATP-citrate lyase","year":2011,"lang":"en","type":"article","venue":"Acta Crystallographica Section A Foundations of Crystallography","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"ATP citrate lyase; Lyase; Chemistry; Domain (mathematical analysis); Adenosine triphosphate; GRASP; Adenosine diphosphate; Biochemistry; Enzyme; Citrate synthase; Computer science; Biology; Mathematics; Platelet","score_opus":0.03307831639457615,"score_gpt":0.29180448927944697,"score_spread":0.2587261728848708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332693961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789787,0.00018123923,0.005144105,0.0025124492,0.0003664774,0.0021134655,0.00017810173,0.00031794014,0.0102075245],"genre_scores_gemma":[0.99389464,0.00018268499,0.0036233624,0.0011105273,0.00026524882,0.000453559,0.00022576253,0.00011399259,0.00013020729],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99544877,0.0003258889,0.0016163476,0.00086975005,0.0010210094,0.0007182279],"domain_scores_gemma":[0.99567854,0.00021386964,0.0008600558,0.0017242737,0.0010755475,0.00044770679],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010250432,0.000612017,0.00091905333,0.00271838,0.0007465392,0.0000819479,0.0006864976,0.0003814035,0.0012920017],"category_scores_gemma":[0.00011087902,0.0005280686,0.0011369071,0.005209562,0.0015786007,0.00050700805,0.00013550496,0.00063981826,0.0000034825748],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021122217,0.0027550946,0.032498468,0.0004227606,0.0023931176,0.000024119492,0.016685817,0.00019225756,0.9296304,0.0069847573,0.0055975174,0.0007034903],"study_design_scores_gemma":[0.013093439,0.009445437,0.27137136,0.0010817412,0.001788251,0.000485158,0.012706657,0.00018549997,0.0057643377,0.033284258,0.6484898,0.0023040636],"about_ca_topic_score_codex":0.0007500572,"about_ca_topic_score_gemma":0.00040778265,"teacher_disagreement_score":0.92386603,"about_ca_system_score_codex":0.00010429175,"about_ca_system_score_gemma":0.00024680744,"threshold_uncertainty_score":0.9997171},"labels":[],"label_agreement":null},{"id":"W2335082354","doi":"10.1021/jp1118663","title":"Linking Distinct Conformations of Nicotinamide Adenine Dinucleotide with Protein Fold/Function","year":2011,"lang":"en","type":"article","venue":"The Journal of Physical Chemistry B","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Nicotinamide adenine dinucleotide; Fold (higher-order function); Chemistry; Biochemistry; Biophysics; Biology; NAD+ kinase; Enzyme; Computer science","score_opus":0.02069299728995471,"score_gpt":0.2521254123955661,"score_spread":0.23143241510561136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335082354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913986,0.00003695607,0.0026408604,0.00018090887,0.000017363574,0.00012355638,0.0000045006855,0.00001260973,0.0055846944],"genre_scores_gemma":[0.9990432,0.000003622832,0.00032112421,0.00003822982,0.0003809962,0.0000040790615,0.0000032725009,0.000013238139,0.00019218816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991509,0.000022990629,0.00033333187,0.000053519983,0.00032632897,0.000112939604],"domain_scores_gemma":[0.9988904,0.000059360926,0.0005128515,0.0001824821,0.0002751663,0.000079731704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001903766,0.000103463884,0.00024563156,0.000018773928,0.00004949362,0.000004515649,0.000120518365,0.000030436231,0.00016374626],"category_scores_gemma":[0.000037784113,0.000059510752,0.00010681232,0.00012675859,0.00016435285,0.000114103605,0.000016475276,0.00033267165,0.0000040468744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019765925,0.00029002238,0.0007977961,0.00018905161,0.00014458549,0.0000060964667,0.0011543455,0.000031853655,0.9945427,0.00013436287,0.000088100256,0.0006444656],"study_design_scores_gemma":[0.0017768372,0.0007579809,0.0037510274,0.0007796859,0.00025611385,0.00023601903,0.00025127927,0.0002778703,0.9905203,0.0010862249,0.00022579655,0.00008087178],"about_ca_topic_score_codex":0.000005516869,"about_ca_topic_score_gemma":4.2024828e-7,"teacher_disagreement_score":0.007644699,"about_ca_system_score_codex":0.000052507057,"about_ca_system_score_gemma":0.00008651852,"threshold_uncertainty_score":0.24267781},"labels":[],"label_agreement":null},{"id":"W2336997490","doi":"10.1158/1535-7163.targ-15-c185","title":"Abstract C185: Targeting PARP and DNA as a novel unimolecular combination model for the enhancement of chemosensitivity","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Olaparib; Synthetic lethality; DNA repair; Poly ADP ribose polymerase; Biology; Cancer research; DNA damage; PARP inhibitor; Programmed cell death; DNA; Polymerase; Genetics; Apoptosis","score_opus":0.07282148049106738,"score_gpt":0.3465300539674201,"score_spread":0.2737085734763527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336997490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6158332,0.004283262,0.3739222,0.0043490543,0.0001686332,0.0010183092,0.000038672286,0.00003186558,0.0003547501],"genre_scores_gemma":[0.99210054,0.00044365923,0.0030849385,0.003958845,0.000055966128,0.00018588346,0.00002652084,0.000048098485,0.00009556151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998659,0.000034130404,0.00032088495,0.00028249546,0.0004484566,0.00025503195],"domain_scores_gemma":[0.9987988,0.00007746973,0.000214675,0.00031744243,0.0004813334,0.00011026983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006198287,0.00020246427,0.0002906314,0.000051814088,0.00008098835,0.000021123973,0.000093227834,0.00009463487,0.000008765296],"category_scores_gemma":[0.000038583712,0.00016616954,0.00010908763,0.00014840688,0.00016308286,0.000053709133,0.000032470794,0.00016099887,0.0000011835764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004224037,0.00023313433,0.00006247206,0.000103943436,0.000345019,0.0000042371016,0.0010494338,0.0016094799,0.986151,0.0010685842,0.00012809465,0.008822233],"study_design_scores_gemma":[0.004630536,0.00025315458,0.00025407944,0.000120098535,0.00027501112,0.000009924431,0.00018935336,0.10620579,0.8823849,0.0021068067,0.0033707817,0.00019959245],"about_ca_topic_score_codex":0.0000655559,"about_ca_topic_score_gemma":0.000005590075,"teacher_disagreement_score":0.37626728,"about_ca_system_score_codex":0.00019101067,"about_ca_system_score_gemma":0.00035070186,"threshold_uncertainty_score":0.6776197},"labels":[],"label_agreement":null},{"id":"W2337001617","doi":"10.1007/s10637-016-0351-x","title":"A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Irinotecan; Medicine; Tolerability; Internal medicine; Regimen; Oncology; Neutropenia; PARP inhibitor; Colorectal cancer; Cancer; Chemotherapy; Adverse effect","score_opus":0.036393349825994216,"score_gpt":0.33026345964885223,"score_spread":0.293870109822858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337001617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454755,0.00016964084,0.0000067751907,0.0034040757,0.00012736922,0.0012639953,0.00035683432,0.000015470247,0.00010826449],"genre_scores_gemma":[0.99845564,0.00003392952,0.00017463703,0.00075298257,0.00017601048,0.0002560842,0.000035709087,0.000023330847,0.000091692185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983245,0.00012898407,0.0005249812,0.0003158844,0.0004660138,0.00023959685],"domain_scores_gemma":[0.99873996,0.00019901356,0.00026576742,0.00013523121,0.00017346328,0.00048656276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033631548,0.00017463682,0.00047920027,0.0003031239,0.00005355698,0.00001140658,0.00007355631,0.00007604884,0.00028488267],"category_scores_gemma":[0.00014637638,0.00012103557,0.000028935425,0.00034716594,0.00022262664,0.00014809507,0.000014135012,0.00012138501,0.0000022989143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016137953,0.0008042946,0.96928036,0.000025872207,0.00017802368,0.0000065664976,0.003229273,0.000015431846,0.003150508,0.0003103803,0.0015396769,0.019845832],"study_design_scores_gemma":[0.080158696,0.0030677537,0.90633535,0.0008763774,0.00011606361,0.000002919999,0.00026802576,0.000014836992,0.0064868033,0.0008607513,0.0015345282,0.00027786498],"about_ca_topic_score_codex":0.1690231,"about_ca_topic_score_gemma":0.20894493,"teacher_disagreement_score":0.07854491,"about_ca_system_score_codex":0.0005828143,"about_ca_system_score_gemma":0.0022822442,"threshold_uncertainty_score":0.8365104},"labels":[],"label_agreement":null},{"id":"W2344035998","doi":"10.12688/f1000research.8463.2","title":"An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells","year":2016,"lang":"en","type":"preprint","venue":"F1000Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Cancer Research UK","keywords":"Poly ADP ribose polymerase; DNA damage; Molecular biology; Biochemistry; DNA repair; Biology; Enzyme; DNA; Chemistry; Polymerase","score_opus":0.0851539735101146,"score_gpt":0.41200234827751153,"score_spread":0.3268483747673969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344035998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92252016,0.0011818546,0.010257286,0.029807279,0.0021348824,0.0068444973,0.0019099779,0.00054181943,0.024802214],"genre_scores_gemma":[0.9903266,0.00018656444,0.0008737232,0.00076482724,0.0021404347,0.00090690545,0.00008778115,0.00018881232,0.0045243627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9929329,0.0013364832,0.0005698342,0.0014920617,0.002394175,0.0012745333],"domain_scores_gemma":[0.99527335,0.00043124353,0.0001487571,0.0024387192,0.00049176195,0.0012161835],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0038934534,0.0005610426,0.0009650473,0.0012893816,0.00011725207,0.00013039363,0.0009341042,0.00083178515,0.0020118952],"category_scores_gemma":[0.0003718903,0.00048511033,0.00025524574,0.00070142216,0.00024570726,0.00019267734,0.0007398103,0.002613428,0.0013080146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004719301,0.0010931342,0.0040614246,0.00043956898,0.00015480732,0.0005986366,0.0006776756,0.00008155626,0.9243914,0.000063137115,0.033113033,0.030606339],"study_design_scores_gemma":[0.0063021933,0.00110635,0.018800562,0.0028413306,0.000053915563,0.000046444893,0.00006427395,0.0009996354,0.92481625,0.0026672636,0.041236162,0.0010656026],"about_ca_topic_score_codex":0.0010153754,"about_ca_topic_score_gemma":0.00021668326,"teacher_disagreement_score":0.0678064,"about_ca_system_score_codex":0.001970157,"about_ca_system_score_gemma":0.00211033,"threshold_uncertainty_score":0.99976003},"labels":[],"label_agreement":null},{"id":"W2394589397","doi":"10.1038/srep22167","title":"Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; University of Toronto; National Natural Science Foundation of China; University of Rochester; Université Laval; National Cancer Institute; National Institutes of Health; Cincinnati Children's Hospital Medical Center","keywords":"PARP1; FANCA; Fanconi anemia; Synthetic lethality; Progenitor cell; Haematopoiesis; Homologous recombination; Cancer research; DNA damage; Biology; DNA repair; Non-homologous end joining; Stem cell; FANCD2; Cell biology; Poly ADP ribose polymerase; Genetics; DNA; Polymerase","score_opus":0.024604773780230425,"score_gpt":0.2815532780821671,"score_spread":0.2569485043019367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394589397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507016,0.00046502225,0.0005394111,0.0005372625,0.0018319649,0.0011150868,0.000019105033,0.000079375866,0.00034261215],"genre_scores_gemma":[0.99693656,0.000020675385,0.0013134596,0.000079771606,0.00009911545,0.00020245169,0.0000057308816,0.000025131527,0.0013170784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975717,0.000080130354,0.000512498,0.0010426347,0.00037468597,0.00041834151],"domain_scores_gemma":[0.99842435,0.00023208982,0.00031863875,0.0005529672,0.00022943642,0.00024250011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013760498,0.0002087467,0.00042553147,0.0001052458,0.0003251129,0.000087227454,0.00004956176,0.00014790683,0.000057554153],"category_scores_gemma":[0.00015714034,0.00013757878,0.0000789902,0.00016881616,0.00085109257,0.0001050533,0.00005198953,0.00011486746,0.000004771156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002918385,0.000083980594,0.0028306837,0.00018681852,0.000022359975,0.0008096091,0.0006617028,1.7238413e-7,0.9830191,0.000038588783,0.0014112415,0.010643894],"study_design_scores_gemma":[0.0011365553,0.0004471292,0.003607084,0.00041002777,0.000075016105,0.0049049924,0.0002696016,0.00000825773,0.98022217,0.0032799302,0.0053885425,0.000250706],"about_ca_topic_score_codex":0.000003840354,"about_ca_topic_score_gemma":0.0000030597157,"teacher_disagreement_score":0.010393188,"about_ca_system_score_codex":0.00013579163,"about_ca_system_score_gemma":0.00023366697,"threshold_uncertainty_score":0.56103},"labels":[],"label_agreement":null},{"id":"W2394806078","doi":"10.1158/1557-3265.ovca15-a11","title":"Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Loss of heterozygosity; PARP inhibitor; Ovarian cancer; Olaparib; Biology; Cancer research; Synthetic lethality; Single-nucleotide polymorphism; Cancer; Genetics; Genotype; DNA repair; Gene; Allele; Poly ADP ribose polymerase","score_opus":0.20544118528878735,"score_gpt":0.5203825821443089,"score_spread":0.3149413968555215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394806078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96303993,0.0011672036,0.00007289694,0.030084796,0.001699169,0.002243273,0.0011504185,0.000087044245,0.00045526944],"genre_scores_gemma":[0.98376936,0.0007443602,0.00027101874,0.0077498187,0.004788698,0.0017784876,0.00005126588,0.0001210471,0.0007259316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939996,0.00040797595,0.0013839345,0.0012367762,0.0017960216,0.0011756809],"domain_scores_gemma":[0.9932846,0.0030520242,0.00028814096,0.0012292963,0.0012744233,0.0008715308],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0032497756,0.00034945307,0.00073807937,0.00019049831,0.0004086194,0.00013868567,0.00077253074,0.00027746038,0.004501434],"category_scores_gemma":[0.001534211,0.00021227358,0.00033854588,0.00065007753,0.0006725979,0.00016991064,0.00027016576,0.0013456342,0.00083746575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064335004,0.0006832248,0.83069575,0.000102484344,0.00027670682,0.00004241616,0.00020638388,0.000033445718,0.049493708,0.00012615198,0.054508526,0.05739773],"study_design_scores_gemma":[0.00818752,0.00056839344,0.90361345,0.0018910422,0.00005573603,6.315067e-7,0.00004933702,0.000035236077,0.0365946,0.00075318204,0.047912586,0.00033826355],"about_ca_topic_score_codex":0.0036034165,"about_ca_topic_score_gemma":0.0010860395,"teacher_disagreement_score":0.07291775,"about_ca_system_score_codex":0.0011566898,"about_ca_system_score_gemma":0.0019563844,"threshold_uncertainty_score":0.9999405},"labels":[],"label_agreement":null},{"id":"W2396152701","doi":"10.1158/1557-3265.ovca15-ia06","title":"Abstract IA06: Regulation of BRCA1- and BRCA2-dependent DNA repair.","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Olaparib; PALB2; Synthetic lethality; DNA repair; Cancer research; PARP inhibitor; Homologous recombination; Ovarian cancer; Cancer; DNA damage; Poly ADP ribose polymerase; BRCA2 Protein; Medicine; Biology; Polymerase; Mutation; DNA; Genetics; Gene; Germline mutation","score_opus":0.291583553690724,"score_gpt":0.5529012675953581,"score_spread":0.2613177139046341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396152701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98216736,0.0016150526,0.000053566848,0.009201571,0.00027607262,0.00052355934,0.000038592676,0.00006992907,0.006054307],"genre_scores_gemma":[0.9914963,0.003998658,0.00016315014,0.00024860507,0.00074286415,0.00008065887,0.0000030375911,0.000027894821,0.0032388037],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972381,0.00023957116,0.0007457297,0.0004941519,0.0009318782,0.0003505584],"domain_scores_gemma":[0.9970892,0.0013122923,0.00014199926,0.0005778479,0.00059075054,0.00028790513],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037818826,0.000106835425,0.00037336766,0.00014932704,0.00007272463,0.000010805888,0.00011852639,0.0001984259,0.0031057475],"category_scores_gemma":[0.0009920552,0.00007211127,0.00014946098,0.00022771019,0.0008166413,0.0001055587,0.00008564942,0.00041994642,0.000080465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066471645,0.0007317736,0.25047266,0.0005358389,0.00037221643,0.000053573083,0.0002245728,0.0000019361762,0.3402953,0.0022146697,0.057595298,0.34085497],"study_design_scores_gemma":[0.005989211,0.000774194,0.9098946,0.0009524918,0.000026309943,0.000012277738,0.000044746423,0.000019506586,0.047713194,0.0028677399,0.031570423,0.00013533857],"about_ca_topic_score_codex":0.0001608959,"about_ca_topic_score_gemma":0.000057770445,"teacher_disagreement_score":0.65942186,"about_ca_system_score_codex":0.00024738058,"about_ca_system_score_gemma":0.00047441846,"threshold_uncertainty_score":0.99780554},"labels":[],"label_agreement":null},{"id":"W2400892605","doi":"","title":"A sensitive assay for the evaluation of cytotoxicity and its pharmacologic modulation in human solid tumor-derived cell lines exposed to cancer-therapeutic agents.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Clonogenic assay; Cytotoxicity; Cancer cell; MTT assay; Cancer research; Radiosensitivity; Cancer; Cisplatin; Cell culture; Biology; In vitro; Chemistry; Pharmacology; Medicine; Chemotherapy; Internal medicine; Radiation therapy; Biochemistry; Genetics","score_opus":0.16803500957553372,"score_gpt":0.4078637624087322,"score_spread":0.23982875283319846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400892605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904433,0.00044996856,0.002328479,0.000822192,0.00014729066,0.0056105955,0.000023025532,0.00002333531,0.00015183356],"genre_scores_gemma":[0.9946999,0.00004282591,0.000059965056,0.0015317606,0.00020326726,0.0033821426,0.000011619316,0.000017400134,0.000051132785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986484,0.00015134366,0.00033819757,0.00023276737,0.0003536744,0.0002756181],"domain_scores_gemma":[0.9989419,0.00025984432,0.00017912725,0.00011146543,0.00042105245,0.00008664074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028057275,0.00012350886,0.00022890506,0.00014935902,0.000076286844,0.000007971323,0.000049519385,0.000054631942,0.000025943094],"category_scores_gemma":[0.00011656985,0.00009823759,0.00004786329,0.0002376837,0.000041010557,0.0000603864,0.0000150152355,0.0000950585,5.2770355e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078507647,0.00014315791,0.00173137,0.000057081394,0.000061391926,0.0000021518308,0.0009999808,0.002066577,0.9598505,0.0000090215035,0.000058995185,0.03423473],"study_design_scores_gemma":[0.0034037782,0.00006039209,0.37402362,0.000018857025,0.00009747826,0.0000017208941,0.00011956155,0.012218604,0.6098778,0.00008493536,0.000026831005,0.00006636519],"about_ca_topic_score_codex":0.000031293937,"about_ca_topic_score_gemma":0.00009776034,"teacher_disagreement_score":0.37229225,"about_ca_system_score_codex":0.0003578436,"about_ca_system_score_gemma":0.000060428614,"threshold_uncertainty_score":0.40060127},"labels":[],"label_agreement":null},{"id":"W2401412515","doi":"10.1016/j.molbiopara.2016.05.012","title":"An Entamoeba histolytica ADP-ribosyl transferase from the diphtheria toxin family modifies the bacterial elongation factor Tu","year":2016,"lang":"en","type":"article","venue":"Molecular and Biochemical Parasitology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Consejo Nacional de Ciencia y Tecnología; Technische Universiteit Eindhoven","keywords":"Elongation factor; Diphtheria toxin; Biology; ADP-ribosylation; Transferase; NAD+ kinase; Escherichia coli; Biochemistry; Shiga toxin; Cholera toxin; ADP ribosylation factor; Molecular biology; Enzyme; Microbiology; Toxin; Gene; RNA","score_opus":0.0164300814039071,"score_gpt":0.2982691427412936,"score_spread":0.2818390613373865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401412515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834274,0.0006506102,0.0040924344,0.010942172,0.00027809816,0.0003307074,0.00012169072,0.000047310332,0.0001095488],"genre_scores_gemma":[0.9966526,0.00009444032,0.00013055361,0.0025894642,0.00033422123,0.000054968394,0.000098743105,0.000021296795,0.00002368879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987468,0.00019111368,0.0002494203,0.00037905932,0.00018183372,0.00025173454],"domain_scores_gemma":[0.9991389,0.00020515025,0.0000498414,0.00042767593,0.000049459264,0.00012898714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008339585,0.00019933542,0.0002647833,0.00002181723,0.00010479189,0.00002486197,0.00017286044,0.00020543905,0.0003001382],"category_scores_gemma":[0.000050834136,0.000096040836,0.00009974589,0.0000658757,0.0005046116,0.000047734935,0.00001907652,0.00015662552,0.000023248407],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000817954,0.00007647149,0.0018076054,0.0000043767477,0.000072738774,0.000018776067,0.00023202413,1.1741231e-7,0.9924059,0.00016871489,0.00090857886,0.0034867437],"study_design_scores_gemma":[0.0020235532,0.0002469574,0.023280524,0.000036287234,0.000086789085,0.00004736741,0.000059076978,0.000019106117,0.9700355,0.00096838025,0.0030308198,0.00016563042],"about_ca_topic_score_codex":0.00008622561,"about_ca_topic_score_gemma":0.0000074215327,"teacher_disagreement_score":0.02237039,"about_ca_system_score_codex":0.000060631413,"about_ca_system_score_gemma":0.000055207864,"threshold_uncertainty_score":0.39164317},"labels":[],"label_agreement":null},{"id":"W2404249197","doi":"10.1016/j.bulcan.2015.07.012","title":"De la découverte du poly(ADP-ribose) aux inhibiteurs PARP en thérapie du cancer","year":2015,"lang":"fr","type":"review","venue":"Bulletin du Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Olaparib; Synthetic lethality; PARP inhibitor; Poly ADP ribose polymerase; Cancer research; DNA repair; Homologous recombination; Ovarian cancer; Cancer; Biology; Medicine; Polymerase; Gene; Genetics","score_opus":0.03400659078244042,"score_gpt":0.35272212096881295,"score_spread":0.31871553018637255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404249197","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040669137,0.92596817,0.00031568136,0.040275954,0.0115492325,0.0026215252,0.0017310625,0.00038462158,0.01674704],"genre_scores_gemma":[0.0007482203,0.9162761,0.00043416346,0.010637587,0.03809706,0.0047844676,0.00025730938,0.00067736296,0.028087754],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9885876,0.002552097,0.0023139818,0.0021413013,0.0018956934,0.0025093008],"domain_scores_gemma":[0.99212176,0.0016906376,0.0015930737,0.0016633084,0.0012233855,0.0017078614],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.003842955,0.0022608885,0.0043985993,0.0005481499,0.0005829515,0.0002933765,0.0013345475,0.0021789945,0.06763544],"category_scores_gemma":[0.0008865495,0.0021097192,0.001459496,0.0011246655,0.0015754902,0.00016472676,0.00047021458,0.002872849,0.003749279],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00035817482,0.00041893125,0.0023874904,0.006272373,0.001270239,0.0004833903,0.0011847984,0.00009022251,0.000042443327,0.0007654943,0.62361974,0.36310673],"study_design_scores_gemma":[0.0069710636,0.0002922614,0.0005848776,0.04356097,0.0030922184,0.0008216926,0.00018737614,0.00010179508,0.0001352172,0.0001765719,0.9420972,0.001978759],"about_ca_topic_score_codex":0.009689887,"about_ca_topic_score_gemma":0.0002533009,"teacher_disagreement_score":0.36112797,"about_ca_system_score_codex":0.009767938,"about_ca_system_score_gemma":0.012973151,"threshold_uncertainty_score":0.99942756},"labels":[],"label_agreement":null},{"id":"W2418205348","doi":"10.1007/978-1-61779-270-0_7","title":"Affinity-Based Assays for the Identification and Quantitative Evaluation of Noncovalent Poly(ADP-Ribose)-Binding Proteins","year":2011,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Effector; Poly ADP ribose polymerase; Cell biology; Cell signaling; Computational biology; Chemistry; Signal transduction; Immunoprecipitation; Ribose; Protein–protein interaction; Biology; Polymerase; Biochemistry; DNA; Enzyme","score_opus":0.22733936039812433,"score_gpt":0.512155520309216,"score_spread":0.28481615991109166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418205348","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060364895,0.0012292375,0.93573076,0.0005307221,0.00018659647,0.0017018429,0.000022451211,0.000011984618,0.00022149594],"genre_scores_gemma":[0.20031473,0.000025546135,0.7986006,0.00018232051,0.000023770546,0.0007996935,0.000029223504,0.000015011969,0.000009109203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974639,0.0015851475,0.00039433988,0.0002608556,0.00014685893,0.00014890982],"domain_scores_gemma":[0.9984895,0.0006321353,0.0002654975,0.00028535764,0.00029994885,0.000027586451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007883258,0.00010550169,0.0002389843,0.00018723201,0.000051080577,0.0000040885443,0.000087005756,0.00012093007,0.000041036597],"category_scores_gemma":[0.0015797709,0.00008064119,0.000072656025,0.00021373297,0.00021744767,0.00002174003,0.00001870528,0.00012351564,0.0000010764169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032581296,0.00009011154,0.0012984392,0.000052159194,0.00006536542,6.8341035e-7,0.00057516334,0.000019371219,0.9677104,0.006995539,0.0000056401077,0.022861337],"study_design_scores_gemma":[0.0022725482,0.00049599237,0.0036686882,0.00006343488,0.00016138049,0.0000039865445,0.00022663857,0.0072052684,0.9716258,0.013986623,0.00020461548,0.00008503953],"about_ca_topic_score_codex":0.000042699743,"about_ca_topic_score_gemma":0.000007792254,"teacher_disagreement_score":0.13994983,"about_ca_system_score_codex":0.00009114901,"about_ca_system_score_gemma":0.00015099275,"threshold_uncertainty_score":0.32884526},"labels":[],"label_agreement":null},{"id":"W2441019106","doi":"10.1158/1538-7445.am2015-4670","title":"Abstract 4670: A novel companion diagnostic predicts response to the PARP inhibitor rucaparib in ovarian cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Germline; Loss of heterozygosity; Ovarian cancer; Indel; Biology; Genetics; PARP inhibitor; Cancer research; Cancer; Computational biology; Single-nucleotide polymorphism; Gene; Allele; Genotype","score_opus":0.18959289508511318,"score_gpt":0.4556190603433872,"score_spread":0.26602616525827405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2441019106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9379356,0.0031010956,0.00011075336,0.053995848,0.001040191,0.0022846828,0.00023678597,0.00008778748,0.0012072591],"genre_scores_gemma":[0.9916289,0.00047107012,0.000109521745,0.001924379,0.0017620096,0.0031370253,0.00001846107,0.0000687377,0.0008798915],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9958015,0.00043283956,0.0004984054,0.00061706814,0.0016948764,0.0009552826],"domain_scores_gemma":[0.9960395,0.0015218183,0.00008124723,0.00079200603,0.0008017921,0.0007636252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045544114,0.00024167566,0.00039930927,0.0005064337,0.00018280126,0.00009127884,0.0004254026,0.0001738324,0.0006771815],"category_scores_gemma":[0.0027227462,0.00018353392,0.00007217954,0.0015919352,0.0003035659,0.00015467971,0.0001689076,0.0011935062,0.0002760486],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024121746,0.00094930816,0.048409455,0.00023274918,0.00015384075,0.00027980865,0.01138177,0.0033992971,0.33518052,0.00029171733,0.5690793,0.0065205125],"study_design_scores_gemma":[0.015240887,0.000981585,0.53785425,0.003146297,0.000035676632,0.00004952985,0.0016772798,0.00032620048,0.052141085,0.00025686357,0.3877894,0.0005009265],"about_ca_topic_score_codex":0.0067065377,"about_ca_topic_score_gemma":0.0032841878,"teacher_disagreement_score":0.4894448,"about_ca_system_score_codex":0.0025486483,"about_ca_system_score_gemma":0.003214896,"threshold_uncertainty_score":0.9999079},"labels":[],"label_agreement":null},{"id":"W2460121490","doi":"10.18632/oncotarget.10308","title":"Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Genome Canada; McGill University Health Centre; Université de Montréal; Université Laval; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"PARP inhibitor; Serous ovarian cancer; Poly ADP ribose polymerase; Cancer research; Ovarian cancer; DNA damage; Serous fluid; Epithelial ovarian cancer; DNA repair; Medicine; Olaparib; Cancer; Biology; Oncology; DNA; Internal medicine; Genetics; Polymerase","score_opus":0.02471521672673271,"score_gpt":0.29488875235394735,"score_spread":0.27017353562721463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460121490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878634,0.000872063,0.00006321496,0.007753236,0.00078375597,0.0009176862,0.00021815326,0.00015508663,0.00045044304],"genre_scores_gemma":[0.994374,0.0005568955,0.00066345965,0.0018626372,0.0009874933,0.00040287143,0.000014261207,0.00006834972,0.0010700353],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9971081,0.0006910533,0.0006079421,0.0005787659,0.00045234276,0.00056178676],"domain_scores_gemma":[0.99800307,0.00086751126,0.000219307,0.00061886,0.00012348854,0.0001677598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010497767,0.00033059396,0.0005172907,0.00017873404,0.0000888298,0.0000149883335,0.00017413645,0.00023245775,0.00038746378],"category_scores_gemma":[0.00028681426,0.0002000535,0.0001711459,0.0005131699,0.00019010213,0.00020022887,0.00006470759,0.00035478186,0.000092982526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013890668,0.0007555971,0.13992679,0.000070882736,0.000080799626,0.000536967,0.0073360205,0.00020078082,0.82758796,0.0004897608,0.008316846,0.0008069524],"study_design_scores_gemma":[0.026262498,0.0015506608,0.52092683,0.0017639669,0.00007559726,0.000042817497,0.0007059621,0.00029791688,0.39493588,0.003451353,0.04919254,0.00079396594],"about_ca_topic_score_codex":0.0015913291,"about_ca_topic_score_gemma":0.0021701471,"teacher_disagreement_score":0.43265206,"about_ca_system_score_codex":0.0011922584,"about_ca_system_score_gemma":0.0006003757,"threshold_uncertainty_score":0.8157945},"labels":[],"label_agreement":null},{"id":"W2462294917","doi":"10.1111/gtc.12387","title":"Synovial sarcoma cell lines showed reduced <scp>DNA</scp> repair activity and sensitivity to a <scp>PARP</scp> inhibitor","year":2016,"lang":"en","type":"article","venue":"Genes to Cells","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Atomic Energy of Canada Limited; Japan Agency for Medical Research and Development","keywords":"Synovial sarcoma; PARP inhibitor; Biology; Sarcoma; Cancer research; Olaparib; Etoposide; Poly ADP ribose polymerase; Cell culture; RAD51; Carboplatin; Molecular biology; Temozolomide; DNA damage; Topoisomerase inhibitor; Topoisomerase; DNA; Chemotherapy; Polymerase; Cisplatin; Pathology; Medicine; Biochemistry; Genetics","score_opus":0.01893163251057881,"score_gpt":0.2698802266368934,"score_spread":0.2509485941263146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462294917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915147,0.00039777736,0.0008482518,0.0016494401,0.0013327808,0.0015312125,0.00022127837,0.00050506095,0.0019995377],"genre_scores_gemma":[0.9804432,0.00019917553,0.0030445762,0.0022954103,0.002529592,0.00015139572,0.000010063412,0.00013009815,0.011196506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99623317,0.00032953918,0.0005500663,0.0012426267,0.0006734373,0.000971148],"domain_scores_gemma":[0.996116,0.0012792262,0.00021704994,0.0010247331,0.00033904464,0.0010239634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078858936,0.0005972294,0.00086183,0.00035272643,0.00020522703,0.00006536196,0.0001380268,0.0003448826,0.000043240783],"category_scores_gemma":[0.00052293064,0.00048763448,0.00028847693,0.0005508146,0.00018290723,0.00018381748,0.0002671679,0.00025941458,0.00060597126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002131022,0.00032555373,0.0011403601,0.00013156046,0.000079348145,0.0001814736,0.00078683835,0.000013488171,0.93566173,0.0000044673966,0.05264263,0.008819453],"study_design_scores_gemma":[0.0026443384,0.0010568349,0.007131769,0.00027366664,0.00008647166,0.00011885526,0.00014863703,0.00004157097,0.8905851,0.00002877458,0.09773845,0.00014548346],"about_ca_topic_score_codex":0.00010199467,"about_ca_topic_score_gemma":0.00008594649,"teacher_disagreement_score":0.045095827,"about_ca_system_score_codex":0.0003198683,"about_ca_system_score_gemma":0.00029564564,"threshold_uncertainty_score":0.9997575},"labels":[],"label_agreement":null},{"id":"W2476746888","doi":"10.1385/0-89603-415-1:365","title":"Protein ADP-Ribosylation","year":2003,"lang":"en","type":"book-chapter","venue":"Humana Press eBooks","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"NAD+ kinase; ADP-ribosylation; Cofactor; Nicotinamide adenine dinucleotide; Biochemistry; Enzyme; Chemistry","score_opus":0.10327073325867672,"score_gpt":0.3091532891676797,"score_spread":0.20588255590900298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2476746888","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005207259,0.005112212,0.00017940172,0.0000771635,0.00025279733,0.0017747314,0.00004255723,0.00020801398,0.99230105],"genre_scores_gemma":[0.001331529,0.00021629907,0.0003740605,0.0010058418,0.00074140955,0.00024392598,0.00010725961,0.00017157015,0.9958081],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822325,0.00002672707,0.0004578141,0.00050837523,0.00051680725,0.00026701525],"domain_scores_gemma":[0.99859947,0.000018238576,0.00031090007,0.00074904837,0.00017420991,0.00014814158],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001328136,0.00041553544,0.0005249003,0.00016465505,0.00010500454,0.000034243592,0.00011937599,0.00045961887,0.0013912115],"category_scores_gemma":[0.000009326192,0.0004191717,0.00022309809,0.0000043826667,0.0001612917,0.000036339916,0.00003365748,0.0005812459,0.00013352426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003310001,0.000039441755,7.105979e-7,0.00063569145,0.00044829416,0.00015748592,0.00036304907,0.000002744084,0.0017342754,0.8984138,0.048701975,0.049171545],"study_design_scores_gemma":[0.0014000755,0.00016949465,0.000004141909,0.001038312,0.00015718656,0.000032847533,0.0000015913807,0.0000056915146,0.007757349,0.017267682,0.9717873,0.0003783757],"about_ca_topic_score_codex":0.000020683565,"about_ca_topic_score_gemma":0.00000930409,"teacher_disagreement_score":0.9230853,"about_ca_system_score_codex":0.00021521225,"about_ca_system_score_gemma":0.00009900073,"threshold_uncertainty_score":0.999826},"labels":[],"label_agreement":null},{"id":"W2479263976","doi":"10.1385/159259851x","title":"Death Receptors in Cancer Therapy","year":2005,"lang":"en","type":"book","venue":"Humana Press eBooks","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Emory University; University of Toronto; Abramson Family Cancer Research Institute; College of Medicine, Catholic University of Korea; Catholic University of Korea; Cancer Research Institute; University of South Carolina; School of Medicine, Emory University; Winship Cancer Institute; University of Texas MD Anderson Cancer Center; St. Jude Children's Research Hospital; University of Pennsylvania","keywords":"Receptor; Cancer therapy; Medicine; Cancer; Oncology; Internal medicine","score_opus":0.16076761697257075,"score_gpt":0.3740503745620925,"score_spread":0.21328275758952175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479263976","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030434298,0.050616458,0.000006330466,0.00013045978,0.0007223249,0.0012772238,0.000050449555,0.00018556435,0.94670683],"genre_scores_gemma":[0.00031059733,0.024299687,0.000112196874,0.0021741868,0.0028552471,0.0007017094,0.000093641414,0.00019353042,0.9692592],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774086,0.000061696475,0.0005746291,0.00063836883,0.00052907225,0.00045537757],"domain_scores_gemma":[0.99867946,0.00005272104,0.00027011987,0.0007242402,0.000110583045,0.00016286841],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016659067,0.00051049434,0.0007976238,0.0003117089,0.000065885884,0.000032031694,0.0002526307,0.0005442089,0.0019035834],"category_scores_gemma":[0.0000050314393,0.0004848014,0.00023395612,0.00001632563,0.0001503705,0.0000436668,0.00004568096,0.0009215631,0.00004779149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094271876,0.00017230162,0.00007031035,0.0003440875,0.000556294,0.00015165328,0.001977073,0.00002675367,0.000110779845,0.016142547,0.53121924,0.44828624],"study_design_scores_gemma":[0.0033656138,0.0001544787,0.000108241984,0.0013429633,0.000061446684,0.000011697469,0.0000038502358,0.0000066848106,0.0016056224,0.0011083499,0.9917878,0.00044323932],"about_ca_topic_score_codex":0.00043115998,"about_ca_topic_score_gemma":0.00022876814,"teacher_disagreement_score":0.46056855,"about_ca_system_score_codex":0.0011848962,"about_ca_system_score_gemma":0.00068538653,"threshold_uncertainty_score":0.9997604},"labels":[],"label_agreement":null},{"id":"W2485585585","doi":"10.1158/1538-7445.am2016-lb-205","title":"Abstract LB-205: Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for poor prognosis acute myeloid leukemia and triple-negative breast cancers","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Decitabine; PARP1; Azacitidine; PARP inhibitor; Cancer research; Triple-negative breast cancer; Poly ADP ribose polymerase; Olaparib; Breast cancer; Cancer; DNMT1; Myeloid leukemia; DNA damage; Biology; Chemistry; Methyltransferase; Polymerase; Medicine; DNA methylation; DNA; Internal medicine; Genetics; Methylation","score_opus":0.09049719143922759,"score_gpt":0.4124340506577376,"score_spread":0.32193685921851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485585585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98802894,0.0017854942,0.0001956358,0.005620244,0.00013101318,0.0028219519,0.0010516044,0.000039021637,0.00032607125],"genre_scores_gemma":[0.9857832,0.0113069005,0.00016213741,0.00018435738,0.00022480838,0.0018523337,0.000021564021,0.000059542166,0.0004051661],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997568,0.00010552958,0.00044987482,0.0005910888,0.00073007954,0.0005554053],"domain_scores_gemma":[0.99771225,0.000666945,0.00013728447,0.00022179174,0.00094377727,0.00031794724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009786362,0.00025789114,0.000485882,0.00035983013,0.00018897004,0.0000452983,0.00012757053,0.00018297635,0.00026971102],"category_scores_gemma":[0.000100605255,0.00018546502,0.00009876919,0.00047860228,0.0008397139,0.00030216223,0.000026117477,0.00032264393,0.0000022430186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063554565,0.00014536557,0.0014197156,0.00022499324,0.00048363977,0.0000061369315,0.0007733293,0.0000023970108,0.8750194,0.00050193415,0.0014203032,0.11364737],"study_design_scores_gemma":[0.02233958,0.0019320926,0.020660913,0.0009370624,0.00007245368,0.000039501425,0.00052041054,0.000031699892,0.95022494,0.001640344,0.0013371599,0.00026382064],"about_ca_topic_score_codex":0.003029651,"about_ca_topic_score_gemma":0.0002679307,"teacher_disagreement_score":0.113383554,"about_ca_system_score_codex":0.0011723838,"about_ca_system_score_gemma":0.0019179665,"threshold_uncertainty_score":0.75630444},"labels":[],"label_agreement":null},{"id":"W2486710394","doi":"10.1158/1538-7445.am2016-lb-057","title":"Abstract LB-057: 1-Benzylquinazoline-2,4(1H,3H)-diones as potent PARP inhibitors. SAR of the quinazoline group and in vivo efficacy of clinical candidate IMP4297","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Olaparib; Medicine; In vivo; Cancer; PARP inhibitor; Poly ADP ribose polymerase; Cancer research; Pharmacology; Quinazoline; Polymerase; Internal medicine; Enzyme; Stereochemistry; Biology; Chemistry; Biochemistry; Genetics","score_opus":0.1029621464948994,"score_gpt":0.4736846207194734,"score_spread":0.37072247422457405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486710394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98856324,0.0025424687,0.000005432974,0.0064098043,0.00055568427,0.0009884296,0.00015180744,0.00002158374,0.00076157664],"genre_scores_gemma":[0.991107,0.007110821,0.000038571834,0.00018909827,0.00080444687,0.00008664175,0.0000044529997,0.00004773602,0.00061122625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99591565,0.00035678473,0.0013090677,0.00058768585,0.001192654,0.00063817005],"domain_scores_gemma":[0.9970816,0.0009491626,0.00035516694,0.00083015667,0.00047783038,0.00030612343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027319891,0.00023590135,0.00078174635,0.00032445078,0.000098020035,0.000013859553,0.00034862745,0.00024866874,0.00076726556],"category_scores_gemma":[0.00076806446,0.00013898112,0.00022337092,0.0006911432,0.0012451739,0.00012711446,0.00023478552,0.0007407794,0.000015681968],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078079524,0.0010827875,0.17255965,0.0005436888,0.00018495272,0.000073158044,0.0005096514,0.000020625337,0.7765207,0.00047664877,0.012009039,0.028211132],"study_design_scores_gemma":[0.015352877,0.000944918,0.38724598,0.0033411284,0.00004515744,0.000038779057,0.00020467541,0.000012704,0.57151926,0.0006496801,0.020374727,0.00027011958],"about_ca_topic_score_codex":0.0030286692,"about_ca_topic_score_gemma":0.0008750502,"teacher_disagreement_score":0.21468633,"about_ca_system_score_codex":0.00032851752,"about_ca_system_score_gemma":0.000909872,"threshold_uncertainty_score":0.840102},"labels":[],"label_agreement":null},{"id":"W2488012951","doi":"10.1158/1538-7445.am2016-3718","title":"Abstract 3718: Sensitization of human tumor cells to chemotherapy drugs by antisense downregulation of RAD51: Targeting DNA repair to induce synthetic lethality","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Synthetic lethality; RAD51; Cancer research; DNA repair; Cisplatin; Biology; DU145; DNA damage; Poly ADP ribose polymerase; PARP inhibitor; Gene knockdown; Homologous recombination; LNCaP; Cancer cell; Molecular biology; Cell culture; Cancer; DNA; Polymerase; Chemotherapy; Genetics","score_opus":0.05097033972402663,"score_gpt":0.4053344101889845,"score_spread":0.3543640704649578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488012951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919131,0.00014653,0.0001908809,0.0058351313,0.00008712422,0.0010337082,0.00015481107,0.000052244308,0.0005865159],"genre_scores_gemma":[0.99822766,0.00009763962,0.00037679792,0.00031349898,0.00023296691,0.00008167544,0.000016105843,0.00005119018,0.0006024918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99732476,0.00022584687,0.0005771052,0.0004810774,0.00096492824,0.0004262569],"domain_scores_gemma":[0.9978255,0.00031093945,0.00018616156,0.0005493766,0.0008792263,0.00024876877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018143333,0.00016051416,0.0004005305,0.00032504718,0.00010242812,0.0000109557,0.0001294518,0.000097107644,0.0008793857],"category_scores_gemma":[0.00021958591,0.00013216079,0.00010294796,0.000666611,0.00022021502,0.00009663958,0.00004536611,0.00018769215,0.00003442534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006032485,0.00010913963,0.00083384325,0.00025072784,0.00003509308,0.0000037554616,0.0009907477,0.000020854523,0.97746575,0.000058629143,0.015946712,0.0036814765],"study_design_scores_gemma":[0.0013755773,0.00026022267,0.012351413,0.0010755301,0.0000089418245,0.0000023112873,0.0001315381,0.000008295493,0.9821055,0.00013371445,0.0024079925,0.00013896945],"about_ca_topic_score_codex":0.00061332854,"about_ca_topic_score_gemma":0.000013528261,"teacher_disagreement_score":0.013538719,"about_ca_system_score_codex":0.0005645434,"about_ca_system_score_gemma":0.0002593682,"threshold_uncertainty_score":0.96286565},"labels":[],"label_agreement":null},{"id":"W2493759960","doi":"10.1158/1538-7445.am2016-2744","title":"Abstract 2744: Synthetic lethal killing of RAD54B-deficient cancer cells by PARP1 silencing and inhibition","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Synthetic lethality; Olaparib; PARP1; Gene silencing; Cancer; Cancer research; RNA interference; Carcinogenesis; Biology; PARP inhibitor; Cancer cell; Genetics; Poly ADP ribose polymerase; Medicine; DNA repair; Polymerase; Gene; RNA","score_opus":0.07891429543170508,"score_gpt":0.4083609491209152,"score_spread":0.3294466536892101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493759960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98588514,0.008993559,0.00025719174,0.0030294305,0.00024272317,0.00052237004,0.00020675099,0.00003876263,0.000824061],"genre_scores_gemma":[0.9880798,0.010544688,0.000058267302,0.0001274026,0.00027238872,0.00028378514,0.000004783005,0.000046678975,0.00058219745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99746853,0.00011198583,0.00039959286,0.00049704633,0.0009359585,0.0005868991],"domain_scores_gemma":[0.99846005,0.0004012094,0.00012478365,0.00034393382,0.00042744417,0.00024259492],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009961365,0.00017290571,0.0003379147,0.00025186857,0.00014700727,0.000022506374,0.00009968086,0.00013192001,0.0017248263],"category_scores_gemma":[0.00007291203,0.00012674012,0.00007208258,0.00035222236,0.0005544995,0.00012691574,0.000060472063,0.00037093987,0.000030638115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030097703,0.0000765836,0.0008567494,0.00029848528,0.000036011385,0.000014579628,0.00042113638,0.000019189662,0.968126,0.000054225235,0.005775293,0.024020743],"study_design_scores_gemma":[0.0017543382,0.0001631455,0.0007208483,0.0027085769,0.000019138159,0.000009456724,0.00026013926,0.000027112479,0.98897105,0.00016659996,0.005045746,0.00015383812],"about_ca_topic_score_codex":0.0009936108,"about_ca_topic_score_gemma":0.000023740316,"teacher_disagreement_score":0.023866905,"about_ca_system_score_codex":0.0007154406,"about_ca_system_score_gemma":0.00042649702,"threshold_uncertainty_score":0.9991877},"labels":[],"label_agreement":null},{"id":"W2503576709","doi":"10.1158/1538-7445.am2016-1045","title":"Abstract 1045: Targeting NAMPT in Ewing's sarcoma cells","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"NAD+ kinase; Nicotinamide phosphoribosyltransferase; Cancer research; Gene knockdown; Apoptosis; Nicotinamide adenine dinucleotide; Cancer cell; DNA damage; Programmed cell death; Biology; Chemistry; Cell biology; Cancer; Biochemistry; Enzyme; DNA; Genetics","score_opus":0.12170945191887249,"score_gpt":0.45279326624017674,"score_spread":0.33108381432130424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503576709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793436,0.0021034286,0.000042497468,0.008205429,0.00030685714,0.0004945878,0.000029255161,0.00006133791,0.009413005],"genre_scores_gemma":[0.99368274,0.0014762027,0.00016710824,0.0003388344,0.0007043635,0.00025424297,0.0000035067417,0.00004555817,0.0033274516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975757,0.000119418255,0.0003203431,0.00041758857,0.00080638233,0.0007605662],"domain_scores_gemma":[0.9986939,0.00038341372,0.00004830764,0.00037237312,0.00027798204,0.00022405671],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014801538,0.00013137641,0.00024468935,0.00035388517,0.00009861155,0.000025528669,0.00019771003,0.000114137794,0.0051883506],"category_scores_gemma":[0.00017248077,0.000093686074,0.00006788857,0.0005283132,0.00024382831,0.00013939678,0.00006637045,0.0005343027,0.00052528223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036824305,0.00007793517,0.008456482,0.00008845678,0.00001880982,0.00010421806,0.0002656557,0.0000033653303,0.9324916,0.00008708673,0.030588165,0.027449982],"study_design_scores_gemma":[0.0037478798,0.00013381304,0.0206038,0.0012383531,0.0000033786466,0.0000068541003,0.00015997852,0.0000067405504,0.83556736,0.0006944259,0.13765733,0.00018008801],"about_ca_topic_score_codex":0.00046907982,"about_ca_topic_score_gemma":0.000065462285,"teacher_disagreement_score":0.107069165,"about_ca_system_score_codex":0.0010595203,"about_ca_system_score_gemma":0.00053247635,"threshold_uncertainty_score":0.99572104},"labels":[],"label_agreement":null},{"id":"W2503626267","doi":"10.1158/1538-7445.am2016-268","title":"Abstract 268: PARP3 inhibitors in cancer therapy","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"DNA damage; Poly ADP ribose polymerase; PARP1; DNA repair; Ku80; Molecular biology; Ku70; Cytotoxicity; DNA; Chemistry; Biology; Cancer research; Biochemistry; Polymerase; In vitro; DNA-binding protein; Transcription factor","score_opus":0.20895128257934573,"score_gpt":0.49957985701153984,"score_spread":0.29062857443219414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503626267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9586495,0.010426724,0.000008382176,0.022565188,0.0004981011,0.0008490339,0.000054475964,0.000076321194,0.0068722474],"genre_scores_gemma":[0.9638545,0.028512288,0.000023159893,0.000764502,0.001248541,0.0015196855,0.00000318893,0.000064039494,0.0040101307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970398,0.00013477245,0.000385892,0.00055098394,0.0010290807,0.0008595055],"domain_scores_gemma":[0.99845135,0.0002881676,0.000065013875,0.00051884714,0.0003900094,0.00028661854],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010922893,0.00019513203,0.00033164528,0.00047919728,0.000105486695,0.000029911207,0.00023002745,0.00017034884,0.008199168],"category_scores_gemma":[0.00009084288,0.0001281527,0.00009853553,0.0008445081,0.0004024743,0.00018831978,0.00004993509,0.0005994511,0.00027114412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001345213,0.00021099143,0.091880985,0.000068629306,0.00006187452,0.00008360702,0.0004123266,0.0000055375112,0.6031771,0.00016802749,0.049358618,0.25322714],"study_design_scores_gemma":[0.008314261,0.00028211632,0.12408304,0.0019349253,0.000004327389,0.0000081772305,0.0001245256,0.0000023110522,0.53055817,0.0010118255,0.33338407,0.00029225386],"about_ca_topic_score_codex":0.0024941498,"about_ca_topic_score_gemma":0.0006265749,"teacher_disagreement_score":0.28402543,"about_ca_system_score_codex":0.001572124,"about_ca_system_score_gemma":0.0011407417,"threshold_uncertainty_score":0.9927075},"labels":[],"label_agreement":null},{"id":"W2509656916","doi":"10.1093/nar/gkw710","title":"Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage","year":2016,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of General Medical Sciences; Medical Research Council","keywords":"Poly ADP ribose polymerase; DNA damage; Biology; DNA; DNA repair; Allosteric regulation; Polymerase; Cell biology; Biophysics; Biochemistry; Enzyme","score_opus":0.04157546708239462,"score_gpt":0.37305573733170955,"score_spread":0.3314802702493149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2509656916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98984176,0.000030556203,0.00007405276,0.008964867,0.00004852172,0.0005487955,0.000030237463,0.000021645867,0.00043955044],"genre_scores_gemma":[0.99796385,0.000044015494,0.0007862937,0.00007891562,0.00005593245,0.00002157147,0.0000062324725,0.000027595297,0.0010155742],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99786437,0.0004529611,0.00030610227,0.00030772339,0.0006998594,0.0003690011],"domain_scores_gemma":[0.99873316,0.00034447538,0.000043744854,0.00042660278,0.00025948058,0.00019255254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001371339,0.000108810265,0.00023096922,0.0005271621,0.000054870095,0.000017893259,0.00011182457,0.00010384214,0.00034418216],"category_scores_gemma":[0.00050592975,0.000078962454,0.000031929492,0.0005542713,0.00030087488,0.00012464273,0.00011264876,0.00019905968,0.0000354393],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009722955,0.00003828246,0.032056686,0.000066441986,0.000016502496,0.000034965746,0.0010785641,0.000004406782,0.92954594,0.0004820013,0.00047638625,0.026476856],"study_design_scores_gemma":[0.0032638372,0.0007741967,0.9311238,0.00044014063,0.0000043626264,0.000029134188,0.00048504793,0.0014355528,0.061036482,0.00054499105,0.0007441592,0.00011831132],"about_ca_topic_score_codex":0.000050558745,"about_ca_topic_score_gemma":0.000043266948,"teacher_disagreement_score":0.8990671,"about_ca_system_score_codex":0.00058413716,"about_ca_system_score_gemma":0.00011892196,"threshold_uncertainty_score":0.3768553},"labels":[],"label_agreement":null},{"id":"W2514747241","doi":"10.3324/haematol.2016.146894","title":"Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells","year":2016,"lang":"en","type":"letter","venue":"Haematologica","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Myeloid; Cancer research; Pharmacology; Leukemia; Chemistry; Medicine; Immunology","score_opus":0.017470193773265478,"score_gpt":0.2635668604704489,"score_spread":0.24609666669718344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514747241","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05926455,0.0019913001,0.00013394239,0.92989975,0.001113575,0.0021407271,0.00036645294,0.000448688,0.0046410332],"genre_scores_gemma":[0.06870414,0.001609939,0.0010414398,0.9010054,0.010031602,0.0014615026,0.00043908236,0.0003693104,0.015337622],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949689,0.00043497872,0.0009234885,0.0012725276,0.0010876316,0.0013124901],"domain_scores_gemma":[0.9964715,0.0008505464,0.00069965573,0.0015786263,0.00019799575,0.00020164369],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00047399077,0.001049995,0.0019084238,0.0004360633,0.00018463343,0.000077568526,0.00070732407,0.0016353854,0.0012125046],"category_scores_gemma":[0.00006308601,0.0005275659,0.00038743173,0.0006085088,0.0008962943,0.0001462265,0.0001726508,0.0032682645,0.00075461785],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014563864,0.000056520483,0.00009585348,0.00029825265,0.00036626298,0.013917593,0.00020884402,0.000001967442,0.013406163,0.00004365084,0.9695746,0.0005739049],"study_design_scores_gemma":[0.00498735,0.0007678213,0.00005814265,0.0018339492,0.00033825135,0.0032370219,0.00004462414,0.0000102692,0.097494215,0.0001804695,0.89025915,0.0007887265],"about_ca_topic_score_codex":0.00009011568,"about_ca_topic_score_gemma":0.00002633917,"teacher_disagreement_score":0.08408805,"about_ca_system_score_codex":0.00073102117,"about_ca_system_score_gemma":0.00071671256,"threshold_uncertainty_score":0.9997176},"labels":[],"label_agreement":null},{"id":"W2515800681","doi":"10.1182/blood.v122.21.1978.1978","title":"Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Veliparib; Bortezomib; PARP inhibitor; Medicine; Proteasome inhibitor; Carfilzomib; Synthetic lethality; Internal medicine; Oncology; Olaparib; Multiple myeloma; PARP1; Ixazomib; Pharmacology; Cancer research; Poly ADP ribose polymerase; DNA repair; Biology","score_opus":0.030036852261257182,"score_gpt":0.30982168037475627,"score_spread":0.2797848281134991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515800681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666214,0.00014684965,0.00001557497,0.00043009198,0.000055641332,0.00260693,0.00001568978,0.00002062431,0.000046449913],"genre_scores_gemma":[0.9986921,0.000020957697,0.00051760674,0.00014653345,0.000024361721,0.00046185416,0.000024232695,0.000025580333,0.00008680686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868786,0.00012725792,0.00036675885,0.00025458797,0.00037377878,0.00018977019],"domain_scores_gemma":[0.998777,0.00038224994,0.00029425562,0.00021937965,0.00027217052,0.0000549423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020094894,0.00020243887,0.00053193094,0.00014731722,0.00004973724,0.000011151471,0.000051175248,0.000068599235,0.000018260844],"category_scores_gemma":[0.00014944263,0.00009675728,0.00002065794,0.00033069885,0.0003056655,0.00021760236,0.00001932779,0.000246557,0.000001590482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.095477276,0.0052454094,0.8921108,0.000052835527,0.00037023166,0.000019233024,0.0046838894,0.000004128476,0.00016257771,0.000012898071,0.00017482255,0.00168588],"study_design_scores_gemma":[0.4302533,0.013388828,0.5532284,0.00041146218,0.0001291586,0.0000035498895,0.0015437066,0.00003555668,0.0008070493,0.000014193167,0.00004973955,0.00013507262],"about_ca_topic_score_codex":0.00012553863,"about_ca_topic_score_gemma":0.00054824643,"teacher_disagreement_score":0.33888245,"about_ca_system_score_codex":0.000077264885,"about_ca_system_score_gemma":0.00013054966,"threshold_uncertainty_score":0.39456472},"labels":[],"label_agreement":null},{"id":"W2517845148","doi":"10.1038/mp.2016.119","title":"PARP-1 is required for retrieval of cocaine-associated memory by binding to the promoter of a novel gene encoding a putative transposase inhibitor","year":2016,"lang":"en","type":"article","venue":"Molecular Psychiatry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research; National Institutes of Health","keywords":"PARP inhibitor; Chromatin immunoprecipitation; Poly ADP ribose polymerase; Biology; Gene; Neuroscience; Polymerase; Genetics; Promoter; Gene expression","score_opus":0.02242497104329691,"score_gpt":0.30358455180220517,"score_spread":0.28115958075890823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517845148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9067045,0.0004401976,0.06748885,0.02160154,0.00046282844,0.0016134342,0.0015704699,0.00003604096,0.00008214388],"genre_scores_gemma":[0.9892592,0.00001666208,0.0074520507,0.0026702604,0.00012765946,0.00010974987,0.0000615407,0.00006329014,0.00023957997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981924,0.00007630918,0.0005960931,0.0003737622,0.0004449919,0.000316435],"domain_scores_gemma":[0.9987682,0.000109117704,0.00033795234,0.0003797413,0.00027797034,0.00012698217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005409757,0.00021293748,0.00043191298,0.00014077289,0.00006793185,0.000006716633,0.00016082625,0.00012715669,0.000032238873],"category_scores_gemma":[0.00017533291,0.00014141708,0.0002812415,0.0004616723,0.000121615856,0.000057264493,0.000018491639,0.00010518849,0.0000044337235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016005435,0.00039064777,0.00025535095,0.00011878225,0.00030326177,0.0000032361363,0.0014927676,0.000003762048,0.9898117,0.00007914009,0.00567404,0.00026677203],"study_design_scores_gemma":[0.009131219,0.0010544037,0.00010342812,0.00083444593,0.00016948962,0.00001329941,0.00018860947,0.000050750445,0.98746544,0.00022714127,0.00057867036,0.0001830849],"about_ca_topic_score_codex":0.000011614835,"about_ca_topic_score_gemma":0.0000036526376,"teacher_disagreement_score":0.08255471,"about_ca_system_score_codex":0.00013271632,"about_ca_system_score_gemma":0.00025705935,"threshold_uncertainty_score":0.57668215},"labels":[],"label_agreement":null},{"id":"W2519805400","doi":"10.1371/journal.pbio.1002543","title":"Sam68 Is Required for DNA Damage Responses via Regulating Poly(ADP-ribosyl)ation","year":2016,"lang":"en","type":"article","venue":"PLoS Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; McGill University; National Institute of General Medical Sciences; University of North Texas; Beckman Research Institute, City of Hope; Johns Hopkins University; American Cancer Society","keywords":"PARP1; DNA damage; Biology; DNA repair; Poly ADP ribose polymerase; DNA; Cell biology; ADP-ribosylation; Molecular biology; Polymerase; Biochemistry; Enzyme; NAD+ kinase","score_opus":0.07221036414622718,"score_gpt":0.35453806341138944,"score_spread":0.28232769926516227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519805400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.956946,0.00035572433,0.013903582,0.02634274,0.00034950473,0.00074576115,0.00029018993,0.00019630563,0.00087020313],"genre_scores_gemma":[0.988566,0.000055770182,0.0042326283,0.0032535223,0.00073451764,0.00018001358,0.00009783348,0.000036786398,0.0028429737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987779,0.00012909531,0.00032744947,0.00035774155,0.00009712791,0.00031065434],"domain_scores_gemma":[0.9986258,0.0005792744,0.00016791062,0.0003891347,0.00015533435,0.00008251572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027696555,0.00014417189,0.00028789765,0.00013527558,0.00009770436,0.000005671237,0.00008864257,0.00019297129,0.00050223357],"category_scores_gemma":[0.00053039496,0.000099235825,0.0000893686,0.00011344287,0.00017327897,0.000080890924,0.000027186788,0.00006217729,0.00008369097],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015401392,0.000052441646,0.004666447,0.000030570733,0.0000737337,0.0000015641143,0.00017919201,3.0907493e-8,0.97364515,0.0007551689,0.0032128713,0.015842717],"study_design_scores_gemma":[0.004349191,0.0009891507,0.006395716,0.000254849,0.000061218525,0.000026944947,0.000033797358,0.00016847067,0.9385991,0.008291484,0.040625952,0.0002041413],"about_ca_topic_score_codex":0.000009708337,"about_ca_topic_score_gemma":0.00000482187,"teacher_disagreement_score":0.037413083,"about_ca_system_score_codex":0.00014176832,"about_ca_system_score_gemma":0.00008628458,"threshold_uncertainty_score":0.54991055},"labels":[],"label_agreement":null},{"id":"W2521539114","doi":"10.1016/j.bmcl.2016.09.054","title":"Design, synthesis and biological activity of novel molecules designed to target PARP and DNA","year":2016,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Chemistry; Moiety; DNA; Chinese hamster ovary cell; DNA repair; DNA damage; Ribose; Biochemistry; Polymerase; Molecular biology; Combinatorial chemistry; Stereochemistry; Biology; Enzyme","score_opus":0.037115696313870954,"score_gpt":0.26791667852399653,"score_spread":0.23080098221012557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521539114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89576596,0.00025843998,0.085865654,0.017727807,0.000033606884,0.00023212648,0.000023380844,0.000044458913,0.000048563605],"genre_scores_gemma":[0.9907125,0.00011567945,0.007033474,0.0018844892,0.00017142687,0.000036118006,0.0000018278663,0.000022686447,0.000021756492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987507,0.000049582708,0.00024377582,0.00042001408,0.00026215555,0.00027379656],"domain_scores_gemma":[0.998872,0.00041776104,0.0001138917,0.0002483112,0.000051511317,0.0002965557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033507645,0.00022267424,0.00041970544,0.000044522818,0.00004422753,0.000005947699,0.0000952407,0.0001346211,0.0002615861],"category_scores_gemma":[0.00045013527,0.00014561851,0.000041188312,0.00013600811,0.00042688983,0.0000398689,0.00004719687,0.000100280085,0.0000034128066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006265418,0.00008166064,0.00090025406,0.00009481624,0.00007006499,0.000036443,0.00008125942,1.5483077e-7,0.99507594,0.0000024104047,0.0006301774,0.0024002586],"study_design_scores_gemma":[0.0017595621,0.00014156247,0.005980444,0.00038460645,0.000059837763,0.00028684802,0.000035661036,0.0000068635404,0.990901,0.0000122050815,0.00025710225,0.00017428852],"about_ca_topic_score_codex":0.000007739932,"about_ca_topic_score_gemma":9.893107e-8,"teacher_disagreement_score":0.094946586,"about_ca_system_score_codex":0.00010061415,"about_ca_system_score_gemma":0.00007298014,"threshold_uncertainty_score":0.5938151},"labels":[],"label_agreement":null},{"id":"W2521759723","doi":"10.1016/j.jhep.2016.08.024","title":"Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease","year":2016,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"NAD+ kinase; Fatty liver; Nonalcoholic fatty liver disease; Nicotinamide adenine dinucleotide; Mitochondrial biogenesis; Mitochondrion; Chemistry; Pharmacology; Biology; Biochemistry; Medicine; Cancer research; Internal medicine; Disease; Enzyme","score_opus":0.022964338376143364,"score_gpt":0.2806071124600241,"score_spread":0.25764277408388075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521759723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98528314,0.0021614882,0.00847712,0.0035375135,0.0001310619,0.000244882,0.000009205517,0.000024934452,0.00013065389],"genre_scores_gemma":[0.9955418,0.0010818285,0.0019260717,0.0010101938,0.00038814778,0.0000123778045,0.000005762723,0.00001794964,0.000015855394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873525,0.00016811505,0.0004830508,0.0001639994,0.0002527117,0.00019688427],"domain_scores_gemma":[0.9986656,0.00018027543,0.00053821254,0.00012677557,0.00023373845,0.0002554095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003291917,0.0001358255,0.00032111924,0.00022543504,0.00007977491,0.000012719394,0.000050830506,0.00009939248,0.00010750609],"category_scores_gemma":[0.000640964,0.00009202162,0.000089553076,0.00010176427,0.00013504963,0.00031907807,0.000025445333,0.00016864609,0.000013030054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017917922,0.0001527963,0.4037291,0.00009809771,0.000078620214,0.00034545525,0.00010981564,7.1913e-7,0.51530224,0.000120509976,0.00036423645,0.07790659],"study_design_scores_gemma":[0.008417468,0.00087670283,0.35519788,0.0013217113,0.00015672739,0.0021340281,0.00005453622,0.00020499055,0.6271864,0.0012542579,0.0029033334,0.0002919663],"about_ca_topic_score_codex":0.000015008454,"about_ca_topic_score_gemma":0.00000945003,"teacher_disagreement_score":0.111884154,"about_ca_system_score_codex":0.0001649991,"about_ca_system_score_gemma":0.00024042412,"threshold_uncertainty_score":0.37525326},"labels":[],"label_agreement":null},{"id":"W2522660323","doi":"10.1155/2016/8289293","title":"The Effect of<i>Poly(ADP-ribose) Polymerase-1</i>Gene 3′Untranslated Region Polymorphism in Colorectal Cancer Risk among Saudi Cohort","year":2016,"lang":"en","type":"article","venue":"Disease Markers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"King Saud University","keywords":"Colorectal cancer; Genotyping; SNP; Single-nucleotide polymorphism; Genotype; Oncology; TaqMan; Biology; Cancer research; SNP genotyping; Poly ADP ribose polymerase; Medicine; Internal medicine; Cancer; Gene; Genetics; Polymerase chain reaction; Polymerase","score_opus":0.00486702718612929,"score_gpt":0.2480792271828174,"score_spread":0.2432121999966881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522660323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98367417,0.010775948,0.00007708724,0.0027902888,0.0005183219,0.0012781337,0.00027531426,0.000091152084,0.00051955873],"genre_scores_gemma":[0.9951791,0.003503581,0.000008646212,0.00017683991,0.00023393755,0.00051898364,0.000034625104,0.00006175851,0.0002824952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975223,0.00049539155,0.00048869,0.00047024334,0.0004964991,0.0005268855],"domain_scores_gemma":[0.998112,0.0006537203,0.00027029918,0.00047804246,0.000066000895,0.0004199065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005465559,0.0003214919,0.00047060542,0.00016437241,0.00015421733,0.000015234567,0.00017877416,0.00012446218,0.0002280475],"category_scores_gemma":[0.00018711618,0.00019057129,0.0002864488,0.00044679493,0.0006151006,0.00011379827,0.000026509913,0.00021077275,0.000013024055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017629249,0.00005712781,0.93256295,0.000057196467,0.00036643806,0.00013156,0.0000514819,0.000003114072,0.023330487,0.000008341876,0.0027865074,0.023015548],"study_design_scores_gemma":[0.007784024,0.0002964965,0.89941597,0.0006739037,0.0004052568,0.000007885808,0.000011386379,0.00008616344,0.09024214,0.00005269142,0.0007727084,0.00025140247],"about_ca_topic_score_codex":0.0015136113,"about_ca_topic_score_gemma":0.00013658327,"teacher_disagreement_score":0.06691165,"about_ca_system_score_codex":0.00035003788,"about_ca_system_score_gemma":0.00027108693,"threshold_uncertainty_score":0.77712715},"labels":[],"label_agreement":null},{"id":"W2523570479","doi":"10.1200/jco.2016.34.15_suppl.5549","title":"Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; PARP inhibitor; Response Evaluation Criteria in Solid Tumors; Serous fluid; Cancer; Cancer research; Progressive disease; Gene; Chemotherapy; Genetics; Biology; Poly ADP ribose polymerase","score_opus":0.15526079202072865,"score_gpt":0.4210538464934026,"score_spread":0.265793054472674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523570479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818878,0.000065990534,0.00015982283,0.01626259,0.00065232033,0.0008943224,0.0000067174883,0.000008192827,0.00006221719],"genre_scores_gemma":[0.9964724,0.000016679227,0.0014295495,0.0009654373,0.0010205383,0.000048987273,1.7412705e-7,0.000027888482,0.000018345685],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9937712,0.0022184409,0.0025990063,0.0002900757,0.0007513922,0.00036990223],"domain_scores_gemma":[0.9855657,0.010360825,0.0026887113,0.0005395481,0.0005662703,0.00027891077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011445463,0.00020497573,0.0015286717,0.00017446438,0.000063212516,0.000007468201,0.00029449395,0.0001963972,0.00004227506],"category_scores_gemma":[0.0073570204,0.00008545303,0.00018774839,0.00044040912,0.0004577384,0.00009965237,0.000043763986,0.00092519174,0.0000017935599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6913412,0.0012101217,0.20626055,0.000044545137,0.000313585,0.00043280938,0.0025709234,0.0003997286,0.091132216,0.000064348504,0.00009299345,0.006136983],"study_design_scores_gemma":[0.11579767,0.06719646,0.7637312,0.0018740675,0.00017446684,0.00034574443,0.0034764933,0.000029860488,0.046110783,0.0005343134,0.000505818,0.00022313576],"about_ca_topic_score_codex":0.000066598455,"about_ca_topic_score_gemma":0.00006220771,"teacher_disagreement_score":0.5755435,"about_ca_system_score_codex":0.0012905964,"about_ca_system_score_gemma":0.0029109966,"threshold_uncertainty_score":0.8807572},"labels":[],"label_agreement":null},{"id":"W2527678564","doi":"10.1097/ppo.0000000000000219","title":"Targeting DNA Repair","year":2016,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Prostate cancer; PALB2; DNA repair; Cancer research; Poly ADP ribose polymerase; PARP inhibitor; Carcinogenesis; Homologous recombination; Synthetic lethality; Medicine; Cancer; Germline; Biology; Polymerase; Gene; Germline mutation; Genetics; Internal medicine; Mutation","score_opus":0.0840063755538523,"score_gpt":0.4215912444155767,"score_spread":0.3375848688617244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527678564","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022093973,0.993924,0.00015545024,0.0014010218,0.0018156962,0.00046511885,0.000045971505,0.00009809305,0.0020924115],"genre_scores_gemma":[0.0000014195556,0.98488575,0.00012556059,0.00092160335,0.010659501,0.00013419571,0.0000070872547,0.00010138617,0.0031634858],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772644,0.0002903221,0.00081895344,0.00028136966,0.00046244307,0.0004204687],"domain_scores_gemma":[0.9980969,0.00018177413,0.00081472134,0.00051362976,0.00017731232,0.00021568974],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011319596,0.00035668508,0.0012773909,0.00013319027,0.0002916424,0.000043952496,0.00036730146,0.00019747975,0.004826362],"category_scores_gemma":[0.00009140576,0.00016054638,0.0010397126,0.00022207419,0.0001398122,0.000072547846,0.000053375505,0.0012420607,0.0002920904],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030198302,0.000011880918,0.0000043258947,0.00199341,0.0005514358,0.00006800206,0.000046958947,3.7846416e-7,0.000010893554,0.00003905052,0.16421303,0.8330304],"study_design_scores_gemma":[0.0005633985,0.000049047725,0.0000013757417,0.043713894,0.0007887291,0.002153264,0.00001036702,8.9454306e-7,0.000007330247,0.00023230618,0.95228255,0.00019683068],"about_ca_topic_score_codex":0.000003682435,"about_ca_topic_score_gemma":4.71363e-7,"teacher_disagreement_score":0.8328336,"about_ca_system_score_codex":0.0010948402,"about_ca_system_score_gemma":0.001542316,"threshold_uncertainty_score":0.9960834},"labels":[],"label_agreement":null},{"id":"W2528228811","doi":"10.1056/nejmoa1611310","title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2458,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cilag; Genentech; PharmaMar; Medac; University College London; Clovis Oncology; Array BioPharma; USC Norris Comprehensive Cancer Center; Massachusetts Medical Society; Ohio State University; Teva Pharmaceutical Industries; Amgen; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company; Mateon Therapeutics; GlaxoSmithKline","keywords":"Ovarian cancer; Platinum; Oncology; Maintenance therapy; Medicine; Internal medicine; Cancer; Chemotherapy; Chemistry; Biochemistry","score_opus":0.03768055663310116,"score_gpt":0.32598956117615746,"score_spread":0.2883090045430563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528228811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80565,0.0063726003,0.00333786,0.17704728,0.0029286616,0.00041432196,0.000014919709,0.000028259423,0.0042061065],"genre_scores_gemma":[0.97472876,0.013911002,0.0006747602,0.0030589157,0.0065878322,0.000006249556,0.0000018245747,0.00002773491,0.0010028891],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980479,0.00012783965,0.00076762534,0.00018885988,0.0005656001,0.00030216997],"domain_scores_gemma":[0.99830747,0.0003110448,0.0004517918,0.0002655843,0.0003457256,0.000318416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010105944,0.00019679309,0.00064153544,0.00031258073,0.000027534807,0.0000046268183,0.00014928645,0.000084549436,0.0011186532],"category_scores_gemma":[0.00044403182,0.00009922735,0.00008748116,0.00027962448,0.00017086923,0.00012014318,0.000013845361,0.00039302136,0.0000075521616],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008868541,0.00011569561,0.023249732,0.000018640767,0.0001480818,0.00055752526,0.0016317886,0.000007104503,0.07047692,0.00035625973,0.051582105,0.8429876],"study_design_scores_gemma":[0.39182845,0.0065935696,0.112280086,0.012004591,0.000100587866,0.0034345186,0.00026095365,0.000027743336,0.020195225,0.0052646175,0.4476508,0.00035889004],"about_ca_topic_score_codex":0.00016736565,"about_ca_topic_score_gemma":0.00010521038,"teacher_disagreement_score":0.8426287,"about_ca_system_score_codex":0.0002993764,"about_ca_system_score_gemma":0.00040825887,"threshold_uncertainty_score":0.9997945},"labels":[],"label_agreement":null},{"id":"W2529000802","doi":"10.1016/s0959-8049(16)31512-x","title":"2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"BRCA mutation; Medicine; Ovarian cancer; Oncology; Internal medicine; Cancer","score_opus":0.08533086144846243,"score_gpt":0.36591788917226764,"score_spread":0.2805870277238052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529000802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965072,0.0015636386,0.00006315637,0.00045844208,0.00019259298,0.0009364191,0.00003090844,0.0000026423384,0.0002449593],"genre_scores_gemma":[0.9988847,0.00027332327,0.00038104304,0.00025874883,0.000102408114,0.000027236712,0.0000037561715,0.000027774688,0.000041060393],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99826586,0.00038654092,0.0006245591,0.00014225238,0.00045313305,0.00012762976],"domain_scores_gemma":[0.99844515,0.00003575129,0.0007371606,0.00018456276,0.000487005,0.00011036631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044703955,0.00014384776,0.0003816925,0.00012346671,0.000026500898,0.000024363711,0.00013830028,0.0000139832255,0.00003959249],"category_scores_gemma":[0.00002311925,0.00008454819,0.000027070177,0.00017969834,0.00007161336,0.00013899834,0.000016232174,0.0001047393,5.259408e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07592023,0.059004027,0.3371652,0.0001401572,0.0019351225,0.0014354876,0.21790972,0.0009853927,0.008663172,0.000006225303,0.001830213,0.29500505],"study_design_scores_gemma":[0.51920533,0.11971546,0.3254942,0.0018461699,0.0012003061,0.00008369805,0.008419341,0.00017900353,0.004426102,0.000010386875,0.019052431,0.00036756526],"about_ca_topic_score_codex":0.00027777016,"about_ca_topic_score_gemma":0.0002343664,"teacher_disagreement_score":0.4432851,"about_ca_system_score_codex":0.00031408056,"about_ca_system_score_gemma":0.00017459919,"threshold_uncertainty_score":0.34477752},"labels":[],"label_agreement":null},{"id":"W2530299456","doi":"10.1212/wnl.86.16_supplement.p3.027","title":"Final Outcomes of the Teriflunomide Phase 2 Extension Study: 13 Years of Efficacy and Safety Results (P3.027)","year":2016,"lang":"en","type":"article","venue":"Neurology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Toronto; Montreal Neurological Institute and Hospital; University of Ottawa; London Health Sciences Centre; Western University","funders":"","keywords":"Teriflunomide; Medicine; Extension (predicate logic); Phase (matter); Environmental health; Computer science; Psychiatry; Chemistry; Multiple sclerosis","score_opus":0.040084508524163294,"score_gpt":0.34165998808320347,"score_spread":0.3015754795590402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530299456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918236,0.00004063172,0.0000141439,0.0072889435,0.00022690561,0.00038120613,0.00004138093,0.000013899858,0.00016924833],"genre_scores_gemma":[0.9984795,0.000054629978,0.0000245125,0.0012464923,0.00004405516,0.000006148129,0.0000010131004,0.000010877102,0.00013275944],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990353,0.00014362228,0.00034591858,0.0002168062,0.00013955419,0.00011880033],"domain_scores_gemma":[0.99892896,0.00039141905,0.0001703895,0.0004176553,0.00005329959,0.000038298596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020031781,0.000080559206,0.00029923237,0.000054877983,0.000021505994,9.789268e-7,0.0000804679,0.000059053644,0.000040645613],"category_scores_gemma":[0.0002459779,0.0000459702,0.000048656195,0.00006934807,0.00024017316,0.000020741722,0.0000559339,0.00010023236,0.0000043335376],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07952905,0.0019945968,0.23577009,0.000032102987,0.00014913696,0.00011481244,0.0010541895,0.000007908308,0.58187306,0.00010018175,0.0019683703,0.09740649],"study_design_scores_gemma":[0.025847629,0.0047327173,0.9601757,0.000026036212,0.000043489923,0.000046401685,0.0000054553498,0.000005107709,0.004805805,0.00005110347,0.0042196717,0.00004091193],"about_ca_topic_score_codex":0.00003637169,"about_ca_topic_score_gemma":0.000013009515,"teacher_disagreement_score":0.7244056,"about_ca_system_score_codex":0.0000082590905,"about_ca_system_score_gemma":0.00003910122,"threshold_uncertainty_score":0.18746103},"labels":[],"label_agreement":null},{"id":"W2531125083","doi":"10.1158/1078-0432.ccr-15-3069","title":"Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent; Hôpital Notre-Dame","funders":"AbbVie","keywords":"Veliparib; Carboplatin; Medicine; Placebo; PARP inhibitor; Internal medicine; Lung cancer; Paclitaxel; Clinical endpoint; Oncology; Urology; Cancer; Surgery; Chemotherapy; Randomized controlled trial; Pathology; Cisplatin; Biology; Poly ADP ribose polymerase","score_opus":0.13960711677473045,"score_gpt":0.5230751276709501,"score_spread":0.3834680108962196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531125083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98038846,0.0033290263,0.0010570833,0.0019635106,0.00018342047,0.012702084,0.0000906733,0.000018186121,0.00026753958],"genre_scores_gemma":[0.983402,0.002485265,0.00050260936,0.00012842356,0.00015905855,0.011898413,0.000006015197,0.000051003586,0.0013671726],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956695,0.0010203872,0.0013434623,0.0006717451,0.0007497838,0.00054515933],"domain_scores_gemma":[0.99082124,0.007218292,0.0003853021,0.00042382994,0.0008947439,0.00025657058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070439093,0.00023641485,0.0016962247,0.0003489449,0.00013549469,0.00001637276,0.00016069645,0.00011428557,0.00016567014],"category_scores_gemma":[0.0013749937,0.00014368979,0.00015915796,0.00044035554,0.0006295765,0.00011810815,0.000079494144,0.00051320065,0.0000012747537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.935886,0.004799736,0.015714705,0.00052074925,0.00043697143,0.000020086782,0.0013922087,0.00005970989,0.003238204,0.000060148315,0.00069413433,0.03717732],"study_design_scores_gemma":[0.9808166,0.010767542,0.0011489979,0.0011943768,0.00029519838,0.0000016200709,0.00072333496,0.0022639723,0.0020366495,0.00035317312,0.00020791795,0.00019064237],"about_ca_topic_score_codex":0.00070162455,"about_ca_topic_score_gemma":0.0011051238,"teacher_disagreement_score":0.04493055,"about_ca_system_score_codex":0.00033492805,"about_ca_system_score_gemma":0.00092067954,"threshold_uncertainty_score":0.58594996},"labels":[],"label_agreement":null},{"id":"W2549069008","doi":"10.18632/oncotarget.13654","title":"The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition","year":2016,"lang":"en","type":"article","venue":"Oncotarget","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; University of Tokyo; CancerCare Manitoba Foundation; Strong; Research Manitoba","keywords":"Synthetic lethality; Colorectal cancer; Medicine; PARP1; Cancer research; Growth inhibition; Pharmacology; Cancer; Lethality; Oncology; Apoptosis; Biology; Internal medicine; Toxicology; Poly ADP ribose polymerase; Genetics; DNA repair; Gene","score_opus":0.008912059232885041,"score_gpt":0.2622032173210953,"score_spread":0.2532911580882103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549069008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98576677,0.001058326,0.005500149,0.004846529,0.00037238933,0.0006240635,0.00024877104,0.00007768343,0.0015053481],"genre_scores_gemma":[0.9964033,0.0013963695,0.00033224063,0.0006031393,0.00020551712,0.00023616935,0.000027598611,0.000054503267,0.00074118027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979211,0.00009610535,0.0004821515,0.0004337539,0.00062868005,0.00043820313],"domain_scores_gemma":[0.9986861,0.000235864,0.0003469801,0.00032100425,0.00026917813,0.00014090417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033644133,0.00026078764,0.00039017096,0.000078717276,0.00020134622,0.000020554851,0.00007591016,0.00013519575,0.0006582368],"category_scores_gemma":[0.000025532981,0.00014667588,0.00012655668,0.00027542986,0.00043131594,0.00012856352,0.000026213029,0.00018633915,0.000060841474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010549879,0.00017317472,0.0006356674,0.000049004804,0.000064348,0.000007585177,0.00057549914,0.00001819051,0.98303825,0.0001044324,0.011733115,0.0025457635],"study_design_scores_gemma":[0.0030579746,0.0006774925,0.0002280777,0.0010306992,0.000064359985,0.00002424871,0.00017454955,0.000052391275,0.9811725,0.00022823969,0.013067435,0.0002220015],"about_ca_topic_score_codex":0.00007275908,"about_ca_topic_score_gemma":0.000019619514,"teacher_disagreement_score":0.010636542,"about_ca_system_score_codex":0.0004252857,"about_ca_system_score_gemma":0.00022584359,"threshold_uncertainty_score":0.72072315},"labels":[],"label_agreement":null},{"id":"W2557666746","doi":"10.1016/s1470-2045(16)30559-9","title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; Clovis Oncology; Ovarian Cancer Research Fund; Stand Up To Cancer; Healthway; U.S. Department of Defense; National Ovarian Cancer Coalition; Ovarian Cancer Research Fund Alliance; American Association for Cancer Research","keywords":"Open label; Oncology; Medicine; Internal medicine; Ovarian carcinoma; Platinum; Ovarian cancer; Clinical trial; Cancer; Chemistry","score_opus":0.14688348836785434,"score_gpt":0.4311228869311657,"score_spread":0.2842393985633114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557666746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389584,0.000045597906,0.00016098154,0.04551269,0.0028035252,0.0017018901,0.00018641306,0.00007823498,0.010552277],"genre_scores_gemma":[0.9863991,0.0002041723,0.0018744243,0.006392455,0.0035674865,0.00032264204,0.00010226329,0.000037618487,0.0010998024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99744517,0.00070461346,0.00058668846,0.00048816067,0.0002766014,0.00049876823],"domain_scores_gemma":[0.99790907,0.00076391915,0.0003131701,0.00071965385,0.00013594546,0.0001582655],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011505918,0.00023274336,0.0007727897,0.000121268626,0.000104701336,0.000037323796,0.00057967554,0.0002370173,0.0010078973],"category_scores_gemma":[0.00033995102,0.00014159924,0.000046594385,0.000195227,0.00031009517,0.00023901864,0.00014932407,0.00042226686,0.00015393637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6919988,0.011997277,0.0075711594,0.000034891647,0.0006844923,0.0017047127,0.0065989406,0.000015418074,0.07713088,0.05217449,0.074634776,0.07545417],"study_design_scores_gemma":[0.74154055,0.005069163,0.0046818783,0.0001850904,0.00010270174,0.00021100549,0.00037045372,0.00032634553,0.0075494763,0.002479778,0.23716561,0.00031796173],"about_ca_topic_score_codex":0.0004780208,"about_ca_topic_score_gemma":0.00055232545,"teacher_disagreement_score":0.16253084,"about_ca_system_score_codex":0.0007400271,"about_ca_system_score_gemma":0.00041835604,"threshold_uncertainty_score":0.9999053},"labels":[],"label_agreement":null},{"id":"W2559317205","doi":"10.1093/annonc/mdw435.26","title":"gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Cohort; Neutropenia; Placebo; Chemotherapy; Progression-free survival; Ovarian cancer; Oncology; Surgery; Cancer; Gastroenterology; Pathology","score_opus":0.11926694906777008,"score_gpt":0.4135565817748023,"score_spread":0.29428963270703223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559317205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981641,0.00017274807,0.0002714893,0.005364407,0.00083364523,0.008579054,0.0001501572,0.00002820485,0.0029592854],"genre_scores_gemma":[0.9948618,0.0014899649,0.0003685221,0.0012275517,0.00029907742,0.0015576702,0.00003307382,0.000041125964,0.000121240046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962566,0.0006675965,0.0012831511,0.0006072068,0.0005889171,0.000596556],"domain_scores_gemma":[0.9956191,0.0013959352,0.001361986,0.00041952613,0.0010107369,0.00019269522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015568027,0.00039492425,0.0023006331,0.00033863998,0.000045075092,0.0000063126367,0.00017705571,0.0003450964,0.00078526797],"category_scores_gemma":[0.00027175888,0.0002140368,0.00023646094,0.0004970724,0.0010953236,0.00013808002,0.000029333674,0.00036045437,0.0000039360248],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9354093,0.0036296418,0.0010463365,0.000024172172,0.00079349405,0.000046876048,0.0007192496,0.000028208231,0.00016935998,0.00029431417,0.0011963884,0.05664265],"study_design_scores_gemma":[0.9225729,0.0667882,0.0011493457,0.000491603,0.00010772539,0.0000071672744,0.00007044272,0.0000119220895,0.0055402634,0.00011353914,0.0028808988,0.00026599134],"about_ca_topic_score_codex":0.0006146976,"about_ca_topic_score_gemma":0.00081043516,"teacher_disagreement_score":0.06315855,"about_ca_system_score_codex":0.0005877931,"about_ca_system_score_gemma":0.0019186549,"threshold_uncertainty_score":0.87281674},"labels":[],"label_agreement":null},{"id":"W2561005546","doi":"10.1371/journal.pone.0167272","title":"Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Olaparib; PARP inhibitor; Cancer research; Pancreatic cancer; Medicine; Synthetic lethality; DNA repair; BRCA mutation; Cancer; Germline mutation; Germline; Poly ADP ribose polymerase; Oncology; Ovarian cancer; Biology; Internal medicine; Mutation; Polymerase; Genetics; DNA; Gene","score_opus":0.017864456370131215,"score_gpt":0.23010722879023932,"score_spread":0.2122427724201081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561005546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933492,0.003674461,0.0000086830205,0.0016825149,0.00003484862,0.0011892535,0.00000842832,0.000020597781,0.00003200631],"genre_scores_gemma":[0.9936784,0.005633139,0.00014958192,0.00015207326,0.000062331186,0.00026999775,0.0000039845763,0.000018238852,0.000032253447],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991904,0.00008739608,0.00020291095,0.00017887216,0.00019578375,0.00014466482],"domain_scores_gemma":[0.9992851,0.00031528893,0.00012862199,0.00014001675,0.00006615417,0.00006481735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007042425,0.0001297526,0.0003796998,0.00008310631,0.000042098192,0.00000790903,0.000020068383,0.00004415229,0.0000143642255],"category_scores_gemma":[0.000050553306,0.00006544361,0.000016935495,0.00014718558,0.00017732938,0.00006350567,0.000010935639,0.00005096013,0.0000011553748],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00659616,0.00097103853,0.09273251,0.0003194987,0.0005985598,0.0000140552065,0.0033542134,7.7824603e-7,0.88250834,0.000078804616,0.000012701787,0.012813367],"study_design_scores_gemma":[0.03485658,0.0032906302,0.040434852,0.0035491618,0.0004962576,0.000005709637,0.000076612094,0.00010159374,0.9169202,0.00008358493,0.00005414586,0.00013068836],"about_ca_topic_score_codex":0.00022627831,"about_ca_topic_score_gemma":0.000069955604,"teacher_disagreement_score":0.05229766,"about_ca_system_score_codex":0.00015733385,"about_ca_system_score_gemma":0.000067843066,"threshold_uncertainty_score":0.26687127},"labels":[],"label_agreement":null},{"id":"W2562145218","doi":"10.1158/1538-7445.am2015-1643","title":"Abstract 1643: Discovery of 1-benzylquinazoline-2,4(1H,3H)-diones as novel and potent PARP inhibitors. SAR of the benzyl group","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Olaparib; Poly ADP ribose polymerase; Cancer; Medicine; In vivo; PARP inhibitor; Breast cancer; Polymerase; Stereochemistry; Cancer research; Pharmacology; Enzyme; Biology; Chemistry; Internal medicine; Biochemistry; Genetics","score_opus":0.1411121291192604,"score_gpt":0.42598993652514633,"score_spread":0.2848778074058859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562145218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867391,0.0056583183,0.000029709245,0.0038369538,0.0004331517,0.0007605357,0.00014461907,0.000018783769,0.0023788374],"genre_scores_gemma":[0.99713343,0.0012038323,0.00007683618,0.00018458469,0.000601973,0.00008486615,0.000011893751,0.000040942767,0.000661641],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997062,0.00009877192,0.00052263733,0.0003836072,0.0014891129,0.00044384832],"domain_scores_gemma":[0.99800825,0.00018267702,0.00019931591,0.00063823164,0.00072195294,0.00024959195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012404326,0.00018433179,0.00043254028,0.00021612695,0.000101945894,0.000030320281,0.00026660762,0.00014365213,0.000096608586],"category_scores_gemma":[0.00026511232,0.00012854776,0.00013191682,0.0005934554,0.000836819,0.00022417936,0.00021193195,0.0005632526,0.000009713332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021974547,0.0007039591,0.017648121,0.0007586644,0.0001982468,0.00002113841,0.0017170487,0.0001279738,0.9534702,0.002723085,0.016178327,0.0042557926],"study_design_scores_gemma":[0.007841965,0.0010342111,0.080905214,0.0019964057,0.00006605972,0.00007463275,0.0019428071,0.000044570792,0.8828489,0.0021020088,0.020838173,0.0003050376],"about_ca_topic_score_codex":0.002647155,"about_ca_topic_score_gemma":0.0001477651,"teacher_disagreement_score":0.070621274,"about_ca_system_score_codex":0.00036162607,"about_ca_system_score_gemma":0.0008981463,"threshold_uncertainty_score":0.5242026},"labels":[],"label_agreement":null},{"id":"W2564388566","doi":"10.3103/s0096392516040106","title":"Evaluating Parp1 domains as gossypol targets","year":2016,"lang":"en","type":"article","venue":"Moscow University Biological Sciences Bulletin","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Gossypol; PARP1; Chemistry; Computational biology; Biology; Toxicology; Biochemistry; Gene","score_opus":0.09586956911952886,"score_gpt":0.3509363813766907,"score_spread":0.2550668122571618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564388566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372501,0.00011631317,0.0014056488,0.027007472,0.00014897784,0.00028543672,0.000017709013,0.00015419714,0.03361419],"genre_scores_gemma":[0.9864306,0.00023129302,0.0059931353,0.0020272934,0.00011722038,0.0000020628077,0.0000030306403,0.000004238602,0.005191135],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983701,0.00019657375,0.00014267593,0.0005125754,0.00037272938,0.0004053296],"domain_scores_gemma":[0.9991447,0.00029952213,0.00009293144,0.00017512296,0.00007893732,0.00020880393],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00077585765,0.00013922584,0.00021254255,0.0000773294,0.00042516887,0.00001560089,0.0002918147,0.00012728982,0.0079409415],"category_scores_gemma":[0.00032307528,0.000079870624,0.000098956276,0.00032702903,0.001216852,0.000054402466,0.00012383003,0.000106825675,0.0009896707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024186764,0.0007326287,0.14735164,0.000026387634,0.00012170912,0.0005579921,0.00048475823,0.000031631418,0.7026853,0.034907993,0.03783576,0.07284552],"study_design_scores_gemma":[0.0059489715,0.005438898,0.036074992,0.00025615617,0.000041172978,0.00011503198,0.0010068157,0.00006458359,0.019091856,0.0035965834,0.92779666,0.00056829315],"about_ca_topic_score_codex":0.00007271609,"about_ca_topic_score_gemma":0.0000028952493,"teacher_disagreement_score":0.8899609,"about_ca_system_score_codex":0.00021762469,"about_ca_system_score_gemma":0.00011366695,"threshold_uncertainty_score":0.99978817},"labels":[],"label_agreement":null},{"id":"W2567043620","doi":"10.1158/1538-7445.am2015-2111","title":"Abstract 2111: Regulation and localization of the cleaved form of PAR-4 in ovarian and endometrial cancers","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Innovation and Economic Development Trois Rivières","funders":"","keywords":"Apoptosis; Cisplatin; Ovarian cancer; Cancer research; Cleavage (geology); Endometrial cancer; Molecular biology; Cancer cell; Biology; Cell culture; Cancer; Chemistry; Biochemistry; Chemotherapy; Genetics","score_opus":0.16210080936872906,"score_gpt":0.43809089986111655,"score_spread":0.2759900904923875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567043620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960527,0.0011669226,0.00009914997,0.00075648644,0.00012273368,0.0005841642,0.000015135742,0.0000041942185,0.0011985381],"genre_scores_gemma":[0.9990925,0.00057652633,0.000041749077,0.000039100698,0.00011746165,0.000052307503,0.000003995823,0.00001050715,0.0000658495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988308,0.00008594446,0.00025643792,0.00015084264,0.0005170134,0.00015893765],"domain_scores_gemma":[0.9991709,0.00012616812,0.00009351335,0.00018517186,0.00033762652,0.00008660286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011170709,0.000057875877,0.00018256524,0.00023917799,0.000036294627,0.000007557877,0.000057475925,0.00006971039,0.00006509496],"category_scores_gemma":[0.00031000128,0.00004379529,0.000019680127,0.0007147822,0.00034919634,0.000081230246,0.000036191672,0.00017499889,3.592416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011623875,0.0001720027,0.56306577,0.0010674149,0.00014090989,0.000006670648,0.012210073,0.0014073624,0.35721913,0.0022272156,0.0062592826,0.04460029],"study_design_scores_gemma":[0.014931295,0.0004395708,0.57949704,0.0009640924,0.000021552729,0.0000076624,0.0009668337,0.0010811613,0.39264008,0.0060357917,0.0032937438,0.00012120866],"about_ca_topic_score_codex":0.00310484,"about_ca_topic_score_gemma":0.0006542995,"teacher_disagreement_score":0.04447908,"about_ca_system_score_codex":0.00042886555,"about_ca_system_score_gemma":0.0006418837,"threshold_uncertainty_score":0.469361},"labels":[],"label_agreement":null},{"id":"W2570932838","doi":"10.3934/genet.2017.1.21","title":"Unfolding of core nucleosomes by PARP-1 revealed by spFRET microscopy","year":2017,"lang":"en","type":"article","venue":"AIMS Genetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Nucleosome; Chromatin; Histone; Biophysics; DNA; Poly ADP ribose polymerase; Chemistry; Cell biology; Polymerase; Biology; Molecular biology; Biochemistry","score_opus":0.03705271441233396,"score_gpt":0.36227121536893053,"score_spread":0.32521850095659655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570932838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842543,0.006798897,0.00020823191,0.0010990883,0.00035073282,0.0002876997,0.0002322952,0.000036272555,0.0025613625],"genre_scores_gemma":[0.9905133,0.0032182203,0.0028226478,0.000864459,0.00015340964,0.000013461189,0.00006210189,0.000046269346,0.0023060858],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989026,0.000016536354,0.00032639966,0.00024526022,0.00025576097,0.0002534235],"domain_scores_gemma":[0.9985415,0.00003612405,0.00031410562,0.0008612574,0.000114292015,0.00013275664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012122791,0.00016002501,0.00033578646,0.000029140216,0.00015713424,0.0000307345,0.0002584879,0.00012820194,0.0002606914],"category_scores_gemma":[0.00004785781,0.00015633533,0.000080836035,0.00005161724,0.00027990658,0.000044459233,0.00005565848,0.00013366732,0.000035771864],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006987761,0.00006124262,0.07761114,0.00006179674,0.00005231377,0.0000043105,0.00012694357,0.0000010618024,0.7265259,0.00003022828,0.19348603,0.0019691517],"study_design_scores_gemma":[0.0025315075,0.0003107513,0.00893215,0.00022665637,0.00007093217,0.000015751502,0.000053207164,0.00006408992,0.8677752,0.00036283967,0.119464375,0.00019254713],"about_ca_topic_score_codex":0.00003522893,"about_ca_topic_score_gemma":0.0000033621175,"teacher_disagreement_score":0.14124928,"about_ca_system_score_codex":0.000051532475,"about_ca_system_score_gemma":0.00006910029,"threshold_uncertainty_score":0.637517},"labels":[],"label_agreement":null},{"id":"W2572611801","doi":"10.1016/j.ygyno.2017.01.016","title":"A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers","year":2017,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Veliparib; Gastroenterology; Internal medicine; Vomiting; Leukopenia; Nausea; Neutropenia; Mucositis; PARP inhibitor; Anemia; Radiation therapy; Oncology; Chemotherapy","score_opus":0.020318732984993104,"score_gpt":0.3261234026123364,"score_spread":0.3058046696273433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2572611801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721503,0.00006302272,0.000028817292,0.00039573482,0.0000611682,0.0021193982,0.000013836345,0.000010496138,0.000092498616],"genre_scores_gemma":[0.9987117,0.000069852926,0.0006275439,0.00006234201,0.0000108187205,0.0004336637,0.000059130143,0.000016004607,0.0000089469195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983098,0.00017644979,0.0005903655,0.00041881556,0.00026935607,0.00023519434],"domain_scores_gemma":[0.9984444,0.00014338076,0.00083032495,0.00026824136,0.00024930708,0.00006436608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040820253,0.0002031686,0.0006870837,0.00037018952,0.000094970135,0.000013470013,0.000071268,0.0001601369,0.000014530241],"category_scores_gemma":[0.00010409572,0.00015924325,0.000015390371,0.0002658682,0.00031590558,0.00030456172,0.000022136423,0.00023387579,1.2206101e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021391084,0.004095309,0.95255715,0.000056411125,0.0000637704,0.00025074746,0.0037703265,0.00052695285,0.0019458887,0.0000101649775,0.0000029917549,0.0153292],"study_design_scores_gemma":[0.09073509,0.022425259,0.8837404,0.00017446991,0.000037982136,0.00007945863,0.0012584241,0.00077357405,0.00058054575,0.000027311507,0.00002184208,0.00014560414],"about_ca_topic_score_codex":0.0017349669,"about_ca_topic_score_gemma":0.009466765,"teacher_disagreement_score":0.06934401,"about_ca_system_score_codex":0.0006869172,"about_ca_system_score_gemma":0.0006122844,"threshold_uncertainty_score":0.64937514},"labels":[],"label_agreement":null},{"id":"W2588456788","doi":"10.1016/j.cotox.2017.01.013","title":"AHR toxicity and signaling: Role of TIPARP and ADP-ribosylation","year":2017,"lang":"en","type":"article","venue":"Current Opinion in Toxicology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Universitetet i Oslo","keywords":"Aryl hydrocarbon receptor; Poly ADP ribose polymerase; Toxicity; Transcription factor; ADP-ribosylation; Cell biology; Signal transduction; Chemistry; Aryl hydrocarbon receptor nuclear translocator; Receptor; Biology; Gene; Biochemistry; Polymerase; Enzyme; NAD+ kinase","score_opus":0.08100227169796398,"score_gpt":0.4026833174039008,"score_spread":0.3216810457059368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588456788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918522,0.0047244737,0.00013505139,0.0010361396,0.0012675081,0.00032078585,0.000015577138,0.000016550412,0.0006316997],"genre_scores_gemma":[0.9979249,0.0015241804,0.00017226841,0.000041138766,0.0002635635,0.000031779262,0.00001584634,0.000008861511,0.000017409706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991713,0.00005533977,0.00027656637,0.00023430788,0.00010826677,0.00015421108],"domain_scores_gemma":[0.9993226,0.00007657131,0.00021976992,0.00024358534,0.000055642202,0.00008185587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022999966,0.00010278376,0.00027546377,0.00011839356,0.00008862693,0.000014248454,0.000068692934,0.0001155812,0.00008009195],"category_scores_gemma":[0.00013254501,0.000101415586,0.000027056953,0.000041333966,0.00026923255,0.00009948475,0.000063772655,0.00016906943,0.0000030546382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007238563,0.00073844945,0.6748761,0.0006757365,0.000046115943,0.0000017117543,0.0013944036,0.000015105995,0.20214733,0.009400444,0.0012354724,0.10874525],"study_design_scores_gemma":[0.009790043,0.0011772846,0.8377739,0.0009965681,0.000033294582,0.00006838447,0.00021577315,0.001815651,0.09065606,0.010860817,0.046289016,0.00032317452],"about_ca_topic_score_codex":0.000010772319,"about_ca_topic_score_gemma":0.0000052255305,"teacher_disagreement_score":0.16289781,"about_ca_system_score_codex":0.000046399,"about_ca_system_score_gemma":0.000056988905,"threshold_uncertainty_score":0.41356078},"labels":[],"label_agreement":null},{"id":"W2588907697","doi":"10.1093/annonc/mdw374.03","title":"Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Nausea; Adverse effect; BRCA mutation; Anemia; PARP inhibitor; Gastroenterology; Surgery; Oncology; Cancer; Ovarian cancer; Poly ADP ribose polymerase","score_opus":0.09173674282299754,"score_gpt":0.38385199959226735,"score_spread":0.2921152567692698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588907697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440163,0.0005539007,0.000030355073,0.0034682248,0.0000893592,0.0007172666,0.0006928438,0.0000072581674,0.00003913949],"genre_scores_gemma":[0.9991317,0.00018728996,0.00016746232,0.0003106016,0.00007618079,0.000021170288,0.000065061395,0.000016743206,0.000023830004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732614,0.0006421839,0.00083629764,0.0006406508,0.0003227033,0.00023203314],"domain_scores_gemma":[0.997154,0.0009585306,0.0007884613,0.00072320964,0.0002017125,0.00017411349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082728814,0.00022279852,0.0011851485,0.00030268653,0.000055760192,0.0000094779825,0.00013298618,0.00020573461,0.00005820175],"category_scores_gemma":[0.00026089192,0.00014431971,0.000056761037,0.0004082333,0.00087948743,0.00023238233,0.00022796018,0.00017710461,2.5431785e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005089515,0.0022052275,0.9634939,0.00003652704,0.0012989466,0.00002009814,0.0009198243,5.426981e-7,0.003066554,0.000028272714,0.000370062,0.02347057],"study_design_scores_gemma":[0.015538889,0.0052819443,0.9692561,0.00012817909,0.0012771556,0.0000076273413,0.0002574931,0.00009204553,0.0077153225,0.00011101974,0.00019337323,0.00014083012],"about_ca_topic_score_codex":0.0032878981,"about_ca_topic_score_gemma":0.0027472356,"teacher_disagreement_score":0.023329739,"about_ca_system_score_codex":0.0000311012,"about_ca_system_score_gemma":0.00022877766,"threshold_uncertainty_score":0.58851874},"labels":[],"label_agreement":null},{"id":"W2589712516","doi":"10.1158/1078-0432.ccr-16-2615","title":"Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Oncology; Ovarian cancer; Internal medicine; BRCA mutation; Serous ovarian cancer; PARP inhibitor; Cancer research; Cancer; Biology; Genetics","score_opus":0.2561304436178418,"score_gpt":0.5529180762777554,"score_spread":0.29678763265991354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589712516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95603925,0.00052491657,0.00012546047,0.040444598,0.0011395278,0.0011389132,0.00008296238,0.00004837543,0.00045597888],"genre_scores_gemma":[0.97771907,0.015365151,0.00009734306,0.0037036275,0.0012582401,0.00044107146,0.000043976965,0.000073045216,0.0012985044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99468845,0.0011044771,0.0012108834,0.0011597514,0.0009938309,0.0008425947],"domain_scores_gemma":[0.99637735,0.0007819505,0.00036359622,0.0014624638,0.00043427193,0.0005803661],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005394236,0.00026710585,0.0008515648,0.0002789211,0.00038377414,0.00018488296,0.00055575796,0.0005005356,0.00036782608],"category_scores_gemma":[0.0019878717,0.00024141796,0.00017829669,0.00033792882,0.0018751133,0.00022448358,0.00024574716,0.002332507,0.000055245266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007784562,0.00055917905,0.90714514,0.00013038276,0.00012342473,0.0006050309,0.00007722843,0.0000033732588,0.005773637,0.0010325194,0.0013281831,0.07543732],"study_design_scores_gemma":[0.011613166,0.000965272,0.9789668,0.0013006348,0.000029943356,0.000010902988,0.000014713826,0.000115997405,0.0019236406,0.00057245407,0.0042420058,0.00024448754],"about_ca_topic_score_codex":0.0011090843,"about_ca_topic_score_gemma":0.0007410409,"teacher_disagreement_score":0.07519283,"about_ca_system_score_codex":0.00043881434,"about_ca_system_score_gemma":0.0009940321,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W2590379099","doi":"10.1200/jco.2015.33.28_suppl.155","title":"Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- <i>BRCA</i>-associated locally advanced or metastatic breast cancer (BC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Veliparib; Medicine; PARP inhibitor; Carboplatin; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; BRCA mutation; Cancer; Placebo; Chemotherapy; Phases of clinical research; Olaparib; Pathology; Cisplatin; Poly ADP ribose polymerase","score_opus":0.10079719884237634,"score_gpt":0.4784896302964782,"score_spread":0.3776924314541018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590379099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666835,0.0012082045,0.000553769,0.0058317953,0.0013528299,0.0033931572,0.00003667323,0.000015871781,0.00093937095],"genre_scores_gemma":[0.99222094,0.0015340847,0.0030971118,0.0018413452,0.0006504033,0.00025653216,0.0000047988983,0.00004158075,0.00035319687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99042696,0.002625612,0.0054200757,0.00032277685,0.00081854477,0.00038601324],"domain_scores_gemma":[0.9857341,0.0067729168,0.0053503867,0.00022863236,0.0012446526,0.00066928606],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012906557,0.00032233255,0.0070538013,0.00026563223,0.000030207537,0.000011912284,0.00016309496,0.0003925674,0.000179344],"category_scores_gemma":[0.009066971,0.0001899614,0.00056289934,0.0003387042,0.0007326777,0.00019265829,0.00003266955,0.0012124494,0.000002096892],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9641,0.006056215,0.0009945902,0.0000366417,0.0019050658,0.00041686013,0.00039839215,0.00024354881,0.00015111583,0.000020948428,0.00070210575,0.024974523],"study_design_scores_gemma":[0.9624398,0.031336624,0.00048899406,0.0006678613,0.0016057984,0.00036493107,0.0003580821,0.0011982183,0.00005752329,0.0003077503,0.0009843269,0.00019009478],"about_ca_topic_score_codex":0.00036888587,"about_ca_topic_score_gemma":0.001201267,"teacher_disagreement_score":0.025280409,"about_ca_system_score_codex":0.00049693725,"about_ca_system_score_gemma":0.00667892,"threshold_uncertainty_score":0.9992801},"labels":[],"label_agreement":null},{"id":"W2593067736","doi":"10.1158/1078-0432.ccr-16-2796","title":"A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PARP inhibitor; Ovarian cancer; Germline; Medicine; Cancer research; Germline mutation; Ovarian carcinoma; Internal medicine; Oncology; Cancer; Mutation; Poly ADP ribose polymerase; Biology; Genetics; DNA; Polymerase","score_opus":0.24196756652240917,"score_gpt":0.5440788431986607,"score_spread":0.3021112766762516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593067736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937222,0.000065539614,0.0000023892867,0.002244046,0.0004094722,0.0029679819,0.00011809471,0.000024454353,0.0004458282],"genre_scores_gemma":[0.9973487,0.00002209593,0.000043313506,0.00053090416,0.0005140903,0.00045564136,0.000009544421,0.000073469106,0.0010021972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948798,0.00083856593,0.001250955,0.0007391693,0.0015752668,0.0007162833],"domain_scores_gemma":[0.99596846,0.00037126598,0.0005155681,0.0018572981,0.00095280726,0.0003346178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028266762,0.00026412096,0.0009271092,0.00019196332,0.00056674,0.000061932704,0.00079286663,0.00018392391,0.0007598149],"category_scores_gemma":[0.0010834886,0.00015155661,0.00014059187,0.0006159633,0.0013493771,0.00016371856,0.00042745564,0.0015010977,0.00001377856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033247806,0.014953321,0.9400382,0.000074353586,0.0001693859,0.00008691428,0.001086474,0.000008601511,0.000302668,0.000011306224,0.0031967987,0.006824173],"study_design_scores_gemma":[0.100829765,0.025381243,0.8667176,0.0007753988,0.00007338111,0.0000033962453,0.00039785236,0.000117793556,0.002906216,0.0000631034,0.0024855589,0.00024869177],"about_ca_topic_score_codex":0.0035715557,"about_ca_topic_score_gemma":0.0040575685,"teacher_disagreement_score":0.0733206,"about_ca_system_score_codex":0.0003265453,"about_ca_system_score_gemma":0.0015399139,"threshold_uncertainty_score":0.83194405},"labels":[],"label_agreement":null},{"id":"W2597439582","doi":"10.1200/jco.2012.30.15_suppl.5022","title":"Use of chemotherapy (CT) in <i>BRCA1/2</i>-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Taxane; Internal medicine; Oncology; Proportional hazards model; Population; PARP inhibitor; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Gastroenterology; Cancer; Surgery; Phases of clinical research; Breast cancer; Poly ADP ribose polymerase","score_opus":0.14114276139837664,"score_gpt":0.4457801977001478,"score_spread":0.3046374363017712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597439582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910608,0.0020960947,0.0002470245,0.0033816006,0.0021355308,0.00078154186,0.000060033035,0.00001374539,0.00022365683],"genre_scores_gemma":[0.98894125,0.0005315482,0.005023542,0.0033592586,0.00182875,0.00004330129,0.000007089882,0.000040991974,0.000224288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942671,0.0006324098,0.003251414,0.00033098474,0.0009984792,0.00051958166],"domain_scores_gemma":[0.9947809,0.00096473226,0.0025210795,0.00036888637,0.00078337686,0.0005809991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021449926,0.0003142745,0.0018696946,0.00034870775,0.00007508281,0.000012134812,0.00020390039,0.00025496518,0.00033831227],"category_scores_gemma":[0.00083370093,0.00021707935,0.00038231927,0.000500482,0.00053507497,0.00045409685,0.000045645356,0.0011469611,0.000007721057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030194206,0.02905584,0.8967087,0.000052086656,0.0006006905,0.00030036017,0.0008392211,0.000072423456,0.000634995,0.000095971765,0.0035996872,0.037845783],"study_design_scores_gemma":[0.06200561,0.007495388,0.83332825,0.00058927934,0.00026342826,0.0001014865,0.00027157448,0.000026405265,0.0016240306,0.000013079989,0.09402387,0.00025760077],"about_ca_topic_score_codex":0.0002974667,"about_ca_topic_score_gemma":0.00051752414,"teacher_disagreement_score":0.09042418,"about_ca_system_score_codex":0.0008051831,"about_ca_system_score_gemma":0.0025959846,"threshold_uncertainty_score":0.88522387},"labels":[],"label_agreement":null},{"id":"W2598833272","doi":"10.1200/jco.2012.30.15_suppl.2013","title":"Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Veliparib; Medicine; Internal medicine; Adverse effect; Oncology; Nausea; PARP inhibitor; Radiation therapy; Surgery","score_opus":0.08408595961704525,"score_gpt":0.4750247566108158,"score_spread":0.39093879699377054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598833272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932365,0.0004737881,0.000162809,0.0050074696,0.00022468055,0.0007618791,0.00000736815,0.000003848923,0.00012164837],"genre_scores_gemma":[0.9970929,0.00025532377,0.00037118574,0.0020409906,0.00017918581,0.000012362331,0.000011517599,0.00001693751,0.000019623545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628925,0.0011042111,0.0018065906,0.00015402598,0.00044271947,0.00020317783],"domain_scores_gemma":[0.9961969,0.0016373448,0.0015592413,0.00012357855,0.00027965076,0.00020324031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003961272,0.00013943184,0.001080842,0.0003148488,0.000019474901,0.0000043549635,0.00007432813,0.00012582357,0.00005751819],"category_scores_gemma":[0.0005456325,0.000093955,0.00006075025,0.00036322957,0.0001385279,0.00027121702,0.0000129322425,0.00061215035,0.0000010919259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04396466,0.03769878,0.6459948,0.000017702483,0.00025757198,0.000043428077,0.0015644754,0.00008880887,0.0002903429,0.00001765586,0.0008103257,0.26925144],"study_design_scores_gemma":[0.21736033,0.07440953,0.6953997,0.00008681325,0.00009928703,0.00003008252,0.00030370947,0.000088028966,0.00015559576,0.000022587894,0.011959862,0.00008447917],"about_ca_topic_score_codex":0.000030741034,"about_ca_topic_score_gemma":0.000053181735,"teacher_disagreement_score":0.26916698,"about_ca_system_score_codex":0.00022127533,"about_ca_system_score_gemma":0.0003785835,"threshold_uncertainty_score":0.38313738},"labels":[],"label_agreement":null},{"id":"W2603996605","doi":"10.1016/j.pep.2017.03.015","title":"A facile method for isolation of recombinant human apolipoprotein A-I from E. coli","year":2017,"lang":"en","type":"article","venue":"Protein Expression and Purification","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Basic Energy Sciences; National Institute of General Medical Sciences; U.S. Department of Energy; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Recombinant DNA; Apolipoprotein B; Cholesterol; Efflux; Biochemistry; Escherichia coli; Chemistry; Reverse cholesterol transport; Lipoprotein; Biology","score_opus":0.05952538894170783,"score_gpt":0.3795228846664732,"score_spread":0.3199974957247654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603996605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6442026,0.00084587286,0.34409064,0.003701083,0.00024388033,0.005293043,0.000127557,0.000085519314,0.001409806],"genre_scores_gemma":[0.89377767,0.00005024268,0.10351205,0.00005102042,0.0001274191,0.0011014183,0.00012340271,0.000017901413,0.0012389008],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990728,0.00006528262,0.0003079614,0.00027867832,0.0001616133,0.00011369154],"domain_scores_gemma":[0.9987021,0.00003748739,0.00047989184,0.0005565519,0.0001482036,0.00007575814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034770774,0.00010790764,0.00022866894,0.000063556276,0.00037184474,0.000039215327,0.00010036684,0.00012340075,0.00013311695],"category_scores_gemma":[0.0001222324,0.000093761475,0.000057344296,0.000026217946,0.00006852184,0.00015516898,0.00002296353,0.00008775844,0.0000030112676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036311414,0.00008710088,0.00033238335,0.000099406905,0.000011506749,1.6442324e-7,0.00028705303,4.3800824e-7,0.9659365,0.0012761513,0.00050982763,0.031096373],"study_design_scores_gemma":[0.0027080558,0.00021171811,0.008417014,0.00053008035,0.000022386375,0.0000011191247,0.000053181782,0.000907553,0.9585773,0.014361967,0.014101012,0.00010862771],"about_ca_topic_score_codex":0.0002885956,"about_ca_topic_score_gemma":0.0000042722513,"teacher_disagreement_score":0.24957505,"about_ca_system_score_codex":0.000030891333,"about_ca_system_score_gemma":0.000034538185,"threshold_uncertainty_score":0.3823482},"labels":[],"label_agreement":null},{"id":"W2604158559","doi":"10.1158/1557-3125.dnarepair16-b24","title":"Abstract B24: Genomic prediction of response to PARP inhibition in breast cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fluidigm (Canada); Université de Montréal","funders":"","keywords":"Olaparib; Veliparib; PARP inhibitor; Cancer research; Breast cancer; Triple-negative breast cancer; Carboplatin; Cancer; Biology; Medicine; Poly ADP ribose polymerase; Oncology; Internal medicine; Gene; Chemotherapy; Genetics; Cisplatin","score_opus":0.0848215422990279,"score_gpt":0.43893050454394916,"score_spread":0.3541089622449213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604158559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97885203,0.00071966054,0.00007438367,0.017630072,0.0001848055,0.00095370854,0.00045092995,0.00002612268,0.0011082768],"genre_scores_gemma":[0.99756396,0.00064635125,0.0000818684,0.00037897422,0.00021681513,0.0007928761,0.000013828355,0.000050611252,0.0002547338],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99739826,0.00021905839,0.00040571447,0.00048009955,0.0009718029,0.00052505085],"domain_scores_gemma":[0.99812824,0.00006219045,0.0001372211,0.00091216393,0.00051428436,0.00024590228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018127058,0.00015808897,0.0003138571,0.0005912844,0.00020282988,0.000059709248,0.000202891,0.00014600206,0.00078767596],"category_scores_gemma":[0.00015842864,0.00016245418,0.00009406669,0.00035232643,0.00027541767,0.00015075156,0.00012714813,0.000542723,0.00004691595],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077427463,0.00013203848,0.027828995,0.00012606895,0.00004782774,0.00021224612,0.00033899152,0.00032092078,0.9559504,0.000037017326,0.0020415534,0.0052212193],"study_design_scores_gemma":[0.0025753607,0.00015648635,0.66068614,0.00091039634,0.000010406288,0.000023049879,0.000052048672,0.000052782638,0.33303493,0.00014395936,0.002253431,0.00010102811],"about_ca_topic_score_codex":0.0053676115,"about_ca_topic_score_gemma":0.00032842474,"teacher_disagreement_score":0.63285714,"about_ca_system_score_codex":0.0013127972,"about_ca_system_score_gemma":0.0009397434,"threshold_uncertainty_score":0.86245},"labels":[],"label_agreement":null},{"id":"W2604170775","doi":"10.1158/1557-3125.dnarepair16-ia08","title":"Abstract IA08: Synthetic viability due to BRCA2 and PARP1 loss","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; PARP1; Olaparib; Cancer research; Biology; Poly ADP ribose polymerase; PARP inhibitor; Cancer cell; Mutation; Cancer; Programmed cell death; Apoptosis; DNA repair; Genetics; Polymerase; DNA; Gene","score_opus":0.08981638857740393,"score_gpt":0.46148543543829396,"score_spread":0.37166904686089003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604170775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639362,0.0011476967,0.00028881364,0.021702336,0.0001499299,0.000998609,0.000039030532,0.000041342675,0.011696057],"genre_scores_gemma":[0.9974244,0.00022113319,0.00025381098,0.00074894563,0.00018979267,0.00045044807,0.0000033667,0.000045194203,0.000662879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974488,0.00012645817,0.00023022632,0.0006284055,0.0009516971,0.0006144155],"domain_scores_gemma":[0.9974954,0.00009762168,0.000059587375,0.0014713195,0.00039548508,0.00048058608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013787727,0.00016599144,0.0003230941,0.00016458638,0.0004856745,0.00017567433,0.0003471684,0.00011641029,0.0008539468],"category_scores_gemma":[0.00053376134,0.00015476227,0.00008332267,0.00015275647,0.0006335756,0.000095603384,0.00022283933,0.0005557004,0.00015393038],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001866022,0.00039313213,0.027705252,0.00081687846,0.00025848602,0.0029181216,0.000854815,0.000038623046,0.8504086,0.0009703624,0.009593207,0.10417651],"study_design_scores_gemma":[0.0032002924,0.0004822314,0.2898436,0.0008754999,0.0000391152,0.00016523547,0.00009267141,0.000065220825,0.62413114,0.0037826071,0.076872624,0.00044979772],"about_ca_topic_score_codex":0.0021204075,"about_ca_topic_score_gemma":0.00014824799,"teacher_disagreement_score":0.26213834,"about_ca_system_score_codex":0.00038461704,"about_ca_system_score_gemma":0.00037110635,"threshold_uncertainty_score":0.93501186},"labels":[],"label_agreement":null},{"id":"W2604289750","doi":"10.1158/1557-3125.dnarepair16-a20","title":"Abstract A20: Synthetic lethality induced by pharmacological inhibition of ATM and PARP1","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP1; Synthetic lethality; DNA damage; Cancer research; Genome instability; Homologous recombination; DNA repair; Mitosis; CHEK1; G2-M DNA damage checkpoint; Biology; Mitotic catastrophe; Chemistry; Cancer; Cell cycle checkpoint; Cell biology; Molecular biology; DNA; Cell cycle; Poly ADP ribose polymerase; Genetics; Polymerase","score_opus":0.16298721908651936,"score_gpt":0.4900513193240388,"score_spread":0.3270641002375194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604289750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871464,0.0015045343,0.000059348396,0.0060562026,0.00007923972,0.00058525556,0.00005975057,0.000023548531,0.0044857427],"genre_scores_gemma":[0.9984056,0.00079122785,0.00005533584,0.00030709055,0.000087105174,0.00022426677,0.000011182567,0.000024645999,0.00009359637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793136,0.00018433716,0.00026462885,0.0004079759,0.0008207255,0.00039097638],"domain_scores_gemma":[0.99876994,0.000084949985,0.00013395475,0.00051563425,0.00027696736,0.00021853561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011175866,0.00013580841,0.00029418909,0.00009882547,0.0002781023,0.00005728981,0.00016435362,0.00015600964,0.0007233728],"category_scores_gemma":[0.00020761197,0.000121690704,0.00007530685,0.0001092062,0.000666145,0.00009646634,0.00012602369,0.0006095187,0.000013812905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042643122,0.00016346935,0.0017172426,0.00013837375,0.00007627646,0.00009646486,0.000073515206,0.000001053992,0.9862324,0.00014032323,0.0020203518,0.008914104],"study_design_scores_gemma":[0.0021652388,0.00024190992,0.023862623,0.00027066478,0.00002978675,0.0000112382095,0.00003093611,0.000020208608,0.9705154,0.00061309244,0.0021226557,0.00011625869],"about_ca_topic_score_codex":0.00093934825,"about_ca_topic_score_gemma":0.000013539429,"teacher_disagreement_score":0.02214538,"about_ca_system_score_codex":0.00020640093,"about_ca_system_score_gemma":0.00021710893,"threshold_uncertainty_score":0.79204243},"labels":[],"label_agreement":null},{"id":"W2604342941","doi":"10.1158/1557-3125.dnarepair16-a05","title":"Abstract A05: Improving outcome in homologous recombination competent epithelial ovarian cancer: Hyperthemia and surgeon's perspective","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; PARP inhibitor; RAD51; Medicine; Hyperthermic intraperitoneal chemotherapy; Ovarian cancer; Cancer research; Homologous recombination; Hsp90 inhibitor; Clonogenic assay; Cancer; Oncology; Cell culture; Internal medicine; Poly ADP ribose polymerase; Hsp90; Biology; Cytoreductive surgery; Heat shock protein; DNA","score_opus":0.08809025331512421,"score_gpt":0.4351979085115385,"score_spread":0.3471076551964143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604342941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760551,0.0029679453,0.000054857825,0.015505414,0.00034673745,0.00088569336,0.00005792833,0.000038246042,0.004088094],"genre_scores_gemma":[0.9972483,0.0011484422,0.00015622299,0.00027748206,0.00017864301,0.00050336006,0.00000795594,0.00005248702,0.00042712153],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974662,0.00015777176,0.00034117463,0.00064235216,0.000756866,0.0006356206],"domain_scores_gemma":[0.9982535,0.000101061894,0.00016188467,0.0007003133,0.0005720947,0.00021114537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013420179,0.00020595652,0.00041594502,0.00038147328,0.00044831456,0.0001546079,0.00029063498,0.00017024933,0.0003459663],"category_scores_gemma":[0.00039249856,0.00019950783,0.00009682481,0.00019522443,0.0004390736,0.00016745209,0.00016631577,0.0009177312,0.000014434831],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013665262,0.00035541458,0.2418105,0.00034573182,0.00021229223,0.0015652794,0.0014765625,0.00005556054,0.6520187,0.003087324,0.0003218938,0.09738417],"study_design_scores_gemma":[0.00946053,0.000354826,0.8319919,0.0006391237,0.000043924207,0.00006393234,0.00069613283,0.0005015486,0.15029378,0.00353696,0.001963659,0.00045365785],"about_ca_topic_score_codex":0.043556366,"about_ca_topic_score_gemma":0.0018551373,"teacher_disagreement_score":0.5901814,"about_ca_system_score_codex":0.0018251473,"about_ca_system_score_gemma":0.00065293006,"threshold_uncertainty_score":0.96281266},"labels":[],"label_agreement":null},{"id":"W2604395271","doi":"10.1158/1557-3125.dnarepair16-a08","title":"Abstract A08: PARP1-mediated E2F1 regulation of DNA repair capacity","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"PARP1; DNA repair; Biology; Cancer research; DNA damage; Transcriptome; Chromatin; Genome instability; ARID1A; Context (archaeology); Synthetic lethality; Genetics; Gene; Poly ADP ribose polymerase; DNA; Gene expression; Polymerase; Mutation","score_opus":0.14254416371849093,"score_gpt":0.4418369842869411,"score_spread":0.2992928205684502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604395271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821447,0.0007523396,0.0001199169,0.0027382015,0.0001751087,0.00068504555,0.000061842744,0.00008432538,0.013238486],"genre_scores_gemma":[0.99803364,0.00029373312,0.0004116484,0.00017319825,0.00020838958,0.00019605242,0.00003190632,0.00004490219,0.0006065293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972279,0.00011191644,0.00037461292,0.00043609994,0.0013644849,0.00048497212],"domain_scores_gemma":[0.9971854,0.000090741305,0.00021968476,0.00144281,0.0008379098,0.00022342298],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013511163,0.00015381657,0.00033575506,0.00023955389,0.00032919436,0.000043173088,0.00031033045,0.00017639267,0.0011459532],"category_scores_gemma":[0.00061183114,0.0001483128,0.00019029126,0.00023763135,0.0006741876,0.00014212859,0.0000948209,0.0005486409,0.000072331844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054429326,0.00016692538,0.009557294,0.00025690667,0.00014903923,0.000081245606,0.0001967589,0.000023421666,0.98011506,0.0006126243,0.006031901,0.0022645209],"study_design_scores_gemma":[0.0021442003,0.00021950503,0.23650965,0.0004698502,0.000024058492,0.000009292997,0.000029827565,0.00020253361,0.7467666,0.0013807312,0.012090708,0.00015299446],"about_ca_topic_score_codex":0.0021081404,"about_ca_topic_score_gemma":0.00011587843,"teacher_disagreement_score":0.23334841,"about_ca_system_score_codex":0.0004097052,"about_ca_system_score_gemma":0.00050077826,"threshold_uncertainty_score":0.9997671},"labels":[],"label_agreement":null},{"id":"W2604408487","doi":"10.1158/1557-3125.dnarepair16-ia10","title":"Abstract IA10: DNA repair mutations in ovarian carcinoma and relationship to therapeutic response","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Homologous recombination; Cancer research; Ovarian cancer; Germline mutation; Ovarian carcinoma; Somatic cell; Poly ADP ribose polymerase; Cancer; BRCA2 Protein; DNA repair; PARP inhibitor; DNA Damage Repair; Germline; Chemotherapy; Mutation; Biology; Gene; Medicine; Genetics; Polymerase","score_opus":0.15278466256170362,"score_gpt":0.46641228470198176,"score_spread":0.3136276221402782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604408487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96326554,0.0009851347,0.00014391802,0.031047242,0.000079503356,0.0011421752,0.000020338142,0.0000394731,0.0032766522],"genre_scores_gemma":[0.9970552,0.000038726324,0.00045064517,0.00074385153,0.000087931665,0.0007510508,0.000006666879,0.000042779826,0.0008231502],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977421,0.00037427494,0.0002844027,0.00046399562,0.0006800087,0.00045521255],"domain_scores_gemma":[0.9980457,0.00031782853,0.00006461133,0.001031991,0.00027301026,0.00026689586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024165078,0.00013436525,0.00021228484,0.0005312442,0.0004973358,0.00011662995,0.0002040376,0.00011994792,0.00022304876],"category_scores_gemma":[0.0010344973,0.000136741,0.00007176808,0.0003605309,0.0002890289,0.00012619338,0.000093233044,0.0005977581,0.000057118104],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00634923,0.0001530191,0.35379827,0.00013685554,0.000094352035,0.0013675333,0.002446257,0.000081329126,0.6268275,0.0025373916,0.0014888211,0.004719451],"study_design_scores_gemma":[0.0020129792,0.00019462209,0.96146226,0.00023464879,0.000013091342,0.000028711978,0.00015416449,0.00007441229,0.030886756,0.001690622,0.0031091738,0.00013857496],"about_ca_topic_score_codex":0.0015525019,"about_ca_topic_score_gemma":0.00034781604,"teacher_disagreement_score":0.607664,"about_ca_system_score_codex":0.0005176908,"about_ca_system_score_gemma":0.00071834854,"threshold_uncertainty_score":0.5576136},"labels":[],"label_agreement":null},{"id":"W2604439647","doi":"10.1158/1557-3125.dnarepair16-b26","title":"Abstract B26: Development of a proximity ligation assay for the detection of PARP-1 trapped to chromatin","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP1; Poly ADP ribose polymerase; PARP inhibitor; Chromatin; Synthetic lethality; Cancer research; Context (archaeology); Chemistry; DNA repair; Biology; Computational biology; Cell biology; DNA; Polymerase; Biochemistry","score_opus":0.1337399826429144,"score_gpt":0.45631497473415955,"score_spread":0.3225749920912452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604439647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94817716,0.0004624219,0.04557253,0.0029034652,0.00009587633,0.002288514,0.000020376345,0.000013047773,0.00046663717],"genre_scores_gemma":[0.9962515,0.000041850602,0.0019714711,0.000060031478,0.000072664414,0.0014883893,0.0000044542985,0.000021549096,0.00008807783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99836814,0.000066695706,0.00032779682,0.00022093611,0.00076341216,0.00025298723],"domain_scores_gemma":[0.99837756,0.00012808143,0.00018715867,0.00057378464,0.00064966496,0.000083765706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020226324,0.000089526664,0.00020217788,0.0001297107,0.00033633795,0.000027514054,0.00024359692,0.00007121492,0.000055476725],"category_scores_gemma":[0.00043817895,0.00006827099,0.0000830305,0.00016483867,0.00016590867,0.000060840714,0.000048862355,0.00019198323,0.0000044570334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056719,0.00006687904,0.0002596414,0.00027536548,0.00009145457,0.0000015238008,0.00066826626,0.000026828353,0.8837826,0.000039255745,0.0001131098,0.114107855],"study_design_scores_gemma":[0.0011503631,0.0001780137,0.049943425,0.00032590728,0.0000152472085,0.0000011621019,0.000083280334,0.0002010989,0.94426817,0.000188744,0.0035825416,0.00006205454],"about_ca_topic_score_codex":0.00037301966,"about_ca_topic_score_gemma":0.00024346038,"teacher_disagreement_score":0.114045806,"about_ca_system_score_codex":0.00026244065,"about_ca_system_score_gemma":0.0006157521,"threshold_uncertainty_score":0.278401},"labels":[],"label_agreement":null},{"id":"W2604471236","doi":"10.1158/1557-3125.dnarepair16-ia02","title":"Abstract IA02: Defects in DNA repair genes revealed by clinical sequencing of advanced cancer patients","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CHEK2; Olaparib; PALB2; Germline; Cancer; DNA repair; Biology; Germline mutation; Prostate cancer; Carcinogenesis; MSH6; Cancer research; Gene; Genetics; Medicine; Oncology; Mutation; DNA mismatch repair; Polymerase","score_opus":0.12731917617420505,"score_gpt":0.4974591766693195,"score_spread":0.3701400004951144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604471236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890739,0.0065846285,0.000012190052,0.0008313458,0.0003073967,0.0010700874,0.000092065784,0.00004096599,0.0019874412],"genre_scores_gemma":[0.9944037,0.003793414,0.00030258056,0.00033979872,0.0001493921,0.000551283,0.000022254191,0.00006487206,0.00037268683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963485,0.00029648075,0.00076200423,0.0006844943,0.00122714,0.0006813842],"domain_scores_gemma":[0.99732673,0.00015673427,0.00033821448,0.0011526011,0.00075874274,0.00026696676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017469479,0.00020923768,0.0005901785,0.00023394225,0.00020782098,0.00003443335,0.00041826745,0.00021557733,0.000330881],"category_scores_gemma":[0.00076334405,0.00020316683,0.00025033773,0.0002873772,0.00051363173,0.00016696312,0.00015686885,0.0008159141,0.000015443286],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010502312,0.00027302816,0.43463197,0.00036604828,0.00012183313,0.00015386342,0.00013528386,0.000060753748,0.5401272,0.000024398214,0.004542745,0.018512636],"study_design_scores_gemma":[0.008108824,0.00054541754,0.4662783,0.001981559,0.00003297377,0.000002209661,0.000065370084,0.000068136615,0.5158397,0.00022521289,0.00655799,0.00029428845],"about_ca_topic_score_codex":0.0034150362,"about_ca_topic_score_gemma":0.0006433622,"teacher_disagreement_score":0.031646345,"about_ca_system_score_codex":0.0010376663,"about_ca_system_score_gemma":0.0011433869,"threshold_uncertainty_score":0.82849026},"labels":[],"label_agreement":null},{"id":"W2604491809","doi":"10.1158/1557-3125.dnarepair16-b33","title":"Abstract B33: PARP-dependent co-modulation of DNA repair and microglial activity as a dual-pronged anti-glioblastoma treatment strategy","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; Research Institute in Oncology and Hematology; University of Manitoba","funders":"","keywords":"Cancer research; DNA repair; Microglia; Poly ADP ribose polymerase; Radioresistance; Cancer; DNA damage; Temozolomide; Cancer cell; Brain tumor; Immune system; PARP inhibitor; Medicine; Radiation therapy; Biology; Immunology; Glioma; Inflammation; Pathology; Internal medicine; DNA; Polymerase","score_opus":0.09384369509480044,"score_gpt":0.4551935700639455,"score_spread":0.36134987496914506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604491809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941033,0.00066209765,0.000024600406,0.0015745602,0.00006770329,0.0011959133,0.00009752212,0.000048833506,0.0022254363],"genre_scores_gemma":[0.9980414,0.0007890345,0.000085499414,0.000045744,0.00015779119,0.00024661177,0.000013282272,0.000045497243,0.00057514344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99749583,0.00015583786,0.0002822917,0.000582607,0.0009914963,0.0004919256],"domain_scores_gemma":[0.998135,0.000047854555,0.00019591274,0.0009891795,0.00038704585,0.00024503452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006445402,0.00021878345,0.00046482144,0.00022555407,0.0003708012,0.00009848442,0.000116443785,0.00017219131,0.00026727133],"category_scores_gemma":[0.000082721905,0.00019985807,0.0001687461,0.00010594213,0.00047455283,0.0001570956,0.00007622288,0.00035662323,0.000016703547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027966558,0.00041653917,0.0069687185,0.00019614284,0.00030622762,0.00068796135,0.0001757436,0.000029671497,0.9680583,0.00004664347,0.00016732869,0.02015008],"study_design_scores_gemma":[0.0044865967,0.0015404845,0.17841858,0.00019075334,0.000042962973,0.00008823098,0.000047583224,0.00014104716,0.8140984,0.000107150285,0.0007003885,0.0001378157],"about_ca_topic_score_codex":0.0032648281,"about_ca_topic_score_gemma":0.00027017537,"teacher_disagreement_score":0.17144985,"about_ca_system_score_codex":0.0006226595,"about_ca_system_score_gemma":0.0008028067,"threshold_uncertainty_score":0.81499755},"labels":[],"label_agreement":null},{"id":"W2604665854","doi":"10.1158/1557-3125.dnarepair16-b30","title":"Abstract B30: Talazoparib efficacy is enhanced by noncytotoxic doses of temozolomide-mediated DNA damage in prostate cancer cell lines","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"LNCaP; Prostate cancer; Cancer research; Enzalutamide; Olaparib; PARP inhibitor; Cancer; Cancer cell; Temozolomide; Poly ADP ribose polymerase; DNA damage; Chemistry; Molecular biology; Biology; Androgen receptor; Medicine; DNA; Internal medicine; Polymerase; Biochemistry","score_opus":0.05409114726025496,"score_gpt":0.4316400059492908,"score_spread":0.37754885868903587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604665854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98155504,0.007885896,0.000016620734,0.0032258604,0.0001910517,0.0017466085,0.0004942726,0.000044721906,0.004839895],"genre_scores_gemma":[0.9890635,0.0075323745,0.00007026013,0.00046824114,0.00014136037,0.0009849704,0.00007456551,0.0001032686,0.0015614487],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99599767,0.00016943438,0.0006984527,0.0007980736,0.0013728417,0.00096350815],"domain_scores_gemma":[0.9971043,0.00017600763,0.00036671662,0.0013500758,0.00068638043,0.0003165519],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009363377,0.00034219466,0.0006875889,0.00028934944,0.0002692157,0.00011021642,0.00066312146,0.00021738393,0.0014699441],"category_scores_gemma":[0.0002811607,0.00032465332,0.00016941402,0.0004691864,0.0007417526,0.00025782725,0.00019297714,0.0008746115,0.00005779567],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013952784,0.0004574912,0.0046507646,0.00044429625,0.00009119459,0.00014569533,0.00075829227,0.00004271584,0.9807274,0.000004682323,0.008445215,0.0028369778],"study_design_scores_gemma":[0.006960566,0.00026336143,0.030938674,0.00091658806,0.000022000817,0.0000015030531,0.00013001284,0.00006290204,0.9555122,0.00004449485,0.0048622154,0.0002854438],"about_ca_topic_score_codex":0.010821115,"about_ca_topic_score_gemma":0.001064494,"teacher_disagreement_score":0.02628791,"about_ca_system_score_codex":0.00073049514,"about_ca_system_score_gemma":0.0012105945,"threshold_uncertainty_score":0.99992055},"labels":[],"label_agreement":null},{"id":"W2604730946","doi":"10.1158/1557-3125.dnarepair16-ia19","title":"Abstract IA19: PARP trapping and Schlafen 11","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Poly ADP ribose polymerase; Cancer research; PARP1; Biology; Cancer cell; Cancer; Homologous recombination; Polymerase; PARP inhibitor; Genetics; DNA","score_opus":0.16942444757704309,"score_gpt":0.4950988911316901,"score_spread":0.32567444355464703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604730946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578343,0.004133824,0.00017222395,0.016760226,0.00013572341,0.0005615098,0.00001643534,0.00004583611,0.020339914],"genre_scores_gemma":[0.9966984,0.0011837541,0.0001913598,0.00050083944,0.00025408124,0.0002162385,0.0000051424595,0.000041933436,0.0009082917],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979988,0.00006558004,0.00018555099,0.00042372398,0.0008007813,0.00052556116],"domain_scores_gemma":[0.9984895,0.000046436162,0.000069980386,0.00085394556,0.00025950323,0.0002806587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083419663,0.00013513242,0.0002342296,0.00017734568,0.00058000075,0.000198316,0.00026116706,0.00010856436,0.0006207897],"category_scores_gemma":[0.00017231952,0.00012802824,0.000072760966,0.00011589309,0.00050405844,0.00013735496,0.00012088704,0.00053041906,0.000047679132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044746257,0.00010733477,0.023810452,0.00033539525,0.00017881572,0.0008439469,0.00038635777,0.0000106179905,0.9118933,0.0016339091,0.008216565,0.05213584],"study_design_scores_gemma":[0.006116947,0.00025685248,0.2537744,0.0012507887,0.00004266956,0.000082649145,0.00019795344,0.00015252376,0.5760408,0.0022350587,0.15942466,0.00042471083],"about_ca_topic_score_codex":0.001404917,"about_ca_topic_score_gemma":0.00011976137,"teacher_disagreement_score":0.3358525,"about_ca_system_score_codex":0.00019266855,"about_ca_system_score_gemma":0.0003581452,"threshold_uncertainty_score":0.6797212},"labels":[],"label_agreement":null},{"id":"W2604832180","doi":"10.1158/1557-3125.dnarepair16-pr21","title":"Abstract PR21: DEK is critical for homologous recombination and its loss is synthetic lethal with DNA-PK inhibition","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RAD51; Homologous recombination; DNA repair; Genome instability; Synthetic lethality; DNA; DNA damage; Biology; Chromatin; Molecular biology; Cancer research; Genetics; Cell biology","score_opus":0.10620283975441815,"score_gpt":0.46351342330453044,"score_spread":0.3573105835501123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604832180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9499546,0.001598742,0.0008520009,0.043631658,0.00010447651,0.0012810588,0.00012987203,0.0000373203,0.002410269],"genre_scores_gemma":[0.99674624,0.00038638915,0.00033785807,0.0008831649,0.00014455544,0.0009364427,0.000017858676,0.0000616232,0.00048585288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769026,0.00008967194,0.00022901519,0.0005959706,0.00082449266,0.00057061407],"domain_scores_gemma":[0.99799293,0.00018008481,0.0000839285,0.00056679675,0.00094025035,0.00023601488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008051914,0.00018257518,0.00027628816,0.00020537541,0.00061198,0.0001741394,0.00015262986,0.00017808478,0.00047538668],"category_scores_gemma":[0.0004303401,0.00016625006,0.00007556082,0.00012205152,0.0006058938,0.0002093015,0.0000680062,0.00047452006,0.000030759194],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005630074,0.00088155223,0.002897938,0.0027900857,0.00043135462,0.0023795606,0.0018113975,0.000007995184,0.92124236,0.009687857,0.014725782,0.037514072],"study_design_scores_gemma":[0.0045554126,0.0010978588,0.008868868,0.0010677768,0.00006370468,0.0002734016,0.00008969526,0.00025060476,0.974202,0.006099491,0.0031507052,0.000280509],"about_ca_topic_score_codex":0.00018538402,"about_ca_topic_score_gemma":0.000025616806,"teacher_disagreement_score":0.05295964,"about_ca_system_score_codex":0.00033025688,"about_ca_system_score_gemma":0.00037381423,"threshold_uncertainty_score":0.67794806},"labels":[],"label_agreement":null},{"id":"W2604904989","doi":"10.1158/1557-3125.dnarepair16-pr04","title":"Abstract PR04: Mechanism for PARPi resistance: Homologous recombination without BRCA1","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; DNA repair; Homologous recombination; DNA damage; Synthetic lethality; Cancer research; Cisplatin; DNA; Chemistry; PARP inhibitor; Molecular biology; Biology; Poly ADP ribose polymerase; Genetics; Polymerase; Chemotherapy","score_opus":0.12238069275435087,"score_gpt":0.47264569107412313,"score_spread":0.35026499831977226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604904989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9197171,0.0023083196,0.006372663,0.03464068,0.00096005044,0.00426786,0.00014661242,0.00017207669,0.031414673],"genre_scores_gemma":[0.9878969,0.00050377485,0.0017409609,0.0005747849,0.00029586675,0.0021930817,0.000035862715,0.000084012136,0.0066747568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727327,0.000104746265,0.0003067977,0.0006122087,0.0010148538,0.0006880987],"domain_scores_gemma":[0.99703085,0.00008908898,0.00018717135,0.0012329778,0.001238964,0.00022094187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014234945,0.00019145926,0.00033971897,0.00023015085,0.0008458093,0.00018921743,0.00045270598,0.00020424619,0.00034775527],"category_scores_gemma":[0.00058405986,0.00018868806,0.00015651326,0.00014401556,0.00031851677,0.00015781533,0.00008538111,0.0005539924,0.00005308735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003847752,0.00045771792,0.002128398,0.0010210912,0.00042390267,0.00047026688,0.0005488602,0.000014834293,0.8831138,0.053210735,0.033502642,0.02126002],"study_design_scores_gemma":[0.008846899,0.00054333085,0.009252496,0.0008898754,0.00006279778,0.00002711236,0.0001362321,0.00016020013,0.8499084,0.09870766,0.031037873,0.00042711923],"about_ca_topic_score_codex":0.0003725486,"about_ca_topic_score_gemma":0.00027593682,"teacher_disagreement_score":0.06817984,"about_ca_system_score_codex":0.000669216,"about_ca_system_score_gemma":0.0006126417,"threshold_uncertainty_score":0.7694476},"labels":[],"label_agreement":null},{"id":"W2605004001","doi":"10.3390/ijms18040788","title":"Microvesicles Contribute to the Bystander Effect of DNA Damage","year":2017,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"","keywords":"Bystander effect; DU145; DNA damage; Microvesicles; Cancer research; Chemistry; Cancer cell; Cell biology; Biology; Molecular biology; DNA; Immunology; Cancer; microRNA; Biochemistry; Genetics; LNCaP","score_opus":0.017817224206142675,"score_gpt":0.36142175823887396,"score_spread":0.3436045340327313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605004001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740364,0.00040084912,0.003232876,0.019985728,0.00074351975,0.00010542521,0.000010191619,0.000002333238,0.001482671],"genre_scores_gemma":[0.9981517,0.00003616984,0.00052295736,0.0010553629,0.00018590825,0.0000017141629,3.666651e-7,0.0000037217742,0.000042081178],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868906,0.00005891231,0.00025550055,0.00008692617,0.00081599207,0.00009358615],"domain_scores_gemma":[0.9987921,0.000102154765,0.00043132433,0.00017141755,0.00043799958,0.00006500288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012020331,0.000064626845,0.00016384975,0.00011181128,0.000114822964,0.00010601526,0.00081761484,0.000020608455,0.000048085298],"category_scores_gemma":[0.00043026998,0.0000364703,0.00012796036,0.000054001306,0.00031049197,0.00014408291,0.00006174228,0.00008950453,0.000005020505],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004915839,0.000038799033,0.008206466,0.000006823242,0.00020284991,0.00018488319,0.00019756846,0.00015263217,0.98112214,0.0009627943,0.0020875067,0.0063459664],"study_design_scores_gemma":[0.0018434061,0.0008155208,0.018790556,0.00025844446,0.00003475204,0.00027888466,0.000057140187,0.000048963408,0.97196287,0.0004893338,0.0053688693,0.000051248786],"about_ca_topic_score_codex":0.000013738074,"about_ca_topic_score_gemma":0.000003141303,"teacher_disagreement_score":0.024115311,"about_ca_system_score_codex":0.00003931426,"about_ca_system_score_gemma":0.00012330525,"threshold_uncertainty_score":0.15193453},"labels":[],"label_agreement":null},{"id":"W2605040750","doi":"10.1158/1557-3125.dnarepair16-a42","title":"Abstract A42: Identification of glutamate and aspartate ADP-ribosylation sites onto histones by mass mass spectrometry","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Université Laval","funders":"","keywords":"Histone; ADP-ribosylation; Chromatin; Nucleosome; Histone-modifying enzymes; Biochemistry; Chemistry; Histone H2A; Biology; DNA; Enzyme; NAD+ kinase","score_opus":0.06802772230277758,"score_gpt":0.4310880905491066,"score_spread":0.363060368246329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605040750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98558205,0.0058698347,0.0020366344,0.0037262882,0.00011802604,0.00054301234,0.000106275205,0.0000306778,0.0019871988],"genre_scores_gemma":[0.99628043,0.0015763552,0.00043123038,0.00005672311,0.0000876132,0.00013574326,0.00005835989,0.000039722854,0.0013338462],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977957,0.000094068775,0.0003729988,0.00042507704,0.00093874,0.00037342333],"domain_scores_gemma":[0.9983174,0.000055361066,0.0002791406,0.0007658002,0.00042777948,0.00015449733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010148913,0.0001468704,0.00027985193,0.0002687659,0.00029859948,0.00012783866,0.00022884883,0.00010766437,0.00034397232],"category_scores_gemma":[0.00017679212,0.00014917937,0.00006971566,0.00018694878,0.00040159162,0.00021809316,0.00004598914,0.00032271072,0.000030236035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002891119,0.000047280875,0.00993877,0.00023146586,0.000080559614,0.00003545389,0.00011029385,0.000010531466,0.9855021,0.00017939985,0.0016861745,0.0018888114],"study_design_scores_gemma":[0.0011902287,0.000110452886,0.0748919,0.00016593511,0.000027422924,0.0000052910414,0.00004584089,0.00016910346,0.9200039,0.0014496768,0.0018115464,0.00012870232],"about_ca_topic_score_codex":0.00081625034,"about_ca_topic_score_gemma":0.00006157412,"teacher_disagreement_score":0.065498255,"about_ca_system_score_codex":0.00039689947,"about_ca_system_score_gemma":0.00016242173,"threshold_uncertainty_score":0.6083358},"labels":[],"label_agreement":null},{"id":"W2605117944","doi":"10.1158/1557-3125.dnarepair16-ia03","title":"Abstract IA03: Targeting the DNA damage response to generate new medicines for cancer treatment","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DNA damage; Cancer; Genome instability; Cancer research; DNA repair; Cancer cell; Synthetic lethality; DNA Damage Repair; Biology; Medicine; DNA; Genetics","score_opus":0.1617560617625099,"score_gpt":0.5000201570030657,"score_spread":0.3382640952405558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605117944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8322744,0.004840066,0.0005377825,0.15839733,0.00044954693,0.0023193,0.00010283304,0.000043140913,0.0010356024],"genre_scores_gemma":[0.9781549,0.0013458171,0.00079208397,0.0035448023,0.0021545186,0.003468545,0.000021862177,0.00011365464,0.010403798],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99712116,0.00021447071,0.00031793892,0.00058752066,0.00094940973,0.0008095012],"domain_scores_gemma":[0.99727494,0.0002839212,0.00012587212,0.0012709993,0.0005683219,0.0004759497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019990879,0.00025062927,0.00036386223,0.00019725245,0.0010608202,0.00019928541,0.0005351925,0.00010521096,0.000740994],"category_scores_gemma":[0.0007577806,0.00016709825,0.00017040131,0.00022731154,0.00028395283,0.000088593086,0.000113681104,0.00033335888,0.000047635105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053699985,0.000058960755,0.0006383639,0.000054034273,0.00020333778,0.00014383862,0.00090459327,0.0002171855,0.8995993,0.00005838752,0.06941856,0.02333345],"study_design_scores_gemma":[0.0038155562,0.00060921925,0.009976032,0.0003248925,0.000051740048,0.000004682934,0.00014939501,0.00012077083,0.6176135,0.00020044515,0.3669547,0.000179023],"about_ca_topic_score_codex":0.006336464,"about_ca_topic_score_gemma":0.0007528141,"teacher_disagreement_score":0.29753616,"about_ca_system_score_codex":0.0010587055,"about_ca_system_score_gemma":0.0019113944,"threshold_uncertainty_score":0.95788807},"labels":[],"label_agreement":null},{"id":"W2605149585","doi":"10.1158/1557-3125.dnarepair16-b37","title":"Abstract B37: PARP inhibitor olaparib induces genomic instability in normal mammalian cells","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Genome instability; Synthetic lethality; Cancer research; PARP inhibitor; DNA damage; Biology; Cancer; DNA repair; Homologous recombination; Poly ADP ribose polymerase; Cancer cell; Genetics; DNA; Polymerase","score_opus":0.09678876057542579,"score_gpt":0.4215421838372961,"score_spread":0.3247534232618703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605149585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98326147,0.0012855399,0.000012684962,0.003952546,0.0004083404,0.0010188121,0.0000601381,0.00003712502,0.009963325],"genre_scores_gemma":[0.99783266,0.00034210796,0.00016190438,0.0003636641,0.0004203534,0.00044307936,0.000015229648,0.000063623906,0.0003573566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99642986,0.00021822637,0.0004940859,0.0007302257,0.0011577175,0.000969886],"domain_scores_gemma":[0.99757683,0.00006879205,0.00015480013,0.001497189,0.00033966918,0.00036269537],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018845447,0.00025033482,0.00042779674,0.00036718894,0.00043359713,0.00021559514,0.00062389066,0.0002521637,0.0012073984],"category_scores_gemma":[0.0001781173,0.00025052068,0.00014493511,0.00027916118,0.0006561965,0.00027220044,0.00028176815,0.0013758518,0.00020476808],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073784875,0.0002456197,0.026300216,0.00020187776,0.000045635803,0.00050651334,0.00037531924,0.000042098374,0.96049625,0.00009407152,0.001124052,0.009830502],"study_design_scores_gemma":[0.003008086,0.00015488044,0.2675357,0.00025664302,0.000009381134,0.0000081931585,0.00010481842,0.000019976502,0.71562284,0.0002830166,0.012764293,0.00023220092],"about_ca_topic_score_codex":0.0072131422,"about_ca_topic_score_gemma":0.0012103773,"teacher_disagreement_score":0.24487342,"about_ca_system_score_codex":0.0011729677,"about_ca_system_score_gemma":0.0011435369,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W2605152816","doi":"10.1158/1557-3125.dnarepair16-ia26","title":"Abstract IA26: Dual functions of PARP1 in prostate cancer: mechanisms and implications for therapeutic intervention","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP1; Prostate cancer; Androgen receptor; Cancer research; DNA repair; Cancer; DNA damage; Medicine; Androgen deprivation therapy; Androgen Receptor Antagonists; Biology; Poly ADP ribose polymerase; Internal medicine; DNA; Genetics","score_opus":0.1285190234829344,"score_gpt":0.4834195393946122,"score_spread":0.3549005159116778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605152816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96225184,0.008008164,0.0062133446,0.01900226,0.0002404532,0.0029063446,0.00043038608,0.000032280437,0.0009149383],"genre_scores_gemma":[0.9944616,0.0014372448,0.00026372145,0.00010736997,0.00005336034,0.0031460824,0.000025080764,0.00002573221,0.00047981765],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99872,0.000058571157,0.00028232156,0.00032516356,0.00028780705,0.0003261184],"domain_scores_gemma":[0.9988532,0.00005854774,0.00013924802,0.00044287078,0.0004103424,0.000095810996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007247733,0.00010610455,0.00021752312,0.00022862406,0.00025988938,0.00005206626,0.00013044939,0.00006795691,0.000119475364],"category_scores_gemma":[0.000061554,0.00010271786,0.000092092836,0.00015152343,0.00024357712,0.00010490561,0.000059614795,0.00026482588,0.0000013740896],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008353008,0.00022429683,0.012487255,0.00041284223,0.00015615881,0.000009267654,0.00025142677,0.000043918528,0.89403486,0.0041154483,0.0009295297,0.086499706],"study_design_scores_gemma":[0.010350105,0.00094850356,0.5491188,0.0014099377,0.00010471985,0.000016431753,0.00045426728,0.00029237533,0.3882004,0.038814366,0.009968037,0.00032206014],"about_ca_topic_score_codex":0.0022928573,"about_ca_topic_score_gemma":0.0013624909,"teacher_disagreement_score":0.5366315,"about_ca_system_score_codex":0.0002468085,"about_ca_system_score_gemma":0.000282396,"threshold_uncertainty_score":0.41887128},"labels":[],"label_agreement":null},{"id":"W2605232456","doi":"10.1158/1557-3125.dnarepair16-ia23","title":"Abstract IA23: Using PARP inhibitors to target ATM-deficient cancers","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Olaparib; Cancer research; Cancer; PARP inhibitor; Poly ADP ribose polymerase; Medicine; DNA damage; Biology; Polymerase; Internal medicine; Genetics; DNA","score_opus":0.1650133318574962,"score_gpt":0.49274205877005106,"score_spread":0.32772872691255484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605232456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97538185,0.002583756,0.0007280574,0.007166158,0.0007560562,0.0012745644,0.00006911141,0.00006710707,0.0119733615],"genre_scores_gemma":[0.9952496,0.00020079002,0.0015415143,0.0011399863,0.00063018827,0.0003910834,0.000010407307,0.000098970435,0.00073742116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958167,0.00010774649,0.00038141705,0.00077222276,0.0018250417,0.0010968441],"domain_scores_gemma":[0.9969951,0.00004271861,0.00014343111,0.0015121831,0.00066166255,0.0006448947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011484708,0.0002670046,0.00040432447,0.00038982797,0.0009141207,0.00025242378,0.00054466684,0.00016143524,0.0010932799],"category_scores_gemma":[0.0002736473,0.00026182932,0.00018577138,0.00042271172,0.00043218126,0.00015374672,0.0002692461,0.0007754326,0.00018520736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070802186,0.000117279335,0.0061669,0.00016564057,0.00015375369,0.0009227549,0.0005228764,0.0036417134,0.9692327,0.00022578129,0.011233318,0.00690926],"study_design_scores_gemma":[0.002978941,0.00034627336,0.013706402,0.0011445188,0.000038026443,0.00005663376,0.0002290606,0.0006069975,0.84936774,0.00040130742,0.13060671,0.0005173804],"about_ca_topic_score_codex":0.008494247,"about_ca_topic_score_gemma":0.00020119075,"teacher_disagreement_score":0.11986496,"about_ca_system_score_codex":0.002704497,"about_ca_system_score_gemma":0.0017678231,"threshold_uncertainty_score":0.9999834},"labels":[],"label_agreement":null},{"id":"W2605257640","doi":"10.1158/1557-3125.dnarepair16-a38","title":"Abstract A38: Targeting Microenvironment Damage Responses via PARP inhibition to Enhance Prostate Cancer Therapy","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer research; Prostate cancer; Bystander effect; Cancer; PARP inhibitor; Tumor microenvironment; Pharmacology; Radiation therapy; Internal medicine; Immunology; Poly ADP ribose polymerase; Biology; DNA","score_opus":0.06317075706267772,"score_gpt":0.45030814344949793,"score_spread":0.3871373863868202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605257640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656624,0.0069411113,0.0003425244,0.023356821,0.00024239818,0.0020440249,0.0001270079,0.000068123285,0.0012155965],"genre_scores_gemma":[0.9837684,0.0077674044,0.0006313162,0.0020985228,0.00043203591,0.002538173,0.000032983025,0.00012173836,0.0026094292],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958361,0.0002738121,0.00046035583,0.00092840847,0.0014475551,0.0010537945],"domain_scores_gemma":[0.9975045,0.00008095607,0.00021201359,0.0013595672,0.00039665506,0.0004463644],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00157933,0.00032816187,0.00040394423,0.00031826692,0.0009614024,0.0002548357,0.0004149028,0.00014882658,0.0015594574],"category_scores_gemma":[0.00018847502,0.00031319546,0.00015130153,0.00027215967,0.00048464665,0.00024128071,0.00022893069,0.000845084,0.00023343685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002813536,0.00017445924,0.0041930987,0.000104210994,0.00010987434,0.00039504975,0.000670706,0.00013286722,0.9504965,0.000011606029,0.00687418,0.034023926],"study_design_scores_gemma":[0.0016222239,0.00033053436,0.037825175,0.00067487254,0.0000127591065,0.000006852287,0.000064467386,0.000024935303,0.90080243,0.00020120028,0.058128443,0.00030612148],"about_ca_topic_score_codex":0.0025070386,"about_ca_topic_score_gemma":0.00013686066,"teacher_disagreement_score":0.05125426,"about_ca_system_score_codex":0.0010982438,"about_ca_system_score_gemma":0.00052588125,"threshold_uncertainty_score":0.999932},"labels":[],"label_agreement":null},{"id":"W2605260868","doi":"10.1158/1557-3125.dnarepair16-a12","title":"Abstract A12: CTCF facilitates DNA double-strand break repair by homologous recombination","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre; Jewish General Hospital","funders":"","keywords":"CTCF; Homologous recombination; DNA repair; DNA; Genome instability; DNA damage; Biology; Molecular biology; Chemistry; Cancer research; Cell biology; Genetics; Gene","score_opus":0.09898827803015828,"score_gpt":0.4448352899452682,"score_spread":0.3458470119151099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605260868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589334,0.004232132,0.00010307808,0.011251646,0.0003049566,0.0010943192,0.00014441584,0.00016998591,0.023766056],"genre_scores_gemma":[0.9930066,0.0010722851,0.00013251576,0.00028255067,0.00012837272,0.00055568956,0.00009913142,0.000057572688,0.004665274],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99694365,0.00013196025,0.00035210865,0.0006767568,0.001183214,0.00071228354],"domain_scores_gemma":[0.99758416,0.000089261586,0.00013007216,0.0012802818,0.0006200247,0.0002962049],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013842685,0.00021403925,0.0003451357,0.00022456712,0.0006708964,0.00017844517,0.00042142862,0.00021648976,0.0014605046],"category_scores_gemma":[0.00018052002,0.00021544866,0.00020079233,0.0001904793,0.0005991683,0.00022042086,0.00010115386,0.0007763684,0.00017576793],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023899744,0.000416321,0.0041094986,0.00038585268,0.00035185387,0.0006849967,0.0004962663,0.000017267042,0.87107664,0.00031191096,0.09238962,0.027369777],"study_design_scores_gemma":[0.011920547,0.0006654077,0.028479576,0.0005081395,0.000047650454,0.000075455944,0.00014529238,0.00007363855,0.85644037,0.0024242129,0.09876078,0.00045895018],"about_ca_topic_score_codex":0.0031248734,"about_ca_topic_score_gemma":0.00012770543,"teacher_disagreement_score":0.034073196,"about_ca_system_score_codex":0.00059643347,"about_ca_system_score_gemma":0.0004373323,"threshold_uncertainty_score":0.9994523},"labels":[],"label_agreement":null},{"id":"W2606696169","doi":"10.18632/oncotarget.17005","title":"Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Olaparib; Medicine; Oncology; Internal medicine; Ovarian cancer; PARP inhibitor; Response Evaluation Criteria in Solid Tumors; BRCA mutation; Breast cancer; Carboplatin; Cancer; Chemotherapy; Progressive disease; Cisplatin; Poly ADP ribose polymerase; Biology","score_opus":0.021528575030926325,"score_gpt":0.3581540459406864,"score_spread":0.3366254709097601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606696169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872645,0.00014440052,0.00013667597,0.009479846,0.0010610247,0.0012450283,0.0004123367,0.000045751654,0.00021042839],"genre_scores_gemma":[0.99529386,0.00010778009,0.0015893028,0.0016716798,0.0005900004,0.00016038274,0.00008917956,0.000052706266,0.00044512303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973171,0.00033763566,0.00089334935,0.0004981874,0.00056702265,0.00038674547],"domain_scores_gemma":[0.9973057,0.00030160078,0.0005433411,0.0011537311,0.00042572065,0.0002699128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016940633,0.00025594558,0.00065982866,0.00014483891,0.00017033199,0.000027194172,0.0003390813,0.00012872035,0.0002962789],"category_scores_gemma":[0.0013393327,0.0001690778,0.00010836488,0.0002780025,0.0002970564,0.00018213646,0.000087356006,0.00041943457,0.000026091873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028593445,0.00075613504,0.9574414,0.0000349562,0.00010300177,0.00004908031,0.00034847722,0.00022616147,0.003099516,0.000007607386,0.007190111,0.0021501186],"study_design_scores_gemma":[0.015961284,0.001467345,0.9258983,0.00064831227,0.000058122718,0.0000032702378,0.000032089352,0.00018937927,0.0042618043,0.000010262887,0.05127145,0.00019839418],"about_ca_topic_score_codex":0.00029155525,"about_ca_topic_score_gemma":0.00046918564,"teacher_disagreement_score":0.04408134,"about_ca_system_score_codex":0.00019617347,"about_ca_system_score_gemma":0.0005778439,"threshold_uncertainty_score":0.68947923},"labels":[],"label_agreement":null},{"id":"W2607668193","doi":"10.1016/j.jtho.2017.04.010","title":"Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ABB (Canada); Centre Hospitalier de l’Université de Montréal","funders":"Eli Lilly and Company","keywords":"Veliparib; Medicine; Hazard ratio; Internal medicine; Carboplatin; Oncology; PARP inhibitor; Lung cancer; Confidence interval; Poly ADP ribose polymerase; Chemotherapy; Genetics; Cisplatin; Biology","score_opus":0.021952441980889303,"score_gpt":0.3739411683643788,"score_spread":0.3519887263834895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607668193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216574,0.00052657205,0.0004503069,0.001966767,0.002410988,0.00055445434,0.000013505563,0.000012572399,0.0018990927],"genre_scores_gemma":[0.99389195,0.00008757853,0.003474066,0.0014162337,0.0007718063,0.000031018197,0.0000028050542,0.000037777423,0.0002867332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814427,0.00017377692,0.00060421904,0.0002673822,0.00043452758,0.00037585341],"domain_scores_gemma":[0.9973349,0.000117173215,0.0012328654,0.00041422006,0.00057952123,0.0003213178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000846946,0.00021253103,0.00075637636,0.00030038913,0.00010991064,0.000016292955,0.00018034113,0.00020070949,0.00008596666],"category_scores_gemma":[0.000171263,0.0001770226,0.00010043784,0.00008531004,0.00012188539,0.000279636,0.000072304814,0.00072767696,0.0000040279165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01471882,0.0010750045,0.8770108,0.00025539624,0.0001664648,0.0009804838,0.002144313,0.0008875728,0.010991273,0.000001712062,0.010265827,0.08150231],"study_design_scores_gemma":[0.009812286,0.0038206724,0.93532836,0.0018597607,0.00029735273,0.00010423667,0.00010878551,0.00014766149,0.010551973,0.0000094677425,0.037675813,0.00028361863],"about_ca_topic_score_codex":0.00007862602,"about_ca_topic_score_gemma":0.00026638928,"teacher_disagreement_score":0.08121869,"about_ca_system_score_codex":0.003925778,"about_ca_system_score_gemma":0.001389529,"threshold_uncertainty_score":0.99989796},"labels":[],"label_agreement":null},{"id":"W2608211931","doi":"10.1158/2159-8290.cd-17-0146","title":"Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Cancer Research UK","keywords":"Reversion; DNA; Mutation; Poly ADP ribose polymerase; DNA damage; Biology; Chemistry; Cancer research; Genetics; Gene; Phenotype","score_opus":0.02755752012958285,"score_gpt":0.3162239602348135,"score_spread":0.2886664401052306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608211931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661475,0.00039752488,0.00060340384,0.0004982576,0.0001968379,0.00032021586,0.0007331306,0.000020528929,0.00061532937],"genre_scores_gemma":[0.9986113,0.00005689038,0.00028068243,0.00015425457,0.000072499904,0.000058711015,0.00008637359,0.000023667637,0.0006556358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998303,0.00005628474,0.00048379766,0.0003669179,0.00057164504,0.00021835505],"domain_scores_gemma":[0.9976384,0.00012740427,0.0008169358,0.0009498405,0.00036140758,0.00010601831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024854642,0.00017133246,0.00057520816,0.00023211272,0.00023032796,0.000049508868,0.00024936578,0.000077534336,0.00004534827],"category_scores_gemma":[0.0002807908,0.00015673082,0.0002513461,0.0005386661,0.00027339076,0.0003900464,0.0000841844,0.00011307602,0.0000010056752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070560846,0.00023039452,0.6701787,0.00025172392,0.0019069124,0.000017994136,0.00096159306,0.003982125,0.31998095,0.000027107933,0.0016080792,0.00014880278],"study_design_scores_gemma":[0.0021236239,0.00007463023,0.52637595,0.0009930313,0.001408378,5.661006e-7,0.00021745042,0.00016109308,0.4683644,0.00004791787,0.00005931078,0.00017363722],"about_ca_topic_score_codex":0.0004392278,"about_ca_topic_score_gemma":0.0026096154,"teacher_disagreement_score":0.14838345,"about_ca_system_score_codex":0.00032087075,"about_ca_system_score_gemma":0.00023161125,"threshold_uncertainty_score":0.63912976},"labels":[],"label_agreement":null},{"id":"W2608337225","doi":"10.1097/01.cot.0000516713.11719.72","title":"Phase III SOLO-2 Data Demonstrates High Survival Benefit of Olaparib","year":2017,"lang":"en","type":"article","venue":"Oncology Times","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Tolerability; Medicine; Oncology; Internal medicine; Ovarian cancer; Clinical endpoint; BRCA mutation; Placebo; PARP inhibitor; Clinical trial; Cancer; Adverse effect; Pathology; Biology","score_opus":0.09102410319965419,"score_gpt":0.4192331876939281,"score_spread":0.3282090844942739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608337225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81690776,0.00078512635,0.0002747159,0.010087153,0.0012919443,0.00043326084,0.00047000268,0.000091658934,0.16965835],"genre_scores_gemma":[0.98980486,0.0002734254,0.0025823931,0.00033798264,0.0004140433,0.000018959327,0.0002886228,0.000020838197,0.006258876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884444,0.000043506487,0.00034782628,0.00034179023,0.00017690286,0.0002455087],"domain_scores_gemma":[0.9976558,0.00018324569,0.00038120744,0.0015421064,0.00012372067,0.00011392217],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004253153,0.00014333065,0.00057268265,0.00006219412,0.000203359,0.00001715723,0.00056189235,0.000201051,0.0019537976],"category_scores_gemma":[0.000131482,0.00012762664,0.00005576415,0.000040332205,0.0006128988,0.000195221,0.00020183233,0.00019871668,0.00009021537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011073432,0.008989904,0.052180633,0.00024992405,0.0022720047,0.0006498053,0.0007815122,0.000016164875,0.21800393,0.037395995,0.3318257,0.336561],"study_design_scores_gemma":[0.14004946,0.010756657,0.044921488,0.00054534577,0.0013368317,0.0005001565,0.0006110145,0.0018981162,0.23496953,0.013707445,0.549676,0.0010279594],"about_ca_topic_score_codex":0.00026753946,"about_ca_topic_score_gemma":0.00011145134,"teacher_disagreement_score":0.33553302,"about_ca_system_score_codex":0.00007180193,"about_ca_system_score_gemma":0.0003768113,"threshold_uncertainty_score":0.9989585},"labels":[],"label_agreement":null},{"id":"W2610261021","doi":"10.1172/jci90825","title":"Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McGill University Health Centre; Princess Margaret Cancer Centre; University of Toronto; Pediatric Oncology Group; University Health Network","funders":"National Institute on Aging; Austrian Science Fund; Temple University; Rotary Foundation; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; National Cancer Institute; National Institutes of Health; European Commission; FP7 Research Potential of Convergence Regions; University of Texas MD Anderson Cancer Center; American Society of Hematology","keywords":"Synthetic lethality; PARP1; Biology; Cancer research; Leukemia; DNA repair; Molecular biology; DNA; Poly ADP ribose polymerase; Polymerase; Genetics","score_opus":0.13283052333399334,"score_gpt":0.4257841127992257,"score_spread":0.2929535894652323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610261021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915471,0.00032327705,0.00045735098,0.0069966763,0.00036891713,0.00018822968,0.0000025452025,0.000010365677,0.00010554877],"genre_scores_gemma":[0.9833257,0.0005043707,0.014283762,0.0010839304,0.0007486129,0.0000044537105,0.0000025882925,0.0000105756,0.000035980338],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979781,0.00020744007,0.0011913779,0.00018557589,0.0003281099,0.00010942094],"domain_scores_gemma":[0.99712247,0.00041046992,0.0016264236,0.00023986674,0.00027161546,0.000329153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020915528,0.00010998472,0.00041659508,0.0000569965,0.00024319168,0.00010383197,0.00008043525,0.0001387396,0.000016784406],"category_scores_gemma":[0.0025878472,0.00008499178,0.00008167515,0.00002626463,0.0005396958,0.00033203498,0.00003243992,0.0003926205,0.0000019927886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046010915,0.0001040547,0.19637008,0.00022016943,0.0000995174,0.00006841694,0.0007557216,0.00005703657,0.78238726,0.00014593842,0.0030255637,0.01630613],"study_design_scores_gemma":[0.004170918,0.00047827835,0.17854297,0.001010667,0.00012429034,0.0004156996,0.000054388427,0.0013737835,0.807596,0.005657655,0.0004451367,0.00013015472],"about_ca_topic_score_codex":0.000013399549,"about_ca_topic_score_gemma":0.000001149981,"teacher_disagreement_score":0.02520879,"about_ca_system_score_codex":0.0000670873,"about_ca_system_score_gemma":0.00030887517,"threshold_uncertainty_score":0.3465864},"labels":[],"label_agreement":null},{"id":"W2611690370","doi":"10.1007/s13402-017-0323-y","title":"Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition","year":2017,"lang":"en","type":"article","venue":"Cellular Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; University of Bristol; Manitoba Health Research Council","keywords":"PARP1; Olaparib; Gene silencing; RNA interference; DNA damage; Carcinogenesis; Apoptosis; Programmed cell death; Biology; Synthetic lethality; Cell biology; Cancer research; Cell; DNA repair; Poly ADP ribose polymerase; Cancer; DNA; Biochemistry; Genetics; Polymerase; RNA","score_opus":0.04226399867575973,"score_gpt":0.3460655269567079,"score_spread":0.30380152828094814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611690370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762212,0.0013638554,0.0023654269,0.0019988813,0.0003682436,0.00025068878,0.000005883197,0.000033439457,0.017392367],"genre_scores_gemma":[0.99595505,0.00023412197,0.0029842446,0.0002917827,0.00031461508,0.000022922019,0.00001376842,0.000021074999,0.00016239064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896795,0.000082618695,0.0003162713,0.00026900758,0.00014643098,0.00021773443],"domain_scores_gemma":[0.9989952,0.000112039175,0.00034209428,0.00038441815,0.00009323115,0.00007301961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039355943,0.00012113568,0.00038390703,0.00004689572,0.00021946053,0.000012978821,0.00007290465,0.00017907316,0.00023543955],"category_scores_gemma":[0.0002174088,0.00011625877,0.000068519,0.000032701908,0.0004534178,0.00012047861,0.00006736568,0.00020565094,0.000020257796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014402768,0.00009650024,0.002188161,0.00014045718,0.000035906545,0.00017001483,0.0011667468,0.000003826051,0.990084,0.0009763607,0.0006515233,0.0043424806],"study_design_scores_gemma":[0.0027408255,0.0006391765,0.0014370837,0.00028281345,0.00009009776,0.00015830861,0.0004884165,0.0001690395,0.976862,0.0023444607,0.014640885,0.00014685345],"about_ca_topic_score_codex":0.0000834564,"about_ca_topic_score_gemma":0.0000045334446,"teacher_disagreement_score":0.019733865,"about_ca_system_score_codex":0.00012305588,"about_ca_system_score_gemma":0.00012794818,"threshold_uncertainty_score":0.4740895},"labels":[],"label_agreement":null},{"id":"W2621490860","doi":"10.1080/15384101.2017.1326767","title":"Proper sister chromatid disjunction requires CDA and PARP-1","year":2017,"lang":"en","type":"letter","venue":"Cell Cycle","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Agence Nationale de la Recherche","keywords":"Sister chromatids; Biology; Chromatid; Genetics; Establishment of sister chromatid cohesion; Cytidine; Chromosome; Biochemistry; Gene","score_opus":0.02728235880492863,"score_gpt":0.2824308399729265,"score_spread":0.2551484811679979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621490860","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07905818,0.0036091632,0.00011343586,0.73076296,0.002689588,0.0016509315,0.00008830643,0.0003017337,0.18172571],"genre_scores_gemma":[0.09884108,0.00083917903,0.00060790667,0.7023025,0.018430773,0.0002488784,0.00078729633,0.00027323695,0.17766914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986019,0.00005226026,0.0002607518,0.000468398,0.000322646,0.00029403786],"domain_scores_gemma":[0.9987681,0.000036911442,0.00023801826,0.0008094297,0.00006693358,0.00008058668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011367501,0.00027985702,0.00041822967,0.00008333583,0.00017591253,0.000090639674,0.000121686055,0.0004933933,0.00074427977],"category_scores_gemma":[0.00002021141,0.00022223486,0.000112286856,0.00003098735,0.000245357,0.00013795456,0.000050397768,0.0007616754,0.00032808285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053690128,0.000029065695,0.00021388443,0.00071294897,0.000045419234,0.00020328302,0.00015287098,4.9671297e-7,0.0051304135,9.992574e-7,0.9920475,0.001409422],"study_design_scores_gemma":[0.0013525502,0.00015998541,0.00091411883,0.0005134673,0.00012856339,0.00010514304,0.000012405319,0.000023282411,0.0070546283,0.00017690723,0.98928034,0.00027861493],"about_ca_topic_score_codex":0.000049186394,"about_ca_topic_score_gemma":0.0000029755886,"teacher_disagreement_score":0.028460443,"about_ca_system_score_codex":0.00012511983,"about_ca_system_score_gemma":0.00008719977,"threshold_uncertainty_score":0.90624744},"labels":[],"label_agreement":null},{"id":"W2623263876","doi":"10.1158/2159-8290.cd-17-0419","title":"Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":417,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Institute of General Medical Sciences; Cancer Research UK","keywords":"Cancer research; PARP inhibitor; Germline mutation; Biology; Olaparib; Mutation; Medicine; Genetics; Gene; Poly ADP ribose polymerase; Polymerase","score_opus":0.024269575607720206,"score_gpt":0.284101260368508,"score_spread":0.25983168476078783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623263876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97850513,0.0015895463,0.00013372602,0.016389437,0.0006201538,0.00094760413,0.00026347162,0.00006098675,0.0014899579],"genre_scores_gemma":[0.9941635,0.00013564884,0.0003425545,0.0019000513,0.00054675736,0.0006697426,0.00004269572,0.00006523703,0.0021338027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979726,0.00010511434,0.00042802683,0.00055841805,0.0004508699,0.00048497674],"domain_scores_gemma":[0.99829847,0.00018512088,0.00034666556,0.00088556693,0.000082956925,0.00020123115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033656173,0.00030147497,0.00049841544,0.00012368926,0.0006373344,0.00030758537,0.00028810135,0.00011427049,0.000046574132],"category_scores_gemma":[0.00016446596,0.00022999971,0.0000663863,0.00025122418,0.00034272924,0.00074081274,0.000089639296,0.0003075131,0.000006564567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002780089,0.00046787015,0.92786616,0.0005917272,0.0005615443,0.00037559294,0.008486041,0.00068735087,0.02768918,0.0034309854,0.024829362,0.002234087],"study_design_scores_gemma":[0.0072435206,0.00017779304,0.97139555,0.0020369461,0.00015921566,0.000020358071,0.00046433296,0.000061096966,0.011942999,0.0009909102,0.0050703185,0.00043696753],"about_ca_topic_score_codex":0.0008509278,"about_ca_topic_score_gemma":0.0088379085,"teacher_disagreement_score":0.043529373,"about_ca_system_score_codex":0.0007709692,"about_ca_system_score_gemma":0.000744751,"threshold_uncertainty_score":0.93791157},"labels":[],"label_agreement":null},{"id":"W2623453429","doi":"10.1158/1557-3265.ovcasymp16-ap27","title":"Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Internal medicine; Oncology; Cancer; Interquartile range; Cancer research; Biology; Gene; Genetics; Poly ADP ribose polymerase","score_opus":0.3201574844223511,"score_gpt":0.4925623626280325,"score_spread":0.1724048782056814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623453429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881981,0.00008303024,0.000010785119,0.0083585465,0.00035817348,0.0027376665,0.000040330935,0.000018579565,0.00019479374],"genre_scores_gemma":[0.9976132,0.000017855597,0.00019925584,0.00019110252,0.0010823932,0.00081218936,0.0000017607472,0.0000488981,0.000033327113],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943192,0.0013957276,0.0011381636,0.0007106875,0.001677582,0.0007586546],"domain_scores_gemma":[0.99211097,0.004361596,0.0006154144,0.0019637258,0.0006187471,0.00032952326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014476553,0.00024477704,0.00078944414,0.0001938486,0.000491177,0.000081940685,0.00074102863,0.00015543995,0.00012615739],"category_scores_gemma":[0.0054924097,0.00013567007,0.00011619171,0.0005445086,0.0012932998,0.0001259452,0.00016684085,0.0017881237,0.0000044492617],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5615221,0.00062711316,0.37921935,0.00020002767,0.00018592528,0.0001711356,0.003628268,0.00040063972,0.05157398,0.00011336154,0.00012051746,0.002237554],"study_design_scores_gemma":[0.029518222,0.0049418663,0.9187985,0.0013530421,0.000023456152,0.0000062419767,0.00210633,0.0000657918,0.042630818,0.0002833669,0.00009462274,0.00017774104],"about_ca_topic_score_codex":0.0034682832,"about_ca_topic_score_gemma":0.000520208,"teacher_disagreement_score":0.53957915,"about_ca_system_score_codex":0.0013263191,"about_ca_system_score_gemma":0.002472995,"threshold_uncertainty_score":0.7768607},"labels":[],"label_agreement":null},{"id":"W2623797673","doi":"10.1016/j.ygyno.2017.03.505","title":"Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study","year":2017,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Olaparib; Oncology; Ovarian cancer; Internal medicine; Progression-free survival; Overall survival; Cancer; Gynecology; Poly ADP ribose polymerase","score_opus":0.02903819638609049,"score_gpt":0.344580774382697,"score_spread":0.3155425779966065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623797673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779229,0.000050716477,0.000029242905,0.013910391,0.00036254924,0.0056909933,0.0002900286,0.000049187212,0.0016939755],"genre_scores_gemma":[0.99553597,0.00008260061,0.0007800544,0.0014630536,0.00019357153,0.0017264839,0.00009502833,0.00003594089,0.00008732497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963429,0.0009770751,0.00071616645,0.00084613386,0.00047021036,0.000647516],"domain_scores_gemma":[0.9945767,0.0026346939,0.0010360177,0.0014636226,0.00020157351,0.000087389395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013062215,0.0004206854,0.0008832277,0.00008342135,0.0005796232,0.000069770984,0.00062360166,0.00023491906,0.00003863508],"category_scores_gemma":[0.0005346222,0.00019036708,0.000062885505,0.0002088416,0.00057216873,0.00014079358,0.000084349515,0.00063327886,0.0000038643393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098121725,0.010244829,0.72779477,0.000006920411,0.00059066206,0.0014570127,0.032042455,0.000071854025,0.0007476596,0.000056264773,0.0005958377,0.12827003],"study_design_scores_gemma":[0.18364497,0.02941713,0.7765718,0.00014444662,0.000119378215,0.00000857959,0.008254242,0.00017367746,0.00022739093,0.00018780566,0.0009969568,0.00025362667],"about_ca_topic_score_codex":0.0043094056,"about_ca_topic_score_gemma":0.025958862,"teacher_disagreement_score":0.12801641,"about_ca_system_score_codex":0.0012105112,"about_ca_system_score_gemma":0.00071510073,"threshold_uncertainty_score":0.99181485},"labels":[],"label_agreement":null},{"id":"W2625362849","doi":"10.1038/s41467-017-00393-y","title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","year":2017,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Medical Research Council; Vetenskapsrådet; Cancerfonden; National Institute for Health and Care Research; Academy of Medical Sciences; Cancer Research UK; NIHR Cambridge Biomedical Research Centre; Pain Relief Foundation; AFA Försäkring; Hutchison Whampoa Limited; Wellcome Trust; AstraZeneca; National Cancer Research Institute; Torsten Söderbergs Stiftelse; Public Health Agency; Cancer Research Institute","keywords":"Prostate cancer; Androgen receptor; Androgen deprivation therapy; Synthetic lethality; Cancer research; PARP inhibitor; Poly ADP ribose polymerase; Downregulation and upregulation; Prostate; Medicine; Cancer; Biology; Internal medicine; DNA repair; Genetics; Gene","score_opus":0.0531525519722865,"score_gpt":0.37111023338033405,"score_spread":0.31795768140804753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625362849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74496317,0.071672,0.000036024612,0.17519322,0.00019342567,0.0015772302,0.00022111952,0.00007544814,0.0060683745],"genre_scores_gemma":[0.98692906,0.011393589,0.00049916806,0.00061081286,0.00009231643,0.00029295878,0.00003684994,0.000016081583,0.00012917948],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904525,0.0002331815,0.00023391983,0.00018010908,0.00015601303,0.000151552],"domain_scores_gemma":[0.99731874,0.00038250833,0.00016180275,0.0019588599,0.00011468694,0.00006338579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081205263,0.000107589214,0.00024729682,0.000044269123,0.00060450996,0.00006343539,0.0006017715,0.00014643214,0.000033465534],"category_scores_gemma":[0.00029735046,0.00007554545,0.000052837582,0.000083724626,0.0006057773,0.00009572989,0.00019807748,0.0010256624,0.000006196903],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012019685,0.0004108511,0.8851793,0.00020700315,0.0005751969,0.000009136278,0.009309393,0.00004326032,0.0076876427,0.029643103,0.0031873228,0.062545866],"study_design_scores_gemma":[0.028448915,0.00018735765,0.29903978,0.0033192458,0.00044834428,0.00005838821,0.0011387711,0.0040838337,0.024208464,0.01840486,0.6194958,0.001166215],"about_ca_topic_score_codex":0.00035081527,"about_ca_topic_score_gemma":0.0005765654,"teacher_disagreement_score":0.6163085,"about_ca_system_score_codex":0.00009290542,"about_ca_system_score_gemma":0.00011982029,"threshold_uncertainty_score":0.46494633},"labels":[],"label_agreement":null},{"id":"W2652345243","doi":"10.1200/po.16.00031","title":"Homologous Recombination Deficiency in Breast Cancer: A Clinical Review","year":2017,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Homologous recombination; Breast cancer; Homologous chromosome; BRCA2 Protein; Medicine; DNA repair; Germline mutation; Germline; Cancer; Clinical significance; Bioinformatics; Mutation; Genetics; Biology; Internal medicine; DNA; Gene","score_opus":0.3056827032087479,"score_gpt":0.5919253871315462,"score_spread":0.2862426839227983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2652345243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000659242,0.97751313,0.000019642242,0.0042633903,0.003145135,0.0031366034,0.00011529006,0.00007367908,0.011726554],"genre_scores_gemma":[0.0000055252326,0.9936821,0.00034725128,0.0019168886,0.0006350143,0.0015015071,0.00014917176,0.000076437835,0.0016861445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936493,0.0015521557,0.0027619735,0.0010897556,0.00045201526,0.00049480563],"domain_scores_gemma":[0.99452,0.001319061,0.0021548897,0.0014317767,0.00032896549,0.00024527565],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004041131,0.00051881524,0.005325775,0.00051291805,0.00012345788,0.000022605773,0.0006711388,0.0014581612,0.0018404872],"category_scores_gemma":[0.0009779878,0.00040332234,0.0009994033,0.00045731594,0.0002968306,0.000115737006,0.00019788455,0.0017522707,0.00060876325],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009452931,0.00059769064,0.000114380004,0.013084238,0.00005141371,0.00021703949,0.000010104752,6.9889786e-8,8.471608e-8,0.000037553214,0.0495903,0.9362026],"study_design_scores_gemma":[0.0018194611,0.00058147364,0.00051812636,0.1300766,0.0006945495,0.0022292025,0.0000015119997,0.0000023818945,8.9513385e-8,0.00020902627,0.86357355,0.0002940251],"about_ca_topic_score_codex":0.000073849675,"about_ca_topic_score_gemma":0.0000744347,"teacher_disagreement_score":0.93590856,"about_ca_system_score_codex":0.002226204,"about_ca_system_score_gemma":0.0040158504,"threshold_uncertainty_score":0.99984187},"labels":[],"label_agreement":null},{"id":"W2654209411","doi":"10.1158/0008-5472.can-17-0190","title":"Functionally Null <i>RAD51D</i> Missense Mutation Associates Strongly with Ovarian Carcinoma","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Women's College Hospital; McGill Genome Centre; Montreal Neurological Institute and Hospital; Centre Hospitalier Universitaire Sainte-Justine; Occupational Cancer Research Centre; Centre hospitalier de l'Université Laval; Jewish General Hospital; McGill University; McGill University Health Centre; Institute for Research in Immunology and Cancer; McGill University and Génome Québec Innovation Centre; Children's Hospital of Eastern Ontario","funders":"Cancer Research UK","keywords":"Missense mutation; Ovarian cancer; Biology; Cancer research; DNA repair; Cancer; Genetics; Oncology; Mutation; Medicine; Gene","score_opus":0.11267073488232499,"score_gpt":0.42971915551476964,"score_spread":0.31704842063244465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2654209411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9678976,0.0006985487,0.00011571517,0.0117982365,0.00030361832,0.00073406886,0.00006481004,0.000065969965,0.018321453],"genre_scores_gemma":[0.9874908,0.00011643595,0.00031029433,0.00028715032,0.0009782158,0.00040933274,0.000042384556,0.000051871797,0.010313549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997418,0.0001419273,0.00022641812,0.00044020877,0.0012184645,0.00055501057],"domain_scores_gemma":[0.9975615,0.00016625578,0.00016368768,0.0007478297,0.0010989116,0.00026181308],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092987437,0.00016462729,0.00031576236,0.00017746502,0.0008845665,0.0001993452,0.00023571601,0.00011801584,0.0011993945],"category_scores_gemma":[0.00023464242,0.0001344321,0.00008256416,0.00018168995,0.00043353077,0.00023651219,0.000053136675,0.00060475233,0.00012451486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026207492,0.0008821258,0.5888761,0.000703296,0.0017354534,0.0030407575,0.0029031092,0.00035097596,0.20819758,0.0074526686,0.13911179,0.020538647],"study_design_scores_gemma":[0.020222364,0.0016856382,0.83987725,0.00082340516,0.00014598166,0.0003289303,0.00067247933,0.0002614738,0.06505589,0.0013495996,0.06903113,0.00054586784],"about_ca_topic_score_codex":0.0012554843,"about_ca_topic_score_gemma":0.00033043962,"teacher_disagreement_score":0.25100112,"about_ca_system_score_codex":0.00085631624,"about_ca_system_score_gemma":0.0013750059,"threshold_uncertainty_score":0.99971366},"labels":[],"label_agreement":null},{"id":"W2725733926","doi":"10.1158/0008-5472.can-16-2704","title":"Posttranscriptional Regulation of <i>PARG</i> mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Cancer research; Gene silencing; PARP inhibitor; PARP1; DNA damage; Poly ADP ribose polymerase; Biology; Olaparib; DNA repair; Downregulation and upregulation; Molecular biology; Chromatin immunoprecipitation; Chemistry; DNA; Gene expression; Polymerase; Genetics; Gene; Promoter","score_opus":0.08398978919994851,"score_gpt":0.41120291101909184,"score_spread":0.3272131218191433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725733926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724664,0.004205277,0.000039604904,0.017835066,0.00018989359,0.00072310184,0.00034708914,0.000053405904,0.0041401256],"genre_scores_gemma":[0.98936707,0.0009389393,0.0004883154,0.00026282965,0.00026255238,0.0002473836,0.0000282687,0.000027035068,0.0083776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99781096,0.000110177665,0.0003305652,0.00045083152,0.00091541867,0.00038206088],"domain_scores_gemma":[0.9981714,0.00011701378,0.00009957501,0.0006908034,0.0006525474,0.0002686422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097549235,0.00013404743,0.00027217108,0.00016733774,0.00043148443,0.000050735023,0.00018353794,0.00010083704,0.00027221107],"category_scores_gemma":[0.00027400625,0.00012930129,0.00007927144,0.00019521329,0.0006432587,0.00021451327,0.000060968505,0.0002884264,0.000018452396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012121648,0.00005167458,0.009823745,0.00022767135,0.000047849015,0.0000039934366,0.00057578745,0.0000023395974,0.8132125,0.00068267493,0.17331864,0.0008409319],"study_design_scores_gemma":[0.002597442,0.0003846235,0.087229505,0.001071283,0.000021556307,0.0000058522696,0.00020930088,0.00001279333,0.62520057,0.002623538,0.28042045,0.0002231104],"about_ca_topic_score_codex":0.00036674214,"about_ca_topic_score_gemma":0.00015859351,"teacher_disagreement_score":0.18801199,"about_ca_system_score_codex":0.00027532448,"about_ca_system_score_gemma":0.00028127557,"threshold_uncertainty_score":0.5272753},"labels":[],"label_agreement":null},{"id":"W2726524491","doi":"10.1038/onc.2017.205","title":"Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma","year":2017,"lang":"en","type":"article","venue":"Oncogene","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Veterans Affairs","keywords":"Biology; STAT1; Repressor; Carcinogenesis; Cancer research; Interferon; Phenotype; Transcription factor; Gene; Transcription (linguistics); Interferon regulatory factors; Regulation of gene expression; Glioma; Gene expression; IRF1; Immunology; Genetics","score_opus":0.05054273691081554,"score_gpt":0.365306122857852,"score_spread":0.31476338594703646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726524491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514085,0.0007165472,0.000021428068,0.0026380136,0.00007121814,0.00045594055,0.0001820004,0.000018686835,0.000755294],"genre_scores_gemma":[0.99851435,0.00010410817,0.000081062244,0.0003516551,0.000090327696,0.000082740065,0.000009430656,0.000019872878,0.0007464776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989682,0.00008541211,0.00029112474,0.00023340863,0.00023873657,0.00018314566],"domain_scores_gemma":[0.999155,0.00007501372,0.00017501472,0.0004479841,0.00008002563,0.00006700577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037550452,0.00012615956,0.0002575582,0.00009646266,0.00014427137,0.000025854293,0.000147245,0.00006933408,0.00033664642],"category_scores_gemma":[0.00006929555,0.00009019292,0.000051948988,0.000055958728,0.00034820844,0.000078171106,0.000020858462,0.00013305714,0.000009398952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026001246,0.00016657005,0.010395532,0.00006380262,0.000069283284,0.000026927552,0.002878059,5.675921e-7,0.98113894,0.00010053084,0.00053228025,0.0020273696],"study_design_scores_gemma":[0.0054682763,0.0014427388,0.20151874,0.00045381478,0.000054944467,0.00005327404,0.00016337539,0.000054328208,0.7840113,0.00046324419,0.0061560795,0.00015985101],"about_ca_topic_score_codex":0.00013001554,"about_ca_topic_score_gemma":0.00013588043,"teacher_disagreement_score":0.19712763,"about_ca_system_score_codex":0.000075828146,"about_ca_system_score_gemma":0.00011935019,"threshold_uncertainty_score":0.3686042},"labels":[],"label_agreement":null},{"id":"W2734917389","doi":"10.1007/978-1-4939-6993-7_27","title":"Purification of DNA Damage-Dependent PARPs from E. coli for Structural and Biochemical Analysis","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"DNA damage; Poly ADP ribose polymerase; DNA; DNA repair; Biology; PARP inhibitor; Enzyme; Computational biology; Cell biology; Chemistry; Biochemistry; Polymerase","score_opus":0.04512648050012863,"score_gpt":0.455292882847519,"score_spread":0.4101664023473904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734917389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5835935,0.0005617357,0.41508523,0.00036373688,0.00006922355,0.00020810888,0.000055184184,0.000006004449,0.000057329697],"genre_scores_gemma":[0.5056928,0.000051131454,0.4939658,0.00011329082,0.000031040392,0.00004731962,0.00008137277,0.00000720787,0.000010062938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895424,0.00026180368,0.00027871414,0.00031231146,0.000057647114,0.00013529105],"domain_scores_gemma":[0.99893844,0.00017317818,0.00021508551,0.00055109634,0.0000730213,0.000049202445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005427421,0.00009905549,0.00041116378,0.00014242048,0.000047835994,0.000009871652,0.00013800547,0.00017432019,0.000036159254],"category_scores_gemma":[0.00041563768,0.00008887513,0.00010299824,0.000085509986,0.00027734248,0.000017299677,0.00004682557,0.0000968444,2.7646595e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019064096,0.000016314234,0.01792561,0.000014653575,0.00026776464,0.0000021454123,0.000055724948,0.0000033630683,0.9741702,0.0008613925,0.000009929754,0.006482264],"study_design_scores_gemma":[0.0015316854,0.000093140334,0.0498673,0.0000130441185,0.00027629954,0.0000017235474,0.000022128701,0.0010277267,0.93247825,0.014378432,0.00022676101,0.000083530875],"about_ca_topic_score_codex":0.00013527232,"about_ca_topic_score_gemma":0.000009894306,"teacher_disagreement_score":0.078880586,"about_ca_system_score_codex":0.00003529864,"about_ca_system_score_gemma":0.000028659382,"threshold_uncertainty_score":0.36242226},"labels":[],"label_agreement":null},{"id":"W2736055518","doi":"10.2174/1389450118666170711151518","title":"PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials","year":2018,"lang":"en","type":"review","venue":"Current Drug Targets","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Olaparib; PARP inhibitor; Medicine; Ovarian cancer; Prostate cancer; Pancreatic cancer; Breast cancer; Clinical trial; Oncology; Cancer; Internal medicine; Cancer research; Poly ADP ribose polymerase; Biology","score_opus":0.20697104244314452,"score_gpt":0.5032244185833384,"score_spread":0.2962533761401939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736055518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052184025,0.98760605,0.0000062790937,0.00017177101,0.0014055723,0.004279759,0.0012288013,0.000022974817,0.000060371756],"genre_scores_gemma":[0.0009629571,0.99541545,0.0001837301,0.00003880776,0.0019102334,0.0007441632,0.0006394966,0.000060749557,0.000044438133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915229,0.0030822563,0.0037485065,0.0007393528,0.00052013947,0.00038681075],"domain_scores_gemma":[0.9950047,0.0011995976,0.0024344793,0.00092585915,0.0002052562,0.0002300818],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005247519,0.000608954,0.0055004084,0.0002749499,0.000046876918,0.000021120413,0.00024248734,0.00024143407,0.0001197184],"category_scores_gemma":[0.00022835752,0.0003459262,0.00087818905,0.00040227926,0.000493404,0.000104053164,0.000032995013,0.00039334685,0.0000136425515],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064842746,0.0015469018,0.00053960056,0.0111440355,0.0005205213,0.000009189639,0.0030931234,1.8347946e-7,0.0000011020164,0.00003862034,0.0038927384,0.9785656],"study_design_scores_gemma":[0.006310442,0.0010369208,0.00021926941,0.025575997,0.002553127,0.00004764797,0.00017746541,0.000012502907,0.000034301123,0.00020927706,0.9634901,0.0003329196],"about_ca_topic_score_codex":0.00011848972,"about_ca_topic_score_gemma":0.000023932747,"teacher_disagreement_score":0.9782326,"about_ca_system_score_codex":0.00030967122,"about_ca_system_score_gemma":0.0013547264,"threshold_uncertainty_score":0.99989927},"labels":[],"label_agreement":null},{"id":"W27361888","doi":"10.1007/978-1-61779-270-0_1","title":"Approaches to Detect PARP-1 Activation In Vivo, In Situ, and In Vitro","year":2011,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Sherbrooke; Terry Fox Research Institute; University of British Columbia; Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval","funders":"RIKEN; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Health Canada","keywords":"Poly ADP ribose polymerase; NAD+ kinase; Gene knockdown; DNA damage; Nicotinamide adenine dinucleotide; DNA repair; Cell biology; Oligonucleotide; In vivo; Chemistry; DNA; Biology; Polymerase; Molecular biology; Biochemistry; Enzyme; Gene; Genetics","score_opus":0.15763001757388703,"score_gpt":0.40723137166093304,"score_spread":0.249601354087046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W27361888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6814781,0.00021415105,0.31604174,0.00031803155,0.000047534908,0.0004275316,0.0000011610275,0.000010560113,0.0014612492],"genre_scores_gemma":[0.5372376,0.000019236484,0.46192095,0.00063712546,0.000010666326,0.00015382092,0.0000029143928,0.000011093325,0.000006598304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798834,0.0010107778,0.00032560737,0.0003674329,0.000048389942,0.0002594338],"domain_scores_gemma":[0.99953645,0.00014534996,0.000049086484,0.00020951364,0.000010110884,0.000049508402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013569467,0.0001311779,0.00035413977,0.00062035787,0.0000068287973,0.0000024887581,0.000071016635,0.0002105556,0.000025069721],"category_scores_gemma":[0.00031703466,0.00012753347,0.000026368121,0.0005237301,0.00007227922,0.000026807777,0.000045129742,0.0002767683,0.0000013633256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007662435,0.00006442205,0.011304664,0.000017647246,0.000006286531,0.000028350501,0.0008872546,0.000010222778,0.9498712,0.0002156882,0.0000016078761,0.036826424],"study_design_scores_gemma":[0.0017474523,0.00015352065,0.021658536,0.000058657854,0.0000028776262,0.000008934888,0.00010031762,0.00009561197,0.9658262,0.010005711,0.00022175057,0.000120426885],"about_ca_topic_score_codex":0.00027840794,"about_ca_topic_score_gemma":0.00019850521,"teacher_disagreement_score":0.14587924,"about_ca_system_score_codex":0.00015820393,"about_ca_system_score_gemma":0.000039001134,"threshold_uncertainty_score":0.5200664},"labels":[],"label_agreement":null},{"id":"W2737281927","doi":"10.1200/jco.2016.34.15_suppl.5540","title":"Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cutoff; Internal medicine; Oncology; Loss of heterozygosity; Gastroenterology; Allele; Gene; Genetics","score_opus":0.14710673438001953,"score_gpt":0.44752144419607326,"score_spread":0.3004147098160537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737281927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996547,0.00005052784,0.00014672597,0.0016001221,0.0004914984,0.0010309654,0.000049635357,0.0000025882002,0.00008095929],"genre_scores_gemma":[0.9981735,0.00007645235,0.0011877888,0.00021167276,0.00025229822,0.000031276482,0.0000033543065,0.000018921937,0.00004478718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944207,0.00053796184,0.0040841214,0.00025927584,0.00045212897,0.0002457813],"domain_scores_gemma":[0.9941122,0.0013415344,0.0034713126,0.00034779267,0.0005499351,0.00017725663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025177677,0.00016800857,0.0020588622,0.00028656874,0.0000189983,0.0000014999932,0.00022034578,0.00023887768,0.00011339785],"category_scores_gemma":[0.00067621464,0.00010710949,0.00023924132,0.00017359747,0.00028853217,0.00008348837,0.00006431241,0.00040264628,4.7622433e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10172181,0.050001472,0.82330763,0.00009808668,0.0004808378,0.000101814825,0.00093082216,0.000029456149,0.003358431,0.00013218955,0.00086077116,0.018976657],"study_design_scores_gemma":[0.1602084,0.13941607,0.6943634,0.0003681489,0.00019463757,0.000013715459,0.0001289168,0.000006695393,0.0022483359,0.00030834702,0.002648611,0.00009470822],"about_ca_topic_score_codex":0.0001373412,"about_ca_topic_score_gemma":0.00036748365,"teacher_disagreement_score":0.12894425,"about_ca_system_score_codex":0.00034230135,"about_ca_system_score_gemma":0.0008728692,"threshold_uncertainty_score":0.43677983},"labels":[],"label_agreement":null},{"id":"W2737389832","doi":"10.1016/s1470-2045(17)30469-2","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1863,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Olaparib; Medicine; BRCA mutation; Ovarian cancer; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical endpoint; Population; Randomized controlled trial; Cancer; Pathology","score_opus":0.05211112076256093,"score_gpt":0.3733703096465478,"score_spread":0.3212591888839869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737389832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710769,0.00020943624,0.000106527325,0.011763165,0.000689771,0.0084555615,0.000056535475,0.00006344953,0.007578632],"genre_scores_gemma":[0.9910946,0.00062429765,0.00031849268,0.003515606,0.0010215628,0.002676675,0.000058087822,0.000053524607,0.00063713564],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973008,0.00046616426,0.0006501529,0.0005628604,0.00038488954,0.0006351458],"domain_scores_gemma":[0.9971354,0.0006848363,0.00092669716,0.00080925104,0.00029612676,0.00014770788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016828789,0.0003670365,0.0015845819,0.00014848867,0.00043861766,0.0000924792,0.0002797686,0.00029106782,0.00018501125],"category_scores_gemma":[0.0003290029,0.00022994308,0.00010023305,0.00015052731,0.0005417186,0.00024011912,0.00004959268,0.0006896918,0.000018444713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9785604,0.0007137279,0.0018979452,0.000020323794,0.00043320868,0.0001393949,0.0015498745,0.00003959517,0.0006978901,0.0004580743,0.0011672177,0.014322332],"study_design_scores_gemma":[0.98058623,0.0056815348,0.0069252714,0.00021541808,0.00015627207,0.0000727819,0.00010872608,0.00026348312,0.00070827716,0.00034321242,0.004665223,0.00027359],"about_ca_topic_score_codex":0.0008258184,"about_ca_topic_score_gemma":0.00078033906,"teacher_disagreement_score":0.020017695,"about_ca_system_score_codex":0.0004338318,"about_ca_system_score_gemma":0.0006244626,"threshold_uncertainty_score":0.93768066},"labels":[],"label_agreement":null},{"id":"W2740388256","doi":"10.1158/1538-7445.am2017-4035","title":"Abstract 4035: A novel combi-molecule engineered to target the putative synthetic lethal interactions between the epidermal growth factor receptor (EGFR) and poly(ADP-ribose)polymerase (PARP)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Synthetic lethality; Cancer research; Olaparib; Poly ADP ribose polymerase; Epidermal growth factor receptor; PARP inhibitor; Biology; DNA repair; Cancer; Polymerase; Biochemistry; Genetics; Enzyme; DNA","score_opus":0.1299726238395984,"score_gpt":0.4405425160021295,"score_spread":0.3105698921625311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740388256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8672713,0.0013946138,0.0012144288,0.12451578,0.00058648974,0.0017040307,0.0013062559,0.00006529249,0.0019417997],"genre_scores_gemma":[0.9956798,0.000160512,0.0002424718,0.0007724564,0.0012737892,0.0007837223,0.000032839172,0.00007003688,0.0009843668],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99720633,0.00022990297,0.0003782934,0.00055958395,0.0008552834,0.00077058596],"domain_scores_gemma":[0.9964897,0.0014063588,0.00015887791,0.0010007913,0.0004943505,0.0004499216],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009833119,0.00028264843,0.00040565064,0.00021342807,0.0013783661,0.00028851486,0.00066172995,0.00010793494,0.0010330958],"category_scores_gemma":[0.0011135169,0.00018254081,0.00012831826,0.00028468372,0.0009416596,0.00025795752,0.00020637955,0.0013663744,0.00012674744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015121995,0.00037599084,0.0076312814,0.00023328546,0.0009913173,0.0000882062,0.009890961,0.000024073788,0.9311356,0.0008911887,0.032929376,0.014296541],"study_design_scores_gemma":[0.0038843923,0.00047163814,0.16566867,0.00069997454,0.000086985834,0.00009334464,0.0014595862,0.00011396543,0.78384817,0.00039184824,0.042759735,0.00052168354],"about_ca_topic_score_codex":0.0020911326,"about_ca_topic_score_gemma":0.00005238235,"teacher_disagreement_score":0.1580374,"about_ca_system_score_codex":0.0004577411,"about_ca_system_score_gemma":0.00047986305,"threshold_uncertainty_score":0.9999217},"labels":[],"label_agreement":null},{"id":"W2744631849","doi":"10.1186/s12885-017-3504-1","title":"A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research; McGill University Health Centre; McGill University","keywords":"DNA repair; DNA damage; Comet assay; Poly ADP ribose polymerase; Mutant; Methyltransferase; DNA; Molecular biology; Temozolomide; Biology; Mutagenesis; Cancer research; Chemistry; Biochemistry; Polymerase; Gene; Glioma","score_opus":0.05367010099862707,"score_gpt":0.31943513102598525,"score_spread":0.2657650300273582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744631849","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26979902,0.005134811,0.7216311,0.00029194733,0.00022846066,0.001783336,0.0000703222,0.000051227682,0.0010097543],"genre_scores_gemma":[0.93044484,0.0011284008,0.06723319,0.00035627402,0.00023393802,0.00035963583,0.000010713464,0.000068650246,0.00016433938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998505,0.000101186364,0.00033777746,0.0004193346,0.00029967708,0.0003370312],"domain_scores_gemma":[0.99844617,0.00031571722,0.00031563296,0.0005234667,0.00028875994,0.00011024214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004979362,0.00026030256,0.00046608454,0.00006242992,0.0004311276,0.000075739685,0.00023044138,0.00008961169,0.000034264107],"category_scores_gemma":[0.0001242192,0.00017500482,0.00008896422,0.0001059215,0.00033663242,0.00014580067,0.000031413558,0.0001906393,7.125464e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001817253,0.00007990169,0.0003114779,0.00029666588,0.00015494582,0.000004622065,0.0007996588,0.0026358215,0.98931354,0.000039819544,0.00026942967,0.004276889],"study_design_scores_gemma":[0.004730129,0.0003171551,0.0006808793,0.00049576274,0.00024457424,0.00000916852,0.0004994298,0.0087900525,0.9836384,0.00008232697,0.0002631465,0.00024896284],"about_ca_topic_score_codex":0.00016753412,"about_ca_topic_score_gemma":0.00002206976,"teacher_disagreement_score":0.66064584,"about_ca_system_score_codex":0.00007367876,"about_ca_system_score_gemma":0.0003761709,"threshold_uncertainty_score":0.713649},"labels":[],"label_agreement":null},{"id":"W2751912349","doi":"10.1016/j.ygyno.2017.08.022","title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","year":2017,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; University Health Network; Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Cancer Research UK; Clovis Oncology","keywords":"Medicine; Germline; Germline mutation; Somatic cell; PARP inhibitor; Poly ADP ribose polymerase; Ovarian carcinoma; Cancer research; Ovarian cancer; Mutation; Oncology; Polymerase; Internal medicine; Cancer; Genetics; Biology; DNA; Gene","score_opus":0.053716048390429094,"score_gpt":0.34390747188256454,"score_spread":0.29019142349213545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751912349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996916,0.000051305316,0.0000389549,0.0009989219,0.00011228975,0.0013277626,0.0004984688,0.000012018301,0.000044289845],"genre_scores_gemma":[0.998433,0.000035790308,0.001132811,0.00011003963,0.000028461776,0.000048268827,0.00014057248,0.00001148186,0.000059558675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808115,0.0003967883,0.0005587729,0.00054935017,0.00021663858,0.00019731732],"domain_scores_gemma":[0.9969353,0.0010083005,0.000826039,0.0009940899,0.00015046773,0.00008578367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005317951,0.00021176427,0.0011293325,0.00019816945,0.00017685334,0.000023918514,0.00026826846,0.00017697884,0.00037784383],"category_scores_gemma":[0.00085343595,0.00011651999,0.000029992854,0.00039421182,0.0007217288,0.00021775947,0.00032247126,0.00024341984,4.1474598e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006735713,0.0017752527,0.9839277,0.000056837365,0.0008730626,0.00008523891,0.0008390877,0.0000059911563,0.0005368621,0.000011330734,0.000055046887,0.0050978777],"study_design_scores_gemma":[0.01710138,0.0041188193,0.9751722,0.000066604036,0.0013496954,0.000010100444,0.00064798235,0.0009337579,0.00033703764,0.0000634766,0.000072519935,0.00012640501],"about_ca_topic_score_codex":0.0021008516,"about_ca_topic_score_gemma":0.022410402,"teacher_disagreement_score":0.02030955,"about_ca_system_score_codex":0.00014795957,"about_ca_system_score_gemma":0.00045119584,"threshold_uncertainty_score":0.9954281},"labels":[],"label_agreement":null},{"id":"W2754327139","doi":"10.1016/s0140-6736(17)32440-6","title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1704,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Janssen Biotech; National Cancer Institute; Stand Up To Cancer; EMD Serono; Genentech; ImmunoGen; Ajinomoto; Clovis Oncology; Amgen; American Association for Cancer Research; National Ovarian Cancer Coalition; Regeneron Pharmaceuticals; University College London; Cancer Research UK; Array BioPharma; Memorial Sloan-Kettering Cancer Center; Ajinomoto Pharmaceuticals; Roche; AbbVie; Merck; Ovarian Cancer Research Fund; AstraZeneca; OncoMed Pharmaceutical; Ovarian Cancer Research Fund Alliance; U.S. Department of Defense","keywords":"Medicine; Placebo; Oncology; Internal medicine; Ovarian carcinoma; Double blind; Ovarian cancer; Surgery; Cancer; Alternative medicine; Pathology","score_opus":0.11880331611037004,"score_gpt":0.39947623135024113,"score_spread":0.2806729152398711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754327139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92725796,0.0007179033,0.0019901777,0.04627028,0.0016778423,0.019570416,0.00037248858,0.00010130939,0.0020416419],"genre_scores_gemma":[0.96761686,0.00020037412,0.0009431456,0.002784961,0.0049566855,0.01929114,0.000038983344,0.00006739749,0.004100477],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99742395,0.00034853216,0.0006251543,0.00054983574,0.00035601313,0.000696534],"domain_scores_gemma":[0.996181,0.0008737039,0.00042865414,0.0020857784,0.00017326542,0.00025757548],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024594215,0.00042213453,0.0014736635,0.00010949543,0.0005453124,0.00022142309,0.00050584483,0.00014385277,0.00031185267],"category_scores_gemma":[0.00046531906,0.000246761,0.0005002679,0.00008218107,0.00017939051,0.000112975,0.000043853543,0.00023547778,0.00006165505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9733529,0.0005789365,0.000088206856,0.000015521578,0.0004136008,0.00004168225,0.00165615,0.000004931262,0.0017593926,0.00023803985,0.012718838,0.009131816],"study_design_scores_gemma":[0.8574194,0.0065399343,0.0002492248,0.00012642426,0.00017764972,0.000027814489,0.00005336974,0.00017446201,0.0033110164,0.00035290554,0.1313151,0.0002527437],"about_ca_topic_score_codex":0.00008054234,"about_ca_topic_score_gemma":0.00006544769,"teacher_disagreement_score":0.118596256,"about_ca_system_score_codex":0.0003791445,"about_ca_system_score_gemma":0.0003858304,"threshold_uncertainty_score":0.99999845},"labels":[],"label_agreement":null},{"id":"W2756156907","doi":"10.18632/oncotarget.20840","title":"Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Nicotinamide phosphoribosyltransferase; Niacin; NAD+ kinase; Cancer research; Cancer; Medicine; Nicotinamide; Pharmacology; Biology; Internal medicine; Biochemistry; Enzyme","score_opus":0.08049095229494345,"score_gpt":0.4392818305098253,"score_spread":0.3587908782148818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756156907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883906,0.000946316,0.0026531874,0.0023971125,0.001110818,0.0013994067,0.0003858462,0.00006404815,0.0026526672],"genre_scores_gemma":[0.991677,0.0009886785,0.0025226665,0.0004979291,0.0015166545,0.0002775409,0.0003013527,0.000057023182,0.0021611582],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979882,0.000042133233,0.0006561098,0.0006373392,0.00031591405,0.000360265],"domain_scores_gemma":[0.99823827,0.00014399856,0.00059982564,0.0005444023,0.0002086594,0.00026485787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049616705,0.00025857287,0.00043562922,0.000105845786,0.0006704787,0.00028985797,0.00019035042,0.00020276563,0.00016752491],"category_scores_gemma":[0.00010299643,0.00026271824,0.00014460813,0.00007041971,0.00038886408,0.00029463464,0.000036383684,0.00035955186,0.000012629294],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002166799,0.00082017004,0.36129978,0.00063839613,0.00026221582,0.000036574605,0.0008506847,0.00004025423,0.605169,0.0009613972,0.02433475,0.0034199764],"study_design_scores_gemma":[0.019377233,0.0021121795,0.72839427,0.0010420309,0.0004208804,0.0001246442,0.00048015825,0.0019019464,0.15788896,0.00064307044,0.086575195,0.0010394517],"about_ca_topic_score_codex":0.00027163138,"about_ca_topic_score_gemma":0.0002098284,"teacher_disagreement_score":0.44728005,"about_ca_system_score_codex":0.00028589234,"about_ca_system_score_gemma":0.0015434133,"threshold_uncertainty_score":0.9999825},"labels":[],"label_agreement":null},{"id":"W2756935441","doi":"10.1158/1535-7163.mct-17-0170","title":"Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Olaparib; PARP inhibitor; Veliparib; Breast cancer; Cancer research; Triple-negative breast cancer; Cancer; Gene signature; Biology; DNA damage; Poly ADP ribose polymerase; Medicine; Molecular biology; Oncology; Internal medicine; Gene expression; Gene; Genetics; DNA","score_opus":0.029570303604162327,"score_gpt":0.32340810719261665,"score_spread":0.2938378035884543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756935441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727645,0.0016194755,0.0013547093,0.021348862,0.0003610798,0.0015275251,0.0005809863,0.000118173455,0.00032469252],"genre_scores_gemma":[0.98506767,0.0004052284,0.00037611264,0.01234796,0.00019604358,0.0008259833,0.000043861393,0.00013140698,0.00060576433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971353,0.00035404728,0.0004350841,0.0006881237,0.0007458617,0.000641601],"domain_scores_gemma":[0.99773943,0.00011018576,0.00042166119,0.0009383175,0.00052743463,0.00026298547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055609556,0.00045999925,0.0006262002,0.00027240356,0.00030335618,0.00011506139,0.00023191363,0.0003480376,0.00021060799],"category_scores_gemma":[0.00010700204,0.00040704777,0.00014522253,0.00055205735,0.00022495778,0.00018512383,0.000064777596,0.000678447,0.00001239777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01619626,0.0003698827,0.008917336,0.0000327508,0.00066966016,0.0006826791,0.0019060485,0.0007648615,0.9619322,0.00005676293,0.00024050895,0.008231091],"study_design_scores_gemma":[0.019555602,0.00084572565,0.35495448,0.0014654244,0.0003225893,0.00008153378,0.00020565321,0.00038196926,0.61786604,0.0006369886,0.0027400267,0.0009439539],"about_ca_topic_score_codex":0.0005626223,"about_ca_topic_score_gemma":0.00096077955,"teacher_disagreement_score":0.34603715,"about_ca_system_score_codex":0.0016112147,"about_ca_system_score_gemma":0.001039043,"threshold_uncertainty_score":0.9998381},"labels":[],"label_agreement":null},{"id":"W2760864027","doi":"10.1093/annonc/mdx372.036","title":"Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Placebo; Hazard ratio; Regimen; Oncology; Chemotherapy; Ovarian cancer; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Progressive disease; Surgery; Cancer; Confidence interval; Pathology","score_opus":0.2223933784517272,"score_gpt":0.4614255025643219,"score_spread":0.2390321241125947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760864027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99170655,0.00015065883,0.000003916698,0.004696866,0.0001415892,0.0018839038,0.00005592951,0.00000653999,0.0013540746],"genre_scores_gemma":[0.9987148,0.00015332826,0.00007853328,0.0006160632,0.000099673154,0.000251217,0.000013101478,0.000016266416,0.00005703848],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970226,0.0011951008,0.0005160012,0.00028949743,0.00074001757,0.00023672634],"domain_scores_gemma":[0.99723417,0.0006672095,0.00066599273,0.000414068,0.0009329498,0.00008561338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037356105,0.00015688462,0.00059624924,0.00018385943,0.00010108159,0.000012483694,0.0001395753,0.00013310392,0.000054327484],"category_scores_gemma":[0.0031722602,0.0001020345,0.000048357524,0.00014386154,0.0003698659,0.0001432825,0.00002876922,0.00025708854,0.0000012384717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7591725,0.0035420535,0.1876885,0.00009689592,0.0002691496,0.000090904294,0.008677457,0.00027135218,0.00418656,0.000101094854,0.0010170913,0.034886416],"study_design_scores_gemma":[0.15591082,0.006646963,0.82976216,0.00059807446,0.00022922861,0.000007528877,0.00034916334,0.0005626562,0.0051853694,0.00024372966,0.00036730038,0.00013699976],"about_ca_topic_score_codex":0.0012338234,"about_ca_topic_score_gemma":0.0023209574,"teacher_disagreement_score":0.64207363,"about_ca_system_score_codex":0.000158581,"about_ca_system_score_gemma":0.001764701,"threshold_uncertainty_score":0.41608465},"labels":[],"label_agreement":null},{"id":"W2761480337","doi":"10.1093/annonc/mdx372.057","title":"A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Debulking; Internal medicine; Ovarian cancer; Tolerability; Oncology; Chemotherapy; Placebo; Maintenance therapy; Surgery; Cancer; Adverse effect; Pathology","score_opus":0.07278291588345867,"score_gpt":0.43210840106546566,"score_spread":0.359325485182007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761480337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98370224,0.0003079948,0.00020314228,0.005058497,0.00057468447,0.008051662,0.000043923115,0.000015553298,0.0020422956],"genre_scores_gemma":[0.9948408,0.000806964,0.00090551004,0.00078361935,0.00016319953,0.0020729725,0.00003162316,0.00003641971,0.00035888221],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772316,0.00020051289,0.0010096598,0.0003738421,0.00030598303,0.00038681296],"domain_scores_gemma":[0.9972794,0.00029135722,0.0013485483,0.000608233,0.000354698,0.00011773865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081843,0.0002901018,0.0025032063,0.00019584133,0.00007305355,0.000010232769,0.00018570905,0.0001789883,0.00015138545],"category_scores_gemma":[0.00017576289,0.00019597179,0.00047903566,0.00007896942,0.00030365106,0.00016592395,0.000019774183,0.00015128996,0.0000019367799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9525692,0.005891161,0.0027921717,0.000025316676,0.0015568997,0.000024398916,0.00055612525,0.000044327666,0.00041445703,0.000033375232,0.00012301785,0.03596957],"study_design_scores_gemma":[0.9752372,0.014760352,0.00061467924,0.00033527694,0.0002753874,8.5074106e-7,0.000038655464,0.00016723687,0.0059123137,0.00004509554,0.0024517893,0.00016115836],"about_ca_topic_score_codex":0.0006501437,"about_ca_topic_score_gemma":0.00036450324,"teacher_disagreement_score":0.035808414,"about_ca_system_score_codex":0.00022379802,"about_ca_system_score_gemma":0.00044568107,"threshold_uncertainty_score":0.79914975},"labels":[],"label_agreement":null},{"id":"W2761652264","doi":"10.1093/annonc/mdx372.059","title":"ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; BRCA mutation; PARP inhibitor; Internal medicine; Oncology; Olaparib; Chemotherapy; Regimen; Ovarian cancer; Chemotherapy regimen; Cancer; Poly ADP ribose polymerase; Genetics; Biology; Polymerase","score_opus":0.12541029186495134,"score_gpt":0.4641550448215745,"score_spread":0.33874475295662315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761652264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718516,0.00036615317,0.000078569974,0.023050789,0.0012586842,0.002875936,0.00017452406,0.000012424739,0.00033130735],"genre_scores_gemma":[0.99436873,0.0026901138,0.0001890044,0.0011223583,0.0005181348,0.0007529485,0.000018235916,0.000028884515,0.00031155843],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835914,0.00016550189,0.0006906434,0.00027777505,0.00029468388,0.00021225748],"domain_scores_gemma":[0.9968309,0.0004457384,0.0011782353,0.0009826595,0.00048744908,0.00007501887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049668364,0.00019380427,0.00076787616,0.00007952774,0.00019664712,0.000012516431,0.00047787436,0.00014187067,0.00018746709],"category_scores_gemma":[0.00012696772,0.00011234878,0.0002640493,0.00007824807,0.00046033485,0.000107003994,0.000025907668,0.000109782835,6.320328e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33773518,0.07243951,0.03334602,0.000180523,0.010396469,0.00003828507,0.03954868,0.00047433088,0.15535001,0.0017516674,0.018332042,0.3304073],"study_design_scores_gemma":[0.3966364,0.035989568,0.028875053,0.0001463421,0.00061013945,0.00001586768,0.0014005664,0.00031456698,0.42960688,0.0009930647,0.10520281,0.00020874299],"about_ca_topic_score_codex":0.0019347173,"about_ca_topic_score_gemma":0.00046843477,"teacher_disagreement_score":0.33019856,"about_ca_system_score_codex":0.00011950662,"about_ca_system_score_gemma":0.0004036174,"threshold_uncertainty_score":0.45814502},"labels":[],"label_agreement":null},{"id":"W2761766456","doi":"10.1021/acschembio.7b00445","title":"Discovery of a Selective Allosteric Inhibitor Targeting Macrodomain 2 of Polyadenosine-Diphosphate-Ribose Polymerase 14","year":2017,"lang":"en","type":"article","venue":"ACS Chemical Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Structural Genomics Consortium; Engineering and Physical Sciences Research Council; Wellcome Trust; Wellcome","keywords":"Allosteric regulation; Biology; Small molecule; Biochemistry; Ribose; Plasma protein binding; Cell biology; Polymerase; Protein structure; DNA; Enzyme","score_opus":0.015367695475892838,"score_gpt":0.3078390839036719,"score_spread":0.29247138842777903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761766456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995619,0.0015781878,0.00009862555,0.0012648756,0.00024520548,0.00025284497,0.00012656157,0.000026874002,0.0007877984],"genre_scores_gemma":[0.9981111,0.00013662533,0.0006979791,0.00043758142,0.0003389815,0.000027823413,0.0000927325,0.000026279156,0.00013085832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858105,0.000055037177,0.00052585016,0.00036263475,0.00013977555,0.00033566792],"domain_scores_gemma":[0.9985331,0.00017594939,0.00053855195,0.0005070118,0.00015304172,0.000092301896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017474404,0.00019985576,0.00061678496,0.00006730371,0.000069271584,0.000010685295,0.00024805678,0.00025216542,0.000056068442],"category_scores_gemma":[0.0005626844,0.00016917125,0.00014592588,0.00010326464,0.0008090921,0.0001256909,0.00016224029,0.00023810222,0.000007886726],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013384739,0.00019005277,0.016129194,0.000072745635,0.00012634012,0.000010281517,0.0001493137,7.235539e-8,0.9794646,0.0002445904,0.0012439791,0.0010303472],"study_design_scores_gemma":[0.002897463,0.00036924754,0.00172532,0.00013085845,0.000052422994,0.000028420816,0.00003801174,0.00000452266,0.99358904,0.00059190765,0.0004212351,0.00015152397],"about_ca_topic_score_codex":0.00015027144,"about_ca_topic_score_gemma":0.0000014495014,"teacher_disagreement_score":0.014403873,"about_ca_system_score_codex":0.00008269092,"about_ca_system_score_gemma":0.00012133814,"threshold_uncertainty_score":0.68986034},"labels":[],"label_agreement":null},{"id":"W2761767010","doi":"10.1093/annonc/mdx372","title":"Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Placebo; Internal medicine; Quality of life (healthcare); Cohort; Ovarian cancer; Oncology; Adverse effect; Population; PARP inhibitor; Cancer; Gynecology; Poly ADP ribose polymerase; Pathology","score_opus":0.23592794112937082,"score_gpt":0.45832444436392733,"score_spread":0.2223965032345565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761767010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98331547,0.0001608979,0.0000053532467,0.010998813,0.0002719583,0.0009285752,0.00052109803,0.000012193503,0.0037856326],"genre_scores_gemma":[0.99802953,0.00020579892,0.0001394177,0.0011180266,0.0002649944,0.00007370089,0.000105834195,0.000017278942,0.00004543693],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979066,0.00034030492,0.00080887676,0.0003237027,0.00037518318,0.00024531598],"domain_scores_gemma":[0.9967325,0.000462439,0.0013369643,0.0008429901,0.00052091817,0.00010419387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000827812,0.00016948907,0.0008164362,0.00007038845,0.000075742064,0.000008497596,0.000253737,0.00016629293,0.00013926666],"category_scores_gemma":[0.00060035894,0.000100359626,0.000074176336,0.00013460957,0.00044897656,0.00008608492,0.000036884052,0.000265229,0.0000027881229],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50602263,0.0016711378,0.45451263,0.00002192487,0.00045182338,0.000006350063,0.0012018414,0.00001068447,0.00019466411,0.00009596543,0.0064628385,0.029347531],"study_design_scores_gemma":[0.16117094,0.008021781,0.8226665,0.00026557883,0.000045722703,3.1583988e-7,0.000065382534,0.0000038532894,0.0011599788,0.00006852598,0.006423379,0.00010799077],"about_ca_topic_score_codex":0.0182683,"about_ca_topic_score_gemma":0.008168434,"teacher_disagreement_score":0.36815393,"about_ca_system_score_codex":0.00008536491,"about_ca_system_score_gemma":0.000731898,"threshold_uncertainty_score":0.98826915},"labels":[],"label_agreement":null},{"id":"W2761888485","doi":"10.1093/annonc/mdx372.003","title":"The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University Health Centre","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Internal medicine; Cohort; Oncology; Proportional hazards model; Logistic regression; Cmax; Pharmacokinetics","score_opus":0.12579169649568753,"score_gpt":0.403958231024017,"score_spread":0.2781665345283295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761888485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766409,0.00021657663,0.000006714434,0.019197134,0.00030696555,0.00079617306,0.00011416448,0.0000064050237,0.0027150123],"genre_scores_gemma":[0.9987617,0.00014041654,0.000117404285,0.0006149077,0.00016346583,0.000038238504,0.00002395561,0.000013867848,0.00012603648],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982196,0.00044092268,0.0006256526,0.00022986114,0.00027769728,0.00020624546],"domain_scores_gemma":[0.9942738,0.0037178511,0.00079361367,0.00085512426,0.00029644565,0.00006317128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019945565,0.00012759029,0.0004100631,0.00006850245,0.00022109674,0.000016659886,0.0002598072,0.00017247384,0.000020862315],"category_scores_gemma":[0.0026927125,0.00007276924,0.000061956955,0.00009422532,0.0007032462,0.0000955821,0.000058603713,0.00028920604,0.000004273875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60848385,0.0006043593,0.35888714,0.000008957707,0.00018231494,0.000010660283,0.0031556354,0.000007875172,0.0004911659,0.0002549767,0.008519971,0.019393127],"study_design_scores_gemma":[0.08430857,0.0067656175,0.89575714,0.00011528733,0.00003291321,0.0000016278037,0.00015919298,0.0000063080734,0.0017140692,0.0005740875,0.010492588,0.00007259056],"about_ca_topic_score_codex":0.00044730725,"about_ca_topic_score_gemma":0.0005243892,"teacher_disagreement_score":0.53687,"about_ca_system_score_codex":0.000037482405,"about_ca_system_score_gemma":0.00033929845,"threshold_uncertainty_score":0.3223623},"labels":[],"label_agreement":null},{"id":"W2762648551","doi":"10.1093/annonc/mdx372.004","title":"Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Adverse effect; Gastroenterology; Cohort; Nausea; Ovarian cancer; Placebo; Chemotherapy; Oncology; Surgery; Cancer; Pathology","score_opus":0.0827514955526723,"score_gpt":0.4175936866276472,"score_spread":0.33484219107497487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762648551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98387176,0.00048887107,0.000016140737,0.0064455066,0.00017796928,0.00036038604,0.00004199007,0.0000059456174,0.0085914135],"genre_scores_gemma":[0.9973379,0.0017637134,0.00020722937,0.00051463494,0.00005942111,0.000022587854,0.000010108837,0.000010627151,0.00007381804],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999066,0.000057555993,0.00035208755,0.0001920069,0.00015202657,0.00018035017],"domain_scores_gemma":[0.9988302,0.000092620154,0.00043178195,0.00032644678,0.0002401225,0.000078833065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002395052,0.000099966084,0.00046551644,0.0000950977,0.00004832745,0.0000037418083,0.0001022416,0.00010726878,0.00010999287],"category_scores_gemma":[0.00010242373,0.000081433616,0.000037344977,0.000059485992,0.00030362708,0.00006959353,0.000032492408,0.00014393436,0.0000015250989],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010220146,0.0013000137,0.3355132,0.00011863564,0.00016031257,0.000016641965,0.0010236748,0.00000835704,0.00075987313,0.00052908796,0.0020811737,0.6482689],"study_design_scores_gemma":[0.016316038,0.0074406466,0.92609185,0.00044234403,0.00003302846,0.0000054040006,0.000030803298,0.000010570716,0.0032923885,0.0001541465,0.046090093,0.00009266973],"about_ca_topic_score_codex":0.0006887349,"about_ca_topic_score_gemma":0.00065526675,"teacher_disagreement_score":0.6481762,"about_ca_system_score_codex":0.00005372212,"about_ca_system_score_gemma":0.00024706978,"threshold_uncertainty_score":0.33207664},"labels":[],"label_agreement":null},{"id":"W2762908383","doi":"10.1093/annonc/mdx372.002","title":"Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Olaparib; Medicine; Hazard ratio; Internal medicine; Oncology; Placebo; Regimen; Chemotherapy; Ovarian cancer; Urology; Surgery; Cancer; Confidence interval; Pathology","score_opus":0.06535725050932524,"score_gpt":0.4049167432473832,"score_spread":0.33955949273805797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762908383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99116254,0.00022033871,0.00007778634,0.0047322097,0.00032431865,0.0017989154,0.00018848789,0.000017670094,0.0014777188],"genre_scores_gemma":[0.99565274,0.0014553907,0.00043052706,0.0017895759,0.00022113712,0.00011584235,0.000047429607,0.000046061235,0.0002413113],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975841,0.00017049511,0.0010364733,0.0004248749,0.00037957536,0.00040448233],"domain_scores_gemma":[0.9960767,0.00032700287,0.0019051457,0.00068507256,0.0008931523,0.000112912276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058265676,0.0002890329,0.0013951055,0.00017960076,0.000084507665,0.0000067911405,0.00027785485,0.00031664752,0.00015670249],"category_scores_gemma":[0.00028174077,0.00022976904,0.00017503717,0.00017640235,0.0007214983,0.00013744371,0.00003457781,0.00031810632,0.0000015896698],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.725066,0.009550442,0.010768858,0.00009733834,0.00089747546,0.000027555321,0.00393032,0.000027798911,0.054283082,0.00011544816,0.011183246,0.18405245],"study_design_scores_gemma":[0.59187263,0.031611856,0.037050333,0.00069562404,0.000060356953,0.000005571058,0.00011296674,0.000064248765,0.3281995,0.00009206324,0.009959785,0.00027506682],"about_ca_topic_score_codex":0.00087003125,"about_ca_topic_score_gemma":0.0001344219,"teacher_disagreement_score":0.27391642,"about_ca_system_score_codex":0.00011599718,"about_ca_system_score_gemma":0.00066360104,"threshold_uncertainty_score":0.93697095},"labels":[],"label_agreement":null},{"id":"W2763073378","doi":"10.1200/jco.2017.35.15_suppl.tps5091","title":"PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Olaparib; Medicine; Enzalutamide; PARP inhibitor; Prostate cancer; Internal medicine; Oncology; Cancer; Cancer research; Poly ADP ribose polymerase; Polymerase; Gene; Androgen receptor; Genetics; Biology","score_opus":0.1398554968757785,"score_gpt":0.5108660853555113,"score_spread":0.3710105884797328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763073378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223346,0.00020317803,0.000090718524,0.0036223163,0.0010506025,0.0025923934,0.000008300717,0.000011649477,0.00018735931],"genre_scores_gemma":[0.9930293,0.00026080437,0.0054835305,0.00052181026,0.00031970127,0.00022375278,0.000010323594,0.000018188259,0.00013257847],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99483216,0.0011609923,0.0030146253,0.0002634071,0.0005186772,0.00021012365],"domain_scores_gemma":[0.9919728,0.0015819808,0.0050299456,0.00024660715,0.0009793901,0.00018927148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008765894,0.00016860593,0.0019787184,0.00016039769,0.00017522747,0.000051481653,0.00010125878,0.00016520951,0.000059516155],"category_scores_gemma":[0.006981861,0.0001133268,0.00025368328,0.0000740782,0.0004459368,0.00037121627,0.000022356091,0.0006268911,9.459628e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93224436,0.0024438202,0.005261798,0.00003800698,0.00054177287,0.00016036264,0.0005036528,0.0000143138095,0.00013455389,0.00003833453,0.00017094385,0.05844811],"study_design_scores_gemma":[0.92994857,0.038308296,0.028550997,0.00030925492,0.00069160183,0.000058468322,0.00005836229,0.00092549477,0.000033655328,0.0007542301,0.00024335452,0.000117728516],"about_ca_topic_score_codex":0.00013490235,"about_ca_topic_score_gemma":0.0003714495,"teacher_disagreement_score":0.05833038,"about_ca_system_score_codex":0.0003414594,"about_ca_system_score_gemma":0.0025121728,"threshold_uncertainty_score":0.8358444},"labels":[],"label_agreement":null},{"id":"W2763294721","doi":"10.1093/annonc/mdx367.008","title":"A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacodynamics; Nicotinamide phosphoribosyltransferase; Internal medicine; Adverse effect; Nausea; Anemia; Pharmacology; Gastroenterology; Pharmacokinetics; Oncology; NAD+ kinase; Enzyme; Biochemistry; Chemistry","score_opus":0.08063440243014508,"score_gpt":0.4291862201817902,"score_spread":0.3485518177516451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763294721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744487,0.000113023554,0.000001055255,0.0009594131,0.00006804489,0.001060486,0.00004588955,0.000005462866,0.00030177867],"genre_scores_gemma":[0.99939173,0.00013923226,0.00008826578,0.00016388264,0.000030779,0.00012863224,0.000008520927,0.000017957158,0.000030988576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982859,0.00009004595,0.0008080106,0.00029239102,0.00025044894,0.00027320656],"domain_scores_gemma":[0.9984166,0.00015929677,0.00070303853,0.0004059696,0.0002479421,0.00006714214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003919241,0.00017119228,0.000933502,0.0003511055,0.000055809167,0.0000043087425,0.00013042592,0.00013504938,0.00004345951],"category_scores_gemma":[0.00021257708,0.00014009002,0.00003451869,0.00017900071,0.0003947661,0.00015971382,0.0000805323,0.00018545431,4.254215e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018587364,0.014970007,0.94605833,0.00040346256,0.00009513825,0.0001996716,0.010932267,0.00008746123,0.0040314975,0.000037213646,0.0004323181,0.0041652503],"study_design_scores_gemma":[0.07290135,0.047301054,0.8639042,0.001418384,0.000024879646,0.0000069541775,0.0018126015,0.000021917676,0.011046632,0.00009190763,0.0012936688,0.00017646844],"about_ca_topic_score_codex":0.00059309555,"about_ca_topic_score_gemma":0.017927349,"teacher_disagreement_score":0.08215417,"about_ca_system_score_codex":0.00008233774,"about_ca_system_score_gemma":0.00018284658,"threshold_uncertainty_score":0.9999929},"labels":[],"label_agreement":null},{"id":"W2763663030","doi":"10.1093/annonc/mdx440.034","title":"ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; BRCA mutation; Oncology; Placebo; Response Evaluation Criteria in Solid Tumors; PARP inhibitor; Progression-free survival; Population; Cancer; Gastroenterology; Ovarian cancer; Phases of clinical research; Chemotherapy; Clinical trial; Pathology; Genetics; Poly ADP ribose polymerase","score_opus":0.2027541194714337,"score_gpt":0.4880903689704883,"score_spread":0.28533624949905456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763663030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763785,0.00010607425,0.00095694774,0.014771535,0.000616593,0.006017371,0.000061951796,0.000027145692,0.0010638695],"genre_scores_gemma":[0.99471015,0.000011272386,0.0015372635,0.0021191924,0.00022784568,0.0010752383,0.000022998649,0.00004725253,0.0002487646],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99752396,0.00028904158,0.0009286573,0.00047205243,0.0003651385,0.00042112658],"domain_scores_gemma":[0.99630535,0.0011040579,0.00085723284,0.0010206148,0.0004551087,0.00025764704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026596657,0.00027319693,0.0012798645,0.00033778546,0.00022705014,0.000022641867,0.00035944034,0.00022450517,0.00010996012],"category_scores_gemma":[0.0007221034,0.00025733912,0.00039095496,0.0001419712,0.00015000091,0.000078521894,0.000043242395,0.00020559506,0.000004200549],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9330648,0.0047299587,0.0016429134,0.000076434946,0.00048095649,0.000052278883,0.003563222,0.000031412983,0.029070402,0.000037603884,0.003952872,0.023297125],"study_design_scores_gemma":[0.79015005,0.054665018,0.00365133,0.00020110338,0.00021737842,0.000010942873,0.00052864605,0.00020693411,0.123682305,0.000110245855,0.026322579,0.00025347597],"about_ca_topic_score_codex":0.00016495322,"about_ca_topic_score_gemma":0.000111369256,"teacher_disagreement_score":0.14291479,"about_ca_system_score_codex":0.00011523455,"about_ca_system_score_gemma":0.0010030284,"threshold_uncertainty_score":0.9999879},"labels":[],"label_agreement":null},{"id":"W2763669093","doi":"10.1200/jco.2017.35.15_suppl.5560","title":"The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Regimen; Oncology; Randomization; Placebo; Ovarian cancer; Population; Cohort; Progression-free survival; Chemotherapy regimen; Surgery; Cancer; Randomized controlled trial; Pathology","score_opus":0.15170531100399004,"score_gpt":0.5279345403881305,"score_spread":0.37622922938414044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763669093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824248,0.00012282268,0.0001079464,0.007828264,0.004056696,0.00060014287,0.00005365957,0.000008563819,0.0047971075],"genre_scores_gemma":[0.99440986,0.0004371733,0.0009618311,0.00065214775,0.0032803465,0.000017099745,0.0000052393375,0.0000322383,0.00020409015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945216,0.00057628856,0.0033393996,0.00025680749,0.0009503918,0.00035551027],"domain_scores_gemma":[0.9880885,0.0023128325,0.0071143843,0.00066836266,0.0014555568,0.00036036954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003983619,0.00021707239,0.0017576107,0.000073370116,0.00034222688,0.000046133282,0.0005741087,0.0004270621,0.00082476105],"category_scores_gemma":[0.003417567,0.00012242295,0.0004142447,0.00012082606,0.0010289847,0.00023630154,0.000083755316,0.001263599,0.000007752754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7771234,0.0049655885,0.15128459,0.00002703518,0.001245786,0.00022591182,0.00021772766,0.0000027626404,0.00036559405,0.0004534505,0.00686359,0.057224605],"study_design_scores_gemma":[0.55657053,0.035019584,0.25086007,0.0003829785,0.0007503233,0.000051983003,0.00008536517,0.00002295195,0.0007774565,0.0007800202,0.15446612,0.00023266331],"about_ca_topic_score_codex":0.0002032839,"about_ca_topic_score_gemma":0.0007999888,"teacher_disagreement_score":0.22055286,"about_ca_system_score_codex":0.0002500004,"about_ca_system_score_gemma":0.0033783284,"threshold_uncertainty_score":0.90305555},"labels":[],"label_agreement":null},{"id":"W2765304775","doi":"10.1158/1078-0432.ccr-17-1621","title":"Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; BC Cancer Agency","funders":"Medical Research and Materiel Command; National Health and Medical Research Council; Canadian Institutes of Health Research; Cancer Institute NSW; Cancer Australia; National Breast Cancer Foundation","keywords":"Homologous recombination; Serous fluid; Ovarian cancer; Retinoblastoma; Biology; DNA repair; Homologous chromosome; Serous ovarian cancer; Cancer; Cancer research; Genetics; DNA; Gene; Biochemistry","score_opus":0.17617826697787467,"score_gpt":0.4742512406429381,"score_spread":0.29807297366506347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765304775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828325,0.0002682384,0.000022168868,0.014386545,0.00043108375,0.0014410932,0.00014948563,0.00011284827,0.00035604485],"genre_scores_gemma":[0.9947388,0.00077050057,0.00011776251,0.00018429289,0.0007369611,0.0013074742,0.00005900277,0.000058574158,0.0020266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953838,0.001140886,0.00071742525,0.0008992512,0.0012021294,0.000656526],"domain_scores_gemma":[0.9970317,0.0005841102,0.00047439744,0.00074475544,0.0008480088,0.00031704246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004820575,0.0002346188,0.00063727575,0.00021924065,0.0005533808,0.000111645844,0.00026833516,0.00043103873,0.00043538457],"category_scores_gemma":[0.0019699621,0.00020174962,0.00011173648,0.00035335516,0.0013063505,0.00026088243,0.0001512534,0.0015630575,0.000016213546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055056494,0.0010963193,0.972224,0.00017966582,0.0002078723,0.0004965131,0.00021761029,0.000014654504,0.0018603158,0.0005901156,0.00093337067,0.01667389],"study_design_scores_gemma":[0.01017367,0.0012801641,0.98244435,0.0017382151,0.000023379696,0.000016146218,0.00009554218,0.0001648844,0.0011757644,0.0019468326,0.00069724186,0.00024379321],"about_ca_topic_score_codex":0.0025196644,"about_ca_topic_score_gemma":0.010066917,"teacher_disagreement_score":0.016430099,"about_ca_system_score_codex":0.0011563508,"about_ca_system_score_gemma":0.0009247758,"threshold_uncertainty_score":0.82271105},"labels":[],"label_agreement":null},{"id":"W2766480817","doi":"10.1158/1538-8514.synthleth-b04","title":"Abstract B04: RAD51 expression as a biomarker of homologous recombination deficiency in ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"RAD51; Homologous recombination; DNA repair; Ovarian cancer; Biology; Molecular biology; DNA damage; Cancer research; PARP inhibitor; Cancer; Olaparib; Synthetic lethality; Poly ADP ribose polymerase; DNA; Genetics; Polymerase","score_opus":0.05492772240357369,"score_gpt":0.37437744291218916,"score_spread":0.3194497205086155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766480817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97708726,0.008212792,0.00089408294,0.004183205,0.0007100939,0.00067103724,0.00003887813,0.000040002018,0.008162678],"genre_scores_gemma":[0.9954651,0.0022739503,0.0004199727,0.0012965441,0.000053855314,0.00021486194,0.000012102799,0.000054173826,0.00020941779],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982684,0.00006860406,0.00045908242,0.0004084463,0.000446246,0.00034921916],"domain_scores_gemma":[0.99834394,0.000033104217,0.00046757766,0.00086529454,0.00019942471,0.00009065374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000295015,0.00023992911,0.00039353888,0.00020914889,0.00015561839,0.000040335544,0.00031608826,0.00022402684,0.00065809983],"category_scores_gemma":[0.000031506162,0.00022595086,0.00014242316,0.00018507431,0.00022573944,0.0001396846,0.00005329796,0.00027680345,0.000009949921],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005916812,0.00032060992,0.017263733,0.00012255048,0.00009809949,0.00010182572,0.00044888197,0.00005549418,0.9313696,0.00027435063,0.00011556359,0.04923758],"study_design_scores_gemma":[0.0048520654,0.00016352253,0.23215368,0.0007723055,0.00009381235,0.000023446142,0.00005360087,0.0002049769,0.75646275,0.0025338458,0.0024065396,0.00027943458],"about_ca_topic_score_codex":0.001363239,"about_ca_topic_score_gemma":0.00012465297,"teacher_disagreement_score":0.21488994,"about_ca_system_score_codex":0.00036723525,"about_ca_system_score_gemma":0.00040989227,"threshold_uncertainty_score":0.9214009},"labels":[],"label_agreement":null},{"id":"W2766575289","doi":"10.1039/c7mb00498b","title":"The nucleosomal surface is the main target of histone ADP-ribosylation in response to DNA damage","year":2017,"lang":"en","type":"article","venue":"Molecular BioSystems","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research","keywords":"Histone; ADP-ribosylation; DNA damage; DNA repair; Nucleosome; DNA; Biology; Poly ADP ribose polymerase; Cell biology; NAD+ kinase; Biochemistry; Chemistry; Enzyme; Polymerase","score_opus":0.01509955947989242,"score_gpt":0.3346707639556706,"score_spread":0.31957120447577814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766575289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698715,0.00051988824,0.00034224347,0.026865054,0.00031738193,0.0008696422,0.00004581389,0.000019774203,0.0011487093],"genre_scores_gemma":[0.9980145,0.000012079865,0.00025129694,0.00069705123,0.000061237755,0.00003195554,0.0000052463492,0.000030376548,0.0008962478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983301,0.00038599115,0.00037862163,0.00024155252,0.0004228038,0.0002408947],"domain_scores_gemma":[0.9980969,0.00012408913,0.00025435357,0.0013432263,0.000101026795,0.0000804461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015857435,0.00014146304,0.00024771894,0.00006254432,0.0002813733,0.00006958557,0.00036827681,0.00008951233,0.000039869636],"category_scores_gemma":[0.0003016943,0.00009259928,0.0001000084,0.00015019641,0.00016068043,0.00006099599,0.00007013968,0.00014599456,0.000044481618],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013016793,0.000035194433,0.0021165197,0.00003268278,0.000034356985,0.000051553132,0.00090524,0.000046737397,0.9931176,0.00031846183,0.0019340576,0.00010596762],"study_design_scores_gemma":[0.0026655872,0.00035212268,0.06312244,0.00047813388,0.000027390268,0.000036508132,0.0005900073,0.0008211916,0.8500302,0.00017635225,0.081483155,0.00021691613],"about_ca_topic_score_codex":0.00030642594,"about_ca_topic_score_gemma":0.00007248761,"teacher_disagreement_score":0.14308736,"about_ca_system_score_codex":0.000196779,"about_ca_system_score_gemma":0.00011537277,"threshold_uncertainty_score":0.37760893},"labels":[],"label_agreement":null},{"id":"W2767374855","doi":"10.1158/1538-8514.synthleth-a04","title":"Abstract A04: Cross-species analysis identifies MUS81, a structure-specific endonuclease, as a novel synthetic lethal interaction with PARP","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biology; Synthetic lethality; Olaparib; PARP inhibitor; Poly ADP ribose polymerase; Homologous recombination; DNA repair; Genetics; Cell biology; DNA damage; Molecular biology; Polymerase; DNA","score_opus":0.0529701463254155,"score_gpt":0.356372261200227,"score_spread":0.3034021148748115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767374855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346263,0.0024737127,0.0063616564,0.0017534815,0.000657573,0.000545969,0.00022311711,0.0001284659,0.0043933727],"genre_scores_gemma":[0.9955828,0.0008623909,0.0007067801,0.0015065416,0.0003081648,0.00010369555,0.00005503863,0.00010819551,0.00076640205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973393,0.00006011804,0.0004978634,0.000754658,0.00083948905,0.0005085535],"domain_scores_gemma":[0.9970579,0.00008499375,0.000596917,0.0016518589,0.0004169987,0.00019131869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021160637,0.000471074,0.000662744,0.0003361565,0.0005455559,0.00069005135,0.00045048838,0.00024120898,0.002117826],"category_scores_gemma":[0.000029850868,0.00040330552,0.00042115443,0.00038332815,0.0006447894,0.00034817948,0.00006763931,0.000631555,0.000039106744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022747417,0.00028691685,0.009290629,0.00010880758,0.0054915277,0.00032544637,0.0010291281,0.0017318836,0.9705445,0.00059859053,0.00008632917,0.008231506],"study_design_scores_gemma":[0.005534276,0.00032790992,0.18907087,0.0004245059,0.0026116073,0.00025612133,0.00044165613,0.00039103234,0.7443717,0.00063609524,0.055053864,0.00088034326],"about_ca_topic_score_codex":0.00041556932,"about_ca_topic_score_gemma":0.00027608225,"teacher_disagreement_score":0.22617276,"about_ca_system_score_codex":0.00050439156,"about_ca_system_score_gemma":0.00022575323,"threshold_uncertainty_score":0.99984187},"labels":[],"label_agreement":null},{"id":"W2767918609","doi":"10.1093/annonc/mdx429.004","title":"ARIEL4: An international, randomised phase 3 study of rucaparib vs chemotherapy as treatment for BRCA1- or BRCA2-mutated, relapsed ovarian cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; BRCA mutation; Ovarian cancer; Internal medicine; Oncology; Olaparib; Chemotherapy; Regimen; Progressive disease; Cancer; PARP inhibitor; Chemotherapy regimen; Poly ADP ribose polymerase; Genetics; Biology","score_opus":0.20836374787434364,"score_gpt":0.5285145537961317,"score_spread":0.320150805921788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767918609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806722,0.0001133733,0.000118381264,0.012009417,0.0007022835,0.00264691,0.00013451089,0.000029982402,0.0035729753],"genre_scores_gemma":[0.99197304,0.0015831938,0.00066265714,0.0023556636,0.0004085326,0.00090716383,0.00006218524,0.000041834683,0.0020057382],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983274,0.00011543012,0.000680248,0.00038024777,0.00023928598,0.00025740222],"domain_scores_gemma":[0.9973351,0.00025338397,0.0009163075,0.00074266974,0.000595975,0.00015655904],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047910088,0.00021846892,0.00094949553,0.00015801867,0.00014255651,0.000018366929,0.00032480477,0.00017797745,0.0011864087],"category_scores_gemma":[0.00022908843,0.0001692036,0.00019126925,0.00006311629,0.00022148553,0.00018064551,0.000021327713,0.00009972069,0.000003915234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59896934,0.029902365,0.0053289295,0.00008566659,0.004825009,0.00015562351,0.01220829,0.00006442421,0.039230946,0.0003988472,0.008443734,0.3003868],"study_design_scores_gemma":[0.6027455,0.088291,0.005631625,0.00014107753,0.00037264102,0.00005492368,0.0010856148,0.0003031204,0.14689183,0.0007917494,0.15341328,0.00027765112],"about_ca_topic_score_codex":0.0017011786,"about_ca_topic_score_gemma":0.000543177,"teacher_disagreement_score":0.30010915,"about_ca_system_score_codex":0.00017749508,"about_ca_system_score_gemma":0.0008327357,"threshold_uncertainty_score":0.99972665},"labels":[],"label_agreement":null},{"id":"W2768074109","doi":"10.1016/j.molmed.2017.10.007","title":"Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer","year":2017,"lang":"en","type":"review","venue":"Trends in Molecular Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Canadian Friends of Hebrew University; Canadian Cancer Society Research Institute; Government of Ontario","keywords":"Synthetic lethality; Biology; Homologous recombination; DNA repair; Carcinogenesis; Epigenetics; Genetics; Computational biology; Genome instability; Phenotype; Gene; DNA damage; DNA","score_opus":0.21399478322066906,"score_gpt":0.43046117677776297,"score_spread":0.2164663935570939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768074109","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055902614,0.9946575,0.0010813434,0.0010453638,0.00038332873,0.001463349,0.000047003505,0.00003401819,0.00072904926],"genre_scores_gemma":[0.0014069739,0.9933061,0.00017458934,0.000086073625,0.00020933065,0.0029358515,0.0008346964,0.000069952024,0.0009764355],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979951,0.00012822925,0.0007450637,0.0006337218,0.00020305127,0.00029487273],"domain_scores_gemma":[0.9986576,0.0000684374,0.00047994003,0.0006379842,0.00006380075,0.000092252565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003891809,0.00042194393,0.0016859553,0.0012069759,0.00007614918,0.00001354037,0.0001534533,0.0003337824,0.00006829276],"category_scores_gemma":[0.00013910244,0.00032489764,0.00015440368,0.0004927364,0.00019130867,0.000055396453,0.000024765332,0.00023918092,0.0000012953662],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043716977,0.00016085837,0.000044643944,0.001910562,0.00006033462,0.000045107823,0.00022301605,9.1625856e-7,0.00016526644,0.0000732178,0.000017719922,0.9972546],"study_design_scores_gemma":[0.009183681,0.0017637413,0.0020631398,0.018265616,0.0012108365,0.00027057022,0.00003099539,0.00015017143,0.00021295097,0.0003181757,0.96598357,0.0005465498],"about_ca_topic_score_codex":0.00013513188,"about_ca_topic_score_gemma":0.00026637944,"teacher_disagreement_score":0.9967081,"about_ca_system_score_codex":0.00087710336,"about_ca_system_score_gemma":0.00018622102,"threshold_uncertainty_score":0.9999203},"labels":[],"label_agreement":null},{"id":"W2769972801","doi":"10.1158/1078-0432.ccr-17-1590","title":"A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Ovarian Cancer Research Fund","keywords":"Veliparib; Topotecan; Medicine; PARP inhibitor; Internal medicine; Neutropenia; Olaparib; Oncology; Febrile neutropenia; Gastroenterology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Surgery; Pharmacology; Clinical trial; Chemotherapy; Poly ADP ribose polymerase; Biology","score_opus":0.2537814787584608,"score_gpt":0.5781930088015869,"score_spread":0.32441153004312606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769972801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98557276,0.0003563994,0.0000041266344,0.010408313,0.0010379275,0.001916827,0.00010634679,0.000015808257,0.0005815134],"genre_scores_gemma":[0.996033,0.0003504369,0.00005647352,0.0005833582,0.002227594,0.0002021178,0.000007921826,0.000043337503,0.0004957694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948389,0.0009285781,0.001557159,0.0007284014,0.001323645,0.00062330323],"domain_scores_gemma":[0.9958495,0.0010044975,0.00056491356,0.0015533973,0.000536579,0.0004911117],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0048343753,0.00021270287,0.0009469802,0.00015744986,0.00037594856,0.0000741093,0.00058337295,0.00029250004,0.00019053594],"category_scores_gemma":[0.0033327267,0.00014036596,0.00023284153,0.00029652668,0.0031756137,0.00015374458,0.00037601357,0.0019018562,0.000009251147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24125555,0.0063201305,0.6428423,0.00009291596,0.00014799404,0.000036639085,0.00015668692,3.7922814e-7,0.00019607498,0.00006147293,0.0046023335,0.10428755],"study_design_scores_gemma":[0.35656843,0.016191103,0.6173348,0.0011369064,0.00006131913,0.0000025735342,0.00007486863,0.000042769272,0.0032854523,0.00021127584,0.0048535103,0.00023703754],"about_ca_topic_score_codex":0.00097084546,"about_ca_topic_score_gemma":0.00032413303,"teacher_disagreement_score":0.115312874,"about_ca_system_score_codex":0.000177166,"about_ca_system_score_gemma":0.0017350502,"threshold_uncertainty_score":0.99953717},"labels":[],"label_agreement":null},{"id":"W2772948229","doi":"10.1158/1538-7445.newfront17-ia13","title":"Abstract IA13: Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for multiple cancers: Key data in AML and triple negative breast cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"PARP1; Decitabine; Cancer research; Poly ADP ribose polymerase; Triple-negative breast cancer; PARP inhibitor; Breast cancer; Olaparib; Azacitidine; Cancer; DNA damage; Biology; Synthetic lethality; DNA repair; Polymerase; DNA methylation; DNA; Genetics; Gene expression; Gene","score_opus":0.2356626354221195,"score_gpt":0.4819503572045696,"score_spread":0.2462877217824501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772948229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98647094,0.0037616491,0.000055116503,0.0039684917,0.00018816418,0.0023190854,0.002941788,0.000016862452,0.00027790203],"genre_scores_gemma":[0.98560035,0.012616234,0.0001303445,0.00012166047,0.00026755623,0.0010088733,0.00007988953,0.000048159625,0.00012691406],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976528,0.0000911594,0.00043580148,0.000698049,0.0006201894,0.0005019983],"domain_scores_gemma":[0.9976005,0.000502777,0.00019476606,0.0008443298,0.00062497635,0.0002326607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014096595,0.00022620508,0.0005013822,0.0002993786,0.00033326185,0.00011815927,0.00037753602,0.00016040236,0.00020207101],"category_scores_gemma":[0.00030846708,0.00020422255,0.000047469763,0.00024565935,0.0008355226,0.00060115696,0.00009934986,0.00049121084,8.907777e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015127109,0.0007550753,0.069068566,0.0009907373,0.0005200137,0.000021367621,0.004096736,0.00006155769,0.7454193,0.00051540654,0.002931315,0.1604928],"study_design_scores_gemma":[0.05194023,0.0011188736,0.5261932,0.0020669869,0.00006217027,0.0000228071,0.0018649565,0.0016994653,0.4100119,0.001860963,0.002641438,0.0005169869],"about_ca_topic_score_codex":0.054712664,"about_ca_topic_score_gemma":0.014168248,"teacher_disagreement_score":0.45712465,"about_ca_system_score_codex":0.0005077145,"about_ca_system_score_gemma":0.0014866907,"threshold_uncertainty_score":0.9515821},"labels":[],"label_agreement":null},{"id":"W2774293944","doi":"10.1042/bcj20170818","title":"Characterization of the catalytic signature of Scabin toxin, a DNA-targeting ADP-ribosyltransferase","year":2017,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Canadian Institutes of Health Research","keywords":"DNA; Biology; Biochemistry; Transferase; Binding site; Enzyme; Base pair; HMG-box; DNA-binding protein; Gene","score_opus":0.014951604598691838,"score_gpt":0.27919341858620655,"score_spread":0.26424181398751473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774293944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628776,0.00021153135,0.00025055264,0.0025751786,0.00026718725,0.00014427998,0.000040413815,0.000006561078,0.00021655894],"genre_scores_gemma":[0.998959,0.00009491045,0.00016626224,0.00023865544,0.00043674777,0.0000027401531,0.000016963446,0.000013668067,0.000071066446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990117,0.000030425828,0.00037232498,0.00011181265,0.00032995164,0.00014378662],"domain_scores_gemma":[0.9989159,0.000022932172,0.0004104693,0.00032910059,0.00021975592,0.000101811995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022475341,0.00009933606,0.00022989545,0.000039038663,0.00014234878,0.00002091098,0.00025579464,0.00012095132,0.00011112808],"category_scores_gemma":[0.00024780972,0.00006645223,0.00017432157,0.00006589192,0.00020738483,0.00008549331,0.000030108393,0.00034793167,0.0000017665423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020397417,0.00008200471,0.0030322592,0.00006602366,0.000041500392,0.0000044581716,0.00014857747,3.313833e-7,0.99521565,0.000020783655,0.0006672385,0.0005171855],"study_design_scores_gemma":[0.0013570236,0.000057881014,0.016703147,0.0005349147,0.000052016643,0.00011645106,0.000020892321,0.000017756547,0.9805792,0.00007915037,0.0004173052,0.000064238964],"about_ca_topic_score_codex":0.0000033917422,"about_ca_topic_score_gemma":1.7511715e-7,"teacher_disagreement_score":0.014636441,"about_ca_system_score_codex":0.000057332214,"about_ca_system_score_gemma":0.00014687878,"threshold_uncertainty_score":0.27098432},"labels":[],"label_agreement":null},{"id":"W2775876811","doi":"10.1016/j.bbrc.2017.12.113","title":"The aryl hydrocarbon receptor regulates the expression of TIPARP and its cis long non-coding RNA, TIPARP-AS1","year":2017,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"FP7 People: Marie-Curie Actions; Canadian Institutes of Health Research; Universitetet i Oslo; European Commission; Dow Chemical Company","keywords":"Aryl hydrocarbon receptor; Biology; Transcription factor; Cell biology; Gene; Transcription (linguistics); Exon; Transcriptional regulation; Aryl hydrocarbon receptor nuclear translocator; RNA; Regulation of gene expression; Signal transduction; Long non-coding RNA; Genetics","score_opus":0.10751030701416557,"score_gpt":0.4154189826587854,"score_spread":0.3079086756446198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775876811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651561,0.003549359,0.000015206854,0.02898188,0.000028763567,0.00045868094,0.00001621039,0.00001638983,0.0017774191],"genre_scores_gemma":[0.98932767,0.009866773,0.00012954009,0.00004825523,0.00015664722,0.000111117406,0.000017023911,0.000013083985,0.00032987574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986446,0.00012886619,0.00024183941,0.00023454784,0.0004655477,0.0002846004],"domain_scores_gemma":[0.9965507,0.0010884024,0.000107066255,0.0018016013,0.0002752334,0.00017704607],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0007324741,0.00011699012,0.00020298306,0.00003966534,0.0016361395,0.00011244246,0.00088785175,0.00010106593,0.000011129811],"category_scores_gemma":[0.00075011654,0.00006401436,0.000069143585,0.00014757147,0.0019714145,0.000085620195,0.000831558,0.0005898694,0.000010879585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019974662,0.000117563235,0.0001151876,0.000039249724,0.00002417181,3.8654844e-7,0.00013135654,4.4427424e-8,0.9934505,0.0014109163,0.0018434458,0.002667398],"study_design_scores_gemma":[0.0005728157,0.00013647569,0.0029039097,0.00043092982,0.000017903028,0.0000039570464,0.0001124911,0.002655951,0.98954195,0.0014164746,0.0021198357,0.00008731076],"about_ca_topic_score_codex":0.00006220248,"about_ca_topic_score_gemma":0.0000043271452,"teacher_disagreement_score":0.028933624,"about_ca_system_score_codex":0.000040335904,"about_ca_system_score_gemma":0.00006766531,"threshold_uncertainty_score":0.9996636},"labels":[],"label_agreement":null},{"id":"W2777724352","doi":"10.1021/acs.molpharmaceut.7b00843","title":"Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer","year":2017,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"U.S. Army; Natural Sciences and Engineering Research Council of Canada; Ontario Trillium Foundation","keywords":"Olaparib; Ovarian cancer; Serous fluid; Cancer research; PARP inhibitor; Spheroid; Medicine; Paclitaxel; Pharmacology; Doxorubicin; Drug; Cancer; Combination therapy; Poly ADP ribose polymerase; Oncology; Biology; Internal medicine; Chemotherapy; Polymerase; Cell culture; Genetics; DNA","score_opus":0.05005587452836661,"score_gpt":0.3733061430112517,"score_spread":0.3232502684828851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777724352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98948985,0.0030782386,0.004603067,0.0011806133,0.00009756853,0.0004162766,0.000023051987,0.000009064046,0.0011022663],"genre_scores_gemma":[0.99714077,0.0018705814,0.000530228,0.00031932944,0.00001711459,0.000027865373,0.000005415684,0.00001878625,0.00006991888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909145,0.000051776213,0.0002918728,0.00018636596,0.0002442048,0.00013434445],"domain_scores_gemma":[0.9992794,0.000019682313,0.0002310297,0.00028226504,0.00010760495,0.00008001239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023946821,0.000115775336,0.0002819601,0.000082336905,0.000048810874,0.0000166241,0.00007872014,0.000076652366,0.000029112594],"category_scores_gemma":[0.000022711032,0.00011957018,0.000029891216,0.0000505867,0.00017140264,0.000111934314,0.00005537476,0.00015209064,2.6655383e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002787032,0.00017184501,0.0069348235,0.00025016628,0.00009536856,0.000038889826,0.000672369,0.001230582,0.980362,0.004242057,0.000026499105,0.0056967116],"study_design_scores_gemma":[0.008218047,0.00009651699,0.005126348,0.00024661073,0.00011674698,0.000017932138,0.000057516354,0.043357663,0.94013196,0.002335735,0.00017853791,0.000116370626],"about_ca_topic_score_codex":0.0003109997,"about_ca_topic_score_gemma":0.000037781476,"teacher_disagreement_score":0.04212708,"about_ca_system_score_codex":0.000057723933,"about_ca_system_score_gemma":0.00008090003,"threshold_uncertainty_score":0.48759305},"labels":[],"label_agreement":null},{"id":"W2782711085","doi":"10.1101/232736","title":"Identifying chemogenetic interactions from CRISPR knockout screens with drugZ","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; University of Texas MD Anderson Cancer Center; Krembil Foundation; Cancer Prevention and Research Institute of Texas","keywords":"CRISPR; Synthetic lethality; Gene; Identification (biology); KRAS; DNA repair; Drug discovery; Drug resistance","score_opus":0.037294669107938196,"score_gpt":0.29835622446700477,"score_spread":0.26106155535906655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782711085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983356,0.0028085888,0.006812187,0.0013718191,0.0024580508,0.0013883451,0.00087497203,0.0007171525,0.00021290679],"genre_scores_gemma":[0.9814413,0.0005501055,0.014602676,0.00060475414,0.0019734344,0.00045681035,0.000004136103,0.00028225785,0.00008449195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963843,0.00010314878,0.0006741726,0.0014567848,0.00072789926,0.0006536638],"domain_scores_gemma":[0.99445796,0.000091313836,0.00088421,0.0032071702,0.0008380587,0.00052131107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003097783,0.0007842188,0.0010103071,0.00038894976,0.00043616325,0.00045173534,0.0006567134,0.0004973622,0.00053839246],"category_scores_gemma":[0.0001567655,0.0007895569,0.00029101956,0.00024340494,0.00030832516,0.0002477243,0.00042520466,0.001582987,0.00032607414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035889007,0.00030636703,0.024541633,0.0004874509,0.0012082866,0.00034143956,0.00006131983,0.000033949258,0.9694978,0.0000821929,0.0030665756,0.000014107412],"study_design_scores_gemma":[0.002925435,0.00010592863,0.34890002,0.0050402475,0.00088026555,2.853225e-7,0.000016283006,0.00014079294,0.623433,0.000010525488,0.017461395,0.001085817],"about_ca_topic_score_codex":0.00067578134,"about_ca_topic_score_gemma":0.000057691454,"teacher_disagreement_score":0.34606478,"about_ca_system_score_codex":0.0007116488,"about_ca_system_score_gemma":0.0011647233,"threshold_uncertainty_score":0.9994555},"labels":[],"label_agreement":null},{"id":"W2783524730","doi":"10.1038/s41467-017-02293-7","title":"Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Knut och Alice Wallenbergs Stiftelse; Karolinska Institutet; Svenska Sällskapet för Medicinsk Forskning; Vetenskapsrådet; Åke Wiberg Stiftelse; Ministerio de Economía y Competitividad; David och Astrid Hageléns Stiftelse; Cancerfonden; Göran Gustafssons Stiftelser; Pain Relief Foundation; Wenner-Gren Foundation","keywords":"Breast cancer; Biology; Cancer research; Gene; Cancer cell; Cancer; Biochemistry; Cell biology; Genetics","score_opus":0.019915632252812662,"score_gpt":0.3322064534999633,"score_spread":0.31229082124715063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783524730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88693124,0.03699021,0.00004485173,0.06407567,0.0009581029,0.0011065411,0.0002888899,0.00034565202,0.009258852],"genre_scores_gemma":[0.99131155,0.0021420873,0.0027949677,0.0028643485,0.00052021304,0.00012917211,0.00006402426,0.000036696227,0.00013695627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987928,0.00011162307,0.00034980927,0.00023613332,0.00024929555,0.00026029785],"domain_scores_gemma":[0.9978791,0.00010101914,0.00010581515,0.0014120616,0.0003817117,0.00012031661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002282191,0.00016373365,0.00023974152,0.0002301859,0.0002085217,0.00002000361,0.00046756509,0.00034077393,0.0002239813],"category_scores_gemma":[0.000030426125,0.00015876105,0.00007961424,0.0008543355,0.00026209117,0.000101852114,0.00013095797,0.0012342144,0.00007447638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028502906,0.0005671492,0.012497225,0.000021134181,0.00011615082,0.0000056586246,0.0013001214,0.00005920471,0.91831666,0.0007159796,0.06481551,0.0013001781],"study_design_scores_gemma":[0.014428032,0.00050962024,0.09737241,0.0018299052,0.000345185,0.00027464778,0.0012386339,0.00957211,0.45168772,0.0010128607,0.4200772,0.0016516622],"about_ca_topic_score_codex":0.0001904046,"about_ca_topic_score_gemma":0.00048056454,"teacher_disagreement_score":0.46662894,"about_ca_system_score_codex":0.0003136672,"about_ca_system_score_gemma":0.00021362994,"threshold_uncertainty_score":0.6474087},"labels":[],"label_agreement":null},{"id":"W2786653356","doi":"10.1016/j.ygyno.2018.01.017","title":"Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer","year":2018,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"AstraZeneca Canada; Israel Cancer Research Fund","keywords":"Medicine; Debulking; Chemotherapy; Oncology; Ovarian cancer; RAD51; Internal medicine; Proportional hazards model; Cancer; Homologous recombination; Carboplatin; Gene; Cisplatin; Biology; Genetics","score_opus":0.03326885898247156,"score_gpt":0.3608988695318598,"score_spread":0.32763001054938823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786653356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394304,0.000046916906,0.00015834818,0.0021699707,0.0007319144,0.0014470147,0.00004022157,0.00012250361,0.0013400554],"genre_scores_gemma":[0.9919281,0.000035863235,0.0029174043,0.003460748,0.00023372764,0.0008299459,0.00013422956,0.000044868997,0.00041510956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973335,0.00046805514,0.0007445789,0.00064636435,0.00029456435,0.0005128957],"domain_scores_gemma":[0.9980945,0.00045593648,0.0005178574,0.00035285484,0.00042939806,0.00014945418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007408113,0.00029014173,0.0008282347,0.00016103206,0.000101700316,0.000011809673,0.0001423478,0.0005348883,0.0020467336],"category_scores_gemma":[0.00036601734,0.00018931265,0.00007076731,0.0003487269,0.0005494606,0.00009935353,0.000044885805,0.00048512442,0.000037210833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060516912,0.0021890819,0.97131914,0.000010959321,0.00009421287,0.000117720934,0.00019664838,0.0000018787827,0.00015882078,0.000007236629,0.0006608246,0.019191813],"study_design_scores_gemma":[0.02285111,0.012869529,0.96105874,0.00013109461,0.00006341976,0.000010685795,0.00002626206,0.000026942984,0.0009237277,0.00015211849,0.0016309309,0.00025542086],"about_ca_topic_score_codex":0.00004480594,"about_ca_topic_score_gemma":0.000618068,"teacher_disagreement_score":0.018936392,"about_ca_system_score_codex":0.0012711089,"about_ca_system_score_gemma":0.00044171148,"threshold_uncertainty_score":0.99886554},"labels":[],"label_agreement":null},{"id":"W2787816336","doi":"10.1200/jco.2017.35.15_suppl.tps5603","title":"ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic <i>BRCA1-</i> or <i>BRCA2-</i>mutated, relapsed, high-grade ovarian carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; PARP inhibitor; BRCA mutation; Oncology; Germline mutation; Chemotherapy; Olaparib; Ovarian cancer; Regimen; Cancer; Mutation; Poly ADP ribose polymerase; Biology; Genetics; Polymerase","score_opus":0.12385259067240226,"score_gpt":0.4860857614442218,"score_spread":0.3622331707718195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787816336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97208345,0.000071679366,0.00013791402,0.020236207,0.0052769403,0.001917197,0.000017941169,0.000015934722,0.00024275355],"genre_scores_gemma":[0.98903364,0.00059295737,0.002573678,0.0049740025,0.0022183866,0.00006759487,0.000006331704,0.0000561922,0.00047722613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907161,0.0020450382,0.0055262907,0.00044440187,0.00090103515,0.00036710777],"domain_scores_gemma":[0.9875072,0.0034100316,0.0068542305,0.001149577,0.00068417395,0.00039473444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069766194,0.00035211956,0.0035390016,0.0002582212,0.00016339577,0.00006170303,0.0010986456,0.0004939686,0.00062558294],"category_scores_gemma":[0.0078820735,0.00018807975,0.00072686956,0.00018854838,0.00088788493,0.00050199474,0.00013583213,0.0016559412,0.0000071685818],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87773204,0.034654457,0.06812872,0.00006844614,0.0016153984,0.001399925,0.0025516376,0.000050839906,0.0019934045,0.00006152822,0.0017610082,0.0099825645],"study_design_scores_gemma":[0.8881212,0.018185005,0.08053874,0.00051150535,0.00073094654,0.00040914546,0.0007383004,0.0011541527,0.0021249,0.0004060703,0.0068369503,0.00024312004],"about_ca_topic_score_codex":0.00023609477,"about_ca_topic_score_gemma":0.0005071948,"teacher_disagreement_score":0.016950198,"about_ca_system_score_codex":0.00031781633,"about_ca_system_score_gemma":0.0019292528,"threshold_uncertainty_score":0.9436148},"labels":[],"label_agreement":null},{"id":"W2789425996","doi":"10.1093/jcag/gwy009.250","title":"A250 HNF4A’S NEW ROLE IN DNA REPAIR COULD BE A POTENTIAL THERAPEUTIC TARGET FOR COLORECTAL CANCER TREATMENT","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"DNA repair; Gene knockin; Homologous recombination; Cancer research; DNA damage; Biology; Molecular biology; Cell biology; DNA; Gene; Genetics","score_opus":0.016514073414415617,"score_gpt":0.28840290503790383,"score_spread":0.2718888316234882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789425996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93918264,0.000102841055,0.00009713313,0.05873922,0.0011554236,0.00043055118,0.00012969751,0.0000065895106,0.00015590685],"genre_scores_gemma":[0.9937475,0.000048991915,0.0004990012,0.0040194155,0.0008443229,0.000020262223,0.000005485603,0.000018431487,0.0007965939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855673,0.00017274171,0.00052313507,0.00012076439,0.00025732184,0.0003693163],"domain_scores_gemma":[0.9983374,0.000048756585,0.0008431597,0.00012014516,0.00042447157,0.00022607228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004958696,0.00012389867,0.00042883804,0.00024553548,0.00008078644,0.00000889648,0.00013330649,0.00015190386,0.00022949777],"category_scores_gemma":[0.000094629184,0.00009524625,0.0003273766,0.00011433026,0.000078197845,0.000057372257,0.000007996578,0.00018146081,0.0000012727058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004287189,0.00017395323,0.9408215,0.0000114766635,0.001034019,0.000009342914,0.00092610164,0.00019139952,0.013247123,0.000053424596,0.03868874,0.0005557175],"study_design_scores_gemma":[0.024072852,0.014694442,0.86659896,0.00016846896,0.00056414667,0.0002012398,0.00026796787,0.00086381263,0.009220447,0.0011624771,0.082039274,0.00014588173],"about_ca_topic_score_codex":0.011463238,"about_ca_topic_score_gemma":0.4915128,"teacher_disagreement_score":0.48004955,"about_ca_system_score_codex":0.0045839436,"about_ca_system_score_gemma":0.0018264271,"threshold_uncertainty_score":0.9992373},"labels":[],"label_agreement":null},{"id":"W2790338852","doi":"10.1158/1538-7445.sabcs17-ot3-04-04","title":"Abstract OT3-04-04: LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline <i>BRCA1/2</i> mutation","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Olaparib; Medicine; Metastatic breast cancer; Internal medicine; BRCA mutation; Oncology; PARP inhibitor; Hazard ratio; Breast cancer; Taxane; Progression-free survival; Eribulin; Cancer; Chemotherapy; Confidence interval","score_opus":0.13096376115481537,"score_gpt":0.46960491233777,"score_spread":0.3386411511829547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790338852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377227,0.00032828224,0.00001562958,0.00084878283,0.00011653128,0.004131279,0.0004706248,0.000020995625,0.00029563042],"genre_scores_gemma":[0.9975932,0.00011344136,0.0003235765,0.00031099303,0.00015414068,0.0012263232,0.000038253158,0.00006888094,0.000171155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658763,0.00029101607,0.0006298418,0.00070863933,0.0011789332,0.00060394855],"domain_scores_gemma":[0.9969446,0.00026719007,0.0002720536,0.00045736224,0.001791289,0.0002674759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009144811,0.00028184865,0.0006265687,0.00043559805,0.00017362586,0.00008884017,0.00027017755,0.00007105565,0.00089478865],"category_scores_gemma":[0.00011070638,0.00022674524,0.000025323021,0.0010433139,0.0006565238,0.00044880572,0.00014893818,0.00056497316,0.000012111267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15107776,0.14053904,0.38942015,0.0018948665,0.002867321,0.0004283284,0.05919161,0.00009650896,0.066024184,0.000039051665,0.004366918,0.18405426],"study_design_scores_gemma":[0.31059307,0.026457863,0.6082453,0.004108063,0.0003095817,0.000018844672,0.0057739243,0.0006183043,0.042253874,0.0001580424,0.0006959559,0.0007671518],"about_ca_topic_score_codex":0.008515189,"about_ca_topic_score_gemma":0.006649112,"teacher_disagreement_score":0.21882518,"about_ca_system_score_codex":0.0008135775,"about_ca_system_score_gemma":0.0005980227,"threshold_uncertainty_score":0.99808717},"labels":[],"label_agreement":null},{"id":"W2792846855","doi":"10.1016/j.bmc.2018.03.020","title":"Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2","year":2018,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Defence Science and Technology Group; Novartis Pharma; Ontario Ministry of Economic Development and Innovation; Ministero dello Sviluppo Economico; Genome Canada; Fundação de Amparo à Pesquisa do Estado de São Paulo; Diamond Light Source; Wellcome Trust; GlaxoSmithKline; European Federation of Pharmaceutical Industries and Associations; Defence Science and Technology Laboratory; Merck KGaA; Engineering and Physical Sciences Research Council; AstraZeneca; Pfizer","keywords":"Chemistry; Polymerase; Allosteric regulation; Poly ADP ribose polymerase; Biochemistry; Stereochemistry; DNA; Enzyme","score_opus":0.024780054690939253,"score_gpt":0.2970631750371324,"score_spread":0.2722831203461932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792846855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848616,0.004347118,0.003959316,0.0032453358,0.0008756598,0.00081421144,0.00042415803,0.00015113509,0.001321438],"genre_scores_gemma":[0.9890697,0.00009502838,0.0015071421,0.0018132478,0.0039367448,0.00008591326,0.0001741799,0.00011380189,0.0032042237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970494,0.000019284575,0.0008619607,0.0006982286,0.0007246412,0.00064647855],"domain_scores_gemma":[0.9979294,0.00014814037,0.00043162773,0.0007684822,0.00035947224,0.00036287613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036851625,0.00045866444,0.0007747236,0.00008725449,0.00013005189,0.000027941696,0.00030668144,0.000324194,0.000875444],"category_scores_gemma":[0.0002798431,0.00041136637,0.00025448736,0.00046339698,0.0008212717,0.0001672017,0.00009872397,0.00025072115,0.00002802895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022306563,0.0005690852,0.000621063,0.00067921024,0.0001851116,0.000025320627,0.00025564551,4.1851493e-8,0.9816509,0.00003380499,0.013171376,0.00057782396],"study_design_scores_gemma":[0.010120707,0.0008065673,0.00060989626,0.0009961403,0.00028558928,0.0004131502,0.00032424403,0.000041516138,0.9800832,0.000036964535,0.0059069954,0.00037500905],"about_ca_topic_score_codex":0.000060315335,"about_ca_topic_score_gemma":0.0000029751416,"teacher_disagreement_score":0.00789005,"about_ca_system_score_codex":0.0003063707,"about_ca_system_score_gemma":0.0006368517,"threshold_uncertainty_score":0.9998338},"labels":[],"label_agreement":null},{"id":"W2794378246","doi":"10.2147/dddt.s130809","title":"Rucaparib: a novel PARP inhibitor for&amp;nbsp;&lt;em&gt;BRCA&lt;/em&gt;&amp;nbsp;advanced ovarian cancer","year":2018,"lang":"en","type":"review","venue":"Drug Design Development and Therapy","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"PARP inhibitor; Ovarian cancer; Cancer research; Medicine; Poly ADP ribose polymerase; Chemistry; Pharmacology; Cancer; Internal medicine; Biochemistry; DNA; Polymerase","score_opus":0.11202327551983936,"score_gpt":0.3535853993551428,"score_spread":0.24156212383530345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794378246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008782032,0.9626936,0.024622101,0.0004677256,0.0026006084,0.007617833,0.00028534114,0.0004405814,0.00039402893],"genre_scores_gemma":[0.00006040504,0.8894089,0.08951828,0.0014182942,0.0024152633,0.0064317994,0.0011373454,0.0005048276,0.009104894],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921333,0.00035409958,0.002456389,0.0021646146,0.0012799435,0.0016116176],"domain_scores_gemma":[0.99505997,0.0006953867,0.0014210969,0.0013117081,0.0007529686,0.0007588478],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0021064938,0.0020701354,0.004070671,0.00086199515,0.0007184327,0.0002935382,0.0006953277,0.0010195978,0.0008414518],"category_scores_gemma":[0.00011600411,0.0017190531,0.00082136126,0.0010884487,0.00034974414,0.00033624857,0.00013378829,0.00086911966,0.00027465844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015037991,0.00054567185,0.000015994017,0.004501616,0.0023039426,0.00001482532,0.005527198,0.0000022595484,0.0014276908,0.00025359372,0.03922874,0.9446747],"study_design_scores_gemma":[0.00966324,0.00023772941,0.000023386248,0.014150593,0.0005056446,0.00011229264,0.00006424277,0.000006321678,0.0016521373,0.00036346764,0.9712301,0.0019908291],"about_ca_topic_score_codex":0.00001502683,"about_ca_topic_score_gemma":0.00013815219,"teacher_disagreement_score":0.9426838,"about_ca_system_score_codex":0.0012138358,"about_ca_system_score_gemma":0.003912806,"threshold_uncertainty_score":0.99920404},"labels":[],"label_agreement":null},{"id":"W2796900308","doi":"10.1158/1535-7163.targ-17-lb-a12","title":"Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-<i>BRCA</i> homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"PARP inhibitor; Olaparib; Oncology; Medicine; Internal medicine; BRCA mutation; Cancer research; Homologous recombination; Ovarian cancer; Cancer; Genetics; Biology; Gene; Poly ADP ribose polymerase","score_opus":0.023965657891026924,"score_gpt":0.29624467251739556,"score_spread":0.2722790146263686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796900308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880126,0.00015064294,0.0010890369,0.005710451,0.0003209566,0.003988193,0.0005802157,0.000059484744,0.000088406545],"genre_scores_gemma":[0.9954149,0.000037453276,0.00048512526,0.0028740852,0.00019314532,0.00063669716,0.00025649657,0.000071199785,0.000030873653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970494,0.00046266025,0.0005853594,0.00080253696,0.0005898682,0.00051019836],"domain_scores_gemma":[0.9978108,0.00033722704,0.0003307503,0.0008558032,0.0005481087,0.00011735923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047178354,0.00046283827,0.000521417,0.00014266111,0.00023466798,0.000057875783,0.00013063417,0.00012788648,0.000015340136],"category_scores_gemma":[0.000025696003,0.00027518946,0.000087189335,0.0006860666,0.00034697808,0.00009366809,0.00003563421,0.00041340914,0.0000075981748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117948085,0.029160809,0.4868185,0.00006877433,0.005160141,0.003303953,0.16293825,0.0046936595,0.054500315,0.00024424907,0.0013876836,0.13377559],"study_design_scores_gemma":[0.052895885,0.009961769,0.8896772,0.0004670092,0.00046093174,0.000015556308,0.0029627373,0.00096108293,0.040505953,0.000096380885,0.001401775,0.0005937146],"about_ca_topic_score_codex":0.0068757837,"about_ca_topic_score_gemma":0.014517188,"teacher_disagreement_score":0.40285873,"about_ca_system_score_codex":0.0011300504,"about_ca_system_score_gemma":0.0004184958,"threshold_uncertainty_score":0.99997},"labels":[],"label_agreement":null},{"id":"W2799587885","doi":"10.1007/s10549-018-4807-x","title":"Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer","year":2018,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Triple-negative breast cancer; Olaparib; PARP inhibitor; Immune system; Biomarker; Breast cancer; Immunology; Immunotherapy; Immunity; Medicine; Homologous recombination; Cancer research; Cancer; DNA repair; Biology; Internal medicine; Poly ADP ribose polymerase; DNA; Genetics","score_opus":0.1224340836293274,"score_gpt":0.4512091297398764,"score_spread":0.32877504611054903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799587885","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017148284,0.9747795,0.0000011351888,0.0010198026,0.00022392695,0.003307514,0.0029344477,0.00004243335,0.0005429941],"genre_scores_gemma":[0.018762162,0.9761331,0.000028101902,0.000041393858,0.00032977824,0.0037939597,0.000107140615,0.000075069955,0.0007292553],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996361,0.0006173131,0.00061889074,0.0009575995,0.0006017878,0.0008433834],"domain_scores_gemma":[0.99798405,0.00032126546,0.0002638528,0.0005191864,0.00052303146,0.00038858582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007104853,0.0005843003,0.0016624517,0.00085011794,0.0003735636,0.00009442254,0.0001667382,0.00025921076,0.0005446033],"category_scores_gemma":[0.000035053017,0.00042389473,0.00017572111,0.0011061016,0.00087930815,0.00015497433,0.00012478505,0.0007196017,0.000029547233],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083540264,0.0012630962,0.0030713705,0.0036949776,0.00042931314,0.00023039425,0.00037538644,8.0790926e-8,0.000007982352,0.000073255826,0.0005100362,0.9895087],"study_design_scores_gemma":[0.05622864,0.011323809,0.40388694,0.14108591,0.0029405323,0.022789005,0.0011953111,0.000047302958,0.00037026018,0.0015712442,0.3549693,0.003591759],"about_ca_topic_score_codex":0.01971865,"about_ca_topic_score_gemma":0.0020289633,"teacher_disagreement_score":0.985917,"about_ca_system_score_codex":0.0038205974,"about_ca_system_score_gemma":0.0022981795,"threshold_uncertainty_score":0.9998213},"labels":[],"label_agreement":null},{"id":"W2799710201","doi":"10.1186/s40169-018-0185-6","title":"Analyses of repeated failures in cancer therapy for solid tumors: poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costs","year":2018,"lang":"en","type":"article","venue":"Clinical and Translational Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":486,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"National Eye Institute; National Institutes of Health; Ministry of Education, Culture, Sports, Science and Technology; National Cancer Institute; University of Pennsylvania","keywords":"Medicine; Cancer; Drug; Drug delivery; Cancer therapy; Oncology; Intensive care medicine; Pharmacology; Internal medicine; Nanotechnology","score_opus":0.09298064257482087,"score_gpt":0.4585024538825066,"score_spread":0.36552181130768574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799710201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721605,0.008991299,0.00038307125,0.017027728,0.000111414054,0.0010453566,0.0000337355,0.00002618618,0.00022067231],"genre_scores_gemma":[0.99473614,0.0017351448,0.00036482187,0.0023353614,0.0005998434,0.000086275075,0.000035059013,0.000020981948,0.00008637501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981711,0.00011596065,0.0008153885,0.00039980805,0.0002547697,0.00024300945],"domain_scores_gemma":[0.9977586,0.0012080768,0.0001840467,0.00016292545,0.00053024845,0.00015607798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006856427,0.00018461361,0.00068761874,0.00017849029,0.00008031937,0.000005505756,0.00007254165,0.00008207396,0.00013915027],"category_scores_gemma":[0.0002147591,0.00013064334,0.00007674927,0.0003379545,0.001162919,0.00007084618,0.000008514715,0.000199685,5.8549676e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060032908,0.0031794237,0.6037823,0.0010288627,0.0024576008,0.00007301687,0.005713608,0.00007739078,0.08653134,0.0028664044,0.0059014987,0.22835566],"study_design_scores_gemma":[0.056449775,0.006131914,0.8806061,0.0023224605,0.00038573684,0.000037222275,0.0005166595,0.0028697264,0.03167502,0.014556417,0.004077214,0.00037176587],"about_ca_topic_score_codex":0.0005452676,"about_ca_topic_score_gemma":0.00016184356,"teacher_disagreement_score":0.27682382,"about_ca_system_score_codex":0.00002918886,"about_ca_system_score_gemma":0.0002700932,"threshold_uncertainty_score":0.5327481},"labels":[],"label_agreement":null},{"id":"W2801377326","doi":"10.18632/oncotarget.25158","title":"The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors","year":2018,"lang":"en","type":"article","venue":"Oncotarget","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Russian Science Foundation; Siberian Branch, Russian Academy of Sciences; Université Laval","keywords":"PARP1; Poly ADP ribose polymerase; Polymerase; Olaparib; Molecular biology; Biology; Biochemistry; Chemistry; DNA","score_opus":0.013316285564899225,"score_gpt":0.28178778538504057,"score_spread":0.26847149982014135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801377326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993375,0.000889982,0.0004142797,0.0034184663,0.0003424294,0.0006218963,0.000016496802,0.000044170774,0.0008772678],"genre_scores_gemma":[0.9978292,0.00009599003,0.00046015944,0.00027170873,0.00060819375,0.00010349848,0.0000063234856,0.00001767662,0.0006072317],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987619,0.000116229305,0.0002478843,0.00023850515,0.0003933274,0.00024218578],"domain_scores_gemma":[0.99891496,0.00026208904,0.0001780795,0.0003385051,0.00020744644,0.000098903736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004921401,0.00015063147,0.00019796636,0.000040683924,0.00043930925,0.00002663243,0.00010623358,0.000067675144,0.00016189081],"category_scores_gemma":[0.00023306673,0.00008086914,0.00009174808,0.00019917535,0.0008840628,0.00008022473,0.000049508377,0.00017138045,0.000024370996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003336876,0.001099779,0.09690562,0.00012437764,0.00034242115,0.000012364678,0.001140001,0.00000871383,0.8548606,0.0017503924,0.025967536,0.014451337],"study_design_scores_gemma":[0.0025892733,0.001074348,0.09138411,0.00024404532,0.00008218611,0.000056649784,0.00029750285,0.0006295988,0.8432111,0.0015396377,0.058674254,0.00021729857],"about_ca_topic_score_codex":0.00017890071,"about_ca_topic_score_gemma":0.00003971008,"teacher_disagreement_score":0.03270672,"about_ca_system_score_codex":0.000054829667,"about_ca_system_score_gemma":0.00016663742,"threshold_uncertainty_score":0.3378856},"labels":[],"label_agreement":null},{"id":"W2802609110","doi":"10.1200/jco.2015.33.15_suppl.e18562","title":"Effect of FK866, NAMPT inhibitor, on small cell lung cancer cell lines.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Cell culture; Apoptosis; Programmed cell death; Viability assay; Cancer research; Nicotinamide adenine dinucleotide; Cell growth; Nicotinamide phosphoribosyltransferase; Biology; NAD+ kinase; Cisplatin; Chemotherapy; Biochemistry; Enzyme; Genetics","score_opus":0.12365408856675252,"score_gpt":0.500820750508073,"score_spread":0.3771666619413204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802609110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690955,0.004274977,0.00009648999,0.0030883676,0.0053746244,0.00034322,0.000008184531,0.000014349742,0.017704275],"genre_scores_gemma":[0.98726743,0.001896754,0.0010838874,0.0034701708,0.00518115,0.000013543176,0.0000022450267,0.000037963102,0.0010468606],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953928,0.00094014365,0.0025910113,0.00022746903,0.0005762162,0.0002723607],"domain_scores_gemma":[0.99210805,0.003547598,0.0025550271,0.00028217013,0.0008334744,0.0006737089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058535966,0.00021262949,0.0019382162,0.0001254707,0.00002165124,0.000005242556,0.00021081037,0.00057251233,0.00030430307],"category_scores_gemma":[0.0016615773,0.00014533306,0.00065326877,0.00015631066,0.00020413681,0.000080809485,0.00004239588,0.0012610488,0.000026759655],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11336922,0.011017732,0.27144852,0.0013325898,0.0011382526,0.0017670958,0.0010935771,0.0012210459,0.028879909,0.000062013256,0.38746613,0.1812039],"study_design_scores_gemma":[0.11266086,0.17709479,0.010998951,0.0015821205,0.0017726807,0.00031092542,0.00014453584,0.0005341463,0.3271743,0.0001932371,0.36705056,0.00048287082],"about_ca_topic_score_codex":0.000062516556,"about_ca_topic_score_gemma":0.000029640041,"teacher_disagreement_score":0.2982944,"about_ca_system_score_codex":0.0005730777,"about_ca_system_score_gemma":0.002773492,"threshold_uncertainty_score":0.592651},"labels":[],"label_agreement":null},{"id":"W2804717005","doi":"10.1093/annonc/mdy181","title":"Safety and dose modification for patients receiving niraparib","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Adverse effect; Population; Gastroenterology; Surgery","score_opus":0.13754265967460957,"score_gpt":0.4458181394990429,"score_spread":0.3082754798244334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804717005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96748614,0.00020210326,0.0016725231,0.0096258335,0.0003409883,0.0006587352,0.000038226728,0.000027636976,0.019947786],"genre_scores_gemma":[0.9948344,0.00050071115,0.0017760134,0.0023992816,0.00021468518,0.000032626554,0.00003264428,0.000009271998,0.00020032395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939346,0.00003290362,0.0002351879,0.00014083067,0.00007129808,0.00012632167],"domain_scores_gemma":[0.9990834,0.00013515302,0.00014381706,0.00013334751,0.000449157,0.00005514794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026219315,0.000056484947,0.00019998383,0.000060455575,0.000048351398,0.0000019652082,0.00003338145,0.00009007713,0.00005391928],"category_scores_gemma":[0.00016139487,0.000052611576,0.00003387572,0.000066740475,0.00016509007,0.000046391964,0.00001171674,0.00004279804,0.000006989476],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070655025,0.0008480507,0.023686267,0.000116730764,0.0001319577,8.3816104e-7,0.001628735,0.0000016261858,0.01413335,0.002836217,0.0374557,0.912095],"study_design_scores_gemma":[0.00881297,0.012454886,0.25268492,0.00010021415,0.00004095557,0.000008541599,0.00006949549,0.0002649801,0.028320178,0.003285427,0.69382745,0.00013001292],"about_ca_topic_score_codex":0.00001012359,"about_ca_topic_score_gemma":0.0000075880416,"teacher_disagreement_score":0.911965,"about_ca_system_score_codex":0.000030368154,"about_ca_system_score_gemma":0.00007183004,"threshold_uncertainty_score":0.21454379},"labels":[],"label_agreement":null},{"id":"W2807249919","doi":"10.1093/toxsci/kfy136","title":"Hepatocyte-Specific Deletion of TIPARP, a Negative Regulator of the Aryl Hydrocarbon Receptor, Is Sufficient to Increase Sensitivity to Dioxin-Induced Wasting Syndrome","year":2018,"lang":"en","type":"article","venue":"Toxicological Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk Fonden; Kreftforeningen; Canadian Institutes of Health Research; Dow Chemical Company","keywords":"Aryl hydrocarbon receptor; Hepatocyte; Endocrinology; Internal medicine; Toxicity; Biology; Chemistry; Biochemistry; Transcription factor; Gene; Medicine","score_opus":0.06133821427838172,"score_gpt":0.32066358978390214,"score_spread":0.25932537550552043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807249919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393725,0.000022456505,0.00020709548,0.003325855,0.0002647564,0.0008584463,0.00001936966,0.00004058135,0.0013241759],"genre_scores_gemma":[0.99660575,0.0000051128654,0.0016170365,0.0015636135,0.00011861225,0.00003628317,6.448987e-7,0.0000069246785,0.000046018424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976917,0.00021146354,0.00042974745,0.00050854887,0.00079968484,0.00035883876],"domain_scores_gemma":[0.99858826,0.00036513965,0.00023502883,0.0003244152,0.00023385856,0.00025330982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014236071,0.00016587722,0.00040940606,0.00012837209,0.00023162106,0.000015775862,0.00023574648,0.00010893197,0.00034448653],"category_scores_gemma":[0.0007635758,0.00010188563,0.00011322398,0.0016070046,0.00090594555,0.000066282795,0.00017405265,0.00014197614,0.000038316135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003682983,0.00026275177,0.0072993604,0.000012543102,0.00001165187,0.0000057993957,0.0009709933,0.00005374649,0.98898697,0.0003320328,0.0004984565,0.001197379],"study_design_scores_gemma":[0.0004537909,0.00406081,0.1201093,0.00030969857,0.000013278982,0.00004549678,0.00031272738,0.0007368713,0.87324876,0.00018436823,0.00037878615,0.00014611053],"about_ca_topic_score_codex":0.00012193436,"about_ca_topic_score_gemma":0.000030420679,"teacher_disagreement_score":0.11573822,"about_ca_system_score_codex":0.00022712647,"about_ca_system_score_gemma":0.00015355408,"threshold_uncertainty_score":0.41547754},"labels":[],"label_agreement":null},{"id":"W2807452056","doi":"10.1038/s41467-018-03234-8","title":"NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Biological and Environmental Research; Basic Energy Sciences; Lawrence Berkeley National Laboratory; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; Canadian Institutes of Health Research; U.S. Department of Energy","keywords":"Allosteric regulation; NAD+ kinase; Poly ADP ribose polymerase; DNA; Chemistry; Biophysics; DNA repair; Nucleobase; DNA damage; DNA-binding domain; Biochemistry; Stereochemistry; Cell biology; Biology; Polymerase; Enzyme; Transcription factor; Gene","score_opus":0.0359313609022584,"score_gpt":0.34264436730787134,"score_spread":0.30671300640561294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807452056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718245,0.0026154572,0.00046782612,0.016672872,0.00021893284,0.00081950583,0.00018708418,0.00016807651,0.0070257154],"genre_scores_gemma":[0.9792465,0.0009884791,0.014324415,0.004143257,0.0001567671,0.00011330487,0.00085599493,0.000044226752,0.00012708429],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841565,0.0002280326,0.00043525003,0.00035536478,0.00027088806,0.00029480396],"domain_scores_gemma":[0.99588674,0.00029067224,0.00017204556,0.003091934,0.00032450192,0.00023408167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040622547,0.00022354444,0.0003331675,0.00022770994,0.0006239749,0.00010076371,0.00083453866,0.00032068044,0.00008344607],"category_scores_gemma":[0.00013658177,0.00022389583,0.00007332267,0.00053529465,0.0002462984,0.00021160705,0.00046193865,0.00087217154,0.00011217642],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001068073,0.0017512861,0.076373026,0.00016197722,0.0015630522,0.00002967804,0.021020696,0.0000051162706,0.7458135,0.1119085,0.032146927,0.008158184],"study_design_scores_gemma":[0.03369419,0.0031198557,0.29576293,0.010166198,0.0024715527,0.0011602242,0.011388614,0.007989619,0.16977876,0.10407429,0.35463935,0.0057544094],"about_ca_topic_score_codex":0.00012750713,"about_ca_topic_score_gemma":0.0013620667,"teacher_disagreement_score":0.5760347,"about_ca_system_score_codex":0.00026309345,"about_ca_system_score_gemma":0.00007830185,"threshold_uncertainty_score":0.9130207},"labels":[],"label_agreement":null},{"id":"W2808864948","doi":"10.1136/esmoopen-2018-000361","title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"European Society for Medical Oncology; Genentech; GlaxoSmithKline; Teva Pharmaceutical Industries; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Discontinuation; Oncology; Metastatic breast cancer; Meta-analysis; Breast cancer; Adverse effect; Neutropenia; PARP inhibitor; Population; Cancer; Chemotherapy; Poly ADP ribose polymerase; Polymerase","score_opus":0.15249025861087392,"score_gpt":0.4081192647699527,"score_spread":0.2556290061590788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808864948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000068553272,0.966957,0.000058752332,0.00049356435,0.00005482446,0.028776227,0.0035914157,0.000015799304,0.000045609107],"genre_scores_gemma":[0.00006587735,0.9792897,0.00050542835,0.00040980437,0.000040253057,0.01831573,0.0004773763,0.000090271635,0.00080554705],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961606,0.0007028493,0.001632533,0.00070178905,0.00050793577,0.00029429526],"domain_scores_gemma":[0.994891,0.0008855207,0.0023225392,0.0010708477,0.0006703654,0.00015976104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006861151,0.0007479239,0.01086509,0.00020602868,0.00014108716,0.00007904647,0.00037916878,0.000092514696,0.0008206913],"category_scores_gemma":[0.000067106484,0.0003220121,0.0019207855,0.0011228494,0.00024866863,0.00010841632,0.00006527189,0.00011150456,0.000010566105],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001378472,0.00075512455,0.000015732812,0.49232268,0.5001175,0.000004711516,0.0003317463,0.0000011909334,9.933778e-9,0.0000049941673,0.0009051742,0.005403313],"study_design_scores_gemma":[0.0016119211,0.0010825018,0.000016418056,0.06054107,0.87165874,0.000020053165,0.000035644785,0.000002675477,0.000005864021,0.000006758883,0.064725965,0.0002923729],"about_ca_topic_score_codex":0.0012159733,"about_ca_topic_score_gemma":0.00048106545,"teacher_disagreement_score":0.4317816,"about_ca_system_score_codex":0.0006298673,"about_ca_system_score_gemma":0.00039790416,"threshold_uncertainty_score":0.99992317},"labels":[],"label_agreement":null},{"id":"W2810583998","doi":"10.1038/s41586-018-0291-z","title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","year":2018,"lang":"en","type":"article","venue":"Nature","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute for Advanced Research; University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Cancer Institute; Medical Research Council; U.S. Department of Defense; European Commission; Prostate Cancer Foundation; Movember Foundation; Prostate Cancer UK; Canadian Institutes of Health Research; National Science Foundation; Cancer Research UK; Krembil Foundation; Stand Up To Cancer; Blood Cancer UK; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"DNA repair; Olaparib; CRISPR; Biology; PARP1; Poly ADP ribose polymerase; PARP inhibitor; Gene; Genome instability; Molecular biology; Polymerase; Cancer research; DNA damage; DNA; Genetics","score_opus":0.022775582447069283,"score_gpt":0.3584049899763154,"score_spread":0.33562940752924614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810583998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790756,0.002443865,0.0009914818,0.004393061,0.0004321689,0.00035055337,0.000020049136,0.00012805837,0.0121651655],"genre_scores_gemma":[0.9904498,0.000119370176,0.0012727021,0.0056338697,0.0008426563,0.000009916943,0.000015237808,0.00003677355,0.001619711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884814,0.000040188654,0.00026882658,0.00027301427,0.00032488184,0.0002449574],"domain_scores_gemma":[0.99898434,0.00006627063,0.00013531074,0.00041170765,0.00027679934,0.0001255825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020048664,0.00014565275,0.00027365846,0.00015944809,0.00012127933,0.000013555845,0.00014500151,0.0006411701,0.00072678656],"category_scores_gemma":[0.00014175623,0.00013128751,0.00014186751,0.00028551655,0.00023957646,0.00006916813,0.00004324271,0.0011503005,0.00017843285],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005504886,0.00016516619,0.008555801,0.0001372535,0.0002388983,0.00003175033,0.0013869941,0.000007827788,0.8447993,0.0014397221,0.13600191,0.006684875],"study_design_scores_gemma":[0.0039978963,0.0006241324,0.15129863,0.0010143343,0.00021430147,0.0002486724,0.0008292272,0.00014313625,0.43808144,0.0021840911,0.4009661,0.0003980387],"about_ca_topic_score_codex":0.00008938377,"about_ca_topic_score_gemma":0.00003184522,"teacher_disagreement_score":0.40671787,"about_ca_system_score_codex":0.00007701664,"about_ca_system_score_gemma":0.00012746721,"threshold_uncertainty_score":0.7957803},"labels":[],"label_agreement":null},{"id":"W2883344686","doi":"10.1007/s10549-018-4888-6","title":"PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Cancer Research Society","keywords":"Vinorelbine; Olaparib; Cancer research; Vinca alkaloid; Pharmacology; Biology; Poly ADP ribose polymerase; Medicine; Internal medicine; Chemotherapy; Biochemistry; Cisplatin; Polymerase","score_opus":0.04040380798639745,"score_gpt":0.36810005989460676,"score_spread":0.3276962519082093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883344686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97604454,0.005715622,0.0000074160344,0.015901629,0.00017011887,0.0008145767,0.00047339595,0.00004188586,0.0008308176],"genre_scores_gemma":[0.97662866,0.019956747,0.000062750594,0.00021837796,0.0011523517,0.00041492656,0.00005291291,0.000043021908,0.0014702328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979113,0.00011760704,0.00030070686,0.0005877139,0.00047421374,0.0006084638],"domain_scores_gemma":[0.9987341,0.000062033345,0.000071077055,0.00026339546,0.00048761725,0.00038173606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024016903,0.0002667528,0.00036445138,0.0002474554,0.00023796612,0.00006849631,0.000048073434,0.00011867403,0.00061180507],"category_scores_gemma":[0.0000050143926,0.00020778972,0.000045844525,0.0004568993,0.000455275,0.0001843145,0.00006301627,0.0001799799,0.000019445059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010138508,0.0021207898,0.70044607,0.00038418322,0.00050981535,0.00029490225,0.0020629123,0.000022608207,0.069416575,0.00025476076,0.0043914826,0.2099574],"study_design_scores_gemma":[0.020715015,0.0018794772,0.90056604,0.0014232154,0.00015472443,0.00094681606,0.000503214,0.00088502286,0.06797198,0.00058857293,0.0038181236,0.00054776866],"about_ca_topic_score_codex":0.022633228,"about_ca_topic_score_gemma":0.007749038,"teacher_disagreement_score":0.20940964,"about_ca_system_score_codex":0.0010205355,"about_ca_system_score_gemma":0.00038492164,"threshold_uncertainty_score":0.98387516},"labels":[],"label_agreement":null},{"id":"W2883374837","doi":"10.1200/jco.2016.34.15_suppl.tps4152","title":"POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline <i>BRCA1/2</i> mutation (g<i>BRCA</i>m).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Clinical endpoint; BRCA mutation; Oncology; Population; Regimen; Cancer; Phases of clinical research; Ovarian cancer; Surgery; Randomized controlled trial; Chemotherapy; Genetics","score_opus":0.06732688848700241,"score_gpt":0.4505925390702192,"score_spread":0.38326565058321677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883374837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817481,0.00053436076,0.0062612076,0.008169742,0.00082389935,0.0019786612,0.000037690283,0.000011116947,0.00043519863],"genre_scores_gemma":[0.9885971,0.0037969789,0.002845751,0.003377438,0.00071424467,0.00017167212,0.0000056980707,0.00004578484,0.0004453446],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915689,0.0016959178,0.0052488334,0.00034029133,0.0007566152,0.0003894415],"domain_scores_gemma":[0.9867499,0.00576575,0.005723587,0.00031545068,0.0011102004,0.00033512127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00602893,0.000296292,0.0046855505,0.0003235324,0.000030110332,0.000007914674,0.00019996583,0.00027737668,0.0003494816],"category_scores_gemma":[0.0034592655,0.00015807181,0.00073721755,0.0002783067,0.0007635668,0.0002521729,0.00001870204,0.0006588701,0.0000044127823],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9007059,0.005478066,0.004434456,0.000040538096,0.0012491746,0.0001856503,0.00033657663,0.00002837901,0.00038698496,0.000074443116,0.0013008065,0.08577907],"study_design_scores_gemma":[0.96017647,0.029557975,0.0027539378,0.0012967814,0.00088625,0.00007237319,0.00006448705,0.00024030062,0.00075253024,0.0008525021,0.0031667172,0.00017970079],"about_ca_topic_score_codex":0.0001605918,"about_ca_topic_score_gemma":0.00013390444,"teacher_disagreement_score":0.08559937,"about_ca_system_score_codex":0.000522155,"about_ca_system_score_gemma":0.0022436306,"threshold_uncertainty_score":0.6445981},"labels":[],"label_agreement":null},{"id":"W2883673963","doi":"10.1016/s1470-2045(18)30343-7","title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Internal medicine; Olaparib; Tolerability; Quality of life (healthcare); Placebo; Clinical endpoint; Oncology; Ovarian cancer; Adverse effect; Nausea; Progression-free survival; Randomized controlled trial; Cancer; Chemotherapy; Surgery","score_opus":0.028783105922643652,"score_gpt":0.3335244201553895,"score_spread":0.30474131423274586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883673963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98211074,0.0003105651,0.00007725537,0.01171437,0.00018652284,0.005222136,0.00009860895,0.00004010319,0.00023969174],"genre_scores_gemma":[0.9922023,0.000104262566,0.0005747293,0.006219851,0.00013271299,0.00065263425,0.000029252433,0.000034927085,0.000049342507],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968846,0.0009253595,0.0009991764,0.00043206237,0.00031355425,0.0004452661],"domain_scores_gemma":[0.9973835,0.0008168407,0.0010268249,0.00034144905,0.00028316653,0.00014822888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008197259,0.00029020495,0.001977123,0.00012041827,0.00009632932,0.000013117091,0.00007063522,0.00018349187,0.00008434101],"category_scores_gemma":[0.00029767913,0.00016921568,0.000059291215,0.00024324642,0.00067012303,0.00008835647,0.000020628719,0.00035502337,0.000001437743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9476436,0.000758966,0.03250853,0.00005692126,0.00054405426,0.000012476839,0.010530485,0.0000065340582,0.00013602292,0.000053328728,0.00026552248,0.007483558],"study_design_scores_gemma":[0.8686193,0.008130614,0.12169332,0.00021577867,0.00007613471,0.000012743075,0.00046679666,0.0001803216,0.0001560703,0.00006919899,0.00019885993,0.00018084342],"about_ca_topic_score_codex":0.00062735984,"about_ca_topic_score_gemma":0.0010279209,"teacher_disagreement_score":0.08918478,"about_ca_system_score_codex":0.000284034,"about_ca_system_score_gemma":0.0005138154,"threshold_uncertainty_score":0.69004154},"labels":[],"label_agreement":null},{"id":"W2883697601","doi":"10.1017/cjn.2018.309","title":"21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Temozolomide; Poly ADP ribose polymerase; Cancer research; DNA repair; PARP inhibitor; Methyltransferase; Downregulation and upregulation; O-6-methylguanine-DNA methyltransferase; Cell culture; DNA methylation; Biology; Methylation; Base excision repair; Medicine; Glioblastoma; DNA; Gene; Polymerase; Genetics; Gene expression","score_opus":0.03356010648035558,"score_gpt":0.30131319750661534,"score_spread":0.26775309102625977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883697601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824156,0.0007688444,0.000030975698,0.014235113,0.0004901389,0.00023716372,0.000008411897,0.000015682084,0.0017980408],"genre_scores_gemma":[0.98828,0.00014286661,0.0031837062,0.00782966,0.0005016713,0.000003486334,7.315198e-8,0.000011958062,0.00004655217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956164,0.00095721724,0.0008799544,0.0006114932,0.000716219,0.0012187588],"domain_scores_gemma":[0.9960795,0.0005463676,0.00052617025,0.00014814225,0.00051409885,0.0021857298],"candidate_categories":["sts"],"consensus_categories":["sts"],"category_scores_codex":[0.0059542977,0.0002877129,0.00055570225,0.0012153594,0.0015184671,0.0003316451,0.00054223475,0.00016515832,0.00007324376],"category_scores_gemma":[0.0030593742,0.00021014159,0.00012331197,0.0017224463,0.0063770767,0.0006205579,0.00006574614,0.0010367538,0.0000039936886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077778986,0.000047696194,0.9771978,0.00001602823,0.000011675717,0.013200151,0.0012806061,0.00030862875,0.0015019067,0.00078307866,0.0017268894,0.003147702],"study_design_scores_gemma":[0.0014480111,0.13580397,0.7649178,0.0007222056,0.00004993753,0.065646514,0.000662208,0.00084409147,0.005552318,0.014376321,0.009265366,0.00071126927],"about_ca_topic_score_codex":0.0008185039,"about_ca_topic_score_gemma":0.31427145,"teacher_disagreement_score":0.31345296,"about_ca_system_score_codex":0.00044078325,"about_ca_system_score_gemma":0.0027243742,"threshold_uncertainty_score":0.9997814},"labels":[],"label_agreement":null},{"id":"W2884001607","doi":"10.1016/s1470-2045(18)30333-4","title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Nova (rocket); Placebo; Double blind; Medicine; Quality of life (healthcare); Oncology; Gynecology; Ovarian cancer; Internal medicine; Cancer; Alternative medicine; Pathology; Nursing","score_opus":0.14681145589951522,"score_gpt":0.4253526568431366,"score_spread":0.2785412009436214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884001607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820429,0.00010411935,0.00006343582,0.003125781,0.00087131746,0.007880219,0.00033013485,0.000058792677,0.0055233124],"genre_scores_gemma":[0.9955879,0.00007016075,0.0002624704,0.00069018564,0.001648259,0.0013663325,0.0002770337,0.00003251456,0.00006518083],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963817,0.0010468207,0.001145069,0.00048967527,0.0004835005,0.0004532484],"domain_scores_gemma":[0.9958993,0.0016686202,0.0010722394,0.0007339268,0.00046516763,0.00016072138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001775898,0.0003052381,0.0021468792,0.00013825597,0.0000806962,0.000012013579,0.00023686184,0.00022301446,0.00042475152],"category_scores_gemma":[0.00039720398,0.00017083637,0.00011030988,0.00046567744,0.0005610806,0.000065450375,0.00002790394,0.00044101867,0.0000115749845],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98739225,0.002152664,0.0038568433,0.000015183191,0.0010828834,0.0000069797106,0.0013418038,0.000016774782,0.00019858064,0.00004968534,0.001749495,0.0021368407],"study_design_scores_gemma":[0.97447187,0.01679018,0.005176454,0.0001577368,0.0003241983,6.9058694e-7,0.000089204936,0.000071572846,0.00056525687,0.000020852112,0.0021272788,0.00020473302],"about_ca_topic_score_codex":0.0030953914,"about_ca_topic_score_gemma":0.0059319353,"teacher_disagreement_score":0.014637516,"about_ca_system_score_codex":0.00046805735,"about_ca_system_score_gemma":0.0010228473,"threshold_uncertainty_score":0.6966505},"labels":[],"label_agreement":null},{"id":"W2886242456","doi":"10.1158/1557-3265.ovca17-pr06","title":"Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; BRCA mutation; Internal medicine; PARP inhibitor; Clinical endpoint; Oncology; Placebo; Population; Cancer; Ovarian cancer; Clinical trial; Pathology; Biology; Genetics; Poly ADP ribose polymerase","score_opus":0.3540392569924878,"score_gpt":0.5998549478083863,"score_spread":0.24581569081589855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886242456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96874326,0.0004981131,0.000895557,0.011992643,0.0015293965,0.015671028,0.00016025451,0.000080997015,0.00042876066],"genre_scores_gemma":[0.98306185,0.00015656573,0.0010041194,0.0016865972,0.002274299,0.010761644,0.000026029762,0.00012658698,0.00090230873],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99230933,0.0014115708,0.0021734906,0.0012362576,0.0018290923,0.0010402374],"domain_scores_gemma":[0.98743695,0.00840083,0.00047274664,0.0011798827,0.0017223845,0.0007871784],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.020835971,0.0004142078,0.001937849,0.00061480934,0.00037167288,0.00008719212,0.0005458688,0.00036607307,0.0017341604],"category_scores_gemma":[0.0032337576,0.00034756772,0.0007252524,0.0011920739,0.0008818436,0.00010256909,0.000096669035,0.0012178635,0.00003731296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9480087,0.0049426146,0.0013806435,0.00015803638,0.0008773056,0.000022307267,0.0021017245,0.000030578816,0.006112043,0.000027017255,0.009048767,0.027290253],"study_design_scores_gemma":[0.9318844,0.017241942,0.001763801,0.0011590844,0.00023960747,0.000001435955,0.00045950012,0.00056345423,0.024265433,0.00015010183,0.021885106,0.00038615047],"about_ca_topic_score_codex":0.0014648727,"about_ca_topic_score_gemma":0.0011662274,"teacher_disagreement_score":0.026904102,"about_ca_system_score_codex":0.00073283154,"about_ca_system_score_gemma":0.0038036176,"threshold_uncertainty_score":0.99989766},"labels":[],"label_agreement":null},{"id":"W2886255359","doi":"10.1200/jco.2017.35.15_suppl.5518","title":"Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with <i>BRCA</i>-mutated (<i>BRCA</i>m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Nausea; Discontinuation; Vomiting; Internal medicine; Adverse effect; Tolerability; Anemia; Oncology; Neutropenia; BRCA mutation; Gastroenterology; Chemotherapy; Ovarian cancer; Cancer","score_opus":0.07173639697451109,"score_gpt":0.4348203187221891,"score_spread":0.363083921747678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886255359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861138,0.00006631414,0.0004430232,0.0064198477,0.002583697,0.0015878855,0.00006282664,0.000029392191,0.0026932415],"genre_scores_gemma":[0.9900374,0.00036039297,0.0024636912,0.005037737,0.0012409693,0.00007256152,0.000023570286,0.00008083822,0.0006828849],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99314034,0.000799581,0.0035775052,0.0006535427,0.0010397865,0.0007892402],"domain_scores_gemma":[0.9884665,0.0011197692,0.0072206003,0.0007610889,0.0017142433,0.00071780145],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0032189926,0.0004873133,0.0030741636,0.00024290936,0.00028123366,0.000024598217,0.0004819337,0.00072686444,0.00020058212],"category_scores_gemma":[0.001985732,0.00033069748,0.0004163254,0.00027290586,0.00076893513,0.0006198338,0.000090857,0.0025214665,0.000027453361],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83598566,0.010223279,0.11200272,0.000049245016,0.0017065621,0.0043603685,0.00072679477,0.00028796378,0.00030451803,0.000041945073,0.0070658005,0.027245164],"study_design_scores_gemma":[0.7874497,0.05415148,0.14294223,0.0019287606,0.00072787463,0.0003986213,0.00032387083,0.00019806721,0.0004693041,0.0001648138,0.0107605485,0.00048471824],"about_ca_topic_score_codex":0.00033691069,"about_ca_topic_score_gemma":0.00093928765,"teacher_disagreement_score":0.04853594,"about_ca_system_score_codex":0.001106371,"about_ca_system_score_gemma":0.004155589,"threshold_uncertainty_score":0.9999145},"labels":[],"label_agreement":null},{"id":"W2886842073","doi":"10.1158/1538-7445.am2018-2925","title":"Abstract 2925: Tandem targeting of poly (ADP-ribose) polymerase (PARP) and epidermal growth factor receptor (EGFR) as a novel strategy for enhancing radio- and chemosensitivity of refractory tumors","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Synthetic lethality; Olaparib; PARP inhibitor; Cancer research; Poly ADP ribose polymerase; Gefitinib; Epidermal growth factor receptor; DNA repair; EGFR inhibitors; Temozolomide; Biology; Polymerase; Chemistry; Cancer; Enzyme; DNA; Biochemistry; Glioma; Genetics","score_opus":0.09278853847039492,"score_gpt":0.41094891737547967,"score_spread":0.31816037890508475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886842073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924892,0.0044053462,0.00029521025,0.0009826812,0.00013709073,0.0008302641,0.00035565926,0.000027926639,0.0004765918],"genre_scores_gemma":[0.99718416,0.000636747,0.000659264,0.00013304959,0.0010298435,0.00008880719,0.000023111195,0.000058477068,0.00018653455],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997379,0.000118016214,0.00061507156,0.0005635592,0.0006714486,0.00065288896],"domain_scores_gemma":[0.9972038,0.00084934855,0.00029901488,0.00028814067,0.0010099298,0.00034973293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015110937,0.00024058556,0.0006518388,0.0002807878,0.00020991328,0.000026747468,0.00011046303,0.00017809724,0.0004270484],"category_scores_gemma":[0.0008191167,0.00022680977,0.00009109705,0.0003458875,0.0010660882,0.00023228479,0.00007143169,0.0004984997,0.0000030883105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016356916,0.00014590943,0.0029990491,0.0007145425,0.000111285444,0.0000076613205,0.0010905429,3.7733236e-7,0.98539376,0.000116649426,0.0010807202,0.0067037996],"study_design_scores_gemma":[0.0034196218,0.0010192117,0.018756418,0.0007761321,0.000021831182,0.000025348334,0.0007311259,0.000041596453,0.97413146,0.00011812883,0.0007590517,0.00020008234],"about_ca_topic_score_codex":0.0019937786,"about_ca_topic_score_gemma":0.00011126162,"teacher_disagreement_score":0.015757369,"about_ca_system_score_codex":0.00031975997,"about_ca_system_score_gemma":0.0010339257,"threshold_uncertainty_score":0.9249034},"labels":[],"label_agreement":null},{"id":"W2887327758","doi":"10.1158/1538-7445.am2018-lb-265","title":"Abstract LB-265: The novel oral Chk1 inhibitor, SRA737, is active in both PARP inhibitor resistant and <i>CCNE1</i> amplified high grade serous ovarian cancers","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alterra Power (Canada)","funders":"","keywords":"Cancer research; CHEK1; PARP inhibitor; Olaparib; Cancer; Medicine; Cell cycle; Biology; Cell cycle checkpoint; Internal medicine; Polymerase; Poly ADP ribose polymerase; DNA; Genetics","score_opus":0.11130941383387813,"score_gpt":0.4127934726606565,"score_spread":0.3014840588267784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887327758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750598,0.0014787499,0.00003061952,0.01790418,0.0008291277,0.0017589101,0.0003974269,0.00008849515,0.002452671],"genre_scores_gemma":[0.9911093,0.0012149626,0.0002088287,0.0030722693,0.0024292422,0.0008017433,0.000025676185,0.00011114845,0.0010268432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99520636,0.00023773347,0.0006430118,0.0010527582,0.0015431199,0.0013169987],"domain_scores_gemma":[0.99737734,0.00039926113,0.00018591977,0.0009325369,0.0006406141,0.00046430706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016191612,0.0004154786,0.00061639823,0.00043229526,0.00058923877,0.00016612715,0.00041052778,0.00030868908,0.00087391725],"category_scores_gemma":[0.00015859914,0.00032207364,0.0001052058,0.0014936792,0.0017324099,0.00030204334,0.00019974049,0.0016619009,0.00005821275],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013749972,0.0005339019,0.003961353,0.00035463224,0.00040458026,0.00018003883,0.0098713385,0.00001809965,0.8578236,0.0015492111,0.09854068,0.013012603],"study_design_scores_gemma":[0.020788763,0.002003607,0.17357507,0.0023894696,0.0000925178,0.00007953483,0.0039280187,0.00008378569,0.59166235,0.0025527258,0.20176592,0.0010782483],"about_ca_topic_score_codex":0.025202418,"about_ca_topic_score_gemma":0.009242092,"teacher_disagreement_score":0.26616126,"about_ca_system_score_codex":0.0027331659,"about_ca_system_score_gemma":0.002142579,"threshold_uncertainty_score":0.9999231},"labels":[],"label_agreement":null},{"id":"W2887425559","doi":"10.1007/978-1-4939-8588-3_8","title":"Methods to Study TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP) Mono-ADP-Ribosyltransferase Activity","year":2018,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Poly ADP ribose polymerase; Polymerase; ADP-ribosylation; Regulator; Transcription factor; Chemistry; Function (biology); Biochemistry; Cell biology; Molecular biology; Biology; Enzyme; Gene; NAD+ kinase","score_opus":0.062395918082453206,"score_gpt":0.5081017112381588,"score_spread":0.44570579315570563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887425559","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36247164,0.0006892829,0.6315735,0.0017926939,0.00083005696,0.0013408451,0.000024693836,0.00013162478,0.0011456333],"genre_scores_gemma":[0.2612732,0.000025172198,0.7329766,0.0044839387,0.00047908598,0.00048239526,0.0000141244645,0.00010179102,0.00016369825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98892456,0.007330091,0.00083737756,0.0015415385,0.00028768549,0.0010787615],"domain_scores_gemma":[0.99662083,0.0007036642,0.00016690428,0.0017167507,0.00023982646,0.0005519941],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0054894686,0.0006310044,0.001315203,0.00088880846,0.00018519134,0.000032978285,0.00048464636,0.0005030311,0.0008228227],"category_scores_gemma":[0.001144754,0.00060207734,0.00029938994,0.0015996424,0.0004168946,0.00008840822,0.00021366718,0.0008416417,0.000089502544],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012162363,0.0010214396,0.0035402216,0.000017364893,0.00023273556,0.0001535947,0.00096944947,0.0000028973075,0.7888181,0.0002699717,0.00007820643,0.20367976],"study_design_scores_gemma":[0.004662928,0.0038236403,0.003111802,0.00005251463,0.00015161994,0.00010319205,0.00025532613,0.00014705097,0.97677183,0.002270376,0.008070142,0.0005795957],"about_ca_topic_score_codex":0.00065031927,"about_ca_topic_score_gemma":0.00005459612,"teacher_disagreement_score":0.20310016,"about_ca_system_score_codex":0.00032516103,"about_ca_system_score_gemma":0.0002849218,"threshold_uncertainty_score":0.9996431},"labels":[],"label_agreement":null},{"id":"W2887442903","doi":"10.1158/1538-7445.am2018-1853","title":"Abstract 1853: The Chk1 inhibitor, SRA737, synergizes with niraparib to kill cancer cells via multiple cell death pathways","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alterra Power (Canada)","funders":"","keywords":"Cancer research; DNA repair; ATG5; Programmed cell death; Autophagy; Cancer; DNA damage; PI3K/AKT/mTOR pathway; Biology; CHEK1; Cell cycle; Cell cycle checkpoint; Signal transduction; Cell biology; Apoptosis; DNA; Biochemistry; Genetics","score_opus":0.09870132601912379,"score_gpt":0.3943640729461013,"score_spread":0.2956627469269775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887442903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815469,0.0023936974,0.00021325109,0.004642069,0.0008678608,0.0019965642,0.0002059578,0.00014542171,0.00798831],"genre_scores_gemma":[0.98773146,0.0011491737,0.00038869283,0.0022301592,0.0033243669,0.0019253356,0.000015341475,0.00013791518,0.0030975863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954371,0.00018080056,0.00044588797,0.00089739705,0.0017172145,0.0013216143],"domain_scores_gemma":[0.9963066,0.00041502027,0.00012674888,0.001138352,0.0013691245,0.0006441733],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010822867,0.00038553463,0.00047259373,0.00032713424,0.0007006319,0.00012825213,0.00057286315,0.0001942147,0.0028482594],"category_scores_gemma":[0.000065445594,0.0002526051,0.00012629255,0.0011701774,0.0008097549,0.00017118445,0.00017499762,0.0010846552,0.00071118586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022848793,0.0002506764,0.004899512,0.000182313,0.00012308444,0.0000666531,0.0022234572,0.00015777008,0.9124569,0.00004922875,0.07067495,0.00663054],"study_design_scores_gemma":[0.0029630375,0.000985847,0.006953027,0.00060304557,0.000033420587,0.000010063802,0.00034930362,0.000099459256,0.8446296,0.000085053034,0.1429498,0.0003383717],"about_ca_topic_score_codex":0.0060147047,"about_ca_topic_score_gemma":0.00236788,"teacher_disagreement_score":0.072274856,"about_ca_system_score_codex":0.0011310896,"about_ca_system_score_gemma":0.0014404731,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W2887754918","doi":"10.1074/jbc.ac118.004412","title":"Substrate N2 atom recognition mechanism in pierisin family DNA-targeting, guanine-specific ADP-ribosyltransferase ScARP","year":2018,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"Ministry of Education, Culture, Sports, Science and Technology","keywords":"Guanine; Subfamily; Stereochemistry; Chemistry; Biochemistry; Biology; Nucleotide","score_opus":0.058212582210831317,"score_gpt":0.2946605896101577,"score_spread":0.23644800739932637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887754918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486077,0.0010534233,0.0011569036,0.00044864323,0.00027302315,0.00012851646,0.000039990267,0.000036708396,0.0020020115],"genre_scores_gemma":[0.99428385,0.001381541,0.0016660633,0.00062676816,0.0019121866,0.00000772287,0.000053832668,0.000020196436,0.000047807822],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980787,0.00007691094,0.0008836331,0.00029561206,0.00031873092,0.0003464098],"domain_scores_gemma":[0.9987535,0.00008171974,0.00034193898,0.00017337101,0.00040212122,0.00024734467],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006967146,0.00023750406,0.00051322655,0.00007538045,0.00006308179,0.000025380548,0.00017087259,0.0003661808,0.0016472806],"category_scores_gemma":[0.000088194916,0.00017898597,0.00022834938,0.00027600292,0.00022845063,0.00009411435,0.000017411716,0.00065334723,0.000047556317],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001284349,0.00022606371,0.0021907892,0.00003362769,0.000037382055,0.0002527294,0.00008480038,4.0930365e-7,0.99246234,0.000019639589,0.0023619097,0.0010459876],"study_design_scores_gemma":[0.0031578422,0.00077919394,0.0046491395,0.000370568,0.000022672382,0.00046994325,0.00027306966,0.000006832386,0.9798261,0.0027347684,0.007491059,0.00021882926],"about_ca_topic_score_codex":0.0000033922968,"about_ca_topic_score_gemma":5.956059e-7,"teacher_disagreement_score":0.01263623,"about_ca_system_score_codex":0.0002042342,"about_ca_system_score_gemma":0.00011957529,"threshold_uncertainty_score":0.9992654},"labels":[],"label_agreement":null},{"id":"W2887969083","doi":"10.1158/1557-3265.ovca17-a01","title":"Abstract A01: Distinct mechanism of action of DNA-damaging agent dianhydrogalactitol (VAL-083) suggests combination therapy with PARP inhibitors","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Delmar (Canada)","funders":"","keywords":"Cancer research; DNA repair; DNA damage; Ovarian cancer; Homologous recombination; Cancer; Cancer cell; Biology; Genome instability; DNA; Medicine; Genetics","score_opus":0.25897635765149857,"score_gpt":0.5231007719225399,"score_spread":0.26412441427104133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887969083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99330443,0.00025702745,0.00018652719,0.0021872863,0.0007009713,0.0009877326,0.000029316392,0.00005258782,0.002294135],"genre_scores_gemma":[0.9967635,0.0014491857,0.00012124553,0.00013309799,0.0010123529,0.0001633795,0.000022737962,0.000055711545,0.0002787828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99610746,0.00040023285,0.0009669188,0.0005397002,0.0015064271,0.0004792833],"domain_scores_gemma":[0.9962839,0.00084515195,0.00046507872,0.0006332284,0.0014917481,0.00028091384],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030320608,0.00020631684,0.00059168413,0.00031550834,0.00016133918,0.000023380475,0.00022306436,0.0002168843,0.0010554147],"category_scores_gemma":[0.00035944098,0.00016361591,0.00018468747,0.0007501305,0.0012750522,0.00018884166,0.00006246624,0.0008405569,0.000038350634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0246887,0.006018648,0.3417281,0.0012393467,0.0010704692,0.00010209816,0.0023588801,0.000015311667,0.3755227,0.003044238,0.011084051,0.23312744],"study_design_scores_gemma":[0.010119275,0.005607402,0.30231225,0.0013661654,0.000053446307,0.000012106708,0.00038034553,0.00015930178,0.67068666,0.0018309607,0.0071989996,0.00027309888],"about_ca_topic_score_codex":0.0006991866,"about_ca_topic_score_gemma":0.00023847194,"teacher_disagreement_score":0.29516393,"about_ca_system_score_codex":0.00037312208,"about_ca_system_score_gemma":0.0008100377,"threshold_uncertainty_score":0.9998578},"labels":[],"label_agreement":null},{"id":"W2888359685","doi":"10.1158/1078-0432.ccr-18-0110","title":"Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Temozolomide; Internal medicine; Rash; Adverse effect; Discontinuation; Phases of clinical research; Radiation therapy; Surgery; Oncology; Clinical trial","score_opus":0.16392363722883577,"score_gpt":0.5337312416333149,"score_spread":0.36980760440447913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888359685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969502,0.000085378975,0.000019378585,0.00045980167,0.00017804977,0.0019764306,0.000027861164,0.000022863725,0.000280036],"genre_scores_gemma":[0.9987128,0.000056017907,0.000051745217,0.000181284,0.0004539617,0.00042122614,0.000014925737,0.00003231725,0.000075727476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967347,0.00036673647,0.00070383603,0.0005127844,0.00127253,0.00040940693],"domain_scores_gemma":[0.997255,0.00046292547,0.00019755549,0.00048492066,0.0013441124,0.00025547793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013768878,0.00014998611,0.00052817335,0.00026733818,0.00011012502,0.000012938042,0.00017479454,0.00010151443,0.00044371097],"category_scores_gemma":[0.00035377583,0.000107268905,0.000039948154,0.0011187928,0.0008148972,0.000106559004,0.00007894264,0.00069900847,0.000016997794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037111185,0.023417499,0.87236756,0.000059508522,0.00013752388,0.000028238903,0.0017606213,0.000010483199,0.00006368912,0.000014484014,0.0029227019,0.062106535],"study_design_scores_gemma":[0.17742948,0.21033816,0.6058908,0.0006125494,0.000048750484,8.228952e-7,0.0005550313,0.00015267004,0.0020131425,0.000017425216,0.0027505767,0.00019056942],"about_ca_topic_score_codex":0.0004322942,"about_ca_topic_score_gemma":0.0015936585,"teacher_disagreement_score":0.26647672,"about_ca_system_score_codex":0.00030323735,"about_ca_system_score_gemma":0.00076202943,"threshold_uncertainty_score":0.4858324},"labels":[],"label_agreement":null},{"id":"W2888493183","doi":"10.1016/j.dnarep.2018.08.022","title":"The comings and goings of PARP-1 in response to DNA damage","year":2018,"lang":"en","type":"review","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":342,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Biology; DNA damage; DNA repair; Chromatin; DNA; Polymerase; Cell biology; Genetics","score_opus":0.04573360199352177,"score_gpt":0.3756352712475349,"score_spread":0.3299016692540131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888493183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011590624,0.98482275,0.0000025583115,0.00081797177,0.00018454329,0.0012408848,0.00003742385,0.00008440733,0.0012188139],"genre_scores_gemma":[0.0001357034,0.9962292,0.0003485492,0.00055379723,0.00016123522,0.00018716618,0.000014273468,0.000056969402,0.0023131052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997978,0.00038437315,0.000725588,0.00038978906,0.00026342084,0.00025885153],"domain_scores_gemma":[0.9976586,0.0010118135,0.00030227198,0.0007847145,0.00010975993,0.00013283968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020224706,0.0002675547,0.0011660665,0.00022964974,0.00006570119,0.000017901859,0.00016860406,0.0002073011,0.00004514026],"category_scores_gemma":[0.0007618827,0.00017708677,0.00025851742,0.000512096,0.0002710882,0.00003975949,0.000095749696,0.00029036406,0.00005783093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006622665,0.00029927283,0.00032730817,0.03128608,0.00076566497,0.00033936085,0.0037807215,8.7881425e-8,0.0009119254,0.0005127736,0.27433547,0.6808187],"study_design_scores_gemma":[0.000634325,0.00033878197,0.00023561435,0.017034404,0.00013291981,0.00006202362,0.00005109042,0.0000018454845,0.00007387014,0.000032031934,0.981245,0.00015811692],"about_ca_topic_score_codex":0.000024719522,"about_ca_topic_score_gemma":0.000020089812,"teacher_disagreement_score":0.7069095,"about_ca_system_score_codex":0.00021740329,"about_ca_system_score_gemma":0.0003811688,"threshold_uncertainty_score":0.7221389},"labels":[],"label_agreement":null},{"id":"W2889698651","doi":"10.1200/jco.2018.36.15_suppl.5003","title":"Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Placebo; Clinical endpoint; Prostate cancer; Abiraterone; Progression-free survival; Oncology; Urology; Randomized controlled trial; Gastroenterology; Cancer; Chemotherapy; Pathology; Androgen receptor","score_opus":0.0999205760092294,"score_gpt":0.4754539768126198,"score_spread":0.37553340080339037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889698651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911366,0.00012533057,0.00017669713,0.005083287,0.00085407763,0.002033791,0.00001719521,0.000011263813,0.0005617543],"genre_scores_gemma":[0.9927165,0.00019361041,0.003755921,0.0022154194,0.0006335062,0.00014547902,0.000009988521,0.000031018815,0.00029857352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943863,0.0011219967,0.0032842876,0.00026903595,0.0006279833,0.00031037896],"domain_scores_gemma":[0.9936955,0.0013659567,0.0030811979,0.00021986032,0.0012930434,0.00034444427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044205016,0.00023003992,0.002872798,0.00020854277,0.000077937584,0.000016862026,0.00012305276,0.0001580015,0.00040905885],"category_scores_gemma":[0.0011389315,0.00012862192,0.00024279507,0.0003125669,0.00085247576,0.00020702381,0.000018696008,0.0007483887,0.000007067281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9739431,0.010111661,0.0021627466,0.000028135893,0.0009129135,0.00026310488,0.00047007567,0.000017591388,0.00021216029,0.00004598457,0.0010914949,0.01074101],"study_design_scores_gemma":[0.7871446,0.20456444,0.002994624,0.00036587866,0.00064835517,0.0000350178,0.000059826598,0.00007037318,0.00026627717,0.00015741517,0.0035713315,0.00012187501],"about_ca_topic_score_codex":0.00007440079,"about_ca_topic_score_gemma":0.00059237896,"teacher_disagreement_score":0.19445278,"about_ca_system_score_codex":0.00033754073,"about_ca_system_score_gemma":0.0032039606,"threshold_uncertainty_score":0.56836885},"labels":[],"label_agreement":null},{"id":"W2890342236","doi":"10.1200/jco.2017.35.15_suppl.5517","title":"Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Randomization; Ovarian cancer; Chemotherapy; Progression-free survival; Oncology; Complete response; Cancer; PARP inhibitor; Gastroenterology; Randomized controlled trial; Poly ADP ribose polymerase","score_opus":0.1039516384024911,"score_gpt":0.477338568951608,"score_spread":0.37338693054911687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890342236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96046567,0.000040553532,0.000101705344,0.037105203,0.00096435554,0.00079365214,0.000017908476,0.0000075284693,0.00050344714],"genre_scores_gemma":[0.9942791,0.000049551483,0.0017415975,0.0028497833,0.0009616029,0.000044847475,0.0000022643121,0.000033991255,0.000037281803],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9956964,0.00094873476,0.0017447526,0.00029968817,0.0009949486,0.0003154422],"domain_scores_gemma":[0.99239844,0.0028361608,0.0029754487,0.00084618403,0.0005975377,0.00034620878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047255615,0.00022134231,0.0013011434,0.00015498679,0.00012125043,0.000021401536,0.00056793133,0.00025578676,0.00015217807],"category_scores_gemma":[0.003878606,0.00011388679,0.00021440111,0.00017365515,0.00046973888,0.00008514508,0.000051241634,0.0011010264,0.0000054496572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4335001,0.004369933,0.41877237,0.00001781807,0.00024336445,0.00009856887,0.00028361467,0.0003071716,0.00006311583,0.000023654075,0.0030352024,0.13928506],"study_design_scores_gemma":[0.076724246,0.049539935,0.8335858,0.001384865,0.000098104894,0.000010057994,0.000030096946,0.000049216942,0.00061005837,0.00001799354,0.037823908,0.00012569675],"about_ca_topic_score_codex":0.000043528085,"about_ca_topic_score_gemma":0.00056531595,"teacher_disagreement_score":0.41481343,"about_ca_system_score_codex":0.00030448977,"about_ca_system_score_gemma":0.002656441,"threshold_uncertainty_score":0.47834733},"labels":[],"label_agreement":null},{"id":"W2891142232","doi":"10.1200/jco.2018.36.15_suppl.5537","title":"Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Placebo; Oncology; Adverse effect; Population; Clinical trial; Pathology","score_opus":0.21567490903444042,"score_gpt":0.5013908320503578,"score_spread":0.2857159230159174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891142232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462646,0.00006216329,0.000018287845,0.003149649,0.00050918414,0.0011856598,0.000012554656,0.0000024038181,0.00043364623],"genre_scores_gemma":[0.99763024,0.00003375275,0.00039032716,0.0011454365,0.0007310398,0.00002983344,0.000009359678,0.000014731781,0.000015281688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923581,0.0030698583,0.002690849,0.0002728101,0.0013790069,0.00022939316],"domain_scores_gemma":[0.99383616,0.002360417,0.0017337471,0.00029450603,0.0015840486,0.00019114153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018023128,0.00016254678,0.0011440841,0.00029458725,0.000031537787,0.0000049645946,0.00015498948,0.00018236265,0.00019206447],"category_scores_gemma":[0.007240306,0.000092891656,0.000101290934,0.00041586367,0.00037119357,0.00011148089,0.000042517433,0.0009035063,0.0000050107715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0846799,0.0065499824,0.8878132,0.000012662969,0.00008295823,0.00025258106,0.0028871344,0.000059883576,0.000011658453,0.000013418209,0.0005869228,0.017049689],"study_design_scores_gemma":[0.052967746,0.031618822,0.91186047,0.00037309184,0.00033729756,0.000032951506,0.0009719578,0.0011734486,0.000040715848,0.00016088749,0.00037123042,0.00009139779],"about_ca_topic_score_codex":0.000138842,"about_ca_topic_score_gemma":0.007289037,"teacher_disagreement_score":0.031712156,"about_ca_system_score_codex":0.00086788513,"about_ca_system_score_gemma":0.0033961514,"threshold_uncertainty_score":0.8667846},"labels":[],"label_agreement":null},{"id":"W2891362692","doi":"10.1200/jco.2018.36.15_suppl.5514","title":"QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; BRCA mutation; Phases of clinical research; Ovarian cancer; Population; Oncology; Chemotherapy; Progressive disease; Refractory (planetary science); Adverse effect; Gastroenterology; Placebo; Cancer; Clinical trial; Pathology","score_opus":0.21810407177131452,"score_gpt":0.529958972689591,"score_spread":0.3118549009182765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891362692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97301394,0.00009630474,0.00012366375,0.019868117,0.0013295179,0.0024984248,0.000009512068,0.000016911961,0.0030436292],"genre_scores_gemma":[0.9717104,0.00021345227,0.0055579487,0.019452116,0.0016469258,0.000093697614,0.0000035668868,0.000079934645,0.0012419496],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99321824,0.0013327394,0.0033693563,0.00061807066,0.0009408922,0.00052070146],"domain_scores_gemma":[0.9930713,0.00089136936,0.0027158326,0.00057163765,0.0020377964,0.00071207253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006129586,0.00034551753,0.002534106,0.00034227618,0.00011135127,0.000045443503,0.00055827096,0.0003625383,0.0008697845],"category_scores_gemma":[0.0017257705,0.00024935466,0.00015669451,0.000548423,0.00038386625,0.0002820635,0.000106018895,0.0012959428,0.00003786092],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31907657,0.12816662,0.16920888,0.000025517065,0.001723646,0.0005296059,0.006261349,0.000016119839,0.0009675659,0.000015453072,0.041361563,0.33264711],"study_design_scores_gemma":[0.38526708,0.3803872,0.14404833,0.000933339,0.00046383767,0.00006494993,0.000596943,0.000115050614,0.0006877379,0.00021496916,0.08683809,0.00038249872],"about_ca_topic_score_codex":0.00019054458,"about_ca_topic_score_gemma":0.0012126197,"teacher_disagreement_score":0.3322646,"about_ca_system_score_codex":0.0012956769,"about_ca_system_score_gemma":0.0030016142,"threshold_uncertainty_score":0.9999959},"labels":[],"label_agreement":null},{"id":"W2891585716","doi":"10.1200/jco.2017.35.15_suppl.tps5608","title":"Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; Baker Hughes (Canada); University Health Network","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; BRCA mutation; Internal medicine; Ovarian cancer; Clinical endpoint; Clinical trial; Cancer","score_opus":0.18879572078453033,"score_gpt":0.5059444769074753,"score_spread":0.317148756122945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891585716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98182994,0.00007138415,0.00009766541,0.0109161325,0.0024894162,0.0043271794,0.000029753752,0.0000072631283,0.00023127983],"genre_scores_gemma":[0.99533004,0.0002580879,0.0014873728,0.001700318,0.00075051014,0.00007020286,0.0000056622134,0.00003667435,0.0003611437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99172395,0.0028436184,0.0039804494,0.00038169432,0.00071835663,0.00035193845],"domain_scores_gemma":[0.98660135,0.003655517,0.0077133775,0.0006836072,0.0010339944,0.00031215142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074283895,0.00029222222,0.0040701316,0.0001322326,0.00028027708,0.00003971035,0.0006383494,0.00037415826,0.000100664525],"category_scores_gemma":[0.005007326,0.0001608004,0.00028469643,0.00013653365,0.00066337746,0.00028411255,0.00021067458,0.0016836659,0.0000034706925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87987626,0.06855939,0.010390281,0.000010384873,0.0014675029,0.00051086687,0.0024434908,0.000043532735,0.00006752838,0.000032585674,0.0011063409,0.035491854],"study_design_scores_gemma":[0.9086906,0.06388432,0.023668624,0.00041761526,0.0009395244,0.000032553387,0.0007231546,0.00025466966,0.000096939235,0.00007226685,0.0010635853,0.00015616756],"about_ca_topic_score_codex":0.0015231844,"about_ca_topic_score_gemma":0.0015339414,"teacher_disagreement_score":0.035335686,"about_ca_system_score_codex":0.0003464701,"about_ca_system_score_gemma":0.0018259315,"threshold_uncertainty_score":0.73147845},"labels":[],"label_agreement":null},{"id":"W2892271101","doi":"10.1200/jco.2017.35.15_suppl.5534","title":"Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Chemotherapy; Ovarian cancer; Randomization; Randomized controlled trial; Oncology; Progression-free survival; BRCA mutation; Surgery; Cancer; Gastroenterology","score_opus":0.2896326746587832,"score_gpt":0.5637847703547282,"score_spread":0.274152095695945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892271101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98097384,0.0019577025,0.00008035169,0.009236553,0.0032283252,0.00022343351,0.000027108636,0.0000038957364,0.0042688036],"genre_scores_gemma":[0.9833952,0.012576694,0.001128911,0.00037567804,0.0018920178,0.000009330964,0.000002201836,0.000015622309,0.0006043177],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965893,0.00014877849,0.002555599,0.00016904701,0.00035472374,0.00018252751],"domain_scores_gemma":[0.9926133,0.0007169187,0.005225538,0.00050190854,0.0006531245,0.00028920808],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012562162,0.00013873348,0.0018774559,0.0001047505,0.000052614614,0.000005973414,0.00024983293,0.00032203656,0.0009667142],"category_scores_gemma":[0.0006905,0.000096498225,0.0007005233,0.000044227356,0.00044927732,0.0000930646,0.000031189633,0.000362211,0.000008036907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008143665,0.0034856321,0.48228386,0.000056967903,0.000917993,0.00018073521,0.00014185243,0.0000071720033,0.001213351,0.00023143386,0.0012981104,0.50203925],"study_design_scores_gemma":[0.021682115,0.021246757,0.9182663,0.00051920454,0.0006153059,0.0001425235,0.000014913046,0.000011354003,0.00565059,0.00047230974,0.031293336,0.000085295665],"about_ca_topic_score_codex":0.00011354782,"about_ca_topic_score_gemma":0.00020594602,"teacher_disagreement_score":0.50195396,"about_ca_system_score_codex":0.0003342086,"about_ca_system_score_gemma":0.0015962541,"threshold_uncertainty_score":0.99994653},"labels":[],"label_agreement":null},{"id":"W2894655078","doi":"10.1002/1878-0261.12390","title":"<scp>HMGA</scp>2 as a functional antagonist of <scp>PARP</scp>1 inhibitors in tumor cells","year":2018,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital Research Institute of Manitoba; University of Manitoba","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society Research Institute; Université Laval; Cure Brain Cancer Foundation; Heart and Stroke Foundation of Canada; Nanyang Technological University; Research Manitoba","keywords":"Olaparib; PARP1; Poly ADP ribose polymerase; DNA damage; Cancer research; PARP inhibitor; DNA repair; Biology; HMGA2; Molecular biology; Chemistry; Polymerase; Biochemistry; DNA; Gene","score_opus":0.016504123151850174,"score_gpt":0.30335873557918464,"score_spread":0.28685461242733445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894655078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9321919,0.000760857,0.0009003412,0.0006462054,0.0014662888,0.0006503039,0.00003759549,0.00008344586,0.063263044],"genre_scores_gemma":[0.9891979,0.00006013215,0.0013658139,0.006319313,0.00082731,0.00014989951,0.00007159783,0.00007782872,0.0019302223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99718684,0.00026513144,0.00076544395,0.00061266444,0.00053951703,0.00063038355],"domain_scores_gemma":[0.9980722,0.00043016544,0.00036202205,0.0005145479,0.00035391006,0.0002671683],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005189905,0.00032323995,0.0007377636,0.00044660908,0.00008933261,0.000015322858,0.00019102113,0.00034693908,0.00026036758],"category_scores_gemma":[0.0004885657,0.00033330434,0.00022349149,0.0006713681,0.00077415875,0.00007675153,0.00010227436,0.00048780485,0.0005784125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015077557,0.000793607,0.004095065,0.000081361046,0.00013810069,0.0010262158,0.0008217851,0.000043165375,0.926471,0.0009733124,0.06434116,0.0010644372],"study_design_scores_gemma":[0.00441033,0.0023865344,0.0035511598,0.00010035315,0.00006354304,0.0003914044,0.00042955406,0.00007986209,0.6600572,0.0007357703,0.32773829,0.000055995315],"about_ca_topic_score_codex":0.00013984823,"about_ca_topic_score_gemma":0.000059096747,"teacher_disagreement_score":0.26641384,"about_ca_system_score_codex":0.00055752054,"about_ca_system_score_gemma":0.00103845,"threshold_uncertainty_score":0.9999119},"labels":[],"label_agreement":null},{"id":"W2895362009","doi":"10.1111/bju.14576","title":"DNA repair defects in prostate cancer: impact for screening, prognostication and treatment","year":2018,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Medicine; Prostate cancer; DNA repair; Poly ADP ribose polymerase; DNA mismatch repair; Cancer; PARP inhibitor; Cancer research; Homologous recombination; BRCA2 Protein; Germline; DNA damage; Germline mutation; DNA Damage Repair; Gene; Bioinformatics; Internal medicine; Genetics; Polymerase; Mutation; DNA; Biology; Colorectal cancer","score_opus":0.055113451563339945,"score_gpt":0.3934676395728771,"score_spread":0.33835418800953715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895362009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003978417,0.9937288,0.00006209603,0.00014176608,0.00019742698,0.0016878644,0.000155535,0.000016866354,0.00003123209],"genre_scores_gemma":[0.0005958095,0.99711454,0.00089800917,0.000117782765,0.0007605171,0.0003398428,0.000052823743,0.000049416238,0.000071256516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983184,0.00018477559,0.0008207303,0.00026551876,0.00012773636,0.00028287986],"domain_scores_gemma":[0.99835074,0.0002520263,0.0008648442,0.00012400247,0.00025253635,0.00015586063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004755246,0.00022769143,0.0014456938,0.00027486644,0.000044219418,0.000021401356,0.00006458954,0.00021260485,0.0000430571],"category_scores_gemma":[0.00022621929,0.00019903819,0.0005062429,0.00014652497,0.00013609458,0.000066178625,0.000012317186,0.00027622323,0.0000014487512],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045937212,0.00013925905,0.0011176306,0.0016493024,0.0004952733,0.00048735007,0.000046121797,0.0000012243596,0.0000014630452,0.0000028940415,0.0031626055,0.9924375],"study_design_scores_gemma":[0.0041105775,0.006037759,0.0020267628,0.013210587,0.0014597034,0.028142678,0.000003650286,0.000012749478,0.000003119399,0.00006986793,0.9447644,0.00015818366],"about_ca_topic_score_codex":0.000098029785,"about_ca_topic_score_gemma":0.00012611263,"teacher_disagreement_score":0.9922793,"about_ca_system_score_codex":0.00039116744,"about_ca_system_score_gemma":0.0008445712,"threshold_uncertainty_score":0.81165415},"labels":[],"label_agreement":null},{"id":"W2896534363","doi":"10.1016/j.bbapap.2018.10.009","title":"Dynamic light scattering study of base excision DNA repair proteins and their complexes","year":2018,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Russian Science Foundation; National Institutes of Health; Commissariat à l'Énergie Atomique et aux Énergies Alternatives; Université de Strasbourg; Université Laval","keywords":"Heterotetramer; XRCC1; AP site; Base excision repair; Polymerase; DNA; Chemistry; DNA polymerase; Dynamic light scattering; DNA repair; Biochemistry; Biophysics; Biology; Protein subunit; Materials science; Gene; Nanotechnology","score_opus":0.020238931994971766,"score_gpt":0.2844962681149783,"score_spread":0.2642573361200065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896534363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898166,0.00011965708,0.00036987127,0.0026679093,0.00008542899,0.006488482,0.00011275029,0.00019677589,0.00014251671],"genre_scores_gemma":[0.9894578,0.00014910901,0.009000865,0.00033682358,0.00025357312,0.00061591016,0.000028671593,0.00008666371,0.00007057812],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975602,0.00018639746,0.000663442,0.00084366614,0.00034003353,0.0004062314],"domain_scores_gemma":[0.99820566,0.00005147509,0.00042277732,0.0008685341,0.0002243129,0.00022722459],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004312984,0.0004942247,0.00074627856,0.00024256425,0.00031016234,0.00007531483,0.00019797811,0.00017768778,0.000032576136],"category_scores_gemma":[0.000045148143,0.00038682696,0.00014882347,0.00036045891,0.00052250637,0.00021745756,0.0002654488,0.00034281175,0.000006135371],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013237466,0.0009534152,0.00006923361,0.0003259374,0.0001811414,0.0000053237704,0.0031028953,2.1626091e-7,0.9928992,0.000054877313,0.00007186014,0.0010121855],"study_design_scores_gemma":[0.0035874825,0.005779701,0.0076107853,0.00067856786,0.00008176594,0.000048124057,0.0006353582,0.00082817895,0.9795065,0.0005430145,0.0002656725,0.00043483527],"about_ca_topic_score_codex":0.00012697396,"about_ca_topic_score_gemma":0.00004612201,"teacher_disagreement_score":0.013392653,"about_ca_system_score_codex":0.00008233902,"about_ca_system_score_gemma":0.0001332205,"threshold_uncertainty_score":0.9998584},"labels":[],"label_agreement":null},{"id":"W2896626889","doi":"10.1038/s41416-018-0274-8","title":"Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes","year":2018,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"NuCana; Myriad Genetics; AstraZeneca","keywords":"Olaparib; PARP inhibitor; Ovarian cancer; Medicine; BRCA mutation; Oncology; Cancer; Internal medicine; Cancer research; Population; Biology; Genetics; Gene; Poly ADP ribose polymerase; Polymerase","score_opus":0.015046316000926513,"score_gpt":0.31371684263174504,"score_spread":0.2986705266308185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896626889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96349436,0.02883145,0.00012913985,0.0047630654,0.0015223562,0.00026225575,0.00016039894,0.00000797019,0.00082897686],"genre_scores_gemma":[0.98421687,0.011460182,0.00024013742,0.001663094,0.0022190262,0.000021457648,0.0000023491139,0.000030534673,0.00014637833],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981502,0.00015577825,0.00068865693,0.00018402559,0.0005216114,0.00029970924],"domain_scores_gemma":[0.9983498,0.00008162407,0.0005594117,0.00018567071,0.00067841,0.00014509531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090045645,0.00014801291,0.0004815355,0.00015385692,0.00009367549,0.000033341064,0.00011868159,0.00010118267,0.00077102816],"category_scores_gemma":[0.00005839038,0.00012827438,0.000163391,0.0004282254,0.00046712797,0.00017655858,0.000029588831,0.00033419725,0.000002494525],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037579874,0.0003305388,0.1920993,0.0001834514,0.001206312,0.0015407703,0.0015299061,0.000091578935,0.32146415,0.000049972725,0.053283114,0.4244629],"study_design_scores_gemma":[0.011939396,0.000583794,0.49775296,0.0052999337,0.0003465522,0.0048556207,0.0004628857,0.00013657588,0.39771014,0.00049078185,0.0799904,0.00043096012],"about_ca_topic_score_codex":0.007931285,"about_ca_topic_score_gemma":0.02932162,"teacher_disagreement_score":0.42403194,"about_ca_system_score_codex":0.00036392006,"about_ca_system_score_gemma":0.0008950224,"threshold_uncertainty_score":0.998675},"labels":[],"label_agreement":null},{"id":"W2897430921","doi":"10.1056/nejmoa1810858","title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2839,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Ovarian cancer; Oncology; Chemotherapy; Internal medicine; Disease; PARP inhibitor; Cancer; Maintenance therapy; Gynecology; Poly ADP ribose polymerase; Polymerase; Biology; Enzyme","score_opus":0.012333391248237449,"score_gpt":0.2875400329087155,"score_spread":0.27520664166047804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897430921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784757,0.00081501255,0.0016312994,0.01591935,0.0011289854,0.00030455517,0.000004875823,0.000014562453,0.0017056904],"genre_scores_gemma":[0.98943824,0.00038414018,0.002415441,0.003367862,0.0039877873,0.0000060984034,0.0000054001566,0.000028615868,0.000366447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982705,0.00006102372,0.0005807381,0.00017577576,0.00062213716,0.0002897989],"domain_scores_gemma":[0.99821675,0.00014737097,0.00042033795,0.00027529206,0.0006017646,0.00033851207],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046520264,0.0001806537,0.000572305,0.00025244313,0.00003719089,0.0000056246854,0.00016245276,0.00006297189,0.0009824937],"category_scores_gemma":[0.00045893775,0.000107998065,0.00004074897,0.00038085642,0.00022257584,0.00015361818,0.000014100393,0.00040427307,0.0000056600134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031608637,0.0004082613,0.55336666,0.00006325376,0.00024908708,0.0005297994,0.0035589922,0.00013905774,0.0020656881,0.00032821583,0.057839353,0.349843],"study_design_scores_gemma":[0.42652023,0.008030143,0.49617237,0.003999267,0.00012479765,0.0001927044,0.000117872216,0.000027147415,0.0005608884,0.0013021458,0.06276653,0.0001858869],"about_ca_topic_score_codex":0.00023183461,"about_ca_topic_score_gemma":0.00032178703,"teacher_disagreement_score":0.3949116,"about_ca_system_score_codex":0.00022741403,"about_ca_system_score_gemma":0.00038210824,"threshold_uncertainty_score":0.99993074},"labels":[],"label_agreement":null},{"id":"W2898091448","doi":"10.1007/s00280-018-3706-5","title":"Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"National Health and Medical Research Council","keywords":"Carboplatin; Gemcitabine; Ovarian cancer; Medicine; Platinum; Internal medicine; Oncology; Chemotherapy; Phases of clinical research; Cancer; Cisplatin; Chemistry","score_opus":0.027892984069719035,"score_gpt":0.3651652371962587,"score_spread":0.3372722531265397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898091448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584824,0.0006492755,0.0000070303736,0.0010736702,0.0005558201,0.0014450769,0.00013432335,0.000020676216,0.00026586247],"genre_scores_gemma":[0.99381334,0.001957246,0.0000499179,0.0031451574,0.00043199232,0.00037668028,0.000011487211,0.00004044289,0.00017373518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982387,0.00013532337,0.0005874988,0.000512613,0.00016519985,0.00036065772],"domain_scores_gemma":[0.99913687,0.00015642267,0.0002406746,0.0001492441,0.00017001071,0.00014680499],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023519121,0.00027416798,0.0006533822,0.00018623457,0.00007484774,0.000008115963,0.00007053561,0.00016301706,0.0035465928],"category_scores_gemma":[0.0000145694785,0.00024387873,0.000030024952,0.00040555632,0.00033534842,0.00010912259,0.000032329244,0.00031335367,0.0000012117601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05910412,0.007839944,0.68830633,0.00049217325,0.00083283713,0.0001978079,0.05750816,0.000055035096,0.1302396,0.000017182698,0.004576133,0.0508307],"study_design_scores_gemma":[0.27322757,0.01301295,0.37766537,0.0005839634,0.00024045119,0.000030362775,0.0014031439,0.0021633008,0.31598222,0.00007507944,0.0148698725,0.0007457125],"about_ca_topic_score_codex":0.0015451009,"about_ca_topic_score_gemma":0.017201487,"teacher_disagreement_score":0.31064093,"about_ca_system_score_codex":0.0002286371,"about_ca_system_score_gemma":0.0002283169,"threshold_uncertainty_score":0.9973643},"labels":[],"label_agreement":null},{"id":"W2898127005","doi":"10.1093/annonc/mdy285.155","title":"Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Chemotherapy; Placebo; Population; Adverse effect; BRCA mutation; Chemotherapy regimen; Clinical endpoint; Subgroup analysis; Randomized controlled trial; Cancer; Ovarian cancer; Confidence interval; Pathology","score_opus":0.0491810136000829,"score_gpt":0.39925487450453656,"score_spread":0.35007386090445364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898127005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933354,0.00024683203,0.000053801086,0.0017339247,0.00013539138,0.0005006347,0.00003646459,0.0000078105895,0.0039497204],"genre_scores_gemma":[0.998689,0.00017295057,0.00040078626,0.0005522372,0.000082678045,0.00002791727,0.000030059464,0.00001540349,0.000028968083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979575,0.0003765792,0.0008524655,0.00030494598,0.00022854767,0.00027990635],"domain_scores_gemma":[0.9980118,0.00059774244,0.0005918326,0.00037916432,0.00035023657,0.00006918586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011848287,0.0001724326,0.001419051,0.00092580396,0.000013965555,0.0000013035562,0.00010224561,0.00024079082,0.00021087764],"category_scores_gemma":[0.00018646421,0.00015707345,0.00023004173,0.001363834,0.00047317162,0.000043947763,0.000026069796,0.00021537134,0.0000026536243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026711235,0.002293794,0.75737983,0.0003754869,0.0024254804,0.0001249512,0.015202812,0.000053131032,0.13319132,0.0010969838,0.0022284084,0.058916576],"study_design_scores_gemma":[0.007951311,0.011306292,0.5927875,0.00020463832,0.00025400223,0.000010353881,0.00014181265,0.00038557278,0.38579357,0.00013190815,0.000913197,0.00011986638],"about_ca_topic_score_codex":0.0009932492,"about_ca_topic_score_gemma":0.0010850809,"teacher_disagreement_score":0.25260225,"about_ca_system_score_codex":0.00013668198,"about_ca_system_score_gemma":0.0002506555,"threshold_uncertainty_score":0.64052695},"labels":[],"label_agreement":null},{"id":"W2898183703","doi":"10.1093/annonc/mdy285.160","title":"Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"OncoMed Pharmaceutical","keywords":"Olaparib; Medicine; Tolerability; Internal medicine; Adverse effect; Nausea; PARP inhibitor; Placebo; Vomiting; Oncology; Gastroenterology; Surgery; Pathology","score_opus":0.12348903694260692,"score_gpt":0.46366195840004004,"score_spread":0.3401729214574331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898183703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796968,0.00036916393,0.0014420864,0.008988474,0.0013489317,0.002723541,0.00028547324,0.00004401323,0.005101503],"genre_scores_gemma":[0.9891869,0.00071257545,0.0007427823,0.0069790375,0.0012574309,0.00040850358,0.000063500804,0.000039552728,0.00060973334],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99735314,0.00023186654,0.0010639536,0.0005244364,0.00029051743,0.00053606374],"domain_scores_gemma":[0.99620706,0.00063151645,0.00090430136,0.00054967724,0.0015349133,0.00017254465],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011557633,0.00026897693,0.0012704764,0.00014203317,0.00010506642,0.0000060658103,0.00017619091,0.0003832682,0.0010637598],"category_scores_gemma":[0.00039279327,0.00023476126,0.0003102056,0.00025104164,0.0009300909,0.00011789969,0.00003435839,0.00025551286,0.000010860854],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6682809,0.004522265,0.0015278585,0.00015352045,0.0010180284,0.000055352903,0.0032541852,0.0000068572017,0.16136041,0.0013888658,0.035494998,0.122936726],"study_design_scores_gemma":[0.36946815,0.0592101,0.0059222477,0.00041074047,0.00013133383,0.00007145185,0.00016630406,0.000116664385,0.5204673,0.0024205204,0.041260052,0.0003551463],"about_ca_topic_score_codex":0.0003382413,"about_ca_topic_score_gemma":0.00018183833,"teacher_disagreement_score":0.35910687,"about_ca_system_score_codex":0.00017398893,"about_ca_system_score_gemma":0.0011170416,"threshold_uncertainty_score":0.9998494},"labels":[],"label_agreement":null},{"id":"W2898217141","doi":"10.1093/annonc/mdy424.041","title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Clinical endpoint; BRCA mutation; Ovarian cancer; Placebo; Chemotherapy; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Randomized controlled trial; Cancer; Pathology","score_opus":0.04305060990265014,"score_gpt":0.3968295337381739,"score_spread":0.3537789238355238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898217141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916055,0.0001729473,0.0007742129,0.0043505556,0.00041677523,0.0015328241,0.000034887635,0.000038810165,0.001073447],"genre_scores_gemma":[0.9902874,0.00017405143,0.0018429491,0.006897588,0.00026029363,0.00037714106,0.00005419895,0.00003947336,0.00006690777],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981112,0.00012909912,0.00061206915,0.0004400945,0.0002832232,0.00042432215],"domain_scores_gemma":[0.9985023,0.00027495684,0.00046648417,0.00025630477,0.00036073916,0.00013921285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039948957,0.00023582164,0.00073827576,0.00021838576,0.000073570096,0.000009684626,0.00009369526,0.00019954832,0.00018732689],"category_scores_gemma":[0.00016202491,0.00020507228,0.00008837688,0.0003675781,0.0002928259,0.00017331344,0.00001360122,0.000204612,0.0000032478772],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3122214,0.0038629519,0.014894521,0.00008304753,0.00036084454,0.0002018734,0.0039252727,0.00009495015,0.009361549,0.00011813426,0.0033209743,0.65155447],"study_design_scores_gemma":[0.90735966,0.034193106,0.018964352,0.0006646558,0.000076257726,0.000010516459,0.00023627398,0.00079097773,0.024511669,0.0002942486,0.012551247,0.00034701842],"about_ca_topic_score_codex":0.00044702302,"about_ca_topic_score_gemma":0.00077641616,"teacher_disagreement_score":0.65120745,"about_ca_system_score_codex":0.000193399,"about_ca_system_score_gemma":0.0006272193,"threshold_uncertainty_score":0.8362605},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2898251516","doi":"10.1093/annonc/mdy284.068","title":"TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Clinical endpoint; Internal medicine; PARP inhibitor; Urology; Oncology; Enzalutamide; Regimen; Surgery; Clinical trial; Cancer; Breast cancer; Poly ADP ribose polymerase","score_opus":0.12984503093746097,"score_gpt":0.44068231539701885,"score_spread":0.3108372844595579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898251516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909418,0.000642418,0.000006952894,0.002461916,0.000029904744,0.005544412,0.00012422513,0.000043710712,0.0002046226],"genre_scores_gemma":[0.99593806,0.00044347788,0.0009737319,0.0013666142,0.00004003781,0.000975439,0.000036754096,0.00006416845,0.00016171536],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99661946,0.0010042621,0.0008169879,0.00073930435,0.00037870623,0.00044128255],"domain_scores_gemma":[0.99739206,0.00042157265,0.0008074002,0.000546984,0.0006071379,0.00022484566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00255514,0.0003886258,0.001091849,0.00031928465,0.00016175836,0.00003293603,0.00019461277,0.000081908474,0.00006814513],"category_scores_gemma":[0.0001404155,0.0003083604,0.00003234823,0.0004951744,0.0007640431,0.00028891023,0.000048223013,0.00024390923,3.7371092e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27392125,0.019458588,0.003852965,0.0001404858,0.00054757175,0.0002477718,0.0064978325,0.000030886993,0.6817655,0.000024704066,0.0006291846,0.012883292],"study_design_scores_gemma":[0.1671317,0.47180656,0.08634186,0.0008700863,0.00017336816,0.000072241535,0.0015825826,0.0013911498,0.26707405,0.000071395654,0.002950634,0.0005343693],"about_ca_topic_score_codex":0.00058250834,"about_ca_topic_score_gemma":0.001372089,"teacher_disagreement_score":0.45234796,"about_ca_system_score_codex":0.00011678727,"about_ca_system_score_gemma":0.001223728,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W2898861270","doi":"10.15252/emmm.201809172","title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","year":2018,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Université Laval; Centre hospitalier de l'Université Laval","funders":"Instituto de Salud Carlos III; European Society for Medical Oncology; Canadian HIV Trials Network, Canadian Institutes of Health Research; National Cancer Institute; Agència de Gestió d'Ajuts Universitaris i de Recerca; Cancer Research UK; Generalitat de Catalunya; Fundación Científica Asociación Española Contra el Cáncer; Fundación Cellex; AstraZeneca","keywords":"Mutation; Molecular biology; Poly ADP ribose polymerase; Chemistry; Biology; Cancer research; Genetics; DNA; Gene; Polymerase","score_opus":0.023860452226213635,"score_gpt":0.3273131591371021,"score_spread":0.3034527069108885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898861270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96076024,0.0019342189,0.0054928437,0.024405563,0.0007421053,0.0010732802,0.00002412179,0.0001770474,0.0053905807],"genre_scores_gemma":[0.9828116,0.000043183398,0.003215182,0.011731235,0.0012574024,0.00012070525,0.00012701514,0.00008718445,0.0006064496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964339,0.00059085217,0.000813163,0.00065932056,0.00092493446,0.0005778025],"domain_scores_gemma":[0.99776685,0.00036304133,0.0002389077,0.0009179636,0.0003530651,0.00036018484],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002251623,0.00037043434,0.000721881,0.00060256623,0.00010151325,0.000017931365,0.00022159619,0.00016199147,0.0012682304],"category_scores_gemma":[0.0027417045,0.0003222958,0.00011066372,0.0011242684,0.0005681052,0.00011419606,0.00006916266,0.00041258743,0.000151925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067060017,0.00029657234,0.0040227817,0.00011969455,0.000109471206,0.0021327515,0.0025808788,0.0000118891185,0.96404225,0.0008287139,0.016474595,0.0026744122],"study_design_scores_gemma":[0.047715623,0.008284053,0.0985722,0.0039081704,0.00034887504,0.0026457007,0.001593721,0.0008964303,0.74915993,0.0076511763,0.078020714,0.001203387],"about_ca_topic_score_codex":0.00026045673,"about_ca_topic_score_gemma":0.00007125743,"teacher_disagreement_score":0.21488228,"about_ca_system_score_codex":0.00045127966,"about_ca_system_score_gemma":0.0004073115,"threshold_uncertainty_score":0.99992293},"labels":[],"label_agreement":null},{"id":"W2899180178","doi":"10.1042/bcj20180347","title":"Characterization of TCDD-inducible poly-ADP-ribose polymerase (TIPARP/ARTD14) catalytic activity","year":2018,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Novo Nordisk Fonden","keywords":"ADP-ribosylation; Cysteine; Biochemistry; Aryl hydrocarbon receptor; Chemistry; Poly ADP ribose polymerase; Iodoacetamide; Zinc finger; Molecular biology; Metallothionein; Cysteine metabolism; Enzyme; Polymerase; Biology; Transcription factor; NAD+ kinase","score_opus":0.0255662451537105,"score_gpt":0.3116908696902169,"score_spread":0.28612462453650644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899180178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467313,0.0002330385,0.0012628373,0.0022962182,0.00052964524,0.00014941188,0.000040517545,0.000037210546,0.0007779712],"genre_scores_gemma":[0.9956286,0.000075091055,0.00030412505,0.000648735,0.0029349907,0.0000062621716,0.000035518104,0.000028997623,0.00033769914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985747,0.00004859882,0.0003976778,0.0002457196,0.0004198973,0.00031344124],"domain_scores_gemma":[0.99869883,0.000032875236,0.0003142118,0.00032609515,0.0002840142,0.00034394988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000233658,0.00017441243,0.00033208003,0.00015806625,0.00010240743,0.000027280872,0.00013194875,0.00016402072,0.00072096824],"category_scores_gemma":[0.00010863043,0.00015433425,0.00015225129,0.00029283424,0.00026613838,0.00017130637,0.00003706366,0.000362936,0.00007490787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072987925,0.00027987422,0.000998638,0.000028981838,0.00006875154,0.000016604554,0.00013463294,1.5680541e-8,0.9901168,0.0000141170785,0.0023401857,0.0052715163],"study_design_scores_gemma":[0.0018904615,0.00035870125,0.005928038,0.00021959149,0.00006284001,0.00069253804,0.000016588669,0.000040333147,0.9880223,0.000056129888,0.002566069,0.0001464039],"about_ca_topic_score_codex":0.000016131575,"about_ca_topic_score_gemma":4.3102023e-7,"teacher_disagreement_score":0.0051251124,"about_ca_system_score_codex":0.00017998538,"about_ca_system_score_gemma":0.00029680517,"threshold_uncertainty_score":0.78940964},"labels":[],"label_agreement":null},{"id":"W2899227888","doi":"10.1186/s13073-018-0590-x","title":"Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors","year":2018,"lang":"en","type":"article","venue":"Genome Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Ministry of Advanced Education; Terry Fox Research Institute; University of Toronto; Canada Research Chairs; Ontario Ministry of Research and Innovation; Princess Margaret Cancer Foundation","keywords":"Debulking; Medicine; Ovarian cancer; Oncology; Serous fluid; Internal medicine; Exome; Cancer; Exome sequencing; Mutation; Biology; Gene; Genetics","score_opus":0.031221294757560282,"score_gpt":0.31068250621393645,"score_spread":0.27946121145637615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899227888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999965,0.0029330994,0.0007748505,0.00472824,0.00049048074,0.0003596776,0.00015909497,0.00003002936,0.00052488537],"genre_scores_gemma":[0.9947011,0.0008493881,0.0005570657,0.0008024135,0.002407781,0.00006041093,0.0003451465,0.000028792858,0.00024791263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985808,0.000055710454,0.00047799517,0.00035132145,0.0002949287,0.00023925964],"domain_scores_gemma":[0.9991484,0.00007700197,0.00009688405,0.00039466028,0.00012328815,0.00015975414],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023533097,0.00017913745,0.00046568975,0.00026043685,0.00006084165,0.000006320158,0.000118547745,0.000095596326,0.0050019682],"category_scores_gemma":[0.000023027296,0.00015221298,0.00003162191,0.0002348358,0.0003810469,0.000060685383,0.00004451215,0.00016977284,0.000020937148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005240768,0.00014785139,0.64038014,0.000078311874,0.00017753734,0.000047248388,0.0045956406,0.000033957414,0.35041183,0.00018101034,0.0008363561,0.0025860472],"study_design_scores_gemma":[0.0040812665,0.0004048387,0.9920129,0.00023811994,0.00008408092,0.00003418326,0.00015355974,0.00010651841,0.0012831416,0.0005322574,0.00092909863,0.00013999484],"about_ca_topic_score_codex":0.0031315575,"about_ca_topic_score_gemma":0.003900318,"teacher_disagreement_score":0.3516328,"about_ca_system_score_codex":0.00013214997,"about_ca_system_score_gemma":0.0001254899,"threshold_uncertainty_score":0.9959076},"labels":[],"label_agreement":null},{"id":"W2900836368","doi":"10.1038/s41388-018-0568-6","title":"Oncogenic activity of poly (ADP-ribose) glycohydrolase","year":2018,"lang":"en","type":"article","venue":"Oncogene","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University; Jewish General Hospital","funders":"Mitacs; Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Northeast Ohio Medical University; Fondation du cancer du sein du Québec; McGill University","keywords":"Biology; Cancer research; SMAD; Cell growth; Phosphorylation; Cell biology; Genetics","score_opus":0.029278122395188323,"score_gpt":0.3373479827287174,"score_spread":0.30806986033352907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900836368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739314,0.00073036726,0.00091812713,0.0011394484,0.00047994827,0.00025499277,0.00005392099,0.00008412319,0.022407727],"genre_scores_gemma":[0.99367946,0.00007718286,0.0015375626,0.000784153,0.0015042134,0.000021312173,0.000011989564,0.00003637547,0.0023477222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874926,0.000052657775,0.00026533185,0.00029360253,0.00036111442,0.00027806681],"domain_scores_gemma":[0.9988441,0.00004986295,0.0001663404,0.0005496331,0.00020052241,0.00018955581],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020865185,0.00016537611,0.00036431747,0.00012646984,0.000065911096,0.000005982887,0.00011156833,0.00012313275,0.0018467704],"category_scores_gemma":[0.000046767283,0.00015440551,0.00016648907,0.00034421872,0.0002750469,0.00008338044,0.000039444818,0.00013396652,0.00052137166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010824479,0.00027965338,0.0010371177,0.000032292017,0.00011018654,0.000022954518,0.00013324598,4.333047e-7,0.9609038,0.00004942934,0.0041771187,0.03217127],"study_design_scores_gemma":[0.0027595677,0.0010110894,0.0016548298,0.00007675763,0.00007581569,0.000103224076,0.000010583229,0.00008027788,0.9296514,0.00014040883,0.06429899,0.00013707479],"about_ca_topic_score_codex":0.00010893138,"about_ca_topic_score_gemma":0.000012614918,"teacher_disagreement_score":0.06012187,"about_ca_system_score_codex":0.00017935931,"about_ca_system_score_gemma":0.0002953769,"threshold_uncertainty_score":0.9990657},"labels":[],"label_agreement":null},{"id":"W2901506506","doi":"10.1158/2159-8290.cd-18-0715","title":"<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":432,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Reversion; PARP inhibitor; Cancer research; Poly ADP ribose polymerase; Ovarian carcinoma; Mutation; Ovarian cancer; Biology; DNA; Genetics; Medicine; Oncology; Cancer; Polymerase; Gene; Phenotype","score_opus":0.0169701192130969,"score_gpt":0.26943818245835754,"score_spread":0.25246806324526067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901506506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872441,0.0015260427,0.00025108145,0.008113303,0.0006780523,0.0009960192,0.00015255972,0.00004105384,0.0009977362],"genre_scores_gemma":[0.9928479,0.00010326124,0.00042973677,0.0046047494,0.0010214737,0.0003865064,0.00005334121,0.000040862622,0.00051216164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806225,0.00012166522,0.0004882615,0.0005524191,0.00036681796,0.0004085647],"domain_scores_gemma":[0.99904394,0.00012914164,0.0001501086,0.00046251126,0.00007592165,0.0001383763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003472445,0.00022524764,0.00037280945,0.00020003816,0.00016485924,0.00006570087,0.00014338737,0.00008431103,0.000052174506],"category_scores_gemma":[0.00008146624,0.00018988448,0.000055841505,0.00076578546,0.0002669751,0.00042810227,0.00008076851,0.00020674437,0.000008684571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038777564,0.0004195191,0.6981724,0.00080137886,0.000114821254,0.00033929772,0.012474967,0.0004091617,0.23596552,0.0015139623,0.043317266,0.002593971],"study_design_scores_gemma":[0.0060493853,0.00020573531,0.95617145,0.0020863626,0.00006571733,0.00003249945,0.00078821526,0.00016764285,0.025849732,0.0006838599,0.0075243297,0.00037505038],"about_ca_topic_score_codex":0.00074027805,"about_ca_topic_score_gemma":0.0023046872,"teacher_disagreement_score":0.2579991,"about_ca_system_score_codex":0.000972196,"about_ca_system_score_gemma":0.0005263136,"threshold_uncertainty_score":0.77432644},"labels":[],"label_agreement":null},{"id":"W2901569771","doi":"10.1016/j.sbi.2018.11.002","title":"PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Structural Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Ribose; Enzyme; Biology; Cell biology; Biochemistry; Transcription (linguistics); Polymerase; DNA; DNA repair; Chemistry","score_opus":0.16931650921587557,"score_gpt":0.4498574468977701,"score_spread":0.2805409376818945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901569771","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009812855,0.9934123,0.00009484229,0.00022385271,0.0039414964,0.00092267146,0.00036473828,0.000019258283,0.00003953361],"genre_scores_gemma":[0.00738398,0.9879959,0.00014487715,0.000016797036,0.001134362,0.00009066772,0.0031976388,0.000022691967,0.000013064657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789643,0.0003041317,0.0009299259,0.0004930621,0.00017026288,0.00020621208],"domain_scores_gemma":[0.998509,0.0001539271,0.0006697228,0.00045838417,0.00015145885,0.000057489222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019691043,0.0003203696,0.0009875924,0.0002862973,0.00007452843,0.000008592615,0.0001878597,0.00036752268,0.0000637992],"category_scores_gemma":[0.00005616416,0.00020503456,0.00028047906,0.00048631724,0.0004921923,0.000061310515,0.000051775132,0.00034390492,0.000006171741],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077173136,0.00002885529,0.0013772609,0.007390677,0.00014046955,5.328569e-8,0.00019604321,0.0000011029528,0.00017194527,0.006023623,0.00076980214,0.983823],"study_design_scores_gemma":[0.0011494481,0.00013923908,0.016203282,0.010602354,0.00028626097,0.0000725584,0.000016974222,0.000114552386,0.00008481929,0.0033244595,0.9676484,0.00035764914],"about_ca_topic_score_codex":0.000028655119,"about_ca_topic_score_gemma":0.0000017622133,"teacher_disagreement_score":0.9834654,"about_ca_system_score_codex":0.00016220564,"about_ca_system_score_gemma":0.00027808142,"threshold_uncertainty_score":0.83610666},"labels":[],"label_agreement":null},{"id":"W2903498998","doi":"10.1101/483289","title":"Serum-dependent and independent regulation of PARP2","year":2018,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Western University","funders":"Natural Sciences and Engineering Research Council of Canada; University of Rochester; Université Laval","keywords":"Cell biology; Biology; Chromatin; Ubiquitin ligase; KLF4; Ubiquitin; Transcription factor; Gene; Genetics","score_opus":0.019160639171694166,"score_gpt":0.25544115239667015,"score_spread":0.23628051322497598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903498998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945805,0.0014051048,0.001026962,0.00040260665,0.0010168819,0.0010425563,0.00023398231,0.00022932993,0.000062097555],"genre_scores_gemma":[0.99509734,0.0005584084,0.0030411584,0.000256177,0.000776717,0.00013227382,6.126791e-7,0.000115124596,0.000022201757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971815,0.00011326505,0.00072366855,0.00088822196,0.0007208316,0.00037255886],"domain_scores_gemma":[0.9969192,0.000045722772,0.0006528929,0.0012897925,0.00079709606,0.00029529916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007026821,0.00045693602,0.0007512434,0.00034281236,0.00008495041,0.000059204816,0.00021148958,0.0006481236,0.00031479113],"category_scores_gemma":[0.00010468038,0.00047957984,0.00013693993,0.0002633758,0.0002699527,0.00010892411,0.00031883793,0.00061041367,0.000041728334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002930489,0.00021655299,0.050133977,0.0011479575,0.0003644256,0.000031449148,0.0000311851,0.000020648737,0.9465749,0.0004984734,0.00067861925,0.000008755272],"study_design_scores_gemma":[0.0015546869,0.00014843175,0.4349953,0.0009888568,0.00017744864,1.1171934e-7,0.0000027117437,0.00013926739,0.5601901,0.000017063438,0.001422057,0.00036394957],"about_ca_topic_score_codex":0.000037919363,"about_ca_topic_score_gemma":0.0000021515598,"teacher_disagreement_score":0.38638481,"about_ca_system_score_codex":0.00037011591,"about_ca_system_score_gemma":0.00062533515,"threshold_uncertainty_score":0.9997656},"labels":[],"label_agreement":null},{"id":"W2905274124","doi":"10.1182/blood-2018-99-120258","title":"Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) Activity Selectively Targets Human Acute Myeloid Leukemia Stem Cells","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CD34; Myeloid leukemia; CD38; Stem cell; Leukemia; Cancer research; Haematopoiesis; Biology; Population; CD33; Bone marrow; Myeloid; Immunology; Medicine; Cell biology","score_opus":0.015579652367410882,"score_gpt":0.2736847430810969,"score_spread":0.25810509071368604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905274124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362254,0.00015380094,0.0012483539,0.000114793795,0.00021645078,0.00063524116,0.00013756935,0.00016506949,0.0037061882],"genre_scores_gemma":[0.9979055,0.000116288844,0.00052266463,0.00026003804,0.0004653373,0.000059462553,0.000028756423,0.00005994498,0.0005819918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981341,0.0000957405,0.00041704962,0.0004933153,0.00044518439,0.0004146055],"domain_scores_gemma":[0.9987434,0.000053919357,0.00020422033,0.00043021046,0.0003797782,0.00018845679],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025909656,0.00029001653,0.0005123201,0.00015561438,0.00018993574,0.000016123278,0.00010360405,0.00019528663,0.0003258065],"category_scores_gemma":[0.000007740847,0.0002909334,0.00018597292,0.0004091545,0.00028809818,0.00018401901,0.000028487912,0.00033224508,0.000070792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005681723,0.0007937275,0.0016433952,0.0000980196,0.00033545066,0.000033835255,0.00083032757,0.000001475226,0.993657,0.00012084379,0.0008448303,0.0010729479],"study_design_scores_gemma":[0.0075134193,0.0017553673,0.0056921584,0.0002212257,0.0003676017,0.000066651475,0.000057701036,0.000017695811,0.983114,0.00021748857,0.00071583694,0.00026086124],"about_ca_topic_score_codex":0.00013145483,"about_ca_topic_score_gemma":0.00004066278,"teacher_disagreement_score":0.010542982,"about_ca_system_score_codex":0.00035143606,"about_ca_system_score_gemma":0.00034288972,"threshold_uncertainty_score":0.9999543},"labels":[],"label_agreement":null},{"id":"W2905645767","doi":"10.1016/j.jval.2018.09.090","title":"PCN7 - A TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF NIRAPARIB COMPARED WITH ROUTINE SURVEILLANCE IN THE MAINTENANCE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN CANCER","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Nausea; Cohort; Internal medicine; Ovarian cancer; Vomiting; Adverse effect; Toxicity; Oncology; Cancer; Gastroenterology; Surgery","score_opus":0.041604897005488584,"score_gpt":0.3369448825303392,"score_spread":0.29533998552485063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905645767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996553,0.0002521886,0.00019927834,0.0010106451,0.00005427026,0.0015323666,0.00025838535,0.000015261403,0.000124593],"genre_scores_gemma":[0.99849373,0.00020583678,0.0006042406,0.00034835946,0.000048569684,0.00016128176,0.00007174064,0.000018075347,0.000048161703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768394,0.00039822437,0.00070905796,0.0003560433,0.0004913289,0.00036142694],"domain_scores_gemma":[0.99839133,0.00016046503,0.0005716087,0.0005269681,0.0002582019,0.00009145112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000588725,0.00021131836,0.0009990039,0.00031058004,0.000043118558,0.000005022668,0.00012695373,0.00004729308,0.0001298204],"category_scores_gemma":[0.00002514187,0.000109748,0.00006405319,0.0020058511,0.00025772103,0.000039629696,0.00000940907,0.000107726584,0.0000014188183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01418617,0.001445012,0.9763568,0.00011192213,0.00041287675,0.0000035752616,0.0043301545,0.0019398214,0.000017167547,0.000044756223,0.00005939189,0.0010923487],"study_design_scores_gemma":[0.016566958,0.006904148,0.96449256,0.0009160178,0.0001233632,0.0000027227175,0.000116262854,0.010304883,0.00016023163,0.0000102534705,0.00026767017,0.00013493498],"about_ca_topic_score_codex":0.01136696,"about_ca_topic_score_gemma":0.00912114,"teacher_disagreement_score":0.011864251,"about_ca_system_score_codex":0.00078804547,"about_ca_system_score_gemma":0.00062118436,"threshold_uncertainty_score":0.9952164},"labels":[],"label_agreement":null},{"id":"W2908639608","doi":"10.1016/j.ygyno.2018.12.009","title":"Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial","year":2019,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"Medac; Clovis Oncology; Russian Science Foundation; Merck KGaA; Teva Pharmaceutical Industries; Genentech; PharmaMar; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Hazard ratio; Internal medicine; Ovarian cancer; Adverse effect; Population; Clinical endpoint; Placebo; Surgery; Anemia; Randomized controlled trial; Confidence interval; Cancer; Oncology; Pathology","score_opus":0.027992143018052515,"score_gpt":0.3271328342064086,"score_spread":0.29914069118835607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908639608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866237,0.0002773281,0.0000067336955,0.003734876,0.0010853164,0.0034294287,0.00018341954,0.00002600853,0.0046331566],"genre_scores_gemma":[0.99660367,0.0010965735,0.00028577686,0.0010906596,0.00017572536,0.00025982913,0.00012193837,0.000017769109,0.00034808647],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979937,0.00030732562,0.000610824,0.000524324,0.00021334211,0.00035048305],"domain_scores_gemma":[0.99735534,0.0016043533,0.00040431385,0.0004400258,0.00010679668,0.00008916382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003939452,0.00021846913,0.0007095262,0.000075821124,0.000039801187,0.0000066998086,0.0001352403,0.00024399688,0.0008427109],"category_scores_gemma":[0.00028024477,0.00013160246,0.000062481486,0.00023312852,0.00022327795,0.000040804458,0.000049285572,0.0002821439,0.000041490694],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50915134,0.0053992225,0.19325638,0.000027060836,0.00054715254,0.00012469233,0.0063468744,0.00011290023,0.0003915409,0.00063642743,0.0037011874,0.28030524],"study_design_scores_gemma":[0.28542638,0.015873661,0.6477721,0.00015167137,0.000087219065,0.0000060963994,0.00019601421,0.000018067482,0.00013977017,0.00015475319,0.050031256,0.00014302855],"about_ca_topic_score_codex":0.0016176433,"about_ca_topic_score_gemma":0.0019448886,"teacher_disagreement_score":0.45451573,"about_ca_system_score_codex":0.0010205504,"about_ca_system_score_gemma":0.0006243583,"threshold_uncertainty_score":0.92270935},"labels":[],"label_agreement":null},{"id":"W2908924740","doi":"10.1038/s41419-018-1274-6","title":"Erythropoietin inhibits chemotherapy-induced cell death and promotes a senescence-like state in leukemia cells","year":2019,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"York University","keywords":"Daunorubicin; Erythropoietin; Erythropoietin receptor; Cancer research; Erythropoiesis; Mdm2; Downregulation and upregulation; DNA damage; Senescence; Apoptosis; Doxorubicin; Myeloid leukemia; Biology; Leukemia; Immunology; Cell biology; Medicine; Chemotherapy; Internal medicine; Anemia; Endocrinology; Gene","score_opus":0.013779279698426749,"score_gpt":0.25378885000207196,"score_spread":0.24000957030364523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908924740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993895,0.0020241428,0.0000440095,0.00029508036,0.00015347135,0.001089299,0.000042451848,0.00007096585,0.0023855912],"genre_scores_gemma":[0.9933067,0.0013497384,0.00033619828,0.0020083063,0.00008471281,0.000048530135,0.000031941214,0.00005483551,0.002779058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982397,0.00006323676,0.00032448437,0.00063749857,0.00027267137,0.00046240125],"domain_scores_gemma":[0.998535,0.0000586504,0.00010821735,0.0003826091,0.00006365501,0.0008518664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016124407,0.00032691186,0.00039222403,0.00014836196,0.00006561506,0.00005448738,0.000070585615,0.00010649887,0.00023505953],"category_scores_gemma":[0.00001189246,0.00029576386,0.00007536179,0.00017739407,0.00007204277,0.00013524953,0.00004713728,0.00023770137,0.00008027535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024910541,0.00069125876,0.27747443,0.001655109,0.000026953869,0.00027555137,0.001829155,0.000016263728,0.7111053,0.000031657855,0.0012818014,0.0031214855],"study_design_scores_gemma":[0.026730536,0.0009843839,0.12836155,0.0009449766,0.00014570782,0.000032177795,0.00038409914,0.0019436798,0.8336186,0.0019964029,0.0037255075,0.0011323858],"about_ca_topic_score_codex":0.00013030418,"about_ca_topic_score_gemma":0.0000056402996,"teacher_disagreement_score":0.14911288,"about_ca_system_score_codex":0.00016370349,"about_ca_system_score_gemma":0.00052643724,"threshold_uncertainty_score":0.99994946},"labels":[],"label_agreement":null},{"id":"W2913561745","doi":"10.1002/ijc.32131","title":"Increased PARP1‐DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1‐DNA trapping is correlated with PARP1 inhibitor's cytotoxicity","year":2019,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chinese Academy of Sciences; State Key Laboratory of Drug Research; National Natural Science Foundation of China; Science and Technology Commission of Shanghai Municipality; Université Laval","keywords":"PARP1; DNA; DNA damage; Cytotoxicity; Chemistry; Molecular biology; Cancer research; Biophysics; Biology; Poly ADP ribose polymerase; Biochemistry; Polymerase; In vitro","score_opus":0.016434696119794912,"score_gpt":0.3044436543614627,"score_spread":0.2880089582416678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913561745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031854,0.0002031759,0.0015073739,0.0040060454,0.0015379686,0.00077538553,0.00015903113,0.000055849672,0.0014366553],"genre_scores_gemma":[0.99533886,0.00015357332,0.00033232078,0.0024537956,0.0012082948,0.000060224906,0.000055718203,0.000077244746,0.00031999795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99588495,0.0001586194,0.0012839725,0.00044309674,0.0018498595,0.00037950356],"domain_scores_gemma":[0.99635637,0.0002108185,0.0014684902,0.00031342354,0.0013352326,0.0003156773],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000682852,0.0004038262,0.0007897383,0.00084300275,0.00007952176,0.00007151157,0.00028131428,0.00022787754,0.0015195122],"category_scores_gemma":[0.00008708096,0.000339757,0.00031416665,0.00054198934,0.000111800364,0.00053389446,0.000043305074,0.0006073448,0.000071474766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015065675,0.0007968288,0.071829915,0.00012586969,0.001827433,0.0003154656,0.0026629493,0.0028239503,0.8934615,0.00030756503,0.005909773,0.004873051],"study_design_scores_gemma":[0.013208596,0.0020359477,0.061611257,0.00689441,0.00023695882,0.0004416179,0.00031422527,0.0010237235,0.9082961,0.0003213958,0.005063379,0.00055235584],"about_ca_topic_score_codex":0.00015761262,"about_ca_topic_score_gemma":0.000051671344,"teacher_disagreement_score":0.01483461,"about_ca_system_score_codex":0.0011471107,"about_ca_system_score_gemma":0.00064319215,"threshold_uncertainty_score":0.99990547},"labels":[],"label_agreement":null},{"id":"W2916900413","doi":"10.1101/gad.314633.118","title":"BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma","year":2019,"lang":"en","type":"article","venue":"Genes & Development","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Genome Canada; Université Laval; Centre hospitalier universitaire de Québec; Lunenfeld-Tanenbaum Research Institute; Centre hospitalier de l'Université Laval; Mount Sinai Hospital","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Ontario Genomics; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; National Institutes of Health; Ludwig Institute for Cancer Research; Institut National Du Cancer; Deutsche Forschungsgemeinschaft; National Institute for Health and Care Research; Genome Canada; Cancer Research Society; Wellcome Trust; Fondation ARC pour la Recherche sur le Cancer","keywords":"DNA damage; Biology; DNA repair; Nucleotide excision repair; Cancer research; Transcription factor; Ku70; Reprogramming; Cell biology; DNA; Genetics; Gene","score_opus":0.01221979137757796,"score_gpt":0.25203895258967834,"score_spread":0.2398191612121004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916900413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973701,0.00050521607,0.000030165216,0.000679205,0.00009256554,0.00083047716,0.0000053008966,0.00014275075,0.0003442086],"genre_scores_gemma":[0.98978007,0.000110471956,0.008507164,0.00040724836,0.000035797293,0.00021951519,0.00015185887,0.000032056665,0.00075579697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985479,0.000052959815,0.0003663626,0.00040560434,0.00036082088,0.00026634577],"domain_scores_gemma":[0.999336,0.000060616418,0.00013958607,0.00027935824,0.000101998114,0.000082465056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002812219,0.00018395575,0.00032737484,0.00013152942,0.00005299904,0.000029598827,0.00005791817,0.0000929183,0.0002291938],"category_scores_gemma":[0.000027637716,0.00015609871,0.000029081915,0.00027287993,0.000041334617,0.0000939796,0.00003597759,0.000094447234,0.00004400177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009617397,0.0006675189,0.80690974,0.0009402567,0.0014147717,0.00023478284,0.027880996,0.0000902856,0.08314087,0.00009292242,0.002072223,0.075593874],"study_design_scores_gemma":[0.007832449,0.0005455982,0.68092835,0.0014703859,0.00009452427,0.00008184478,0.0012543979,0.0002237375,0.29808637,0.00020496354,0.008763809,0.0005135629],"about_ca_topic_score_codex":0.00010454283,"about_ca_topic_score_gemma":0.00006130066,"teacher_disagreement_score":0.2149455,"about_ca_system_score_codex":0.0002512244,"about_ca_system_score_gemma":0.00023572019,"threshold_uncertainty_score":0.6365521},"labels":[],"label_agreement":null},{"id":"W2917679477","doi":"10.1186/s12885-018-5250-4","title":"Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University","funders":"Jewish General Hospital; Canadian Cancer Society Research Institute; Cancer Research Society; Israel Cancer Research Fund","keywords":"Olaparib; Cancer research; Ovarian cancer; Chemotherapy; Paclitaxel; Doxorubicin; Medicine; Cell cycle; Oncology; Biology; Cancer; Internal medicine; Poly ADP ribose polymerase; Polymerase; Genetics","score_opus":0.04501213914723758,"score_gpt":0.33412900512501004,"score_spread":0.2891168659777725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917679477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97508967,0.008322331,0.002836886,0.0011630659,0.0041432334,0.000783092,0.00010832444,0.00012815444,0.007425244],"genre_scores_gemma":[0.99274176,0.00035596493,0.00081492466,0.0010372426,0.0013770947,0.0001986872,0.000017633967,0.000048222828,0.0034084518],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99856603,0.00004125073,0.00034610994,0.00032819295,0.00042987385,0.0002885216],"domain_scores_gemma":[0.9992147,0.000052095922,0.00018746729,0.00026392925,0.00019249637,0.00008930005],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019122034,0.00016792363,0.00032485864,0.000100890655,0.000051784988,0.000012652713,0.000089260444,0.00009645353,0.014405923],"category_scores_gemma":[0.000010972623,0.00015565932,0.00014972223,0.0002385723,0.00006747474,0.00011332847,0.00002557806,0.0002026723,0.000067641166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011824844,0.00010015791,0.48786244,0.00046626967,0.00036894475,0.000003427295,0.00035459144,0.002199468,0.49761286,0.0015915073,0.0029723605,0.005285474],"study_design_scores_gemma":[0.01744611,0.00041607136,0.4608427,0.0018939751,0.00048331678,0.000035653993,0.00032790343,0.0039712125,0.33252913,0.00074526144,0.180373,0.00093566417],"about_ca_topic_score_codex":0.00092467107,"about_ca_topic_score_gemma":0.00008640039,"teacher_disagreement_score":0.17740063,"about_ca_system_score_codex":0.00042458763,"about_ca_system_score_gemma":0.000753822,"threshold_uncertainty_score":0.986495},"labels":[],"label_agreement":null},{"id":"W2918322716","doi":"10.1002/cncr.32004","title":"Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; BC Cancer Agency; University of British Columbia","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute, Cairo University; National Cancer Institute; Cancer Research UK; Prospect Creek Foundation; Ovarian Cancer Research Foundation; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Breast Cancer Research Foundation; Cancer Prevention and Research Institute of Texas; American Cancer Society","keywords":"Medicine; Ovarian cancer; Disease; Cancer; Chemotherapy; Immunotherapy; Oncology; Translational research; Internal medicine; Intensive care medicine; Pathology","score_opus":0.19829181108970612,"score_gpt":0.5442586415414359,"score_spread":0.34596683045172977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2918322716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801288,0.0008304129,0.00002443067,0.012375173,0.00059797644,0.0014191461,0.00039428164,0.000019966015,0.004209762],"genre_scores_gemma":[0.98570704,0.0028561458,0.00036726866,0.000128391,0.002138696,0.0024351536,0.000034829125,0.000036606485,0.0062958444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975149,0.00025424728,0.0003978079,0.0005400186,0.0007160523,0.0005769888],"domain_scores_gemma":[0.9967817,0.0006326117,0.00013076136,0.00036732244,0.0018850034,0.00020257013],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013794992,0.0001375785,0.00046189644,0.00035330057,0.00012455271,0.00003927892,0.0000936655,0.00013538385,0.0012326685],"category_scores_gemma":[0.00045606555,0.00012958563,0.000048349844,0.00072171027,0.00050468417,0.00017809356,0.000027258131,0.00039722276,0.000006334913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050069457,0.0013340841,0.7518647,0.00047307127,0.00036555497,0.00012629302,0.005694621,0.00008106875,0.13742766,0.023258708,0.009871824,0.064495526],"study_design_scores_gemma":[0.015618909,0.006309169,0.57988286,0.0028204843,0.00018135499,0.0000575174,0.002976394,0.00087360915,0.09859733,0.012136613,0.27976784,0.00077791576],"about_ca_topic_score_codex":0.02251972,"about_ca_topic_score_gemma":0.016348694,"teacher_disagreement_score":0.269896,"about_ca_system_score_codex":0.0032610933,"about_ca_system_score_gemma":0.0020273824,"threshold_uncertainty_score":0.99968034},"labels":[],"label_agreement":null},{"id":"W2920791670","doi":"10.1158/1538-7445.sabcs18-p3-10-11","title":"Abstract P3-10-11: Clinical implications of 63-gene signature associated with response to PARP inhibition in triple-negative and luminal B breast cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Breast cancer; Triple-negative breast cancer; Olaparib; Medicine; Gene signature; Oncology; Internal medicine; Cancer; Lymph node; Cohort; Proportional hazards model; Gene expression; Cancer research; Gene; Biology; Poly ADP ribose polymerase; Genetics","score_opus":0.09127050448730092,"score_gpt":0.46599694516867,"score_spread":0.37472644068136907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920791670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98179835,0.00043805264,0.000006960873,0.014857191,0.00009425492,0.0016155398,0.00082669395,0.000025339512,0.00033762198],"genre_scores_gemma":[0.99657327,0.00034353381,0.00007088785,0.00044423196,0.00021919595,0.00071979145,0.00004437825,0.000040726107,0.001543956],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99717885,0.0004926123,0.0005401385,0.0005764592,0.0007210634,0.00049085915],"domain_scores_gemma":[0.99689627,0.001083924,0.000175886,0.00040942617,0.0011283486,0.0003061496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025492525,0.0001769826,0.0004893772,0.00044633297,0.00008336644,0.000022952507,0.00010725518,0.00024458638,0.0013293672],"category_scores_gemma":[0.00044014535,0.00015134976,0.000065567576,0.0013685793,0.00039342762,0.0001361305,0.00005897149,0.0007363474,0.000020349962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046352047,0.00067152584,0.31420684,0.00017339013,0.00021598767,0.00005108229,0.0011893413,0.0001342918,0.61221856,0.00006503118,0.020011254,0.004710662],"study_design_scores_gemma":[0.007272007,0.0008680056,0.94636536,0.0014454807,0.000023266626,0.000018930272,0.00024027834,0.00001548686,0.04238546,0.00015549888,0.0010324675,0.0001777672],"about_ca_topic_score_codex":0.0008513313,"about_ca_topic_score_gemma":0.0021627273,"teacher_disagreement_score":0.6321585,"about_ca_system_score_codex":0.0009647491,"about_ca_system_score_gemma":0.0015383341,"threshold_uncertainty_score":0.99958354},"labels":[],"label_agreement":null},{"id":"W2921576264","doi":"10.1038/s41467-019-08859-x","title":"Emerging roles of eraser enzymes in the dynamic control of protein ADP-ribosylation","year":2019,"lang":"en","type":"review","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval; University of Alberta; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"ADP-ribosylation; Ribose; Enzyme; Computational biology; Poly ADP ribose polymerase; Biochemistry; Identification (biology); Biology; Chemistry; Cell biology; NAD+ kinase; Polymerase","score_opus":0.04257265650994749,"score_gpt":0.40940734820567265,"score_spread":0.36683469169572513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921576264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033143722,0.9942217,0.00011684316,0.0017126722,0.00005876103,0.0026693107,0.0001757056,0.000017131211,0.0009947448],"genre_scores_gemma":[0.12218294,0.8761011,0.00049875065,0.00012193837,0.000029289999,0.00046374594,0.0005048871,0.00003079371,0.00006654967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791586,0.0006611416,0.0008044026,0.0001749769,0.00031388056,0.00012972782],"domain_scores_gemma":[0.9959026,0.00062718656,0.0006886741,0.0025278064,0.0002320692,0.00002165143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063981797,0.0002163324,0.0011098266,0.00033599854,0.000052206975,0.0000068372074,0.0009496228,0.0005094081,0.00003422713],"category_scores_gemma":[0.00019532647,0.00014974267,0.00034158683,0.0006411037,0.00012853013,0.000056423596,0.00007078949,0.0016538723,0.000008065369],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013762883,0.0011635731,0.00027616182,0.025186984,0.0009800801,0.0000024308947,0.0016718755,0.000055381166,0.0003979636,0.062520616,0.00089207443,0.9067152],"study_design_scores_gemma":[0.0010380152,0.000064308486,0.0000977715,0.018706625,0.00064125133,0.000012245791,0.0001126067,0.0006612591,0.00002507009,0.0001365683,0.9783474,0.00015682944],"about_ca_topic_score_codex":0.00001414323,"about_ca_topic_score_gemma":0.00018550879,"teacher_disagreement_score":0.9774554,"about_ca_system_score_codex":0.00013730838,"about_ca_system_score_gemma":0.00037100894,"threshold_uncertainty_score":0.7185344},"labels":[],"label_agreement":null},{"id":"W2921616646","doi":"10.1136/ejhpharm-2019-eahpconf.49","title":"2SPD-009 Analysis of olaparib and talazoparib as possible therapeutic alternatives in advanced breast cancer and a germline BRCA mutation","year":2019,"lang":"en","type":"article","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universidad de Sevilla","keywords":"Eribulin; Olaparib; Medicine; Vinorelbine; Oncology; Internal medicine; Taxane; Capecitabine; BRCA mutation; Breast cancer; Metastatic breast cancer; Anthracycline; Population; Cancer; Chemotherapy; Colorectal cancer; Genetics","score_opus":0.010384799303078517,"score_gpt":0.33087144118773526,"score_spread":0.32048664188465675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921616646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472183,0.0016623762,0.00014823505,0.0012717409,0.000050036662,0.00038417638,0.000048975737,0.000023593953,0.0016890081],"genre_scores_gemma":[0.9967604,0.0010646617,0.00028642392,0.0007075812,0.00002354393,0.00003847491,0.00002772647,0.00001466863,0.0010764872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989652,0.00003665376,0.00031389052,0.0003099261,0.0002117057,0.00016261853],"domain_scores_gemma":[0.9993957,0.00008368006,0.00014674269,0.00018482431,0.00011428523,0.00007472671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014677279,0.00014148827,0.00046607,0.00042238715,0.000020056856,0.0000144214955,0.000040527473,0.000052072628,0.0007444413],"category_scores_gemma":[0.000007782191,0.00011727316,0.000057247966,0.00067014614,0.000090198126,0.00018239827,0.000018781708,0.000105765874,0.000004165683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014121652,0.0002295321,0.822463,0.00013693963,0.0012677767,0.00001202921,0.0019223235,0.0009137489,0.11475762,0.001080333,0.000013159398,0.055791423],"study_design_scores_gemma":[0.0051344754,0.00023277117,0.96773016,0.00015769963,0.00036481512,0.00004282266,0.000389456,0.008928519,0.01635214,0.00044886203,0.00006880103,0.00014948823],"about_ca_topic_score_codex":0.0009744262,"about_ca_topic_score_gemma":0.0004171963,"teacher_disagreement_score":0.1452672,"about_ca_system_score_codex":0.00008033705,"about_ca_system_score_gemma":0.00008283469,"threshold_uncertainty_score":0.815111},"labels":[],"label_agreement":null},{"id":"W2922010177","doi":"10.1200/jco.2019.37.7_suppl.tps346","title":"Personalized use of metronomic cyclophosphamide for DNA repair deficient castration-resistant prostate cancer: A phase II trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; PARP inhibitor; Veliparib; Oncology; Internal medicine; Cyclophosphamide; Clinical endpoint; Cancer; Cancer research; Clinical trial; Chemotherapy; Poly ADP ribose polymerase; DNA; Biology","score_opus":0.18840276535886388,"score_gpt":0.5044325240745496,"score_spread":0.3160297587156857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922010177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99057555,0.0010981911,0.00015534431,0.003929967,0.002450952,0.0015069561,0.000093799514,0.000014491348,0.00017473013],"genre_scores_gemma":[0.98348135,0.0012606119,0.010926385,0.0017450883,0.0009154133,0.00007932337,0.000009966568,0.000030497078,0.0015513847],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954504,0.00029478446,0.003371388,0.00025550375,0.00037526278,0.00025270382],"domain_scores_gemma":[0.99265975,0.0025790737,0.003405449,0.00025469545,0.00082822586,0.00027279067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003387318,0.0001586338,0.0018144804,0.00015111905,0.00005072711,0.000007705437,0.0001095595,0.00024551948,0.0004491436],"category_scores_gemma":[0.0019937002,0.00012070449,0.0011362041,0.00014609275,0.00022384158,0.00015148275,0.000022934479,0.0004483069,0.0000049779064],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90862906,0.009725011,0.006761783,0.0001864141,0.0015169982,0.00008572484,0.0004958949,0.00033162677,0.027439523,0.00064354483,0.016846083,0.027338361],"study_design_scores_gemma":[0.4238098,0.11313837,0.0050601214,0.0003306027,0.00081242813,0.00006674397,0.00021916785,0.00049802853,0.0032045534,0.00020521354,0.45248035,0.00017461684],"about_ca_topic_score_codex":0.000043903845,"about_ca_topic_score_gemma":0.00003165833,"teacher_disagreement_score":0.48481923,"about_ca_system_score_codex":0.00050165213,"about_ca_system_score_gemma":0.004192624,"threshold_uncertainty_score":0.74375343},"labels":[],"label_agreement":null},{"id":"W2922151518","doi":"10.1200/jco.2019.37.7_suppl.tps340","title":"PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Olaparib; Prostate cancer; Internal medicine; Clinical endpoint; Population; Oncology; Prednisone; Enzalutamide; Placebo; Hazard ratio; Cancer; Urology; Randomized controlled trial; Pathology; Confidence interval","score_opus":0.10858592777829928,"score_gpt":0.4756403416663116,"score_spread":0.3670544138880123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922151518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897708,0.0003785823,0.000045955727,0.004063197,0.00035959974,0.0052527967,0.00001169336,0.000005026933,0.0001123352],"genre_scores_gemma":[0.9970889,0.0008202283,0.00091439695,0.0007615349,0.00017993928,0.00010616675,0.000007535038,0.000025381367,0.00009593048],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99443936,0.001358815,0.0030502998,0.00023593823,0.0007004936,0.00021511967],"domain_scores_gemma":[0.9912137,0.004147522,0.003392901,0.0002248634,0.00086434936,0.00015669735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069234143,0.00020668276,0.0024404528,0.000107080494,0.000053269516,0.0000144646065,0.00011559289,0.00011082555,0.00020356236],"category_scores_gemma":[0.0010966903,0.0000933799,0.00016706002,0.00022124794,0.00049790286,0.0001402796,0.000016773627,0.0006983704,0.0000016554936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9618908,0.0041364795,0.0070821075,0.00004675663,0.0009811423,0.00003086371,0.00069792476,0.0004164058,0.0002365168,0.00003169398,0.00002685754,0.02442242],"study_design_scores_gemma":[0.8058321,0.1777753,0.014503447,0.0005092219,0.00043940172,0.000019024674,0.00007384716,0.00028764817,0.00010937019,0.000085445405,0.0002729857,0.00009221455],"about_ca_topic_score_codex":0.00008918019,"about_ca_topic_score_gemma":0.00013243184,"teacher_disagreement_score":0.17363882,"about_ca_system_score_codex":0.00014020684,"about_ca_system_score_gemma":0.0023370138,"threshold_uncertainty_score":0.41457623},"labels":[],"label_agreement":null},{"id":"W2922329974","doi":"10.1200/jco.2019.37.7_suppl.tps342","title":"TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Taxane; Prostate cancer; Internal medicine; Clinical endpoint; Urology; Oncology; Enzalutamide; Progression-free survival; Cancer; Chemotherapy; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.20163990613291013,"score_gpt":0.48499839965607117,"score_spread":0.283358493523161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922329974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914417,0.00019953745,0.000023900771,0.002927915,0.00009517222,0.005185824,0.000047681522,0.000018977935,0.000059255297],"genre_scores_gemma":[0.9946689,0.00027637678,0.0024768615,0.001862127,0.0000989793,0.0002577682,0.000008102858,0.000063969084,0.00028689348],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99402434,0.002048668,0.002268785,0.0006402643,0.0006167462,0.00040117744],"domain_scores_gemma":[0.9946236,0.0018006455,0.0020630648,0.0004502311,0.00055271306,0.00050976337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076141027,0.00037790995,0.002187153,0.00032459156,0.00008921753,0.00005126363,0.0002475787,0.00013042142,0.000118879376],"category_scores_gemma":[0.000616219,0.00024482742,0.00007645552,0.0003966285,0.00030337708,0.00034758943,0.000056946257,0.00070808,8.626233e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72455484,0.028165078,0.029474037,0.000106865584,0.0009053544,0.00096815685,0.0027582822,0.00013712041,0.2010811,0.000010117584,0.00017356474,0.011665483],"study_design_scores_gemma":[0.24227205,0.53138393,0.2124747,0.0010852523,0.00029878944,0.00014880797,0.00076160056,0.00066048634,0.009655983,0.000025947356,0.00088419486,0.00034823385],"about_ca_topic_score_codex":0.00015457858,"about_ca_topic_score_gemma":0.00080677815,"teacher_disagreement_score":0.5032189,"about_ca_system_score_codex":0.0002554141,"about_ca_system_score_gemma":0.0027104756,"threshold_uncertainty_score":0.99837726},"labels":[],"label_agreement":null},{"id":"W2922348865","doi":"10.1200/jco.2019.37.7_suppl.202","title":"Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Taxane; Internal medicine; Cancer; Oncology; Cancer research; Breast cancer","score_opus":0.07907273652936153,"score_gpt":0.44528852209238573,"score_spread":0.3662157855630242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922348865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739087,0.0003826791,0.0000028965715,0.0004848771,0.00032940527,0.0012263578,0.000047670885,0.0000057320326,0.00012950927],"genre_scores_gemma":[0.9982067,0.00026394342,0.0010902784,0.00022365901,0.0000990222,0.000019020898,0.0000073452948,0.00001860391,0.00007145356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995322,0.00054555276,0.0031023887,0.0002625067,0.0005705381,0.00019703616],"domain_scores_gemma":[0.9947407,0.001034239,0.0030174504,0.00025293566,0.0007582436,0.00019640393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021949657,0.00016746437,0.0016129947,0.00024070666,0.000026115968,0.0000030695007,0.00009522771,0.00013156238,0.000043955723],"category_scores_gemma":[0.0006440596,0.00011620018,0.00016915335,0.00025027274,0.00020068337,0.00013769775,0.000039321396,0.0004903297,8.1330063e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34892726,0.045552183,0.57965946,0.00028401127,0.0013912547,0.00032155946,0.003001165,0.00053207885,0.005837517,0.0000092906275,0.0007967041,0.013687502],"study_design_scores_gemma":[0.1420886,0.30351135,0.55144054,0.00041481273,0.00046015767,0.000022090187,0.0004502492,0.00005273194,0.0009355097,0.000029835162,0.0004951766,0.00009892044],"about_ca_topic_score_codex":0.00013833279,"about_ca_topic_score_gemma":0.00035830238,"teacher_disagreement_score":0.2579592,"about_ca_system_score_codex":0.00013930914,"about_ca_system_score_gemma":0.0014534501,"threshold_uncertainty_score":0.47385058},"labels":[],"label_agreement":null},{"id":"W2923414225","doi":"10.1007/s40259-019-00347-4","title":"PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ovarian cancer; Medicine; Cancer; Oncology; Pharmacotherapy; Internal medicine","score_opus":0.04552099282661187,"score_gpt":0.3574579287860135,"score_spread":0.31193693595940164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923414225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.3142436e-7,0.98423296,0.000004073631,0.0009943456,0.0004725369,0.0029295257,0.00008215509,0.000032428998,0.011251155],"genre_scores_gemma":[0.00000952736,0.99571365,0.00011125451,0.0010471854,0.0003573751,0.0005329907,0.000060900333,0.000053046435,0.0021140454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799204,0.00019821976,0.00081380806,0.00040636858,0.00035856405,0.00023099773],"domain_scores_gemma":[0.9983079,0.00017726807,0.0006494876,0.00070136314,0.000084976054,0.00007905112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007514173,0.0003597708,0.0021981425,0.00015648082,0.000048505954,0.00001836566,0.00019021875,0.00016463765,0.0006656626],"category_scores_gemma":[0.000036246634,0.00020393317,0.00050212553,0.00047345628,0.00018477393,0.000044395052,0.00010610138,0.0003064881,0.00006844507],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000353744,0.00002075974,0.000019857865,0.22702117,0.00058563,0.000006651648,0.000061013245,1.8275191e-8,2.10376e-7,0.00048131318,0.046599094,0.7251689],"study_design_scores_gemma":[0.0015762139,0.00001885706,0.00000897431,0.20967817,0.0029653714,0.000033588385,0.000012804804,0.000001468072,0.0000011914522,0.000017147333,0.7855277,0.00015852237],"about_ca_topic_score_codex":0.0000474952,"about_ca_topic_score_gemma":0.0000017733507,"teacher_disagreement_score":0.7389286,"about_ca_system_score_codex":0.00009613201,"about_ca_system_score_gemma":0.00021682335,"threshold_uncertainty_score":0.8316154},"labels":[],"label_agreement":null},{"id":"W2935541805","doi":"10.1016/s1470-2045(19)30029-4","title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":537,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; BRCA mutation; Oncology; Progressive disease; Chemotherapy; Progression-free survival; Population; Phases of clinical research; Carboplatin; Combination therapy; Surgery; Gastroenterology; Cancer; Cisplatin","score_opus":0.24555150791936622,"score_gpt":0.4816545343169153,"score_spread":0.23610302639754907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935541805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556818,0.0015929674,0.0005653496,0.02727901,0.0019136475,0.008377397,0.00033588408,0.0000790354,0.004174937],"genre_scores_gemma":[0.96995115,0.002940644,0.0059324647,0.007960144,0.0034657284,0.0027192926,0.0001604646,0.000103298305,0.006766839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981915,0.00022301881,0.00055625127,0.0003878538,0.00017222625,0.0004691967],"domain_scores_gemma":[0.9980692,0.00054866925,0.00042826074,0.0006918242,0.00015986688,0.00010217861],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004694136,0.00025204784,0.0012571242,0.000073772855,0.00007872333,0.00002044171,0.00033481428,0.0001907979,0.0013218476],"category_scores_gemma":[0.000034855468,0.0001656186,0.0001200971,0.00018737983,0.00015324338,0.000077342906,0.000034606583,0.00013669845,0.000037997044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7075873,0.023263782,0.00036267185,0.00011784896,0.0012694707,0.00001944347,0.0029781393,0.00011944393,0.1236561,0.0015975718,0.007833914,0.13119431],"study_design_scores_gemma":[0.54338145,0.03649398,0.000042030457,0.00006787481,0.00021667875,0.000010686525,0.000072020215,0.0013405011,0.023033194,0.0005610614,0.3946285,0.0001520198],"about_ca_topic_score_codex":0.0004103262,"about_ca_topic_score_gemma":0.00022918945,"teacher_disagreement_score":0.38679457,"about_ca_system_score_codex":0.0006964681,"about_ca_system_score_gemma":0.0004957653,"threshold_uncertainty_score":0.99959105},"labels":[],"label_agreement":null},{"id":"W2935753526","doi":"10.1038/s41392-019-0042-0","title":"Signal-induced PARP1-Erk synergism mediates IEG expression","year":2019,"lang":"en","type":"review","venue":"Signal Transduction and Targeted Therapy","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute on Drug Abuse; Efficacy and Mechanism Evaluation Programme","keywords":"MAPK/ERK pathway; PARP1; Cell biology; Mechanism (biology); Intracellular; Stimulation; Signal transduction; Immediate early gene; Biology; Phosphorylation; Neuroscience; Gene expression; Chemistry; Gene; Genetics; Polymerase","score_opus":0.09188745218005683,"score_gpt":0.35047668787206465,"score_spread":0.2585892356920078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935753526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005985477,0.9941701,0.00046002594,0.0002595408,0.0012926104,0.0022716944,0.000109258755,0.00031495493,0.00052325614],"genre_scores_gemma":[0.002819439,0.9929655,0.00026454258,0.00042129456,0.0015153023,0.00042368175,0.000613139,0.0002153366,0.0007617494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99610317,0.0004683355,0.0010612373,0.0010771707,0.0007080492,0.0005820513],"domain_scores_gemma":[0.9981583,0.00023696886,0.00048224808,0.0005603725,0.00016893394,0.0003931868],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004242404,0.0009568494,0.0025009287,0.0005499021,0.00021326246,0.00006762131,0.00020606778,0.0009253409,0.0060373656],"category_scores_gemma":[0.000008309838,0.0007211367,0.00090246147,0.0005911014,0.00016431572,0.00021534842,0.000014408256,0.0011189063,0.00017900424],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053540454,0.00029453856,0.0000058596634,0.0056154607,0.0008226634,0.0000331542,0.0004248388,0.0000029873372,0.03669033,0.00005779101,0.0012348227,0.95428216],"study_design_scores_gemma":[0.0036807896,0.00083829334,0.0000090819185,0.009220435,0.00060309883,0.00022393889,0.00006540229,0.000010911781,0.01983293,0.00024075517,0.96445495,0.0008193869],"about_ca_topic_score_codex":0.000015344758,"about_ca_topic_score_gemma":6.694255e-7,"teacher_disagreement_score":0.9632202,"about_ca_system_score_codex":0.0001679805,"about_ca_system_score_gemma":0.00047005992,"threshold_uncertainty_score":0.999524},"labels":[],"label_agreement":null},{"id":"W2941565373","doi":"10.1097/01.ju.0000556206.58679.60","title":"MP41-20 DISEASE-SPECIFIC COSTS OF NONMETASTATIC AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN QUEBEC","year":2019,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Castration; Oncology; Disease; Internal medicine; Prostate disease; Urology; Cancer; Gynecology; Hormone","score_opus":0.023248339039741467,"score_gpt":0.3004488236951757,"score_spread":0.27720048465543423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941565373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831323,0.009528854,0.00010854528,0.0065190163,0.00018592546,0.0003769501,0.000041626055,0.0000027533504,0.00010401828],"genre_scores_gemma":[0.9969968,0.0019672064,0.0001520826,0.00055682,0.000048033402,0.0000072570306,0.0000022829986,0.000013771995,0.0002557499],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99867827,0.000258848,0.0005516914,0.00009293208,0.00025571877,0.00016255744],"domain_scores_gemma":[0.99882317,0.0003139445,0.00044829422,0.00017282035,0.0001447363,0.000097045966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006437109,0.000105475476,0.0003872735,0.00016443667,0.000019703479,0.000006942221,0.000090237736,0.000023347142,0.00033365982],"category_scores_gemma":[0.00003111504,0.000068182984,0.00005270569,0.00015450256,0.00017931983,0.00009524101,0.000018474744,0.00023668472,0.000006115654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054887537,0.0009151608,0.08068638,0.0007526862,0.0011259305,0.00079998426,0.010950998,0.012560414,0.8050242,0.0029332251,0.0033157247,0.026047759],"study_design_scores_gemma":[0.05282124,0.010262665,0.8672106,0.0019456253,0.0025531584,0.0025852283,0.005024757,0.0033373977,0.015208695,0.0113731865,0.026807295,0.0008701368],"about_ca_topic_score_codex":0.0003600518,"about_ca_topic_score_gemma":0.0013883278,"teacher_disagreement_score":0.7898155,"about_ca_system_score_codex":0.000117619464,"about_ca_system_score_gemma":0.00032800625,"threshold_uncertainty_score":0.3653341},"labels":[],"label_agreement":null},{"id":"W2943789407","doi":"10.1021/acs.jmedchem.8b01709","title":"Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity","year":2019,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research; St. John's University; Breast Cancer Research Foundation; Susan G. Komen for the Cure","keywords":"Chemistry; Poly ADP ribose polymerase; Stereochemistry; Polymerase; Carboxamide; IC50; Ribose; Enzyme; Biochemistry; In vitro","score_opus":0.012183134242263888,"score_gpt":0.28577525198179415,"score_spread":0.2735921177395303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943789407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924088,0.004109998,0.00033180113,0.0023031754,0.00013115254,0.00031053083,0.000024186937,0.000009174624,0.00037118883],"genre_scores_gemma":[0.9984383,0.00028833546,0.00034590872,0.00018347224,0.0006047264,0.000002846541,0.0000016344671,0.000033301214,0.00010148645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977006,0.00012634284,0.0007820489,0.00025663848,0.0008361373,0.00029827034],"domain_scores_gemma":[0.99754155,0.0007446076,0.0008114126,0.0003164749,0.00021891663,0.00036705568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012862924,0.00028819946,0.0008607117,0.00019449172,0.00005974815,0.000013027377,0.00017332297,0.000160113,0.0002449149],"category_scores_gemma":[0.00054079667,0.0001872177,0.00019458184,0.0003340221,0.00017620545,0.0001122248,0.00004025653,0.00060860266,0.0000020294392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002633947,0.00023447633,0.008657267,0.00039746144,0.00032393422,0.00005899825,0.0004897796,0.000070257556,0.97966605,0.000001289446,0.0010124692,0.0064540743],"study_design_scores_gemma":[0.0028508832,0.0017844522,0.010309125,0.002990616,0.0002605445,0.0014732189,0.00037113894,0.00013415019,0.97958785,0.000027920489,0.000052229338,0.00015789655],"about_ca_topic_score_codex":0.00008218485,"about_ca_topic_score_gemma":4.4442618e-7,"teacher_disagreement_score":0.006296178,"about_ca_system_score_codex":0.0002482045,"about_ca_system_score_gemma":0.00038400074,"threshold_uncertainty_score":0.76345164},"labels":[],"label_agreement":null},{"id":"W2947096198","doi":"10.1200/jco.2019.37.15_suppl.5521","title":"Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ozmosis Research (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Oncology; PARP inhibitor; BRCA mutation; Progression-free survival; Ovarian cancer; Clinical trial; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Progressive disease; Chemotherapy","score_opus":0.15581672792770404,"score_gpt":0.5288553929845182,"score_spread":0.37303866505681416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947096198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96030456,0.000557149,0.00023362973,0.021376854,0.013398041,0.002386422,0.00017673607,0.00001999152,0.0015466373],"genre_scores_gemma":[0.9834078,0.0011315937,0.0019069073,0.0037358182,0.009292261,0.00006288646,0.000043812106,0.00005254111,0.0003664073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9853333,0.0018792246,0.010372421,0.00062696455,0.0012369696,0.00055108423],"domain_scores_gemma":[0.9862539,0.0052877115,0.005858805,0.0005215319,0.0012977048,0.0007803202],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012463906,0.00038951339,0.004397187,0.0004320704,0.00009912933,0.000013988902,0.00045547617,0.0013044741,0.003036553],"category_scores_gemma":[0.0047223195,0.00031763347,0.0015898118,0.0004885338,0.0007263889,0.00035349952,0.00008927967,0.002793902,0.000018704162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8862453,0.04064291,0.0066759526,0.00007583853,0.0007688312,0.00026593133,0.00029272927,0.000028678749,0.0026214689,0.00031768277,0.0054197866,0.056644857],"study_design_scores_gemma":[0.72395223,0.17211814,0.0040138625,0.00043148044,0.00047177964,0.00009201471,0.00007353837,0.00016256132,0.00047629324,0.00041706627,0.09755078,0.00024025883],"about_ca_topic_score_codex":0.00007266093,"about_ca_topic_score_gemma":0.00013265651,"teacher_disagreement_score":0.16229312,"about_ca_system_score_codex":0.00033059705,"about_ca_system_score_gemma":0.010325395,"threshold_uncertainty_score":0.999992},"labels":[],"label_agreement":null},{"id":"W2947120195","doi":"10.1200/jco.2019.37.15_suppl.5539","title":"Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Adverse effect; Internal medicine; Neutropenia; Nausea; Placebo; Vomiting; Anemia; Surgery; Oncology; Gastroenterology; Chemotherapy","score_opus":0.04655180867685195,"score_gpt":0.4359048671981457,"score_spread":0.38935305852129376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947120195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932672,0.00015717033,0.0003819546,0.0029779233,0.0011772489,0.0013819975,0.000013006352,0.000011611804,0.0006319061],"genre_scores_gemma":[0.9925413,0.000715326,0.0029840993,0.0029593667,0.00042694458,0.00007232964,0.000010113503,0.000033309054,0.00025721267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963219,0.00039459582,0.0020416963,0.00036684633,0.00052593206,0.0003490388],"domain_scores_gemma":[0.9952055,0.001119729,0.0024579572,0.00023285382,0.00061038625,0.0003735596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014027603,0.00022917717,0.0016010229,0.0001954113,0.000036387373,0.0000053786744,0.00013019539,0.00030030086,0.00022171534],"category_scores_gemma":[0.00074052287,0.00015175853,0.00016334471,0.00027738197,0.00019594081,0.00035951778,0.000023903034,0.0009629588,0.000012170121],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5816995,0.005913096,0.23599328,0.00005480715,0.0004417805,0.0008546471,0.00056485576,0.0003893976,0.000119695396,0.00004967628,0.00068583555,0.17323342],"study_design_scores_gemma":[0.75282025,0.05398756,0.18107326,0.00095819304,0.00022838073,0.00013636221,0.00034441304,0.00019765433,0.000049310744,0.00012575761,0.009880317,0.00019856471],"about_ca_topic_score_codex":0.00009424126,"about_ca_topic_score_gemma":0.0004236359,"teacher_disagreement_score":0.17303485,"about_ca_system_score_codex":0.00049659965,"about_ca_system_score_gemma":0.0018874703,"threshold_uncertainty_score":0.61885333},"labels":[],"label_agreement":null},{"id":"W2947529777","doi":"10.1200/jco.2019.37.15_suppl.tps5609","title":"NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Oncology; Ovarian cancer; Clinical endpoint; Endometrial cancer; Randomized controlled trial; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","score_opus":0.21656716718570007,"score_gpt":0.4681063172353258,"score_spread":0.25153915004962574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947529777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897263,0.0016626731,0.00016104974,0.0027337067,0.0022724003,0.0030070047,0.0000096061685,0.000010536291,0.00041671525],"genre_scores_gemma":[0.9973121,0.000955571,0.0005080074,0.0005984389,0.0003801032,0.000114975286,0.0000031577254,0.000028354149,0.000099277386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99130255,0.0028980316,0.0041014017,0.00035946342,0.0009477477,0.00039077943],"domain_scores_gemma":[0.98667,0.008135397,0.0039440203,0.0002933739,0.0006262471,0.00033095406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013413241,0.00028906955,0.004602538,0.000432872,0.00008519793,0.00002645737,0.00024265853,0.0001576635,0.0003174983],"category_scores_gemma":[0.0041325246,0.000158096,0.00052693236,0.0005620355,0.0006693681,0.00017639753,0.000091340946,0.0010605125,0.0000025107388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9294261,0.024578592,0.0050384197,0.0001401064,0.00295406,0.0001366646,0.0067718388,0.00019065714,0.0010382136,0.00005776162,0.00021174565,0.029455893],"study_design_scores_gemma":[0.8796871,0.1077991,0.0023063333,0.00062476395,0.001761932,0.0001645729,0.0040985635,0.0010995946,0.0001559842,0.000111053625,0.0020157464,0.00017529391],"about_ca_topic_score_codex":0.00009426274,"about_ca_topic_score_gemma":0.00013465401,"teacher_disagreement_score":0.083220504,"about_ca_system_score_codex":0.00095700286,"about_ca_system_score_gemma":0.0010925512,"threshold_uncertainty_score":0.6446968},"labels":[],"label_agreement":null},{"id":"W2947644019","doi":"10.1200/jco.2019.37.15_suppl.9022","title":"A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; PALB2; FANCA; Population; CHEK2; Cancer; Internal medicine; Oncology; Carboplatin; Cancer research; Chemotherapy; Fanconi anemia; DNA repair; Mutation; Germline mutation; Gene; Cisplatin; Genetics","score_opus":0.034810740560160626,"score_gpt":0.42832962319926315,"score_spread":0.3935188826391025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947644019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994145,0.00041155936,0.000030701838,0.0004761719,0.0015195668,0.0025432585,0.000025915633,0.000021226613,0.00082663127],"genre_scores_gemma":[0.9986898,0.000071425064,0.00018032332,0.0004651289,0.00017716213,0.0000464656,0.000008541098,0.00003685006,0.00032432878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993909,0.0011708785,0.0032147616,0.00046716558,0.00086508424,0.0003731222],"domain_scores_gemma":[0.9933321,0.0012551278,0.0034431822,0.00039821235,0.001315905,0.0002554571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003181413,0.00026905505,0.001944778,0.00040616578,0.00007542734,0.000007329398,0.00023656627,0.00032294486,0.00028556603],"category_scores_gemma":[0.0005421787,0.00020285469,0.00030253537,0.0004517046,0.00017270661,0.00023168189,0.000088183835,0.0013396734,0.000006038074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023484834,0.10596542,0.8624721,0.00008915488,0.0002658013,0.0004260626,0.0023571937,0.0002117497,0.00017185064,0.000008794966,0.0010036172,0.003543428],"study_design_scores_gemma":[0.12902819,0.25653678,0.6114205,0.0001767628,0.00051653234,0.000020236565,0.001386159,0.0002884102,0.00018451907,0.000017233962,0.00023515728,0.00018950575],"about_ca_topic_score_codex":0.000244903,"about_ca_topic_score_gemma":0.0003065105,"teacher_disagreement_score":0.2510516,"about_ca_system_score_codex":0.0009117255,"about_ca_system_score_gemma":0.0017239245,"threshold_uncertainty_score":0.8272174},"labels":[],"label_agreement":null},{"id":"W2947750347","doi":"10.1200/jco.2019.37.15_suppl.5551","title":"Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Oncology; Ovarian cancer; Placebo; BRCA mutation; Progression-free survival; Cancer; Chemotherapy; Pathology","score_opus":0.09327385480056455,"score_gpt":0.49854041473171123,"score_spread":0.4052665599311467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947750347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862246,0.00029604815,0.0011385557,0.006825823,0.002841176,0.0022531932,0.000051083774,0.000006083248,0.00036341845],"genre_scores_gemma":[0.99007577,0.00081612973,0.001351472,0.0065000937,0.00072709663,0.00012122292,0.000022073027,0.000023965214,0.00036217156],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99533534,0.00053042435,0.0031361931,0.00025387472,0.00044851087,0.00029565688],"domain_scores_gemma":[0.9865822,0.009087345,0.0032166806,0.00025778392,0.00068973756,0.00016623968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034597036,0.00016618198,0.0015605789,0.00011602152,0.000032576394,0.000007813676,0.00028184376,0.00033288097,0.00037268698],"category_scores_gemma":[0.006555063,0.000098271055,0.00044713763,0.00024489805,0.00017232077,0.00017836374,0.000018136063,0.0007385461,0.000006956945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6256917,0.011865123,0.0024591943,0.00006504293,0.00031852318,0.00008563999,0.00065531797,0.00018646421,0.000980619,0.00018370272,0.043418918,0.31408972],"study_design_scores_gemma":[0.8279894,0.0506786,0.01422487,0.00039433673,0.00023194226,0.000033231958,0.0002286447,0.00020027328,0.00030833972,0.00062775344,0.104946114,0.00013650145],"about_ca_topic_score_codex":0.000047040437,"about_ca_topic_score_gemma":0.00008373698,"teacher_disagreement_score":0.31395322,"about_ca_system_score_codex":0.00031177292,"about_ca_system_score_gemma":0.0016465536,"threshold_uncertainty_score":0.7847496},"labels":[],"label_agreement":null},{"id":"W2947836162","doi":"10.1200/jco.2019.37.15_suppl.5522","title":"Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Dysgeusia; Internal medicine; Clinical endpoint; Adverse effect; Anemia; Oncology; Placebo; Population; Nausea; BRCA mutation; Clinical trial; Surgery; Cancer; Ovarian cancer; Pathology","score_opus":0.08156899300859487,"score_gpt":0.4479196416337377,"score_spread":0.3663506486251428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947836162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996889,0.000055599055,0.000015809153,0.0013495455,0.0005554617,0.0008421107,0.00020208456,0.0000022253453,0.00008816525],"genre_scores_gemma":[0.9991689,0.00003144615,0.00009882264,0.0005565322,0.0000728938,0.000003690801,0.000049740927,0.000010470416,0.0000075485495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99508524,0.0020267845,0.0019131006,0.0002841726,0.00054762437,0.00014308398],"domain_scores_gemma":[0.99131674,0.0047977436,0.00269237,0.00073356915,0.00035745703,0.00010211001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036349753,0.0001628329,0.0018780163,0.00013275765,0.000032427168,0.0000044113995,0.0003112241,0.00015233364,0.000051999832],"category_scores_gemma":[0.0015195147,0.00006908082,0.00020828561,0.00044267136,0.00029030783,0.00009745854,0.00013640574,0.00086259155,0.0000012554171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059662156,0.002844578,0.9221982,0.000007368104,0.0017503841,0.000034076857,0.0005334635,0.00002584074,0.000049317692,0.000005196337,0.00026078123,0.012628654],"study_design_scores_gemma":[0.045717496,0.03985663,0.9112468,0.00029944992,0.0015163661,0.0000031302873,0.0005018489,0.0003380985,0.0001925304,0.000007479644,0.00025824172,0.00006194298],"about_ca_topic_score_codex":0.00006513543,"about_ca_topic_score_gemma":0.0001701556,"teacher_disagreement_score":0.03701205,"about_ca_system_score_codex":0.00012241853,"about_ca_system_score_gemma":0.0003750626,"threshold_uncertainty_score":0.37475792},"labels":[],"label_agreement":null},{"id":"W2947842052","doi":"10.1200/jco.2019.37.15_suppl.e12567","title":"Associations with response to poly (ADP-ribose) polymerase (PARP) inhibitors in metastatic breast cancer: Results of a meta-regression analysis.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; BRCA mutation; Oncology; Breast cancer; Internal medicine; Metastatic breast cancer; Chemotherapy; Germline; Meta-analysis; Cancer; Germline mutation; PARP inhibitor; Mutation; Poly ADP ribose polymerase; Polymerase; Genetics; Biology","score_opus":0.11975684818303342,"score_gpt":0.4893155801934462,"score_spread":0.3695587320104128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947842052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94178885,0.0009832273,0.00014295294,0.055492636,0.0005559818,0.00038570786,0.00031391767,0.000008544674,0.0003281642],"genre_scores_gemma":[0.99276114,0.00020137074,0.0030914184,0.0029923862,0.00040839298,0.000016989476,0.000009930131,0.000022244642,0.00049614743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925848,0.0019496105,0.003981757,0.0003260825,0.00085399474,0.0003037493],"domain_scores_gemma":[0.98885375,0.0052688285,0.004151755,0.0003940237,0.0008481239,0.00048350397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008845587,0.00022778439,0.0037205494,0.0010303581,0.000028508874,0.000008301128,0.00019491804,0.00025365973,0.0004097585],"category_scores_gemma":[0.0027595176,0.00013511619,0.0010688532,0.0017076744,0.00014590278,0.00016775445,0.000039737944,0.00089732104,0.000013979472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37305838,0.0070554903,0.5180879,0.000060090268,0.03628292,0.0009637873,0.0015327759,0.003975429,0.01755219,0.00005924618,0.011668934,0.029702831],"study_design_scores_gemma":[0.039125793,0.014974401,0.91615707,0.00050659984,0.01334658,0.00022221237,0.0003165582,0.00014422006,0.0036054507,0.00008100789,0.011258219,0.00026190066],"about_ca_topic_score_codex":0.00053244253,"about_ca_topic_score_gemma":0.00061627576,"teacher_disagreement_score":0.3980691,"about_ca_system_score_codex":0.0005505191,"about_ca_system_score_gemma":0.003359521,"threshold_uncertainty_score":0.5959646},"labels":[],"label_agreement":null},{"id":"W2947961029","doi":"10.1002/cncr.32079","title":"High <i>EMSY</i> expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Cancer Research UK","keywords":"Medicine; Hazard ratio; Chemotherapy; Internal medicine; Serous fluid; Oncology; Cohort; Ovarian carcinoma; Phenotype; Cancer research; Ovarian cancer; Cancer; Confidence interval; Gene; Biology; Genetics","score_opus":0.017016815929336685,"score_gpt":0.25517128386961097,"score_spread":0.23815446794027428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947961029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586236,0.00037133278,0.00015312269,0.0015584282,0.0005710463,0.0008736798,0.00011377966,0.0000625971,0.00043364055],"genre_scores_gemma":[0.99646044,0.00003904937,0.0016147824,0.00095219765,0.00027679783,0.00012228414,0.000025513302,0.000050496856,0.00045846103],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99855614,0.00007327886,0.00023985041,0.00046389428,0.00036672023,0.0003001053],"domain_scores_gemma":[0.9990014,0.000085756765,0.00014081462,0.00041923177,0.00016640588,0.00018641063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001467001,0.00023266276,0.0005517775,0.000095237825,0.000052834504,0.00001290893,0.000063048385,0.00011510582,0.00012805095],"category_scores_gemma":[0.000012628931,0.00018426895,0.00004491029,0.0002525033,0.000101136946,0.000100591875,0.000043150307,0.00018737084,0.000011432204],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043098824,0.00014217616,0.295566,0.0003405746,0.000102652164,0.000059917886,0.0011878205,0.00014471408,0.69455045,0.00035224052,0.0012208958,0.0020226385],"study_design_scores_gemma":[0.011373811,0.0011750996,0.641678,0.000852135,0.00012452803,0.00012485159,0.00029663075,0.000053894513,0.34083,0.00008429729,0.0029620228,0.00044477682],"about_ca_topic_score_codex":0.0016960459,"about_ca_topic_score_gemma":0.00041149545,"teacher_disagreement_score":0.3537205,"about_ca_system_score_codex":0.00012894071,"about_ca_system_score_gemma":0.0001707468,"threshold_uncertainty_score":0.751427},"labels":[],"label_agreement":null},{"id":"W2947993621","doi":"10.1200/jco.2019.37.15_suppl.tps5603","title":"ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Carboplatin; Oncology; Tolerability; Internal medicine; Olaparib; BRCA mutation; Debulking; Placebo; Chemotherapy; Gynecology; Surgery; Cancer; Adverse effect; Immunotherapy; Pathology","score_opus":0.07951074915557566,"score_gpt":0.45804426383334607,"score_spread":0.3785335146777704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947993621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984636,0.0005777472,0.00093647774,0.0032059988,0.00079757784,0.009433621,0.000070712806,0.0000147230285,0.00032710584],"genre_scores_gemma":[0.9918376,0.004314971,0.0014460701,0.00049339404,0.0006925392,0.00068210217,0.0000111566615,0.000056183046,0.00046597727],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939962,0.0005473863,0.004083753,0.00046200512,0.0005108168,0.0003998263],"domain_scores_gemma":[0.98684657,0.0053426595,0.0057757,0.00037900632,0.0013011412,0.00035491568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002446315,0.0004145897,0.007292719,0.00026100085,0.00006239382,0.000009053909,0.00019048937,0.00037169177,0.00031796785],"category_scores_gemma":[0.00049104955,0.00025154912,0.00078218087,0.00022031968,0.0004695091,0.00016591598,0.00001968544,0.00051759975,0.0000022621653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9123033,0.013270389,0.0005642347,0.00008058929,0.0053146565,0.000075866934,0.0014350566,0.0009714399,0.0015082015,0.00004091555,0.00007981036,0.06435552],"study_design_scores_gemma":[0.8948741,0.09354519,0.00032105047,0.0003222116,0.0019252114,0.00014692242,0.0005673067,0.0016229639,0.0024850278,0.000111149,0.0038801958,0.0001986545],"about_ca_topic_score_codex":0.0001607256,"about_ca_topic_score_gemma":0.0003059497,"teacher_disagreement_score":0.0802748,"about_ca_system_score_codex":0.00058671046,"about_ca_system_score_gemma":0.0022608603,"threshold_uncertainty_score":0.9999937},"labels":[],"label_agreement":null},{"id":"W2948947061","doi":"10.1200/jco.18.02238","title":"Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Chemotherapy; Ovarian cancer; Oncology; Complete response; Internal medicine; Cancer","score_opus":0.08218152378833052,"score_gpt":0.43926064476605997,"score_spread":0.3570791209777294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948947061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9430346,0.00012766091,0.00006766291,0.052979764,0.0016862454,0.0018924132,0.000008869251,0.00000553612,0.00019724188],"genre_scores_gemma":[0.9643627,0.0001444743,0.00039031054,0.033588074,0.0012704975,0.0001669501,0.0000018886719,0.000027951572,0.000047174624],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9944699,0.0020436635,0.0020524026,0.00030641616,0.000731753,0.00039588023],"domain_scores_gemma":[0.9947463,0.0031189504,0.001156845,0.0004535793,0.00035149918,0.00017278187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007995066,0.00022395191,0.0011482232,0.00019665858,0.00002941366,0.000020771717,0.00036880968,0.00028457918,0.00066723046],"category_scores_gemma":[0.0008968971,0.000105853345,0.00029406644,0.0005267288,0.00017616466,0.00008857192,0.000018092629,0.001530396,0.000025136706],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7062255,0.0023589388,0.234462,0.0000045125244,0.000094598356,0.00006478202,0.0008835577,0.000135596,0.00003466101,0.00000981074,0.0026576088,0.053068403],"study_design_scores_gemma":[0.21350248,0.03053394,0.61928993,0.0002722278,0.00002208455,0.00000878192,0.00007451654,0.00003724728,0.000037055812,0.000027670438,0.136089,0.00010507322],"about_ca_topic_score_codex":0.000047704867,"about_ca_topic_score_gemma":0.00060928403,"teacher_disagreement_score":0.49272305,"about_ca_system_score_codex":0.00041364777,"about_ca_system_score_gemma":0.0019844119,"threshold_uncertainty_score":0.73057055},"labels":[],"label_agreement":null},{"id":"W2949261846","doi":"10.1139/bcb-2018-0345","title":"Serum-dependent and -independent regulation of PARP2","year":2019,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Western University","funders":"","keywords":"Biology; Cell biology; Embryonic stem cell; Chromatin; DNA damage; Gene; Biochemistry; DNA","score_opus":0.009094858188142232,"score_gpt":0.2522124663430903,"score_spread":0.24311760815494807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949261846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884853,0.0015952303,0.000019410632,0.00016830808,0.000066376386,0.00011220689,0.000015981226,0.000011417409,0.00952578],"genre_scores_gemma":[0.9969113,0.00034080105,0.00008900103,0.0001106777,0.000058715683,0.0000048025586,0.000030240437,0.0000048114766,0.0024496359],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995073,0.0000139415615,0.00013680656,0.00019798288,0.00005176929,0.000092219605],"domain_scores_gemma":[0.9996754,0.000022292736,0.0000725079,0.00014469311,0.000031875556,0.000053217005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082959676,0.000074330994,0.00015191155,0.000018146138,0.000014812015,0.0000023330376,0.00002376863,0.00014636671,0.0003448054],"category_scores_gemma":[0.0000047658527,0.00006426339,0.000021458989,0.00002948178,0.000074394506,0.000011665113,0.000023540359,0.000066489134,0.000007189998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011912508,0.000029627528,0.04208604,0.00015334507,0.000013775629,7.3898707e-7,0.00002942231,4.544677e-7,0.9555049,0.0000779442,0.00005767052,0.0019269765],"study_design_scores_gemma":[0.0014040807,0.000154608,0.015579496,0.000028401428,0.0000156548,0.00003606842,0.00007460396,0.000021890315,0.9803121,0.00021230824,0.0020940271,0.00006674254],"about_ca_topic_score_codex":0.000005784806,"about_ca_topic_score_gemma":2.2311845e-7,"teacher_disagreement_score":0.026506543,"about_ca_system_score_codex":0.00001621687,"about_ca_system_score_gemma":0.000028881223,"threshold_uncertainty_score":0.3775377},"labels":[],"label_agreement":null},{"id":"W2951058429","doi":"10.1093/annonc/mdz192","title":"A decade of clinical development of PARP inhibitors in perspective","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":730,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundación Fero; Institute of Cancer Research; Prostate Cancer Foundation; Cancer Research UK; National Institute on Handicapped Research; Department of Health and Aged Care, Australian Government; Instituto de Salud Carlos III; National Institute for Health and Care Research","keywords":"Medicine; Perspective (graphical); Intensive care medicine; Medical physics; Artificial intelligence","score_opus":0.5086532471183037,"score_gpt":0.6122749549852945,"score_spread":0.10362170786699076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951058429","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018688104,0.98581624,0.000008455545,0.00035382994,0.00045972917,0.0010191533,0.000033240536,0.0000070972724,0.0104334215],"genre_scores_gemma":[0.0012388318,0.99668473,0.0014237734,0.00021037536,0.0001884124,0.00007351047,0.000024913843,0.000031940726,0.00012352443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955678,0.000450219,0.0030533196,0.00038785255,0.00029717997,0.00024360286],"domain_scores_gemma":[0.99578756,0.0009679334,0.0021891622,0.0003773144,0.0005822388,0.0000957911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017615033,0.00025394716,0.004792005,0.0004991971,0.000007580404,6.6463434e-7,0.00019353704,0.0008054019,0.00013696858],"category_scores_gemma":[0.000559534,0.00021086553,0.0007149464,0.0004145347,0.00032146845,0.000026878522,0.00007814182,0.0005912249,0.000025959462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003151231,0.0009869501,0.0003926357,0.009357343,0.0005856875,0.000017121729,0.0008920785,3.8032817e-7,0.000008866622,0.00036413714,0.0025283054,0.98455137],"study_design_scores_gemma":[0.0017962322,0.002001109,0.00040066673,0.016363904,0.00022866963,0.000024067305,0.00023528261,3.218567e-7,0.00049987726,0.00011594562,0.97818655,0.0001473472],"about_ca_topic_score_codex":0.000036995563,"about_ca_topic_score_gemma":0.000027948963,"teacher_disagreement_score":0.984404,"about_ca_system_score_codex":0.00022724818,"about_ca_system_score_gemma":0.006034455,"threshold_uncertainty_score":0.9996004},"labels":[],"label_agreement":null},{"id":"W2951114010","doi":"10.1038/s41467-019-10460-1","title":"Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","year":2019,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":218,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Institut Du Cancer de Montréal; Institute of Cancer Research; Terry Fox Research Institute; Cancer Research Society","keywords":"Senescence; Synthetic lethality; Poly ADP ribose polymerase; Cancer; Cancer cell; Computational biology; Biology; Chemistry; Cell biology; Cancer research; DNA repair; Genetics; DNA; Polymerase","score_opus":0.03698215318576393,"score_gpt":0.3457667546787226,"score_spread":0.30878460149295867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951114010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9596212,0.0066653746,0.00038186126,0.011689939,0.00035579395,0.00068355375,0.00008446579,0.00019574765,0.020322043],"genre_scores_gemma":[0.9933284,0.002731931,0.0022353427,0.00072088954,0.0001236179,0.000109131,0.00015333449,0.000029268938,0.00056810764],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895835,0.00013650849,0.0002789925,0.00027383547,0.00016539208,0.00018689578],"domain_scores_gemma":[0.9980314,0.00039557595,0.00013197819,0.0011023025,0.00023255093,0.0001062075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016955577,0.00015187176,0.0002418298,0.00011670039,0.00021017365,0.0000308672,0.00020972827,0.00019551176,0.00038323336],"category_scores_gemma":[0.00007657134,0.00015543823,0.00007185373,0.00029117937,0.00010448305,0.00031371083,0.00017922217,0.0010885831,0.00006427704],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033606158,0.0009990396,0.25997117,0.0007622432,0.0005199675,0.000014642039,0.008346735,0.00005153704,0.6897357,0.0071393657,0.012110329,0.020013196],"study_design_scores_gemma":[0.019107725,0.0011236914,0.111541346,0.015723087,0.0019128632,0.00086947245,0.024353389,0.017003529,0.3612605,0.0025595753,0.44102627,0.0035185278],"about_ca_topic_score_codex":0.00018638172,"about_ca_topic_score_gemma":0.00023873868,"teacher_disagreement_score":0.42891595,"about_ca_system_score_codex":0.00029253014,"about_ca_system_score_gemma":0.000094718154,"threshold_uncertainty_score":0.6338587},"labels":[],"label_agreement":null},{"id":"W2953786622","doi":"10.1038/s41467-019-10741-9","title":"Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks","year":2019,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome Canada; Université de Montréal; Centre hospitalier universitaire de Québec; University of Alberta; Université Laval","funders":"National Institute of General Medical Sciences; CIHR Skin Research Training Centre; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Government of Canada; University of Pennsylvania; Cancer Prevention and Research Institute of Texas; Welch Foundation","keywords":"Poly ADP ribose polymerase; DNA; Polymerase; DNA repair; Homologous recombination; DNA damage; Chromatin; PARP inhibitor; Molecular biology; Replication protein A; Biology; Chemistry; Cell biology; Genetics; DNA-binding protein; Gene; Transcription factor","score_opus":0.027204463734246218,"score_gpt":0.3447171171856746,"score_spread":0.3175126534514284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953786622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7301066,0.07462596,0.00008289832,0.062191907,0.0017648011,0.0017880407,0.00021669272,0.0005619109,0.12866117],"genre_scores_gemma":[0.98960316,0.0016628089,0.00077426754,0.0020385925,0.0003262125,0.0000835595,0.00054876,0.000045692836,0.0049169487],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862397,0.00011069896,0.00032693808,0.00030848468,0.00035343808,0.00027648752],"domain_scores_gemma":[0.99664736,0.00017238206,0.00012458919,0.0026836896,0.00021837454,0.0001536172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022201179,0.00019904718,0.00029021187,0.00019789979,0.00036691342,0.00003455944,0.0005239101,0.00045429813,0.0007874003],"category_scores_gemma":[0.00002891495,0.00018827771,0.00015234147,0.00048041597,0.00015441443,0.00016795614,0.00018417966,0.0012235116,0.000388933],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010364695,0.0020041373,0.08529665,0.00030981618,0.0010848873,0.000020814683,0.002587239,0.000020672742,0.73248607,0.028284678,0.12524997,0.012290362],"study_design_scores_gemma":[0.016778652,0.0005089546,0.025826406,0.00045165824,0.00022626863,0.00049513445,0.00034385128,0.0008531562,0.23965901,0.00031627718,0.71385545,0.0006852133],"about_ca_topic_score_codex":0.00013209505,"about_ca_topic_score_gemma":0.0004893985,"teacher_disagreement_score":0.58860546,"about_ca_system_score_codex":0.00034331164,"about_ca_system_score_gemma":0.00015123408,"threshold_uncertainty_score":0.8621481},"labels":[],"label_agreement":null},{"id":"W2954169217","doi":"10.1016/j.ygyno.2019.04.016","title":"Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT24-OV16/NOVA trial","year":2019,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Placebo; Toxicity; Ovarian cancer; Quality of life (healthcare); Internal medicine; Oncology; Clinical trial; Gynecology; Cancer; Pathology","score_opus":0.03176221160617492,"score_gpt":0.3358377955198109,"score_spread":0.304075583913636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954169217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99009067,0.000046160898,0.00001124618,0.0009424236,0.0015986591,0.0032575247,0.00009956708,0.000042802363,0.0039109197],"genre_scores_gemma":[0.9971257,0.0000680358,0.0002668159,0.00048493734,0.000098583245,0.000537076,0.000049842707,0.00002391522,0.0013451332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734324,0.00047625843,0.0006818178,0.0006140961,0.0003624341,0.0005221687],"domain_scores_gemma":[0.99742234,0.00097334996,0.00064842706,0.0006455205,0.00020100034,0.00010937875],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004968594,0.00032229206,0.001343423,0.0003053988,0.00006542364,0.0000089759915,0.00023931472,0.0003023228,0.004392539],"category_scores_gemma":[0.0003258099,0.00017829942,0.00023531854,0.0013674961,0.00028935756,0.00006310056,0.000069880334,0.00032486368,0.000037505244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3832473,0.0033745335,0.58856165,0.000035716857,0.0031032006,0.000019112322,0.0011363091,0.0011000212,0.0003119759,0.00006171248,0.0004947203,0.01855376],"study_design_scores_gemma":[0.29676685,0.032914326,0.6594246,0.00018768346,0.0018839783,0.0000034389136,0.0001643488,0.0010674811,0.00031900307,0.000015623229,0.0069019254,0.00035075122],"about_ca_topic_score_codex":0.00031156998,"about_ca_topic_score_gemma":0.005688313,"teacher_disagreement_score":0.08648044,"about_ca_system_score_codex":0.0037701207,"about_ca_system_score_gemma":0.0010728291,"threshold_uncertainty_score":0.9965176},"labels":[],"label_agreement":null},{"id":"W2954523493","doi":"10.1200/jco.19.03107","title":"Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Medicine; Placebo; Internal medicine; Adverse effect; Nausea; Population; Cohort; Clinical endpoint; Surgery; Randomized controlled trial; Pathology","score_opus":0.08038333448786252,"score_gpt":0.4210685781791244,"score_spread":0.3406852436912619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954523493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860938,0.0001227786,0.0001737496,0.0075207828,0.0012312691,0.0043661185,0.000015859125,0.0000053329577,0.00047027555],"genre_scores_gemma":[0.99670035,0.00015821631,0.0008049308,0.0018197171,0.00030400686,0.00015651272,0.000007996672,0.000017891676,0.00003035519],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921573,0.0014411643,0.005341207,0.00027656907,0.0004963347,0.0002874356],"domain_scores_gemma":[0.99222076,0.0030265448,0.0038205874,0.00019757092,0.00036330035,0.00037126287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002148404,0.00024879078,0.0057167863,0.00021868244,0.000014841435,0.000005523978,0.00012534959,0.00025691997,0.00010860486],"category_scores_gemma":[0.0038855693,0.00014350683,0.00087155285,0.00019935983,0.00025428244,0.00007719506,0.00002349594,0.00072120136,0.000001916185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87725025,0.015520278,0.08183074,0.000013640474,0.00064280606,0.0002545855,0.00081990735,0.000020625459,0.0000067707874,0.000031348245,0.00016566219,0.023443365],"study_design_scores_gemma":[0.8987293,0.08312267,0.016100107,0.00018297712,0.00036071092,0.000008699817,0.00010721557,0.00025104324,0.000020251717,0.00006514673,0.0009470151,0.000104838735],"about_ca_topic_score_codex":0.000056610552,"about_ca_topic_score_gemma":0.000071734656,"teacher_disagreement_score":0.067602396,"about_ca_system_score_codex":0.0004985733,"about_ca_system_score_gemma":0.0017387314,"threshold_uncertainty_score":0.5852039},"labels":[],"label_agreement":null},{"id":"W2954686273","doi":"10.1158/1538-7445.am2019-ct158","title":"Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Nivolumab; Oncology; Internal medicine; Chemotherapy; Debulking; PARP inhibitor; BRCA mutation; Cancer; Cancer research; Immunotherapy; Poly ADP ribose polymerase; Biology","score_opus":0.08737768898067304,"score_gpt":0.44119662403155485,"score_spread":0.3538189350508818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954686273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725346,0.0034591286,0.00018493879,0.0016421055,0.0007434973,0.018323248,0.0000754064,0.000087862216,0.002949242],"genre_scores_gemma":[0.986302,0.0005193494,0.00014526595,0.00039576154,0.00069767446,0.0094539635,0.00005060991,0.00017770029,0.0022576563],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923061,0.0007436644,0.0018891628,0.0012240646,0.0024943142,0.0013426582],"domain_scores_gemma":[0.99548817,0.0014752903,0.000576189,0.0013235493,0.0007098212,0.00042700104],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006371867,0.0006240837,0.0031556683,0.0012401823,0.00021074229,0.000092104594,0.0006196982,0.0003752157,0.008477651],"category_scores_gemma":[0.00019491895,0.00053223246,0.0006860889,0.0012468265,0.0003406813,0.00028243856,0.00008459274,0.0017428041,0.000084193554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91917217,0.0034123228,0.0035983212,0.00028868072,0.0015096474,0.00009694825,0.005111808,0.0018140809,0.06076456,0.00004691368,0.00090142764,0.003283131],"study_design_scores_gemma":[0.9651235,0.001322955,0.0002586832,0.0013346958,0.0002014029,0.0000034430002,0.0016615109,0.0029727276,0.025851723,0.00009163693,0.0007034875,0.00047428507],"about_ca_topic_score_codex":0.018453747,"about_ca_topic_score_gemma":0.0034434167,"teacher_disagreement_score":0.04595129,"about_ca_system_score_codex":0.001741427,"about_ca_system_score_gemma":0.0026928284,"threshold_uncertainty_score":0.99971294},"labels":[],"label_agreement":null},{"id":"W2955535371","doi":"10.1073/pnas.1908547116","title":"Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function","year":2019,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Army","keywords":"FOXA1; Prostate cancer; Cancer research; Poly ADP ribose polymerase; Androgen receptor; DNA repair; Biology; Transcription factor; PARP inhibitor; Cancer; Cell biology; Genetics; Gene; Polymerase","score_opus":0.0319409483270281,"score_gpt":0.32125836023919524,"score_spread":0.28931741191216714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955535371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652416,0.00064565084,0.0000031766926,0.0012305764,0.00003287374,0.00043484557,0.00003069322,0.000007950271,0.0010901031],"genre_scores_gemma":[0.99839956,0.00028396043,0.0010271074,0.00013616118,0.00007083616,0.000021296955,6.3700355e-7,0.0000060273824,0.000054397155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833435,0.000009556668,0.00042418702,0.00022857614,0.00088321103,0.00012009819],"domain_scores_gemma":[0.9982515,0.000090170775,0.0008177805,0.000007167094,0.00080929144,0.000024103381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092483516,0.00009183497,0.00024275995,0.0001221799,0.000076246564,0.0000057546804,0.00012151601,0.000074762334,0.000032253123],"category_scores_gemma":[0.00020988956,0.000064165404,0.00006009743,0.0007407507,0.00050012826,0.0004956973,0.000042928383,0.00013621076,4.0213067e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023761278,0.00003707754,0.08552128,0.00039020635,0.000039085327,8.189785e-10,0.0010779153,0.00006246942,0.90781534,0.0044361143,0.00018881669,0.00019408342],"study_design_scores_gemma":[0.0005929964,0.00023212988,0.021590445,0.00067038793,0.000029056411,0.0000023485597,0.0005279494,0.0002097031,0.96058244,0.015454219,0.00004596591,0.00006233804],"about_ca_topic_score_codex":0.000020405167,"about_ca_topic_score_gemma":5.504155e-8,"teacher_disagreement_score":0.06393084,"about_ca_system_score_codex":0.00006147031,"about_ca_system_score_gemma":0.00007286929,"threshold_uncertainty_score":0.26165894},"labels":[],"label_agreement":null},{"id":"W2955546107","doi":"10.1158/1538-7445.am2019-ct025","title":"Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Neutropenia; Tolerability; Internal medicine; Nausea; Gastroenterology; Anemia; Vomiting; Toxicity; Refractory (planetary science); Adverse effect","score_opus":0.056301588110646575,"score_gpt":0.4262352520521331,"score_spread":0.3699336639414865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955546107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604475,0.000080029036,0.0000028385998,0.00012867937,0.000049532173,0.0027439245,0.000013518703,0.000016762368,0.0009199634],"genre_scores_gemma":[0.99933815,0.000023108765,0.000018066252,0.000034119545,0.000033834633,0.0003214837,0.000049663297,0.000036567228,0.0001449833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99737084,0.00016990231,0.0004390479,0.00039364715,0.0012573014,0.000369267],"domain_scores_gemma":[0.9985802,0.00012277252,0.0001583988,0.00041824477,0.0006189251,0.00010141727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076076924,0.00014649647,0.00038137418,0.0006457693,0.000036930065,0.000016684206,0.00012481786,0.00007538391,0.00037118065],"category_scores_gemma":[0.000042318345,0.000115988645,0.000018201872,0.0009772416,0.00010577201,0.00029749813,0.000027031329,0.00065790635,0.000017440621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018722063,0.009351571,0.94978684,0.00022345751,0.000050091017,0.000026991975,0.0036188697,0.00035514648,0.011834351,0.000015592079,0.00011073574,0.00590431],"study_design_scores_gemma":[0.055078417,0.008995674,0.92768735,0.0011753383,0.000007752506,5.546258e-7,0.0012164019,0.000092418406,0.0054902527,0.000022289223,0.000101679325,0.00013188581],"about_ca_topic_score_codex":0.0013802812,"about_ca_topic_score_gemma":0.0010860804,"teacher_disagreement_score":0.036356356,"about_ca_system_score_codex":0.000927933,"about_ca_system_score_gemma":0.0005335725,"threshold_uncertainty_score":0.47298795},"labels":[],"label_agreement":null},{"id":"W2955997569","doi":"10.1093/jjco/hyz085","title":"An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION","year":2019,"lang":"en","type":"article","venue":"Japanese Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Durvalumab; Olaparib; Oncology; Gynecologic oncology; Internal medicine; Clinical endpoint; Ovarian cancer; Biomarker; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Chemotherapy; Targeted therapy; Clinical trial; Cancer; Nivolumab; Phases of clinical research","score_opus":0.0878502810883729,"score_gpt":0.4397574802038167,"score_spread":0.3519071991154438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955997569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949992,0.00007118188,0.000007679092,0.0005768729,0.0010262507,0.0029825908,0.000013011003,0.000023656374,0.00029960577],"genre_scores_gemma":[0.9982203,0.00014726432,0.0006035194,0.0006105143,0.00024988496,0.00009859768,0.000018773882,0.000040089948,0.000011020604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914491,0.0031031033,0.0035775949,0.00057389785,0.00085368054,0.000442592],"domain_scores_gemma":[0.99302465,0.0018933937,0.0031609952,0.0005356348,0.0009879549,0.00039736708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004017949,0.00034198555,0.0024718998,0.00046920858,0.00006574314,0.0000115886705,0.00038521554,0.00040911022,0.0006214491],"category_scores_gemma":[0.0004001762,0.00023149254,0.00022368324,0.00067586475,0.00025130148,0.00023939014,0.00005168486,0.0010994363,0.000008541925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080105074,0.05515864,0.8028031,0.000019999394,0.0006643853,0.00025501574,0.0043275882,0.0001681188,0.0043838974,0.000006228831,0.00005736414,0.05205058],"study_design_scores_gemma":[0.0727916,0.24778892,0.6743348,0.000093582115,0.00013470938,0.000024161423,0.0041796775,0.00011844397,0.000031163152,0.000032269938,0.00030967902,0.00016095788],"about_ca_topic_score_codex":0.00038613382,"about_ca_topic_score_gemma":0.0020221022,"teacher_disagreement_score":0.19263028,"about_ca_system_score_codex":0.0008233502,"about_ca_system_score_gemma":0.0009516986,"threshold_uncertainty_score":0.9439992},"labels":[],"label_agreement":null},{"id":"W2956115948","doi":"10.3233/jad-190269","title":"Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 Diabetes Patients with Mild Cognitive Impairment","year":2019,"lang":"en","type":"article","venue":"Journal of Alzheimer s Disease","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cognitive impairment; Type 2 diabetes; Cognition; Memory impairment; Medicine; Diabetes mellitus; Psychology; Audiology; Neuroscience; Endocrinology","score_opus":0.03174828632413355,"score_gpt":0.29180689562717266,"score_spread":0.2600586093030391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956115948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963562,0.0020713909,0.000004836917,0.0002619192,0.00054923055,0.00046739622,0.000046286525,0.000007303144,0.0002354583],"genre_scores_gemma":[0.9991965,0.000029509369,0.000109999804,0.00037527742,0.00014278808,0.000007928602,0.000022044653,0.000026938913,0.00008899855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998632,0.000060514303,0.00044553462,0.00014746284,0.00053569616,0.00017880723],"domain_scores_gemma":[0.9986254,0.000069179536,0.00043377225,0.00014679277,0.0004923325,0.00023251674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016437728,0.00016058357,0.00036544658,0.00023932842,0.00001813135,0.0000080964455,0.000059227827,0.000040453797,0.0005404018],"category_scores_gemma":[0.00003080672,0.00011163886,0.00010830096,0.00023967771,0.00005446093,0.00024344704,0.000018070865,0.00018597543,0.000014052438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00878683,0.0009454223,0.9870271,0.000082501414,0.00073022454,0.000021236798,0.00022811013,0.00014715908,0.0003958016,0.0000015242528,0.0006978809,0.00093623006],"study_design_scores_gemma":[0.014003322,0.0012766483,0.9805116,0.0010817684,0.0005962697,0.0000022556915,0.000055778506,0.00008025163,0.0021776478,0.000035197972,0.000056777302,0.00012248658],"about_ca_topic_score_codex":0.000005845106,"about_ca_topic_score_gemma":0.0000012442946,"teacher_disagreement_score":0.006515483,"about_ca_system_score_codex":0.000078429926,"about_ca_system_score_gemma":0.0002323806,"threshold_uncertainty_score":0.5917021},"labels":[],"label_agreement":null},{"id":"W2956118764","doi":"10.1158/1538-7445.am2019-300","title":"Abstract 300: A new combination therapy to treat metastatic breast cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Vinorelbine; Eribulin; Vinca alkaloid; Olaparib; Microtubule polymerization; Cancer research; Vinca; Mechanism of action; Tubulin; Medicine; Mitosis; Pharmacology; Microtubule; Breast cancer; Cancer; Chemistry; Poly ADP ribose polymerase; Metastatic breast cancer; Biology; Polymerase; Cell biology; Chemotherapy; Internal medicine; Biochemistry; Vincristine; In vitro; DNA; Cisplatin","score_opus":0.14919311792366122,"score_gpt":0.47943616552378726,"score_spread":0.330243047600126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956118764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96432346,0.0027066255,0.000035517907,0.024236431,0.00037458265,0.0019257483,0.00012473183,0.00008215191,0.0061907736],"genre_scores_gemma":[0.9712064,0.0026447007,0.00011111448,0.0021215333,0.00055325933,0.0007712346,0.000022658285,0.000074391646,0.022494676],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973022,0.00010669514,0.00028098185,0.000515206,0.001155645,0.00063931424],"domain_scores_gemma":[0.9981628,0.00016039802,0.000059456816,0.0005467541,0.00058054255,0.00049003353],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006122115,0.00019927676,0.00036721243,0.00041573748,0.00010835674,0.00007030736,0.00022499925,0.00007662918,0.023407804],"category_scores_gemma":[0.000025099407,0.00016673523,0.00010126315,0.00097648334,0.00008723797,0.00017789338,0.000040134826,0.0005012965,0.0012019079],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004167989,0.00046996013,0.014945554,0.0003047506,0.0002363752,0.000039355942,0.0016079476,0.00016506159,0.6027063,0.00071692804,0.15827417,0.21636556],"study_design_scores_gemma":[0.0328421,0.0019948105,0.38297436,0.0022081118,0.000072848015,0.00011260712,0.0006774006,0.000111841815,0.34571704,0.0026047474,0.22975045,0.00093368505],"about_ca_topic_score_codex":0.005169843,"about_ca_topic_score_gemma":0.00015759049,"teacher_disagreement_score":0.3680288,"about_ca_system_score_codex":0.001201952,"about_ca_system_score_gemma":0.001438385,"threshold_uncertainty_score":0.9995758},"labels":[],"label_agreement":null},{"id":"W2963339930","doi":"10.1634/theoncologist.2019-0272","title":"Chemotherapy Toxicity in <i>BRCA</i> Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Medicine; Neutropenia; BRCA mutation; Chemotherapy; Internal medicine; Germline mutation; Oncology; Ovarian cancer; Absolute neutrophil count; Mitoxantrone; Febrile neutropenia; Toxicity; Germline; Mutation; Cancer; Gastroenterology; Genetics","score_opus":0.02314792721266745,"score_gpt":0.30981821872294474,"score_spread":0.2866702915102773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963339930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95999587,0.00020200193,0.0015016068,0.025808072,0.00036516355,0.0013512693,0.000013608791,0.0001677232,0.010594698],"genre_scores_gemma":[0.97940964,0.00019349689,0.0008601158,0.01818439,0.00024185493,0.0000997667,0.000037284975,0.000052372394,0.0009211075],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983286,0.00011260895,0.00043269503,0.00038242966,0.00036012795,0.0003835058],"domain_scores_gemma":[0.9984597,0.00058699644,0.00023206057,0.00055416714,0.00007632534,0.00009072963],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066120876,0.00025212314,0.00044249065,0.00011349844,0.0001207371,0.00002858706,0.00020923876,0.00019354648,0.0010144378],"category_scores_gemma":[0.000086300155,0.00018809114,0.00013484883,0.00046217418,0.00024844732,0.000087819506,0.000016204287,0.00038438506,0.00012155126],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032462038,0.0049835974,0.44964805,0.0015128187,0.0010180685,0.00046413642,0.015784722,0.09646598,0.23740165,0.0034104604,0.034022264,0.12282621],"study_design_scores_gemma":[0.1571185,0.010332219,0.17241889,0.0020273228,0.00019565805,0.0002878808,0.0033082115,0.043861423,0.4677334,0.0087563535,0.13158871,0.0023714132],"about_ca_topic_score_codex":0.00018832125,"about_ca_topic_score_gemma":0.00067241304,"teacher_disagreement_score":0.27722916,"about_ca_system_score_codex":0.000953765,"about_ca_system_score_gemma":0.00045504599,"threshold_uncertainty_score":0.9998988},"labels":[],"label_agreement":null},{"id":"W2966848497","doi":"10.1074/jbc.ra119.009200","title":"Structural and functional analysis of parameters governing tankyrase-1 interaction with telomeric repeat-binding factor 1 and GDP-mannose 4,6-dehydratase","year":2019,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Office of Extramural Research, National Institutes of Health; Government of Canada; National Institutes of Health; National Cancer Institute; Canadian Institutes of Health Research; National Institute of General Medical Sciences","keywords":"Ankyrin repeat; Plasma protein binding; Biology; Binding domain; Cell biology; Ankyrin; Binding protein; Biochemistry; Binding site","score_opus":0.034448152156046664,"score_gpt":0.2870931859423481,"score_spread":0.25264503378630143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966848497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993313,0.00025802536,0.000068819696,0.000066573906,0.000051991377,0.000051947143,0.00007606839,0.000006057366,0.000089213136],"genre_scores_gemma":[0.99911267,0.000092405484,0.0005701506,0.000051289157,0.00006322349,0.0000010561173,0.000057702986,0.0000050971535,0.00004638997],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99913627,0.000023832486,0.0003557157,0.00016997983,0.00020839278,0.00010582504],"domain_scores_gemma":[0.9989797,0.00016937286,0.0005385003,0.00009521399,0.00010416328,0.0001130552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011954838,0.000120844095,0.00042409598,0.0000805646,0.000028537668,0.000014988248,0.0000330719,0.000093047034,0.00048717114],"category_scores_gemma":[0.0000770661,0.00007450314,0.00010575299,0.00022520212,0.000120119475,0.000103254206,0.000018645746,0.00028473962,7.3108566e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016042332,0.000028727176,0.2955841,0.0000678215,0.0006243008,0.000030352347,0.00005646372,0.00013587579,0.70119244,9.3162635e-7,0.000026331654,0.0006484218],"study_design_scores_gemma":[0.0045746583,0.0017947803,0.58992577,0.0004631428,0.0010602635,0.0022694054,0.0014455474,0.0008653876,0.39683273,0.000026559845,0.00041378455,0.00032797136],"about_ca_topic_score_codex":0.0000041450353,"about_ca_topic_score_gemma":2.1875042e-7,"teacher_disagreement_score":0.30435967,"about_ca_system_score_codex":0.000093146984,"about_ca_system_score_gemma":0.000032482905,"threshold_uncertainty_score":0.53341824},"labels":[],"label_agreement":null},{"id":"W2969815104","doi":"10.1186/s13073-019-0665-3","title":"Identifying chemogenetic interactions from CRISPR screens with drugZ","year":2019,"lang":"en","type":"article","venue":"Genome Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Institute of General Medical Sciences; National Cancer Institute; Canadian Institutes of Health Research; Cancer Prevention and Research Institute of Texas","keywords":"CRISPR; Computational biology; Gene; Drug resistance; Drug discovery; Biology; Bioinformatics; Genetics","score_opus":0.03123001022705107,"score_gpt":0.3184032611629535,"score_spread":0.2871732509359024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969815104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96130806,0.0023822216,0.0033960347,0.008767251,0.0007182974,0.00067539886,0.000026097816,0.00014377681,0.022582866],"genre_scores_gemma":[0.9860369,0.00018980069,0.0027332294,0.0035250806,0.0012445023,0.000042959582,0.00018994407,0.00005499117,0.005982604],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984486,0.00003053166,0.0003363821,0.0004235222,0.00046533952,0.00029562204],"domain_scores_gemma":[0.9985633,0.000089499044,0.00013003277,0.0008485379,0.00015019809,0.00021843919],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014965903,0.000210551,0.00044639895,0.00020211248,0.00006650682,0.00001076198,0.00017030608,0.000054799802,0.0106225675],"category_scores_gemma":[0.00003453374,0.00015673359,0.00006016853,0.00032540804,0.000146345,0.00008506019,0.000047907746,0.0003026208,0.0008661768],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066904665,0.00012482356,0.04004413,0.00012958676,0.0004384802,0.00010528201,0.0034119992,0.00003483573,0.9454869,0.00009648936,0.0066114888,0.0028469076],"study_design_scores_gemma":[0.024734395,0.0022717088,0.65778154,0.0030078539,0.00088569004,0.0006599142,0.006603915,0.00020198207,0.03643154,0.0013482196,0.26526585,0.00080735324],"about_ca_topic_score_codex":0.0005059911,"about_ca_topic_score_gemma":0.00009050088,"teacher_disagreement_score":0.9090554,"about_ca_system_score_codex":0.0001809407,"about_ca_system_score_gemma":0.00008550727,"threshold_uncertainty_score":0.9999118},"labels":[],"label_agreement":null},{"id":"W2972107575","doi":"10.1038/s41416-019-0565-8","title":"Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells","year":2019,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary; Cumming School of Medicine, University of Calgary; National Cancer Institute; U.S. Department of Health and Human Services; Government of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Olaparib; Cancer research; Ataxia-telangiectasia; PARP inhibitor; Poly ADP ribose polymerase; Lung cancer; Adenocarcinoma; Cancer; Biology; Molecular biology; Medicine; DNA damage; Pathology; Polymerase; Genetics; DNA","score_opus":0.006268429481743964,"score_gpt":0.27431340489859357,"score_spread":0.26804497541684963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972107575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85167354,0.14212438,0.00011521623,0.0015647825,0.0022662964,0.0009121346,0.00064485054,0.00011022366,0.00058855116],"genre_scores_gemma":[0.9819114,0.013642241,0.00022421652,0.0015471552,0.00075110426,0.00007628068,0.00013642012,0.00015505949,0.0015561044],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958079,0.00021008302,0.0014006576,0.0006369712,0.0010929508,0.000851451],"domain_scores_gemma":[0.9971247,0.000105938605,0.0011114305,0.00035509394,0.00066824903,0.00063461764],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050622434,0.00051606796,0.0011133049,0.00046755973,0.0002282642,0.00017777375,0.00021382097,0.00034945688,0.0039374777],"category_scores_gemma":[0.000047714027,0.00055685337,0.0003816332,0.0007153108,0.00025115669,0.0005612469,0.00007942962,0.0011241798,0.000057026406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008503275,0.0018887204,0.061166927,0.0016497953,0.0039428407,0.012982912,0.0031896285,0.0018176526,0.6846778,0.00011226218,0.12671533,0.09335287],"study_design_scores_gemma":[0.07105635,0.003285466,0.095308505,0.018561028,0.0025755041,0.024693444,0.001122455,0.003574891,0.7376517,0.00038278976,0.038847424,0.0029404564],"about_ca_topic_score_codex":0.00234068,"about_ca_topic_score_gemma":0.00019111241,"teacher_disagreement_score":0.13023786,"about_ca_system_score_codex":0.0009286372,"about_ca_system_score_gemma":0.000778002,"threshold_uncertainty_score":0.99968827},"labels":[],"label_agreement":null},{"id":"W2972300920","doi":"10.1016/j.neuropharm.2019.107755","title":"Poly(ADP-ribose) polymerase-1 inhibits mitochondrial respiration by suppressing PGC-1α activity in neurons","year":2019,"lang":"en","type":"article","venue":"Neuropharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital; University of Manitoba; Health Sciences Centre","funders":"Research Manitoba","keywords":"TFAM; PARP1; NAD+ kinase; Sirtuin 1; Sirtuin; Coactivator; Biology; Nicotinamide mononucleotide; Nicotinamide adenine dinucleotide; Molecular biology; Poly ADP ribose polymerase; Biochemistry; Transcription factor; Cell biology; Mitochondrion; Chemistry; Polymerase; Mitochondrial biogenesis; DNA; Enzyme","score_opus":0.01787357802489328,"score_gpt":0.3206952173324018,"score_spread":0.30282163930750855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972300920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608524,0.0005118749,0.000058957685,0.006631474,0.0037046636,0.00091018854,0.000053323005,0.00014076055,0.0019035134],"genre_scores_gemma":[0.98721415,0.000077003075,0.000066268374,0.010150812,0.0010446651,0.00008172334,0.000031490537,0.000073411655,0.0012604994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997431,0.000543279,0.000423603,0.0007062535,0.00033609936,0.0005597578],"domain_scores_gemma":[0.99887186,0.00029839957,0.00019131883,0.00037094235,0.0000650972,0.00020238583],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012676592,0.00028933826,0.00047418388,0.0003050647,0.000086237116,0.000029375378,0.00015167246,0.00020828965,0.0015134371],"category_scores_gemma":[0.00007927685,0.0003089615,0.000108821005,0.00042547873,0.00012827716,0.00027777394,0.00007476183,0.0007959234,0.0002795084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024812897,0.00036404896,0.0032422198,0.00004030123,0.000020487447,0.000119448785,0.00009650534,0.000018412338,0.970939,0.000010943522,0.017751839,0.0049155266],"study_design_scores_gemma":[0.010676074,0.0008088589,0.008211898,0.000042394917,0.000045917703,0.00008880823,0.0000065107565,0.0005591491,0.932599,0.000011228792,0.04671127,0.00023888705],"about_ca_topic_score_codex":0.000076735705,"about_ca_topic_score_gemma":0.00000826929,"teacher_disagreement_score":0.038339972,"about_ca_system_score_codex":0.00018541834,"about_ca_system_score_gemma":0.00023103505,"threshold_uncertainty_score":0.9999362},"labels":[],"label_agreement":null},{"id":"W2972664697","doi":"10.1200/jco.19.00917","title":"Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université de Sherbrooke","funders":"","keywords":"Medicine; Toxicity; Internal medicine; Ovarian cancer; Adverse effect; Nausea; Vomiting; Oncology; Cancer; Gastroenterology; Surgery","score_opus":0.12231099046240816,"score_gpt":0.478143250639471,"score_spread":0.3558322601770628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972664697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863674,0.0003975748,0.00004135152,0.006420068,0.0045950655,0.00087716855,0.000054660486,0.0000104695455,0.001236239],"genre_scores_gemma":[0.99552923,0.0011265911,0.00034884128,0.0008347723,0.0011570039,0.000026877387,0.000006661936,0.000021569602,0.000948476],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994226,0.0010316096,0.0033993567,0.0003903192,0.0005718721,0.0003808672],"domain_scores_gemma":[0.99223185,0.0028113048,0.0036331064,0.00057264295,0.0005041662,0.00024696317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036626605,0.00026954646,0.003224113,0.0002757904,0.000031169435,0.000010643452,0.00034753318,0.00038933332,0.0009001686],"category_scores_gemma":[0.0020393843,0.00014846564,0.0011977324,0.001037014,0.00033691953,0.00008143393,0.00005876318,0.00085851137,0.0000130815915],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6206474,0.0048442474,0.29909027,0.00003679469,0.0066251005,0.00008251366,0.00035828416,0.00032273246,0.001462967,0.00008805745,0.0011923427,0.065249346],"study_design_scores_gemma":[0.36016476,0.056237932,0.5431153,0.00040653028,0.002460925,0.000051559935,0.00009145407,0.0027707557,0.0004928984,0.00006201235,0.03384318,0.00030268167],"about_ca_topic_score_codex":0.00036158162,"about_ca_topic_score_gemma":0.0028768617,"teacher_disagreement_score":0.26048258,"about_ca_system_score_codex":0.001477472,"about_ca_system_score_gemma":0.0031948155,"threshold_uncertainty_score":0.9856215},"labels":[],"label_agreement":null},{"id":"W2974732176","doi":"10.1136/ijgc-2019-esgo.1167","title":"EP1125 Chemotherapy reduces par glycohydrolase (PARG) expression in high-grade serous ovarian cancer patients","year":2019,"lang":"fr","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Ovarian cancer; Serous fluid; Immunohistochemistry; Chemotherapy; Cancer; Cancer research; Internal medicine; Medicine; Biology; Oncology","score_opus":0.01883457527051502,"score_gpt":0.3270956318515802,"score_spread":0.3082610565810652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974732176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9321021,0.013944879,0.000066655906,0.026096886,0.026358716,0.00059240643,0.00024633805,0.00002071112,0.00057130924],"genre_scores_gemma":[0.96976614,0.017415345,0.00070449663,0.00575731,0.004184475,0.00009863389,0.000026647713,0.00005838257,0.0019885483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953482,0.00034023848,0.0015461328,0.0005307313,0.0015470897,0.0006875899],"domain_scores_gemma":[0.9963545,0.0005262822,0.0013748612,0.00023002895,0.0011238618,0.00039042678],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006540037,0.00045338937,0.00094801805,0.00043326814,0.000060513223,0.00008788485,0.0007843502,0.0005224442,0.030466251],"category_scores_gemma":[0.00025852007,0.00037182303,0.0003547987,0.00036692256,0.000241639,0.0006136523,0.00010589143,0.0011619483,0.00014522125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009679141,0.0054832357,0.7651662,0.00014727884,0.0013567132,0.0009710302,0.0012304813,0.008410317,0.08887216,0.00035895332,0.023145424,0.09517902],"study_design_scores_gemma":[0.03974796,0.00279454,0.7193162,0.0055911075,0.00017190515,0.0001356257,0.00016746945,0.0005759786,0.11921919,0.0022756488,0.109203115,0.00080128864],"about_ca_topic_score_codex":0.0005427608,"about_ca_topic_score_gemma":0.00012521073,"teacher_disagreement_score":0.09437773,"about_ca_system_score_codex":0.0035138582,"about_ca_system_score_gemma":0.0008626694,"threshold_uncertainty_score":0.9998734},"labels":[],"label_agreement":null},{"id":"W2974744095","doi":"10.1136/ijgc-2019-igcs.2","title":"2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Barts Health NHS Trust; Universitätsklinikum Heidelberg; Universiteit Leiden; Calgary Laboratory Services","keywords":"Medicine; Discontinuation; Internal medicine; Dysgeusia; Anemia; Adverse effect; Population; Placebo; Nausea; Oncology","score_opus":0.019188474624683326,"score_gpt":0.32760682534098606,"score_spread":0.30841835071630275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974744095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971109,0.0003751772,0.000018146995,0.00030121868,0.00034840594,0.0017560248,0.00005001377,0.0000026433042,0.000037450067],"genre_scores_gemma":[0.9994463,0.00012551431,0.00009212411,0.00012412942,0.000015115115,0.00016674043,0.000010148215,0.00000805257,0.000011908101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745286,0.00030424754,0.0012325472,0.00021427401,0.00064862584,0.00014745785],"domain_scores_gemma":[0.9974073,0.00050593837,0.0012228449,0.00012647908,0.0006559315,0.00008148285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039299717,0.00018150045,0.001662621,0.00071840064,0.0000096662825,0.000009464229,0.00012097001,0.00006509608,0.0002879948],"category_scores_gemma":[0.00021700698,0.00010150943,0.0002411534,0.00027726148,0.00009261183,0.00009985111,0.00003105826,0.00017375882,2.6300208e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3627101,0.00578037,0.62350464,0.000006078388,0.0018780006,0.00004587702,0.0012321824,0.00026346938,0.00006509476,0.000010680807,0.0000030777921,0.004500435],"study_design_scores_gemma":[0.47026935,0.006405837,0.52167076,0.00017445964,0.000409677,0.0000017321884,0.0005482061,0.00035722574,0.000074256706,0.00001581817,0.000008881946,0.00006378978],"about_ca_topic_score_codex":0.00013048592,"about_ca_topic_score_gemma":0.0003132675,"teacher_disagreement_score":0.10755927,"about_ca_system_score_codex":0.00061951985,"about_ca_system_score_gemma":0.000172702,"threshold_uncertainty_score":0.41394347},"labels":[],"label_agreement":null},{"id":"W2975141952","doi":"10.1056/nejmoa1910962","title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2262,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Eisai; Pacira BioSciences; Mylan; Clovis Oncology; Pacira Pharmaceuticals; Karyopharm Therapeutics; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; Fujirebio US; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ovarian cancer; Medicine; Oncology; Cancer; Gynecology; Internal medicine","score_opus":0.01026469645237137,"score_gpt":0.2782807913748217,"score_spread":0.2680160949224503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975141952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865412,0.0011192517,0.000228133,0.009312531,0.00093546335,0.00036562717,0.0000032811336,0.000010434667,0.0014840409],"genre_scores_gemma":[0.9943871,0.000377085,0.0010252595,0.0022846058,0.0014331823,0.000004628821,0.000008524545,0.000026977885,0.00045264701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835795,0.00005648608,0.0005354158,0.00015753589,0.0006637251,0.00022886106],"domain_scores_gemma":[0.9986111,0.00017812724,0.00037453917,0.00026765268,0.00028272672,0.00028585302],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038344698,0.00016615825,0.00060820725,0.0002781984,0.000016706366,0.000004747011,0.00013573786,0.00006271848,0.0016682941],"category_scores_gemma":[0.00018260743,0.000101039885,0.00004476717,0.0003183011,0.000060982875,0.00015104534,0.000011339619,0.00043870878,0.000008813256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012429773,0.00021322515,0.8585938,0.000055435834,0.00014197959,0.00017856738,0.0012808013,0.0006061533,0.0014749967,0.000109383116,0.008111889,0.116803974],"study_design_scores_gemma":[0.4066121,0.0050277873,0.5546208,0.002615581,0.00009962523,0.0000961655,0.00010093299,0.000018998437,0.00026832096,0.0005613969,0.029832538,0.00014575149],"about_ca_topic_score_codex":0.00018634321,"about_ca_topic_score_gemma":0.00009214768,"teacher_disagreement_score":0.39418232,"about_ca_system_score_codex":0.00018574735,"about_ca_system_score_gemma":0.00035238525,"threshold_uncertainty_score":0.99924433},"labels":[],"label_agreement":null},{"id":"W2977439036","doi":"10.1093/annonc/mdz248.054","title":"A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Medicine; Prednisone; Abiraterone; Prostate cancer; Urology; Placebo; Internal medicine; Oncology; Cancer; Pathology; Androgen deprivation therapy","score_opus":0.06863615528930514,"score_gpt":0.39325762996660624,"score_spread":0.32462147467730107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977439036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823602,0.0021088156,0.00002323726,0.00085476495,0.00027469156,0.013879178,0.000102193815,0.000030374933,0.00036657456],"genre_scores_gemma":[0.9956118,0.0014323613,0.0002829737,0.00025180317,0.000034259,0.0018200121,0.000049518887,0.000065210734,0.00045206677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583954,0.0006467834,0.0015930699,0.0007457007,0.0005627439,0.0006121853],"domain_scores_gemma":[0.9968356,0.0005551903,0.0013042764,0.0004827155,0.0005846417,0.0002375735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015574739,0.0005112473,0.0037162423,0.00049023586,0.000060782302,0.000024776575,0.00014587128,0.00016373069,0.00014155784],"category_scores_gemma":[0.00006008943,0.0003821674,0.00011461875,0.00039069596,0.00062676455,0.00033513576,0.000103874576,0.00035082528,0.0000049807118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9686092,0.0055040945,0.006231735,0.00037320677,0.0027741664,0.000035802557,0.009773592,0.0004690885,0.0013097504,0.000023752957,0.000095878306,0.004799708],"study_design_scores_gemma":[0.95582354,0.036199518,0.0020128964,0.0003140571,0.0009473424,0.00001054616,0.0012389199,0.0004778966,0.0024670123,0.000051730054,0.00013742213,0.00031910386],"about_ca_topic_score_codex":0.00072200206,"about_ca_topic_score_gemma":0.00057291234,"teacher_disagreement_score":0.030695423,"about_ca_system_score_codex":0.00014218737,"about_ca_system_score_gemma":0.0004769096,"threshold_uncertainty_score":0.999863},"labels":[],"label_agreement":null},{"id":"W2978650206","doi":"10.1093/annonc/mdz250.009","title":"Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Ovarian cancer; Platinum; Ovarian carcinoma; Phases of clinical research; Cancer","score_opus":0.03346109098614352,"score_gpt":0.3772049853250598,"score_spread":0.3437438943389163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978650206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943546,0.00002182211,0.000015967069,0.0012382849,0.000073677875,0.0035194603,0.000055584333,0.0000062664835,0.0007143362],"genre_scores_gemma":[0.9988043,0.0000071239406,0.00010073603,0.0008199172,0.000018908291,0.00018145055,0.000022578677,0.000020504514,0.000024529067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972592,0.0010885557,0.00069981115,0.00032637623,0.00033925494,0.00028678938],"domain_scores_gemma":[0.99742746,0.0013184785,0.00045657888,0.00048016405,0.00025157942,0.00006573563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015400562,0.00023116413,0.0010080892,0.00033213763,0.000016065465,0.000002359212,0.00012953335,0.00011232901,0.00005585831],"category_scores_gemma":[0.00013508175,0.00014809445,0.000092646565,0.00048908027,0.00013550885,0.000035885947,0.000015088209,0.00018349806,0.0000036933538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42729223,0.01313993,0.49983653,0.0001033168,0.00018574798,0.00009086919,0.014772788,0.00027230155,0.008061151,0.000031407206,0.00038241746,0.035831306],"study_design_scores_gemma":[0.15162462,0.27053472,0.48322868,0.0004691312,0.000047882146,0.0000075425005,0.0011446526,0.00013063892,0.091682024,0.00000985331,0.0009635272,0.00015669825],"about_ca_topic_score_codex":0.0003373918,"about_ca_topic_score_gemma":0.0002975503,"teacher_disagreement_score":0.2756676,"about_ca_system_score_codex":0.00024376805,"about_ca_system_score_gemma":0.00038201618,"threshold_uncertainty_score":0.60391164},"labels":[],"label_agreement":null},{"id":"W2980301843","doi":"10.1182/blood.v120.21.1862.1862","title":"Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Veliparib; Bortezomib; PARP inhibitor; Medicine; Proteasome inhibitor; Multiple myeloma; Internal medicine; Ixazomib; Pharmacology; Carfilzomib; Plasma cell leukemia; Oncology; Tolerability; Cancer research; Adverse effect; Poly ADP ribose polymerase; Biology","score_opus":0.019029572776951803,"score_gpt":0.281547447479599,"score_spread":0.2625178747026472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980301843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789435,0.00006619433,0.0000051776315,0.000059421254,0.000109984525,0.0017033789,0.000012541152,0.000021788683,0.00012718781],"genre_scores_gemma":[0.9994462,0.000003537259,0.00013211387,0.00009401137,0.00005654765,0.00017234261,0.000020820182,0.000030047968,0.00004433656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985906,0.000132804,0.0003724182,0.00019726752,0.0004667486,0.00024019387],"domain_scores_gemma":[0.99911153,0.00008451002,0.00022589075,0.00038774233,0.00011701255,0.00007331302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023775685,0.00015430583,0.00029704254,0.0001445137,0.00003696768,0.0000049917535,0.00008350301,0.00006998406,0.000028801243],"category_scores_gemma":[0.00007743142,0.00008902045,0.0000219215,0.00050507986,0.00006685867,0.00017958075,0.00002250443,0.00025029838,0.0000025608733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00560877,0.045128785,0.94396496,0.00003111351,0.000062536354,0.000007697381,0.0032766722,0.0000031892803,0.00093638676,0.0000039757138,0.000055076198,0.0009208563],"study_design_scores_gemma":[0.15251374,0.0070715416,0.8307131,0.00030885453,0.00008154753,0.0000034919642,0.0007050091,0.00001035572,0.008313476,0.0000019940949,0.00016136453,0.000115526156],"about_ca_topic_score_codex":0.00008944528,"about_ca_topic_score_gemma":0.00033089088,"teacher_disagreement_score":0.14690498,"about_ca_system_score_codex":0.00011016453,"about_ca_system_score_gemma":0.000112210255,"threshold_uncertainty_score":0.36301485},"labels":[],"label_agreement":null},{"id":"W2981132995","doi":"10.1051/medsci/2019148","title":"Inhibiteurs de PARP","year":2019,"lang":"fr","type":"article","venue":"médecine/sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Chemistry; Poly ADP ribose polymerase; Biochemistry; DNA; Polymerase","score_opus":0.039954678925794476,"score_gpt":0.3509442969600026,"score_spread":0.31098961803420816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981132995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7653925,0.044553827,0.0005396963,0.026272168,0.007520155,0.00061219535,0.000038833492,0.00012735673,0.15494326],"genre_scores_gemma":[0.93352467,0.0025987641,0.0030768926,0.0086824475,0.002564708,0.00003605506,0.000006585839,0.000044549895,0.04946534],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645346,0.00021039156,0.0005148441,0.0007605909,0.0008594141,0.0012013],"domain_scores_gemma":[0.99846417,0.00047384834,0.00019691368,0.00043016011,0.000093119525,0.0003417785],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019069758,0.00033370496,0.000486391,0.00027937844,0.0002947534,0.0001209937,0.00044597517,0.00022945435,0.010263805],"category_scores_gemma":[0.00016637269,0.00030443535,0.00018424742,0.0012595232,0.0015281787,0.00039787492,0.00008642199,0.00040155597,0.0059006037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018465245,0.00076799217,0.7373264,0.00044491203,0.00011528339,0.00011716535,0.0014806432,0.0018513867,0.046851307,0.087143496,0.093419895,0.030296898],"study_design_scores_gemma":[0.011708943,0.0050662216,0.09708308,0.0047710524,0.0002216782,0.0008686056,0.0035214352,0.006477207,0.055959057,0.027240193,0.7857139,0.0013685938],"about_ca_topic_score_codex":0.00024040698,"about_ca_topic_score_gemma":0.000014483584,"teacher_disagreement_score":0.69229406,"about_ca_system_score_codex":0.00039876183,"about_ca_system_score_gemma":0.0009926758,"threshold_uncertainty_score":0.99994075},"labels":[],"label_agreement":null},{"id":"W2981369308","doi":"10.1016/j.jtho.2019.08.1192","title":"P1.14-41 The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Olaparib; Cancer research; PARP inhibitor; Clonogenic assay; Medicine; Cell culture; Molecular biology; Biology; Poly ADP ribose polymerase; Polymerase; Genetics; DNA","score_opus":0.011966453007747574,"score_gpt":0.3631862019969051,"score_spread":0.35121974898915753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981369308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624099,0.0064803963,0.00011432027,0.024666881,0.0039265356,0.0011300917,0.000018119224,0.000010527569,0.0012432401],"genre_scores_gemma":[0.99544775,0.00075534004,0.00017365259,0.0019348187,0.00079528976,0.00003772345,0.0000012634381,0.000028458518,0.00082567945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970945,0.00083737687,0.00085972634,0.00022175064,0.0006802876,0.00030633505],"domain_scores_gemma":[0.99652296,0.00077878573,0.0015013482,0.00034700774,0.00074823736,0.000101651945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021990696,0.00021773319,0.00072486093,0.00012328023,0.00021120974,0.000026921736,0.00031241908,0.00021294477,0.00017354137],"category_scores_gemma":[0.00016078012,0.00010360367,0.00028511597,0.00041646574,0.0005473349,0.00013963529,0.00010878962,0.0009373591,0.000007646227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03577878,0.0030754937,0.06700038,0.0011190603,0.0026612694,0.00008536821,0.028568316,0.0022154138,0.6181594,0.003080099,0.17755435,0.06070203],"study_design_scores_gemma":[0.034193218,0.006388429,0.090568334,0.0024334136,0.002637158,0.0017976881,0.0043943315,0.0040986575,0.68408793,0.003001527,0.1656703,0.0007289891],"about_ca_topic_score_codex":0.00004195429,"about_ca_topic_score_gemma":0.000028759741,"teacher_disagreement_score":0.06592851,"about_ca_system_score_codex":0.0007366298,"about_ca_system_score_gemma":0.00085082976,"threshold_uncertainty_score":0.4224835},"labels":[],"label_agreement":null},{"id":"W2982132795","doi":"10.1101/19007757","title":"Machine learning-based prediction of response to PARP inhibition across cancer types","year":2019,"lang":"en","type":"preprint","venue":"medRxiv","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Olaparib; PARP inhibitor; Medicine; Cancer; Oncology; Ovarian cancer; Cancer research; Internal medicine; Biology; Gene; Genetics; Poly ADP ribose polymerase","score_opus":0.036512178769715416,"score_gpt":0.3442558285280128,"score_spread":0.3077436497582974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982132795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887345,0.001221064,0.0020880206,0.0037444988,0.0012935183,0.0011573012,0.0012408439,0.00020325731,0.00031700084],"genre_scores_gemma":[0.99558866,0.00027396466,0.000244839,0.0008674364,0.0003885993,0.00037935382,0.0003725888,0.00008373851,0.001800793],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751234,0.0003314136,0.0005970279,0.0006209865,0.0006107634,0.00032744827],"domain_scores_gemma":[0.9981247,0.00017718092,0.0004022281,0.00070728065,0.00041002722,0.00017858471],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011494512,0.00032549797,0.00065322965,0.00026477632,0.000067909634,0.000020816142,0.00012827812,0.00039606894,0.00064981345],"category_scores_gemma":[0.00035727595,0.00031165362,0.00021931714,0.0003006695,0.00010414601,0.00004124511,0.000114850845,0.0009030671,0.0001124084],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021263417,0.0003685039,0.52467614,0.0014270501,0.0003123628,0.000040720523,0.0020085543,0.10744221,0.3378296,0.000008783762,0.0024905687,0.0021320914],"study_design_scores_gemma":[0.0070884465,0.001690884,0.40035617,0.005451716,0.0002575727,0.000017057899,0.000079266996,0.009118132,0.5063358,0.00011237343,0.068899825,0.000592764],"about_ca_topic_score_codex":0.00026656355,"about_ca_topic_score_gemma":0.000042899694,"teacher_disagreement_score":0.16850619,"about_ca_system_score_codex":0.0004303451,"about_ca_system_score_gemma":0.0005826634,"threshold_uncertainty_score":0.99993354},"labels":[],"label_agreement":null},{"id":"W2982698348","doi":"10.1073/pnas.1916581116","title":"Epigenetic targeting of DNA repair in lung cancer","year":2019,"lang":"en","type":"letter","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Epigenetics; DNA repair; Lung cancer; DNA; Biology; DNA methylation; Computational biology; Cancer epigenetics; Cancer research; DNA damage; Genetics; Medicine; Gene; Gene expression; Pathology","score_opus":0.044845735687002626,"score_gpt":0.35351726628299807,"score_spread":0.30867153059599545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982698348","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36534607,0.004381021,4.6320093e-7,0.6203468,0.00018681471,0.0011194869,0.00017851789,0.0000289621,0.008411916],"genre_scores_gemma":[0.80299425,0.0007948305,0.0019012602,0.19049701,0.0018400319,0.00009943347,0.0000023403443,0.000032100652,0.0018387504],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99666196,0.000012024397,0.0007399483,0.0003776769,0.0019775287,0.00023083811],"domain_scores_gemma":[0.9980816,0.00021598584,0.0011737886,0.000015788572,0.0004940218,0.000018766816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014300657,0.00016570558,0.00047802378,0.00044089707,0.000051220482,0.000004934962,0.0006042308,0.0003684627,0.000099872406],"category_scores_gemma":[0.0004463794,0.00011732456,0.00020733158,0.0009355975,0.0008111656,0.00016452387,0.00009436464,0.00081341155,9.3809115e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004691202,0.000041072333,0.042663988,0.002667575,0.00008355536,6.935902e-8,0.00030268714,0.00011981291,0.19890998,0.0004685164,0.75462353,0.000072273084],"study_design_scores_gemma":[0.0019936722,0.00023508094,0.08194653,0.010132509,0.00020111952,0.000025247171,0.00017715158,0.0026717554,0.7978058,0.011138945,0.09312849,0.0005437289],"about_ca_topic_score_codex":0.000031577172,"about_ca_topic_score_gemma":6.5824715e-8,"teacher_disagreement_score":0.6614951,"about_ca_system_score_codex":0.00019671202,"about_ca_system_score_gemma":0.00024149784,"threshold_uncertainty_score":0.47843567},"labels":[],"label_agreement":null},{"id":"W2982713520","doi":"10.1523/eneuro.0239-19.2019","title":"Loss of Tiparp Results in Aberrant Layering of the Cerebral Cortex","year":2019,"lang":"en","type":"article","venue":"eNeuro","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Seventh Framework Programme; FP7 People: Marie-Curie Actions; Universitetet i Oslo; European Commission","keywords":"Cortex (anatomy); Tubulin; Prefrontal cortex; Cerebral cortex; Biology; Cell biology; Neural stem cell; Phenotype; Progenitor cell; Progenitor; Cytoskeleton; Neuroscience; Cell; Microtubule; Stem cell; Biochemistry; Gene","score_opus":0.01901960907113507,"score_gpt":0.27895009648651875,"score_spread":0.25993048741538366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982713520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98750234,0.00005237063,0.0000030278943,0.00073338515,0.00032693674,0.00019682135,0.000017975808,0.000009107293,0.011158027],"genre_scores_gemma":[0.99860966,0.00001885872,0.000038078048,0.00032627216,0.00003968433,0.0000034330187,0.000001904237,0.000010876318,0.00095122325],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99927986,0.000035494202,0.00027088486,0.00012575717,0.00018484633,0.00010315809],"domain_scores_gemma":[0.9994173,0.00006581571,0.000114291004,0.0003493053,0.000031133644,0.00002217526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012054043,0.00005934586,0.00017745278,0.00004367599,0.000006629018,0.0000012020577,0.000086683904,0.000032005733,0.000111359805],"category_scores_gemma":[0.000047055873,0.000042796397,0.000055984896,0.00015948722,0.000049454895,0.000023468654,0.000027162981,0.00011881442,0.000014767912],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013937522,0.00018376851,0.32468677,0.00019275876,0.000030313391,0.000020693988,0.0013572101,0.0004830051,0.66875434,0.0005225157,0.0015397537,0.00083513133],"study_design_scores_gemma":[0.0043925787,0.00018164239,0.6768323,0.000320764,0.0000083598015,0.000023368446,0.00003999931,0.00017783149,0.31298956,0.00010019182,0.004872814,0.00006058471],"about_ca_topic_score_codex":0.00006015657,"about_ca_topic_score_gemma":0.0000149302605,"teacher_disagreement_score":0.35576478,"about_ca_system_score_codex":0.000023326744,"about_ca_system_score_gemma":0.000049880517,"threshold_uncertainty_score":0.17451864},"labels":[],"label_agreement":null},{"id":"W2984793218","doi":"10.1136/ijgc-2019-esgo.28","title":"Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Regimen; Oncology; Placebo; Progression-free survival; Population; BRCA mutation; Ovarian cancer; Chemotherapy; Cancer; Pathology","score_opus":0.020466524810887073,"score_gpt":0.35341917229194064,"score_spread":0.3329526474810536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984793218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967728,0.0000544698,0.00008805838,0.0009627446,0.00047696248,0.001380473,0.00016642862,0.0000065239565,0.000091515925],"genre_scores_gemma":[0.9993266,0.000005393373,0.00020030496,0.00021482841,0.00010578931,0.00007765145,0.000044289496,0.000014951451,0.000010190262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699223,0.00059851125,0.00082833855,0.00029294775,0.0010953164,0.00019265794],"domain_scores_gemma":[0.9950504,0.0028540457,0.0011079964,0.00039945787,0.0005062878,0.000081841674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087604934,0.00024705633,0.00079460297,0.00019696113,0.00004404179,0.000024451776,0.0004638944,0.00007330553,0.0004931696],"category_scores_gemma":[0.00055016635,0.000108938046,0.00036756112,0.00030652722,0.00012276074,0.000100102196,0.000051885294,0.00035614945,0.000001586108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04240315,0.0042537544,0.93816847,0.0000072812322,0.0021957997,0.00010856387,0.0011308986,0.0022489724,0.00031803868,0.000020730875,0.000051820247,0.009092542],"study_design_scores_gemma":[0.048877202,0.028100992,0.91456187,0.0006268544,0.0007489647,0.0000022763581,0.0003108775,0.002091943,0.0045077302,0.000024010904,0.000028553739,0.00011873004],"about_ca_topic_score_codex":0.00029303166,"about_ca_topic_score_gemma":0.00017174993,"teacher_disagreement_score":0.023847237,"about_ca_system_score_codex":0.00077741157,"about_ca_system_score_gemma":0.00020949237,"threshold_uncertainty_score":0.53998613},"labels":[],"label_agreement":null},{"id":"W2984886575","doi":"10.1136/ijgc-2019-000623","title":"Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Foundation Medicine; National Institute for Health and Care Research; Wellcome Trust; Clovis Oncology; University College London; Wellcome","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Poly ADP ribose polymerase; Polymerase; Cancer research; BRCA mutation; Olaparib; Oncology; Internal medicine; Pharmacology; Cancer; Gene; Genetics; Biology","score_opus":0.010216513708256455,"score_gpt":0.2947875185163555,"score_spread":0.28457100480809905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984886575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99009484,0.00018680339,0.000027815735,0.007276462,0.0014792915,0.00047853508,0.0002242326,0.000010970145,0.00022102795],"genre_scores_gemma":[0.9959805,0.00042744388,0.00024350024,0.0027831034,0.00041713685,0.00001694127,0.000012154478,0.000026644137,0.000092591974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977779,0.00017627969,0.0005938946,0.00031080935,0.00090153015,0.0002396309],"domain_scores_gemma":[0.9980627,0.00023612032,0.0008258251,0.0002001335,0.0005217607,0.0001534684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026985593,0.00024225083,0.0005405204,0.0002100476,0.000054948716,0.000028987837,0.00025089947,0.00014859026,0.00089985825],"category_scores_gemma":[0.00007969937,0.00014981553,0.00011334394,0.00022603339,0.00021204221,0.00030752367,0.00004644789,0.00061999477,0.000004348846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054580905,0.002386562,0.86410576,0.00003041678,0.0008223455,0.00018247307,0.0004590999,0.001307533,0.039646246,0.0012947146,0.00034565647,0.034838315],"study_design_scores_gemma":[0.020810524,0.0023923086,0.90867186,0.00055003876,0.000047044217,0.000048467395,0.000044329634,0.00009098097,0.06602048,0.00024355236,0.00088105793,0.00019935652],"about_ca_topic_score_codex":0.0008139394,"about_ca_topic_score_gemma":0.0002186177,"teacher_disagreement_score":0.04456613,"about_ca_system_score_codex":0.00076623575,"about_ca_system_score_gemma":0.0004489305,"threshold_uncertainty_score":0.98528165},"labels":[],"label_agreement":null},{"id":"W2988004744","doi":"10.1136/ijgc-2019-esgo.179","title":"P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; PARP inhibitor; Internal medicine; Oncology; Chemotherapy; Placebo; BRCA mutation; Nivolumab; Ovarian cancer; Cancer; Immunotherapy; Poly ADP ribose polymerase; Pathology; Polymerase; Biology","score_opus":0.034188081077340865,"score_gpt":0.3591871224557714,"score_spread":0.3249990413784305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988004744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97155607,0.0030434805,0.00028903622,0.013789705,0.005350638,0.0049082655,0.00013226106,0.000034139604,0.00089640653],"genre_scores_gemma":[0.9902152,0.00025195495,0.00020561389,0.0044450187,0.003046266,0.0008365465,0.00001637386,0.00008195686,0.00090106117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99302137,0.0006329339,0.0025845103,0.00068535906,0.002401466,0.00067435694],"domain_scores_gemma":[0.9939472,0.0016478774,0.0024832394,0.0006743276,0.00094277225,0.00030459499],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002182107,0.0006777101,0.0019275717,0.0005071118,0.00020306672,0.00013055596,0.0012727237,0.00037665266,0.004069871],"category_scores_gemma":[0.00048621587,0.00038916199,0.0012689234,0.00059097057,0.00025880957,0.0004090125,0.00014087248,0.001561607,0.000015105787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85614115,0.010492175,0.05706483,0.00005847921,0.0047349585,0.0003634371,0.0032224024,0.0046020243,0.048618827,0.00007324419,0.007729698,0.006898755],"study_design_scores_gemma":[0.95799345,0.0028587196,0.010072175,0.00093215855,0.0006658036,0.00010636072,0.0012090078,0.0022551476,0.01815126,0.00009464092,0.0050660535,0.0005952195],"about_ca_topic_score_codex":0.0012379242,"about_ca_topic_score_gemma":0.00063732226,"teacher_disagreement_score":0.10185228,"about_ca_system_score_codex":0.0017973434,"about_ca_system_score_gemma":0.0017674341,"threshold_uncertainty_score":0.99985605},"labels":[],"label_agreement":null},{"id":"W2989981864","doi":"10.1007/s00018-019-03366-0","title":"Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity","year":2019,"lang":"en","type":"review","venue":"Cellular and Molecular Life Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; DNA repair; Biology; DNA damage; Polymerase; Computational biology; Ankyrin repeat; Genetics; Genome; Cell biology; DNA; Gene","score_opus":0.05178790177863034,"score_gpt":0.33610512077544563,"score_spread":0.2843172189968153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989981864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021907338,0.9954135,0.00084650464,0.00080269965,0.00024928193,0.0008479726,0.00004333193,0.000016493323,0.001561145],"genre_scores_gemma":[0.0037722287,0.9943949,0.0002636744,0.000921913,0.00015302554,0.000042171876,0.000020482454,0.00002447033,0.00040713226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784523,0.00027813183,0.0005322165,0.0005787101,0.00044905403,0.0003166453],"domain_scores_gemma":[0.9987118,0.00019286244,0.00037444683,0.00045622478,0.000072885254,0.00019174525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010932041,0.00034323562,0.0014593564,0.00018774731,0.00014540345,0.00004521394,0.0003087974,0.00019095867,0.00005161579],"category_scores_gemma":[0.00017105011,0.00019059576,0.00035906114,0.0004208736,0.0024895621,0.000060491828,0.00013372519,0.0004200587,0.000009263527],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042624664,0.00030107272,0.00008767002,0.04569889,0.0014835038,0.00025817295,0.0015212686,0.0000013789393,0.006257247,0.07383166,0.0018636365,0.86826926],"study_design_scores_gemma":[0.0019870193,0.0002669453,0.0000066592497,0.006469428,0.001048099,0.00022408823,0.00021165008,0.00003858876,0.0027734498,0.0004250331,0.9861325,0.0004165082],"about_ca_topic_score_codex":0.00006852333,"about_ca_topic_score_gemma":7.110329e-7,"teacher_disagreement_score":0.9842689,"about_ca_system_score_codex":0.000028806253,"about_ca_system_score_gemma":0.0007351548,"threshold_uncertainty_score":0.9172895},"labels":[],"label_agreement":null},{"id":"W2990471413","doi":"10.1056/nejmc1711644","title":"Olaparib for Metastatic Germline <i>BRCA</i>-Mutated Breast Cancer","year":2017,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Queen's University; Women's College Hospital","funders":"","keywords":"Olaparib; Medicine; Germline; BRCA mutation; Metastatic breast cancer; Breast cancer; Oncology; Germline mutation; Internal medicine; Mutation; Cancer; Cancer research; Gynecology; Genetics; Poly ADP ribose polymerase; DNA; Gene; Biology; Polymerase","score_opus":0.055788616891964,"score_gpt":0.36844705082319545,"score_spread":0.31265843393123144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990471413","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013740876,0.009421267,0.0015913566,0.98073524,0.005026588,0.000763014,0.00041338027,0.000034609064,0.0006404407],"genre_scores_gemma":[0.0075741853,0.0054221624,0.0026281434,0.7431182,0.22569874,0.000065427754,0.0006032508,0.00026709025,0.01462277],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613756,0.00014934606,0.0014779217,0.0003846542,0.0012742043,0.00057631463],"domain_scores_gemma":[0.9941398,0.00063513103,0.0024798564,0.00086855557,0.0013932684,0.00048340848],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013427291,0.000582789,0.0022711477,0.0005438638,0.00014914136,0.000037980946,0.00063249684,0.00042280016,0.0018089615],"category_scores_gemma":[0.0006791576,0.0003751774,0.0004350889,0.00015039208,0.00034269382,0.00017213193,0.000034499895,0.002684216,0.000009580485],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026598938,0.000052736592,0.000106388994,0.00060075434,0.0013589477,0.0028873917,0.00027122672,0.000010492615,0.0019968154,0.000004868387,0.9507045,0.039345954],"study_design_scores_gemma":[0.10913609,0.0015384721,0.0003248507,0.005159802,0.0026488588,0.017573824,0.00001707874,0.000031172243,0.0002941271,0.0011003105,0.8618791,0.00029632827],"about_ca_topic_score_codex":0.00028634933,"about_ca_topic_score_gemma":0.000027122043,"teacher_disagreement_score":0.23761703,"about_ca_system_score_codex":0.00034824465,"about_ca_system_score_gemma":0.0016110542,"threshold_uncertainty_score":0.99987},"labels":[],"label_agreement":null},{"id":"W2991497553","doi":"10.1038/s41416-019-0645-9","title":"Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer","year":2019,"lang":"en","type":"letter","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Pancreatic cancer; Phenotype; Synthetic lethality; Genotype; Germline mutation; Biology; Mutation; Cancer research; Genetics; Germline; Homologous recombination; BRCA2 Protein; Population; PARP inhibitor; DNA repair; Cancer; Poly ADP ribose polymerase; Medicine; DNA; Gene; Polymerase","score_opus":0.017641569561614383,"score_gpt":0.30194003280151366,"score_spread":0.28429846323989927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991497553","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.303013,0.20607114,0.0005167084,0.46459168,0.015662368,0.0028155188,0.0011923476,0.00012772098,0.006009544],"genre_scores_gemma":[0.13253163,0.044273555,0.00038025566,0.79070985,0.014056785,0.00022605836,0.0006199702,0.00040338072,0.016798526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99665636,0.00021620923,0.0012338267,0.0003444537,0.0010775847,0.00047158913],"domain_scores_gemma":[0.99676466,0.00025273356,0.0016147773,0.00021554565,0.0010601745,0.00009209014],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042650595,0.0003270042,0.0011617411,0.00041594682,0.00006197861,0.00008362962,0.00020393766,0.0008462576,0.0033038715],"category_scores_gemma":[0.00022414961,0.00038089635,0.00031590008,0.00049144746,0.00008862831,0.00024195347,0.000017905748,0.0029908107,0.000049493396],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037141767,0.00009203628,0.014273532,0.0003885735,0.0008205999,0.0042601074,0.00025749463,0.0014703021,0.00023376549,0.0000018445922,0.94806415,0.029766183],"study_design_scores_gemma":[0.013816542,0.0004920683,0.17007276,0.022765081,0.0013679872,0.0027001414,0.000049500406,0.00043115567,0.00022974444,0.0004315644,0.78675073,0.00089272106],"about_ca_topic_score_codex":0.004507523,"about_ca_topic_score_gemma":0.0021597159,"teacher_disagreement_score":0.32611817,"about_ca_system_score_codex":0.0024063182,"about_ca_system_score_gemma":0.0020154554,"threshold_uncertainty_score":0.9998643},"labels":[],"label_agreement":null},{"id":"W2991608936","doi":"10.1136/ijgc-2019-esgo.29","title":"Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Context (archaeology); Oncology; Population; Adverse effect; Nausea; Placebo; Tolerability; Pathology","score_opus":0.03350772699812896,"score_gpt":0.33854867216716467,"score_spread":0.3050409451690357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991608936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733084,0.0004560242,0.000007853349,0.0005345313,0.0003798588,0.0010095886,0.00022007684,0.0000037831037,0.0000574342],"genre_scores_gemma":[0.9990436,0.00009417862,0.00008658706,0.0006182082,0.000022831728,0.000064179294,0.00005311346,0.000010655087,0.0000066583416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775183,0.0002474113,0.00077987765,0.0002384844,0.0007702223,0.00021218737],"domain_scores_gemma":[0.9980548,0.00035579415,0.00070668635,0.00012660533,0.00066958996,0.000086513624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115068055,0.00020054185,0.0005131109,0.00023681071,0.000023172815,0.000025500718,0.000105015904,0.000061635656,0.00015841918],"category_scores_gemma":[0.00013842514,0.00011250181,0.000085752465,0.00017399696,0.00009323974,0.0001800105,0.000026458194,0.00025032458,0.0000010647911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010833731,0.0070517384,0.9500087,0.0000082481665,0.00036348304,0.000418811,0.012829025,0.00019726774,0.0004005477,0.000020028576,0.000087792956,0.017780615],"study_design_scores_gemma":[0.03028152,0.018620737,0.93894356,0.00014088053,0.00007297828,0.0000122318,0.010936534,0.000042155632,0.000547369,0.000035947753,0.00023470163,0.00013136092],"about_ca_topic_score_codex":0.00025250032,"about_ca_topic_score_gemma":0.00032004362,"teacher_disagreement_score":0.019447789,"about_ca_system_score_codex":0.000953693,"about_ca_system_score_gemma":0.00021300273,"threshold_uncertainty_score":0.45876905},"labels":[],"label_agreement":null},{"id":"W2991847413","doi":"10.18433/jpps30684","title":"The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells","year":2019,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Triple-negative breast cancer; PI3K/AKT/mTOR pathway; Cancer research; RAD51; Homologous recombination; LY294002; Apoptosis; DNA repair; DNA damage; Breast cancer; Biology; Chemistry; Cancer; DNA; Genetics","score_opus":0.04728507481200597,"score_gpt":0.40723372616394904,"score_spread":0.3599486513519431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991847413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989175,0.0006102006,0.000043056945,0.00791304,0.000998086,0.00043146382,0.000013238354,0.00001401131,0.00080185366],"genre_scores_gemma":[0.99666005,0.0021125549,0.00025680417,0.0006873989,0.00016562846,0.000013386179,5.079384e-7,0.000008591251,0.00009508153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803615,0.00021701255,0.00063022994,0.00018680484,0.00068237865,0.00024744327],"domain_scores_gemma":[0.9984366,0.00037308756,0.0005689251,0.00008224888,0.00041052618,0.00012860227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014920479,0.0001265039,0.00028145654,0.0002304035,0.00010341175,0.000023689896,0.00013760872,0.00003088036,0.000650358],"category_scores_gemma":[0.00004005726,0.0000740887,0.00012458778,0.0007772376,0.00042901063,0.0006005021,0.000021386206,0.0004909218,0.000008633151],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014431002,0.0012570842,0.08946673,0.00019985727,0.0002474637,0.000098136516,0.0013705166,0.0018268023,0.78262055,0.00033205427,0.0038695857,0.10428019],"study_design_scores_gemma":[0.015009557,0.0013395281,0.015357367,0.00080693315,0.00015509533,0.0010270469,0.0010738809,0.01163913,0.9414082,0.00045505582,0.011531724,0.00019649047],"about_ca_topic_score_codex":0.000104885556,"about_ca_topic_score_gemma":0.000017822404,"teacher_disagreement_score":0.15878761,"about_ca_system_score_codex":0.00033684057,"about_ca_system_score_gemma":0.0003912736,"threshold_uncertainty_score":0.71209633},"labels":[],"label_agreement":null},{"id":"W2995202816","doi":"10.1136/ijgc-2019-esgo.18","title":"Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Sherbrooke","funders":"","keywords":"Incidence (geometry); Medicine; Adverse effect; Internal medicine; Ovarian cancer; Chemotherapy; Oncology; Cancer","score_opus":0.036556426443372654,"score_gpt":0.37193563605527485,"score_spread":0.3353792096119022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995202816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875526,0.0003078529,0.00012431722,0.0059844423,0.0039411816,0.0007353401,0.0003937422,0.0000068188347,0.0009537345],"genre_scores_gemma":[0.99685365,0.00072367734,0.00033020257,0.0010524044,0.0008615558,0.000033217173,0.00006619458,0.000013795366,0.00006531159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701595,0.00016585228,0.0011375574,0.00025808183,0.0012218264,0.00020072116],"domain_scores_gemma":[0.99678993,0.0007629939,0.0011451881,0.00021136459,0.0009924142,0.00009809589],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000622154,0.00017978878,0.00053227093,0.0001266312,0.000025402058,0.000025431807,0.00043134898,0.00012286099,0.0042644446],"category_scores_gemma":[0.00021189875,0.0001022531,0.00017123006,0.00018424512,0.00010914665,0.00014725685,0.00006141351,0.0006195646,0.0000044561657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11897018,0.0009237862,0.85523844,0.000007056038,0.0005578896,0.00003395774,0.00016128954,0.0005280919,0.00015764625,0.0001441365,0.00061270595,0.022664797],"study_design_scores_gemma":[0.1038459,0.0022616906,0.89087176,0.00059810287,0.00006372874,0.0000041828425,0.00002007496,0.000039228646,0.00014745268,0.00009297441,0.0019473716,0.00010753122],"about_ca_topic_score_codex":0.0002997759,"about_ca_topic_score_gemma":0.0005324557,"teacher_disagreement_score":0.0356333,"about_ca_system_score_codex":0.0013214329,"about_ca_system_score_gemma":0.0007538859,"threshold_uncertainty_score":0.9966458},"labels":[],"label_agreement":null},{"id":"W2996282900","doi":"10.1002/cam4.2738","title":"Biguanides in combination with olaparib limits tumorigenesis of drug‐resistant ovarian cancer cells through inhibition of Snail","year":2019,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Olaparib; Biguanide; Ovarian cancer; Medicine; Cancer research; Metformin; Combination therapy; Cancer; Oncology; Internal medicine; Pharmacology; Biology; Poly ADP ribose polymerase","score_opus":0.024863865741893486,"score_gpt":0.3030605347359692,"score_spread":0.27819666899407575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996282900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98393506,0.0047505563,0.00013860675,0.0063718753,0.000659129,0.0009918885,0.000065995155,0.00003616021,0.003050755],"genre_scores_gemma":[0.99500334,0.0026352147,0.00034308428,0.0008552275,0.00022437033,0.00019615659,0.00004631921,0.00004983485,0.00064642704],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977115,0.00007965163,0.0007830871,0.0004151343,0.0007101321,0.00030050683],"domain_scores_gemma":[0.9981882,0.00012731958,0.0005408723,0.00054686813,0.00049639307,0.00010032738],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035834042,0.0002623235,0.00089268526,0.00030219552,0.000031104442,0.0000032368994,0.00013102268,0.00010543276,0.0017498784],"category_scores_gemma":[0.000034636414,0.00020240569,0.00006568425,0.0010556518,0.00033351444,0.0001737733,0.000021270409,0.00018021044,0.0000066836856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029187484,0.0003497747,0.053308953,0.0015224239,0.00014830256,0.000026413414,0.003407793,0.00027666352,0.931197,0.0017084714,0.0034986709,0.001636779],"study_design_scores_gemma":[0.017179761,0.001365541,0.063131355,0.007302649,0.00020654612,0.0000081280195,0.0012314861,0.0000914092,0.90558946,0.00060601614,0.0030324263,0.00025524563],"about_ca_topic_score_codex":0.0039632004,"about_ca_topic_score_gemma":0.0008263919,"teacher_disagreement_score":0.025607571,"about_ca_system_score_codex":0.00048855774,"about_ca_system_score_gemma":0.000508206,"threshold_uncertainty_score":0.9991627},"labels":[],"label_agreement":null},{"id":"W2997269993","doi":"10.1016/j.ajhg.2019.12.006","title":"Bi-allelic Mutations in NADSYN1 Cause Multiple Organ Defects and Expand the Genotypic Spectrum of Congenital NAD Deficiency Disorders","year":2019,"lang":"en","type":"article","venue":"The American Journal of Human Genetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Western University","funders":"National Health and Medical Research Council; Canadian Institutes of Health Research","keywords":"NAD+ kinase; Missense mutation; Biology; Complementation; Genetics; Allele; Genotype; Phenotype; Gene; Enzyme; Biochemistry","score_opus":0.014307906033562969,"score_gpt":0.28490242001567107,"score_spread":0.2705945139821081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997269993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642223,0.0022542044,0.00008637521,0.0007085106,0.000082959814,0.00028278015,0.000005672982,0.0000046018245,0.00015266979],"genre_scores_gemma":[0.9986933,0.0007619179,0.0001682586,0.00024569235,0.000071069066,0.0000032416242,0.0000012935876,0.000022194788,0.000033018143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988985,0.0001235831,0.00040717924,0.00010923942,0.00026975566,0.00019171475],"domain_scores_gemma":[0.99888706,0.00021590949,0.0004666905,0.00027513868,0.000085182255,0.00007001162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026738664,0.00012017892,0.000305014,0.00015216638,0.000092850125,0.000014236052,0.00018541428,0.000019830608,0.000058689242],"category_scores_gemma":[0.000036638077,0.00007473328,0.00007471554,0.00030774152,0.0006407835,0.000031395615,0.000031008054,0.00025124106,0.00000455444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053487415,0.0003155316,0.73949164,0.000048419028,0.00024757435,0.000022825401,0.015875313,0.0015247342,0.23601235,0.00020068254,0.000098742144,0.0056273253],"study_design_scores_gemma":[0.004411466,0.0039343424,0.96583176,0.000101327074,0.0002244835,0.0003811272,0.009289766,0.00019002824,0.013066325,0.0021472399,0.00021529815,0.00020684768],"about_ca_topic_score_codex":0.00008445289,"about_ca_topic_score_gemma":0.00038231947,"teacher_disagreement_score":0.22634012,"about_ca_system_score_codex":0.00005821236,"about_ca_system_score_gemma":0.00013715909,"threshold_uncertainty_score":0.30475345},"labels":[],"label_agreement":null},{"id":"W2998080630","doi":"10.1136/ijgc-2019-esgo.9","title":"Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 study","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Ovarian cancer; Internal medicine; Oncology; Neutropenia; Population; Clinical endpoint; Chemotherapy; Progression-free survival; Gastroenterology; Randomized controlled trial; Cancer","score_opus":0.013153484769935895,"score_gpt":0.3148937811599277,"score_spread":0.30174029638999184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998080630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259794,0.0009164026,0.00006890028,0.0029744133,0.0016659517,0.0013264841,0.00004226585,0.000025048816,0.00038261953],"genre_scores_gemma":[0.99071187,0.0010427404,0.0005267355,0.006653852,0.0004330258,0.00033206854,0.000008314868,0.000047499085,0.00024389707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970114,0.00012600725,0.00082043034,0.00040287717,0.0012691286,0.00037013282],"domain_scores_gemma":[0.9975268,0.00027855692,0.0006283683,0.00024300526,0.0011350471,0.00018818394],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034817436,0.00032401472,0.0006975044,0.000311716,0.000030558924,0.0000519195,0.00041303877,0.00015448016,0.011416249],"category_scores_gemma":[0.000085548185,0.00021816163,0.00018382515,0.00030330743,0.000092258,0.0003791542,0.000043488893,0.00062664674,0.000021700595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020246187,0.002663505,0.92162037,0.0000087256,0.0006485759,0.000193665,0.0006268824,0.0007351092,0.00045404423,0.000025729341,0.00036486003,0.05241235],"study_design_scores_gemma":[0.052008715,0.0043299044,0.9370347,0.00026559093,0.000036905778,0.000010819588,0.00011632807,0.000021129155,0.00037027005,0.00016694922,0.0053834086,0.00025525055],"about_ca_topic_score_codex":0.00012776876,"about_ca_topic_score_gemma":0.00021934294,"teacher_disagreement_score":0.0521571,"about_ca_system_score_codex":0.0013109971,"about_ca_system_score_gemma":0.00048424792,"threshold_uncertainty_score":0.98948747},"labels":[],"label_agreement":null},{"id":"W2998366738","doi":"10.18632/oncoscience.474","title":"Translating the role of PARP inhibitors in triple-negative breast cancer","year":2019,"lang":"en","type":"article","venue":"Oncoscience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; PARP inhibitor; Medicine; Cancer research; Oncology; Poly ADP ribose polymerase; Cancer; Internal medicine; Biology; Genetics; DNA; Polymerase","score_opus":0.013217617071932659,"score_gpt":0.3055497948607467,"score_spread":0.29233217778881404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998366738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979997,0.0005022478,0.000028986871,0.0028677694,0.00030615056,0.000517778,0.00003121973,0.000017576138,0.015731286],"genre_scores_gemma":[0.9989604,0.000056870176,0.00020209354,0.00037881258,0.000077732744,0.000041937456,5.6105625e-7,0.000008069506,0.00027356623],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99892896,0.000046873734,0.00024540766,0.0002189247,0.00035550966,0.00020431184],"domain_scores_gemma":[0.9994616,0.000097968936,0.0001150904,0.00021036362,0.000064552725,0.00005042712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037234178,0.00008709329,0.00019070542,0.00007651773,0.00004162022,0.0000079995325,0.00014236644,0.0000389882,0.00030722446],"category_scores_gemma":[0.000027803722,0.000058247155,0.000053078566,0.0006854323,0.00021687681,0.0001364976,0.000014804215,0.00017141123,0.000016785118],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028908864,0.00014263355,0.43016526,0.000041523723,0.000011918054,0.0000031231525,0.007056926,0.00026493444,0.46149603,0.000740808,0.000115601935,0.09967215],"study_design_scores_gemma":[0.007763632,0.00046147444,0.541027,0.0017060745,0.00003403794,0.00008698965,0.0064008916,0.008427107,0.42399675,0.0028419492,0.0068467734,0.00040731108],"about_ca_topic_score_codex":0.0007841399,"about_ca_topic_score_gemma":0.00017788752,"teacher_disagreement_score":0.11086174,"about_ca_system_score_codex":0.00014295941,"about_ca_system_score_gemma":0.00030502735,"threshold_uncertainty_score":0.33638924},"labels":[],"label_agreement":null},{"id":"W3001602950","doi":"10.1097/ogx.0000000000000756","title":"Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer","year":2020,"lang":"en","type":"article","venue":"Obstetrical & Gynecological Survey","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Aalborg Universitet; Pacira BioSciences; Mylan; Fujirebio US; Clovis Oncology; Pacira Pharmaceuticals; Gentofte Hospital; University of South Carolina; Eisai; Thomas Jefferson University; McGill University Health Centre; McGill University; Karyopharm Therapeutics; Roche; GlaxoSmithKline; Takeda Oncology; Rigshospitalet; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Taxane; Epithelial ovarian cancer; Regimen; Ovarian cancer; Chemotherapy; Oncology; Internal medicine; Cytoreductive surgery; Gynecology; Cancer; Breast cancer","score_opus":0.042375018950862556,"score_gpt":0.2939501556881457,"score_spread":0.25157513673728316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001602950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944757,0.00049983314,0.00035379746,0.002072828,0.0002821096,0.0010272196,0.00011449893,0.00014407489,0.0010299366],"genre_scores_gemma":[0.9904682,0.00008372183,0.0011133661,0.00782477,0.00006274726,0.00018638396,0.00015470712,0.000033790962,0.00007231907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732655,0.00036659147,0.00049509323,0.0006735036,0.00057682424,0.00056144025],"domain_scores_gemma":[0.995713,0.003078507,0.00013865794,0.0002515139,0.00024298672,0.0005753601],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019253853,0.00028890636,0.00070478034,0.00010123673,0.00006534574,0.000025942145,0.00019448213,0.00024957515,0.0027125096],"category_scores_gemma":[0.0063076755,0.00020358314,0.00009086837,0.0019488044,0.00013257047,0.00011313981,0.0000668534,0.0005840119,0.00010977747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00253287,0.00083032885,0.9748515,0.000018364683,0.000043064938,0.00012077868,0.00007054383,0.00025339538,0.000055782166,0.00007204078,0.0013357248,0.01981563],"study_design_scores_gemma":[0.01805937,0.0020517367,0.97551674,0.000036253903,0.000018721204,4.5618546e-7,0.000013207793,0.00011738225,0.000055565,0.0000567829,0.003794315,0.0002794497],"about_ca_topic_score_codex":0.00021721282,"about_ca_topic_score_gemma":0.00016121552,"teacher_disagreement_score":0.019536179,"about_ca_system_score_codex":0.00043870372,"about_ca_system_score_gemma":0.00015765551,"threshold_uncertainty_score":0.99819916},"labels":[],"label_agreement":null},{"id":"W3004496476","doi":"10.1038/s41598-020-59072-6","title":"Alkyladenine DNA glycosylase deficiency uncouples alkylation-induced strand break generation from PARP-1 activation and glycolysis inhibition","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"University of Surrey; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Qassim University; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Royal Society of Medicine","keywords":"NAD+ kinase; Poly ADP ribose polymerase; DNA glycosylase; DNA repair; DNA damage; Nicotinamide phosphoribosyltransferase; Methyl methanesulfonate; Biology; Biochemistry; Base excision repair; Molecular biology; Cell biology; Chemistry; DNA; Enzyme; Polymerase","score_opus":0.04418332269564847,"score_gpt":0.27443945238746115,"score_spread":0.23025612969181267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004496476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879427,0.00024523304,0.0056952033,0.0036511756,0.0011634943,0.0006657506,0.00002472522,0.00014944944,0.00046228853],"genre_scores_gemma":[0.99664766,0.000024485282,0.0006793951,0.000518016,0.0006030158,0.000056392124,0.0013015554,0.000028407525,0.00014105575],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970637,0.00005857979,0.00072705036,0.0010443748,0.00084807724,0.00025825098],"domain_scores_gemma":[0.99839884,0.000053416723,0.00044196824,0.00047887198,0.0003170231,0.00030985815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004610309,0.00023048707,0.00032067896,0.00017151989,0.0004041235,0.00027246,0.000042407042,0.00014068357,0.0004755179],"category_scores_gemma":[0.00024203883,0.00022066849,0.00009824884,0.0007856296,0.00015540363,0.0005452695,0.00003129361,0.00017108531,0.000021955553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012334435,0.00008399714,0.00217317,0.000026398184,0.000029675008,0.000107390304,0.00081267057,0.00012940315,0.9856914,0.00005551991,0.0057540876,0.0050129164],"study_design_scores_gemma":[0.001457169,0.00017182539,0.0058608353,0.0001008047,0.0001136683,0.00012628722,0.000185956,0.003766574,0.9822758,0.0016969319,0.0039729895,0.00027116734],"about_ca_topic_score_codex":0.00012539448,"about_ca_topic_score_gemma":0.000047587517,"teacher_disagreement_score":0.008704998,"about_ca_system_score_codex":0.00013966423,"about_ca_system_score_gemma":0.00026978875,"threshold_uncertainty_score":0.89986},"labels":[],"label_agreement":null},{"id":"W3006191171","doi":"10.7150/thno.41219","title":"ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma","year":2020,"lang":"en","type":"article","venue":"Theranostics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"ATRX; Glioma; Cancer research; Temozolomide; Biology; PARP1; DNA methylation; Genetics; Gene expression; Poly ADP ribose polymerase; Gene; Mutation; Polymerase","score_opus":0.04874761959183217,"score_gpt":0.31553454559911415,"score_spread":0.266786926007282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006191171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93775374,0.0024115175,0.012840932,0.041710358,0.00020242344,0.0011992025,0.00011552882,0.00061670976,0.0031495935],"genre_scores_gemma":[0.9788403,0.00010294063,0.009758517,0.010537159,0.00047279248,0.000029435565,0.000035647958,0.00010813268,0.00011508111],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978546,0.00010908949,0.0005813134,0.00042389313,0.00040392065,0.00062720926],"domain_scores_gemma":[0.9985931,0.00034955106,0.000105486295,0.00037771123,0.00021180676,0.00036238035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002966489,0.00024787177,0.0005278061,0.00009045505,0.00006975586,0.000032180902,0.00019978835,0.00012657265,0.00022517785],"category_scores_gemma":[0.0006170905,0.00024571107,0.00008571871,0.0006390255,0.00012298796,0.000036653688,0.000067971494,0.00025792894,0.000106040556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038100225,0.00018341363,0.01314372,0.00018476268,0.00012591171,0.00037179718,0.003258564,0.00029789036,0.9600928,0.0052078688,0.010771025,0.0025522232],"study_design_scores_gemma":[0.01755889,0.0018420448,0.21149027,0.0014868184,0.00017676513,0.0000612353,0.0005730651,0.0017707956,0.51937175,0.007553552,0.23674814,0.0013666832],"about_ca_topic_score_codex":0.000013457747,"about_ca_topic_score_gemma":0.000044623845,"teacher_disagreement_score":0.44072106,"about_ca_system_score_codex":0.00016731248,"about_ca_system_score_gemma":0.00012003407,"threshold_uncertainty_score":0.9999995},"labels":[],"label_agreement":null},{"id":"W3006784906","doi":"10.1200/jco.2020.38.6_suppl.134","title":"PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Taxane; Medicine; Enzalutamide; Hazard ratio; Oncology; Internal medicine; Cohort; Prostate cancer; Population; Olaparib; Cancer; Confidence interval; Breast cancer; Gene; Androgen receptor; Genetics; Biology","score_opus":0.10803314538210798,"score_gpt":0.425071431637462,"score_spread":0.317038286255354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006784906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154043,0.0003746807,0.00012907624,0.0067558065,0.00026975325,0.0008351089,0.00004637457,0.0000129614855,0.00003579287],"genre_scores_gemma":[0.98812646,0.00063052314,0.009097455,0.0018390272,0.00015108605,0.000033092838,0.000029401313,0.000021541438,0.0000714431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961838,0.00055517274,0.0023821085,0.0002737393,0.00041591082,0.00018924706],"domain_scores_gemma":[0.9953553,0.0011419628,0.0022849634,0.0001415136,0.0007977452,0.00027848972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012649555,0.00015895844,0.0011255231,0.00012416116,0.000046927173,0.0000164362,0.00007576833,0.0001516793,0.00006189239],"category_scores_gemma":[0.002155742,0.000119031116,0.000141223,0.00026109396,0.00023543822,0.00029933386,0.000019379255,0.00063987833,0.0000014434028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0812556,0.011000472,0.78335077,0.0004394148,0.0016231196,0.0006821241,0.0026452441,0.0006091672,0.01391297,0.00013653561,0.011187438,0.09315713],"study_design_scores_gemma":[0.07568185,0.05094979,0.8603689,0.00047708803,0.0007076623,0.00013311904,0.0001792931,0.0005063517,0.0032391169,0.00012212023,0.007363328,0.0002713449],"about_ca_topic_score_codex":0.00008095853,"about_ca_topic_score_gemma":0.00016815524,"teacher_disagreement_score":0.09288578,"about_ca_system_score_codex":0.0002660907,"about_ca_system_score_gemma":0.0014346201,"threshold_uncertainty_score":0.4853948},"labels":[],"label_agreement":null},{"id":"W3007379615","doi":"10.1136/ijgc-2019-esgo.17","title":"Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Ovarian cancer; Surgery; Placebo; Oncology; Chemotherapy; Cancer; Pathology","score_opus":0.027395970010690433,"score_gpt":0.3306703729266041,"score_spread":0.3032744029159137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007379615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942116,0.0006063987,0.00011676778,0.0033573227,0.0007538169,0.00085500546,0.000078553596,0.0000052795335,0.000015233203],"genre_scores_gemma":[0.9973311,0.00023154255,0.00019603736,0.0018299967,0.0001731335,0.00017795937,0.00001974097,0.00001912036,0.00002139741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976452,0.00022391495,0.0008720958,0.00026800408,0.0007076409,0.00028313312],"domain_scores_gemma":[0.9952608,0.0034703158,0.000735243,0.0001109232,0.00034100586,0.00008173667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008782255,0.00021261603,0.0006681601,0.00020508652,0.00003587622,0.000043240565,0.0001566302,0.00009139019,0.00041430624],"category_scores_gemma":[0.0006209636,0.00011233506,0.00014139018,0.00021653011,0.0001775865,0.00025425092,0.000023778566,0.00041927793,3.048102e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46707216,0.0019039453,0.47105914,0.000040401585,0.0005817301,0.0005130464,0.003127215,0.0008817867,0.0005574484,0.000012974468,0.001429921,0.052820224],"study_design_scores_gemma":[0.20714739,0.0019089656,0.7874956,0.0012276331,0.00007355322,0.000032601787,0.0007379949,0.0002680518,0.00049204525,0.00008019569,0.00031968503,0.00021626694],"about_ca_topic_score_codex":0.00017743286,"about_ca_topic_score_gemma":0.00023052396,"teacher_disagreement_score":0.31643647,"about_ca_system_score_codex":0.0005246912,"about_ca_system_score_gemma":0.0006683933,"threshold_uncertainty_score":0.45808908},"labels":[],"label_agreement":null},{"id":"W3007397555","doi":"10.1016/j.ygyno.2019.11.045","title":"Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; PARP inhibitor; Internal medicine; Adverse effect; Ovarian cancer; Oncology; Clinical trial; Cancer; Poly ADP ribose polymerase; Surgery; Polymerase","score_opus":0.05037637286026122,"score_gpt":0.3320429756358292,"score_spread":0.281666602775568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007397555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95831496,0.00062021834,0.00002071977,0.036680795,0.00044537566,0.0021879976,0.0010585993,0.00003305758,0.000638262],"genre_scores_gemma":[0.9951781,0.001967736,0.0009853886,0.0012734684,0.0002849699,0.0001341674,0.000111463756,0.000017703227,0.00004697419],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99711514,0.00052018615,0.0012234001,0.00058405276,0.00027126467,0.00028597662],"domain_scores_gemma":[0.9969931,0.0014577858,0.0008593636,0.00042522035,0.00012291143,0.00014161188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057078834,0.0002510026,0.001049182,0.00007825171,0.000049097696,0.0000043546634,0.0001641709,0.00030491233,0.00011040552],"category_scores_gemma":[0.00075636903,0.00015487395,0.00010657742,0.0004927187,0.00035712685,0.000036311216,0.000063662046,0.00039175208,0.0000020928526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9325185,0.0020597922,0.0052151284,0.000045414796,0.00037417677,0.00009838233,0.00773641,0.0006984756,0.0044283043,0.00008729485,0.0014421529,0.045295995],"study_design_scores_gemma":[0.77844244,0.047670778,0.11041918,0.0005075854,0.0003155176,0.000010048268,0.000448371,0.00076001155,0.015616874,0.00046471224,0.04497695,0.00036755038],"about_ca_topic_score_codex":0.0010167527,"about_ca_topic_score_gemma":0.0021157046,"teacher_disagreement_score":0.15407605,"about_ca_system_score_codex":0.0005191848,"about_ca_system_score_gemma":0.0007869422,"threshold_uncertainty_score":0.63155764},"labels":[],"label_agreement":null},{"id":"W3008873783","doi":"10.1200/jco.2020.38.6_suppl.119","title":"TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Docetaxel; Oncology; Taxane; Phases of clinical research; Interim analysis; Febrile neutropenia; Urology; Cancer; Chemotherapy; Neutropenia; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.15250295692949076,"score_gpt":0.5082804380046673,"score_spread":0.3557774810751765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008873783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909367,0.00022313933,0.00018056897,0.0072306506,0.00008662828,0.00092054287,0.000044541644,0.000012921963,0.0003643251],"genre_scores_gemma":[0.9968467,0.0001588513,0.002059565,0.00058549026,0.00015282027,0.00008519204,0.000010253553,0.000019972891,0.00008116865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955264,0.00054654095,0.0029270642,0.00032720182,0.00047249874,0.00020033063],"domain_scores_gemma":[0.9958913,0.0008289739,0.0021587277,0.00020349784,0.0005333274,0.00038421393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018009644,0.0001908119,0.0019230642,0.0003296194,0.000073539675,0.000012380673,0.00011398517,0.00010096001,0.00019304403],"category_scores_gemma":[0.0008767313,0.00013940057,0.00029520754,0.0009352063,0.000343566,0.00021119353,0.00004994894,0.00067357096,8.125788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15676092,0.064072706,0.5959372,0.00088030606,0.033140384,0.011813786,0.06558753,0.009429417,0.038227737,0.00010651861,0.0035550422,0.020488454],"study_design_scores_gemma":[0.15400991,0.2900496,0.49662554,0.0006626729,0.014837684,0.00031779002,0.02682865,0.009967391,0.0016834264,0.00018864832,0.004284409,0.00054426456],"about_ca_topic_score_codex":0.0002136994,"about_ca_topic_score_gemma":0.0026414506,"teacher_disagreement_score":0.2259769,"about_ca_system_score_codex":0.00018508216,"about_ca_system_score_gemma":0.0012683214,"threshold_uncertainty_score":0.568459},"labels":[],"label_agreement":null},{"id":"W3010406759","doi":"10.1158/1078-0432.ccr-19-0514","title":"PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Cancer Institute; National Institutes of Health; National Institute of Dental and Craniofacial Research; U.S. Department of Veterans Affairs","keywords":"Olaparib; Head and neck squamous-cell carcinoma; Cancer research; PARP inhibitor; Gene knockdown; DNA damage; Biology; Radiation therapy; Head and neck cancer; Medicine; Poly ADP ribose polymerase; Cell culture; Internal medicine; Gene; DNA; Genetics","score_opus":0.31904800252865156,"score_gpt":0.5218961593901456,"score_spread":0.202848156861494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010406759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806692,0.0140009625,0.00006737003,0.0023905053,0.00010238413,0.00086908706,0.000026414304,0.000032458986,0.0018416414],"genre_scores_gemma":[0.9961949,0.0017574787,0.00020685146,0.00088901556,0.00053983956,0.00023732347,0.00001836429,0.000040060364,0.00011618874],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968969,0.00040523207,0.00086488,0.00065351103,0.00071829103,0.0004611485],"domain_scores_gemma":[0.9986565,0.00034742334,0.00012628276,0.0002994897,0.00019015122,0.00038013016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094845024,0.00018139069,0.00062462874,0.00017025703,0.00010026841,0.00002346807,0.00012408184,0.00017971054,0.0004267785],"category_scores_gemma":[0.00006108555,0.00016466333,0.00013753172,0.00049184967,0.0007173028,0.000115785755,0.00006974012,0.000661978,0.0000071280933],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073542693,0.0025736382,0.07461534,0.0005647431,0.00004561273,0.00010997202,0.008148375,0.0004548092,0.89789706,0.0006900912,0.003170071,0.0043760375],"study_design_scores_gemma":[0.023736682,0.012318635,0.015914008,0.00041533646,0.000018472218,0.0000075367675,0.0014624171,0.0047594314,0.93613535,0.0006433426,0.004217641,0.00037116025],"about_ca_topic_score_codex":0.0008633077,"about_ca_topic_score_gemma":0.000105648825,"teacher_disagreement_score":0.058701333,"about_ca_system_score_codex":0.00038074297,"about_ca_system_score_gemma":0.0004037805,"threshold_uncertainty_score":0.67147756},"labels":[],"label_agreement":null},{"id":"W3011487857","doi":"10.3390/cancers12030687","title":"ATM-Deficient Cancers Provide New Opportunities for Precision Oncology","year":2020,"lang":"en","type":"review","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; National Institutes of Health; Alberta Cancer Foundation; Cancer Research Society","keywords":"PARP inhibitor; Cancer research; Poly ADP ribose polymerase; Synthetic lethality; Ataxia-telangiectasia; Cancer; DNA damage; Ovarian cancer; Cytotoxic T cell; Medicine; DNA repair; Polymerase; Gene; Biology; DNA; Internal medicine; Genetics; In vitro","score_opus":0.30292238567366414,"score_gpt":0.4471689206659985,"score_spread":0.14424653499233436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011487857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001276956,0.9800892,0.0009950621,0.0018367979,0.0025021979,0.0045107,0.0004998825,0.00018085427,0.009384067],"genre_scores_gemma":[0.0000019587792,0.9816776,0.0014298875,0.0027082528,0.002394401,0.0015997232,0.00042977277,0.00017934197,0.009579051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969691,0.00011714459,0.0009900074,0.0008827306,0.00045261215,0.00058838306],"domain_scores_gemma":[0.9973955,0.00038105997,0.00074846734,0.0005885009,0.00018638311,0.00070005324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026240697,0.0006385723,0.0027848089,0.00024455236,0.00012111457,0.000034948007,0.00032522058,0.0005320166,0.00059529376],"category_scores_gemma":[0.00016148,0.0005474311,0.0008980929,0.00038602712,0.0002039153,0.00008104693,0.00006437225,0.0005816366,0.000060154896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002465028,0.000007593421,1.4280873e-7,0.0077869687,0.00027030354,0.000060129245,0.0002018968,0.000028529437,0.0000022826887,0.00012652687,0.23055978,0.76070935],"study_design_scores_gemma":[0.0018562499,0.0011996998,8.063646e-8,0.015527366,0.00141169,0.00011736879,0.00027185606,0.000046417048,0.000022315835,0.000066262735,0.9790079,0.00047278576],"about_ca_topic_score_codex":0.00032289836,"about_ca_topic_score_gemma":0.000070974034,"teacher_disagreement_score":0.76023656,"about_ca_system_score_codex":0.026723888,"about_ca_system_score_gemma":0.055143915,"threshold_uncertainty_score":0.99969774},"labels":[],"label_agreement":null},{"id":"W3012410365","doi":"10.1101/2020.03.13.991166","title":"ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cumming School of Medicine, University of Calgary; Alberta Cancer Foundation; Cancer Research Society","keywords":"Olaparib; PARP inhibitor; Cancer research; Prostate cancer; Pancreatic cancer; Lung cancer; Cancer; Medicine; Prostate; Apoptosis; Poly ADP ribose polymerase; Oncology; Internal medicine; Biology; Polymerase; Biochemistry","score_opus":0.014263968221869639,"score_gpt":0.24813467360886943,"score_spread":0.23387070538699978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012410365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770408,0.0029183947,0.0004058169,0.014581094,0.0007474808,0.0035830834,0.00060262287,0.00011055268,0.000010149011],"genre_scores_gemma":[0.9942235,0.002007544,0.000479916,0.0022045744,0.0003745142,0.0006052014,7.8560623e-7,0.000089610716,0.0000143799525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744153,0.00028168835,0.0005780084,0.0008035423,0.0005488911,0.00034631407],"domain_scores_gemma":[0.99732953,0.00020147396,0.0006527944,0.00077002414,0.00078924285,0.00025692058],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070195954,0.00046893986,0.0008655307,0.0001293916,0.00020226692,0.00011970378,0.00018636261,0.00023409314,0.00001513988],"category_scores_gemma":[0.00017422104,0.0003185979,0.00011900693,0.00048141493,0.0004731941,0.00006526203,0.00038255134,0.0006926939,0.000010692248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026077593,0.0002568375,0.01489216,0.0026210716,0.0011347798,0.00008211408,0.0015925625,0.00017972614,0.9696715,0.0013225426,0.005615551,0.000023385726],"study_design_scores_gemma":[0.007259411,0.00030573015,0.16833782,0.0037814036,0.0012729806,2.9114426e-7,0.00014029638,0.00253787,0.81086177,0.000008864701,0.0047350745,0.0007584808],"about_ca_topic_score_codex":0.00017759456,"about_ca_topic_score_gemma":0.000008509664,"teacher_disagreement_score":0.15880974,"about_ca_system_score_codex":0.00031995136,"about_ca_system_score_gemma":0.00046764966,"threshold_uncertainty_score":0.9999266},"labels":[],"label_agreement":null},{"id":"W3012828029","doi":"","title":"Acquired multiple secondary <i>BRCA2</i> mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a <i>BRCA2</i> germline mutation.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Power Generation","funders":"","keywords":"Olaparib; Medicine; Pancreatic cancer; PARP inhibitor; Germline mutation; Cancer research; PTEN; KRAS; Germline; Metastasis; Cancer; Oncology; BRCA2 Protein; PALB2; Internal medicine; Mutation; Biology; Genetics; Gene; Poly ADP ribose polymerase; Colorectal cancer; PI3K/AKT/mTOR pathway","score_opus":0.039121353088805336,"score_gpt":0.2691174818229154,"score_spread":0.22999612873411007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012828029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631706,0.010286389,0.0011939055,0.016857032,0.0004711033,0.0045741256,0.00053600076,0.00037746603,0.0025333725],"genre_scores_gemma":[0.97572446,0.00029690267,0.002783836,0.0075166575,0.00026178994,0.012904601,0.00019761456,0.000088307985,0.0002258497],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99682224,0.00018750675,0.0009671123,0.0007084935,0.00058996317,0.0007247007],"domain_scores_gemma":[0.99822646,0.00033823986,0.00035030112,0.00039429162,0.00019718731,0.0004935155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000297285,0.00036254263,0.0006951599,0.00021960898,0.00012935113,0.00005654595,0.00015718649,0.00008692883,0.00024277483],"category_scores_gemma":[0.0005115557,0.00036878977,0.00017027905,0.0011064293,0.00011173066,0.0003556471,0.000045847923,0.0003246022,0.000028903349],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029861229,0.005671211,0.13990374,0.010167163,0.00547581,0.007230954,0.081051506,0.017349789,0.053839862,0.0020325438,0.05222841,0.5951878],"study_design_scores_gemma":[0.06467848,0.00071890786,0.6320113,0.0018584272,0.0017604541,0.00017045287,0.0033758446,0.010978775,0.10753944,0.003025792,0.17067361,0.0032085297],"about_ca_topic_score_codex":0.00019676684,"about_ca_topic_score_gemma":0.0007077131,"teacher_disagreement_score":0.59197927,"about_ca_system_score_codex":0.0005525939,"about_ca_system_score_gemma":0.00034934818,"threshold_uncertainty_score":0.9998764},"labels":[],"label_agreement":null},{"id":"W3013900427","doi":"10.1158/1538-7445.sabcs19-p1-19-03","title":"Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Cohort; Metastatic breast cancer; Oncology; Breast cancer; Regimen; PARP inhibitor; Avelumab; Cancer; Immunotherapy; Pembrolizumab; Poly ADP ribose polymerase","score_opus":0.16122024825631753,"score_gpt":0.47931689957853846,"score_spread":0.3180966513222209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013900427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97671145,0.0031763555,0.00002179711,0.010252972,0.00040750357,0.0028888737,0.0049788714,0.00014690116,0.0014152466],"genre_scores_gemma":[0.9931789,0.0023872857,0.000098347264,0.0008830493,0.0013902298,0.0013823517,0.00022416544,0.00012356715,0.00033209196],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99364406,0.00031891387,0.0012348786,0.001356878,0.0024531032,0.0009921519],"domain_scores_gemma":[0.99581945,0.0005557681,0.00039134378,0.00105241,0.0011209869,0.0010600325],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010586428,0.00043084662,0.0011263805,0.00029258148,0.00026122926,0.00005878665,0.00055784587,0.00021895958,0.0035881756],"category_scores_gemma":[0.0004513991,0.0004003851,0.0001743381,0.001365091,0.0004761235,0.00024600484,0.0002218337,0.001435136,0.00011327468],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1676855,0.013003948,0.014444756,0.0013767213,0.0030388366,0.002669818,0.06289142,0.0033943383,0.4926737,0.000050142044,0.1464773,0.09229353],"study_design_scores_gemma":[0.45303497,0.010434585,0.1465093,0.0060310625,0.00078046817,0.00012013267,0.02827246,0.0031180119,0.2831065,0.00050022337,0.06530174,0.0027905265],"about_ca_topic_score_codex":0.015907455,"about_ca_topic_score_gemma":0.0015256293,"teacher_disagreement_score":0.28534946,"about_ca_system_score_codex":0.0014961576,"about_ca_system_score_gemma":0.0026894202,"threshold_uncertainty_score":0.9998448},"labels":[],"label_agreement":null},{"id":"W3014505500","doi":"10.1038/s41419-020-2405-4","title":"Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells","year":2020,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; V Foundation for Cancer Research; U.S. Department of Veterans Affairs; U.S. Department of Health and Human Services","keywords":"Demethylase; DNA repair; Cancer research; Histone; DNA damage; Ubiquitin; RAD51; Ubiquitin ligase; Biology; Chromatin; Prostate cancer; Ectopic expression; Chemistry; Cell biology; Molecular biology; DNA; Gene; Cancer; Genetics","score_opus":0.01986833149242749,"score_gpt":0.278940114980924,"score_spread":0.2590717834884965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014505500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741375,0.024535239,0.000035888537,0.00036476477,0.000044517725,0.00044484064,0.00024912562,0.000041806492,0.00014635663],"genre_scores_gemma":[0.99723995,0.001590116,0.00046913401,0.00026300302,0.00004765027,0.000032239375,0.000018143277,0.000018932082,0.0003208191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990785,0.000038397295,0.00025964496,0.00029219134,0.00018737794,0.00014387941],"domain_scores_gemma":[0.9988804,0.000039853257,0.00015359346,0.0001773464,0.00007335802,0.0006754345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051070325,0.00015082113,0.00030398794,0.00004104034,0.000040398332,0.0000042973957,0.000035725912,0.000040235962,0.00008616599],"category_scores_gemma":[0.00005897897,0.000120038196,0.00007726394,0.0000922441,0.0001442877,0.00006422906,0.000024628558,0.00007114092,6.155686e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022325683,0.00016865453,0.0834964,0.002744418,0.00002082651,0.000031571853,0.0012811772,0.000002971953,0.90738904,0.000014518302,0.0024774147,0.00014045322],"study_design_scores_gemma":[0.0023601167,0.00014925245,0.018546317,0.00038002728,0.0001418748,3.2681018e-7,0.00009595236,0.00006373366,0.97613484,0.000086559885,0.0019122323,0.00012879666],"about_ca_topic_score_codex":0.000024440551,"about_ca_topic_score_gemma":0.0000013185434,"teacher_disagreement_score":0.068745784,"about_ca_system_score_codex":0.000027162536,"about_ca_system_score_gemma":0.00017797301,"threshold_uncertainty_score":0.48950157},"labels":[],"label_agreement":null},{"id":"W3014627414","doi":"10.1126/science.aax6367","title":"Structural basis for allosteric PARP-1 retention on DNA breaks","year":2020,"lang":"en","type":"article","venue":"Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":331,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health; Cancer Research UK; National Cancer Institute; Breast Cancer Now","keywords":"Poly ADP ribose polymerase; Allosteric regulation; DNA; DNA repair; Polymerase; Chemistry; DNA damage; PARP inhibitor; Computational biology; Cancer research; Biochemistry; Biology; Enzyme","score_opus":0.0836537283378432,"score_gpt":0.34084948136979104,"score_spread":0.25719575303194786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014627414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98343396,0.000043274053,0.00074413617,0.012585484,0.00041913733,0.00039220665,0.000023506407,0.00007229826,0.0022860216],"genre_scores_gemma":[0.9914244,0.0000065033414,0.0013860047,0.006764452,0.00022632797,0.000025664931,0.00000527157,0.0000072183316,0.00015415296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990384,0.000009177323,0.000118661286,0.00030040424,0.00033971074,0.000193676],"domain_scores_gemma":[0.9995188,0.000028437893,0.000048869355,0.00015634394,0.00009370369,0.00015385619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016008869,0.0000700309,0.00010228106,0.000049946062,0.00012914135,0.00002823107,0.00012398916,0.000023419363,0.00016462935],"category_scores_gemma":[0.00015148868,0.00005679131,0.00005054995,0.00041107758,0.00021293035,0.00013587173,0.000018667524,0.00006130313,0.00004393739],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049498584,0.00001449931,0.0012406879,0.000054820106,0.000008106406,0.0000045638094,0.00069118635,0.000021302758,0.9742792,0.0008210009,0.0023685826,0.020001065],"study_design_scores_gemma":[0.004971683,0.00356495,0.16915402,0.0003220361,0.00006219657,0.00007588471,0.00041202654,0.012523408,0.76473963,0.0022425589,0.041436575,0.00049505755],"about_ca_topic_score_codex":0.0000020812518,"about_ca_topic_score_gemma":5.145228e-7,"teacher_disagreement_score":0.20953959,"about_ca_system_score_codex":0.00008987395,"about_ca_system_score_gemma":0.000121359655,"threshold_uncertainty_score":0.23158823},"labels":[],"label_agreement":null},{"id":"W3015368557","doi":"10.1136/ijgc-2020-001288","title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","year":2020,"lang":"en","type":"review","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Poly ADP ribose polymerase; Adverse effect; Polymerase; PARP inhibitor; Internal medicine; Enzyme; Biochemistry","score_opus":0.0755815279870802,"score_gpt":0.41434140622800464,"score_spread":0.33875987824092446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015368557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000790659,0.989901,0.00003912198,0.0047352077,0.0029118154,0.0006074611,0.00041688062,0.000031382715,0.0005664572],"genre_scores_gemma":[0.0017197342,0.9909408,0.00032880504,0.0016469036,0.004404835,0.00012037753,0.00005879977,0.000054862252,0.0007248444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970564,0.00017791861,0.0012771927,0.00043019064,0.00076585537,0.00029244716],"domain_scores_gemma":[0.9972679,0.00035965507,0.0013178698,0.00016842672,0.00039979615,0.0004863423],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017311618,0.0005231576,0.0019455028,0.0003556592,0.000056220815,0.000024129735,0.00036604147,0.0003484201,0.0026551294],"category_scores_gemma":[0.00019890194,0.00034933753,0.0009412187,0.00020200615,0.00014086142,0.00016404134,0.00011355883,0.00064783375,0.00005811506],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071949884,0.0003858884,0.00021142424,0.00049436407,0.0026945272,0.002058841,0.00006606287,0.0000013977254,0.000014831576,0.000061603525,0.0021349683,0.9911566],"study_design_scores_gemma":[0.0036782487,0.0012561347,0.0003587513,0.0050608157,0.0015142304,0.001194411,0.000019888788,0.0000037657499,0.00005564893,0.00009093408,0.98648036,0.000286833],"about_ca_topic_score_codex":0.000030776744,"about_ca_topic_score_gemma":0.000009942429,"teacher_disagreement_score":0.99086976,"about_ca_system_score_codex":0.0023568457,"about_ca_system_score_gemma":0.00094005896,"threshold_uncertainty_score":0.9998959},"labels":[],"label_agreement":null},{"id":"W3015673613","doi":"10.1007/s42764-020-00011-0","title":"ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738","year":2020,"lang":"en","type":"article","venue":"Genome Instability & Disease","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cumming School of Medicine, University of Calgary; Alberta Cancer Foundation; Cancer Research Society","keywords":"Olaparib; PARP inhibitor; Cancer research; Prostate cancer; Poly ADP ribose polymerase; Apoptosis; Pancreatic cancer; Lung cancer; Programmed cell death; Medicine; Cancer; Chemistry; Internal medicine; Polymerase; Biochemistry; DNA","score_opus":0.01542149582609048,"score_gpt":0.26278315751944903,"score_spread":0.24736166169335855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015673613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578564,0.002090388,0.00010332455,0.036425836,0.00009581588,0.0026577928,0.0006547922,0.000033926863,0.00008169747],"genre_scores_gemma":[0.9940502,0.0003977868,0.000041647992,0.005070061,0.00011592012,0.00023876695,0.000025502113,0.000020499372,0.000039635255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983905,0.00022762943,0.00036708903,0.000428868,0.0003648486,0.00022106522],"domain_scores_gemma":[0.9985939,0.0001680111,0.0001766782,0.00038190343,0.00028876727,0.00039073694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037881854,0.00019569197,0.00038583335,0.000034347773,0.0001725776,0.000036693724,0.00008023911,0.00003700484,0.000052507716],"category_scores_gemma":[0.00018367007,0.00012026082,0.00008995193,0.00029614725,0.0005530964,0.00007285296,0.000113190865,0.00016670392,0.0000081933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09439552,0.0030091375,0.43647268,0.009757389,0.0018063759,0.00019971057,0.23614453,0.002559368,0.18856455,0.002200947,0.0065778303,0.01831196],"study_design_scores_gemma":[0.012571272,0.00057942816,0.9568516,0.00041393173,0.001071711,0.000007777503,0.00569019,0.0034947325,0.012429226,0.00035227506,0.0060858093,0.00045206823],"about_ca_topic_score_codex":0.000121727855,"about_ca_topic_score_gemma":0.000026652662,"teacher_disagreement_score":0.5203789,"about_ca_system_score_codex":0.00017018663,"about_ca_system_score_gemma":0.00021547814,"threshold_uncertainty_score":0.4904094},"labels":[],"label_agreement":null},{"id":"W3022078556","doi":"10.1101/2020.05.05.078097","title":"PARP12-catalyzed mono-ADP-ribosylation of Golgin-97 controls the transport of E-cadherin","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; Medical Research Council; Associazione Italiana per la Ricerca sul Cancro; Fondazione Cariplo","keywords":"Exocytosis; Cell biology; ADP-ribosylation; ADP ribosylation factor; Golgi apparatus; Compartment (ship); Chemistry; Mutagenesis; Mutant; Enzyme; Biology; Biochemistry; Cell; Membrane; Gene; NAD+ kinase","score_opus":0.0292511132802511,"score_gpt":0.2556243838116016,"score_spread":0.22637327053135048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022078556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98636323,0.0022781212,0.0049997503,0.0022224204,0.0007530868,0.002301548,0.00075746025,0.00025884734,0.000065523505],"genre_scores_gemma":[0.9963675,0.00051699294,0.0017792295,0.00035693112,0.00048408486,0.0003447769,0.000003656455,0.00013836824,0.000008436232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99662644,0.00015995667,0.0012750808,0.0007940659,0.0007466405,0.0003977941],"domain_scores_gemma":[0.99608666,0.00014381064,0.0011795936,0.0015784297,0.0007548289,0.0002566794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072342984,0.00055396504,0.0013425602,0.00020086912,0.00007084374,0.000022678778,0.00050428556,0.0005141507,0.00019161977],"category_scores_gemma":[0.00016644446,0.00048236805,0.00045164066,0.00061420404,0.0003491588,0.00010007775,0.00010914372,0.00087974226,0.000037336045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072933687,0.00019827594,0.017464092,0.0011052968,0.0006039304,0.000025563544,0.0000699333,0.000119693745,0.9787902,0.00070060306,0.00018682268,0.000006229271],"study_design_scores_gemma":[0.0032621953,0.00015527976,0.16647531,0.0010047872,0.00056638266,4.075629e-8,0.000008749946,0.00038756282,0.8229114,0.000012940091,0.0047671082,0.00044828272],"about_ca_topic_score_codex":0.00010133158,"about_ca_topic_score_gemma":0.0000021677608,"teacher_disagreement_score":0.15587887,"about_ca_system_score_codex":0.00022625345,"about_ca_system_score_gemma":0.0010031097,"threshold_uncertainty_score":0.9997628},"labels":[],"label_agreement":null},{"id":"W3022356865","doi":"10.1200/edbk_288015","title":"PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair","year":2020,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"DNA Damage Repair; Ovarian cancer; Serous fluid; Cancer; PARP inhibitor; DNA damage; DNA repair; Medicine; Olaparib; Biology; Oncology; Poly ADP ribose polymerase; Cancer research; Internal medicine; Bioinformatics; DNA; Genetics","score_opus":0.12921200137641028,"score_gpt":0.5227415520295526,"score_spread":0.3935295506531423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022356865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014562922,0.9043251,0.00056808104,0.08918481,0.0013746815,0.0035518862,0.0004918677,0.000053454212,0.00030448392],"genre_scores_gemma":[0.00003577099,0.8976822,0.0862107,0.008922114,0.0019389908,0.0034815392,0.0012313282,0.000056849938,0.00044049986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955533,0.00027289253,0.0026198614,0.00084949913,0.00038982142,0.00031462914],"domain_scores_gemma":[0.9938895,0.0029481826,0.0019457149,0.00033277288,0.00039485135,0.0004889879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00127933,0.00039801636,0.0028936248,0.00016800445,0.00012426681,0.000009279438,0.00023933015,0.0004178833,0.0001479319],"category_scores_gemma":[0.0006385177,0.00038012737,0.0008755585,0.0006836647,0.00072031515,0.00007568981,0.00010250305,0.00096023415,0.000015999796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064278676,0.002083225,0.0024654418,0.0025493477,0.00055310514,8.2036877e-7,0.0006413961,5.84931e-7,0.0000012790999,0.0015630878,0.14012884,0.8499486],"study_design_scores_gemma":[0.0018895721,0.00048254404,0.01288295,0.0025840504,0.0003713091,0.00001272838,0.0002474823,0.000008048888,0.0000015582092,0.00010183749,0.98110163,0.0003162837],"about_ca_topic_score_codex":0.000027097463,"about_ca_topic_score_gemma":0.000010702821,"teacher_disagreement_score":0.8496323,"about_ca_system_score_codex":0.0013317493,"about_ca_system_score_gemma":0.020423522,"threshold_uncertainty_score":0.99986506},"labels":[],"label_agreement":null},{"id":"W3023738757","doi":"10.1016/s1470-2045(20)30061-9","title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Manchester Biomedical Research Centre; Clovis Oncology; Memorial Sloan-Kettering Cancer Center; Stand Up To Cancer; Entertainment Industry Foundation; V Foundation for Cancer Research; University College London; American Association for Cancer Research","keywords":"Placebo; Medicine; Oncology; Internal medicine; Ovarian carcinoma; Ovarian cancer; Cancer; Alternative medicine; Pathology","score_opus":0.04068493652222073,"score_gpt":0.3485534876066515,"score_spread":0.3078685510844308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023738757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94540614,0.00010878446,0.0005585403,0.041160095,0.00063332537,0.008467938,0.002356452,0.00010456289,0.0012041817],"genre_scores_gemma":[0.9856491,0.00003978945,0.0028330376,0.007347767,0.0013187564,0.00060266705,0.0021193908,0.000039153212,0.000050311715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974719,0.00055622566,0.00075833144,0.00052342645,0.00029038146,0.00039971858],"domain_scores_gemma":[0.996346,0.0022034233,0.0005613186,0.0003727097,0.00029573232,0.0002208462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073929963,0.0003036253,0.0015885502,0.000050279465,0.00021128813,0.00002629036,0.0001391361,0.00020091514,0.000085294596],"category_scores_gemma":[0.0009917811,0.00017183399,0.00014654784,0.0001365496,0.0002268333,0.00006914426,0.000055085507,0.00039827405,0.000008376133],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97918904,0.0005097961,0.0011851772,0.00001852905,0.00044625596,0.000028740187,0.002092366,0.00000379825,0.00042758114,0.00009376711,0.005989914,0.010015048],"study_design_scores_gemma":[0.95955133,0.011966951,0.0040475284,0.00006977442,0.00045286672,0.000008262092,0.00018693307,0.0010036641,0.0003624383,0.00007632558,0.02206791,0.00020599349],"about_ca_topic_score_codex":0.000055997276,"about_ca_topic_score_gemma":0.00003535869,"teacher_disagreement_score":0.040243007,"about_ca_system_score_codex":0.00016091218,"about_ca_system_score_gemma":0.00030455008,"threshold_uncertainty_score":0.7007187},"labels":[],"label_agreement":null},{"id":"W3025118874","doi":"10.1101/2020.05.11.089375","title":"The SARS-CoV-2 conserved macrodomain is a mono-ADP-ribosylhydrolase","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"University of Oxford","keywords":"Biology; Ribose; Population; Virology; Enzyme; Biochemistry; Medicine","score_opus":0.03913652967567851,"score_gpt":0.28333951384626527,"score_spread":0.24420298417058675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025118874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653,0.0042195884,0.001029686,0.023141949,0.0019968941,0.002382465,0.0007992695,0.0010398625,0.000090237736],"genre_scores_gemma":[0.9808397,0.0013304972,0.0024618476,0.012992341,0.0013139492,0.00072740996,0.0000010339883,0.00031120918,0.00002195682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99527174,0.0003109236,0.0010427174,0.0015645128,0.0008734503,0.00093666],"domain_scores_gemma":[0.9952126,0.00023971905,0.0007183712,0.002690983,0.0006679267,0.00047039724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089407305,0.0009383759,0.0011274932,0.00020147755,0.00045057156,0.00035835075,0.00083294266,0.0007670926,0.0001039193],"category_scores_gemma":[0.0004053386,0.0008304472,0.00052477786,0.00070109696,0.0004924354,0.00011443138,0.0005758234,0.0019009141,0.00054931676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006183056,0.00014866928,0.002261474,0.00044776022,0.0006292206,0.00042398393,0.000039681316,0.0000032352698,0.96364343,0.00048245885,0.031298555,0.0000031968968],"study_design_scores_gemma":[0.0027630376,0.00014874236,0.006563,0.00073682127,0.00030117077,2.5720104e-7,0.000005149805,0.0007020675,0.86693996,0.00003413783,0.12097338,0.0008322675],"about_ca_topic_score_codex":0.00010314332,"about_ca_topic_score_gemma":0.0000046032383,"teacher_disagreement_score":0.096703485,"about_ca_system_score_codex":0.0007060654,"about_ca_system_score_gemma":0.0017696038,"threshold_uncertainty_score":0.9994146},"labels":[],"label_agreement":null},{"id":"W3026647982","doi":"10.1158/1557-3265.ovcasymp18-gmm-048","title":"Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"PARP inhibitor; Loss of heterozygosity; Oncology; Medicine; Internal medicine; Ovarian cancer; Progression-free survival; Cancer; Biology; Allele; Chemotherapy; Genetics; Poly ADP ribose polymerase; DNA; Gene","score_opus":0.2549700596045747,"score_gpt":0.530908562304738,"score_spread":0.27593850270016335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026647982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8349172,0.0005831151,0.0000021901399,0.15484604,0.0020576692,0.0046338215,0.00014727455,0.00006130989,0.0027514114],"genre_scores_gemma":[0.98123604,0.00062210177,0.000047489015,0.003651664,0.0038270785,0.0014472498,0.000009772834,0.000087235836,0.009071354],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9892244,0.004690808,0.001123068,0.0010604205,0.0029204052,0.0009809512],"domain_scores_gemma":[0.9704145,0.025649322,0.00021758238,0.002401064,0.00058539683,0.0007321149],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03125756,0.0003372736,0.00068858487,0.00022519004,0.0005106737,0.00021047525,0.00093898544,0.00041467196,0.0022908212],"category_scores_gemma":[0.018298497,0.00018576124,0.00026792093,0.00061979675,0.0011036597,0.00011999954,0.00055944885,0.0029427155,0.0007480009],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7824968,0.00082313624,0.0042280667,0.00005037052,0.0001232,0.00004514238,0.00041728158,0.000008557956,0.0045046704,0.00035274084,0.20143902,0.0055110115],"study_design_scores_gemma":[0.0763294,0.02051868,0.15751682,0.0018029356,0.000053067964,0.000013801522,0.00068258675,0.00005319034,0.0029036314,0.0009967405,0.7387104,0.0004187261],"about_ca_topic_score_codex":0.00017401484,"about_ca_topic_score_gemma":0.00009816674,"teacher_disagreement_score":0.7061674,"about_ca_system_score_codex":0.00042696265,"about_ca_system_score_gemma":0.0022934633,"threshold_uncertainty_score":0.9993575},"labels":[],"label_agreement":null},{"id":"W3026903046","doi":"10.1158/1078-0432.ccr-19-4121","title":"EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Genomics; Ozmosis Research (Canada); Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Olaparib; Ovarian cancer; Medicine; PARP inhibitor; Oncology; Clinical trial; Internal medicine; Phases of clinical research; Open label; Cancer; Cancer research; Poly ADP ribose polymerase; Biology","score_opus":0.5458711143040862,"score_gpt":0.62167981321802,"score_spread":0.07580869891393383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026903046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94828486,0.0026751184,0.0011469733,0.03691716,0.0010640423,0.008640682,0.0009018842,0.000060888695,0.00030840017],"genre_scores_gemma":[0.983943,0.0015548,0.0035781588,0.0030165538,0.003955021,0.0035664786,0.00012863145,0.00007642555,0.00018094719],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99428284,0.000778546,0.0020409615,0.0011009494,0.0011750057,0.0006216764],"domain_scores_gemma":[0.9957126,0.0015464411,0.00035644035,0.00040399417,0.0011712228,0.00080930267],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004188747,0.00027734102,0.0010935552,0.0001296122,0.00026110653,0.000083451145,0.00028212962,0.00047284534,0.0012856182],"category_scores_gemma":[0.0014489915,0.00023451506,0.0002736668,0.00050041545,0.0012661506,0.00031601786,0.00026797023,0.0012710129,0.000008370742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7895216,0.0148142995,0.0057904455,0.0006438408,0.0003690317,0.00003593486,0.0009254917,0.0000039570946,0.006766545,0.00015949218,0.013736011,0.16723338],"study_design_scores_gemma":[0.8546994,0.050029717,0.0037945085,0.0021770792,0.00033529336,0.0000043527584,0.00011060966,0.0076446673,0.005471082,0.0007259474,0.07452828,0.0004790997],"about_ca_topic_score_codex":0.00009941899,"about_ca_topic_score_gemma":0.00008686982,"teacher_disagreement_score":0.16675428,"about_ca_system_score_codex":0.0001510928,"about_ca_system_score_gemma":0.0017408725,"threshold_uncertainty_score":0.99962735},"labels":[],"label_agreement":null},{"id":"W3027236667","doi":"10.1369/0022155420926022","title":"Assessment of PARP-1 Distribution in Tissues of Cynomolgus Monkeys","year":2020,"lang":"en","type":"article","venue":"Journal of Histochemistry & Cytochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise; Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; Biology; PARP inhibitor; Malignancy; Cell biology; Cancer research; Polymerase; DNA; Genetics","score_opus":0.02182162040626043,"score_gpt":0.33028831737859937,"score_spread":0.3084666969723389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027236667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114907,0.0017089285,0.001835534,0.0014560503,0.00006373167,0.00016292131,0.00011428787,0.000014096747,0.0034953805],"genre_scores_gemma":[0.99706644,0.00018119019,0.0021159083,0.000093179035,0.00033450732,0.000009297705,0.00007205995,0.000021577836,0.000105835716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974554,0.000026142066,0.0013891063,0.00023284099,0.00068314816,0.00021332533],"domain_scores_gemma":[0.99749404,0.00006913897,0.00134284,0.0003020139,0.00052110496,0.0002708705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023243681,0.00022224402,0.00084533176,0.000044183955,0.000020264095,0.0000054951083,0.00024849974,0.00020434559,0.00034316402],"category_scores_gemma":[0.00021609121,0.00022183653,0.00030743532,0.0003073984,0.00021318372,0.0000805103,0.000041539242,0.00058154005,0.0000010500446],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052051916,0.00034178444,0.010395296,0.0011040906,0.00010369554,0.00013671955,0.00017749511,0.00009278943,0.9833683,0.000015094639,0.0033173289,0.00042693334],"study_design_scores_gemma":[0.0030926168,0.00034933278,0.0063301423,0.00082505454,0.000115483046,0.00029481726,0.00023986818,0.0001336333,0.98626363,0.000057084315,0.002137067,0.00016127469],"about_ca_topic_score_codex":0.000009224487,"about_ca_topic_score_gemma":1.5661527e-7,"teacher_disagreement_score":0.005917375,"about_ca_system_score_codex":0.0005577634,"about_ca_system_score_gemma":0.00068667467,"threshold_uncertainty_score":0.9046231},"labels":[],"label_agreement":null},{"id":"W3028840094","doi":"10.1200/jco.2020.38.15_suppl.5539","title":"Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Enzalutamide; Prostate cancer; Cohort; Internal medicine; Oncology; Population; Quality of life (healthcare); Randomized controlled trial; Cancer; Androgen receptor; Poly ADP ribose polymerase","score_opus":0.36714487974955307,"score_gpt":0.5279855929166039,"score_spread":0.1608407131670508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028840094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465277,0.0012800542,0.0007981244,0.048802834,0.0008867439,0.0015489298,0.00007306784,0.000028080787,0.000054458957],"genre_scores_gemma":[0.9710159,0.0009706031,0.023331355,0.0039868653,0.00035554706,0.00016773591,0.0000372468,0.00003245208,0.000102331265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99215215,0.0013106123,0.0054658917,0.00032972643,0.00044993867,0.0002916632],"domain_scores_gemma":[0.99063474,0.0028870646,0.0047744997,0.00019109261,0.0010942871,0.0004182871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005074088,0.0001953776,0.0021381876,0.00015474812,0.0000690524,0.000011810314,0.00011775243,0.00021007769,0.00012298301],"category_scores_gemma":[0.0055640517,0.00013923498,0.00029360317,0.0004156486,0.00024582024,0.00023148637,0.00001611521,0.00072709046,0.0000023599207],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.848769,0.008588866,0.044618424,0.002429042,0.0047704377,0.0007054939,0.006156839,0.0059152623,0.01663957,0.001556879,0.00886769,0.050982468],"study_design_scores_gemma":[0.3447808,0.30311176,0.31940246,0.0019326315,0.001587357,0.0004527146,0.0028525044,0.0053507583,0.0051073073,0.00272117,0.011716062,0.0009844908],"about_ca_topic_score_codex":0.0003264391,"about_ca_topic_score_gemma":0.002193478,"teacher_disagreement_score":0.5039882,"about_ca_system_score_codex":0.0006405681,"about_ca_system_score_gemma":0.008734177,"threshold_uncertainty_score":0.99688536},"labels":[],"label_agreement":null},{"id":"W3029321131","doi":"10.1200/jco.2020.38.15_suppl.6070","title":"Patterns of progression and subsequent management of patients with <i>BRCA1/2</i> mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Placebo; Clinical endpoint; Ovarian cancer; Progression-free survival; Oncology; Progressive disease; Gastroenterology; Surgery; Cancer; Urology; Chemotherapy; Clinical trial; Pathology","score_opus":0.12830437491644747,"score_gpt":0.4527451347805888,"score_spread":0.32444075986414134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029321131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890083,0.00017446258,0.00015156875,0.006959748,0.0017286368,0.0015596657,0.00007456344,0.000011292234,0.0003317279],"genre_scores_gemma":[0.9963038,0.0004944159,0.001310924,0.00086330547,0.00093576557,0.000040988976,0.000015109532,0.000027871893,0.000007805088],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99553126,0.000768344,0.0022563892,0.0003167325,0.0008594237,0.00026787104],"domain_scores_gemma":[0.9938911,0.0013498425,0.0036096263,0.00019921213,0.000652493,0.00029771408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016178888,0.00023859182,0.0013705501,0.0000787084,0.000069035676,0.00001168126,0.00016010246,0.0002479723,0.00006573831],"category_scores_gemma":[0.00042958252,0.0001358969,0.0002627922,0.00018784871,0.00038762504,0.00008517007,0.00007610246,0.0009863933,0.0000013324175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75188076,0.0024318066,0.019508088,0.00018983912,0.001500379,0.00024413766,0.00092225167,0.00005843756,0.00018427818,0.000082857674,0.00040224614,0.22259489],"study_design_scores_gemma":[0.6459227,0.15199886,0.17651977,0.004700556,0.0020461685,0.00003914017,0.00085573434,0.00036594836,0.00795084,0.00006001162,0.009159144,0.00038112103],"about_ca_topic_score_codex":0.000012030873,"about_ca_topic_score_gemma":0.0000143300185,"teacher_disagreement_score":0.22221376,"about_ca_system_score_codex":0.0002022075,"about_ca_system_score_gemma":0.00070540915,"threshold_uncertainty_score":0.5541715},"labels":[],"label_agreement":null},{"id":"W3029414691","doi":"10.1200/jco.2020.38.15_suppl.tps3167","title":"Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Olaparib; Medicine; Isocitrate dehydrogenase; IDH1; Cancer; Cancer research; PARP inhibitor; Internal medicine; Oncology; Poly ADP ribose polymerase; Mutation; Biology; Genetics; Polymerase; Enzyme","score_opus":0.12185797537720819,"score_gpt":0.47379261583734217,"score_spread":0.351934640460134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029414691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931138,0.00010145561,0.00005307063,0.0053948686,0.00035098975,0.00045023215,0.000018572435,0.0000082481365,0.0005087531],"genre_scores_gemma":[0.99403065,0.00021494205,0.0007847835,0.0042700223,0.0006438905,0.0000060479,0.000007535715,0.000021057524,0.00002105593],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99557424,0.00054617616,0.0030005323,0.00022245359,0.00043609878,0.00022048436],"domain_scores_gemma":[0.9958983,0.0007001599,0.002320799,0.00012731261,0.0004422461,0.00051116844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018940432,0.00015912425,0.0019397944,0.00011291689,0.00003294171,0.0000048073025,0.000114572125,0.0002648812,0.00015589356],"category_scores_gemma":[0.0019049243,0.00011515857,0.00024389906,0.00025143515,0.00032015718,0.00012245358,0.000037170656,0.00095446256,0.0000035950347],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88632035,0.021251608,0.029460862,0.00009306807,0.0006975136,0.001140625,0.001187676,0.00006273447,0.0018306279,0.00002587512,0.0027262534,0.055202782],"study_design_scores_gemma":[0.73158735,0.24885364,0.011425198,0.0002476981,0.00029913575,0.00010324896,0.00013429413,0.0005053077,0.002593452,0.00016187748,0.003938765,0.00015001252],"about_ca_topic_score_codex":0.000011251903,"about_ca_topic_score_gemma":0.000012846836,"teacher_disagreement_score":0.22760202,"about_ca_system_score_codex":0.000117579766,"about_ca_system_score_gemma":0.0015604356,"threshold_uncertainty_score":0.46960303},"labels":[],"label_agreement":null},{"id":"W3029554970","doi":"10.1200/jco.2020.38.15_suppl.6057","title":"Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Clinical endpoint; Interim analysis; Progression-free survival; Oncology; Ovarian cancer; BRCA mutation; Tolerability; Phases of clinical research; Adverse effect; Chemotherapy; Surgery; Cancer; Clinical trial","score_opus":0.1323261844005708,"score_gpt":0.4935033366550821,"score_spread":0.3611771522545113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029554970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8822407,0.0002307221,0.071371324,0.039002758,0.0044544428,0.0015698061,0.00033647538,0.000051877894,0.00074186135],"genre_scores_gemma":[0.9575495,0.0013585974,0.0085878465,0.028384645,0.0036520278,0.00006359213,0.00015658846,0.00007739015,0.00016978507],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99320966,0.00049548066,0.004537828,0.00063051254,0.0005790626,0.00054744625],"domain_scores_gemma":[0.9902953,0.001934353,0.0044521494,0.00034486983,0.0020839162,0.00088943803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022388557,0.00041160366,0.0034188735,0.00033228646,0.000108062006,0.000026135443,0.00032335188,0.00067310093,0.00044522065],"category_scores_gemma":[0.002311448,0.00032774577,0.0015593116,0.0008506547,0.00033762155,0.00025148247,0.000055177683,0.0015450077,0.000020715286],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34369868,0.016029023,0.047330253,0.0003100066,0.024874052,0.0009169142,0.0054515274,0.0020636013,0.02208324,0.00014054675,0.1825487,0.35455346],"study_design_scores_gemma":[0.4085389,0.10948082,0.11188426,0.0013396777,0.0050555435,0.0001416252,0.00062434404,0.06149987,0.008854204,0.00053466705,0.29083574,0.0012103326],"about_ca_topic_score_codex":0.00006012631,"about_ca_topic_score_gemma":0.00003344593,"teacher_disagreement_score":0.35334313,"about_ca_system_score_codex":0.0006661578,"about_ca_system_score_gemma":0.0019637605,"threshold_uncertainty_score":0.99991745},"labels":[],"label_agreement":null},{"id":"W3029686450","doi":"10.1200/jco.2020.38.15_suppl.5566","title":"TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Internal medicine; Oncology; Prostate cancer; Docetaxel; Clinical endpoint; Taxane; Enzalutamide; Phases of clinical research; Urology; Cancer; Surgery; Chemotherapy; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.13251995318821508,"score_gpt":0.494144011813852,"score_spread":0.3616240586256369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029686450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956688,0.00008992304,0.0001182119,0.0028475868,0.00014989292,0.0009392616,0.00007207103,0.000011597952,0.00010261301],"genre_scores_gemma":[0.99730164,0.00006892082,0.0014600732,0.0008961979,0.00012163062,0.00004906643,0.000038464488,0.000018493243,0.000045502824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953629,0.0006536317,0.0029854798,0.00032289606,0.000482745,0.00019234647],"domain_scores_gemma":[0.9961706,0.0003506571,0.0021464266,0.00020835076,0.0007666952,0.00035727155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013024788,0.00018980417,0.0017544245,0.0003029775,0.00006293094,0.000014022678,0.000105573214,0.00009921,0.00023589973],"category_scores_gemma":[0.000589389,0.00013829388,0.0002451278,0.0008436293,0.00022751621,0.00024449953,0.000050187035,0.00063644885,8.632587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08197122,0.04879446,0.8122274,0.0002149969,0.012236073,0.0016104871,0.011571927,0.0024357983,0.012473646,0.00003241517,0.0022426392,0.014188933],"study_design_scores_gemma":[0.11683125,0.2342643,0.63107866,0.00028569068,0.006566052,0.000038684993,0.0032337466,0.0033749812,0.0010817158,0.000037823153,0.0028809893,0.0003261188],"about_ca_topic_score_codex":0.00011701164,"about_ca_topic_score_gemma":0.0011364482,"teacher_disagreement_score":0.18546984,"about_ca_system_score_codex":0.00016163244,"about_ca_system_score_gemma":0.0009640615,"threshold_uncertainty_score":0.56394607},"labels":[],"label_agreement":null},{"id":"W3029871260","doi":"10.1200/jco.2020.38.15_suppl.1091","title":"Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with g<i>BRCA</i>-associated advanced breast cancer: Exploratory results from BROCADE3.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Internal medicine; Veliparib; Breast cancer; Oncology; Carboplatin; Cancer; Discontinuation; PARP inhibitor; Progression-free survival; Urology; Chemotherapy; Cisplatin; Poly ADP ribose polymerase","score_opus":0.07922342325583095,"score_gpt":0.392223272220946,"score_spread":0.312999848965115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029871260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980148,0.0005919025,0.00014659119,0.01740288,0.00068304397,0.00061499956,0.00012500142,0.000039590854,0.00024799825],"genre_scores_gemma":[0.9861375,0.0011683255,0.0013531395,0.010596763,0.00056884595,0.000033349057,0.000057741036,0.000067880406,0.000016471875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99489605,0.00069845095,0.002679956,0.00047815175,0.0008798895,0.00036750693],"domain_scores_gemma":[0.9939504,0.0014923994,0.0030260298,0.00025646444,0.00078610715,0.0004885925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013329304,0.00032284128,0.0019504306,0.00014514898,0.00006456022,0.000018956016,0.00023951524,0.00045812983,0.000053881806],"category_scores_gemma":[0.00069905777,0.00022927098,0.00031130126,0.0005458531,0.0001707021,0.00044740934,0.000021304104,0.001495634,0.000004696861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1930981,0.004249371,0.69707614,0.00001153081,0.0016393524,0.000288424,0.0023961493,0.00085533754,0.000993026,0.0000120776,0.001347444,0.09803308],"study_design_scores_gemma":[0.17324962,0.021167122,0.79919666,0.0005925041,0.00016043556,0.0000064151113,0.00030535532,0.00014467147,0.0003917627,0.000109298,0.004393607,0.00028253917],"about_ca_topic_score_codex":0.00013330439,"about_ca_topic_score_gemma":0.00018121411,"teacher_disagreement_score":0.102120556,"about_ca_system_score_codex":0.00067760074,"about_ca_system_score_gemma":0.0019596356,"threshold_uncertainty_score":0.9349399},"labels":[],"label_agreement":null},{"id":"W3029883096","doi":"10.1200/jco.2020.38.15_suppl.tps6104","title":"DUETTE: A randomized phase II study to assess a second maintenance treatment with olaparib (ola) or ola+ceralasertib (cer), in patients (pts) with platinum-sensitive relapsed (PSR) epithelial ovarian cancer who have previously received PARP inhibitor maintenance treatment (NCT04239014).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Ovarian cancer; Oncology; BRCA mutation; Population; Internal medicine; Cancer; Clinical trial; Maintenance therapy; Chemotherapy; Biology","score_opus":0.09539568677493485,"score_gpt":0.4226898474471354,"score_spread":0.3272941606722005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029883096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713377,0.00009897177,0.00088771235,0.019245252,0.0006672466,0.0070528043,0.00019094668,0.00004183608,0.0004775401],"genre_scores_gemma":[0.9835245,0.00072878296,0.0030271886,0.009016238,0.0014416965,0.0007255756,0.00002385313,0.00012020794,0.0013919272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99005646,0.0025439349,0.004473569,0.001079991,0.00093796256,0.00090811565],"domain_scores_gemma":[0.9900223,0.002978155,0.0037490593,0.00051384245,0.0013907872,0.0013458742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025212748,0.0008323239,0.006225911,0.00028146012,0.0001774215,0.000046852685,0.00026800713,0.00041349302,0.000517074],"category_scores_gemma":[0.0020019682,0.00045389181,0.0006782276,0.0005637443,0.0004969078,0.00031964298,0.000074979056,0.0013496316,0.000016506643],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8939086,0.022778278,0.03468816,0.00004393673,0.0036214378,0.004317211,0.009612056,0.0002816311,0.00026774115,0.000008211843,0.0031650804,0.02730761],"study_design_scores_gemma":[0.6772853,0.28935483,0.013853129,0.001252844,0.0014011862,0.00017081387,0.0012257159,0.00052488217,0.00097345887,0.000014530567,0.013489145,0.0004541387],"about_ca_topic_score_codex":0.00027409365,"about_ca_topic_score_gemma":0.00435694,"teacher_disagreement_score":0.26657653,"about_ca_system_score_codex":0.0033258877,"about_ca_system_score_gemma":0.0046421895,"threshold_uncertainty_score":0.99979126},"labels":[],"label_agreement":null},{"id":"W3030227576","doi":"10.1200/jco.2020.38.15_suppl.3073","title":"A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Olaparib; Medicine; Cohort; Durvalumab; Internal medicine; Oncology; Clinical endpoint; Cancer; Surgery; Clinical trial; Immunotherapy; Nivolumab; Genetics; Biology","score_opus":0.16799720416196628,"score_gpt":0.4745135682877819,"score_spread":0.3065163641258156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030227576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915409,0.0021802122,0.00015048383,0.004825941,0.00019449668,0.0010194503,0.0000029246125,0.00000912724,0.00007646791],"genre_scores_gemma":[0.99606836,0.0005336457,0.0012760137,0.0018234454,0.00025585204,0.00002410153,1.9703837e-7,0.00001574471,0.00000264949],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99589187,0.000917368,0.0023407617,0.00022817327,0.0004463024,0.00017553844],"domain_scores_gemma":[0.9964061,0.0009895624,0.0019742453,0.00017056047,0.000306666,0.00015290896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027804158,0.00013067124,0.001374406,0.00008796311,0.000030883577,0.000005875341,0.00014224729,0.00019718827,0.000010992111],"category_scores_gemma":[0.0009969126,0.00008634155,0.00026612854,0.00034194067,0.00039144032,0.000040847346,0.000092199356,0.0008822634,7.785398e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18491712,0.012640388,0.39758235,0.00025122834,0.0017231997,0.0010428862,0.006050485,0.0005132301,0.02276201,0.00007334354,0.00018903597,0.37225473],"study_design_scores_gemma":[0.44602168,0.21124528,0.3146952,0.0016006357,0.0021395953,0.00054448936,0.0044177966,0.006111438,0.006225216,0.00035772333,0.0062799584,0.0003609638],"about_ca_topic_score_codex":0.00009732756,"about_ca_topic_score_gemma":0.00006792795,"teacher_disagreement_score":0.37189376,"about_ca_system_score_codex":0.00006940242,"about_ca_system_score_gemma":0.0009032486,"threshold_uncertainty_score":0.38330445},"labels":[],"label_agreement":null},{"id":"W3030500223","doi":"10.1002/cncr.32979","title":"Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Olaparib; Medicine; Pancreatic cancer; Cancer; Clinical trial; Oncology; Internal medicine","score_opus":0.4767647067149932,"score_gpt":0.5299381205005466,"score_spread":0.05317341378555335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030500223","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1426139,0.033406135,0.0010708341,0.7958741,0.010714522,0.01021719,0.0010885049,0.0004201695,0.0045946394],"genre_scores_gemma":[0.6689266,0.014801351,0.00070135907,0.26654458,0.039837707,0.008388943,0.00004615681,0.00012584215,0.0006274967],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978968,0.0001519266,0.00060316984,0.00051118684,0.00042038143,0.00041655742],"domain_scores_gemma":[0.9979082,0.0007154418,0.0003303138,0.00040299178,0.00030639835,0.00033665044],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006332333,0.00022877914,0.00056792557,0.000027521493,0.00015653073,0.000035282592,0.0002121431,0.00020934263,0.0012257636],"category_scores_gemma":[0.0009503821,0.00015617919,0.0003105921,0.00027196557,0.00020283987,0.00017601572,0.00004246894,0.00053584296,0.000041195435],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27499068,0.0007118969,0.0034240647,0.00034592452,0.0016118475,0.00008289067,0.004736052,0.000016685139,0.006478019,0.0023465294,0.4731063,0.23214911],"study_design_scores_gemma":[0.048529327,0.0012147413,0.0013121335,0.000127846,0.0004910262,0.000015173854,0.0002390755,0.00033373505,0.0018159125,0.00008426641,0.94563115,0.00020559688],"about_ca_topic_score_codex":0.00055155816,"about_ca_topic_score_gemma":0.00009119189,"teacher_disagreement_score":0.52932954,"about_ca_system_score_codex":0.00026950592,"about_ca_system_score_gemma":0.0007722208,"threshold_uncertainty_score":0.99968725},"labels":[],"label_agreement":null},{"id":"W3030546310","doi":"10.1200/jco.2020.38.15_suppl.6068","title":"Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Tolerability; Hazard ratio; Internal medicine; Oncology; BRCA mutation; Placebo; Ovarian cancer; Confidence interval; Gynecology; Cancer; Adverse effect; Pathology","score_opus":0.10362392140859569,"score_gpt":0.46857242414566164,"score_spread":0.3649485027370659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030546310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386877,0.000063093146,0.00022481853,0.004366856,0.00036434628,0.00088223803,0.00006912269,0.0000055431574,0.0001552414],"genre_scores_gemma":[0.99709266,0.00015109601,0.0005536015,0.001945511,0.00021922316,0.0000080464715,0.000008510926,0.00001618543,0.00000514419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505574,0.0008485476,0.0030241986,0.00030292413,0.0005512399,0.00021734484],"domain_scores_gemma":[0.9940842,0.001957845,0.002694188,0.00022458668,0.00069109944,0.00034813074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018941008,0.00018770467,0.0024923782,0.000294481,0.00004384654,0.000005489393,0.00018482564,0.00018222346,0.000061595965],"category_scores_gemma":[0.0019929372,0.00011926772,0.00031211317,0.0014026999,0.00024931316,0.0000757401,0.000094126466,0.00095548324,6.2159694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14042296,0.0071967845,0.74893135,0.000040934992,0.006202368,0.00031581993,0.0068785944,0.0021332807,0.0016282315,0.000018642406,0.00039150237,0.08583953],"study_design_scores_gemma":[0.095472924,0.02255606,0.8755605,0.00038089912,0.0027874864,0.000009358056,0.0012493388,0.0007695327,0.00033561364,0.0000075116864,0.0007405953,0.00013013693],"about_ca_topic_score_codex":0.00009232372,"about_ca_topic_score_gemma":0.00041483098,"teacher_disagreement_score":0.12662919,"about_ca_system_score_codex":0.00023146585,"about_ca_system_score_gemma":0.0009838638,"threshold_uncertainty_score":0.48635966},"labels":[],"label_agreement":null},{"id":"W3030566019","doi":"10.1200/jco.2020.38.15_suppl.6002","title":"Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Hazard ratio; Oncology; Placebo; Ovarian cancer; Clinical endpoint; PARP inhibitor; Progression-free survival; BRCA mutation; Chemotherapy; Cancer; Confidence interval; Randomized controlled trial; Pathology","score_opus":0.15828171610380812,"score_gpt":0.45732561498715135,"score_spread":0.29904389888334326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030566019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97830075,0.000067316374,0.0012662451,0.017506665,0.00128582,0.000547661,0.000115250856,0.000016026104,0.0008942799],"genre_scores_gemma":[0.9851008,0.00019036843,0.0055251177,0.0068548108,0.0021954672,0.000012240761,0.000040909807,0.00002945293,0.000050839513],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946778,0.00079671445,0.0031199486,0.00046490994,0.00060944294,0.00033118608],"domain_scores_gemma":[0.99232,0.0034485175,0.0029042617,0.00016903372,0.000656592,0.0005016119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021743986,0.00024012069,0.0018565798,0.00011765337,0.00006949923,0.000035264402,0.00012059609,0.00041699258,0.00010308252],"category_scores_gemma":[0.0048135878,0.00018195013,0.00021326655,0.00023739245,0.00029517515,0.0003384654,0.00004071842,0.0016904105,0.000003885231],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.914829,0.0027623181,0.017779198,0.000020219191,0.0005463613,0.002026281,0.0018851889,0.00018036936,0.0003096104,0.000058380883,0.004639241,0.054963794],"study_design_scores_gemma":[0.79555553,0.02487744,0.16992252,0.0006186906,0.00028530325,0.00006459017,0.00029652618,0.0016726044,0.00009463966,0.00021490984,0.006168873,0.00022837135],"about_ca_topic_score_codex":0.00027507657,"about_ca_topic_score_gemma":0.00020562416,"teacher_disagreement_score":0.15214331,"about_ca_system_score_codex":0.00037551904,"about_ca_system_score_gemma":0.0024291074,"threshold_uncertainty_score":0.74197114},"labels":[],"label_agreement":null},{"id":"W3031022693","doi":"10.1200/jco.2020.38.15_suppl.1097","title":"Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative g<i>BRCA</i>-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Internal medicine; Hazard ratio; Veliparib; PARP inhibitor; Breast cancer; Progression-free survival; Oncology; Carboplatin; Biomarker; Cancer; Gastroenterology; Confidence interval; Chemotherapy; Cisplatin; Poly ADP ribose polymerase","score_opus":0.11059681942288144,"score_gpt":0.48148630515514185,"score_spread":0.37088948573226044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031022693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889796,0.0005501684,0.00001124609,0.009379527,0.00026711542,0.0005839718,0.000056484783,0.000014969995,0.00015690931],"genre_scores_gemma":[0.98937106,0.00055932486,0.00057281146,0.009202762,0.00015946134,0.000072195726,0.0000049876917,0.00004068042,0.0000167018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590963,0.0007228874,0.0020262438,0.00040198115,0.0006064047,0.0003328475],"domain_scores_gemma":[0.9957867,0.0014768727,0.0017587764,0.0001544817,0.00042346562,0.00039969655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008703723,0.0002952408,0.0018180299,0.00021672244,0.000038262217,0.00001629985,0.00011917812,0.0004157186,0.00013191605],"category_scores_gemma":[0.0010218628,0.00019633348,0.00020761808,0.00045994294,0.00034911954,0.0002927618,0.00003549123,0.0011850963,0.0000029265093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1139149,0.001745,0.841914,0.000022954231,0.0004082976,0.00017867849,0.0008134816,0.00010540237,0.00013142679,0.0000014357707,0.00034439383,0.040420003],"study_design_scores_gemma":[0.068097234,0.007890081,0.9220573,0.00064202276,0.00009379946,0.0000059694303,0.00023253032,0.00009650009,0.00015217268,0.00004782495,0.00049403275,0.000190553],"about_ca_topic_score_codex":0.000057112367,"about_ca_topic_score_gemma":0.00030380322,"teacher_disagreement_score":0.08014326,"about_ca_system_score_codex":0.00055821193,"about_ca_system_score_gemma":0.00083798816,"threshold_uncertainty_score":0.80062467},"labels":[],"label_agreement":null},{"id":"W3031086551","doi":"10.1200/jco.2020.38.15_suppl.6014","title":"Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Concordance; Internal medicine; Surrogate endpoint; Olaparib; Progressive disease; Oncology; Chemotherapy","score_opus":0.04868816954206076,"score_gpt":0.404535055806061,"score_spread":0.3558468862640002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031086551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647968,0.00020516582,0.00014012899,0.033214286,0.00016456403,0.001242474,0.000064814085,0.000027419283,0.00014438828],"genre_scores_gemma":[0.97881913,0.00042273643,0.0038230722,0.015880777,0.0007542415,0.000075195465,0.0000144547375,0.000071671835,0.00013872412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99518937,0.0009634699,0.0022029153,0.00056482153,0.0006452818,0.00043416585],"domain_scores_gemma":[0.9947271,0.0014652228,0.0017388605,0.0002492351,0.0010084179,0.00081116706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001600786,0.00037173217,0.0020098076,0.00018690711,0.00005433885,0.000021210823,0.00013956003,0.00041383517,0.00016605573],"category_scores_gemma":[0.0010511035,0.00023350479,0.00015037127,0.00071085,0.00045003145,0.00018197909,0.00003301487,0.0012718533,0.000009243151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4211328,0.0006761007,0.48879302,0.000018455028,0.0003352523,0.0010827142,0.00072421756,0.000015241247,0.00087452884,8.863959e-7,0.0010147488,0.085332036],"study_design_scores_gemma":[0.081615955,0.04921241,0.8420549,0.0015099549,0.000106312094,0.000092329974,0.000077756915,0.000031854877,0.0023603018,0.00001405623,0.022644328,0.0002798476],"about_ca_topic_score_codex":0.0000837066,"about_ca_topic_score_gemma":0.00007904867,"teacher_disagreement_score":0.35326186,"about_ca_system_score_codex":0.00042465766,"about_ca_system_score_gemma":0.0017164765,"threshold_uncertainty_score":0.9522049},"labels":[],"label_agreement":null},{"id":"W3031754935","doi":"10.1200/jco.2020.38.15_suppl.1077","title":"Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Olaparib; PARP inhibitor; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple-negative breast cancer; Response Evaluation Criteria in Solid Tumors; Tolerability; Clinical endpoint; Phases of clinical research; Cancer; Gastroenterology; Adverse effect; Clinical trial; Poly ADP ribose polymerase","score_opus":0.1740430128635073,"score_gpt":0.5207388288404442,"score_spread":0.3466958159769369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031754935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947067,0.00014287725,0.000053880784,0.0026570286,0.00027369236,0.0019621206,0.000087467444,0.000005144446,0.00011112738],"genre_scores_gemma":[0.998691,0.00019746282,0.0004735677,0.00037851965,0.00018965326,0.000030395036,0.000009573106,0.000021651344,0.0000081584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327004,0.00096280937,0.0044687656,0.0003629283,0.0007421084,0.00019333817],"domain_scores_gemma":[0.99238,0.0017486392,0.004393516,0.00040035453,0.0008642342,0.00021324544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033324505,0.0001864064,0.0029809505,0.00026544658,0.000020106234,0.0000017660387,0.00041505057,0.00016150122,0.000089669775],"category_scores_gemma":[0.0025308174,0.00014323184,0.0001262814,0.00070313347,0.0002934681,0.0002467583,0.00015056103,0.0010429936,3.5776694e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21059707,0.107332826,0.6295634,0.00014357163,0.0009958987,0.00057876314,0.008901054,0.00077398337,0.0016358561,0.0000073691895,0.00042496345,0.03904526],"study_design_scores_gemma":[0.15569344,0.17826866,0.6596296,0.00056677056,0.00039960706,0.000048854585,0.004172522,0.0005841299,0.00047133147,0.000022894974,0.00005296724,0.00008921284],"about_ca_topic_score_codex":0.00024010848,"about_ca_topic_score_gemma":0.00044970412,"teacher_disagreement_score":0.07093584,"about_ca_system_score_codex":0.0002106463,"about_ca_system_score_gemma":0.0020875202,"threshold_uncertainty_score":0.5840825},"labels":[],"label_agreement":null},{"id":"W3032154372","doi":"10.1200/jco.2020.38.15_suppl.6015","title":"Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Internal medicine; BRCA mutation; Oncology; PARP inhibitor; Ovarian cancer; Loss of heterozygosity; Cancer; Poly ADP ribose polymerase; Allele; Polymerase; Genetics; Gene","score_opus":0.16166968674323198,"score_gpt":0.48598209628339095,"score_spread":0.32431240954015894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032154372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97422594,0.00006237665,0.00047590418,0.02402468,0.00075556606,0.0003049998,0.000024605813,0.000005102516,0.00012083414],"genre_scores_gemma":[0.98979306,0.00054628367,0.0007790809,0.007999076,0.0008087155,0.000011759321,0.000009594689,0.000015598223,0.000036844234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970331,0.00039605313,0.0018976819,0.00016866287,0.0003544455,0.00015001233],"domain_scores_gemma":[0.9970003,0.00046240247,0.0015199586,0.00011341326,0.00054057874,0.00036334357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009360645,0.00010506399,0.0010193896,0.00013942827,0.000012439534,0.0000041312114,0.00011694336,0.00017945557,0.00033083287],"category_scores_gemma":[0.0013036896,0.00007645222,0.00013397573,0.00028128785,0.00009173554,0.00009774689,0.000025301168,0.00055778807,0.0000073129772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05153063,0.0013216097,0.8571147,0.00005185762,0.00012137296,0.0001181885,0.00051221176,0.0000069491257,0.00465311,0.000014778252,0.0004671557,0.08408744],"study_design_scores_gemma":[0.012205491,0.018032258,0.9561124,0.00041534024,0.000086171356,0.000014247157,0.000014140927,0.000010847358,0.0013351829,0.000008869857,0.011692519,0.000072565876],"about_ca_topic_score_codex":0.00000894914,"about_ca_topic_score_gemma":0.000049801874,"teacher_disagreement_score":0.09899767,"about_ca_system_score_codex":0.00021412405,"about_ca_system_score_gemma":0.0014010263,"threshold_uncertainty_score":0.3622388},"labels":[],"label_agreement":null},{"id":"W3032366211","doi":"10.1200/jco.2020.38.15_suppl.5538","title":"Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Brief Pain Inventory; Internal medicine; Enzalutamide; Oncology; Population; Cohort; Prostate cancer; Clinical endpoint; Cancer; Randomized controlled trial; Physical therapy; Chronic pain","score_opus":0.21953474328731185,"score_gpt":0.5179045079760652,"score_spread":0.2983697646887534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032366211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862358,0.00062940654,0.00011017669,0.011930553,0.00024820265,0.0004918981,0.0000571864,0.000003900314,0.0002928693],"genre_scores_gemma":[0.9954354,0.0005604577,0.0013980798,0.0016190095,0.0008865387,0.000010140027,0.000005124067,0.00002066562,0.00006453817],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947884,0.00069438247,0.003428872,0.00020419463,0.0006559168,0.00022825296],"domain_scores_gemma":[0.99299854,0.0019763561,0.0039136275,0.0001706689,0.0005788249,0.0003619659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023514698,0.0001819972,0.002041195,0.00014828025,0.000012861564,0.0000037873613,0.0001747455,0.00015559293,0.00021610456],"category_scores_gemma":[0.002421264,0.00013289112,0.00063666713,0.00035241354,0.0002267609,0.00010944539,0.00002168565,0.00078117795,0.0000024829042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16556188,0.010021088,0.128342,0.001382679,0.0057797357,0.00078047375,0.008244208,0.018999934,0.26384625,0.00032452872,0.04208921,0.35462803],"study_design_scores_gemma":[0.043228276,0.1469839,0.7794897,0.0019715256,0.00092740625,0.000032864777,0.0005559959,0.0015770277,0.009307119,0.0008791956,0.014736798,0.00031018959],"about_ca_topic_score_codex":0.0008579634,"about_ca_topic_score_gemma":0.00016475614,"teacher_disagreement_score":0.65114766,"about_ca_system_score_codex":0.00038736948,"about_ca_system_score_gemma":0.005757421,"threshold_uncertainty_score":0.999879},"labels":[],"label_agreement":null},{"id":"W3032723625","doi":"10.1200/jco.2020.38.15_suppl.tps596","title":"KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Chemotherapy; Internal medicine; Carboplatin; Pembrolizumab; Olaparib; Induction chemotherapy; Immunotherapy; Cancer; Cisplatin","score_opus":0.11161118700935518,"score_gpt":0.44691181015717585,"score_spread":0.33530062314782066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032723625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754114,0.00046851032,0.0012654525,0.0141648445,0.0008685165,0.007512219,0.0000947006,0.00003482212,0.00017953823],"genre_scores_gemma":[0.9825232,0.0024716964,0.0034026708,0.009481585,0.00084884744,0.00074405555,0.000025524332,0.00014492986,0.0003574702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98897934,0.001940999,0.0057849614,0.0010041494,0.0015519031,0.000738647],"domain_scores_gemma":[0.98856246,0.002337175,0.005425943,0.00057789765,0.00219482,0.0009017194],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035203563,0.00084444234,0.007566139,0.00045969375,0.0001710043,0.00006491752,0.0007215413,0.0004716495,0.0020303049],"category_scores_gemma":[0.0012031274,0.0005185518,0.00041664863,0.0013394232,0.000811444,0.00077396457,0.0001559373,0.002441577,0.000005290711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9283372,0.02780454,0.002544963,0.00020148016,0.0036386691,0.00042591398,0.0076520136,0.0012486113,0.00004544774,0.0000044144017,0.0019723196,0.026124435],"study_design_scores_gemma":[0.84303784,0.13927929,0.008666274,0.001294277,0.0012994587,0.00019597025,0.0010447585,0.0026197254,0.00013502411,0.00003582254,0.0018672415,0.0005243008],"about_ca_topic_score_codex":0.0006315143,"about_ca_topic_score_gemma":0.0016236961,"teacher_disagreement_score":0.11147475,"about_ca_system_score_codex":0.0019469763,"about_ca_system_score_gemma":0.009431979,"threshold_uncertainty_score":0.9998598},"labels":[],"label_agreement":null},{"id":"W3032852436","doi":"10.1200/jco.2020.38.15_suppl.tps6101","title":"ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Carboplatin; Internal medicine; Bevacizumab; Oncology; Performance status; Urology; Maintenance therapy; Surgery; Chemotherapy; Gastroenterology","score_opus":0.19125014731522183,"score_gpt":0.4841571363752475,"score_spread":0.29290698906002566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032852436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801565,0.0035820818,0.0009879962,0.0065340633,0.0007690283,0.006987312,0.0006499473,0.000028335222,0.00030473742],"genre_scores_gemma":[0.9908354,0.005864096,0.0011459688,0.0010261107,0.00057340506,0.0003428838,0.000027432861,0.00008662087,0.00009805197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9884604,0.0014871499,0.0072735706,0.0006953834,0.0015579509,0.00052549585],"domain_scores_gemma":[0.9831674,0.005289421,0.007929851,0.00065162557,0.0022891115,0.00067258155],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032237933,0.0006419868,0.008344642,0.00031804873,0.00012148243,0.000014098039,0.0004808275,0.0004935655,0.0011507082],"category_scores_gemma":[0.001195832,0.00041551667,0.0014939684,0.00071858533,0.0007183704,0.00016960008,0.00006360781,0.0009706168,0.0000020293173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91472274,0.03524105,0.010458858,0.00015716882,0.0061605736,0.0006995538,0.0126913395,0.0007499338,0.0005173556,0.00002245805,0.0010432734,0.017535673],"study_design_scores_gemma":[0.7020187,0.26837555,0.00027100794,0.00032341917,0.001645721,0.0000140437505,0.008470041,0.00020136719,0.003967606,0.000012374825,0.014460294,0.00023988228],"about_ca_topic_score_codex":0.0014343883,"about_ca_topic_score_gemma":0.0025089732,"teacher_disagreement_score":0.2331345,"about_ca_system_score_codex":0.0009188233,"about_ca_system_score_gemma":0.005300913,"threshold_uncertainty_score":0.99982965},"labels":[],"label_agreement":null},{"id":"W3035124962","doi":"10.1101/2020.06.09.137612","title":"Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Cancer Science Institute of Singapore, National University of Singapore; Medical Research Council; National Medical Research Council; National Research Foundation Singapore; National Research Foundation; Ovarian Cancer Action; Cancer Research UK","keywords":"RAD51; Ovarian cancer; Cancer research; Biology; Ovarian carcinoma; Homologous recombination; Immunohistochemistry; Immune system; Immune checkpoint; Cancer; Immunotherapy; Immunology; Oncology; Gene; Medicine; Genetics","score_opus":0.011624755279216276,"score_gpt":0.2135923329779812,"score_spread":0.20196757769876492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035124962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924359,0.0025299222,0.00030316343,0.0024057333,0.00063534715,0.0014253809,0.00012445294,0.000102569786,0.000037579106],"genre_scores_gemma":[0.99341416,0.0003670393,0.0054556206,0.0002467158,0.00019471555,0.00021262401,0.000001821748,0.00009736879,0.000009909113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99735314,0.00025488625,0.0007011856,0.0008082492,0.0005820796,0.00030044036],"domain_scores_gemma":[0.99756604,0.00010959349,0.00076773425,0.0010895932,0.00030788485,0.00015912266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005027296,0.00041474897,0.00080144545,0.00022108224,0.00011513556,0.00003125704,0.00030747644,0.0004501824,0.000030507774],"category_scores_gemma":[0.00016786001,0.0003289078,0.00008681587,0.0005746335,0.00024174736,0.00010629782,0.00043226813,0.0009354922,0.0000016866826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008818797,0.00013892316,0.023717329,0.0011364243,0.00004771207,0.000074746145,0.00008906013,0.000014556943,0.9734495,0.00029158226,0.00015646213,0.0000017832199],"study_design_scores_gemma":[0.00251808,0.00008559487,0.477312,0.0022590952,0.000057490273,8.722323e-8,0.0000046311743,0.000013498563,0.51734525,0.000029084476,0.00014194429,0.00023323987],"about_ca_topic_score_codex":0.00006816504,"about_ca_topic_score_gemma":0.000007548978,"teacher_disagreement_score":0.45610428,"about_ca_system_score_codex":0.00055615127,"about_ca_system_score_gemma":0.0008695211,"threshold_uncertainty_score":0.9999163},"labels":[],"label_agreement":null},{"id":"W3035853607","doi":"10.3390/cancers12061607","title":"Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer","year":2020,"lang":"en","type":"review","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Cancer research; Synthetic lethality; DNA repair; PARP1; Epigenetics; Poly ADP ribose polymerase; DNA damage; PARP inhibitor; Downregulation and upregulation; Medicine; Biology; Chemistry; Polymerase; Genetics; DNA","score_opus":0.057697715111653364,"score_gpt":0.3641052842361608,"score_spread":0.3064075691245074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035853607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019865522,0.9930026,0.000020049558,0.00058850413,0.00077639666,0.001161531,0.0002347452,0.00006483768,0.004131476],"genre_scores_gemma":[0.00008722841,0.99553037,0.00051218923,0.00080901413,0.0013491092,0.0005216434,0.000050652045,0.000120588265,0.0010192153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976134,0.000104617175,0.00074114057,0.00079026335,0.0003186531,0.0004319782],"domain_scores_gemma":[0.9987446,0.00015303437,0.00037679952,0.00039149472,0.000045510194,0.00028854352],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001645677,0.0005088932,0.0020970237,0.00021022213,0.000065521606,0.000034081786,0.0001403509,0.00035558388,0.00032632498],"category_scores_gemma":[0.000068064306,0.00047347925,0.00024690578,0.0006362816,0.00014580878,0.000089506946,0.00005214592,0.0008267188,0.000021983707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040655825,0.000016349672,0.00016552441,0.039879434,0.0004564822,0.0005436024,0.0009017385,0.0000063554826,0.00003793757,0.0005424507,0.030890688,0.9261529],"study_design_scores_gemma":[0.0015703447,0.000039831866,0.000020834306,0.047785018,0.00032910594,0.000026555395,0.00003066802,0.000007712342,0.000020904718,0.00006044691,0.94970196,0.00040662178],"about_ca_topic_score_codex":0.00027327094,"about_ca_topic_score_gemma":0.0005815078,"teacher_disagreement_score":0.92574626,"about_ca_system_score_codex":0.0059523364,"about_ca_system_score_gemma":0.0037181447,"threshold_uncertainty_score":0.9997717},"labels":[],"label_agreement":null},{"id":"W3036245422","doi":"10.1007/s11060-020-03561-1","title":"PARP inhibition suppresses the emergence of temozolomide resistance in a model system","year":2020,"lang":"en","type":"article","venue":"Journal of Neuro-Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Cancer Research Society","keywords":"Temozolomide; PARP inhibitor; Poly ADP ribose polymerase; Methyltransferase; Biology; Cancer research; DNA repair; O-6-methylguanine-DNA methyltransferase; Mutation; Methylation; Genetics; Gene; Polymerase; Glioma","score_opus":0.0575485637994204,"score_gpt":0.3342644032891917,"score_spread":0.2767158394897713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036245422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92766273,0.0018789661,0.003157346,0.061067205,0.00054092536,0.00043533611,0.000021952208,0.000023702216,0.005211832],"genre_scores_gemma":[0.9942578,0.00060134643,0.0014989199,0.0033286603,0.00026494832,0.0000124236,8.9679713e-7,0.000017158729,0.000017810742],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99807197,0.0002827176,0.0009754017,0.00015334752,0.0003398321,0.00017672403],"domain_scores_gemma":[0.99823,0.00035751166,0.00083474576,0.00017085685,0.00028167976,0.00012523508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045405843,0.00011689379,0.0005519853,0.00011322839,0.000034241377,0.000004780643,0.00015710067,0.00010182975,0.000047742542],"category_scores_gemma":[0.00036492982,0.00008290425,0.00013630133,0.000333392,0.0001318131,0.00011859725,0.000031881013,0.00050894957,0.000004359058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053165313,0.00024114297,0.0015449605,0.0004454588,0.00006447401,0.0010306635,0.003181217,0.006347655,0.9321312,0.0011605795,0.048094135,0.000442034],"study_design_scores_gemma":[0.036154795,0.014494586,0.008887268,0.0039960532,0.0007826708,0.0069000036,0.012142004,0.0464825,0.70165396,0.0042638257,0.16340151,0.0008408491],"about_ca_topic_score_codex":0.000003670756,"about_ca_topic_score_gemma":0.000018198614,"teacher_disagreement_score":0.23047721,"about_ca_system_score_codex":0.00016621262,"about_ca_system_score_gemma":0.0005122297,"threshold_uncertainty_score":0.3380737},"labels":[],"label_agreement":null},{"id":"W3041199890","doi":"10.1158/1557-3265.ovcasymp18-nt-117","title":"Abstract NT-117: INHIBITION OF PARG, SENSITIZES OVARIAN CANCER CELLS TO PARP INHIBITORS AND DNA DAMAGING AGENTS","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Poly ADP ribose polymerase; Synthetic lethality; DNA repair; Cancer research; Biology; Molecular biology; PARP inhibitor; Cisplatin; DNA damage; Blot; Ovarian cancer; Cell culture; Cancer; Chemistry; DNA; Polymerase; Biochemistry; Genetics; Gene; Chemotherapy","score_opus":0.18412665830304098,"score_gpt":0.5119869042786367,"score_spread":0.3278602459755957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041199890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868347,0.00076264073,0.000012276221,0.0070810425,0.0010570934,0.0013908439,0.00013265356,0.000052734475,0.0026760094],"genre_scores_gemma":[0.9932821,0.0022491547,0.00020621408,0.0019427789,0.0011876347,0.00018165563,0.000020621172,0.000066147855,0.00086372346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995772,0.00035396704,0.0010638522,0.0008466651,0.0012313062,0.0007322283],"domain_scores_gemma":[0.9968866,0.00085630565,0.00021644573,0.00064695056,0.0007397636,0.0006539425],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003093004,0.00024681457,0.00073616585,0.00036467926,0.00012752229,0.00005358771,0.00014977808,0.00027087724,0.002434478],"category_scores_gemma":[0.00027171528,0.00022801266,0.00018169844,0.00071664026,0.00049758656,0.00016657946,0.00020331782,0.0010984519,0.00021792228],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038803325,0.0006172041,0.18226123,0.0010876138,0.00032921447,0.00015438836,0.0013473739,0.00014905402,0.69636726,0.00016532048,0.06834954,0.045291502],"study_design_scores_gemma":[0.010228982,0.0011900042,0.41444123,0.004156691,0.000086259366,0.000013112623,0.0007287006,0.00020719566,0.523092,0.00055938313,0.044706967,0.0005895137],"about_ca_topic_score_codex":0.0015689124,"about_ca_topic_score_gemma":0.00017646316,"teacher_disagreement_score":0.23218,"about_ca_system_score_codex":0.00036986926,"about_ca_system_score_gemma":0.0007991061,"threshold_uncertainty_score":0.99847746},"labels":[],"label_agreement":null},{"id":"W3041327040","doi":"10.1136/ijgc-2020-001723","title":"Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Poly ADP ribose polymerase; Medicine; PARP inhibitor; Polymerase; Ovarian cancer; Homologous recombination; Cancer research; Gene; Cancer; Internal medicine; Genetics; Biology","score_opus":0.025651223492386497,"score_gpt":0.3256051834118799,"score_spread":0.29995395991949336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041327040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91003543,0.0096549345,0.0003632635,0.07767306,0.001254153,0.00026183948,0.0004423728,0.000014507589,0.00030041236],"genre_scores_gemma":[0.9831107,0.004968012,0.0008905326,0.00881243,0.0021080917,0.000022648079,0.000017048467,0.000020101343,0.000050418887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977211,0.00009930626,0.0009966352,0.0003070536,0.0006384568,0.00023746454],"domain_scores_gemma":[0.9980077,0.00042933054,0.0006559624,0.00010592391,0.00049424474,0.0003068241],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022800105,0.00020996532,0.00063079916,0.000121963974,0.000027722082,0.000025221821,0.00030308953,0.00015078994,0.004637027],"category_scores_gemma":[0.0005830306,0.00016259876,0.00015466216,0.00022984456,0.00020425043,0.00020061243,0.00009500716,0.0005332637,0.000006246033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057423137,0.001665008,0.54008967,0.000108728316,0.002312797,0.0025823305,0.0025251324,0.000730261,0.23894438,0.0009273922,0.029509144,0.12318202],"study_design_scores_gemma":[0.030995771,0.0015723235,0.8661112,0.0014060839,0.00019137959,0.0001362839,0.00026708693,0.0003954737,0.057813555,0.0007262715,0.039952602,0.00043195474],"about_ca_topic_score_codex":0.00044216448,"about_ca_topic_score_gemma":0.00010079255,"teacher_disagreement_score":0.32602155,"about_ca_system_score_codex":0.00045262297,"about_ca_system_score_gemma":0.0004437856,"threshold_uncertainty_score":0.99627286},"labels":[],"label_agreement":null},{"id":"W3045084972","doi":"10.3390/genes11080856","title":"Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers","year":2020,"lang":"en","type":"review","venue":"Genes","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Ovarian cancer; Breast cancer; Focus (optics); Medicine; Oncology; Gene; Internal medicine; Cancer; Cancer research; Gynecology; Biology; Genetics","score_opus":0.027598217053468505,"score_gpt":0.3434438496598919,"score_spread":0.3158456326064234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045084972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000049301975,0.99504036,0.000013586052,0.0014407885,0.0001695905,0.0015446747,0.0009596039,0.000040994102,0.0007854612],"genre_scores_gemma":[0.0000057895277,0.9962086,0.00045135774,0.0015307157,0.00087824,0.0005085749,0.00015418931,0.00009168037,0.00017085922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981912,0.00011413596,0.00051206106,0.0005669959,0.00038340114,0.00023225769],"domain_scores_gemma":[0.9986941,0.000046205318,0.0004342993,0.00043245303,0.00017608386,0.00021682786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001206018,0.00047213177,0.0020977221,0.00012751496,0.000046606645,0.000023756647,0.0001167187,0.00020506972,0.00018715988],"category_scores_gemma":[0.000015932097,0.0003170013,0.0002620288,0.000620965,0.000095235446,0.000044511522,0.0000322362,0.0003752723,0.0000069758266],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000166259,0.000015099385,0.000007238507,0.17089538,0.00049354014,0.00014267677,0.00009540964,3.7030722e-7,0.00001908466,0.00003433365,0.0012453282,0.8268853],"study_design_scores_gemma":[0.0004483297,0.00020941913,0.0000056778604,0.41870433,0.0011703041,0.0013934363,0.0000024868464,5.611206e-7,0.00006366502,0.000006630256,0.5778162,0.0001789644],"about_ca_topic_score_codex":0.00010953711,"about_ca_topic_score_gemma":0.000016391394,"teacher_disagreement_score":0.8267063,"about_ca_system_score_codex":0.0003579294,"about_ca_system_score_gemma":0.0016173874,"threshold_uncertainty_score":0.99992824},"labels":[],"label_agreement":null},{"id":"W3046539828","doi":"10.1016/j.jmoldx.2020.06.002","title":"Poly (ADP Ribose) Polymerase Inhibitors for Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Loxo Oncology; EMD Serono; Association for Molecular Pathology; Janssen Pharmaceuticals; AstraZeneca; Merck; Astellas Pharma; Astellas Pharma US; Pfizer; Bristol-Myers Squibb","keywords":"Poly ADP ribose polymerase; Polymerase; Carcinogenesis; PARP inhibitor; Ovarian cancer; Cancer research; Homologous recombination; Cancer; Germline; Breast cancer; Biology; Genetics; Medicine; Gene; Bioinformatics","score_opus":0.026671945003831483,"score_gpt":0.32407448849740556,"score_spread":0.2974025434935741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046539828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5573432,0.12537734,0.12470927,0.18690678,0.0033768406,0.0012839591,0.0003264508,0.00008588046,0.00059027574],"genre_scores_gemma":[0.95608366,0.003266322,0.007362822,0.02903254,0.004092338,0.000032497745,0.000011653008,0.00007950283,0.000038669135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985541,0.000038282746,0.00056824327,0.00015160623,0.00044996786,0.00023776015],"domain_scores_gemma":[0.9983213,0.00025409734,0.00040078643,0.00013813093,0.0004402944,0.00044541407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014620028,0.00016825531,0.0004074573,0.00010303872,0.00004493908,0.000022812657,0.000121175064,0.0001005188,0.00012763699],"category_scores_gemma":[0.0010465363,0.00015051125,0.0003222112,0.0002143802,0.00006155683,0.000074311305,0.00002059825,0.0002974356,0.000008151056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028659666,0.000715682,0.01242636,0.0004812647,0.0011873994,0.0026643001,0.0013153906,0.00036651158,0.617665,0.0008677245,0.30133155,0.058112837],"study_design_scores_gemma":[0.006202966,0.0016754818,0.0007165583,0.00050407165,0.0004856251,0.00020473164,0.00009140423,0.00014417018,0.83152163,0.00032799,0.15789692,0.00022845995],"about_ca_topic_score_codex":0.000008480199,"about_ca_topic_score_gemma":8.4781243e-7,"teacher_disagreement_score":0.39874047,"about_ca_system_score_codex":0.00011933545,"about_ca_system_score_gemma":0.00043262722,"threshold_uncertainty_score":0.613767},"labels":[],"label_agreement":null},{"id":"W3047016852","doi":"10.1200/jco.20.00799","title":"Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center; AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Olaparib; Ovarian cancer; Oncology; Placebo; Confidence interval; Surgery; Gastroenterology; Cancer; Pathology","score_opus":0.07789584514667676,"score_gpt":0.42765471376798503,"score_spread":0.3497588686213083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047016852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660933,0.00013616227,0.013680474,0.018417189,0.0005054933,0.0010214812,0.00008137021,0.00000930794,0.000055239943],"genre_scores_gemma":[0.9799657,0.00015006174,0.011340772,0.0072942795,0.0011132925,0.00006253619,0.000030595933,0.000023531762,0.000019250148],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966951,0.00029262257,0.001977411,0.00028951542,0.0005166535,0.00022871849],"domain_scores_gemma":[0.98778695,0.007964162,0.0026957963,0.00021812826,0.0010375206,0.00029746667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009663393,0.000174581,0.0017786736,0.0000740217,0.0000615252,0.00001100611,0.00023713379,0.0002077535,0.00023855428],"category_scores_gemma":[0.0040093404,0.00009263876,0.0005765159,0.0005819806,0.00031135374,0.00013185573,0.000018989293,0.0006284933,0.0000014861618],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82140905,0.0022434744,0.13214557,0.000024723427,0.0057197916,0.000121812875,0.0010570961,0.0018544688,0.00008009278,0.00011315664,0.004335615,0.030895183],"study_design_scores_gemma":[0.45023373,0.040159985,0.49667796,0.00020930378,0.0037241753,0.000005768235,0.0001605286,0.00035436839,0.00007203346,0.00018049355,0.008085141,0.00013651846],"about_ca_topic_score_codex":0.00007052836,"about_ca_topic_score_gemma":0.00020852349,"teacher_disagreement_score":0.3711753,"about_ca_system_score_codex":0.00015473638,"about_ca_system_score_gemma":0.00149801,"threshold_uncertainty_score":0.47998446},"labels":[],"label_agreement":null},{"id":"W3047222536","doi":"10.5167/uzh-163446","title":"Identification of NF-κB dependent genes which are regulated by specific coactivators","year":2006,"lang":"en","type":"dissertation","venue":"Zurich Open Repository and Archive (University of Zurich)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Harvard University; College of Engineering, Michigan State University; Universität Zürich; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; McGill University; National Science Foundation; Università degli Studi di Napoli Federico II; National Cancer Institute; Michigan State University; University of Southern California; Yonsei University","keywords":"Molecular biology; Chemistry; Biology","score_opus":0.00960485917172838,"score_gpt":0.23446277201877874,"score_spread":0.22485791284705037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047222536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98186594,0.001983597,0.0009411882,0.000103890234,0.00040074575,0.001055187,0.00034645665,0.0000404065,0.013262601],"genre_scores_gemma":[0.95904076,0.0013710175,0.000845873,0.000013457594,0.0001031444,0.000004547972,0.0024798245,0.000052535648,0.036088847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978542,0.00033599252,0.000492669,0.0006375668,0.0004801096,0.0001994995],"domain_scores_gemma":[0.99736404,0.00015996592,0.0013872788,0.0005160455,0.00043583586,0.00013682555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000365494,0.00029318983,0.0007257159,0.00031211396,0.00036100633,0.000045002384,0.00042436423,0.00026372538,0.00007605871],"category_scores_gemma":[0.000013049587,0.0003519989,0.00013671443,0.00037738815,0.00016955295,0.00027909683,0.00010113798,0.00031260776,0.0000056049716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023368907,0.0005234561,0.007553636,0.0007100388,0.0004567834,0.00007709722,0.0016207537,0.00002261445,0.9376922,0.00017486811,0.047458753,0.0013728824],"study_design_scores_gemma":[0.0044967355,0.00045984215,0.21709368,0.0015980442,0.00077239913,0.00009792686,0.009922883,0.00009396789,0.7441767,0.00060845364,0.019895108,0.0007842865],"about_ca_topic_score_codex":0.00077080633,"about_ca_topic_score_gemma":0.00021631335,"teacher_disagreement_score":0.20954004,"about_ca_system_score_codex":0.00012348425,"about_ca_system_score_gemma":0.00020369283,"threshold_uncertainty_score":0.9998932},"labels":[],"label_agreement":null},{"id":"W3047663499","doi":"10.1158/1538-7445.pedca19-a14","title":"Abstract A14: Exploiting DNA damage repair defects to enhance PD-L1 expression in Ewing sarcoma","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Cancer research; Biology; DNA damage; Poly ADP ribose polymerase; Apoptosis; PARP inhibitor; Cell culture; DNA repair; Molecular biology; Polymerase; Genetics","score_opus":0.1526339092066052,"score_gpt":0.46741168541344963,"score_spread":0.31477777620684444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047663499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850971,0.0012662589,0.00016131089,0.0067530065,0.00013224082,0.0009410884,0.000016168204,0.00020855962,0.005424234],"genre_scores_gemma":[0.99391603,0.00028192962,0.0009926902,0.0028667657,0.0009280041,0.0006467504,0.00001021994,0.00007265955,0.00028494943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99667066,0.00021059449,0.00043707225,0.00076312094,0.0010711083,0.0008474448],"domain_scores_gemma":[0.9982403,0.00033382932,0.000065935514,0.0005091854,0.0002550992,0.0005956304],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011315295,0.00019966153,0.00037204812,0.0003160805,0.00018067926,0.000049824986,0.0002740195,0.00012303436,0.0011980257],"category_scores_gemma":[0.00073574216,0.00019764384,0.000115046656,0.0011848229,0.00011181254,0.00023494619,0.00020209304,0.0010876692,0.000284337],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009867577,0.000066882305,0.0051153507,0.00037176546,0.000014693481,0.00028497723,0.0029715926,0.000078400204,0.9710183,0.000021143,0.0146826375,0.0043874905],"study_design_scores_gemma":[0.0012723,0.00028036188,0.022579286,0.002313591,0.000004377649,0.0000040476507,0.00095935183,0.0000888693,0.9535988,0.00009164028,0.018590422,0.00021692997],"about_ca_topic_score_codex":0.00020205478,"about_ca_topic_score_gemma":0.000059177444,"teacher_disagreement_score":0.017463936,"about_ca_system_score_codex":0.00075923477,"about_ca_system_score_gemma":0.00046131137,"threshold_uncertainty_score":0.99971503},"labels":[],"label_agreement":null},{"id":"W3049239269","doi":"10.1158/1078-0432.ccr-20-1439","title":"A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen's University; University of Toronto; Lunenfeld-Tanenbaum Research Institute; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; McGill University; McGill Genome Centre; Ontario Institute for Cancer Research; McGill University and Génome Québec Innovation Centre; McGill University Health Centre","funders":"Canadian Cancer Society Research Institute; Cancer Research Society; McGill University Health Centre; Terry Fox Research Institute; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Transcriptome; Pancreatic cancer; Homologous recombination; PARP inhibitor; Cancer research; Biology; Genome instability; Cancer; Medicine; Oncology; Internal medicine; Gene; Genetics; Poly ADP ribose polymerase; DNA damage; Gene expression; DNA","score_opus":0.2549166930190127,"score_gpt":0.5434493464092846,"score_spread":0.28853265339027184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049239269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97476673,0.0052939965,0.00010239787,0.014151272,0.000693297,0.0041310554,0.00012359777,0.00008180795,0.00065585953],"genre_scores_gemma":[0.9870759,0.007469226,0.00012773677,0.0020975827,0.0004354601,0.0026154867,0.000042338943,0.000052073137,0.0000841927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99356407,0.0016831832,0.0015443836,0.0012036529,0.0013234087,0.00068130373],"domain_scores_gemma":[0.9961338,0.0016944031,0.0002391699,0.00043284657,0.00079823774,0.0007015529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035140389,0.0002462684,0.0008613643,0.00027664282,0.00014127539,0.000072279174,0.00023243937,0.00036745914,0.000634583],"category_scores_gemma":[0.0038630434,0.00022334566,0.00020750544,0.001333448,0.0010168757,0.00012572386,0.0002105218,0.0016561048,0.00003479377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20939255,0.0025456839,0.7046978,0.0003679617,0.0015125567,0.0005703047,0.0017567589,0.00008779618,0.0017713307,0.00006794794,0.0196827,0.05754662],"study_design_scores_gemma":[0.15510017,0.02108954,0.8026633,0.0014910277,0.0003961218,0.000021070695,0.00073445815,0.0073444294,0.0023374807,0.00095818087,0.007202698,0.00066147],"about_ca_topic_score_codex":0.0010363731,"about_ca_topic_score_gemma":0.000101970865,"teacher_disagreement_score":0.09796557,"about_ca_system_score_codex":0.0006403758,"about_ca_system_score_gemma":0.0013583673,"threshold_uncertainty_score":0.91077715},"labels":[],"label_agreement":null},{"id":"W3051088666","doi":"10.1016/j.semcancer.2020.08.005","title":"Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers","year":2020,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill Genome Centre; Centre Hospitalier de l’Université de Montréal; McGill University; McGill University Health Centre","funders":"Terry Fox Research Institute","keywords":"Biology; Genome instability; Homologous recombination; DNA repair; Cancer research; DNA damage; Ovarian carcinoma; Serous fluid; Olaparib; Chemotherapy; Mutation; Germline mutation; RAD51; BRCA2 Protein; Ovarian cancer; Gene; Poly ADP ribose polymerase; Polymerase; Genetics; DNA; Cancer","score_opus":0.1670744176508005,"score_gpt":0.41690660654517236,"score_spread":0.24983218889437186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3051088666","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015789359,0.98559886,0.00036446922,0.0056575797,0.001263081,0.0012725763,0.0034440109,0.00007339228,0.0007470816],"genre_scores_gemma":[0.0064186594,0.9879905,0.00093740504,0.00092282274,0.0011470787,0.00052445603,0.0017460645,0.000159119,0.00015388454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956922,0.0005983518,0.0012155621,0.0015437129,0.00027313826,0.0006770349],"domain_scores_gemma":[0.99772465,0.00070561265,0.0006500408,0.0006483232,0.000048723323,0.0002226336],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003613012,0.0007435009,0.0029952063,0.0005021186,0.000086979766,0.00003175712,0.00039227481,0.001146941,0.000718802],"category_scores_gemma":[0.000120093486,0.00072827516,0.00037358663,0.0010054972,0.00038612736,0.000077100456,0.00006727672,0.0013774172,0.000023809158],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018478429,0.00011009288,0.00401562,0.0021915436,0.0006605893,0.0005042551,0.0048615113,0.000005891283,0.000935965,0.0009157485,0.0019942096,0.9819567],"study_design_scores_gemma":[0.0055955495,0.000173326,0.00043176796,0.022588326,0.00039875612,0.000012018017,0.00054715935,0.000021568625,0.00020815035,0.014948812,0.9542811,0.0007934576],"about_ca_topic_score_codex":0.0051955576,"about_ca_topic_score_gemma":0.005762312,"teacher_disagreement_score":0.98116326,"about_ca_system_score_codex":0.0056289844,"about_ca_system_score_gemma":0.0019137744,"threshold_uncertainty_score":0.99951684},"labels":[],"label_agreement":null},{"id":"W3080218538","doi":"10.1016/j.ygyno.2020.05.045","title":"The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"Iovance Biotherapeutics; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; National Cancer Institute; AbbVie Deutschland; Janssen Research and Development; EMD Serono; Genentech; Yale University; PharmaMar; V Foundation for Cancer Research; Eisai; Takeda Oncology; ImmunoGen; Syndax Pharmaceuticals; Ajinomoto; Clovis Oncology; Ovarian Cancer Research Fund; Gateway Foundation; Janssen Biotech; Les Laboratories Pierre Fabre; Syneos Health; AstraZeneca; Novocure; National Institutes of Health; Regeneron Pharmaceuticals; Ludwig Institute for Cancer Research; Array BioPharma; F. Hoffmann-La Roche; AbbVie; Sanofi; Merck; Amgen; Pfizer","keywords":"Medicine; Post-hoc analysis; Oncology; Ovarian carcinoma; Ovarian cancer; Internal medicine; Post hoc; Exploratory analysis; Cancer; Data science","score_opus":0.017801241321812575,"score_gpt":0.29966237430249415,"score_spread":0.28186113298068155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080218538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941024,0.00012830064,0.000038890503,0.0011436464,0.00011091804,0.004215584,0.00008157898,0.000021979482,0.00015669492],"genre_scores_gemma":[0.9986793,0.000038412338,0.00008819161,0.00078434794,0.0000087047265,0.00032394798,0.000055396238,0.000017590746,0.0000041357675],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965884,0.001437853,0.0008460835,0.00047320029,0.0003430676,0.00031136387],"domain_scores_gemma":[0.9952666,0.0033083255,0.00071199227,0.0003813165,0.00018885353,0.00014286693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076193124,0.00029588214,0.0021651813,0.00023913023,0.00007657072,0.000007418408,0.00014567266,0.00011174355,0.000037544505],"category_scores_gemma":[0.00092721224,0.00014730848,0.00017338422,0.0007165582,0.00057027984,0.00003466872,0.00006467545,0.00031385612,0.0000011149367],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50020814,0.0025582195,0.4791204,0.00003173815,0.0015414107,0.00011015614,0.0034764288,0.000057523044,0.000027599084,0.00002752484,0.000025684807,0.012815182],"study_design_scores_gemma":[0.36615056,0.0943552,0.5369074,0.000043507855,0.0012233959,0.0000011744274,0.0009046944,0.000094981806,0.00006056009,0.00000257158,0.00014015117,0.000115797884],"about_ca_topic_score_codex":0.000039615625,"about_ca_topic_score_gemma":0.00046022423,"teacher_disagreement_score":0.13405757,"about_ca_system_score_codex":0.0002795134,"about_ca_system_score_gemma":0.00017560353,"threshold_uncertainty_score":0.6007066},"labels":[],"label_agreement":null},{"id":"W3081315565","doi":"10.1016/s1470-2045(20)30447-2","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; AstraZeneca; Invitae; PharmaMar; Eisai; Pfizer","keywords":"Veliparib; Carboplatin; Oncology; Medicine; Placebo; Breast cancer; Internal medicine; BRCA mutation; Paclitaxel; Cancer; Chemotherapy; Biology; Genetics; Alternative medicine; Poly ADP ribose polymerase; Cisplatin; Pathology","score_opus":0.07829391178294297,"score_gpt":0.3971052690556947,"score_spread":0.3188113572727517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081315565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9326614,0.0015015197,0.00014311692,0.056082655,0.00027443093,0.006016455,0.000102577076,0.00011935085,0.0030984583],"genre_scores_gemma":[0.9857097,0.00078285974,0.0002868385,0.008336835,0.0017096607,0.0029525093,0.00003386688,0.000048618003,0.00013908098],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764043,0.0004130554,0.0006279975,0.0004898752,0.00028578,0.00054288254],"domain_scores_gemma":[0.9983895,0.00059791637,0.00034252802,0.00031043225,0.00011196867,0.00024767144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073060795,0.00031574076,0.0017032678,0.00009657546,0.00009438824,0.000023503022,0.00017793645,0.00020630559,0.00030606045],"category_scores_gemma":[0.000090552145,0.00019804196,0.00009749698,0.000438664,0.0003055,0.00009982499,0.000041730233,0.00073359016,0.000014889445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9814091,0.00029073103,0.0002815467,0.000062834115,0.00032940027,0.0001338397,0.0018495368,0.00029942117,0.0067710914,0.0001069876,0.0013017458,0.007163808],"study_design_scores_gemma":[0.9863515,0.002965583,0.00019844565,0.00012573789,0.00028086733,0.00023351092,0.0003802267,0.0011754838,0.00080844865,0.00006856104,0.0071781403,0.000233481],"about_ca_topic_score_codex":0.00019923065,"about_ca_topic_score_gemma":0.00041222188,"teacher_disagreement_score":0.053048294,"about_ca_system_score_codex":0.00030132022,"about_ca_system_score_gemma":0.0006606851,"threshold_uncertainty_score":0.8075917},"labels":[],"label_agreement":null},{"id":"W3082941820","doi":"10.1084/jem.20191688","title":"Loss of ZBTB24 impairs nonhomologous end-joining and class-switch recombination in patients with ICF syndrome","year":2020,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"FP7 People: Marie-Curie Actions; European Research Council; Institut National Du Cancer; Natural Sciences and Engineering Research Council of Canada; Ministère de l'Enseignement Supérieur et de la Recherche; Ligue Contre le Cancer; Agence Nationale de la Recherche; Fondation ARC pour la Recherche sur le Cancer; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Fondation pour la Recherche Médicale; KWF Kankerbestrijding; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","keywords":"Immunoglobulin class switching; PARP1; Poly ADP ribose polymerase; Biology; Genetics; V(D)J recombination; Genome instability; Polymerase; Non-homologous end joining; DNA repair; Molecular biology; DNA; Mutation; Gene; Recombination; DNA damage; Antibody; B cell","score_opus":0.01879032027998686,"score_gpt":0.2878766422145968,"score_spread":0.26908632193460996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082941820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945785,0.0016920055,0.00004196052,0.008023207,0.00014908152,0.00026398973,0.0000022400275,0.000006829252,0.00036283606],"genre_scores_gemma":[0.9983724,0.000116531584,0.00020912336,0.0011656452,0.00010214982,0.0000031067113,0.0000041675935,0.000018475737,0.000008419152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998581,0.000095802745,0.00057237846,0.00010432716,0.00050662865,0.00013988205],"domain_scores_gemma":[0.99900603,0.000116600044,0.00045896202,0.00014295011,0.00012886472,0.00014656929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045040945,0.00013497159,0.0004757931,0.00013284246,0.000031154414,0.0000025294592,0.0001240655,0.00004600141,0.00021138464],"category_scores_gemma":[0.00008897807,0.00007712669,0.000032142594,0.0002335121,0.00027807895,0.00011503024,0.000035092315,0.00029597234,0.000001263145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027824031,0.001943447,0.6141053,0.00029523385,0.00064610795,0.00076345715,0.054985266,0.00005831399,0.29189003,0.00023574746,0.0032129693,0.0040401444],"study_design_scores_gemma":[0.07937233,0.07325561,0.6557411,0.0043769507,0.00035282326,0.0045415103,0.016177809,0.00021701414,0.16488414,0.00033344445,0.00035523096,0.00039203846],"about_ca_topic_score_codex":0.0000226834,"about_ca_topic_score_gemma":8.874784e-7,"teacher_disagreement_score":0.12700589,"about_ca_system_score_codex":0.00013806004,"about_ca_system_score_gemma":0.000060551964,"threshold_uncertainty_score":0.31451353},"labels":[],"label_agreement":null},{"id":"W3083572265","doi":"10.1093/nar/gkaa718","title":"Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo","year":2020,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Biology; Poly ADP ribose polymerase; In vivo; DNA damage; PARP1; DNA; Genetics; Molecular biology; Cell biology; Polymerase","score_opus":0.17427446144395553,"score_gpt":0.4446949844921173,"score_spread":0.2704205230481618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083572265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9610022,0.0004713953,0.00000895038,0.019694695,0.0002013475,0.0009524665,0.00006820222,0.00016304334,0.017437698],"genre_scores_gemma":[0.9899832,0.0012088806,0.00037915367,0.003976393,0.001924797,0.0001442812,0.000031758285,0.0001017065,0.0022498337],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99468994,0.0008039111,0.0008708714,0.0009426871,0.001669237,0.0010233732],"domain_scores_gemma":[0.9972714,0.00070012285,0.00010744991,0.00075423706,0.0003161291,0.00085064996],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028295473,0.00028198538,0.00066609733,0.00035364187,0.00021493497,0.00007358285,0.0004267864,0.0003845099,0.009485518],"category_scores_gemma":[0.0010230475,0.00026154987,0.00022955828,0.0013397229,0.00074674125,0.00019703618,0.0005446098,0.0016625372,0.0020285458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033107095,0.0005642092,0.37163937,0.00047859814,0.00011103536,0.0010076889,0.003976958,0.000004660354,0.30053997,0.00019784852,0.30584797,0.012320955],"study_design_scores_gemma":[0.013879527,0.002981625,0.09021466,0.00066848175,0.000036034853,0.000038697348,0.0012618209,0.0012915477,0.17738071,0.00028320373,0.71128637,0.0006773288],"about_ca_topic_score_codex":0.000047903093,"about_ca_topic_score_gemma":0.00005113123,"teacher_disagreement_score":0.40543836,"about_ca_system_score_codex":0.0005073238,"about_ca_system_score_gemma":0.00025261228,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W3083593114","doi":"10.1136/ijgc-2020-001694","title":"DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Epithelial ovarian cancer; Oncology; Internal medicine; Ovarian cancer; Randomized controlled trial; Maintenance therapy; Phases of clinical research; Gynecology; Clinical trial; Cancer; Chemotherapy; Adverse effect","score_opus":0.024050440850557023,"score_gpt":0.31408328392920226,"score_spread":0.29003284307864524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083593114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97217613,0.00039932938,0.00013822553,0.022541247,0.00042753515,0.003802345,0.00044803525,0.000013658443,0.000053514326],"genre_scores_gemma":[0.99396425,0.00033615695,0.00034361376,0.004186796,0.00051443203,0.00042447445,0.000011692698,0.000029100598,0.0001894861],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99640965,0.0005731029,0.0013863908,0.00054019515,0.00071222946,0.00037841467],"domain_scores_gemma":[0.996511,0.0008224537,0.0010713422,0.00021918133,0.00096160715,0.0004144371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005443278,0.00042609734,0.0014435895,0.00015191406,0.00009850945,0.000038570255,0.00023653997,0.0000944788,0.00044724124],"category_scores_gemma":[0.0009426373,0.00022936471,0.00024183592,0.0002126575,0.00045245947,0.00016611144,0.000085047315,0.00037978461,0.000001542212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7318855,0.012248677,0.19072999,0.000038572343,0.0032811682,0.0006322927,0.031774234,0.0008842258,0.0032906646,0.000024533287,0.000904628,0.02430553],"study_design_scores_gemma":[0.67738813,0.03293845,0.27246097,0.0010797605,0.0005624734,0.00003204201,0.0010683823,0.00083206734,0.01141531,0.00003923086,0.0017725391,0.00041066154],"about_ca_topic_score_codex":0.00072989345,"about_ca_topic_score_gemma":0.0010293683,"teacher_disagreement_score":0.08173096,"about_ca_system_score_codex":0.0017437768,"about_ca_system_score_gemma":0.000536767,"threshold_uncertainty_score":0.93532217},"labels":[],"label_agreement":null},{"id":"W3083740002","doi":"10.1101/2020.09.04.283309","title":"Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Medical Research Council; AstraZeneca","keywords":"Allosteric regulation; Poly ADP ribose polymerase; Chemistry; DNA; Biophysics; Mutagenesis; Point mutation; DNA repair; Steric effects; PARP inhibitor; Veliparib; DNA damage; Stereochemistry; Mutant; Cell biology; Biology; Biochemistry; Polymerase; Enzyme","score_opus":0.024827547801385574,"score_gpt":0.2573459877258045,"score_spread":0.23251843992441895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083740002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959983,0.00039527327,0.0003177406,0.0018525159,0.00020130347,0.0009905135,0.00017940711,0.00005264046,0.000012291741],"genre_scores_gemma":[0.99857515,0.00047513205,0.000394133,0.00028160666,0.000117494914,0.00008959709,0.0000016331051,0.00006407488,0.0000011879051],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99783707,0.00017762938,0.0007421869,0.0006065526,0.00040630336,0.0002302887],"domain_scores_gemma":[0.9979969,0.00009190383,0.00079463323,0.00070189097,0.00027943228,0.0001352365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005158355,0.0003382937,0.000674782,0.00023558973,0.000048620906,0.00004612997,0.0001796376,0.00041259194,0.000011457377],"category_scores_gemma":[0.00013313378,0.00031523066,0.00008976463,0.0004965695,0.0003609344,0.00020664517,0.00032568508,0.0006163959,4.949819e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003251349,0.00011162155,0.14395936,0.0017915117,0.00010186519,0.000012131833,0.000048307942,0.000034500023,0.8522334,0.0013360234,0.000038578808,0.0000075417543],"study_design_scores_gemma":[0.0010368573,0.000042521853,0.50135064,0.0014834835,0.000057357232,4.4586738e-8,0.000007275528,0.0003069908,0.4954421,0.000082233186,0.000017422688,0.00017308918],"about_ca_topic_score_codex":0.00006335121,"about_ca_topic_score_gemma":0.000019258918,"teacher_disagreement_score":0.3573913,"about_ca_system_score_codex":0.0003009174,"about_ca_system_score_gemma":0.0004964838,"threshold_uncertainty_score":0.99992996},"labels":[],"label_agreement":null},{"id":"W3087988414","doi":"10.1016/j.annonc.2020.08.952","title":"813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Chemotherapy; Internal medicine; Placebo; Progression-free survival; Oncology; Ovarian cancer; Gastroenterology; Surgery; Cancer; Pathology","score_opus":0.09531459648497898,"score_gpt":0.3987324027835507,"score_spread":0.30341780629857174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087988414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96513283,0.00011826761,0.00018106493,0.028875625,0.00053292426,0.004275845,0.0003586142,0.00004721901,0.00047758396],"genre_scores_gemma":[0.99120975,0.00014818386,0.00068948645,0.006538175,0.0007943457,0.00040644477,0.00013354329,0.000057767564,0.000022306187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975985,0.00029496508,0.0007617443,0.00046092935,0.00045246494,0.00043138544],"domain_scores_gemma":[0.9970013,0.0008377727,0.0009199813,0.00029335366,0.00078116095,0.00016647024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000483133,0.0002996047,0.0009302592,0.00009315905,0.00011153046,0.000011103828,0.00016784284,0.00021951944,0.00011880471],"category_scores_gemma":[0.00031506224,0.00020268555,0.0002231596,0.00029401298,0.0004464385,0.00005787749,0.000026438349,0.00035812837,0.0000039011456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8171312,0.0030811713,0.0011298441,0.00016140098,0.0011457105,0.000019325955,0.007057875,0.00018259787,0.0067566116,0.00023588978,0.006724704,0.15637363],"study_design_scores_gemma":[0.48539773,0.110036924,0.015066721,0.0012153481,0.00041893215,0.000015067556,0.00037409013,0.00092672504,0.33412692,0.00017580533,0.051642057,0.00060368155],"about_ca_topic_score_codex":0.0000657331,"about_ca_topic_score_gemma":0.000022826829,"teacher_disagreement_score":0.3317335,"about_ca_system_score_codex":0.0001541096,"about_ca_system_score_gemma":0.000778643,"threshold_uncertainty_score":0.8265277},"labels":[],"label_agreement":null},{"id":"W3088267903","doi":"10.1016/j.annonc.2020.08.883","title":"624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; AstraZeneca France; Meso Scale Diagnostics","keywords":"Medicine; Tolerability; Adverse effect; Enzalutamide; Internal medicine; Nausea; Prostate cancer; Population; Olaparib; Surgery; Oncology; Cancer","score_opus":0.09026358163181142,"score_gpt":0.38053623638333,"score_spread":0.2902726547515186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088267903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989185,0.00041050217,0.000042134394,0.008686266,0.00006612232,0.0011949348,0.00010071148,0.000024208744,0.0002901525],"genre_scores_gemma":[0.9955967,0.00031337384,0.0022468877,0.0014660717,0.000027311935,0.00022628024,0.000078664656,0.000014460023,0.000030223895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983394,0.00022477792,0.00069421093,0.00032462503,0.00022820705,0.00018876785],"domain_scores_gemma":[0.99850863,0.00013187756,0.0004227708,0.0001805538,0.0006560436,0.00010011049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039511305,0.00013933604,0.0005439185,0.00011188487,0.000040218427,0.000005830012,0.00004901681,0.000095610856,0.00007539812],"category_scores_gemma":[0.00018103178,0.00012180579,0.000049784903,0.00030488631,0.00022203045,0.0001594869,0.000018500506,0.0001998205,0.0000010887596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027107093,0.007049228,0.80832255,0.0025080666,0.0010700711,0.00014135489,0.017336749,0.0012316994,0.06228208,0.0013534212,0.0044818264,0.06711588],"study_design_scores_gemma":[0.026413186,0.04024688,0.8399936,0.00050568866,0.00027224357,0.00003680078,0.00075014285,0.0011728368,0.084527254,0.0021782287,0.003447967,0.0004551792],"about_ca_topic_score_codex":0.0002528289,"about_ca_topic_score_gemma":0.00048500602,"teacher_disagreement_score":0.0666607,"about_ca_system_score_codex":0.00012525263,"about_ca_system_score_gemma":0.0005357076,"threshold_uncertainty_score":0.4967096},"labels":[],"label_agreement":null},{"id":"W3088796366","doi":"10.1016/j.annonc.2020.08.950","title":"811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Progression-free survival; Ovarian cancer; Randomization; Oncology; Chemotherapy; Urology; Cancer; Gastroenterology; Surgery; Randomized controlled trial","score_opus":0.05051790121081382,"score_gpt":0.35246625525895836,"score_spread":0.3019483540481445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088796366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731692,0.0005829496,0.003701333,0.01928595,0.00038275655,0.0013310638,0.00047869488,0.000056272682,0.0010117777],"genre_scores_gemma":[0.9773923,0.0008115545,0.0064388304,0.014319111,0.00023503866,0.0004462167,0.0001757046,0.000044301938,0.00013692534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985062,0.00006579512,0.00041080487,0.0004570967,0.00021524135,0.00034488318],"domain_scores_gemma":[0.99826014,0.0003845195,0.0003657759,0.00019475505,0.0005647205,0.0002300707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011431043,0.00020461118,0.0006117167,0.000066220455,0.00006598471,0.000009371018,0.000100179335,0.00016843282,0.0001882644],"category_scores_gemma":[0.00034806604,0.00017727548,0.00009144868,0.00019122774,0.00017479947,0.00016381178,0.000029515737,0.00016759035,0.000008468977],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081477195,0.001866061,0.07609982,0.0006416412,0.0017535902,0.0002258838,0.012540501,0.0004302249,0.018493915,0.0041993763,0.14895593,0.65331584],"study_design_scores_gemma":[0.29914373,0.05643654,0.16704744,0.0014461343,0.00074199523,0.000033309192,0.0021021285,0.0018120813,0.027859014,0.011066871,0.43097103,0.0013397152],"about_ca_topic_score_codex":0.00041273757,"about_ca_topic_score_gemma":0.0003972273,"teacher_disagreement_score":0.65197617,"about_ca_system_score_codex":0.000092202055,"about_ca_system_score_gemma":0.00035193644,"threshold_uncertainty_score":0.72290844},"labels":[],"label_agreement":null},{"id":"W3089112078","doi":"10.1016/j.annonc.2020.08.870","title":"610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Meso Scale Diagnostics; AstraZeneca","keywords":"Olaparib; Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Population; Oncology; Cohort; Progression-free survival; Randomized controlled trial; Urology; Cancer; Chemotherapy; Androgen receptor","score_opus":0.12535697421102335,"score_gpt":0.3941244951630284,"score_spread":0.26876752095200507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089112078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575263,0.00017755937,0.00007207201,0.0026893376,0.000057192217,0.0007864054,0.00031520842,0.000017551978,0.00013204764],"genre_scores_gemma":[0.99685967,0.00027836286,0.0012093602,0.0011835828,0.00003340189,0.00014242684,0.00020500793,0.000018443408,0.00006973061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979401,0.00028082513,0.0008700176,0.0003561654,0.00032753838,0.000225352],"domain_scores_gemma":[0.9979379,0.0002395619,0.0007826794,0.00020555012,0.0007426421,0.00009164158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003193869,0.00018355623,0.0009818573,0.0003076216,0.000039650786,0.000006520779,0.00007212707,0.000075223565,0.000088452965],"category_scores_gemma":[0.00013578741,0.00015323082,0.00010420429,0.00079767243,0.0002034693,0.00018225044,0.000023182094,0.0001509521,6.269955e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06553342,0.009264202,0.6602392,0.0023564338,0.010758467,0.00016279587,0.015172034,0.015626619,0.1957659,0.0010571608,0.0020953314,0.02196841],"study_design_scores_gemma":[0.016391862,0.021552598,0.9077635,0.0002539088,0.001566508,0.0000041337034,0.00027925367,0.0026212467,0.048518945,0.00017363668,0.0005846949,0.00028974167],"about_ca_topic_score_codex":0.0010708031,"about_ca_topic_score_gemma":0.0032271228,"teacher_disagreement_score":0.24752425,"about_ca_system_score_codex":0.00012478235,"about_ca_system_score_gemma":0.00054422073,"threshold_uncertainty_score":0.6248571},"labels":[],"label_agreement":null},{"id":"W3089120395","doi":"10.1016/j.annonc.2020.08.458","title":"356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Metastatic breast cancer; Induction chemotherapy; Breast cancer; Cancer; Immunotherapy; Polymerase","score_opus":0.09994990229484879,"score_gpt":0.4189594626512683,"score_spread":0.31900956035641953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089120395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9398067,0.0013189173,0.0004467277,0.04577614,0.0005234658,0.0099788,0.0003443026,0.000086378364,0.0017185683],"genre_scores_gemma":[0.9709304,0.009225475,0.0015977317,0.013809278,0.0005161831,0.0031783811,0.000084748506,0.00014574174,0.00051206694],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933013,0.0012032483,0.0025486967,0.0011399991,0.0008962304,0.00091057224],"domain_scores_gemma":[0.9952154,0.0006197213,0.0018118313,0.000691329,0.0011660189,0.0004956834],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015695116,0.00082478294,0.004677182,0.0005597522,0.00013285385,0.0000467082,0.0006388604,0.00042714525,0.0035556355],"category_scores_gemma":[0.00033843872,0.00062107254,0.00036663917,0.001596596,0.0010197776,0.00061290525,0.00013819795,0.00093646767,0.000008167367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88817286,0.010271781,0.00002981507,0.00028482216,0.00158655,0.00011610085,0.005916544,0.000051541894,0.0031384977,0.00010063172,0.0055148364,0.084815994],"study_design_scores_gemma":[0.9098848,0.06001913,0.00011241415,0.0007680199,0.0004066189,0.00027267577,0.00038782365,0.0010767658,0.017860869,0.00028909274,0.008345691,0.0005761165],"about_ca_topic_score_codex":0.0011839462,"about_ca_topic_score_gemma":0.00035358523,"teacher_disagreement_score":0.08423988,"about_ca_system_score_codex":0.00053182605,"about_ca_system_score_gemma":0.004018574,"threshold_uncertainty_score":0.9996241},"labels":[],"label_agreement":null},{"id":"W3089125873","doi":"10.1016/j.annonc.2020.08.960","title":"821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Internal medicine; Placebo; PARP inhibitor; Population; Phases of clinical research; Ovarian cancer; Surgery; Cancer; Clinical trial; Poly ADP ribose polymerase","score_opus":0.1877396312442508,"score_gpt":0.46425494564890574,"score_spread":0.27651531440465493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089125873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840328,0.00025704925,0.00022841721,0.012959377,0.00010113556,0.0018089593,0.00007643537,0.000009602324,0.00052621285],"genre_scores_gemma":[0.9974412,0.00031358792,0.00023948599,0.0012508043,0.00011782466,0.00056726433,0.00000922348,0.000013309698,0.00004732906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988694,0.00009987126,0.00041412943,0.00022939582,0.00016400764,0.00022314776],"domain_scores_gemma":[0.9991788,0.00011613105,0.00029377895,0.00019078238,0.00015164203,0.00006884539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024803213,0.00013119985,0.00050189917,0.00006381666,0.000036837446,7.3869006e-7,0.00010268169,0.000051066156,0.000094246905],"category_scores_gemma":[0.000035068348,0.000084942854,0.00008435661,0.00019603806,0.00007406339,0.00004132129,0.000014610593,0.00010377836,8.8404516e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2902157,0.04759702,0.112804234,0.0013317979,0.004402627,0.0008851574,0.2060042,0.0020281707,0.03703786,0.0009238033,0.00696438,0.28980505],"study_design_scores_gemma":[0.3905341,0.3018177,0.090732366,0.0020382246,0.0012262823,0.00013121612,0.03777058,0.0024122964,0.09410321,0.0004932538,0.077887654,0.0008531451],"about_ca_topic_score_codex":0.00020393396,"about_ca_topic_score_gemma":0.00032594585,"teacher_disagreement_score":0.2889519,"about_ca_system_score_codex":0.00012742341,"about_ca_system_score_gemma":0.00031323195,"threshold_uncertainty_score":0.3463869},"labels":[],"label_agreement":null},{"id":"W3089157576","doi":"10.1016/j.ejca.2020.08.021","title":"Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Response Evaluation Criteria in Solid Tumors; Internal medicine; Concordance; Oncology; Progression-free survival; Placebo; Ovarian cancer; Cancer; Chemotherapy; Progressive disease; Pathology","score_opus":0.018693872539351578,"score_gpt":0.3029631482047462,"score_spread":0.2842692756653946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089157576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793995,0.0006777817,0.00011225376,0.017758084,0.000097400414,0.0016238537,0.00006673334,0.000017653412,0.00024671288],"genre_scores_gemma":[0.9902822,0.0004236092,0.00044867917,0.008039075,0.0005063669,0.00007777097,0.000009067251,0.00008783371,0.00012543338],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.996596,0.001135477,0.0008124817,0.00040744906,0.0006829004,0.00036569007],"domain_scores_gemma":[0.9981564,0.0002020348,0.0006427768,0.00023833293,0.0005011633,0.00025927485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001206362,0.00034257717,0.00069725537,0.00018302556,0.0000628731,0.000052606305,0.00018572978,0.000056441364,0.00012596269],"category_scores_gemma":[0.00012051435,0.00019464846,0.00006589741,0.0008438082,0.00020080227,0.00017275696,0.000018579634,0.00070982677,0.000004615875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7531212,0.00020741914,0.19090281,0.000016521417,0.0002137729,0.0011443672,0.008914668,0.00009963903,0.0017819883,8.4114805e-7,0.00085994083,0.042736817],"study_design_scores_gemma":[0.1908883,0.012902612,0.780287,0.0022993495,0.00005916741,0.00004113203,0.00023313024,0.000018245282,0.0028725152,0.0000032514145,0.010103878,0.0002913758],"about_ca_topic_score_codex":0.00013126055,"about_ca_topic_score_gemma":0.000106952044,"teacher_disagreement_score":0.58938426,"about_ca_system_score_codex":0.00033614394,"about_ca_system_score_gemma":0.00040140992,"threshold_uncertainty_score":0.7937534},"labels":[],"label_agreement":null},{"id":"W3089254712","doi":"10.1016/j.ygyno.2020.09.006","title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Sherbrooke","funders":"Genentech; Medac; Eisai; Merck KGaA; Clovis Oncology; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Takeda Oncology; Amgen; Pfizer; PharmaMar; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Placebo; Ovarian cancer; Oncology; Internal medicine; Nova (rocket); Term (time); Gynecology; Cancer; Pathology; Alternative medicine","score_opus":0.06628635318853937,"score_gpt":0.35598437165624364,"score_spread":0.28969801846770427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089254712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781489,0.0001395185,0.00005997878,0.011712954,0.0011830238,0.0039046472,0.0004999311,0.00013201141,0.0042190403],"genre_scores_gemma":[0.9938486,0.00016153329,0.00027501368,0.0033640778,0.0006964126,0.0005305002,0.0010214725,0.00003888419,0.00006350031],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968359,0.0005283921,0.0008107406,0.00084823486,0.00040024158,0.0005764917],"domain_scores_gemma":[0.99673045,0.0017909969,0.0005269957,0.00048726812,0.00019616904,0.00026813385],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039904797,0.0003962374,0.00094038725,0.00008257966,0.00014724083,0.000020165016,0.00028066468,0.00036647724,0.0019343538],"category_scores_gemma":[0.0004482063,0.00023555601,0.00008598138,0.0006315717,0.00034016007,0.000091945985,0.00006834948,0.00079177687,0.000043958975],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8929302,0.0018864955,0.05278011,0.000009033079,0.000425346,0.0002472392,0.0013149285,0.0000719762,0.00004045326,0.000019850148,0.0036085253,0.04666583],"study_design_scores_gemma":[0.73870665,0.03946495,0.20358846,0.000100004254,0.0003213662,0.0000028111929,0.0001459739,0.000059182512,0.00012316916,0.0000066132907,0.017173026,0.0003077695],"about_ca_topic_score_codex":0.0005496535,"about_ca_topic_score_gemma":0.0047222185,"teacher_disagreement_score":0.15422355,"about_ca_system_score_codex":0.0014000885,"about_ca_system_score_gemma":0.0009871363,"threshold_uncertainty_score":0.998978},"labels":[],"label_agreement":null},{"id":"W3089265467","doi":"10.1016/j.annonc.2020.08.958","title":"819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"North Carolina GlaxoSmithKline Foundation","keywords":"Medicine; Internal medicine; Adverse effect; Ovarian cancer; Clinical endpoint; Hazard ratio; Progression-free survival; Urology; Randomized controlled trial; Gastroenterology; Oncology; Chemotherapy; Gynecology; Cancer; Confidence interval","score_opus":0.0793094299621809,"score_gpt":0.3875644351331859,"score_spread":0.308255005171005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089265467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96074563,0.000674408,0.000043968223,0.034294315,0.00020653357,0.0014312653,0.00039938907,0.0000168605,0.0021876348],"genre_scores_gemma":[0.990862,0.0012838752,0.0004754716,0.0068668094,0.0002958014,0.000076352146,0.00009013739,0.000021603935,0.000027950167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809694,0.00022149281,0.00075800554,0.0003790661,0.00028631586,0.00025814975],"domain_scores_gemma":[0.9980712,0.00072283857,0.0005102396,0.00030754053,0.00025519045,0.00013299678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000344559,0.0001763369,0.0007094365,0.00005745854,0.000038234575,0.000003687994,0.00014382278,0.00016528119,0.00016109916],"category_scores_gemma":[0.00037299108,0.00012239552,0.00006385498,0.000300346,0.00027590475,0.00008063422,0.00005024725,0.00029463167,0.0000033768856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65099126,0.0019477482,0.019073999,0.00008364951,0.00046940125,0.00002608858,0.011560247,0.0001745854,0.0036473903,0.00019870987,0.014612785,0.29721412],"study_design_scores_gemma":[0.46921495,0.015640387,0.3939724,0.0005595239,0.0001329666,0.0000029162927,0.00035374484,0.00005911929,0.00977471,0.00013232246,0.10989315,0.00026383455],"about_ca_topic_score_codex":0.00053273706,"about_ca_topic_score_gemma":0.00023244691,"teacher_disagreement_score":0.37489837,"about_ca_system_score_codex":0.00006636949,"about_ca_system_score_gemma":0.000368461,"threshold_uncertainty_score":0.49911445},"labels":[],"label_agreement":null},{"id":"W3090035818","doi":"10.1016/j.mehy.2020.110278","title":"Causing DNA damage and stopping DNA repair – Vitamin D supplementation with Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors may cause selective cell death of cancer cells: A novel therapeutic paradigm utilizing elevated copper levels within the tumour","year":2020,"lang":"en","type":"article","venue":"Medical Hypotheses","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université Laval; Shastri Indo-Canadian Institute","keywords":"PARP1; DNA damage; Cancer research; DNA repair; Poly ADP ribose polymerase; Cancer cell; Cancer; Apoptosis; Programmed cell death; Polymerase; Biology; DNA; Biochemistry; Genetics","score_opus":0.06984002658780294,"score_gpt":0.3205759946927598,"score_spread":0.2507359681049569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090035818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98371714,0.0017028275,0.0016217526,0.011182476,0.00016549094,0.0010577157,0.00020091707,0.00017697978,0.00017471061],"genre_scores_gemma":[0.9910903,0.00017081441,0.0008505295,0.0071642236,0.00040874447,0.00012419444,0.000024930801,0.00009671871,0.00006954079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99668306,0.00027814516,0.000742596,0.0006438372,0.0011313794,0.00052098616],"domain_scores_gemma":[0.99802196,0.00063945004,0.00043040104,0.0003081998,0.0001450702,0.00045493207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005805846,0.00043235172,0.00063863746,0.0001436799,0.00026341758,0.000043920754,0.00015225678,0.00017280802,0.00033565497],"category_scores_gemma":[0.0001695803,0.00029553755,0.00011511668,0.000610252,0.0005388646,0.00019854239,0.00006597568,0.00058190804,0.0000031387779],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013485041,0.0003487878,0.015523738,0.0003994918,0.00057677715,0.0001513626,0.009687062,0.000031953445,0.9702299,0.00027162718,0.00073388236,0.00069686945],"study_design_scores_gemma":[0.005691684,0.0007646069,0.008011428,0.0011117461,0.0004797568,0.00008855106,0.0039770645,0.0026499794,0.97617525,0.00003888508,0.00061874086,0.00039229312],"about_ca_topic_score_codex":0.0009874142,"about_ca_topic_score_gemma":0.00020396904,"teacher_disagreement_score":0.0075123105,"about_ca_system_score_codex":0.00023366798,"about_ca_system_score_gemma":0.00086747826,"threshold_uncertainty_score":0.9999497},"labels":[],"label_agreement":null},{"id":"W3091465868","doi":"10.1158/1557-3265.covid-19-po-068","title":"Abstract PO-068: Efforts to define biochemical and pharmacologic pathways potentially beneficial to both cancer and COVID-19 patients","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Windsor","funders":"","keywords":"Cancer; Medicine; Oncogene; Hydroxychloroquine; Drug repositioning; Pharmacology; Coronavirus disease 2019 (COVID-19); Drug; Bioinformatics; Biology; Cell cycle; Internal medicine; Disease","score_opus":0.32684767632827366,"score_gpt":0.539831035403601,"score_spread":0.21298335907532734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091465868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9416147,0.0015297389,0.000092856484,0.0541408,0.00031567996,0.0015488003,0.00037683835,0.00007569059,0.0003049033],"genre_scores_gemma":[0.94750893,0.0028008386,0.00037464924,0.047149744,0.0015448137,0.00047186922,0.000033750293,0.00004749792,0.00006791594],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99637014,0.00015330338,0.00074159674,0.0010313562,0.0009834978,0.00072012964],"domain_scores_gemma":[0.9957207,0.00063284324,0.000093649556,0.00025457022,0.00040071868,0.0028975324],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012729806,0.00024488586,0.00059240486,0.00015581271,0.00022367222,0.00006367444,0.00022543705,0.0002495844,0.0014366],"category_scores_gemma":[0.0017103243,0.00021509804,0.00010793987,0.00059940724,0.00039112938,0.00006569418,0.00030326104,0.0009623197,0.000064409964],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025881464,0.0012076426,0.2829701,0.0011414898,0.0003410121,0.00031336214,0.0012733313,0.0001773399,0.13348486,0.000108254004,0.39400786,0.15909328],"study_design_scores_gemma":[0.029845087,0.008816742,0.62124807,0.00068795576,0.00023644723,0.000016233356,0.00019956393,0.00023697082,0.036115553,0.0007765982,0.3005682,0.0012526067],"about_ca_topic_score_codex":0.0005743307,"about_ca_topic_score_gemma":0.00009520322,"teacher_disagreement_score":0.33827794,"about_ca_system_score_codex":0.00041770295,"about_ca_system_score_gemma":0.0011933383,"threshold_uncertainty_score":0.9994762},"labels":[],"label_agreement":null},{"id":"W3091531293","doi":"10.1136/ijgc-2020-001849","title":"Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Government of Ontario; Ontario Institute for Cancer Research","keywords":"Medicine; Serous fluid; Ovarian cancer; Serous ovarian cancer; Abdominal pain; Abdominal distension; Poly ADP ribose polymerase; Internal medicine; Oncology; Polymerase; Gastroenterology; Cancer; Gynecology; Pathology; Enzyme","score_opus":0.028620173436476336,"score_gpt":0.37068385931199804,"score_spread":0.3420636858755217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091531293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.865077,0.0036841899,0.00022318253,0.12904495,0.001215082,0.00032574,0.00031727884,0.00003560034,0.000076986995],"genre_scores_gemma":[0.97562,0.00047120085,0.0011436339,0.020232188,0.0022988482,0.00010810642,0.00002153268,0.000035846537,0.00006868522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970228,0.00017662394,0.00083657354,0.0003733127,0.0011751029,0.00041557068],"domain_scores_gemma":[0.9977485,0.0002846826,0.00067293947,0.000120457225,0.00057822606,0.000595218],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039505254,0.00029475338,0.0006170459,0.00017046642,0.0000796166,0.00007937154,0.0003708334,0.00016977658,0.0032619608],"category_scores_gemma":[0.0004832542,0.00020048006,0.00019105955,0.00041914117,0.00024397868,0.00038318106,0.000086907814,0.0007439483,0.0000063177235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037213445,0.0020381694,0.61571324,0.00016913554,0.0030830204,0.014573834,0.006014463,0.0028189954,0.08566336,0.0008052651,0.038608547,0.19329855],"study_design_scores_gemma":[0.09032343,0.014952279,0.3911481,0.004307171,0.00064693054,0.0023752928,0.0035797376,0.0006611891,0.34829295,0.0016491818,0.13994513,0.0021186292],"about_ca_topic_score_codex":0.00034681056,"about_ca_topic_score_gemma":0.00028866227,"teacher_disagreement_score":0.26262957,"about_ca_system_score_codex":0.0008271647,"about_ca_system_score_gemma":0.00085581397,"threshold_uncertainty_score":0.9976492},"labels":[],"label_agreement":null},{"id":"W3093265161","doi":"10.1016/s0140-6736(10)60892-6","title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1636,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Susan G. Komen; Cancer Research Society; AstraZeneca","keywords":"Olaparib; Medicine; Tolerability; Breast cancer; Cohort; PARP inhibitor; Internal medicine; BRCA mutation; Oncology; Adverse effect; Nausea; Cancer; Poly ADP ribose polymerase; Polymerase; Biology; Genetics","score_opus":0.018824207311866577,"score_gpt":0.3056834608736979,"score_spread":0.28685925356183134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093265161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903143,0.00026790547,0.00003718056,0.007888073,0.0005131182,0.0014770518,0.00056458556,0.000049844948,0.00017077864],"genre_scores_gemma":[0.9965024,0.000016503756,0.00066545396,0.0009241822,0.0012898839,0.00026802195,0.000062258936,0.000036195896,0.00023507263],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99855185,0.00009410274,0.0003675884,0.0002996463,0.00033559196,0.00035121266],"domain_scores_gemma":[0.99891335,0.0001251196,0.00021906957,0.0004839017,0.00013716509,0.00012139937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023895098,0.00020979391,0.0005967083,0.00009794931,0.000090499336,0.000023369103,0.00015630203,0.000094816874,0.00032281707],"category_scores_gemma":[0.00006923412,0.000126074,0.000043357006,0.00038799626,0.00037361434,0.00018577157,0.000033316486,0.00044857874,0.0000022663528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45121282,0.0024018292,0.23419955,0.00026980214,0.00040554712,0.00003963166,0.0061617545,0.000062860716,0.011485716,0.00049254927,0.007507123,0.2857608],"study_design_scores_gemma":[0.5666901,0.0038424558,0.33716446,0.0011265812,0.00028745516,0.0001116498,0.00043741637,0.00018897161,0.08032095,0.00040233415,0.008599053,0.0008285542],"about_ca_topic_score_codex":0.0003047847,"about_ca_topic_score_gemma":0.0006393711,"teacher_disagreement_score":0.28493226,"about_ca_system_score_codex":0.000066870125,"about_ca_system_score_gemma":0.0003306019,"threshold_uncertainty_score":0.5141148},"labels":[],"label_agreement":null},{"id":"W3093731804","doi":"10.2147/cmar.s249540","title":"&lt;p&gt;Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets&lt;/p&gt;","year":2020,"lang":"en","type":"review","venue":"Cancer Management and Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Ovarian carcinoma; Ovarian cancer; Cancer research; Medicine; Serous fluid; Carcinogenesis; Targeted therapy; Immune system; Kinome; Bevacizumab; Cancer; Chemotherapy; Immunology; Kinase; Biology; Internal medicine","score_opus":0.18286264737513697,"score_gpt":0.40648633523991506,"score_spread":0.2236236878647781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093731804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002740201,0.9900356,0.001095293,0.0018779105,0.0005978231,0.002763371,0.00011370671,0.000077703786,0.0034111715],"genre_scores_gemma":[0.008923763,0.9854399,0.00017092597,0.00015917652,0.00096940616,0.0007097678,0.0001187019,0.00017487902,0.0033334747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99525744,0.00054180436,0.0007836686,0.0010112211,0.0015410321,0.00086483],"domain_scores_gemma":[0.99834836,0.00012304426,0.00029480355,0.00070553826,0.00018690026,0.00034133947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009419668,0.0005704522,0.0018534778,0.00091709435,0.0002877713,0.0000983638,0.00045888821,0.00035677527,0.00092499604],"category_scores_gemma":[0.000010416951,0.00045802936,0.00043792353,0.0013756399,0.0005153568,0.0000874522,0.00035728057,0.00076271076,0.00004089003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050748256,0.00023215686,0.000031073443,0.05719071,0.00570482,0.0007072451,0.0006819881,0.00001014024,0.00033003904,0.020964714,0.01310795,0.9005317],"study_design_scores_gemma":[0.002268539,0.00029519576,0.000077575074,0.008701952,0.0018112186,0.00003282369,0.00028526533,0.00003381223,0.00005103675,0.0016651558,0.9843374,0.00044001816],"about_ca_topic_score_codex":0.00006433893,"about_ca_topic_score_gemma":0.000025327281,"teacher_disagreement_score":0.97122943,"about_ca_system_score_codex":0.0012441153,"about_ca_system_score_gemma":0.0005067066,"threshold_uncertainty_score":0.9999883},"labels":[],"label_agreement":null},{"id":"W3093968467","doi":"10.1158/1557-3265.ovcasymp18-nt-101","title":"Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Population; Ovarian cancer; Clinical endpoint; Progressive disease; Progression-free survival; Carboplatin; Oncology; Refractory (planetary science); Gastroenterology; Phases of clinical research; Surgery; Clinical trial; Cancer; Cisplatin","score_opus":0.3252451303081464,"score_gpt":0.5403688162190448,"score_spread":0.21512368591089837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093968467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720783,0.0004663058,0.000006484614,0.008397825,0.0005738482,0.015681874,0.00014468942,0.000074694275,0.0025759547],"genre_scores_gemma":[0.9848803,0.0006327195,0.0003602996,0.0022169894,0.00048947695,0.003378873,0.000065477885,0.0002125377,0.0077632815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9909943,0.0012227667,0.0017809789,0.0021104463,0.0024249032,0.0014666317],"domain_scores_gemma":[0.9942658,0.0009604765,0.000466275,0.0018475003,0.001459989,0.0009999863],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043511055,0.0006490672,0.0017401542,0.00054034434,0.00026750786,0.00023650232,0.00080337847,0.00031070336,0.0040067434],"category_scores_gemma":[0.0003814683,0.00050460384,0.00016379001,0.0013044274,0.0003800422,0.00029869296,0.00025314032,0.001449931,0.00026712718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16593961,0.13604744,0.49402216,0.0001699078,0.001666092,0.00020529727,0.007129106,0.00013063088,0.005873239,0.0000099006265,0.011259001,0.17754763],"study_design_scores_gemma":[0.3802533,0.13829848,0.42235005,0.0031381508,0.00025645606,0.00000341705,0.0014758795,0.0002070377,0.0062988596,0.000095377705,0.0464077,0.0012153016],"about_ca_topic_score_codex":0.005240074,"about_ca_topic_score_gemma":0.0053406497,"teacher_disagreement_score":0.21431367,"about_ca_system_score_codex":0.0056487457,"about_ca_system_score_gemma":0.0025257648,"threshold_uncertainty_score":0.99974054},"labels":[],"label_agreement":null},{"id":"W3095106929","doi":"10.1042/bcj20200525","title":"PARP-1 activation after oxidative insult promotes energy stress-dependent phosphorylation of YAP1 and reduces cell viability","year":2020,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"Ministerio de Educación, Cultura y Deporte; Cancer Research UK","keywords":"Poly ADP ribose polymerase; NAD+ kinase; Oxidative stress; Phosphorylation; AMPK; YAP1; Cell biology; Viability assay; Oxidative phosphorylation; Biology; Chemistry; Molecular biology; Biochemistry; Protein kinase A; Cell; Transcription factor; Enzyme; Polymerase","score_opus":0.016062238890759414,"score_gpt":0.2588169490171647,"score_spread":0.24275471012640526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095106929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563116,0.00063572504,0.0011883745,0.0021610677,0.00004136086,0.00012659843,0.000025697556,0.00001543771,0.00017459672],"genre_scores_gemma":[0.9980544,0.00019988716,0.0009965985,0.0003805347,0.00030900017,0.000012903328,0.00001881507,0.000011467505,0.000016391214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99898213,0.000053610413,0.0003351343,0.00020144437,0.00030751326,0.00012019349],"domain_scores_gemma":[0.99922854,0.000053356922,0.00022332581,0.00008515776,0.00020999504,0.00019964456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108138156,0.00011491192,0.00020098212,0.000035710425,0.000033213575,0.000017763903,0.00004940523,0.00010257117,0.00020812865],"category_scores_gemma":[0.00012617868,0.000094841394,0.000057592984,0.000114981216,0.00010711987,0.000113747046,0.000026518364,0.0002245536,0.0000013843835],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011945516,0.00017176787,0.003926997,0.00006475097,0.000033953493,0.000003965186,0.0006038802,0.0000016938252,0.99135035,0.0000076241017,0.00036186166,0.0022786192],"study_design_scores_gemma":[0.0013182111,0.00028449605,0.005167805,0.00013534531,0.000028502998,0.000018472312,0.00016671275,0.00007783586,0.9922164,0.00030164633,0.00019597732,0.00008860958],"about_ca_topic_score_codex":0.000007432288,"about_ca_topic_score_gemma":1.2706293e-7,"teacher_disagreement_score":0.0024232608,"about_ca_system_score_codex":0.00008451616,"about_ca_system_score_gemma":0.00009349899,"threshold_uncertainty_score":0.38675198},"labels":[],"label_agreement":null},{"id":"W3095304830","doi":"10.1055/s-0040-1718222","title":"Efficacy and safety of niraparib in older patients with advanced ovarian cancer (OC): results from the PRIMA/ENGOT-OV26/GOG-3012 trial","year":2020,"lang":"en","type":"article","venue":"Geburtshilfe und Frauenheilkunde","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ovarian cancer; Medicine; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.023278961009623275,"score_gpt":0.2920825911296032,"score_spread":0.26880363011997993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095304830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98001146,0.0019840498,0.0005633617,0.011778729,0.00036679264,0.0030004873,0.00072110805,0.00008889096,0.0014851227],"genre_scores_gemma":[0.9927896,0.0006284382,0.0012300805,0.0041781743,0.0006206461,0.0001301396,0.0002939478,0.000069727444,0.000059228325],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969676,0.0001778839,0.0009376495,0.0007747181,0.00067081494,0.00047130894],"domain_scores_gemma":[0.9977871,0.000633743,0.00044069794,0.00066202,0.00018547292,0.00029093566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003018598,0.00038722757,0.000760958,0.00008855851,0.00013093496,0.000035132794,0.00025013214,0.00021078925,0.00024552026],"category_scores_gemma":[0.0003039668,0.00027348063,0.0000974533,0.00062395685,0.00032864994,0.0001967714,0.000087646324,0.0005875663,0.0000100173675],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7611863,0.002114867,0.11160374,0.00019711738,0.0012569078,0.0000512987,0.019199375,0.0008717629,0.0024083988,0.00077208335,0.007146238,0.09319194],"study_design_scores_gemma":[0.3702971,0.0016686212,0.5901333,0.0007271331,0.00030015214,0.0000015413206,0.0002517076,0.0001275761,0.0013698107,0.00022775457,0.034424957,0.00047035172],"about_ca_topic_score_codex":0.0008271497,"about_ca_topic_score_gemma":0.00026589166,"teacher_disagreement_score":0.47852954,"about_ca_system_score_codex":0.00019714527,"about_ca_system_score_gemma":0.0003468281,"threshold_uncertainty_score":0.99997175},"labels":[],"label_agreement":null},{"id":"W3095507416","doi":"10.1128/jvi.01969-20","title":"The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase","year":2020,"lang":"en","type":"article","venue":"Journal of Virology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Government of Canada; National Institutes of Health; National Institute of General Medical Sciences; U.S. Department of Energy","keywords":"Biology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Coronavirus disease 2019 (COVID-19); Betacoronavirus; 2019-20 coronavirus outbreak; Genetics; Infectious disease (medical specialty)","score_opus":0.06252856760727135,"score_gpt":0.3446819701713304,"score_spread":0.2821534025640591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095507416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82739013,0.001427428,0.0005825605,0.16958961,0.00029363544,0.000121763864,0.000007680616,0.000014698962,0.0005725088],"genre_scores_gemma":[0.9207165,0.00059244584,0.00044388138,0.07741794,0.0007358352,0.00000464117,8.13478e-7,0.000021582915,0.00006634455],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986035,0.0001766718,0.0005793752,0.00013682079,0.000254232,0.00024935722],"domain_scores_gemma":[0.99881047,0.00024326092,0.00044183584,0.0001993066,0.00015620657,0.0001489007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045326832,0.00013086741,0.0004060297,0.000058123525,0.00009945297,0.000018030341,0.00019447652,0.0001171555,0.00016926986],"category_scores_gemma":[0.00020328043,0.000086291526,0.00022283837,0.00014223227,0.00022885913,0.00006360194,0.00003135155,0.00053384167,0.00009644967],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049564084,0.00008422889,0.0023225392,0.000018186514,0.00029695308,0.00071303867,0.0007964101,0.000008518373,0.85238415,0.00017661981,0.13682348,0.001419452],"study_design_scores_gemma":[0.009786961,0.0034056737,0.002778126,0.000051464795,0.00017987363,0.0038304501,0.00014677116,0.0008817729,0.40620372,0.0024655927,0.5701148,0.00015483942],"about_ca_topic_score_codex":0.000006054492,"about_ca_topic_score_gemma":0.0000042274182,"teacher_disagreement_score":0.44618046,"about_ca_system_score_codex":0.00006532117,"about_ca_system_score_gemma":0.0001973489,"threshold_uncertainty_score":0.35188663},"labels":[],"label_agreement":null},{"id":"W3096187499","doi":"10.1186/s13058-020-01349-9","title":"Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study","year":2020,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; BRCA mutation; Cancer; Surgical oncology; Ovarian cancer; Population; Gynecology","score_opus":0.19465051266261743,"score_gpt":0.4692230717019279,"score_spread":0.27457255903931044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096187499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8710503,0.00054997986,0.000026493984,0.09058794,0.00013104313,0.0025661427,0.03413999,0.00006070807,0.0008874038],"genre_scores_gemma":[0.99557346,0.0008106152,0.00027514526,0.0009813817,0.00069693255,0.001069802,0.00014979705,0.00004247495,0.00040041303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99434084,0.0010079179,0.0010346556,0.0008736761,0.0021296763,0.000613241],"domain_scores_gemma":[0.9959991,0.0011872138,0.00031617552,0.000648035,0.0015208522,0.00032860553],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00136744,0.00029525365,0.0005863025,0.00016239528,0.0002130518,0.000052419473,0.0005795483,0.00006483538,0.0016717328],"category_scores_gemma":[0.00034935135,0.00023111117,0.00012826997,0.003193973,0.00062652887,0.00025490878,0.00018811258,0.0007802972,0.00003593067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011363749,0.0011996968,0.9609229,0.0002869266,0.00053727237,0.00008973559,0.0072210003,0.0014564783,0.0009430473,0.0002954097,0.0053021945,0.010381592],"study_design_scores_gemma":[0.008501672,0.00022722625,0.98607695,0.0008003608,0.00013011572,0.000024977046,0.0019341441,0.0010256568,0.00028334127,0.00057125237,0.00023128443,0.00019300562],"about_ca_topic_score_codex":0.17515601,"about_ca_topic_score_gemma":0.03322979,"teacher_disagreement_score":0.14192623,"about_ca_system_score_codex":0.0013532522,"about_ca_system_score_gemma":0.0026683905,"threshold_uncertainty_score":0.9992409},"labels":[],"label_agreement":null},{"id":"W3096590361","doi":"10.1182/blood-2020-142404","title":"Nicotinamide Phosphoribosyltransferase Inhibitors Induce Apoptosis of AML Stem Cells through Dysregulation of Lipid Metabolism","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Nicotinamide phosphoribosyltransferase; CD38; NAD+ kinase; Leukemia; Biology; Stem cell; Cancer research; Myeloid leukemia; CD34; Pharmacology; Chemistry; Biochemistry; Cell biology; Immunology; Enzyme","score_opus":0.02651859232030287,"score_gpt":0.257494335165797,"score_spread":0.23097574284549413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096590361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952375,0.0009528049,0.0006238968,0.0012252505,0.00032726227,0.00051261525,0.00009899193,0.00007433909,0.0009472911],"genre_scores_gemma":[0.99707216,0.00031948552,0.0014110564,0.00055997865,0.00050770456,0.000025230267,0.000020681335,0.000043469805,0.000040236893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99821997,0.000072007344,0.0006902094,0.00032514718,0.00047802698,0.00021465532],"domain_scores_gemma":[0.99900025,0.00007021217,0.0002600612,0.0003224924,0.00020398699,0.00014302236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013366257,0.00020949113,0.00060870685,0.00006643974,0.00003282463,0.0000062382633,0.00011813683,0.00014739412,0.00018561917],"category_scores_gemma":[0.000020171354,0.00020306732,0.000213836,0.00054506277,0.00011504752,0.00015015037,0.000023854396,0.00019859447,0.0000141784885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031877094,0.00057258486,0.0018818129,0.00033848456,0.00022684694,0.0000019578822,0.0024393706,0.00004355964,0.9918744,0.00050439755,0.000734996,0.0010628441],"study_design_scores_gemma":[0.005916016,0.0003880922,0.0010639934,0.00020180702,0.00038841582,0.0000043007562,0.00029203712,0.000020848262,0.98867697,0.00006116512,0.0028277803,0.00015859364],"about_ca_topic_score_codex":0.000054152155,"about_ca_topic_score_gemma":0.0000010170278,"teacher_disagreement_score":0.0055972454,"about_ca_system_score_codex":0.000026228126,"about_ca_system_score_gemma":0.0001266743,"threshold_uncertainty_score":0.8280845},"labels":[],"label_agreement":null},{"id":"W3096683801","doi":"10.3390/cancers12113178","title":"RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; University of Toronto; McMaster University; Health Sciences Centre; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Mitacs; National Cancer Institute; National Institutes of Health; CancerCare Manitoba Foundation; National Institute of Neurological Disorders and Stroke; Terry Fox Research Institute; Canada Foundation for Innovation; Research Manitoba; St. Jude Children's Research Hospital","keywords":"PTEN; RAD51; Homologous recombination; Olaparib; DNA repair; Cancer research; DNA damage; Gene knockdown; Biology; Synthetic lethality; PARP inhibitor; Genome instability; Molecular biology; Poly ADP ribose polymerase; DNA; Cell culture; Genetics; Polymerase; Apoptosis; PI3K/AKT/mTOR pathway","score_opus":0.03302493491512143,"score_gpt":0.2994024106940213,"score_spread":0.26637747577889986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096683801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98162854,0.0009471889,0.0005973227,0.00879061,0.00050093455,0.00052476145,0.00028557875,0.0001117481,0.006613322],"genre_scores_gemma":[0.9929754,0.00029989044,0.00027175815,0.0058917874,0.00014196342,0.00003212638,0.0001880329,0.00002025855,0.00017875609],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998925,0.000031231968,0.00027386876,0.0002278994,0.000357459,0.00018454407],"domain_scores_gemma":[0.9992825,0.000058376798,0.00016015889,0.00012430258,0.00018800789,0.00018667018],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000073982934,0.00010369165,0.00022180416,0.00007673532,0.000030386609,0.0000052458436,0.00006165258,0.00008408272,0.001868207],"category_scores_gemma":[0.00009713956,0.000106287276,0.00006754041,0.00028731854,0.00009811069,0.000069522524,0.000012595702,0.00015671628,0.000057855257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007789617,0.00035853803,0.053191587,0.0014790569,0.001840649,0.0003690627,0.044501852,0.003303838,0.54882234,0.0026791343,0.24965873,0.08600561],"study_design_scores_gemma":[0.040319953,0.0035066798,0.12349172,0.00054326915,0.00033982753,0.00014707366,0.0036601583,0.012529268,0.6810896,0.0035592231,0.12970567,0.0011076],"about_ca_topic_score_codex":0.00011718421,"about_ca_topic_score_gemma":0.0000057391167,"teacher_disagreement_score":0.13226725,"about_ca_system_score_codex":0.0010685634,"about_ca_system_score_gemma":0.0010408036,"threshold_uncertainty_score":0.99904424},"labels":[],"label_agreement":null},{"id":"W3100601686","doi":"10.1016/j.molcel.2020.10.044","title":"Bridging a DNA Break to Leave a Poly(ADP-Ribose) Mark on Chromatin","year":2020,"lang":"en","type":"letter","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Biotechnology and Biological Sciences Research Council; Canadian Institutes of Health Research","keywords":"Chromatin; Biology; DNA; DNA damage; Nucleosome; Poly ADP ribose polymerase; Cell biology; DNA repair; Context (archaeology); Genetics; Polymerase","score_opus":0.014420237022582872,"score_gpt":0.2569893186674573,"score_spread":0.2425690816448744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100601686","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033533294,0.0007795635,0.0053619742,0.9388052,0.00067436654,0.0013683301,0.0001671469,0.00031976277,0.049170308],"genre_scores_gemma":[0.015823176,0.000020488484,0.0014283812,0.9684006,0.006019868,0.00018334437,0.00058231107,0.0003004721,0.0072413357],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966439,0.00016827822,0.0004924327,0.0010048201,0.0009942367,0.00069633586],"domain_scores_gemma":[0.99831843,0.000059461443,0.00021472538,0.0010021519,0.000087220185,0.0003179904],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000102712766,0.00063870486,0.0008350612,0.00033438846,0.000079690464,0.00007094506,0.00031123514,0.0005381771,0.00075462024],"category_scores_gemma":[0.00004870411,0.00067202095,0.00044326246,0.00041972834,0.00006634481,0.000026310245,0.00010483594,0.0018840318,0.0026139917],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015523507,0.000049785784,0.000004086387,0.00045544872,0.00011059311,0.009754429,0.00019628867,0.0000047077865,0.12144999,0.0000034944644,0.86550725,0.0023087168],"study_design_scores_gemma":[0.0017817961,0.0004987144,0.000018730332,0.00077957776,0.00012743258,0.000102371065,0.0000079517,0.000050135473,0.23974423,0.00003970746,0.7563424,0.0005069522],"about_ca_topic_score_codex":0.000052628395,"about_ca_topic_score_gemma":7.7652453e-7,"teacher_disagreement_score":0.11829425,"about_ca_system_score_codex":0.0004695405,"about_ca_system_score_gemma":0.00026212324,"threshold_uncertainty_score":0.9995731},"labels":[],"label_agreement":null},{"id":"W3101707478","doi":"10.1016/j.annonc.2020.11.001","title":"PARP inhibition in homologous-recombination-deficient early-stage breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Radius Health; Merck; AstraZeneca; Pfizer","keywords":"Olaparib; Medicine; Breast cancer; BRCA mutation; PARP inhibitor; Oncology; Internal medicine; Chemotherapy; Cancer; Poly ADP ribose polymerase; Polymerase; Genetics; Biology","score_opus":0.11407792136650188,"score_gpt":0.40758879029384,"score_spread":0.29351086892733813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101707478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90681404,0.00033349407,0.000075540775,0.08580516,0.00017641943,0.0003179182,0.00011036057,0.000039265633,0.006327797],"genre_scores_gemma":[0.9857108,0.00070864474,0.00009192364,0.013055853,0.00014195254,0.00009293824,0.000027974613,0.000017466018,0.00015246808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874,0.00010451452,0.00043317783,0.0002673442,0.00019782485,0.00025709686],"domain_scores_gemma":[0.9991918,0.00007505851,0.00020822411,0.00014125356,0.00024815582,0.00013546443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024788623,0.000121186495,0.00040737452,0.000153253,0.00002723056,0.000004310935,0.000054207158,0.00015599205,0.0011637383],"category_scores_gemma":[0.00004989906,0.000120743636,0.000089933834,0.0003936651,0.00014152795,0.00008470286,0.00003130274,0.00023278991,0.000053383603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009861892,0.007949411,0.42670125,0.0011451642,0.00056025386,0.0019671265,0.019228784,0.0026473708,0.15980266,0.016672477,0.12384937,0.22961424],"study_design_scores_gemma":[0.015585909,0.007847202,0.75073445,0.00043404495,0.00006467053,0.00019057622,0.0007549699,0.0007117874,0.123945065,0.0019671759,0.09727851,0.00048563804],"about_ca_topic_score_codex":0.00036895068,"about_ca_topic_score_gemma":0.00007329368,"teacher_disagreement_score":0.3240332,"about_ca_system_score_codex":0.00012580446,"about_ca_system_score_gemma":0.0003107709,"threshold_uncertainty_score":0.99974936},"labels":[],"label_agreement":null},{"id":"W3101818514","doi":"10.1186/s12967-020-02613-4","title":"Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy","year":2020,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"Institute of Cancer Research; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Serous ovarian cancer; Ovarian cancer; Poly ADP ribose polymerase; Medicine; Olaparib; Polymerase; Serous fluid; Cancer research; Identification (biology); Oncology; Cancer; Biomarker; Internal medicine; Biology; Bioinformatics; Enzyme; Genetics; Biochemistry","score_opus":0.03785929472940596,"score_gpt":0.3037435053309077,"score_spread":0.26588421060150175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101818514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337527,0.0027015507,0.036477614,0.025243415,0.00050013606,0.0008426663,0.00046680446,0.000009202381,0.000005880424],"genre_scores_gemma":[0.9840336,0.00011481279,0.014637503,0.0005185778,0.0005144821,0.000037966467,0.0001063713,0.000026009737,0.000010708744],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966881,0.00015858722,0.0017229437,0.00021962904,0.0010612032,0.00014948542],"domain_scores_gemma":[0.99675924,0.00046734224,0.0012062282,0.00013199147,0.0011749784,0.0002602363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011417379,0.00019211837,0.00064366165,0.00043716398,0.00005840822,0.0000031296145,0.0001096853,0.00010483433,0.000142986],"category_scores_gemma":[0.0004377235,0.00015580095,0.00011329903,0.00048421204,0.00018772285,0.0001450371,0.000009950814,0.00015028365,2.4638965e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074540645,0.00056788564,0.018410636,0.00025548352,0.0012695227,0.0000029145167,0.008193865,0.00019841944,0.8771779,0.00003910231,0.002045665,0.017297978],"study_design_scores_gemma":[0.023934152,0.0032642197,0.5463638,0.00093895546,0.00028719965,0.000016293305,0.00033832333,0.00031020454,0.4227136,0.0001794041,0.0014967747,0.00015708769],"about_ca_topic_score_codex":0.000034251938,"about_ca_topic_score_gemma":0.000004218593,"teacher_disagreement_score":0.52795315,"about_ca_system_score_codex":0.000110224624,"about_ca_system_score_gemma":0.00075434137,"threshold_uncertainty_score":0.6353378},"labels":[],"label_agreement":null},{"id":"W3102925784","doi":"10.1136/ijgc-2020-igcs.17","title":"17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University","funders":"","keywords":"Medicine; Population; Adverse effect; Placebo; Clinical endpoint; Internal medicine; Oncology; Randomized controlled trial; Pathology","score_opus":0.04570199330148044,"score_gpt":0.34951643181102754,"score_spread":0.3038144385095471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102925784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97035956,0.00027344894,0.00004545912,0.026918337,0.00093880645,0.00047945356,0.000017370885,0.0000086401105,0.0009589475],"genre_scores_gemma":[0.98586524,0.00040786713,0.00016258814,0.01317391,0.0003236065,0.000030807274,0.000006106872,0.000009503963,0.00002035931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975852,0.00016588194,0.0010487319,0.0001970129,0.00081758783,0.00018563318],"domain_scores_gemma":[0.99832207,0.0005369482,0.0005934483,0.00008491888,0.0003469549,0.00011566795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045864654,0.00014763985,0.0004483501,0.00013790555,0.000030410674,0.000034644858,0.00024138081,0.00010828785,0.000668517],"category_scores_gemma":[0.0014471669,0.00009151591,0.00013038202,0.00018555172,0.00008064343,0.0001729533,0.000055508768,0.00056839833,0.0000022642637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037486523,0.00074091676,0.91286504,0.000007713116,0.00021219887,0.0002741452,0.0015535572,0.0001475944,0.00012145649,0.00006846685,0.0018888075,0.044633586],"study_design_scores_gemma":[0.051682837,0.0017112219,0.93247604,0.000097271084,0.000029236528,0.000027936332,0.00016445755,0.000051997235,0.000064723514,0.00018074788,0.013406676,0.00010682886],"about_ca_topic_score_codex":0.000030260582,"about_ca_topic_score_gemma":0.000054638676,"teacher_disagreement_score":0.04452676,"about_ca_system_score_codex":0.00048347787,"about_ca_system_score_gemma":0.00017855664,"threshold_uncertainty_score":0.73197925},"labels":[],"label_agreement":null},{"id":"W3105152741","doi":"10.3390/cancers12113468","title":"Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Mount Sinai Hospital","funders":"Centro de Investigación Biomédica en Red de Cáncer; Women's College Hospital","keywords":"Serous fluid; Serous carcinoma; BRCA mutation; Medicine; Genetic testing; Oncology; Internal medicine; Cancer; Ovarian cancer","score_opus":0.07036319199292808,"score_gpt":0.3338995633652542,"score_spread":0.26353637137232616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105152741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613094,0.0007486638,0.00013599842,0.0020799313,0.00017380153,0.00033947255,0.000010940084,0.00005807128,0.00032216823],"genre_scores_gemma":[0.9946779,0.000022121681,0.0024585845,0.0024531237,0.0002507723,0.000043525408,0.000020388567,0.000023223152,0.000050334107],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991402,0.000027013006,0.00020910491,0.00026989792,0.00015651382,0.00019727343],"domain_scores_gemma":[0.9995988,0.00004475982,0.00007843657,0.00008801433,0.00005191499,0.00013808352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000693463,0.00011651707,0.00020034189,0.000052851632,0.000043546475,0.000015510628,0.000041522075,0.000033587443,0.00006398717],"category_scores_gemma":[0.000086496024,0.000121982266,0.000013553176,0.0002965588,0.00006784442,0.0001087463,0.000016070546,0.00013276919,0.000009823179],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016800707,0.00007702567,0.47762784,0.001035077,0.00013681322,0.0024669054,0.012136532,0.01468369,0.45268166,0.00023603863,0.009978169,0.027260186],"study_design_scores_gemma":[0.029920198,0.0034595747,0.36861774,0.0011500869,0.00018990242,0.0004580948,0.0032679806,0.03330826,0.55096763,0.00043687312,0.0071392218,0.0010844726],"about_ca_topic_score_codex":0.00075428345,"about_ca_topic_score_gemma":0.00002586891,"teacher_disagreement_score":0.10901011,"about_ca_system_score_codex":0.00074976037,"about_ca_system_score_gemma":0.00030635446,"threshold_uncertainty_score":0.49742925},"labels":[],"label_agreement":null},{"id":"W3105684072","doi":"10.1136/ijgc-2020-igcs.3","title":"3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital","funders":"","keywords":"Internal medicine; Medicine; Oncology; Ovarian cancer; BRCA mutation; Placebo; Nausea; Clinical endpoint; Cancer; Clinical trial; Pathology","score_opus":0.05720377875601789,"score_gpt":0.3614086970169437,"score_spread":0.3042049182609258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105684072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99128675,0.00005190086,0.00008224489,0.007307947,0.00029993124,0.0006891554,0.00020252744,0.000011166679,0.000068370646],"genre_scores_gemma":[0.9978473,0.000008697073,0.00021132588,0.0016590406,0.00016068398,0.000030699506,0.00005248697,0.000017365754,0.0000124028265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977327,0.00021138597,0.00068288477,0.00022198498,0.000995054,0.00015601779],"domain_scores_gemma":[0.99661255,0.0010983951,0.00088953297,0.0001040502,0.0011694279,0.00012605236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019016332,0.00018481821,0.00049638475,0.00008606412,0.00005134756,0.000027160308,0.00023574138,0.00007835039,0.0010802064],"category_scores_gemma":[0.0008484642,0.000087821354,0.00008443415,0.00027081708,0.0001342456,0.000120280274,0.000040444585,0.00048300845,0.0000016934923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025302341,0.004681445,0.956738,0.000002591371,0.0010663565,0.00031034346,0.004232712,0.00035070477,0.00008836766,0.000009312284,0.00029021243,0.0069276225],"study_design_scores_gemma":[0.040752556,0.009864109,0.9472759,0.00030676657,0.00017092004,0.0000065387962,0.0010333841,0.00011387847,0.0002338409,0.000018741273,0.00011235258,0.000111010144],"about_ca_topic_score_codex":0.00011457884,"about_ca_topic_score_gemma":0.00037179276,"teacher_disagreement_score":0.015450216,"about_ca_system_score_codex":0.0004247692,"about_ca_system_score_gemma":0.00034626984,"threshold_uncertainty_score":0.9998329},"labels":[],"label_agreement":null},{"id":"W3108385506","doi":"10.1080/23723556.2020.1848233","title":"Inducing DNA damage through R-loops to kill cancer cells","year":2020,"lang":"en","type":"article","venue":"Molecular & Cellular Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton General Hospital","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Institutes of Health","keywords":"DNA damage; Transcription (linguistics); DNA replication; Cell biology; Cancer cell; DNA; Biology; Cancer research; Chemistry; Molecular biology; Cancer; Genetics","score_opus":0.04827537327325641,"score_gpt":0.35122003426645027,"score_spread":0.30294466099319384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108385506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9125593,0.0013263789,0.03241438,0.037756555,0.0008041313,0.0010058142,0.000032132393,0.00020329896,0.0138980495],"genre_scores_gemma":[0.89836895,0.000118980344,0.008871904,0.09112525,0.00070036255,0.00019852602,0.000049121387,0.00011385722,0.00045305793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976799,0.00019632386,0.0004510521,0.00072157686,0.00038461277,0.0005665642],"domain_scores_gemma":[0.99865264,0.00005180295,0.00014068908,0.00050670165,0.0001535581,0.0004946137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017341215,0.00030909159,0.0006435344,0.00008865015,0.000091267735,0.00002059453,0.00024580164,0.00030291796,0.0016730953],"category_scores_gemma":[0.00006863875,0.00032037718,0.00019432479,0.0005707391,0.00011436197,0.00007385199,0.00014062347,0.0005128994,0.00063498126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025425394,0.00012833379,0.00010753323,0.000068420224,0.00012473924,0.0016117741,0.0023186288,0.0003902381,0.98119515,0.00024805346,0.011507612,0.0020452868],"study_design_scores_gemma":[0.0018508638,0.00073288917,0.000059431313,0.00005283299,0.000095886455,0.000018689254,0.00013753952,0.00010091872,0.6875468,0.00008701813,0.30909485,0.00022228614],"about_ca_topic_score_codex":0.00016217049,"about_ca_topic_score_gemma":0.000015272273,"teacher_disagreement_score":0.29758722,"about_ca_system_score_codex":0.00048141365,"about_ca_system_score_gemma":0.00049657666,"threshold_uncertainty_score":0.99992484},"labels":[],"label_agreement":null},{"id":"W3108435873","doi":"10.1016/j.annonc.2020.10.088","title":"68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Internal medicine; Pembrolizumab; Carboplatin; Induction chemotherapy; Phases of clinical research; Chemotherapy; Cancer; Immunotherapy; Cisplatin","score_opus":0.1168465376839712,"score_gpt":0.4061263004334042,"score_spread":0.289279762749433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108435873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983046,0.00040138722,0.0003833641,0.0076434715,0.0001753577,0.007442681,0.000059912047,0.00005625796,0.0007916021],"genre_scores_gemma":[0.98900604,0.00090204546,0.0017167941,0.0061247647,0.00013390061,0.0016201227,0.000110349814,0.00010841022,0.00027755572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948177,0.0007066359,0.0018967671,0.0010028983,0.00088428904,0.000691757],"domain_scores_gemma":[0.9959629,0.00047090452,0.0012681485,0.0006929674,0.0012100221,0.0003950391],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011554589,0.0006682533,0.003408522,0.00042803984,0.00012898169,0.000033437434,0.0004905707,0.0002422769,0.0010887065],"category_scores_gemma":[0.0003552221,0.00046674124,0.0001396482,0.0012933817,0.00050906395,0.00047879323,0.00018051974,0.000725319,0.000008646073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92609406,0.038503606,0.0013036453,0.00045214145,0.0015190323,0.00017121246,0.009252797,0.00020705245,0.0009128285,0.000014677421,0.0033858598,0.018183108],"study_design_scores_gemma":[0.8198687,0.16314042,0.0008607573,0.00078496785,0.0005227715,0.000052761716,0.0009776102,0.00064784376,0.0063993637,0.00004190132,0.006193753,0.00050919695],"about_ca_topic_score_codex":0.00043183652,"about_ca_topic_score_gemma":0.0008755355,"teacher_disagreement_score":0.12463681,"about_ca_system_score_codex":0.000284163,"about_ca_system_score_gemma":0.0013255411,"threshold_uncertainty_score":0.9998244},"labels":[],"label_agreement":null},{"id":"W3113008414","doi":"","title":"PBRM1 deficiency in cancer is synthetic lethal with DNA repair inhibitors","year":2020,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"DNA repair; Cancer; Cancer research; DNA; Genetics; Medicine; Biology; Computational biology","score_opus":0.02463917889428803,"score_gpt":0.27536363580632,"score_spread":0.250724456912032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113008414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80250514,0.006251399,0.010082885,0.103782974,0.00056208525,0.002025063,0.0002405079,0.0009145381,0.07363541],"genre_scores_gemma":[0.9810557,0.0011401308,0.012259055,0.00110798,0.00008786369,0.00042074264,0.00023090014,0.000110823305,0.0035868355],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994716,0.002008015,0.00074813236,0.0012590203,0.0007859669,0.00048287748],"domain_scores_gemma":[0.99519366,0.0005541537,0.00051823445,0.0021001077,0.0013218457,0.00031201963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022780597,0.00047645948,0.00069363654,0.00031910365,0.00017356545,0.00012216583,0.0006093488,0.00037131194,0.00054084416],"category_scores_gemma":[0.0005092479,0.00046059702,0.00030104938,0.00079195737,0.00042389755,0.00010300069,0.0005680772,0.0012533896,0.00006952604],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028116263,0.013867287,0.31545472,0.012041855,0.0020551374,0.001299713,0.25343546,0.0013667672,0.11152573,0.07181535,0.09094985,0.12337652],"study_design_scores_gemma":[0.012089177,0.000021286472,0.055219978,0.061789278,0.00080306694,0.00034690925,0.0014947099,0.021853793,0.7222129,0.0072641806,0.11305186,0.003852871],"about_ca_topic_score_codex":0.0019701163,"about_ca_topic_score_gemma":0.0016367583,"teacher_disagreement_score":0.61068714,"about_ca_system_score_codex":0.0005899638,"about_ca_system_score_gemma":0.0011862228,"threshold_uncertainty_score":0.9997846},"labels":[],"label_agreement":null},{"id":"W3116889989","doi":"10.1016/s2352-3026(20)30375-6","title":"PARP inhibitors—understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; Veliparib; Internal medicine; Ovarian cancer; Cancer research; Carboplatin; Cancer; Chemotherapy; Poly ADP ribose polymerase; Polymerase; Biology; Genetics","score_opus":0.05215419540124464,"score_gpt":0.28976288000656997,"score_spread":0.23760868460532533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116889989","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043801513,0.0026575606,0.0016654959,0.94781715,0.0011399002,0.0010233376,0.00029867102,0.000165406,0.0014309982],"genre_scores_gemma":[0.46693048,0.003844031,0.00024264952,0.52386576,0.0044057807,0.00015617453,0.00013679659,0.0001384132,0.00027994905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699694,0.00070738647,0.0006738978,0.0005347076,0.0004729789,0.0006140823],"domain_scores_gemma":[0.99608886,0.0020499474,0.0007597031,0.0009576343,0.00006183492,0.0000819898],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004804945,0.00047046313,0.002231299,0.00013205287,0.00028282,0.00003309749,0.00048148556,0.0006760855,0.00016356702],"category_scores_gemma":[0.00020330453,0.00026606675,0.00022423426,0.00030873634,0.0017771804,0.000058697027,0.0001854521,0.0034288738,0.00006652143],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040851574,0.00001262567,0.002487166,0.0009573541,0.0012585681,0.0037145165,0.00094596145,0.0000047726157,0.0003035529,0.0014202627,0.98843384,0.000052848314],"study_design_scores_gemma":[0.014856674,0.0020432824,0.0037054687,0.003935597,0.01047679,0.11071223,0.0012037838,0.00053510925,0.0029165666,0.1336787,0.71399975,0.0019360773],"about_ca_topic_score_codex":0.000032812906,"about_ca_topic_score_gemma":0.0000051768416,"teacher_disagreement_score":0.4239514,"about_ca_system_score_codex":0.00020603927,"about_ca_system_score_gemma":0.00019796373,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W3118051387","doi":"10.3126/jpn.v10i2.29862","title":"A brief overview of homologous recombination deficiency testing in cancers for the ‘Next-Generation’ Pathologist","year":2020,"lang":"en","type":"article","venue":"Journal of Pathology of Nepal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Homologous recombination; Genome instability; DNA repair; Homologous chromosome; Synthetic lethality; Cancer; Medicine; Genetics; Non-allelic homologous recombination; Poly ADP ribose polymerase; Cancer research; Computational biology; Bioinformatics; Biology; Gene; DNA; DNA damage; Recombination; Polymerase; Genetic recombination","score_opus":0.3224953253130878,"score_gpt":0.38509393682172083,"score_spread":0.06259861150863305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118051387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798439,0.007686653,0.0042936783,0.007283226,0.00036123596,0.00032837683,0.000020468055,0.0000061615933,0.00017626928],"genre_scores_gemma":[0.98958427,0.0008238536,0.008036412,0.0012988963,0.00022263298,0.000014423594,0.0000029854455,0.000010013797,0.0000065089016],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99864316,0.00014645263,0.00076391397,0.00012491108,0.00018440209,0.00013713533],"domain_scores_gemma":[0.99809086,0.0004449462,0.0008587592,0.00011221434,0.00044745777,0.000045786473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009816191,0.000090504385,0.00041792792,0.000112465386,0.000047578636,0.0000041341136,0.00013350594,0.000092722454,0.000030268498],"category_scores_gemma":[0.0014251915,0.00006640615,0.00013265687,0.0003070059,0.00022132733,0.0000788347,0.000016323977,0.00027434318,4.6244688e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011750888,0.00040986968,0.036734175,0.0004769542,0.000079435085,0.0005915134,0.0042129313,0.0028320905,0.8917511,0.001058656,0.0031281756,0.057550013],"study_design_scores_gemma":[0.049851622,0.05000744,0.63316125,0.0026949458,0.0013767281,0.020151377,0.0055611157,0.03552922,0.18677022,0.009760182,0.0041186614,0.0010172622],"about_ca_topic_score_codex":0.000020744166,"about_ca_topic_score_gemma":0.000014907397,"teacher_disagreement_score":0.7049809,"about_ca_system_score_codex":0.000117167656,"about_ca_system_score_gemma":0.00036655102,"threshold_uncertainty_score":0.27079642},"labels":[],"label_agreement":null},{"id":"W3118469637","doi":"10.2139/ssrn.3707266","title":"Nicotinamide Phosphoribosyltransferase Inhibitors Selectively Induce Apoptosis of AML Stem Cells by Disrupting Lipid Homeostasis","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Nicotinamide phosphoribosyltransferase; Stem cell; Apoptosis; Chemistry; Homeostasis; Cancer research; Cell biology; Nicotinamide; Pharmacology; Biochemistry; NAD+ kinase; Enzyme; Biology","score_opus":0.01432409440312657,"score_gpt":0.25525356249976583,"score_spread":0.24092946809663926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118469637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828544,0.0054936744,0.0059459466,0.004566782,0.00029600243,0.00043381512,0.00006427168,0.00009382642,0.000251248],"genre_scores_gemma":[0.98868275,0.009277985,0.0001435868,0.00084860495,0.0007467654,0.000018162535,0.000012431464,0.000095626274,0.00017409127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99566156,0.00017741902,0.0008866203,0.00047358687,0.00072103797,0.0020797502],"domain_scores_gemma":[0.9985039,0.00011793975,0.00043673848,0.00021586109,0.00029591407,0.0004296271],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00096079457,0.00038006683,0.0006975676,0.00015906236,0.00020993921,0.000040130206,0.0002621451,0.00018783649,0.00009924673],"category_scores_gemma":[0.000051691834,0.00036200724,0.00035695996,0.0009009047,0.00011690114,0.00025281945,0.000031051317,0.002898076,0.0000266038],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014950942,0.00036090508,0.003943368,0.00013533492,0.0008180269,0.000006458158,0.0018219249,0.000042675358,0.93225795,0.0009712338,0.0033603215,0.05478668],"study_design_scores_gemma":[0.00403669,0.0024075666,0.00006767577,0.0001972495,0.00021245207,0.00019412691,0.0035299007,0.00005304957,0.98496556,0.0005707302,0.003404616,0.00036036977],"about_ca_topic_score_codex":0.00007195936,"about_ca_topic_score_gemma":0.000017759194,"teacher_disagreement_score":0.05442631,"about_ca_system_score_codex":0.001616096,"about_ca_system_score_gemma":0.0023764307,"threshold_uncertainty_score":0.9998832},"labels":[],"label_agreement":null},{"id":"W3118885655","doi":"10.1002/jcb.29887","title":"Mitochondria are devoid of poly(ADP‐ribose)polymerase‐1, but harbor its product oligo(ADP‐ribose)","year":2021,"lang":"en","type":"article","venue":"Journal of Cellular Biochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universität Konstanz; Centre National de la Recherche Scientifique; Université Laval","keywords":"Polymerase; Poly ADP ribose polymerase; Mitochondrion; Biochemistry; Ribose; Cytosol; Organelle; Biology; Enzyme; Molecular biology","score_opus":0.01467460200617631,"score_gpt":0.2663993940549563,"score_spread":0.25172479204877996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118885655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9145292,0.07536632,0.0005452362,0.006662273,0.0013382809,0.00020901472,0.00014783388,0.000033542077,0.0011682846],"genre_scores_gemma":[0.98581827,0.0006515002,0.0023605165,0.0005588413,0.005744638,0.000009933325,0.0000588185,0.0000807783,0.0047166785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966502,0.000096912045,0.0012920387,0.00046390193,0.001036365,0.00046056285],"domain_scores_gemma":[0.9958695,0.000067764544,0.0013771341,0.00079442776,0.0014154378,0.0004757333],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036785536,0.00039135775,0.00094022695,0.00015687458,0.00008585201,0.000043005,0.000326212,0.00028405996,0.0010705249],"category_scores_gemma":[0.000514859,0.00036994152,0.00058347516,0.0004894354,0.00017777528,0.00014669218,0.000076023076,0.00076267746,0.000025151545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005073868,0.0005350169,0.0007557437,0.0007259003,0.0004162575,0.0010740834,0.00008897256,0.0000033737101,0.98055,0.000009305616,0.014937789,0.00039616798],"study_design_scores_gemma":[0.0033130369,0.00016404391,0.00032809834,0.0013111237,0.00028403176,0.001554905,0.0003291289,0.000010278503,0.98184407,0.000034934797,0.010508046,0.00031827527],"about_ca_topic_score_codex":0.000004977849,"about_ca_topic_score_gemma":4.4808587e-7,"teacher_disagreement_score":0.074714825,"about_ca_system_score_codex":0.00025904056,"about_ca_system_score_gemma":0.0014045911,"threshold_uncertainty_score":0.99987525},"labels":[],"label_agreement":null},{"id":"W3120580407","doi":"10.1016/j.cllc.2021.01.001","title":"Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G","year":2021,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Pfizer","keywords":"Medicine; Homologous recombination; Lung cancer; Cancer research; Lung; Homologous chromosome; Oncology; Internal medicine; DNA; Biology; Genetics","score_opus":0.026244174818530565,"score_gpt":0.40082861854724255,"score_spread":0.37458444372871197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120580407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883708,0.0056869215,0.000040093964,0.00045330802,0.0018874719,0.002886204,0.00011635447,0.00011896264,0.00043991936],"genre_scores_gemma":[0.9968655,0.00038958117,0.000107108855,0.00059992785,0.00021333211,0.00083246414,0.000113676346,0.00007309099,0.00080527813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954491,0.0004842902,0.0016455117,0.0010612244,0.0008443722,0.0005154616],"domain_scores_gemma":[0.99681795,0.00043603318,0.00066150405,0.0009021552,0.0009285003,0.00025385496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008084322,0.00036505325,0.0011171749,0.00019034666,0.0001082842,0.000019942692,0.00019081174,0.00023955308,0.00078140455],"category_scores_gemma":[0.00019332269,0.00032582518,0.00024455128,0.00086774677,0.00018237693,0.00012917866,0.000099085664,0.00075152685,0.0000049857676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034453946,0.02988156,0.95386577,0.00041901777,0.00027864656,0.0001462378,0.0011545136,0.0004353799,0.00006645667,0.000010235693,0.008452301,0.0018444762],"study_design_scores_gemma":[0.11535675,0.010096442,0.8643635,0.00095123466,0.0013632051,0.0000050779367,0.00083316583,0.0038804663,0.0014466941,0.000015710666,0.0010155123,0.0006722467],"about_ca_topic_score_codex":0.0005060324,"about_ca_topic_score_gemma":0.00085038296,"teacher_disagreement_score":0.11191136,"about_ca_system_score_codex":0.0011401577,"about_ca_system_score_gemma":0.0009835851,"threshold_uncertainty_score":0.99991935},"labels":[],"label_agreement":null},{"id":"W3122892082","doi":"10.1016/j.tim.2021.01.002","title":"When PARPs Meet Antiviral Innate Immunity","year":2021,"lang":"en","type":"review","venue":"Trends in Microbiology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Natural Science Foundation of China","keywords":"Biology; PARP1; Innate immune system; ADP-ribosylation; Poly ADP ribose polymerase; DNA repair; DNA damage; Polymerase; Immunity; DNA; NAD+ kinase; Computational biology; Genetics; Cell biology; Immune system; Enzyme; Biochemistry","score_opus":0.08336648720866009,"score_gpt":0.40091511191548557,"score_spread":0.3175486247068255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122892082","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009931228,0.9909867,0.000005909315,0.00023888324,0.00074231444,0.00025802577,0.00037131936,0.00007042636,0.0072271293],"genre_scores_gemma":[0.00005186546,0.9893343,0.0005893097,0.00045593033,0.00027230105,0.000114958275,0.004397904,0.000077254044,0.0047062202],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968748,0.0009186555,0.00095318106,0.0006478467,0.000059992402,0.00054551667],"domain_scores_gemma":[0.9985165,0.00017639714,0.00035676564,0.00082535425,0.000058186033,0.00006678427],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004368483,0.0005444999,0.0031375547,0.00083210797,0.00004764226,0.000013708513,0.0003032636,0.00088405824,0.002368356],"category_scores_gemma":[0.000041582705,0.0004615987,0.0006421943,0.00075856934,0.00029374,0.000036637306,0.00017371676,0.001111598,0.00015180503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003204395,0.00018073512,0.00003610345,0.0019278991,0.0003587721,0.00026122917,0.00013999805,4.7606544e-8,0.00040958912,0.00015783781,0.026564514,0.96993124],"study_design_scores_gemma":[0.0011662748,0.00012836792,0.0000092950095,0.008761331,0.00033488267,0.00096993684,0.000011986109,1.6339213e-7,0.00009367486,0.000046148896,0.9881086,0.0003693545],"about_ca_topic_score_codex":0.00005162476,"about_ca_topic_score_gemma":0.00008372615,"teacher_disagreement_score":0.9695619,"about_ca_system_score_codex":0.0004254543,"about_ca_system_score_gemma":0.00037323058,"threshold_uncertainty_score":0.9997836},"labels":[],"label_agreement":null},{"id":"W3123637537","doi":"10.1093/nar/gkab020","title":"Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition","year":2021,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Medical Research Council; Canadian Institutes of Health Research; Wellcome Trust; Francis Crick Institute; Cancer Research UK; AstraZeneca","keywords":"Biology; Poly ADP ribose polymerase; Allosteric regulation; Substrate (aquarium); Dynamics (music); Biophysics; Cell biology; Biochemistry; Genetics; DNA; Enzyme; Ecology; Polymerase","score_opus":0.06808524777878441,"score_gpt":0.37751585039371144,"score_spread":0.30943060261492705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123637537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943275,0.00021035034,0.000039944553,0.0035885423,0.000030287269,0.00034967897,0.000018937051,0.000007865809,0.0014268924],"genre_scores_gemma":[0.9991271,0.0004151179,0.000101163925,0.00010074843,0.000037625887,0.000022055683,0.000021725682,0.00001803024,0.00015642836],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99823,0.00033185282,0.00033696435,0.00025531437,0.00062833354,0.00021755336],"domain_scores_gemma":[0.99890596,0.00022310323,0.000101641555,0.00035712725,0.00034332921,0.00006886147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010337586,0.00009045332,0.00023993774,0.00019364514,0.00006845926,0.00002575468,0.00008686687,0.00013165864,0.00008033366],"category_scores_gemma":[0.00019491842,0.0000750619,0.00003612486,0.0006746057,0.00054520345,0.00021117966,0.00016091981,0.00038639834,7.3699135e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007174972,0.00022122671,0.31762803,0.00062821887,0.000045233093,0.000024614901,0.0009439329,0.0000111958125,0.6666569,0.0043649734,0.00028420784,0.0084739635],"study_design_scores_gemma":[0.0015768224,0.00009311138,0.5462819,0.0005305637,0.0000068346653,0.000021010686,0.0005952322,0.00039267677,0.44445178,0.005936484,0.00005564414,0.000057986523],"about_ca_topic_score_codex":0.00006607414,"about_ca_topic_score_gemma":0.00016815399,"teacher_disagreement_score":0.2286538,"about_ca_system_score_codex":0.00018287741,"about_ca_system_score_gemma":0.00026081898,"threshold_uncertainty_score":0.30609354},"labels":[],"label_agreement":null},{"id":"W3124745349","doi":"10.7554/elife.60480","title":"Chemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-relevant protein targets","year":2021,"lang":"en","type":"article","venue":"eLife","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; Pew Charitable Trusts; National Institutes of Health; National Cancer Institute; National Eye Institute; Oregon Health and Science University","keywords":"Poly ADP ribose polymerase; Proteome; Biology; Zinc finger; Innate immune system; Regulator; ADP-ribosylation; Computational biology; Cell biology; Genetics; Immune system; Biochemistry; Polymerase; Transcription factor; Enzyme; Gene; NAD+ kinase","score_opus":0.013660935258867067,"score_gpt":0.25572205804169573,"score_spread":0.24206112278282865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124745349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858189,0.0056187594,0.0010396816,0.0056419387,0.000098600234,0.0009896151,0.00003991372,0.00008147883,0.000671109],"genre_scores_gemma":[0.9861512,0.00031205927,0.0077599753,0.0022694997,0.00040916906,0.00023029819,0.00030388922,0.000048777296,0.0025150876],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998437,0.00007011274,0.00040235752,0.0003721165,0.00043266732,0.0002857451],"domain_scores_gemma":[0.9991873,0.000049917704,0.00012518144,0.00032016443,0.00015585774,0.00016158186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002490873,0.00018231604,0.00030128547,0.000054090273,0.00006958779,0.000023743407,0.000044458146,0.00012683646,0.00010954659],"category_scores_gemma":[0.00019038915,0.00017584462,0.00006190687,0.00017390258,0.00006124967,0.00004719741,0.000046360965,0.00027269433,0.00006075069],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017686877,0.00009264022,0.0028780596,0.00014489568,0.000041271727,0.000051564766,0.00017953572,0.000004427029,0.9898816,0.000017717715,0.005128104,0.001403355],"study_design_scores_gemma":[0.0024443462,0.0001887115,0.005842773,0.000589265,0.000018690056,0.000050817587,0.000030361241,0.0001746478,0.9487358,0.00007013512,0.0416571,0.00019735002],"about_ca_topic_score_codex":0.000007670546,"about_ca_topic_score_gemma":9.640637e-7,"teacher_disagreement_score":0.041145757,"about_ca_system_score_codex":0.0001451962,"about_ca_system_score_gemma":0.00011512046,"threshold_uncertainty_score":0.7170735},"labels":[],"label_agreement":null},{"id":"W3124903498","doi":"10.1172/jci.insight.138382","title":"p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors","year":2021,"lang":"en","type":"article","venue":"JCI Insight","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; McGill University; Occupational Cancer Research Centre; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Cancer Society; Canadian Institutes of Health Research; Cancer Research Society; McGill University","keywords":"Cancer research; Doxorubicin; Cytotoxic T cell; Poly ADP ribose polymerase; Triple-negative breast cancer; DNA damage; Genome instability; Medicine; Breast cancer; Biology; Internal medicine; Chemotherapy; In vitro; Cancer; Polymerase; DNA; Genetics","score_opus":0.02001040109675004,"score_gpt":0.29442475160202003,"score_spread":0.27441435050526997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124903498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805389,0.0011174983,0.00012343714,0.01314282,0.0009081181,0.00069549377,0.00014830001,0.00006832621,0.0032571023],"genre_scores_gemma":[0.99227107,0.00016129597,0.00041138806,0.0035300788,0.00036117897,0.00012253837,0.000016158385,0.000037965692,0.003088337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998094,0.00031736866,0.00044999545,0.00035886426,0.00048657585,0.00029319906],"domain_scores_gemma":[0.998311,0.00032765605,0.00016579866,0.00058363716,0.0004190808,0.0001928399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035666456,0.00020348116,0.0003898612,0.00015097535,0.00012634549,0.000023406299,0.00013406185,0.00010534875,0.0007833894],"category_scores_gemma":[0.00035756108,0.00014636254,0.00018564955,0.00094958174,0.0001852377,0.0000953196,0.000065670916,0.00025218958,0.000075916956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009237257,0.00028905002,0.0026348284,0.00008168063,0.00038482208,0.0002525421,0.007951339,0.00012681693,0.924436,0.00035516286,0.051516537,0.00273399],"study_design_scores_gemma":[0.0029866882,0.00039392928,0.031683583,0.0004063608,0.000078270445,0.0002260119,0.0012205117,0.000028462615,0.9171436,0.00022345159,0.04540304,0.00020612034],"about_ca_topic_score_codex":0.00017940847,"about_ca_topic_score_gemma":0.000095332085,"teacher_disagreement_score":0.029048754,"about_ca_system_score_codex":0.00043587925,"about_ca_system_score_gemma":0.00092030043,"threshold_uncertainty_score":0.8577564},"labels":[],"label_agreement":null},{"id":"W3129286763","doi":"10.1158/1538-7445.sabcs20-ot-30-01","title":"Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Olaparib; Internal medicine; Chemotherapy; Gemcitabine; Atezolizumab; PARP inhibitor; Carboplatin; Cancer; Immunotherapy; Cisplatin","score_opus":0.07989167611688573,"score_gpt":0.41428373338485575,"score_spread":0.33439205726797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129286763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781826,0.0023985882,0.00020787006,0.0029856646,0.00036870426,0.014825257,0.0005742699,0.00009235927,0.00036469573],"genre_scores_gemma":[0.9787925,0.0055397917,0.00032372237,0.00086780655,0.0003680883,0.012164438,0.00017174052,0.00032925644,0.0014426884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9893611,0.0013908885,0.0020356851,0.0021162354,0.003335125,0.0017609877],"domain_scores_gemma":[0.99249417,0.0006945172,0.000881409,0.0015721496,0.0036457083,0.0007120287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019617896,0.0011661403,0.0036983814,0.0010457399,0.00046495476,0.00033039812,0.0008928426,0.00032900926,0.008502541],"category_scores_gemma":[0.00027180754,0.0008347822,0.00021067869,0.0035389243,0.0011044225,0.00097123487,0.00025661965,0.0021890248,0.000026290452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9524135,0.013182088,0.001568356,0.0012118622,0.0026071598,0.0005407911,0.011042004,0.001803999,0.00058600167,0.000014649663,0.0012544992,0.013775104],"study_design_scores_gemma":[0.9573155,0.011714975,0.015179115,0.0049359775,0.00043912252,0.00011978072,0.0022874135,0.0015105004,0.004649753,0.00006535693,0.0007035924,0.0010788887],"about_ca_topic_score_codex":0.0099760825,"about_ca_topic_score_gemma":0.011767551,"teacher_disagreement_score":0.013610759,"about_ca_system_score_codex":0.006685438,"about_ca_system_score_gemma":0.0121333,"threshold_uncertainty_score":0.9994103},"labels":[],"label_agreement":null},{"id":"W3129575296","doi":"10.1002/cjp2.203","title":"Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer","year":2021,"lang":"en","type":"review","venue":"The Journal of Pathology Clinical Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Chugai Pharmaceutical; Genentech; Astellas Pharma; National Institute for Health and Care Research; Incyte; Ipsen; Clovis Oncology; Royal Marsden NHS Foundation Trust; University of Chicago; Bristol-Myers Squibb; AstraZeneca; American Society of Clinical Oncology; Sanofi; Les Laboratories Pierre Fabre; Amgen; Pfizer","keywords":"Olaparib; Medicine; Prostate cancer; PARP inhibitor; Molecular diagnostics; Bioinformatics; Cancer; Computational biology; Oncology; Internal medicine; Poly ADP ribose polymerase; Gene; Polymerase; Biology; Genetics","score_opus":0.5958416978514839,"score_gpt":0.6270654534842924,"score_spread":0.031223755632808547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129575296","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011834975,0.9768957,0.0008715143,0.0047225724,0.000625933,0.004859179,0.000089870904,0.000024697309,0.00007554017],"genre_scores_gemma":[0.0010502979,0.95311826,0.044904638,0.00022793631,0.00024092724,0.00027166674,0.000057784055,0.000053382406,0.00007510947],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.98964816,0.0065899957,0.0022592375,0.00033476946,0.00075304526,0.0004148128],"domain_scores_gemma":[0.954518,0.039241657,0.0014938727,0.00035528987,0.0042411317,0.00015002872],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.019625556,0.00021392731,0.001756347,0.00048900524,0.00021140988,0.000035113502,0.0001013453,0.000277425,0.00006707982],"category_scores_gemma":[0.04812433,0.00012672835,0.00034393763,0.000744785,0.0005905513,0.00013711532,0.000056506517,0.0030081088,0.0000048680286],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00400781,0.0042424486,0.004784812,0.007995705,0.0019344959,0.008601844,0.0009327968,0.00021439069,0.000003902349,0.0003332475,0.010812392,0.95613617],"study_design_scores_gemma":[0.12649414,0.11337411,0.024351468,0.31875682,0.032334615,0.10305491,0.0031951936,0.0015869684,0.00006192439,0.027606005,0.24581246,0.003371403],"about_ca_topic_score_codex":0.0000071543163,"about_ca_topic_score_gemma":0.00001407825,"teacher_disagreement_score":0.95276475,"about_ca_system_score_codex":0.000520241,"about_ca_system_score_gemma":0.0054676402,"threshold_uncertainty_score":0.999292},"labels":[],"label_agreement":null},{"id":"W3130146550","doi":"10.1158/1538-7445.sabcs20-ps11-03","title":"Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline <i>BRCA1</i> or <i>BRCA2</i> mutations from the phase 3 BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Veliparib; Carboplatin; Internal medicine; Hazard ratio; Breast cancer; Metastatic breast cancer; Oncology; Neutropenia; Paclitaxel; Chemotherapy; Gastroenterology; Cancer; Confidence interval; Cisplatin","score_opus":0.06069596838321386,"score_gpt":0.4208892218136763,"score_spread":0.36019325343046243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130146550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882719,0.0015152651,0.00016173796,0.0016408061,0.000093504146,0.0021751665,0.0060283053,0.000015530275,0.000097820724],"genre_scores_gemma":[0.996114,0.0017309322,0.00047585642,0.0002560023,0.00013252684,0.0005553239,0.0004914399,0.000053345982,0.00019058582],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99568045,0.0004994251,0.0011270525,0.0007187458,0.0014306842,0.0005436407],"domain_scores_gemma":[0.99341744,0.0036690175,0.0004674723,0.0006749416,0.0015187677,0.00025238635],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078312284,0.00031032966,0.0012677137,0.0003991117,0.0001616194,0.000034260713,0.00024464197,0.00011065997,0.0018327931],"category_scores_gemma":[0.0006805766,0.00019680413,0.0001707441,0.0039215204,0.00083527697,0.00019185245,0.00008684894,0.00075453153,0.0000019765118],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89767015,0.0041211434,0.022335745,0.00057587866,0.008126252,0.00016234974,0.007939565,0.01090511,0.012062341,0.000051828527,0.00054100616,0.03550864],"study_design_scores_gemma":[0.46728295,0.0035197553,0.4985768,0.003029569,0.002857473,0.000009866464,0.003510784,0.0015044989,0.018241726,0.00007627359,0.00079542707,0.00059488363],"about_ca_topic_score_codex":0.009464671,"about_ca_topic_score_gemma":0.0217411,"teacher_disagreement_score":0.47624105,"about_ca_system_score_codex":0.0007709438,"about_ca_system_score_gemma":0.003523091,"threshold_uncertainty_score":0.99907964},"labels":[],"label_agreement":null},{"id":"W3130563236","doi":"10.1158/1538-7445.sabcs20-ps10-11","title":"Abstract PS10-11: Associations with response to poly(ADP-ribose) polymerase (PARP) inhibitors in patients with BRCA mutated metastatic breast cancer: Results of a meta-regression analysis","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; BRCA mutation; Oncology; Internal medicine; Breast cancer; Metastatic breast cancer; Chemotherapy; Cancer; Meta-analysis","score_opus":0.06755840244320246,"score_gpt":0.41028482165536156,"score_spread":0.3427264192121591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130563236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794289,0.0016469423,0.000030186113,0.012807693,0.00007107044,0.0010742617,0.00478806,0.00004114461,0.00011175296],"genre_scores_gemma":[0.9971082,0.00013776775,0.00033050432,0.0003076879,0.00010068721,0.00076329295,0.00040956735,0.00007185995,0.00077044097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938513,0.0009993747,0.0009186049,0.00092085457,0.002467221,0.0008426194],"domain_scores_gemma":[0.9947948,0.00079725304,0.00040450782,0.00090482435,0.0025698591,0.0005287585],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020106107,0.00038063247,0.0012803596,0.0017556179,0.00020000702,0.000061931925,0.00022709841,0.00012405867,0.0011059064],"category_scores_gemma":[0.00047135644,0.00026055978,0.0002646421,0.008867092,0.00027285374,0.00023383058,0.000089009074,0.0006586823,0.000009672905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14648218,0.004215419,0.685174,0.00040780436,0.023745647,0.0009022122,0.005876412,0.006128583,0.11015876,0.000019498799,0.009459604,0.00742991],"study_design_scores_gemma":[0.016115578,0.0007340048,0.83566463,0.0011469487,0.0024017878,0.000008391519,0.0005871568,0.000038252947,0.14213853,0.000011495639,0.0007607606,0.0003925019],"about_ca_topic_score_codex":0.01336757,"about_ca_topic_score_gemma":0.011580533,"teacher_disagreement_score":0.15049063,"about_ca_system_score_codex":0.0017208441,"about_ca_system_score_gemma":0.003206648,"threshold_uncertainty_score":0.9999847},"labels":[],"label_agreement":null},{"id":"W3131966309","doi":"10.1038/s41598-021-82671-w","title":"A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"PharmaMar; AstraZeneca España; AstraZeneca","keywords":"Olaparib; Medicine; Neutropenia; Tolerability; Internal medicine; Oncology; Pharmacokinetics; PARP inhibitor; Nausea; Adverse effect; Gastroenterology; Pharmacology; Chemotherapy; Poly ADP ribose polymerase; Polymerase; Biology; Genetics; DNA","score_opus":0.01939617000832062,"score_gpt":0.33131200065912236,"score_spread":0.31191583065080175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131966309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804735,0.00034012814,0.000016763584,0.00003453062,0.0006597147,0.0007123483,0.000003964905,0.000021346415,0.00016382308],"genre_scores_gemma":[0.99929476,0.000012212849,0.00039685715,0.000033211065,0.000021228308,0.000027172373,0.000035519377,0.000016762491,0.00016226464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815667,0.000039996794,0.0005284067,0.0006046232,0.00045911063,0.00021119535],"domain_scores_gemma":[0.9988792,0.000021842889,0.00029886104,0.0003698189,0.00030641287,0.00012384943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040836848,0.00013397243,0.00033558678,0.00021589777,0.00009208329,0.000046224075,0.000027643684,0.000029481724,0.000052941454],"category_scores_gemma":[0.00008692193,0.000117400006,0.000018029794,0.00064864417,0.0001678359,0.00011130023,0.000047847418,0.00013119528,3.1247242e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008320142,0.0046826713,0.7804881,0.00018743136,0.00009786357,0.0016201701,0.00516242,0.00008527699,0.19593036,0.00000473246,0.00039054273,0.010518429],"study_design_scores_gemma":[0.063073136,0.004037434,0.66241765,0.0013354433,0.00025566807,0.00068421767,0.0024315417,0.0004580776,0.2621853,0.0003093752,0.0022193624,0.00059275655],"about_ca_topic_score_codex":0.000010004335,"about_ca_topic_score_gemma":0.000023266408,"teacher_disagreement_score":0.1180704,"about_ca_system_score_codex":0.000052579016,"about_ca_system_score_gemma":0.00015833466,"threshold_uncertainty_score":0.4787433},"labels":[],"label_agreement":null},{"id":"W3132375495","doi":"10.1016/j.neuropharm.2021.108502","title":"PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics","year":2021,"lang":"en","type":"article","venue":"Neuropharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba; Health Sciences Centre","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; University of Manitoba; Canada Foundation for Innovation; Research Manitoba; CancerCare Manitoba Foundation; Heart and Stroke Foundation of Canada","keywords":"Olaparib; PARP inhibitor; Poly ADP ribose polymerase; Neurodegeneration; DNA damage; DNA repair; Biology; Cancer research; Chemistry; Pharmacology; Polymerase; Medicine; DNA; Biochemistry; Disease; Internal medicine","score_opus":0.06037500789546683,"score_gpt":0.37395141910372637,"score_spread":0.3135764112082595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132375495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97651726,0.0006377884,0.001758952,0.01833776,0.0008165113,0.0012373968,0.00031299048,0.00011938019,0.00026196576],"genre_scores_gemma":[0.9923396,0.00032763238,0.0006358345,0.0055476953,0.00043804737,0.0005318113,0.0000651974,0.000046269888,0.0000678904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978934,0.0002997262,0.000639266,0.00059984665,0.00017244992,0.0003953131],"domain_scores_gemma":[0.99763197,0.00078947685,0.00020842976,0.0005778116,0.00051222777,0.00028010513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023795839,0.00022600203,0.0005142363,0.000089566216,0.00013133565,0.000010730775,0.00013439676,0.000097452124,0.0002637213],"category_scores_gemma":[0.00021307023,0.00022996354,0.00033517464,0.0003524876,0.00035062552,0.00006959459,0.000054176,0.00025424996,0.0000073056276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001197854,0.0006770305,0.024329908,0.00028163337,0.00017362289,0.00001499274,0.00012267735,0.00006419079,0.9664368,0.00024793347,0.0012692912,0.005184058],"study_design_scores_gemma":[0.006535007,0.0005279421,0.25144026,0.000043448723,0.0007820131,0.00004485543,0.000063357766,0.00023152548,0.66733336,0.0018803832,0.070845835,0.00027202343],"about_ca_topic_score_codex":0.0000022691452,"about_ca_topic_score_gemma":0.0000016175138,"teacher_disagreement_score":0.29910347,"about_ca_system_score_codex":0.00013379622,"about_ca_system_score_gemma":0.00063105556,"threshold_uncertainty_score":0.9377641},"labels":[],"label_agreement":null},{"id":"W3133740787","doi":"10.1007/s40262-020-00983-y","title":"The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McGill University; Jewish General Hospital","funders":"National Center for Advancing Translational Sciences; Pfizer","keywords":"Medicine; Tolerability; Renal function; Pharmacokinetics; Cmax; Urology; Dosing; Adverse effect; Internal medicine; Kidney disease","score_opus":0.01753290672712802,"score_gpt":0.3691539646569015,"score_spread":0.35162105792977344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133740787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959729,0.00046274552,0.000033500637,0.00167124,0.00027981825,0.0009611666,0.00004697136,0.000012607778,0.0005590811],"genre_scores_gemma":[0.9970482,0.0017046618,0.000115599134,0.0008722884,0.0001146876,0.000037564645,0.00001883679,0.000028451306,0.000059729053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742836,0.00046471847,0.0010436254,0.00030160058,0.00049830886,0.00026339342],"domain_scores_gemma":[0.9963896,0.0024300695,0.0003916467,0.0004094294,0.00024286077,0.00013636114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010107146,0.00021305098,0.00057562115,0.000040038638,0.00006369049,0.000007839565,0.00014947465,0.0000642883,0.00009838241],"category_scores_gemma":[0.00036916157,0.00011255625,0.00012975848,0.00030816157,0.000605208,0.000024186134,0.00008590895,0.00054824736,0.000002260907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06849856,0.0032250502,0.79229164,0.0005806716,0.0010148551,0.00010282204,0.00030846018,0.0036734978,0.025209041,0.0002523846,0.00642623,0.09841679],"study_design_scores_gemma":[0.050788663,0.012501857,0.509327,0.0011255485,0.0004443861,0.000012013661,0.0000472059,0.0012954231,0.4141425,0.0000951692,0.009934693,0.00028556032],"about_ca_topic_score_codex":0.0000010782952,"about_ca_topic_score_gemma":0.0000011368006,"teacher_disagreement_score":0.38893345,"about_ca_system_score_codex":0.000048858623,"about_ca_system_score_gemma":0.00010415512,"threshold_uncertainty_score":0.45899105},"labels":[],"label_agreement":null},{"id":"W3134036596","doi":"10.1101/2021.02.24.21252396","title":"Genetics of symptom remission in outpatients with COVID-19","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; McGill University Health Centre; Université de Montréal; Montreal Heart Institute","funders":"Fonds de Recherche du Québec - Santé; Université de Montréal","keywords":"Internal medicine; Placebo; Allele; Medicine; Coronavirus disease 2019 (COVID-19); Complete remission; Colchicine; Genome-wide association study; Spontaneous remission; Disease; Gastroenterology; Gene; Genotype; Genetics; Single-nucleotide polymorphism; Chemotherapy; Alternative medicine; Biology; Pathology","score_opus":0.05297844550587311,"score_gpt":0.3568329060163683,"score_spread":0.3038544605104952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134036596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387115,0.0017823889,0.0013133083,0.0010459564,0.0003037006,0.00053941633,0.000025852947,0.000038272447,0.0010799734],"genre_scores_gemma":[0.9946694,0.0008698184,0.002835465,0.0009909616,0.00009657329,0.00007080748,0.00014024449,0.000042761963,0.00028401637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820185,0.00011130857,0.00048549625,0.00047575714,0.0005355909,0.00018998983],"domain_scores_gemma":[0.99844617,0.00007169618,0.0002893833,0.00076394127,0.00017945466,0.00024937282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025878628,0.0002192759,0.0005525582,0.00020184339,0.000018583101,0.000009597932,0.00015026366,0.0002637128,0.00034710972],"category_scores_gemma":[0.00018552078,0.00018648646,0.00009003171,0.00023465558,0.00010110262,0.000016153916,0.00016688797,0.00050585426,0.0000036627048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055889407,0.0002910851,0.98173875,0.0015153595,0.000090334164,0.0002048235,0.00206535,0.0012300547,0.010858529,0.0000095317455,0.00036284642,0.0010744708],"study_design_scores_gemma":[0.023681937,0.0016018539,0.6312037,0.01843565,0.0004709503,0.00020958864,0.0011957343,0.001482491,0.2842638,0.0010320799,0.03491305,0.0015091371],"about_ca_topic_score_codex":0.000094719246,"about_ca_topic_score_gemma":0.000036701287,"teacher_disagreement_score":0.35053498,"about_ca_system_score_codex":0.000370734,"about_ca_system_score_gemma":0.0012059499,"threshold_uncertainty_score":0.76046973},"labels":[],"label_agreement":null},{"id":"W3134411589","doi":"10.1200/jco.2021.39.6_suppl.126","title":"Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta","funders":"","keywords":"Olaparib; Medicine; Oncology; Enzalutamide; CHEK2; Prostate cancer; Clinical endpoint; PALB2; Internal medicine; PARP inhibitor; Population; Cancer research; Cancer; Clinical trial; Gene; Genetics; Mutation; Poly ADP ribose polymerase; Biology; Germline mutation; Androgen receptor","score_opus":0.11753096355619325,"score_gpt":0.46210208616355647,"score_spread":0.3445711226073632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134411589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954341,0.0012210157,0.0001729858,0.0022585853,0.00040687984,0.000273335,0.00009048881,0.000004430228,0.0001381583],"genre_scores_gemma":[0.9931442,0.0011759674,0.003830796,0.0014440955,0.00015768872,0.000034162134,0.000050583636,0.000020663207,0.00014182518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99521744,0.0006889066,0.002930386,0.0002668629,0.000661816,0.00023456164],"domain_scores_gemma":[0.9945288,0.0007008162,0.0024813216,0.00024806525,0.0017734066,0.000267601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018495483,0.00016246176,0.0019503928,0.00030947296,0.000028133269,0.000009655544,0.000105879495,0.00015678152,0.00030715548],"category_scores_gemma":[0.00070727675,0.00011928145,0.00037587606,0.001017414,0.00021751816,0.00017369131,0.000021423557,0.0006145385,0.0000023265657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025292976,0.008981821,0.89659375,0.00014532967,0.010481876,0.00134302,0.001133737,0.0018843153,0.025943201,0.000041437223,0.0032620332,0.024896514],"study_design_scores_gemma":[0.04911347,0.018153643,0.88479203,0.0004300906,0.007341492,0.000064338536,0.00074932544,0.00020209202,0.02622553,0.00018564485,0.012405361,0.00033697134],"about_ca_topic_score_codex":0.00005168938,"about_ca_topic_score_gemma":0.00091748725,"teacher_disagreement_score":0.024559543,"about_ca_system_score_codex":0.00045826746,"about_ca_system_score_gemma":0.004409492,"threshold_uncertainty_score":0.78222495},"labels":[],"label_agreement":null},{"id":"W3134684911","doi":"10.3390/cells10030623","title":"PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells","year":2021,"lang":"en","type":"article","venue":"Cells","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Estrogen receptor; Breast cancer; Cancer research; Human breast; Estrogen; Cancer; Poly ADP ribose polymerase; Chemistry; Biology; Medicine; Internal medicine; Biochemistry; Gene","score_opus":0.019884674197747983,"score_gpt":0.29469723983712076,"score_spread":0.2748125656393728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134684911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962735,0.0010929194,0.0000963554,0.001229886,0.00022986234,0.00027882162,0.00007412918,0.000043207838,0.0006812887],"genre_scores_gemma":[0.99585843,0.0004651166,0.0010816681,0.00049181824,0.00033642168,0.000047632744,0.00004894698,0.000038063317,0.0016319249],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987673,0.00008829088,0.0003156255,0.0003760492,0.00019835467,0.00025437298],"domain_scores_gemma":[0.9993489,0.00005137907,0.000120358796,0.00021121927,0.00013568839,0.00013249143],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016052979,0.000166845,0.0002886688,0.00008870146,0.00007910301,0.000032052198,0.00004635283,0.00010940164,0.0014632839],"category_scores_gemma":[0.0000054405077,0.00017356266,0.00005753781,0.0002721801,0.000081167986,0.00011295526,0.000027407017,0.00019516231,0.000033576565],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009034606,0.0000651646,0.005461704,0.00006447592,0.000036051824,0.000027217033,0.00064410473,0.00035902843,0.9893681,0.00007629607,0.0011718173,0.0026357058],"study_design_scores_gemma":[0.0019685861,0.000043319927,0.0076319333,0.00037284137,0.000032775453,0.000018239467,0.00017434981,0.00020658465,0.9854822,0.00032521575,0.003565006,0.00017891524],"about_ca_topic_score_codex":0.00012737027,"about_ca_topic_score_gemma":0.00002121658,"teacher_disagreement_score":0.0038858552,"about_ca_system_score_codex":0.00021633477,"about_ca_system_score_gemma":0.00014715405,"threshold_uncertainty_score":0.9994495},"labels":[],"label_agreement":null},{"id":"W3134943972","doi":"10.1200/jco.2021.39.6_suppl.114","title":"A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Adverse effect; Urology; Hydroxychloroquine; Cancer; Oncology; Gastroenterology","score_opus":0.0846700058237099,"score_gpt":0.4817066438143889,"score_spread":0.397036637990679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134943972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179894,0.00091385026,0.000009103056,0.0059974706,0.00017169633,0.00036897536,0.000021435844,0.0000041988337,0.0007143441],"genre_scores_gemma":[0.9971417,0.0013447467,0.0007180285,0.00031941978,0.0002636474,0.000013457942,0.000006866417,0.000015127908,0.00017696709],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583775,0.000363392,0.0029591199,0.00024944777,0.00042419028,0.00016611246],"domain_scores_gemma":[0.9958912,0.0008848337,0.0021174026,0.00020871358,0.00068646134,0.00021135384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002327209,0.00013162517,0.0014167042,0.00015505668,0.00002072534,0.000002845337,0.000077020806,0.00023120786,0.000060858885],"category_scores_gemma":[0.0010821825,0.00009579639,0.0001269964,0.00033275687,0.00027332894,0.000107462176,0.000045927205,0.00075429457,3.695017e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3344023,0.0977073,0.23685928,0.00034492736,0.0019157421,0.0032328584,0.008964064,0.00039095888,0.18520702,0.0000711154,0.006727129,0.12417731],"study_design_scores_gemma":[0.45096982,0.20872319,0.24390532,0.0016320179,0.0011085279,0.0007835602,0.0034265073,0.0008386957,0.081336886,0.00051171996,0.006427269,0.0003364933],"about_ca_topic_score_codex":0.00006356104,"about_ca_topic_score_gemma":0.00016005083,"teacher_disagreement_score":0.12384082,"about_ca_system_score_codex":0.00013395135,"about_ca_system_score_gemma":0.0013789763,"threshold_uncertainty_score":0.39064637},"labels":[],"label_agreement":null},{"id":"W3135084125","doi":"10.1200/jco.2021.39.6_suppl.93","title":"TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Enzalutamide; Oncology; Clinical endpoint; Taxane; Urology; Cancer; Surgery; Clinical trial; Breast cancer; Androgen receptor","score_opus":0.11234208764431837,"score_gpt":0.48639998507008797,"score_spread":0.3740578974257696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135084125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965096,0.00027457753,0.000019505562,0.0018623312,0.0003432285,0.0006661853,0.000041065145,0.000008023761,0.00027546976],"genre_scores_gemma":[0.99680823,0.00020212417,0.0019608268,0.0005633052,0.00015899634,0.000041090843,0.000014270875,0.000018651532,0.00023250912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958765,0.00060356513,0.0025597448,0.00027331265,0.0004941652,0.0001927448],"domain_scores_gemma":[0.9962371,0.000596261,0.0016245118,0.00023487017,0.0010627738,0.00024450204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014514374,0.00015933925,0.0012817439,0.00015846611,0.00007345623,0.000011893059,0.00006605964,0.00010034756,0.00015567827],"category_scores_gemma":[0.0008459767,0.00011806097,0.00014963592,0.0003242714,0.00021408917,0.00022076684,0.00004084377,0.00061973714,6.928073e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044032432,0.09568464,0.7827418,0.00032265176,0.0027351442,0.0047949725,0.0074418085,0.00066515483,0.011710608,0.00015460142,0.0027971012,0.046919085],"study_design_scores_gemma":[0.1429184,0.15120867,0.69225603,0.00066429115,0.00114389,0.00020159346,0.0030692196,0.00033312035,0.0017741428,0.00016996304,0.006002151,0.00025851463],"about_ca_topic_score_codex":0.00006758551,"about_ca_topic_score_gemma":0.0015372398,"teacher_disagreement_score":0.09888597,"about_ca_system_score_codex":0.0001852606,"about_ca_system_score_gemma":0.0022520265,"threshold_uncertainty_score":0.48143867},"labels":[],"label_agreement":null},{"id":"W3135215220","doi":"10.1073/pnas.2019408118","title":"Zinc finger protein E4F1 cooperates with PARP-1 and BRG1 to promote DNA double-strand break repair","year":2021,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"DNA repair; Biology; Zinc finger; Chromatin remodeling; Poly ADP ribose polymerase; DNA damage; Chromatin; Homologous recombination; Replication protein A; DNA; Cell biology; Genetics; SMARCA4; DNA-binding protein; Molecular biology; Polymerase; Transcription factor; Gene","score_opus":0.043828776515763966,"score_gpt":0.3234266831985245,"score_spread":0.2795979066827606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135215220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746579,0.0002494011,0.000001322924,0.018696874,0.000009038826,0.00054929435,0.000013636545,0.000026337231,0.005796187],"genre_scores_gemma":[0.9921057,0.000026330776,0.0056527737,0.0010197737,0.00008717958,0.000056672834,3.025988e-7,0.0000070651913,0.0010441702],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99821585,0.000005102275,0.00027634567,0.00033758485,0.0010045037,0.0001606258],"domain_scores_gemma":[0.9990037,0.00003560482,0.00018737136,0.000013668141,0.00067837426,0.00008129553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000785352,0.00011136605,0.00021094282,0.000102463295,0.00016728969,0.00003201543,0.00018270941,0.0000678978,0.000043924592],"category_scores_gemma":[0.00017774146,0.0000686848,0.000047282167,0.00089661713,0.0006252145,0.00027699614,0.00006545845,0.0001559596,0.0000012686768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034797448,0.00008602037,0.005189834,0.00021295813,0.000045601628,1.303052e-7,0.0004360473,0.0000202932,0.983787,0.008399711,0.0011761886,0.0002982695],"study_design_scores_gemma":[0.0012453938,0.00023084458,0.018298991,0.00076932553,0.000022501426,0.000102470636,0.00013495331,0.000105855295,0.9739979,0.0027673272,0.0022254274,0.00009901611],"about_ca_topic_score_codex":0.0000056590206,"about_ca_topic_score_gemma":3.274549e-7,"teacher_disagreement_score":0.0176771,"about_ca_system_score_codex":0.000038703907,"about_ca_system_score_gemma":0.00015300265,"threshold_uncertainty_score":0.28008848},"labels":[],"label_agreement":null},{"id":"W3135473217","doi":"10.1200/jco.2021.39.6_suppl.27","title":"Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in <i>BRCA1</i>, <i>BRCA2</i> or <i>ATM</i>: Results from the PROfound study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Enzalutamide; Oncology; Internal medicine; BRCA mutation; Cohort; Cancer; Proportional hazards model; Progression-free survival; Prostate cancer; Cancer research; Gene; Chemotherapy; Ovarian cancer; Poly ADP ribose polymerase; Androgen receptor; Genetics","score_opus":0.1359905281967922,"score_gpt":0.44993887441197955,"score_spread":0.31394834621518736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135473217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038285,0.0003208509,0.000015562502,0.0068622036,0.0007667022,0.0013556862,0.00009576999,0.000013717765,0.00018664898],"genre_scores_gemma":[0.993951,0.00008777407,0.0017755519,0.003446016,0.0005243422,0.000080787606,0.00003368383,0.00004302744,0.0000577845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925865,0.0015967842,0.004155836,0.00047654813,0.0007992476,0.00038507997],"domain_scores_gemma":[0.99041694,0.005666894,0.0023866727,0.00041038598,0.0008820998,0.000236985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033343409,0.00025836285,0.0015160403,0.000120197554,0.00013405972,0.00006297053,0.00019221054,0.00008184705,0.000090261405],"category_scores_gemma":[0.004594014,0.00015522003,0.0001985712,0.0007179429,0.00018422381,0.00028804413,0.000048989597,0.0014835568,0.0000043501836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060004495,0.016369892,0.8781088,0.00006789567,0.0013659546,0.01036313,0.009998291,0.004531593,0.0017502332,0.000028613294,0.0011792352,0.016231868],"study_design_scores_gemma":[0.08033637,0.0062324004,0.90598625,0.0010584706,0.00045407075,0.00013301922,0.002271777,0.00014275087,0.00029344083,0.00007489826,0.0027982541,0.0002182784],"about_ca_topic_score_codex":0.00071916525,"about_ca_topic_score_gemma":0.01385489,"teacher_disagreement_score":0.02787747,"about_ca_system_score_codex":0.00061925914,"about_ca_system_score_gemma":0.005886683,"threshold_uncertainty_score":0.999749},"labels":[],"label_agreement":null},{"id":"W3135952602","doi":"10.3390/cancers13061296","title":"Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; Université de Montréal; Centre Hospitalier de l’Université de Montréal; McGill University; McGill Genome Centre","funders":"","keywords":"Olaparib; PARP inhibitor; Synthetic lethality; Cancer research; Biology; Medicine; Genetics; DNA repair; Gene; Poly ADP ribose polymerase","score_opus":0.11235976040530386,"score_gpt":0.41416880621115426,"score_spread":0.3018090458058504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135952602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97981286,0.015553626,0.000046575486,0.0003122207,0.00033252762,0.00015037361,0.002587483,0.00002047958,0.0011838455],"genre_scores_gemma":[0.9937088,0.003361456,0.0006179098,0.0005045288,0.00023606136,0.000016955777,0.0005779568,0.000033631837,0.00094269984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850494,0.00013500603,0.00047521046,0.00042373684,0.00026292456,0.00019818451],"domain_scores_gemma":[0.99801886,0.00014692394,0.00030994826,0.0011741993,0.00023196088,0.00011808667],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023102945,0.00015747301,0.0005159238,0.000075372365,0.000043637574,0.0000072645225,0.00026442463,0.00008114911,0.0029706033],"category_scores_gemma":[0.00006153668,0.00015596891,0.00010017039,0.00027839487,0.00019312552,0.000097291624,0.000108390515,0.00012295756,0.0000034889144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030848493,0.00002780843,0.0053979037,0.00011501473,0.00037433143,0.000026256208,0.00034416243,0.00037818085,0.9766831,0.0000031902182,0.013023135,0.00054208847],"study_design_scores_gemma":[0.0031091296,0.0001539754,0.016484099,0.00038242276,0.0004016554,0.0000029811818,0.00079649326,0.0003575082,0.967168,0.00003088759,0.010942115,0.00017076232],"about_ca_topic_score_codex":0.023956541,"about_ca_topic_score_gemma":0.004087074,"teacher_disagreement_score":0.019869467,"about_ca_system_score_codex":0.0010764096,"about_ca_system_score_gemma":0.0027682486,"threshold_uncertainty_score":0.99794084},"labels":[],"label_agreement":null},{"id":"W3137288611","doi":"10.1038/s41388-021-01744-2","title":"Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand","year":2021,"lang":"en","type":"review","venue":"Oncogene","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Synthetic lethality; Biology; DNA repair; Polymerase; Cancer research; Fanconi anemia; PARP1; Protein-fragment complementation assay; Genetics; Phenotype; Gene; Poly ADP ribose polymerase; Complementation","score_opus":0.11147004397536552,"score_gpt":0.40464038321918183,"score_spread":0.2931703392438163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137288611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003899241,0.9889152,0.0009052773,0.0009110778,0.0006435434,0.0013995816,0.0004094966,0.00015268539,0.0066241403],"genre_scores_gemma":[0.000015254105,0.9910305,0.003450708,0.0003958026,0.0011337565,0.00052883895,0.00016118557,0.00019123079,0.0030927216],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958404,0.00040807243,0.0011750262,0.0010874865,0.00083790545,0.00065114896],"domain_scores_gemma":[0.9973171,0.00025410406,0.00045518117,0.001213516,0.00026411857,0.0004960167],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008312834,0.00067978905,0.002992662,0.00025155835,0.0001399679,0.000072453884,0.00027734993,0.00036375818,0.0025597448],"category_scores_gemma":[0.00021401267,0.0005991683,0.0008512793,0.00078509504,0.00009044482,0.000050335373,0.00016372987,0.00067887193,0.0005674025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033469172,0.00031844497,0.0000046423597,0.044415314,0.00039851083,0.0012865034,0.00038483043,0.000008959654,0.00026180103,0.00018033636,0.010798998,0.9419082],"study_design_scores_gemma":[0.00046140162,0.00014621502,2.7098912e-7,0.1267098,0.00049470924,0.0009661187,0.00017305891,0.0000012669077,0.00047572074,0.000019110606,0.870067,0.00048530055],"about_ca_topic_score_codex":0.000016906608,"about_ca_topic_score_gemma":0.000005881118,"teacher_disagreement_score":0.9414229,"about_ca_system_score_codex":0.0010379376,"about_ca_system_score_gemma":0.0017913649,"threshold_uncertainty_score":0.99964595},"labels":[],"label_agreement":null},{"id":"W3137926322","doi":"10.1016/j.ygyno.2021.03.015","title":"Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2","year":2021,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"National Cancer Institute; Cancer Research UK; Clovis Oncology","keywords":"Medicine; Internal medicine; Cmax; Adverse effect; Gastroenterology; Aspartate transaminase; Population; Response Evaluation Criteria in Solid Tumors; Urology; Oncology; Alanine transaminase; Pharmacokinetics; Surgery; Progressive disease; Chemotherapy","score_opus":0.05311737377274775,"score_gpt":0.3609906774511664,"score_spread":0.3078733036784187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137926322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625134,0.0006230128,0.00011459313,0.00066654163,0.00030350804,0.0016141918,0.000061101455,0.000033687236,0.00033200678],"genre_scores_gemma":[0.99636865,0.00004498923,0.0022675272,0.0004108853,0.00009505102,0.00023794732,0.0004779963,0.000017866216,0.00007908357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981011,0.00032816923,0.0005138956,0.000603837,0.00017095098,0.0002820591],"domain_scores_gemma":[0.998297,0.0008824158,0.00020971979,0.00028141958,0.00020463746,0.00012480917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030252375,0.0002110856,0.00071093586,0.00013096083,0.000116127936,0.000019750247,0.000053445405,0.00021985517,0.00037720578],"category_scores_gemma":[0.0004440945,0.00017271475,0.00003840668,0.0002316394,0.00009214204,0.000078546705,0.000057143923,0.00020667087,0.0000021231904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042759655,0.002193672,0.96403277,0.000019472242,0.00013497901,0.00006110664,0.0008089007,0.000019628129,0.00014196416,0.000052899646,0.00012702637,0.02813163],"study_design_scores_gemma":[0.028825764,0.012938034,0.9552389,0.000027143798,0.00021596107,0.00000691574,0.00061964657,0.000046234385,0.00007233309,0.00031094556,0.0015236533,0.00017450537],"about_ca_topic_score_codex":0.0001734746,"about_ca_topic_score_gemma":0.00152497,"teacher_disagreement_score":0.027957125,"about_ca_system_score_codex":0.00037164238,"about_ca_system_score_gemma":0.00021322601,"threshold_uncertainty_score":0.7043103},"labels":[],"label_agreement":null},{"id":"W3139290764","doi":"10.1158/1078-0432.ccr-20-4068","title":"Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIHR Imperial Biomedical Research Centre; Medical Research Council; Sierra Oncology; National Institute for Health and Care Research; Cancer Research UK; NuCana; Ovarian Cancer Action; AstraZeneca; UK Research and Innovation; Wellcome Trust; Pancreatic Cancer UK; Beatson Cancer Charity; Pfizer","keywords":"Serous fluid; Biology; Ovarian carcinoma; Serous carcinoma; Structural variation; Homologous recombination; Somatic cell; Ovarian cancer; Homologous chromosome; Genome; Genetics; Carcinoma; Cancer; Cancer research; Gene","score_opus":0.17509979765269706,"score_gpt":0.46818482929358285,"score_spread":0.2930850316408858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139290764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802388,0.0064228354,0.000012934951,0.011180545,0.00043314893,0.00066527416,0.00008585356,0.000056718873,0.0009039138],"genre_scores_gemma":[0.99463195,0.0006493807,0.0001504134,0.0015697695,0.00048594465,0.00015831464,0.00003555121,0.000047878424,0.0022707842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99425787,0.0017987165,0.0011293446,0.0008096136,0.0012044166,0.0008000129],"domain_scores_gemma":[0.99573505,0.0017629664,0.00024891194,0.0013318363,0.00064600003,0.00027525003],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030988732,0.00021405637,0.0008047559,0.00014795402,0.00028464256,0.000026309053,0.0004278604,0.0003227088,0.001266953],"category_scores_gemma":[0.00091634283,0.00015935762,0.0003025775,0.0013661798,0.001347289,0.00006256555,0.0004499645,0.0018288459,0.0000378169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022398666,0.000511862,0.9680157,0.00028434125,0.00010900067,0.0011390052,0.0007250892,0.0001839229,0.0025685928,0.0004253809,0.018432103,0.00536519],"study_design_scores_gemma":[0.006691748,0.0006946221,0.978565,0.000318303,0.00005112478,0.0003217104,0.00066635926,0.0004197538,0.0065936055,0.0012685192,0.004193568,0.00021571077],"about_ca_topic_score_codex":0.00518851,"about_ca_topic_score_gemma":0.006434599,"teacher_disagreement_score":0.014393188,"about_ca_system_score_codex":0.0007667385,"about_ca_system_score_gemma":0.0012875805,"threshold_uncertainty_score":0.999646},"labels":[],"label_agreement":null},{"id":"W3140798780","doi":"10.15252/emmm.202114002","title":"Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors","year":2021,"lang":"en","type":"letter","venue":"EMBO Molecular Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Wnt signaling pathway; Synthetic lethality; Cancer research; Poly ADP ribose polymerase; Biology; Signal transduction; Pharmacology; Cell biology; DNA repair; Genetics; DNA","score_opus":0.04385354316161951,"score_gpt":0.3170772317245287,"score_spread":0.2732236885629092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140798780","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13110696,0.0017570304,0.0021197787,0.85474956,0.0023801888,0.001844259,0.00004839633,0.0003068682,0.0056869937],"genre_scores_gemma":[0.2379269,0.00007273922,0.000581718,0.7500174,0.00844504,0.00033673126,0.0016571672,0.0002747949,0.00068749057],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9928125,0.00066212524,0.0014666396,0.0016636559,0.0023527697,0.0010423004],"domain_scores_gemma":[0.99578667,0.00027893827,0.00051587797,0.0020107953,0.0007883353,0.0006194003],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010205295,0.0010382228,0.0020259593,0.00083512714,0.00015401197,0.00005383235,0.0003443736,0.0015318422,0.002393162],"category_scores_gemma":[0.001225145,0.0009722013,0.00050853845,0.0010353848,0.00036465703,0.00007675028,0.0001981061,0.0036628651,0.00020662932],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009986085,0.0000696735,0.000020092282,0.0006095696,0.00032667356,0.008835901,0.0005008776,0.000012168669,0.47288826,0.00006144691,0.5160182,0.0005572958],"study_design_scores_gemma":[0.004317204,0.0011375438,0.00006443249,0.010814292,0.0008796776,0.00083400356,0.00028526495,0.000009660421,0.49667957,0.0007008575,0.48317772,0.0010997516],"about_ca_topic_score_codex":0.00028253766,"about_ca_topic_score_gemma":0.000005581623,"teacher_disagreement_score":0.10681996,"about_ca_system_score_codex":0.0009060397,"about_ca_system_score_gemma":0.00078521715,"threshold_uncertainty_score":0.9997644},"labels":[],"label_agreement":null},{"id":"W3146717266","doi":"10.1093/annonc/mdx370.053","title":"The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Olaparib; PARP inhibitor; PALB2; Prostate cancer; Oncology; Taxane; Internal medicine; CHEK2; Docetaxel; Cancer research; Germline mutation; Cancer; Androgen receptor; Breast cancer; Mutation; Genetics; Poly ADP ribose polymerase; Biology; Gene","score_opus":0.2420030461297958,"score_gpt":0.4813160704545564,"score_spread":0.23931302432476056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146717266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892886,0.00022020814,0.0000027292235,0.00558673,0.00055215124,0.003590113,0.000039907194,0.000009902241,0.0007096422],"genre_scores_gemma":[0.99871135,0.00018557448,0.00007899677,0.00014083814,0.00005939327,0.0007013344,0.000034634708,0.000017331868,0.00007055862],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963364,0.0011371116,0.0010227314,0.00029785951,0.00088247994,0.00032344228],"domain_scores_gemma":[0.99474484,0.00054215896,0.0021602914,0.00051675754,0.0019719386,0.00006399726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005200168,0.00016230645,0.0005533283,0.000079119425,0.00028007233,0.000028786166,0.00023535614,0.00014274477,0.000022274342],"category_scores_gemma":[0.002510607,0.00008798456,0.000106011146,0.00025661383,0.000799251,0.00014300378,0.000030739677,0.00030990486,7.3242853e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15969934,0.011946532,0.28003356,0.000113649854,0.0007693377,0.000014664049,0.0020566797,0.00027412333,0.0005423081,0.0004662189,0.0018447803,0.54223883],"study_design_scores_gemma":[0.16330782,0.0340445,0.7951551,0.0005456388,0.00054347684,0.000004804205,0.0003338656,0.0003220707,0.003574063,0.0012403917,0.00073968986,0.00018859017],"about_ca_topic_score_codex":0.00040333584,"about_ca_topic_score_gemma":0.004282526,"teacher_disagreement_score":0.54205024,"about_ca_system_score_codex":0.00030320702,"about_ca_system_score_gemma":0.0022419426,"threshold_uncertainty_score":0.39771098},"labels":[],"label_agreement":null},{"id":"W3147648981","doi":"10.1096/fj.202001636rrr","title":"ATR prevents Ca <sup>2+</sup> overload‐induced necrotic cell death through phosphorylation‐mediated inactivation of PARP1 without DNA damage signaling","year":2021,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IONICS Mass Spectrometry (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health","keywords":"Programmed cell death; PARP1; DNA damage; Ionomycin; Cell biology; Biology; Phosphorylation; Quinolinic acid; Mitochondrion; Apoptosis; Molecular biology; Biochemistry; Poly ADP ribose polymerase; DNA; Polymerase","score_opus":0.0361540549545537,"score_gpt":0.29478452672105687,"score_spread":0.25863047176650317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147648981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936623,0.00036256353,0.003024091,0.00077782053,0.00021963584,0.0003860333,0.000027952647,0.00003401301,0.0015055838],"genre_scores_gemma":[0.99616766,0.00016949335,0.0015215768,0.0008186981,0.00045630036,0.000014923729,0.00007503529,0.000046940506,0.00072939735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769,0.00034357203,0.00066658045,0.00024262843,0.0007213241,0.00033589877],"domain_scores_gemma":[0.9982012,0.00024648462,0.00056270714,0.00041169283,0.00042182198,0.00015612744],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006140693,0.0002348906,0.00042305037,0.000087344495,0.00029065568,0.00005286346,0.00017321626,0.0001291172,0.0012133464],"category_scores_gemma":[0.00018090439,0.0001815935,0.00019670064,0.00042987696,0.00006977839,0.00033064705,0.000041358144,0.0006846045,0.00003825125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004782574,0.0002571494,0.008168863,0.00006939826,0.000202005,0.00008005831,0.004254093,0.0034832135,0.982213,0.000038390324,0.00055938977,0.00019616375],"study_design_scores_gemma":[0.0045061,0.00026562702,0.004478426,0.00056365173,0.00022481612,0.000371606,0.0017480718,0.0038877171,0.98265004,0.0008335573,0.00027880722,0.00019156956],"about_ca_topic_score_codex":0.00006193445,"about_ca_topic_score_gemma":0.0000017169332,"teacher_disagreement_score":0.0040278425,"about_ca_system_score_codex":0.00036400734,"about_ca_system_score_gemma":0.000657469,"threshold_uncertainty_score":0.99969965},"labels":[],"label_agreement":null},{"id":"W3155089045","doi":"10.1016/s1470-2045(21)00098-x","title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; BRCA mutation; Internal medicine; Ovarian cancer; Clinical endpoint; Oncology; Olaparib; Placebo; Quality of life (healthcare); Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Progressive disease; Chemotherapy; Pathology","score_opus":0.02288432002918147,"score_gpt":0.3707904252599238,"score_spread":0.34790610523074234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155089045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890843,0.000989765,0.000028709172,0.005227059,0.0002607075,0.0042272056,0.000112768656,0.00002736359,0.000042103205],"genre_scores_gemma":[0.995641,0.0009740201,0.0005126354,0.0017305639,0.0000683369,0.0009401643,0.000086098,0.000023946404,0.000023223998],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99762255,0.0009075076,0.00043812307,0.0003690903,0.00025677183,0.00040598406],"domain_scores_gemma":[0.9973162,0.0016812404,0.00044295806,0.0002677316,0.000097941636,0.00019393006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037360174,0.00020569359,0.0009839534,0.00007657329,0.00008329705,0.000012025856,0.00004501672,0.00007235478,0.00004374947],"category_scores_gemma":[0.0010106608,0.000113474154,0.00004093829,0.00021171109,0.00015569874,0.000072123614,0.000030392486,0.00024730733,4.3262082e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77754176,0.00077275845,0.053993244,0.00021935017,0.00008200283,0.000080301186,0.001962863,0.00006167531,0.000061974795,0.000019316652,0.00023855787,0.16496618],"study_design_scores_gemma":[0.89968085,0.015188108,0.08232863,0.0012729132,0.000090730646,0.0000051251022,0.00020039972,0.0001629407,0.00025603714,0.000055131866,0.0006255241,0.00013359883],"about_ca_topic_score_codex":0.00008623534,"about_ca_topic_score_gemma":0.0003466947,"teacher_disagreement_score":0.16483259,"about_ca_system_score_codex":0.0003656444,"about_ca_system_score_gemma":0.00069711055,"threshold_uncertainty_score":0.46273416},"labels":[],"label_agreement":null},{"id":"W3155825173","doi":"10.1038/s41388-021-01761-1","title":"Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma","year":2021,"lang":"en","type":"article","venue":"Oncogene","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Veterans Affairs; National Institute of Neurological Disorders and Stroke; U.S. Department of Health and Human Services","keywords":"Biology; Cancer research; Carcinogenesis; Repressor; Pancreatic cancer; Cell cycle; Cell cycle progression; Cell growth; Transcription factor; Pancreatic ductal adenocarcinoma; In vivo; Cell; Cancer; Gene; Genetics","score_opus":0.03457828552423421,"score_gpt":0.3170432154693964,"score_spread":0.2824649299451622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155825173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96854436,0.011686078,0.0004792444,0.0032329217,0.00025181565,0.00027519857,0.000019596522,0.000062742874,0.01544806],"genre_scores_gemma":[0.9878539,0.00028605346,0.0040758136,0.0039613442,0.00036607817,0.00007510719,0.000064164014,0.000044870383,0.0032726927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866647,0.00005284146,0.00029363067,0.00036509105,0.00030886775,0.0003131334],"domain_scores_gemma":[0.9992284,0.000056405355,0.000060677456,0.000410329,0.000106580024,0.000137578],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014849665,0.00017037096,0.00035742862,0.000110085064,0.00004203879,0.000017836286,0.00007933959,0.00010678059,0.0021434838],"category_scores_gemma":[0.000054605207,0.00016621075,0.000105803876,0.00045933636,0.00006202189,0.00006698571,0.00003270468,0.00021425044,0.0002908745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030461253,0.00046524886,0.09401438,0.000059028134,0.00015711629,0.0009856945,0.00044889856,0.000015437636,0.9011636,0.0009987315,0.00038442118,0.0010028485],"study_design_scores_gemma":[0.015395877,0.0006666624,0.21145996,0.0005550461,0.00022269832,0.004648863,0.0007810627,0.00038309477,0.728758,0.0037671858,0.03273579,0.0006257962],"about_ca_topic_score_codex":0.00006881502,"about_ca_topic_score_gemma":0.000022792732,"teacher_disagreement_score":0.17240562,"about_ca_system_score_codex":0.0002561826,"about_ca_system_score_gemma":0.00060692086,"threshold_uncertainty_score":0.9987687},"labels":[],"label_agreement":null},{"id":"W3155907637","doi":"10.1073/pnas.2105547118","title":"Setting molecular traps in yeast for identification of anticancer drug targets","year":2021,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Government of Canada; National Institutes of Health; National Human Genome Research Institute; Canadian Cancer Society; Natural Sciences and Engineering Research Council of Canada","keywords":"Synthetic lethality; Poly ADP ribose polymerase; DNA repair; Homologous recombination; Context (archaeology); PARP1; Biology; Polymerase; DNA; Genetics; Chemistry","score_opus":0.03487447023599046,"score_gpt":0.35652023547989053,"score_spread":0.3216457652439001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155907637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98831016,0.00047398888,0.000024469877,0.009488152,0.00002480895,0.00025927954,0.0000343784,0.0000046862046,0.001380092],"genre_scores_gemma":[0.9969742,0.000038173373,0.002494366,0.0003393302,0.000040214654,0.000023222672,4.9973454e-7,0.0000036176561,0.00008639913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985876,0.0000050600866,0.00039490746,0.00017419652,0.0007447152,0.000093489776],"domain_scores_gemma":[0.9990131,0.00006433729,0.00038755036,0.000008135115,0.0005089616,0.000017900053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012167018,0.00005128445,0.00014520451,0.00012750842,0.00004427777,0.000006319715,0.00018334635,0.00003872307,0.000012144971],"category_scores_gemma":[0.0005334415,0.00004044259,0.00007288716,0.0006724023,0.00034708137,0.00016533601,0.00002481416,0.00008002863,2.0297416e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025532712,0.000051041192,0.006294755,0.00017154198,0.000011306715,8.564317e-9,0.00026187804,0.00006871237,0.9781422,0.014248261,0.00029636838,0.00042841202],"study_design_scores_gemma":[0.00042819718,0.000013970586,0.055958427,0.0002261609,0.000011160275,0.000004645038,0.0002602244,0.0010961517,0.9155668,0.026266174,0.00013298547,0.00003508957],"about_ca_topic_score_codex":0.0000018245726,"about_ca_topic_score_gemma":5.3666938e-8,"teacher_disagreement_score":0.06257537,"about_ca_system_score_codex":0.000043246742,"about_ca_system_score_gemma":0.00009312111,"threshold_uncertainty_score":0.16492008},"labels":[],"label_agreement":null},{"id":"W3158356388","doi":"10.3791/62553","title":"Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging","year":2021,"lang":"en","type":"article","venue":"Journal of Visualized Experiments","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"DNA damage; DNA repair; Homologous recombination; DNA; Biology; DNA polymerase; Synthetic lethality; Molecular biology; Cancer research; Genetics","score_opus":0.046951938408087826,"score_gpt":0.4733516214727652,"score_spread":0.4263996830646774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158356388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98050916,0.0011700705,0.016207684,0.00013940432,0.00041795423,0.0002071332,0.000007568782,0.000013118136,0.001327882],"genre_scores_gemma":[0.9849232,0.00011463116,0.0145747615,0.00011346766,0.00019830347,0.000005421471,0.000013334326,0.00002618277,0.000030727613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783117,0.00010917432,0.0007344566,0.00020075655,0.0009086257,0.00021584399],"domain_scores_gemma":[0.99819154,0.000032670505,0.0007576763,0.00017435943,0.00069993763,0.00014383775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041144624,0.00017449078,0.00046692573,0.00011124863,0.000097310294,0.00004988489,0.00006987755,0.000057214485,0.000222452],"category_scores_gemma":[0.000014631344,0.00015043248,0.00013693995,0.00032436626,0.00006609199,0.00033681444,0.000023792041,0.00017827615,6.032573e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023579486,0.0007371621,0.011623875,0.000110213776,0.0001868054,0.00013376714,0.0005235686,0.00042420308,0.98363215,0.00008125547,0.00003259045,0.0001564617],"study_design_scores_gemma":[0.02522228,0.0005130676,0.005974354,0.0010294445,0.00023128392,0.00055227475,0.0019423028,0.005006982,0.95925504,0.00006468491,0.000055861758,0.00015243006],"about_ca_topic_score_codex":0.000055195604,"about_ca_topic_score_gemma":0.00000593765,"teacher_disagreement_score":0.024377113,"about_ca_system_score_codex":0.00081479934,"about_ca_system_score_gemma":0.0005682117,"threshold_uncertainty_score":0.6134458},"labels":[],"label_agreement":null},{"id":"W3159728738","doi":"10.1038/s41467-021-22582-6","title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Université de Montréal; Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development; National Cancer Institute; Stand Up To Cancer; Genentech; Foundation Medicine; Sierra Oncology; PharmaMar; AstraZeneca Australia; Eisai; Mateon Therapeutics; National Breast Cancer Foundation; BeiGene; Clovis Oncology; Amgen; American Association for Cancer Research; National Ovarian Cancer Coalition; Regeneron Pharmaceuticals; Ludwig Institute for Cancer Research; Exelixis; Eli Lilly and Company; U.S. Department of Defense; Sanofi; GlaxoSmithKline; Ovarian Cancer Research Fund; Bristol-Myers Squibb; AstraZeneca; Pfizer; Ovarian Cancer Research Fund Alliance; Array BioPharma","keywords":"Cancer research; PARP inhibitor; Ovarian cancer; Medicine; Biomarker; Oncology; Homologous recombination; Biology; Bioinformatics; Cancer; Internal medicine; Poly ADP ribose polymerase; Genetics; Gene; Polymerase","score_opus":0.06698202711603134,"score_gpt":0.4452275900725575,"score_spread":0.37824556295652617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159728738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9382378,0.042847577,0.000050068866,0.017984405,0.00006927269,0.0005698289,0.000112404676,0.000007986075,0.00012068414],"genre_scores_gemma":[0.97781503,0.00830757,0.012807322,0.0006902544,0.000016038133,0.00024306717,0.000018246004,0.000010851721,0.00009162414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907535,0.00022029348,0.00030986784,0.00021969315,0.000073112315,0.000101689926],"domain_scores_gemma":[0.99838114,0.00057069433,0.00007013238,0.00072397356,0.00015102656,0.000103062746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034807535,0.00008955796,0.00027462453,0.00006873037,0.00006773597,0.000010676318,0.000075633376,0.00015174139,0.0000037122713],"category_scores_gemma":[0.00039046147,0.00008496536,0.000034776484,0.00016065055,0.00012934541,0.000027011682,0.000077866054,0.00022397029,1.2056256e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03126003,0.003387146,0.7826131,0.0005660281,0.0006503023,0.00010868999,0.0072947964,0.000009659552,0.03391911,0.023283968,0.0041405275,0.11276663],"study_design_scores_gemma":[0.013136538,0.0014413673,0.7637515,0.0018573635,0.00034805833,0.0000670819,0.00053021533,0.00096999976,0.019459607,0.0019457506,0.19609609,0.00039644077],"about_ca_topic_score_codex":0.00002825176,"about_ca_topic_score_gemma":0.006321067,"teacher_disagreement_score":0.19195557,"about_ca_system_score_codex":0.000082225364,"about_ca_system_score_gemma":0.0002282001,"threshold_uncertainty_score":0.35273036},"labels":[],"label_agreement":null},{"id":"W3163066855","doi":"10.1101/2021.05.19.444852","title":"HPF1 dynamically controls the PARP1/2 balance between initiating and elongating ADP- ribose modifications","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Institutes of Health","keywords":"PARP1; Poly ADP ribose polymerase; Serine; DNA damage; ADP-ribosylation; Biochemistry; DNA repair; Histone; Biology; DNA; Ribose; Cell biology; Chemistry; Enzyme; NAD+ kinase; Polymerase","score_opus":0.025921807747714232,"score_gpt":0.2715199988163353,"score_spread":0.24559819106862107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163066855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97871715,0.003015279,0.010575128,0.0044385684,0.0005816676,0.0016302322,0.0005211077,0.0004488004,0.00007204177],"genre_scores_gemma":[0.98654974,0.00048647902,0.009324255,0.0012469293,0.0015052127,0.0007322467,0.000004737538,0.0001446294,0.0000057931593],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964393,0.0003395763,0.0009413119,0.0011001932,0.0005744918,0.0006051591],"domain_scores_gemma":[0.9958337,0.0005913984,0.00073907466,0.0016069827,0.0008728977,0.00035594488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010047234,0.00057786074,0.0009480782,0.00015710974,0.00044259778,0.00036208646,0.00039687543,0.0005210873,0.000056647597],"category_scores_gemma":[0.00088504143,0.00052684237,0.00019814594,0.00050191925,0.00033572374,0.00016419582,0.00036124038,0.0016182701,0.000016848357],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000762212,0.00020124238,0.11000002,0.0008823499,0.00092496845,0.000105584295,0.00014129722,0.00011109186,0.8862165,0.0009914673,0.00030933373,0.000039918126],"study_design_scores_gemma":[0.004368761,0.00014127081,0.87220925,0.004388995,0.0009436532,4.7367922e-7,0.0000771562,0.010695528,0.10286087,0.000024993042,0.002752178,0.0015368446],"about_ca_topic_score_codex":0.000052624964,"about_ca_topic_score_gemma":0.0000027699004,"teacher_disagreement_score":0.78335565,"about_ca_system_score_codex":0.00040179008,"about_ca_system_score_gemma":0.0010451715,"threshold_uncertainty_score":0.9997183},"labels":[],"label_agreement":null},{"id":"W3163516971","doi":"10.1101/2021.05.14.444217","title":"Mammary lineage dictates homologous recombination repair and PARP inhibitor vulnerability","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"RAD51; Homologous recombination; Biology; DNA repair; Lineage (genetic); Homologous chromosome; Poly ADP ribose polymerase; Cancer research; Cell biology; DNA; BRCA2 Protein; PARP inhibitor; Non-homologous end joining; DNA damage; Molecular biology; Genetics; Gene; Polymerase; Mutation","score_opus":0.017089982617813984,"score_gpt":0.2558895760019592,"score_spread":0.23879959338414525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163516971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863432,0.0063910675,0.0012571713,0.0014088197,0.0019479237,0.0012393773,0.00014209133,0.0012376261,0.000032705728],"genre_scores_gemma":[0.9808896,0.0023009034,0.0144599425,0.0008416603,0.0008209824,0.00051046803,0.000004876944,0.00014594631,0.000025596182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960228,0.0003866231,0.0009047902,0.0016225881,0.0005226851,0.00054049434],"domain_scores_gemma":[0.99602365,0.00018429887,0.00047920056,0.0018929525,0.0009829766,0.00043688997],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011454802,0.00066464103,0.0010210697,0.00031605308,0.00020432049,0.00021415851,0.00024007709,0.0008886846,0.00011542429],"category_scores_gemma":[0.00061939744,0.0007259064,0.00031254068,0.0005144004,0.00028014468,0.00026757192,0.0005181733,0.0014565076,0.00001700646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004307703,0.0016475755,0.080915086,0.0045521026,0.0010804018,0.0014484253,0.0001232717,0.000026160804,0.90501034,0.0006810784,0.004034603,0.00005020818],"study_design_scores_gemma":[0.0033097614,0.00037323567,0.30030432,0.0020244021,0.00036399416,9.958361e-7,0.0000136277395,0.0007752024,0.6865347,0.000020631354,0.0050156354,0.0012634553],"about_ca_topic_score_codex":0.00005361766,"about_ca_topic_score_gemma":0.0000027939354,"teacher_disagreement_score":0.21938924,"about_ca_system_score_codex":0.00066981,"about_ca_system_score_gemma":0.0010551452,"threshold_uncertainty_score":0.9995192},"labels":[],"label_agreement":null},{"id":"W3164115667","doi":"10.1016/j.ejca.2021.03.029","title":"Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Samsung; Genentech; Merck Sharp and Dohme; Eisai; MacroGenics; Puma Biotechnology; PharmaMar; Celgene; Jounce Therapeutics; Mylan; Genomic Health; Ipsen; Syndax Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Olaparib; Metastatic breast cancer; Internal medicine; Oncology; Taxane; Nausea; BRCA mutation; Breast cancer; Interim analysis; Adverse effect; Cancer; Clinical trial","score_opus":0.04795153637465649,"score_gpt":0.4481784648935772,"score_spread":0.4002269285189207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164115667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917503,0.0033249112,0.0012719978,0.0017259632,0.0004532901,0.00031769075,0.00020775737,0.000013858442,0.0009342258],"genre_scores_gemma":[0.99195373,0.0057728887,0.00097434863,0.00060008274,0.0003757493,0.000021406577,0.000012403577,0.00007255344,0.00021682598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931108,0.003470603,0.0021403597,0.00041591938,0.0005287408,0.00033358243],"domain_scores_gemma":[0.99651283,0.00065160776,0.0013336559,0.00034240718,0.0009262664,0.00023323216],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004023026,0.00030055217,0.0016057325,0.0009170924,0.000028068225,0.000025853546,0.00021290928,0.000040302195,0.001396962],"category_scores_gemma":[0.00017801505,0.0002597752,0.00058234495,0.0024921063,0.00020638025,0.00019905026,0.000043040734,0.000829339,0.0000037196867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03754733,0.0046195826,0.6848266,0.0006708327,0.010481573,0.0077842954,0.004237555,0.014681321,0.059795484,0.000039725124,0.00058353157,0.17473213],"study_design_scores_gemma":[0.04376302,0.00087940687,0.91732603,0.005002081,0.00138629,0.00018703706,0.0003808671,0.0009904376,0.028487409,0.00008724018,0.0011624108,0.0003477751],"about_ca_topic_score_codex":0.00077003584,"about_ca_topic_score_gemma":0.002100003,"teacher_disagreement_score":0.23249939,"about_ca_system_score_codex":0.0006927628,"about_ca_system_score_gemma":0.0009158318,"threshold_uncertainty_score":0.99998546},"labels":[],"label_agreement":null},{"id":"W3164484186","doi":"10.1016/j.neuint.2021.105077","title":"PARP-1 activation leads to cytosolic accumulation of TDP-43 in neurons","year":2021,"lang":"en","type":"article","venue":"Neurochemistry International","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health","keywords":"Poly ADP ribose polymerase; Cytosol; Oxidative stress; Neuroprotection; PARP inhibitor; Cell biology; Chromosomal translocation; DNA damage; Biology; Programmed cell death; Biochemistry; Chemistry; Polymerase; Apoptosis; DNA; Pharmacology; Enzyme","score_opus":0.06958642996495426,"score_gpt":0.3903616640927807,"score_spread":0.3207752341278265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164484186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829266,0.0000094986335,0.0006181023,0.006001324,0.0002262583,0.000098142984,0.000021323433,0.000027526246,0.0100712115],"genre_scores_gemma":[0.9962521,0.000016709795,0.00037711696,0.0019323396,0.00025362594,0.000028628992,0.00015685617,0.000015700336,0.0009669239],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989371,0.000020268162,0.0003051421,0.00026299592,0.0003576785,0.000116857555],"domain_scores_gemma":[0.9992841,0.00007030119,0.000093504415,0.00021274963,0.00027044717,0.00006893721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048737184,0.00009814699,0.00014459257,0.00009515138,0.000015468942,0.0000122210995,0.00009722024,0.00006526127,0.0007412066],"category_scores_gemma":[0.00034264254,0.00011619726,0.000061416096,0.00026365902,0.00002410875,0.000086454806,0.00003874976,0.00017097597,0.000017934608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016679411,0.00014796399,0.025436327,0.000030181307,0.000012539792,0.00002296089,0.0000876674,0.00057526794,0.97183424,0.00009805125,0.0009096195,0.00067838246],"study_design_scores_gemma":[0.001108925,0.000032944714,0.10166173,0.00011500815,0.0000058337337,0.000059700407,0.000022200316,0.0004047642,0.8920264,0.00008519965,0.0044040196,0.00007323287],"about_ca_topic_score_codex":0.0000075308685,"about_ca_topic_score_gemma":0.0000033313236,"teacher_disagreement_score":0.079807796,"about_ca_system_score_codex":0.00012987245,"about_ca_system_score_gemma":0.00015027825,"threshold_uncertainty_score":0.8115692},"labels":[],"label_agreement":null},{"id":"W3164882245","doi":"10.1101/2021.05.24.445484","title":"Cancer Prognosis According to Parthanatos Features","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cytarabine; Idarubicin; PARP1; Cancer; Myeloid leukemia; Chemotherapy; Cancer research; Poly ADP ribose polymerase; Leukemia; Anthracycline; Myeloid; Oncology; Medicine; Internal medicine; Biology; Polymerase; Breast cancer; DNA","score_opus":0.02539775392952386,"score_gpt":0.288730299241264,"score_spread":0.2633325453117401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164882245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98154896,0.007866069,0.00058670255,0.0040989155,0.0028340314,0.0020030905,0.00030112377,0.000717836,0.000043265674],"genre_scores_gemma":[0.98314667,0.0013609106,0.006710001,0.0039256047,0.0018411637,0.0027372274,0.0000010641343,0.0002512865,0.000026076395],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961117,0.0001273929,0.0006352569,0.0015308623,0.00077929295,0.000815527],"domain_scores_gemma":[0.996257,0.00006318581,0.00035682393,0.0015350002,0.0010627994,0.0007251946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040163673,0.00074273587,0.0010856757,0.0004410366,0.0001786711,0.00032214544,0.00042109858,0.0006962204,0.00037193537],"category_scores_gemma":[0.00024069905,0.0007980123,0.0003529315,0.0010051917,0.000094781826,0.00014597901,0.0005023086,0.0012902133,0.00006858717],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020625557,0.00030930986,0.09061774,0.001167871,0.0008799462,0.00037024627,0.000056984525,0.00012824625,0.89980274,0.00013076137,0.0062994943,0.000030415242],"study_design_scores_gemma":[0.0011541512,0.000090895235,0.13833699,0.0040523335,0.00036397483,1.0945245e-7,0.000026110598,0.00003266113,0.84029853,7.028984e-7,0.014670591,0.0009729306],"about_ca_topic_score_codex":0.00019751674,"about_ca_topic_score_gemma":0.000015184065,"teacher_disagreement_score":0.05950417,"about_ca_system_score_codex":0.00093655474,"about_ca_system_score_gemma":0.0019366307,"threshold_uncertainty_score":0.99944705},"labels":[],"label_agreement":null},{"id":"W3167506735","doi":"10.1158/1557-3265.ovcasymp18-nt-118","title":"Abstract NT-118: SEQUENTIAL THERAPEUTIC TARGETING OF OVARIAN CANCER HARBORING DYSFUNCTIONAL BRCA1","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Ovarian cancer; Olaparib; Chemotherapy; Medicine; Cancer research; Cisplatin; Paclitaxel; Debulking; Cancer; Oncology; PARP inhibitor; Carboplatin; Doxorubicin; Internal medicine; Biology; Poly ADP ribose polymerase","score_opus":0.2990487219853393,"score_gpt":0.5437371260757348,"score_spread":0.24468840409039544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167506735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766812,0.0053667803,0.00007739773,0.0053582983,0.0027125082,0.0009875125,0.00008440554,0.000064808744,0.0086671],"genre_scores_gemma":[0.9913685,0.0025875983,0.00019997996,0.00084251905,0.0028689946,0.0002488876,0.00003180334,0.00006357638,0.0017881739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568903,0.0003169986,0.0010600114,0.0007028237,0.0015126806,0.00071847416],"domain_scores_gemma":[0.9969362,0.0009843073,0.0002456065,0.0005680796,0.00094287266,0.00032295616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038566464,0.00020371561,0.0006201316,0.0002261759,0.00014239701,0.000037458976,0.00029725724,0.00028180014,0.034664437],"category_scores_gemma":[0.00027124718,0.00018007586,0.00031790687,0.0005955502,0.0005056408,0.00015665121,0.00011502965,0.0016777868,0.00025476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007676911,0.0008620077,0.6572781,0.0010448729,0.001100706,0.00005289901,0.0003090564,0.00045459488,0.25500476,0.0016761288,0.021098765,0.053441197],"study_design_scores_gemma":[0.0144944,0.0012228016,0.7785622,0.0018341289,0.00013286846,0.000011410851,0.000295423,0.0007897843,0.048471406,0.0016252619,0.15198101,0.00057931687],"about_ca_topic_score_codex":0.0014384689,"about_ca_topic_score_gemma":0.00006178303,"teacher_disagreement_score":0.20653336,"about_ca_system_score_codex":0.0005550015,"about_ca_system_score_gemma":0.0019918876,"threshold_uncertainty_score":0.966218},"labels":[],"label_agreement":null},{"id":"W3169161004","doi":"10.1200/jco.2021.39.15_suppl.586","title":"Impact of different sequencing strategies of talazoparib and carboplatin combination upon efficacy and toxicity in BRCA-wild type and BRCA-mutant triple-negative breast cancer models.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"Pfizer Canada","keywords":"Carboplatin; Medicine; PARP inhibitor; Olaparib; BRCA mutation; Concomitant; Cancer; Combination therapy; Population; Internal medicine; Ovarian cancer; Oncology; Breast cancer; Triple-negative breast cancer; Veliparib; Pharmacology; Cancer research; Chemotherapy; Biology; Poly ADP ribose polymerase; Cisplatin","score_opus":0.1231611615651621,"score_gpt":0.4682478282487527,"score_spread":0.3450866666835906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169161004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969474,0.001105,0.00006987067,0.0012288678,0.00020038986,0.00017062445,0.000026600155,0.000002667915,0.00024854814],"genre_scores_gemma":[0.99552524,0.0040064277,0.00025041177,0.00009176055,0.00010616574,0.0000018195493,0.000002063497,0.00000927045,0.000006850081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763685,0.00038857124,0.0014424942,0.00017077864,0.00022601834,0.00013526878],"domain_scores_gemma":[0.9964455,0.0014413358,0.0012085796,0.000090052185,0.0006449532,0.00016959163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009108433,0.00012941603,0.0012745117,0.00012039563,0.000019117197,0.00000890712,0.000039132472,0.00022372541,0.000043077518],"category_scores_gemma":[0.0007292599,0.00009437681,0.00010354307,0.0001890916,0.0002572428,0.00016990262,0.00003589933,0.00054829987,4.2002235e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027625829,0.00443751,0.5825407,0.0004780351,0.0016650301,0.00047112015,0.0043004397,0.0029472697,0.29187727,0.0021475232,0.00013074989,0.08137851],"study_design_scores_gemma":[0.019320259,0.0063966447,0.957924,0.00061639625,0.00017498662,0.0005096677,0.00056097336,0.0041338108,0.006014475,0.004256446,0.000003620067,0.000088697154],"about_ca_topic_score_codex":0.00031490528,"about_ca_topic_score_gemma":0.00038228638,"teacher_disagreement_score":0.37538332,"about_ca_system_score_codex":0.00032509217,"about_ca_system_score_gemma":0.0021198974,"threshold_uncertainty_score":0.38485745},"labels":[],"label_agreement":null},{"id":"W3169492982","doi":"10.1200/jco.2021.39.15_suppl.5517","title":"Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Oncology; BRCA mutation; Hazard ratio; Cisplatin; Chemotherapy; Clinical endpoint; Progression-free survival; Confidence interval; Gastroenterology; Randomized controlled trial; Ovarian cancer; Cancer","score_opus":0.09322569958094554,"score_gpt":0.500486568795579,"score_spread":0.40726086921463345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169492982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376637,0.00043384382,0.0006699131,0.002316033,0.0007831708,0.0015472696,0.00002725518,0.0000046616437,0.0004514701],"genre_scores_gemma":[0.99756014,0.00036784165,0.001127127,0.00049833104,0.00030219698,0.00006379842,0.000023248194,0.00001845973,0.000038828504],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920051,0.0037728215,0.0032179365,0.00029632906,0.00047712645,0.00023067354],"domain_scores_gemma":[0.96647274,0.029593302,0.002765873,0.00041836625,0.0006020982,0.00014761619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0113487765,0.00023255523,0.004890972,0.0003008327,0.00003836983,0.0000063657913,0.00011854271,0.0002910267,0.000112467686],"category_scores_gemma":[0.0051778853,0.0001393056,0.0019207996,0.00077667896,0.00032239975,0.000071693175,0.000015736729,0.0005574169,8.531962e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9036213,0.011709564,0.03618085,0.00003942541,0.010546708,0.0012694934,0.0020247616,0.00050227385,0.0024623354,0.00008447478,0.00008198163,0.031476792],"study_design_scores_gemma":[0.8817035,0.07175176,0.025223665,0.00006249996,0.010067611,0.00014482805,0.0011765972,0.00096238026,0.008055746,0.00013020086,0.000606461,0.00011475782],"about_ca_topic_score_codex":0.00013395475,"about_ca_topic_score_gemma":0.00037010343,"teacher_disagreement_score":0.060042195,"about_ca_system_score_codex":0.00032013826,"about_ca_system_score_gemma":0.0013441674,"threshold_uncertainty_score":0.61987865},"labels":[],"label_agreement":null},{"id":"W3170209696","doi":"10.1136/ijgc-2020-002240","title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Takeda Oncology; Janssen Research and Development; EMD Serono; Genentech; Shire; Astellas Pharma; Eisai; University College London; Syndax Pharmaceuticals; Mersana Therapeutics; National Institute for Health and Care Research; Clovis Oncology; U.S. Department of Defense; National Comprehensive Cancer Network; Ovarian Cancer Research Fund; Gateway Foundation; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Amgen; American Association for Cancer Research; National Ovarian Cancer Coalition; National Institutes of Health; Regeneron Pharmaceuticals; Ipsen; Array BioPharma; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; PharmaMar; Yale University; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Sanofi; GlaxoSmithKline; Bristol-Myers Squibb; NuCana; Incyte; Pfizer; Ovarian Cancer Research Fund Alliance; Stand Up To Cancer; Entertainment Industry Foundation","keywords":"Medicine; Internal medicine; Progression-free survival; Population; Oncology; Placebo; Randomized controlled trial; Confidence interval; PARP inhibitor; Gastroenterology; Surgery; Chemotherapy; Poly ADP ribose polymerase; Pathology; Polymerase","score_opus":0.035228706060634864,"score_gpt":0.3851610700811711,"score_spread":0.34993236402053624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170209696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643179,0.0062893573,0.00041627168,0.025437495,0.0014270528,0.0019656143,0.00003757601,0.0000040144882,0.000104673905],"genre_scores_gemma":[0.9937606,0.0037030103,0.00035383023,0.0012351086,0.0004990573,0.00038737044,0.0000057208067,0.000007826522,0.0000475008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99819756,0.00039696938,0.00066716335,0.00017946181,0.00041697858,0.00014188098],"domain_scores_gemma":[0.9936031,0.0053283926,0.0004921167,0.00014636976,0.00037246005,0.00005755421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000991204,0.00015386549,0.00062681385,0.00006985356,0.000063747146,0.000036513484,0.0002103149,0.00007323529,0.00009682264],"category_scores_gemma":[0.002199664,0.00006668288,0.00022824731,0.00007482223,0.00029748946,0.000049988448,0.0000414247,0.00024460827,1.1277712e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8659853,0.0017672796,0.00037907518,0.000034454697,0.0006232174,0.00015453383,0.001880208,0.000005068556,0.00059683126,0.0025427719,0.00053701404,0.12549426],"study_design_scores_gemma":[0.9657434,0.00882454,0.0129975425,0.00073357817,0.00023748558,0.00016646633,0.00028139944,0.00010772829,0.0023150898,0.0026405693,0.005858679,0.00009348225],"about_ca_topic_score_codex":0.000016949058,"about_ca_topic_score_gemma":0.000040345607,"teacher_disagreement_score":0.12540077,"about_ca_system_score_codex":0.000268314,"about_ca_system_score_gemma":0.00025520395,"threshold_uncertainty_score":0.27192488},"labels":[],"label_agreement":null},{"id":"W3170461786","doi":"10.1093/toxsci/kfab075","title":"2,3,7,8-Tetrachlorodibenzo-<i>p</i>-Dioxin (TCDD)-Inducible Poly-ADP-Ribose Polymerase (TIPARP/PARP7) Catalytic Mutant Mice (<i>TiparpH532A</i>) Exhibit Increased Sensitivity to TCDD-Induced Hepatotoxicity and Lethality","year":2021,"lang":"en","type":"article","venue":"Toxicological Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Aryl hydrocarbon receptor; Biology; Mutant; CYP1B1; Chemistry; Molecular biology; Gene; Biochemistry; Enzyme; Cytochrome P450; Transcription factor","score_opus":0.06247968317217434,"score_gpt":0.3332812802719636,"score_spread":0.27080159709978924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170461786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802351,0.00089795934,0.000273722,0.011844664,0.00049610256,0.0010767767,0.00018093728,0.0003349273,0.004659825],"genre_scores_gemma":[0.9839599,0.00008731912,0.0019360753,0.013001204,0.00056746305,0.0001230843,0.000028529248,0.000034833713,0.0002615839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9929851,0.0009942364,0.0009504942,0.0021715187,0.0014328449,0.0014657754],"domain_scores_gemma":[0.99564993,0.0012806423,0.00030188097,0.00086416083,0.00031286597,0.0015904956],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033692673,0.0006808819,0.0012568231,0.00027302984,0.0008724151,0.00027235434,0.00035351768,0.00048516408,0.0009285915],"category_scores_gemma":[0.0022322591,0.0005612465,0.0002893949,0.002240322,0.0011300982,0.00047163732,0.00044566888,0.0008411866,0.00017577274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048562489,0.0011768684,0.0120896185,0.00006242343,0.00005896613,0.0012674193,0.00031037346,0.000011688908,0.9791957,0.0004722804,0.0005664532,0.004302564],"study_design_scores_gemma":[0.0022033453,0.0012864578,0.053398725,0.00018025508,0.00010359858,0.0013395121,0.000495389,0.00045507858,0.93795365,0.00063169096,0.001196775,0.0007555216],"about_ca_topic_score_codex":0.001469283,"about_ca_topic_score_gemma":0.00065132417,"teacher_disagreement_score":0.041309107,"about_ca_system_score_codex":0.00049237575,"about_ca_system_score_gemma":0.0010546884,"threshold_uncertainty_score":0.9999847},"labels":[],"label_agreement":null},{"id":"W3170977860","doi":"10.1200/jco.2021.39.15_suppl.5515","title":"Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Manitoba; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Internal medicine; BRCA mutation; Clinical endpoint; Oncology; Tolerability; Ovarian cancer; Discontinuation; Gastroenterology; Cancer; Clinical trial; Adverse effect","score_opus":0.06458866069387688,"score_gpt":0.4171793893224604,"score_spread":0.35259072862858354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170977860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98640287,0.00040564203,0.0000746126,0.010150612,0.0011656131,0.0006731899,0.00020623131,0.000010859715,0.00091034477],"genre_scores_gemma":[0.99639016,0.0010455726,0.00055400224,0.0012928774,0.00033368787,0.000024207333,0.00014579645,0.00002282372,0.0001908479],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948691,0.001586982,0.0022294596,0.00045441347,0.0005602483,0.00029981154],"domain_scores_gemma":[0.9932949,0.0033633828,0.0019658604,0.00025969045,0.00087965495,0.00023652562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018747529,0.00023082268,0.0011647348,0.00009869351,0.00015066807,0.00002447431,0.00008707195,0.00029828827,0.00009301269],"category_scores_gemma":[0.0020089713,0.00014685016,0.00014356768,0.00026201995,0.00016606203,0.00019042459,0.000039144616,0.0008222396,0.0000026518985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1445242,0.066986196,0.37148538,0.000018227815,0.0020703226,0.0034415901,0.022633417,0.0002874973,0.0009924052,0.00012942935,0.00881892,0.3786124],"study_design_scores_gemma":[0.25743082,0.08890727,0.6409263,0.00026407957,0.00061212067,0.000095876065,0.0023369032,0.00019031786,0.00069775706,0.00046094638,0.007837213,0.0002403823],"about_ca_topic_score_codex":0.0008925645,"about_ca_topic_score_gemma":0.0021265063,"teacher_disagreement_score":0.378372,"about_ca_system_score_codex":0.0010856274,"about_ca_system_score_gemma":0.0018527218,"threshold_uncertainty_score":0.59883755},"labels":[],"label_agreement":null},{"id":"W3171070684","doi":"10.1200/jco.2021.39.15_suppl.9024","title":"A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Institutes of Health","keywords":"Medicine; Internal medicine; Oncology; Cohort; Lung cancer; Cancer; Interim analysis; Stage (stratigraphy); PARP inhibitor; Clinical trial; Genetics; Poly ADP ribose polymerase","score_opus":0.058909348607396515,"score_gpt":0.4388653226790993,"score_spread":0.3799559740717028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171070684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632335,0.0005500034,0.000033211396,0.00077403773,0.00095159025,0.0012289315,0.000034855067,0.0000076647875,0.00009638041],"genre_scores_gemma":[0.9974474,0.00040850596,0.00046907697,0.0009018741,0.00038084935,0.00003651256,0.0000081261705,0.0000392987,0.00030839755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505186,0.0007313166,0.0029842986,0.00040182087,0.00049981236,0.00033087464],"domain_scores_gemma":[0.9951295,0.0009753709,0.0022828223,0.00032109485,0.00091800245,0.00037317508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016753762,0.0002499571,0.0021580774,0.00022668493,0.00006116993,0.0000101319365,0.00017594283,0.00026476185,0.00048345342],"category_scores_gemma":[0.00031673422,0.00017756912,0.0001626799,0.0003435807,0.00016590119,0.00010600479,0.00011562648,0.001190412,0.0000017318406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04178005,0.065152496,0.87972426,0.00013408948,0.0009896812,0.0022143668,0.0025193915,0.00017305334,0.001098934,0.0000012299475,0.0010941997,0.0051182625],"study_design_scores_gemma":[0.21973146,0.13103816,0.6439323,0.00031079576,0.00090379734,0.000031392807,0.0016415374,0.00019148667,0.00075408816,0.0000069271,0.0012533137,0.0002047676],"about_ca_topic_score_codex":0.0002670294,"about_ca_topic_score_gemma":0.0015180416,"teacher_disagreement_score":0.23579197,"about_ca_system_score_codex":0.00047447393,"about_ca_system_score_gemma":0.0033167782,"threshold_uncertainty_score":0.72410583},"labels":[],"label_agreement":null},{"id":"W3171679244","doi":"10.1158/1078-0432.ccr-21-0748","title":"Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g <i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)","year":2021,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Carboplatin; Veliparib; Medicine; Paclitaxel; BRCA mutation; Oncology; Breast cancer; Internal medicine; Cancer; Chemotherapy; Cisplatin; Genetics; Biology; DNA","score_opus":0.14512049466977472,"score_gpt":0.5106776394598908,"score_spread":0.36555714479011603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171679244","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.110548355,0.03736978,0.001026561,0.80038184,0.004351501,0.015556552,0.029965144,0.00021439478,0.0005858853],"genre_scores_gemma":[0.09826736,0.07060445,0.024772817,0.6678613,0.04114138,0.0682902,0.0051449044,0.0018766338,0.022040972],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.992355,0.00057284674,0.0019781978,0.001983603,0.0018400257,0.0012703254],"domain_scores_gemma":[0.9880903,0.006326867,0.0008782112,0.0015516994,0.0027751569,0.0003777915],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018932301,0.00070969976,0.0018939155,0.00036760242,0.0003690028,0.00010682782,0.0006076981,0.0016760437,0.0004984306],"category_scores_gemma":[0.0017004055,0.0006360888,0.00082675874,0.0006489152,0.00144524,0.00023351988,0.00026973398,0.0041716597,0.000005550939],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040733274,0.00045991462,0.0025648805,0.004071218,0.0006106929,0.00008027786,0.0003200464,0.00003537323,0.002600848,0.00003411929,0.87192327,0.07656607],"study_design_scores_gemma":[0.033185966,0.004481231,0.004516601,0.014316314,0.00037240167,0.00004182284,0.00015307066,0.00030146525,0.008162313,0.0022161915,0.9312529,0.0009997323],"about_ca_topic_score_codex":0.00023690473,"about_ca_topic_score_gemma":0.00017418338,"teacher_disagreement_score":0.13252056,"about_ca_system_score_codex":0.00096164044,"about_ca_system_score_gemma":0.0020360597,"threshold_uncertainty_score":0.99961996},"labels":[],"label_agreement":null},{"id":"W3172184696","doi":"10.1200/jco.2021.39.15_suppl.5537","title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical trial; Pathology; Genetics; Gene; Poly ADP ribose polymerase; Alternative medicine; Polymerase","score_opus":0.10476870770512772,"score_gpt":0.45278381508441456,"score_spread":0.34801510737928687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172184696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825362,0.00058223796,0.0036853561,0.010255822,0.0022059693,0.00028461815,0.0003712868,0.0000053046992,0.000073187184],"genre_scores_gemma":[0.96924704,0.0058337646,0.017670514,0.0050276993,0.0019319968,0.00002976579,0.000086012646,0.000027561677,0.00014561538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571615,0.00030037193,0.0031023733,0.0003237526,0.00032802342,0.00022930051],"domain_scores_gemma":[0.9936577,0.0022194772,0.0022454574,0.00023099658,0.0012598591,0.00038651028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008607099,0.00018517727,0.00201908,0.000057345584,0.00004041792,0.000009530554,0.00010233426,0.00047300835,0.0003370495],"category_scores_gemma":[0.0017045471,0.0001450999,0.00056884164,0.00007912832,0.00039713635,0.00006738919,0.00003883103,0.0004940182,0.0000020304822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013213284,0.005950852,0.68105984,0.000053200587,0.002267738,0.00035147843,0.00014925878,0.000011807856,0.003735172,0.0018260699,0.0027583411,0.28862295],"study_design_scores_gemma":[0.032257434,0.00809799,0.9199454,0.00030829274,0.00066098425,0.000036409125,0.000030944797,0.0000602987,0.0017822257,0.0047317566,0.031957835,0.00013041147],"about_ca_topic_score_codex":0.000056066387,"about_ca_topic_score_gemma":0.000048170474,"teacher_disagreement_score":0.28849253,"about_ca_system_score_codex":0.00022900656,"about_ca_system_score_gemma":0.0018117514,"threshold_uncertainty_score":0.5917002},"labels":[],"label_agreement":null},{"id":"W3172653524","doi":"10.1200/jco.2021.39.15_suppl.5044","title":"CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; PARP inhibitor; Nivolumab; Cohort; Clinical endpoint; Docetaxel; Taxane; Cancer; Clinical trial; Immunotherapy; Poly ADP ribose polymerase; Breast cancer; Androgen receptor","score_opus":0.15264023800292983,"score_gpt":0.502956627245222,"score_spread":0.35031638924229225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172653524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96050483,0.0035193062,0.00206001,0.030738238,0.0015469916,0.0007513831,0.00017868384,0.000025314457,0.0006752255],"genre_scores_gemma":[0.95550966,0.004443545,0.023244236,0.011630377,0.0016552745,0.00014175697,0.00009273834,0.00006573775,0.003216674],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99423414,0.00054954377,0.0036481188,0.00044837687,0.00067174673,0.0004480987],"domain_scores_gemma":[0.99213076,0.0015984882,0.0027933044,0.00038441218,0.0026078431,0.00048517413],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035161516,0.0002793765,0.0026416737,0.00026972103,0.000114145296,0.000040210223,0.00019320784,0.00020290303,0.0016692209],"category_scores_gemma":[0.0015301168,0.00022631552,0.0014987498,0.00063859747,0.00027400136,0.00019475594,0.000023995874,0.0008799646,0.000012269719],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1318,0.016139515,0.275947,0.0010931413,0.08645225,0.011876108,0.0018610165,0.0041753286,0.08736579,0.0020846257,0.07435156,0.30685365],"study_design_scores_gemma":[0.083853155,0.022817114,0.49761963,0.0006320387,0.021517785,0.002536823,0.0012944692,0.002283806,0.013442047,0.003056266,0.35006204,0.00088481087],"about_ca_topic_score_codex":0.00011311442,"about_ca_topic_score_gemma":0.0006890283,"teacher_disagreement_score":0.30596885,"about_ca_system_score_codex":0.000548504,"about_ca_system_score_gemma":0.00745472,"threshold_uncertainty_score":0.9992434},"labels":[],"label_agreement":null},{"id":"W3174414035","doi":"10.1096/fasebj.27.1_supplement.1140.17","title":"Poly ADP‐Ribose polymerase (PARP‐1) and DNA damage in pulmonary arterial hypertension","year":2013,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"NFAT; Poly ADP ribose polymerase; Oxidative stress; DNA damage; Cancer research; DNA repair; Apoptosis; PARP inhibitor; Chemistry; Biology; Pharmacology; Transcription factor; Polymerase; DNA; Endocrinology; Gene; Biochemistry","score_opus":0.021404363987280534,"score_gpt":0.25419718302031646,"score_spread":0.23279281903303592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174414035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855011,0.001974604,0.000035602603,0.01057401,0.00050881255,0.00025444888,0.0000082227425,0.000023360848,0.0011198175],"genre_scores_gemma":[0.99436826,0.00031767855,0.0001584201,0.003176313,0.0014686976,0.000016177239,0.0000069911052,0.000025239982,0.0004622043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987811,0.00013877844,0.00033581903,0.00016682546,0.00027165838,0.00030582168],"domain_scores_gemma":[0.9992403,0.00007537224,0.000120589706,0.0002643577,0.00006695211,0.00023245279],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003221034,0.00015809083,0.00025236572,0.00014070996,0.0001703777,0.00007160967,0.00010725555,0.000074191696,0.0013520317],"category_scores_gemma":[0.00003358614,0.000102131395,0.00006727465,0.0001375569,0.00015247105,0.00023779737,0.00003656044,0.00046758712,0.00009845292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000555339,0.00013161097,0.0026132215,0.000008824307,0.000027847454,0.00041960878,0.0002931095,8.488669e-7,0.9791839,0.000018559918,0.0049635335,0.011783559],"study_design_scores_gemma":[0.0165664,0.00088117115,0.3893764,0.0009488372,0.00016877403,0.028938923,0.0016474553,0.002168511,0.5502127,0.0032955748,0.0051439316,0.0006513466],"about_ca_topic_score_codex":0.000112774556,"about_ca_topic_score_gemma":0.00000558362,"teacher_disagreement_score":0.42897126,"about_ca_system_score_codex":0.00007604324,"about_ca_system_score_gemma":0.00009875804,"threshold_uncertainty_score":0.9995609},"labels":[],"label_agreement":null},{"id":"W3178615988","doi":"10.1093/narcan/zcab028","title":"Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance","year":2021,"lang":"en","type":"article","venue":"NAR Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Stand Up To Cancer; National Institutes of Health; Mayo Foundation for Medical Education and Research; Sierra Oncology; National Institute of General Medical Sciences; National Institute for Health and Care Research; Eisai; BeiGene; National Breast Cancer Foundation; Clovis Oncology; Ovarian Cancer Research Alliance; AstraZeneca","keywords":"Cancer research; Ovarian cancer; PARP inhibitor; Methylation; Biology; Medicine; Cancer; Oncology; Internal medicine; Poly ADP ribose polymerase; Gene; Genetics; Polymerase","score_opus":0.02601494094062143,"score_gpt":0.2916127471130123,"score_spread":0.26559780617239087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178615988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415654,0.0016643739,0.0015969822,0.0012994205,0.0004236015,0.00035652632,0.0002565393,0.000052336814,0.00019368292],"genre_scores_gemma":[0.9896595,0.0014419849,0.0058175274,0.00044537903,0.00030034568,0.0003485645,0.00007985976,0.000050357838,0.0018565212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799585,0.000044006447,0.0006945822,0.00041350038,0.0005600695,0.0002920058],"domain_scores_gemma":[0.998587,0.000018065784,0.00040933868,0.0003719681,0.0004974106,0.000116204435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011500445,0.00021332683,0.00051970454,0.00010663685,0.00008882024,0.000008780167,0.00009940845,0.00013914217,0.00037682208],"category_scores_gemma":[0.000019736486,0.00022031357,0.00009019718,0.0005141348,0.00008263545,0.00013522824,0.00004006698,0.00017871278,0.000002619505],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006181804,0.00015606277,0.0029200122,0.0007211134,0.00013971126,0.000014370697,0.0020162931,0.00043157378,0.99135965,0.0001146585,0.00016340365,0.0013449689],"study_design_scores_gemma":[0.003171698,0.000020915943,0.02160545,0.0016814682,0.00006396578,0.0000056792605,0.00007194465,0.0002194299,0.9707941,0.000057974896,0.0020979145,0.00020949605],"about_ca_topic_score_codex":0.00008080854,"about_ca_topic_score_gemma":0.00029037555,"teacher_disagreement_score":0.020565588,"about_ca_system_score_codex":0.0005559062,"about_ca_system_score_gemma":0.0016708159,"threshold_uncertainty_score":0.89841264},"labels":[],"label_agreement":null},{"id":"W3178688808","doi":"10.1158/1538-7445.am2021-1066","title":"Abstract 1066: Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Carboplatin; Triple-negative breast cancer; PARP inhibitor; Medicine; Breast cancer; Cancer research; Cancer; Combination therapy; Internal medicine; Oncology; Chemotherapy; Poly ADP ribose polymerase; Biology; Cisplatin; DNA","score_opus":0.11768069951727021,"score_gpt":0.4877386973206827,"score_spread":0.3700579978034125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178688808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897021,0.0034758868,0.0000051206634,0.0040122666,0.00031261484,0.0007590446,0.0002050638,0.000019972696,0.0015078989],"genre_scores_gemma":[0.99411756,0.0040649907,0.00007152909,0.00016630141,0.00035063864,0.000445421,0.000024621533,0.000031971213,0.00072694756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971727,0.00036794168,0.00067564484,0.0005244912,0.00083158264,0.00042761743],"domain_scores_gemma":[0.99767214,0.00062755734,0.00015101516,0.0003352199,0.0009900038,0.00022405747],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001468403,0.00015686819,0.0005192787,0.00025917313,0.00007380179,0.000028223218,0.00009823875,0.00019938474,0.0015209314],"category_scores_gemma":[0.00042233468,0.00015246606,0.000082419254,0.0009418925,0.0005352949,0.00014524908,0.00009129322,0.00097309734,0.000006707061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074366364,0.0021760913,0.6212182,0.0014575222,0.00042519352,0.00035186083,0.004432003,0.00007911844,0.26618674,0.0010732859,0.016004156,0.0791592],"study_design_scores_gemma":[0.009805186,0.00023323744,0.87062347,0.0014492505,0.000021764476,0.000031538908,0.00044432178,0.00016147122,0.11530786,0.000857959,0.0009000508,0.00016386465],"about_ca_topic_score_codex":0.004416351,"about_ca_topic_score_gemma":0.0024145832,"teacher_disagreement_score":0.24940531,"about_ca_system_score_codex":0.0007310282,"about_ca_system_score_gemma":0.0018123911,"threshold_uncertainty_score":0.9993918},"labels":[],"label_agreement":null},{"id":"W3181900713","doi":"10.1158/1538-7445.am2021-lb130","title":"Abstract LB130: Combination of IGF-1R targeted alpha therapy with Olaparib results in synergistic efficacy against colorectal and lung cancer xenografts","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"General Fusion (Canada)","funders":"","keywords":"Olaparib; Cancer research; Medicine; PARP inhibitor; Poly ADP ribose polymerase; Cancer; DNA repair; Apoptosis; Targeted therapy; DNA damage; Biology; Polymerase; Internal medicine; DNA","score_opus":0.06077148724054904,"score_gpt":0.4142986896277987,"score_spread":0.35352720238724966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181900713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791386,0.015025989,0.000009281015,0.00269023,0.00018107708,0.0009357742,0.00013722829,0.00003598593,0.0018458392],"genre_scores_gemma":[0.9885222,0.0101616625,0.00006697909,0.00017498186,0.00018724061,0.00037262452,0.00013042615,0.000049490023,0.00033441678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99723834,0.0002244239,0.00048258252,0.0005674996,0.0009416168,0.000545546],"domain_scores_gemma":[0.99775416,0.0005066705,0.00014351419,0.00036039765,0.0010301126,0.00020512678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008564993,0.0002037848,0.00046347096,0.0003650496,0.0001208186,0.00004418476,0.00013257068,0.00014869856,0.00027793783],"category_scores_gemma":[0.00025087714,0.0001766756,0.000054117867,0.0013260324,0.0004709266,0.00012646611,0.000047416517,0.00071480364,0.0000032774756],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01722352,0.0013256944,0.038537163,0.0006804848,0.00047913147,0.00047470455,0.003302975,0.0007088613,0.9059408,0.0002530806,0.0059741805,0.025099441],"study_design_scores_gemma":[0.030581338,0.0008629215,0.35784584,0.002589449,0.000032169995,0.000014372286,0.0004184815,0.0005588736,0.6030962,0.00006235634,0.0035993562,0.00033866163],"about_ca_topic_score_codex":0.0013772651,"about_ca_topic_score_gemma":0.0015062506,"teacher_disagreement_score":0.31930867,"about_ca_system_score_codex":0.00073360075,"about_ca_system_score_gemma":0.0016978917,"threshold_uncertainty_score":0.7204622},"labels":[],"label_agreement":null},{"id":"W3182206294","doi":"10.1016/j.ejca.2021.05.037","title":"Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Veliparib; Medicine; Carboplatin; Internal medicine; Hazard ratio; Oncology; Metastatic breast cancer; Breast cancer; Placebo; Population; Clinical endpoint; Surgery; Cancer; Confidence interval; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.022183947749891336,"score_gpt":0.3362273108954843,"score_spread":0.31404336314559295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182206294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928461,0.005057759,0.00015336758,0.00088414794,0.00024289463,0.00044181096,0.00022711475,0.0000046915948,0.0001421519],"genre_scores_gemma":[0.992937,0.0059945453,0.0004681101,0.00016921967,0.0003312846,0.0000058566643,0.000016964987,0.00003415325,0.00004282496],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966777,0.0005306564,0.0018160105,0.00028385926,0.0005033161,0.00018845756],"domain_scores_gemma":[0.99694043,0.00037863015,0.0013934646,0.00025341837,0.00081860495,0.00021545216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013220792,0.0002019923,0.0014058086,0.00027395785,0.000032445907,0.000010139267,0.00008700345,0.000047351612,0.00022539862],"category_scores_gemma":[0.00023872622,0.00015399134,0.00023792921,0.0006885811,0.00022699514,0.00010562867,0.000037113183,0.00036330995,1.4429557e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48877147,0.0007398471,0.45364606,0.000115312585,0.0022875115,0.00008359173,0.000451262,0.0016786484,0.00040871213,0.0000027346732,0.000053404343,0.051761463],"study_design_scores_gemma":[0.35785234,0.0013448759,0.6376666,0.0007536245,0.0013822328,0.000012448583,0.00003487204,0.000111631576,0.00019302989,0.0000015330274,0.00054082647,0.000105998035],"about_ca_topic_score_codex":0.000054015123,"about_ca_topic_score_gemma":0.0002434249,"teacher_disagreement_score":0.18402053,"about_ca_system_score_codex":0.000102586826,"about_ca_system_score_gemma":0.0002947613,"threshold_uncertainty_score":0.6279584},"labels":[],"label_agreement":null},{"id":"W3183970717","doi":"10.1111/febs.16142","title":"ADP‐ribosyltransferases, an update on function and nomenclature","year":2021,"lang":"en","type":"article","venue":"FEBS Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute of Cancer Research; Université Laval","funders":"National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; Cancer Research UK; National Institutes of Health; RWTH Aachen University; Deutsche Forschungsgemeinschaft; Wellcome Trust","keywords":"Nomenclature; Function (biology); Computational biology; Chemistry; Biology; Genetics; Zoology; Taxonomy (biology)","score_opus":0.020640992603546824,"score_gpt":0.2970770958095009,"score_spread":0.2764361032059541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183970717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98212576,0.0024105185,0.0031733483,0.0080046505,0.00092554843,0.00009199875,0.000022255834,0.00004460286,0.003201337],"genre_scores_gemma":[0.98788005,0.0014489938,0.000877743,0.0077316607,0.0014372519,0.000003954437,0.000048953247,0.000021851969,0.00054952153],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991876,0.00006444517,0.00017195565,0.00016904216,0.00024464625,0.00016229755],"domain_scores_gemma":[0.9994202,0.00001775361,0.000043020715,0.00015283443,0.0001287621,0.00023741768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015369819,0.0001032104,0.00015534037,0.000077138226,0.00014733124,0.000062819236,0.000028774459,0.00008079155,0.0020035917],"category_scores_gemma":[0.000015693044,0.000087557935,0.000055840013,0.00012172108,0.000030145284,0.00016162815,0.000004945268,0.0005143538,0.000034622844],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009660987,0.0018465319,0.037805475,0.00020497521,0.00092726777,0.003562945,0.0015853557,0.00012644718,0.6761573,0.012381145,0.10180309,0.1539385],"study_design_scores_gemma":[0.019475037,0.004910478,0.24560173,0.0010025982,0.0003943778,0.020620227,0.0005719843,0.00014580047,0.08276809,0.02476218,0.5990562,0.000691317],"about_ca_topic_score_codex":0.0000010949149,"about_ca_topic_score_gemma":0.00000410105,"teacher_disagreement_score":0.5933892,"about_ca_system_score_codex":0.00007818016,"about_ca_system_score_gemma":0.00014045545,"threshold_uncertainty_score":0.9989087},"labels":[],"label_agreement":null},{"id":"W3184513615","doi":"10.3390/biom11071044","title":"Enzymatic and Chemical Syntheses of Vacor Analogs of Nicotinamide Riboside, NMN and NAD","year":2021,"lang":"en","type":"article","venue":"Biomolecules","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norges Forskningsråd; European Commission; Ministère de l'Économie, de la Science et de l'Innovation - Québec","keywords":"NAD+ kinase; Nicotinamide mononucleotide; Nicotinamide adenine dinucleotide; Riboside; Nicotinamide phosphoribosyltransferase; Nicotinamide; Chemistry; Biochemistry; Enzyme; Nucleotide salvage; Moiety; Niacinamide; Glycerol-3-phosphate dehydrogenase; Cofactor; Stereochemistry; Nucleotide","score_opus":0.017564449982520876,"score_gpt":0.28116106842009936,"score_spread":0.2635966184375785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184513615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99171245,0.0060631214,0.00028781506,0.0007514601,0.000027119531,0.00009117406,0.000032371427,0.000013551277,0.001020908],"genre_scores_gemma":[0.99649024,0.00045235598,0.0027814892,0.0001712826,0.000024252975,0.000006362449,0.000007968908,0.000010832325,0.000055199496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99932307,0.00003387439,0.000238684,0.00016363927,0.00014087939,0.00009987072],"domain_scores_gemma":[0.9994098,0.00016163269,0.00009068548,0.00016894446,0.00009982387,0.000069133835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007587457,0.00008648341,0.00027963024,0.00005700971,0.00001295599,0.0000049924615,0.000030477113,0.00005594558,0.00006852943],"category_scores_gemma":[0.00024588176,0.00007729398,0.000043189968,0.00013362204,0.000295459,0.000022693504,0.000035763693,0.000044631306,0.0000010746032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066102926,0.00008476848,0.0034895262,0.00039055126,0.000066789995,0.00002193919,0.00012789249,8.09507e-8,0.9912316,0.0010936926,0.00024219409,0.0031848608],"study_design_scores_gemma":[0.00067099044,0.000089645735,0.0064301076,0.0005216598,0.0000650051,0.00014317218,0.00017919973,0.000040224637,0.9910225,0.00047539806,0.00029263453,0.000069412425],"about_ca_topic_score_codex":0.00003637873,"about_ca_topic_score_gemma":0.0000059696185,"teacher_disagreement_score":0.0056107654,"about_ca_system_score_codex":0.000014803784,"about_ca_system_score_gemma":0.00006731221,"threshold_uncertainty_score":0.3151957},"labels":[],"label_agreement":null},{"id":"W3184815468","doi":"10.1016/j.ejca.2021.06.024","title":"Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Oncology; Nomogram; Ovarian cancer; Internal medicine; Chemotherapy; Progression-free survival; Complete response; BRCA mutation; Cancer; Poly ADP ribose polymerase; Biology; Gene","score_opus":0.020710705882438084,"score_gpt":0.3215840565726184,"score_spread":0.30087335069018034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184815468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861818,0.0011754491,0.0011929204,0.009311519,0.000694873,0.0010903736,0.00008560317,0.000017452081,0.00025003875],"genre_scores_gemma":[0.9919488,0.0003143224,0.004937422,0.0020944553,0.00035727693,0.00009984364,0.000011541461,0.000086580156,0.00014979845],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978243,0.0004376908,0.0005270367,0.000322808,0.00057206914,0.00031606128],"domain_scores_gemma":[0.9980014,0.0003257197,0.00036342192,0.0002430526,0.00084464153,0.00022179332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009497788,0.00023332187,0.00043682646,0.00019444713,0.00009976423,0.00005162229,0.00011535439,0.000032775508,0.00005064182],"category_scores_gemma":[0.00043429135,0.00017425224,0.00012188988,0.00040224026,0.000065926164,0.00011272322,0.000021669919,0.00031954123,0.0000012654787],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12408679,0.0013641312,0.2850636,0.00008213854,0.00095578743,0.00090967503,0.008200036,0.00071595126,0.006126827,0.00005019723,0.00234666,0.5700982],"study_design_scores_gemma":[0.03823312,0.0052309907,0.9315194,0.0043060733,0.00007942534,0.000028458247,0.00031295928,0.00005210659,0.0036792564,0.00004102009,0.016214708,0.000302473],"about_ca_topic_score_codex":0.000006294884,"about_ca_topic_score_gemma":0.000052467247,"teacher_disagreement_score":0.6464558,"about_ca_system_score_codex":0.00032742327,"about_ca_system_score_gemma":0.00047746542,"threshold_uncertainty_score":0.71058},"labels":[],"label_agreement":null},{"id":"W3184904659","doi":"10.1158/0008-5472.can-21-0774","title":"Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Cancer Council Tasmania; Cancer Council Victoria; Cancer Council South Australia; Victorian Cancer Agency; Entertainment Industry Foundation; Stand Up To Cancer; Medical Research Council; Peter MacCallum Foundation; AstraZeneca Australia; Medical Research and Materiel Command; Eisai; Ovarian Cancer Research Fund; Cancer Australia; National Cancer Institute; Australian Cancer Research Foundation; Mayo Foundation for Medical Education and Research; State Government of Victoria; Australian Government; Cancer Council NSW; Ovarian Cancer Australia; National Breast Cancer Foundation; Clovis Oncology; Sierra Oncology; National Ovarian Cancer Coalition; American Association for Cancer Research; National Health and Medical Research Council; Cancer Research Institute; AstraZeneca; Ovarian Cancer Research Fund Alliance; National Institutes of Health","keywords":"Serous fluid; PARP inhibitor; Ovarian carcinoma; Methylation; Cancer research; Medicine; Ovarian cancer; Oncology; Internal medicine; Biology; Poly ADP ribose polymerase; Cancer; Gene; Genetics; Polymerase","score_opus":0.09252431265740614,"score_gpt":0.4020122372412097,"score_spread":0.3094879245838036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184904659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97018266,0.007583152,0.00007068926,0.019248309,0.0005039541,0.00096460595,0.00009059058,0.00008546796,0.0012705481],"genre_scores_gemma":[0.99021447,0.0009255889,0.0008723296,0.00076247606,0.0011084041,0.00080515095,0.00009037954,0.0000848488,0.0051363776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99568886,0.00068033545,0.0005502816,0.0008629998,0.0013131355,0.0009043979],"domain_scores_gemma":[0.997651,0.00025347588,0.000096434764,0.00085247454,0.0008465987,0.00030002365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011067792,0.00025485066,0.0005084376,0.00039027093,0.00020289242,0.00009215384,0.00020839449,0.0002418644,0.0008556135],"category_scores_gemma":[0.0002411217,0.00025509368,0.00009948566,0.0019119773,0.00033625614,0.00025583326,0.00011682785,0.0006911419,0.00006959417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002371279,0.000587249,0.058548387,0.00085993053,0.0001463013,0.002440632,0.0031973268,0.000035310783,0.90854913,0.0021196527,0.019141547,0.0020032784],"study_design_scores_gemma":[0.0072520175,0.00019122007,0.08660529,0.0010179234,0.000031458443,0.00005981634,0.0003059607,0.000020847794,0.8572535,0.0035578883,0.043328863,0.00037524497],"about_ca_topic_score_codex":0.0009868202,"about_ca_topic_score_gemma":0.0030219483,"teacher_disagreement_score":0.05129563,"about_ca_system_score_codex":0.0016159557,"about_ca_system_score_gemma":0.0017709775,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W3185711966","doi":"10.3389/fimmu.2021.712556","title":"The Critical Role of PARPs in Regulating Innate Immune Responses","year":2021,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Natural Science Foundation of Jiangxi Province; National Natural Science Foundation of China","keywords":"Innate immune system; Immune system; Immunology; Biology; Medicine","score_opus":0.030906135438289094,"score_gpt":0.36340028276839276,"score_spread":0.3324941473301037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185711966","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001947257,0.996216,0.000061517785,0.00041456553,0.0017185054,0.00053160684,0.000020685926,0.000021457052,0.0008209089],"genre_scores_gemma":[0.00026636303,0.99665576,0.0021156962,0.000039132385,0.00008506125,0.00027384103,0.000050763258,0.00005715054,0.00045623173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99608195,0.0013298023,0.0014800085,0.000410458,0.000195396,0.0005023873],"domain_scores_gemma":[0.997396,0.001236176,0.00036741552,0.0008486177,0.00011874654,0.000033043096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010210596,0.00031945997,0.0024861726,0.0005761036,0.00007113089,0.000013412189,0.0003344906,0.0006105857,0.000053330932],"category_scores_gemma":[0.0018446335,0.00025001605,0.0003665012,0.00081555033,0.0008215325,0.000045160323,0.0001450937,0.0012066098,0.000006107374],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044599254,0.00010895331,0.0002549806,0.0016922638,0.00035357467,0.00009890749,0.00027400593,5.8579235e-7,0.00015328337,0.001961784,0.0006624419,0.9939932],"study_design_scores_gemma":[0.0009947541,0.00013552734,0.000204252,0.019698972,0.00014665333,0.00021284666,0.00074414717,0.000011860078,0.00021733827,0.001405396,0.9760169,0.00021137756],"about_ca_topic_score_codex":0.000046529967,"about_ca_topic_score_gemma":0.0000087336675,"teacher_disagreement_score":0.99378186,"about_ca_system_score_codex":0.00050894753,"about_ca_system_score_gemma":0.0008579815,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W3185777435","doi":"10.1158/1078-0432.ccr-21-0310","title":"Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study","year":2021,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; Institute of Cancer Research","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Eisai; Cancer Research UK; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; GlaxoSmithKline; Celgene; Amgen; University of Texas MD Anderson Cancer Center; Pfizer; MacroGenics; Cancer Research Institute","keywords":"Breast cancer; Oncology; Medicine; Germline; Internal medicine; Cancer; Germline mutation; Mutation; Genetics; Biology; Gene","score_opus":0.22352135960730762,"score_gpt":0.525599806114159,"score_spread":0.3020784465068514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185777435","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04881354,0.02720599,0.00017485868,0.9030826,0.0018484278,0.0135896625,0.0038489786,0.00025800357,0.0011779564],"genre_scores_gemma":[0.04480616,0.029451508,0.0009259933,0.7840386,0.04498702,0.042004656,0.002290016,0.0012347562,0.050261308],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9878877,0.0018841837,0.0022125638,0.0028182538,0.0032560509,0.001941266],"domain_scores_gemma":[0.9853313,0.0067263492,0.0007651956,0.0024109685,0.0041521746,0.0006139982],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005018974,0.0010072682,0.0023101293,0.00041183503,0.0009967473,0.0003787512,0.0010268018,0.0012338526,0.004486023],"category_scores_gemma":[0.0009488176,0.0006970374,0.0005820193,0.0015146283,0.0027662287,0.00026744712,0.00041868936,0.00824138,0.00007345202],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006141113,0.0010579642,0.010466132,0.0011641944,0.0020164244,0.0005528374,0.00050496386,0.000047716097,0.00017244973,0.000015719612,0.9532294,0.024631046],"study_design_scores_gemma":[0.019882677,0.0035284746,0.008949834,0.0026150746,0.00093796017,0.00020294932,0.0008449562,0.00008322529,0.00024617312,0.00035911272,0.9613668,0.0009828062],"about_ca_topic_score_codex":0.0011882962,"about_ca_topic_score_gemma":0.0014862415,"teacher_disagreement_score":0.119044,"about_ca_system_score_codex":0.0010108046,"about_ca_system_score_gemma":0.0056110923,"threshold_uncertainty_score":0.99994767},"labels":[],"label_agreement":null},{"id":"W3187741617","doi":"10.1101/gad.348479.121","title":"The <i>trans</i> cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells","year":2021,"lang":"en","type":"article","venue":"Genes & Development","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; National Institutes of Health; Gray Foundation","keywords":"RAD51; Biology; DNA repair; Cell cycle; DNA replication; DNA; Cell biology; DNA damage; Poly ADP ribose polymerase; Homologous recombination; Molecular biology; Cancer research; Cell; Genetics; Polymerase","score_opus":0.011943859212601889,"score_gpt":0.23750331040745526,"score_spread":0.22555945119485338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187741617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97962886,0.009372554,0.0050810496,0.0014158168,0.0014032664,0.00074304704,0.000008973919,0.00009631356,0.0022501256],"genre_scores_gemma":[0.99412775,0.0023039577,0.0019722055,0.0007606092,0.00012422822,0.0001244556,0.000017734812,0.00004065145,0.0005284077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979334,0.000139095,0.0004900694,0.00043242946,0.000542411,0.00046259433],"domain_scores_gemma":[0.9987035,0.00031423147,0.0001541243,0.00042135594,0.0002543213,0.00015249965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035298616,0.0002699683,0.0003819423,0.000058467675,0.00025028744,0.00003045718,0.00014445627,0.00011335875,0.00004996171],"category_scores_gemma":[0.000018366412,0.00019754056,0.00015586213,0.00042481426,0.00011693385,0.000039730843,0.00007437416,0.0002096719,0.000032300883],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107660584,0.0005091208,0.0010484188,0.00051975093,0.00017485442,0.00003433262,0.004285178,0.00015692417,0.9233448,0.000040172086,0.0023580005,0.06742079],"study_design_scores_gemma":[0.001392061,0.00008875032,0.0031699222,0.00015776251,0.000036696518,0.000019269395,0.0003018347,0.000014120498,0.88247615,0.00013701333,0.11201007,0.00019636944],"about_ca_topic_score_codex":0.000011778206,"about_ca_topic_score_gemma":0.000024479194,"teacher_disagreement_score":0.109652065,"about_ca_system_score_codex":0.00031597,"about_ca_system_score_gemma":0.0011566906,"threshold_uncertainty_score":0.805547},"labels":[],"label_agreement":null},{"id":"W3190145293","doi":"10.1016/j.ygyno.2021.07.016","title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","year":2021,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; AstraZeneca","keywords":"Olaparib; Medicine; Tolerability; Adverse effect; Discontinuation; Internal medicine; Neutropenia; Nausea; Vomiting; Placebo; Oncology; Anemia; Ovarian cancer; Surgery; Cancer; Chemotherapy","score_opus":0.01888383592380004,"score_gpt":0.3414188082779412,"score_spread":0.32253497235414114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190145293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904302,0.0003290626,0.00018360383,0.0043789386,0.0003507877,0.003362216,0.000023879475,0.000015516163,0.0009258011],"genre_scores_gemma":[0.9943642,0.00033279264,0.0010744896,0.002239416,0.00004761852,0.0018456314,0.000055578446,0.0000094522775,0.000030846295],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99735916,0.0009977306,0.0007471813,0.00040175582,0.00019679077,0.00029741158],"domain_scores_gemma":[0.9961617,0.0029070403,0.00038222468,0.00025965806,0.00023448792,0.000054865504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013242575,0.00016722549,0.0011415058,0.00009942799,0.000042427473,0.000006980739,0.0000874211,0.0001941986,0.00030657306],"category_scores_gemma":[0.0019201885,0.000106663654,0.000074901356,0.00041785542,0.00039795454,0.00008315196,0.000026941154,0.00032351416,9.103993e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88499534,0.004983613,0.02786956,0.000064566484,0.000099148645,0.00044035382,0.003762201,0.00024345811,0.0004529977,0.00042665916,0.00016781614,0.07649431],"study_design_scores_gemma":[0.91324234,0.0034384232,0.080166794,0.00007857393,0.000077129625,0.000014741084,0.0006648155,0.0001931157,0.00021981035,0.00109192,0.00069995475,0.00011236953],"about_ca_topic_score_codex":0.00026865955,"about_ca_topic_score_gemma":0.003285401,"teacher_disagreement_score":0.07638194,"about_ca_system_score_codex":0.0004799962,"about_ca_system_score_gemma":0.00077630824,"threshold_uncertainty_score":0.43496177},"labels":[],"label_agreement":null},{"id":"W3190815019","doi":"10.1097/coc.0000000000000856","title":"Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy","year":2021,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"FOLFIRINOX; Medicine; Hazard ratio; Internal medicine; Interquartile range; Confidence interval; Oncology; Pancreatic cancer; Progression-free survival; Olaparib; Chemotherapy; Gastroenterology; Surgery; Cancer; Irinotecan","score_opus":0.028545416360479522,"score_gpt":0.3923611423485976,"score_spread":0.36381572598811807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190815019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881647,0.00075599225,0.00044320477,0.009417965,0.0003549701,0.00055223244,0.000023477669,0.000010421668,0.00027701777],"genre_scores_gemma":[0.9891244,0.002631217,0.0024843048,0.005195398,0.00033424204,0.00006183021,0.0000067618926,0.000041935844,0.0001198769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961896,0.00055106246,0.0020211863,0.0003541903,0.0005340143,0.00034996858],"domain_scores_gemma":[0.99258095,0.0031710018,0.0025506276,0.00032534992,0.00085727836,0.0005147818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074706285,0.00022375968,0.0020142612,0.00011621991,0.00003733581,0.000004689709,0.00015887922,0.00009767307,0.0004873905],"category_scores_gemma":[0.0020761893,0.00017246205,0.00029623782,0.00041955337,0.0007465755,0.000098110555,0.00002466834,0.00059123535,0.000004761135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04116133,0.0019543788,0.8192672,0.000053776374,0.0003793744,0.00023896503,0.00011263229,0.00050341146,0.00021775856,0.0000043506197,0.00012037902,0.13598643],"study_design_scores_gemma":[0.033696044,0.020357307,0.93856984,0.0010651499,0.0003687441,0.00003126623,0.000081902945,0.000042002397,0.00035415005,0.000101119695,0.0051547787,0.00017769301],"about_ca_topic_score_codex":0.000048597438,"about_ca_topic_score_gemma":0.00015820921,"teacher_disagreement_score":0.13580874,"about_ca_system_score_codex":0.0004935759,"about_ca_system_score_gemma":0.0024398617,"threshold_uncertainty_score":0.70327985},"labels":[],"label_agreement":null},{"id":"W3194003153","doi":"10.1007/s10555-021-09983-1","title":"Targeting DNA damage repair pathways in pancreas cancer","year":2021,"lang":"en","type":"review","venue":"Cancer and Metastasis Reviews","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"National Cancer Institute","keywords":"Olaparib; PARP inhibitor; Medicine; Pancreatic cancer; DNA repair; Cancer; Cancer research; Synthetic lethality; Veliparib; Internal medicine; Oncology; Biology; Poly ADP ribose polymerase; Polymerase; Genetics","score_opus":0.16125346269232504,"score_gpt":0.4247926491141929,"score_spread":0.26353918642186785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194003153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030508269,0.9948101,0.000017586812,0.00012078024,0.00072539423,0.00276753,0.00053779536,0.000095247604,0.00089507375],"genre_scores_gemma":[0.0000012114765,0.990218,0.0010717021,0.0011160431,0.0010239492,0.0052521955,0.0003950168,0.00014446783,0.0007774152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994964,0.0008020487,0.0020027193,0.0012221012,0.0003660374,0.0006431102],"domain_scores_gemma":[0.9975929,0.00016038163,0.00085619296,0.00087459746,0.00014831066,0.00036756668],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015736367,0.00088867475,0.0065850657,0.00032482937,0.000101852,0.000047724876,0.00019016876,0.00033899417,0.0020634907],"category_scores_gemma":[0.0002878593,0.00066929194,0.0014196883,0.0011494496,0.00012674119,0.0001319857,0.00012362683,0.00091809075,0.000041746716],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012320507,0.000060193208,0.000061158134,0.04502709,0.00039443834,0.00012058567,0.00009722418,3.91491e-7,0.000019742529,0.000061037244,0.022668418,0.9314774],"study_design_scores_gemma":[0.0007361017,0.000035240595,0.000013343588,0.09912686,0.0027634047,0.00005384625,0.000029708117,0.0000026704165,0.000017462962,0.0000072498433,0.89667124,0.0005428949],"about_ca_topic_score_codex":0.00023010533,"about_ca_topic_score_gemma":0.00009223798,"teacher_disagreement_score":0.9309345,"about_ca_system_score_codex":0.00082467886,"about_ca_system_score_gemma":0.0014339571,"threshold_uncertainty_score":0.99957585},"labels":[],"label_agreement":null},{"id":"W3194717113","doi":"10.3389/fmolb.2021.697359","title":"NAD+ Degrading Enzymes, Evidence for Roles During Infection","year":2021,"lang":"en","type":"review","venue":"Frontiers in Molecular Biosciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Trent University; Nottingham Trent University","keywords":"NAD+ kinase; Poly ADP ribose polymerase; Nicotinamide adenine dinucleotide; Enzyme; Ribose; PARP1; Biochemistry; ADP-ribosylation; Biology; Nicotinamide; Polymerase; Cofactor; Immune system; Chemistry; Genetics","score_opus":0.08780270436815213,"score_gpt":0.4107637151362846,"score_spread":0.3229610107681325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194717113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019050243,0.9698624,0.026656108,0.00010058155,0.0018372346,0.0011993436,0.000015933836,0.0000542494,0.00008362653],"genre_scores_gemma":[0.00008954431,0.9774478,0.021386739,0.00011092171,0.00020357221,0.0004975327,0.000035881836,0.000044063316,0.00018393855],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737483,0.00019571303,0.00061402743,0.0008606586,0.00048544368,0.0004693249],"domain_scores_gemma":[0.998943,0.00010073001,0.0003152593,0.00041227552,0.00009506268,0.0001337037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006254185,0.00037941796,0.0013716789,0.00075476465,0.00016342105,0.000100229685,0.0002711634,0.00030194948,0.000015824204],"category_scores_gemma":[0.0005679125,0.00033617966,0.00059217983,0.0014103453,0.00024762284,0.00018230989,0.000059368213,0.00033990576,0.000002588818],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051303123,0.00013485986,0.0018948256,0.022657989,0.00027948772,0.00026359767,0.00015919666,0.000018410119,0.001147418,0.00034333018,0.0042371512,0.9688124],"study_design_scores_gemma":[0.00071461493,0.00017438873,0.00006116178,0.08149415,0.0005537498,0.00022486688,0.00008497985,0.00007565679,0.005644623,0.00015295514,0.91018313,0.00063570903],"about_ca_topic_score_codex":0.000024114719,"about_ca_topic_score_gemma":0.000009709265,"teacher_disagreement_score":0.9681767,"about_ca_system_score_codex":0.0006736675,"about_ca_system_score_gemma":0.00087615044,"threshold_uncertainty_score":0.99990904},"labels":[],"label_agreement":null},{"id":"W3195241595","doi":"10.1016/s0090-8258(21)00656-9","title":"1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study","year":2021,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; BRCA mutation; Internal medicine; Oncology; Clinical endpoint; Ovarian cancer; Olaparib; Population; PARP inhibitor; Cisplatin; Chemotherapy; Phases of clinical research; Cancer; Randomized controlled trial","score_opus":0.016220450158818758,"score_gpt":0.33061010917231853,"score_spread":0.3143896590134998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195241595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923113,0.00096832414,0.00022290931,0.0022113041,0.0005159063,0.00300426,0.000040020936,0.0000602655,0.0006656971],"genre_scores_gemma":[0.9933257,0.0007957604,0.0026669907,0.002134335,0.00007906004,0.00073470897,0.0001735031,0.000028883249,0.00006105522],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99768484,0.00048043352,0.00060433923,0.0006838327,0.0002101227,0.00033642232],"domain_scores_gemma":[0.99722755,0.0018463472,0.0002898737,0.00029060495,0.00018838533,0.00015723179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039149448,0.0002816731,0.0013126879,0.00010658861,0.000121630634,0.000021472906,0.00006569319,0.00023693616,0.0008268187],"category_scores_gemma":[0.00040096635,0.00022728505,0.000051181803,0.00029736356,0.0003295453,0.00009386785,0.000047655038,0.00035134726,0.000002984011],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82172674,0.00493645,0.022149568,0.000019486182,0.0008122376,0.00079165684,0.0062188385,0.000041478143,0.00042027904,0.00005761358,0.000062884545,0.14276275],"study_design_scores_gemma":[0.8644645,0.008193548,0.1229471,0.000053250064,0.00027738325,0.000019987121,0.0010030912,0.000089877125,0.000111422865,0.00013737402,0.0024673378,0.0002351095],"about_ca_topic_score_codex":0.00017718339,"about_ca_topic_score_gemma":0.0010214787,"teacher_disagreement_score":0.14252764,"about_ca_system_score_codex":0.0005453692,"about_ca_system_score_gemma":0.000507091,"threshold_uncertainty_score":0.92684156},"labels":[],"label_agreement":null},{"id":"W3199611447","doi":"10.1002/cam4.4260","title":"Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Stand Up To Cancer; Janssen Research and Development; EMD Serono; Genentech; Astellas Pharma; Eisai; NuCana; Pfizer; Incyte; Mersana Therapeutics; Syndax Pharmaceuticals; National Institute for Health and Care Research; Clovis Oncology; U.S. Department of Defense; National Comprehensive Cancer Network; Ovarian Cancer Research Fund; Gateway Foundation; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Amgen; National Ovarian Cancer Coalition; National Institutes of Health; Regeneron Pharmaceuticals; PharmaMar; Yale University; Sanofi; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Bristol-Myers Squibb; Ovarian Cancer Research Fund Alliance; Ipsen; Array BioPharma","keywords":"Medicine; Internal medicine; Placebo; Regimen; Population; Chemotherapy; Chemotherapy regimen; Gastroenterology; Oncology; Surgery; Pathology","score_opus":0.02721668678693314,"score_gpt":0.3441977582989541,"score_spread":0.316981071512021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199611447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9246161,0.007491591,0.001034356,0.05674856,0.00028323007,0.009574566,0.00016042292,0.000020354224,0.00007082582],"genre_scores_gemma":[0.9896182,0.0012922719,0.00033786322,0.0035518755,0.00037643808,0.0041887304,0.00010296099,0.000044408906,0.00048728517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978073,0.00052747846,0.00055469095,0.0005233472,0.00030925966,0.00027788183],"domain_scores_gemma":[0.9934857,0.005063171,0.00021813462,0.0006169801,0.00017716578,0.00043888477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010753192,0.0002950274,0.0011058461,0.00014498437,0.00008983628,0.000006618989,0.000066173554,0.000054484783,0.00006136624],"category_scores_gemma":[0.0037059742,0.00016339046,0.000076136326,0.00031805327,0.00041164926,0.000025531146,0.000024867064,0.00012665037,4.9329816e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.981547,0.00072107295,0.00030022662,0.00034403492,0.000142031,0.00016576832,0.0014619868,0.000038047077,0.004230492,0.00009850866,0.0017570116,0.00919382],"study_design_scores_gemma":[0.9517339,0.016437193,0.0013520208,0.0060594524,0.00067567546,0.000016631959,0.0001201526,0.0008903771,0.0063735857,0.00003729193,0.01613117,0.00017253174],"about_ca_topic_score_codex":0.00011227581,"about_ca_topic_score_gemma":0.00019317596,"teacher_disagreement_score":0.06500208,"about_ca_system_score_codex":0.00050953514,"about_ca_system_score_gemma":0.00075912866,"threshold_uncertainty_score":0.66628695},"labels":[],"label_agreement":null},{"id":"W3199858532","doi":"10.1007/s00520-021-06519-9","title":"The application of “Omics” to accelerate precision medicine in Supportive Care in Cancer","year":2021,"lang":"en","type":"editorial","venue":"Supportive Care in Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Public Health Ontario; University of Toronto","funders":"","keywords":"Pain medicine; Medicine; Nursing research; Precision medicine; Omics; Cancer; Health informatics; Intensive care medicine; Bioinformatics; Internal medicine; Public health; Nursing; Anesthesiology; Pathology; Biology","score_opus":0.024304399565746433,"score_gpt":0.40423825191030777,"score_spread":0.37993385234456134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199858532","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07836702,0.12800625,0.0001325774,0.00923127,0.7584054,0.012213832,0.008316019,0.00010754803,0.0052201287],"genre_scores_gemma":[0.4473977,0.077148445,0.00016240726,0.0017185182,0.44551754,0.018950459,0.007319281,0.00046110706,0.0013245438],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99401134,0.00030012135,0.0020071287,0.0013520807,0.001539407,0.0007899478],"domain_scores_gemma":[0.99380666,0.0009715545,0.00097236125,0.00095872924,0.0030629335,0.00022774366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007653152,0.00066323957,0.001699545,0.00077427947,0.00007070776,0.000026254056,0.00050971075,0.00097310566,0.00061232893],"category_scores_gemma":[0.0009755031,0.00054344354,0.00020436221,0.0018089158,0.00032424703,0.00015531511,0.00018411735,0.0017483819,0.000008846231],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006375828,0.00018706894,0.032973725,0.0020260843,0.00018842248,0.00023603806,0.038240798,0.0006854552,0.003354283,0.000028478375,0.8207514,0.0949524],"study_design_scores_gemma":[0.007575403,0.0010147104,0.010733523,0.009526905,0.00014885602,0.0000020585398,0.022191228,0.000023973987,0.016818374,0.00011376436,0.9311299,0.000721338],"about_ca_topic_score_codex":0.0153822405,"about_ca_topic_score_gemma":0.11534355,"teacher_disagreement_score":0.36903068,"about_ca_system_score_codex":0.008243458,"about_ca_system_score_gemma":0.006333857,"threshold_uncertainty_score":0.99970174},"labels":[],"label_agreement":null},{"id":"W3201876104","doi":"10.1016/j.ejca.2021.08.023","title":"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Medac; PharmaMar; Deutsche Krebshilfe; Eisai; European Commission; Chugai Pharmaceutical; Seagen; F. Hoffmann-La Roche; Incyte; Mersana Therapeutics; Karyopharm Therapeutics; Clovis Oncology; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Bevacizumab; Medicine; Hazard ratio; Oncology; Placebo; Internal medicine; Population; Ovarian cancer; Cancer; Confidence interval; Chemotherapy; Pathology; Biology","score_opus":0.13387170100280063,"score_gpt":0.42754352639227555,"score_spread":0.2936718253894749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201876104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854989,0.007279042,0.00023681673,0.004985444,0.0008440989,0.00078197673,0.00008356154,0.00001022168,0.00027992897],"genre_scores_gemma":[0.9946349,0.003313433,0.0004888454,0.00031521925,0.00019234767,0.00003728379,0.0000067651904,0.00004223726,0.0009689563],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948795,0.0022816616,0.0017448966,0.0002324977,0.0006244868,0.00023699497],"domain_scores_gemma":[0.995407,0.0011184214,0.002361925,0.0003097536,0.00071430515,0.00008863862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023242114,0.00022836184,0.0010739517,0.0001386303,0.00009718234,0.000023963074,0.00017522028,0.000046614015,0.00040371314],"category_scores_gemma":[0.0018485696,0.00010195663,0.00019058636,0.0006231252,0.00013666583,0.00014897049,0.000039634662,0.0002874233,5.7654455e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020563101,0.0007749973,0.17005333,0.0002267725,0.0011836557,0.00021584798,0.010521236,0.008048126,0.049174204,0.00012809082,0.0016602266,0.7374504],"study_design_scores_gemma":[0.073323436,0.0023937388,0.8683776,0.006261362,0.0008359375,0.00015789596,0.0015919612,0.0014835221,0.04202949,0.00021036254,0.0030513469,0.00028334509],"about_ca_topic_score_codex":0.00033054056,"about_ca_topic_score_gemma":0.0017492026,"teacher_disagreement_score":0.73716706,"about_ca_system_score_codex":0.0007710705,"about_ca_system_score_gemma":0.0011609875,"threshold_uncertainty_score":0.4420376},"labels":[],"label_agreement":null},{"id":"W3202472345","doi":"10.1016/j.ejphar.2021.174546","title":"Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications","year":2021,"lang":"en","type":"review","venue":"European Journal of Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Aligarh Muslim University; Université Laval","keywords":"Poly ADP ribose polymerase; Cancer stem cell; Stem cell; Cancer research; Cancer; Polymerase; Cancer cell; PARP inhibitor; Biology; Medicine; Pharmacology; Internal medicine; Genetics; Enzyme; Biochemistry","score_opus":0.08094684685098626,"score_gpt":0.4283480544015976,"score_spread":0.3474012075506114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202472345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008414749,0.98690754,0.00005917864,0.002205778,0.0013628853,0.00065959396,0.0002568102,0.000014392646,0.0001190556],"genre_scores_gemma":[0.029210085,0.9670575,0.000034921082,0.0013950195,0.001977763,0.000062511506,0.000023112274,0.000119957935,0.000119107935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99506843,0.0020964658,0.0016618643,0.0004400338,0.00025194162,0.00048124278],"domain_scores_gemma":[0.99783283,0.0001411894,0.0013279944,0.00020395707,0.00020565715,0.0002883395],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009226862,0.0004837758,0.0019397847,0.0009497439,0.000060469978,0.00003472105,0.00017850018,0.00014931096,0.001159864],"category_scores_gemma":[0.000005404223,0.00040578045,0.00050756516,0.00073398976,0.00018199362,0.00011757794,0.000073422096,0.0014750265,0.000014144058],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030505296,0.00047383882,0.00012084249,0.0016312711,0.000822993,0.003307448,0.0003031741,0.00006102402,0.022470556,0.0000072671437,0.0054916446,0.96500486],"study_design_scores_gemma":[0.0125303175,0.0010885125,0.0011394573,0.020178424,0.003516347,0.006377984,0.00007969609,0.000024167939,0.0055984748,0.000012219815,0.9486671,0.00078731775],"about_ca_topic_score_codex":0.00008710771,"about_ca_topic_score_gemma":0.000016747881,"teacher_disagreement_score":0.96421754,"about_ca_system_score_codex":0.001184506,"about_ca_system_score_gemma":0.0017802139,"threshold_uncertainty_score":0.9998394},"labels":[],"label_agreement":null},{"id":"W3204360130","doi":"10.1136/ijgc-2021-002933","title":"ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Clovis Oncology; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.028380843124332988,"score_gpt":0.37404610184741677,"score_spread":0.3456652587230838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204360130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96850216,0.0022221624,0.005194073,0.019959731,0.0012133097,0.0022106855,0.000046333447,0.000028705224,0.00062283466],"genre_scores_gemma":[0.98451376,0.0029923194,0.0033341988,0.006760126,0.00058611715,0.0011408787,0.000035739664,0.00006538178,0.0005714903],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99553055,0.000512786,0.0015732319,0.00065997953,0.0012134716,0.00051000103],"domain_scores_gemma":[0.9968169,0.0008800075,0.0008646021,0.00026823636,0.0008439559,0.0003263405],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014823017,0.0005137799,0.0017647451,0.0005250311,0.00008648438,0.00011489827,0.00031875473,0.00025390318,0.0022519266],"category_scores_gemma":[0.0005405405,0.00036709008,0.0004786818,0.0004644273,0.00018558018,0.00027846248,0.00003630528,0.00057626737,0.0000061935884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9292773,0.005587657,0.0046203476,0.000020725414,0.00186727,0.0013734996,0.0034179064,0.0048240214,0.008056595,0.0008906093,0.00033452502,0.039729565],"study_design_scores_gemma":[0.970534,0.005463549,0.00249875,0.0009510367,0.00024136223,0.0001754208,0.0003320869,0.0058076065,0.006751525,0.0030375004,0.003741344,0.00046579482],"about_ca_topic_score_codex":0.0014511604,"about_ca_topic_score_gemma":0.000984413,"teacher_disagreement_score":0.041256744,"about_ca_system_score_codex":0.003331222,"about_ca_system_score_gemma":0.0019116577,"threshold_uncertainty_score":0.9998781},"labels":[],"label_agreement":null},{"id":"W3204497870","doi":"10.1016/j.annonc.2021.08.1158","title":"645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"LEO Pharma; Unicancer; EUSA Pharma; Ipsen; Cilag; Astellas Pharma; Incyte; Daiichi Sankyo Europe; Sanofi; Exelixis; Eisai; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Double blind; Oncology; Cancer; Pathology; Androgen receptor; Alternative medicine","score_opus":0.09777747175227228,"score_gpt":0.4186201061047073,"score_spread":0.320842634352435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204497870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99008083,0.0006038845,0.0001314693,0.0008559606,0.00024239007,0.0071356827,0.00027438585,0.000038169048,0.0006372416],"genre_scores_gemma":[0.9958509,0.00039801208,0.0005033054,0.00086639327,0.000067800895,0.0015289348,0.00044344316,0.00006311891,0.0002780575],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951913,0.0009765681,0.0017125207,0.0007328067,0.00078639475,0.0006004194],"domain_scores_gemma":[0.9952752,0.00064835546,0.001313071,0.0004918403,0.0020328895,0.00023863639],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092266675,0.00046255253,0.0027746158,0.00047759942,0.00008156007,0.00001841158,0.00013312286,0.00018017236,0.00023510467],"category_scores_gemma":[0.00021819035,0.000397039,0.00021332529,0.000996456,0.00052363507,0.00022673502,0.00006837744,0.0004578634,0.000005474115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9498651,0.008090793,0.0016425725,0.00019216366,0.002403109,0.0012630573,0.018076643,0.004852013,0.010107253,0.00004182348,0.00036443508,0.0031010627],"study_design_scores_gemma":[0.8342311,0.010417625,0.001045325,0.0003507092,0.00067009317,0.00010511519,0.0032099052,0.0006500659,0.14878358,0.000047282978,0.00016427516,0.00032495536],"about_ca_topic_score_codex":0.001961177,"about_ca_topic_score_gemma":0.002857727,"teacher_disagreement_score":0.13867633,"about_ca_system_score_codex":0.00049291796,"about_ca_system_score_gemma":0.002935621,"threshold_uncertainty_score":0.9998481},"labels":[],"label_agreement":null},{"id":"W3204649495","doi":"10.1016/j.ygyno.2021.08.030","title":"Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer","year":2021,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Centre Hospitalier de l’Université de Montréal; University Health Network; Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Internal medicine; Loss of heterozygosity; Ovarian cancer; Oncology; BRCA mutation; Gastroenterology; Cancer; PARP inhibitor; Poly ADP ribose polymerase; Polymerase; Genetics; Gene; Allele; Biology","score_opus":0.03602718748914839,"score_gpt":0.3533486661188181,"score_spread":0.3173214786296697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204649495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485034,0.000090901354,0.00007698865,0.0029682722,0.00049763627,0.0008974925,0.00010825296,0.000024604165,0.0004855343],"genre_scores_gemma":[0.9962012,0.00030688907,0.0005929621,0.0013749901,0.000071089264,0.00059803214,0.0003008224,0.000014747311,0.00053922716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986803,0.00023062636,0.00036033773,0.00033404198,0.00014451171,0.00025020164],"domain_scores_gemma":[0.99904555,0.00018722568,0.00017614188,0.00023912932,0.00024680156,0.00010515803],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000117108626,0.00014910488,0.0004900317,0.00016235175,0.00003066856,0.000004645642,0.000053421787,0.00014919054,0.0015600112],"category_scores_gemma":[0.000119596974,0.00011579374,0.000043530952,0.00037063225,0.00006491163,0.000042153668,0.00002820746,0.00010093077,0.000016044913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037854747,0.002184779,0.9131271,0.000033727465,0.00007733348,0.00017696363,0.00062585814,0.0000065353715,0.022197807,0.00004591263,0.00004329617,0.057695165],"study_design_scores_gemma":[0.0064014955,0.005715629,0.965061,0.00008980409,0.000057130906,0.000009860754,0.000028753153,0.0000023524883,0.016167656,0.000014823316,0.0063422914,0.00010918747],"about_ca_topic_score_codex":0.000033327808,"about_ca_topic_score_gemma":0.0011268225,"teacher_disagreement_score":0.05758598,"about_ca_system_score_codex":0.0014952496,"about_ca_system_score_gemma":0.0009991305,"threshold_uncertainty_score":0.9993527},"labels":[],"label_agreement":null},{"id":"W3206587650","doi":"10.1016/j.annonc.2021.10.005","title":"PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later","year":2021,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olympiad; Oncology; PARP inhibitor; Metastatic breast cancer; Internal medicine; Breast cancer; Cancer; Poly ADP ribose polymerase","score_opus":0.054898949890507795,"score_gpt":0.4199216757541365,"score_spread":0.3650227258636287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206587650","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18469372,0.004313077,0.000008645082,0.015078347,0.7889508,0.001063496,0.0033064832,0.0001264997,0.0024588932],"genre_scores_gemma":[0.21620773,0.0121054,0.0003702804,0.0037844237,0.7612941,0.00034666434,0.0035264674,0.0002751401,0.0020897666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99561536,0.00093838543,0.001196452,0.000827623,0.00077569927,0.00064649584],"domain_scores_gemma":[0.99611217,0.0009515594,0.0007496197,0.00064910285,0.0012497525,0.000287784],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014777278,0.00049419113,0.0021659331,0.00044920205,0.000045833895,0.000016935153,0.00014694339,0.0014315279,0.0010989372],"category_scores_gemma":[0.00030319896,0.00048073806,0.00032497276,0.00052526203,0.00034741103,0.00017423781,0.0000886575,0.0014540226,0.000034070938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016641313,0.0014661963,0.0009824056,0.00042102422,0.00073379127,0.002138054,0.00059852714,0.00004854693,0.0051243077,0.000016288684,0.96598107,0.020825647],"study_design_scores_gemma":[0.009758873,0.0024388547,0.0037691502,0.0018267514,0.00039850042,0.00035226074,0.00014548244,0.00006605012,0.010304258,0.00029582097,0.9699981,0.00064584735],"about_ca_topic_score_codex":0.0015869656,"about_ca_topic_score_gemma":0.0025185444,"teacher_disagreement_score":0.031513996,"about_ca_system_score_codex":0.0005095727,"about_ca_system_score_gemma":0.0040063737,"threshold_uncertainty_score":0.9998648},"labels":[],"label_agreement":null},{"id":"W3207301911","doi":"10.1038/s41416-021-01560-1","title":"Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Cancer Research UK; Ottawa Hospital Research Institute; AstraZeneca","keywords":"Olaparib; PARP inhibitor; Oncology; Medicine; Internal medicine; Biomarker; Ovarian cancer; Cancer; Poly ADP ribose polymerase; Biology","score_opus":0.017735269981261938,"score_gpt":0.34137995415041744,"score_spread":0.3236446841691555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207301911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698403,0.0065853815,0.00044680425,0.021976825,0.00042528094,0.0002891172,0.00011583168,0.000013080056,0.00030738744],"genre_scores_gemma":[0.99215937,0.0010651115,0.00038802018,0.0052133226,0.00037623255,0.000030101033,0.0000014231042,0.000026881362,0.0007395228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976665,0.00046100112,0.00060450437,0.00020598716,0.0008204068,0.00024165082],"domain_scores_gemma":[0.99743384,0.00052422367,0.00040914936,0.00037889724,0.0010977604,0.00015613678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017948684,0.00014280318,0.0006768804,0.00024879773,0.00018826114,0.00008947816,0.00026294836,0.00005577452,0.000759929],"category_scores_gemma":[0.0012083023,0.000097282,0.0004894127,0.0017690627,0.00011999079,0.00010963349,0.000059858172,0.00043452467,0.0000024930162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007948967,0.0003918374,0.7211997,0.00005923672,0.02078225,0.0012928075,0.01599873,0.003477882,0.14373164,0.00013246485,0.026594346,0.058390137],"study_design_scores_gemma":[0.0012801298,0.00030850427,0.96764094,0.0005953748,0.0011271334,0.0003222286,0.0019764064,0.000016692682,0.015488112,0.0000686346,0.011071188,0.000104653955],"about_ca_topic_score_codex":0.0002374476,"about_ca_topic_score_gemma":0.0013359737,"teacher_disagreement_score":0.24644125,"about_ca_system_score_codex":0.00037124509,"about_ca_system_score_gemma":0.00046892854,"threshold_uncertainty_score":0.832069},"labels":[],"label_agreement":null},{"id":"W3208204329","doi":"10.1016/s1470-2045(21)00531-3","title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Olaparib; Ovarian cancer; Mutation; BRCA mutation; Clinical trial; Cancer","score_opus":0.04020537618833177,"score_gpt":0.3627496910676291,"score_spread":0.32254431487929736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208204329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805338,0.00058224966,0.0030580754,0.005115569,0.0010247177,0.008479343,0.00020580851,0.000052189873,0.00094828976],"genre_scores_gemma":[0.98567486,0.0005321234,0.003514387,0.0019946895,0.0008555947,0.00648051,0.00019431459,0.000053458683,0.0007000906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978985,0.00027343104,0.0006334309,0.0004446194,0.0002879424,0.00046207625],"domain_scores_gemma":[0.996686,0.0015360771,0.0006005306,0.00042876048,0.00062286155,0.00012581711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078436814,0.00025995245,0.0015102553,0.000083555984,0.00013328448,0.000020246302,0.00014079061,0.00018235463,0.00018040418],"category_scores_gemma":[0.000561215,0.00017141049,0.00018451716,0.00026049773,0.00024138675,0.00011264736,0.000031499516,0.0002705628,0.0000029722528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9824301,0.0007580012,0.00023227367,0.00010311848,0.00062678446,0.000037074064,0.0009652442,0.00010789671,0.0014844767,0.0010946294,0.0022200972,0.009940309],"study_design_scores_gemma":[0.9838487,0.0049564145,0.00018052912,0.00019752458,0.0005985782,0.000025844027,0.00025305967,0.00025150884,0.0013455815,0.0007785377,0.007372088,0.0001916186],"about_ca_topic_score_codex":0.00006928024,"about_ca_topic_score_gemma":0.00042352983,"teacher_disagreement_score":0.009748691,"about_ca_system_score_codex":0.00026097437,"about_ca_system_score_gemma":0.0008816245,"threshold_uncertainty_score":0.69899166},"labels":[],"label_agreement":null},{"id":"W3208700567","doi":"10.3389/fonc.2021.745981","title":"Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents","year":2021,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Cisplatin; Clonogenic assay; Poly ADP ribose polymerase; Apoptosis; Cancer research; Cell cycle; Flow cytometry; Programmed cell death; Gene knockdown; Chemistry; Biology; Molecular biology; Polymerase; Chemotherapy; Biochemistry; Enzyme","score_opus":0.015622517029747039,"score_gpt":0.3059885350703799,"score_spread":0.29036601804063283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208700567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713832,0.007014864,0.0015331734,0.011671764,0.005131899,0.00089918607,0.00045729807,0.00008607167,0.0018225436],"genre_scores_gemma":[0.97395897,0.00079323,0.014522639,0.0077486243,0.0014427525,0.00017059968,0.00015937655,0.00009194315,0.001111881],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968161,0.00036442984,0.0009180252,0.00079186424,0.00043734998,0.00067224866],"domain_scores_gemma":[0.99828964,0.0001463587,0.00034289755,0.00048734984,0.00022943644,0.0005043297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036447027,0.00040184802,0.0010805022,0.0006785484,0.000106387895,0.00002240807,0.00009543924,0.00048183385,0.00040980527],"category_scores_gemma":[0.00014357996,0.00044287182,0.00015749021,0.000869912,0.0003179429,0.00017475312,0.00014022163,0.0004955204,0.000017988925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004997608,0.0010658074,0.023718469,0.0002699381,0.00037679015,0.0029006877,0.0053857826,0.000085636486,0.72889173,0.000065534434,0.15333222,0.07890981],"study_design_scores_gemma":[0.013596098,0.0011678439,0.0056470437,0.0007283287,0.0002029136,0.0002844266,0.0017711784,0.0004848232,0.9301557,0.000342652,0.04505574,0.00056324626],"about_ca_topic_score_codex":0.0007561864,"about_ca_topic_score_gemma":0.00025460313,"teacher_disagreement_score":0.20126398,"about_ca_system_score_codex":0.0009647223,"about_ca_system_score_gemma":0.0010442568,"threshold_uncertainty_score":0.9998023},"labels":[],"label_agreement":null},{"id":"W3208867838","doi":"10.1136/ijgc-2021-igcs.16","title":"O016/#233 Clinical and molecular characteristics of ariel3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical trial; Randomized controlled trial; Pathology; Biology; Genetics; Poly ADP ribose polymerase; Alternative medicine","score_opus":0.04660154904484661,"score_gpt":0.36745396807519604,"score_spread":0.32085241903034944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208867838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838443,0.0009454919,0.0033298675,0.00794374,0.002189397,0.00026914864,0.0014119531,0.000008084996,0.00005801745],"genre_scores_gemma":[0.9862158,0.0049908427,0.0040742364,0.0031297691,0.0011424691,0.00009907239,0.00015405723,0.000021946971,0.00017181262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976976,0.000078388024,0.0011081266,0.00032552224,0.0005748654,0.00021552638],"domain_scores_gemma":[0.996174,0.0005489684,0.00084949244,0.00013833889,0.0020792345,0.00020998725],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018538492,0.00021113582,0.0007392368,0.00008208974,0.000045133922,0.000032980748,0.00017826211,0.0002005378,0.002166409],"category_scores_gemma":[0.0004781268,0.00016338499,0.00031787166,0.00007688392,0.00023537953,0.000104777726,0.000055553624,0.0002508122,0.0000017859124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065593286,0.0026954068,0.86530143,0.000048412865,0.0033391935,0.0003919788,0.00023888881,0.00011729404,0.023103597,0.004311588,0.002317183,0.09157569],"study_design_scores_gemma":[0.013541228,0.0011850913,0.9573428,0.00039868327,0.00027007688,0.000031991898,0.000036067348,0.000112181566,0.012741323,0.005532156,0.008628382,0.00018003755],"about_ca_topic_score_codex":0.00013889628,"about_ca_topic_score_gemma":0.00008075342,"teacher_disagreement_score":0.09204134,"about_ca_system_score_codex":0.0006017276,"about_ca_system_score_gemma":0.0005740075,"threshold_uncertainty_score":0.99874574},"labels":[],"label_agreement":null},{"id":"W3212892569","doi":"10.1038/s41467-021-27043-8","title":"HPF1 dynamically controls the PARP1/2 balance between initiating and elongating ADP-ribose modifications","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"CIHR Skin Research Training Centre; National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Cancer Institute; U.S. Department of Health and Human Services; Government of Canada; National Institutes of Health; Natural Sciences and Engineering Research Council of Canada","keywords":"PARP1; Serine; Poly ADP ribose polymerase; DNA damage; ADP-ribosylation; Ribose; Biochemistry; DNA repair; Chemistry; DNA; Cell biology; Biology; Biophysics; Enzyme; NAD+ kinase; Polymerase","score_opus":0.0445343287808125,"score_gpt":0.3681422679594799,"score_spread":0.3236079391786674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212892569","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3348795,0.0668382,0.013771508,0.5166508,0.0004791295,0.0026404655,0.0007576277,0.00072469533,0.06325807],"genre_scores_gemma":[0.98074496,0.0011753752,0.013403473,0.0036503181,0.00024770506,0.0002071543,0.00040538184,0.000026424694,0.00013921341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985803,0.00031782835,0.00039576273,0.00025271223,0.00023971761,0.00021371833],"domain_scores_gemma":[0.99574745,0.0014954222,0.00016465223,0.0019759035,0.0005052993,0.00011130112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039773918,0.00014782151,0.00026966695,0.000050984923,0.0007403599,0.00007411442,0.0004513244,0.00023036623,0.00003434472],"category_scores_gemma":[0.0010635834,0.00012232913,0.00008156663,0.00045951668,0.00026271373,0.00011081876,0.000214619,0.0015291318,0.000012888281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001849736,0.001470984,0.4355625,0.00031351525,0.0020708337,0.000043263917,0.008396218,0.00023750185,0.16049595,0.31191432,0.017347695,0.06196225],"study_design_scores_gemma":[0.011071685,0.00023530253,0.59983945,0.001689231,0.0011939163,0.0005684649,0.004539629,0.14980325,0.006017661,0.014415319,0.20921287,0.0014131963],"about_ca_topic_score_codex":0.000013278449,"about_ca_topic_score_gemma":0.000086247506,"teacher_disagreement_score":0.64586544,"about_ca_system_score_codex":0.00010022991,"about_ca_system_score_gemma":0.00023452213,"threshold_uncertainty_score":0.6643402},"labels":[],"label_agreement":null},{"id":"W3213169138","doi":"10.1158/2767-9764.crc-21-0064","title":"BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin","year":2021,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"Kurozumi Medical Foundation; Ministry of Education, Culture, Sports, Science and Technology; Japan Society for the Promotion of Science; Nakatomi Foundation","keywords":"Olaparib; Gene knockdown; Transactivation; Synthetic lethality; Poly ADP ribose polymerase; Cancer research; PARP inhibitor; Biology; Transcription factor; Molecular biology; RAD51; Homologous recombination; Chemistry; Cell culture; DNA repair; Gene; Genetics; Polymerase","score_opus":0.16309682700075723,"score_gpt":0.4551863214761788,"score_spread":0.2920894944754216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213169138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7652189,0.016005455,0.0004985658,0.20902942,0.00009661501,0.0014383135,0.00017076397,0.00009255434,0.007449377],"genre_scores_gemma":[0.98358434,0.009919675,0.002013478,0.0019969854,0.000066762375,0.0010976545,0.00010870891,0.000033467546,0.0011789047],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977948,0.00045987085,0.00039980398,0.00038226938,0.0005808022,0.00038242366],"domain_scores_gemma":[0.9968111,0.00057986786,0.000046506724,0.0014709034,0.0008246051,0.0002670432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008964342,0.00012699135,0.0002561622,0.0003891871,0.00028263574,0.000056035366,0.0003067348,0.000113155285,0.00030678062],"category_scores_gemma":[0.0005140935,0.00014034822,0.000043394284,0.002161759,0.0002769283,0.00017058046,0.00014764485,0.00080228795,0.000031568816],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023053088,0.0017368037,0.103007324,0.00086634106,0.00036823546,0.00009131743,0.031167015,0.00014704053,0.7200918,0.0068042357,0.100983456,0.0324311],"study_design_scores_gemma":[0.011451767,0.0003139932,0.10302289,0.0052157217,0.000057898094,0.000016348544,0.006760971,0.0036125453,0.20639078,0.00617364,0.656085,0.0008984247],"about_ca_topic_score_codex":0.00044800795,"about_ca_topic_score_gemma":0.009073807,"teacher_disagreement_score":0.5551016,"about_ca_system_score_codex":0.0007294873,"about_ca_system_score_gemma":0.0009295287,"threshold_uncertainty_score":0.57232344},"labels":[],"label_agreement":null},{"id":"W3213781114","doi":"10.3390/ijms222212127","title":"Mechanisms of Nucleosome Reorganization by PARP1","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institutes of Health; Lomonosov Moscow State University; National Cancer Institute; Russian Science Foundation; Department of Science and Technology, Ministry of Science and Technology, India","keywords":"Nucleosome; Linker DNA; Histone; Chromatin; Cell biology; Biology; PARP1; Chromatosome; Histone H1; DNA; Molecular biology; Chemistry; Biophysics; Genetics; Polymerase; Poly ADP ribose polymerase","score_opus":0.013308967694438557,"score_gpt":0.3114310064742109,"score_spread":0.29812203877977234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213781114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86797947,0.0014806843,0.1158366,0.010344408,0.001168289,0.00005412506,0.000014190167,0.0000077620525,0.0031144496],"genre_scores_gemma":[0.98763233,0.00018881573,0.010676216,0.0013678202,0.000060157225,4.643161e-7,0.000006145065,0.0000056593753,0.00006241747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985083,0.00004051642,0.00033771945,0.000099423145,0.0009423085,0.000071749644],"domain_scores_gemma":[0.99845695,0.000027422926,0.0003154688,0.000067269066,0.001076622,0.000056283396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003156415,0.000053920216,0.0001356258,0.00013009769,0.000023358087,0.00002810962,0.00021730832,0.000030741583,0.00048573062],"category_scores_gemma":[0.00015337278,0.000046468114,0.00008443174,0.00027066137,0.0001105667,0.0001431198,0.000026595213,0.000076420896,0.0000033270132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034509158,0.00009315938,0.00053894875,0.0000039268284,0.00007796895,0.00016019934,0.00008063072,0.00007397307,0.9889187,0.007996781,0.0009331584,0.0010880249],"study_design_scores_gemma":[0.0007681412,0.00020496646,0.000560981,0.0001280721,0.000018998135,0.0007547699,0.00015616902,0.00006600225,0.9845027,0.011150508,0.0016431155,0.000045605186],"about_ca_topic_score_codex":0.000002441985,"about_ca_topic_score_gemma":2.9190306e-7,"teacher_disagreement_score":0.119652815,"about_ca_system_score_codex":0.000053619104,"about_ca_system_score_gemma":0.00031268917,"threshold_uncertainty_score":0.531841},"labels":[],"label_agreement":null},{"id":"W3216246920","doi":"10.3390/ijms222312628","title":"BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Prostate cancer; Carcinogenesis; Germline; Synthetic lethality; Germline mutation; Cancer; Cancer research; DNA repair; Biology; Somatic cell; Poly ADP ribose polymerase; DNA damage; Prostate; PARP inhibitor; Chromoplexy; Mutation; Genome instability; Genetics; Medicine; Gene; Polymerase; DNA; PCA3","score_opus":0.09424596685189343,"score_gpt":0.485535620611989,"score_spread":0.3912896537600956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216246920","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010743192,0.9920034,0.0002051705,0.0051550344,0.00040561875,0.00036510723,0.00010732901,0.0000060134166,0.0006780157],"genre_scores_gemma":[0.0041142283,0.99105704,0.004198202,0.00028275288,0.00012783696,0.00011903354,0.000034692526,0.000012920667,0.000053281008],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982478,0.00013681363,0.000760167,0.0002483216,0.00047586518,0.00013100704],"domain_scores_gemma":[0.99838734,0.00021777434,0.0006323754,0.00011338061,0.0005502741,0.000098882134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030444894,0.00017748501,0.00068037247,0.000624952,0.00008199978,0.00015598422,0.00015383313,0.000059647216,0.0001234646],"category_scores_gemma":[0.00008199465,0.00013698205,0.00025020153,0.0003611142,0.00024173547,0.00016164538,0.000030941155,0.000214777,0.0000013261557],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000073182778,0.00036349185,0.0011763558,0.00019560588,0.000911981,0.00094951695,0.0003200871,0.00019229279,0.00021884742,0.0091011645,0.00025877252,0.9863046],"study_design_scores_gemma":[0.002983042,0.00067701354,0.0011576974,0.019836865,0.0011643476,0.011220519,0.0003204615,0.000056535588,0.00021107227,0.0040379865,0.95788974,0.00044471584],"about_ca_topic_score_codex":0.000041611413,"about_ca_topic_score_gemma":0.000040306524,"teacher_disagreement_score":0.9858599,"about_ca_system_score_codex":0.000642845,"about_ca_system_score_gemma":0.004115536,"threshold_uncertainty_score":0.73007834},"labels":[],"label_agreement":null},{"id":"W3217079453","doi":"10.1016/j.annonc.2021.11.018","title":"Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; Vifor Pharma; AbbVie; Roche; Pfizer","keywords":"Carboplatin; Veliparib; Medicine; Internal medicine; Placebo; Hazard ratio; PARP inhibitor; Paclitaxel; Oncology; Breast cancer; Interim analysis; Clinical endpoint; Chemotherapy; Randomized controlled trial; Urology; Cancer; Confidence interval; Pathology; Cisplatin","score_opus":0.12010783699426184,"score_gpt":0.4370745556466084,"score_spread":0.3169667186523466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217079453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032116,0.0023378672,0.000060175873,0.0047500473,0.0004452679,0.0010675528,0.00080983463,0.0000315627,0.00017651942],"genre_scores_gemma":[0.9944679,0.0021506283,0.00013433101,0.0020590315,0.00015572955,0.00019359154,0.0007527402,0.00004234276,0.000043673568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99672693,0.0005883232,0.0012417441,0.00047504102,0.00060778443,0.00036017864],"domain_scores_gemma":[0.99647003,0.00075805566,0.0011312688,0.0004961213,0.001042063,0.00010246934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065637415,0.00028663,0.00125776,0.00017231437,0.00008062393,0.000010049883,0.00018569085,0.00026891104,0.00008074191],"category_scores_gemma":[0.00023350438,0.0002192172,0.00025331098,0.00083795656,0.00018311295,0.00020344641,0.000029324423,0.00035714594,9.471265e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7267358,0.013599709,0.02426258,0.00003530011,0.0041484977,0.00008805224,0.01032904,0.0018266513,0.06724604,0.000074406686,0.0035145965,0.14813936],"study_design_scores_gemma":[0.80330336,0.012016857,0.12679735,0.000628808,0.0002289834,0.0000021944263,0.0009990374,0.0002609846,0.052911393,0.000316932,0.0021638947,0.00037021172],"about_ca_topic_score_codex":0.001365722,"about_ca_topic_score_gemma":0.00082879455,"teacher_disagreement_score":0.14776915,"about_ca_system_score_codex":0.00032855695,"about_ca_system_score_gemma":0.0013209562,"threshold_uncertainty_score":0.8939418},"labels":[],"label_agreement":null},{"id":"W3217140412","doi":"10.1016/j.ygyno.2020.05.070","title":"ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Olaparib; Pembrolizumab; Oncology; Internal medicine; PARP inhibitor; Ovarian cancer; Carboplatin; Chemotherapy; Regimen; BRCA mutation; Placebo; Gynecology; Cancer; Immunotherapy; Poly ADP ribose polymerase; Cisplatin; Pathology","score_opus":0.032601625682014336,"score_gpt":0.348120337627277,"score_spread":0.31551871194526265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217140412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742504,0.0004632201,0.0015227989,0.010944012,0.00040579014,0.0111369295,0.0004057939,0.00009427158,0.0007768048],"genre_scores_gemma":[0.98653215,0.0023742844,0.0029831685,0.0017786777,0.00046519254,0.0052986154,0.000098263365,0.000057885514,0.00041174534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997368,0.00018146676,0.0009691062,0.0006961948,0.00023188542,0.00055333995],"domain_scores_gemma":[0.99662936,0.0013936487,0.0010165063,0.00030839862,0.00038130573,0.00027076248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025471993,0.00045645397,0.0025300267,0.00013169646,0.000111737936,0.000006418509,0.0001459598,0.0003605955,0.00087651936],"category_scores_gemma":[0.0003092816,0.0003232794,0.00025008802,0.00027898676,0.00046640143,0.00008449998,0.00002371447,0.00020058481,0.00000230645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8662546,0.0033303767,0.000048264385,0.00011698202,0.0011509301,0.00006205364,0.001954129,0.0005221433,0.024559107,0.00010793439,0.00028616044,0.1016073],"study_design_scores_gemma":[0.86868256,0.08017229,0.00022996002,0.000063271655,0.0005498094,0.00003656747,0.00027788413,0.0025988582,0.022370122,0.0001445664,0.024606321,0.00026779843],"about_ca_topic_score_codex":0.00011162789,"about_ca_topic_score_gemma":0.000280486,"teacher_disagreement_score":0.101339504,"about_ca_system_score_codex":0.001063002,"about_ca_system_score_gemma":0.0013176913,"threshold_uncertainty_score":0.9999219},"labels":[],"label_agreement":null},{"id":"W3217809703","doi":"10.5489/cuaj.7621","title":"Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context","year":2021,"lang":"en","type":"review","venue":"Canadian Urological Association Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; McMaster University; Centre Hospitalier de l’Université de Montréal; University of British Columbia; University of Alberta","funders":"Daiichi Sankyo Europe; EMD Serono; Seagen; Astellas Pharma; F. Hoffmann-La Roche; Ipsen; Canadian Urological Association; Eisai; Sanofi; AstraZeneca; Pfizer","keywords":"Germline; Olaparib; Genetic testing; Medicine; Prostate cancer; Context (archaeology); Germline mutation; Somatic cell; Oncology; Population; Cancer; Internal medicine; Bioinformatics; Genetics; Biology; Mutation; Gene","score_opus":0.053386085370792966,"score_gpt":0.31474328751191455,"score_spread":0.26135720214112157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217809703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068927025,0.92951304,0.000007423887,0.056362208,0.00041627587,0.0045956434,0.0014271523,0.00001676879,0.0007688004],"genre_scores_gemma":[0.088431,0.9018104,0.000109464316,0.008096418,0.00013318799,0.0007410123,0.0003815605,0.00002941244,0.00026752733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99729896,0.0008246554,0.0008033268,0.00026069654,0.0004829591,0.0003294208],"domain_scores_gemma":[0.997785,0.00047164233,0.00072445255,0.00023547647,0.0004954657,0.00028801226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012231854,0.00021801176,0.0006145767,0.00030645335,0.0005547813,0.0001824174,0.0001063881,0.00014395783,0.0003012243],"category_scores_gemma":[0.00028368295,0.000120459124,0.00016493084,0.00045032147,0.000085119806,0.00006558077,0.0000069489492,0.0006991251,0.0000065163217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030253537,0.0019892845,0.14184397,0.006766517,0.02101028,0.0031847365,0.012365853,0.000562029,0.000004626097,0.11630179,0.27315792,0.42251045],"study_design_scores_gemma":[0.0014124761,0.00026456974,0.046325415,0.003347268,0.0015909927,0.00017490375,0.00033786692,0.000017716331,0.0000017454918,0.00045971473,0.94578403,0.00028327532],"about_ca_topic_score_codex":0.01507546,"about_ca_topic_score_gemma":0.27540952,"teacher_disagreement_score":0.67262614,"about_ca_system_score_codex":0.002228811,"about_ca_system_score_gemma":0.002643694,"threshold_uncertainty_score":0.9914832},"labels":[],"label_agreement":null},{"id":"W326717049","doi":"10.1074/jbc.m115.660100","title":"Loss of the Mono-ADP-ribosyltransferase, Tiparp, Increases Sensitivity to Dioxin-induced Steatohepatitis and Lethality","year":2015,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; College of Engineering, Michigan State University; University of Toronto; Michigan State University","keywords":"Lethality; Steatohepatitis; Nonalcoholic steatohepatitis; Chemistry; Biology; Internal medicine; Medicine; Toxicology; Fatty liver","score_opus":0.06186908249249825,"score_gpt":0.3105845808863915,"score_spread":0.24871549839389326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W326717049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692094,0.00024490905,0.00011565203,0.0019202363,0.000071557726,0.00011290879,0.000050820167,0.000009429956,0.0005535239],"genre_scores_gemma":[0.99875927,0.00009996979,0.0002205702,0.00059878064,0.00028093366,0.0000026400628,0.00000266409,0.0000064419805,0.00002873415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99882936,0.00014382372,0.00042272697,0.0001484676,0.000304723,0.00015092203],"domain_scores_gemma":[0.9987216,0.00019869996,0.00021238145,0.00020013952,0.00032840503,0.0003387808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007065014,0.00013385297,0.00044778993,0.000017758863,0.00003151399,0.000008041065,0.00009220615,0.00015923454,0.000054393517],"category_scores_gemma":[0.0007105126,0.00007700347,0.00014714488,0.00013230901,0.00018705137,0.00004037502,0.000046427584,0.00032313424,0.0000011631641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069244223,0.00018439148,0.17959051,0.000045824436,0.00006026338,0.00008557533,0.00007112956,0.0000039578867,0.8182159,0.0000057018183,0.00038656566,0.00065771793],"study_design_scores_gemma":[0.0015386726,0.00038775176,0.10551658,0.00019067412,0.000040702897,0.00111824,0.00010963206,0.000004689368,0.89013755,0.00020935977,0.00065221405,0.00009395448],"about_ca_topic_score_codex":0.00006344621,"about_ca_topic_score_gemma":0.0000032899884,"teacher_disagreement_score":0.07407393,"about_ca_system_score_codex":0.00010668841,"about_ca_system_score_gemma":0.0001677126,"threshold_uncertainty_score":0.314011},"labels":[],"label_agreement":null},{"id":"W35931135","doi":"10.1016/j.neuropsychologia.2022.108342","title":"TGFβ-mediated transcription is regulated by PARP-1/PARG-balanced ADP-ribosylation","year":2010,"lang":"en","type":"article","venue":"Neuropsychologia","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"SMAD; Cell biology; R-SMAD; Transcription factor; Smad2 Protein; Biology; Phosphorylation; Signal transduction; Chemistry; Molecular biology; Biochemistry; Gene","score_opus":0.016353846055688376,"score_gpt":0.3006911595919363,"score_spread":0.2843373135362479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W35931135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836784,0.00011210696,0.0005649318,0.006521212,0.0018567275,0.00057885284,0.00011187213,0.00054602,0.0060298545],"genre_scores_gemma":[0.9868484,0.0001442314,0.0004088796,0.010343036,0.00029802474,0.000063080144,0.00037300907,0.000062522224,0.0014587964],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980585,0.00009508652,0.00044673766,0.0006194597,0.00038937724,0.0003908514],"domain_scores_gemma":[0.99871165,0.00005876092,0.00017681216,0.00067421474,0.00017496572,0.00020357444],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020947699,0.0002688683,0.00032049656,0.00013424632,0.000099753524,0.00003142083,0.00015837522,0.00034208896,0.0022575217],"category_scores_gemma":[0.000092720176,0.00024785838,0.0001229626,0.0005212213,0.00017188078,0.00015304072,0.000008931887,0.0007875382,0.0005238147],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053606107,0.00019457162,0.006028652,0.0000129092505,0.000025391537,0.000018309524,0.00013721973,0.0000013548289,0.897686,0.00003898887,0.091080524,0.004240013],"study_design_scores_gemma":[0.011141408,0.0010943358,0.45029777,0.00007605422,0.00009355912,0.00024695418,0.000025012472,0.0006408948,0.29217416,0.00044569318,0.24317357,0.0005905653],"about_ca_topic_score_codex":0.000009969665,"about_ca_topic_score_gemma":0.0000028112543,"teacher_disagreement_score":0.60551184,"about_ca_system_score_codex":0.00004368571,"about_ca_system_score_gemma":0.00004103539,"threshold_uncertainty_score":0.9999974},"labels":[],"label_agreement":null},{"id":"W4200041838","doi":"10.1101/2021.12.15.472832","title":"Crystal structures and functional analysis of the ZnF5-WWE1-WWE2 region of PARP13/ZAP define a new mode of engaging poly(ADP-ribose)","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Lawrence Berkeley National Laboratory; Basic Energy Sciences; Biological and Environmental Research; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Institutes of Health; Université de Montréal; University of Saskatchewan; Canadian Light Source; U.S. Department of Energy","keywords":"Ribose; Monomer; Nucleotide; Dimer; Binding site; Stereochemistry; Chemistry; Biophysics; Biochemistry; Biology; Polymer; Enzyme; Gene","score_opus":0.024422192203004,"score_gpt":0.25282488424217886,"score_spread":0.22840269203917485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200041838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98711354,0.0049814605,0.005870196,0.00057524286,0.00053727126,0.0004860009,0.00036406243,0.00005852761,0.000013715086],"genre_scores_gemma":[0.9948414,0.00043485643,0.0041142805,0.00020173703,0.0002977392,0.00003109169,0.0000033447868,0.00006592989,0.000009626681],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997036,0.00020629975,0.0009642313,0.0007492647,0.00073755666,0.00030668837],"domain_scores_gemma":[0.9962449,0.00013706328,0.0011724541,0.0014144143,0.0008244818,0.00020668558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033172042,0.00044632072,0.001296653,0.0006207012,0.00008941683,0.000031788288,0.00025088445,0.0004105189,0.00013595968],"category_scores_gemma":[0.00024382153,0.00039008405,0.00052989356,0.0014665603,0.0003554065,0.00008661973,0.0003276435,0.0006889932,2.6382716e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003428254,0.00015409663,0.07153155,0.0009560615,0.0032784375,0.000016602471,0.00012823594,0.0012170313,0.9210373,0.0009623885,0.00036656394,0.000008875599],"study_design_scores_gemma":[0.0016168446,0.000070827045,0.4221558,0.0011463115,0.0028028178,3.0671129e-7,0.000036031444,0.0010057851,0.5704328,0.000018301069,0.00035385613,0.00036034262],"about_ca_topic_score_codex":0.00059757207,"about_ca_topic_score_gemma":0.000025122627,"teacher_disagreement_score":0.35062426,"about_ca_system_score_codex":0.0002118237,"about_ca_system_score_gemma":0.0014326023,"threshold_uncertainty_score":0.9998551},"labels":[],"label_agreement":null},{"id":"W4200167174","doi":"10.1158/1535-7163.targ-21-p081","title":"Abstract P081: <i>In vitro</i> activity and efficacy of novel dual PARP-HDAC inhibitors","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"PARP inhibitor; Poly ADP ribose polymerase; DNA repair; Cancer research; Molecular biology; Synthetic lethality; Chemistry; Histone; Biology; Polymerase; DNA; Biochemistry","score_opus":0.03704472708377646,"score_gpt":0.3269870545350563,"score_spread":0.2899423274512798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200167174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881277,0.007198435,0.00056346785,0.0023614592,0.00026943703,0.0003138541,0.000071765535,0.000031622407,0.00106226],"genre_scores_gemma":[0.9950552,0.0013153703,0.00086501124,0.002467921,0.00012607401,0.000043724667,0.000011314885,0.000054857403,0.00006054839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983302,0.000051201227,0.00036545674,0.0004185499,0.0005089887,0.00032565588],"domain_scores_gemma":[0.999003,0.000088191504,0.00016095102,0.00041547706,0.00021488535,0.00011752168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019693136,0.00024359314,0.00046805615,0.000105233434,0.000038752034,0.000018752682,0.00006256866,0.00017115385,0.00009106185],"category_scores_gemma":[0.000023269542,0.00024724158,0.0001461549,0.0004002586,0.00017179962,0.00006821992,0.000044606066,0.00035563868,0.0000034543743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007572045,0.0006516395,0.0008415464,0.00011580898,0.00020872535,0.00013462633,0.00029349182,0.00008952363,0.9652841,0.00006828612,0.000035728182,0.031519286],"study_design_scores_gemma":[0.0067165066,0.000080013895,0.022079384,0.00024162799,0.00011763758,0.000049593236,0.000056156805,0.00013377066,0.9641863,0.000058753798,0.006053272,0.00022699498],"about_ca_topic_score_codex":0.00011889233,"about_ca_topic_score_gemma":0.000031705527,"teacher_disagreement_score":0.031292293,"about_ca_system_score_codex":0.00023015113,"about_ca_system_score_gemma":0.0004988267,"threshold_uncertainty_score":0.999998},"labels":[],"label_agreement":null},{"id":"W4200247581","doi":"10.1158/2767-9764.crc-21-0099","title":"Influence of Germline<i>BRCA</i>Genotype on the Survival of Patients with Triple-Negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"National Cancer Institute; Breast Cancer Research Foundation; Conquer Cancer Foundation; Avon Foundation for Women; American Cancer Society","keywords":"Triple-negative breast cancer; Breast cancer; Genotype; Germline; Oncology; Medicine; Triple negative; Internal medicine; Cancer; Biology; Genetics; Gene","score_opus":0.11314913289926067,"score_gpt":0.43653980548928767,"score_spread":0.323390672590027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200247581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97700393,0.0018815437,0.000014222428,0.017212838,0.00004056425,0.000746943,0.00095939677,0.000015427458,0.0021251251],"genre_scores_gemma":[0.9931583,0.005405006,0.00018209375,0.00026372037,0.00004009006,0.0005819941,0.00004927397,0.000026266687,0.0002932831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759495,0.0006130775,0.00035139624,0.00022094008,0.0009536388,0.0002660209],"domain_scores_gemma":[0.99216855,0.00093374983,0.00016457423,0.002122228,0.0045048296,0.00010606733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006114855,0.00012044737,0.00029381755,0.00010365273,0.00025858087,0.000011582729,0.0006611827,0.00005695964,0.0005638708],"category_scores_gemma":[0.00025814003,0.00008304169,0.00006584571,0.0013639765,0.0010277658,0.00008517049,0.00022767692,0.00066612265,0.000008545408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015053213,0.008078852,0.79514986,0.0014307196,0.004067618,0.000018017747,0.011739048,0.011460722,0.064015366,0.057800476,0.0109276865,0.020258442],"study_design_scores_gemma":[0.0054254653,0.00044902955,0.9500198,0.0027197595,0.0001004342,0.0000032896048,0.0009588673,0.0003189616,0.034382727,0.0008197177,0.0045762346,0.00022571956],"about_ca_topic_score_codex":0.0015007362,"about_ca_topic_score_gemma":0.0009580609,"teacher_disagreement_score":0.15486996,"about_ca_system_score_codex":0.00034640057,"about_ca_system_score_gemma":0.0017818878,"threshold_uncertainty_score":0.61739904},"labels":[],"label_agreement":null},{"id":"W4200270594","doi":"10.1038/s41594-021-00692-5","title":"Evolution of a histone variant involved in compartmental regulation of NAD metabolism","year":2021,"lang":"en","type":"article","venue":"Nature Structural & Molecular Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"NAD+ kinase; Chromatin; Biology; Histone; Biochemistry; Cell biology; Poly ADP ribose polymerase; Genetics; Gene; Enzyme; Polymerase","score_opus":0.007885386370023388,"score_gpt":0.34580319626901224,"score_spread":0.33791780989898884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200270594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850525,0.012419321,0.0008661907,0.0007118258,0.00042644827,0.00022230014,0.000050425835,0.000012692755,0.00023828946],"genre_scores_gemma":[0.9953787,0.000020747824,0.0038140435,0.0003534614,0.00005877889,0.00000742109,0.00033556047,0.000010051844,0.000021265227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998926,0.00015962851,0.00036776345,0.000245253,0.00015177207,0.00014962438],"domain_scores_gemma":[0.9992897,0.00001861927,0.0001868274,0.00023930226,0.00022551951,0.000040018036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008833325,0.00012266124,0.00042420684,0.0001512166,0.000015655663,0.0000013308722,0.00005941877,0.0003364893,0.00013407186],"category_scores_gemma":[0.0000695505,0.000109282475,0.000109881694,0.000360101,0.00015651963,0.000028770111,0.000029073459,0.00031363463,6.2227656e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002809893,0.000027466585,0.0022951064,0.00003959664,0.00006647087,0.000026233902,0.00006315832,0.00003522823,0.9493933,0.0473792,0.00007893039,0.00031435228],"study_design_scores_gemma":[0.0028885063,0.00010981149,0.19008157,0.000065962784,0.00005748822,0.00013390914,0.00004716767,0.0002605213,0.78854614,0.017184755,0.0005252883,0.000098863806],"about_ca_topic_score_codex":0.000060925446,"about_ca_topic_score_gemma":0.000032090113,"teacher_disagreement_score":0.18778646,"about_ca_system_score_codex":0.0002147045,"about_ca_system_score_gemma":0.00017380538,"threshold_uncertainty_score":0.445641},"labels":[],"label_agreement":null},{"id":"W4200276328","doi":"10.1097/ppo.0000000000000557","title":"With Our Powers Combined: Exploring PARP Inhibitors and Immunotherapy.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Poly ADP ribose polymerase; PARP inhibitor; Clinical trial; Medicine; Immunotherapy; Biomarker; Drug; Ovarian cancer; Drug development; Oncology; Cancer research; Cancer; Polymerase; Pharmacology; Internal medicine; Biology","score_opus":0.04303746637506662,"score_gpt":0.24615326759232456,"score_spread":0.20311580121725795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200276328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883993,0.0012456408,0.000025221008,0.005790606,0.00058914465,0.001003107,0.000011799701,0.0001518961,0.0027832869],"genre_scores_gemma":[0.99005777,0.00021772365,0.00009957495,0.0015876589,0.00015568819,0.0069398577,0.000010877636,0.000044229957,0.0008866431],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99883854,0.000050568324,0.00017618785,0.00025099932,0.00036188337,0.0003217892],"domain_scores_gemma":[0.99949074,0.00002273256,0.00007459618,0.00024052295,0.000030036044,0.00014135003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028826718,0.0001352652,0.00021006084,0.0001304273,0.00017828235,0.000020771331,0.00006489309,0.000021087097,0.00007761993],"category_scores_gemma":[0.000009608937,0.000120519,0.000042602114,0.0002581078,0.000042149353,0.00011636124,0.000045948367,0.00024897774,0.00000283332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015022264,0.0012169433,0.2786524,0.0002139004,0.0012966439,0.00053927815,0.0073786215,0.00023430069,0.0059402348,0.0013565266,0.041108515,0.64704037],"study_design_scores_gemma":[0.028132686,0.0017131995,0.5024373,0.00007840127,0.00011634781,0.0006789747,0.010406097,0.0000263822,0.01878538,0.0004500805,0.43628746,0.0008876874],"about_ca_topic_score_codex":0.000027313019,"about_ca_topic_score_gemma":0.0000016281072,"teacher_disagreement_score":0.6461527,"about_ca_system_score_codex":0.00019227329,"about_ca_system_score_gemma":0.000040110976,"threshold_uncertainty_score":0.4914622},"labels":[],"label_agreement":null},{"id":"W4200437485","doi":"10.3390/ph14121270","title":"Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer","year":2021,"lang":"en","type":"review","venue":"Pharmaceuticals","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Université de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Breast cancer; Triple-negative breast cancer; BRCA mutation; PARP inhibitor; Metastatic breast cancer; Oncology; Chemotherapy; Internal medicine; Cancer; Cancer research; Poly ADP ribose polymerase; Polymerase; Biology; Gene; Genetics","score_opus":0.2316399911823588,"score_gpt":0.492579449085121,"score_spread":0.2609394579027622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200437485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031491898,0.9929678,0.00001124501,0.0013705263,0.00027376047,0.0020184973,0.00011957176,0.000016756718,0.000072677976],"genre_scores_gemma":[0.003368487,0.9948306,0.0000573241,0.00075613294,0.00013761787,0.0006597899,0.000027854363,0.000052400952,0.000109784785],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974327,0.00063368876,0.00091369584,0.00040473888,0.00033261432,0.00028257596],"domain_scores_gemma":[0.99802756,0.0011688382,0.00034304307,0.00024344886,0.000105051404,0.00011208125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005606929,0.00032924663,0.0015471217,0.00035844764,0.000035188616,0.000033133485,0.00009323239,0.00020882793,0.00043012918],"category_scores_gemma":[0.0001500926,0.00023418205,0.00020008892,0.00090680766,0.0002153895,0.00014517277,0.000044508102,0.00070502836,0.000004315583],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029741097,0.0003444354,0.0012740698,0.0039676116,0.00026966183,0.000048611884,0.00077001983,0.0000058419937,0.0001286125,0.00015316824,0.0005597745,0.99218076],"study_design_scores_gemma":[0.010676149,0.000086671615,0.00069218595,0.060298383,0.0007212008,0.00022849278,0.00017504914,0.00015064336,0.002763817,0.00026229143,0.9233922,0.00055292307],"about_ca_topic_score_codex":0.0002152707,"about_ca_topic_score_gemma":0.000028545595,"teacher_disagreement_score":0.9916279,"about_ca_system_score_codex":0.00047009293,"about_ca_system_score_gemma":0.0004212047,"threshold_uncertainty_score":0.9549667},"labels":[],"label_agreement":null},{"id":"W4200504528","doi":"10.1158/1535-7163.mct-21-0615","title":"RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors","year":2021,"lang":"en","type":"letter","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent; Telesta Therapeutics (Canada); Aegera Therapeutics (Canada)","funders":"","keywords":"Kinase; Olaparib; Pharmacology; In vivo; DNA damage; PARP inhibitor; PI3K/AKT/mTOR pathway; Cancer research; Chemistry; Biology; Biochemistry; Signal transduction; DNA; Poly ADP ribose polymerase","score_opus":0.04383461660618057,"score_gpt":0.33004020380099386,"score_spread":0.28620558719481326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200504528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5880611,0.03883379,0.0033460413,0.36205402,0.0005297603,0.006372121,0.00019034334,0.0001313403,0.00048146353],"genre_scores_gemma":[0.5149267,0.0075756903,0.0007239834,0.4737989,0.0006095039,0.0016561494,0.00014925198,0.00030798506,0.000251859],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99599147,0.000413838,0.0006679162,0.0014040584,0.00085383316,0.00066887465],"domain_scores_gemma":[0.9983562,0.00027759743,0.0003897884,0.0005396734,0.00029762535,0.00013909127],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00034101613,0.0008206949,0.0012934541,0.000553044,0.00007606114,0.000109395565,0.00013910647,0.001266112,0.000025863761],"category_scores_gemma":[0.000014534016,0.00076759333,0.00017462358,0.0007625483,0.00037454147,0.0002025493,0.000072858435,0.002669179,0.0000019024999],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05595026,0.010254471,0.19154719,0.009518212,0.026592784,0.019801343,0.07007995,0.0034530659,0.23848769,0.0006323247,0.079713084,0.29396963],"study_design_scores_gemma":[0.15246643,0.0122785615,0.021742446,0.025592288,0.0039602877,0.0018147395,0.0013224886,0.014919832,0.49817568,0.016321143,0.2433088,0.008097304],"about_ca_topic_score_codex":0.0005584962,"about_ca_topic_score_gemma":0.0002389486,"teacher_disagreement_score":0.2858723,"about_ca_system_score_codex":0.001018439,"about_ca_system_score_gemma":0.00067172974,"threshold_uncertainty_score":0.9996317},"labels":[],"label_agreement":null},{"id":"W4200532207","doi":"10.1097/ppo.0000000000000557","title":"With Our Powers Combined","year":2021,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Poly ADP ribose polymerase; Ovarian cancer; Drug; Drug development; Oncology; Biomarker; Cancer research; Cancer; Polymerase; Pharmacology; Internal medicine; Biology","score_opus":0.09549906900283468,"score_gpt":0.43432956745982276,"score_spread":0.3388304984569881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200532207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005460211,0.99331087,0.00009142693,0.0034123568,0.001125422,0.00046115284,0.00002999374,0.000029907256,0.0015334212],"genre_scores_gemma":[0.0000110533765,0.99338454,0.000116215706,0.0013677905,0.0024402838,0.00011497038,0.000024130448,0.00009886097,0.0024421385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980746,0.00024879372,0.00052475,0.00026238826,0.000543609,0.00034586174],"domain_scores_gemma":[0.99829745,0.000057140922,0.0005981867,0.0005482825,0.00026439346,0.00023454119],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046052525,0.000369855,0.0015913168,0.00011906311,0.00020794936,0.000092537375,0.00033042813,0.00015546908,0.0012225244],"category_scores_gemma":[0.000021871414,0.00018207422,0.0005546563,0.00043646997,0.000073362586,0.000051631912,0.00003574695,0.001689472,0.000047381323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014578436,0.000054721855,0.0000133578515,0.0023728712,0.0018020881,0.000523953,0.00012502453,0.0000049020446,0.0000015355729,0.000079080775,0.12931302,0.8655637],"study_design_scores_gemma":[0.0014238294,0.00019648275,0.0000030136011,0.038530417,0.0018810699,0.007339484,0.00013658227,4.7026296e-7,0.00000570808,0.000035677833,0.9502332,0.00021404577],"about_ca_topic_score_codex":0.000008730817,"about_ca_topic_score_gemma":0.000004202994,"teacher_disagreement_score":0.8653496,"about_ca_system_score_codex":0.00081269676,"about_ca_system_score_gemma":0.0031273228,"threshold_uncertainty_score":0.9996905},"labels":[],"label_agreement":null},{"id":"W4205422786","doi":"10.1016/j.ygyno.2021.12.025","title":"Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck; AstraZeneca","keywords":"Medicine; Olaparib; Clinical endpoint; Internal medicine; Oncology; Adverse effect; Ovarian cancer; BRCA mutation; Tolerability; Progression-free survival; Discontinuation; Progressive disease; Population; Nausea; Chemotherapy; Cancer; Surgery; Clinical trial","score_opus":0.021674573050316847,"score_gpt":0.326532917806484,"score_spread":0.3048583447561672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205422786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807679,0.00036626015,0.000841031,0.0068339757,0.0016272158,0.0018154442,0.00024272577,0.00016165394,0.007343808],"genre_scores_gemma":[0.9800306,0.00034105446,0.0024231153,0.01353447,0.00021044967,0.001717189,0.00080968253,0.00004412569,0.00088931294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963952,0.0007812716,0.00090368313,0.0008291636,0.0004801754,0.0006105496],"domain_scores_gemma":[0.99789315,0.00060137635,0.0006505568,0.00041904746,0.00028597735,0.00014986655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008610321,0.00032768562,0.0011533174,0.0006752813,0.0002782915,0.00001290194,0.00020525351,0.00027983944,0.00352997],"category_scores_gemma":[0.0001890806,0.00031776677,0.0002475748,0.0017744997,0.00020460463,0.00011475058,0.00012239952,0.00083667727,0.000025160958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013383544,0.0056459154,0.8666165,0.00009710408,0.002817749,0.0010597659,0.007078984,0.017540809,0.0041020913,0.0008288783,0.011272814,0.06955586],"study_design_scores_gemma":[0.031178921,0.0044493256,0.9077471,0.000042424654,0.00037011204,0.00008937546,0.0007041898,0.0032059364,0.00032334047,0.00070480525,0.050666843,0.00051765004],"about_ca_topic_score_codex":0.00041451104,"about_ca_topic_score_gemma":0.00062097353,"teacher_disagreement_score":0.069038205,"about_ca_system_score_codex":0.0050744885,"about_ca_system_score_gemma":0.00091964705,"threshold_uncertainty_score":0.99992746},"labels":[],"label_agreement":null},{"id":"W4205632236","doi":"10.1177/17588359211059601","title":"Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1</i> / <i>2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Hazard ratio; Veliparib; Breast cancer; Metastatic breast cancer; Clinical endpoint; Placebo; BRCA mutation; Germline mutation","score_opus":0.026685671906534997,"score_gpt":0.392095379246344,"score_spread":0.36540970733980904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205632236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95167816,0.03669081,0.0032473279,0.005014655,0.00025809626,0.001757726,0.0012191662,0.000031532778,0.000102513404],"genre_scores_gemma":[0.9517725,0.04028705,0.0033164374,0.0036401511,0.00014385371,0.00028939277,0.00046716494,0.000050307335,0.000033158827],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99623203,0.00075178064,0.0011387785,0.00061476126,0.00077303353,0.000489621],"domain_scores_gemma":[0.9941836,0.004485149,0.00048793704,0.00030654197,0.00023736547,0.00029940152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047573177,0.00034725244,0.0013115425,0.00010014847,0.00009366125,0.000011045759,0.0001540424,0.00019519601,0.00042685826],"category_scores_gemma":[0.00048429772,0.00022324586,0.000060844464,0.0007928552,0.0013563902,0.00021384715,0.00006127159,0.0007249322,9.264098e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36913848,0.0037969942,0.007409877,0.00009544042,0.0008220122,0.000100875426,0.0036258262,0.0004179586,0.0021748492,0.00009134481,0.00010671563,0.61221963],"study_design_scores_gemma":[0.87500465,0.013418138,0.0690365,0.001497107,0.0010688864,0.00007965499,0.0048396112,0.0015811236,0.0017382265,0.0009792494,0.02993872,0.0008181622],"about_ca_topic_score_codex":0.0005834138,"about_ca_topic_score_gemma":0.002391572,"teacher_disagreement_score":0.6114015,"about_ca_system_score_codex":0.0004997524,"about_ca_system_score_gemma":0.0015563896,"threshold_uncertainty_score":0.91037023},"labels":[],"label_agreement":null},{"id":"W4205835660","doi":"10.3390/ijms23020920","title":"Reduced Colonic Mucosal Injury in 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Poly ADP-Ribose Polymerase (TIPARP/PARP7)-Deficient Mice","year":2022,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; University of Toronto","keywords":"Aryl hydrocarbon receptor; Inflammation; Immune system; Poly ADP ribose polymerase; Biology; Receptor; Chemokine; Signal transduction; CXCL1; Chemistry; Immunology; Molecular biology; Biochemistry; Polymerase; Transcription factor; Gene","score_opus":0.019066004776773105,"score_gpt":0.33532039568390465,"score_spread":0.31625439090713153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205835660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97961575,0.003552148,0.00027380802,0.012762646,0.0024243963,0.00017608106,0.000044374458,0.000016872078,0.001133949],"genre_scores_gemma":[0.9951624,0.000106150444,0.0010597768,0.0032133132,0.00031656597,0.000023041533,0.0000074530294,0.000017599026,0.000093685994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996038,0.00022481661,0.0008006889,0.00033423057,0.0022661255,0.00033613015],"domain_scores_gemma":[0.99865687,0.00009311519,0.0005670939,0.00016620326,0.00033847793,0.00017823484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014712504,0.00017907044,0.00031467405,0.001032313,0.0001584673,0.00008201362,0.0009014584,0.00004882246,0.0007680911],"category_scores_gemma":[0.00017738562,0.00016916732,0.00023289835,0.0007959424,0.00028217488,0.00025919446,0.00016753483,0.0005871255,0.000011916511],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019905556,0.0010659094,0.0037763438,0.000009469887,0.00017380317,0.0024281414,0.0010253342,0.0019667975,0.9757716,0.0015429013,0.0024100975,0.0078390455],"study_design_scores_gemma":[0.008611763,0.004343916,0.013190654,0.00038825534,0.00010026533,0.008483512,0.0026288915,0.0013809728,0.9397442,0.0018242694,0.01865296,0.00065035245],"about_ca_topic_score_codex":0.00009829715,"about_ca_topic_score_gemma":0.000005400063,"teacher_disagreement_score":0.036027417,"about_ca_system_score_codex":0.0006992669,"about_ca_system_score_gemma":0.0011560862,"threshold_uncertainty_score":0.8410059},"labels":[],"label_agreement":null},{"id":"W4206015794","doi":"10.1038/s41556-021-00819-2","title":"Unsprung traps keep PARP inhibitors effective","year":2022,"lang":"en","type":"letter","venue":"Nature Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canada Research Chairs","keywords":"Poly ADP ribose polymerase; PARP1; PARP inhibitor; Polymerase; Cell biology; Ubiquitin; Cytotoxicity; DNA damage; Chemistry; DNA; Molecular biology; Biology; Biochemistry; In vitro; Gene","score_opus":0.007273215401923557,"score_gpt":0.28219298505240364,"score_spread":0.2749197696504801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206015794","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012665623,0.04876779,0.0000402421,0.84513706,0.02071089,0.0043634586,0.0011054189,0.00069137424,0.06651815],"genre_scores_gemma":[0.03481294,0.0007791233,0.0001541613,0.93675506,0.015813578,0.00074790104,0.0054549454,0.00017568158,0.0053065936],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967371,0.00058534706,0.00047126142,0.0010965815,0.00037830282,0.00073135976],"domain_scores_gemma":[0.9980017,0.00065435126,0.00035923522,0.0007317646,0.00014129885,0.00011167915],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0003005385,0.00062383094,0.0010636952,0.0004727482,0.0001670841,0.000012749547,0.00032464383,0.0052175494,0.0037348946],"category_scores_gemma":[0.000072726514,0.0005459219,0.00050303404,0.00044490022,0.00029266026,0.00003087246,0.00010807903,0.013873095,0.00015368605],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033475878,0.000066816836,0.00027066233,0.0002971127,0.00024105531,0.0007169399,0.00010532705,0.0000011016435,0.015260881,0.00002673698,0.9775916,0.005087046],"study_design_scores_gemma":[0.0022188853,0.0011356428,0.00011436715,0.0000899437,0.00019362279,0.00012358851,0.000018078848,0.000002041427,0.020041725,0.0004783376,0.97509766,0.000486109],"about_ca_topic_score_codex":0.00003589199,"about_ca_topic_score_gemma":0.0000036346146,"teacher_disagreement_score":0.091618024,"about_ca_system_score_codex":0.00069786253,"about_ca_system_score_gemma":0.00025316898,"threshold_uncertainty_score":0.99969923},"labels":[],"label_agreement":null},{"id":"W4206811576","doi":"10.3390/curroncol29010029","title":"Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Relative risk; Nausea; Placebo; Gastroenterology; Adverse effect; Vomiting; Neutropenia; Meta-analysis; Chemotherapy; Confidence interval; Pathology","score_opus":0.3526335006968984,"score_gpt":0.5171390244212152,"score_spread":0.16450552372431676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206811576","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.4911064e-8,0.9811977,0.00023934907,0.0009600048,0.0003851845,0.014698155,0.0019907132,0.00003555246,0.000493225],"genre_scores_gemma":[6.203052e-7,0.96362436,0.00024355772,0.0009675784,0.00009254657,0.0333134,0.0007189598,0.000063482206,0.00097549777],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951652,0.001117813,0.0021947077,0.0007738761,0.00037391717,0.00037448187],"domain_scores_gemma":[0.9951168,0.000990112,0.0025275873,0.0009180039,0.00029085064,0.0001566591],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018016546,0.0005806646,0.01611467,0.00041119946,0.00010375947,0.000008033343,0.00032779534,0.00023724377,0.007246309],"category_scores_gemma":[0.00029172082,0.0003775175,0.0039515593,0.0011660162,0.00016936142,0.0000355729,0.000081664606,0.0005617903,0.000009272633],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008458221,0.00025346485,6.9652117e-7,0.77664757,0.12859432,0.000004332589,0.000056080084,1.6994838e-7,9.331906e-8,0.000438226,0.0041515813,0.0897689],"study_design_scores_gemma":[0.0006914852,0.0003408654,1.6001086e-7,0.019179216,0.4362634,0.00005849745,0.000008399864,0.0000021100304,3.111924e-7,0.000027922506,0.5432679,0.00015973684],"about_ca_topic_score_codex":0.000026550615,"about_ca_topic_score_gemma":0.000010662108,"teacher_disagreement_score":0.75746834,"about_ca_system_score_codex":0.0008772855,"about_ca_system_score_gemma":0.0015761916,"threshold_uncertainty_score":0.9998677},"labels":[],"label_agreement":null},{"id":"W4206819073","doi":"10.1200/jco.2021.39.15_suppl.5545","title":"Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Clinical endpoint; Progression-free survival; Ovarian cancer; Oncology; Progressive disease; Phases of clinical research; BRCA mutation; Placebo; Cancer; Chemotherapy; Clinical trial; Pathology","score_opus":0.08132424089107043,"score_gpt":0.47161472250334985,"score_spread":0.3902904816122794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206819073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9334654,0.0006505261,0.038726415,0.01733144,0.006292816,0.0013001453,0.00036673064,0.000041397627,0.0018251217],"genre_scores_gemma":[0.9401475,0.0048108087,0.02193941,0.026741913,0.0044120466,0.00010073008,0.00054844713,0.00011188464,0.0011872533],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927986,0.0006554432,0.004561938,0.0006713767,0.00070836756,0.0006042751],"domain_scores_gemma":[0.98814905,0.002866664,0.0042524925,0.00050559803,0.0035722353,0.0006539388],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030983493,0.00040493684,0.0035850736,0.0003958652,0.00014065213,0.000028164943,0.00024624233,0.0007915306,0.00045795421],"category_scores_gemma":[0.0020039368,0.000333784,0.0017042042,0.0009929613,0.0003255291,0.00025786422,0.00005552198,0.0015206254,0.00001325633],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1879217,0.030330908,0.07768453,0.00038240643,0.029846746,0.0025105907,0.00206691,0.0019979517,0.028722802,0.00019380263,0.15167002,0.48667163],"study_design_scores_gemma":[0.35684767,0.034426425,0.3399415,0.001402172,0.0050993785,0.0003711696,0.0003186164,0.010705344,0.010265997,0.0009288564,0.23867594,0.0010169214],"about_ca_topic_score_codex":0.00005117765,"about_ca_topic_score_gemma":0.00006174415,"teacher_disagreement_score":0.4856547,"about_ca_system_score_codex":0.0011336529,"about_ca_system_score_gemma":0.0048315628,"threshold_uncertainty_score":0.9999114},"labels":[],"label_agreement":null},{"id":"W4206836066","doi":"10.2196/36385","title":"Correction: Candidemia Risk Prediction (CanDETEC) Model for Patients With Malignancy: Model Development and Validation in a Single-Center Retrospective Study","year":2022,"lang":"en","type":"erratum","venue":"JMIR Medical Informatics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Medicine; Malignancy; Retrospective cohort study; Intensive care medicine; Medical physics; Internal medicine","score_opus":0.0217497516415571,"score_gpt":0.28499340462216605,"score_spread":0.2632436529806089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206836066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83792365,0.0001752205,0.10565595,0.00030817298,0.018669127,0.02317232,0.002435057,0.0005462209,0.011114308],"genre_scores_gemma":[0.88506776,0.00086433627,0.01870344,0.0030825043,0.0018514023,0.024088226,0.01934841,0.00048719073,0.046506718],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9959151,0.00006398819,0.0013550692,0.0003573809,0.0019159195,0.00039250354],"domain_scores_gemma":[0.9981618,0.00006338753,0.000802873,0.00032909142,0.00035271214,0.00029014863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064891233,0.0004232696,0.0007477799,0.0004196924,0.00024693078,0.00004372853,0.00013762448,0.000528709,0.000106692336],"category_scores_gemma":[0.00020148192,0.00036110668,0.00007022776,0.00033575288,0.00009923994,0.00028973288,0.00010500314,0.0016872773,0.0000017282981],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034422302,0.0044820495,0.23035519,0.0012830949,0.0006105507,0.0000159662,0.060588434,0.003499479,3.6363704e-7,0.000009783387,0.6844347,0.011278145],"study_design_scores_gemma":[0.018945727,0.0029811147,0.011947843,0.0019842302,0.00021857941,0.000035149045,0.0018241231,0.9466063,0.0000055629657,0.00009421196,0.014831057,0.0005261477],"about_ca_topic_score_codex":0.000018125265,"about_ca_topic_score_gemma":0.0001837898,"teacher_disagreement_score":0.9431068,"about_ca_system_score_codex":0.0025404387,"about_ca_system_score_gemma":0.0016785003,"threshold_uncertainty_score":0.99988407},"labels":[],"label_agreement":null},{"id":"W4210274145","doi":"10.1016/j.ygyno.2022.01.024","title":"Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Tolerability; Hazard ratio; Internal medicine; Oncology; Discontinuation; Placebo; Ovarian cancer; Cohort; PARP inhibitor; Confidence interval; Cancer; Adverse effect; Pathology","score_opus":0.026386577534941197,"score_gpt":0.3524282690015788,"score_spread":0.32604169146663764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210274145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954862,0.00004494266,0.00004403253,0.00064033153,0.00031270357,0.0027360127,0.00022222377,0.000021584594,0.00049196836],"genre_scores_gemma":[0.9986023,0.000021488104,0.00015637759,0.0006885123,0.000019173101,0.00039662994,0.00007739491,0.000014701537,0.000023441637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973027,0.0007726722,0.000765963,0.00048060404,0.0003585397,0.00031951416],"domain_scores_gemma":[0.9978547,0.0009007857,0.0005913502,0.0003602726,0.00019668412,0.00009619864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007608417,0.00020495136,0.0011604667,0.0004868347,0.00017795687,0.000004011613,0.00017699003,0.00009327274,0.00038920544],"category_scores_gemma":[0.00026965895,0.00014935713,0.00009337131,0.0021594716,0.00018781936,0.000034277473,0.00026622356,0.00044685043,5.2103127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029122967,0.0097506875,0.87280047,0.000029063858,0.0029383604,0.00017544962,0.018109087,0.009984899,0.0029322002,0.00006292248,0.00018293655,0.05391093],"study_design_scores_gemma":[0.047788057,0.013075934,0.930646,0.00003954642,0.0012344867,0.0000052578584,0.0056530875,0.0003758405,0.00035361986,0.000015122836,0.00064345356,0.0001695887],"about_ca_topic_score_codex":0.0004805538,"about_ca_topic_score_gemma":0.0024788347,"teacher_disagreement_score":0.057845507,"about_ca_system_score_codex":0.0011373805,"about_ca_system_score_gemma":0.0003530767,"threshold_uncertainty_score":0.6090607},"labels":[],"label_agreement":null},{"id":"W4210332821","doi":"10.1016/s1470-2045(21)00757-9","title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Janssen Biotech; Daiichi Sankyo Europe; National Cancer Institute; Pharmacyclics; Stand Up To Cancer; Janssen Research and Development; EMD Serono; Genentech; Ipsen; Astellas Pharma; Daiichi-Sankyo; Seagen; Pfizer; Incyte; National Institutes of Health; Menarini Silicon Biosystems; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Exelixis; Flatiron Health; Advanced Accelerator Applications; Endocyte; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; American Association for Cancer Research; Amgen","keywords":"Prostate cancer; DNA repair; Gene; DNA; DNA Damage Repair; Phase (matter); Cancer","score_opus":0.08052415143704984,"score_gpt":0.39797207989690686,"score_spread":0.31744792845985703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210332821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916382,0.0005547708,0.000004282063,0.00286471,0.0002885885,0.0039005014,0.000255927,0.00005012623,0.00044290267],"genre_scores_gemma":[0.9922467,0.0001430164,0.0012976038,0.0032473218,0.00017693147,0.0024718756,0.00012492659,0.00003209997,0.00025955352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979945,0.00054885756,0.00038885872,0.000369797,0.00031460368,0.00038340865],"domain_scores_gemma":[0.99898326,0.00020914932,0.0002685485,0.00036180308,0.00008542295,0.000091816815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081237906,0.00017628497,0.0006278191,0.00008240715,0.00022255098,0.000024550089,0.00017952968,0.00003482892,0.00024163359],"category_scores_gemma":[0.000055946017,0.00012286931,0.000026252656,0.00033250678,0.00015320214,0.000099751844,0.0001269435,0.00036468776,0.0000029704886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9305204,0.008661733,0.024905825,0.0001676834,0.0006718786,0.0004481533,0.0058770357,0.00026400885,0.011357681,0.0004992569,0.009280877,0.0073454385],"study_design_scores_gemma":[0.90873975,0.020560721,0.018674962,0.000083192164,0.00038580532,0.000049525475,0.000554871,0.00047096988,0.00096219487,0.00022502965,0.048980445,0.00031256024],"about_ca_topic_score_codex":0.00033912805,"about_ca_topic_score_gemma":0.00091791386,"teacher_disagreement_score":0.03969957,"about_ca_system_score_codex":0.0006083083,"about_ca_system_score_gemma":0.00063168176,"threshold_uncertainty_score":0.5010465},"labels":[],"label_agreement":null},{"id":"W4210532624","doi":"10.3390/curroncol29020049","title":"An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; Internal medicine; Pancreatic cancer; BRCA mutation; Ovarian cancer; Adenocarcinoma; Chemotherapy; Metastatic breast cancer; Cancer research; Cancer; Breast cancer; Poly ADP ribose polymerase","score_opus":0.11462980701418775,"score_gpt":0.4355525727982325,"score_spread":0.3209227657840448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210532624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98994094,0.0055581094,0.00007151304,0.0013819619,0.00078730774,0.0016688377,0.000112908325,0.00019609705,0.00028234755],"genre_scores_gemma":[0.99266165,0.0009097284,0.00038581772,0.00028017093,0.00019465633,0.004866737,0.00040643502,0.0000672172,0.00022755405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974726,0.0006195519,0.0005072299,0.0006223593,0.00032929558,0.00044897696],"domain_scores_gemma":[0.998899,0.00007154367,0.00025592823,0.00043616007,0.0001317953,0.000205573],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017807496,0.00032684085,0.00078665646,0.0003744914,0.00017733408,0.000013995078,0.00011911763,0.000042861564,0.0023724975],"category_scores_gemma":[0.0000070660203,0.00027098402,0.00008179454,0.0010462747,0.00016214787,0.00010436905,0.000015869295,0.00039907443,0.0000098986075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067387536,0.043792684,0.2978134,0.0004461993,0.0036441546,0.0031317484,0.03744075,0.012790588,0.16659613,0.00036759477,0.0059075556,0.36068168],"study_design_scores_gemma":[0.24287286,0.13414405,0.106121995,0.00119311,0.0033348207,0.008894881,0.01806363,0.021840205,0.06755964,0.0009162709,0.39192054,0.003138005],"about_ca_topic_score_codex":0.00084651506,"about_ca_topic_score_gemma":0.0002921037,"teacher_disagreement_score":0.38601297,"about_ca_system_score_codex":0.004369657,"about_ca_system_score_gemma":0.0012098512,"threshold_uncertainty_score":0.99997425},"labels":[],"label_agreement":null},{"id":"W4210699573","doi":"10.1101/2022.01.24.477471","title":"Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; PARP inhibitor; Poly ADP ribose polymerase; Synthetic lethality; Cancer research; Cytotoxicity; Medicine; Chemistry; Pharmacology; DNA repair; Biochemistry; Enzyme; In vitro; Polymerase","score_opus":0.035295155704558184,"score_gpt":0.2989730520393319,"score_spread":0.2636778963347737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210699573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98712015,0.0010343099,0.0032808941,0.003608258,0.00039912507,0.0027506643,0.0016262295,0.00017034511,0.000010041763],"genre_scores_gemma":[0.9890778,0.0005108092,0.006851769,0.00027729513,0.00015776108,0.0030282582,0.000013401488,0.00007994921,0.0000029724781],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965085,0.00022783088,0.0014682552,0.0010718685,0.00033438488,0.00038917558],"domain_scores_gemma":[0.9966934,0.0005411394,0.00089831336,0.0009931576,0.0006455318,0.00022850557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013509545,0.0004201006,0.000950724,0.00033521853,0.00019453719,0.00006310077,0.00021497553,0.0004634831,0.000042000764],"category_scores_gemma":[0.0008463206,0.00047240037,0.00020699338,0.0005664298,0.00035677408,0.00013177715,0.00027574968,0.0009026476,0.0000011664189],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003936675,0.0019264839,0.37842745,0.001605442,0.00018658747,0.000002351603,0.00005531884,0.00002953524,0.6142681,0.002565004,0.0005274176,0.000012646872],"study_design_scores_gemma":[0.008179724,0.0008372492,0.8592326,0.0016506593,0.00031679438,7.580788e-8,0.000056767454,0.0010218272,0.12575932,0.0004587486,0.0014084856,0.0010777469],"about_ca_topic_score_codex":0.000056014982,"about_ca_topic_score_gemma":0.000004200991,"teacher_disagreement_score":0.4885088,"about_ca_system_score_codex":0.00046877496,"about_ca_system_score_gemma":0.0007769422,"threshold_uncertainty_score":0.9997728},"labels":[],"label_agreement":null},{"id":"W4211106526","doi":"10.1158/1078-0432.ccr-21-3045","title":"Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; National Institutes of Health; Breast Cancer Alliance; Sierra Oncology; Ipsen; Genentech; Deutsche Krebshilfe; G1 Therapeutics; Stand Up To Cancer; EMD Serono; Mersana Therapeutics; Merck KGaA; Dana-Farber/Harvard Cancer Center; GlaxoSmithKline; Breast Cancer Research Foundation; Pfizer; Symphogen; Carrick Therapeutics; American Association for Cancer Research; AstraZeneca; Eli Lilly and Company; Astex Pharmaceuticals","keywords":"Olaparib; PARP inhibitor; Clinical trial; Breast cancer; Cancer; Phases of clinical research; Poly ADP ribose polymerase","score_opus":0.2879403571378599,"score_gpt":0.59430337590085,"score_spread":0.3063630187629901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211106526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766904,0.0005687833,0.00023406897,0.0060924855,0.0021349543,0.010166166,0.0034235776,0.00011898346,0.0005705669],"genre_scores_gemma":[0.97138363,0.0011149074,0.0010222828,0.0028317133,0.0034822319,0.017080456,0.00028981475,0.00018784394,0.0026071398],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9914276,0.0015025913,0.0017277364,0.0015344536,0.002620842,0.0011867568],"domain_scores_gemma":[0.9911167,0.004059516,0.00056428794,0.0009921896,0.0023921411,0.0008751495],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005262504,0.0003990364,0.0014121989,0.00026851238,0.0007924484,0.000060941373,0.00057475176,0.00023086795,0.0031555414],"category_scores_gemma":[0.0011843863,0.00029371833,0.0004282995,0.0013171684,0.0014481533,0.00024041953,0.00025532235,0.002987245,0.000020079664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8375576,0.011500262,0.016856601,0.00009673581,0.00065126125,0.000039085593,0.00020976679,0.00009600284,0.00001795593,0.00007446827,0.035281856,0.09761837],"study_design_scores_gemma":[0.8135908,0.07038568,0.017915614,0.00036463072,0.00024212807,0.00001173389,0.00039894783,0.00041512572,0.000101726866,0.00022054014,0.09582731,0.0005257607],"about_ca_topic_score_codex":0.00043230798,"about_ca_topic_score_gemma":0.00029756656,"teacher_disagreement_score":0.097092606,"about_ca_system_score_codex":0.0016660623,"about_ca_system_score_gemma":0.0058660917,"threshold_uncertainty_score":0.9999515},"labels":[],"label_agreement":null},{"id":"W4212780237","doi":"10.1200/jco.2022.40.6_suppl.012","title":"Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Abiraterone acetate; Enzalutamide; Oncology; Progression-free survival; Cancer; Androgen deprivation therapy; Androgen receptor; Randomized controlled trial; Chemotherapy","score_opus":0.08166941178403357,"score_gpt":0.42743641200162674,"score_spread":0.34576700021759316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212780237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355954,0.00050843856,0.000061262384,0.0036595794,0.00015344049,0.0018845665,0.000105420266,0.000017357754,0.00005042055],"genre_scores_gemma":[0.99179184,0.0014571393,0.0056816568,0.000528049,0.000077691606,0.0002485818,0.000039121165,0.000039623475,0.0001362869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955411,0.0007618254,0.0022717547,0.000454565,0.00071367505,0.00025705446],"domain_scores_gemma":[0.9955055,0.0005561537,0.0025796266,0.0002684256,0.00086877844,0.00022149808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024953932,0.00027101778,0.0014018224,0.00028131623,0.00018866907,0.000022704226,0.0001040277,0.00008377186,0.00005894652],"category_scores_gemma":[0.0002452209,0.00017908184,0.00007212204,0.0003863501,0.00039590348,0.0002601509,0.000038951915,0.0007312207,3.4559343e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40788275,0.028646132,0.5135117,0.0001473063,0.0020366206,0.00088135124,0.0052577136,0.0033942896,0.0005081762,0.000010480139,0.00033196618,0.037391488],"study_design_scores_gemma":[0.2617451,0.3602795,0.37263873,0.00031002448,0.00064172025,0.00051369925,0.0007581025,0.0003533793,0.0005284859,0.00008971786,0.0018706485,0.00027088734],"about_ca_topic_score_codex":0.00029957388,"about_ca_topic_score_gemma":0.0030425787,"teacher_disagreement_score":0.33163336,"about_ca_system_score_codex":0.00031672232,"about_ca_system_score_gemma":0.0012714288,"threshold_uncertainty_score":0.73027456},"labels":[],"label_agreement":null},{"id":"W4212814600","doi":"10.15252/embj.2021108650","title":"PABP prevents the untimely decay of select mRNA populations in human cells","year":2022,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Vetenskapsrådet; Universities Space Research Association","keywords":"Library science; Judaism; Conceptualization; History; Computer science; Artificial intelligence; Archaeology","score_opus":0.060842454203455076,"score_gpt":0.3579697066817,"score_spread":0.2971272524782449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212814600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927145,0.0004595359,0.0001120691,0.0030953581,0.00031857987,0.00026544594,0.000010065806,0.000009406655,0.0030150164],"genre_scores_gemma":[0.99781924,0.000033676282,0.00012392555,0.0005750016,0.0002244548,0.000022473201,0.0000038953704,0.00001594561,0.0011814035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859035,0.00036110237,0.00036776028,0.00008034244,0.00042707144,0.00017335372],"domain_scores_gemma":[0.9993692,0.00006526816,0.00023748158,0.00023495572,0.000048081023,0.0000450331],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010745237,0.000078385914,0.00015983042,0.00010399608,0.00048197206,0.0000137332645,0.00024289539,0.000016151034,0.0021022917],"category_scores_gemma":[0.000010538159,0.000046995578,0.00010308173,0.00034318696,0.000059913276,0.00004293165,0.00004861323,0.0006515417,0.00000653467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013115822,0.001830812,0.08515232,0.00007331758,0.00065963704,0.00018492254,0.018966423,0.02769726,0.72653484,0.011712586,0.11785063,0.008025653],"study_design_scores_gemma":[0.02258684,0.003235884,0.36189568,0.00084682484,0.0007699475,0.007304719,0.0059028943,0.0018280209,0.37960976,0.1242207,0.09088641,0.0009123239],"about_ca_topic_score_codex":0.000045211906,"about_ca_topic_score_gemma":0.000015739324,"teacher_disagreement_score":0.3469251,"about_ca_system_score_codex":0.00018131838,"about_ca_system_score_gemma":0.0001288758,"threshold_uncertainty_score":0.99880993},"labels":[],"label_agreement":null},{"id":"W4213056115","doi":"10.3390/cancers14040915","title":"Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"PharmaMar; AstraZeneca España","keywords":"Olaparib; Medicine; Tolerability; Internal medicine; Oncology; Statistical significance; Ovarian cancer; Clinical trial; Phases of clinical research; Clinical significance; Gastroenterology; Cancer; Gene; Adverse effect; Biology; Polymerase","score_opus":0.02350924898876809,"score_gpt":0.332311343456145,"score_spread":0.3088020944673769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213056115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941834,0.00009328771,0.0000055633586,0.00016089383,0.00018431187,0.00503507,0.00017891965,0.000013891543,0.00014461152],"genre_scores_gemma":[0.9994222,0.0000039372935,0.000023274551,0.000052986412,0.000053401698,0.00037405675,0.000038659273,0.000016215105,0.000015277139],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99779487,0.00029821394,0.00074327574,0.00032166304,0.00068852096,0.00015344367],"domain_scores_gemma":[0.99888664,0.00026775672,0.00033178672,0.00032286212,0.00013712855,0.000053811094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006292965,0.00014212968,0.0006099406,0.00013054466,0.00008325164,0.0000041363787,0.000116133815,0.00001993799,0.00005912579],"category_scores_gemma":[0.00009330816,0.00010303082,0.00004655683,0.00050647254,0.0002174632,0.000056549034,0.00003407394,0.00025653152,8.563861e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9155576,0.0073542288,0.026422938,0.000038544556,0.00021806001,0.000006911979,0.029269239,0.018360402,0.00014931084,0.000014875667,0.0001116885,0.0024961634],"study_design_scores_gemma":[0.90517765,0.03009413,0.057750635,0.0000720827,0.000105300016,0.0000011721833,0.0058352323,0.000503868,0.00022846379,0.000021366712,0.00009033529,0.00011975923],"about_ca_topic_score_codex":0.0005430546,"about_ca_topic_score_gemma":0.00024168724,"teacher_disagreement_score":0.0313277,"about_ca_system_score_codex":0.0005772371,"about_ca_system_score_gemma":0.0006722913,"threshold_uncertainty_score":0.4201475},"labels":[],"label_agreement":null},{"id":"W4213174616","doi":"10.1200/jco.2022.40.6_suppl.tps221","title":"Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Olaparib; PARP inhibitor; Prostate cancer; Internal medicine; Oncology; Placebo; Androgen receptor; Cancer; Poly ADP ribose polymerase; Pathology; Genetics; Biology; Gene","score_opus":0.15707699717238072,"score_gpt":0.4840448733343991,"score_spread":0.3269678761620184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213174616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917149,0.00029987836,0.00009953671,0.0006834383,0.0015970767,0.005282289,0.000121447025,0.000016467193,0.00018495275],"genre_scores_gemma":[0.9974956,0.00014572384,0.000835627,0.0005166722,0.00024723742,0.0005483452,0.000071120594,0.000053340755,0.00008636396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904537,0.002709536,0.00450455,0.0004741064,0.0014179617,0.0004401475],"domain_scores_gemma":[0.9895832,0.003667052,0.0047950502,0.00031296533,0.0012601227,0.0003816207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044171843,0.00036092603,0.0039570946,0.0005193793,0.00012377312,0.000016185062,0.0002185823,0.00016021432,0.0003283927],"category_scores_gemma":[0.0010804555,0.00027627512,0.00045023576,0.0007259299,0.00048741224,0.00023299803,0.00009618821,0.0017993607,0.0000031412474],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9547411,0.011342919,0.005114655,0.000038234924,0.0028505488,0.0016503253,0.0043277727,0.015856337,0.00026551867,0.000012629051,0.00017910622,0.0036208362],"study_design_scores_gemma":[0.93657756,0.05131045,0.004936619,0.00012124664,0.0017323988,0.00014795783,0.0030733428,0.00084836484,0.0007063762,0.000028090373,0.000276707,0.00024091521],"about_ca_topic_score_codex":0.00040834327,"about_ca_topic_score_gemma":0.00055452756,"teacher_disagreement_score":0.03996753,"about_ca_system_score_codex":0.0016034083,"about_ca_system_score_gemma":0.0058071217,"threshold_uncertainty_score":0.99996895},"labels":[],"label_agreement":null},{"id":"W4213423873","doi":"10.1016/j.annonc.2022.02.222","title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Confidence interval; Olaparib; Discontinuation; PARP inhibitor; Adverse effect; Proportional hazards model; Oncology; Ovarian cancer; Hazard ratio; Cancer; Gastroenterology; Surgery; Poly ADP ribose polymerase","score_opus":0.23275347347698438,"score_gpt":0.49864760601548924,"score_spread":0.26589413253850486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213423873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276967,0.0005671283,0.0000027751962,0.014067579,0.0003198922,0.0008003817,0.00011710508,0.00000818147,0.0013472751],"genre_scores_gemma":[0.996385,0.002554421,0.000018279068,0.00030066897,0.00013034297,0.0004537522,0.000032538457,0.000010225199,0.000114822986],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99849415,0.00049096666,0.0004319236,0.0002077346,0.0001759046,0.00019930796],"domain_scores_gemma":[0.9989541,0.00033544542,0.00033336572,0.0002486599,0.00008605627,0.000042359417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052470015,0.00015755063,0.00041161964,0.00012690353,0.00013227582,0.000004818278,0.000060713253,0.00006075039,0.000095471565],"category_scores_gemma":[0.000031914176,0.00008316395,0.0001637891,0.0001725767,0.00016411052,0.000030993764,0.000021826221,0.00017732581,0.0000012844681],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019551583,0.003994631,0.011972099,0.000016938788,0.0009905917,0.000056571687,0.031248232,0.0013358186,0.011813945,0.00105081,0.0031515518,0.9148172],"study_design_scores_gemma":[0.03406105,0.2144218,0.639521,0.00025597238,0.00042236826,0.0007996085,0.018123696,0.0011354262,0.033316936,0.001874281,0.055588953,0.0004789267],"about_ca_topic_score_codex":0.0024534527,"about_ca_topic_score_gemma":0.0003304326,"teacher_disagreement_score":0.9143383,"about_ca_system_score_codex":0.0012420454,"about_ca_system_score_gemma":0.00027962605,"threshold_uncertainty_score":0.3708903},"labels":[],"label_agreement":null},{"id":"W4214737304","doi":"10.3791/62553-v","title":"Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging","year":2021,"lang":"en","type":"article","venue":"Journal of Visualized Experiments","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"DNA damage; DNA repair; Homologous recombination; DNA; Biology; DNA polymerase; Molecular biology; Synthetic lethality; Cancer research; Genetics","score_opus":0.046951938408087826,"score_gpt":0.4733516214727652,"score_spread":0.4263996830646774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214737304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98050916,0.0011700705,0.016207684,0.00013940432,0.00041795423,0.0002071332,0.000007568782,0.000013118136,0.001327882],"genre_scores_gemma":[0.9849232,0.00011463116,0.0145747615,0.00011346766,0.00019830347,0.000005421471,0.000013334326,0.00002618277,0.000030727613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783117,0.00010917432,0.0007344566,0.00020075655,0.0009086257,0.00021584399],"domain_scores_gemma":[0.99819154,0.000032670505,0.0007576763,0.00017435943,0.00069993763,0.00014383775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041144624,0.00017449078,0.00046692573,0.00011124863,0.000097310294,0.00004988489,0.00006987755,0.000057214485,0.000222452],"category_scores_gemma":[0.000014631344,0.00015043248,0.00013693995,0.00032436626,0.00006609199,0.00033681444,0.000023792041,0.00017827615,6.032573e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023579486,0.0007371621,0.011623875,0.000110213776,0.0001868054,0.00013376714,0.0005235686,0.00042420308,0.98363215,0.00008125547,0.00003259045,0.0001564617],"study_design_scores_gemma":[0.02522228,0.0005130676,0.005974354,0.0010294445,0.00023128392,0.00055227475,0.0019423028,0.005006982,0.95925504,0.00006468491,0.000055861758,0.00015243006],"about_ca_topic_score_codex":0.000055195604,"about_ca_topic_score_gemma":0.00000593765,"teacher_disagreement_score":0.024377113,"about_ca_system_score_codex":0.00081479934,"about_ca_system_score_gemma":0.0005682117,"threshold_uncertainty_score":0.6134458},"labels":[],"label_agreement":null},{"id":"W4220654447","doi":"10.1038/s42003-022-03210-5","title":"Pre-activation of autophagy impacts response to olaparib in prostate cancer cells","year":2022,"lang":"en","type":"article","venue":"Communications Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Institut Du Cancer de Montréal; Université de Montréal; University of Ottawa; Canadian Urological Oncology Group; Canadian Urological Association","keywords":"Olaparib; PARP1; Autophagy; Cancer research; Poly ADP ribose polymerase; PARP inhibitor; DNA damage; DNA repair; Prostate cancer; RAD51; Biology; Cancer; Cell biology; Medicine; Polymerase; Internal medicine; DNA; Apoptosis; Biochemistry","score_opus":0.04803122551558377,"score_gpt":0.3973253626240847,"score_spread":0.34929413710850093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220654447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847899,0.000917199,0.00007072095,0.01272274,0.00009635385,0.0007114181,0.00014044711,0.000033101165,0.0005181304],"genre_scores_gemma":[0.995423,0.00039434302,0.0014324012,0.001340927,0.000011745471,0.0009944307,0.00009505368,0.000013017907,0.00029507754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986884,0.00061120157,0.00031950636,0.0001497985,0.00007503683,0.00015605308],"domain_scores_gemma":[0.99833995,0.00030702606,0.00013904239,0.0010671531,0.000091313836,0.000055503715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005452435,0.00007643356,0.00020185084,0.00028519004,0.000110789166,0.0000026012904,0.0003253795,0.000037927002,0.00032676072],"category_scores_gemma":[0.00011097036,0.000079656784,0.000034329798,0.00058480474,0.000121719735,0.0000342983,0.00027523987,0.00025641284,0.000006600099],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028639212,0.0002737281,0.012000193,0.000013614248,0.000024928253,6.379711e-7,0.002904187,0.0005127656,0.97709215,0.000584459,0.0009020787,0.0028273144],"study_design_scores_gemma":[0.004941816,0.0019004911,0.22666222,0.00016053992,0.00002774152,0.000022118109,0.00081909855,0.000989903,0.510603,0.0011616164,0.2524302,0.0002812169],"about_ca_topic_score_codex":0.0005041384,"about_ca_topic_score_gemma":0.0000718613,"teacher_disagreement_score":0.46648914,"about_ca_system_score_codex":0.00044044963,"about_ca_system_score_gemma":0.00035630475,"threshold_uncertainty_score":0.35778007},"labels":[],"label_agreement":null},{"id":"W4220672160","doi":"10.1016/s1470-2045(22)00122-x","title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Clovis Oncology","keywords":"Ovarian cancer; Chemotherapy; Mutation; Cancer; Phases of clinical research; Poly ADP ribose polymerase; Clinical trial","score_opus":0.07535907588749029,"score_gpt":0.4198910124240871,"score_spread":0.3445319365365968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220672160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902804,0.00016068017,0.00005842535,0.0045566885,0.0009530988,0.0028353042,0.00031195596,0.000028053744,0.00081542856],"genre_scores_gemma":[0.9941001,0.00027261704,0.0012356614,0.0024091997,0.00034219358,0.0012680873,0.00026434875,0.000035471196,0.00007230532],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983406,0.0003805698,0.00039405626,0.0003129011,0.00034724077,0.0002246386],"domain_scores_gemma":[0.9988611,0.00024151559,0.00033512615,0.00033278097,0.00016503835,0.000064444874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062914594,0.00015528376,0.0006882032,0.00010470873,0.00014190513,0.000029116236,0.0003333296,0.00007464616,0.00088579353],"category_scores_gemma":[0.000069613845,0.0001082691,0.000024168781,0.00023870257,0.00016409345,0.00015219959,0.00008416198,0.00032317094,6.360544e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95226115,0.0009773719,0.0009207275,0.000022537983,0.00021989965,0.0000373069,0.0049206098,0.000046338624,0.00023471832,0.0001679607,0.0006129754,0.039578408],"study_design_scores_gemma":[0.9209877,0.038322702,0.0010469366,0.000045592653,0.00008400075,0.000018692435,0.0007306434,0.00012986494,0.00029808702,0.00007202832,0.038125806,0.00013792416],"about_ca_topic_score_codex":0.00019266317,"about_ca_topic_score_gemma":0.0005330877,"teacher_disagreement_score":0.039440487,"about_ca_system_score_codex":0.00082993036,"about_ca_system_score_gemma":0.00075080135,"threshold_uncertainty_score":0.9698818},"labels":[],"label_agreement":null},{"id":"W4220707985","doi":"10.1158/1538-7445.sabcs21-ot2-24-02","title":"Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Triple-negative breast cancer; Cancer; Chemotherapy","score_opus":0.07882265798531476,"score_gpt":0.42161315977992964,"score_spread":0.3427905017946149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220707985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98685384,0.0005420461,0.000013854159,0.00024408179,0.00008684002,0.0113097,0.00069192174,0.00004267858,0.00021506366],"genre_scores_gemma":[0.98930436,0.00015665512,0.00014871439,0.00018609726,0.000081399914,0.009876717,0.00003529802,0.00011395049,0.00009677728],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928717,0.0020028523,0.0009998573,0.00097106403,0.0023015563,0.000852972],"domain_scores_gemma":[0.9946084,0.0025580737,0.0005836718,0.00044333225,0.0015549298,0.00025160538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003649599,0.00045663762,0.0014632705,0.00061112497,0.0005271944,0.00005542631,0.0002155239,0.0000693671,0.0032582541],"category_scores_gemma":[0.00044670366,0.00031855152,0.00009111521,0.0022127605,0.00085855764,0.00027071935,0.0001331201,0.0014341645,0.0000016173677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9113379,0.0028707234,0.048938725,0.00012981507,0.0011551615,0.00017888536,0.02049387,0.0009535201,0.0034756272,0.0000028296656,0.000025886917,0.010437051],"study_design_scores_gemma":[0.716274,0.007749123,0.2569768,0.0013672394,0.00015073888,0.000025993537,0.007787316,0.00034151497,0.008844617,0.000050195194,0.0000070408646,0.00042535513],"about_ca_topic_score_codex":0.008186072,"about_ca_topic_score_gemma":0.0014097025,"teacher_disagreement_score":0.20803809,"about_ca_system_score_codex":0.0016579282,"about_ca_system_score_gemma":0.0024117937,"threshold_uncertainty_score":0.9999266},"labels":[],"label_agreement":null},{"id":"W4220744079","doi":"10.1016/j.annonc.2022.03.008","title":"VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Medical Research Council; European Society for Medical Oncology; Cancer Council Victoria; Eisai; Department of Health, State Government of Victoria; National Breast Cancer Foundation; National Health and Medical Research Council; Cancer Research UK; Invitae; Gilead Sciences; Merck KGaA; Eli Lilly and Company; American Association for Cancer Research; AstraZeneca; Myriad Genetics; National Cancer Research Institute; Teva Pharmaceutical Industries; Pfizer; Daiichi Sankyo Europe; Breast Cancer Research Foundation; U.S. Department of Health and Human Services","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Oncology; Placebo; Breast cancer; Cancer; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.07982892465250224,"score_gpt":0.4337723077020927,"score_spread":0.35394338304959044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220744079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112755,0.00043625906,0.00003494387,0.005551579,0.0003618543,0.0009820426,0.00095924566,0.000010657995,0.0005358639],"genre_scores_gemma":[0.9975221,0.0005934404,0.000013875024,0.00086937874,0.0001108701,0.00030949488,0.00046326235,0.000017663644,0.00009990169],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995909,0.001260045,0.0014423582,0.00033119452,0.0007470443,0.00031038251],"domain_scores_gemma":[0.99736774,0.0006258944,0.0012411698,0.00036793566,0.0003371338,0.00006009812],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002472454,0.00017875449,0.0013929652,0.00076181703,0.000043741646,0.0000029950886,0.00026181858,0.00014956213,0.0017256998],"category_scores_gemma":[0.00014961658,0.00015745145,0.00036822874,0.0017557386,0.0001481507,0.000067910325,0.000068966714,0.0003854995,4.971745e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6178739,0.046336383,0.044594876,0.00021711347,0.010006211,0.00045709344,0.0354862,0.071562275,0.08517339,0.0018812569,0.00969017,0.07672115],"study_design_scores_gemma":[0.36289543,0.011451127,0.5990668,0.00018485049,0.0015425634,0.000028940456,0.0021732608,0.010924657,0.006655209,0.0005074572,0.0041816165,0.00038811617],"about_ca_topic_score_codex":0.0030774928,"about_ca_topic_score_gemma":0.00372412,"teacher_disagreement_score":0.5544719,"about_ca_system_score_codex":0.0005017814,"about_ca_system_score_gemma":0.00071088696,"threshold_uncertainty_score":0.9991869},"labels":[],"label_agreement":null},{"id":"W4220761957","doi":"10.1016/j.jbc.2022.101892","title":"Crystal structures of pertussis toxin with NAD+ and analogs provide structural insights into the mechanism of its cytosolic ADP-ribosylation activity","year":2022,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Health and Medical Research Council; Turun Yliopistosäätiö; Suomen Kulttuurirahasto; Suomen Tiedeseura; Australian Synchrotron; Turun Yliopisto; Australian Nuclear Science and Technology Organisation","keywords":"NAD+ kinase; Heterotrimeric G protein; Nicotinamide adenine dinucleotide; ADP-ribosylation; Cholera toxin; Pertussis toxin; Endoplasmic reticulum; Benzamide; Protein subunit; Biology; Biochemistry; Nicotinamide; G protein; Chemistry; Enzyme; Signal transduction; Stereochemistry; Microbiology","score_opus":0.02146742511293634,"score_gpt":0.2737902788672496,"score_spread":0.2523228537543133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220761957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99818015,0.00086968,0.00009059405,0.0005809151,0.00003507889,0.00012339177,0.000017411236,0.000005516621,0.00009726045],"genre_scores_gemma":[0.9993571,0.00011700181,0.00026809738,0.00010256188,0.000120560755,0.0000057677835,0.000005968408,0.0000063130256,0.00001662238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989712,0.00008802356,0.00034315264,0.00013571732,0.00035589474,0.00010596706],"domain_scores_gemma":[0.9988951,0.00010988438,0.00062867283,0.00012233068,0.00016655585,0.00007745517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018081318,0.00012401408,0.000359258,0.000037240825,0.00010371294,0.000006120552,0.00012608808,0.00008659171,0.00025756107],"category_scores_gemma":[0.00009537217,0.00006240274,0.000093823124,0.00014982182,0.00018191787,0.000059792223,0.000063406376,0.0004126631,2.8588458e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015007178,0.000045709257,0.002367232,0.00009033005,0.00010126124,0.000014375541,0.00056463695,0.000048350117,0.9942547,0.000106059895,0.00001706333,0.00088955637],"study_design_scores_gemma":[0.0014196937,0.0011766187,0.024242247,0.000054807646,0.00005338557,0.00045800474,0.00060395745,0.00013080522,0.96934307,0.0022233755,0.00020744641,0.000086619606],"about_ca_topic_score_codex":0.000009755365,"about_ca_topic_score_gemma":0.0000018555752,"teacher_disagreement_score":0.024911668,"about_ca_system_score_codex":0.0001033844,"about_ca_system_score_gemma":0.00014034947,"threshold_uncertainty_score":0.2820113},"labels":[],"label_agreement":null},{"id":"W4220822578","doi":"10.1200/jco.21.02011","title":"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Michigan Comprehensive Cancer Center; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; University of Florida Health; Genentech; National Institutes of Health; University of California, San Francisco; Barbara Ann Karmanos Cancer Institute; University of Arkansas for Medical Sciences; Hamilton Health Sciences; University of South Alabama; Florida Department of Health; Sidney Kimmel Comprehensive Cancer Center; West Virginia University; National Cancer Institute; Cleveland Clinic; NRG Oncology; Incyte; Medical College of Wisconsin; Wayne State University; AstraZeneca","keywords":"Olaparib; Ovarian cancer; Chemotherapy; Paclitaxel; Phases of clinical research; Germline","score_opus":0.23370454872828425,"score_gpt":0.5331871418585143,"score_spread":0.29948259313023007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220822578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96518576,0.00035650542,0.0012557327,0.017949339,0.007302539,0.004798073,0.00008184256,0.00003324878,0.0030369759],"genre_scores_gemma":[0.9767447,0.00052352593,0.007731514,0.010817859,0.0030646063,0.00061285734,0.00002790249,0.000085024025,0.0003919928],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907562,0.0028251512,0.0043188683,0.00053728966,0.0010662988,0.0004961736],"domain_scores_gemma":[0.98603034,0.008047416,0.004480233,0.0003724516,0.0005695615,0.00050000194],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010237859,0.00038655766,0.004850702,0.0003390059,0.00017627685,0.000036551508,0.0004637934,0.0003634637,0.0029423074],"category_scores_gemma":[0.0021813845,0.00026118796,0.000448007,0.0006193488,0.00048742202,0.00020784323,0.00010226589,0.0028962875,0.0000049186096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9322037,0.010311985,0.00026076136,0.000017964116,0.001153552,0.0012734585,0.0007431038,0.00025567634,0.00015680946,0.00008080566,0.0038106297,0.049731538],"study_design_scores_gemma":[0.87390876,0.08529351,0.000082997634,0.00031580045,0.00056634005,0.000256719,0.00041374742,0.0030607479,0.00018616914,0.00008488005,0.035553113,0.00027720936],"about_ca_topic_score_codex":0.00022192634,"about_ca_topic_score_gemma":0.0004956184,"teacher_disagreement_score":0.074981526,"about_ca_system_score_codex":0.001363196,"about_ca_system_score_gemma":0.010040414,"threshold_uncertainty_score":0.999984},"labels":[],"label_agreement":null},{"id":"W4220913811","doi":"10.1038/s41523-022-00405-1","title":"Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Breast Cancer Foundation","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; BRCA mutation; Chemotherapy; Metastatic breast cancer; PARP inhibitor; Cancer; Olaparib; Proportional hazards model; Meta-analysis; Clinical trial; Poly ADP ribose polymerase; Confidence interval; Polymerase; Biology","score_opus":0.010978979176223775,"score_gpt":0.28127023104745524,"score_spread":0.2702912518712315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220913811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95547676,0.00049874804,0.000042430864,0.031109689,0.00045485666,0.0014321455,0.010633892,0.00012370679,0.00022778838],"genre_scores_gemma":[0.9891888,0.000015260759,0.00025746363,0.006695458,0.00036556905,0.0022706278,0.00016949547,0.00013119909,0.00090615073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962736,0.0003594744,0.00052801846,0.0007176863,0.0013877882,0.00073345477],"domain_scores_gemma":[0.9982226,0.00011751044,0.00031694898,0.00054193067,0.00036826901,0.0004327674],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043810284,0.00041862662,0.00063697185,0.0005548552,0.0003365085,0.00004176187,0.00020244473,0.000061126666,0.0043487228],"category_scores_gemma":[0.000020032665,0.00035528975,0.00009651558,0.00176905,0.000117133255,0.0002481443,0.000093694696,0.0005666524,0.000023698844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041485317,0.0013063423,0.92984265,0.000038944825,0.000497415,0.00008995636,0.0017023843,0.0013973729,0.0014494825,0.000019989688,0.008869164,0.013300976],"study_design_scores_gemma":[0.013611779,0.0007098645,0.97834104,0.00035941516,0.00021418148,0.00012723121,0.00032593613,0.00002754997,0.00069415435,0.0000087141,0.0050635487,0.0005165925],"about_ca_topic_score_codex":0.006698012,"about_ca_topic_score_gemma":0.0013305618,"teacher_disagreement_score":0.048498377,"about_ca_system_score_codex":0.0038183166,"about_ca_system_score_gemma":0.0016906274,"threshold_uncertainty_score":0.9999165},"labels":[],"label_agreement":null},{"id":"W4220971922","doi":"10.1101/2022.03.04.22271927","title":"Persistence of targetable lesions, predicted therapy sensitivity and proteomes through disease evolution in pediatric acute lymphoblastic leukemia","year":2022,"lang":"en","type":"preprint","venue":"medRxiv","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"University of British Columbia; Canada Research Chairs; Michael Smith Health Research BC; BC Children's Hospital; Children's Hospital Foundation","keywords":"Proteome; Disease; Persistence (discontinuity); Medicine; Oncology; Precision medicine; Genome; Lymphoblastic Leukemia; Bioinformatics; Computational biology; Biology; Leukemia; Internal medicine; Genetics; Gene; Pathology","score_opus":0.029528644763310543,"score_gpt":0.2833009894371145,"score_spread":0.253772344673804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220971922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98661345,0.008942009,0.0010060318,0.00050367194,0.00038885864,0.0018349021,0.00044626216,0.000106742744,0.00015807406],"genre_scores_gemma":[0.98569846,0.012247358,0.00074515643,0.00014321931,0.0002279543,0.0005553704,0.00017157682,0.000051019502,0.00015990384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971986,0.00042184838,0.00056589965,0.0007765868,0.0006892649,0.00034783577],"domain_scores_gemma":[0.9984107,0.00017628257,0.0003938035,0.0006686149,0.00016340958,0.00018717974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058850955,0.00036418022,0.000715012,0.0003156514,0.00011525147,0.00001548272,0.00014018848,0.00019981268,0.00031885915],"category_scores_gemma":[0.00019769599,0.00034751056,0.00018278709,0.0004908264,0.00020193632,0.000119243145,0.00030368983,0.0006917111,0.000003307523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018121719,0.00038008104,0.98187286,0.0013001988,0.00018865617,0.00028534446,0.0009783763,0.0022335171,0.010370268,0.00006428464,0.00028458523,0.00022966541],"study_design_scores_gemma":[0.0031384502,0.00022448004,0.9898113,0.00041935925,0.0003055243,0.000027231841,0.000111584304,0.0030329667,0.0015198634,0.00084660575,0.00024023073,0.00032237655],"about_ca_topic_score_codex":0.00018746236,"about_ca_topic_score_gemma":0.000008182559,"teacher_disagreement_score":0.008850404,"about_ca_system_score_codex":0.0011284626,"about_ca_system_score_gemma":0.0018726401,"threshold_uncertainty_score":0.9998977},"labels":[],"label_agreement":null},{"id":"W4221025353","doi":"10.1016/j.gim.2022.01.249","title":"eP213: Phase 2 multiple ascending-dose study of SRP-5051 PPMO in patients with DMD amenable to exon 51 skipping: Part A results","year":2022,"lang":"en","type":"article","venue":"Genetics in Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Exon skipping; Exon; Phase (matter); Medicine; Physics; Biology; Genetics; Gene","score_opus":0.04944078362720004,"score_gpt":0.35465616199710787,"score_spread":0.3052153783699078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221025353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946533,0.00030326698,0.000045598208,0.0010883588,0.00046800426,0.0025438666,0.00006992541,0.000031392163,0.0007963256],"genre_scores_gemma":[0.9972304,0.000067851666,0.000726124,0.00093616685,0.00019859357,0.00040332237,0.00013905228,0.00005125327,0.0002472105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963993,0.000223851,0.0010438793,0.0006190057,0.0012392161,0.00047476712],"domain_scores_gemma":[0.998182,0.00015399844,0.00028983972,0.0009786775,0.00017051699,0.00022498083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010796364,0.00026785638,0.0007232959,0.00070333306,0.00008761413,0.00000483648,0.0003044951,0.000054347995,0.000305316],"category_scores_gemma":[0.00043332338,0.00023503309,0.000031368483,0.001362766,0.00013459178,0.00003325939,0.00019406088,0.0004795214,0.0000042321562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0321307,0.018685523,0.85756576,0.00021639152,0.00021816506,0.00040094162,0.04391914,0.011451953,0.00894687,0.000021818612,0.014480315,0.011962406],"study_design_scores_gemma":[0.39255175,0.09412394,0.416193,0.0020979603,0.0002516279,0.000025181947,0.026784064,0.0011806114,0.0071167476,0.00018504485,0.05857149,0.0009185718],"about_ca_topic_score_codex":0.0003292971,"about_ca_topic_score_gemma":0.0003568486,"teacher_disagreement_score":0.44137278,"about_ca_system_score_codex":0.0004879374,"about_ca_system_score_gemma":0.00013715553,"threshold_uncertainty_score":0.9584371},"labels":[],"label_agreement":null},{"id":"W4223503917","doi":"10.3390/cells11081284","title":"Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease","year":2022,"lang":"en","type":"article","venue":"Cells","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Sapienza Università di Roma","keywords":"Neuroprotection; Neuroscience; Disease; Drosophila (subgenus); Alzheimer's disease; Neurodegeneration; Biology; Medicine; Genetics; Internal medicine; Gene","score_opus":0.021563076737582218,"score_gpt":0.2677628496917756,"score_spread":0.24619977295419337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223503917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941718,0.0025633697,0.00008623715,0.00030175215,0.0004058441,0.0011403301,0.000049584665,0.000025366344,0.0012557409],"genre_scores_gemma":[0.9992422,0.00005949908,0.0000662716,0.0002763843,0.000058698686,0.0002051297,0.000007162117,0.000025915564,0.000058732207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988522,0.00013571396,0.00030436,0.00021863262,0.00034026455,0.00014882968],"domain_scores_gemma":[0.9993227,0.00008350394,0.00015430374,0.00029074983,0.00004820511,0.000100540856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013954358,0.00010910304,0.00029690334,0.00017154354,0.000029495948,0.0000014584475,0.00007683485,0.000026506637,0.00009832128],"category_scores_gemma":[0.000020700478,0.00011376951,0.000108595705,0.00033286627,0.000094124356,0.000047198355,0.00006816831,0.00021827048,0.0000033831163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015955165,0.0011814381,0.0018488517,0.00060080434,0.00010786627,0.00027029152,0.0017590271,0.018126665,0.9700581,0.0006376695,0.0016195355,0.0021942488],"study_design_scores_gemma":[0.0033178949,0.000545272,0.0048238924,0.00020736744,0.00010260038,0.000004155006,0.00007274162,0.0017314316,0.9839117,0.004712099,0.00043489455,0.00013595255],"about_ca_topic_score_codex":0.000042645755,"about_ca_topic_score_gemma":3.8973877e-7,"teacher_disagreement_score":0.016395234,"about_ca_system_score_codex":0.00007462336,"about_ca_system_score_gemma":0.00012902131,"threshold_uncertainty_score":0.46393856},"labels":[],"label_agreement":null},{"id":"W4224033732","doi":"10.1101/2022.04.13.488115","title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"National Cancer Institute","keywords":"CRISPR; RAD51; Biology; DNA repair; Poly ADP ribose polymerase; CHEK2; Genetics; Cancer research; Prostate cancer; PARP inhibitor; DNA damage; Gene; Synthetic lethality; DNA Damage Repair; Mutation; Cancer; DNA; Germline mutation","score_opus":0.018444846009704956,"score_gpt":0.27734476867807123,"score_spread":0.25889992266836626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224033732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890173,0.0072241463,0.000034804274,0.00037318387,0.00061510183,0.0015133454,0.0010979071,0.00011199632,0.000012220823],"genre_scores_gemma":[0.9904296,0.002467556,0.0056587467,0.00032429473,0.00031918372,0.00063958735,4.974567e-7,0.00013662137,0.000023908415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645376,0.0003465489,0.0009073518,0.0011256962,0.000605653,0.0005609788],"domain_scores_gemma":[0.9974531,0.000105477906,0.00068214483,0.0010844489,0.00041015755,0.00026468208],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008784407,0.0005214646,0.0010834635,0.0003898489,0.00011055299,0.000037527396,0.00015926117,0.00029464936,0.0000638736],"category_scores_gemma":[0.00015889952,0.0005951414,0.00012643868,0.000565204,0.00028969176,0.000089931586,0.00040620117,0.0010057744,0.0000024932347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080309727,0.00021848272,0.53741294,0.0023499767,0.00010520067,0.00085906684,0.00007666955,0.000039898034,0.4575591,0.00002799328,0.000535403,0.000012155555],"study_design_scores_gemma":[0.00185701,0.00009573548,0.7752186,0.0023983514,0.00011637083,1.4638755e-7,0.0000083124105,0.000086066335,0.21793817,0.000004416447,0.0017504194,0.0005263636],"about_ca_topic_score_codex":0.0006484568,"about_ca_topic_score_gemma":0.00034152882,"teacher_disagreement_score":0.23962094,"about_ca_system_score_codex":0.00068630866,"about_ca_system_score_gemma":0.0011842941,"threshold_uncertainty_score":0.99965},"labels":[],"label_agreement":null},{"id":"W4225145422","doi":"10.3390/cancers14092251","title":"The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Université de Sherbrooke; McGill Genome Centre; Montreal Neurological Institute and Hospital; Jewish General Hospital; Université de Montréal; Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; McGill University; Centre hospitalier universitaire de Québec; Centre Hospitalier Universitaire de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Taibah University; Fondation du cancer du sein du Québec; McGill University; American Diabetes Association; Saudi Arabian Cultural Bureau; Fonds de recherche du Québec; Université de Sherbrooke","keywords":"Olaparib; Genetics; Biology; Population; Oncology; Internal medicine; Medicine; Cancer research; Gene","score_opus":0.027226573298501564,"score_gpt":0.32976468348504884,"score_spread":0.30253811018654725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225145422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98149115,0.016227826,0.00025169132,0.0012275556,0.00017265764,0.00039834363,0.00015557883,0.000017117523,0.00005811077],"genre_scores_gemma":[0.9967168,0.0020051491,0.00041836163,0.00052103377,0.00006349219,0.00017627882,0.000054190332,0.000021815287,0.000022892546],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99881923,0.0001592237,0.00032071662,0.00029732517,0.0002317208,0.00017175556],"domain_scores_gemma":[0.99939597,0.00008921502,0.00012300974,0.00026196695,0.00005091753,0.00007891193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013708917,0.00012240442,0.0002522057,0.000098150675,0.0001308158,0.00001737287,0.00008878596,0.0000478065,0.00018140618],"category_scores_gemma":[0.000026498177,0.00010756372,0.0000363269,0.000320199,0.00014492957,0.00003827086,0.00006583807,0.0001659442,1.669349e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002204915,0.000050808772,0.16307522,0.00016253773,0.0008377767,0.00028188218,0.002012281,0.012862148,0.78254074,0.000453669,0.0016790094,0.033839],"study_design_scores_gemma":[0.0038843495,0.00017619558,0.9605605,0.00013132853,0.00019844796,0.00006163552,0.0006456155,0.0048208684,0.023710867,0.0049159946,0.00067513814,0.00021907002],"about_ca_topic_score_codex":0.01235253,"about_ca_topic_score_gemma":0.0005475495,"teacher_disagreement_score":0.79748523,"about_ca_system_score_codex":0.00054154533,"about_ca_system_score_gemma":0.00032109674,"threshold_uncertainty_score":0.9942243},"labels":[],"label_agreement":null},{"id":"W4229035333","doi":"10.21203/rs.3.rs-1370330/v1","title":"Catalytic-independent function of PARP-1 is essential in regulating human islet-cell differentiation from stem cells","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Manitoba; University of Alberta","funders":"Department of Biotechnology, Ministry of Science and Technology, India; Université Laval","keywords":"Poly ADP ribose polymerase; Biology; Cell biology; Cancer research; Stem cell; Islet; Cellular differentiation; PARP inhibitor; Endocrinology; Diabetes mellitus; Polymerase; Genetics; Biochemistry; Enzyme","score_opus":0.0735355362185894,"score_gpt":0.3926827854042496,"score_spread":0.31914724918566023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229035333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931704,0.00080994185,0.00047002008,0.00033628696,0.00063317164,0.0018878138,0.00061152497,0.00006006709,0.002020769],"genre_scores_gemma":[0.9947756,0.00020276019,0.00006472778,0.000032972912,0.00058227783,0.00042153697,0.0017458454,0.000082412036,0.0020918695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994097,0.0007506593,0.00092210807,0.000977898,0.0027051612,0.00054716435],"domain_scores_gemma":[0.9974525,0.00027141947,0.0004489534,0.0011909578,0.0004730259,0.00016316213],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013680218,0.00031228317,0.0006862158,0.0008895583,0.00021923975,0.000070108596,0.00033826134,0.00040930562,0.0043570683],"category_scores_gemma":[0.000023927818,0.00033771468,0.00027854618,0.0005026887,0.00012557121,0.00008336447,0.00085746066,0.0024445946,0.00004061793],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024515055,0.0023147194,0.049306743,0.006907974,0.00048770828,0.00011706781,0.00843466,0.002226268,0.91283125,0.00026847725,0.008879273,0.0057743685],"study_design_scores_gemma":[0.007004593,0.000839254,0.07287251,0.0030230007,0.00016282803,0.0000020853795,0.0043754303,0.002704906,0.90380454,0.0034343058,0.0012113815,0.000565156],"about_ca_topic_score_codex":0.003038227,"about_ca_topic_score_gemma":0.00015251272,"teacher_disagreement_score":0.023565775,"about_ca_system_score_codex":0.0014819076,"about_ca_system_score_gemma":0.0005169539,"threshold_uncertainty_score":0.9999075},"labels":[],"label_agreement":null},{"id":"W4229919511","doi":"10.1345/aph.1g045","title":"Death Receptors in Cancer Therapy","year":2005,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Emory University; University of Toronto; Abramson Family Cancer Research Institute; College of Medicine, Catholic University of Korea; Catholic University of Korea; Cancer Research Institute; University of South Carolina; School of Medicine, Emory University; Winship Cancer Institute; University of Texas MD Anderson Cancer Center; St. Jude Children's Research Hospital; University of Pennsylvania","keywords":"Medicine; Cancer; Cancer therapy; Oncology; Intensive care medicine; Receptor; Internal medicine","score_opus":0.1986235138234836,"score_gpt":0.48478811095985774,"score_spread":0.28616459713637415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229919511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513574,0.017348971,0.00003423583,0.026504245,0.00028706013,0.00050512847,0.000019775056,0.00007256058,0.0038705957],"genre_scores_gemma":[0.8565142,0.11103248,0.00054627476,0.029404247,0.00076682115,0.00014342324,0.0000070602514,0.00005669077,0.0015288116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985856,0.000069979236,0.0004315558,0.0002633431,0.0003102822,0.00033925776],"domain_scores_gemma":[0.9992877,0.000047707366,0.00014679389,0.00022921928,0.00015545126,0.00013309414],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031420906,0.00019519802,0.00037562512,0.0002525898,0.000026747006,0.0000067200094,0.00013005311,0.00008057813,0.0058124145],"category_scores_gemma":[0.0000053139984,0.00017302451,0.00016040234,0.0003626173,0.00007022897,0.00016075178,0.000006314652,0.0002027423,0.000036184763],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022540404,0.0008608558,0.04118778,0.000029365847,0.0002123707,0.0000071138534,0.001058787,0.00019188403,0.58636916,0.00022062774,0.043185495,0.3244225],"study_design_scores_gemma":[0.0038384388,0.00016958396,0.003931104,0.00008108562,0.0000038825974,0.0000036285828,0.000011685134,0.00007864105,0.6030803,0.00011739734,0.3885714,0.00011283012],"about_ca_topic_score_codex":0.00016709685,"about_ca_topic_score_gemma":0.000013310675,"teacher_disagreement_score":0.34538594,"about_ca_system_score_codex":0.000065887434,"about_ca_system_score_gemma":0.00014087149,"threshold_uncertainty_score":0.9950964},"labels":[],"label_agreement":null},{"id":"W4231329669","doi":"10.1182/blood.v116.21.789.789","title":"Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Poly ADP ribose polymerase; PARP1; Bortezomib; DNA damage; Proteasome; DNA repair; Biology; Proteasome inhibitor; PARP inhibitor; Ubiquitin; Molecular biology; Synthetic lethality; Cancer research; Genome instability; Apoptosis; Cell culture; Cell biology; Polymerase; DNA; Multiple myeloma; Biochemistry; Genetics; Immunology; Gene","score_opus":0.014639103231341108,"score_gpt":0.26892369678760053,"score_spread":0.25428459355625943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231329669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938415,0.000030704385,0.000032863325,0.0014082578,0.0013764756,0.0006201751,0.000033340955,0.00022766537,0.0024289857],"genre_scores_gemma":[0.9933578,0.000007369037,0.002405297,0.0021752408,0.0014864269,0.00007767879,0.000020366637,0.00006042287,0.00040942273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843246,0.00003699636,0.0003398946,0.00042102757,0.00036765114,0.00040194555],"domain_scores_gemma":[0.99863815,0.00011041258,0.000089556335,0.00058304536,0.00017273893,0.00040608173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020276998,0.00023419865,0.0003540487,0.00016165464,0.00009894209,0.000032400232,0.00010949197,0.00020828439,0.00025030275],"category_scores_gemma":[0.000110868925,0.00022324367,0.000113565315,0.00031747395,0.000062821535,0.00007281881,0.00004678077,0.0004426901,0.0003706123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012932192,0.0003686237,0.008522317,0.000028384315,0.000066293294,0.00012130012,0.00044745905,0.0000020642904,0.9847443,0.00003191587,0.0032859514,0.0022520812],"study_design_scores_gemma":[0.0056488817,0.0002284988,0.017604966,0.00008132537,0.00008096148,0.00016759333,0.00012627123,0.000014414812,0.96094805,0.000034513898,0.014798814,0.00026569157],"about_ca_topic_score_codex":0.00010936916,"about_ca_topic_score_gemma":0.00013596933,"teacher_disagreement_score":0.02379622,"about_ca_system_score_codex":0.000033458844,"about_ca_system_score_gemma":0.0001638654,"threshold_uncertainty_score":0.91036123},"labels":[],"label_agreement":null},{"id":"W4234697648","doi":"10.3410/f.733574619.793565198","title":"Faculty Opinions recommendation of CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.","year":2019,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; National Science Foundation; Canadian Institutes of Health Research; U.S. Department of Defense; European Commission; Prostate Cancer Foundation; Movember Foundation; Prostate Cancer UK; Cancer Research UK; Stand Up To Cancer; Krembil Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Olaparib; CRISPR; DNA repair; Biology; PARP inhibitor; PARP1; Poly ADP ribose polymerase; Polymerase; DNA damage; Cancer research; Genome instability; Nucleotide excision repair; DNA; Gene; Molecular biology; Genetics","score_opus":0.05944328981461636,"score_gpt":0.40575110115355395,"score_spread":0.3463078113389376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234697648","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010324202,0.0023015118,0.00018959992,0.15189551,0.0008833167,0.0024421397,0.8421193,0.000046059304,0.00011227451],"genre_scores_gemma":[0.00009081267,0.0015985472,0.00085502124,0.008035849,0.00039653602,0.00021936599,0.9872756,0.000063103245,0.0014651667],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931362,0.00059888395,0.002843147,0.00090617285,0.0020385978,0.0004769805],"domain_scores_gemma":[0.98659974,0.000304847,0.0032521074,0.002356573,0.0070791426,0.00040761143],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001906003,0.00069899287,0.0018710879,0.0007709777,0.00022124543,0.00008149611,0.0014431257,0.00092369184,0.0011622657],"category_scores_gemma":[0.005475299,0.0004968911,0.0012376534,0.0022630806,0.0006593569,0.00033942502,0.00049426436,0.0014645001,0.0001380113],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008442073,0.0005321911,0.000029789377,0.014076346,0.0004237884,4.652919e-7,0.00017675443,6.9625116e-7,0.00012095537,0.00011997871,0.98255914,0.0018754693],"study_design_scores_gemma":[0.0018686637,0.00029149328,0.0039018388,0.032715376,0.00052356307,0.00010662095,0.00009907517,0.000011988571,0.00031774343,0.000032580123,0.95973915,0.00039188823],"about_ca_topic_score_codex":0.0002087874,"about_ca_topic_score_gemma":0.0000057710076,"teacher_disagreement_score":0.14515634,"about_ca_system_score_codex":0.00025792525,"about_ca_system_score_gemma":0.0012024249,"threshold_uncertainty_score":0.9997508},"labels":[],"label_agreement":null},{"id":"W4235227157","doi":"10.1136/ijgc-2019-igcs.310","title":"310 Chemotherapy reduces PAR glycohydrolase (PARG) expression in high-grade serous ovarian cancer patients","year":2019,"lang":"fr","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Immunohistochemistry; Ovarian cancer; Chemotherapy; Serous fluid; Cancer; Cancer research; Medicine; Internal medicine; Oncology; Pathology; Biology","score_opus":0.018739081395368617,"score_gpt":0.3266469672862661,"score_spread":0.30790788589089746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235227157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93325543,0.013212155,0.0000596331,0.025619535,0.026460292,0.0005795594,0.00023840218,0.000020582835,0.00055438525],"genre_scores_gemma":[0.9699704,0.017287042,0.00070090126,0.0057106325,0.004248018,0.000095567695,0.000026114833,0.000057791956,0.0019035545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954248,0.00032837235,0.0015152723,0.00052113767,0.0015354406,0.00067495304],"domain_scores_gemma":[0.99642384,0.0005054151,0.0013531005,0.00022511634,0.0011070349,0.0003854956],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006343994,0.00044517269,0.00093132776,0.00042141433,0.000059273054,0.000087500506,0.00077177444,0.00051827525,0.030040497],"category_scores_gemma":[0.0002487764,0.00036456567,0.0003474402,0.00035770645,0.00024181374,0.00060550217,0.000103383274,0.0011673267,0.00014003254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010496219,0.005810914,0.72860515,0.00015296873,0.0014223885,0.0010157061,0.0013504021,0.008480298,0.12037917,0.00036214085,0.025646545,0.09627807],"study_design_scores_gemma":[0.03995538,0.0028421672,0.6967141,0.005436735,0.00016959528,0.00013558056,0.00016921764,0.0005666652,0.13686742,0.0021787302,0.11416332,0.0008010834],"about_ca_topic_score_codex":0.00052807713,"about_ca_topic_score_gemma":0.00012644609,"teacher_disagreement_score":0.095476985,"about_ca_system_score_codex":0.0034479299,"about_ca_system_score_gemma":0.0008495085,"threshold_uncertainty_score":0.9998806},"labels":[],"label_agreement":null},{"id":"W4235576132","doi":"10.1161/res.121.suppl_1.316","title":"Abstract 316: Adap1 Prevents Cardiomyocyte Hypertrophy by Interfering with Integrin Signaling","year":2017,"lang":"en","type":"article","venue":"Circulation Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Muscle hypertrophy; Biology; Internal medicine; Integrin; Endocrinology; Cell biology; Myocyte; Western blot; Cell; Signal transduction; Gene; Medicine; Biochemistry","score_opus":0.13857101709336078,"score_gpt":0.42304657605606943,"score_spread":0.28447555896270865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235576132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828965,0.0002816551,0.0025908833,0.0007850788,0.00010936295,0.00055365014,0.0000099458575,0.000056354405,0.012716562],"genre_scores_gemma":[0.99852985,0.000038729613,0.0002949719,0.000057292076,0.00028949598,0.00009271025,0.000030127769,0.000040670413,0.00062613207],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980322,0.000083287996,0.00023985162,0.00037199745,0.00089772826,0.00037494217],"domain_scores_gemma":[0.9984693,0.000093034796,0.00011073231,0.0007583071,0.00038769393,0.0001809255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000857663,0.00013515506,0.00023856758,0.00019179731,0.00051847217,0.00017740848,0.00022336503,0.00009652051,0.00037603316],"category_scores_gemma":[0.00015105159,0.00011552962,0.00007686748,0.00013147443,0.00023636322,0.0002962805,0.00006815839,0.0005957031,0.00009673344],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012906246,0.0001906442,0.10844359,0.00028037018,0.00032756856,0.00014360867,0.0005940812,0.0011846122,0.85341233,0.00015138509,0.0034257658,0.030555401],"study_design_scores_gemma":[0.009137507,0.00073038484,0.7273164,0.002882523,0.00006924988,0.00016953445,0.0005850263,0.0037115528,0.23132792,0.0006280871,0.022764565,0.0006772984],"about_ca_topic_score_codex":0.00030768823,"about_ca_topic_score_gemma":0.00000862047,"teacher_disagreement_score":0.62208444,"about_ca_system_score_codex":0.00035230018,"about_ca_system_score_gemma":0.0001740115,"threshold_uncertainty_score":0.47111613},"labels":[],"label_agreement":null},{"id":"W4236289131","doi":"10.1016/s1470-2045(21)00073-5","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck; AstraZeneca","keywords":"Olaparib; Medicine; BRCA mutation; Internal medicine; Clinical endpoint; Ovarian cancer; Oncology; Placebo; Progression-free survival; PARP inhibitor; Randomized controlled trial; Cancer; Chemotherapy; Pathology","score_opus":0.05218418572592092,"score_gpt":0.3670435714528127,"score_spread":0.31485938572689176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236289131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98857445,0.0003609026,0.00027935609,0.0047464264,0.00022317164,0.0039072447,0.0001127913,0.000029383507,0.0017662983],"genre_scores_gemma":[0.99446124,0.00052912114,0.00043994852,0.0024060793,0.00030574386,0.0013453108,0.00018781752,0.00002857634,0.00029613916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719626,0.0007050096,0.0007692005,0.00049760216,0.0003881238,0.00044383245],"domain_scores_gemma":[0.9971926,0.0010586248,0.00068603625,0.00044080027,0.000522828,0.00009906299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012873437,0.0002802238,0.0020615472,0.00031384322,0.00010086359,0.000022526341,0.00011442099,0.00021855009,0.00032911415],"category_scores_gemma":[0.00024108983,0.00018465499,0.00017777091,0.0011538834,0.00028923448,0.00009859209,0.000028818487,0.00047921008,0.0000031484574],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9821005,0.0010810226,0.002179453,0.000022023545,0.0031645778,0.00017727318,0.002687767,0.00052485516,0.0014781944,0.00035918277,0.00027488742,0.0059502707],"study_design_scores_gemma":[0.98369384,0.0041553704,0.006467306,0.00013788437,0.0013426712,0.00004474492,0.0003035956,0.00110283,0.0016857807,0.00013299794,0.0007358519,0.00019713194],"about_ca_topic_score_codex":0.000499985,"about_ca_topic_score_gemma":0.0012403902,"teacher_disagreement_score":0.005886838,"about_ca_system_score_codex":0.00036708268,"about_ca_system_score_gemma":0.00092014193,"threshold_uncertainty_score":0.75300115},"labels":[],"label_agreement":null},{"id":"W4239010921","doi":"10.1016/j.annonc.2020.10.228","title":"234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Ovarian cancer; Oncology; Progression-free survival; Cancer; Clinical endpoint; Maintenance therapy; Randomization; Gastroenterology; Chemotherapy; Surgery; Urology; Clinical trial","score_opus":0.05065239076537644,"score_gpt":0.35254642273326353,"score_spread":0.3018940319678871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239010921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734016,0.00059200975,0.00363496,0.019165386,0.00037825303,0.0013179904,0.0004721913,0.000056390334,0.0009811851],"genre_scores_gemma":[0.97827953,0.00078300585,0.006211548,0.013701984,0.00023182236,0.00043950454,0.00017526158,0.000043881704,0.00013347453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985188,0.000065044296,0.0004071388,0.0004532765,0.00021360075,0.00034211192],"domain_scores_gemma":[0.9982798,0.000376214,0.00036285393,0.00019308383,0.00056010025,0.00022796492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011284905,0.00020267967,0.00060680526,0.000064725275,0.00006538589,0.000009270331,0.00009915822,0.00016704875,0.00018185533],"category_scores_gemma":[0.00034561014,0.00017553417,0.00009129618,0.0001894983,0.00017394625,0.00016248487,0.000029087263,0.00016611312,0.000008349311],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08318003,0.0018893222,0.077359386,0.0006433129,0.0017569477,0.00022556617,0.012892581,0.00043624552,0.01895354,0.0042796885,0.14478429,0.6535991],"study_design_scores_gemma":[0.31226295,0.058067787,0.17710565,0.0014828604,0.0007579817,0.00003384955,0.0023758325,0.0018648043,0.028759,0.011315331,0.4045919,0.0013820571],"about_ca_topic_score_codex":0.0003924233,"about_ca_topic_score_gemma":0.00039960147,"teacher_disagreement_score":0.65221703,"about_ca_system_score_codex":0.00009133323,"about_ca_system_score_gemma":0.00035119383,"threshold_uncertainty_score":0.71580756},"labels":[],"label_agreement":null},{"id":"W4239693212","doi":"10.1038/labinvest.2018.11","title":"USCAP 2018 Abstracts: Gynecologic and Obstetric Pathology (1127–1316)","year":2018,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Gynecology; Pathology; Obstetrics","score_opus":0.026466626784267033,"score_gpt":0.2825359965507054,"score_spread":0.25606936976643835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239693212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929666,0.00083473837,0.0000513479,0.0018504641,0.0007649715,0.0003100415,0.000031364267,0.00016608149,0.003024405],"genre_scores_gemma":[0.98749137,0.0001343368,0.0024838955,0.008879447,0.0006185772,0.00005234804,0.000045029054,0.0000254003,0.00026958087],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987847,0.00010643818,0.00033932843,0.00033964022,0.0001978439,0.00023202195],"domain_scores_gemma":[0.9988044,0.00013259637,0.00019051919,0.00030055371,0.00036101308,0.0002109439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031899984,0.0001588204,0.00021941765,0.00018097773,0.00011960909,0.000025899839,0.000058343885,0.00021627865,0.0003141285],"category_scores_gemma":[0.00053161447,0.00014969303,0.000023406721,0.0006099022,0.00069977023,0.00020987511,0.000020712074,0.00019268974,0.00032377162],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001879683,0.00017739693,0.1690448,0.00023058422,0.000099637335,0.00016313778,0.0024286285,0.000008206036,0.76500344,0.0041066054,0.053706083,0.004843538],"study_design_scores_gemma":[0.0034057721,0.0014752999,0.6898864,0.00014588893,0.000100729776,0.00011448843,0.0003211443,0.00012621026,0.20577905,0.007921129,0.090294205,0.00042968435],"about_ca_topic_score_codex":0.000008384563,"about_ca_topic_score_gemma":0.000012845495,"teacher_disagreement_score":0.55922437,"about_ca_system_score_codex":0.0001500026,"about_ca_system_score_gemma":0.00024262512,"threshold_uncertainty_score":0.6104305},"labels":[],"label_agreement":null},{"id":"W4240735956","doi":"10.1200/jco.2015.33.15_suppl.tps1102","title":"Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-<i>BRCA</i>-associated locally advanced or metastatic breast cancer (BC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Veliparib; Medicine; PARP inhibitor; Carboplatin; Internal medicine; Metastatic breast cancer; Oncology; Cancer; Placebo; Chemotherapy; Phases of clinical research; BRCA mutation; Breast cancer; Olaparib; Pathology; Cisplatin; Poly ADP ribose polymerase","score_opus":0.1113354754180309,"score_gpt":0.48724063156258096,"score_spread":0.37590515614455006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240735956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867654,0.0011852719,0.00046891862,0.006263021,0.0013217104,0.0030941444,0.000040033476,0.000015126511,0.00084641017],"genre_scores_gemma":[0.99180084,0.0014766081,0.0037302468,0.0017422142,0.0006474475,0.0002383252,0.0000044614562,0.00004183153,0.0003180468],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99072284,0.002764686,0.0050194813,0.0003136364,0.00080466585,0.00037471135],"domain_scores_gemma":[0.985835,0.0070684757,0.004965703,0.00022360233,0.0012501045,0.00065707776],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012585567,0.0003125624,0.006486134,0.00026705817,0.000027606951,0.000011774223,0.0001582218,0.00038060272,0.0001781983],"category_scores_gemma":[0.01119446,0.0001833689,0.0005491195,0.00033219438,0.00071425125,0.00018795973,0.000030681116,0.0011822447,0.000002472359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96197456,0.00618965,0.0014435347,0.0000404745,0.0018102851,0.00042148557,0.00034655503,0.00023597316,0.00014366573,0.000019811187,0.0006250831,0.0267489],"study_design_scores_gemma":[0.960171,0.033452738,0.0007173641,0.00066064944,0.0015294809,0.00037155024,0.0003137617,0.001187741,0.000056271896,0.00034663058,0.0010093534,0.00018347568],"about_ca_topic_score_codex":0.00030257725,"about_ca_topic_score_gemma":0.0010718118,"teacher_disagreement_score":0.027263088,"about_ca_system_score_codex":0.0004956211,"about_ca_system_score_gemma":0.006637239,"threshold_uncertainty_score":0.99899423},"labels":[],"label_agreement":null},{"id":"W4242437290","doi":"10.5489/cuaj.619","title":"The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers","year":2013,"lang":"en","type":"article","venue":"Canadian Urological Association Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Southlake Regional Health Center; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Ontario Institute for Cancer Research; Women's College Hospital; Sunnybrook Health Science Centre","funders":"Prostate Cancer Canada","keywords":"Medicine; Cisplatin; Radiation therapy; Toxicity; Oncology; Internal medicine; Prostate cancer; Therapeutic index; PARP inhibitor; Cancer research; Chemotherapy; Poly ADP ribose polymerase; Pharmacology; Cancer; Drug; Biology","score_opus":0.031047687834461598,"score_gpt":0.29638742067072515,"score_spread":0.26533973283626355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242437290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7365065,0.002432452,0.00043377164,0.25495514,0.0006538778,0.0041669356,0.00013011562,0.000054314438,0.00066683296],"genre_scores_gemma":[0.97032917,0.0015515184,0.00032864365,0.018443692,0.00048810084,0.0009181906,0.000028192315,0.000035427725,0.007877082],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814,0.00022527919,0.0004948594,0.00021907005,0.00027436527,0.00064643164],"domain_scores_gemma":[0.998252,0.0005213069,0.0003097806,0.00015141082,0.00032902422,0.00043649136],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005731977,0.00018661817,0.00030828235,0.00013030149,0.0004274869,0.00019914226,0.00012989945,0.00019219947,0.0016924781],"category_scores_gemma":[0.00021473141,0.000106650674,0.00014274518,0.0002747831,0.000053178606,0.00013732698,0.0000031408601,0.0003180719,0.000023495815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039669126,0.00025529624,0.71741873,0.000021656171,0.0017528404,0.00009904355,0.0048464015,0.001282443,0.0051793535,0.00039328975,0.15249096,0.11229308],"study_design_scores_gemma":[0.01641679,0.003428013,0.44495657,0.000045881217,0.00009404556,0.00013339805,0.00042769217,0.012150874,0.0009877306,0.00448637,0.5164865,0.0003860856],"about_ca_topic_score_codex":0.005651512,"about_ca_topic_score_gemma":0.008646954,"teacher_disagreement_score":0.36399558,"about_ca_system_score_codex":0.0066359807,"about_ca_system_score_gemma":0.0018856189,"threshold_uncertainty_score":0.99922013},"labels":[],"label_agreement":null},{"id":"W4243694231","doi":"10.1093/annonc/mdv050.06","title":"A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) with Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Veliparib; Carboplatin; Internal medicine; PARP inhibitor; Lung cancer; Neutropenia; Oncology; Clinical endpoint; Gastroenterology; Randomized controlled trial; Chemotherapy; Cisplatin","score_opus":0.1672549693496572,"score_gpt":0.46000483917913826,"score_spread":0.29274986982948104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243694231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987361,0.004039028,0.00017212251,0.0011004488,0.00015999597,0.004372486,0.00004686032,0.000016896855,0.0027311316],"genre_scores_gemma":[0.9937469,0.002241317,0.0018460088,0.00050746603,0.00009103512,0.0011159524,0.00003540768,0.000033511584,0.00038243775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997761,0.00035204247,0.0009476595,0.0003304018,0.0002618803,0.0003470021],"domain_scores_gemma":[0.99767095,0.0006052846,0.0007199841,0.00027179252,0.00050315645,0.00022883309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013426131,0.00024386818,0.0018152375,0.00028086497,0.000017524655,0.0000050261638,0.00008970271,0.00014266685,0.000088799265],"category_scores_gemma":[0.00018208746,0.00016912507,0.000106677355,0.0004111861,0.00032308992,0.000090268244,0.000026285798,0.00021824511,0.0000012003609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9847027,0.0014665249,0.00034751263,0.0003300069,0.00040802112,0.00010491086,0.0032210746,0.00023754715,0.0017083804,0.000025156172,0.0005448405,0.006903324],"study_design_scores_gemma":[0.96373403,0.0129957935,0.000022482025,0.00041194612,0.0005085026,0.00003341462,0.00043312044,0.0005378849,0.019972136,0.000071023765,0.001116504,0.00016314881],"about_ca_topic_score_codex":0.0012675765,"about_ca_topic_score_gemma":0.0010919166,"teacher_disagreement_score":0.020968657,"about_ca_system_score_codex":0.00011142501,"about_ca_system_score_gemma":0.0017531489,"threshold_uncertainty_score":0.689672},"labels":[],"label_agreement":null},{"id":"W4244108171","doi":"10.12688/f1000research.8463.1","title":"An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells","year":2016,"lang":"en","type":"preprint","venue":"F1000Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Cancer Research UK","keywords":"DNA damage; Poly ADP ribose polymerase; Molecular biology; DNA repair; DNA; Biochemistry; Enzyme; Biology; Chemistry; Polymerase","score_opus":0.0851539735101146,"score_gpt":0.41200234827751153,"score_spread":0.3268483747673969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244108171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92252016,0.0011818546,0.010257286,0.029807279,0.0021348824,0.0068444973,0.0019099779,0.00054181943,0.024802214],"genre_scores_gemma":[0.9903266,0.00018656444,0.0008737232,0.00076482724,0.0021404347,0.00090690545,0.00008778115,0.00018881232,0.0045243627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9929329,0.0013364832,0.0005698342,0.0014920617,0.002394175,0.0012745333],"domain_scores_gemma":[0.99527335,0.00043124353,0.0001487571,0.0024387192,0.00049176195,0.0012161835],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0038934534,0.0005610426,0.0009650473,0.0012893816,0.00011725207,0.00013039363,0.0009341042,0.00083178515,0.0020118952],"category_scores_gemma":[0.0003718903,0.00048511033,0.00025524574,0.00070142216,0.00024570726,0.00019267734,0.0007398103,0.002613428,0.0013080146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004719301,0.0010931342,0.0040614246,0.00043956898,0.00015480732,0.0005986366,0.0006776756,0.00008155626,0.9243914,0.000063137115,0.033113033,0.030606339],"study_design_scores_gemma":[0.0063021933,0.00110635,0.018800562,0.0028413306,0.000053915563,0.000046444893,0.00006427395,0.0009996354,0.92481625,0.0026672636,0.041236162,0.0010656026],"about_ca_topic_score_codex":0.0010153754,"about_ca_topic_score_gemma":0.00021668326,"teacher_disagreement_score":0.0678064,"about_ca_system_score_codex":0.001970157,"about_ca_system_score_gemma":0.00211033,"threshold_uncertainty_score":0.99976003},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4245473243","doi":"10.1093/annonc/mdy483.002","title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Oncology; Internal medicine; Clinical endpoint; Ovarian cancer; Placebo; BRCA mutation; Hazard ratio; Progression-free survival; Chemotherapy; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.04305060990265014,"score_gpt":0.3968295337381739,"score_spread":0.3537789238355238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245473243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916055,0.0001729473,0.0007742129,0.0043505556,0.00041677523,0.0015328241,0.000034887635,0.000038810165,0.001073447],"genre_scores_gemma":[0.9902874,0.00017405143,0.0018429491,0.006897588,0.00026029363,0.00037714106,0.00005419895,0.00003947336,0.00006690777],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981112,0.00012909912,0.00061206915,0.0004400945,0.0002832232,0.00042432215],"domain_scores_gemma":[0.9985023,0.00027495684,0.00046648417,0.00025630477,0.00036073916,0.00013921285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039948957,0.00023582164,0.00073827576,0.00021838576,0.000073570096,0.000009684626,0.00009369526,0.00019954832,0.00018732689],"category_scores_gemma":[0.00016202491,0.00020507228,0.00008837688,0.0003675781,0.0002928259,0.00017331344,0.00001360122,0.000204612,0.0000032478772],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3122214,0.0038629519,0.014894521,0.00008304753,0.00036084454,0.0002018734,0.0039252727,0.00009495015,0.009361549,0.00011813426,0.0033209743,0.65155447],"study_design_scores_gemma":[0.90735966,0.034193106,0.018964352,0.0006646558,0.000076257726,0.000010516459,0.00023627398,0.00079097773,0.024511669,0.0002942486,0.012551247,0.00034701842],"about_ca_topic_score_codex":0.00044702302,"about_ca_topic_score_gemma":0.00077641616,"teacher_disagreement_score":0.65120745,"about_ca_system_score_codex":0.000193399,"about_ca_system_score_gemma":0.0006272193,"threshold_uncertainty_score":0.8362605},"labels":[],"label_agreement":null},{"id":"W4246592895","doi":"10.3410/f.727132391.793539669","title":"Faculty Opinions recommendation of XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia.","year":2017,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Hyperactivation; Ataxia; Cerebellar ataxia; XRCC1; Mutation; Psychology; Neuroscience; Genetics; Medicine; Internal medicine; Biology; Genotype","score_opus":0.045348120547410484,"score_gpt":0.38487446964419014,"score_spread":0.33952634909677964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246592895","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012445386,0.0008511221,0.000038879512,0.18038031,0.00040245045,0.0016862265,0.81651574,0.00003794909,0.000074886746],"genre_scores_gemma":[0.00010068133,0.00070572726,0.0004799466,0.006408337,0.00027346768,0.00027397083,0.9904938,0.0000415608,0.0012225377],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954571,0.00038495226,0.001400118,0.00074244663,0.0016961835,0.00031921512],"domain_scores_gemma":[0.9873485,0.0002185863,0.003101015,0.0015543981,0.0074815494,0.00029596215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012291671,0.0005526633,0.0011798219,0.00038725228,0.00040086877,0.00014534532,0.0006614752,0.00080007885,0.00043769035],"category_scores_gemma":[0.006692065,0.00036115383,0.00035637914,0.0011586517,0.00052283594,0.0005485966,0.00018805456,0.0010759501,0.000023041846],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075718635,0.0003846489,0.000062733794,0.004465319,0.0003839829,8.840884e-7,0.0001729445,7.46165e-8,0.000007881144,0.00003681561,0.9922665,0.0021425383],"study_design_scores_gemma":[0.0023365957,0.00032664472,0.008692342,0.024028983,0.00047940383,0.00012449277,0.000033115328,0.000013413368,0.00012160504,0.000028657638,0.9634811,0.00033364442],"about_ca_topic_score_codex":0.00007144895,"about_ca_topic_score_gemma":0.000008969354,"teacher_disagreement_score":0.17397805,"about_ca_system_score_codex":0.00022257335,"about_ca_system_score_gemma":0.0007833006,"threshold_uncertainty_score":0.99988407},"labels":[],"label_agreement":null},{"id":"W4246859680","doi":"10.1016/j.jval.2019.04.414","title":"PCN295 PATIENT-CENTERED OUTCOMES IN ARIEL3, A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH RECURRENT OVARIAN CARCINOMA","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Placebo; Internal medicine; Confidence interval; Nausea; Adverse effect; Vomiting","score_opus":0.0278019643634444,"score_gpt":0.31318732152585166,"score_spread":0.28538535716240726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246859680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811736,0.0002856978,0.000016547974,0.00054222456,0.0003802235,0.017396687,0.000051221516,0.000018421522,0.00013542673],"genre_scores_gemma":[0.99806,0.0000624724,0.0001907039,0.0002995089,0.000015304962,0.001230432,0.000041938976,0.000034100372,0.000065528024],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99555033,0.0011509621,0.0017100843,0.0005350704,0.00051469734,0.00053885125],"domain_scores_gemma":[0.9980387,0.00048366396,0.00067344477,0.00054547883,0.0000974826,0.00016123381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010125389,0.00033964156,0.0024087455,0.00058704236,0.000024836285,0.00000882129,0.000099406134,0.00007672806,0.000054412685],"category_scores_gemma":[0.0001418466,0.00023268371,0.00013896183,0.00042521372,0.000058457415,0.00006767874,0.000021862728,0.00027551645,0.00000595201],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40313616,0.011680445,0.57556933,0.000099585384,0.00009253653,0.000018619186,0.0070854807,0.00050660037,0.0000035426858,0.00004668967,0.000008616385,0.0017524235],"study_design_scores_gemma":[0.8291078,0.011980699,0.15435207,0.000831726,0.000032373668,0.0000017757441,0.0010636606,0.002386243,0.000016667556,0.000042430507,0.000025759191,0.00015875141],"about_ca_topic_score_codex":0.012113947,"about_ca_topic_score_gemma":0.0010706646,"teacher_disagreement_score":0.4259717,"about_ca_system_score_codex":0.0016314582,"about_ca_system_score_gemma":0.0005989411,"threshold_uncertainty_score":0.99446446},"labels":[],"label_agreement":null},{"id":"W4249033362","doi":"10.1161/circ.116.suppl_16.ii_212-d","title":"Abstract 1063: Intracardiac Injection of Epoetin-α Upregulates Stem Cell Chemoattractant Gene Expression In a Rat Myocardial Infarction Model","year":2007,"lang":"en","type":"article","venue":"Circulation","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Muscular Dystrophy Canada","funders":"","keywords":"Medicine; Cardiology; Myocardial infarction; Ejection fraction; Internal medicine; Erythropoietin; Infarction; Ventricular remodeling; Angiogenesis; Cardiac function curve; Cardioprotection; Dobutamine; Cardiac output; Hemodynamics; Heart failure","score_opus":0.022808687132942065,"score_gpt":0.27883956263933385,"score_spread":0.2560308755063918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249033362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775016,0.00034542952,0.019185852,0.00006212524,0.00041243015,0.0005854788,0.000005380189,0.000073974785,0.0018277647],"genre_scores_gemma":[0.99826753,0.00007664852,0.0011070223,0.00006951854,0.00030987995,0.000027391721,0.00008072038,0.000035074758,0.000026216714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982212,0.000041015417,0.0007008494,0.00033450648,0.00044542085,0.00025696054],"domain_scores_gemma":[0.99900424,0.00007259942,0.00034418,0.00029612996,0.00018621628,0.0000966432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076264545,0.00018398974,0.0003391328,0.0003378717,0.000055209322,0.000012876591,0.000046547393,0.00027153024,0.000035912217],"category_scores_gemma":[0.000019568482,0.0001940439,0.00015661035,0.00036272698,0.00005248632,0.00028725932,0.000014335345,0.00026163147,0.000009250815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004881039,0.00014533687,0.05572725,0.000090844806,0.000017010554,0.000004142993,0.0006627137,0.0484602,0.88577193,0.00001772511,0.00005810281,0.008556619],"study_design_scores_gemma":[0.0015341837,0.0000382872,0.37759262,0.00014816612,0.000028267752,0.000027162983,0.000112496346,0.007291426,0.61283326,0.0002184705,0.000046422378,0.00012921177],"about_ca_topic_score_codex":0.000025209507,"about_ca_topic_score_gemma":0.000003678098,"teacher_disagreement_score":0.32186538,"about_ca_system_score_codex":0.00045765497,"about_ca_system_score_gemma":0.00010786178,"threshold_uncertainty_score":0.7912881},"labels":[],"label_agreement":null},{"id":"W4249418649","doi":"10.3410/f.725335877.793533572","title":"Faculty Opinions recommendation of Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.","year":2017,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Homologous recombination; Recombination; Homologous chromosome; Genetics; Biology; Computer science; DNA; Gene","score_opus":0.04426283176459484,"score_gpt":0.38866189327904066,"score_spread":0.3443990615144458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249418649","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004874746,0.001090909,0.000011767806,0.2434992,0.0018545538,0.0020888078,0.7511665,0.00009750154,0.00018582963],"genre_scores_gemma":[0.00008751928,0.00084562687,0.0002855462,0.00961754,0.00043029673,0.0005581233,0.98597485,0.000056986442,0.0021435083],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99279886,0.00062432303,0.002250757,0.0011062343,0.0026883401,0.0005314904],"domain_scores_gemma":[0.98364776,0.0002875194,0.00407596,0.0031051124,0.008387423,0.0004962488],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021298872,0.00078443915,0.0016495935,0.0007722779,0.00049137266,0.00012927476,0.0016198831,0.0010526191,0.0009242969],"category_scores_gemma":[0.012899927,0.0005374262,0.0011946029,0.0014235359,0.00063925213,0.00028614994,0.0003948002,0.0018232322,0.00021190484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008487739,0.0013799673,0.00005695392,0.0058762184,0.00026600418,0.000002710531,0.00007661065,2.901374e-7,0.0000035622463,0.00015358241,0.9912996,0.00079959363],"study_design_scores_gemma":[0.0023883209,0.00050865917,0.008928184,0.026182929,0.0003667667,0.00013334198,0.000044350396,0.000009693148,0.000069182184,0.000030891508,0.9608974,0.00044032294],"about_ca_topic_score_codex":0.00008071797,"about_ca_topic_score_gemma":0.000011585742,"teacher_disagreement_score":0.2348083,"about_ca_system_score_codex":0.0005727535,"about_ca_system_score_gemma":0.0011340695,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4249938708","doi":"10.1158/1538-7445.sabcs18-ct158","title":"Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Nivolumab; Oncology; Placebo; Double blind; Chemotherapy; Internal medicine; Front line; Cancer; Immunotherapy; Pathology","score_opus":0.19404139443175017,"score_gpt":0.49649106199942367,"score_spread":0.3024496675676735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249938708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687488,0.0011258652,0.00072486367,0.0015191612,0.0027865784,0.023363147,0.000073591844,0.000117895215,0.0015400623],"genre_scores_gemma":[0.9923868,0.00032987798,0.0005876992,0.0013931211,0.0018030505,0.0025539284,0.00006414561,0.0001347055,0.00074665056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98556966,0.0029762215,0.008271399,0.0012603479,0.0011815908,0.00074079947],"domain_scores_gemma":[0.9785153,0.016204923,0.003195172,0.001358359,0.00028984793,0.00043639034],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.034071017,0.000724853,0.009766722,0.00048567675,0.0000929258,0.000063104424,0.00044996606,0.0007075239,0.0050784987],"category_scores_gemma":[0.004513682,0.0005578664,0.0027164018,0.0004953641,0.00024355663,0.00019891521,0.000048290054,0.0012038938,0.00010788217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97055763,0.008660137,0.004377664,0.00010020047,0.003161559,0.00005693956,0.0010202226,0.0005655075,0.004830905,0.000037811427,0.00053622166,0.0060952306],"study_design_scores_gemma":[0.9880661,0.0024640916,0.0003560325,0.00093936373,0.0012350227,0.000002399139,0.0004683077,0.0023464353,0.0028453807,0.00021475529,0.00054495514,0.00051719334],"about_ca_topic_score_codex":0.0012541097,"about_ca_topic_score_gemma":0.00025744725,"teacher_disagreement_score":0.029557336,"about_ca_system_score_codex":0.00032384132,"about_ca_system_score_gemma":0.0012135684,"threshold_uncertainty_score":0.99968725},"labels":[],"label_agreement":null},{"id":"W4250070562","doi":"10.1055/s-0034-1368808","title":"Sarkome – Prognostische Prädiktoren in der Nuklearmedizin","year":2014,"lang":"de","type":"article","venue":"RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Philosophy","score_opus":0.01985066989894406,"score_gpt":0.30508973715177384,"score_spread":0.28523906725282977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250070562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.543059,0.36741558,0.005589687,0.015217515,0.015454004,0.013186091,0.0012161643,0.0020978022,0.03676419],"genre_scores_gemma":[0.96918875,0.005964227,0.005216134,0.005727085,0.00822804,0.0007500768,0.0011612588,0.000841355,0.0029230572],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9833029,0.0012550016,0.0038553989,0.0037884733,0.0033456874,0.004452527],"domain_scores_gemma":[0.9915139,0.0010718828,0.0013370832,0.0032034416,0.00074695254,0.0021267484],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0031540876,0.0026531632,0.0032278618,0.0016003948,0.0006908862,0.00063585077,0.0016912604,0.0023782703,0.0028528613],"category_scores_gemma":[0.00068820704,0.002733608,0.0011709633,0.002397601,0.0013694568,0.0012846456,0.00066920405,0.003561666,0.005294826],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063250773,0.0072514955,0.42784762,0.0046127154,0.023518253,0.004061846,0.00921876,0.0011668752,0.013579788,0.008081838,0.26718855,0.22714719],"study_design_scores_gemma":[0.02782885,0.0025472492,0.101200126,0.004359089,0.007994159,0.0006006969,0.00049202406,0.00336957,0.022453113,0.005233414,0.81860495,0.0053167874],"about_ca_topic_score_codex":0.0009944772,"about_ca_topic_score_gemma":0.00063718314,"teacher_disagreement_score":0.5514164,"about_ca_system_score_codex":0.0011551062,"about_ca_system_score_gemma":0.0021037774,"threshold_uncertainty_score":0.99891686},"labels":[],"label_agreement":null},{"id":"W4254582434","doi":"10.1109/serp4iot.2019.00007","title":"SERP4IoT 2019 Program Committee","year":2019,"lang":"en","type":"article","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Chicoutimi; Université du Québec à Montréal; Polytechnique Montréal; École de Technologie Supérieure","funders":"","keywords":"Computer science","score_opus":0.015210799763221783,"score_gpt":0.3314695092530673,"score_spread":0.3162587094898455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254582434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5663867,0.00023477848,0.00015853868,0.0054766443,0.004429587,0.0015189283,0.0000062454524,0.00071605097,0.42107254],"genre_scores_gemma":[0.89998955,0.00004685203,0.007993224,0.00535835,0.0019113427,0.0000874391,0.000041649597,0.000037254587,0.08453431],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993304,0.000013296715,0.00012628207,0.0001584284,0.00020496707,0.0001666141],"domain_scores_gemma":[0.9994404,0.000038370257,0.000027386784,0.000345743,0.000068816305,0.00007928501],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000088727684,0.000081151135,0.00015407622,0.000040321782,0.000016735985,0.000012007891,0.000055540517,0.000064448366,0.0056615085],"category_scores_gemma":[0.0000072012567,0.000063834814,0.000057784287,0.00011459312,0.000028202696,0.000050339066,0.00001547908,0.00013145368,0.0044308803],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019069588,0.00035882855,0.0525278,0.000064490276,0.00006772567,0.000009413701,0.00009037398,0.0000028932325,0.013982096,0.0023122714,0.89742905,0.03296434],"study_design_scores_gemma":[0.0028245912,0.0006210942,0.01618563,0.000058972495,0.000013776431,0.00002699283,0.000047929647,0.00016410135,0.013603986,0.00023242325,0.96609247,0.0001280142],"about_ca_topic_score_codex":0.000025797763,"about_ca_topic_score_gemma":0.0000026690211,"teacher_disagreement_score":0.33653823,"about_ca_system_score_codex":0.000050920593,"about_ca_system_score_gemma":0.000055900004,"threshold_uncertainty_score":0.99634427},"labels":[],"label_agreement":null},{"id":"W4280526636","doi":"10.1016/j.ygyno.2022.05.005","title":"Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Stand Up To Cancer Canada; Cure JM Foundation; Fondazione Guido Berlucchi; Honorable Tina Brozman Foundation; Deborah Bunn Alley Ovarian Cancer Research Foundation; Stand Up To Cancer; Gilead Sciences","keywords":"Olaparib; PARP inhibitor; Medicine; In vivo; Cancer research; Ovarian cancer; Apoptosis; Poly ADP ribose polymerase; Biology; Internal medicine; Cancer; Polymerase; Enzyme; Biochemistry; Genetics","score_opus":0.020725371044592197,"score_gpt":0.316739489115801,"score_spread":0.2960141180712088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280526636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97360075,0.0022012517,0.00035936362,0.019238584,0.0013586092,0.0017696668,0.000101083744,0.00015742723,0.0012132674],"genre_scores_gemma":[0.98961014,0.000099246565,0.0018442863,0.007022946,0.00017618625,0.0006360758,0.000111516085,0.000045104818,0.0004544983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959637,0.0010498433,0.0007812291,0.0010304039,0.0003973733,0.0007774833],"domain_scores_gemma":[0.9971502,0.0015688011,0.0003445372,0.0004516369,0.00014243033,0.0003424267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015638218,0.00039908243,0.0009993407,0.00046230637,0.00036108514,0.00002493584,0.00016732486,0.00039216568,0.0007393053],"category_scores_gemma":[0.00058214396,0.0003610352,0.0000907062,0.0009464468,0.00035452138,0.00012852356,0.00037441205,0.0013082912,0.000023714365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030726127,0.017704137,0.6390379,0.00033440418,0.00044492897,0.023058232,0.0067153014,0.0017437739,0.13769491,0.0045395303,0.012615958,0.12538478],"study_design_scores_gemma":[0.0381792,0.060130727,0.8338773,0.00015050216,0.00035450765,0.0083412025,0.0013156477,0.0014949423,0.01749105,0.0023423147,0.034749243,0.0015733307],"about_ca_topic_score_codex":0.00042442937,"about_ca_topic_score_gemma":0.0005787159,"teacher_disagreement_score":0.1948394,"about_ca_system_score_codex":0.0014316747,"about_ca_system_score_gemma":0.0006503717,"threshold_uncertainty_score":0.9998842},"labels":[],"label_agreement":null},{"id":"W4281260123","doi":"10.1093/hmg/ddac116","title":"Genetic and pharmacological PARP inhibition reduces axonal degeneration in <i>C. elegans</i> models of ALS","year":2022,"lang":"en","type":"article","venue":"Human Molecular Genetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Rare Disease Foundation","keywords":"Biology; Axonal degeneration; Degeneration (medical); Caenorhabditis elegans; Amyotrophic lateral sclerosis; Poly ADP ribose polymerase; Neurodegeneration; Phenotype; Context (archaeology); Neuroscience; Genetics; Gene; Polymerase; Pathology; Disease","score_opus":0.04116196433824804,"score_gpt":0.31795150919060056,"score_spread":0.2767895448523525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281260123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935679,0.003280304,0.0018856638,0.00022712866,0.000058392616,0.00045381108,0.00002455177,0.000020510937,0.0004817556],"genre_scores_gemma":[0.9954326,0.0003194354,0.0028715597,0.001022007,0.00007099809,0.00016652486,0.00006176262,0.000024251236,0.000030818166],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857724,0.000174273,0.00039185432,0.0002899734,0.00038245998,0.00018421804],"domain_scores_gemma":[0.9995892,0.000014374219,0.00011201107,0.0001440671,0.000064522406,0.00007579321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018443166,0.00013281465,0.00022372724,0.00014998314,0.0000985871,0.000010379126,0.00005691955,0.0000585647,0.00023471772],"category_scores_gemma":[0.0000045227625,0.00014984442,0.000055604334,0.00018876245,0.00010776349,0.000028435468,0.00007001137,0.00019633867,8.328038e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088474655,0.00018790191,0.0007415141,0.000021279131,0.000022043076,0.00007875087,0.00021081543,0.01837463,0.97884125,0.00055629434,0.000314437,0.00056259177],"study_design_scores_gemma":[0.0031421047,0.0007228476,0.0061591556,0.000031266274,0.00008878535,0.00012938188,0.00008968347,0.0051629385,0.97813934,0.005621617,0.00050547207,0.00020740091],"about_ca_topic_score_codex":0.000007550867,"about_ca_topic_score_gemma":0.000003894843,"teacher_disagreement_score":0.013211692,"about_ca_system_score_codex":0.00009529441,"about_ca_system_score_gemma":0.00008025947,"threshold_uncertainty_score":0.6110478},"labels":[],"label_agreement":null},{"id":"W4281652361","doi":"10.1101/2022.06.06.494829","title":"Proteome-wide microarray-based screening of PAR-binding proteins","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Proteome; DNA-binding protein; Biochemistry; Plasma protein binding; Nucleic acid; Biology; Transcription factor; Binding site; DNA; Chemistry; Computational biology; Cell biology; Gene","score_opus":0.024895788481436795,"score_gpt":0.2589038195838203,"score_spread":0.2340080311023835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281652361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97856736,0.0009660703,0.0122829685,0.001075476,0.00089351577,0.0048611774,0.0006552582,0.00064783863,0.000050349296],"genre_scores_gemma":[0.93629634,0.000061158506,0.059514426,0.0006787019,0.00047768853,0.0026482085,0.0000036598158,0.00029688148,0.000022931898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99545574,0.0002685888,0.0011215528,0.0013154281,0.001066202,0.0007724984],"domain_scores_gemma":[0.99563307,0.00012470668,0.0011984444,0.002024775,0.0006231377,0.00039585988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001195777,0.00075410615,0.0012274699,0.00079484616,0.00029021062,0.000084391715,0.00060898357,0.0005408861,0.0008995491],"category_scores_gemma":[0.00035792583,0.00085816387,0.00046034422,0.0009882434,0.0002787546,0.00011276708,0.00045017057,0.0018266126,0.000030298825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004485994,0.00033058622,0.041169815,0.0018668565,0.00033501902,0.00011978688,0.000019591806,0.00030305557,0.954865,0.00004979636,0.00048967905,0.0000022495715],"study_design_scores_gemma":[0.0027880333,0.000286237,0.036390528,0.002479113,0.00021983603,4.8921695e-8,0.000007372908,0.00018187104,0.94356334,0.0000013969717,0.013284861,0.0007973835],"about_ca_topic_score_codex":0.00008532704,"about_ca_topic_score_gemma":0.0000010270107,"teacher_disagreement_score":0.047231458,"about_ca_system_score_codex":0.0007474691,"about_ca_system_score_gemma":0.0022358939,"threshold_uncertainty_score":0.9993869},"labels":[],"label_agreement":null},{"id":"W4281666355","doi":"10.1200/jco.22.01003","title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke","funders":"National Cancer Institute; Genentech; Eisai; National Institute for Health and Care Research; MacroGenics; Clovis Oncology; NuCana; Novocure; Puma Biotechnology; Regeneron Pharmaceuticals; Array BioPharma; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Pfizer","keywords":"Medicine; Population; Hazard ratio; Internal medicine; Ovarian cancer; Clinical endpoint; Placebo; Oncology; BRCA mutation; Surgery; Cancer; Clinical trial; Confidence interval; Pathology","score_opus":0.10373829953680314,"score_gpt":0.4865092343933121,"score_spread":0.382770934856509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281666355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725434,0.0004131105,0.0006040084,0.018828822,0.002665017,0.004083162,0.00004043208,0.000018805578,0.0008032287],"genre_scores_gemma":[0.97500145,0.0016161955,0.0021814664,0.016819822,0.0019186864,0.0016889716,0.0000144940495,0.00007036678,0.0006885434],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.991651,0.0026058725,0.0037345998,0.0004844511,0.0010049081,0.00051919324],"domain_scores_gemma":[0.99234796,0.0033708126,0.002686708,0.00040919316,0.00052354304,0.00066179223],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006626099,0.00035397478,0.0037343255,0.00036379218,0.00012004307,0.000017755996,0.00030009964,0.00023249091,0.0023442411],"category_scores_gemma":[0.0016108013,0.00023197121,0.0008287961,0.00044551678,0.00024623697,0.00012783826,0.000050415012,0.0011675247,0.000017000166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8868774,0.010759607,0.004140001,0.000004653581,0.0010836282,0.0005454744,0.0012287819,0.0011353225,0.00002710477,0.00009323227,0.003099129,0.09100565],"study_design_scores_gemma":[0.8412972,0.07603286,0.0026793734,0.00011309878,0.0004875579,0.000046069006,0.00014625069,0.00020810035,0.00003457932,0.00045005287,0.07829754,0.0002073327],"about_ca_topic_score_codex":0.000775651,"about_ca_topic_score_gemma":0.0002051313,"teacher_disagreement_score":0.09079832,"about_ca_system_score_codex":0.0022774716,"about_ca_system_score_gemma":0.0050729,"threshold_uncertainty_score":0.99856776},"labels":[],"label_agreement":null},{"id":"W4281673802","doi":"10.1200/jco.2022.40.16_suppl.tps5096","title":"TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Olaparib; PARP inhibitor; Prostate cancer; Placebo; Internal medicine; Androgen receptor; Oncology; Cancer; Pathology; Poly ADP ribose polymerase; Genetics; Biology; Gene","score_opus":0.1576914169105703,"score_gpt":0.4849085811949972,"score_spread":0.32721716428442693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281673802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914437,0.0003535415,0.000108309905,0.00072278274,0.0017579828,0.0052464437,0.00012235518,0.00001597911,0.00022893953],"genre_scores_gemma":[0.99728876,0.0001810725,0.00088462594,0.00056821026,0.0002828894,0.0005830892,0.00006004075,0.000055561195,0.00009574199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903561,0.0026736367,0.004538094,0.00049148937,0.0014827038,0.00045800672],"domain_scores_gemma":[0.98951113,0.0037400972,0.004815754,0.0003269579,0.0012108309,0.00039521887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045264564,0.00037295165,0.0039750934,0.00052442506,0.00013103595,0.00001791486,0.00023423418,0.00016641163,0.00031206492],"category_scores_gemma":[0.0010190519,0.0002855703,0.0004836921,0.0006873584,0.0005035668,0.00025268376,0.00010424146,0.0018843904,0.000003735375],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9526773,0.010786604,0.0063631088,0.00004138565,0.0027694881,0.0016268122,0.004354943,0.017048685,0.00016907926,0.000017536615,0.00022462482,0.0039204345],"study_design_scores_gemma":[0.9386192,0.04987513,0.0040896474,0.0001263038,0.0017484722,0.00016801279,0.0034802908,0.0007090355,0.00049899856,0.000034783177,0.00039875918,0.000251395],"about_ca_topic_score_codex":0.0004053627,"about_ca_topic_score_gemma":0.0005827794,"teacher_disagreement_score":0.03908852,"about_ca_system_score_codex":0.0016636588,"about_ca_system_score_gemma":0.0060661747,"threshold_uncertainty_score":0.99995965},"labels":[],"label_agreement":null},{"id":"W4281708097","doi":"10.1200/jco.2022.40.16_suppl.5019","title":"Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Tolerability; Prostate cancer; Hazard ratio; Internal medicine; Interim analysis; Adverse effect; Clinical endpoint; Placebo; Confidence interval; Enzalutamide; Oncology; Clinical trial; Surgery; Cancer; Pathology","score_opus":0.12185701098343013,"score_gpt":0.44461756509497885,"score_spread":0.3227605541115487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281708097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98443884,0.00012139128,0.00003211236,0.01248439,0.00056718005,0.001865712,0.00030422208,0.0000067845776,0.00017938815],"genre_scores_gemma":[0.99703944,0.00006217183,0.0008474687,0.0015108477,0.00021546627,0.00015183096,0.000039765513,0.00002528821,0.00010769806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932022,0.0017289663,0.0036006174,0.00032224643,0.00089933455,0.00024659716],"domain_scores_gemma":[0.99283814,0.0019995738,0.0038445576,0.00038913768,0.0007417089,0.00018686226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004755991,0.0001978327,0.0016798383,0.00008733591,0.00008607184,0.000011708534,0.00022787589,0.00011136419,0.00037255892],"category_scores_gemma":[0.0007710324,0.000104881416,0.00017875915,0.00035267556,0.00043667664,0.00013977684,0.00004275143,0.0015358969,0.0000010973234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94364685,0.012148623,0.026883032,0.000023386481,0.0006819386,0.00016785464,0.0019261739,0.0009177482,0.00042826726,0.000013006632,0.0012193082,0.0119437985],"study_design_scores_gemma":[0.7433648,0.14324364,0.10387382,0.00025788706,0.0005652058,0.000020311274,0.0010295908,0.00012480134,0.00029834034,0.00021091152,0.006841797,0.00016887137],"about_ca_topic_score_codex":0.0005255336,"about_ca_topic_score_gemma":0.0013128818,"teacher_disagreement_score":0.20028204,"about_ca_system_score_codex":0.00050539535,"about_ca_system_score_gemma":0.0034463496,"threshold_uncertainty_score":0.6672793},"labels":[],"label_agreement":null},{"id":"W4281759436","doi":"10.3390/curroncol29060333","title":"A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Clovis Oncology","keywords":"Medicine; Prostate cancer; PARP inhibitor; Cancer research; Oncology; DNA repair; Internal medicine; Cancer; Gene; Bioinformatics; Poly ADP ribose polymerase; Genetics; Biology","score_opus":0.2219823104923473,"score_gpt":0.5133659858623679,"score_spread":0.29138367537002063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281759436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957214,0.00039959684,0.000024689718,0.0011800025,0.00034624586,0.0022364988,0.00007070123,0.000010560798,0.000010293506],"genre_scores_gemma":[0.99741304,0.000029201685,0.00032852098,0.00020129741,0.000031163152,0.0019598352,0.000010506865,0.000011989745,0.00001442151],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9976143,0.0009410614,0.00071538566,0.00031602633,0.00025823028,0.00015497487],"domain_scores_gemma":[0.9990197,0.0003120889,0.0002538928,0.00017645188,0.00012000225,0.0001179028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009325885,0.00011010264,0.0004452189,0.00020930395,0.00007819457,0.0000060199172,0.00003170514,0.000018342893,0.00008691125],"category_scores_gemma":[0.00009972592,0.000093672774,0.000025553663,0.0003124158,0.00006350034,0.000038663224,0.00004611711,0.0002809163,5.457085e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24233304,0.026449075,0.2591769,0.00036426462,0.00046699663,0.03246517,0.19851534,0.004536537,0.009991463,0.0000719596,0.0017570528,0.2238722],"study_design_scores_gemma":[0.17119408,0.32754877,0.16609602,0.0007695188,0.0011987344,0.029624535,0.19430889,0.0053483304,0.0011471218,0.00014661464,0.101420745,0.0011966478],"about_ca_topic_score_codex":0.0004225794,"about_ca_topic_score_gemma":0.0022103372,"teacher_disagreement_score":0.3010997,"about_ca_system_score_codex":0.00037420416,"about_ca_system_score_gemma":0.0008173064,"threshold_uncertainty_score":0.3819865},"labels":[],"label_agreement":null},{"id":"W4281768533","doi":"10.1200/jco.2022.40.16_suppl.5020","title":"Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; CHEK2; FANCA; Clinical endpoint; Prostate cancer; Abiraterone acetate; Oncology; Internal medicine; PALB2; Cancer research; Carboplatin; Cancer; Gene; Fanconi anemia; DNA repair; Chemotherapy; Clinical trial; Mutation; Genetics; Androgen deprivation therapy; Biology; Germline mutation","score_opus":0.06013094499180042,"score_gpt":0.401546616470539,"score_spread":0.3414156714787386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281768533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635875,0.00062026107,0.000047220423,0.001731539,0.00009493947,0.001067714,0.000058006655,0.000005488933,0.000016067068],"genre_scores_gemma":[0.99616647,0.000534215,0.0024357291,0.00054977706,0.000035204703,0.00018941684,0.000033799864,0.000016146296,0.00003924859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99531,0.001603407,0.0019734255,0.00031816252,0.00060226576,0.0001927052],"domain_scores_gemma":[0.99695235,0.000547462,0.0017218655,0.00021608392,0.00045587608,0.0001063827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032306768,0.00017050754,0.0011739226,0.00038451597,0.00010084946,0.000017583692,0.000109749126,0.00006355746,0.000045868223],"category_scores_gemma":[0.00015381014,0.000109836,0.00008597543,0.0007597269,0.00020269949,0.00015405801,0.000036490823,0.0006190288,1.263855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020794677,0.009143085,0.9488753,0.000043235756,0.0020419583,0.00044155697,0.004512558,0.005102714,0.001580725,0.00000436696,0.00018760309,0.0072722244],"study_design_scores_gemma":[0.035723697,0.04677002,0.91318816,0.000035728503,0.0015767603,0.00013144215,0.0015760419,0.0003590994,0.0003520912,0.00006588926,0.000095427364,0.00012562217],"about_ca_topic_score_codex":0.0003792822,"about_ca_topic_score_gemma":0.0033024065,"teacher_disagreement_score":0.037626937,"about_ca_system_score_codex":0.00028309185,"about_ca_system_score_gemma":0.0006098527,"threshold_uncertainty_score":0.4478982},"labels":[],"label_agreement":null},{"id":"W4281789885","doi":"10.1200/jco.2022.40.16_suppl.5519","title":"Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; BRCA mutation; Oncology; Internal medicine; Ovarian cancer; Cancer","score_opus":0.0630377280027824,"score_gpt":0.3949587414549937,"score_spread":0.3319210134522113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281789885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920023,0.00012272783,0.00012335568,0.0051013962,0.0010865304,0.0009780325,0.00034925374,0.000023510449,0.00021291374],"genre_scores_gemma":[0.99287945,0.00020921671,0.001493567,0.0046401164,0.00034694196,0.00006194472,0.00007062486,0.000039597086,0.00025856684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929467,0.002866702,0.0026679111,0.00043739396,0.0007596836,0.0003215953],"domain_scores_gemma":[0.9905575,0.005471596,0.0029416138,0.0002962527,0.000543135,0.00018991527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054032374,0.0002215099,0.001214777,0.00012228516,0.00016036085,0.000016621067,0.00014925144,0.00019864137,0.00026556166],"category_scores_gemma":[0.0033658382,0.00013849926,0.00014479141,0.00030802557,0.00021220773,0.00015577095,0.0000742737,0.0014182855,0.0000023490493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23722664,0.010378634,0.69413084,0.000025706175,0.001680398,0.0017385471,0.008497522,0.0011390389,0.00021919812,0.000050491642,0.017195605,0.027717358],"study_design_scores_gemma":[0.10508625,0.027632397,0.85596144,0.00019473153,0.0003103953,0.00014136595,0.0021503682,0.0008937674,0.000047345136,0.00042418975,0.0069452827,0.00021246493],"about_ca_topic_score_codex":0.0011021587,"about_ca_topic_score_gemma":0.0013202564,"teacher_disagreement_score":0.16183057,"about_ca_system_score_codex":0.0010614924,"about_ca_system_score_gemma":0.0013610543,"threshold_uncertainty_score":0.6161824},"labels":[],"label_agreement":null},{"id":"W4281837772","doi":"10.1200/jco.2022.40.16_suppl.11560","title":"Synergistic activity of PARP inhibitors (PARPi) in combination with standard chemotherapy (CTx) in leiomyosarcoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Olaparib; Doxorubicin; Cancer research; Temozolomide; Leiomyosarcoma; Pharmacology; Dacarbazine; Combination therapy; Oncology; Internal medicine; Chemotherapy; Melanoma; Poly ADP ribose polymerase; Pathology; Biology; DNA","score_opus":0.08447537777278068,"score_gpt":0.4460339659641407,"score_spread":0.36155858819136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281837772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875566,0.00016839785,0.00041460473,0.009943786,0.0006475087,0.00028477606,0.000008274955,0.0000061898354,0.0009698847],"genre_scores_gemma":[0.99744856,0.00022071412,0.0010104269,0.0009990982,0.00022741336,0.000018304832,0.0000022700526,0.000019771016,0.000053465006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605,0.00087320106,0.0019981076,0.00018588408,0.00068946194,0.00020332298],"domain_scores_gemma":[0.9959239,0.0015384508,0.0019661214,0.00017658158,0.00025454187,0.00014043527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004771581,0.00012673874,0.0014621769,0.0003953947,0.00003050659,0.0000032871474,0.00014654781,0.00016925682,0.00031403085],"category_scores_gemma":[0.00065948657,0.00010301568,0.00020459727,0.0005300368,0.00024992749,0.00011045681,0.000036789457,0.0014341866,8.692452e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10589486,0.013417609,0.6759107,0.00012120544,0.00038508547,0.0017638042,0.0010944152,0.0015946489,0.011742339,0.00074942666,0.0033254812,0.1840004],"study_design_scores_gemma":[0.11136039,0.077597894,0.73179275,0.0005376453,0.00014903645,0.00045628133,0.00075075426,0.0004924022,0.010325184,0.003474983,0.06274167,0.00032102977],"about_ca_topic_score_codex":0.00006226647,"about_ca_topic_score_gemma":0.000115625306,"teacher_disagreement_score":0.18367937,"about_ca_system_score_codex":0.0011274272,"about_ca_system_score_gemma":0.0021470326,"threshold_uncertainty_score":0.6230907},"labels":[],"label_agreement":null},{"id":"W4282921591","doi":"10.1158/1538-7445.am2022-2996","title":"Abstract 2996: Pre-activation of autophagy impacts PARP inhibitor sensitivity of prostate cancer cells","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal","funders":"","keywords":"Olaparib; LNCaP; Autophagy; Cancer research; Clonogenic assay; PARP inhibitor; Prostate cancer; Biology; Cancer; Cell biology; Cell culture; Poly ADP ribose polymerase; Apoptosis","score_opus":0.0761107896073613,"score_gpt":0.42853906030834416,"score_spread":0.35242827070098287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282921591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947487,0.0011065174,0.000014636874,0.0013353113,0.0003343895,0.001204578,0.0005963657,0.000035775818,0.0006237248],"genre_scores_gemma":[0.99715674,0.0007678587,0.00004457873,0.00014543333,0.00030375127,0.000725786,0.000032171687,0.000047834612,0.000775855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99669063,0.00040012543,0.0004789839,0.00039118464,0.0015229145,0.0005161706],"domain_scores_gemma":[0.99797916,0.00034038568,0.00028330594,0.00044867018,0.00076079054,0.00018766563],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020376425,0.00015965923,0.0004247161,0.000359285,0.00018659368,0.000012214353,0.00012050695,0.00007487366,0.0026377672],"category_scores_gemma":[0.00011260797,0.0001574436,0.000112424255,0.00092450617,0.00032012933,0.00015456443,0.00013833177,0.0008081603,0.000005200083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002542963,0.00030088477,0.0041494477,0.0006612384,0.000101423444,0.000024276163,0.0019203314,0.0018464891,0.97392356,0.00003261079,0.008095305,0.006401459],"study_design_scores_gemma":[0.0019037359,0.00043123215,0.04136176,0.00039619752,0.000015116277,0.0000059236313,0.0003348961,0.00014733657,0.9500283,0.00008524555,0.0051669437,0.00012328707],"about_ca_topic_score_codex":0.006479185,"about_ca_topic_score_gemma":0.00009925457,"teacher_disagreement_score":0.037212316,"about_ca_system_score_codex":0.0012956328,"about_ca_system_score_gemma":0.0019734045,"threshold_uncertainty_score":0.99827397},"labels":[],"label_agreement":null},{"id":"W4282936736","doi":"10.1158/1538-7445.am2022-5990","title":"Abstract 5990: Targeted nanoparticles reduce tumor progression and lung metastasis by limiting DNA damage repair and immune suppression in metastatic triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Olaparib; Cancer research; PARP inhibitor; PARP1; Biology; Medicine; Poly ADP ribose polymerase; Biochemistry; Polymerase","score_opus":0.05990157005565653,"score_gpt":0.4212244016056191,"score_spread":0.36132283154996253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282936736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693365,0.024112241,0.0000012425985,0.0038666795,0.00013931582,0.0015631036,0.00076844805,0.00008522175,0.00012723778],"genre_scores_gemma":[0.99481547,0.0013769025,0.00032375357,0.00017207094,0.00008755398,0.0028574765,0.000052706528,0.000066795044,0.0002472827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99596334,0.0008089948,0.00057483494,0.00075451884,0.0011287966,0.0007695039],"domain_scores_gemma":[0.99843955,0.00044147286,0.00019868866,0.00036329695,0.0002549757,0.00030200527],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023318501,0.00025713112,0.0005296739,0.00041616714,0.00064460264,0.00006963763,0.00016374167,0.000045458753,0.0020400241],"category_scores_gemma":[0.00023376143,0.00022778034,0.00007575342,0.0010930155,0.00044347768,0.00031550892,0.00032770046,0.0010835328,0.0000017617316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029628961,0.0002849027,0.006678197,0.00046321694,0.00016530792,0.00019285244,0.0016776475,0.000033585882,0.96717685,0.00001953678,0.008911429,0.011433596],"study_design_scores_gemma":[0.00793347,0.00041357838,0.09728588,0.0014760856,0.0001047246,0.00014535648,0.0045609106,0.0014700836,0.8846984,0.00018635816,0.0013428377,0.00038231857],"about_ca_topic_score_codex":0.001720881,"about_ca_topic_score_gemma":0.000087734734,"teacher_disagreement_score":0.09060768,"about_ca_system_score_codex":0.0009169693,"about_ca_system_score_gemma":0.0005826221,"threshold_uncertainty_score":0.9988722},"labels":[],"label_agreement":null},{"id":"W4282939778","doi":"10.1158/1538-7445.am2022-1058","title":"Abstract 1058: Evaluation of a novel class of bifunctional DNA alkylating agent and PARP inhibitor","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"PARP1; Propidium iodide; Poly ADP ribose polymerase; DNA damage; Molecular biology; DNA repair; PARP inhibitor; Biology; Cancer research; Flow cytometry; DNA; Chemistry; Polymerase; Programmed cell death; Biochemistry; Apoptosis","score_opus":0.3031036381395359,"score_gpt":0.4876622091104945,"score_spread":0.18455857097095862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282939778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942988,0.0018898916,0.00003447123,0.0011409543,0.00022112214,0.0006302169,0.0001435804,0.000010704653,0.001630239],"genre_scores_gemma":[0.998628,0.00010711844,0.00012640808,0.000080579855,0.00025709343,0.0005769914,0.00003275122,0.000018928818,0.00017212133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672145,0.00017290772,0.0003474586,0.00025235835,0.0022839108,0.00022194516],"domain_scores_gemma":[0.9984545,0.00021679996,0.00014142357,0.00021574936,0.0008815594,0.000089979905],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003590902,0.000078530255,0.00019996028,0.00028130226,0.00017390285,0.0000069461717,0.000074156625,0.00004082954,0.0035851733],"category_scores_gemma":[0.00020084968,0.000078336816,0.00005378651,0.0004957565,0.00022339287,0.000058519487,0.000097791715,0.0004060183,0.0000020347793],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008162721,0.0003048536,0.0037301306,0.00023491142,0.00009832064,0.0000021937763,0.0008654772,0.0016592807,0.97158736,0.0002883812,0.0052455906,0.015167235],"study_design_scores_gemma":[0.026398247,0.0021760822,0.20815603,0.0011552189,0.00020222885,0.00006781998,0.0056125624,0.013418531,0.7120595,0.0016411591,0.028675325,0.0004373115],"about_ca_topic_score_codex":0.00024853516,"about_ca_topic_score_gemma":0.00001848495,"teacher_disagreement_score":0.2595279,"about_ca_system_score_codex":0.0007149169,"about_ca_system_score_gemma":0.0010535073,"threshold_uncertainty_score":0.99732566},"labels":[],"label_agreement":null},{"id":"W4282941936","doi":"10.1158/1538-7445.am2022-1794","title":"Abstract 1794: The combination of Talazoparib with anti-her2 drugs shows efficacy in drug resistant Her2+ and low Her2 PDX models","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Breast cancer; PARP inhibitor; Cancer research; Cancer; Combination therapy; SKBR3; Internal medicine; Oncology; Poly ADP ribose polymerase; Biology; Polymerase; DNA","score_opus":0.060370640494501644,"score_gpt":0.3836592425164361,"score_spread":0.3232886020219345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282941936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871342,0.0022314112,0.000008254548,0.0054955003,0.000088637054,0.0012461537,0.00008323347,0.000027635708,0.0036849447],"genre_scores_gemma":[0.996993,0.0006868933,0.0000323567,0.00023451947,0.0000747267,0.0006327787,0.000022276516,0.00004755109,0.0012758817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968739,0.00034237714,0.00037834694,0.00043811926,0.0014932209,0.00047401187],"domain_scores_gemma":[0.99852324,0.00038320746,0.00012405055,0.0005283021,0.000314869,0.00012636339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022305707,0.00016256886,0.00035449708,0.00029936322,0.00032289748,0.000040059265,0.0002787511,0.000051262323,0.00067015557],"category_scores_gemma":[0.000040332496,0.00012241643,0.000051388208,0.0009535045,0.00049636123,0.00014716403,0.00014592215,0.0010483715,0.0000033995545],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042307984,0.009467046,0.03945017,0.004530798,0.0011258448,0.00092761684,0.076976836,0.059491012,0.59285367,0.020291343,0.0911547,0.06142297],"study_design_scores_gemma":[0.081127584,0.00573533,0.46918505,0.006367006,0.00020388191,0.00017926481,0.038886502,0.019527417,0.29689595,0.015253655,0.06442963,0.0022087272],"about_ca_topic_score_codex":0.0037149463,"about_ca_topic_score_gemma":0.0007159264,"teacher_disagreement_score":0.4297349,"about_ca_system_score_codex":0.00076231523,"about_ca_system_score_gemma":0.00077756593,"threshold_uncertainty_score":0.73377335},"labels":[],"label_agreement":null},{"id":"W4282944829","doi":"10.1158/1538-7445.am2022-5342","title":"Abstract 5342: Identifying therapeutic targets in combination with PARP inhibitors using a 63-gene signature in triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Olaparib; Cancer research; Gene signature; Breast cancer; PARP inhibitor; Cancer; Carboplatin; Gene knockdown; DNA repair; Biology; Medicine; Gene; Internal medicine; Genetics; Gene expression; Poly ADP ribose polymerase; Chemotherapy; Cisplatin","score_opus":0.10838948347366295,"score_gpt":0.43063272836412786,"score_spread":0.3222432448904649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282944829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98713636,0.0073495824,0.00004241216,0.0028074526,0.000396042,0.0018092163,0.00018825426,0.000041532938,0.0002291552],"genre_scores_gemma":[0.9964892,0.00057982584,0.00007712843,0.00040604116,0.00024534386,0.0018541688,0.000039026167,0.00007677137,0.00023248889],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996093,0.0004745867,0.00045074878,0.00062630576,0.001581683,0.0007736856],"domain_scores_gemma":[0.9987744,0.00020502832,0.00015783812,0.0003140958,0.0003952795,0.00015334583],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015848831,0.00023909418,0.0004167974,0.0010663988,0.00034896174,0.000055612647,0.00023278223,0.00012037262,0.0024260792],"category_scores_gemma":[0.00003476287,0.00022493966,0.00006745026,0.002732346,0.00023494655,0.00028929175,0.00011096307,0.0020942886,0.0000046845157],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011035232,0.0014227881,0.12470443,0.00056335004,0.00031139082,0.00080580125,0.013012751,0.013887782,0.8106211,0.0001643488,0.0021588672,0.021312179],"study_design_scores_gemma":[0.046835653,0.0011780185,0.57350516,0.0041642534,0.00009109485,0.00026936806,0.012510319,0.0032609105,0.35033518,0.003853263,0.0025801724,0.0014165748],"about_ca_topic_score_codex":0.00709199,"about_ca_topic_score_gemma":0.0025798997,"teacher_disagreement_score":0.4602859,"about_ca_system_score_codex":0.005148028,"about_ca_system_score_gemma":0.001647963,"threshold_uncertainty_score":0.9995199},"labels":[],"label_agreement":null},{"id":"W4282963647","doi":"10.1158/1538-7445.am2022-4133","title":"Abstract 4133: High prevalence and heterogeneity of emergence of <i>BRCA</i> reversion mutations at progression on niraparib treatment in <i>BRCA</i>-mutant metastatic castration-resistant prostate cancer (mCRPC) patients","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Reversion; Frameshift mutation; Prostate cancer; Medicine; Missense mutation; Cancer research; Mutation; Cancer; Nonsense mutation; Allele; Oncology; Internal medicine; Biology; Genetics; Phenotype; Gene","score_opus":0.08300330439989648,"score_gpt":0.4233405694843785,"score_spread":0.34033726508448203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282963647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202836,0.0030576468,0.000001009025,0.0005986675,0.00016147085,0.0024291526,0.0016333765,0.00001456064,0.00007575255],"genre_scores_gemma":[0.99273366,0.0043425173,0.00009062334,0.000049381964,0.000025870095,0.0024251428,0.000118664146,0.000031451742,0.00018268258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99645555,0.0003642308,0.0006865597,0.0005820209,0.0014688843,0.0004427532],"domain_scores_gemma":[0.99841154,0.00020153883,0.00034411415,0.00041089853,0.0004603368,0.00017157578],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007012861,0.00021791944,0.00043536813,0.0003501663,0.00031620293,0.000010504085,0.00015241491,0.000046260335,0.0010336782],"category_scores_gemma":[0.000057392135,0.00018795497,0.000081217004,0.00082522025,0.0003362888,0.00012377482,0.0001243931,0.00034247802,0.0000024950616],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007916032,0.002032742,0.2014671,0.0016283827,0.0001634407,0.00006423902,0.0028343773,0.0022513089,0.7725875,0.00005166447,0.00078798993,0.008215247],"study_design_scores_gemma":[0.007439575,0.004163739,0.22944333,0.0014256493,0.000091493224,0.000006251277,0.00048454956,0.00008119488,0.7555224,0.00014610714,0.00094788143,0.0002478807],"about_ca_topic_score_codex":0.0024729744,"about_ca_topic_score_gemma":0.00089989183,"teacher_disagreement_score":0.02797624,"about_ca_system_score_codex":0.001496745,"about_ca_system_score_gemma":0.0007700738,"threshold_uncertainty_score":0.99987954},"labels":[],"label_agreement":null},{"id":"W4282967222","doi":"10.1158/1538-7445.am2022-ct007","title":"Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Prostate cancer; Olaparib; Oncology; Pharmacodynamics; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Progressive disease; PARP inhibitor; Cancer; Gastroenterology; Clinical trial; Phases of clinical research; Adverse effect; Chemotherapy","score_opus":0.15561641512835195,"score_gpt":0.4129968895698667,"score_spread":0.25738047444151474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282967222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932565,0.0001723483,0.000001501451,0.0023703123,0.00031006656,0.0031278853,0.000085476684,0.000013667998,0.00066221],"genre_scores_gemma":[0.99549735,0.00012915391,0.000015841473,0.00012198803,0.00039041537,0.0034810207,0.00008987403,0.000045044926,0.00022929275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964259,0.00045449368,0.0006848318,0.00050786376,0.0013980283,0.00052885065],"domain_scores_gemma":[0.99863863,0.00034858013,0.00019008527,0.000426861,0.00030313423,0.00009271939],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012615076,0.00018542662,0.0003886809,0.0007041548,0.00041605573,0.00003586892,0.00027053984,0.00010174516,0.0012374831],"category_scores_gemma":[0.0002495833,0.00014290214,0.00006996873,0.0025103467,0.00029409313,0.00019194074,0.00010365733,0.0013806932,0.0000039949464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14650981,0.008621599,0.7289718,0.00072335446,0.00022387416,0.00019075365,0.023664871,0.01995455,0.03306123,0.00040532884,0.033068527,0.004604315],"study_design_scores_gemma":[0.22206445,0.006428138,0.7300905,0.0012979397,0.00003024117,0.000008303758,0.003386629,0.0006783798,0.025817335,0.0002780424,0.009379674,0.00054036896],"about_ca_topic_score_codex":0.0046212003,"about_ca_topic_score_gemma":0.054352637,"teacher_disagreement_score":0.07555464,"about_ca_system_score_codex":0.003576321,"about_ca_system_score_gemma":0.0014452798,"threshold_uncertainty_score":0.9996755},"labels":[],"label_agreement":null},{"id":"W4283020357","doi":"10.3390/curroncol29060348","title":"A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Fluidigm (Canada); McGill University; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; Jewish General Hospital; Sunnybrook Health Science Centre; Sinai Health System; University of Manitoba; CancerCare Manitoba; Occupational Cancer Research Centre; Health Sciences Centre; University Health Network; University of Toronto; University of British Columbia","funders":"AstraZeneca Canada","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; Maintenance therapy; Ovarian cancer; Internal medicine; Serous fluid; Carboplatin; Chemotherapy; Gynecology; Front line; Poly ADP ribose polymerase; Intensive care medicine; Cisplatin; Cancer; Polymerase; Biology","score_opus":0.07324022133867346,"score_gpt":0.3717722777892413,"score_spread":0.29853205645056785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283020357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95121264,0.01139301,0.00023029407,0.026786603,0.004463944,0.0032901124,0.002097106,0.00008645282,0.00043982256],"genre_scores_gemma":[0.9876988,0.004236584,0.0016513487,0.0030193585,0.00055878185,0.0022286365,0.00031200453,0.000055581597,0.00023888462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778634,0.0001312768,0.0005086617,0.0006372047,0.00028840895,0.0006481002],"domain_scores_gemma":[0.99844736,0.0004965226,0.0002251382,0.0002609554,0.00012794443,0.00044205552],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041662413,0.0002823815,0.0006142547,0.00035778078,0.00049285585,0.000017440794,0.000092762675,0.000090458154,0.00016284133],"category_scores_gemma":[0.0001302431,0.0002852831,0.00006965546,0.00029620624,0.0002914849,0.000040464467,0.00008180421,0.00048541083,0.0000034153347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02290922,0.0025556686,0.013033243,0.001952619,0.00068574765,0.0008616128,0.0035975035,0.0010889332,0.008416658,0.0045109205,0.21876281,0.72162503],"study_design_scores_gemma":[0.020713944,0.006067165,0.0028640016,0.0001341956,0.000087762906,0.00032800456,0.000503738,0.0002464971,0.0006439527,0.00033703962,0.96776253,0.00031116648],"about_ca_topic_score_codex":0.002437278,"about_ca_topic_score_gemma":0.007003754,"teacher_disagreement_score":0.7489997,"about_ca_system_score_codex":0.004649479,"about_ca_system_score_gemma":0.0013496437,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W4283025170","doi":"10.3389/fgene.2022.852159","title":"The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes","year":2022,"lang":"en","type":"article","venue":"Frontiers in Genetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research; National Science Foundation","keywords":"Homologous recombination; Gene; Biology; DNA methylation; Breast cancer; Methylation; Ovarian cancer; Allele; Genetics; Cancer research; Cancer; Oncology; Medicine; Gene expression","score_opus":0.014582100894561974,"score_gpt":0.27023034349007014,"score_spread":0.25564824259550817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283025170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774633,0.011008846,0.0046980586,0.0014372902,0.0030062397,0.0015302808,0.0004563458,0.000084271705,0.00031536736],"genre_scores_gemma":[0.9854048,0.0012410261,0.009669268,0.000606838,0.00009214125,0.0008108625,0.00022294924,0.00005702648,0.0018951092],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986649,0.00010857184,0.0003833726,0.00025133157,0.00035061786,0.00024120539],"domain_scores_gemma":[0.9990658,0.00009815029,0.00023762898,0.00038533338,0.00017083908,0.000042258103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005213921,0.00011783464,0.0002641933,0.00013237975,0.00022182928,0.000012288911,0.00016289478,0.00005557585,0.000034711433],"category_scores_gemma":[0.00014750902,0.00010681218,0.00009920271,0.0003712672,0.00013568343,0.000027248361,0.00005521167,0.00019187633,3.304117e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011112817,0.0004587203,0.23579547,0.00013070155,0.00011552729,0.000015251353,0.0007269774,0.0009569662,0.0018188828,0.00009926689,0.75273305,0.006037932],"study_design_scores_gemma":[0.021811388,0.004941005,0.12080698,0.00030026224,0.00044195334,0.00015940417,0.01986105,0.023792213,0.0830555,0.013679401,0.71002024,0.0011305938],"about_ca_topic_score_codex":0.000034293225,"about_ca_topic_score_gemma":0.000018321374,"teacher_disagreement_score":0.11498849,"about_ca_system_score_codex":0.00052807323,"about_ca_system_score_gemma":0.00012754327,"threshold_uncertainty_score":0.4355674},"labels":[],"label_agreement":null},{"id":"W4283515927","doi":"10.3390/ijms23137107","title":"Human PARP1 Facilitates Transcription through a Nucleosome and Histone Displacement by Pol II In Vitro","year":2022,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Nucleosome; Histone; Transcription (linguistics); Cell biology; In vitro; Biology; Chemistry; Genetics; DNA","score_opus":0.022833876828015135,"score_gpt":0.34682302455343544,"score_spread":0.3239891477254203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283515927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671854,0.0020598231,0.0006063144,0.0097827,0.0003226814,0.00009429233,0.000032966986,0.0000050502144,0.00037763346],"genre_scores_gemma":[0.9975178,0.00009226039,0.00076941715,0.0014430428,0.000035081892,0.0000117254895,0.0000068092186,0.000004700843,0.000119135846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838305,0.00006997478,0.0003382769,0.0001437343,0.00095169415,0.00011324905],"domain_scores_gemma":[0.99963003,0.000014955839,0.00017172386,0.00004798211,0.00008715315,0.000048169037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004820647,0.00007468593,0.00014134172,0.0001962744,0.00015517334,0.000026255002,0.00021231681,0.000015192403,0.00021023377],"category_scores_gemma":[0.0000143382995,0.00006751799,0.000068176836,0.0001449087,0.00019966031,0.0002062804,0.00004468312,0.00017144607,5.632914e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023411989,0.00019803687,0.00041305157,0.0000037403215,0.000041899355,0.0000822353,0.0018051008,0.00014151739,0.9949678,0.00063390256,0.00052609394,0.00095248653],"study_design_scores_gemma":[0.0152735235,0.005850715,0.00640477,0.00029748658,0.00008861432,0.002555281,0.0076699387,0.00083060336,0.87085515,0.014754986,0.074888036,0.00053091935],"about_ca_topic_score_codex":0.000067847104,"about_ca_topic_score_gemma":0.0000019262034,"teacher_disagreement_score":0.12411269,"about_ca_system_score_codex":0.00028143544,"about_ca_system_score_gemma":0.00008063496,"threshold_uncertainty_score":0.27533036},"labels":[],"label_agreement":null},{"id":"W4283693701","doi":"10.1093/oncolo/oyac114","title":"Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer Canada; McGill University; Pfizer","keywords":"Randomized controlled trial; Medicine; Psychological intervention; Clinical trial; Intervention (counseling); Intensive care medicine; Alternative medicine; Real world data; Medical physics; Oncology; Internal medicine; Data science; Pathology; Nursing; Computer science","score_opus":0.3162898071314984,"score_gpt":0.4826416858563563,"score_spread":0.1663518787248579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283693701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003752589,0.9458914,3.8919148e-7,0.012279156,0.00007117236,0.0023965887,0.00011344786,0.000012018978,0.039232075],"genre_scores_gemma":[0.00005461015,0.9959335,0.00016416232,0.0015834009,0.00007129611,0.0010812739,0.000059298403,0.000019966486,0.0010325045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806714,0.00066881033,0.00057710585,0.00032843108,0.0001734339,0.00018505797],"domain_scores_gemma":[0.9923549,0.0066513084,0.000427934,0.0003292656,0.0001078083,0.00012877383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011551213,0.00021001727,0.0013878691,0.00030959735,0.00013091096,0.00000811759,0.00015581216,0.00011150232,0.00032190635],"category_scores_gemma":[0.0027686202,0.00014916805,0.00011125979,0.00072911615,0.00051646377,0.000049910264,0.000064565145,0.00063904695,0.0000046282435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003091055,0.00008465059,0.00003866136,0.010201617,0.00016334814,0.00006125323,0.0006646667,6.140127e-7,2.5964727e-7,0.007850686,0.009691422,0.9712119],"study_design_scores_gemma":[0.00029199832,0.00032631846,0.00025610923,0.01571446,0.0010656421,0.00012348991,0.00044531285,0.0000010366917,7.3700974e-8,0.00024384586,0.9814111,0.00012063345],"about_ca_topic_score_codex":0.036986403,"about_ca_topic_score_gemma":0.36083266,"teacher_disagreement_score":0.9717197,"about_ca_system_score_codex":0.003367831,"about_ca_system_score_gemma":0.0050706444,"threshold_uncertainty_score":0.9694264},"labels":[],"label_agreement":null},{"id":"W4283775908","doi":"10.1016/j.annonc.2022.06.011","title":"Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Hazard ratio; Internal medicine; Placebo; Chemotherapy; Oncology; Ovarian cancer; Population; Cohort; Surgery; Cancer; Confidence interval; Pathology","score_opus":0.1289920043521299,"score_gpt":0.4438730939755801,"score_spread":0.3148810896234502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283775908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754036,0.00031824398,0.000020712941,0.0070259464,0.0012200719,0.003037769,0.0005723064,0.000019428695,0.00024517765],"genre_scores_gemma":[0.99740106,0.00017081824,0.0003189157,0.0010904393,0.00020172341,0.00062249973,0.00010694481,0.000041173756,0.000046406905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975396,0.00035361337,0.0007654672,0.00035840343,0.0005801313,0.0004028284],"domain_scores_gemma":[0.99690723,0.0005277395,0.001227757,0.0004157188,0.00083621213,0.00008533982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006262442,0.00022807368,0.00082908524,0.00017555623,0.00013803049,0.000004450422,0.0002592194,0.00011393829,0.000255665],"category_scores_gemma":[0.00023079362,0.00015606276,0.00031247115,0.00042448097,0.00039776767,0.00004092945,0.000054120137,0.0002983584,4.531437e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9072874,0.004177757,0.0008040537,0.00010689976,0.0010865256,0.000004144519,0.0012994711,0.0005034569,0.011188869,0.00013478426,0.0027237672,0.070682876],"study_design_scores_gemma":[0.6179365,0.13817665,0.014309518,0.0006615984,0.0005381283,0.000008072846,0.00048330732,0.00018906401,0.19474126,0.00013605302,0.032432083,0.00038774457],"about_ca_topic_score_codex":0.00014801692,"about_ca_topic_score_gemma":0.00004230331,"teacher_disagreement_score":0.28935087,"about_ca_system_score_codex":0.00035433282,"about_ca_system_score_gemma":0.0012383406,"threshold_uncertainty_score":0.6364054},"labels":[],"label_agreement":null},{"id":"W4283809062","doi":"10.1016/j.ygyno.2022.06.017","title":"Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Manitoba; CancerCare Manitoba","funders":"National Cancer Institute; Merck Sharp and Dohme; Memorial Sloan-Kettering Cancer Center; Merck; AstraZeneca","keywords":"Olaparib; Medicine; Homologous recombination; Ovarian cancer; Oncology; BRCA mutation; Cancer research; Mutation; Internal medicine; Cancer; Genetics; Poly ADP ribose polymerase; Gene; Biology; Polymerase","score_opus":0.027858502885559872,"score_gpt":0.3588367873183201,"score_spread":0.33097828443276023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283809062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98806196,0.00070710795,0.00073561084,0.0037171654,0.0005996893,0.0034515935,0.0005644599,0.00011791667,0.002044471],"genre_scores_gemma":[0.99032605,0.00022375712,0.0009693416,0.001506039,0.000055703615,0.0045970134,0.0011989892,0.000024921712,0.0010981591],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.997376,0.0005844866,0.000577711,0.0007337675,0.00025775592,0.00047028312],"domain_scores_gemma":[0.99809116,0.00084141066,0.00047536066,0.00026212027,0.000190702,0.0001392164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069457205,0.00026427535,0.00083541044,0.000422567,0.00087955606,0.00001461916,0.0000781218,0.0001727692,0.000903577],"category_scores_gemma":[0.0001641074,0.00024289273,0.00014958812,0.0007901409,0.00010914817,0.00008640582,0.000080768295,0.0002514439,0.0000026785954],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02043008,0.08319217,0.05529848,0.00012237717,0.00863863,0.0016703996,0.057362087,0.0025344868,0.044572454,0.00089224026,0.02520795,0.70007867],"study_design_scores_gemma":[0.23219158,0.4533137,0.13114838,0.000022094135,0.013770903,0.00055221055,0.031393025,0.005682518,0.007440542,0.0029526865,0.119901784,0.0016305703],"about_ca_topic_score_codex":0.00032693628,"about_ca_topic_score_gemma":0.00041704698,"teacher_disagreement_score":0.69844806,"about_ca_system_score_codex":0.0050595896,"about_ca_system_score_gemma":0.00062849786,"threshold_uncertainty_score":0.9987598},"labels":[],"label_agreement":null},{"id":"W4284700495","doi":"10.1016/j.molcel.2022.06.011","title":"Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery","year":2022,"lang":"en","type":"article","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Cancer Research UK","keywords":"PARP1; Poly ADP ribose polymerase; NAD+ kinase; Biology; Allosteric regulation; Active site; Biophysics; Biochemistry; DNA damage; Molecular mechanics; DNA; Cell biology; Enzyme; Molecular dynamics; Chemistry; Polymerase; Computational chemistry","score_opus":0.014311591857158225,"score_gpt":0.2558549279518664,"score_spread":0.24154333609470816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284700495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986488,0.0013835733,0.0014721614,0.0028441118,0.00019305138,0.0011130482,0.0001460326,0.000011692602,0.006348333],"genre_scores_gemma":[0.99669456,0.00005445378,0.000096795775,0.0027760225,0.000017301834,0.0001297371,0.00004043308,0.000022090642,0.00016860383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832207,0.00043139592,0.00031840618,0.00018813353,0.0005497955,0.00019017403],"domain_scores_gemma":[0.9990779,0.00009630586,0.00021374832,0.0005184401,0.00006209638,0.000031514886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054792006,0.00012200928,0.00024778192,0.00007116495,0.000050239792,0.0000038762887,0.00025832778,0.000036578887,0.00019358119],"category_scores_gemma":[0.000018847537,0.00008256615,0.00012841716,0.00032486563,0.00005821708,0.000019998939,0.000081537626,0.00036181966,0.0000021403196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011262012,0.0004993216,0.00018193453,0.00012804875,0.00012771136,0.00027176458,0.013544684,0.002273269,0.9764584,0.00044150368,0.0040241885,0.00092297595],"study_design_scores_gemma":[0.0032504096,0.0006173466,0.0005514866,0.000050944378,0.00008859947,0.00004075775,0.0034448295,0.00030931004,0.97600865,0.0034895851,0.012002812,0.00014528084],"about_ca_topic_score_codex":0.00009489449,"about_ca_topic_score_gemma":0.0000103811835,"teacher_disagreement_score":0.010206565,"about_ca_system_score_codex":0.00008704679,"about_ca_system_score_gemma":0.000121243844,"threshold_uncertainty_score":0.336695},"labels":[],"label_agreement":null},{"id":"W4285121612","doi":"10.1177/23978473221108881","title":"Preclinical safety assessments of nicotinamide riboside hydrogen malate","year":2022,"lang":"en","type":"article","venue":"Toxicology Research and Application","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Nicotinamide; Niacinamide; Pharmacology; Niacin; Genotoxicity; Chemistry; Ames test; Adverse effect; Micronucleus test; Medicine; Biochemistry; Toxicity; Biology; Internal medicine","score_opus":0.1129487361253337,"score_gpt":0.4950228579512169,"score_spread":0.38207412182588324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285121612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890086,0.00025887432,0.0005938036,0.004013564,0.00002486143,0.0009400688,0.000038443595,0.000029078454,0.0050926823],"genre_scores_gemma":[0.99699265,0.00023083451,0.0004143108,0.0002890185,0.0000596709,0.0007586084,0.00007660306,0.000012144307,0.0011661714],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984836,0.00028249552,0.00030369833,0.00029136144,0.00039087125,0.00024799866],"domain_scores_gemma":[0.9990668,0.00031552077,0.00009062419,0.00029157804,0.000118261734,0.000117170435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001601151,0.00006323972,0.00019478933,0.00012255224,0.00023495605,0.000003846026,0.000114751456,0.00006747121,0.00051503995],"category_scores_gemma":[0.000051075836,0.00006402314,0.000033052856,0.00029353477,0.00031344302,0.000030675452,0.00017473084,0.00047164396,0.000017830753],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042934846,0.0016055272,0.10387298,0.000121481105,0.00014555665,0.00001139617,0.00016533506,0.00008793772,0.83303475,0.010369748,0.0035991222,0.042692687],"study_design_scores_gemma":[0.013590088,0.013688785,0.45134726,0.00006944518,0.00008824554,0.00042476182,0.00067396957,0.008109808,0.2793068,0.042941857,0.18934259,0.00041638524],"about_ca_topic_score_codex":0.00002110565,"about_ca_topic_score_gemma":0.0000042592133,"teacher_disagreement_score":0.5537279,"about_ca_system_score_codex":0.00017363604,"about_ca_system_score_gemma":0.00017005084,"threshold_uncertainty_score":0.56393266},"labels":[],"label_agreement":null},{"id":"W4285498413","doi":"10.1016/j.jmb.2022.167720","title":"Binding Adaptation of GS-441524 Diversifies Macro Domains and Downregulates SARS-CoV-2 de-MARylation Capacity","year":2022,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Innovative Medicines Initiative; Goethe-Universität Frankfurt am Main; HORIZON EUROPE Framework Programme; General Secretariat for Research and Technology; Kungliga Tekniska Högskolan; Ontario Genomics Institute; Janssen Pharmaceuticals; Merck KGaA; Genome Canada; McGill University; Boehringer Ingelheim; Deutsche Forschungsgemeinschaft; Bristol-Myers Squibb; Takeda Pharmaceutical Company; European Regional Development Fund; European Commission; FP7 Research Potential of Convergence Regions; Pfizer","keywords":"Polymerase; Biology; Viral protein; Viral replication; Cell biology; Biochemistry; Virology; Virus; Enzyme","score_opus":0.036396086021553906,"score_gpt":0.31516252504154796,"score_spread":0.27876643901999404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285498413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876239,0.00078853895,0.010269739,0.00094471494,0.0001498741,0.00008821111,0.000024039835,0.0000055591113,0.00010546127],"genre_scores_gemma":[0.99646,0.00011994895,0.0030210468,0.0003211569,0.000048605438,0.0000028900288,0.000012014464,0.000007797848,0.000006538024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915683,0.00018490897,0.0002989934,0.00009157793,0.00015239629,0.00011526861],"domain_scores_gemma":[0.9993276,0.000059872513,0.00038662116,0.00007760774,0.00011427019,0.000034011213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044598858,0.000074666765,0.00023036338,0.00022438551,0.00008054829,0.0000041117155,0.000058015146,0.00005825886,0.00004154443],"category_scores_gemma":[0.00004580679,0.00006897397,0.00009009657,0.00013031162,0.00011984466,0.000045374945,0.000037558868,0.00019251084,4.5303955e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004103828,0.000044012122,0.008310245,0.00002067696,0.00012435124,0.000042064312,0.0006727133,0.0002953142,0.98764807,0.0008146188,0.000107199754,0.0015103811],"study_design_scores_gemma":[0.003811891,0.0018786604,0.015410904,0.00006980742,0.00015944385,0.0016127366,0.0010913983,0.0004189879,0.96682245,0.0062357956,0.0023550326,0.00013289627],"about_ca_topic_score_codex":0.00003844369,"about_ca_topic_score_gemma":0.0000031584375,"teacher_disagreement_score":0.020825595,"about_ca_system_score_codex":0.00015002357,"about_ca_system_score_gemma":0.00008181226,"threshold_uncertainty_score":0.2812677},"labels":[],"label_agreement":null},{"id":"W4286293776","doi":"10.1200/jco.2022.40.16_suppl.5060","title":"Health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Brief Pain Inventory; Placebo; Prednisone; Abiraterone acetate; Quality of life (healthcare); Internal medicine; Percentile; Oncology; Cancer; Androgen deprivation therapy; Physical therapy; Pathology; Chronic pain","score_opus":0.10602322050026562,"score_gpt":0.4325382791948476,"score_spread":0.32651505869458197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319303,0.0010125788,0.000016706359,0.004355352,0.000076891316,0.0013004984,0.000030088206,0.000004430691,0.000010413893],"genre_scores_gemma":[0.99720013,0.0005202287,0.0014169696,0.00071009947,0.000016616736,0.000100200516,0.000010311612,0.0000123466625,0.000013104387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921255,0.004170821,0.0028229295,0.0002433631,0.00047773976,0.00015962683],"domain_scores_gemma":[0.9954381,0.0012137691,0.0027183802,0.00015551844,0.00035521222,0.000119005854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009915648,0.0001360277,0.0012691804,0.00019880741,0.00008089962,0.0000083697305,0.00006746115,0.000059727266,0.00001812874],"category_scores_gemma":[0.0005921036,0.00008834973,0.000041924708,0.0003178629,0.00027079656,0.00012326367,0.000030984815,0.0006194919,3.3767048e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032632492,0.007425714,0.93188524,0.00021612502,0.000477256,0.00009793985,0.0083040325,0.0008748136,0.00022462069,0.000027412541,0.00010906821,0.017725285],"study_design_scores_gemma":[0.037959125,0.06593437,0.8924679,0.00011261982,0.00012688704,0.00006335036,0.0028613221,0.000189744,0.000014916296,0.00015731703,0.000034740613,0.00007767435],"about_ca_topic_score_codex":0.0010619428,"about_ca_topic_score_gemma":0.0045099757,"teacher_disagreement_score":0.058508653,"about_ca_system_score_codex":0.00018991523,"about_ca_system_score_gemma":0.001026353,"threshold_uncertainty_score":0.36027974},"labels":[],"label_agreement":null},{"id":"W4286294464","doi":"10.1200/jco.2022.40.16_suppl.5544","title":"Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; PARP inhibitor; Oncology; BRCA mutation; Placebo; Clinical endpoint; Ovarian cancer; Cancer; Clinical trial; Pathology; Poly ADP ribose polymerase; Genetics; Gene","score_opus":0.06077571247806247,"score_gpt":0.3681802976767992,"score_spread":0.30740458519873676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286294464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631405,0.000072496034,0.00011655768,0.0018354774,0.00043971796,0.0004579249,0.00006511954,0.0000054665325,0.0006931742],"genre_scores_gemma":[0.9981698,0.00010214841,0.0010396676,0.0005122136,0.00006238456,0.000014332453,0.000041343406,0.000014203051,0.000043934604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673885,0.0007920123,0.001594571,0.00024616468,0.00043239768,0.00019597347],"domain_scores_gemma":[0.99472547,0.002334227,0.0022154844,0.00014482252,0.00043914316,0.00014085337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014161743,0.00014984621,0.0011949855,0.00014716455,0.0000696902,0.0000037195605,0.000078539764,0.00014747094,0.00006973415],"category_scores_gemma":[0.0009586243,0.00010008181,0.000105621955,0.00023949833,0.00025052647,0.000058465077,0.000032758388,0.0007369812,4.6460514e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10830764,0.010142429,0.81198525,0.000008426345,0.0004144954,0.0006343896,0.0013433874,0.0002989756,0.00007177011,0.00016277416,0.00024291773,0.06638757],"study_design_scores_gemma":[0.058423303,0.064116985,0.87575483,0.00016872896,0.00018531975,0.00010026313,0.00021237753,0.00013247869,0.00009850953,0.00013591355,0.00057868153,0.000092584196],"about_ca_topic_score_codex":0.00014357513,"about_ca_topic_score_gemma":0.00017430657,"teacher_disagreement_score":0.06629498,"about_ca_system_score_codex":0.0011446611,"about_ca_system_score_gemma":0.0012138659,"threshold_uncertainty_score":0.40812176},"labels":[],"label_agreement":null},{"id":"W4286295274","doi":"10.1200/jco.2022.40.16_suppl.5050","title":"Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Abiraterone; Abiraterone acetate; Placebo; Internal medicine; Pharmacokinetics; Urology; Oncology; Pharmacology; Cancer; Androgen deprivation therapy; Androgen receptor; Chemistry; Pathology","score_opus":0.3205997998601303,"score_gpt":0.5146648703228783,"score_spread":0.194065070462748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286295274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.924477,0.003570867,0.000070335074,0.06805882,0.0011483923,0.0018201014,0.00029527608,0.000012200692,0.0005470029],"genre_scores_gemma":[0.9759597,0.010646445,0.0013962328,0.009464469,0.0016816715,0.0002195584,0.00009130378,0.00004435494,0.0004962621],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99466044,0.0013206151,0.0025767293,0.00034657473,0.0008269764,0.00026866453],"domain_scores_gemma":[0.9943628,0.002342023,0.002229776,0.0005453831,0.0003124523,0.00020757124],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005050593,0.00019778276,0.0013151332,0.00008504818,0.0001382405,0.000025546231,0.0006084176,0.00007904205,0.0015100826],"category_scores_gemma":[0.0005383856,0.00011104108,0.0001378047,0.00032476112,0.0002596643,0.00017066387,0.00013071713,0.0016019035,0.0000069171942],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87067086,0.005259044,0.005806425,0.000030311992,0.0020116426,0.0021511912,0.0015145646,0.005598471,0.0024415336,0.000035078818,0.045541625,0.058939252],"study_design_scores_gemma":[0.44730628,0.062156454,0.013795983,0.00018638097,0.0007906917,0.00031912507,0.0009597921,0.0028113595,0.0004727871,0.00065863266,0.4702807,0.00026179277],"about_ca_topic_score_codex":0.00070342136,"about_ca_topic_score_gemma":0.000866526,"teacher_disagreement_score":0.4247391,"about_ca_system_score_codex":0.0005056091,"about_ca_system_score_gemma":0.005529054,"threshold_uncertainty_score":0.9994027},"labels":[],"label_agreement":null},{"id":"W4286297405","doi":"10.1200/jco.2022.40.16_suppl.5558","title":"OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Ovarian cancer; Oncology; BRCA mutation; Cancer; Gynecology; Internal medicine; Gynecologic cancer; Poly ADP ribose polymerase","score_opus":0.20796135304604615,"score_gpt":0.4907434038774964,"score_spread":0.28278205083145025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286297405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99000734,0.0005138894,0.00010978586,0.0066457517,0.0015083201,0.0008458252,0.00006878085,0.00000720036,0.00029313247],"genre_scores_gemma":[0.9960358,0.00091522606,0.0006321064,0.0017455332,0.0004917994,0.0001300346,0.0000030353503,0.000027204678,0.000019234714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99402165,0.0013111915,0.0033259788,0.000323626,0.0007254245,0.0002921451],"domain_scores_gemma":[0.9933663,0.0009937665,0.0039956747,0.0004524698,0.0007684449,0.0004233519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005835776,0.00019613338,0.0025410922,0.00043161758,0.00010056463,0.0000075897183,0.00028867717,0.00020720644,0.00044850504],"category_scores_gemma":[0.0015994349,0.00012622183,0.0011841655,0.000951507,0.00023355619,0.00012381077,0.00019995528,0.0011741784,4.4835858e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20711434,0.010773479,0.54531074,0.00013559074,0.01948468,0.00027990056,0.009947181,0.0068654413,0.011430456,0.00016897469,0.014231349,0.17425787],"study_design_scores_gemma":[0.08363086,0.09388689,0.79116315,0.0006066981,0.006049863,0.00013294967,0.006071766,0.0010424401,0.0017491363,0.00039070434,0.014856771,0.00041880034],"about_ca_topic_score_codex":0.0001786167,"about_ca_topic_score_gemma":0.00017911503,"teacher_disagreement_score":0.24585238,"about_ca_system_score_codex":0.00085681205,"about_ca_system_score_gemma":0.0028416815,"threshold_uncertainty_score":0.5147177},"labels":[],"label_agreement":null},{"id":"W4288447073","doi":"10.3390/cancers14153684","title":"IKKε Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP-β-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Canadian Urological Oncology Group","keywords":"Olaparib; Cancer research; PARP inhibitor; Prostate cancer; DNA damage; RAD51; Biology; Cell growth; Poly ADP ribose polymerase; Cancer; DNA; Polymerase; Biochemistry","score_opus":0.02821694291268772,"score_gpt":0.29431530018697316,"score_spread":0.26609835727428544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288447073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996437,0.002094971,0.00003215275,0.0038701023,0.0008068355,0.0015177282,0.0009205817,0.00007268772,0.00072059955],"genre_scores_gemma":[0.9971389,0.00043976266,0.0000753398,0.0010470155,0.00018441721,0.00062875386,0.00010512321,0.00004702933,0.00033363083],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976641,0.0003332557,0.0005401915,0.00042917876,0.0006016753,0.00043159287],"domain_scores_gemma":[0.99902624,0.000118547316,0.00026797113,0.000364752,0.00013597007,0.00008650444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054393476,0.00024489593,0.00046351465,0.0001144804,0.00019997268,0.000015139716,0.00010891607,0.000073005525,0.0006244004],"category_scores_gemma":[0.000039668128,0.00020344932,0.00013417758,0.0008608717,0.00033464594,0.00016161527,0.000033213088,0.0005738133,0.0000034309342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004103673,0.00014381013,0.00428967,0.0002889926,0.00015312416,0.00013516411,0.012599755,0.007471832,0.96562624,0.00018395393,0.0033618705,0.0016419155],"study_design_scores_gemma":[0.021986324,0.0024962956,0.034708083,0.0012681327,0.0003525974,0.00019391444,0.014467766,0.0046077534,0.8156419,0.00085486006,0.102264695,0.0011577205],"about_ca_topic_score_codex":0.00859899,"about_ca_topic_score_gemma":0.0027486994,"teacher_disagreement_score":0.14998437,"about_ca_system_score_codex":0.0031806407,"about_ca_system_score_gemma":0.001831774,"threshold_uncertainty_score":0.9980028},"labels":[],"label_agreement":null},{"id":"W4291016626","doi":"10.3390/cancers14163877","title":"Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Urological Association","keywords":"Olaparib; DU145; Cancer research; LNCaP; Biology; Prostate cancer; DNA repair; Cancer; Medicine; Poly ADP ribose polymerase; Gene; Genetics; Polymerase","score_opus":0.024991165904329697,"score_gpt":0.3081018750259518,"score_spread":0.2831107091216221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291016626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847273,0.0041413093,0.0013553747,0.0012799186,0.0008737991,0.0017651018,0.00074419775,0.00019193374,0.004921022],"genre_scores_gemma":[0.96631217,0.00013413995,0.009836292,0.0018322095,0.00007065866,0.0016179867,0.000109044995,0.00008751145,0.01999996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975257,0.00007212477,0.0005372454,0.00052103255,0.0008923117,0.00045161822],"domain_scores_gemma":[0.99860793,0.000045717035,0.00041623134,0.00039077626,0.0003361257,0.00020322349],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037208392,0.00025729247,0.00048289666,0.00011409197,0.0003171953,0.000016621183,0.0002342551,0.000053778174,0.00088876823],"category_scores_gemma":[0.000028515784,0.00025386066,0.00007263618,0.00080603245,0.00008263685,0.000100263016,0.00007818295,0.00015384963,0.000005363723],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010030758,0.00026164445,0.0014304963,0.00074271514,0.00075612764,0.00009813036,0.019258806,0.0056186444,0.9089907,0.0007070455,0.050814692,0.0012902457],"study_design_scores_gemma":[0.007978012,0.00039562417,0.006796518,0.0014763691,0.00018549127,0.000003455453,0.0040400266,0.00004232055,0.830513,0.0003531424,0.14740796,0.0008080565],"about_ca_topic_score_codex":0.00011747366,"about_ca_topic_score_gemma":0.004057829,"teacher_disagreement_score":0.09659327,"about_ca_system_score_codex":0.0073312595,"about_ca_system_score_gemma":0.0030458728,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W4292212795","doi":"10.1136/bmjopen-2021-059538","title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol","year":2022,"lang":"en","type":"review","venue":"BMJ Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Jadad scale; Breast cancer; Cochrane Library; MEDLINE; Protocol (science); Clinical trial; Internal medicine; Oncology; Meta-analysis; Cancer; Bioinformatics; Pathology; Alternative medicine","score_opus":0.0906763586914873,"score_gpt":0.48715489095699605,"score_spread":0.3964785322655088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292212795","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006726076,0.23887935,4.1889135e-7,0.00006532351,0.00006789445,0.75940704,0.0004554406,0.000020333287,0.0010369091],"genre_scores_gemma":[0.000017182401,0.3163497,0.000020067813,0.00009362862,0.0000068200316,0.6832085,0.00011816361,0.00005845859,0.00012746222],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99596256,0.0008665376,0.0016171085,0.00048791643,0.00079792156,0.00026792634],"domain_scores_gemma":[0.9963905,0.00018951298,0.0021910693,0.0009785449,0.00016177664,0.00008857064],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014014575,0.00045905708,0.0043054963,0.00041524175,0.00005078152,0.00003086727,0.0005987958,0.000119007214,0.0010605957],"category_scores_gemma":[0.00018028298,0.00027011117,0.0004808643,0.0010503895,0.00004913723,0.00012832615,0.00014503958,0.00029418318,0.00001722525],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006670809,0.000989077,0.013249501,0.9424154,0.00057726895,0.000018453546,0.00003554877,4.4170943e-7,9.369993e-9,0.0000067898504,0.00052596396,0.04151444],"study_design_scores_gemma":[0.0050625387,0.0030671835,0.019449797,0.968208,0.0011955589,0.000083599865,0.0000047323274,3.6854232e-7,5.2111254e-8,0.00000600599,0.0025331068,0.00038904505],"about_ca_topic_score_codex":0.0006707311,"about_ca_topic_score_gemma":0.000016159187,"teacher_disagreement_score":0.077470325,"about_ca_system_score_codex":0.0021135854,"about_ca_system_score_gemma":0.0017887909,"threshold_uncertainty_score":0.9999751},"labels":[],"label_agreement":null},{"id":"W4292672242","doi":"10.1016/j.clim.2022.109094","title":"PARP14 promotes the growth and glycolysis of acute myeloid leukemia cells by regulating HIF-1α expression","year":2022,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Myeloid leukemia; Cell growth; Biology; Cancer research; Downregulation and upregulation; Glycolysis; Apoptosis; Transfection; Cell culture; Cell biology; Biochemistry; Metabolism; Gene","score_opus":0.02753766834323048,"score_gpt":0.3359920885292091,"score_spread":0.30845442018597863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292672242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992821,0.0022253054,0.00011381077,0.0034963554,0.00043441608,0.00038392848,0.00004585823,0.000048198675,0.00043112098],"genre_scores_gemma":[0.9960891,0.001245106,0.0006930285,0.0010733431,0.00011335937,0.000117816046,0.000038557606,0.000024522515,0.0006051708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979541,0.00052074285,0.0007462902,0.00034998337,0.00019921745,0.00022970143],"domain_scores_gemma":[0.99809885,0.00092782284,0.00038900645,0.0004673649,0.00006192866,0.00005505573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006607859,0.00013567838,0.00049725,0.000047270565,0.00025002257,0.000006791065,0.00020649648,0.00014910335,0.00054591947],"category_scores_gemma":[0.00017559445,0.00009841392,0.00015458028,0.0001971504,0.00067125715,0.000042644766,0.0003066847,0.000672639,0.000006813516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010278438,0.00016846819,0.003960573,0.000019991867,0.00041633498,0.000009821047,0.00031760338,0.000002058539,0.9806451,0.000117827214,0.007054192,0.0062601916],"study_design_scores_gemma":[0.0066075213,0.0028462852,0.012571919,0.0001083361,0.0004357265,0.00014744246,0.00057758496,0.00021210228,0.96024156,0.0020238545,0.013982186,0.00024546587],"about_ca_topic_score_codex":0.000028719833,"about_ca_topic_score_gemma":3.0367914e-7,"teacher_disagreement_score":0.02040352,"about_ca_system_score_codex":0.00008313821,"about_ca_system_score_gemma":0.00012288593,"threshold_uncertainty_score":0.5977435},"labels":[],"label_agreement":null},{"id":"W4293083622","doi":"10.1200/jco.2022.40.17_suppl.lba5500","title":"ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; BRCA mutation; Clinical endpoint; Population; Oncology; Placebo; Ovarian cancer; PARP inhibitor; Cancer; Surgery; Clinical trial; Pathology","score_opus":0.2784281856441137,"score_gpt":0.5579846632316603,"score_spread":0.2795564775875466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293083622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92633086,0.0006436216,0.0018006318,0.05986158,0.005509777,0.005332982,0.000030606458,0.000036867266,0.00045304294],"genre_scores_gemma":[0.97618216,0.00084803096,0.0063637067,0.0102517,0.0029886463,0.0025387874,0.000016115515,0.00012167199,0.0006891633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98790514,0.004206278,0.005172579,0.00069769943,0.0013043996,0.0007138876],"domain_scores_gemma":[0.9775993,0.01737311,0.003347343,0.0005887938,0.00037503228,0.0007163722],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024114804,0.0005164164,0.0042610075,0.00063846895,0.00027846373,0.00003535918,0.00044340713,0.00042686716,0.0019019477],"category_scores_gemma":[0.005156356,0.00041191856,0.0019629644,0.0007567266,0.0002138905,0.0001436122,0.00005608645,0.0016787761,0.00001696693],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9266429,0.0058596833,0.0001932913,0.000010113373,0.0015139277,0.0008748999,0.0015547702,0.009828616,0.0013049775,0.000043447817,0.0007799549,0.051393397],"study_design_scores_gemma":[0.8378996,0.106951505,0.000048583122,0.00021632733,0.00051164965,0.00008138158,0.0002807611,0.0038200254,0.0006906146,0.00022359278,0.048965648,0.0003102968],"about_ca_topic_score_codex":0.0003877806,"about_ca_topic_score_gemma":0.00023405229,"teacher_disagreement_score":0.101091824,"about_ca_system_score_codex":0.004257562,"about_ca_system_score_gemma":0.008934733,"threshold_uncertainty_score":0.9998333},"labels":[],"label_agreement":null},{"id":"W4293105208","doi":"10.1001/jamaoncol.2022.3524","title":"Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply","year":2022,"lang":"en","type":"letter","venue":"JAMA Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Otorhinolaryngology; Family medicine; MEDLINE; Neurology; Psychiatry","score_opus":0.2685709622888784,"score_gpt":0.554625176787541,"score_spread":0.2860542144986626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293105208","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.070462875,0.0019851523,0.000023553273,0.9197756,0.0023890776,0.00083040126,0.002118737,0.000034883647,0.002379703],"genre_scores_gemma":[0.007363953,0.0018304395,0.00014190422,0.9821467,0.0019454876,0.00060426316,0.0015887453,0.00006511653,0.0043134303],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9834784,0.008849445,0.005540027,0.00079006725,0.0009145847,0.00042745494],"domain_scores_gemma":[0.978719,0.015744284,0.0041624797,0.00097508787,0.0002641238,0.0001350436],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012042762,0.00037562265,0.0077411365,0.0011952452,0.000031653242,0.000006342073,0.0004201478,0.001423461,0.0110547645],"category_scores_gemma":[0.0052876095,0.00032939587,0.0020434014,0.0013127562,0.00044932723,0.00004423262,0.00012856773,0.0038351943,0.000008353767],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002011741,0.00046318135,0.19217739,0.0002039057,0.0059221955,0.00008335229,0.00026606137,0.00002858863,0.00007662056,0.000021378264,0.79427075,0.0044748555],"study_design_scores_gemma":[0.010652301,0.00057137565,0.03062802,0.00006131143,0.0027264182,0.0000015704177,0.00015034224,0.000041607942,0.00003569888,0.000056877034,0.9548258,0.00024866042],"about_ca_topic_score_codex":0.0051214476,"about_ca_topic_score_gemma":0.0010464577,"teacher_disagreement_score":0.16154937,"about_ca_system_score_codex":0.0012724246,"about_ca_system_score_gemma":0.0023893877,"threshold_uncertainty_score":0.99991584},"labels":[],"label_agreement":null},{"id":"W4293776856","doi":"10.3390/cancers14174219","title":"Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Duke Cancer Institute; Ottawa Hospital Research Institute","keywords":"Ovarian cancer; Immunotherapy; Medicine; Immune system; Cancer research; Serous fluid; Cancer immunotherapy; Serous ovarian cancer; Cancer; Oncology; Immunology; Internal medicine","score_opus":0.035346787831202806,"score_gpt":0.28800405695889353,"score_spread":0.2526572691276907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293776856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804956,0.00040813274,0.00046279113,0.00028546914,0.00013263307,0.00026359616,0.00016806704,0.000016698927,0.0002130383],"genre_scores_gemma":[0.9971205,0.00035585486,0.0012074257,0.0005381036,0.000040625324,0.00021241893,0.000060127546,0.000018609624,0.00044631035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992093,0.00001846391,0.0002620394,0.0001661086,0.00022876149,0.0001153196],"domain_scores_gemma":[0.9995454,0.0000072009057,0.00016380877,0.00014106752,0.00007891121,0.000063601496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010723142,0.000086328284,0.00022471989,0.00009805396,0.000059835354,0.0000016448145,0.00004766583,0.000023070443,0.00044072323],"category_scores_gemma":[0.0000040858363,0.000091152775,0.000025565661,0.00019108236,0.000052586773,0.00003725639,0.000037949038,0.00008337402,3.1831246e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005766291,0.000036105448,0.0020929407,0.00022489387,0.00010883856,0.0000030897909,0.0021720445,0.004233558,0.98188794,0.00024858775,0.00011089835,0.008304453],"study_design_scores_gemma":[0.0054063643,0.00021336431,0.0065392167,0.00023545678,0.00009707309,0.000017018656,0.0003064225,0.019020597,0.95354843,0.000051612453,0.014322604,0.00024186813],"about_ca_topic_score_codex":0.00011051455,"about_ca_topic_score_gemma":0.000017290973,"teacher_disagreement_score":0.028339557,"about_ca_system_score_codex":0.0009489084,"about_ca_system_score_gemma":0.0012847801,"threshold_uncertainty_score":0.48256102},"labels":[],"label_agreement":null},{"id":"W4294069110","doi":"10.1101/2022.08.29.505711","title":"Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Doxorubicin; Ovarian cancer; Folate receptor; Cancer research; Drug delivery; Pharmacology; Chemistry; Targeted drug delivery; Drug; Chemotherapy; Cancer; Cancer cell; Medicine; Internal medicine","score_opus":0.02987567849151285,"score_gpt":0.2784307494570247,"score_spread":0.24855507096551183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294069110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856077,0.0074288626,0.00026201506,0.0010748826,0.0013021468,0.0023497597,0.001722384,0.00025004288,0.000002240302],"genre_scores_gemma":[0.98663205,0.0022229874,0.007353466,0.00031251242,0.0004737522,0.0028130305,0.000005057032,0.00017082195,0.000016319149],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99720573,0.0001448187,0.00075224513,0.00096743484,0.00037186508,0.00055792584],"domain_scores_gemma":[0.99769616,0.00013910818,0.000636443,0.00085571,0.0003700974,0.0003024938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037299455,0.00056619104,0.0011908251,0.0002682287,0.00021451448,0.000055125845,0.00017735524,0.00033009052,0.00030929776],"category_scores_gemma":[0.00006523021,0.0005723524,0.00021056438,0.0003593169,0.00015777764,0.000081682956,0.00013552362,0.00027605816,0.000002690691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013279344,0.0004201143,0.01352248,0.00053779373,0.00089261064,0.000026235786,0.00013255519,0.00009984357,0.9819478,0.00082774955,0.00023561488,0.000029293571],"study_design_scores_gemma":[0.007896378,0.0016489169,0.0351159,0.00054686196,0.00058244437,7.384999e-8,0.000023253142,0.00019438742,0.9400443,0.000017738572,0.013330336,0.0005994426],"about_ca_topic_score_codex":0.0009536726,"about_ca_topic_score_gemma":0.000013724629,"teacher_disagreement_score":0.04190351,"about_ca_system_score_codex":0.0010530683,"about_ca_system_score_gemma":0.0008839271,"threshold_uncertainty_score":0.9996728},"labels":[],"label_agreement":null},{"id":"W4294897419","doi":"10.1126/sciadv.abq0414","title":"A two-step mechanism governing PARP1-DNA retention by PARP inhibitors","year":2022,"lang":"en","type":"article","venue":"Science Advances","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Cancer Institute","keywords":"PARP1; Mechanism (biology); Poly ADP ribose polymerase; DNA; Chemistry; Computational biology; Biophysics; Cell biology; Computer science; Biology; Biochemistry; Polymerase; Physics","score_opus":0.01650530221225041,"score_gpt":0.3085844771133841,"score_spread":0.29207917490113366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294897419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96621877,0.005197461,0.004987299,0.0032118096,0.003578193,0.00088063796,0.00013287076,0.00038134906,0.015411607],"genre_scores_gemma":[0.99397653,0.00009907013,0.0026525734,0.0013413776,0.00017681978,0.00019627427,0.000024523908,0.0000191331,0.0015136775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972377,0.00006294924,0.0002850192,0.00057324755,0.0013928914,0.00044823936],"domain_scores_gemma":[0.99916637,0.000042408126,0.00021267212,0.0003186437,0.000091630674,0.00016829095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010151452,0.00014800687,0.00020728122,0.0001542136,0.00089026574,0.00004553824,0.00028148465,0.000020452499,0.00062708836],"category_scores_gemma":[0.000086735825,0.0001425243,0.00007699241,0.0011656244,0.0004102407,0.00074183336,0.00013758807,0.00026239414,0.000047162834],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119890516,0.00009308822,0.001336954,0.000022567694,0.000008608299,0.000018446277,0.0003380417,0.00014134473,0.97279114,0.002317967,0.0035586793,0.019253295],"study_design_scores_gemma":[0.0027572915,0.0009303918,0.00029124037,0.00012100548,0.000033258708,0.00015404368,0.003822615,0.00075414404,0.6715691,0.005765351,0.3133763,0.00042524145],"about_ca_topic_score_codex":0.000027207412,"about_ca_topic_score_gemma":0.0000052560395,"teacher_disagreement_score":0.3098176,"about_ca_system_score_codex":0.0005406536,"about_ca_system_score_gemma":0.0002697961,"threshold_uncertainty_score":0.6866178},"labels":[],"label_agreement":null},{"id":"W4295012314","doi":"10.21203/rs.3.rs-2014554/v1","title":"Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Toronto; Natural Sciences and Engineering Research Council of Canada; U.S. Department of Defense","keywords":"Doxorubicin; Ovarian cancer; Folate receptor; Cancer research; Serous fluid; Pharmacology; Drug delivery; In vivo; Drug; Cancer; Medicine; Chemotherapy; Chemistry; Oncology; Cancer cell; Internal medicine; Materials science; Biology; Nanotechnology","score_opus":0.12328242161218575,"score_gpt":0.43989668107353225,"score_spread":0.31661425946134647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295012314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770182,0.011976281,0.00006735705,0.0043484857,0.00041808272,0.0041379025,0.0018528798,0.00008684676,0.00009398981],"genre_scores_gemma":[0.98522997,0.0057700286,0.0015598752,0.00007786994,0.00039897976,0.0054755663,0.00062539114,0.000090777176,0.0007715549],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966813,0.00044726377,0.00053974014,0.0007593726,0.00087885174,0.00069348095],"domain_scores_gemma":[0.9977813,0.0005375743,0.00021833739,0.00064383337,0.00053417386,0.00028478503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091365544,0.00031680043,0.00089556386,0.0004070237,0.0003040918,0.00004770576,0.0001645707,0.00024015874,0.0012116123],"category_scores_gemma":[0.00012891201,0.00028443683,0.0002018012,0.00035559587,0.00023685637,0.00004796608,0.00024373214,0.0004891574,0.0000031941136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03051406,0.0035187346,0.061671723,0.009266608,0.0043929443,0.00022088995,0.022667477,0.0014945182,0.7674556,0.0069706766,0.010517609,0.081309184],"study_design_scores_gemma":[0.036397845,0.02541306,0.030796217,0.004146749,0.00052161515,0.000034666096,0.005366287,0.0014462449,0.7842678,0.012598371,0.09787839,0.0011327971],"about_ca_topic_score_codex":0.0059858235,"about_ca_topic_score_gemma":0.0002174805,"teacher_disagreement_score":0.087360784,"about_ca_system_score_codex":0.0014699565,"about_ca_system_score_gemma":0.0009983445,"threshold_uncertainty_score":0.9999608},"labels":[],"label_agreement":null},{"id":"W4295078726","doi":"10.1200/jco.22.01549","title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":475,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; NRG Oncology; Sanofi; AstraZeneca","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Ovarian cancer; Hazard ratio; Clinical endpoint; Oncology; Placebo; Cancer; Veliparib; BRCA mutation; Clinical trial; Surgery; Poly ADP ribose polymerase; Confidence interval; Pathology","score_opus":0.0555831528157147,"score_gpt":0.3980408485949811,"score_spread":0.34245769577926644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295078726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829684,0.00018509774,0.0001138045,0.013383229,0.002006334,0.0008550347,0.000021339718,0.000008842786,0.00045791984],"genre_scores_gemma":[0.99239784,0.00022855356,0.0011162886,0.005045392,0.0006198644,0.0001348221,0.0000080438285,0.000029995375,0.00041919266],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99651206,0.00073105295,0.0014366048,0.00028911393,0.0007279065,0.00030328933],"domain_scores_gemma":[0.9952398,0.0023183767,0.0016285571,0.0002185164,0.00036813846,0.00022660538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002179637,0.0001772311,0.0011600049,0.00009441567,0.00014780885,0.000012173125,0.00017588309,0.00013641245,0.000448143],"category_scores_gemma":[0.0009345552,0.000103304,0.00017499531,0.00025047452,0.00029440483,0.00013396172,0.00007866536,0.0012334168,0.0000018156851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7321832,0.0016133755,0.23983485,0.000015385967,0.00046773604,0.0007390929,0.00079766905,0.00113173,0.000012151402,0.00028968597,0.003683691,0.019231418],"study_design_scores_gemma":[0.54100716,0.035552334,0.39654776,0.00013442678,0.0001942548,0.00012625223,0.00033481134,0.000052066156,0.0000042494084,0.00050210307,0.025393337,0.00015123165],"about_ca_topic_score_codex":0.00010060441,"about_ca_topic_score_gemma":0.00090589636,"teacher_disagreement_score":0.19117604,"about_ca_system_score_codex":0.0007488106,"about_ca_system_score_gemma":0.0019944229,"threshold_uncertainty_score":0.53586507},"labels":[],"label_agreement":null},{"id":"W4295817612","doi":"10.1016/j.annonc.2022.07.645","title":"517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Ovarian cancer; Progression-free survival; Clinical endpoint; Oncology; Maintenance therapy; Cancer; Urology; Chemotherapy; Randomized controlled trial; Surgery; Gastroenterology; Gynecology","score_opus":0.04887063730822915,"score_gpt":0.3490527267444434,"score_spread":0.3001820894362142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670965,0.00024195119,0.000020733745,0.008752528,0.0006547748,0.0017927414,0.00010038851,0.000018999148,0.0017082547],"genre_scores_gemma":[0.9927871,0.0006178265,0.00016469386,0.0048146364,0.000110152316,0.0009911321,0.00009879414,0.00003414982,0.00038148332],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719465,0.00072954834,0.00062204653,0.00047781548,0.0005071895,0.0004687655],"domain_scores_gemma":[0.99829215,0.0006270804,0.00045397555,0.00032431367,0.00021179933,0.00009066055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009867396,0.00022716918,0.0007316904,0.00022192253,0.00012438123,0.000010050562,0.0001955038,0.00013454595,0.00039115144],"category_scores_gemma":[0.00030332504,0.00018317449,0.000089092515,0.00046124755,0.00018370335,0.00014640583,0.00008519393,0.0004630272,0.0000030129431],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65832204,0.004075224,0.20666282,0.00016631313,0.0004598992,0.0006215194,0.022576349,0.0036245084,0.0016472396,0.002272376,0.02731674,0.07225501],"study_design_scores_gemma":[0.56185055,0.021715919,0.37415272,0.00030689605,0.000082410384,0.000031574058,0.001975919,0.0002328594,0.00045750014,0.0021165833,0.03662232,0.00045472966],"about_ca_topic_score_codex":0.0015020801,"about_ca_topic_score_gemma":0.005978533,"teacher_disagreement_score":0.16748992,"about_ca_system_score_codex":0.00058980985,"about_ca_system_score_gemma":0.0005088486,"threshold_uncertainty_score":0.7469639},"labels":[],"label_agreement":null},{"id":"W4295817627","doi":"10.1016/j.annonc.2022.07.655","title":"527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Ovarian cancer; Disease; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.055474002945644904,"score_gpt":0.3812908630487363,"score_spread":0.32581686010309135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909786,0.00039957635,0.00005720299,0.0050656036,0.0003207692,0.002409054,0.0003983261,0.000034364613,0.0003364981],"genre_scores_gemma":[0.9923539,0.00019653648,0.000200746,0.0038713554,0.0000891816,0.0030917483,0.00004999098,0.000048341426,0.00009819359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974922,0.00039208983,0.0006233218,0.00055416534,0.00045313497,0.00048510512],"domain_scores_gemma":[0.99805456,0.00037162396,0.00052273896,0.0005782612,0.00020277068,0.00027002743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007536698,0.00028584836,0.00067782315,0.00023227751,0.00028648917,0.000014182999,0.00025384052,0.00004876822,0.00019013764],"category_scores_gemma":[0.000120223434,0.00020007197,0.00011291419,0.00060815335,0.000105138504,0.00009066582,0.000118413926,0.00034665357,0.000007826664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019332321,0.009059698,0.89077306,0.000014367679,0.0003816983,0.0002819604,0.01242182,0.008295971,0.000050533785,0.00043898192,0.0008396681,0.05810992],"study_design_scores_gemma":[0.10332094,0.07193032,0.78272194,0.00029271407,0.0005867682,0.000017249917,0.017273389,0.00057531125,0.00051075197,0.000676795,0.02144861,0.00064522226],"about_ca_topic_score_codex":0.005905607,"about_ca_topic_score_gemma":0.0029036014,"teacher_disagreement_score":0.10805113,"about_ca_system_score_codex":0.00087644375,"about_ca_system_score_gemma":0.0006775594,"threshold_uncertainty_score":0.89275503},"labels":[],"label_agreement":null},{"id":"W4295837229","doi":"10.1016/j.annonc.2022.07.1500","title":"1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer Pharmaceuticals; Genentech; Sierra Oncology; Astellas Pharma; Menarini Silicon Biosystems; Vertex Pharmaceuticals; Merck Sharp and Dohme; Eisai; National Evidence-based Healthcare Collaborating Agency; Sanofi; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Taxane; Clinical endpoint; Olaparib; Primary tumor; Progression-free survival; Hormonal therapy; Population; Cancer; Breast cancer; Chemotherapy; Clinical trial; Genetics; Metastasis; Gene; Poly ADP ribose polymerase; Biology","score_opus":0.10781632104742811,"score_gpt":0.38532978992712075,"score_spread":0.27751346887969264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899511,0.0004548293,0.00008402573,0.0071344418,0.000057439516,0.0017063539,0.00043514825,0.000027735861,0.0001489695],"genre_scores_gemma":[0.9955749,0.00015884844,0.0010085836,0.00094385317,0.000023469604,0.0017905046,0.00019817981,0.000046743826,0.0002549492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753547,0.0005678896,0.0007387292,0.0003453086,0.0004980291,0.00031459314],"domain_scores_gemma":[0.9979228,0.00026644662,0.0008080359,0.00031896803,0.0005967849,0.000086977736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009816851,0.00021517948,0.00063291605,0.00035280085,0.00012989588,0.000011448041,0.000114823175,0.00005064705,0.00020852717],"category_scores_gemma":[0.000081062244,0.00018919667,0.000059305137,0.0007881496,0.00022802687,0.00021720468,0.00002488232,0.00027615484,7.083641e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12509924,0.005099539,0.02253826,0.00020785947,0.0012861689,0.00076450774,0.021044012,0.07931815,0.7381891,0.0006379382,0.0010865954,0.0047286036],"study_design_scores_gemma":[0.05141435,0.09612111,0.276809,0.00093081535,0.00060147245,0.000233673,0.008127634,0.0054387394,0.54784304,0.0021612481,0.009167934,0.0011509517],"about_ca_topic_score_codex":0.00019741447,"about_ca_topic_score_gemma":0.0027874212,"teacher_disagreement_score":0.25427073,"about_ca_system_score_codex":0.00031218232,"about_ca_system_score_gemma":0.0016026056,"threshold_uncertainty_score":0.7715216},"labels":[],"label_agreement":null},{"id":"W4296006449","doi":"10.1016/j.annonc.2022.07.659","title":"531P Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Ovarian cancer; Oncology; Germline; Internal medicine; BRCA mutation; Germline mutation; Gynecology; Cancer; Mutation; Genetics; Poly ADP ribose polymerase","score_opus":0.07970447347517559,"score_gpt":0.37320506674236126,"score_spread":0.2935005932671857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296006449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773901,0.00013154278,0.00027760255,0.015966017,0.0013595925,0.002074845,0.0011735909,0.000039861286,0.0015868191],"genre_scores_gemma":[0.99052507,0.00033190998,0.00055485853,0.006218047,0.0006791459,0.0004603232,0.0008727613,0.0000587016,0.00029916273],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99613553,0.0008790785,0.0010773239,0.0006808546,0.0007295878,0.0004975945],"domain_scores_gemma":[0.996932,0.0008675404,0.0010650894,0.00052327005,0.0005000249,0.00011206201],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013564846,0.00032531458,0.0009014732,0.00018186067,0.00019744581,0.000014745236,0.0002413199,0.00020051163,0.0003024812],"category_scores_gemma":[0.00023610155,0.00025406058,0.00015456165,0.00044771703,0.00025187945,0.00015084785,0.000073746116,0.00078226515,0.000006366622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90730125,0.002703943,0.016908487,0.000026784859,0.0007329664,0.00014864345,0.011559582,0.004274571,0.0014563794,0.00034446563,0.023486042,0.031056914],"study_design_scores_gemma":[0.6122606,0.028408187,0.29571474,0.00056573364,0.000109425826,0.000041151743,0.0011810687,0.002524872,0.002369359,0.0011527713,0.055018254,0.000653884],"about_ca_topic_score_codex":0.0054379827,"about_ca_topic_score_gemma":0.0010558935,"teacher_disagreement_score":0.29504067,"about_ca_system_score_codex":0.0005978662,"about_ca_system_score_gemma":0.0010949088,"threshold_uncertainty_score":0.9999912},"labels":[],"label_agreement":null},{"id":"W4296007126","doi":"10.1016/j.annonc.2022.07.646","title":"518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Oncology; Internal medicine; Chemotherapy; Ovarian carcinoma; Ovarian cancer; BRCA mutation; Gynecology; Cancer","score_opus":0.04698401234661571,"score_gpt":0.3723534837227811,"score_spread":0.3253694713761654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296007126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571186,0.00010626702,0.00009048125,0.002000702,0.00021466834,0.0011202232,0.00015878928,0.000028354067,0.00056867325],"genre_scores_gemma":[0.9964288,0.000028064833,0.0007946255,0.0021899743,0.000058606947,0.00013847784,0.0003001801,0.000033679775,0.000027620845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977839,0.000393216,0.0006555085,0.00048386445,0.00040275953,0.0002807447],"domain_scores_gemma":[0.99862057,0.0002677101,0.0004961763,0.00032033096,0.00019546418,0.00009976458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005665171,0.00019501898,0.00067181874,0.0002106142,0.00011927748,0.000015243383,0.00009695438,0.00008689702,0.000104695864],"category_scores_gemma":[0.00006922484,0.00019138615,0.00004552322,0.00027196432,0.000106076106,0.00017430917,0.00005097943,0.00034335916,6.1207606e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3420545,0.0218382,0.37749135,0.0000589444,0.0007652777,0.0011032649,0.043131012,0.0005388918,0.0067122425,0.0000933374,0.0012550446,0.20495793],"study_design_scores_gemma":[0.22709115,0.035697535,0.73010296,0.00006439089,0.0000613987,0.000024089863,0.002338405,0.00028812303,0.00090373534,0.0002924006,0.0028710745,0.00026471744],"about_ca_topic_score_codex":0.0010294857,"about_ca_topic_score_gemma":0.00017606407,"teacher_disagreement_score":0.3526116,"about_ca_system_score_codex":0.00021164892,"about_ca_system_score_gemma":0.0003701044,"threshold_uncertainty_score":0.7804501},"labels":[],"label_agreement":null},{"id":"W4296122547","doi":"10.1158/1557-3265.sarcomas22-a024","title":"Abstract A024: <i>In vitro</i> efficacy of a novel dual PARP-HDAC inhibitor in ewing sarcoma","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; PARP1; PARP inhibitor; Cancer research; Poly ADP ribose polymerase; Histone deacetylase; Viability assay; Biology; DNA damage; DNA repair; Histone; Molecular biology; Pharmacology; In vitro; Polymerase; Biochemistry; DNA","score_opus":0.31842042250211033,"score_gpt":0.5424239836674453,"score_spread":0.22400356116533493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296122547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897305,0.0016516845,0.0000056182175,0.004949321,0.0005602698,0.0010010565,0.00014533738,0.000031298394,0.0019249489],"genre_scores_gemma":[0.99680495,0.0004158327,0.0002144794,0.00083951873,0.00076916727,0.000612445,0.000025389032,0.000054099415,0.0002641313],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.994327,0.00055857835,0.0015020147,0.00072130456,0.0020795993,0.0008114838],"domain_scores_gemma":[0.9959602,0.0026618624,0.00018583913,0.00061358797,0.0003026209,0.00027593336],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0086395135,0.00018326154,0.0007628028,0.00057310425,0.00012938083,0.000017510634,0.00032844135,0.00016339976,0.0014506842],"category_scores_gemma":[0.0013794424,0.00018380208,0.0002509166,0.0016092478,0.0005226641,0.000091540096,0.00037125967,0.0030822663,0.000022809847],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04852177,0.016209353,0.12835771,0.000853625,0.00022036771,0.0012061,0.002090362,0.0007805876,0.6898959,0.0003495936,0.039507583,0.072007045],"study_design_scores_gemma":[0.09060924,0.0037037213,0.6616084,0.002020959,0.000046501555,0.000080042904,0.001876035,0.001084293,0.12645377,0.00054547575,0.11108528,0.0008862982],"about_ca_topic_score_codex":0.0014931422,"about_ca_topic_score_gemma":0.00018968672,"teacher_disagreement_score":0.5634421,"about_ca_system_score_codex":0.001250718,"about_ca_system_score_gemma":0.002110906,"threshold_uncertainty_score":0.9994621},"labels":[],"label_agreement":null},{"id":"W4296301827","doi":"10.1101/2022.09.19.505646","title":"Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"3v Geomatics (Canada); University of British Columbia; Université de Montréal; HEC Montréal","funders":"Canadian Institutes of Health Research; Svenska Sällskapet för Medicinsk Forskning; Cancerfonden; Science for Life Laboratory; Michael Smith Health Research BC; Pain Relief Foundation; Karolinska Institutet; Torsten Söderbergs Stiftelse","keywords":"Drug discovery; Drug; PARP1; Computational biology; Drug development; Biology; Target protein; Pharmacology; Plasma protein binding; Cell biology; Chemistry; Biochemistry; Enzyme; Poly ADP ribose polymerase; Gene","score_opus":0.018640220102795795,"score_gpt":0.26715962489077516,"score_spread":0.24851940478797938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296301827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849358,0.0018063763,0.0030616364,0.0021332947,0.0032360572,0.0033294861,0.00047219868,0.0008939271,0.00013119723],"genre_scores_gemma":[0.97769666,0.00033359474,0.014835337,0.0027186994,0.0015428984,0.0024932579,0.000003884098,0.0003113373,0.00006431372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954593,0.00020457638,0.00075827364,0.0016481113,0.00098728,0.00094245624],"domain_scores_gemma":[0.9965465,0.00010883332,0.0004884307,0.0015966998,0.00053313584,0.0007263766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012011698,0.00084637554,0.0010780267,0.0006157422,0.00038751506,0.00010199401,0.00059904746,0.00031247246,0.00329367],"category_scores_gemma":[0.000051348034,0.0008789805,0.00022475015,0.00084370945,0.00015447634,0.00009010393,0.0007478656,0.0021345944,0.00016554433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073482585,0.0006539162,0.007964523,0.0007837988,0.0009117869,0.00070649583,0.00007883883,0.008904228,0.9662486,0.00012336501,0.0128882155,0.0000014357113],"study_design_scores_gemma":[0.0034320483,0.0004336947,0.004547372,0.00056855916,0.0005320991,1.01643735e-7,0.000029954243,0.0006426861,0.8044586,9.91358e-7,0.1842318,0.0011220549],"about_ca_topic_score_codex":0.000053697448,"about_ca_topic_score_gemma":9.666255e-7,"teacher_disagreement_score":0.1713436,"about_ca_system_score_codex":0.0016628366,"about_ca_system_score_gemma":0.0016523006,"threshold_uncertainty_score":0.9993661},"labels":[],"label_agreement":null},{"id":"W4297381243","doi":"10.3389/fonc.2022.1023500","title":"Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases","year":2022,"lang":"en","type":"editorial","venue":"Frontiers in Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Medical Research Council; National Institutes of Health; Cancer Research UK","keywords":"Kinase; DNA-PKcs; DNA damage; Cancer research; DNA repair; DNA Damage Repair; DNA; Medicine; Cell biology; Biology; Protein kinase A; Genetics","score_opus":0.007419690897691648,"score_gpt":0.29821176093967694,"score_spread":0.2907920700419853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297381243","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013834501,0.008789054,0.00007581822,0.009956584,0.97525376,0.0017705739,0.0007198951,0.00021079199,0.0018400532],"genre_scores_gemma":[0.00013077208,0.0035573915,0.0015350292,0.0018016438,0.98832095,0.0011261627,0.00055505347,0.00016457029,0.0028084428],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99115205,0.0041274466,0.0011032657,0.0010424303,0.0017790606,0.00079576374],"domain_scores_gemma":[0.9889639,0.00846111,0.00079462794,0.0012101652,0.00038908017,0.00018112782],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009661805,0.0006141527,0.0017607523,0.00042863167,0.0007072922,0.00006872349,0.0007234254,0.0014106042,0.0004371652],"category_scores_gemma":[0.007312899,0.00041732527,0.0003854977,0.0005885384,0.0019931106,0.00010972917,0.0004810233,0.00401312,0.000005536323],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050708197,0.00010126175,0.00015127522,0.00010051533,0.0003175977,0.00027521845,0.0017821762,0.000008450558,0.00011586555,0.00005634223,0.9455641,0.0008190167],"study_design_scores_gemma":[0.014775334,0.0018566991,0.00004065162,0.00012550554,0.0003437218,0.000017958135,0.0030537858,0.000028309196,0.000060289174,0.0014029497,0.9779009,0.0003938747],"about_ca_topic_score_codex":0.00013812467,"about_ca_topic_score_gemma":0.00006189947,"teacher_disagreement_score":0.035932865,"about_ca_system_score_codex":0.0034456193,"about_ca_system_score_gemma":0.0036573454,"threshold_uncertainty_score":0.9998858},"labels":[],"label_agreement":null},{"id":"W4297821473","doi":"10.1016/j.annonc.2022.08.025","title":"LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Takeda Oncology; EMD Serono; Eisai Canada; Ipsen; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Verastem Oncology; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; Clovis Oncology; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Meso Scale Diagnostics; Merck Sharp and Dohme; KU Leuven; Pfizer; Incyte; F. Hoffmann-La Roche; Seagen; Roche; Carrick Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Bevacizumab; Olaparib; Clinical endpoint; Population; Progression-free survival; Oncology; Ovarian cancer; BRCA mutation; Cancer; Chemotherapy; Gastroenterology; Randomized controlled trial","score_opus":0.13532923228084562,"score_gpt":0.42844639030923365,"score_spread":0.293117158028388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297821473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98148346,0.0004008346,0.00012579594,0.010874394,0.0014599646,0.0024655801,0.0014523224,0.000049262562,0.0016883693],"genre_scores_gemma":[0.9905376,0.00031460053,0.0006880214,0.005832017,0.00052296434,0.0011563412,0.00057479343,0.000059262788,0.0003144213],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947666,0.0011796234,0.0013316829,0.0008273499,0.0011237201,0.00077101024],"domain_scores_gemma":[0.9952212,0.0021055483,0.0011519418,0.0007765006,0.0005570188,0.00018781681],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020610222,0.00038310717,0.0011725134,0.00017238158,0.00030667795,0.00001844198,0.00045821033,0.00018231598,0.00095078285],"category_scores_gemma":[0.0011911399,0.00030426038,0.00019503648,0.00055814115,0.0002608033,0.00019415646,0.0001837038,0.0010182274,0.0000066251573],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8569155,0.0029013003,0.0017314297,0.000021790074,0.00038565992,0.00019997757,0.0039357105,0.0060991882,0.000883302,0.00040474386,0.01777645,0.10874495],"study_design_scores_gemma":[0.90900654,0.03129384,0.016084563,0.0003170731,0.00015498674,0.000011619755,0.00082409335,0.0016620398,0.0005438137,0.0010416743,0.038616627,0.00044315076],"about_ca_topic_score_codex":0.004713854,"about_ca_topic_score_gemma":0.0022182711,"teacher_disagreement_score":0.108301796,"about_ca_system_score_codex":0.0010503198,"about_ca_system_score_gemma":0.0022704382,"threshold_uncertainty_score":0.9999625},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4304084160","doi":"10.1016/j.annonc.2022.09.159","title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; University of Illinois at Urbana-Champaign; National Institutes of Health; Karolinska Institutet; Clovis Oncology; National Institute for Health and Care Research; Seagen; Cilag; Puma Biotechnology; NRG Oncology; Les Laboratories Pierre Fabre; Institut Bergonié; Amgen; Rush University; University of Pennsylvania; Genentech; Institut Gustave-Roussy; Merck KGaA; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; School of Medicine, Indiana University; European Commission; Sanofi; Genomic Health; Ochsner Health; MSD; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Placebo; Hazard ratio; Breast cancer; Confidence interval; Cancer; Pathology; Biology; Polymerase","score_opus":0.038108095548947445,"score_gpt":0.3551060294228056,"score_spread":0.31699793387385816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304084160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954574,0.00028571294,0.0000036273884,0.0022579536,0.00025172238,0.00096125336,0.00064087,0.0000047031735,0.00013675715],"genre_scores_gemma":[0.9982827,0.0004124288,0.00002421728,0.0008998717,0.00008193007,0.00021412219,0.000051741208,0.0000164003,0.000016592867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976158,0.00075564615,0.000676829,0.00027857334,0.00039149862,0.00028166818],"domain_scores_gemma":[0.99891293,0.00023691561,0.00043171196,0.00025195585,0.000112877235,0.00005360201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322768,0.00014571777,0.00072565017,0.00026351018,0.000033763103,0.0000030394071,0.00014488459,0.000090321875,0.0002654778],"category_scores_gemma":[0.000035597044,0.00011068839,0.00005070327,0.00042141118,0.00015640711,0.00007534803,0.00005925496,0.00040980417,3.9479076e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33054397,0.009670939,0.59435356,0.00004634524,0.00016636339,0.00017023501,0.0045269327,0.00023440753,0.0011748428,0.00027470544,0.00045372,0.058383975],"study_design_scores_gemma":[0.23461707,0.00885249,0.75557464,0.000057288675,0.000029721126,0.000011341309,0.000116215924,0.00003866259,0.00007931422,0.0001735447,0.00035968362,0.0000900234],"about_ca_topic_score_codex":0.008189053,"about_ca_topic_score_gemma":0.0022756273,"teacher_disagreement_score":0.16122109,"about_ca_system_score_codex":0.00013941465,"about_ca_system_score_gemma":0.00046149254,"threshold_uncertainty_score":0.9984155},"labels":[],"label_agreement":null},{"id":"W4306174526","doi":"10.18632/oncotarget.28278","title":"HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: Implications for their use in combination with PARP inhibitors and chemotherapeutic drugs","year":2022,"lang":"en","type":"article","venue":"Oncotarget","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health","keywords":"PARP1; Cancer research; DNA repair; Histone deacetylase; DNA damage; Synthetic lethality; Biology; Poly ADP ribose polymerase; Cancer cell; Cancer; Histone; Pharmacology; DNA; Biochemistry","score_opus":0.027715354914745815,"score_gpt":0.2871518624437431,"score_spread":0.2594365075289973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306174526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99012727,0.0017955144,0.00014474547,0.0030231131,0.00005995335,0.004488476,0.0002471325,0.00009020904,0.000023582683],"genre_scores_gemma":[0.9930924,0.000090107686,0.0016932025,0.00034075955,0.00003973386,0.0044672443,0.00012317755,0.000051999286,0.000101369566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982074,0.00015614646,0.00047376036,0.00057338044,0.00023263133,0.00035671325],"domain_scores_gemma":[0.99913716,0.00013315248,0.0002684586,0.00023858767,0.00010763339,0.000114998045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046068802,0.00025964895,0.0003924757,0.00029160266,0.00021195732,0.000045845343,0.000047688976,0.00011520775,0.000031381773],"category_scores_gemma":[0.00003254416,0.0002429431,0.000038364262,0.00046549892,0.00014829278,0.0003478709,0.000051461575,0.00028065004,2.3138095e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021934577,0.00084722496,0.46079215,0.000570405,0.000092549875,0.0000040583413,0.009166506,0.0000942327,0.5194834,0.0011324318,0.00038919397,0.005234387],"study_design_scores_gemma":[0.01817837,0.0017344537,0.4108556,0.00080486736,0.000069891554,0.000036582558,0.0026506437,0.003039265,0.5505399,0.005102529,0.0062015513,0.00078632176],"about_ca_topic_score_codex":0.00065318885,"about_ca_topic_score_gemma":0.00035593632,"teacher_disagreement_score":0.049936563,"about_ca_system_score_codex":0.00054645597,"about_ca_system_score_gemma":0.00021054663,"threshold_uncertainty_score":0.9906932},"labels":[],"label_agreement":null},{"id":"W4306250689","doi":"10.1200/po.22.00355","title":"State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Ovarian cancer; Medicine; Oncology; Biomarker; Cancer; Internal medicine; Medical physics; Biology","score_opus":0.30856198912367905,"score_gpt":0.5672117160136698,"score_spread":0.25864972688999077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306250689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96981,0.00083457405,0.00032780264,0.010509286,0.008375198,0.001149269,0.000104744315,0.000026924903,0.008862165],"genre_scores_gemma":[0.9951329,0.00023164196,0.0009886399,0.002112271,0.0003198887,0.0005963507,0.000008559863,0.000014894651,0.0005948554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497,0.0012313591,0.0018499009,0.00049799413,0.0011769721,0.00027375968],"domain_scores_gemma":[0.9963387,0.0015769239,0.001261314,0.00033388668,0.0003898555,0.000099281664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02421014,0.000117322874,0.00068570656,0.0003664105,0.00028573937,0.000010143165,0.0003429285,0.000081106395,0.0006492273],"category_scores_gemma":[0.0060486225,0.00008629613,0.00016683691,0.0012338981,0.0005782501,0.00012480828,0.00034577193,0.0005424258,0.0000013298115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008196748,0.0010480958,0.40180248,0.00004619326,0.00021905286,0.000548228,0.002407452,0.034221083,0.11980745,0.0003477387,0.027965387,0.40339008],"study_design_scores_gemma":[0.011601937,0.0005912846,0.44073153,0.0006065204,0.00007451034,0.00055730145,0.00021912836,0.0042869286,0.00755393,0.0026452406,0.5308853,0.00024641014],"about_ca_topic_score_codex":0.0005743124,"about_ca_topic_score_gemma":0.0002100246,"teacher_disagreement_score":0.5029199,"about_ca_system_score_codex":0.0018382927,"about_ca_system_score_gemma":0.007795554,"threshold_uncertainty_score":0.9978293},"labels":[],"label_agreement":null},{"id":"W4306409663","doi":"10.1038/s41467-022-33731-w","title":"Mammalian N1-adenosine PARylation is a reversible DNA modification","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"Deutsche Forschungsgemeinschaft","keywords":"DNA; PARP1; Chemistry; Nucleic acid; Biochemistry; Molecular biology; Biology; Poly ADP ribose polymerase; Polymerase","score_opus":0.05765458110716982,"score_gpt":0.3608714185884914,"score_spread":0.3032168374813216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306409663","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23637272,0.040392026,0.0024392777,0.61315686,0.0015080613,0.003879187,0.0008489414,0.0010885663,0.10031437],"genre_scores_gemma":[0.98570085,0.00053488306,0.003979439,0.005940762,0.00009384477,0.00036631647,0.0010179188,0.000028196388,0.0023378085],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876714,0.00017163523,0.00027356786,0.00023447526,0.00039128127,0.00016191299],"domain_scores_gemma":[0.9974067,0.00007737646,0.00013711452,0.0020986164,0.00019647404,0.00008367192],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029092643,0.000118187905,0.00016186187,0.00020285102,0.0007524668,0.000019550378,0.0005523347,0.00014102274,0.0012089298],"category_scores_gemma":[0.00005166689,0.00013379788,0.00009830595,0.0007866429,0.000075463366,0.00012541666,0.0002280786,0.0011728965,0.00007230544],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074765645,0.0022955977,0.026082681,0.00010949222,0.0003390222,0.000011698502,0.0060286648,0.0005708361,0.072209276,0.08438954,0.79942185,0.007793687],"study_design_scores_gemma":[0.0018648715,0.00016295735,0.011977244,0.000038429695,0.00011591582,0.00009518394,0.0005884227,0.0082813995,0.0037954873,0.0017907372,0.9710373,0.0002520496],"about_ca_topic_score_codex":0.000032676387,"about_ca_topic_score_gemma":0.00002015072,"teacher_disagreement_score":0.74932814,"about_ca_system_score_codex":0.00045319038,"about_ca_system_score_gemma":0.0001536248,"threshold_uncertainty_score":0.9997041},"labels":[],"label_agreement":null},{"id":"W4306882918","doi":"10.1016/j.eururo.2022.09.031","title":"BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"letter","venue":"European Urology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Reversion; Prostate cancer; Oncology; Castration; Prostate; Internal medicine; Cancer; Gynecology; Gene; Phenotype; Hormone; Genetics","score_opus":0.03672269609017749,"score_gpt":0.308578188326128,"score_spread":0.2718554922359505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306882918","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013153965,0.0020104833,0.00003087844,0.95965075,0.0013538643,0.0013438147,0.0007063856,0.00015061977,0.021599226],"genre_scores_gemma":[0.02872258,0.00050603517,0.00040569104,0.94982886,0.0016589244,0.00035004897,0.003022027,0.00021804939,0.015287759],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680763,0.0011695896,0.00059444964,0.0006086905,0.0003867644,0.00043288578],"domain_scores_gemma":[0.9988791,0.00019651832,0.00031170028,0.0004585156,0.000088624816,0.000065590735],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042015946,0.0002999164,0.0004759676,0.00046615765,0.00012734174,0.000019073552,0.0001813559,0.000110192064,0.006818666],"category_scores_gemma":[0.00007214547,0.0003089866,0.00012472643,0.00037581442,0.00015533702,0.0000594475,0.00007136026,0.0020942898,0.00025075063],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000521109,0.00006319082,0.0002525244,0.00016193918,0.00013005993,0.011132055,0.00081451045,0.0003683225,0.0017386955,0.000020264572,0.98413765,0.0006596786],"study_design_scores_gemma":[0.002263061,0.00060615817,0.0023486977,0.000059787213,0.0002007175,0.0002622637,0.0000534767,0.000028289738,0.000040621864,0.000109756,0.99378043,0.00024670974],"about_ca_topic_score_codex":0.00016733806,"about_ca_topic_score_gemma":0.00006486462,"teacher_disagreement_score":0.015568615,"about_ca_system_score_codex":0.00040809985,"about_ca_system_score_gemma":0.00040315965,"threshold_uncertainty_score":0.9999362},"labels":[],"label_agreement":null},{"id":"W4306926620","doi":"10.1016/j.ygyno.2022.08.021","title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Genentech; National Institutes of Health; PharmaMar; Seagen; NRG Oncology; Ipsen; Clovis Oncology; Gateway Foundation; Eisai; National Comprehensive Cancer Network; Regeneron Pharmaceuticals; Mersana Therapeutics; Shire; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Oncology; Clinical trial; PARP inhibitor; Loss of heterozygosity; Placebo; Randomized controlled trial; Polymerase; Pathology; Gene; Genetics; Poly ADP ribose polymerase; Biology","score_opus":0.038899492123703604,"score_gpt":0.33057337883320553,"score_spread":0.29167388670950195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306926620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293226,0.000112866524,0.0009135223,0.0025342472,0.00095217547,0.00108681,0.0012453127,0.000027304637,0.00019551573],"genre_scores_gemma":[0.98915976,0.00012981314,0.0056468905,0.0029476052,0.00017568689,0.0008411815,0.0009342426,0.000022274262,0.00014257162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814004,0.00020593265,0.00069066783,0.00047746554,0.00018121448,0.00030470188],"domain_scores_gemma":[0.9981637,0.00084638206,0.000419091,0.00027097433,0.00016106568,0.00013881113],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025612098,0.00019439496,0.0008206252,0.00007482941,0.00015275468,0.000005084022,0.00011307833,0.000209007,0.001031247],"category_scores_gemma":[0.00020444475,0.00017671485,0.0001510756,0.000084547486,0.00031032469,0.00002534098,0.000102286824,0.00021516897,0.000003634018],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037196467,0.0036579836,0.9242523,0.00003340691,0.0004354936,0.0001373192,0.00044010917,0.00002018227,0.005722274,0.006940955,0.0018564758,0.0527839],"study_design_scores_gemma":[0.01588806,0.011677186,0.94276565,0.000009875225,0.0001900348,0.000015387339,0.00010768242,0.00013217927,0.0007143487,0.0069191596,0.021421032,0.00015939481],"about_ca_topic_score_codex":0.000116677686,"about_ca_topic_score_gemma":0.000028087892,"teacher_disagreement_score":0.052624505,"about_ca_system_score_codex":0.00067713147,"about_ca_system_score_gemma":0.00033884903,"threshold_uncertainty_score":0.9998819},"labels":[],"label_agreement":null},{"id":"W4306957266","doi":"10.1200/po.22.00033","title":"Germline Testing and Somatic Tumor Testing for<i>BRCA1/2</i>Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Germline; Olaparib; PARP inhibitor; Ovarian cancer; Medicine; Genetic testing; Oncology; BRCA mutation; Germline mutation; Population; Internal medicine; Cancer; Biology; Genetics; Mutation; Polymerase; Poly ADP ribose polymerase","score_opus":0.09293274554144984,"score_gpt":0.3785759257374067,"score_spread":0.2856431801959569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306957266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874656,0.0025802576,0.0008906072,0.0055199564,0.0006977707,0.0020360015,0.00016256716,0.00006677853,0.0005804268],"genre_scores_gemma":[0.8901165,0.00010312769,0.10430122,0.0037325998,0.00027834953,0.0012778507,0.0000117382715,0.000056623787,0.000121964185],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99726915,0.00034834788,0.00094285543,0.0005677817,0.0004211247,0.000450721],"domain_scores_gemma":[0.9913171,0.007078435,0.00066610985,0.00045374283,0.00036798633,0.000116654206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020815732,0.00023469666,0.00065638195,0.00022372924,0.0003487916,0.000033860262,0.0002929242,0.00009846754,0.00025637558],"category_scores_gemma":[0.0029150967,0.00019474956,0.00007356068,0.0010758878,0.00023362713,0.0002039863,0.0002958568,0.0005269294,0.0000026269329],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097630604,0.0004369023,0.053628374,0.00022694565,0.00006151981,0.00020729327,0.0025241212,0.003556006,0.62652904,0.00007140638,0.00061636884,0.31116575],"study_design_scores_gemma":[0.05060912,0.02889894,0.26281306,0.0075039486,0.00097327185,0.015477233,0.007151074,0.55026513,0.032034434,0.026415013,0.015731942,0.0021268218],"about_ca_topic_score_codex":0.00029958863,"about_ca_topic_score_gemma":0.000026772874,"teacher_disagreement_score":0.5944946,"about_ca_system_score_codex":0.00064076664,"about_ca_system_score_gemma":0.0011795379,"threshold_uncertainty_score":0.7941657},"labels":[],"label_agreement":null},{"id":"W4307450084","doi":"10.1136/ijgc-2022-esgo.1018","title":"2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246)","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Oncology; Internal medicine; Germline; Ovarian cancer; Medicine; Frameshift mutation; Germline mutation; Missense mutation; BRCA mutation; Cancer; Genetics; Cancer research; Biology; Mutation; Gene","score_opus":0.030882319487714607,"score_gpt":0.32630780080521254,"score_spread":0.29542548131749796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307450084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98905575,0.0009778411,0.00080885825,0.005951704,0.00096721906,0.0009438939,0.0010855615,0.00004566128,0.00016349295],"genre_scores_gemma":[0.992408,0.00040831266,0.00025696386,0.0050075757,0.0005875889,0.000907963,0.00014341575,0.000053936816,0.00022624832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952015,0.00053368806,0.0009932675,0.0006003209,0.0022284742,0.00044272168],"domain_scores_gemma":[0.99556226,0.000794936,0.0012830805,0.00043016425,0.0016311391,0.0002984045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067061436,0.00043242594,0.00089087966,0.00038821364,0.00033091943,0.00010094995,0.0008551419,0.00009630112,0.014483385],"category_scores_gemma":[0.00018795201,0.0002428776,0.00036302526,0.0012241596,0.0002652279,0.0003069473,0.00016363077,0.0009228247,0.0000072494436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019376265,0.004835766,0.93812835,0.000003710432,0.011201948,0.0012180718,0.0013843972,0.003508326,0.00045166747,0.000033613593,0.008781497,0.011076401],"study_design_scores_gemma":[0.04343637,0.0049140383,0.9245771,0.00012789134,0.0023452311,0.00003305292,0.0022447642,0.0004996625,0.00019675212,0.00009186626,0.02109688,0.00043638994],"about_ca_topic_score_codex":0.0011895585,"about_ca_topic_score_gemma":0.0015073632,"teacher_disagreement_score":0.024060108,"about_ca_system_score_codex":0.0021423835,"about_ca_system_score_gemma":0.0007333882,"threshold_uncertainty_score":0.9904261},"labels":[],"label_agreement":null},{"id":"W4307500250","doi":"10.1016/j.celrep.2022.111529","title":"Crystal structures and functional analysis of the ZnF5-WWE1-WWE2 region of PARP13/ZAP define a distinctive mode of engaging poly(ADP-ribose)","year":2022,"lang":"en","type":"article","venue":"Cell Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Biological and Environmental Research; Canadian Light Source; Natural Sciences and Engineering Research Council of Canada; Basic Energy Sciences; National Research Council; National Institute of General Medical Sciences; National Institutes of Health; Lawrence Berkeley National Laboratory; Université de Montréal; University of Saskatchewan; Canada Foundation for Innovation; Canadian Institutes of Health Research; U.S. Department of Energy","keywords":"Ribose; Mode (computer interface); Cell biology; Chemistry; Poly ADP ribose polymerase; Biology; Computer science; Biochemistry; DNA; Enzyme","score_opus":0.01980742778143468,"score_gpt":0.2642572010739316,"score_spread":0.2444497732924969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307500250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498296,0.0009155748,0.0012869266,0.00020397539,0.0002294458,0.00023808455,0.00007982329,0.000013726978,0.002049478],"genre_scores_gemma":[0.99924135,0.000020507881,0.00019600005,0.00008738489,0.000050843453,0.000024015017,0.00007499139,0.00001479707,0.0002900875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832165,0.00010835225,0.0006009519,0.00029107294,0.0005474154,0.00013056965],"domain_scores_gemma":[0.9982938,0.000110878165,0.00089981547,0.00047630267,0.00016377078,0.000055397864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025036393,0.00012927153,0.00045325316,0.00022650491,0.00012413612,0.0000029536302,0.000049584167,0.000042252617,0.00032993453],"category_scores_gemma":[0.00007961179,0.00010149426,0.00024188135,0.00065047055,0.00022336487,0.00003344837,0.00010093278,0.00020882423,3.410976e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014584202,0.00052735023,0.49453434,0.0004251055,0.0020732023,0.00026312206,0.004269682,0.010006499,0.48148277,0.00076334784,0.0029110322,0.0012851505],"study_design_scores_gemma":[0.0027408274,0.0005448513,0.49028903,0.00015481147,0.0039646574,0.0014531445,0.002848489,0.0030550407,0.48523676,0.0050897705,0.004231337,0.0003912724],"about_ca_topic_score_codex":0.00031292773,"about_ca_topic_score_gemma":0.000018708297,"teacher_disagreement_score":0.0069514574,"about_ca_system_score_codex":0.00010669777,"about_ca_system_score_gemma":0.00017583228,"threshold_uncertainty_score":0.4138816},"labels":[],"label_agreement":null},{"id":"W4307638653","doi":"10.1158/2767-9764.crc-22-0240","title":"<i>Ad hoc</i> Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline <i>BRCA</i> Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects","year":2022,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Homologous recombination; Germline; Ovarian cancer; Medicine; Oncology; Biology; Cancer; Genetics; Internal medicine; DNA; Gene","score_opus":0.15425510176700669,"score_gpt":0.47739420077474237,"score_spread":0.3231390990077357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307638653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97091615,0.014376468,0.00002314734,0.009654488,0.0002631189,0.0033168246,0.00021321788,0.00010181775,0.0011347674],"genre_scores_gemma":[0.98809993,0.0069848667,0.00019033064,0.00040352615,0.000042590338,0.003622639,0.0002434899,0.000050168343,0.00036244575],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941775,0.0024877167,0.00079347723,0.00059521827,0.0014120557,0.000534001],"domain_scores_gemma":[0.9937783,0.00069574,0.00034552527,0.0038403666,0.0011775307,0.0001625403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030482789,0.00023899013,0.0006962509,0.001168995,0.0009741763,0.000029862947,0.0014094048,0.0000773451,0.00084589474],"category_scores_gemma":[0.0002606572,0.00019927527,0.00025271633,0.011409002,0.0005870605,0.00012003564,0.000852023,0.0019431445,0.000002907127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052597657,0.117359295,0.3145347,0.0006304478,0.026335469,0.00019724318,0.08757466,0.05601785,0.036528602,0.0048736488,0.05417203,0.2491784],"study_design_scores_gemma":[0.1802712,0.025964191,0.28754672,0.0027799278,0.010640393,0.00008962051,0.020542141,0.06195235,0.005267895,0.0009875488,0.40113777,0.0028202431],"about_ca_topic_score_codex":0.0045169704,"about_ca_topic_score_gemma":0.021518162,"teacher_disagreement_score":0.34696573,"about_ca_system_score_codex":0.0022723216,"about_ca_system_score_gemma":0.0019034265,"threshold_uncertainty_score":0.9963366},"labels":[],"label_agreement":null},{"id":"W4307988486","doi":"10.21203/rs.3.rs-2227540/v1","title":"PARP1 mediated PARylation contributes to myogenic progressionand glucocorticoid transcriptional response.","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Trent University; Nottingham Trent University","keywords":"Glucocorticoid; PARP1; Cell biology; Biology; Endocrinology; Genetics; Gene; Poly ADP ribose polymerase","score_opus":0.10747475802232778,"score_gpt":0.4686011896728733,"score_spread":0.3611264316505455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307988486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9369073,0.011485961,0.00060926314,0.03737866,0.0010233058,0.009489107,0.0017535822,0.0003115951,0.0010412082],"genre_scores_gemma":[0.98369837,0.0008102334,0.00042375212,0.0008044181,0.00042263823,0.0067562414,0.003482511,0.00011378147,0.00348808],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99212885,0.0018943063,0.000779575,0.0010752096,0.003223818,0.0008982614],"domain_scores_gemma":[0.9954525,0.0015716638,0.0001586859,0.0010341957,0.001282095,0.0005008495],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004454592,0.00036626696,0.0006975126,0.0012605728,0.0004104779,0.00011446808,0.00040202326,0.00043955617,0.0065088687],"category_scores_gemma":[0.0016880741,0.00035031675,0.00033827106,0.0013007676,0.00022548842,0.000075907694,0.00053875253,0.0025625627,0.00037176145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14520684,0.0032801249,0.13410088,0.0055361674,0.0019801417,0.0010144565,0.004177488,0.003575302,0.5529574,0.0029321264,0.13321148,0.012027587],"study_design_scores_gemma":[0.008616512,0.0026234833,0.45544216,0.004042553,0.00010999074,0.000043973083,0.0009551555,0.0010095391,0.012228359,0.0034542747,0.51075387,0.0007201406],"about_ca_topic_score_codex":0.00004874865,"about_ca_topic_score_gemma":0.000010414494,"teacher_disagreement_score":0.54072905,"about_ca_system_score_codex":0.002073664,"about_ca_system_score_gemma":0.0034548705,"threshold_uncertainty_score":0.99989486},"labels":[],"label_agreement":null},{"id":"W4308564938","doi":"10.1101/2022.11.08.515634","title":"Clinical PARP inhibitors allosterically induce PARP2 retention on DNA","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Allosteric regulation; PARP1; DNA damage; Poly ADP ribose polymerase; DNA; Chemistry; DNA repair; Cell biology; Biology; Cancer research; Biochemistry; Enzyme; Polymerase","score_opus":0.04991117370171597,"score_gpt":0.3125301449260652,"score_spread":0.2626189712243492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308564938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869181,0.00062074943,0.00022599137,0.0023749184,0.006551563,0.0018818893,0.0003123971,0.0008768148,0.00023758397],"genre_scores_gemma":[0.98799795,0.0008979134,0.0025174427,0.004153889,0.0031859474,0.0008779025,0.0000051222037,0.00030524447,0.000058587793],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.993392,0.0006961538,0.001741151,0.0020194005,0.0013555341,0.0007957809],"domain_scores_gemma":[0.994946,0.00022608753,0.0010910222,0.002504752,0.00054121367,0.0006909335],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020117615,0.00086479867,0.0013553447,0.00048103018,0.00027467802,0.00014280614,0.0005912801,0.00108728,0.0010768679],"category_scores_gemma":[0.0005427962,0.0009268177,0.00071710575,0.0007535047,0.00028662977,0.00013459046,0.0007253997,0.0033640268,0.00027901627],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027856724,0.0032987997,0.1086742,0.0013861208,0.0016253699,0.00120947,0.000042655945,0.00009775789,0.8459581,0.0012134309,0.033623725,0.00008467833],"study_design_scores_gemma":[0.007951813,0.0027141613,0.5158599,0.0034609854,0.0008629777,3.4533767e-7,0.000018913104,0.00016981132,0.21181573,0.000021469856,0.25427178,0.002852089],"about_ca_topic_score_codex":0.000020979573,"about_ca_topic_score_gemma":6.610941e-7,"teacher_disagreement_score":0.6341424,"about_ca_system_score_codex":0.0012196343,"about_ca_system_score_gemma":0.0014574471,"threshold_uncertainty_score":0.99983627},"labels":[],"label_agreement":null},{"id":"W4308813967","doi":"10.1101/2022.11.10.515994","title":"A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Mitacs; St. Baldrick's Foundation","keywords":"Olaparib; PARP inhibitor; PARP1; Cancer research; Sarcoma; Poly ADP ribose polymerase; Vorinostat; DNA damage; Biology; Pharmacology; Histone deacetylase; Medicine; DNA; Biochemistry; Histone; Polymerase; Pathology","score_opus":0.025645195860229807,"score_gpt":0.25349693608121737,"score_spread":0.22785174022098756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308813967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322796,0.0008469701,0.00097393716,0.001141683,0.0015387627,0.001431622,0.00026255482,0.00049946725,0.0000770318],"genre_scores_gemma":[0.99391127,0.0001681393,0.002434737,0.0007683756,0.0010999339,0.0013589236,0.0000018209109,0.0002297499,0.000027068909],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9957863,0.00026570086,0.0006256525,0.0014617746,0.0011042854,0.00075630704],"domain_scores_gemma":[0.9971894,0.00013244126,0.000494985,0.0014689661,0.00034640334,0.00036781174],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008232542,0.0007343576,0.0009903987,0.00075003965,0.00023145256,0.00011165963,0.00031243873,0.00048125684,0.000859784],"category_scores_gemma":[0.00011714843,0.0007521234,0.00022670737,0.0011708082,0.00020240968,0.00022469848,0.00045875247,0.0023664983,0.00004767822],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022443242,0.0011974272,0.12916481,0.0011170468,0.00047212577,0.0008262251,0.00004372084,0.00038583166,0.8626143,0.0003343749,0.0015876698,0.000012138753],"study_design_scores_gemma":[0.0065440116,0.00047914192,0.62639093,0.0020445806,0.00021087474,5.0013386e-7,0.000014484891,0.00034039497,0.34174728,0.0000057234743,0.020820875,0.0014011929],"about_ca_topic_score_codex":0.00015055027,"about_ca_topic_score_gemma":0.000011085305,"teacher_disagreement_score":0.520867,"about_ca_system_score_codex":0.0020975766,"about_ca_system_score_gemma":0.0023020646,"threshold_uncertainty_score":0.9999351},"labels":[],"label_agreement":null},{"id":"W4309035055","doi":"10.3390/cancers14225559","title":"Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; PARP inhibitor; Cytotoxicity; Medicine; Poly ADP ribose polymerase; Cancer research; Pharmacology; Synthetic lethality; Drug; Oncology; Chemistry; In vitro; DNA repair; Enzyme; Biochemistry","score_opus":0.04663301491096264,"score_gpt":0.3396292865219929,"score_spread":0.29299627161103026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309035055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99003345,0.00052362966,0.0014834977,0.0060022026,0.00015983716,0.0010887373,0.00043706293,0.00003749486,0.00023406527],"genre_scores_gemma":[0.99688995,0.00013356491,0.00091117376,0.0005366422,0.000049580252,0.0012579601,0.00016389703,0.000015526024,0.000041693434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866205,0.000083207044,0.00058448163,0.00033322416,0.00015735289,0.00017969447],"domain_scores_gemma":[0.9989746,0.0003390847,0.00024041304,0.0002281543,0.00013086897,0.00008682954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047699056,0.00011138169,0.00031376834,0.000104098486,0.0001647962,0.000009238712,0.00006324553,0.000058858805,0.00005152256],"category_scores_gemma":[0.00019270038,0.000119293305,0.0000764588,0.00032629233,0.00022760294,0.00007683787,0.000039033603,0.00021757864,2.729363e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025444468,0.001417464,0.75727487,0.0008160222,0.0002047705,0.0000015924004,0.0031999256,0.0010786252,0.19468746,0.010412552,0.013819272,0.014543019],"study_design_scores_gemma":[0.07577951,0.011027251,0.6718177,0.0015016039,0.00055038027,0.00007056065,0.015331898,0.02092509,0.08059236,0.094481915,0.02561313,0.0023085831],"about_ca_topic_score_codex":0.00012577015,"about_ca_topic_score_gemma":0.000030992032,"teacher_disagreement_score":0.11409509,"about_ca_system_score_codex":0.0008938523,"about_ca_system_score_gemma":0.000492543,"threshold_uncertainty_score":0.486464},"labels":[],"label_agreement":null},{"id":"W4309093661","doi":"10.1158/1078-0432.ccr-22-2074","title":"A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Imperial Experimental Cancer Medicine Centre; National Institute for Health and Care Research; Sierra Oncology; Cancer Research UK","keywords":"Gemcitabine; Medicine; Neutropenia; Internal medicine; Cancer; Tolerability; Nausea; Lung cancer; Cervical cancer; Gastroenterology; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Adverse effect; Chemotherapy","score_opus":0.12067813214337975,"score_gpt":0.5118891438458054,"score_spread":0.39121101170242567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309093661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201137,0.00034139663,0.0000058622595,0.0033141258,0.00039487277,0.003475367,0.00016351897,0.000024756477,0.0002687172],"genre_scores_gemma":[0.9954701,0.00029640188,0.00011319722,0.00031852804,0.00018623708,0.003186846,0.000105815874,0.000056914465,0.00026594847],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99481153,0.0008315366,0.0010717999,0.0006920616,0.0019738742,0.000619188],"domain_scores_gemma":[0.99784946,0.00041477,0.00029411374,0.0005032042,0.0007135443,0.00022488803],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026719018,0.00021343496,0.00080706377,0.0005834158,0.00016167342,0.000011993289,0.00027025337,0.0001117337,0.0012054339],"category_scores_gemma":[0.00028898992,0.00017617848,0.0000918916,0.0020834256,0.00055783207,0.00018519131,0.00021403731,0.0017334961,0.0000033956042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65185124,0.02488641,0.25068676,0.00017397689,0.000106874475,0.00006816259,0.00059718516,0.0005878715,0.00047607743,0.000064357715,0.0018842296,0.06861686],"study_design_scores_gemma":[0.7711384,0.086033694,0.13100867,0.00093445426,0.000033918444,0.0000013342541,0.00026994367,0.0002774267,0.0011841753,0.00016984648,0.008631717,0.0003163828],"about_ca_topic_score_codex":0.0015905362,"about_ca_topic_score_gemma":0.0014598152,"teacher_disagreement_score":0.11967809,"about_ca_system_score_codex":0.0014132045,"about_ca_system_score_gemma":0.0020903854,"threshold_uncertainty_score":0.9997076},"labels":[],"label_agreement":null},{"id":"W4309184100","doi":"10.1001/jamaoncol.2022.5228","title":"Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors","year":2022,"lang":"en","type":"letter","venue":"JAMA Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Foundation Medicine; Genentech; Astellas Pharma; Incyte; National Center for Advancing Translational Sciences; Seagen; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Symphogen; GlaxoSmithKline; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Avelumab; Cancer; Lung cancer; Breast cancer; Immunogenicity; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Immunotherapy; Antigen; Immunology; Phases of clinical research; Chemotherapy; Clinical trial; Pembrolizumab","score_opus":0.014103020392398594,"score_gpt":0.3020944315400396,"score_spread":0.28799141114764104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309184100","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15403104,0.00030676898,0.00003196989,0.8054116,0.0023650408,0.0030624582,0.00036725012,0.00021850194,0.034205403],"genre_scores_gemma":[0.032218438,0.00006208402,0.0007676162,0.95588523,0.0023799404,0.0013180091,0.0031092162,0.00019014698,0.004069345],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968657,0.00029241008,0.00066951034,0.0007494724,0.0007162527,0.0007066612],"domain_scores_gemma":[0.9983276,0.00023737141,0.0005235491,0.0006334197,0.00017562209,0.00010244524],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021355163,0.00043284893,0.0013273166,0.00047628145,0.00008546004,0.000015091807,0.00027268525,0.00088252284,0.0040303287],"category_scores_gemma":[0.00007917117,0.0003964938,0.00013255134,0.00040301553,0.00021117326,0.00010338382,0.00012617331,0.004193044,0.00009882074],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049360413,0.00034867055,0.0053549088,0.00017771262,0.00013551426,0.0039659827,0.00043847243,0.00011437732,0.000018716277,0.000012152413,0.974759,0.009738456],"study_design_scores_gemma":[0.024968948,0.0058961427,0.01473311,0.00025707652,0.00006880415,0.00014527973,0.00005910091,0.000015296244,0.000046476045,0.000072022245,0.953338,0.00039974472],"about_ca_topic_score_codex":0.00006531122,"about_ca_topic_score_gemma":0.000042039766,"teacher_disagreement_score":0.15047362,"about_ca_system_score_codex":0.0047968747,"about_ca_system_score_gemma":0.0016630451,"threshold_uncertainty_score":0.9998487},"labels":[],"label_agreement":null},{"id":"W4309350451","doi":"10.1001/jamanetworkopen.2022.42370","title":"Characterization of Oncology Clinical Trials Using Germline Genetic Data","year":2022,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Clinical trial; Medicine; Germline; Oncology; PARP inhibitor; Cancer; Internal medicine; Psychological intervention; Genetics; Biology; Poly ADP ribose polymerase; Nursing","score_opus":0.5107098225571897,"score_gpt":0.5561134537289499,"score_spread":0.04540363117176027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309350451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98451114,0.0005608919,0.00468664,0.004766028,0.0017727407,0.0018553614,0.0003779538,0.000026931879,0.0014423183],"genre_scores_gemma":[0.9536165,0.0010937692,0.02190487,0.011238544,0.0077697216,0.00018024935,0.0034026217,0.00007368332,0.0007200626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950722,0.0026495068,0.0014292493,0.00038159254,0.0002670102,0.00020047133],"domain_scores_gemma":[0.9972893,0.00063604466,0.0009767626,0.00091098924,0.000086680455,0.00010024291],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011455505,0.00010063797,0.00088177994,0.000047059242,0.00012871888,0.000028399338,0.00067359494,0.00010715046,0.0030740905],"category_scores_gemma":[0.0004389073,0.00009652825,0.00008766325,0.00033825918,0.00006906202,0.00015132019,0.0011806855,0.00035947742,0.000008095027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020856762,0.0021313438,0.14997193,0.000117221054,0.0012817242,0.00023052706,0.0004784857,0.004734072,0.105358586,0.00045569506,0.095687665,0.618696],"study_design_scores_gemma":[0.014699281,0.0016379528,0.1199574,0.0002058287,0.00042578648,0.00020778856,0.00006741193,0.043199204,0.00053491106,0.00034247656,0.8184732,0.00024876188],"about_ca_topic_score_codex":0.000045057343,"about_ca_topic_score_gemma":0.000004418753,"teacher_disagreement_score":0.72278553,"about_ca_system_score_codex":0.0001386634,"about_ca_system_score_gemma":0.0006032777,"threshold_uncertainty_score":0.99783725},"labels":[],"label_agreement":null},{"id":"W4310603348","doi":"10.1111/bcp.15624","title":"Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug–drug interaction study","year":2022,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Cmax; Itraconazole; Pharmacokinetics; Pharmacology; CYP3A4; Rifampicin; Drug interaction; Oral administration; Area under the curve; Medicine; Chemistry; Internal medicine; Antibiotics; Cytochrome P450; Metabolism; Biochemistry","score_opus":0.05507445758018992,"score_gpt":0.46079835455134427,"score_spread":0.40572389697115435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310603348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991361,0.0010963551,0.0000048305933,0.0036706314,0.0027284608,0.0009866633,0.000033024826,0.000006514092,0.00011249533],"genre_scores_gemma":[0.99516207,0.00089585065,0.000021667049,0.002890716,0.0009158609,0.000055995006,0.000002266801,0.000024359068,0.000031196978],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99326634,0.003545233,0.0021301233,0.00024469823,0.00057795714,0.00023566223],"domain_scores_gemma":[0.9948449,0.003335108,0.0013006285,0.00011581543,0.00023005233,0.00017345863],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006696158,0.00015721786,0.0010457813,0.0002501229,0.000080704005,0.000009137073,0.00019672065,0.000059067515,0.0007891269],"category_scores_gemma":[0.0004721132,0.00013840017,0.00024890297,0.0003126611,0.00025361837,0.00009294566,0.00011978936,0.0023492717,0.0000011992411],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2275866,0.027492486,0.2889874,0.0009611309,0.0035764563,0.0038678148,0.005330484,0.0034973924,0.044166014,0.00002737222,0.23272894,0.16177791],"study_design_scores_gemma":[0.3674427,0.20644608,0.23852381,0.0033007215,0.004347863,0.014001122,0.013081161,0.0043103094,0.09552168,0.0002029493,0.051582247,0.0012393625],"about_ca_topic_score_codex":0.00015296481,"about_ca_topic_score_gemma":0.000032224776,"teacher_disagreement_score":0.1811467,"about_ca_system_score_codex":0.00016855667,"about_ca_system_score_gemma":0.0002770512,"threshold_uncertainty_score":0.9999524},"labels":[],"label_agreement":null},{"id":"W4310753925","doi":"10.1016/j.annonc.2022.10.195","title":"158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Abiraterone acetate; Medicine; Prednisone; Prostate cancer; Abiraterone; Oncology; Homologous recombination; Internal medicine; Gene; Cancer; Androgen deprivation therapy; Genetics; Biology; Androgen receptor","score_opus":0.0458447475444037,"score_gpt":0.346556760170719,"score_spread":0.3007120126263153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310753925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310356,0.0004544998,0.00003430404,0.0032047112,0.000051547555,0.0028100808,0.0002002678,0.000027890064,0.000113110254],"genre_scores_gemma":[0.99643415,0.0004720495,0.00071648485,0.00067316403,0.000012720621,0.0013441545,0.00015505767,0.000036284193,0.00015593169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970812,0.00070407934,0.00077289005,0.000514662,0.00062553235,0.0003015892],"domain_scores_gemma":[0.9977794,0.00012757619,0.00084282213,0.0004854306,0.0006839429,0.00008082612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008017134,0.0002746041,0.0008783689,0.0004995425,0.00022261922,0.000015606001,0.00014426779,0.000048767102,0.00016695018],"category_scores_gemma":[0.000030113033,0.00017920528,0.00008345306,0.0016361882,0.000306084,0.00016717825,0.00004832445,0.00027423454,3.5098455e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038652346,0.011774819,0.88832104,0.00015125165,0.0074433694,0.00016821262,0.017395362,0.019378645,0.0028514916,0.00006948228,0.00016650699,0.013627477],"study_design_scores_gemma":[0.024935747,0.07200355,0.8941305,0.000103612074,0.0013614893,0.00004460909,0.0022572384,0.0005053578,0.0039964234,0.00011121166,0.00027656314,0.00027365],"about_ca_topic_score_codex":0.001674102,"about_ca_topic_score_gemma":0.013310473,"teacher_disagreement_score":0.060228735,"about_ca_system_score_codex":0.00023560024,"about_ca_system_score_gemma":0.0005385209,"threshold_uncertainty_score":0.74275565},"labels":[],"label_agreement":null},{"id":"W4310755787","doi":"10.1016/j.annonc.2022.10.214","title":"178O Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Ovarian cancer; Internal medicine; Oncology; Disease; Gynecology; Cancer","score_opus":0.05208790311417248,"score_gpt":0.3768303549252736,"score_spread":0.3247424518111011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310755787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087954,0.00037423655,0.0000683631,0.005072329,0.00032327962,0.0025699656,0.000351494,0.000035225385,0.00032559672],"genre_scores_gemma":[0.9923037,0.00018306887,0.00019316598,0.003755494,0.00009072823,0.0032490634,0.000053791147,0.00004840788,0.0001225567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743,0.00037559326,0.0006669044,0.000568543,0.00046062647,0.0004983033],"domain_scores_gemma":[0.9980128,0.0003589428,0.0005617826,0.0005891723,0.0002004547,0.00027688223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007758649,0.000294615,0.0007298008,0.00023662871,0.00030876423,0.000014276427,0.00026023257,0.00005089908,0.00021089557],"category_scores_gemma":[0.000119709,0.00020688659,0.0001162643,0.00060701754,0.000109906294,0.00009361243,0.00012500123,0.00035491327,0.0000066206094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028827192,0.010304994,0.86653256,0.000015071255,0.0004871004,0.0003231807,0.016875353,0.009321511,0.00006823427,0.0005052426,0.00095696806,0.065782584],"study_design_scores_gemma":[0.15948562,0.07635671,0.71826005,0.00032990138,0.0006972327,0.000019668547,0.021726025,0.0007524682,0.00052527623,0.00079007127,0.020319482,0.000737494],"about_ca_topic_score_codex":0.0067151776,"about_ca_topic_score_gemma":0.0032637208,"teacher_disagreement_score":0.14827253,"about_ca_system_score_codex":0.0008877765,"about_ca_system_score_gemma":0.0006909143,"threshold_uncertainty_score":0.9998992},"labels":[],"label_agreement":null},{"id":"W4310962312","doi":"10.1038/s41416-022-02022-y","title":"Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10","year":2022,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency","funders":"EMD Serono; Genentech; Foundation Medicine; Sierra Oncology; PharmaMar; Newcastle University; MacroGenics; Relay Therapeutics; NGM Biopharmaceuticals; Loxo Oncology; Ribon Therapeutics; Mersana Therapeutics; Eisai; Adaptive Biotechnologies; Pharmacyclics; Agios Pharmaceuticals; Syndax Pharmaceuticals; BeiGene; Mirati Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; TG Therapeutics; Moderna; NuCana; Pfizer; HCA Healthcare; Incyte; Taiho Pharmaceutical; Merck KGaA; Array BioPharma; Revolution Medicines; Exelixis; GlaxoSmithKline; Verastem Oncology; Jounce Therapeutics; Celgene; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Ovarian cancer; BRCA mutation; Adverse effect; Oncology; Cancer; Progressive disease; Disease","score_opus":0.018940959345750533,"score_gpt":0.2929071395730326,"score_spread":0.2739661802272821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310962312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923923,0.0047712727,0.0000044448348,0.0005166216,0.000265313,0.0007439067,0.0011304668,0.00000741442,0.00016823472],"genre_scores_gemma":[0.9974038,0.0017080194,0.00015973498,0.00014126766,0.00015874024,0.000078233075,0.00004789436,0.000028056544,0.00027427205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784803,0.00018268419,0.000837963,0.00025852112,0.00067138823,0.0002013876],"domain_scores_gemma":[0.99868214,0.00010286879,0.0006573106,0.00016055802,0.00026261137,0.00013453496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000295263,0.00015466509,0.00058908423,0.00014453326,0.00011075537,0.000019227966,0.00010090302,0.00003867559,0.0011095944],"category_scores_gemma":[0.000037040118,0.00014993596,0.00006450923,0.00030264514,0.0000765785,0.00010332839,0.000030418823,0.0003566218,4.0196016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14572382,0.00539763,0.6170193,0.000028094955,0.0013871954,0.0013873938,0.004523486,0.0036314486,0.0002480602,0.000002484956,0.0026793012,0.21797179],"study_design_scores_gemma":[0.12065355,0.005275365,0.8645774,0.0007679638,0.00024789476,0.0001223832,0.00041189784,0.00001239124,0.00022270752,0.000015631413,0.0075517967,0.0001409968],"about_ca_topic_score_codex":0.0116785895,"about_ca_topic_score_gemma":0.0032076638,"teacher_disagreement_score":0.24755812,"about_ca_system_score_codex":0.00100934,"about_ca_system_score_gemma":0.00067651493,"threshold_uncertainty_score":0.99980354},"labels":[],"label_agreement":null},{"id":"W4311356946","doi":"10.3390/pharmaceutics14122795","title":"Repurposing Antimalarial Pyronaridine as a DNA Repair Inhibitor to Exploit the Full Potential of Gold-Nanoparticle-Mediated Radiation Response","year":2022,"lang":"en","type":"article","venue":"Pharmaceutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia; University of Alberta; University of Victoria","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Kuwait Foundation for the Advancement of Sciences; Alberta Cancer Foundation; NanoMedicines Innovation Network","keywords":"HeLa; DNA damage; Cancer research; Repurposing; DNA repair; Chemistry; Drug; Pharmacology; DNA; Cell; Medicine; Biology; Biochemistry","score_opus":0.03552928453907052,"score_gpt":0.34187009503625954,"score_spread":0.30634081049718903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311356946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852361,0.000978741,0.00013711784,0.010751475,0.001310426,0.0011494153,0.00010626673,0.00022050903,0.000109960056],"genre_scores_gemma":[0.9940809,0.00011909203,0.0003471283,0.004116749,0.00064959726,0.00021383652,0.00004749244,0.00005493252,0.000370248],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997253,0.0005605815,0.0006097391,0.00036098194,0.0008401266,0.00037557262],"domain_scores_gemma":[0.99853486,0.00034339985,0.00024739932,0.0004787791,0.0001705953,0.00022494988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015866084,0.00019320092,0.00029913522,0.00020446721,0.0002647683,0.000020617257,0.00018093715,0.000054868586,0.0007266247],"category_scores_gemma":[0.0005421236,0.0001768612,0.00018570665,0.0008026015,0.00010806525,0.00010994831,0.00018431216,0.0004219624,0.000052398686],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027716445,0.0003464881,0.0005259256,0.000030312329,0.00013199897,0.000102844235,0.0015025827,0.0016856582,0.9535465,0.000048164493,0.011417329,0.0029457235],"study_design_scores_gemma":[0.0066026724,0.0015069928,0.0008868137,0.00004339082,0.0002695459,0.0002859531,0.00052740786,0.013124186,0.6858293,0.000045509372,0.29065245,0.00022579834],"about_ca_topic_score_codex":0.000019960338,"about_ca_topic_score_gemma":5.9595095e-7,"teacher_disagreement_score":0.27923512,"about_ca_system_score_codex":0.00040322833,"about_ca_system_score_gemma":0.00036663967,"threshold_uncertainty_score":0.7956031},"labels":[],"label_agreement":null},{"id":"W4311361627","doi":"10.1038/s41598-022-25405-w","title":"Role of poly(ADP-ribose) polymerase-1 in regulating human islet cell differentiation","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Université Laval; University of Alberta","funders":"Department of Biotechnology, Ministry of Science and Technology, India; Université Laval","keywords":"Poly ADP ribose polymerase; Polymerase; Islet; Cell biology; Cellular differentiation; Biology; Biochemistry; Diabetes mellitus; Enzyme; Gene; Endocrinology","score_opus":0.014153529540827256,"score_gpt":0.27480968109381104,"score_spread":0.2606561515529838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311361627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228245,0.0007392165,0.00002381173,0.00021570406,0.0017570356,0.00034198884,0.000009322843,0.000045473673,0.00458501],"genre_scores_gemma":[0.9951374,0.0000010183411,0.00013542495,0.000051358922,0.000111636386,0.000062370644,0.00021971337,0.00002068888,0.0042603714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976108,0.000092201226,0.0007130961,0.0005237333,0.0008086759,0.00025147418],"domain_scores_gemma":[0.9985974,0.000020400117,0.00053391256,0.0006963238,0.00007716252,0.00007479773],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009952302,0.00011527257,0.000252079,0.00041084128,0.0003283861,0.00003350198,0.00007966746,0.000037591384,0.0017073542],"category_scores_gemma":[0.000026826528,0.00012241937,0.00010320432,0.00070930546,0.00011952441,0.000088232206,0.000087344124,0.00019245749,0.0000031002232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002884289,0.00025019306,0.035335068,0.000032651267,0.000008261414,0.000058706017,0.0010473564,0.00006549216,0.95951927,0.000067681925,0.0025363103,0.001050189],"study_design_scores_gemma":[0.0009366774,0.00011140611,0.025238838,0.0000694715,0.000023302651,0.00016260926,0.0007678817,0.00030376014,0.9600011,0.0048396857,0.0073872255,0.000158013],"about_ca_topic_score_codex":0.00015890613,"about_ca_topic_score_gemma":0.00001311343,"teacher_disagreement_score":0.01009623,"about_ca_system_score_codex":0.00021518386,"about_ca_system_score_gemma":0.00015700668,"threshold_uncertainty_score":0.99920523},"labels":[],"label_agreement":null},{"id":"W4311933686","doi":"10.1016/j.chembiol.2022.11.012","title":"Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling","year":2022,"lang":"en","type":"article","venue":"Cell chemical biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health","keywords":"Regulator; Biology; Interferon; Innate immune system; Signal transduction; Function (biology); Cell biology; Gene; Immune system; Embryonic stem cell; Biochemistry; Immunology","score_opus":0.014421896227398737,"score_gpt":0.25101741208670847,"score_spread":0.23659551585930974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311933686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969156,0.0013899643,0.00015677039,0.00073609775,0.00019733787,0.0002863112,0.000002009312,0.000033828026,0.0002821117],"genre_scores_gemma":[0.99854106,0.000013076556,0.0006436037,0.000421363,0.0002701077,0.000012054442,0.000047193957,0.00001898089,0.00003254189],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872226,0.00013791973,0.0004435933,0.00034356536,0.00013694324,0.00021573294],"domain_scores_gemma":[0.9992517,0.00021845734,0.00020807693,0.00020061854,0.000039330025,0.00008177712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018183446,0.00015400411,0.00030611918,0.000080269696,0.00011734774,0.0000071828413,0.00008228923,0.0001074252,0.0001077194],"category_scores_gemma":[0.00009464275,0.0001142806,0.000059685735,0.00026801758,0.00023200287,0.000034659806,0.00013577843,0.00041346284,0.0000011070689],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040992853,0.000019856896,0.0033659742,0.00004854563,0.00001586631,0.0000035939186,0.0016614432,0.000027311913,0.97472167,0.00008854525,0.00013433627,0.0195029],"study_design_scores_gemma":[0.0019275312,0.0003100889,0.0011548591,0.00006790966,0.000037706795,0.000027802465,0.000721595,0.0006357479,0.9832386,0.008487653,0.003229426,0.00016108369],"about_ca_topic_score_codex":0.00019999863,"about_ca_topic_score_gemma":0.000020834455,"teacher_disagreement_score":0.019341817,"about_ca_system_score_codex":0.0001694077,"about_ca_system_score_gemma":0.0001065896,"threshold_uncertainty_score":0.46602276},"labels":[],"label_agreement":null},{"id":"W4312018465","doi":"10.1016/j.chembiol.2022.11.006","title":"Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitors","year":2022,"lang":"en","type":"article","venue":"Cell chemical biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of Neurological Disorders and Stroke; Biocenter Finland; Canadian Institutes of Health Research; CSC – IT Center for Science; Sigrid Juséliuksen Säätiö; Magyar Tudományos Akadémia; Oregon Health and Science University; AstraZeneca; St. Baldrick's Foundation; Sarcoma Foundation of America; National Institutes of Health; Pew Charitable Trusts","keywords":"Allosteric regulation; Cytotoxicity; Poly ADP ribose polymerase; NAD+ kinase; PARP inhibitor; DNA; Chemistry; DNA replication; Binding site; Biochemistry; Biology; Cell biology; Stereochemistry; In vitro; Enzyme; Polymerase","score_opus":0.015757984114153516,"score_gpt":0.26143367165474296,"score_spread":0.24567568754058944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312018465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980599,0.0002314978,0.00004506713,0.0006371582,0.000058668713,0.0002610498,0.000051827425,0.000016395552,0.00063838117],"genre_scores_gemma":[0.99900526,0.000010617816,0.0004813569,0.00022826875,0.00005848455,0.000038512877,0.00009048957,0.000010316092,0.00007670641],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990286,0.00013771022,0.00031784663,0.00022701982,0.00013983916,0.00014898802],"domain_scores_gemma":[0.99915946,0.0002789086,0.00024290443,0.00021743386,0.00005369183,0.0000475864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026616585,0.000099995144,0.00027088184,0.00006530017,0.000055548113,0.00000160531,0.000100121106,0.00008628609,0.0005302583],"category_scores_gemma":[0.000056102086,0.000077429744,0.00006454369,0.00021061243,0.00040997326,0.000018095618,0.00009112103,0.00018294931,0.000003927744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032015055,0.00007019094,0.009820894,0.00004664702,0.000012728569,0.000001486165,0.00011952547,0.0000110211,0.98894787,0.000037661586,0.0005475105,0.000064296],"study_design_scores_gemma":[0.0009726846,0.0002763161,0.001772606,0.00003048689,0.000020171527,0.000015339603,0.00004353155,0.00024954905,0.9957506,0.00050733995,0.00028965817,0.00007170995],"about_ca_topic_score_codex":0.000009177726,"about_ca_topic_score_gemma":9.784846e-8,"teacher_disagreement_score":0.008048288,"about_ca_system_score_codex":0.00008021801,"about_ca_system_score_gemma":0.00007109358,"threshold_uncertainty_score":0.5805957},"labels":[],"label_agreement":null},{"id":"W4312139724","doi":"10.1136/ijgc-2022-igcs.5","title":"O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Placebo; Clinical endpoint; Oncology; Population; Discontinuation; Randomized controlled trial","score_opus":0.07927624418906286,"score_gpt":0.40390224494664057,"score_spread":0.3246260007575777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312139724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864944,0.00023260507,0.0019070092,0.011621929,0.0040308046,0.0026506723,0.00075152126,0.000020074138,0.00013595364],"genre_scores_gemma":[0.9939981,0.00001605175,0.0016058531,0.0025139218,0.0007326587,0.000821178,0.000079527876,0.000034632663,0.0001980762],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99526656,0.0007276462,0.0016835559,0.0004319923,0.001601275,0.0002889555],"domain_scores_gemma":[0.992931,0.004477536,0.0012454609,0.00025452967,0.0008478074,0.00024364215],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036719183,0.0002795612,0.0011960757,0.00041719284,0.00014012416,0.000048155973,0.00053686334,0.00010443114,0.0017347194],"category_scores_gemma":[0.001543758,0.00022817863,0.0006614626,0.0002381625,0.00007389417,0.00009230619,0.000092177244,0.00055929105,0.0000013815076],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9768022,0.0033973062,0.0020658358,0.000005903937,0.0012276114,0.00023798943,0.002033949,0.004423882,0.005397394,0.000056910598,0.0016634332,0.0026876307],"study_design_scores_gemma":[0.9662048,0.012179393,0.0061246357,0.00012163341,0.0003055056,0.000022940487,0.0006332494,0.0011694584,0.0032128277,0.00036058066,0.009405423,0.00025953804],"about_ca_topic_score_codex":0.00032763655,"about_ca_topic_score_gemma":0.00010342078,"teacher_disagreement_score":0.015348669,"about_ca_system_score_codex":0.0013953567,"about_ca_system_score_gemma":0.0010129324,"threshold_uncertainty_score":0.9991778},"labels":[],"label_agreement":null},{"id":"W4312139790","doi":"10.1136/ijgc-2022-igcs.354","title":"EP263/#849 Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: characterization of long-term/short-term treatment duration in light","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Manitoba; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Ovarian cancer; Oncology; Internal medicine; BRCA mutation; Chemotherapy; Paclitaxel; Cancer; Biology","score_opus":0.014314468246697822,"score_gpt":0.29310357414764676,"score_spread":0.27878910590094896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312139790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966475,0.0002249569,0.00016069038,0.0013266862,0.00053787115,0.0007393412,0.00027591892,0.000009081507,0.000077956814],"genre_scores_gemma":[0.9978495,0.0010102727,0.00008371181,0.0001724227,0.00006372886,0.00026869445,0.00046171734,0.000016922952,0.000073001516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978806,0.00020249917,0.0008286454,0.00027832264,0.00060511066,0.00020483711],"domain_scores_gemma":[0.99841756,0.00013372926,0.0007688439,0.0000831298,0.00051437336,0.000082340965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020353094,0.00019993438,0.0004241095,0.00040124214,0.00006693209,0.000023576711,0.00008436752,0.00009180736,0.0005111646],"category_scores_gemma":[0.000051581388,0.00015491605,0.00006794035,0.00026024348,0.00006693533,0.00028427973,0.000024517443,0.00021272371,4.4232678e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047817435,0.0023577316,0.9197463,0.00001318774,0.00019118059,0.00026395413,0.0017981795,0.0005085537,0.0140411705,0.000035427085,0.000013716629,0.056248873],"study_design_scores_gemma":[0.012721741,0.0052698255,0.97339743,0.00013936928,0.0000712761,0.0000708604,0.000103457875,0.00013458615,0.007819147,0.00003664123,0.00009274046,0.0001429018],"about_ca_topic_score_codex":0.00022443001,"about_ca_topic_score_gemma":0.00044403897,"teacher_disagreement_score":0.05610597,"about_ca_system_score_codex":0.0047661085,"about_ca_system_score_gemma":0.00038121274,"threshold_uncertainty_score":0.99905443},"labels":[],"label_agreement":null},{"id":"W4312907710","doi":"10.2139/ssrn.4291221","title":"Identification of Differential Polypharmacology Between the PARP Inhibitor Rucaparib and Its Major Metabolite","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Identification (biology); Poly ADP ribose polymerase; Metabolite; PARP inhibitor; Computational biology; Pharmacology; Chemistry; Biology; Biochemistry","score_opus":0.01299021670264738,"score_gpt":0.29695224550435234,"score_spread":0.28396202880170496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312907710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833417,0.0108951535,0.0008704052,0.0040347315,0.00045512477,0.00031435635,0.00004076103,0.000014759252,0.000033009554],"genre_scores_gemma":[0.99556446,0.0024174554,0.0000051970646,0.00022115897,0.0008931919,0.00005208401,0.000017538554,0.000022471268,0.00080643286],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978397,0.000287695,0.0004798831,0.00017846037,0.000400398,0.0008139012],"domain_scores_gemma":[0.9992566,0.000065190594,0.0003638839,0.00014418598,0.00009252279,0.00007759907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013740801,0.000121819765,0.0002666515,0.00014428051,0.00037945286,0.000016265216,0.00016967,0.00004108144,0.00022324664],"category_scores_gemma":[0.00002701887,0.00009407327,0.00010921385,0.00021082413,0.00008037292,0.00006211197,0.00007064505,0.0015113202,0.000003997889],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010411218,0.00021664142,0.010618962,0.00003163115,0.0012326704,0.0000049061605,0.00054921,0.000015324284,0.9439211,0.03203452,0.0005192366,0.009814661],"study_design_scores_gemma":[0.027712146,0.0042990064,0.13150635,0.00005810931,0.0036855335,0.0059673456,0.0054471,0.0005468443,0.6719306,0.1274186,0.020552691,0.0008756865],"about_ca_topic_score_codex":0.000011018579,"about_ca_topic_score_gemma":0.0000056287477,"teacher_disagreement_score":0.27199054,"about_ca_system_score_codex":0.00039896896,"about_ca_system_score_gemma":0.0009007214,"threshold_uncertainty_score":0.65660185},"labels":[],"label_agreement":null},{"id":"W4313147584","doi":"10.1136/ijgc-2022-esgo.488","title":"2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Placebo; Oncology; Regimen; Population; Chemotherapy regimen; Chemotherapy; Clinical trial","score_opus":0.07666200252183013,"score_gpt":0.3994733332075067,"score_spread":0.3228113306856766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313147584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803863,0.00022120151,0.0014902633,0.010107909,0.0042451,0.0024265163,0.0009733214,0.000020262813,0.00012912341],"genre_scores_gemma":[0.9945088,0.000019834317,0.001114909,0.0023890322,0.0008398087,0.00073846465,0.00010216091,0.00003809339,0.00024888953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99539125,0.00053092936,0.0015903467,0.00047565778,0.0016941291,0.00031769247],"domain_scores_gemma":[0.99429977,0.0031747606,0.0011596396,0.0002869412,0.0008046631,0.00027424656],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027922536,0.00029222385,0.0009351047,0.0004235514,0.00016191408,0.00005012625,0.00059657084,0.00011163123,0.00234019],"category_scores_gemma":[0.0011027787,0.00024978825,0.0005611453,0.00027091024,0.000052786338,0.000101447455,0.000100422156,0.0006244863,0.0000015862147],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9620987,0.0038616934,0.0032992223,0.000007398974,0.0012041002,0.0003141668,0.0018569824,0.0042938143,0.015337437,0.000021622287,0.0033681854,0.0043366533],"study_design_scores_gemma":[0.92818755,0.021568432,0.01735991,0.00015683775,0.0003193593,0.000034012246,0.001032107,0.0011986801,0.00775807,0.0002772315,0.021734519,0.00037327866],"about_ca_topic_score_codex":0.0002524199,"about_ca_topic_score_gemma":0.00014467414,"teacher_disagreement_score":0.03391116,"about_ca_system_score_codex":0.001559697,"about_ca_system_score_gemma":0.0011181871,"threshold_uncertainty_score":0.9999954},"labels":[],"label_agreement":null},{"id":"W4316041109","doi":"10.1101/2023.01.12.23284477","title":"The Impact of Homologous Recombination Deficiency on First-line Adjuvant Chemotherapy and First-line PARPi Maintenance Therapy in Chinese Patients with Epithelial Ovarian Cancer","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Oncology; Maintenance therapy; Cohort; Ovarian cancer; Homologous recombination; Epithelial ovarian cancer; Cancer; DNA; Biology","score_opus":0.024846202195807254,"score_gpt":0.31737267960333926,"score_spread":0.292526477407532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316041109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932123,0.0013499979,0.00021711338,0.005583722,0.0007212977,0.002226147,0.00036289752,0.0000979052,0.0001197151],"genre_scores_gemma":[0.9705851,0.027763445,0.00008259743,0.00023069615,0.00021598095,0.00064830016,0.00013325464,0.00012891293,0.00021171913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969629,0.00015224231,0.00084834686,0.0008447639,0.0006359458,0.00055578875],"domain_scores_gemma":[0.9973142,0.0004263245,0.00073526293,0.00094918016,0.0004314796,0.0001435189],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000835833,0.00062591006,0.00097439747,0.00034033356,0.0002088203,0.000038539125,0.0003612987,0.00032462287,0.000103098464],"category_scores_gemma":[0.00022236873,0.00034800076,0.00023460644,0.00063094264,0.0003432174,0.00006386522,0.00010109079,0.0008680505,0.00000691582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007625269,0.0012038836,0.9485651,0.00020836211,0.00029303247,0.000032526787,0.0013233821,0.0074103014,0.00014959503,0.000039337934,0.00024025758,0.03290895],"study_design_scores_gemma":[0.013842218,0.0029534237,0.97588193,0.0014400752,0.000028345676,0.000007779538,0.000014451665,0.0014804443,0.0005889381,0.0032017932,0.00018504247,0.0003755806],"about_ca_topic_score_codex":0.0021807274,"about_ca_topic_score_gemma":0.0016043665,"teacher_disagreement_score":0.03253337,"about_ca_system_score_codex":0.0005908783,"about_ca_system_score_gemma":0.0003217576,"threshold_uncertainty_score":0.9998972},"labels":[],"label_agreement":null},{"id":"W4316804884","doi":"10.1038/s41467-023-35880-y","title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"National Cancer Institute; U.S. Department of Health and Human Services; U.S. Department of Defense","keywords":"CRISPR; PARP inhibitor; RAD51; Prostate cancer; Biology; Cancer research; Poly ADP ribose polymerase; DNA repair; Synthetic lethality; DNA damage; Homologous recombination; Genome editing; Cancer; Genetics; Gene; DNA","score_opus":0.033391693771538,"score_gpt":0.3740719636274361,"score_spread":0.3406802698558981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316804884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789823,0.012803161,0.000004891371,0.006797656,0.00008209944,0.0005063269,0.0001629181,0.00006215081,0.00059848814],"genre_scores_gemma":[0.9877498,0.0075223437,0.0038522622,0.00037676768,0.000043663444,0.00012068954,0.000031319465,0.000020124644,0.00028303318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896383,0.00017356897,0.00030711846,0.00019437516,0.00018034353,0.00018075804],"domain_scores_gemma":[0.9984308,0.00022347615,0.00010951682,0.0009836537,0.00018582927,0.00006675649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033745187,0.0001068796,0.00025703802,0.00017572774,0.00009575901,0.0000069238286,0.00013284943,0.00014357094,0.0000045042134],"category_scores_gemma":[0.00015621817,0.00010620012,0.00003733904,0.0006692654,0.0002088718,0.000056858258,0.00013254273,0.0005714242,0.0000037927255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045213138,0.00022502293,0.94109607,0.00034416368,0.000054879216,0.00007755562,0.0021188199,0.000023557393,0.0359724,0.0006125653,0.012471782,0.0065510534],"study_design_scores_gemma":[0.0014461381,0.000042546464,0.98240095,0.00086196855,0.000036230438,0.000019045627,0.0001678224,0.0011795133,0.0058639264,0.0004354455,0.0073939883,0.00015240366],"about_ca_topic_score_codex":0.00023482644,"about_ca_topic_score_gemma":0.018604208,"teacher_disagreement_score":0.041304905,"about_ca_system_score_codex":0.00008526372,"about_ca_system_score_gemma":0.00013539888,"threshold_uncertainty_score":0.9993037},"labels":[],"label_agreement":null},{"id":"W4318672091","doi":"10.1002/cncr.34662","title":"A phase 1 dose‐escalation study of the poly(ADP‐ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Nausea; Internal medicine; PARP inhibitor; Toxicity; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Phases of clinical research; Surgery; Poly ADP ribose polymerase","score_opus":0.02478210772695709,"score_gpt":0.3547496842867705,"score_spread":0.3299675765598134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318672091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966754,0.0000858587,0.0000034193783,0.0010740439,0.00042776144,0.0014568889,0.00010772024,0.00006717511,0.00010175875],"genre_scores_gemma":[0.9984534,0.000014625003,0.00001634913,0.00028769873,0.00022259144,0.00035173577,0.00004262258,0.000040174058,0.0005708189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832445,0.00007590526,0.00044118855,0.0003315152,0.00050481525,0.00032214978],"domain_scores_gemma":[0.99907726,0.00003419399,0.00022966493,0.0004129687,0.00013434573,0.00011153979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113052236,0.00019680806,0.00035505238,0.00018847489,0.000073002964,0.000009588051,0.00010745606,0.00006212617,0.00016737756],"category_scores_gemma":[0.000027753797,0.00013725187,0.000059207094,0.0012070927,0.00010326143,0.00013170489,0.00003391696,0.00022827007,0.00001083086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006651994,0.00642967,0.8826432,0.00018739005,0.00022732036,0.000058184734,0.00874874,0.001129596,0.053525977,0.000016020402,0.004712405,0.03566949],"study_design_scores_gemma":[0.053264327,0.0027806798,0.8521055,0.0010273776,0.00009696294,0.000002884917,0.0017619175,0.00017640683,0.08726578,0.000025672378,0.0011769716,0.00031548986],"about_ca_topic_score_codex":0.0002977533,"about_ca_topic_score_gemma":0.00025968015,"teacher_disagreement_score":0.046612334,"about_ca_system_score_codex":0.00029717927,"about_ca_system_score_gemma":0.00022751144,"threshold_uncertainty_score":0.5596969},"labels":[],"label_agreement":null},{"id":"W4320486696","doi":"10.1158/1535-7163.mct-22-0583","title":"A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Institute, University of Pittsburgh; Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; University of Texas MD Anderson Cancer Center; Pfizer; Yale Cancer Center; Merck KGaA; Princess Margaret Cancer Foundation; Johns Hopkins University; Dana-Farber/Harvard Cancer Center; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Regeneron Pharmaceuticals; California Space Grant Consortium","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Radium-223; Cancer; Adverse effect; Urology; Bone metastasis","score_opus":0.047131900191674674,"score_gpt":0.35707104660009653,"score_spread":0.30993914640842185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320486696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199307,0.0036998743,0.00030270868,0.0014295783,0.000038161863,0.0022293646,0.00015330498,0.00007125553,0.00008265637],"genre_scores_gemma":[0.9969482,0.0010003697,0.0003400525,0.00041651158,0.000016548864,0.0010095594,0.00006582576,0.00007689388,0.00012608375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997835,0.00019254943,0.00049228244,0.00044927985,0.0006759643,0.00035491664],"domain_scores_gemma":[0.9989492,0.000062502164,0.00028444943,0.00035765563,0.00023481523,0.00011135317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031005434,0.00031434992,0.00061212137,0.00035332356,0.00008014023,0.000036762565,0.00008225703,0.000044908815,0.000036103986],"category_scores_gemma":[0.0000045742454,0.00024470902,0.000041624382,0.0012208351,0.0001805748,0.0001269743,0.000021247011,0.00022034271,0.0000010757985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027523374,0.013462672,0.037682947,0.0012565348,0.006427654,0.0024822475,0.029333066,0.005162602,0.8345515,0.00067445484,0.00023118457,0.04121173],"study_design_scores_gemma":[0.34908846,0.038577076,0.058554705,0.0027744356,0.006944751,0.00024564136,0.024437418,0.016215647,0.49555036,0.00094636116,0.0044247694,0.002240392],"about_ca_topic_score_codex":0.0013182816,"about_ca_topic_score_gemma":0.0014761483,"teacher_disagreement_score":0.33900118,"about_ca_system_score_codex":0.00023411441,"about_ca_system_score_gemma":0.00039509404,"threshold_uncertainty_score":0.99789447},"labels":[],"label_agreement":null},{"id":"W4321004823","doi":"10.1093/nar/gkad066","title":"PARP1 associates with R-loops to promote their resolution and genome stability","year":2023,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Université Laval","funders":"National Institute of Environmental Health Sciences; National Heart, Lung, and Blood Institute; Masonic Cancer Center, University of Minnesota; Université Pierre et Marie Curie; National Institutes of Health; National Center for Advancing Translational Sciences; Thomas Jefferson University; National Institute of General Medical Sciences; Merck","keywords":"Biology; PARP1; Genome instability; DNA; ADP-ribosylation; Nucleic acid; DNA damage; Poly ADP ribose polymerase; Cell biology; Molecular biology; Genetics; Biochemistry; Polymerase; Enzyme; NAD+ kinase","score_opus":0.11052310989167333,"score_gpt":0.38469265768529676,"score_spread":0.27416954779362346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321004823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852352,0.00016838589,0.000050475497,0.009635836,0.00003196169,0.0010952802,0.000057737056,0.00022644976,0.003498651],"genre_scores_gemma":[0.9970567,0.00020385806,0.000663649,0.00022540934,0.00017946094,0.00020529164,0.000036236634,0.0000469048,0.0013824421],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974733,0.00024518036,0.00020591677,0.0004888815,0.0009045268,0.00068218616],"domain_scores_gemma":[0.9984762,0.00019638657,0.00003187327,0.0004983462,0.0004692679,0.0003279102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002704017,0.00013915452,0.00026062806,0.0002976339,0.00029953194,0.00005803653,0.00013824186,0.00011685704,0.00032142908],"category_scores_gemma":[0.00034227583,0.000104715,0.000037026646,0.0014641983,0.00030156234,0.00009722868,0.00015611677,0.0005143849,0.0003397898],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003700545,0.00044241938,0.11019928,0.00045719952,0.00029287863,0.00014817677,0.013435397,0.000021105456,0.8339528,0.0005376003,0.013255262,0.023557337],"study_design_scores_gemma":[0.004018807,0.0036707176,0.8271796,0.0003783072,0.00002333929,0.00005218912,0.002973072,0.0008138059,0.046089042,0.002805756,0.11158798,0.00040735476],"about_ca_topic_score_codex":0.00007122954,"about_ca_topic_score_gemma":0.000032430966,"teacher_disagreement_score":0.78786373,"about_ca_system_score_codex":0.0004522384,"about_ca_system_score_gemma":0.00021521813,"threshold_uncertainty_score":0.4367424},"labels":[],"label_agreement":null},{"id":"W4321786013","doi":"10.1038/s41598-023-28424-3","title":"Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer","year":2023,"lang":"en","type":"article","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; U.S. Department of Defense; University of Toronto; NanoMedicines Innovation Network","keywords":"Doxorubicin; Serous fluid; Serous ovarian cancer; Folate receptor; Ovarian cancer; Cancer research; Medicine; Oncology; Cancer; Internal medicine; Chemotherapy; Cancer cell","score_opus":0.02744745387514204,"score_gpt":0.31217936999095386,"score_spread":0.28473191611581183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321786013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898806,0.0015207554,0.00008170195,0.0024855696,0.004642468,0.001210177,0.00005743528,0.00010033477,0.000020908687],"genre_scores_gemma":[0.9960206,0.00038645245,0.00024507474,0.00008936412,0.00017262062,0.00044051075,0.00012485182,0.00002717615,0.002493342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816823,0.00004065152,0.0004997698,0.0005471907,0.00037407537,0.0003700534],"domain_scores_gemma":[0.9987654,0.00008767846,0.00031328306,0.00051521335,0.00018134236,0.00013709094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006934041,0.00016375871,0.0003349992,0.0001479253,0.00040392805,0.000086125154,0.000053240325,0.000061348444,0.00016100868],"category_scores_gemma":[0.00005157929,0.000109931956,0.0001129367,0.0005418539,0.00029827052,0.00007752912,0.000019659781,0.00005195587,0.000006749405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007578026,0.00015905363,0.0046076826,0.000053039166,0.00035089496,0.00023169852,0.003098496,0.00027443992,0.9692672,0.00016527568,0.007836943,0.013197476],"study_design_scores_gemma":[0.0038754437,0.001109571,0.006706523,0.00014599207,0.00031414896,0.00024831752,0.0006409321,0.0009765748,0.9270827,0.005177989,0.053517684,0.00020413123],"about_ca_topic_score_codex":0.002034942,"about_ca_topic_score_gemma":0.00020480216,"teacher_disagreement_score":0.045680743,"about_ca_system_score_codex":0.00013598974,"about_ca_system_score_gemma":0.00029401557,"threshold_uncertainty_score":0.4482895},"labels":[],"label_agreement":null},{"id":"W4322500012","doi":"10.1038/s41598-023-30081-5","title":"Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer","year":2023,"lang":"en","type":"article","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Institute of Cancer Research; Ontario Institute for Cancer Research; Institut Du Cancer de Montréal; Génome Québec; Ovarian Cancer Canada; Cancer Research Society","keywords":"Nicotinamide phosphoribosyltransferase; Cancer research; Olaparib; PARP inhibitor; Ovarian cancer; Poly ADP ribose polymerase; NAD+ kinase; Cancer; Cancer cell; Medicine; Biology; Chemistry; Polymerase; Internal medicine; Biochemistry; Enzyme","score_opus":0.016085755878995984,"score_gpt":0.27179277436400767,"score_spread":0.2557070184850117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322500012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982507,0.0014772889,0.000028865948,0.0025687492,0.0047010253,0.0007708656,0.000089799505,0.00020990119,0.00032843702],"genre_scores_gemma":[0.99607956,0.0001231665,0.00028615008,0.00028001398,0.00030575498,0.00012579896,0.00020450554,0.000059197217,0.0025358405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960731,0.00011555601,0.0011703927,0.0011064457,0.0009368789,0.00059758057],"domain_scores_gemma":[0.99789,0.0000852958,0.0006484218,0.00090447726,0.00021317932,0.00025865127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014862269,0.00030346593,0.0005883435,0.0008295878,0.0002132831,0.00011432154,0.00008737584,0.00015311934,0.00013085263],"category_scores_gemma":[0.00017074432,0.00030273062,0.000114960414,0.0021434068,0.00068443664,0.00034544876,0.000099568446,0.00020731211,0.000013755445],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043698464,0.00022791525,0.03716663,0.0003799623,0.00005592436,0.0026064033,0.0020005524,0.000020734149,0.94030404,0.0002666591,0.014180028,0.0023541949],"study_design_scores_gemma":[0.004228693,0.00014231644,0.11700597,0.0026234202,0.000071285634,0.00027373905,0.000599967,0.00007860949,0.8598379,0.0045845117,0.009985313,0.0005682636],"about_ca_topic_score_codex":0.00073161285,"about_ca_topic_score_gemma":0.00091919897,"teacher_disagreement_score":0.0804661,"about_ca_system_score_codex":0.00043290784,"about_ca_system_score_gemma":0.00051867805,"threshold_uncertainty_score":0.9999425},"labels":[],"label_agreement":null},{"id":"W4323024632","doi":"10.1177/17588359231157644","title":"Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Cancer research; Poly ADP ribose polymerase; Internal medicine; Cancer; Pharmacology; DNA; Biology; Genetics","score_opus":0.09070451031767579,"score_gpt":0.4848637584573334,"score_spread":0.39415924813965764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323024632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025789852,0.98710847,0.000095143434,0.0027099098,0.0017878653,0.0020135513,0.00008262711,0.00016149352,0.0060151746],"genre_scores_gemma":[0.00006857803,0.99174094,0.00044474154,0.0015337495,0.0015773356,0.003060272,0.00017239405,0.00016519954,0.0012367686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939951,0.0009140983,0.0020847372,0.0010566303,0.0009179124,0.0010315616],"domain_scores_gemma":[0.9962099,0.0020342239,0.0006877125,0.0005981009,0.000109040935,0.00036100834],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001134455,0.00082050863,0.00418085,0.0007790268,0.000081916805,0.000023018247,0.00044967447,0.0014046209,0.0016082923],"category_scores_gemma":[0.00022089781,0.00061024417,0.00043379288,0.0014270241,0.000600933,0.00021481946,0.000081816695,0.0017105102,0.00014372841],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00047706926,0.00038646773,0.000019656503,0.0066284873,0.0002535174,0.0017129084,0.0005262682,0.000008037991,0.000004811979,0.0013850457,0.000083088315,0.98851466],"study_design_scores_gemma":[0.004848033,0.0008226239,0.000020251182,0.038071506,0.00036537202,0.000118133925,0.00047967336,0.0000102538215,0.0000064926976,0.002517454,0.95226127,0.00047893095],"about_ca_topic_score_codex":0.00016541108,"about_ca_topic_score_gemma":0.0063160756,"teacher_disagreement_score":0.98803574,"about_ca_system_score_codex":0.0049055903,"about_ca_system_score_gemma":0.008329125,"threshold_uncertainty_score":0.99989176},"labels":[],"label_agreement":null},{"id":"W4323312607","doi":"10.3390/cimb45030135","title":"The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer","year":2023,"lang":"en","type":"review","venue":"Current Issues in Molecular Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Sault Area Hospital","funders":"","keywords":"Pancreatic cancer; BRCA2 Protein; Cancer research; Gene; DNA repair; Biology; RAD51; PARP inhibitor; Germline mutation; Somatic cell; Ovarian cancer; Cancer; Mutation; Prostate cancer; Homologous recombination; Genetics; Poly ADP ribose polymerase; Polymerase","score_opus":0.06945523662706116,"score_gpt":0.4431509062315858,"score_spread":0.37369566960452466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323312607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027412925,0.9711342,0.000018237997,0.00023769084,0.00027348826,0.00082202465,0.00005883084,0.00002061099,0.000021984815],"genre_scores_gemma":[0.0008508171,0.9984242,0.00005370689,0.00007602762,0.00010998999,0.0003312848,0.00003637152,0.00006077401,0.00005685498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973912,0.0010771836,0.00066331576,0.00044397547,0.00010843924,0.00031584958],"domain_scores_gemma":[0.99864036,0.00065510627,0.00027309507,0.00034367814,0.00003672013,0.00005105508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010304766,0.00031591777,0.0012604559,0.00030929773,0.00003822857,0.000012799005,0.00015705706,0.00024757648,0.000028488348],"category_scores_gemma":[0.00017918271,0.00020926783,0.00011048343,0.00039165228,0.00034497434,0.000009714218,0.000098338365,0.0003772295,0.000003991019],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005633163,0.00009941314,0.012888786,0.01318113,0.00048598376,0.0000673942,0.0008534146,0.0000027135648,0.003854315,0.00082051125,0.00015837437,0.9670246],"study_design_scores_gemma":[0.0009992088,0.00017441553,0.0004437953,0.013247431,0.00024366727,0.000021361695,0.00008112436,0.000033687156,0.00019285546,0.00048361538,0.9838218,0.00025700137],"about_ca_topic_score_codex":0.000054845237,"about_ca_topic_score_gemma":0.000033561006,"teacher_disagreement_score":0.98366344,"about_ca_system_score_codex":0.00007222066,"about_ca_system_score_gemma":0.00017293196,"threshold_uncertainty_score":0.8533695},"labels":[],"label_agreement":null},{"id":"W4323347677","doi":"10.1136/ijgc-2022-003698","title":"Overcoming PARP inhibitor resistance in ovarian cancer","year":2023,"lang":"en","type":"review","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; DNA repair; Ovarian cancer; Synthetic lethality; Homologous recombination; Chemotherapy; Drug resistance; Epigenetics; Cancer research; Dosing; Cancer; Bioinformatics; Pharmacology; Internal medicine; DNA; Genetics; Biology; Gene","score_opus":0.13180094881557272,"score_gpt":0.4535494446225136,"score_spread":0.32174849580694087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323347677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032525058,0.9892797,0.000032182965,0.0026365211,0.005853209,0.00052359834,0.00021290797,0.00003251775,0.0011041423],"genre_scores_gemma":[0.0004158822,0.99206805,0.0004051465,0.00095423864,0.0038655465,0.0003148239,0.000021406626,0.00007650578,0.0018783684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958621,0.00021053075,0.0019611502,0.00041851684,0.0011550772,0.00039257438],"domain_scores_gemma":[0.9963068,0.00089616945,0.0016527445,0.00020716862,0.00071917794,0.00021797296],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007779558,0.0004250746,0.0021147316,0.00075789355,0.000040280698,0.00006212613,0.000644328,0.0005127099,0.002864888],"category_scores_gemma":[0.00068139,0.00031301152,0.0008471337,0.0005915805,0.00012889685,0.00017548831,0.0001198839,0.0014440587,0.00005701094],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001775856,0.0007145509,0.0024550837,0.006609161,0.0037409489,0.007574594,0.00026480923,0.00008008997,0.000063652384,0.0012641035,0.045508627,0.9299485],"study_design_scores_gemma":[0.0021914057,0.00011848104,0.001171639,0.037878472,0.00035451562,0.00014573101,0.000014095957,0.0000023558835,0.000015652864,0.00064553914,0.9571738,0.00028827752],"about_ca_topic_score_codex":0.00007266191,"about_ca_topic_score_gemma":0.00054182636,"teacher_disagreement_score":0.92966026,"about_ca_system_score_codex":0.0040612966,"about_ca_system_score_gemma":0.0020327696,"threshold_uncertainty_score":0.99993217},"labels":[],"label_agreement":null},{"id":"W4323971781","doi":"10.1038/s41389-023-00453-7","title":"Overexpression of tripartite motif-containing 47 (TRIM47) confers sensitivity to PARP inhibition via ubiquitylation of BRCA1 in triple negative breast cancer cells","year":2023,"lang":"en","type":"article","venue":"Oncogenesis","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Education Department of Jiangxi Province; Gannan Medical University; Peking University; Natural Science Foundation of Jiangxi Province; National Natural Science Foundation of China; Sun Yat-sen University; Natural Science Foundation of Guangdong Province","keywords":"Olaparib; Triple-negative breast cancer; Cancer research; PARP inhibitor; Poly ADP ribose polymerase; Homologous recombination; Ubiquitin ligase; DNA damage; Biology; DNA repair; Breast cancer; Ubiquitin; Molecular biology; Cancer; DNA; Polymerase; Gene; Genetics","score_opus":0.03146967025083622,"score_gpt":0.32532026899415406,"score_spread":0.29385059874331787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323971781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966295,0.00004103089,0.00083185686,0.0006483031,0.00019515729,0.00080193114,0.00038842286,0.00006573236,0.00039810015],"genre_scores_gemma":[0.9989115,0.00012596889,0.00025980864,0.00025047915,0.00013136421,0.00010575715,0.000060912942,0.000035007397,0.0001192307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980123,0.0002446932,0.00062565826,0.0003687115,0.00045363634,0.00029502035],"domain_scores_gemma":[0.9986524,0.00025567072,0.0003551654,0.00026766935,0.0003267832,0.00014231232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006880718,0.00019625068,0.0005885824,0.00049168733,0.000049200033,0.0000068583818,0.000042304255,0.00015216917,0.00016182625],"category_scores_gemma":[0.0000679856,0.00020033092,0.0001347374,0.0012305994,0.00008004563,0.0001609118,0.000047442754,0.00012354454,0.000021689182],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022227794,0.00016159953,0.013561926,0.00016285197,0.000050323622,0.000017098162,0.0017407303,0.0022129805,0.9667966,0.000019234762,0.00042193694,0.012631958],"study_design_scores_gemma":[0.0039329557,0.00021612922,0.13933806,0.0011096874,0.000047533664,0.000008663293,0.00044914047,0.0019567502,0.852649,0.000065267,0.00007241583,0.00015442108],"about_ca_topic_score_codex":0.002282724,"about_ca_topic_score_gemma":0.00037173813,"teacher_disagreement_score":0.12577614,"about_ca_system_score_codex":0.0003837509,"about_ca_system_score_gemma":0.00024894704,"threshold_uncertainty_score":0.81692576},"labels":[],"label_agreement":null},{"id":"W4324136789","doi":"10.1200/jco.2023.41.6_suppl.18","title":"Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Docetaxel; Population; Progression-free survival; Interim analysis; Cancer; Randomized controlled trial; Chemotherapy; Androgen receptor","score_opus":0.2779043447976356,"score_gpt":0.49502006637751983,"score_spread":0.21711572157988424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324136789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892908,0.0013407685,0.000113956405,0.0053174854,0.0025516364,0.0010158101,0.0002326247,0.000022282335,0.000114637645],"genre_scores_gemma":[0.98837525,0.0043016486,0.002807799,0.0011939518,0.0023139252,0.000106154825,0.000055825436,0.000049030656,0.00079643313],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.995214,0.00052917347,0.0031469476,0.00032862503,0.00045798757,0.00032327135],"domain_scores_gemma":[0.9936503,0.0027053487,0.0022864158,0.00021142035,0.00081615173,0.00033037405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036841817,0.00024497721,0.0018381684,0.0002369471,0.00008250385,0.000030506884,0.000132866,0.000265687,0.00038474146],"category_scores_gemma":[0.0014472349,0.00017008274,0.00045767258,0.00026699342,0.00025228,0.00022118456,0.000031283453,0.0005361956,0.000003566575],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18051352,0.0051424936,0.0077859396,0.0007834155,0.004001401,0.00058743905,0.0026002966,0.0002850202,0.5386808,0.0009417705,0.04111544,0.21756247],"study_design_scores_gemma":[0.22705969,0.11013368,0.10041767,0.0012904727,0.0015061137,0.0007508597,0.0013048061,0.0020329836,0.1451413,0.002435411,0.40689942,0.0010275929],"about_ca_topic_score_codex":0.000032736654,"about_ca_topic_score_gemma":0.0003747955,"teacher_disagreement_score":0.3935395,"about_ca_system_score_codex":0.0001790654,"about_ca_system_score_gemma":0.0030182947,"threshold_uncertainty_score":0.6935773},"labels":[],"label_agreement":null},{"id":"W4324137014","doi":"10.1200/jco.2023.41.6_suppl.tps279","title":"TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; PARP inhibitor; Prostate cancer; Internal medicine; Placebo; Oncology; Cancer; Androgen receptor; Cancer research; Pathology; Poly ADP ribose polymerase; Genetics; Biology; Gene","score_opus":0.14805231365607274,"score_gpt":0.4902022351030057,"score_spread":0.34214992144693296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324137014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920579,0.00018666696,0.00013745685,0.001067039,0.0010353231,0.0052379277,0.00008686921,0.000032061802,0.00015874866],"genre_scores_gemma":[0.997092,0.00044898028,0.0007843924,0.0006558574,0.0003608147,0.00036094853,0.00006441378,0.00006370877,0.00016888672],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99080706,0.0018595156,0.0050354614,0.0005080255,0.0012562759,0.0005336556],"domain_scores_gemma":[0.9894305,0.0037575602,0.004384754,0.00033596088,0.0016292473,0.00046199333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0049569146,0.0004048834,0.0045392783,0.0007031952,0.000076524695,0.000023353028,0.00020557977,0.0002838746,0.00010902346],"category_scores_gemma":[0.0014470143,0.00028844672,0.0004950944,0.001012645,0.0005878513,0.00030532962,0.00006510156,0.001424761,0.000017238766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95353574,0.006647633,0.017435286,0.00008321133,0.0024519002,0.002080868,0.0044357665,0.008150993,0.00032133248,0.000013473133,0.0004298577,0.0044139656],"study_design_scores_gemma":[0.94638836,0.027068648,0.019772451,0.00042589905,0.0014918948,0.0001495914,0.0017998077,0.0011781382,0.0011664478,0.00007396875,0.00021544323,0.00026934873],"about_ca_topic_score_codex":0.0003244792,"about_ca_topic_score_gemma":0.00070485513,"teacher_disagreement_score":0.020421015,"about_ca_system_score_codex":0.00084073294,"about_ca_system_score_gemma":0.0049439543,"threshold_uncertainty_score":0.9999568},"labels":[],"label_agreement":null},{"id":"W4327967417","doi":"10.3390/cancers15061849","title":"Advances in PARP Inhibitors for Prostate Cancer","year":2023,"lang":"en","type":"review","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Pfizer Canada","keywords":"Olaparib; Medicine; Prostate cancer; Synthetic lethality; PARP inhibitor; Oncology; Population; Clinical trial; Cochrane Library; DNA repair; Internal medicine; Cancer; Bioinformatics; Poly ADP ribose polymerase; Randomized controlled trial; Biology; Polymerase; Genetics","score_opus":0.08867855785025577,"score_gpt":0.44382494532036054,"score_spread":0.35514638747010474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327967417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000049201944,0.99164677,0.000013439455,0.00015089635,0.0023113054,0.004098788,0.0006222205,0.00017821582,0.0009734731],"genre_scores_gemma":[0.000003583247,0.9861464,0.00008427391,0.00026534195,0.0013646766,0.008991923,0.00025132243,0.0002118644,0.002680626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99747306,0.00005455618,0.0008606024,0.00071397284,0.00029742194,0.00060036033],"domain_scores_gemma":[0.9986657,0.00022115144,0.000439456,0.000390348,0.000105622894,0.00017771655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002679618,0.00049799663,0.0020033638,0.00044542275,0.000058794674,0.000019921341,0.0001658601,0.00031221154,0.00011124982],"category_scores_gemma":[0.000073890995,0.00042595263,0.0005276217,0.0010160283,0.00013927066,0.00013187394,0.000029256682,0.00046520258,0.00006602457],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009715537,0.000007767291,0.000018599081,0.040972795,0.00010237513,0.00002294319,0.000119988865,0.000072859206,6.864177e-7,0.00003009265,0.012283718,0.946271],"study_design_scores_gemma":[0.0013690742,0.00011838324,0.0000012888684,0.06596287,0.0003372788,0.000008696471,0.000051736002,0.000011770696,0.000019735082,0.00014917438,0.9315791,0.00039086383],"about_ca_topic_score_codex":0.00019365585,"about_ca_topic_score_gemma":0.000444588,"teacher_disagreement_score":0.9458802,"about_ca_system_score_codex":0.0066858134,"about_ca_system_score_gemma":0.0048626503,"threshold_uncertainty_score":0.9998192},"labels":[],"label_agreement":null},{"id":"W4327976817","doi":"10.31083/j.fbl2803052","title":"PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin","year":2023,"lang":"en","type":"article","venue":"Frontiers in Bioscience-Landmark","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Cancer Research Society","keywords":"Eribulin; Olaparib; Propidium iodide; Cancer research; Cell cycle; Apoptosis; Chemistry; Breast cancer; Biology; Cancer; Medicine; Poly ADP ribose polymerase; Metastatic breast cancer; Programmed cell death; Internal medicine; Biochemistry; Polymerase","score_opus":0.015599663192141332,"score_gpt":0.29234950032901397,"score_spread":0.2767498371368726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327976817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97350585,0.00020765964,0.002694339,0.014963389,0.0051091206,0.000859781,0.00042899925,0.00033350915,0.0018973183],"genre_scores_gemma":[0.98521507,0.0010317191,0.0054692742,0.005017153,0.00065791537,0.00020092425,0.00006526293,0.000044913042,0.0022977798],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9977212,0.000070602444,0.0003702268,0.00061893335,0.0005574953,0.00066154817],"domain_scores_gemma":[0.9991121,0.000037343838,0.00008381567,0.00034318972,0.00010581296,0.00031769532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005589374,0.000227242,0.00038972285,0.0006932776,0.00014466398,0.000050071973,0.00013906696,0.00013450412,0.0002064183],"category_scores_gemma":[0.000040103445,0.00020618856,0.00008862292,0.0025592763,0.0002361341,0.00016360272,0.00006665501,0.00021813212,0.00021991311],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077959656,0.000116494295,0.08928633,0.000078128556,0.000027975033,0.00021704755,0.0010814464,0.0004066748,0.23091812,0.000029881023,0.66346467,0.013593649],"study_design_scores_gemma":[0.010082264,0.00067997316,0.5399453,0.0021694452,0.000090896145,0.00027813413,0.0030729363,0.008672115,0.3084671,0.0016982418,0.12317676,0.0016668716],"about_ca_topic_score_codex":0.00014209926,"about_ca_topic_score_gemma":0.000044729506,"teacher_disagreement_score":0.5402879,"about_ca_system_score_codex":0.00044810152,"about_ca_system_score_gemma":0.00022811674,"threshold_uncertainty_score":0.84081256},"labels":[],"label_agreement":null},{"id":"W4328049371","doi":"10.1038/s41416-023-02226-w","title":"Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Pfizer Canada; Université de Montréal; Pfizer","keywords":"Carboplatin; Triple-negative breast cancer; Cancer research; Micrometastasis; Medicine; Metastasis; PARP inhibitor; Breast cancer; Oncology; Cancer; Internal medicine; Chemotherapy; Biology; Poly ADP ribose polymerase; Cisplatin","score_opus":0.015518409706924417,"score_gpt":0.29165390653839224,"score_spread":0.2761354968314678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328049371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986985,0.01030132,0.000058063713,0.0013200503,0.00026163642,0.0003043366,0.00051215774,0.00001822437,0.0002392054],"genre_scores_gemma":[0.98699784,0.011700372,0.0005312746,0.00023303795,0.00038240204,0.000046269215,0.000010864924,0.00004240261,0.000055519537],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99793017,0.000119769495,0.00077373785,0.00022944521,0.0006356167,0.000311278],"domain_scores_gemma":[0.99856365,0.00009310336,0.00065418746,0.00006601209,0.00045104878,0.00017197417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005164491,0.00017654715,0.00069976563,0.000266966,0.000058701702,0.00003288193,0.00008149498,0.00006522684,0.00018073813],"category_scores_gemma":[0.000070926864,0.00016696297,0.00010570394,0.00075965904,0.00019587883,0.0002724604,0.000032358297,0.00043224165,4.26135e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015512012,0.0005999222,0.26386085,0.0027457497,0.002465453,0.0074513927,0.0049026837,0.0013579037,0.53592604,0.0001099522,0.010687057,0.15438096],"study_design_scores_gemma":[0.025872653,0.0006330879,0.7284697,0.013605578,0.000582774,0.005733204,0.0013294416,0.00014862679,0.22205304,0.00051016844,0.00047435876,0.000587316],"about_ca_topic_score_codex":0.0034324615,"about_ca_topic_score_gemma":0.0014437954,"teacher_disagreement_score":0.4646089,"about_ca_system_score_codex":0.00032979512,"about_ca_system_score_gemma":0.0007539914,"threshold_uncertainty_score":0.6808553},"labels":[],"label_agreement":null},{"id":"W4353084629","doi":"10.1101/2023.03.20.23287465","title":"<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Council Victoria; National Health and Medical Research Council; Medical Research Council; National Cancer Institute; National Institutes of Health; Swiss Cancer Research Foundation; AstraZeneca; QIMR Berghofer Medical Research Institute; Victorian Cancer Agency; Clovis Oncology; Ovarian Cancer Research Fund","keywords":"PARP inhibitor; Exon; Exon skipping; splice; Genetics; Splice site mutation; Mutation; RNA splicing; Resistance (ecology); Poly ADP ribose polymerase; Biology; Gene; Alternative splicing; Polymerase","score_opus":0.03749625307624769,"score_gpt":0.3074278683154971,"score_spread":0.2699316152392494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353084629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699264,0.0060237283,0.0011779319,0.009101021,0.002397617,0.0014675286,0.00060088735,0.00076710916,0.008537748],"genre_scores_gemma":[0.96731377,0.0043794457,0.0060633626,0.0032852783,0.0028309075,0.0011215827,0.00096337683,0.00032119546,0.013721076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969578,0.00013235767,0.0007518239,0.0011186423,0.0005593101,0.00048011198],"domain_scores_gemma":[0.9976998,0.0003123171,0.00039856797,0.0010080377,0.00026044567,0.00032086266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005437618,0.00048447296,0.00077660556,0.00036337902,0.00022501632,0.00007234764,0.00019694258,0.0004324637,0.00021966868],"category_scores_gemma":[0.00017765418,0.0005124962,0.00022109291,0.00038071966,0.00031900185,0.00011523448,0.00037604093,0.0014185837,0.00028494548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028277803,0.0010000789,0.3772507,0.019429913,0.0038768647,0.0045341393,0.033321626,0.0007381816,0.2141343,0.00297547,0.32618982,0.013721119],"study_design_scores_gemma":[0.01337297,0.00038592218,0.46726686,0.01775946,0.0012028203,0.00029498243,0.001819694,0.0006919254,0.05936826,0.025902508,0.40848172,0.0034529038],"about_ca_topic_score_codex":0.00005075707,"about_ca_topic_score_gemma":0.0002866453,"teacher_disagreement_score":0.15476604,"about_ca_system_score_codex":0.0002711611,"about_ca_system_score_gemma":0.0005080577,"threshold_uncertainty_score":0.9997327},"labels":[],"label_agreement":null},{"id":"W4360828195","doi":"10.1126/sciadv.adf7175","title":"Clinical PARP inhibitors allosterically induce PARP2 retention on DNA","year":2023,"lang":"en","type":"article","venue":"Science Advances","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Allosteric regulation; PARP1; DNA damage; Poly ADP ribose polymerase; DNA; DNA repair; Chemistry; Cancer research; Biology; Cell biology; Biochemistry; Enzyme; Polymerase","score_opus":0.08361955253947974,"score_gpt":0.42443285336040376,"score_spread":0.34081330082092404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360828195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846453,0.00014914677,0.000071050534,0.004510829,0.002194853,0.0003152335,0.0000058882165,0.0003096835,0.007798008],"genre_scores_gemma":[0.9944038,0.00041470106,0.0008846877,0.0023739454,0.0006632383,0.000049863065,0.0000108361955,0.000016656433,0.0011822858],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99742126,0.00006184578,0.00046578475,0.0006436642,0.0009548223,0.00045259815],"domain_scores_gemma":[0.9988422,0.00016522789,0.00016120037,0.0004182333,0.00016154874,0.0002516171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015523996,0.00014411192,0.0002548043,0.00026683253,0.00024272974,0.00004286166,0.00024648916,0.000072733856,0.00008923057],"category_scores_gemma":[0.0005421511,0.00011533438,0.00011197158,0.0019802032,0.0010406076,0.00055806467,0.000065592925,0.00025669762,0.000746143],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073415093,0.00039495967,0.08061602,0.00007980555,0.000029865396,0.00013675346,0.0004258278,0.00012945177,0.44060567,0.0011336745,0.012050452,0.46366337],"study_design_scores_gemma":[0.0044964626,0.004283285,0.34965807,0.0011304793,0.000050332103,0.00006630116,0.00111326,0.00033199505,0.33069262,0.008033481,0.2993374,0.00080632005],"about_ca_topic_score_codex":0.0000020930736,"about_ca_topic_score_gemma":0.000002224269,"teacher_disagreement_score":0.46285704,"about_ca_system_score_codex":0.00011882299,"about_ca_system_score_gemma":0.00027948024,"threshold_uncertainty_score":0.95904076},"labels":[],"label_agreement":null},{"id":"W4361245262","doi":"10.1093/oncolo/oyad008","title":"Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"Janssen Biotech; Janssen Research and Development; Amgen; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; UroGen Pharma; Dendreon Pharmaceuticals; Progenics Pharmaceuticals; Sanofi; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Androgen receptor; Abiraterone; Androgen deprivation therapy; Internal medicine; Oncology; Cancer research; PARP1; Testosterone (patch); Pharmacology; Cancer; Poly ADP ribose polymerase; Polymerase; Gene; Biology; Genetics","score_opus":0.08989458193043044,"score_gpt":0.41774564722702856,"score_spread":0.32785106529659813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361245262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811773,0.00035843058,0.00006614098,0.012609091,0.00014978349,0.004327928,0.000733274,0.00021209651,0.00036597784],"genre_scores_gemma":[0.99164313,0.00032938732,0.0006021159,0.00037825358,0.00013399373,0.002342287,0.00013604668,0.00003911685,0.004395666],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983671,0.00013649989,0.00044200144,0.00041259965,0.00028482272,0.00035697932],"domain_scores_gemma":[0.9988224,0.00024657458,0.0002554058,0.00039018184,0.00017609485,0.0001093343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010181123,0.00021978535,0.0004212264,0.000081396414,0.0004735909,0.000053567,0.00010799991,0.0000359933,0.000018356412],"category_scores_gemma":[0.00008016164,0.00013057828,0.000036795576,0.00039668853,0.00039791683,0.0000960574,0.00004350705,0.00015762566,0.000009122232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35462525,0.016378747,0.0065137357,0.0015964865,0.0053684423,0.0017473168,0.096751854,0.0041397065,0.3096387,0.0013726213,0.11676438,0.08510273],"study_design_scores_gemma":[0.45886204,0.23863389,0.06999059,0.0014483795,0.004788694,0.00041000862,0.037504,0.0059508313,0.051245395,0.0025221894,0.1265062,0.002137802],"about_ca_topic_score_codex":0.00050885696,"about_ca_topic_score_gemma":0.0023129424,"teacher_disagreement_score":0.25839332,"about_ca_system_score_codex":0.00018817188,"about_ca_system_score_gemma":0.00033992756,"threshold_uncertainty_score":0.53248274},"labels":[],"label_agreement":null},{"id":"W4361812602","doi":"10.1158/1078-0432.c.6532290.v1","title":"Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; National Institutes of Health; Breast Cancer Alliance; Sierra Oncology; Ipsen; Genentech; Deutsche Krebshilfe; G1 Therapeutics; Stand Up To Cancer; EMD Serono; Mersana Therapeutics; Merck KGaA; Dana-Farber/Harvard Cancer Center; GlaxoSmithKline; Breast Cancer Research Foundation; Pfizer; Symphogen; Carrick Therapeutics; American Association for Cancer Research; AstraZeneca; Eli Lilly and Company; Astex Pharmaceuticals","keywords":"Medicine; Olaparib; Internal medicine; Triple-negative breast cancer; Breast cancer; Oncology; Cohort; Cancer; BRCA mutation; PARP inhibitor; Adverse effect","score_opus":0.21909590388795208,"score_gpt":0.48417969822566465,"score_spread":0.26508379433771256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361812602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6827373,0.000303705,0.03399462,0.004322884,0.009372016,0.02662368,0.24087545,0.0009608153,0.0008095211],"genre_scores_gemma":[0.6430583,0.0033111342,0.10375974,0.008054177,0.02016415,0.019232359,0.18875319,0.0014630498,0.01220388],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944921,0.00018141423,0.0014347751,0.0022800507,0.0010293114,0.0005823426],"domain_scores_gemma":[0.9934779,0.0012316466,0.0010938024,0.002736096,0.0010039721,0.00045660094],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005958476,0.0007471414,0.0019249119,0.00017100754,0.00012360656,0.00008121732,0.00080500863,0.0005482003,0.0011284265],"category_scores_gemma":[0.00039331487,0.00050798326,0.0002548645,0.00029253034,0.00035860768,0.0002881909,0.00057411223,0.0012508286,0.00004601146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89609903,0.0046383734,0.002918801,0.00021551382,0.0031044926,0.000030140829,0.00023571722,0.0001608703,0.000010290464,0.000019285551,0.071357,0.021210471],"study_design_scores_gemma":[0.95882875,0.007933341,0.010151033,0.0027258426,0.0016785038,0.0000039410234,0.00020261254,0.0031163157,0.00013057144,0.0005655442,0.013600907,0.0010626127],"about_ca_topic_score_codex":0.0015361992,"about_ca_topic_score_gemma":0.0018702241,"teacher_disagreement_score":0.06976513,"about_ca_system_score_codex":0.00059478555,"about_ca_system_score_gemma":0.0029318954,"threshold_uncertainty_score":0.99978465},"labels":[],"label_agreement":null},{"id":"W4361812693","doi":"10.1158/1078-0432.c.6532290","title":"Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; National Institutes of Health; Breast Cancer Alliance; Sierra Oncology; Ipsen; Genentech; Deutsche Krebshilfe; G1 Therapeutics; Stand Up To Cancer; EMD Serono; Mersana Therapeutics; Merck KGaA; Dana-Farber/Harvard Cancer Center; GlaxoSmithKline; Breast Cancer Research Foundation; Pfizer; Symphogen; Carrick Therapeutics; American Association for Cancer Research; AstraZeneca; Eli Lilly and Company; Astex Pharmaceuticals","keywords":"Medicine; Olaparib; Internal medicine; Triple-negative breast cancer; Breast cancer; Oncology; Cohort; Cancer; BRCA mutation; PARP inhibitor; Adverse effect","score_opus":0.21909590388795208,"score_gpt":0.48417969822566465,"score_spread":0.26508379433771256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361812693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6827373,0.000303705,0.03399462,0.004322884,0.009372016,0.02662368,0.24087545,0.0009608153,0.0008095211],"genre_scores_gemma":[0.6430583,0.0033111342,0.10375974,0.008054177,0.02016415,0.019232359,0.18875319,0.0014630498,0.01220388],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944921,0.00018141423,0.0014347751,0.0022800507,0.0010293114,0.0005823426],"domain_scores_gemma":[0.9934779,0.0012316466,0.0010938024,0.002736096,0.0010039721,0.00045660094],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005958476,0.0007471414,0.0019249119,0.00017100754,0.00012360656,0.00008121732,0.00080500863,0.0005482003,0.0011284265],"category_scores_gemma":[0.00039331487,0.00050798326,0.0002548645,0.00029253034,0.00035860768,0.0002881909,0.00057411223,0.0012508286,0.00004601146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89609903,0.0046383734,0.002918801,0.00021551382,0.0031044926,0.000030140829,0.00023571722,0.0001608703,0.000010290464,0.000019285551,0.071357,0.021210471],"study_design_scores_gemma":[0.95882875,0.007933341,0.010151033,0.0027258426,0.0016785038,0.0000039410234,0.00020261254,0.0031163157,0.00013057144,0.0005655442,0.013600907,0.0010626127],"about_ca_topic_score_codex":0.0015361992,"about_ca_topic_score_gemma":0.0018702241,"teacher_disagreement_score":0.06976513,"about_ca_system_score_codex":0.00059478555,"about_ca_system_score_gemma":0.0029318954,"threshold_uncertainty_score":0.99978465},"labels":[],"label_agreement":null},{"id":"W4361826965","doi":"10.1158/0008-5472.c.6513498.v1","title":"Data from Acquired &lt;i&gt;RAD51C&lt;/i&gt; Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Council Tasmania; Cancer Council Victoria; Cancer Council South Australia; Cancer Research Institute; AstraZeneca; National Health and Medical Research Council; Entertainment Industry Foundation; Stand Up To Cancer; Medical Research Council; Peter MacCallum Foundation; AstraZeneca Australia; Medical Research and Materiel Command; Eisai; Ovarian Cancer Research Fund; Cancer Australia; National Cancer Institute; Australian Cancer Research Foundation; National Breast Cancer Foundation; Clovis Oncology; Cancer Council NSW; Ovarian Cancer Australia; Sierra Oncology; State Government of Victoria; Mayo Foundation for Medical Education and Research; National Ovarian Cancer Coalition; American Association for Cancer Research; Australian Government; Ovarian Cancer Research Fund Alliance; National Institutes of Health","keywords":"Cancer research; DNA methylation; Methylation; Gene silencing; CpG site; Biology; Molecular biology; Gene; Genetics; Gene expression","score_opus":0.08580829755801006,"score_gpt":0.3277233592894588,"score_spread":0.24191506173144872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361826965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95060855,0.0051962235,0.004058702,0.018624332,0.005050311,0.0046401042,0.008627924,0.001389149,0.0018047082],"genre_scores_gemma":[0.9544823,0.0008477349,0.015650868,0.00087334303,0.0031012949,0.0007261592,0.01596834,0.00035620484,0.007993737],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99208367,0.0006104695,0.0018928286,0.002944717,0.0014972412,0.0009710938],"domain_scores_gemma":[0.99280435,0.00054240203,0.00080812967,0.0050987094,0.0003372824,0.00040914566],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012245583,0.0010582069,0.0017620742,0.00073507085,0.00015966195,0.00020164195,0.0012789703,0.0012594546,0.00093700126],"category_scores_gemma":[0.0003634644,0.0010438456,0.00024708064,0.00086440815,0.00032378503,0.00046693542,0.0015981692,0.001045967,0.00037482375],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077850237,0.002687232,0.041404977,0.004257039,0.003105405,0.004910779,0.007478114,0.0005181072,0.61458147,0.0062041837,0.30544344,0.0016242259],"study_design_scores_gemma":[0.026660059,0.00048142666,0.6418796,0.0092053795,0.0014917896,0.00007068397,0.00022925893,0.0028267403,0.1114144,0.057289276,0.14382233,0.0046290644],"about_ca_topic_score_codex":0.0017904836,"about_ca_topic_score_gemma":0.0186026,"teacher_disagreement_score":0.6004746,"about_ca_system_score_codex":0.0013288279,"about_ca_system_score_gemma":0.0011546368,"threshold_uncertainty_score":0.9999763},"labels":[],"label_agreement":null},{"id":"W4361950512","doi":"10.1158/1078-0432.c.6532884","title":"Data from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and &lt;i&gt;BRCA1, BRCA2&lt;/i&gt;, or &lt;i&gt;ATM&lt;/i&gt; Alterations Identified by Testing Circulating Tumor DNA","year":2023,"lang":"en","type":"preprint","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Enzalutamide; Internal medicine; Hazard ratio; Cohort; Prostate cancer; Oncology; Progression-free survival; Population; PARP inhibitor; Cancer; Gastroenterology; Poly ADP ribose polymerase; Overall survival; Confidence interval; Gene; Biology; Androgen receptor; Genetics","score_opus":0.08377876986514131,"score_gpt":0.3297492467324734,"score_spread":0.2459704768673321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361950512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686722,0.0020646926,0.0015819663,0.0010755557,0.0011786852,0.0067601306,0.017236825,0.00066673965,0.0007632084],"genre_scores_gemma":[0.9547872,0.00032000104,0.0135675175,0.0005884449,0.00057946576,0.0019577446,0.024294266,0.0004698773,0.0034354713],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9898212,0.0004967203,0.0029589247,0.003327662,0.002068944,0.0013265373],"domain_scores_gemma":[0.991736,0.0018011497,0.0017992673,0.0029248744,0.0010773694,0.0006613387],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00134468,0.0014614449,0.0020931757,0.00073457806,0.00068735157,0.00083127787,0.0009210053,0.00035629573,0.00078343705],"category_scores_gemma":[0.0015999882,0.0012765932,0.00017764188,0.0014220098,0.00045657993,0.0009134812,0.001026825,0.0012336333,0.00007634677],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006547707,0.0045700064,0.033084285,0.0042812247,0.005590433,0.00137786,0.007583522,0.012831092,0.8593584,0.0008835824,0.056761853,0.0071300683],"study_design_scores_gemma":[0.087073766,0.0024712805,0.7457377,0.03192438,0.006583258,0.00016991956,0.00069844624,0.08371167,0.010092522,0.002182968,0.020455243,0.008898882],"about_ca_topic_score_codex":0.0011148205,"about_ca_topic_score_gemma":0.018978775,"teacher_disagreement_score":0.8492659,"about_ca_system_score_codex":0.0011679069,"about_ca_system_score_gemma":0.0027057813,"threshold_uncertainty_score":0.9998135},"labels":[],"label_agreement":null},{"id":"W4361954371","doi":"10.1158/1078-0432.c.6532884.v1","title":"Data from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and &lt;i&gt;BRCA1, BRCA2&lt;/i&gt;, or &lt;i&gt;ATM&lt;/i&gt; Alterations Identified by Testing Circulating Tumor DNA","year":2023,"lang":"en","type":"preprint","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Enzalutamide; Internal medicine; Cohort; Hazard ratio; Prostate cancer; Oncology; Progression-free survival; Population; Cancer; Gastroenterology; Overall survival; Poly ADP ribose polymerase; Confidence interval; Gene; Biology; Genetics; Androgen receptor","score_opus":0.08377876986514131,"score_gpt":0.3297492467324734,"score_spread":0.2459704768673321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361954371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686722,0.0020646926,0.0015819663,0.0010755557,0.0011786852,0.0067601306,0.017236825,0.00066673965,0.0007632084],"genre_scores_gemma":[0.9547872,0.00032000104,0.0135675175,0.0005884449,0.00057946576,0.0019577446,0.024294266,0.0004698773,0.0034354713],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9898212,0.0004967203,0.0029589247,0.003327662,0.002068944,0.0013265373],"domain_scores_gemma":[0.991736,0.0018011497,0.0017992673,0.0029248744,0.0010773694,0.0006613387],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00134468,0.0014614449,0.0020931757,0.00073457806,0.00068735157,0.00083127787,0.0009210053,0.00035629573,0.00078343705],"category_scores_gemma":[0.0015999882,0.0012765932,0.00017764188,0.0014220098,0.00045657993,0.0009134812,0.001026825,0.0012336333,0.00007634677],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006547707,0.0045700064,0.033084285,0.0042812247,0.005590433,0.00137786,0.007583522,0.012831092,0.8593584,0.0008835824,0.056761853,0.0071300683],"study_design_scores_gemma":[0.087073766,0.0024712805,0.7457377,0.03192438,0.006583258,0.00016991956,0.00069844624,0.08371167,0.010092522,0.002182968,0.020455243,0.008898882],"about_ca_topic_score_codex":0.0011148205,"about_ca_topic_score_gemma":0.018978775,"teacher_disagreement_score":0.8492659,"about_ca_system_score_codex":0.0011679069,"about_ca_system_score_gemma":0.0027057813,"threshold_uncertainty_score":0.9998135},"labels":[],"label_agreement":null},{"id":"W4361961028","doi":"10.1158/1078-0432.c.6518824","title":"Data from Tumor Growth Inhibition by Olaparib in &lt;i&gt;BRCA2&lt;/i&gt; Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts","year":2023,"lang":"en","type":"preprint","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Olaparib; PARP inhibitor; Cancer research; Carboplatin; Synthetic lethality; Ovarian cancer; Serous fluid; Cancer; Medicine; Poly ADP ribose polymerase; Biology; DNA repair; Cisplatin; Internal medicine; Chemotherapy; DNA; Genetics","score_opus":0.05379661990637228,"score_gpt":0.3274010365602044,"score_spread":0.2736044166538321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361961028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9177674,0.005934905,0.005080023,0.011970288,0.0061289184,0.005719255,0.0420813,0.0020593212,0.0032585622],"genre_scores_gemma":[0.8759111,0.0043599647,0.0040727966,0.0046793427,0.0024101145,0.0023100076,0.1036691,0.00058501225,0.0020025738],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9921204,0.0004120023,0.0020975785,0.0028517365,0.001395685,0.0011226041],"domain_scores_gemma":[0.994604,0.00030077604,0.0009646954,0.0029743111,0.0005670141,0.0005891822],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063457084,0.001175044,0.0017961274,0.000810234,0.00016968272,0.00018716266,0.0009020135,0.0009524455,0.004627818],"category_scores_gemma":[0.00028603495,0.0011972571,0.00022630328,0.0010727214,0.00030851067,0.00043636363,0.001792174,0.0017546918,0.00061992614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011910704,0.0006955706,0.00077124534,0.00045540836,0.0006261803,0.00066473254,0.0009464994,0.00016844505,0.6598776,0.000108753724,0.3324922,0.0020022765],"study_design_scores_gemma":[0.03388049,0.0011873456,0.018462991,0.012887069,0.0014272146,0.00012238472,0.00039031095,0.009407337,0.66893953,0.009210467,0.23857385,0.005510987],"about_ca_topic_score_codex":0.007917243,"about_ca_topic_score_gemma":0.0073784026,"teacher_disagreement_score":0.093918346,"about_ca_system_score_codex":0.001323262,"about_ca_system_score_gemma":0.0012563535,"threshold_uncertainty_score":0.99904776},"labels":[],"label_agreement":null},{"id":"W4362484348","doi":"10.1158/1541-7786.22526957.v1","title":"Supplementary Table 1 from CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors","year":2023,"lang":"en","type":"supplementary-materials","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; Sierra Oncology; Medical Research Council; Eisai; Marshfield Clinic Research Foundation; BeiGene; Australian Cancer Research Foundation; Australian Government; Clovis Oncology; Genentech; AstraZeneca","keywords":"CRISPR; Gene; DNA repair; DNA; Cas9; Poly ADP ribose polymerase; Genetics; Biology; Computational biology; Polymerase","score_opus":0.04155117886225874,"score_gpt":0.32083057784145474,"score_spread":0.279279398979196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362484348","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.502368,0.0005236695,0.00014141413,0.0076004723,0.0050842166,0.0057390206,0.4770851,0.00064219336,0.0008159024],"genre_scores_gemma":[0.15221249,0.0011178331,0.004584563,0.012681737,0.0084171435,0.0036345094,0.8095473,0.0005538038,0.0072505926],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99212086,0.00036842946,0.0022844342,0.0022304268,0.0016185085,0.0013773413],"domain_scores_gemma":[0.9963361,0.0005299534,0.0006706685,0.0014485724,0.00030064865,0.00071403227],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0005396956,0.001365066,0.0024836168,0.0006891617,0.00027921665,0.00031429558,0.00046170433,0.0009939031,0.29637587],"category_scores_gemma":[0.00011001231,0.0012535421,0.00038689404,0.0007623051,0.00018219659,0.0003565076,0.00053284917,0.0008526193,0.0010843844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092771614,0.00037154692,0.0007292552,0.00043246255,0.00070061215,0.00037753416,0.00033882665,0.00001489632,0.16305855,0.00003212994,0.8327165,0.00029994705],"study_design_scores_gemma":[0.004290691,0.001034268,0.00013169202,0.0018994209,0.00049319287,0.000020887022,0.0013598793,0.00000973829,0.6613378,0.0023238673,0.32601818,0.0010803753],"about_ca_topic_score_codex":0.14640199,"about_ca_topic_score_gemma":0.020001395,"teacher_disagreement_score":0.5066983,"about_ca_system_score_codex":0.001209268,"about_ca_system_score_gemma":0.0008036485,"threshold_uncertainty_score":0.99991},"labels":[],"label_agreement":null},{"id":"W4362484426","doi":"10.1158/1541-7786.22526954","title":"Supplementary Table 2 from CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors","year":2023,"lang":"en","type":"supplementary-materials","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; Sierra Oncology; Medical Research Council; Eisai; Marshfield Clinic Research Foundation; BeiGene; Australian Cancer Research Foundation; Australian Government; Clovis Oncology; Genentech; AstraZeneca","keywords":"Olaparib; Poly ADP ribose polymerase; Toxicity; Positive control; CRISPR; DNA; Biology; Chemistry; Gene; Medicine; Internal medicine; Genetics; Polymerase","score_opus":0.040172437980931446,"score_gpt":0.3202204757800217,"score_spread":0.28004803779909027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362484426","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50452805,0.00053630257,0.0001394701,0.007621597,0.00515458,0.005774488,0.47475716,0.0006471549,0.0008411858],"genre_scores_gemma":[0.15005258,0.0011480093,0.004486127,0.012689052,0.008546015,0.0035666046,0.81168,0.0005533151,0.007278284],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99212253,0.00036830554,0.002285468,0.002228761,0.0016181088,0.0013768378],"domain_scores_gemma":[0.99634624,0.000522445,0.0006716141,0.001445795,0.00029998,0.00071393215],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0005367407,0.0013646311,0.0024842254,0.0006887093,0.00027923717,0.00031497984,0.00046144662,0.000993909,0.29241103],"category_scores_gemma":[0.000108680106,0.0012531314,0.00038681898,0.0007617109,0.00018219407,0.00035675266,0.000532774,0.0008524225,0.0010727885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009273738,0.0003733256,0.0007096833,0.00043862616,0.0007042032,0.0003898821,0.00034084832,0.00001504473,0.15923119,0.000032864533,0.83652705,0.00030993434],"study_design_scores_gemma":[0.0042953575,0.0010285396,0.00012882563,0.0018652495,0.0004885984,0.00002081412,0.0013382924,0.000009617802,0.6557161,0.0023290117,0.3317076,0.0010719512],"about_ca_topic_score_codex":0.14766379,"about_ca_topic_score_gemma":0.020117788,"teacher_disagreement_score":0.50481945,"about_ca_system_score_codex":0.0012096153,"about_ca_system_score_gemma":0.0008000627,"threshold_uncertainty_score":0.9999105},"labels":[],"label_agreement":null},{"id":"W4362541711","doi":"10.1158/1538-7445.am2023-6098","title":"Abstract 6098: Genome wide CRISPR screen reveals genetic vulnerabilities of next generation PARP1 inhibitor AZD5305","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Synthetic lethality; PARP1; CRISPR; PARP inhibitor; Genetic screen; Biology; Genetics; Cancer research; Gene; Mutant; Poly ADP ribose polymerase; Polymerase","score_opus":0.25147998503733265,"score_gpt":0.4536434933570905,"score_spread":0.20216350831975782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362541711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876771,0.0049980627,0.00007356249,0.003939908,0.0003253482,0.001118299,0.00014943712,0.00013241863,0.001585871],"genre_scores_gemma":[0.98811054,0.0039569917,0.0003047212,0.00046855272,0.0021511032,0.00074792845,0.00013063801,0.00008081222,0.004048711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99630487,0.00027269017,0.0006846533,0.00057866925,0.0013847179,0.00077437033],"domain_scores_gemma":[0.9974411,0.00043080602,0.0001282996,0.00076764775,0.00093695516,0.0002951644],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017719357,0.0002142201,0.0004652988,0.00061597873,0.00024260138,0.00006628546,0.0002585821,0.00017861846,0.0023945004],"category_scores_gemma":[0.00041740848,0.00020390103,0.00014258505,0.0012485732,0.00047516637,0.00019913596,0.00010867791,0.0006320739,0.000337133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031895458,0.00007545893,0.008340863,0.00047300282,0.000092344104,0.00004553027,0.00082526193,0.00044016438,0.9150223,0.00007144582,0.068896376,0.005398279],"study_design_scores_gemma":[0.0040860362,0.0009705898,0.32104805,0.0010152945,0.000059424106,0.000022205837,0.0013846647,0.0006216774,0.6144682,0.0018249573,0.053900253,0.0005986586],"about_ca_topic_score_codex":0.0009198933,"about_ca_topic_score_gemma":0.00011065496,"teacher_disagreement_score":0.3127072,"about_ca_system_score_codex":0.00060936494,"about_ca_system_score_gemma":0.0007903819,"threshold_uncertainty_score":0.99851745},"labels":[],"label_agreement":null},{"id":"W4362542513","doi":"10.1158/1538-7445.am2023-6194","title":"Abstract 6194: A bifunctional inhibitor of PARP and HDAC enzymes with activity in Ewing sarcoma 3D spheroid and metastasis models","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; PARP inhibitor; Propidium iodide; PARP1; Histone deacetylase; Cancer research; Poly ADP ribose polymerase; Biology; Viability assay; Vorinostat; Molecular biology; Histone; Programmed cell death; Polymerase; Cell; Apoptosis; Biochemistry; DNA","score_opus":0.16218327571532282,"score_gpt":0.41834854464282134,"score_spread":0.2561652689274985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362542513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945144,0.0027214217,0.000069658934,0.0015206769,0.00004641061,0.00043810034,0.000073129326,0.00003574734,0.00058044994],"genre_scores_gemma":[0.9972941,0.0017687086,0.00024290044,0.00004908808,0.00014489747,0.00024760465,0.000007753044,0.00003029093,0.00021465415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817336,0.000103840975,0.00020171533,0.0003825572,0.0007419907,0.00039654138],"domain_scores_gemma":[0.9990442,0.00033354157,0.000053466225,0.00021254379,0.00019896618,0.00015732403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000979787,0.00013272,0.00032104683,0.0004071595,0.000095002586,0.000026008947,0.00005774824,0.00007624834,0.00020307576],"category_scores_gemma":[0.000049097365,0.00011015576,0.000029756007,0.00090478273,0.00038216662,0.00024205181,0.00007280765,0.0004668339,0.0000045872757],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075197075,0.00044947752,0.06476953,0.0018417576,0.00050775363,0.00024837386,0.0029830195,0.0016690565,0.7497105,0.00069803343,0.006330196,0.16327262],"study_design_scores_gemma":[0.013508546,0.0013400901,0.33908835,0.0025263664,0.00007050211,0.00007880795,0.0019866095,0.0049893307,0.6289547,0.0025030528,0.0044174287,0.00053617015],"about_ca_topic_score_codex":0.001117816,"about_ca_topic_score_gemma":0.0004178571,"teacher_disagreement_score":0.27431884,"about_ca_system_score_codex":0.00020891814,"about_ca_system_score_gemma":0.00042416167,"threshold_uncertainty_score":0.44920215},"labels":[],"label_agreement":null},{"id":"W4362592451","doi":"10.1158/1538-7445.am2023-2182","title":"Abstract 2182: The evolution of high grade serous ovarian cancer under the pressure of non-cytotoxic and cytotoxic treatment","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Olaparib; Cancer research; Cytotoxic T cell; Homologous recombination; Synthetic lethality; Serous fluid; Ovarian cancer; Biology; Cisplatin; Cancer; Medicine; Chemotherapy; DNA repair; Internal medicine; Genetics; Gene; In vitro; Poly ADP ribose polymerase","score_opus":0.10094327415207974,"score_gpt":0.4243555562334652,"score_spread":0.3234122820813855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362592451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980694,0.00587107,0.00003065077,0.01116427,0.00019055899,0.0014564118,0.00022477933,0.000034787965,0.0003334656],"genre_scores_gemma":[0.9909678,0.0054472014,0.000012129853,0.00009103528,0.00036064477,0.0011485791,0.00001035318,0.000037704936,0.0019245473],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978508,0.00017939624,0.0003217013,0.00033527764,0.0008568241,0.0004560024],"domain_scores_gemma":[0.99839854,0.0004084848,0.00012887588,0.0006394999,0.00031457187,0.00011004621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008589951,0.00016539244,0.0003306207,0.0002084594,0.00024717685,0.000020266414,0.00023082066,0.000117983094,0.00045775293],"category_scores_gemma":[0.000030301175,0.0000929373,0.00008879928,0.0010296821,0.0006964669,0.000067236164,0.00007440876,0.00039679106,0.000013323052],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014167808,0.00029584422,0.009260709,0.000708249,0.0010521454,0.000021365508,0.0032666065,0.0031070067,0.961436,0.0020499786,0.010443305,0.0069420114],"study_design_scores_gemma":[0.005237934,0.0007325849,0.6433342,0.0007636491,0.00018137666,0.000017317143,0.0025205598,0.00046361538,0.33836597,0.00273015,0.005463724,0.00018888203],"about_ca_topic_score_codex":0.018642858,"about_ca_topic_score_gemma":0.0010571512,"teacher_disagreement_score":0.63407356,"about_ca_system_score_codex":0.0007873625,"about_ca_system_score_gemma":0.0010061897,"threshold_uncertainty_score":0.9878921},"labels":[],"label_agreement":null},{"id":"W4362677814","doi":"10.1016/j.ygyno.2023.03.019","title":"Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial","year":2023,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Oncology; Internal medicine; BRCA mutation; Ovarian cancer; Cancer; Adverse effect","score_opus":0.018461943462107312,"score_gpt":0.30804972464802394,"score_spread":0.2895877811859166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362677814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925115,0.00008042003,0.000025907008,0.0042492226,0.0003272647,0.0022320303,0.00007866401,0.000103014194,0.0003919527],"genre_scores_gemma":[0.9948406,0.00016023648,0.00068177516,0.0033082997,0.000031368032,0.00063557015,0.00014905518,0.000022897353,0.00017015502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977282,0.0006828957,0.0005284664,0.00043301488,0.00020784231,0.00041955756],"domain_scores_gemma":[0.9977383,0.0015874872,0.00031337712,0.00019762492,0.00009984863,0.00006338411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011501873,0.00020371319,0.0005688775,0.0002412722,0.00009225309,0.000013760481,0.0000592469,0.00025996743,0.00006264646],"category_scores_gemma":[0.00073744124,0.00013687275,0.000034523335,0.00050601823,0.00022976001,0.000086616456,0.00003083063,0.00033601135,0.000006905202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02427852,0.0012836381,0.944186,0.0000686493,0.00016897943,0.00047695552,0.005663232,0.00011391664,0.00027705345,0.00034866633,0.0030829958,0.020051444],"study_design_scores_gemma":[0.09824022,0.004788321,0.89314824,0.000052418814,0.00004978121,0.000031413143,0.00070847076,0.0005466852,0.000056006334,0.001081286,0.0011287511,0.00016843107],"about_ca_topic_score_codex":0.0003876259,"about_ca_topic_score_gemma":0.0012313818,"teacher_disagreement_score":0.073961705,"about_ca_system_score_codex":0.0006988929,"about_ca_system_score_gemma":0.00022264296,"threshold_uncertainty_score":0.5581509},"labels":[],"label_agreement":null},{"id":"W4365514037","doi":"10.1158/1538-7445.am2023-ct018","title":"Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Neutropenia; Oncology; Phases of clinical research; Clinical trial; Chemotherapy; Adverse effect; Biology","score_opus":0.03680148951694935,"score_gpt":0.34670898946915435,"score_spread":0.309907499952205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365514037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993373,0.0004448257,0.0000044735502,0.0037987253,0.0000729914,0.0019960927,0.00012241809,0.00008214329,0.000105366664],"genre_scores_gemma":[0.99896324,0.00023981826,0.000028033372,0.000061374565,0.00009375629,0.00028852615,0.000068252375,0.00007633732,0.0001806701],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967677,0.00037751917,0.0005959316,0.000590213,0.0009961613,0.00067247194],"domain_scores_gemma":[0.9975564,0.0009875391,0.00018400712,0.0005928753,0.0004003261,0.00027887532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018424173,0.0002901519,0.0005076481,0.00066493906,0.00038521743,0.00007154908,0.00018148196,0.00012556641,0.00006680909],"category_scores_gemma":[0.0003068174,0.00019672583,0.000046055648,0.0019807643,0.0008933921,0.00022284426,0.00013249762,0.0009000098,0.000010440539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19675888,0.0011047375,0.57811064,0.00082356646,0.00061600516,0.00070932414,0.009517597,0.0012961072,0.19909894,0.0001797289,0.0063820225,0.0054024477],"study_design_scores_gemma":[0.017396418,0.0021815426,0.9368607,0.0018940758,0.00004248073,0.000009844,0.00059170346,0.00021270575,0.03992884,0.00002842805,0.00058961543,0.0002636553],"about_ca_topic_score_codex":0.00053174986,"about_ca_topic_score_gemma":0.00079998525,"teacher_disagreement_score":0.35875005,"about_ca_system_score_codex":0.00040280624,"about_ca_system_score_gemma":0.00069934985,"threshold_uncertainty_score":0.8022247},"labels":[],"label_agreement":null},{"id":"W4366769160","doi":"10.1038/s41420-023-01420-2","title":"PARP1 mediated PARylation contributes to myogenic progression and glucocorticoid transcriptional response","year":2023,"lang":"en","type":"article","venue":"Cell Death Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Trent University; Nottingham Trent University","keywords":"Myogenesis; Biology; PARP1; Cell biology; Skeletal muscle; Myocyte; Regulator; Glucocorticoid; Endocrinology; Gene; Genetics; Poly ADP ribose polymerase","score_opus":0.025140704486895676,"score_gpt":0.31602105878773923,"score_spread":0.2908803543008436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366769160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992168,0.0013080402,0.0012683369,0.0034066993,0.0003010253,0.0009091437,0.000103370425,0.00017032563,0.00036502254],"genre_scores_gemma":[0.995025,0.0004195127,0.00016096649,0.0012839196,0.000094135765,0.00020425141,0.00036708484,0.000030828207,0.0024143136],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99864954,0.00010015207,0.00029389022,0.00034326882,0.00032491688,0.0002882174],"domain_scores_gemma":[0.9991892,0.00030560786,0.00006197289,0.000219844,0.00006969946,0.00015369858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003864769,0.00015785292,0.0002449497,0.00022836088,0.00008644555,0.00005317401,0.000050490813,0.0001014787,0.00007101998],"category_scores_gemma":[0.00012164305,0.00013818184,0.00007923983,0.00046283237,0.00005233198,0.00020691496,0.00002565711,0.0001222925,0.0002514844],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071667875,0.00011447984,0.0465358,0.000108632325,0.00004928229,0.00005395951,0.00027355034,0.0000765856,0.9409373,0.00032136138,0.0032483086,0.001113957],"study_design_scores_gemma":[0.0045370073,0.00058713177,0.78450847,0.00038052056,0.0000906512,0.000021220927,0.0001338294,0.0008401931,0.18441321,0.0006367591,0.023589902,0.0002611185],"about_ca_topic_score_codex":0.0000036344559,"about_ca_topic_score_gemma":0.0000013446528,"teacher_disagreement_score":0.7565241,"about_ca_system_score_codex":0.00012400238,"about_ca_system_score_gemma":0.0001936908,"threshold_uncertainty_score":0.5634892},"labels":[],"label_agreement":null},{"id":"W4367602020","doi":"10.1158/1078-0432.ccr-22-2595","title":"Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Hospital; Université de Montréal; University of Calgary; MEG-3 (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Ovarian cancer; Clinical trial; Confidence interval; Phases of clinical research; Cyclophosphamide; Population; Progressive disease; Surgery; Cancer; Randomized controlled trial; Gastroenterology; Chemotherapy","score_opus":0.34198666322784144,"score_gpt":0.5729524062175213,"score_spread":0.23096574298967987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367602020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859231,0.0018993113,0.0000059024132,0.0064567174,0.0012168061,0.004030192,0.00011565138,0.000110338355,0.00024198278],"genre_scores_gemma":[0.9892238,0.0051079732,0.00026860763,0.0008000084,0.001556787,0.0020829062,0.00010277567,0.00011052061,0.00074665603],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933782,0.0010459559,0.0018933588,0.0012147585,0.0013705373,0.0010971901],"domain_scores_gemma":[0.99563193,0.0018816967,0.00035131956,0.0007971989,0.00074148894,0.0005963608],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008491022,0.0003302286,0.0010966952,0.00046116827,0.0004592009,0.00009882063,0.00032909968,0.00032939372,0.00089921814],"category_scores_gemma":[0.0012435196,0.00026069107,0.00022903687,0.0016080533,0.0007715551,0.00016049792,0.00018907392,0.0022781529,0.000024877158],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26323843,0.006463065,0.34813917,0.00017528779,0.00022705123,0.00004377717,0.00042538578,0.000030153506,0.00020941184,0.000027192025,0.0038206459,0.37720042],"study_design_scores_gemma":[0.5411429,0.032767665,0.40007448,0.0035825705,0.00007468209,0.0000021921055,0.00023629155,0.0015843606,0.0005249038,0.00029548648,0.019070566,0.0006439149],"about_ca_topic_score_codex":0.0012361535,"about_ca_topic_score_gemma":0.00047854846,"teacher_disagreement_score":0.37655652,"about_ca_system_score_codex":0.00058547204,"about_ca_system_score_gemma":0.002914177,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W4376114963","doi":"10.51731/cjht.2023.640","title":"Olaparib (Lynparza)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Reimbursement; Medicine; Oncology; Germline; Internal medicine; BRCA mutation; Adjuvant; Drug; Human Epidermal Growth Factor Receptor 2; Chemotherapy; Breast cancer; Gynecology; Cancer; Pharmacology; Political science; Genetics; Biology","score_opus":0.06684353766478728,"score_gpt":0.3530063722913855,"score_spread":0.2861628346265982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376114963","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4335095,0.071291775,0.0004483238,0.48774603,0.0021418068,0.0005783745,0.00005129909,0.0010509576,0.0031819346],"genre_scores_gemma":[0.99611294,0.0013386226,0.00046545808,0.0017542075,0.00003182628,0.000007151451,0.000003869233,0.00001759444,0.00026833641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875015,0.000029083143,0.00047687744,0.00010206859,0.00017788868,0.0004639329],"domain_scores_gemma":[0.9991394,0.000043377815,0.0002688854,0.00024040244,0.00016496233,0.0001429635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006678274,0.00009387394,0.00034570092,0.0010624701,0.0001704974,0.000016391716,0.00018882922,0.00012617052,0.000075507145],"category_scores_gemma":[0.00037809229,0.00008124526,0.00008192173,0.0008251901,0.0002001972,0.0000707672,0.0000096985295,0.0004393972,0.00009037116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045057037,0.000017572049,0.015891923,0.00018516608,0.00009038772,0.0009140553,0.00050409534,0.00002687297,0.00050179905,0.0030338624,0.28879535,0.68999386],"study_design_scores_gemma":[0.0012287252,0.0006619479,0.02084637,0.00050980295,0.000012012292,0.0010189604,0.0027160307,0.00001716361,0.0024891065,0.008081855,0.9622969,0.000121124394],"about_ca_topic_score_codex":0.0008094752,"about_ca_topic_score_gemma":0.0006535354,"teacher_disagreement_score":0.68987274,"about_ca_system_score_codex":0.00050985394,"about_ca_system_score_gemma":0.0037667234,"threshold_uncertainty_score":0.66820055},"labels":[],"label_agreement":null},{"id":"W4376640530","doi":"10.1158/1078-0432.ccr-23-0652","title":"An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer","year":2023,"lang":"en","type":"editorial","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Ovarian cancer; Poly ADP ribose polymerase; Synthetic lethality; PARP inhibitor; Medicine; Homologous recombination; BRCA mutation; Cancer; Cancer research; Oncology; Internal medicine; Biology; DNA repair; Genetics; Gene; Polymerase","score_opus":0.29480428928941865,"score_gpt":0.5911166845717124,"score_spread":0.29631239528229375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376640530","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05447722,0.0045248335,0.000007449843,0.061317116,0.871847,0.0048937122,0.0015966555,0.00027911947,0.0010568913],"genre_scores_gemma":[0.019350871,0.027371073,0.00008526603,0.00093989604,0.9402401,0.007490422,0.00031600543,0.00046679156,0.0037396161],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98821455,0.0014664301,0.0017010252,0.0021983078,0.004687482,0.001732183],"domain_scores_gemma":[0.9856052,0.008425736,0.00031830647,0.0023812845,0.0021428145,0.001126665],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.010959757,0.0006401838,0.0015648444,0.00073088077,0.00033496734,0.00017414086,0.0013622185,0.001967872,0.0014252199],"category_scores_gemma":[0.0029102694,0.00043658557,0.0002929233,0.0028326854,0.0009165653,0.00015213639,0.0003669967,0.009534179,0.00031748452],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005620459,0.00037749077,0.006107424,0.0003017003,0.00026275567,0.0002353458,0.00069526926,0.00009876369,0.000052038613,0.0000292261,0.95644116,0.029778386],"study_design_scores_gemma":[0.005528883,0.0031531486,0.0061141057,0.005008196,0.0000907982,0.0000015952783,0.0005462062,0.00003476119,0.00018815968,0.00035176627,0.97839224,0.0005901132],"about_ca_topic_score_codex":0.011533755,"about_ca_topic_score_gemma":0.048467208,"teacher_disagreement_score":0.06839306,"about_ca_system_score_codex":0.002385455,"about_ca_system_score_gemma":0.0070402618,"threshold_uncertainty_score":0.9998086},"labels":[],"label_agreement":null},{"id":"W4378781378","doi":"10.1158/0008-5472.can-22-2319","title":"Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Genome Canada; Canadian Institutes of Health Research; Fondation du cancer du sein du Québec; Ontario Research Foundation; Breast Cancer Research Foundation","keywords":"Missense mutation; Breast cancer; Ovarian cancer; Biology; Clinical significance; Cancer research; Olaparib; Genetics; DNA repair; Internal medicine; Medicine; Cancer; Gene; Mutation; Polymerase; Poly ADP ribose polymerase","score_opus":0.27271650083026494,"score_gpt":0.5002358237862455,"score_spread":0.2275193229559806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378781378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968184,0.000094840965,0.00047633238,0.0012806832,0.00024033274,0.0008534739,0.0001404596,0.000019346693,0.00007611186],"genre_scores_gemma":[0.9975208,0.00090736576,0.00014017978,0.000055403554,0.0002444115,0.00031074663,0.0000701817,0.00002433988,0.0007265597],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980564,0.0002289894,0.00059000205,0.00034197012,0.0004888052,0.0002938012],"domain_scores_gemma":[0.9979723,0.0009869261,0.00017727214,0.00021122475,0.00056757004,0.00008471305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025218092,0.000091351045,0.00036193721,0.00042941494,0.00006756886,0.000012162183,0.000074626456,0.00010904075,0.00014158401],"category_scores_gemma":[0.00092755485,0.00008997574,0.000056297973,0.0010978106,0.0002982135,0.00011674852,0.000042078736,0.0002693492,0.0000032072774],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00256657,0.000119881035,0.027483892,0.00055632566,0.00007135273,0.0000147062965,0.00044613116,0.000020212154,0.96248984,0.00028986498,0.0006889499,0.0052522807],"study_design_scores_gemma":[0.0040135207,0.00034103973,0.88495964,0.00091004244,0.000015514748,0.0000066731036,0.00044438348,0.0013559113,0.10671916,0.00086629373,0.0002712756,0.00009657064],"about_ca_topic_score_codex":0.00028354622,"about_ca_topic_score_gemma":0.000030529805,"teacher_disagreement_score":0.8574757,"about_ca_system_score_codex":0.00015728465,"about_ca_system_score_gemma":0.00060842204,"threshold_uncertainty_score":0.36691043},"labels":[],"label_agreement":null},{"id":"W4378836689","doi":"10.1101/2023.05.30.542910","title":"Poly(ADP-ribose) mediates bioenergetic defects and redox imbalance in neurons following oxygen and glucose deprivation","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Glycolysis; Bioenergetics; Hexokinase; Pentose phosphate pathway; Cell biology; Mitochondrion; Biology; Biochemistry; Programmed cell death; Oxidative phosphorylation; NAD+ kinase; Chemistry; Metabolism; Apoptosis; Enzyme","score_opus":0.018181518229553845,"score_gpt":0.2527889516478958,"score_spread":0.23460743341834192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378836689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847617,0.010867485,0.0001853406,0.0014909104,0.0012713994,0.00087479595,0.00010764713,0.0004355652,0.000005145152],"genre_scores_gemma":[0.9924029,0.003914875,0.0020654995,0.00053227035,0.0005508307,0.0003393968,0.0000025218635,0.00018442859,0.0000072676307],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969724,0.00015599794,0.0006304865,0.0012081512,0.00043903987,0.00059396913],"domain_scores_gemma":[0.9981027,0.00019578316,0.00030809594,0.0008839694,0.00015332151,0.0003561072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006531373,0.0005556162,0.00078044215,0.0006093196,0.00012521907,0.00012776084,0.00020050613,0.0005056548,0.000012184175],"category_scores_gemma":[0.0005407748,0.0006177206,0.00012723917,0.0007315271,0.00016187974,0.0001585442,0.00037008408,0.0007772943,0.000025569925],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009162429,0.00008480952,0.23094507,0.0005660762,0.00012222711,0.00027927384,0.000036104993,0.00001571119,0.76749736,0.000102690945,0.00025116993,0.000007917285],"study_design_scores_gemma":[0.002153738,0.00009531596,0.7938344,0.0015230707,0.00015322404,1.6321788e-7,0.0000062139716,0.0005384626,0.20015655,0.000026233061,0.0009154857,0.00059713575],"about_ca_topic_score_codex":0.00012653181,"about_ca_topic_score_gemma":0.000015960335,"teacher_disagreement_score":0.5673408,"about_ca_system_score_codex":0.00031557484,"about_ca_system_score_gemma":0.00041322442,"threshold_uncertainty_score":0.9996274},"labels":[],"label_agreement":null},{"id":"W4379281638","doi":"10.1200/jco.2023.41.16_suppl.e17589","title":"A DMBA-induced ovarian cancer model: Could it be clinically useful to test OncoTherad and erythropoietin as anticancer approaches?","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Ovarian cancer; Medicine; Ovarian carcinoma; Context (archaeology); Serous fluid; Immunohistochemistry; KRAS; Erythropoietin; Cancer; Ovary; Cancer research; Pathology; Oncology; Internal medicine; Biology; Colorectal cancer","score_opus":0.44756353311683394,"score_gpt":0.5529489784331576,"score_spread":0.10538544531632366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72950655,0.00014816473,0.0006024309,0.26317912,0.0014547331,0.000507892,0.000021530279,0.00006028435,0.004519318],"genre_scores_gemma":[0.9128738,0.0068585705,0.0074368324,0.068292536,0.0032602255,0.000060773684,0.0000037304524,0.00008761443,0.0011258807],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939831,0.00042773486,0.0036861757,0.0005491225,0.00081663707,0.0005372384],"domain_scores_gemma":[0.9920998,0.003936075,0.0017878335,0.00043742155,0.00061690103,0.0011219248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065148897,0.00029812654,0.0021873727,0.0003956456,0.00009595929,0.000030967825,0.00030398308,0.000826384,0.0006966227],"category_scores_gemma":[0.0053940853,0.00023455381,0.000523581,0.00079714914,0.0003608444,0.00014883991,0.000118549535,0.0018982167,0.00012896596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036944035,0.00975359,0.19829643,0.000282966,0.002939529,0.0026410883,0.0043375646,0.002854143,0.01399574,0.00076009735,0.38042158,0.34677324],"study_design_scores_gemma":[0.05684964,0.07040024,0.16863352,0.0015256703,0.0015087825,0.0013461513,0.0016484029,0.019382792,0.0013068891,0.0046314793,0.67159534,0.0011711251],"about_ca_topic_score_codex":0.00008598039,"about_ca_topic_score_gemma":0.00010481042,"teacher_disagreement_score":0.34560212,"about_ca_system_score_codex":0.00030778666,"about_ca_system_score_gemma":0.004053327,"threshold_uncertainty_score":0.9564827},"labels":[],"label_agreement":null},{"id":"W4379281653","doi":"10.1200/jco.2023.41.16_suppl.e17547","title":"Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Oncology; Internal medicine; PARP inhibitor; BRCA mutation; Chemotherapy; Cancer; Progression-free survival; Ovarian cancer; Maintenance therapy; Response Evaluation Criteria in Solid Tumors; Progressive disease; Poly ADP ribose polymerase; Biology","score_opus":0.12067771473555423,"score_gpt":0.4522124393765086,"score_spread":0.3315347246409544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8711821,0.00028332445,0.0009064977,0.123279534,0.0030538077,0.0011231033,0.00005538495,0.000069860966,0.00004638776],"genre_scores_gemma":[0.9752803,0.0033817678,0.0022598593,0.01689674,0.0012385977,0.00009999448,0.000008599494,0.00010245556,0.0007316815],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.992278,0.0018535814,0.0035000273,0.00069563335,0.00084041903,0.0008323444],"domain_scores_gemma":[0.9916189,0.0046035666,0.0016211004,0.0005121517,0.00086225773,0.0007820252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012860744,0.00041375952,0.0019493735,0.000903721,0.00015890626,0.000033105523,0.00041134167,0.0007854974,0.0002474358],"category_scores_gemma":[0.0059605986,0.00034359234,0.0004163476,0.001950429,0.00026683914,0.00017339035,0.00008309272,0.0014880451,0.000043892866],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5572085,0.0064914064,0.038641702,0.000084657695,0.00047714272,0.0043946314,0.0035751637,0.007910985,0.16500764,0.000029483224,0.08688032,0.12929842],"study_design_scores_gemma":[0.07744805,0.07625929,0.6001886,0.0025872758,0.00015202182,0.001288268,0.00039152452,0.0019681705,0.015691422,0.0013000371,0.22177012,0.0009552028],"about_ca_topic_score_codex":0.00020786886,"about_ca_topic_score_gemma":0.00022308918,"teacher_disagreement_score":0.5615469,"about_ca_system_score_codex":0.0020233076,"about_ca_system_score_gemma":0.0030016515,"threshold_uncertainty_score":0.9999016},"labels":[],"label_agreement":null},{"id":"W4379281665","doi":"10.1200/jco.2023.41.16_suppl.tps5623","title":"Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Olaparib; Triple-negative breast cancer; Medicine; Ovarian cancer; PARP inhibitor; PALB2; Cancer research; Cancer; BRCA mutation; Oncology; Breast cancer; Internal medicine; Germline mutation; Biology; Mutation; Genetics","score_opus":0.09415033928534335,"score_gpt":0.4692976871396335,"score_spread":0.37514734785429016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823722,0.00013954248,0.0000068602135,0.015955951,0.0008990977,0.00051129516,0.00005624952,0.000004424848,0.0000543271],"genre_scores_gemma":[0.9966026,0.0021634987,0.00011701711,0.0005705634,0.0004260419,0.000043703338,8.933226e-7,0.000012116563,0.00006355369],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99754906,0.00043370403,0.0013788821,0.00014742535,0.00032592102,0.00016503946],"domain_scores_gemma":[0.9963455,0.0012828561,0.0018063686,0.0001172345,0.0002968513,0.00015117465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018525013,0.00010446735,0.0011255312,0.00013948743,0.000030208488,0.000004285014,0.00008639511,0.0001966006,0.000055653225],"category_scores_gemma":[0.0004523026,0.00006444326,0.00007822104,0.00044275954,0.0004302504,0.00010500793,0.000029426656,0.000608851,1.98544e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69954956,0.0051105125,0.048358813,0.00019400002,0.001129541,0.00028358752,0.0044944533,0.0001090198,0.0043991096,0.00033305906,0.0020480016,0.23399034],"study_design_scores_gemma":[0.39948454,0.020370053,0.5746072,0.0006332262,0.00020169807,0.00029944902,0.0007165831,0.00012131669,0.0008912858,0.0018020731,0.00078320195,0.00008939248],"about_ca_topic_score_codex":0.0006891785,"about_ca_topic_score_gemma":0.0003951425,"teacher_disagreement_score":0.52624834,"about_ca_system_score_codex":0.00031197947,"about_ca_system_score_gemma":0.0016354833,"threshold_uncertainty_score":0.29012772},"labels":[],"label_agreement":null},{"id":"W4379281712","doi":"10.1200/jco.2023.41.16_suppl.5525","title":"Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Medicine; Olaparib; PARP inhibitor; Oncology; Biomarker; Ovarian cancer; Internal medicine; Endometrial cancer; PALB2; Somatic cell; Circulating tumor cell; Multiplex; Loss of heterozygosity; Cancer; Germline mutation; Bioinformatics; Gene; Metastasis; Poly ADP ribose polymerase; Biology; Mutation","score_opus":0.07966472871351292,"score_gpt":0.4464484640246096,"score_spread":0.36678373531109665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489903,0.00019803009,0.00002661476,0.003316032,0.0010862089,0.00025745775,0.0001374252,0.000010269183,0.00006893661],"genre_scores_gemma":[0.9967246,0.0004545216,0.0018794378,0.00055452087,0.00033169836,0.000007019832,0.00001295861,0.000016770988,0.000018481589],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960795,0.00073836197,0.002300367,0.00022141448,0.00046134074,0.00019898804],"domain_scores_gemma":[0.98011893,0.017165309,0.0019029895,0.00017266536,0.0003906477,0.00024947536],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035543565,0.00012335677,0.0012489004,0.0005304475,0.000017880355,0.0000034227355,0.000097010576,0.000243567,0.000054279095],"category_scores_gemma":[0.013888174,0.00008864685,0.0001555656,0.0006887431,0.00029262438,0.00007234517,0.000021925614,0.0005232673,0.000002724463],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60239583,0.0010138758,0.3626523,0.000016876465,0.00040612638,0.00030183265,0.00008472191,0.0003545104,0.0011248933,0.0000015498417,0.00063953234,0.031007934],"study_design_scores_gemma":[0.1544326,0.027105125,0.8142067,0.0004627686,0.00021721757,0.0000060668153,0.000038327278,0.00008439937,0.0007045842,0.000059993356,0.002605115,0.00007709775],"about_ca_topic_score_codex":0.000059011243,"about_ca_topic_score_gemma":0.000054746415,"teacher_disagreement_score":0.45155442,"about_ca_system_score_codex":0.00014017282,"about_ca_system_score_gemma":0.0019406187,"threshold_uncertainty_score":0.99441826},"labels":[],"label_agreement":null},{"id":"W4379283170","doi":"10.1200/jco.2023.41.16_suppl.e17587","title":"Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Population; Oncology; PARP inhibitor; Cancer; Ovarian cancer; Meta-analysis; Confidence interval; Poly ADP ribose polymerase","score_opus":0.22325241492691433,"score_gpt":0.489723068872906,"score_spread":0.2664706539459917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000853187,0.9898597,0.000044377815,0.0051138094,0.00028295812,0.004401264,0.00013942324,0.000023280943,0.00004986605],"genre_scores_gemma":[0.00010226174,0.9888829,0.0007470811,0.008365985,0.00055762357,0.0008093671,0.000031853026,0.00012393104,0.0003789924],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9865173,0.003050005,0.00808207,0.00073930254,0.0010684191,0.0005428753],"domain_scores_gemma":[0.98160744,0.004586587,0.011420674,0.00081069156,0.00088612025,0.0006885161],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005876052,0.00082345784,0.031590518,0.0008662355,0.00005306217,0.000032348817,0.00042024392,0.0007440586,0.0002837676],"category_scores_gemma":[0.0016521404,0.0003944071,0.0036312446,0.0021907182,0.00037743003,0.00016739848,0.00005740217,0.0023260005,0.000014258802],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055101775,0.0033333192,0.0015294884,0.41876292,0.49843135,0.0029028596,0.000096908334,0.0000036979977,3.6590873e-8,0.00003033499,0.0038606268,0.06553827],"study_design_scores_gemma":[0.016809786,0.010626744,0.0007127197,0.14832003,0.7265706,0.00024239632,0.000016601736,0.0000012412385,1.2949296e-7,0.000011044104,0.096209876,0.00047881607],"about_ca_topic_score_codex":0.00013221234,"about_ca_topic_score_gemma":0.0003333044,"teacher_disagreement_score":0.2704429,"about_ca_system_score_codex":0.00060185074,"about_ca_system_score_gemma":0.0047403956,"threshold_uncertainty_score":0.9999757},"labels":[],"label_agreement":null},{"id":"W4379329045","doi":"10.1200/jco.2023.41.16_suppl.e12611","title":"Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Oncology; Breast cancer; BRCA mutation; Meta-analysis; PARP inhibitor; Randomized controlled trial; Cancer; Chemotherapy; Cisplatin; Biology; Genetics; Poly ADP ribose polymerase; Polymerase","score_opus":0.24861264601890962,"score_gpt":0.5261196172802644,"score_spread":0.2775069712613547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379329045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020225089,0.993918,0.000012582489,0.002207477,0.00030594476,0.0030979905,0.0002051266,0.000017102366,0.000033514287],"genre_scores_gemma":[0.00029921794,0.99653894,0.00042237111,0.001546598,0.00038558067,0.0005242142,0.000022792541,0.000077938086,0.00018237458],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9868243,0.0025543063,0.00888392,0.0005248345,0.0008732705,0.0003393921],"domain_scores_gemma":[0.98213625,0.004935163,0.01080669,0.00044289904,0.0012290031,0.00044999056],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.005905407,0.00055631856,0.024511065,0.0008479384,0.000043980384,0.00002497537,0.0002501352,0.0005870395,0.00023765792],"category_scores_gemma":[0.002472369,0.00030437755,0.0035236944,0.0018345249,0.0002734821,0.00018819906,0.00006371081,0.0021351392,0.000020305883],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062359695,0.001485476,0.0025030316,0.5729662,0.38997567,0.00071827247,0.00013493246,0.000017272123,9.423003e-9,0.000012924067,0.000616047,0.030946527],"study_design_scores_gemma":[0.003847896,0.0020408689,0.006043354,0.16345853,0.8160761,0.00015035433,0.000016103299,0.0000021814058,3.7851745e-8,0.000028105524,0.00804195,0.00029453755],"about_ca_topic_score_codex":0.00012882765,"about_ca_topic_score_gemma":0.00018684253,"teacher_disagreement_score":0.42610043,"about_ca_system_score_codex":0.0006593296,"about_ca_system_score_gemma":0.0025879783,"threshold_uncertainty_score":0.9999408},"labels":[],"label_agreement":null},{"id":"W4379335592","doi":"10.1200/jco.2023.41.16_suppl.5053","title":"Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Medicine; Anemia; Enzalutamide; Population; Adverse effect; Placebo; Internal medicine; Prostate cancer; Phases of clinical research; Cancer; Clinical trial; Oncology; Androgen receptor; Pathology","score_opus":0.25554562833408717,"score_gpt":0.5647169066209956,"score_spread":0.30917127828690844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379335592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97258955,0.0022846211,0.0002264155,0.018383577,0.0018492221,0.0037524006,0.0001402472,0.000038814575,0.0007351733],"genre_scores_gemma":[0.99117476,0.00315023,0.0006460449,0.002508758,0.001362513,0.0004578943,0.00003017965,0.00004485973,0.00062475353],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9871398,0.0044205487,0.0064030616,0.00045698095,0.0010807432,0.0004988414],"domain_scores_gemma":[0.97298163,0.021778196,0.0038101608,0.00043376727,0.00061399303,0.00038224456],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0153105315,0.0003658022,0.0051503554,0.00035086198,0.0001455218,0.000048658287,0.00034825335,0.00023765865,0.000639218],"category_scores_gemma":[0.009591021,0.00020896997,0.0012667826,0.0008327637,0.0006057152,0.00023417256,0.00007029939,0.0016614923,0.00004216203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95453006,0.0031529036,0.005148006,0.00002644216,0.0045352275,0.002875966,0.0020144316,0.0055173435,0.002435232,0.00006437554,0.004143815,0.015556226],"study_design_scores_gemma":[0.957874,0.0059783435,0.016217012,0.00031558063,0.0030968532,0.00009242351,0.002977896,0.0045344033,0.00025250035,0.0011910867,0.007225564,0.00024431033],"about_ca_topic_score_codex":0.00090142543,"about_ca_topic_score_gemma":0.0024391324,"teacher_disagreement_score":0.018585239,"about_ca_system_score_codex":0.0006928869,"about_ca_system_score_gemma":0.004670123,"threshold_uncertainty_score":0.99875164},"labels":[],"label_agreement":null},{"id":"W4379336528","doi":"10.1200/jco.2023.41.16_suppl.tps5629","title":"A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"Olaparib; Medicine; Durvalumab; Oncology; Clinical endpoint; Internal medicine; PARP inhibitor; Pharmacology; Randomized controlled trial; Cancer; Nivolumab; Immunotherapy","score_opus":0.2684857014458186,"score_gpt":0.4735416012764046,"score_spread":0.20505589983058597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379336528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97868925,0.0040779575,0.0002311224,0.00765398,0.0037504362,0.0050006304,0.00010319542,0.00009381557,0.00039962213],"genre_scores_gemma":[0.9899603,0.006275369,0.00071260944,0.0011717218,0.0009804593,0.0005337322,0.00003359735,0.00012774729,0.00020443839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98134625,0.005735954,0.0081009,0.0011293594,0.0023789986,0.0013085367],"domain_scores_gemma":[0.97356874,0.017208388,0.0058308393,0.0008075313,0.0013578818,0.0012266112],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.022815939,0.0009256852,0.008583974,0.0015514025,0.0005274698,0.00012605597,0.0007349532,0.00050102634,0.00030029292],"category_scores_gemma":[0.013933194,0.00058887596,0.0010732835,0.0024907838,0.0029266633,0.0005363419,0.00040893728,0.0027271963,0.000008191438],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88383514,0.03582397,0.0054906798,0.0005275741,0.008391891,0.0009522774,0.018295357,0.00031061156,0.0011608159,0.00019123212,0.002577422,0.04244302],"study_design_scores_gemma":[0.8962279,0.070430905,0.004194872,0.0014075151,0.0051645525,0.000630519,0.011046662,0.004451835,0.0001876918,0.00041323516,0.0051976,0.0006467324],"about_ca_topic_score_codex":0.00048037322,"about_ca_topic_score_gemma":0.00083217025,"teacher_disagreement_score":0.041796286,"about_ca_system_score_codex":0.0014340035,"about_ca_system_score_gemma":0.002661763,"threshold_uncertainty_score":0.9997868},"labels":[],"label_agreement":null},{"id":"W4379535356","doi":"10.1158/1078-0432.ccr-22-3897","title":"A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; iCo Therapeutics (Canada); University of British Columbia","funders":"Mitacs; National Research Council Canada; St. Baldrick's Foundation","keywords":"Olaparib; PARP inhibitor; PARP1; Cancer research; DNA damage; Vorinostat; Biology; Comet assay; Ex vivo; Histone deacetylase; Poly ADP ribose polymerase; Molecular biology; In vivo; Biochemistry; Histone; DNA","score_opus":0.4469852012513099,"score_gpt":0.5868546534968304,"score_spread":0.1398694522455205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379535356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98243815,0.00026468723,0.000035689365,0.013575564,0.0004493824,0.00065080414,0.000026650689,0.00014478112,0.002414271],"genre_scores_gemma":[0.9934936,0.000851754,0.00009900806,0.0006268729,0.0016400894,0.0006445778,0.000016265965,0.00004871669,0.002579097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628747,0.0005120301,0.0004750904,0.00065544,0.0013247391,0.00074525044],"domain_scores_gemma":[0.9971468,0.0016293399,0.0000666047,0.0004592418,0.00036210797,0.0003359052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004031973,0.00015236446,0.0004401956,0.0004873792,0.0001565259,0.000034918707,0.00015881527,0.00019859757,0.0009011696],"category_scores_gemma":[0.0006078214,0.000120681885,0.00012466805,0.0024041103,0.0006010743,0.00014074956,0.0001263522,0.001712104,0.00044107097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0141017875,0.0009573043,0.8148704,0.00030388587,0.00017179959,0.00061846804,0.000270029,0.00006789815,0.012043083,0.00025551996,0.0691185,0.08722132],"study_design_scores_gemma":[0.010889672,0.0018681681,0.9064074,0.0011084208,0.000018063718,0.000022319087,0.00020437202,0.0007166299,0.007845671,0.0008762182,0.06976475,0.00027827887],"about_ca_topic_score_codex":0.00044394383,"about_ca_topic_score_gemma":0.00040858777,"teacher_disagreement_score":0.091537036,"about_ca_system_score_codex":0.0005384676,"about_ca_system_score_gemma":0.0013893822,"threshold_uncertainty_score":0.9867176},"labels":[],"label_agreement":null},{"id":"W4379662245","doi":"10.1200/jco.2023.41.17_suppl.lba5506","title":"Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Bevacizumab; Internal medicine; Carboplatin; Taxane; Population; Oncology; Paclitaxel; BRCA mutation; Ovarian cancer; Urology; Cancer; Chemotherapy; Cisplatin; Breast cancer","score_opus":0.032711900382277684,"score_gpt":0.39351388607395377,"score_spread":0.3608019856916761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98107624,0.0006456696,0.0005064607,0.010511565,0.0009833218,0.005775509,0.000209748,0.000043535194,0.00024795477],"genre_scores_gemma":[0.99249846,0.001585932,0.0016479071,0.0025098638,0.0006193147,0.0006811095,0.0000865944,0.000081077276,0.00028977136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99022496,0.0025613746,0.0047147362,0.0008116028,0.0010512127,0.000636122],"domain_scores_gemma":[0.97469383,0.018321525,0.0052103954,0.00047507705,0.00075726735,0.00054187357],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009345078,0.00054332905,0.004866627,0.00026437867,0.00019035532,0.00006723715,0.00025444562,0.00042246512,0.00006190777],"category_scores_gemma":[0.012464691,0.00030994145,0.00041701752,0.00059279543,0.0008810122,0.00039430166,0.0000635865,0.0015657736,0.0000043241344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96267784,0.0016423385,0.0046500587,0.000022988537,0.0012607173,0.00071297976,0.001286225,0.00026032768,0.00011725527,0.000016898666,0.004493875,0.02285848],"study_design_scores_gemma":[0.95379174,0.020023583,0.017881634,0.0011194636,0.0012082749,0.00009163793,0.00058671273,0.0035184764,0.000048220016,0.00038227788,0.000994512,0.00035349664],"about_ca_topic_score_codex":0.00080717885,"about_ca_topic_score_gemma":0.0015056152,"teacher_disagreement_score":0.022504983,"about_ca_system_score_codex":0.000518295,"about_ca_system_score_gemma":0.0022320899,"threshold_uncertainty_score":0.99993527},"labels":[],"label_agreement":null},{"id":"W4379791219","doi":"10.1097/01.hjh.0000939052.67173.a2","title":"VEGF INHIBITION-INDUCED PARP OVERACTIVATION LEADS TO ENDOTHELIAL DYSFUNCTION AND INFLAMMATION: ROLE OF SIRTUIN 1 SIGNALLING","year":2023,"lang":"en","type":"article","venue":"Journal of Hypertension","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Olaparib; PARP inhibitor; Endothelial dysfunction; Sirtuin 1; Cancer research; Poly ADP ribose polymerase; Pharmacology; Internal medicine; Endocrinology; Biology; Biochemistry; Downregulation and upregulation","score_opus":0.04124830879777826,"score_gpt":0.27828463040709805,"score_spread":0.2370363216093198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379791219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962316,0.00016576218,0.000345854,0.0025893028,0.00032548752,0.00019450863,0.0000034694344,0.00002810833,0.000115875395],"genre_scores_gemma":[0.9980435,0.00024965484,0.00048816417,0.00033239124,0.0008092083,0.000005003642,0.000009003896,0.000019991563,0.000043127777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863833,0.000053620086,0.00056241354,0.0001274395,0.00049010734,0.0001281159],"domain_scores_gemma":[0.9986397,0.00015014558,0.00039740457,0.00010312073,0.00059342827,0.00011617668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004433277,0.00011008998,0.00031963893,0.00044022064,0.00006884962,0.000014855288,0.000027725686,0.00008900573,0.00004720641],"category_scores_gemma":[0.0002404283,0.00009365653,0.00008594983,0.00038169834,0.000020024865,0.00029228968,0.000016986232,0.0002034082,0.000020303016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009922354,0.000042002204,0.0010665506,0.00003375419,0.000033852994,0.000039417246,0.00036649755,0.0004040749,0.98393047,0.000056334073,0.00064042956,0.012394408],"study_design_scores_gemma":[0.0032323063,0.0010924938,0.015881663,0.0007486035,0.00007399065,0.00052262435,0.00047203337,0.0010764815,0.97384125,0.00069142063,0.0022604251,0.00010671561],"about_ca_topic_score_codex":0.0000104540995,"about_ca_topic_score_gemma":0.0000015342598,"teacher_disagreement_score":0.014815113,"about_ca_system_score_codex":0.00009312118,"about_ca_system_score_gemma":0.000101565725,"threshold_uncertainty_score":0.38192022},"labels":[],"label_agreement":null},{"id":"W4380992939","doi":"10.1158/1078-0432.ccr-23-0797","title":"Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Eisai; Seagen; Ontario Institute for Cancer Research; Novocure; Regeneron Pharmaceuticals; Princess Margaret Cancer Foundation; Genentech; PharmaMar; AstraZeneca","keywords":"Olaparib; PARP inhibitor; Ovarian cancer; Cancer research; Cancer; Medicine; Oncology; DNA; Pharmacology; Internal medicine; Poly ADP ribose polymerase; Biology; Genetics; Polymerase","score_opus":0.2764266495127368,"score_gpt":0.565274280103611,"score_spread":0.2888476305908742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380992939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916794,0.0015400782,0.00027820762,0.000951237,0.0006627017,0.003915971,0.0007407492,0.000052311516,0.00017935707],"genre_scores_gemma":[0.9943608,0.00052522,0.00077521167,0.00007176474,0.0006292227,0.001945934,0.000101102254,0.000078838035,0.0015119244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940232,0.0005289482,0.0022475668,0.000760699,0.0017071825,0.0007323881],"domain_scores_gemma":[0.9955599,0.001747357,0.00082314276,0.00061725447,0.0009932106,0.00025915474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069999634,0.00022561793,0.0012799696,0.00045094694,0.00018213126,0.000012216259,0.00033606015,0.0002772786,0.0005256517],"category_scores_gemma":[0.002080801,0.00020853772,0.00035876044,0.0017119077,0.0005917461,0.0001270787,0.00026731845,0.0006680423,0.0000067508986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1658381,0.0015660763,0.0007436206,0.0021754345,0.00018636903,0.000031583062,0.0009878214,0.000026511234,0.80080307,0.00020243599,0.020839365,0.006599613],"study_design_scores_gemma":[0.2813635,0.0077798655,0.0011683006,0.010134283,0.00013902165,0.0000024817384,0.0004617761,0.0036558479,0.68759215,0.0036362761,0.0036497456,0.00041673635],"about_ca_topic_score_codex":0.00032235557,"about_ca_topic_score_gemma":0.0002402669,"teacher_disagreement_score":0.11552541,"about_ca_system_score_codex":0.0007796123,"about_ca_system_score_gemma":0.0016572012,"threshold_uncertainty_score":0.85039216},"labels":[],"label_agreement":null},{"id":"W4381550340","doi":"10.1016/j.sbi.2023.102643","title":"PARP–nucleic acid interactions: Allosteric signaling, PARP inhibitor types, DNA bridges, and viral RNA surveillance","year":2023,"lang":"en","type":"review","venue":"Current Opinion in Structural Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Nucleic acid; Poly ADP ribose polymerase; RNA; Biology; DNA; Polymerase; PARP inhibitor; Allosteric regulation; Computational biology; Enzyme; Genetics; Biochemistry; Gene","score_opus":0.12577957805518217,"score_gpt":0.43485644975532606,"score_spread":0.30907687170014386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381550340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003478478,0.9762738,0.000009378403,0.00016694651,0.018103644,0.0011847964,0.0005710909,0.00017384575,0.00003803296],"genre_scores_gemma":[0.0033639045,0.9901032,0.00006165327,0.000046447174,0.0029729211,0.00027262405,0.003026817,0.00009210818,0.000060321374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963937,0.0005175417,0.0013131797,0.0009938552,0.00019888055,0.0005828621],"domain_scores_gemma":[0.9982127,0.00033922843,0.00067247206,0.00047348597,0.00010605832,0.00019605698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029482885,0.0006952374,0.0020917235,0.00053001544,0.000101252,0.000047033507,0.00025140456,0.00045275807,0.0002218164],"category_scores_gemma":[0.00016170624,0.00055752875,0.00034191844,0.000547834,0.000323597,0.000110171575,0.00020791839,0.0011194842,0.00015581593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016062328,0.000036158966,0.0010881913,0.015008418,0.0002452195,0.000008148199,0.000092350696,7.079345e-7,0.00030614686,0.0003929165,0.004275291,0.9783858],"study_design_scores_gemma":[0.0011860966,0.00025531114,0.0006105417,0.014896549,0.00008343762,0.00027973362,0.000014687565,0.000026249574,0.000029748704,0.00032630045,0.98171294,0.00057838316],"about_ca_topic_score_codex":0.000032213942,"about_ca_topic_score_gemma":0.000010227673,"teacher_disagreement_score":0.97780746,"about_ca_system_score_codex":0.0004494688,"about_ca_system_score_gemma":0.00027313863,"threshold_uncertainty_score":0.9996876},"labels":[],"label_agreement":null},{"id":"W4381597538","doi":"10.1158/1078-0432.ccr-23-0563","title":"Assessment of Homologous Recombination Deficiency in Ovarian Cancer","year":2023,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Ovarian cancer; Homologous recombination; Homologous chromosome; Biomarker; Chemotherapy; Medicine; Cancer; Oncology; Cancer research; Internal medicine; Biology; Genetics; DNA; Gene","score_opus":0.42896126329092593,"score_gpt":0.6229724124775339,"score_spread":0.19401114918660795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381597538","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033041768,0.002750585,0.00005116743,0.9451723,0.004051446,0.0024517875,0.00037514156,0.00010586487,0.011999912],"genre_scores_gemma":[0.2792708,0.074920334,0.001130518,0.5402228,0.025832739,0.012776034,0.0013510151,0.00083051494,0.0636652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926214,0.0014614915,0.0016966548,0.0010904109,0.0021642146,0.0009658346],"domain_scores_gemma":[0.9946514,0.0026602505,0.00041027117,0.00095415494,0.0011627256,0.00016121929],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.006686168,0.00029250386,0.0012222634,0.001118346,0.00009451629,0.000029523737,0.0005405081,0.0014746492,0.0024741131],"category_scores_gemma":[0.00083366997,0.00027242006,0.00033902813,0.0020030097,0.00084895664,0.00006652172,0.00020298289,0.008258368,0.00008718916],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020506173,0.00035384315,0.050862532,0.0010069992,0.00011169409,0.0006141861,0.00006162646,0.000021632022,0.00021894342,0.00012116195,0.9353174,0.01110493],"study_design_scores_gemma":[0.00972134,0.0024164722,0.47075894,0.005348297,0.00014099636,0.00002080599,0.00007934561,0.00032149348,0.0005826338,0.0056761247,0.5042464,0.0006871445],"about_ca_topic_score_codex":0.004006858,"about_ca_topic_score_gemma":0.0006914363,"teacher_disagreement_score":0.43107098,"about_ca_system_score_codex":0.0021016067,"about_ca_system_score_gemma":0.0050104265,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4383107148","doi":"10.1016/j.ejca.2023.112966","title":"Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis","year":2023,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency","funders":"Eisai; National Institute for Health and Care Research; Genentech; AstraZeneca; Mersana Therapeutics; Clovis Oncology; Cancer Research UK; Amgen","keywords":"Ovarian cancer; Cancer; Oncology; Internal medicine; Poly ADP ribose polymerase; Medicine; Polymerase; Cancer research; Biology; Genetics; DNA","score_opus":0.12187028416771417,"score_gpt":0.3790859937164474,"score_spread":0.25721570954873324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383107148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009650151,0.98111194,0.00011345633,0.002572833,0.0024869512,0.0016571037,0.0021967143,0.000039874285,0.00017100127],"genre_scores_gemma":[0.04880686,0.9475677,0.00006695652,0.0005427508,0.0014392846,0.00053151464,0.00015466093,0.0002684696,0.0006217797],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9912296,0.0019028859,0.0037843643,0.0010814347,0.0011247202,0.0008769999],"domain_scores_gemma":[0.9941676,0.00033831675,0.0035119164,0.0005302438,0.00096559117,0.00048631732],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026117458,0.0011769282,0.0064477855,0.0026996974,0.00015247548,0.00011562719,0.00052255514,0.0003047163,0.0021488087],"category_scores_gemma":[0.00020169266,0.0008730702,0.0020010113,0.0032738238,0.00028065027,0.00036907048,0.0002053485,0.0018669283,0.000008668943],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031511202,0.0015224449,0.031112755,0.011849629,0.15526505,0.0038385838,0.0033242798,0.0065830047,0.000052457326,0.000069082314,0.0027321812,0.7804994],"study_design_scores_gemma":[0.05177716,0.0038166263,0.09132457,0.069315985,0.43870157,0.0001353115,0.00043810578,0.0024349724,0.00026698408,0.00012715337,0.33590046,0.005761113],"about_ca_topic_score_codex":0.0034666073,"about_ca_topic_score_gemma":0.026783757,"teacher_disagreement_score":0.7747383,"about_ca_system_score_codex":0.0028239843,"about_ca_system_score_gemma":0.002127279,"threshold_uncertainty_score":0.999372},"labels":[],"label_agreement":null},{"id":"W4383186570","doi":"10.18553/jmcp.2023.29.7.758","title":"Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects","year":2023,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Olaparib; Cohort; Taxane; Breast cancer; Cancer; Poly ADP ribose polymerase; Biology","score_opus":0.09824664513683765,"score_gpt":0.43613664796998347,"score_spread":0.33789000283314585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383186570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935327,0.0014493119,0.0000098202145,0.00048725386,0.00025092304,0.0039105103,0.00032088446,0.000015801364,0.000022785947],"genre_scores_gemma":[0.99825907,0.0006166012,0.0006105233,0.00020593956,0.00008179224,0.00011769936,0.000045799392,0.000037136717,0.000025420839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964814,0.00040954168,0.0018524162,0.000271965,0.0006987091,0.00028596199],"domain_scores_gemma":[0.99652046,0.00021337744,0.0019535725,0.00020454817,0.0008641393,0.00024387764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013248475,0.00021983222,0.001123779,0.0004196611,0.000093951,0.000025000254,0.00016210217,0.0000236102,0.000032793934],"category_scores_gemma":[0.00017414175,0.00018146247,0.00009406948,0.0006580104,0.00007831452,0.0002544252,0.000050624218,0.0002695027,4.2327474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16966929,0.024339968,0.6960234,0.007482384,0.0044404226,0.00035005683,0.047997195,0.0010018955,0.02556226,0.00004183258,0.0046863058,0.018404998],"study_design_scores_gemma":[0.46566,0.015267184,0.49749583,0.0017483776,0.0009954161,0.000009785077,0.012545745,0.00027156062,0.004659743,0.00005359843,0.0008676014,0.0004251435],"about_ca_topic_score_codex":0.0012832412,"about_ca_topic_score_gemma":0.0023011041,"teacher_disagreement_score":0.29599074,"about_ca_system_score_codex":0.00034767826,"about_ca_system_score_gemma":0.00068092614,"threshold_uncertainty_score":0.7399825},"labels":[],"label_agreement":null},{"id":"W4383198701","doi":"10.3389/fonc.2023.1197168","title":"Global trends in BRCA-related breast cancer research from 2013 to 2022: A scientometric analysis","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Web of science; Bibliometrics; Oncology; Medicine; Cancer; Incidence (geometry); Demography; Internal medicine; Library science; Meta-analysis; Computer science","score_opus":0.058921481928579086,"score_gpt":0.46580727643543135,"score_spread":0.40688579450685225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383198701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96600354,0.0019084447,0.0002539657,0.023841282,0.0023079666,0.00038128113,0.0005641273,0.000097667165,0.0046417527],"genre_scores_gemma":[0.98973805,0.0012610324,0.0015294905,0.0009702498,0.00025408377,0.00042450574,0.0002337687,0.000027232341,0.0055616032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967667,0.00043569878,0.0005172443,0.000716228,0.00073108554,0.00083305925],"domain_scores_gemma":[0.99883646,0.00015777664,0.0000789048,0.00043137302,0.0001945574,0.000300909],"candidate_categories":["bibliometrics","insufficient_payload"],"consensus_categories":["bibliometrics"],"category_scores_codex":[0.0017092387,0.0001629653,0.00075178547,0.015785273,0.00006891171,0.000019503048,0.00030794472,0.00032747304,0.0028999972],"category_scores_gemma":[0.00012884341,0.00016435132,0.00014120068,0.09022275,0.00024282101,0.00007856133,0.00013864618,0.0005114892,0.00018404858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005158963,0.00015435297,0.58164924,0.0000040414016,0.00028114842,0.00018983752,0.00048604194,0.0013476053,0.00016415614,0.000012612027,0.32780588,0.08738916],"study_design_scores_gemma":[0.0040101125,0.00023180449,0.95048875,0.000049531376,0.00009842016,0.000009244893,0.0006444257,0.0041414853,0.000029565183,0.0007278523,0.039413266,0.00015556214],"about_ca_topic_score_codex":0.011920744,"about_ca_topic_score_gemma":0.00991522,"teacher_disagreement_score":0.36883947,"about_ca_system_score_codex":0.005741473,"about_ca_system_score_gemma":0.0005291233,"threshold_uncertainty_score":0.9980753},"labels":[{"model":"gemma","categories":["bibliometrics"],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":["bibliometrics"],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4383552852","doi":"10.3390/curroncol30070479","title":"Peripheral Neuropathy Potentially Associated to Poly (ADP-Ribose) Polymerase Inhibitors: An Analysis of the Eudravigilance Database","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fundação para a Ciência e a Tecnologia; European Regional Development Fund; Programa Operacional Regional do Centro","keywords":"Medicine; Pharmacovigilance; Peripheral neuropathy; Drug reaction; Drug; Adverse drug reaction; Internal medicine; Adverse effect; Cancer; Pharmacology; Bioinformatics; Oncology; Database; Diabetes mellitus; Endocrinology; Biology","score_opus":0.08478300463459079,"score_gpt":0.4177107845374358,"score_spread":0.33292777990284506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383552852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98957145,0.00060775987,0.00031253728,0.0049449685,0.0029842188,0.0004951927,0.00064932636,0.00017605408,0.00025851792],"genre_scores_gemma":[0.99626887,0.00013578888,0.00008411664,0.001662708,0.0007143436,0.00007535999,0.00070995436,0.000039204828,0.00030965288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747306,0.0004646421,0.00057785783,0.00051374413,0.0005101037,0.00046060662],"domain_scores_gemma":[0.9982619,0.00011399738,0.0003077175,0.0007747865,0.00025279666,0.00028878418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004948701,0.00022647716,0.0006649769,0.0005004229,0.00013374955,0.000016868693,0.00031794145,0.00011998479,0.00029516144],"category_scores_gemma":[0.00029281538,0.00018269908,0.00032336861,0.003244054,0.00017579572,0.00010997245,0.00016526286,0.00036996044,0.00004251167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001993418,0.004164745,0.43186095,0.00014267032,0.0018849588,0.00027249474,0.005110822,0.0010087264,0.40207598,0.00034972388,0.047377806,0.10375771],"study_design_scores_gemma":[0.007999281,0.0026337516,0.7847608,0.00044215468,0.0032629215,0.000042444444,0.0007948696,0.008887286,0.02679237,0.000057037778,0.16358978,0.00073730614],"about_ca_topic_score_codex":0.00010758254,"about_ca_topic_score_gemma":0.0001777232,"teacher_disagreement_score":0.3752836,"about_ca_system_score_codex":0.00038572474,"about_ca_system_score_gemma":0.00042347529,"threshold_uncertainty_score":0.7450252},"labels":[],"label_agreement":null},{"id":"W4384339320","doi":"10.1158/2159-8290.cd-22-0412","title":"Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i> –Associated Pancreatic Cancer in the Clinical and Preclinical Setting","year":2023,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Ontario Institute for Cancer Research","funders":"Terry Fox Research Institute; Tel Aviv University; Hebrew University of Jerusalem; Canadian Cancer Society Research Institute; Ministry of Science, Technology and Space; Israel Science Foundation; Pancreatic Cancer Canada Foundation; Princess Margaret Cancer Foundation; Deutsches Krebsforschungszentrum; AstraZeneca","keywords":"Germline; Pancreatic cancer; Poly ADP ribose polymerase; Cancer research; PARP inhibitor; Olaparib; Medicine; BRCA mutation; Cancer; Germline mutation; Biology; Genetics; Bioinformatics; Oncology; Mutation; Polymerase; Ovarian cancer; DNA; Gene","score_opus":0.04817231314042761,"score_gpt":0.39999979350532516,"score_spread":0.3518274803648975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384339320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802175,0.0017733906,0.0000054501284,0.016599584,0.00033477362,0.0007444124,0.00019020586,0.0000330041,0.00010167893],"genre_scores_gemma":[0.9935206,0.0030459845,0.000027101298,0.0024625931,0.00034364397,0.0002786581,0.000013153633,0.00003035942,0.00027791195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740225,0.0005180013,0.0009301791,0.00045849485,0.00032200888,0.0003690796],"domain_scores_gemma":[0.997342,0.0020191255,0.00020789099,0.00028281452,0.000034464912,0.000113714195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027766982,0.00018861309,0.00061983115,0.00020740248,0.00004273245,0.000029910774,0.00010002741,0.00015705824,0.000031707725],"category_scores_gemma":[0.0009458696,0.00014504358,0.00008243617,0.0009255314,0.0002642244,0.00014495541,0.00008315489,0.00045838804,0.0000028754898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003783686,0.00011817291,0.98450476,0.00009852669,0.000061014165,0.000052593412,0.0018998813,0.00016803324,0.003392704,0.000021216492,0.0029803554,0.0029190334],"study_design_scores_gemma":[0.004866634,0.00033839073,0.9894773,0.0016884087,0.00005758365,0.0000059260183,0.0006572757,0.00028972756,0.0012956522,0.0003479137,0.00080495386,0.00017025536],"about_ca_topic_score_codex":0.00043813032,"about_ca_topic_score_gemma":0.0019420363,"teacher_disagreement_score":0.014136991,"about_ca_system_score_codex":0.00018128614,"about_ca_system_score_gemma":0.00043370065,"threshold_uncertainty_score":0.59147054},"labels":[],"label_agreement":null},{"id":"W4384692356","doi":"10.3389/fimmu.2023.1253094","title":"Corrigendum: The critical role of PARPs in regulating innate immune responses","year":2023,"lang":"en","type":"erratum","venue":"Frontiers in Immunology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Innate immune system; Immunology; Immunity; Medicine; Immune system; Biology","score_opus":0.02493103892302413,"score_gpt":0.3092031461174488,"score_spread":0.2842721071944247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384692356","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06402757,0.45251185,0.0007214757,0.02278983,0.39610243,0.003988662,0.0005552015,0.0005984655,0.05870454],"genre_scores_gemma":[0.29599428,0.055545744,0.00923486,0.0022876307,0.004535178,0.0022814174,0.001947382,0.0011058197,0.6270677],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99650973,0.0007212262,0.001219567,0.00051873043,0.00034626503,0.0006844666],"domain_scores_gemma":[0.99801546,0.00042109034,0.00036625122,0.0009969792,0.0001595702,0.00004063965],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010221273,0.00036674517,0.0013233516,0.0011239203,0.00008046021,0.000012030994,0.00048525908,0.001086091,0.00013112453],"category_scores_gemma":[0.0017599767,0.00031624912,0.00020642857,0.0010008408,0.0011954138,0.00006075858,0.00018521083,0.0025548716,0.000027935952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004997188,0.00024078504,0.00933991,0.00033676662,0.000517507,0.00027805447,0.0031703245,0.000011564551,0.010807184,0.0013821577,0.9572841,0.011634449],"study_design_scores_gemma":[0.0067140716,0.0010757911,0.109246515,0.0058708,0.00020657307,0.00026117457,0.010128995,0.0012374391,0.0076881703,0.027952088,0.8286763,0.00094208965],"about_ca_topic_score_codex":0.00043761177,"about_ca_topic_score_gemma":0.00007810357,"teacher_disagreement_score":0.56836313,"about_ca_system_score_codex":0.0005412883,"about_ca_system_score_gemma":0.0007650258,"threshold_uncertainty_score":0.99992895},"labels":[],"label_agreement":null},{"id":"W4384819754","doi":"10.1200/jco.23.00402","title":"Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sumitomo Dainippon Pharma Oncology; Sierra Oncology; Bavarian Nordic; PharmaMar; Eisai; Springworks Therapeutics; Seagen; MacroGenics; Pfizer; Incyte; Moderna; Puma Biotechnology; Agios Pharmaceuticals; Mirati Therapeutics; Clovis Oncology; Astex Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Foghorn Therapeutics; Calithera Biosciences; AstraZeneca; Novocure; Ipsen; Jazz Pharmaceuticals; Array BioPharma; Exelixis; Karyopharm Therapeutics; Merck KGaA; Sanofi; GlaxoSmithKline; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Olaparib; Temozolomide; Internal medicine; Oncology; Neutropenia; Clinical endpoint; Phases of clinical research; Chemotherapy; Surgery; Clinical trial","score_opus":0.25019151630043096,"score_gpt":0.6109909192460797,"score_spread":0.3607994029456488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384819754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715398,0.000025828942,0.00021629097,0.004753278,0.00059240253,0.02251875,0.000013203604,0.000023388715,0.00031703763],"genre_scores_gemma":[0.982593,0.00010650883,0.005037497,0.0012533709,0.0012976874,0.008999393,0.00000354069,0.00003563173,0.00067339843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996196,0.00026692866,0.0027726653,0.00021661211,0.00031826808,0.00022957708],"domain_scores_gemma":[0.9950946,0.001892211,0.001962295,0.00022519765,0.0005446171,0.000281078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003316945,0.0001420338,0.0016179959,0.00021043008,0.000066368775,0.000004221631,0.00014197352,0.0002110631,0.000087214],"category_scores_gemma":[0.002010772,0.00010529119,0.00027989075,0.00024138446,0.00019218588,0.00011182331,0.000081745966,0.00051131885,0.000003506098],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12147525,0.03617193,0.017141527,0.00045246465,0.0011201508,0.0007798698,0.0008898972,0.000039455037,0.028397875,0.00012931104,0.026073707,0.76732856],"study_design_scores_gemma":[0.21405515,0.3318891,0.018085226,0.0001929654,0.0002143608,0.00030182864,0.0005560329,0.00022476235,0.0024336695,0.00090400013,0.43100834,0.00013455623],"about_ca_topic_score_codex":0.0000036532178,"about_ca_topic_score_gemma":0.000012651675,"teacher_disagreement_score":0.76719403,"about_ca_system_score_codex":0.000082003724,"about_ca_system_score_gemma":0.00074387935,"threshold_uncertainty_score":0.429365},"labels":[],"label_agreement":null},{"id":"W4385155205","doi":"10.1016/j.ejca.2023.113249","title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; PARP inhibitor; Androgen receptor; Cancer research; Poly ADP ribose polymerase; DNA repair; Medicine; Cancer; Internal medicine; Oncology; Biology; Gene; Polymerase; Genetics","score_opus":0.10310390274270996,"score_gpt":0.4134314400773371,"score_spread":0.31032753733462715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385155205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003796653,0.9935954,0.000067527115,0.0022637397,0.0013466418,0.0011411656,0.0010629331,0.000026200043,0.00011667786],"genre_scores_gemma":[0.00022959147,0.99575853,0.00030175512,0.00027257617,0.0018198076,0.00019605964,0.00009752054,0.00017079466,0.0011533501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671733,0.00071962696,0.0015093858,0.00032829447,0.0003320351,0.0003933224],"domain_scores_gemma":[0.9966508,0.0004786179,0.0019482195,0.00023254713,0.0004458255,0.00024396038],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017079173,0.0004079919,0.0013035253,0.000260946,0.0003136912,0.00010867298,0.00015761002,0.00006522855,0.00009452883],"category_scores_gemma":[0.0001481857,0.00025970643,0.00042679755,0.0002526106,0.00024876613,0.00011762809,0.000039706614,0.00056853256,0.000012678663],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007581287,0.000040822393,0.000013860641,0.0035885226,0.0016175673,0.0001381166,0.0004681131,0.000002183835,0.0007895245,0.00010956601,0.010290323,0.9821833],"study_design_scores_gemma":[0.0029763419,0.0007884737,0.000015650518,0.016994754,0.0017012074,0.00023024346,0.00010679453,0.0000027931594,0.00028091198,0.00006913971,0.9765747,0.00025896335],"about_ca_topic_score_codex":0.000036442238,"about_ca_topic_score_gemma":0.00004823453,"teacher_disagreement_score":0.9819243,"about_ca_system_score_codex":0.00032694876,"about_ca_system_score_gemma":0.0012206185,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W4385161863","doi":"10.3390/cells12141904","title":"Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance","year":2023,"lang":"en","type":"review","venue":"Cells","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"PARP1; Carcinogenesis; Cancer; Expansive; Genome instability; Biology; Poly ADP ribose polymerase; DNA repair; Cancer research; DNA damage; Bioinformatics; Medicine; Polymerase; Genetics; DNA","score_opus":0.08809149080466544,"score_gpt":0.3831396569275624,"score_spread":0.29504816612289697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385161863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008677488,0.9968706,0.00005617449,0.0002917334,0.00008006277,0.0013619809,0.00038131303,0.000021932241,0.00006845782],"genre_scores_gemma":[0.00051038974,0.9977343,0.00032087858,0.00005648537,0.00014229932,0.0008438677,0.000022231332,0.000060806655,0.00030872016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988351,0.000060922855,0.00049110985,0.00032353896,0.000093106944,0.00019624288],"domain_scores_gemma":[0.9986138,0.00064660306,0.0003059646,0.00032650027,0.00006271149,0.00004446846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033939313,0.00021439715,0.00096661766,0.00015177994,0.000086412096,0.000019846451,0.00010359869,0.00011811489,0.00000886478],"category_scores_gemma":[0.000018506498,0.00015152553,0.00013419168,0.00033569228,0.00013714236,0.000030322568,0.000027590886,0.00014885621,0.0000014462023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049320333,0.000049390117,0.00034019694,0.025417248,0.00039542437,0.0000012735004,0.0009392301,0.0000023184589,0.002237871,0.0011483843,0.0005445564,0.9688748],"study_design_scores_gemma":[0.00047466392,0.000021652397,0.0003089483,0.013828234,0.00037189672,0.0000034699392,0.0002385938,0.000003986577,0.0021530031,0.0014240358,0.98099005,0.00018143833],"about_ca_topic_score_codex":0.000028206285,"about_ca_topic_score_gemma":0.000031088504,"teacher_disagreement_score":0.9804455,"about_ca_system_score_codex":0.00007557766,"about_ca_system_score_gemma":0.00016589709,"threshold_uncertainty_score":0.6179032},"labels":[],"label_agreement":null},{"id":"W4385357652","doi":"10.21037/tcr-23-365","title":"Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer","year":2023,"lang":"en","type":"letter","venue":"Translational Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Triple-negative breast cancer; Oncology; Medicine; Breast cancer; Triple negative; Internal medicine; Chemotherapy; Metastatic breast cancer; BRCA mutation; Poly ADP ribose polymerase; Cancer; Cancer research; Biology; Genetics; Gene; Polymerase","score_opus":0.14416618798342226,"score_gpt":0.4350276307718343,"score_spread":0.2908614427884121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385357652","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1025201,0.002910295,0.00002482787,0.8871599,0.0003758191,0.0028836257,0.0037136632,0.0001589333,0.00025285763],"genre_scores_gemma":[0.61353517,0.010693938,0.00085732475,0.344027,0.0061618276,0.009358997,0.0035177192,0.0010368057,0.0108111985],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9948168,0.000622533,0.00074539025,0.0009072081,0.0020124596,0.0008956076],"domain_scores_gemma":[0.996575,0.002217325,0.0002107453,0.000257946,0.0005467982,0.00019218167],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00140126,0.00047597598,0.00096601265,0.0010923479,0.00025003846,0.00009366299,0.00016049383,0.00053338596,0.0016766879],"category_scores_gemma":[0.000103297476,0.00042527827,0.00012939562,0.0017168587,0.0006332378,0.000159692,0.000025009362,0.00317786,0.000011595256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01623414,0.0005725902,0.06831793,0.003882432,0.0024427762,0.0013343315,0.008637314,0.00075582205,0.0024193383,0.00008296752,0.8640446,0.03127574],"study_design_scores_gemma":[0.17569882,0.0028569833,0.52452016,0.027935069,0.0009468252,0.00024920833,0.0012350804,0.022966864,0.0060020313,0.011799669,0.22111467,0.004674646],"about_ca_topic_score_codex":0.0054891864,"about_ca_topic_score_gemma":0.0031849046,"teacher_disagreement_score":0.64293,"about_ca_system_score_codex":0.0008747498,"about_ca_system_score_gemma":0.0026327746,"threshold_uncertainty_score":0.9998199},"labels":[],"label_agreement":null},{"id":"W4385442656","doi":"10.2217/fon-2023-0228","title":"TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple-negative breast cancer; Internal medicine; Triple negative; Cancer","score_opus":0.05001610890154408,"score_gpt":0.3967505803952925,"score_spread":0.3467344714937484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385442656","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2597716,0.008221367,0.023104852,0.60723025,0.042886764,0.025527623,0.014222128,0.0034895118,0.015545948],"genre_scores_gemma":[0.7269709,0.017763454,0.05472384,0.060981322,0.035734765,0.03005938,0.0036951934,0.0009877854,0.06908336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977624,0.00023157184,0.00050866266,0.00056490983,0.00029675046,0.00063572143],"domain_scores_gemma":[0.99824804,0.0004934901,0.00021327977,0.0003738301,0.00039568462,0.00027565868],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044902143,0.00030962648,0.0007729273,0.00026486118,0.00019510614,0.000019728865,0.00018233819,0.00021219796,0.0025788213],"category_scores_gemma":[0.00014007291,0.00022703905,0.0001760536,0.0008642035,0.00016240517,0.00011212845,0.00004945621,0.0003985622,0.00016176103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021291452,0.00083386374,0.0005789305,0.000560217,0.00095852057,0.00031306825,0.0025327273,0.000082605526,0.0039185984,0.001979566,0.4137519,0.5531985],"study_design_scores_gemma":[0.02718349,0.0037449435,0.007734699,0.00041048345,0.0004887836,0.0010481016,0.0029824623,0.0012916246,0.0026636913,0.001613897,0.9503112,0.0005266688],"about_ca_topic_score_codex":0.00013616633,"about_ca_topic_score_gemma":0.00097521767,"teacher_disagreement_score":0.55267185,"about_ca_system_score_codex":0.00096871465,"about_ca_system_score_gemma":0.0019610052,"threshold_uncertainty_score":0.998333},"labels":[],"label_agreement":null},{"id":"W4385767120","doi":"10.1101/2023.08.07.552262","title":"pADP-ribosylation Regulates the Cytoplasmic Localization, Cleavage and Pro-apoptotic Function of HuR","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; McGill University","funders":"Canadian Institutes of Health Research; King Abdullah University of Science and Technology; Taibah University; McGill University","keywords":"PARP1; Apoptosis; Cell biology; Cleavage (geology); Cytoplasm; ADP-ribosylation; Programmed cell death; Poly ADP ribose polymerase; Biology; Chemistry; Enzyme; NAD+ kinase; Biochemistry","score_opus":0.024703160956120823,"score_gpt":0.2483102943829494,"score_spread":0.22360713342682859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385767120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98271286,0.0013881816,0.010661387,0.0013781752,0.0013322242,0.0018227582,0.00012831537,0.00056095474,0.0000151652575],"genre_scores_gemma":[0.9975321,0.0006901674,0.0005429376,0.00037174634,0.00046882324,0.00022573498,0.0000028272234,0.00013734434,0.00002826537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977099,0.00014706627,0.00066170486,0.0006913877,0.00048466938,0.00030528448],"domain_scores_gemma":[0.99755913,0.0001179339,0.0005737959,0.0010104869,0.0006037114,0.00013491695],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071513414,0.00038018337,0.00052665354,0.0002867306,0.00017706005,0.00007578051,0.00016811573,0.00043086364,0.000037957794],"category_scores_gemma":[0.00021616506,0.00032738308,0.000114156006,0.00065422314,0.00026235392,0.00011508683,0.00016640402,0.00051098445,0.000037682392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059421745,0.00021875439,0.059248555,0.0028711348,0.00067698915,0.000020547637,0.0001007281,0.0015337893,0.9264255,0.0019396642,0.006350246,0.000019860185],"study_design_scores_gemma":[0.001610654,0.00022458893,0.43527296,0.0017355441,0.00048999744,9.593645e-8,0.000016319664,0.0040233335,0.55213344,0.000083512685,0.0039021175,0.0005074153],"about_ca_topic_score_codex":0.000031600914,"about_ca_topic_score_gemma":0.0000027473682,"teacher_disagreement_score":0.37602443,"about_ca_system_score_codex":0.00023148269,"about_ca_system_score_gemma":0.00040699364,"threshold_uncertainty_score":0.9999178},"labels":[],"label_agreement":null},{"id":"W4385949342","doi":"10.3390/curroncol30080556","title":"Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Calgary; McGill University; Jewish General Hospital","funders":"LEO Pharma; AstraZeneca Canada; Purdue University; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Olaparib; Breast cancer; Oncology; Adjuvant; Disease; Internal medicine; Cancer; Gynecology","score_opus":0.5057417256418567,"score_gpt":0.6184643480533307,"score_spread":0.11272262241147402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385949342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000040553564,0.9683691,0.0015108675,0.01567089,0.0048581297,0.006568606,0.0027749953,0.000039796065,0.00020354245],"genre_scores_gemma":[0.000091574075,0.988494,0.001242095,0.00040348773,0.0020662418,0.0072841165,0.00025644372,0.00006531221,0.00009672447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745935,0.00039591285,0.0011698611,0.0004885599,0.00016449508,0.00032179087],"domain_scores_gemma":[0.98644316,0.01002367,0.00096624653,0.00038445863,0.0019582564,0.0002241944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012379751,0.0002888444,0.0017435477,0.00027412962,0.00022752318,0.000021556816,0.00015191296,0.00043603923,0.00009298489],"category_scores_gemma":[0.0039129374,0.00019989508,0.0007080919,0.00029554515,0.00033234994,0.00007725185,0.00002525554,0.0007617124,0.000019615825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023324862,0.00027500335,0.000025573836,0.0027548303,0.0009149132,0.0000039555057,0.0012587545,7.088564e-7,3.9050477e-7,0.010142858,0.052227072,0.9321627],"study_design_scores_gemma":[0.0017586167,0.0008460277,0.00004328162,0.005454679,0.0038056043,0.000157134,0.0009724787,0.000066306144,4.818785e-7,0.0018800116,0.9848457,0.0001696737],"about_ca_topic_score_codex":0.022966785,"about_ca_topic_score_gemma":0.110686064,"teacher_disagreement_score":0.9326186,"about_ca_system_score_codex":0.0030176353,"about_ca_system_score_gemma":0.014097073,"threshold_uncertainty_score":0.9914921},"labels":[],"label_agreement":null},{"id":"W4386035677","doi":"10.1093/narcan/zcad043","title":"The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors","year":2023,"lang":"en","type":"article","venue":"NAR Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval","funders":"Canadian Institutes of Health Research","keywords":"PARP1; Context (archaeology); DNA repair; Genome instability; Poly ADP ribose polymerase; DNA Damage Repair; DNA damage; Biology; Chemistry; Computational biology; DNA; Polymerase; Biochemistry","score_opus":0.023317430258493057,"score_gpt":0.3375704797925897,"score_spread":0.31425304953409666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386035677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98853,0.0019341151,0.000057256468,0.007946648,0.0001931567,0.0007963835,0.000053096,0.000019193612,0.00047019057],"genre_scores_gemma":[0.99520284,0.0039689774,0.000013239421,0.0002867942,0.00007646422,0.00031651292,0.000008136461,0.000016922977,0.00011013198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987291,0.00006367049,0.00036768275,0.00020561767,0.00042713128,0.00020676089],"domain_scores_gemma":[0.99918747,0.00017865648,0.00019882276,0.00026696527,0.00013587171,0.000032224452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006691152,0.00012180939,0.00024097928,0.0001165367,0.000058594374,0.0000074058,0.000118736134,0.00006904563,0.000014587986],"category_scores_gemma":[0.000059761318,0.000070125585,0.00005992883,0.00058384,0.00019564951,0.000039971335,0.000019065596,0.0002771636,0.0000040303803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016322069,0.001837454,0.35332268,0.0062916954,0.0010762939,0.00021188894,0.08458578,0.010115599,0.18739587,0.0045783296,0.017489057,0.3167733],"study_design_scores_gemma":[0.011256858,0.0019418814,0.8942491,0.0049851397,0.00017322741,0.000043482632,0.009761722,0.009210624,0.046363838,0.012060727,0.00940426,0.00054915476],"about_ca_topic_score_codex":0.0001681146,"about_ca_topic_score_gemma":0.00030025156,"teacher_disagreement_score":0.5409264,"about_ca_system_score_codex":0.00020082702,"about_ca_system_score_gemma":0.00017619615,"threshold_uncertainty_score":0.28596383},"labels":[],"label_agreement":null},{"id":"W4386183400","doi":"10.5376/cge.2023.11.0001","title":"Exploration of the Classification and Risk Factors of Female Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Public health; Gynecology; Incidence (geometry); Cancer; Family medicine; Oncology; Internal medicine; Pathology","score_opus":0.09102674641630593,"score_gpt":0.3434631315789065,"score_spread":0.2524363851626006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386183400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355465,0.004573013,0.00020260648,0.0007111393,0.00024655936,0.00025962526,0.0003861372,0.000012732507,0.00005355099],"genre_scores_gemma":[0.8712309,0.12837107,0.00009463877,0.000035842477,0.00008795619,0.00003907717,0.000009149433,0.000016669088,0.00011469333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992191,0.00003438773,0.0002595737,0.00017328575,0.00019153483,0.00012212015],"domain_scores_gemma":[0.99927545,0.000035545716,0.00021585192,0.00023676168,0.00017095706,0.000065463806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009352872,0.00010195437,0.00018421983,0.000062166364,0.00006910672,0.0000068750123,0.000054375694,0.0000731384,0.000031701074],"category_scores_gemma":[0.000011678366,0.000076209384,0.000040363506,0.00029766298,0.000215324,0.000025262654,0.00003614976,0.00007721818,4.841451e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004020786,0.00002139646,0.9407314,0.00013024795,0.00006644771,1.2499956e-7,0.0013912864,0.0011125554,0.037876196,0.000067819004,0.0002115132,0.018350827],"study_design_scores_gemma":[0.00048635536,0.00006288337,0.9310209,0.00010701355,0.00011979301,0.0000010800052,0.0004885167,0.0019766109,0.06411858,0.0003613243,0.0011824998,0.000074438125],"about_ca_topic_score_codex":0.0002612898,"about_ca_topic_score_gemma":0.000111482055,"teacher_disagreement_score":0.123798065,"about_ca_system_score_codex":0.000033826607,"about_ca_system_score_gemma":0.00011321258,"threshold_uncertainty_score":0.31077287},"labels":[],"label_agreement":null},{"id":"W4386208799","doi":"","title":"Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.","year":2023,"lang":"en","type":"article","venue":"PubMed","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Serous fluid; Ovarian cancer; Medicine; Oncology; Epithelial ovarian cancer; Homologous recombination; Cancer research; Serous ovarian cancer; Internal medicine; Cancer; Biology; Genetics; Gene","score_opus":0.09207707661634072,"score_gpt":0.36184679135349446,"score_spread":0.2697697147371537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386208799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90173995,0.0009256373,0.012983334,0.0645902,0.0033032647,0.013751862,0.0006918595,0.001399871,0.00061399676],"genre_scores_gemma":[0.9479407,0.001597106,0.013882788,0.0042715305,0.00020731709,0.031333555,0.00009829729,0.00007379605,0.0005949126],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967519,0.0000634671,0.00084750995,0.00061406073,0.00052899146,0.0011940764],"domain_scores_gemma":[0.99729633,0.0009109459,0.00043846408,0.0005190728,0.0005028402,0.0003323418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011047194,0.0002928268,0.00060312357,0.0014631338,0.0004949373,0.00005308349,0.00028087493,0.00019341068,0.00003394049],"category_scores_gemma":[0.0023418735,0.00023750031,0.00010051831,0.005603752,0.000102185695,0.00013445878,0.00008027848,0.00033602474,0.000017770313],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006757525,0.00030952686,0.0032618216,0.00004179648,0.000059588176,0.000019971118,0.00032513923,0.00012215455,0.000491706,0.0018667139,0.0054374924,0.9873883],"study_design_scores_gemma":[0.036926445,0.009377143,0.78305054,0.00072086,0.00008366672,0.0004024251,0.0013724295,0.0007889963,0.011829242,0.015903817,0.1383069,0.0012375315],"about_ca_topic_score_codex":0.0003988079,"about_ca_topic_score_gemma":0.00013978183,"teacher_disagreement_score":0.9861508,"about_ca_system_score_codex":0.0014422138,"about_ca_system_score_gemma":0.00085748243,"threshold_uncertainty_score":0.9684982},"labels":[],"label_agreement":null},{"id":"W4386323182","doi":"10.3390/curroncol30090584","title":"Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen receptor; DNA repair; Androgen deprivation therapy; Oncology; Poly ADP ribose polymerase; Cancer research; Bioinformatics; Internal medicine; Cancer; Biology; Computational biology; Genetics; Polymerase; Gene","score_opus":0.5119666223549992,"score_gpt":0.5395145540920439,"score_spread":0.027547931737044618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386323182","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003013696,0.986456,0.0000034729028,0.0024557114,0.0016235971,0.005046816,0.0011842246,0.00005413617,0.0001623693],"genre_scores_gemma":[0.000021551976,0.9953119,0.000017550141,0.000798329,0.00025556152,0.0019014553,0.00041862426,0.0000709582,0.0012040507],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972951,0.00037151118,0.0011381586,0.0004725795,0.00032256,0.00040011102],"domain_scores_gemma":[0.99817723,0.0004006142,0.00063592306,0.0004095327,0.0002558464,0.00012087333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035003902,0.00034260665,0.0017529761,0.00043325286,0.00003739483,0.00001188963,0.000109916065,0.00022556208,0.0009070582],"category_scores_gemma":[0.0001657499,0.000234402,0.00029398833,0.0009623559,0.00014520284,0.00006188174,0.00011804475,0.0005962799,0.0011531682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011907703,0.00050982274,0.00035030692,0.009221141,0.00012688614,0.00002059423,0.00090133626,0.0000072860726,0.0000024413691,0.0000061072924,0.1603636,0.8283714],"study_design_scores_gemma":[0.0011897325,0.00044771595,0.00014393049,0.030107688,0.00042730005,0.0000074086884,0.0000078042785,0.00001719044,0.000010884659,0.000013348309,0.9674316,0.00019539025],"about_ca_topic_score_codex":0.000053113527,"about_ca_topic_score_gemma":0.000038188864,"teacher_disagreement_score":0.828176,"about_ca_system_score_codex":0.0009443642,"about_ca_system_score_gemma":0.00084856676,"threshold_uncertainty_score":0.99962455},"labels":[],"label_agreement":null},{"id":"W4386349084","doi":"10.1158/1078-0432.c.6717743.v2","title":"Data from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Olaparib; PARP inhibitor; PARP1; Cancer research; DNA damage; Biology; Vorinostat; Ex vivo; Molecular biology; Propidium iodide; Histone deacetylase; Comet assay; Poly ADP ribose polymerase; In vivo; Chemistry; Programmed cell death; Biochemistry; Histone; DNA; Apoptosis; Polymerase","score_opus":0.20521382156163762,"score_gpt":0.37570179993175845,"score_spread":0.17048797837012084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386349084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708878,0.00031504716,0.009271949,0.00819612,0.002057548,0.0012978744,0.0032908847,0.0006704607,0.0040123304],"genre_scores_gemma":[0.98061424,0.00021025202,0.0066616074,0.0010836484,0.0024266967,0.00032910268,0.005495394,0.00014642133,0.0030326252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997074,0.00010394337,0.0004160514,0.0013057134,0.00074469956,0.00035559924],"domain_scores_gemma":[0.99725246,0.0003216273,0.00019873862,0.0019708886,0.00009448712,0.00016178792],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000430158,0.00038866102,0.00068468245,0.0003261287,0.00005411238,0.00005879412,0.00038758203,0.00037280252,0.0013094186],"category_scores_gemma":[0.00008706363,0.00031958302,0.00008702958,0.0003397304,0.0001137568,0.00019183803,0.0010734439,0.0013497963,0.00028014177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01882702,0.0036218928,0.5015337,0.0022155065,0.0037211874,0.0023177706,0.0013403115,0.0012289729,0.061045673,0.00034918118,0.3782723,0.025526492],"study_design_scores_gemma":[0.0237255,0.00074624334,0.8413413,0.012588469,0.0005948525,0.00011330504,0.00060591847,0.017367404,0.033404216,0.008894654,0.058091797,0.0025263412],"about_ca_topic_score_codex":0.003340454,"about_ca_topic_score_gemma":0.0024690223,"teacher_disagreement_score":0.3398076,"about_ca_system_score_codex":0.00047560368,"about_ca_system_score_gemma":0.00092309195,"threshold_uncertainty_score":0.9999256},"labels":[],"label_agreement":null},{"id":"W4386498504","doi":"10.1016/j.xcrm.2023.101191","title":"PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy","year":2023,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Universität Zürich; Canada Research Chairs; McGill University; National Science Foundation","keywords":"Cytarabine; Idarubicin; Poly ADP ribose polymerase; Biology; Chemotherapy; Myeloid leukemia; Apoptosis; Cancer research; Leukemia; Polymerase; Immunology; DNA; Genetics","score_opus":0.01652070448842994,"score_gpt":0.2948674724442065,"score_spread":0.27834676795577656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386498504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761992,0.0011768995,0.00004518844,0.009546817,0.0011811386,0.0006637373,0.0000042571482,0.00066298654,0.010519772],"genre_scores_gemma":[0.96808845,0.0011401671,0.00009264794,0.00354106,0.0006311742,0.00012844062,0.00014772348,0.00010958193,0.02612078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968777,0.000035119105,0.00095885317,0.00070850574,0.0008029988,0.0006168744],"domain_scores_gemma":[0.997678,0.00012228826,0.00045903065,0.0012278855,0.00012413983,0.00038869656],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006814835,0.0003699325,0.00079622975,0.00030680772,0.00016069296,0.000014619765,0.00013902668,0.00019155702,0.00091580837],"category_scores_gemma":[0.00031340064,0.0002853234,0.00014969386,0.00070006907,0.00022918209,0.00010974081,0.000060783183,0.0004191031,0.00008272911],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010954095,0.00006656919,0.05356307,0.00025775924,0.000127883,0.0018481371,0.0012220879,0.00000781138,0.7661251,0.0000051954353,0.17322084,0.0034460227],"study_design_scores_gemma":[0.009331575,0.0004625308,0.10891781,0.00080189254,0.00016048527,0.0010055372,0.0012158863,0.000091530754,0.7430873,0.000592813,0.13370387,0.0006287927],"about_ca_topic_score_codex":0.00014078844,"about_ca_topic_score_gemma":0.0000028536451,"teacher_disagreement_score":0.05535474,"about_ca_system_score_codex":0.00038682512,"about_ca_system_score_gemma":0.0002515372,"threshold_uncertainty_score":0.9999975},"labels":[],"label_agreement":null},{"id":"W4386945070","doi":"10.1007/s40265-023-01934-0","title":"Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options","year":2023,"lang":"en","type":"review","venue":"Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; DNA repair; Drug resistance; Cancer; Cancer research; Homologous recombination; Poly ADP ribose polymerase; Tumor microenvironment; Disease; Polymerase; Biology; Internal medicine; DNA; Genetics","score_opus":0.07922667141945612,"score_gpt":0.4102456523476324,"score_spread":0.3310189809281763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386945070","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022287963,0.9944177,0.000005244336,0.001038443,0.0011438353,0.0012021791,0.0010754768,0.000088635294,0.0010061808],"genre_scores_gemma":[0.0000044650865,0.99390274,0.000098029894,0.000043647757,0.0030349563,0.0011764581,0.00075112766,0.000072419985,0.00091617316],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984427,0.00007662724,0.000581121,0.00041352396,0.00026653745,0.00021945749],"domain_scores_gemma":[0.9989626,0.000075459546,0.0003168614,0.00039437765,0.00009003292,0.00016068116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000078397374,0.0003740756,0.0014610934,0.00025308153,0.00007222479,0.000014376492,0.000045562618,0.00022355953,0.00040743864],"category_scores_gemma":[0.0000035569956,0.00028285314,0.00039712034,0.00046811765,0.00010822065,0.000039936298,0.000023432984,0.00021123218,0.00006851902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016620317,0.00014783889,0.000004292695,0.010041485,0.00032808306,0.000016676428,0.00047223317,1.3458886e-7,0.0000010323547,0.0012718466,0.0033170218,0.98438275],"study_design_scores_gemma":[0.0013686944,0.00015090258,0.000014431989,0.012189511,0.0013459582,0.000058802118,0.00007121022,0.0000011714321,0.000011108467,0.00016101156,0.9844184,0.00020879968],"about_ca_topic_score_codex":0.000043597836,"about_ca_topic_score_gemma":0.000008029385,"teacher_disagreement_score":0.98417395,"about_ca_system_score_codex":0.00048152456,"about_ca_system_score_gemma":0.00057992496,"threshold_uncertainty_score":0.9999624},"labels":[],"label_agreement":null},{"id":"W4386947981","doi":"10.1016/j.ygyno.2023.06.127","title":"Evaluating the real-world impact of first line PARP inhibitor maintenance therapy in patients with BRCA mutated ovarian tumors (1213)","year":2023,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; PARP inhibitor; Oncology; Ovarian cancer; BRCA mutation; Poly ADP ribose polymerase; Cancer research; Internal medicine; Gynecology; Cancer; Genetics; Gene; Biology; Polymerase","score_opus":0.06548004029207989,"score_gpt":0.40365563801673904,"score_spread":0.33817559772465916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386947981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914298,0.00003554303,0.000010925032,0.0034234447,0.0003541636,0.0018032849,0.000044353867,0.00015275225,0.002745751],"genre_scores_gemma":[0.9972451,0.00023531607,0.00035497293,0.0009827504,0.00016462783,0.00039147932,0.00012750101,0.00004431028,0.00045394854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971983,0.00044875962,0.0007850378,0.0004833887,0.0004048899,0.0006796449],"domain_scores_gemma":[0.9968715,0.0014581516,0.00055398035,0.0005166783,0.00047884134,0.00012087276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014738297,0.0003021642,0.0008112291,0.00037945912,0.00014315211,0.000010211218,0.00023758055,0.00020027507,0.0008478282],"category_scores_gemma":[0.0007462062,0.00017225425,0.00015074175,0.0018520259,0.00038860843,0.0000754118,0.00007076179,0.0005034186,0.00005342729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061245873,0.0010854674,0.9616224,0.000036335114,0.00021430463,0.0001491959,0.0009246761,0.0030640194,0.0011884967,0.00006222555,0.0036211563,0.021907147],"study_design_scores_gemma":[0.016286448,0.025092846,0.95500314,0.00015427869,0.0000330191,0.000009740925,0.00014892299,0.0014327086,0.0003437162,0.0005215967,0.00078059686,0.00019296187],"about_ca_topic_score_codex":0.000678636,"about_ca_topic_score_gemma":0.0017412261,"teacher_disagreement_score":0.024007378,"about_ca_system_score_codex":0.0015060266,"about_ca_system_score_gemma":0.0008600761,"threshold_uncertainty_score":0.9283124},"labels":[],"label_agreement":null},{"id":"W4386948615","doi":"10.1016/j.ygyno.2023.06.508","title":"Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)","year":2023,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Ovarian cancer; Internal medicine; Germline; Cancer; Gene; Genetics; Biology","score_opus":0.07166682431699495,"score_gpt":0.3849911861315105,"score_spread":0.31332436181451556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386948615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217296,0.00010659144,0.000014966208,0.0027447771,0.0011190041,0.0019526877,0.000056985922,0.000032967637,0.0017990767],"genre_scores_gemma":[0.9980225,0.00049550284,0.000059565453,0.0006706463,0.00017912331,0.0003413242,0.00013955342,0.000014976847,0.000076838434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768656,0.00049854536,0.0006545264,0.0004053424,0.0003175251,0.00043748727],"domain_scores_gemma":[0.998354,0.00090700097,0.00028656374,0.00028252412,0.000095630036,0.00007428272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012013855,0.00020926118,0.00073439156,0.0002623883,0.00005537499,0.000007418924,0.00016399914,0.000248658,0.0006760608],"category_scores_gemma":[0.00019299191,0.00014071006,0.000058651607,0.00060053676,0.00025399655,0.00006335247,0.0000618258,0.0004775094,0.000007651791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2250956,0.005464049,0.6510623,0.000096765296,0.00015137008,0.00033016587,0.0020992379,0.000062415864,0.00014836976,0.00069097755,0.0015760623,0.11322268],"study_design_scores_gemma":[0.25228214,0.009545676,0.73545814,0.00007041132,0.0000449731,0.0000054848556,0.000099284414,0.000028114844,0.000018676335,0.00014389471,0.0021783733,0.00012482404],"about_ca_topic_score_codex":0.00019347637,"about_ca_topic_score_gemma":0.0035651948,"teacher_disagreement_score":0.113097854,"about_ca_system_score_codex":0.00054553413,"about_ca_system_score_gemma":0.000506897,"threshold_uncertainty_score":0.74023914},"labels":[],"label_agreement":null},{"id":"W4386949040","doi":"10.1016/j.ygyno.2023.06.329","title":"Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: Retrospective US cohort study (2209)","year":2023,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Tolerability; Ovarian cancer; Oncology; Retrospective cohort study; PARP inhibitor; Cohort; Internal medicine; Gynecology; Cancer; Poly ADP ribose polymerase; Adverse effect","score_opus":0.05951657630883816,"score_gpt":0.42353143367182217,"score_spread":0.364014857362984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386949040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756765,0.00009686295,0.0000032880334,0.0015774609,0.0014554583,0.004963355,0.00004077082,0.00019279761,0.01599352],"genre_scores_gemma":[0.9951386,0.00029200196,0.00022845532,0.0002446941,0.0002092407,0.003356127,0.000054333384,0.000026620344,0.00044996894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99580896,0.0011199113,0.0009810368,0.0008060254,0.0007773339,0.00050672615],"domain_scores_gemma":[0.9973704,0.00069720525,0.0004648827,0.00060408766,0.00074129284,0.00012209125],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005244164,0.00024966017,0.0011619993,0.0004970227,0.00008758678,0.000005797815,0.00015812546,0.00026489215,0.0020789285],"category_scores_gemma":[0.0013140639,0.0002334297,0.00011153113,0.0018251612,0.00023321122,0.000100244826,0.00009124727,0.00047096037,0.00005238276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078418053,0.0014650886,0.97677344,0.000030457553,0.00013066696,0.00006525822,0.0007651423,0.001187782,0.0028997152,0.00014888599,0.0008948698,0.014854523],"study_design_scores_gemma":[0.010938182,0.0033892065,0.97944903,0.000045116954,0.00021350944,0.000004356269,0.0007602629,0.0007422246,0.0010076656,0.002134528,0.0011280167,0.00018791427],"about_ca_topic_score_codex":0.0017554759,"about_ca_topic_score_gemma":0.018589377,"teacher_disagreement_score":0.019462073,"about_ca_system_score_codex":0.0062958016,"about_ca_system_score_gemma":0.0015356619,"threshold_uncertainty_score":0.9993188},"labels":[],"label_agreement":null},{"id":"W4387135441","doi":"10.1136/ijgc-2023-esgo.45","title":"#1056 Mirvetuximab soravtansine demonstrates efficacy over investigator’s choice chemotherapy regardless of prior PARPi exposure in phase III MIRASOL trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Confidence interval; Oncology; Progression-free survival; Clinical endpoint; Chemotherapy; Metastatic breast cancer; Topotecan; Clinical trial; Cancer; Breast cancer","score_opus":0.06036787237546302,"score_gpt":0.4109277313982548,"score_spread":0.35055985902279174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387135441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98800045,0.000964596,0.000058849997,0.008428284,0.0016328917,0.0005605466,0.00006184904,0.00003726933,0.0002552423],"genre_scores_gemma":[0.99417865,0.0015602601,0.00036531393,0.0023865937,0.0011860337,0.000053335265,0.00002039183,0.000029249833,0.00022017886],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968965,0.00014357793,0.0013715384,0.0002814151,0.0010018144,0.00030517636],"domain_scores_gemma":[0.9969938,0.0008761343,0.0009236055,0.0001722686,0.0007639895,0.00027025028],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074035686,0.00024285083,0.00081001216,0.0004476084,0.00003494374,0.0000326451,0.0004071839,0.00023871726,0.0021164373],"category_scores_gemma":[0.0013905403,0.00018889084,0.0003288787,0.00052124157,0.0002800056,0.00020068177,0.000043449065,0.0005702955,0.00000873688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33216223,0.011853945,0.15337531,0.00018341199,0.0032568,0.0025458988,0.0020310867,0.0014667753,0.2920455,0.00067598105,0.04918109,0.15122196],"study_design_scores_gemma":[0.6096227,0.006700262,0.29394057,0.0013820061,0.00018332039,0.00018642595,0.00019850113,0.00060139014,0.05268399,0.0013477745,0.03260569,0.00054737844],"about_ca_topic_score_codex":0.00006881122,"about_ca_topic_score_gemma":0.0000714749,"teacher_disagreement_score":0.27746046,"about_ca_system_score_codex":0.0004963525,"about_ca_system_score_gemma":0.00085745845,"threshold_uncertainty_score":0.99879575},"labels":[],"label_agreement":null},{"id":"W4387135575","doi":"10.1136/ijgc-2023-esgo.899","title":"#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Shota Rustaveli National Science Foundation; National Science Foundation","keywords":"Bevacizumab; Medicine; Carboplatin; Oncology; Internal medicine; Olaparib; Progression-free survival; Clinical endpoint; Urology; Ovarian cancer; Surgery; Cancer; Chemotherapy; Randomized controlled trial; Cisplatin","score_opus":0.024671418381854684,"score_gpt":0.31675219718426856,"score_spread":0.2920807788024139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387135575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977193,0.00041062533,0.00035447627,0.016018322,0.0022780213,0.001950536,0.0012623288,0.000109381836,0.0004233133],"genre_scores_gemma":[0.99262,0.00061261916,0.0013550932,0.0026152127,0.0014440374,0.0006434803,0.00028130418,0.0000950046,0.00033325847],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9931215,0.00059879443,0.001939127,0.00089503714,0.00265147,0.0007940459],"domain_scores_gemma":[0.99228704,0.002728293,0.0019344284,0.00053753133,0.0021670738,0.00034566273],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013685728,0.0006445002,0.0012125539,0.0003217095,0.00024752162,0.0001671975,0.0009718823,0.0002995055,0.0012728304],"category_scores_gemma":[0.0025249694,0.00038812152,0.00032384915,0.00097183796,0.00040642917,0.00059458276,0.00014146669,0.0016503629,0.000043062744],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7439813,0.0023752127,0.14299937,0.00005350298,0.003554271,0.0038377962,0.0063539734,0.025520748,0.00054148707,0.00060520926,0.009077073,0.061100062],"study_design_scores_gemma":[0.29034626,0.00389903,0.69755167,0.0017093759,0.00025777443,0.00008744286,0.00081321,0.000804735,0.00026279202,0.0012604897,0.002449588,0.00055764726],"about_ca_topic_score_codex":0.0013049778,"about_ca_topic_score_gemma":0.0031837916,"teacher_disagreement_score":0.55455226,"about_ca_system_score_codex":0.00244836,"about_ca_system_score_gemma":0.0015490535,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W4387135996","doi":"10.1136/ijgc-2023-esgo.22","title":"#161 Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"","keywords":"Hazard ratio; Medicine; Internal medicine; Cohort; Ovarian cancer; Oncology; Progression-free survival; Proportional hazards model; Cancer; Chemotherapy; Confidence interval","score_opus":0.07927103726113195,"score_gpt":0.40133592823622494,"score_spread":0.322064890975093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387135996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225587,0.0002569165,0.000042581953,0.004933425,0.001665723,0.00048326593,0.00009578617,0.00000676014,0.00025966184],"genre_scores_gemma":[0.9973996,0.0013469493,0.000043930533,0.0005684242,0.0005125448,0.00005185925,0.000026336264,0.000010815552,0.000039520968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976737,0.00017705595,0.000790048,0.00019707065,0.000945024,0.00021712818],"domain_scores_gemma":[0.99840057,0.00046040968,0.00048899354,0.000104328814,0.00046714064,0.00007855112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083103677,0.00015703384,0.0004424432,0.0002956186,0.000024958208,0.000023035527,0.00026852894,0.00009737898,0.0011137502],"category_scores_gemma":[0.00022926035,0.000095100695,0.000102562546,0.00031547924,0.00013756489,0.00013976365,0.00004330267,0.00050081,0.0000017232261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17046499,0.002090179,0.7758058,0.000028264298,0.00029645488,0.00031535045,0.0005181757,0.00027504424,0.00016160366,0.0003382249,0.0006796755,0.04902629],"study_design_scores_gemma":[0.12488157,0.0026877308,0.87062407,0.00036479175,0.000035424473,0.000014469764,0.000037065634,0.00004140194,0.000055131997,0.00016064367,0.0010012296,0.000096497424],"about_ca_topic_score_codex":0.000109892746,"about_ca_topic_score_gemma":0.0007141637,"teacher_disagreement_score":0.094818294,"about_ca_system_score_codex":0.0005305745,"about_ca_system_score_gemma":0.00033633749,"threshold_uncertainty_score":0.9997994},"labels":[],"label_agreement":null},{"id":"W4387142310","doi":"10.1136/ijgc-2023-esgo.507","title":"#66 Survival of PARP inhibitor (PARPi) naïve ovarian cancer patients with a BRCA-mutation receiving maintenance olaparib after chemotherapy for first recurrence. An exploratory analysis of the solo2/engot-ov21 trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Internal medicine; Oncology; BRCA mutation; Placebo; Ovarian cancer; Chemotherapy; Maintenance therapy; Cancer; Poly ADP ribose polymerase; Biology; Pathology","score_opus":0.036841560699802454,"score_gpt":0.3359133151894682,"score_spread":0.2990717544896658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387142310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99173146,0.00015612015,0.0006101782,0.0033356377,0.002770331,0.00077425234,0.00056831626,0.00001812857,0.00003557248],"genre_scores_gemma":[0.99718225,0.00053774804,0.00031443397,0.00065681315,0.00076521793,0.00040562532,0.000050564176,0.00002791059,0.000059452697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696773,0.00017207378,0.0011006299,0.00032105506,0.0011530633,0.00028541894],"domain_scores_gemma":[0.9949149,0.0006078473,0.0015372558,0.00022438818,0.002583437,0.00013219009],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080622104,0.0002305578,0.00077509996,0.00041615978,0.00007559672,0.00002755385,0.00041946166,0.00016443749,0.0009460143],"category_scores_gemma":[0.0005732912,0.00014545982,0.00046513035,0.0009937356,0.00024646855,0.0002987617,0.000048394395,0.00031603026,0.0000010432918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22610348,0.0026667884,0.6996346,0.00016291,0.009899362,0.00005671026,0.004982326,0.008443004,0.0022018328,0.0002977915,0.00433402,0.041217133],"study_design_scores_gemma":[0.054583117,0.0029111824,0.931755,0.0007880657,0.0009201042,0.0000046777536,0.00036169207,0.0010433361,0.004007485,0.00046113582,0.002883034,0.00028117653],"about_ca_topic_score_codex":0.000061132916,"about_ca_topic_score_gemma":0.0010603179,"teacher_disagreement_score":0.23212036,"about_ca_system_score_codex":0.00066722883,"about_ca_system_score_gemma":0.0005844728,"threshold_uncertainty_score":0.9999673},"labels":[],"label_agreement":null},{"id":"W4387297143","doi":"10.1158/1078-0432.ccr-23-2260","title":"Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"Ontario Institute for Cancer Research","keywords":"PALB2; Olaparib; Pancreatic cancer; PARP inhibitor; Reversion; Medicine; Cancer; Oncology; Clinical trial; Poly ADP ribose polymerase; DNA repair; Cancer research; BRCA mutation; Internal medicine; Bioinformatics; Mutation; Biology; Genetics; Germline mutation; DNA; Breast cancer; Phenotype; Polymerase","score_opus":0.49625347445507545,"score_gpt":0.5922869451710471,"score_spread":0.09603347071597162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387297143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96783006,0.00076976715,0.000039535124,0.02813271,0.00055267767,0.0010908268,0.000040649695,0.00012168419,0.0014220853],"genre_scores_gemma":[0.9879465,0.0047640493,0.00006485677,0.0030304056,0.0013658522,0.0015374029,0.0000060283865,0.00005064956,0.0012342673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99601054,0.0008328663,0.0006271812,0.0006125402,0.0010318486,0.00088501564],"domain_scores_gemma":[0.9954082,0.003092126,0.00005449772,0.0007076892,0.00034289694,0.00039461907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008321794,0.00015647696,0.00049034867,0.00023270214,0.00019860931,0.000043179116,0.00021896476,0.00015526044,0.0006870371],"category_scores_gemma":[0.0015828799,0.00011195161,0.00014884365,0.0024552117,0.00038962337,0.00005936917,0.00024198108,0.0013500156,0.0006250715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024757222,0.00025788843,0.79046416,0.00019000405,0.00014799277,0.0006475768,0.00177179,0.0011754349,0.014431988,0.0003331685,0.06899883,0.11910546],"study_design_scores_gemma":[0.002598461,0.0003618593,0.9298522,0.0010142156,0.000022169743,0.00000881242,0.000606768,0.001576332,0.0032311217,0.0009680905,0.059541892,0.00021807238],"about_ca_topic_score_codex":0.0025547699,"about_ca_topic_score_gemma":0.004227927,"teacher_disagreement_score":0.13938805,"about_ca_system_score_codex":0.0006140995,"about_ca_system_score_gemma":0.0009695697,"threshold_uncertainty_score":0.8034238},"labels":[],"label_agreement":null},{"id":"W4387339999","doi":"10.1016/j.annonc.2023.09.3110","title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"MSD Italia; Eisai; Incyte; AstraZeneca; Les Laboratories Pierre Fabre; Gilead Sciences; Clovis Oncology; Servier; Pfizer","keywords":"Medicine; Olaparib; PARP inhibitor; Ovarian cancer; Oncology; Internal medicine; Cancer; Poly ADP ribose polymerase; Polymerase; Genetics","score_opus":0.07819275097947659,"score_gpt":0.3885708198044928,"score_spread":0.31037806882501623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387339999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98905146,0.000109288776,0.000033334454,0.005151385,0.00023435126,0.0028363306,0.00019120268,0.00013727622,0.0022553778],"genre_scores_gemma":[0.9959186,0.00060326286,0.00037552667,0.0013699591,0.00029134302,0.0008215135,0.00020758386,0.00007426316,0.0003379937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970337,0.00034167647,0.0007958008,0.000634626,0.00047120184,0.00072298443],"domain_scores_gemma":[0.9977306,0.00033928704,0.00059852743,0.00044340707,0.0006605024,0.00022766968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006843665,0.00035760688,0.0011424698,0.0004254834,0.00006964114,0.000008516406,0.000120670906,0.00030565544,0.00012329864],"category_scores_gemma":[0.00020171881,0.00026968823,0.000111574074,0.001093835,0.00032417045,0.00014893022,0.000037283506,0.00049272116,0.00002321066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86092806,0.006556646,0.028253512,0.00023106707,0.0011862846,0.0012805989,0.0074007353,0.00014605503,0.0031777069,0.0003119819,0.02296311,0.06756425],"study_design_scores_gemma":[0.8084946,0.08856959,0.0631471,0.0031041454,0.0002985123,0.00005528786,0.00079628173,0.00020275112,0.015822837,0.00018020795,0.018482083,0.0008465886],"about_ca_topic_score_codex":0.00040420707,"about_ca_topic_score_gemma":0.00075618044,"teacher_disagreement_score":0.082012944,"about_ca_system_score_codex":0.00034484122,"about_ca_system_score_gemma":0.00078223814,"threshold_uncertainty_score":0.9999755},"labels":[],"label_agreement":null},{"id":"W4387539498","doi":"10.1139/cjpp-2023-0031","title":"PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Olaparib; Apoptosis; Cell cycle; Programmed cell death; Cell culture; Cancer research; Biology; Triple-negative breast cancer; Cell; Cell biology; Mutant; Cell cycle checkpoint; Cancer; Breast cancer; Poly ADP ribose polymerase; Genetics; DNA","score_opus":0.03154290000055318,"score_gpt":0.3123883096925164,"score_spread":0.28084540969196325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387539498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959927,0.0011474399,0.000009979726,0.00079088437,0.0014570209,0.0002492971,0.0000393397,0.000018099012,0.0002952449],"genre_scores_gemma":[0.9972036,0.00070186215,0.000056619283,0.00087249617,0.0010104226,0.000024553503,0.000010467628,0.000034288372,0.00008571839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981874,0.00026243503,0.0005571279,0.00033882054,0.000100707766,0.00055351516],"domain_scores_gemma":[0.9984809,0.0002271489,0.00040779437,0.00010679909,0.00019874447,0.00057862554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004384482,0.00024315885,0.00057277526,0.00048881967,0.00032716466,0.000012843073,0.00010850257,0.00022430028,0.00051673653],"category_scores_gemma":[0.000019001844,0.00023599128,0.00006802818,0.0003899833,0.00016959108,0.00017144385,0.000027093407,0.0008149709,0.0000036893],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044713952,0.00006121121,0.0067730295,0.0001790989,0.00009134718,0.00011480018,0.0012235558,0.00049590576,0.9893759,0.000008692772,0.00066893816,0.0005603799],"study_design_scores_gemma":[0.009699734,0.00088779896,0.08503609,0.00021931098,0.0003261047,0.00018523488,0.0006774228,0.00049514964,0.9010338,0.0007753718,0.0003319443,0.00033202433],"about_ca_topic_score_codex":0.0077283806,"about_ca_topic_score_gemma":0.0029533084,"teacher_disagreement_score":0.088342085,"about_ca_system_score_codex":0.00038492083,"about_ca_system_score_gemma":0.0008492531,"threshold_uncertainty_score":0.99887925},"labels":[],"label_agreement":null},{"id":"W4387563335","doi":"10.1093/nar/gkad791","title":"ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance","year":2023,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; University of Alberta; Université Laval","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Biology; RAD51; DNA damage; DNA repair; Homologous recombination; Poly ADP ribose polymerase; Zinc finger; DNA; Gene knockdown; Molecular biology; Cell biology; Mutation; Genetics; Cell culture; Gene; Transcription factor; Polymerase","score_opus":0.07106778286150568,"score_gpt":0.39272461291644223,"score_spread":0.32165683005493656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387563335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874513,0.00031078813,0.00010747947,0.008299134,0.00008021771,0.00068836514,0.00003354886,0.00018515425,0.0028439828],"genre_scores_gemma":[0.99556255,0.00065112254,0.00045682248,0.00025919973,0.0002572497,0.00006676578,0.000038189384,0.000037798945,0.002670273],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99761397,0.00031145875,0.00022575722,0.0005400807,0.00080415455,0.00050458795],"domain_scores_gemma":[0.9984305,0.0005252616,0.000034910572,0.0003437558,0.00037039098,0.00029517704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022278267,0.00014035481,0.0002436014,0.0003516765,0.00035633924,0.00007559377,0.000047027967,0.00013700209,0.000049673097],"category_scores_gemma":[0.000655137,0.00013829011,0.000026637295,0.0013537258,0.0002584059,0.00018134118,0.00013260753,0.00044114745,0.00017287522],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043507693,0.000113847615,0.09548396,0.000601491,0.000082627244,0.00023751264,0.0032509626,0.00007254703,0.8057111,0.0013509587,0.07232396,0.01642025],"study_design_scores_gemma":[0.004280194,0.0010250164,0.8249536,0.0011313879,0.000020896183,0.00009200358,0.0008443076,0.007850538,0.10746848,0.0042730314,0.047608018,0.00045253255],"about_ca_topic_score_codex":0.00005596341,"about_ca_topic_score_gemma":0.00012962378,"teacher_disagreement_score":0.72946966,"about_ca_system_score_codex":0.0001819293,"about_ca_system_score_gemma":0.0000806474,"threshold_uncertainty_score":0.5639307},"labels":[],"label_agreement":null},{"id":"W4387617011","doi":"10.1038/s42003-023-05406-9","title":"Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response","year":2023,"lang":"en","type":"article","venue":"Communications Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"RIKEN; Japan Society for the Promotion of Science; Kyoto University Research Coordination Alliance; Uehara Memorial Foundation","keywords":"Biology; RAD51; Gene; DNA damage; Cell biology; DNA; DNA replication; Genetics","score_opus":0.12747012419807174,"score_gpt":0.4239942885843246,"score_spread":0.29652416438625284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387617011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839417,0.0013310767,0.00007323993,0.013308686,0.000050422484,0.0005342418,0.000097187854,0.00021417357,0.00044928546],"genre_scores_gemma":[0.994209,0.0030970124,0.00063528604,0.0004475914,0.00006213651,0.00031482388,0.00034508345,0.000021873586,0.00086720154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986107,0.000519398,0.00032201447,0.0002683488,0.0000736455,0.00020593859],"domain_scores_gemma":[0.99638444,0.0004789561,0.00014033155,0.0028362595,0.00010458097,0.000055446446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076658034,0.00011248904,0.00017107112,0.00015447116,0.000725303,0.000020868814,0.00046238612,0.00007458819,0.000058767066],"category_scores_gemma":[0.000070555725,0.00009058313,0.00004341349,0.00030866262,0.00044437035,0.000033971,0.00042049578,0.00020574385,0.000053349733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001542752,0.00006456103,0.020930346,0.00002656701,0.000056273537,9.1564436e-7,0.0008393008,0.000012002956,0.97123307,0.003436812,0.0010461359,0.0021997169],"study_design_scores_gemma":[0.0034021195,0.00035967032,0.26424953,0.00016226045,0.000087090506,0.00006000384,0.0021872572,0.0010979997,0.3917265,0.0017244654,0.33454204,0.00040103664],"about_ca_topic_score_codex":0.000058275127,"about_ca_topic_score_gemma":0.00007342148,"teacher_disagreement_score":0.5795066,"about_ca_system_score_codex":0.00010112301,"about_ca_system_score_gemma":0.00003801946,"threshold_uncertainty_score":0.55785173},"labels":[],"label_agreement":null},{"id":"W4387675283","doi":"10.1016/j.celrep.2023.113256","title":"Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages","year":2023,"lang":"en","type":"article","venue":"Cell Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Canadian Cancer Society; University Health Network","keywords":"DNA damage; Poly ADP ribose polymerase; PARP inhibitor; Vulnerability (computing); DNA repair; Biology; Cell biology; DNA; Differential (mechanical device); Genetics; Cancer research; Computer science; Computer security; Polymerase","score_opus":0.017723193120151345,"score_gpt":0.2767810509385777,"score_spread":0.25905785781842633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387675283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952092,0.000118645075,0.000044068092,0.00071214966,0.0010517818,0.00042252414,0.000015678033,0.00021200355,0.00221391],"genre_scores_gemma":[0.99557513,0.00010280717,0.00012406366,0.00014370288,0.000426425,0.000033936474,0.000022360446,0.000022622484,0.0035489528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984637,0.00009234225,0.00053024595,0.00037031434,0.00034822908,0.00019517753],"domain_scores_gemma":[0.99859136,0.00009917163,0.000259096,0.0008549609,0.000092427355,0.00010300749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003984816,0.00014371357,0.00029673113,0.000064069856,0.00009068838,0.000011248432,0.000059095,0.000105919695,0.00014185492],"category_scores_gemma":[0.00017812643,0.00009977988,0.00018616248,0.0002517517,0.00021194834,0.000055757493,0.00013337856,0.00020959269,0.0000050367225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017156832,0.0002648838,0.117805615,0.00055692054,0.000069690504,0.0007351891,0.0005716455,0.0000080222035,0.8592042,0.000041090752,0.018981291,0.0015899168],"study_design_scores_gemma":[0.0008333751,0.00010885105,0.23658012,0.00012334622,0.0000596739,0.00015209698,0.00004696375,0.00012973421,0.7511276,0.0006507532,0.010063404,0.00012405257],"about_ca_topic_score_codex":0.000021180085,"about_ca_topic_score_gemma":0.0000034817933,"teacher_disagreement_score":0.11877451,"about_ca_system_score_codex":0.000040220602,"about_ca_system_score_gemma":0.00013191611,"threshold_uncertainty_score":0.40689054},"labels":[],"label_agreement":null},{"id":"W4387809547","doi":"10.1016/j.annonc.2023.10.087","title":"LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Research and Development; Astellas Pharma; National Evidence-based Healthcare Collaborating Agency; Sanofi; AstraZeneca; Pfizer","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Oncology; Abiraterone; Homologous recombination; Internal medicine; Cancer research; Gene; Cancer; Androgen deprivation therapy; Genetics; Androgen receptor; Biology","score_opus":0.0732502613041532,"score_gpt":0.36291371368569875,"score_spread":0.28966345238154556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396557,0.0009181713,0.00009234659,0.0034528838,0.000043242355,0.0012149863,0.00020825653,0.00005006842,0.00005445814],"genre_scores_gemma":[0.98889047,0.0072805164,0.0025102352,0.00041824073,0.000021361791,0.00038297614,0.0003546228,0.00003297795,0.00010857337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978938,0.00018990118,0.0007255186,0.0004901871,0.00037376073,0.0003268141],"domain_scores_gemma":[0.9981942,0.00013835741,0.00056697027,0.00030366046,0.0006882592,0.000108509106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005775243,0.000258959,0.00087053137,0.000621135,0.00009428835,0.000017805025,0.00007469227,0.00010048174,0.00009980227],"category_scores_gemma":[0.000044559943,0.00020592501,0.00006971754,0.0011355343,0.00034280666,0.00021116449,0.000030955507,0.00017451831,0.0000028807185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08029248,0.004936753,0.7601989,0.0012353213,0.010492877,0.00058434345,0.008605551,0.022797408,0.015062575,0.0006088285,0.0011817584,0.094003215],"study_design_scores_gemma":[0.039013784,0.037629277,0.8975377,0.0003785114,0.0010421647,0.000050054663,0.00034621038,0.0050527155,0.016555648,0.0013454038,0.000574015,0.0004745161],"about_ca_topic_score_codex":0.00069597067,"about_ca_topic_score_gemma":0.006091752,"teacher_disagreement_score":0.1373388,"about_ca_system_score_codex":0.00011380606,"about_ca_system_score_gemma":0.00040246078,"threshold_uncertainty_score":0.83973783},"labels":[],"label_agreement":null},{"id":"W4387810093","doi":"10.1016/j.annonc.2023.09.2783","title":"1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Université de Montréal; McGill University Health Centre; University of Calgary","funders":"Eisai; Exelixis; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; PALB2; Prostate cancer; CHEK2; Internal medicine; Oncology; Cancer; FANCA; Gene mutation; Germline mutation; DNA repair; Mutation; Gene; Fanconi anemia; Genetics","score_opus":0.05293878818306228,"score_gpt":0.4007037831249236,"score_spread":0.3477649949418613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945567,0.0001574362,0.0000011417417,0.0012933679,0.00009484793,0.0032657185,0.000048251808,0.000051178555,0.0005313504],"genre_scores_gemma":[0.99734807,0.00028864972,0.0000827504,0.0007935457,0.000029888552,0.0010046521,0.00000287415,0.000021436821,0.00042814208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851847,0.00015079592,0.00040916287,0.00032811964,0.0003088744,0.00028455828],"domain_scores_gemma":[0.9986104,0.00019549025,0.0002602923,0.00035648755,0.0005075645,0.00006979725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004712726,0.0001376137,0.00045033125,0.00018716637,0.000030748983,0.0000016473895,0.00012056075,0.00004247181,0.00004175915],"category_scores_gemma":[0.0001974821,0.00009225105,0.000059842092,0.0008293896,0.00014448064,0.000066709086,0.00006207859,0.0001408892,0.000007862556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007326892,0.0017923835,0.96311677,0.00031355128,0.00012911425,0.000041938823,0.009834594,0.0002347136,0.0018245938,0.000011386045,0.0011315296,0.0142425615],"study_design_scores_gemma":[0.0070667975,0.02752707,0.94828206,0.00038094207,0.000049793172,0.0000028191985,0.00062699296,0.000017155617,0.0147824865,0.000078999845,0.0010856373,0.00009922474],"about_ca_topic_score_codex":0.000101294274,"about_ca_topic_score_gemma":0.0005026109,"teacher_disagreement_score":0.025734687,"about_ca_system_score_codex":0.0001253125,"about_ca_system_score_gemma":0.0002924076,"threshold_uncertainty_score":0.37618887},"labels":[],"label_agreement":null},{"id":"W4387810225","doi":"10.1016/j.annonc.2023.09.2760","title":"1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; PharmaMar; Novartis Farmacéutica; Cilag; Astellas Pharma; Eisai; Ipsen; Clovis Oncology; Astellas Pharma Canada; Daiichi Sankyo Europe; Sanofi; Exelixis; F. Hoffmann-La Roche; Gilead Sciences; MacroGenics; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; CHEK2; Prostate cancer; Population; Internal medicine; Oncology; Enzalutamide; Cancer; Cancer research; Androgen receptor; Germline mutation; Genetics; Biology; Mutation; Gene","score_opus":0.11355469973697349,"score_gpt":0.39981697517091896,"score_spread":0.28626227543394545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922977,0.000055951496,0.00092142326,0.0057583,0.00012496136,0.00058507157,0.00012295182,0.00003533948,0.000098270844],"genre_scores_gemma":[0.99803865,0.00023594945,0.000933935,0.00015381756,0.00005883179,0.00008495584,0.00045995985,0.000010598177,0.000023328648],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99856156,0.0003044981,0.0005214253,0.00019134935,0.00028541443,0.0001357676],"domain_scores_gemma":[0.9985669,0.0002724172,0.00059532805,0.00022025123,0.00031885767,0.000026245732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077073387,0.00009734589,0.00039823033,0.00029391542,0.000065262815,0.00000546993,0.000056198733,0.00010497617,0.000019984298],"category_scores_gemma":[0.00016807711,0.000078888086,0.00006787046,0.000564231,0.00010414053,0.00023234788,0.000017103956,0.000117951444,0.0000019097074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038465748,0.007716483,0.29737964,0.0006168538,0.00082949473,0.00016216443,0.016303528,0.013992499,0.62028,0.0063126013,0.004113585,0.02844656],"study_design_scores_gemma":[0.0029441253,0.002856017,0.934728,0.00012783923,0.00011366933,0.000022790005,0.00043225428,0.0058725527,0.048082076,0.004640155,0.00007095946,0.00010951465],"about_ca_topic_score_codex":0.0005668156,"about_ca_topic_score_gemma":0.00027061187,"teacher_disagreement_score":0.6373484,"about_ca_system_score_codex":0.00007231048,"about_ca_system_score_gemma":0.00015149043,"threshold_uncertainty_score":0.32169628},"labels":[],"label_agreement":null},{"id":"W4387810248","doi":"10.1016/j.annonc.2023.09.2753","title":"1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; AstraZeneca España; Genentech; UroGen Pharma; Advanced Accelerator Applications; Sanofi Genzyme; Pfizer; Incyte; Ipsen; BeiGene; Constellation Pharmaceuticals; Clovis Oncology; Sanofi; Exelixis; Boston Scientific Corporation; Les Laboratories Pierre Fabre; Teva Pharmaceutical Industries; AstraZeneca; Invitae; Daiichi Sankyo Europe; Gilead Sciences; Amgen","keywords":"Medicine; Abiraterone; Prostate cancer; Oncology; Placebo; Internal medicine; Olaparib; BRCA mutation; Cancer; Urology; Gynecology; Ovarian cancer; Androgen receptor; Poly ADP ribose polymerase","score_opus":0.08187992572353721,"score_gpt":0.39519426297467053,"score_spread":0.31331433725113333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902447,0.0000858026,0.000017343376,0.0046371417,0.00016700357,0.004136545,0.00014388628,0.0000119523,0.0005556203],"genre_scores_gemma":[0.99773145,0.00019467609,0.00013258726,0.00064597436,0.00007310847,0.0009664181,0.0001541876,0.000028353974,0.00007324203],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968459,0.00065382785,0.0011412518,0.0003257857,0.0006520421,0.0003812073],"domain_scores_gemma":[0.99743253,0.0008079513,0.0008539112,0.00039929556,0.00045687854,0.00004942126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020303573,0.00022952308,0.000783705,0.00034579044,0.000053119235,0.000011356959,0.00025960876,0.00011155221,0.00005599287],"category_scores_gemma":[0.00021708364,0.00013833099,0.00010068306,0.0011121201,0.00036371071,0.000140771,0.000023489229,0.0003154606,0.0000069985126],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7024452,0.013880619,0.04013509,0.0023162419,0.0011662631,0.00042460047,0.12049919,0.007590222,0.055471927,0.00061409286,0.012761542,0.042695023],"study_design_scores_gemma":[0.2917446,0.047328204,0.6135502,0.0012329214,0.00040841126,0.00002534117,0.0075624078,0.0009609647,0.032287218,0.00062059757,0.0037839294,0.00049519347],"about_ca_topic_score_codex":0.0011987856,"about_ca_topic_score_gemma":0.0020246943,"teacher_disagreement_score":0.5734151,"about_ca_system_score_codex":0.00012697733,"about_ca_system_score_gemma":0.00091299065,"threshold_uncertainty_score":0.5640974},"labels":[],"label_agreement":null},{"id":"W4387810265","doi":"10.1016/j.annonc.2023.09.2748","title":"1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); BC Cancer Agency; University of Alberta; University of Calgary","funders":"Ipsen; Eisai; AstraZeneca; Amgen; Pfizer; Astellas Pharma; F. Hoffmann-La Roche","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; PARP inhibitor; Docetaxel; Cancer; Poly ADP ribose polymerase","score_opus":0.1348306269186467,"score_gpt":0.4325496976513883,"score_spread":0.2977190707327416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886433,0.00044339403,0.00002120469,0.008124955,0.00021065453,0.0013028702,0.00030921274,0.00013804832,0.00080634997],"genre_scores_gemma":[0.9937698,0.0018225427,0.0010333767,0.0013821408,0.00014888342,0.00069355173,0.00007260845,0.000052666535,0.0010244073],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979545,0.0001849727,0.000694684,0.000495826,0.0002352543,0.00043479397],"domain_scores_gemma":[0.99797934,0.00048499895,0.00056951004,0.00034594783,0.00041086038,0.00020934292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035661831,0.00026490516,0.00080856885,0.00055594696,0.000074827134,0.000010837461,0.000107099906,0.00007872092,0.00010513148],"category_scores_gemma":[0.00011685124,0.00022292088,0.000091691254,0.0007575179,0.0001450258,0.00014053786,0.00007304082,0.00012552021,0.0000077767645],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0100165345,0.0020708663,0.1945833,0.0009730037,0.0016167588,0.00058610266,0.0064425254,0.00032074493,0.25341547,0.00008842326,0.0074477065,0.5224386],"study_design_scores_gemma":[0.008677038,0.017409418,0.28651726,0.00082255685,0.0003148722,0.00007262137,0.00040356038,0.0001384582,0.6830163,0.00030039306,0.0019701174,0.00035736474],"about_ca_topic_score_codex":0.004097497,"about_ca_topic_score_gemma":0.0021053255,"teacher_disagreement_score":0.5220812,"about_ca_system_score_codex":0.00029840562,"about_ca_system_score_gemma":0.00064627215,"threshold_uncertainty_score":0.909045},"labels":[],"label_agreement":null},{"id":"W4387810308","doi":"10.1016/j.annonc.2023.09.2759","title":"1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Foundation Medicine; Pharmacyclics; Takeda Oncology; Chugai Pharmaceutical; EMD Serono; Genentech; Ipsen; PharmaMar; Novartis Farmacéutica; Astellas Pharma; Eisai; Plexxikon; Seagen; UroGen Pharma; Pfizer; Incyte; Arog Pharmaceuticals; Exelixis; Karyopharm Therapeutics; MEI Pharma; Clovis Oncology; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Boston Scientific Corporation; Bayer Yakuhin; Novartis; Astellas Foundation for Research on Metabolic Disorders; Endocyte; Merck KGaA; Sanofi; Cilag; Puma Biotechnology; Advanced Accelerator Applications; Janssen Biotech; Teva Pharmaceutical Industries; Amgen; Myriad Genetics; ImmunoMedics; Eli Lilly and Company; Invitae; AstraZeneca; Lantheus Medical Imaging","keywords":"Enzalutamide; Medicine; Prostate cancer; Oncology; Internal medicine; Placebo; Cancer; Androgen receptor; Pathology; Alternative medicine","score_opus":0.07905098879133958,"score_gpt":0.4067292390465667,"score_spread":0.3276782502552271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883337,0.00024304283,0.000011524676,0.00538208,0.00019705482,0.0036900362,0.0005870938,0.00022511138,0.00083071674],"genre_scores_gemma":[0.99566156,0.0003128839,0.00067412265,0.00043106102,0.000034598343,0.0016641229,0.0006169825,0.000055879445,0.0005487921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995763,0.00055020646,0.0017228696,0.000855914,0.00057718257,0.0005308236],"domain_scores_gemma":[0.99639696,0.0010853318,0.0012047477,0.0005101087,0.0006129789,0.00018989826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014768436,0.00037476126,0.0011303741,0.00064703374,0.00018202313,0.000029904984,0.00010520932,0.00015144146,0.00007327561],"category_scores_gemma":[0.00084673066,0.00033092123,0.000112478374,0.0010506284,0.0002839929,0.00031600715,0.00006478878,0.00037602693,0.0000061026044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17712219,0.02453113,0.41502258,0.00067989225,0.008794677,0.011445315,0.16029066,0.0045672925,0.069952175,0.00023806281,0.018846193,0.10850981],"study_design_scores_gemma":[0.19298579,0.03910686,0.7017781,0.0011259757,0.0012881408,0.00029739775,0.031189851,0.0038754954,0.022114052,0.0022693467,0.002734386,0.0012345919],"about_ca_topic_score_codex":0.0041784304,"about_ca_topic_score_gemma":0.00556803,"teacher_disagreement_score":0.28675553,"about_ca_system_score_codex":0.00032595472,"about_ca_system_score_gemma":0.00085580343,"threshold_uncertainty_score":0.9999143},"labels":[],"label_agreement":null},{"id":"W4387824808","doi":"10.1016/j.annonc.2023.09.1967","title":"789P Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Eisai; BeiGene; Australian Government; American Society of Clinical Oncology; GlaxoSmithKline; Clovis Oncology; AstraZeneca; Pfizer","keywords":"Medicine; Epithelial ovarian cancer; Ovarian cancer; Oncology; Duration (music); Internal medicine; Cancer","score_opus":0.1456934424015971,"score_gpt":0.45004545396042467,"score_spread":0.3043520115588276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387824808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97839,0.0002065516,0.000016832088,0.017843729,0.00031339758,0.0014323973,0.000099508856,0.000040835785,0.0016567856],"genre_scores_gemma":[0.98595387,0.010986972,0.00008435804,0.0008571387,0.00022241825,0.00071249803,0.000041267205,0.000031843094,0.0011096393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978573,0.00020580157,0.0009706293,0.00037318797,0.00021097131,0.00038211685],"domain_scores_gemma":[0.9987336,0.00022871654,0.00041290413,0.0003575223,0.0001924881,0.00007481105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073052075,0.00020921884,0.0008772792,0.0006894168,0.000029349143,0.0000030268866,0.000114504386,0.00014090422,0.00028746392],"category_scores_gemma":[0.000051160845,0.0001842676,0.00011314619,0.0010837921,0.00012287138,0.00007575135,0.000021687109,0.00016164387,0.000016221999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020833036,0.010316291,0.7141639,0.00023124894,0.0008212378,0.00062722433,0.026135417,0.0040511102,0.052449718,0.0011292178,0.007656053,0.16158555],"study_design_scores_gemma":[0.036974832,0.018639127,0.85136557,0.00051194587,0.00005988386,0.000010277666,0.0012027117,0.0012519642,0.04924497,0.0015197144,0.038890667,0.00032836187],"about_ca_topic_score_codex":0.014370581,"about_ca_topic_score_gemma":0.058622114,"teacher_disagreement_score":0.16125719,"about_ca_system_score_codex":0.0005613028,"about_ca_system_score_gemma":0.00052624627,"threshold_uncertainty_score":0.9921928},"labels":[],"label_agreement":null},{"id":"W4387950784","doi":"10.2217/fon-2023-0526","title":"TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Olaparib; Placebo; Androgen deprivation therapy; Clinical trial; Androgen receptor; Cancer; Poly ADP ribose polymerase; Gene; Pathology; Biology; Polymerase","score_opus":0.13084474820022168,"score_gpt":0.5230714336123913,"score_spread":0.3922266854121696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387950784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88938123,0.000021108097,0.000017546268,0.0017678842,0.0013236934,0.106576584,0.00007450112,0.000093841496,0.0007435807],"genre_scores_gemma":[0.83581454,0.000045589077,0.00032333325,0.00058398827,0.0018896767,0.16057801,0.00008945276,0.00004885143,0.0006265579],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963118,0.0009024829,0.001447469,0.0005424372,0.00040150023,0.0003943516],"domain_scores_gemma":[0.9982294,0.0004524892,0.00056023797,0.0003442137,0.00026015766,0.00015351782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017554921,0.0002432696,0.0011937195,0.00031220337,0.00006093897,0.000008953164,0.00009997907,0.00020718916,0.00022029628],"category_scores_gemma":[0.00018601264,0.00020637887,0.00013843412,0.0008899193,0.00020038971,0.00009257857,0.00004909299,0.00061653287,0.0000296662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83237594,0.02042129,0.00804625,0.00043305728,0.0012173717,0.0041725924,0.030460129,0.0007755735,0.008246495,0.00037136133,0.018313538,0.075166404],"study_design_scores_gemma":[0.88837206,0.03797112,0.010495934,0.0001900557,0.00031960141,0.00009138611,0.015286885,0.00083023263,0.0021023673,0.00015234553,0.043850087,0.0003379361],"about_ca_topic_score_codex":0.0003168575,"about_ca_topic_score_gemma":0.0022854463,"teacher_disagreement_score":0.07482847,"about_ca_system_score_codex":0.0004916751,"about_ca_system_score_gemma":0.0019519128,"threshold_uncertainty_score":0.8415886},"labels":[],"label_agreement":null},{"id":"W4387997193","doi":"10.1101/2023.10.27.564493","title":"Molecular mechanism of NAD <sup>+</sup> binding to the Nudix homology domains of DBC1","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"NAD+ kinase; Isothermal titration calorimetry; Nicotinamide adenine dinucleotide; PARP1; Nicotinamide mononucleotide; Biochemistry; DNA repair; DNA; Polymerase; Binding site; Hydrogen bond; Chemistry; Biology; Enzyme; Stereochemistry; Poly ADP ribose polymerase; Molecule","score_opus":0.0234446839381743,"score_gpt":0.26637048827296417,"score_spread":0.24292580433478986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387997193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98341405,0.00060607697,0.009825973,0.0022831417,0.0010904672,0.0017431484,0.0007016538,0.00030729925,0.000028188062],"genre_scores_gemma":[0.9927621,0.00025008916,0.005103197,0.00078667345,0.00038561635,0.00046906818,0.0000011899419,0.00022389411,0.000018192519],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99642706,0.00024942757,0.0009844285,0.0009485263,0.0007677037,0.0006228832],"domain_scores_gemma":[0.9959644,0.0001728037,0.0006648723,0.0021570735,0.0007418665,0.0002989617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011595787,0.00055230927,0.0011377678,0.00070359,0.0001089105,0.000030108924,0.00072406157,0.0006256808,0.000104546816],"category_scores_gemma":[0.00038505055,0.0005023908,0.00036475243,0.0011539691,0.00024633948,0.000046370245,0.0005843948,0.0008715139,0.00014136075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012769102,0.00015063638,0.0010407257,0.0007739523,0.000624512,0.00014912183,0.00010385788,0.0011388429,0.9861319,0.008804912,0.00095204666,0.0000018075103],"study_design_scores_gemma":[0.0014772726,0.00029692778,0.004419917,0.0015639382,0.00033976143,1.7970227e-7,0.000030997722,0.00039132385,0.98794836,0.00006220342,0.002940992,0.0005281422],"about_ca_topic_score_codex":0.00010852889,"about_ca_topic_score_gemma":0.000002697849,"teacher_disagreement_score":0.009348027,"about_ca_system_score_codex":0.000409434,"about_ca_system_score_gemma":0.00095170835,"threshold_uncertainty_score":0.99974275},"labels":[],"label_agreement":null},{"id":"W4388007145","doi":"10.1016/j.jbc.2023.105397","title":"ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification","year":2023,"lang":"en","type":"review","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Poly ADP ribose polymerase; PARP1; Genome instability; Polymerase; DNA repair; DNA damage; Ribose; Biology; DNA; ADP-ribosylation; Enzyme; Cell biology; Computational biology; Genetics; Biochemistry; NAD+ kinase","score_opus":0.22823539917614002,"score_gpt":0.42468748810749524,"score_spread":0.1964520889313552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388007145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12717114,0.865371,0.0012745601,0.00091514166,0.00010953556,0.0018040929,0.003169354,0.000037632184,0.00014756639],"genre_scores_gemma":[0.1346123,0.86357236,0.00042619757,0.00007754984,0.0006971189,0.00012987666,0.00043162567,0.000026802238,0.00002618921],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977786,0.0001043948,0.0013836088,0.00028531512,0.00023124312,0.00021685248],"domain_scores_gemma":[0.99674803,0.0011397661,0.0012825923,0.0002837071,0.00031661332,0.0002292681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010597988,0.0002662258,0.0019145615,0.00009047941,0.00004742082,0.000010804846,0.00018802584,0.0004586951,0.000059112208],"category_scores_gemma":[0.001250651,0.00018359316,0.00056033535,0.00025507598,0.00020311505,0.000025060472,0.000033893626,0.0004855318,0.0000013071044],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027251055,0.0016660381,0.0001267921,0.058678504,0.0018791192,0.000092573646,0.00036759928,0.000018433473,0.9018327,0.00044960962,0.0012811392,0.030882373],"study_design_scores_gemma":[0.008144633,0.005080092,0.0016219671,0.049667604,0.002839042,0.00037652787,0.00030752717,0.000037995233,0.26177058,0.0036104813,0.6652139,0.0013296581],"about_ca_topic_score_codex":8.386808e-7,"about_ca_topic_score_gemma":1.4051058e-7,"teacher_disagreement_score":0.66393274,"about_ca_system_score_codex":0.00026943412,"about_ca_system_score_gemma":0.00027005127,"threshold_uncertainty_score":0.7486712},"labels":[],"label_agreement":null},{"id":"W4388182309","doi":"10.1016/j.euo.2023.10.004","title":"Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Abiraterone; Medicine; Prostate cancer; Pharmacokinetics; Pharmacology; Oncology; Internal medicine; Drug; Abiraterone acetate; Urology; Cancer; Androgen deprivation therapy; Androgen receptor; Chemistry","score_opus":0.20734976340744182,"score_gpt":0.4296062803691044,"score_spread":0.2222565169616626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388182309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8697729,0.0028321312,0.0013743595,0.098947406,0.0063879197,0.009078934,0.005593343,0.00066864985,0.005344326],"genre_scores_gemma":[0.9565493,0.0018495056,0.0023624508,0.022927867,0.0050740195,0.0013200316,0.005420948,0.00024533083,0.0042505693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967939,0.0010618784,0.0006845297,0.000709271,0.00022011876,0.00053029746],"domain_scores_gemma":[0.99752593,0.0009330596,0.00033006817,0.00091388734,0.00016187543,0.0001351562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015201336,0.00025499397,0.00053417135,0.000091039066,0.0002303807,0.000030887313,0.0005911305,0.000075236334,0.00041404815],"category_scores_gemma":[0.00028490354,0.00018291558,0.00007838289,0.00030035785,0.00042115425,0.00008724944,0.00023376667,0.00041482027,0.00046340155],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20404355,0.0006622451,0.00035566694,0.00010170111,0.0015023531,0.0012164997,0.003034857,0.0011895174,0.11249442,0.00027987745,0.6476668,0.027452487],"study_design_scores_gemma":[0.11975656,0.004453168,0.0030104306,0.000020974307,0.00084558775,0.000060550177,0.00017336273,0.004487287,0.0007644435,0.00024668098,0.8659479,0.00023304047],"about_ca_topic_score_codex":0.000105664236,"about_ca_topic_score_gemma":0.00024166483,"teacher_disagreement_score":0.21828109,"about_ca_system_score_codex":0.00016740867,"about_ca_system_score_gemma":0.0008119801,"threshold_uncertainty_score":0.7459081},"labels":[],"label_agreement":null},{"id":"W4388185443","doi":"10.1101/2023.10.25.564012","title":"Length-dependent Intramolecular Coil-to-Globule Transition in Poly(ADP-ribose) Induced by Cations","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Brookhaven National Laboratory; Basic Energy Sciences; National Institute of General Medical Sciences; Biological and Environmental Research; Natural Sciences and Engineering Research Council of Canada; Empire State Development Corporation; U.S. Department of Energy; Division of Materials Research; Office of Science; National Institutes of Health; National Science Foundation","keywords":"Small-angle X-ray scattering; Intramolecular force; Stacking; Molecular dynamics; Persistence length; Chemistry; Crystallography; Random coil; Bond length; Biophysics; Stereochemistry; Scattering; Molecule; Computational chemistry; Circular dichroism; Physics; Biology","score_opus":0.025230558755336738,"score_gpt":0.27125411681020256,"score_spread":0.2460235580548658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388185443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97582316,0.0010192549,0.0074977274,0.009187042,0.0018605292,0.0025126648,0.0011501249,0.0009210569,0.000028438346],"genre_scores_gemma":[0.9936373,0.00034425932,0.0016344248,0.0020732859,0.0007150344,0.0012811515,0.000011042076,0.0002822157,0.000021286385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99581045,0.0002228552,0.00094730826,0.0014060299,0.00083111407,0.00078221655],"domain_scores_gemma":[0.9969999,0.00007333941,0.00030681258,0.0015600971,0.00049572,0.0005641032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007592751,0.0006820444,0.00087460177,0.00083051505,0.00013658556,0.00013349431,0.00042682345,0.0008476344,0.000120647404],"category_scores_gemma":[0.00019914054,0.0008335198,0.00020996609,0.0012667873,0.00009257791,0.00013171793,0.00018001955,0.0014562597,0.00038392367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014506286,0.00040793273,0.0007252709,0.00033011934,0.00020362854,0.00015685915,0.00009846491,0.00013565713,0.9948188,0.00017790159,0.0027930476,0.0000072474368],"study_design_scores_gemma":[0.0034387044,0.00025599936,0.04577363,0.0018861631,0.00023802833,1.5772282e-7,0.000027469721,0.00032885539,0.9414594,0.000013368133,0.0052977516,0.0012804683],"about_ca_topic_score_codex":0.0005893227,"about_ca_topic_score_gemma":0.0000261213,"teacher_disagreement_score":0.053359404,"about_ca_system_score_codex":0.0014448089,"about_ca_system_score_gemma":0.0011897023,"threshold_uncertainty_score":0.9994116},"labels":[],"label_agreement":null},{"id":"W4388219690","doi":"10.1001/jamanetworkopen.2023.41165","title":"Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors","year":2023,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; Kelowna General Hospital","funders":"","keywords":"Medicine; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Colorectal cancer; Interim analysis; Microsatellite instability; Discontinuation; Population; Cancer; Endometrial cancer; Clinical trial; Phases of clinical research","score_opus":0.01666644259954912,"score_gpt":0.2948210933346356,"score_spread":0.27815465073508644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388219690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569416,0.00011230898,0.000048042715,0.0010605293,0.00008572054,0.0014464348,0.000030879448,0.00007701109,0.0014449385],"genre_scores_gemma":[0.9979023,0.00025435002,0.00088904676,0.00054580736,0.00008032113,0.000075799406,0.00004142277,0.000037069225,0.00017390802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985272,0.00011122496,0.0003522434,0.00036016296,0.0003071017,0.00034201506],"domain_scores_gemma":[0.9991097,0.00010818793,0.0001979426,0.00039443574,0.000094767434,0.00009496604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007082316,0.00016677941,0.00051042665,0.00010162317,0.00008196417,0.00003332742,0.00014613858,0.000071159724,0.000077362696],"category_scores_gemma":[0.000019929705,0.00013634632,0.00004906029,0.00077013863,0.000098473996,0.00019989282,0.00012142179,0.00019673049,0.000010351233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015221574,0.000344482,0.97152835,0.00008778777,0.00009934397,0.000039594463,0.0006660921,0.0018356276,0.0002496901,0.00009272972,0.0045931963,0.0052415463],"study_design_scores_gemma":[0.012063617,0.00066006783,0.9826381,0.00085500727,0.000016108399,0.0000048402862,0.0000810457,0.0012398787,0.00067316607,0.00010044347,0.0015077438,0.0001599358],"about_ca_topic_score_codex":0.00024812782,"about_ca_topic_score_gemma":0.00007136723,"teacher_disagreement_score":0.011109811,"about_ca_system_score_codex":0.00011389105,"about_ca_system_score_gemma":0.0001231359,"threshold_uncertainty_score":0.55600417},"labels":[],"label_agreement":null},{"id":"W4388487685","doi":"10.1158/1078-0432.ccr-23-2249","title":"Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Clinical endpoint; Cohort; Bevacizumab; Internal medicine; Oncology; Durvalumab; PARP inhibitor; Adverse effect; Cancer; Clinical trial; Chemotherapy; Nivolumab; Poly ADP ribose polymerase; Biology","score_opus":0.317749283599929,"score_gpt":0.5762641648363642,"score_spread":0.25851488123643523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388487685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98438394,0.00031421424,0.000014879536,0.0034973864,0.0008478394,0.009322258,0.00023775731,0.00032328194,0.0010584175],"genre_scores_gemma":[0.97054577,0.0024440263,0.00022426891,0.00051597925,0.0013405891,0.009153813,0.00011086421,0.00018755811,0.01547713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9904517,0.0017580045,0.0017483114,0.0020225674,0.002412559,0.001606842],"domain_scores_gemma":[0.99450654,0.00181538,0.0003319439,0.0013652327,0.0010681212,0.00091278774],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0052511273,0.00063508196,0.001968741,0.0008179876,0.0006482223,0.000092150236,0.00036588046,0.00046138166,0.0012482639],"category_scores_gemma":[0.0011135763,0.000457449,0.0002668944,0.0032810534,0.0010379736,0.000221224,0.00029740197,0.0022531399,0.00033260314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14034532,0.015423232,0.7681303,0.00017529808,0.0022269753,0.0062575475,0.0152668515,0.00037910452,0.0010889955,0.00003565286,0.006846633,0.04382408],"study_design_scores_gemma":[0.41945982,0.09432239,0.42679745,0.003399825,0.0007806589,0.00016028975,0.016960537,0.009540199,0.008329791,0.00011156054,0.01835691,0.0017805749],"about_ca_topic_score_codex":0.021857075,"about_ca_topic_score_gemma":0.028001003,"teacher_disagreement_score":0.34133288,"about_ca_system_score_codex":0.0045085982,"about_ca_system_score_gemma":0.0072982516,"threshold_uncertainty_score":0.99978775},"labels":[],"label_agreement":null},{"id":"W4388494993","doi":"10.1136/ijgc-2023-igcs.318","title":"EP244/#277  Examining real-world treatment benefits of first-line maintenance niraparib in non-BRCA mutant high grade serous ovarian cancers","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Oncology; Internal medicine; Ovarian cancer; BRCA mutation; Chemotherapy; Progression-free survival; Population; Bevacizumab; Maintenance therapy; Cancer","score_opus":0.07316367645092837,"score_gpt":0.35850553879708075,"score_spread":0.2853418623461524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388494993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860842,0.00029211986,0.00009422261,0.009403886,0.0024891899,0.0003284955,0.00020318,0.00003486802,0.0010698015],"genre_scores_gemma":[0.98771334,0.009300195,0.00045445558,0.0007326997,0.0009511518,0.00010949541,0.000027383232,0.000030421957,0.0006808519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722993,0.00006774614,0.0011390032,0.00032274929,0.00083599193,0.00040455762],"domain_scores_gemma":[0.9977257,0.00055203296,0.0007997526,0.0001882928,0.00054286345,0.00019134487],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048525035,0.00026597845,0.00074764906,0.0006519385,0.000049219263,0.000021873708,0.00035333034,0.00014270181,0.0013449787],"category_scores_gemma":[0.00017601108,0.0001995205,0.00021009211,0.0006037099,0.00014923637,0.00014892466,0.00006180824,0.00036188186,0.000014539928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007984794,0.0014669043,0.6998069,0.000111093206,0.002199301,0.00443994,0.0019330533,0.18357415,0.008979742,0.0028258408,0.006743895,0.07993435],"study_design_scores_gemma":[0.012755057,0.0025163877,0.961066,0.0012358489,0.00011229476,0.0001763751,0.00019471254,0.0017147203,0.010553164,0.0011029585,0.0082827965,0.00028969688],"about_ca_topic_score_codex":0.004285396,"about_ca_topic_score_gemma":0.011151923,"teacher_disagreement_score":0.26125905,"about_ca_system_score_codex":0.004665629,"about_ca_system_score_gemma":0.0005827862,"threshold_uncertainty_score":0.9995679},"labels":[],"label_agreement":null},{"id":"W4388495257","doi":"10.1136/ijgc-2023-igcs.300","title":"EP222/#246  Quantifying platinum sensitivity as a marker for response to PARP inhibition in patients with advanced ovarian cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Debulking; Ovarian cancer; PARP inhibitor; Proportional hazards model; Progression-free survival; Chemotherapy; Cancer; Multivariate analysis; Log-rank test; Retrospective cohort study; Cohort; Poly ADP ribose polymerase; Biology","score_opus":0.04336273576673604,"score_gpt":0.3839761170429713,"score_spread":0.34061338127623525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388495257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826017,0.00005081349,0.00075849757,0.014467445,0.0011156955,0.000686557,0.0001709966,0.000035143643,0.00011313133],"genre_scores_gemma":[0.9943952,0.00010108723,0.0013476356,0.0033016065,0.00034831683,0.00024235649,0.000027207494,0.000028888739,0.00020770867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781436,0.00017108528,0.00060382584,0.00028870575,0.00080285233,0.00031919457],"domain_scores_gemma":[0.9971112,0.00095706456,0.00039868333,0.000108617285,0.0012378963,0.0001865487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010826373,0.00018783608,0.00041364116,0.00046780985,0.00005805049,0.00003520118,0.000093767856,0.00012286984,0.0007022738],"category_scores_gemma":[0.0012160966,0.00014366805,0.00013670282,0.0004452762,0.000060647442,0.000235406,0.00004734413,0.00031661725,0.00001907806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1882619,0.00085606956,0.68553275,0.00005987728,0.0006096765,0.0013971962,0.0008188584,0.015204695,0.046767432,0.00020383633,0.004069694,0.056218006],"study_design_scores_gemma":[0.012888755,0.0017469132,0.9716569,0.00076588185,0.00003531258,0.000046068864,0.00009661889,0.0002863525,0.0039681527,0.0003126101,0.007997994,0.00019843246],"about_ca_topic_score_codex":0.00005962158,"about_ca_topic_score_gemma":0.00026141878,"teacher_disagreement_score":0.28612414,"about_ca_system_score_codex":0.0012340916,"about_ca_system_score_gemma":0.00045355764,"threshold_uncertainty_score":0.76894057},"labels":[],"label_agreement":null},{"id":"W4388662575","doi":"10.1200/jco.23.00339","title":"Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Medical Research Council; National Institute for Health and Care Research; AstraZeneca","keywords":"Olaparib; Medicine; Prostate cancer; Oncology; Internal medicine; PARP inhibitor; Cancer; Clinical trial; Prostate; Gynecology; Poly ADP ribose polymerase","score_opus":0.20027265815935,"score_gpt":0.501004182842899,"score_spread":0.300731524683549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388662575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98574275,0.00046055022,0.000022412527,0.011409499,0.0003096051,0.0019773287,0.000046819867,0.000002171043,0.00002886503],"genre_scores_gemma":[0.99467564,0.0029807724,0.0005672158,0.0010082973,0.0002719103,0.00037626814,0.000008086107,0.000009590788,0.00010219726],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979269,0.00028127435,0.0013126513,0.000120415505,0.0002232252,0.00013555573],"domain_scores_gemma":[0.99434304,0.004536141,0.0007521476,0.000103973645,0.0002049086,0.000059806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017955487,0.00009194258,0.00065037597,0.000086715685,0.00004993441,0.000012854215,0.00005379563,0.00005932796,0.000009826947],"category_scores_gemma":[0.0004310602,0.00003807205,0.00008257081,0.00022971658,0.00020519688,0.00007824699,0.0000051922425,0.0001994323,2.2874299e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7464764,0.009391191,0.10070356,0.00016941254,0.0011369326,0.00022233705,0.009911883,0.00044606705,0.00026802087,0.00046148757,0.0028118212,0.1280009],"study_design_scores_gemma":[0.35667643,0.09157249,0.50311494,0.00024924916,0.0007270996,0.000037299797,0.0016063773,0.0003835728,0.0000849438,0.0007706861,0.04466157,0.00011535558],"about_ca_topic_score_codex":0.000068213274,"about_ca_topic_score_gemma":0.0023914578,"teacher_disagreement_score":0.40241134,"about_ca_system_score_codex":0.00010640496,"about_ca_system_score_gemma":0.0010482274,"threshold_uncertainty_score":0.18595104},"labels":[],"label_agreement":null},{"id":"W4388722434","doi":"10.1093/nar/gkad1064","title":"Structural and biochemical analysis of the PARP1-homology region of PARP4/vault PARP","year":2023,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Biology; NAD+ kinase; Poly ADP ribose polymerase; Biochemistry; ADP-ribosylation; DNA; Molecular biology; Polymerase; Enzyme","score_opus":0.10207429491731945,"score_gpt":0.41394923807796635,"score_spread":0.3118749431606469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388722434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536026,0.00025843305,0.000009888273,0.0030351724,0.00005679079,0.00026067768,0.000025026526,0.00002971113,0.0009640595],"genre_scores_gemma":[0.99890924,0.00032802767,0.00007867936,0.000081730774,0.00006585149,0.000022094244,0.000022987775,0.000016490108,0.00047489055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980168,0.00026525647,0.00033468605,0.0002893429,0.0007487484,0.00034517163],"domain_scores_gemma":[0.9985184,0.00033697853,0.00009272006,0.00059276744,0.00035282903,0.000106314255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071478257,0.00009782081,0.00041049428,0.0005444703,0.000093526796,0.000006852148,0.00022105,0.00016091789,0.00021355772],"category_scores_gemma":[0.00035631395,0.000066677174,0.00016087577,0.0031697275,0.0011489112,0.00003230051,0.00018846331,0.00039630843,0.000009266793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012428685,0.000098258955,0.4872643,0.00031949955,0.0015871961,0.000061236824,0.0022412962,0.000045055756,0.470245,0.002767549,0.02637549,0.007752223],"study_design_scores_gemma":[0.0022218267,0.0004694007,0.8379838,0.00015640832,0.0003737744,0.000074057636,0.00090377755,0.0048502227,0.14739372,0.002698396,0.002720392,0.00015423176],"about_ca_topic_score_codex":0.000114040085,"about_ca_topic_score_gemma":0.000008512059,"teacher_disagreement_score":0.35071948,"about_ca_system_score_codex":0.00007016844,"about_ca_system_score_gemma":0.0001117477,"threshold_uncertainty_score":0.4233211},"labels":[],"label_agreement":null},{"id":"W4388845885","doi":"10.1038/s41467-023-42701-9","title":"Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; BC Children's Hospital; University of British Columbia","funders":"CIHR Skin Research Training Centre; Canadian Institutes of Health Research; BC Children's Hospital; Michael Smith Health Research BC; Canada Research Chairs; Government of Canada; Children's Hospital Foundation","keywords":"Proteome; Disease; Genome; Medicine; Computational biology; Transcriptome; Lymphoblastic Leukemia; Bioinformatics; Oncology; Biology; Leukemia; Internal medicine; Genetics; Gene; Gene expression","score_opus":0.02582398150362697,"score_gpt":0.32575360678750104,"score_spread":0.29992962528387407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388845885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9545147,0.02640518,0.0008806845,0.014075235,0.00023468981,0.0018767716,0.00023243405,0.00056126626,0.0012190756],"genre_scores_gemma":[0.96699494,0.030299194,0.0012106389,0.0004975744,0.00013571893,0.00037186,0.00028208594,0.000030636325,0.00017733996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986696,0.00024169154,0.00025835892,0.0002888747,0.00026958637,0.00027184314],"domain_scores_gemma":[0.99807173,0.00034555764,0.00008019765,0.0012169456,0.00014322811,0.00014233237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033769922,0.00017114909,0.00023844713,0.0002627631,0.00031286862,0.000023122011,0.0001954303,0.00022474141,0.000024563975],"category_scores_gemma":[0.00024086634,0.00015793691,0.00007031687,0.0012460828,0.00015034847,0.00022008723,0.00016452998,0.000766128,0.00005009126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015311689,0.0015336056,0.91052026,0.00038029172,0.00045986424,0.00021408756,0.0028393958,0.0022540719,0.019577296,0.020968456,0.036451094,0.0032704172],"study_design_scores_gemma":[0.0030327148,0.000083654464,0.96379846,0.00013808966,0.00013293496,0.000029104482,0.00009729733,0.023694392,0.00018045296,0.0030598831,0.005515436,0.00023756015],"about_ca_topic_score_codex":0.00006549505,"about_ca_topic_score_gemma":0.00008400773,"teacher_disagreement_score":0.053278226,"about_ca_system_score_codex":0.0004690056,"about_ca_system_score_gemma":0.00060328306,"threshold_uncertainty_score":0.64404804},"labels":[],"label_agreement":null},{"id":"W4388940697","doi":"10.1007/s11357-023-00999-9","title":"A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment","year":2023,"lang":"en","type":"article","venue":"GeroScience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of Mental Health; National Institute on Aging; National Institute of General Medical Sciences; National Institute of Mental Health and Neurosciences","keywords":"Montreal Cognitive Assessment; Neurocognitive; Placebo; Medicine; Randomized controlled trial; Internal medicine; Cerebral blood flow; Adverse effect; Cognition; Psychology; Cognitive impairment; Psychiatry; Pathology; Disease","score_opus":0.01869730895418832,"score_gpt":0.3122000357029465,"score_spread":0.2935027267487582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388940697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99032277,0.00005812862,0.00034761743,0.0005802515,0.0002563587,0.007341185,0.000011830225,0.00007323584,0.0010086518],"genre_scores_gemma":[0.9967319,0.00008834824,0.00017608816,0.00035143932,0.000058822523,0.0018560532,0.0000070423125,0.000014482337,0.0007158267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979345,0.00020782423,0.0005237637,0.0003831993,0.00059388875,0.0003568147],"domain_scores_gemma":[0.9984893,0.000836123,0.0002448172,0.00020225291,0.00012449398,0.00010301883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017222642,0.00015973524,0.000871178,0.00029772916,0.00004920066,0.000011807523,0.00010348242,0.00005431602,0.000079815916],"category_scores_gemma":[0.0004956394,0.000109369474,0.00015114542,0.0009478857,0.00048154595,0.00008724231,0.000028861377,0.00014185921,0.000026946545],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99591637,0.00031567382,0.00036748563,0.000038116563,0.000027187929,0.00002131486,0.0017167762,0.00002910416,0.001237734,0.000025589528,0.00011521709,0.00018945141],"study_design_scores_gemma":[0.9833913,0.0010370947,0.0032564935,0.0011801092,0.000052452637,0.000009250257,0.00055827654,0.0016682027,0.008670153,0.000054983924,0.0000041386966,0.00011753808],"about_ca_topic_score_codex":0.00007698568,"about_ca_topic_score_gemma":0.000028281347,"teacher_disagreement_score":0.012525042,"about_ca_system_score_codex":0.00008934891,"about_ca_system_score_gemma":0.00028760964,"threshold_uncertainty_score":0.44599578},"labels":[],"label_agreement":null},{"id":"W4388945418","doi":"10.3389/fonc.2023.1287444","title":"Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health","keywords":"Clofarabine; Fludarabine; PARP1; Olaparib; Cancer research; Cytotoxicity; Pharmacology; Silibinin; Transplantation; DNA damage; PARP inhibitor; DNA repair; Poly ADP ribose polymerase; Chemistry; Cytarabine; Biology; Medicine; Biochemistry; Chemotherapy; Internal medicine; In vitro; Cyclophosphamide; Enzyme","score_opus":0.018210124573201567,"score_gpt":0.310798092935116,"score_spread":0.2925879683619144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388945418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907085,0.0006708604,0.0010984032,0.0013671365,0.0017108518,0.0005784521,0.00004257443,0.000069192734,0.003754047],"genre_scores_gemma":[0.9902777,0.0017440396,0.006075536,0.00058251864,0.00014093664,0.000121450335,0.00004071792,0.000034740453,0.000982337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822336,0.00016027002,0.000597759,0.00039143546,0.00020064779,0.00042652249],"domain_scores_gemma":[0.9991642,0.0002094075,0.00015388646,0.0002851706,0.00006712289,0.00012018149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053743727,0.00018307698,0.0007794352,0.00071896665,0.000026889633,0.0000043971536,0.00011865364,0.0002663787,0.00006573184],"category_scores_gemma":[0.00017329508,0.00018795303,0.000058293368,0.00096144446,0.00035572317,0.00006191801,0.00006173799,0.00037101988,0.000020820715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032561226,0.00086061796,0.6375824,0.0005903311,0.00014708863,0.0011922844,0.0022687288,0.000905436,0.16205345,0.0010009108,0.15703161,0.033111025],"study_design_scores_gemma":[0.02591012,0.0031045603,0.77023095,0.000593833,0.0001169037,0.00007363541,0.0017921334,0.009692541,0.10820386,0.0064784265,0.07304539,0.00075765565],"about_ca_topic_score_codex":0.00015297547,"about_ca_topic_score_gemma":0.00011192347,"teacher_disagreement_score":0.13264854,"about_ca_system_score_codex":0.00042430533,"about_ca_system_score_gemma":0.00026757192,"threshold_uncertainty_score":0.7664502},"labels":[],"label_agreement":null},{"id":"W4389034252","doi":"10.1096/fasebj.30.1_supplement.1268.3","title":"THE DUAL ACTIONS OF DNA REPAIR ENZYME, PARP‐1, IN COLON INFLAMMATION AND CARCINOGENESIS","year":2016,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Canadian Bureau for International Education","keywords":"Carcinogenesis; Cancer research; Genome instability; Colorectal cancer; DNA repair; Poly ADP ribose polymerase; Mouse model of colorectal and intestinal cancer; Inflammation; Adenomatous polyposis coli; Biology; DNA damage; Cancer; Immunology; Polymerase; Genetics; DNA","score_opus":0.03208335108758823,"score_gpt":0.29390199906048675,"score_spread":0.2618186479728985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389034252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901045,0.0006133597,0.000117782176,0.00830142,0.00016453316,0.00015152464,0.0000067291085,0.000014236869,0.000525902],"genre_scores_gemma":[0.99752665,0.0015599688,0.00005098811,0.00008079165,0.00032277597,0.000014287717,5.2005635e-7,0.000008246517,0.00043574994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915206,0.00014361231,0.00029100003,0.00007045265,0.00020692273,0.00013597439],"domain_scores_gemma":[0.9991932,0.0003053486,0.00017521916,0.00017655076,0.000092748065,0.000056949422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007517978,0.000066508575,0.00011892903,0.00006700098,0.00019626122,0.000011636535,0.000051918025,0.000038743492,0.00008552272],"category_scores_gemma":[0.00010794361,0.000029783325,0.000061371495,0.000116403724,0.00016843587,0.00008413021,0.000014611534,0.00013703377,0.0000051320226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005196347,0.000019759094,0.018129611,0.00000835022,0.00005974857,0.000012563767,0.00052365125,0.0000088166125,0.9676759,0.0004868776,0.0013135663,0.011241501],"study_design_scores_gemma":[0.002805187,0.00021875532,0.10552824,0.00022789543,0.000060109873,0.0007723891,0.00051175326,0.000055716784,0.8811948,0.0010733533,0.007483721,0.00006807962],"about_ca_topic_score_codex":0.000015791953,"about_ca_topic_score_gemma":0.00006483356,"teacher_disagreement_score":0.08739863,"about_ca_system_score_codex":0.00011383551,"about_ca_system_score_gemma":0.0001177989,"threshold_uncertainty_score":0.15095025},"labels":[],"label_agreement":null},{"id":"W4389227464","doi":"10.1158/1535-7163.targ-23-lb_c11","title":"Abstract LB_C11: Small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; PARP1; PARP inhibitor; Histone deacetylase; Pharmacology; Cancer research; Vorinostat; DNA repair; Poly ADP ribose polymerase; Synthetic lethality; Biology; Polymerase; Histone; Enzyme; Biochemistry; DNA","score_opus":0.04751386002510425,"score_gpt":0.32016666766537677,"score_spread":0.2726528076402725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790444,0.012965931,0.00052118243,0.003801733,0.0005451713,0.0004824463,0.00008206317,0.00022092147,0.002336202],"genre_scores_gemma":[0.99264586,0.0031482747,0.00028443633,0.0030786952,0.00021456047,0.000118932934,0.00005279587,0.0000776737,0.00037877765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983774,0.00004231707,0.00040232434,0.00037290255,0.0004558841,0.00034921212],"domain_scores_gemma":[0.99909604,0.00006807457,0.00016158067,0.000352116,0.00018279217,0.00013940119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002049687,0.000249881,0.00035706288,0.00024224816,0.00007695151,0.0000205277,0.000097443015,0.0001615184,0.00024887692],"category_scores_gemma":[0.000013162466,0.0002396492,0.00015943157,0.00059862185,0.0002264282,0.00004701098,0.000045700253,0.00024413964,0.000026871254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047175953,0.00016412616,0.009820237,0.0003737069,0.0007656203,0.00011728171,0.00050725683,0.00023716014,0.9655184,0.0011131923,0.001976562,0.018934676],"study_design_scores_gemma":[0.00287213,0.00028219813,0.02252742,0.0003107371,0.00022773094,0.00003370326,0.00017238868,0.0003519129,0.9294434,0.0008804642,0.04254176,0.0003561087],"about_ca_topic_score_codex":0.00007114948,"about_ca_topic_score_gemma":0.000011444447,"teacher_disagreement_score":0.0405652,"about_ca_system_score_codex":0.00010447814,"about_ca_system_score_gemma":0.00024832235,"threshold_uncertainty_score":0.9772611},"labels":[],"label_agreement":null},{"id":"W4389239811","doi":"10.1158/1535-7163.targ-23-b020","title":"Abstract B020: <i>SF3B1 </i>hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; Synthetic lethality; Mutant; DNA repair; DNA damage; Cancer research; DNA replication; Transcriptome; Genetics; DNA; Gene; Gene expression","score_opus":0.06120906213030747,"score_gpt":0.3779009795185503,"score_spread":0.3166919173882428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389239811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622239,0.00043131498,0.015436661,0.018316092,0.00025853657,0.00142394,0.00044487833,0.0005137256,0.00095097366],"genre_scores_gemma":[0.98250437,0.00030776666,0.00062362524,0.015055842,0.00016974875,0.00071995455,0.0002829772,0.0001075474,0.00022819711],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973926,0.00031522778,0.00043124607,0.00077004515,0.0005994079,0.0004914999],"domain_scores_gemma":[0.9978105,0.0003518977,0.00018231585,0.000959633,0.00051087484,0.00018477085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00070069043,0.00032718352,0.00037570353,0.0002454906,0.00020815872,0.00005834188,0.00007932168,0.00020224118,0.00014047505],"category_scores_gemma":[0.00013702721,0.00034705346,0.00020088306,0.0012196257,0.00014940127,0.00015012955,0.00004494267,0.00035272934,0.00024918246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002523163,0.0001837042,0.0010334371,0.000074596544,0.0003080404,0.0002603452,0.002796325,0.002431648,0.98330116,0.0004435515,0.0009963837,0.005647615],"study_design_scores_gemma":[0.0026053977,0.00029504884,0.070156746,0.00042029086,0.0002353175,0.000057097892,0.0005402236,0.00047510874,0.89547706,0.0015511431,0.02770414,0.000482443],"about_ca_topic_score_codex":0.00019649955,"about_ca_topic_score_gemma":0.00007405605,"teacher_disagreement_score":0.08782414,"about_ca_system_score_codex":0.0006012739,"about_ca_system_score_gemma":0.00041317745,"threshold_uncertainty_score":0.99989814},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4389241566","doi":"10.1158/2326-6074.tumimm23-b054","title":"Abstract B054: Immunological control by PARP inhibitors for successful immunotherapy in metastatic ovarian carcinoma","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Immunotherapy; Cytotoxic T cell; DNA repair; DNA damage; Cancer; Immunology; Biology; Ovarian cancer; Immune system; Medicine; Internal medicine; DNA; In vitro; Genetics","score_opus":0.10298796408779382,"score_gpt":0.43308032806995667,"score_spread":0.33009236398216285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493593,0.031200754,0.00013911231,0.014246102,0.00080776366,0.0028996407,0.00035610268,0.00024240115,0.0007488014],"genre_scores_gemma":[0.98635453,0.005704808,0.000089315254,0.0006126651,0.00025061725,0.005420746,0.00020963339,0.00010388211,0.0012538203],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.995434,0.00053079944,0.0008731608,0.0008526218,0.00063645816,0.0016729652],"domain_scores_gemma":[0.99684936,0.0014895528,0.00016408725,0.00079419406,0.0005526905,0.00015010424],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00270285,0.00037037273,0.00092668174,0.0010405896,0.00034444578,0.00006488405,0.00055075367,0.0004178717,0.0013974634],"category_scores_gemma":[0.00036194175,0.00033303283,0.00024842587,0.001845825,0.0010945416,0.0001946443,0.000095615775,0.0015305971,0.00024760055],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012351514,0.0006134745,0.058375545,0.00023209707,0.0010797102,0.00027405642,0.00088843034,0.000040445062,0.8389036,0.00071649964,0.037227258,0.04929739],"study_design_scores_gemma":[0.06560551,0.0034777764,0.58635753,0.0006478218,0.000089770736,0.00012492112,0.00284338,0.0005602524,0.15050101,0.005212745,0.18345547,0.0011238221],"about_ca_topic_score_codex":0.0012740027,"about_ca_topic_score_gemma":0.000067879104,"teacher_disagreement_score":0.6884026,"about_ca_system_score_codex":0.0009937729,"about_ca_system_score_gemma":0.00092638034,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W4389280739","doi":"10.1016/j.annonc.2023.10.384","title":"258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Prednisone; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.08289055712942077,"score_gpt":0.3990372821216814,"score_spread":0.3161467249922606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389280739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912784,0.00019509446,0.0000058145856,0.0047764024,0.000097544675,0.0029515105,0.00029561057,0.000017484655,0.000382115],"genre_scores_gemma":[0.99766606,0.0002044736,0.00005321221,0.00056389824,0.00002409891,0.000915905,0.00011125514,0.000028166087,0.00043293033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970162,0.0006473677,0.00099189,0.00042617501,0.0005041425,0.000414209],"domain_scores_gemma":[0.9982179,0.00022373967,0.00060730736,0.0005791485,0.0002990798,0.00007286238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084950594,0.0002944873,0.0010799655,0.00050243706,0.00007256746,0.000016240645,0.00025349826,0.00007617869,0.0002564784],"category_scores_gemma":[0.000051100677,0.00017118957,0.00016161667,0.0019790577,0.0002626634,0.0001119322,0.00005545621,0.00022052346,0.0000065503045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031124463,0.0126751,0.7893061,0.00051334966,0.008049515,0.0004891827,0.11643674,0.021115009,0.0024000846,0.000059559963,0.00081924803,0.017011669],"study_design_scores_gemma":[0.022510957,0.016991358,0.95069087,0.00016017821,0.0008519567,0.000005190138,0.0051780944,0.0003241825,0.0022677288,0.000097907236,0.0007413421,0.00018023895],"about_ca_topic_score_codex":0.004114424,"about_ca_topic_score_gemma":0.10823216,"teacher_disagreement_score":0.16138479,"about_ca_system_score_codex":0.00048792176,"about_ca_system_score_gemma":0.00068809284,"threshold_uncertainty_score":0.9080403},"labels":[],"label_agreement":null},{"id":"W4389696920","doi":"","title":"Rucaparib: a novel PARP inhibitor for&nbsp;BRCA&nbsp;advanced ovarian cancer","year":2018,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ovarian cancer; PARP inhibitor; Medicine; Poly ADP ribose polymerase; Oncology; Cancer research; Internal medicine; Cancer; Biology; Genetics","score_opus":0.3210301875822707,"score_gpt":0.6011849707378332,"score_spread":0.28015478315556247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389696920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92865753,0.025738878,0.012738706,0.005621475,0.0070726527,0.004572508,0.000895723,0.000293369,0.014409147],"genre_scores_gemma":[0.97595847,0.0070110643,0.0056217834,0.004502875,0.003991283,0.00088781724,0.000057576108,0.00023496312,0.0017341609],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99530196,0.00013545042,0.001581107,0.0009463827,0.0011255225,0.00090959214],"domain_scores_gemma":[0.99503577,0.00037727048,0.0013986799,0.001022858,0.0014750315,0.00069037406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013890123,0.00062854815,0.0015115084,0.0008995824,0.00048400403,0.00065425,0.001767145,0.00029529864,0.017148612],"category_scores_gemma":[0.00046465575,0.0005783969,0.00044834008,0.0013978484,0.0005262633,0.0020487672,0.0004918424,0.00064124144,0.000051127146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040721395,0.0008108582,0.0631579,0.00028730527,0.000740313,0.000025860583,0.0006844151,0.000065795226,0.7502809,0.00041747984,0.14770178,0.031755205],"study_design_scores_gemma":[0.013486469,0.00021776423,0.16536476,0.003190518,0.00043968897,0.00010180965,0.00021442924,0.00026402713,0.49356517,0.006631258,0.3153242,0.0011999385],"about_ca_topic_score_codex":0.0007966172,"about_ca_topic_score_gemma":0.00018861321,"teacher_disagreement_score":0.25671577,"about_ca_system_score_codex":0.000597661,"about_ca_system_score_gemma":0.00087369455,"threshold_uncertainty_score":0.99966675},"labels":[],"label_agreement":null},{"id":"W4389978835","doi":"10.1007/s10549-023-07165-x","title":"Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Metastatic breast cancer; Internal medicine; Oncology; BRCA mutation; Breast cancer; Taxane; Population; Eribulin; Cancer","score_opus":0.11391323041243315,"score_gpt":0.4893376363452184,"score_spread":0.37542440593278525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389978835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939097,0.0006884287,0.000004505818,0.0018199001,0.000033193017,0.0010975836,0.0022386962,0.000017875536,0.00019009208],"genre_scores_gemma":[0.9871716,0.011721749,0.000053894924,0.000019082188,0.000042374464,0.00075909967,0.000056230052,0.000023099346,0.00015290073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687165,0.0008018298,0.00070830947,0.0005789159,0.00054219225,0.0004970972],"domain_scores_gemma":[0.99761856,0.0013795818,0.00016936635,0.0002730584,0.00032549285,0.0002339394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017104138,0.00022424685,0.0011115728,0.0014437016,0.0000634563,0.000013387426,0.00007212773,0.00006777907,0.00023646424],"category_scores_gemma":[0.00004238491,0.00017678543,0.00014268377,0.0040268893,0.00055099715,0.00008377523,0.000067229696,0.00029129573,0.0000019361373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013142256,0.00088273874,0.89627385,0.0003054835,0.0024722617,0.00016932804,0.0007865353,0.00041889743,0.00043394917,0.00008806298,0.000027945365,0.08499871],"study_design_scores_gemma":[0.012639526,0.00059396744,0.9822053,0.0011522871,0.00043165957,0.000025549743,0.0003763402,0.0010507643,0.0011348131,0.0002434824,0.000026275035,0.00012005994],"about_ca_topic_score_codex":0.074859165,"about_ca_topic_score_gemma":0.04813588,"teacher_disagreement_score":0.08593145,"about_ca_system_score_codex":0.0010129927,"about_ca_system_score_gemma":0.0007754746,"threshold_uncertainty_score":0.96923316},"labels":[],"label_agreement":null},{"id":"W4390048145","doi":"10.1002/cncr.35151","title":"NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Holden Comprehensive Cancer Center, University of Iowa; University of Oklahoma Health Sciences Center; Seagen; NRG Oncology; Eisai; Alvin J. Siteman Cancer Center; AstraZeneca; University of Oklahoma; Natera; GlaxoSmithKline","keywords":"Olaparib; Medicine; Internal medicine; Oncology; Hazard ratio; Clinical endpoint; PARP inhibitor; BRCA mutation; Randomized controlled trial; Ovarian cancer; Cancer; Confidence interval","score_opus":0.07955989394311878,"score_gpt":0.38555481672630076,"score_spread":0.30599492278318197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390048145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989288,0.0038719224,0.000066707085,0.0010245319,0.0007738037,0.0045215324,0.00008344459,0.00008120246,0.00028886835],"genre_scores_gemma":[0.99250674,0.0030226791,0.00003639455,0.0002206747,0.00018533051,0.0036217317,0.000023510524,0.000048340953,0.00033456602],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969455,0.0005865532,0.0008357664,0.00047183302,0.00069024623,0.0004701213],"domain_scores_gemma":[0.9976299,0.0011627248,0.00045564823,0.00034697243,0.0002494741,0.00015531131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00233794,0.00031466866,0.0016973235,0.0005350726,0.00012903642,0.000042689826,0.0001686119,0.000057162277,0.00045172084],"category_scores_gemma":[0.0004058346,0.00018860416,0.0001485216,0.0018197122,0.0005530836,0.00016712188,0.00005552397,0.0003646284,0.0000045412557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94356734,0.0016001022,0.008756297,0.00059586373,0.002632883,0.000050545386,0.02945673,0.00044446188,0.0013185353,0.00025685664,0.0011852282,0.010135136],"study_design_scores_gemma":[0.97902983,0.0017536387,0.0029893366,0.00082386966,0.0010587343,0.000013646219,0.0076106424,0.0049101063,0.00062610954,0.0001341242,0.0007531886,0.0002967591],"about_ca_topic_score_codex":0.0009453985,"about_ca_topic_score_gemma":0.00042291725,"teacher_disagreement_score":0.035462484,"about_ca_system_score_codex":0.0005604698,"about_ca_system_score_gemma":0.00037698605,"threshold_uncertainty_score":0.76910543},"labels":[],"label_agreement":null},{"id":"W4390126073","doi":"10.1016/j.jval.2023.09.1034","title":"PT44 Cost-Effectiveness of Olaparib Vs. Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer – the Canadian Perspective","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; McGill University Health Centre; McGill University","funders":"","keywords":"Olaparib; Prostate cancer; Medicine; Oncology; Perspective (graphical); Internal medicine; Gynecology; Cancer; Poly ADP ribose polymerase; Computer science; Biology; Artificial intelligence","score_opus":0.07375261166157042,"score_gpt":0.37935217719536884,"score_spread":0.3055995655337984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390126073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791242,0.0005351259,0.0000561063,0.008723544,0.00033022897,0.009637145,0.0013454771,0.000043985776,0.00020420873],"genre_scores_gemma":[0.9967991,0.00011964942,0.00027391998,0.00048915105,0.000038442777,0.002062654,0.00013152628,0.000035767414,0.000049779497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981838,0.00032710546,0.00037939087,0.00029580682,0.00035136586,0.0004625538],"domain_scores_gemma":[0.998316,0.0005355939,0.0002075433,0.00025037685,0.00048522913,0.00020525987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011856278,0.00015484706,0.00039549396,0.00026137382,0.00021322064,0.000016378042,0.000082361825,0.0000388152,0.000019986002],"category_scores_gemma":[0.00014337646,0.00010892352,0.00005177125,0.00080743246,0.00013557958,0.00006786176,0.0000072300454,0.0001836979,0.0000037729842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035576023,0.0017928297,0.68185234,0.01143821,0.0015215825,0.000084349565,0.06122033,0.110140726,0.0013086889,0.08193716,0.0064633545,0.0066643897],"study_design_scores_gemma":[0.017379083,0.0037479308,0.95803547,0.0029554847,0.000110822606,0.00000674002,0.003130823,0.004082786,0.0013293817,0.004801804,0.0040690354,0.00035062796],"about_ca_topic_score_codex":0.5572669,"about_ca_topic_score_gemma":0.2667785,"teacher_disagreement_score":0.29048836,"about_ca_system_score_codex":0.0025466406,"about_ca_system_score_gemma":0.004483235,"threshold_uncertainty_score":0.7953067},"labels":[],"label_agreement":null},{"id":"W4390144023","doi":"10.1101/2023.12.21.572541","title":"PARP inhibitors enhance reovirus-mediated cell killing through the death-inducing signaling complex (DISC) with an associated NF-κB-regulated immune response","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Oncolytics Biotech","keywords":"Oncolytic virus; Poly ADP ribose polymerase; PARP inhibitor; Cancer research; Biology; Immune system; Oncolytic adenovirus; Apoptosis; Melanoma; Immunology; Polymerase; DNA","score_opus":0.040641496586887885,"score_gpt":0.2814832094479049,"score_spread":0.24084171286101702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390144023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888482,0.0013080826,0.0017010529,0.001687587,0.0013519193,0.0024625896,0.0005073625,0.0021176243,0.00001559436],"genre_scores_gemma":[0.9926023,0.00036351595,0.0038834782,0.0008414058,0.00094190834,0.0006021545,0.000027246462,0.0006845085,0.000053521897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9915824,0.0014045332,0.0017914341,0.0022045535,0.0015302685,0.0014868396],"domain_scores_gemma":[0.992269,0.001013984,0.0017923296,0.0029599608,0.0014437931,0.00052097486],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0033643157,0.0013891101,0.0017124282,0.00050385797,0.00087342685,0.00039086305,0.00094028644,0.0012006037,0.00014400358],"category_scores_gemma":[0.00067811494,0.0011732673,0.00039432902,0.0020914588,0.00046621996,0.00040689597,0.00044489422,0.0028151195,0.00016064619],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025934053,0.00039817605,0.0027200258,0.00030941932,0.00068190705,0.00033222334,0.00034743646,0.0018061588,0.9904699,0.000028976743,0.00031114617,0.0000012262806],"study_design_scores_gemma":[0.003521834,0.0006130012,0.047183633,0.004522183,0.0005709726,2.786885e-7,0.000115387425,0.0020190903,0.9383323,0.0000121768035,0.0014921561,0.0016169746],"about_ca_topic_score_codex":0.0006026479,"about_ca_topic_score_gemma":0.000014219352,"teacher_disagreement_score":0.052137583,"about_ca_system_score_codex":0.001628006,"about_ca_system_score_gemma":0.002048926,"threshold_uncertainty_score":0.9998859},"labels":[],"label_agreement":null},{"id":"W4390617976","doi":"10.1007/s12672-023-00857-2","title":"Vitality, viability, long-term clonogenic survival, cytotoxicity, cytostasis and lethality: what do they mean when testing new investigational oncology drugs?","year":2024,"lang":"en","type":"letter","venue":"Discover Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Cytostasis; Clonogenic assay; Lethality; Synthetic lethality; Medicine; Toxicity; Cytotoxicity; Oncology; Cancer research; Cancer; Viability assay; Pharmacology; Cell; Internal medicine; Biology; Toxicology; DNA repair; In vitro","score_opus":0.08801739612951723,"score_gpt":0.36929807072254556,"score_spread":0.2812806745930283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390617976","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2006999,0.0056949384,0.00014465337,0.7751934,0.004346793,0.0024944476,0.0007324323,0.0003728308,0.010320581],"genre_scores_gemma":[0.07345716,0.0028359992,0.0026542137,0.8906904,0.02063773,0.0005409171,0.0041084387,0.00055391056,0.004521216],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99200815,0.001521075,0.001663663,0.0022548025,0.0013246874,0.0012276021],"domain_scores_gemma":[0.9934909,0.0032858606,0.0008305638,0.0013843408,0.0003967714,0.0006115694],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001908252,0.0011601833,0.0024617845,0.00059615175,0.00024511633,0.0005802526,0.00063452346,0.002762409,0.00092230516],"category_scores_gemma":[0.0005051657,0.0010864148,0.0005702092,0.00046148017,0.0016424175,0.00080948323,0.0009785647,0.004322378,0.00032028632],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0008039254,0.0007721106,0.06082203,0.0037279432,0.0030901444,0.0046601896,0.00957609,0.000011944846,0.0056956434,0.0011871113,0.8651587,0.044494174],"study_design_scores_gemma":[0.009707116,0.004372385,0.011950986,0.0040062596,0.0033532837,0.003917232,0.0010459789,0.000027787813,0.0030612256,0.17554578,0.78022784,0.0027841325],"about_ca_topic_score_codex":0.001167601,"about_ca_topic_score_gemma":0.0010717321,"teacher_disagreement_score":0.17435867,"about_ca_system_score_codex":0.0039232955,"about_ca_system_score_gemma":0.0066344207,"threshold_uncertainty_score":0.999991},"labels":[],"label_agreement":null},{"id":"W4390726324","doi":"10.1158/1538-7445.dnarepair24-b001","title":"Abstract B001: Identification of monoallelic <i>ATM</i> loss-of-function and homologous recombination deficiency (HRD) in high-grade ovarian tumor with prolonged response to camonsertib and low-dose gemcitabine combination therapy","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Carboplatin; Medicine; Gemcitabine; Debulking; Olaparib; Internal medicine; Oncology; Ovarian cancer; Neutropenia; Progressive disease; Cisplatin; Surgery; Chemotherapy; Cancer","score_opus":0.04393376931211829,"score_gpt":0.36786548185211565,"score_spread":0.32393171253999736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390726324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98948,0.0032001848,0.00014789464,0.0052663623,0.00013781991,0.0016596032,0.00002977673,0.000041051968,0.00003728023],"genre_scores_gemma":[0.9978157,0.0011440845,0.00007273557,0.00007061541,0.000033747077,0.000643286,0.000024328323,0.000035198904,0.00016026312],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99785215,0.0002924565,0.00048890413,0.0004883475,0.0005954707,0.00028268175],"domain_scores_gemma":[0.9986647,0.00033287724,0.000116150266,0.00030563265,0.0004705203,0.00011016935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024942064,0.00014937873,0.00028183722,0.0009112823,0.00008667121,0.000050679006,0.00009390332,0.00008443869,0.00004056968],"category_scores_gemma":[0.00016746603,0.00012971666,0.000026509157,0.0012940418,0.00029562874,0.00022808443,0.000028221946,0.00037627044,0.0000040458553],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016139286,0.0005723556,0.014384208,0.00068273436,0.00005129753,0.00005605069,0.0015874351,0.0000873261,0.952071,0.0014091567,0.000132725,0.012826388],"study_design_scores_gemma":[0.006027077,0.0023941195,0.85082585,0.0008926388,0.00002048617,0.000043158157,0.00021087167,0.00048581947,0.1359254,0.0028777556,0.00013813566,0.00015870485],"about_ca_topic_score_codex":0.00081493706,"about_ca_topic_score_gemma":0.00013958267,"teacher_disagreement_score":0.83644164,"about_ca_system_score_codex":0.00038091428,"about_ca_system_score_gemma":0.00046352734,"threshold_uncertainty_score":0.52896917},"labels":[],"label_agreement":null},{"id":"W4391034644","doi":"10.3390/curroncol31010039","title":"Combination of Osimertinib and Olaparib Therapy to Treat Non-Small Cell Lung Cancer and High-Grade Serous Ovarian Carcinoma: A Case Report","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Osimertinib; Olaparib; Ovarian cancer; Oncology; Regimen; Lung cancer; Internal medicine; Combination therapy; Targeted therapy; Cancer; KRAS; Colorectal cancer","score_opus":0.07037647280412043,"score_gpt":0.3969825259791531,"score_spread":0.32660605317503266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391034644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97213644,0.021813689,0.00044127236,0.0028440575,0.0013515429,0.0009222421,0.000047499252,0.000052836527,0.0003904038],"genre_scores_gemma":[0.99714094,0.0015137283,0.0002651191,0.00021588453,0.0002597792,0.0002800767,0.00003837062,0.000030428995,0.00025567456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987359,0.000068245274,0.00040379172,0.00043937648,0.00012885037,0.00022381126],"domain_scores_gemma":[0.99921674,0.00013182592,0.000121645186,0.0002226662,0.00012274798,0.00018435899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023727343,0.00018736398,0.000433245,0.00020345823,0.000059137194,0.000020361707,0.000040299565,0.00013187194,0.00006777488],"category_scores_gemma":[0.000015093952,0.00016413172,0.00004996422,0.00023735703,0.00010061376,0.000052199637,0.000035513287,0.0002332374,0.0000021077583],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026871448,0.0036609909,0.3046539,0.0049773925,0.00049333676,0.04053694,0.025093973,0.000028417651,0.11031505,0.0015871037,0.034019355,0.4719464],"study_design_scores_gemma":[0.087298214,0.015187275,0.21299392,0.003191006,0.0028447162,0.10812132,0.0018738168,0.013792554,0.25685495,0.0013285361,0.29424545,0.0022682268],"about_ca_topic_score_codex":0.0007389748,"about_ca_topic_score_gemma":0.00007932454,"teacher_disagreement_score":0.46967816,"about_ca_system_score_codex":0.00029721088,"about_ca_system_score_gemma":0.00035142738,"threshold_uncertainty_score":0.66930974},"labels":[],"label_agreement":null},{"id":"W4391070551","doi":"10.1016/j.annonc.2024.01.003","title":"Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Response Biomedical (Canada)","funders":"Cancer Research UK; National Centre for the Replacement, Refinement and Reduction of Animals in Research; Memorial Sloan-Kettering Cancer Center; Engineering and Physical Sciences Research Council; AstraZeneca","keywords":"Medicine; Breast cancer; PARP inhibitor; Cancer research; Cancer; Genetics; Gene; Internal medicine; Biology; Polymerase; Poly ADP ribose polymerase","score_opus":0.07608235447031829,"score_gpt":0.43704381216784643,"score_spread":0.36096145769752813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391070551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97823155,0.009504773,0.000050729774,0.009501132,0.0005423102,0.00043716523,0.00029783318,0.000070705064,0.0013638207],"genre_scores_gemma":[0.9955194,0.0027193276,0.00041584412,0.0007049733,0.00021834458,0.00013448598,0.000037239257,0.000024451658,0.00022595136],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984484,0.00009241953,0.0005271579,0.00039576326,0.00022563568,0.00031067844],"domain_scores_gemma":[0.9990925,0.00026948488,0.00013516554,0.0001786881,0.00020402372,0.00012014213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004433015,0.00016609089,0.0004452591,0.00035002705,0.00008174784,0.000021793225,0.000068640315,0.0001410366,0.00021784347],"category_scores_gemma":[0.00007773587,0.00015953167,0.000087747045,0.00038183085,0.00025661846,0.00023612751,0.00004019838,0.00030963973,0.000011735516],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057096044,0.0012767772,0.21228765,0.0039824094,0.000992609,0.0020623822,0.0058996584,0.0006009632,0.4761111,0.003800058,0.041213673,0.24606308],"study_design_scores_gemma":[0.013231556,0.003472311,0.41414338,0.011841269,0.00047014814,0.00131473,0.005792987,0.000977476,0.37346256,0.00595662,0.16809408,0.0012428636],"about_ca_topic_score_codex":0.00021473983,"about_ca_topic_score_gemma":0.0002096586,"teacher_disagreement_score":0.24482022,"about_ca_system_score_codex":0.00017798951,"about_ca_system_score_gemma":0.000507926,"threshold_uncertainty_score":0.65055126},"labels":[],"label_agreement":null},{"id":"W4391104521","doi":"10.1101/2024.01.20.575817","title":"PARP1 condensates differentially partition DNA repair proteins and enhance DNA ligation","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; University of Toronto","keywords":"PARP1; XRCC1; DNA repair; DNA damage; DNA; DNA ligase; Poly ADP ribose polymerase; Cell biology; Biology; Chemistry; Polymerase; Molecular biology; Biochemistry; Gene","score_opus":0.015446916657149467,"score_gpt":0.25739822293080356,"score_spread":0.24195130627365408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391104521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98970944,0.0032805037,0.00057396747,0.0014588957,0.0013031978,0.0019855143,0.00023768996,0.0014217222,0.000029076515],"genre_scores_gemma":[0.9939336,0.00066675193,0.002420626,0.00045761163,0.0011269769,0.0011681404,0.0000030164938,0.00017392638,0.0000493156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967947,0.00013702286,0.0007294205,0.0013030388,0.0005527758,0.0004830568],"domain_scores_gemma":[0.9976387,0.00005677974,0.00039244007,0.0010792243,0.0004989969,0.00033387143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004938205,0.00060913875,0.00072685094,0.0002935351,0.00014452595,0.00021764432,0.00015636701,0.00062700274,0.00014697034],"category_scores_gemma":[0.0001519451,0.0006243277,0.00023488676,0.0003521563,0.0002400774,0.00012032375,0.00030774047,0.0010040783,0.00014269278],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013630906,0.00014561984,0.0019566037,0.0021555135,0.00034604638,0.000088508794,0.000034322613,0.0000028468573,0.9933619,0.0008328922,0.0009336878,0.0000057598777],"study_design_scores_gemma":[0.00081391697,0.00017865871,0.03492519,0.003587482,0.0003798754,1.4557654e-7,0.0000033222243,0.0003495493,0.9563991,0.000118361764,0.002609135,0.00063526287],"about_ca_topic_score_codex":0.000024251649,"about_ca_topic_score_gemma":0.000004680492,"teacher_disagreement_score":0.03696279,"about_ca_system_score_codex":0.00043779807,"about_ca_system_score_gemma":0.00068737933,"threshold_uncertainty_score":0.9996208},"labels":[],"label_agreement":null},{"id":"W4391288586","doi":"10.1016/j.ejca.2024.113580","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Veliparib; Carboplatin; Paclitaxel; Medicine; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; Biology; Cisplatin; Genetics","score_opus":0.032102466033714055,"score_gpt":0.34669834975439096,"score_spread":0.3145958837206769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391288586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700507,0.019420823,0.00036125848,0.0055094855,0.0015214029,0.0007126043,0.00073131354,0.000045211873,0.0016471884],"genre_scores_gemma":[0.9916357,0.004543741,0.0005013446,0.00047341202,0.0020827372,0.00003326116,0.000025717734,0.00008676601,0.00061736646],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99663377,0.00075697,0.0012462517,0.00039964326,0.0006443884,0.0003189853],"domain_scores_gemma":[0.99825054,0.00046900974,0.0005357942,0.000194252,0.00028346662,0.0002669086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015592945,0.00031216143,0.0010729579,0.0002744562,0.000044690543,0.00008752309,0.00012209236,0.00005100186,0.00035597704],"category_scores_gemma":[0.0001579245,0.00021900622,0.00019132247,0.00033827047,0.00020873346,0.00028042484,0.000024384613,0.0007810088,0.000005637642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9426694,0.00015821168,0.00012689142,0.000051444073,0.000676153,0.0018441163,0.0016897592,0.000587523,0.0077143894,0.000019450992,0.0018504136,0.042612266],"study_design_scores_gemma":[0.978718,0.0011293428,0.004045166,0.0040092026,0.0004548844,0.0002791008,0.00012155008,0.00080290955,0.0009399207,0.0000843303,0.009117629,0.00029797162],"about_ca_topic_score_codex":0.0004641055,"about_ca_topic_score_gemma":0.00017054577,"teacher_disagreement_score":0.042314295,"about_ca_system_score_codex":0.0003346668,"about_ca_system_score_gemma":0.00073599076,"threshold_uncertainty_score":0.8930815},"labels":[],"label_agreement":null},{"id":"W4391302045","doi":"10.1200/jco.2024.42.4_suppl.105","title":"Patient-reported outcomes (PRO) in patients (pts) with <i>BRCA1/2</i>-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Abiraterone acetate; Prostate cancer; Prednisone; Abiraterone; Internal medicine; Oncology; Cancer; Castration; Androgen deprivation therapy; Hormone; Androgen receptor","score_opus":0.09669820922149745,"score_gpt":0.4317309454260764,"score_spread":0.3350327362045789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391302045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927142,0.0006887634,0.00003335627,0.003819753,0.00091940304,0.0014886742,0.00014107386,0.00003475075,0.00015997842],"genre_scores_gemma":[0.9940606,0.00042164064,0.004149099,0.0007937551,0.0002196737,0.000089781286,0.00003103112,0.00005830966,0.00017612796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933597,0.00072750525,0.0039836555,0.000633057,0.00090292166,0.0003931848],"domain_scores_gemma":[0.99465346,0.0015557571,0.0023640567,0.0003378111,0.0007154029,0.00037348006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002168916,0.00036262744,0.001948103,0.00028212072,0.00006680985,0.00007994082,0.00011821922,0.00016423267,0.00007221679],"category_scores_gemma":[0.0008063032,0.00022275482,0.00014587956,0.00039976527,0.00028546026,0.0004053407,0.00004585266,0.0011864398,0.0000040311393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08345566,0.004854341,0.8245428,0.00012874053,0.0032955552,0.0034000569,0.0053719915,0.00026372244,0.00062171684,0.0000027821507,0.0007404088,0.07332222],"study_design_scores_gemma":[0.061078236,0.034857243,0.8984747,0.0012793109,0.0010648714,0.0000940516,0.0008650427,0.00010088249,0.00014038601,0.000083979314,0.0017089937,0.00025228542],"about_ca_topic_score_codex":0.00058121997,"about_ca_topic_score_gemma":0.003196457,"teacher_disagreement_score":0.07393192,"about_ca_system_score_codex":0.000416078,"about_ca_system_score_gemma":0.0019171693,"threshold_uncertainty_score":0.9083678},"labels":[],"label_agreement":null},{"id":"W4391303280","doi":"10.1200/jco.2024.42.4_suppl.tps356","title":"ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Window of opportunity; Oncology; Randomized controlled trial; Open label; Internal medicine; Cancer","score_opus":0.19313651286179898,"score_gpt":0.532625601221301,"score_spread":0.339489088359502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979739,0.00080538983,0.00013414619,0.012637491,0.00023375577,0.006375772,0.000014911048,0.000007802847,0.00005170599],"genre_scores_gemma":[0.99462277,0.0013587587,0.0014794655,0.001860519,0.0001264383,0.00048198126,0.000005142677,0.000020079522,0.00004482582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943714,0.0022154103,0.0025592977,0.00029610965,0.00032428867,0.00023348107],"domain_scores_gemma":[0.9900995,0.00796356,0.001018715,0.00017450248,0.00038342,0.00036031785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012806458,0.0001750173,0.0023452956,0.00027155108,0.000031367337,0.000020778903,0.00022515882,0.00017338117,0.000020881782],"category_scores_gemma":[0.006513081,0.00008521701,0.00007371185,0.000537306,0.00073990895,0.00022379139,0.00007500963,0.0007670814,2.5578152e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90446603,0.01637465,0.019407414,0.00039805286,0.0006975865,0.0008649533,0.0030430022,0.000057010933,0.006111344,0.00023208733,0.0008758532,0.04747201],"study_design_scores_gemma":[0.81318563,0.14957272,0.024525495,0.0016667433,0.00046388022,0.0001447631,0.0006947483,0.0011572107,0.0029329942,0.0037656247,0.0017189154,0.00017127347],"about_ca_topic_score_codex":0.00026813502,"about_ca_topic_score_gemma":0.0004587205,"teacher_disagreement_score":0.13319805,"about_ca_system_score_codex":0.00017829568,"about_ca_system_score_gemma":0.003118297,"threshold_uncertainty_score":0.77972364},"labels":[],"label_agreement":null},{"id":"W4391303701","doi":"10.1200/jco.2024.42.4_suppl.165","title":"Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Abiraterone; Homologous recombination; PARP inhibitor; Internal medicine; Oncology; Enzalutamide; Placebo; Cancer research; Gene; Urology; Cancer; Poly ADP ribose polymerase; Androgen receptor; Genetics; Pathology; Polymerase; Biology","score_opus":0.14794484308262323,"score_gpt":0.44795023381165994,"score_spread":0.3000053907290367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391303701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252397,0.00046849073,0.00009442367,0.0035109478,0.0008882321,0.0021156117,0.000020387432,0.000018280616,0.000359662],"genre_scores_gemma":[0.996186,0.000158537,0.0028734047,0.0002558426,0.00018784768,0.00018641396,0.000022139333,0.000029003895,0.00010077754],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99537283,0.0010229992,0.0024230375,0.00029703972,0.0006320259,0.0002520692],"domain_scores_gemma":[0.9950094,0.0026853366,0.0014069286,0.00022071465,0.0005613702,0.000116238094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032198115,0.0001918283,0.0011345218,0.00033277847,0.000041696596,0.000025540592,0.00014229494,0.00015667849,0.000048283677],"category_scores_gemma":[0.0010729758,0.000109839784,0.00018139138,0.0006643536,0.00032794473,0.00022027463,0.000014372778,0.0009043236,0.0000032693185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94289243,0.008311389,0.0033662987,0.00025774082,0.0010866948,0.0017683847,0.0047555594,0.0062168795,0.0005462296,0.00013732458,0.0006730068,0.029988049],"study_design_scores_gemma":[0.7394571,0.15372261,0.0971169,0.0018325989,0.0013570184,0.00026069765,0.0012536534,0.0014924739,0.0006296258,0.00026870592,0.0022891974,0.00031944326],"about_ca_topic_score_codex":0.00017427802,"about_ca_topic_score_gemma":0.0015258013,"teacher_disagreement_score":0.20343538,"about_ca_system_score_codex":0.0012398585,"about_ca_system_score_gemma":0.0047722785,"threshold_uncertainty_score":0.8465817},"labels":[],"label_agreement":null},{"id":"W4391390283","doi":"10.21037/tcr-23-577","title":"Can we successfully define and target BRCA-like breast cancers?","year":2024,"lang":"en","type":"editorial","venue":"Translational Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Seagen; Gilead Sciences; Avon Foundation for Women; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Oncology; Medicine; Breast cancer; Internal medicine; Gynecology; Biology; Cancer","score_opus":0.0586367320877046,"score_gpt":0.42458981555825454,"score_spread":0.36595308347054994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391390283","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001183716,0.16324726,0.00007717362,0.11046249,0.6836987,0.0026330545,0.030241197,0.00036104393,0.0080953445],"genre_scores_gemma":[0.017888203,0.036400054,0.00042923848,0.00033496725,0.92229116,0.001624493,0.0036519722,0.00036758793,0.017012352],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925678,0.00022780405,0.0006310561,0.0012416708,0.004380822,0.0009508688],"domain_scores_gemma":[0.9963502,0.00096943876,0.00010121121,0.00049385807,0.0015687253,0.00051655644],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012170878,0.0005334927,0.0008034413,0.0008555941,0.00031694488,0.00019910341,0.00033022882,0.000887365,0.004437887],"category_scores_gemma":[0.00006438153,0.0005041454,0.00021384044,0.0010793423,0.00071945693,0.00014945114,0.00007090446,0.0036322773,0.000109208806],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00173721,0.000051809788,0.0003507974,0.002036742,0.00045568802,0.000117672585,0.0005991246,0.00006537583,0.00038483457,0.0004848949,0.9892803,0.0044355616],"study_design_scores_gemma":[0.0029083367,0.00022303368,0.0003316614,0.0022759205,0.00015435358,0.00006384186,0.000044945176,0.00014120451,0.00017073813,0.0062998827,0.98692554,0.00046056378],"about_ca_topic_score_codex":0.008005361,"about_ca_topic_score_gemma":0.0053933775,"teacher_disagreement_score":0.2385924,"about_ca_system_score_codex":0.0018036613,"about_ca_system_score_gemma":0.011674183,"threshold_uncertainty_score":0.999741},"labels":[],"label_agreement":null},{"id":"W4391589947","doi":"10.1016/j.ygyno.2024.01.021","title":"Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"GlaxoSmithKline","keywords":"Medicine; Nausea; Quality of life (healthcare); Placebo; Constipation; Internal medicine; Vomiting; Ovarian cancer; Cancer; Randomized controlled trial; Surgery","score_opus":0.03742922405848668,"score_gpt":0.3674416813460257,"score_spread":0.330012457287539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391589947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734125,0.0015159562,0.00017308188,0.013441345,0.00093348743,0.008432369,0.0008013233,0.00021853248,0.0010714176],"genre_scores_gemma":[0.9920906,0.00045764897,0.0009889517,0.0031359035,0.00016721121,0.00213105,0.0007958147,0.000055630724,0.00017722949],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926032,0.0030001272,0.0022949348,0.00091126113,0.00052917394,0.0006613199],"domain_scores_gemma":[0.9838484,0.013676781,0.0012700643,0.0006519604,0.00027214424,0.00028062877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029949723,0.00046499813,0.002919504,0.00021880011,0.00013173657,0.000023120205,0.00024999442,0.00046891833,0.000834035],"category_scores_gemma":[0.0032763148,0.0002619964,0.00021059425,0.00094287086,0.00071725086,0.00014211844,0.000046947513,0.0008692087,0.00001676087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9615347,0.0025227962,0.008779331,0.00006567969,0.0009176027,0.00009475654,0.0019491292,0.00041859486,0.00006058641,0.00023673952,0.0029514146,0.02046867],"study_design_scores_gemma":[0.94202644,0.013253417,0.040370274,0.00039146506,0.0002835093,0.0000031083764,0.00019204189,0.00028620954,0.00006285308,0.00033521483,0.002497699,0.0002977506],"about_ca_topic_score_codex":0.007968978,"about_ca_topic_score_gemma":0.00589733,"teacher_disagreement_score":0.031590942,"about_ca_system_score_codex":0.0014931103,"about_ca_system_score_gemma":0.003225202,"threshold_uncertainty_score":0.99998325},"labels":[],"label_agreement":null},{"id":"W4391592402","doi":"10.1093/nar/gkae059","title":"Tankyrase-1 regulates RBP-mediated mRNA turnover to promote muscle fiber formation","year":2024,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; McGill University","funders":"Canadian Institutes of Health Research; King Abdullah University of Science and Technology","keywords":"Myogenesis; Myogenin; Biology; Gene knockdown; Cell biology; Myocyte; Molecular biology; Genetics; Gene","score_opus":0.05725089834885358,"score_gpt":0.38059400417685946,"score_spread":0.32334310582800585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391592402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662146,0.00092936866,0.0001427577,0.0129262395,0.00028046302,0.0013465503,0.00007395001,0.00044063828,0.01764541],"genre_scores_gemma":[0.9810937,0.00013463416,0.0013017724,0.0006389201,0.0007142924,0.00021539335,0.000118007476,0.000097117285,0.015686154],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99696416,0.00013202461,0.0003667136,0.00047807454,0.0013711791,0.00068786467],"domain_scores_gemma":[0.99843127,0.0001960568,0.000026824522,0.0005609089,0.00039877792,0.00038619168],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012875529,0.00018457847,0.00024383928,0.0006367993,0.0001803187,0.00017853294,0.00020522163,0.00019029371,0.0076041888],"category_scores_gemma":[0.00027564925,0.0001569151,0.00010685465,0.0013764036,0.00016167629,0.00039937036,0.000118524564,0.0007611325,0.010745993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054029666,0.0001800733,0.00027152622,0.00071834284,0.000117574404,0.0002642796,0.003422953,0.00001632911,0.51647425,0.00049866573,0.38624632,0.09124941],"study_design_scores_gemma":[0.0012620736,0.00063043175,0.006970517,0.0009795246,0.000018870789,0.00008841909,0.00012955327,0.0035279843,0.08465287,0.00088110316,0.9006291,0.00022955581],"about_ca_topic_score_codex":0.000032665983,"about_ca_topic_score_gemma":0.000008565714,"teacher_disagreement_score":0.5143828,"about_ca_system_score_codex":0.000691402,"about_ca_system_score_gemma":0.0002327823,"threshold_uncertainty_score":0.993303},"labels":[],"label_agreement":null},{"id":"W4391643537","doi":"10.1016/j.chembiol.2024.01.007","title":"Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite","year":2024,"lang":"en","type":"article","venue":"Cell chemical biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"H2020 European Research Council; Institute of Cancer Research; European Regional Development Fund; Instituto de Salud Carlos III; Fundació la Marató de TV3; Agència de Gestió d'Ajuts Universitaris i de Recerca; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; Universitat de Barcelona; Generalitat de Catalunya; Ministerio de Ciencia e Innovación; Institució Catalana de Recerca i Estudis Avançats; Consejo Superior de Investigaciones Científicas; Federación Española de Enfermedades Raras; “la Caixa” Foundation","keywords":"Identification (biology); PARP inhibitor; Metabolite; Poly ADP ribose polymerase; Differential (mechanical device); Computational biology; Chemistry; Pharmacology; Biology; Biochemistry; Physics; DNA; Botany","score_opus":0.025533674876772727,"score_gpt":0.29741376252496293,"score_spread":0.2718800876481902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391643537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917846,0.0062032333,0.00025351509,0.0011127372,0.00019140658,0.00019494137,0.000100029894,0.000043460594,0.00011611298],"genre_scores_gemma":[0.99860287,0.0006996829,0.00002165688,0.00007169856,0.00043735982,0.000035392794,0.00005980282,0.00000992657,0.00006160774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904644,0.00009787299,0.00026962414,0.00034661626,0.00006798049,0.00017145935],"domain_scores_gemma":[0.99932647,0.00032882518,0.00007258194,0.00014844949,0.000039151928,0.00008450506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001739515,0.00013283257,0.00032191697,0.00004760054,0.000035208766,0.000014312475,0.00006677243,0.00023265884,0.000057567675],"category_scores_gemma":[0.00005996791,0.000079632344,0.000064412714,0.00011284998,0.00039318512,0.000031373565,0.000076351454,0.00023310429,0.000007666627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096448406,0.000036955673,0.0019013531,0.000094474846,0.00006188854,0.0000010904325,0.000056047436,1.2516943e-8,0.9926134,0.0013343213,0.000074834774,0.0037291965],"study_design_scores_gemma":[0.0005145194,0.00008601099,0.008092077,0.000023499657,0.000100978,0.000013155486,0.000009384925,0.00007591261,0.9876991,0.0014430596,0.0018581894,0.00008414982],"about_ca_topic_score_codex":0.000006717671,"about_ca_topic_score_gemma":1.6831989e-7,"teacher_disagreement_score":0.006818309,"about_ca_system_score_codex":0.000021810687,"about_ca_system_score_gemma":0.00002510413,"threshold_uncertainty_score":0.32473126},"labels":[],"label_agreement":null},{"id":"W4391756023","doi":"10.1016/j.ijbiomac.2024.130131","title":"Molecular mechanism of NAD+ and NMN binding to the Nudix homology domains of DBC1","year":2024,"lang":"en","type":"article","venue":"International Journal of Biological Macromolecules","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Natural Science Foundation of China","keywords":"NAD+ kinase; Isothermal titration calorimetry; Nicotinamide mononucleotide; Nicotinamide adenine dinucleotide; Biochemistry; Mutagenesis; DNA; DNA repair; Chemistry; PARP1; Docking (animal); Biology; Polymerase; Stereochemistry; Molecular biology; Enzyme; Mutant; Poly ADP ribose polymerase; Gene","score_opus":0.023556777445171966,"score_gpt":0.33259056395137315,"score_spread":0.30903378650620117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391756023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97422266,0.0018863212,0.0145723475,0.008098622,0.00059677544,0.00011493496,0.00006220951,0.000009299254,0.00043682443],"genre_scores_gemma":[0.9962783,0.00045865824,0.0022030226,0.00085251057,0.00017196817,0.0000044630324,0.0000045721526,0.000008944021,0.000017551361],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988402,0.000087450164,0.0004846655,0.00013632076,0.00033725295,0.00011409787],"domain_scores_gemma":[0.9991328,0.00019874099,0.00019723603,0.00008856843,0.00030520564,0.000077451325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003930239,0.00010281953,0.0002734407,0.00022969743,0.00001740234,0.000016890905,0.00024483717,0.000084833635,0.00011495855],"category_scores_gemma":[0.00018661466,0.00005956495,0.00016653513,0.0001399682,0.00017933683,0.00003154756,0.000082450424,0.00019614553,0.000005925922],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030700138,0.000075353055,0.00046218553,0.000022375645,0.00043301997,0.0005797964,0.00019830013,0.00001807326,0.93812674,0.05495663,0.00021339013,0.004607158],"study_design_scores_gemma":[0.0016434739,0.0026591935,0.0034612445,0.0009820475,0.0001070747,0.0047303806,0.0003414679,0.00012327064,0.94203013,0.03690748,0.00684445,0.00016980527],"about_ca_topic_score_codex":0.0000070364154,"about_ca_topic_score_gemma":0.0000010346577,"teacher_disagreement_score":0.022055645,"about_ca_system_score_codex":0.000057375033,"about_ca_system_score_gemma":0.00006897031,"threshold_uncertainty_score":0.24289882},"labels":[],"label_agreement":null},{"id":"W4391945800","doi":"10.1042/bcj20230406","title":"Novel modifications of PARP inhibitor veliparib increase PARP1 binding to DNA breaks","year":2024,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Lawrence Berkeley National Laboratory; National Institutes of Health; Canadian HIV Trials Network, Canadian Institutes of Health Research","keywords":"PARP1; Poly ADP ribose polymerase; Allosteric regulation; Veliparib; DNA; Chemistry; DNA damage; Pharmacophore; Biochemistry; DNA-binding domain; Biology; Biophysics; Cell biology; Polymerase; Enzyme; Transcription factor","score_opus":0.03655483576735423,"score_gpt":0.3305545888772642,"score_spread":0.29399975310990994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391945800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832147,0.0011710298,0.008219555,0.0052187443,0.00058612204,0.00023294364,0.00012466396,0.00008440975,0.0011478496],"genre_scores_gemma":[0.9917185,0.00009861749,0.0058957324,0.00050529325,0.0014566211,0.000027823933,0.00002833313,0.000034005392,0.00023507772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984784,0.000023592987,0.00053384743,0.00025767108,0.00043216057,0.00027428946],"domain_scores_gemma":[0.9988628,0.00010432076,0.00009311555,0.00023891912,0.00018913661,0.0005117194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031168028,0.00015929945,0.0002708706,0.00027867555,0.00007399522,0.00007444275,0.0001362383,0.00013413682,0.00028058133],"category_scores_gemma":[0.00018879744,0.00013687319,0.00018572618,0.0004939113,0.000095745185,0.000104990315,0.00004167418,0.0004425631,0.00011201435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019190094,0.00018393886,0.00011881036,0.00006902308,0.00009285802,0.000025868458,0.00017241511,0.0000041570815,0.95408887,0.00033105043,0.042802095,0.0019189918],"study_design_scores_gemma":[0.0012967015,0.000157592,0.00070659845,0.0011691131,0.000111506764,0.0014552943,0.000110729605,0.00019347091,0.97077304,0.00019138976,0.023644287,0.00019026297],"about_ca_topic_score_codex":0.000014016008,"about_ca_topic_score_gemma":3.2970655e-7,"teacher_disagreement_score":0.019157808,"about_ca_system_score_codex":0.00024731221,"about_ca_system_score_gemma":0.0003511419,"threshold_uncertainty_score":0.5581527},"labels":[],"label_agreement":null},{"id":"W4392030006","doi":"10.5194/egusphere-2023-2625-ac1","title":"Reply on RC1/RC2","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Environmental science","score_opus":0.07207785681830353,"score_gpt":0.40708434350453054,"score_spread":0.335006486686227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392030006","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013083803,0.09050056,0.000015333315,0.4441721,0.0051635527,0.0005900712,0.00017529316,0.0003199452,0.45906183],"genre_scores_gemma":[0.0000066719485,0.022768669,0.00017247496,0.27278107,0.0024356677,0.00015378259,0.00073285477,0.00008330234,0.7008655],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785304,0.00003657445,0.00047868688,0.00065393193,0.00072485954,0.00025288414],"domain_scores_gemma":[0.998448,0.00008361756,0.000107224216,0.0010250533,0.00017770084,0.00015836641],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032712708,0.0003555606,0.0008236622,0.00018891919,0.00002461046,0.00002189449,0.00013153366,0.00023444074,0.03046756],"category_scores_gemma":[0.00010424998,0.00025890267,0.00039582903,0.00027069406,0.000052434803,0.000017045873,0.00003920181,0.0009413784,0.010496417],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003785955,0.000042236592,5.411629e-7,0.006838858,0.00015327333,0.00013866613,0.000009605495,8.567298e-8,0.000016104495,0.000506468,0.98415357,0.008102741],"study_design_scores_gemma":[0.00043320897,0.00028300812,0.0000032488047,0.03500183,0.00035317635,0.00012250799,0.0000025401653,0.000001937203,0.0003296967,0.00039505996,0.9628345,0.00023932652],"about_ca_topic_score_codex":0.00008087929,"about_ca_topic_score_gemma":0.0000093587305,"teacher_disagreement_score":0.24180366,"about_ca_system_score_codex":0.00033915436,"about_ca_system_score_gemma":0.0004243507,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W4392587188","doi":"10.3390/curroncol31030107","title":"The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Ovarian Cancer Canada; University of British Columbia; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Saskatchewan Health Research Foundation; Saskatchewan Cancer Agency; Ovarian Cancer Canada","keywords":"Medicine; Ovarian cancer; Usability; Decision aids; Harm; Test (biology); Oncology; Family medicine; Medical physics; Internal medicine; Gynecology; Cancer; Pathology; Alternative medicine; Psychology; Computer science","score_opus":0.12094029761651336,"score_gpt":0.39776055335103994,"score_spread":0.27682025573452657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392587188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97122884,0.021921672,0.0019737766,0.0017042148,0.0012648683,0.0016963556,0.000030545903,0.00005921785,0.00012051356],"genre_scores_gemma":[0.95364696,0.0037246593,0.03841644,0.00042746478,0.00020328716,0.003327312,0.000019553783,0.000078577206,0.00015572591],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848235,0.00006592589,0.00050277275,0.00038175067,0.00022384651,0.00034336813],"domain_scores_gemma":[0.9981854,0.0010175335,0.0002604084,0.0001863654,0.00026465862,0.00008561553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056139886,0.00018649327,0.00042284315,0.00011284746,0.0002095649,0.000030233046,0.00008108959,0.00007933911,0.000014645903],"category_scores_gemma":[0.00017378214,0.000108964756,0.000044265125,0.00025074295,0.00024619492,0.000038572474,0.000050884915,0.0002209703,0.0000017764987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009254388,0.00024778233,0.041769817,0.00024881263,0.00016192415,0.000021296346,0.0033200574,0.000024982688,0.0005272992,0.00039102708,0.0029388897,0.94942266],"study_design_scores_gemma":[0.006407005,0.002610475,0.007707455,0.005979075,0.00006723807,0.0002343964,0.00076369196,0.0010620486,0.014647896,0.0011960076,0.95907253,0.00025215693],"about_ca_topic_score_codex":0.0000068497425,"about_ca_topic_score_gemma":0.000029884115,"teacher_disagreement_score":0.95613366,"about_ca_system_score_codex":0.00038885672,"about_ca_system_score_gemma":0.00088395004,"threshold_uncertainty_score":0.44434538},"labels":[],"label_agreement":null},{"id":"W4392631890","doi":"10.1136/ijgc-2024-esgo.584","title":"176 Rucaparib maintenance treatment in patients (Pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA-MONO study","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Population; Placebo; Stage (stratigraphy); Chemotherapy; Ovarian cancer; Cancer; Surgery; Gynecology; Pathology","score_opus":0.02559736903672858,"score_gpt":0.3509724077453201,"score_spread":0.3253750387085915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392631890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98854315,0.0012866323,0.00050713983,0.00621681,0.0020013351,0.0010303727,0.0002596865,0.00003433444,0.0001205287],"genre_scores_gemma":[0.995711,0.00068211765,0.00035104182,0.0018179824,0.00062265975,0.0006260117,0.000010766366,0.000039541705,0.00013885616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729204,0.00013987589,0.0008297257,0.00044374098,0.00094985,0.0003447582],"domain_scores_gemma":[0.99777126,0.00063344603,0.00046186993,0.00021534877,0.0005830934,0.00033497697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057205075,0.00031467873,0.00050042046,0.00030009728,0.00010837765,0.00015837348,0.00039613398,0.000070736336,0.00064384466],"category_scores_gemma":[0.00037676914,0.00017131554,0.00019947477,0.00040552067,0.000090831716,0.00026253937,0.000066773646,0.0005483154,0.000016696711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010097576,0.002652376,0.91021216,0.00001223818,0.0010097977,0.001582668,0.002532731,0.011170974,0.000058509097,0.0005598569,0.0004275779,0.05968352],"study_design_scores_gemma":[0.030120557,0.006756726,0.95187616,0.0013275318,0.0004952333,0.00003948314,0.0013814906,0.0014521236,0.000113053306,0.0007639481,0.0053202296,0.00035347656],"about_ca_topic_score_codex":0.0012737011,"about_ca_topic_score_gemma":0.0020098216,"teacher_disagreement_score":0.059330042,"about_ca_system_score_codex":0.0030687721,"about_ca_system_score_gemma":0.00069455843,"threshold_uncertainty_score":0.80247325},"labels":[],"label_agreement":null},{"id":"W4392631905","doi":"10.1136/ijgc-2024-esgo.637","title":"380 Real world clinical outcomes of niraparib first line maintenance therapy in patients with BRCA wildtype advanced ovarian cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Oncology; Internal medicine; Ovarian cancer; Single Center; Progression-free survival; Proportional hazards model; Chemotherapy; Retrospective cohort study; Cancer; Stage (stratigraphy); Cohort; Maintenance therapy; Biology","score_opus":0.04213907978529078,"score_gpt":0.3982500482550754,"score_spread":0.3561109684697846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392631905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982593,0.0013375342,0.00017972356,0.01119184,0.0032770932,0.00037047672,0.00010166534,0.000028258684,0.00092039787],"genre_scores_gemma":[0.9858838,0.0095074065,0.0007739793,0.0024168016,0.00059643434,0.00005854883,0.000011406698,0.00003100002,0.00072067033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971576,0.00008520638,0.0012729476,0.0003198724,0.00089285587,0.00027153126],"domain_scores_gemma":[0.99732715,0.0006584021,0.0005864594,0.000162825,0.0011090006,0.00015617997],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051399076,0.00023443105,0.0007546406,0.00036556533,0.000026728334,0.000030863277,0.00034618014,0.00014001012,0.0023481313],"category_scores_gemma":[0.00022720991,0.00014488502,0.00029974463,0.00040832837,0.00022930559,0.00024482506,0.000042328906,0.00070172996,0.0000056916724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00703145,0.00075828953,0.9206885,0.00002217484,0.0008423535,0.00019102759,0.000089078094,0.0007801329,0.000054305423,0.00037804813,0.0014993744,0.067665234],"study_design_scores_gemma":[0.01121177,0.0019327049,0.96161747,0.00096921565,0.000054105403,0.000010125201,0.000014005888,0.00008378545,0.0001911254,0.00041905724,0.023334302,0.00016232037],"about_ca_topic_score_codex":0.00022892973,"about_ca_topic_score_gemma":0.0014645975,"teacher_disagreement_score":0.067502916,"about_ca_system_score_codex":0.00085610955,"about_ca_system_score_gemma":0.0006200287,"threshold_uncertainty_score":0.9985639},"labels":[],"label_agreement":null},{"id":"W4392799091","doi":"10.2139/ssrn.4750763","title":"A Phase Ii, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair–Proficient Colorectal or Pancreatic Cancer","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Durvalumab; Medicine; Colorectal cancer; Oncology; Internal medicine; Randomized controlled trial; Open label; Pancreatic cancer; Cancer; Nivolumab; Chemistry","score_opus":0.025723967782771275,"score_gpt":0.3491605832684948,"score_spread":0.32343661548572356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392799091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831669,0.0036794161,0.00024725965,0.0007676397,0.0009353191,0.010535739,0.00014576402,0.000097694145,0.00042427555],"genre_scores_gemma":[0.98689365,0.0055824434,0.0008120625,0.00017667258,0.0006026912,0.00233844,0.000114483555,0.00019964871,0.0032799016],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99290717,0.0006399062,0.0018553175,0.0009771844,0.0014699786,0.0021504685],"domain_scores_gemma":[0.99673826,0.00028512688,0.0014305192,0.00064057834,0.00065043557,0.0002551047],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0043882676,0.0007880406,0.0031829057,0.0005766252,0.00019623988,0.000113381946,0.0005770358,0.0003968104,0.00044138587],"category_scores_gemma":[0.00027002307,0.00043946435,0.00032893624,0.00081663474,0.0003559501,0.00013200559,0.00037986014,0.0057044365,0.000004913205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.98284143,0.007527087,0.00027924054,0.0004939048,0.004446764,0.00012552441,0.0011072638,0.00008408382,0.000104251456,0.0004797434,0.00031685366,0.0021938414],"study_design_scores_gemma":[0.9378469,0.04766142,0.00002450242,0.006042983,0.0024674698,0.0003446873,0.00040592914,0.00056805747,0.00036533788,0.0035851148,0.00012135901,0.00056623225],"about_ca_topic_score_codex":0.00092966494,"about_ca_topic_score_gemma":0.0029555962,"teacher_disagreement_score":0.044994533,"about_ca_system_score_codex":0.005190432,"about_ca_system_score_gemma":0.033457518,"threshold_uncertainty_score":0.9998057},"labels":[],"label_agreement":null},{"id":"W4392906690","doi":"10.1096/fj.202302559r","title":"Poly( <scp>ADP</scp> ‐ribose) mediates bioenergetic defects and redox imbalance in neurons following oxygen and glucose deprivation","year":2024,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"National Institute of Neurological Disorders and Stroke; National Institute on Aging; U.S. Department of Veterans Affairs","keywords":"Glycolysis; Bioenergetics; Hexokinase; Pentose phosphate pathway; Cell biology; Mitochondrion; Biochemistry; Programmed cell death; Biology; Oxidative phosphorylation; Chemistry; Metabolism; Apoptosis","score_opus":0.013898317681113912,"score_gpt":0.26983297798592315,"score_spread":0.2559346603048092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392906690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540536,0.042371973,0.00023020976,0.0023236566,0.00053893053,0.00015582897,0.0000074163004,0.000045709956,0.00027266817],"genre_scores_gemma":[0.99374056,0.00464393,0.00024612976,0.0007324073,0.00043573815,0.000012222309,0.0000066720677,0.000029959534,0.00015237658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988235,0.00012408869,0.00028316732,0.00021336888,0.0002705947,0.0002852544],"domain_scores_gemma":[0.99917394,0.00040550923,0.000072258845,0.00015562742,0.000027749014,0.00016494081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006129278,0.0001547884,0.00020962316,0.00021092498,0.00015356408,0.00012637851,0.00008357686,0.000066677385,0.000017692728],"category_scores_gemma":[0.0002407217,0.00010966424,0.00007630709,0.00031149396,0.0000973626,0.00017645532,0.000039065926,0.00047962437,0.0000116332485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053206564,0.000043369037,0.070576094,0.00008291805,0.00011224689,0.0005928326,0.00213367,0.000023891076,0.9177549,0.0002253072,0.0017761396,0.0066254037],"study_design_scores_gemma":[0.006857828,0.000729987,0.41436696,0.0025696452,0.00043674142,0.0059882794,0.0014499134,0.006106608,0.5427432,0.010531437,0.007921995,0.00029736524],"about_ca_topic_score_codex":0.00001678894,"about_ca_topic_score_gemma":0.000013807436,"teacher_disagreement_score":0.37501168,"about_ca_system_score_codex":0.00009386027,"about_ca_system_score_gemma":0.00011056361,"threshold_uncertainty_score":0.4471978},"labels":[],"label_agreement":null},{"id":"W4392968990","doi":"10.1101/2024.03.12.584665","title":"Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institutes of Health; St. Jude Children's Research Hospital","keywords":"DNA damage; Cancer research; Biology; PARP1; Cell biology; Poly ADP ribose polymerase; DNA; Polymerase; Genetics","score_opus":0.01698238781180989,"score_gpt":0.2725188780945896,"score_spread":0.2555364902827797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392968990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910109,0.002645189,0.00015315684,0.001967935,0.0011775008,0.0016585714,0.0005486597,0.0007676797,0.00007042216],"genre_scores_gemma":[0.9966884,0.00059483206,0.00043720027,0.00051293365,0.0005404512,0.0009287113,0.00000904365,0.00024383518,0.000044558074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953145,0.0002270726,0.0010670266,0.001879606,0.00083157216,0.00068025984],"domain_scores_gemma":[0.99631995,0.00016139874,0.00075318833,0.00176311,0.0007007622,0.00030158923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010704497,0.00072746805,0.00093528844,0.00056704454,0.0001270409,0.00019347697,0.00034312234,0.001032008,0.00010553573],"category_scores_gemma":[0.0005494404,0.0008300259,0.00020373089,0.0010297262,0.00017310845,0.00015098439,0.000395824,0.0021581654,0.00014179453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016086668,0.00046253737,0.019267108,0.00076795917,0.00039650823,0.0002158522,0.00010624908,0.00010979556,0.9745145,0.00024135898,0.003750874,0.000006419449],"study_design_scores_gemma":[0.0022000526,0.00015650116,0.068666235,0.004860318,0.00033213128,3.1226918e-7,0.000021035286,0.00040943676,0.92061025,0.000052934487,0.001655832,0.0010349355],"about_ca_topic_score_codex":0.00036091864,"about_ca_topic_score_gemma":0.00003372608,"teacher_disagreement_score":0.053904198,"about_ca_system_score_codex":0.0037969293,"about_ca_system_score_gemma":0.0014626158,"threshold_uncertainty_score":0.99941504},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4392985102","doi":"10.1101/2024.03.19.24304522","title":"The Landscape of RAD51D in Chinese Ovarian Cancer Patients: Prevalence, Correlation with HRD Score, and Correlation with Efficacy","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Peking Union Medical College Hospital","keywords":"Correlation; Ovarian cancer; Medicine; Internal medicine; Oncology; Positive correlation; Negative correlation; Cancer; Demography; Mathematics; Sociology","score_opus":0.011279591687691892,"score_gpt":0.2783973791942476,"score_spread":0.26711778750655574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392985102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920128,0.0034516125,0.00033937165,0.00064561516,0.0006442866,0.0015042685,0.00005823161,0.00005514228,0.0012886557],"genre_scores_gemma":[0.9971276,0.0015677388,0.00015284843,0.000060127284,0.00016763217,0.00027294437,0.00010079058,0.000054785192,0.00049556117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820596,0.00010078224,0.00047443958,0.0005032107,0.00051544927,0.00020015547],"domain_scores_gemma":[0.99864167,0.00022378856,0.0003747142,0.00045057372,0.0002295889,0.000079676836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034869387,0.00030140873,0.00042732438,0.00023151757,0.00006419372,0.00003896375,0.0001168902,0.00019268713,0.0000694448],"category_scores_gemma":[0.000081767255,0.00016801457,0.00005112785,0.00047968424,0.00020226822,0.000062035746,0.000103666905,0.0008068288,0.0000050570457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017862222,0.0001166152,0.9903629,0.00083623925,0.00013462995,0.000009737447,0.001110339,0.0029191303,0.000034090837,0.00012642218,0.00012075233,0.0024429476],"study_design_scores_gemma":[0.0044233724,0.000454372,0.98283136,0.005108262,0.00021385275,0.000012608032,0.000029657398,0.0060112667,0.00006441069,0.0004736148,0.00017395057,0.00020328596],"about_ca_topic_score_codex":0.00012519665,"about_ca_topic_score_gemma":0.00025745173,"teacher_disagreement_score":0.007531527,"about_ca_system_score_codex":0.00013381522,"about_ca_system_score_gemma":0.00033153463,"threshold_uncertainty_score":0.68514353},"labels":[],"label_agreement":null},{"id":"W4393086019","doi":"10.1158/1538-7445.am2024-4529","title":"Abstract 4529: Characterization of PARP inhibitor combination therapies in triple-negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"PARP inhibitor; Breast cancer; Triple-negative breast cancer; Cancer; Oncology; Medicine; Internal medicine; Poly ADP ribose polymerase; Biology; Genetics; Polymerase; DNA","score_opus":0.07488099161520893,"score_gpt":0.42956798928539136,"score_spread":0.3546869976701824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393086019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98621976,0.0025231435,0.000026322647,0.0084399115,0.0006095169,0.0009756116,0.0004037955,0.00006354581,0.00073839293],"genre_scores_gemma":[0.9927653,0.0045752875,0.000013529772,0.00013164738,0.00053013663,0.00085273635,0.00006145174,0.000045924786,0.0010239531],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99790704,0.00014551982,0.00041004198,0.0003770185,0.0007969335,0.00036344063],"domain_scores_gemma":[0.99883807,0.00019249781,0.000075269505,0.00022526184,0.000569301,0.00009958131],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083131134,0.00014923478,0.00030119647,0.00066168566,0.00006590023,0.000054638098,0.00011443186,0.00012791163,0.0026166602],"category_scores_gemma":[0.00004506969,0.00013167511,0.00007297868,0.0013579729,0.00027365875,0.0003174264,0.000030306674,0.0006028353,0.000033108154],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010917145,0.000221204,0.008003208,0.0007594979,0.00011549271,0.00002802008,0.003414867,0.000007198352,0.93861794,0.0006887929,0.0018696291,0.045182414],"study_design_scores_gemma":[0.0038060693,0.00021453822,0.55137444,0.004220704,0.00001957795,0.000012839288,0.00048100593,0.00030611092,0.4332083,0.0012274432,0.004909717,0.00021926296],"about_ca_topic_score_codex":0.0012166708,"about_ca_topic_score_gemma":0.00021000707,"teacher_disagreement_score":0.54337126,"about_ca_system_score_codex":0.0009589373,"about_ca_system_score_gemma":0.0009102722,"threshold_uncertainty_score":0.99829507},"labels":[],"label_agreement":null},{"id":"W4393221527","doi":"10.1158/1078-0432.ccr-23-3689","title":"Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Vancouver Coastal Health Research Institute; Canadian Cancer Society","keywords":"Endometrial cancer; Medicine; Carcinosarcoma; Serous fluid; Ovarian cancer; Whole genome sequencing; DNA sequencing; Cancer; Oncology; Internal medicine; Cancer research; Biology; Genome; Gene; Carcinoma; Genetics","score_opus":0.5458716065322252,"score_gpt":0.5526852119305065,"score_spread":0.006813605398281242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393221527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9018618,0.08016004,0.00004011063,0.011823543,0.0017806797,0.0010811007,0.00018282974,0.00016298561,0.0029069057],"genre_scores_gemma":[0.96256715,0.029463856,0.00004932261,0.0010112429,0.0016599786,0.00045834345,0.000043623397,0.0000662384,0.004680225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596715,0.00062860973,0.0008901279,0.00076795,0.0010141445,0.0007320475],"domain_scores_gemma":[0.99673134,0.0021290984,0.000060028862,0.00039866127,0.00030458532,0.00037630321],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0052436963,0.00021377025,0.00060602574,0.00095074775,0.00014667126,0.00021061867,0.00021890974,0.0002424028,0.0015232712],"category_scores_gemma":[0.00058476476,0.00018736244,0.00017428263,0.0013038502,0.0010608705,0.00024499267,0.00012478424,0.0016749821,0.00006785899],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015148541,0.0005750089,0.108986765,0.0052305902,0.002940831,0.0067416728,0.0110052,0.0003291148,0.35278368,0.0050456855,0.024227235,0.46698567],"study_design_scores_gemma":[0.026587792,0.0047299573,0.113613494,0.0077474616,0.0003675349,0.00022442552,0.011986341,0.0040597967,0.0091804005,0.022628685,0.7970505,0.00182363],"about_ca_topic_score_codex":0.0016333249,"about_ca_topic_score_gemma":0.0008546784,"teacher_disagreement_score":0.7728232,"about_ca_system_score_codex":0.0017107072,"about_ca_system_score_gemma":0.003435253,"threshold_uncertainty_score":0.99938947},"labels":[],"label_agreement":null},{"id":"W4393235169","doi":"10.26508/lsa.202302316","title":"pADP-ribosylation regulates the cytoplasmic localization, cleavage, and pro-apoptotic function of HuR","year":2024,"lang":"en","type":"article","venue":"Life Science Alliance","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; McGill University","funders":"Canadian Institutes of Health Research; King Abdullah University of Science and Technology; Taibah University; Faculty of Medicine, McGill University; McGill University","keywords":"Apoptosis; Cleavage (geology); Cell biology; PARP1; Cytoplasm; Programmed cell death; Transcription factor; Biology; Poly ADP ribose polymerase; Chemistry; Enzyme; Genetics; Biochemistry; Gene","score_opus":0.023480976776672463,"score_gpt":0.3040792565672382,"score_spread":0.28059827979056573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393235169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95523846,0.006250968,0.024220055,0.009785773,0.0011544531,0.0008749025,0.000009247456,0.00020611064,0.0022600503],"genre_scores_gemma":[0.9972296,0.00043050104,0.00034091948,0.0011950041,0.00015817871,0.000024729703,0.000004262297,0.000011241665,0.0006056134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987843,0.000025390535,0.0002405068,0.00032641663,0.00044608608,0.000177309],"domain_scores_gemma":[0.9993558,0.00007082596,0.00007593633,0.00025796003,0.00015614802,0.00008334405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005627452,0.00009391209,0.00012366741,0.00008036557,0.00018442902,0.000072746625,0.00010776747,0.00004066873,0.000051662864],"category_scores_gemma":[0.00014959062,0.00006515097,0.000028664934,0.0011298318,0.000779322,0.00039121349,0.000023913812,0.00010627415,0.000031395637],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008651339,0.00024953243,0.069876574,0.002033991,0.00019190759,0.000016442213,0.0060180896,0.007888231,0.7294578,0.065295756,0.04732706,0.070779465],"study_design_scores_gemma":[0.0018036601,0.00094855134,0.25971395,0.0026266163,0.0002028657,0.000102391954,0.0008324919,0.1850864,0.46112278,0.016008046,0.07103015,0.0005221259],"about_ca_topic_score_codex":0.0000065915547,"about_ca_topic_score_gemma":0.0000028029042,"teacher_disagreement_score":0.26833504,"about_ca_system_score_codex":0.00006612795,"about_ca_system_score_gemma":0.00029917673,"threshold_uncertainty_score":0.28714445},"labels":[],"label_agreement":null},{"id":"W4393437058","doi":"10.5281/zenodo.1424041","title":"Developing A Tryptophan Fluorescence Assay For Screening Ligands Against Usp5 Zf-Ubd","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Fluorescence; Tryptophan; Chemistry; Computational biology; Combinatorial chemistry; Biochemistry; Biology; Physics; Amino acid","score_opus":0.1035740607283512,"score_gpt":0.36372336258495447,"score_spread":0.2601493018566033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393437058","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000037906543,0.00044618742,0.00008262071,0.000297181,0.00046697,0.0012166456,0.9972121,0.00014605254,0.00012842742],"genre_scores_gemma":[0.000009296535,0.000082769206,0.0042421864,0.0033911152,0.0034949204,0.0014953009,0.98696643,0.000093170485,0.00022479295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746406,0.000039006998,0.0005479649,0.0007638727,0.0005625255,0.0006225866],"domain_scores_gemma":[0.9975894,0.00031793158,0.00042681512,0.00085456594,0.0005603358,0.00025097103],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00019017866,0.00052987586,0.00071535056,0.00027169596,0.00024680753,0.000101360296,0.000488835,0.0006524352,0.039591126],"category_scores_gemma":[0.0018905083,0.0005192175,0.0002810201,0.00034416822,0.00003169494,0.00012617586,0.0001616218,0.0005550896,0.0012930091],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015535788,0.0000292786,0.0000014055756,0.0016997904,0.00012405419,0.000053464362,0.000023268194,6.132674e-7,0.00015010382,0.0000010249356,0.99546945,0.0022921844],"study_design_scores_gemma":[0.0018460832,0.00020004291,0.00003529125,0.02895363,0.0000593476,0.00003071895,0.000011713465,0.00005878514,0.008419664,0.00001592279,0.9598067,0.0005621381],"about_ca_topic_score_codex":0.00000793285,"about_ca_topic_score_gemma":0.000018117325,"teacher_disagreement_score":0.03829812,"about_ca_system_score_codex":0.00034245246,"about_ca_system_score_gemma":0.0008768339,"threshold_uncertainty_score":0.99972594},"labels":[],"label_agreement":null},{"id":"W4393485203","doi":"10.5281/zenodo.3382319","title":"Preliminary investigation of caspase6 cleavage of HTT and HTT-HAP40 2019/07/15","year":2019,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cleavage (geology); Geology; Paleontology","score_opus":0.04992357775856541,"score_gpt":0.28748609122215685,"score_spread":0.23756251346359145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393485203","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007594007,0.00082062493,0.000089234716,0.00058585865,0.00020778777,0.0012922658,0.98417807,0.00016226845,0.005069883],"genre_scores_gemma":[0.011448355,0.00147559,0.00015869937,0.00026065888,0.00021220667,1.3032738e-7,0.9847383,0.0009441022,0.0007619405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976023,0.00034689932,0.0005991271,0.00051531306,0.0006523374,0.00028401107],"domain_scores_gemma":[0.9975046,0.000065664135,0.0005466172,0.0009309592,0.00073155283,0.00022061571],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00066794973,0.0002586376,0.00051755866,0.000497333,0.0003291524,0.00008470931,0.00052883395,0.00024999512,0.007828109],"category_scores_gemma":[0.0004439,0.0002715211,0.000086914166,0.0004410555,0.0005093768,0.0001697777,0.0007014819,0.0005172511,0.0027690397],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005589933,0.00011783198,0.0000069437906,0.0013276247,0.00011404957,0.00001833893,0.00030725353,0.000005389154,0.005818524,0.000051448606,0.9890366,0.0026369812],"study_design_scores_gemma":[0.0015745587,0.0015960328,0.00092479074,0.0006464453,0.00013585121,0.00023156144,0.000108352826,0.000025259815,0.005795578,0.000054521784,0.9886879,0.00021918661],"about_ca_topic_score_codex":0.00007028604,"about_ca_topic_score_gemma":3.436735e-7,"teacher_disagreement_score":0.0050590695,"about_ca_system_score_codex":0.00015343129,"about_ca_system_score_gemma":0.00002959229,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W4393489310","doi":"10.5281/zenodo.1424040","title":"Developing A Tryptophan Fluorescence Assay For Screening Ligands Against Usp5 Zf-Ubd","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tryptophan; Fluorescence; Chemistry; Combinatorial chemistry; Computational biology; Computer science; Biochemistry; Biology; Amino acid; Physics; Optics","score_opus":0.07271363272787874,"score_gpt":0.32011587314475654,"score_spread":0.2474022404168778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393489310","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025987657,0.00020219249,0.016526219,0.0015056042,0.0004945922,0.0019511962,0.9747667,0.0008927128,0.0034009079],"genre_scores_gemma":[0.00040515006,0.00068711385,0.004469631,0.0013176436,0.0016544199,8.870211e-7,0.9889373,0.002001579,0.00052626315],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966044,0.00024847058,0.00063236494,0.00094342016,0.0008184649,0.00075291743],"domain_scores_gemma":[0.99659383,0.00009011512,0.00038165937,0.0010478818,0.0015169099,0.00036961556],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013948001,0.00043841763,0.0005515613,0.0005925354,0.0023077119,0.00066315796,0.0012279556,0.0003514331,0.0054624416],"category_scores_gemma":[0.0015987778,0.00046334852,0.0001846069,0.00078316,0.0003571329,0.00021824297,0.00088315975,0.0006956418,0.0032112598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042745337,0.00009875357,5.359147e-7,0.0005061737,0.00016811934,0.000032871114,0.00014755192,0.0000028921738,0.0027051414,0.00011421515,0.97245634,0.023339938],"study_design_scores_gemma":[0.0022454364,0.0005936206,0.00003203682,0.00103416,0.000082558196,0.00017511313,0.00007813536,0.00013089592,0.0038221849,0.00006297663,0.99126536,0.0004775036],"about_ca_topic_score_codex":0.000015336636,"about_ca_topic_score_gemma":8.579142e-7,"teacher_disagreement_score":0.022862434,"about_ca_system_score_codex":0.00060917164,"about_ca_system_score_gemma":0.00005802624,"threshold_uncertainty_score":0.99978185},"labels":[],"label_agreement":null},{"id":"W4393498666","doi":"10.5281/zenodo.1304433","title":"The Process Of Hdac11 Assay Development: Effect Of Dmso","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Process (computing); HDAC11; Chemistry; Computer science; Computational biology; Combinatorial chemistry; Biology; Biochemistry; Programming language; Gene; Histone; Histone deacetylase","score_opus":0.02445094812200839,"score_gpt":0.30535403229800173,"score_spread":0.28090308417599336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393498666","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003426297,0.00047514308,0.00015013533,0.000344824,0.00034481465,0.0018459328,0.97937846,0.0002932771,0.01374114],"genre_scores_gemma":[0.0058666314,0.00041920878,0.00005238412,0.00007897925,0.00029436595,2.0660427e-7,0.99183214,0.0010239109,0.00043219473],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99744153,0.0005354308,0.00054515246,0.00036609746,0.000799444,0.0003123607],"domain_scores_gemma":[0.9972425,0.00013050855,0.00049224653,0.00081034587,0.0011908605,0.00013350527],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019457105,0.00022795117,0.00041545692,0.00025310658,0.0010166983,0.00011365466,0.0010297131,0.00016299576,0.0075677657],"category_scores_gemma":[0.0014105882,0.0001699047,0.00008817967,0.00055786566,0.00055235275,0.00007063239,0.00050404266,0.00041117118,0.0018888476],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005619257,0.00009413379,0.000001417576,0.0010786622,0.00018112417,0.0000054558996,0.0002559197,0.0000010204908,0.0006621699,0.000016408725,0.98443246,0.012709289],"study_design_scores_gemma":[0.001121255,0.00095041055,0.00005045075,0.00045294716,0.00007109992,0.00007518819,0.00004044922,0.0000047184844,0.015596129,0.000015790487,0.9814813,0.00014023711],"about_ca_topic_score_codex":0.000009296688,"about_ca_topic_score_gemma":4.9538704e-7,"teacher_disagreement_score":0.01493396,"about_ca_system_score_codex":0.00017310127,"about_ca_system_score_gemma":0.000036980353,"threshold_uncertainty_score":0.9988883},"labels":[],"label_agreement":null},{"id":"W4393600404","doi":"10.5281/zenodo.1304432","title":"The Process Of Hdac11 Assay Development: Effect Of Dmso","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Process (computing); Computer science; Chemistry; Computational biology; Biology; Programming language","score_opus":0.02445094812200839,"score_gpt":0.30535403229800173,"score_spread":0.28090308417599336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393600404","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003426297,0.00047514308,0.00015013533,0.000344824,0.00034481465,0.0018459328,0.97937846,0.0002932771,0.01374114],"genre_scores_gemma":[0.0058666314,0.00041920878,0.00005238412,0.00007897925,0.00029436595,2.0660427e-7,0.99183214,0.0010239109,0.00043219473],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99744153,0.0005354308,0.00054515246,0.00036609746,0.000799444,0.0003123607],"domain_scores_gemma":[0.9972425,0.00013050855,0.00049224653,0.00081034587,0.0011908605,0.00013350527],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019457105,0.00022795117,0.00041545692,0.00025310658,0.0010166983,0.00011365466,0.0010297131,0.00016299576,0.0075677657],"category_scores_gemma":[0.0014105882,0.0001699047,0.00008817967,0.00055786566,0.00055235275,0.00007063239,0.00050404266,0.00041117118,0.0018888476],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005619257,0.00009413379,0.000001417576,0.0010786622,0.00018112417,0.0000054558996,0.0002559197,0.0000010204908,0.0006621699,0.000016408725,0.98443246,0.012709289],"study_design_scores_gemma":[0.001121255,0.00095041055,0.00005045075,0.00045294716,0.00007109992,0.00007518819,0.00004044922,0.0000047184844,0.015596129,0.000015790487,0.9814813,0.00014023711],"about_ca_topic_score_codex":0.000009296688,"about_ca_topic_score_gemma":4.9538704e-7,"teacher_disagreement_score":0.01493396,"about_ca_system_score_codex":0.00017310127,"about_ca_system_score_gemma":0.000036980353,"threshold_uncertainty_score":0.9988883},"labels":[],"label_agreement":null},{"id":"W4393704048","doi":"10.5281/zenodo.1293893","title":"The Process Of Hdac11 Assay Development: Buffer Optimization Again","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Buffer (optical fiber); Process (computing); Computer science; Telecommunications; Operating system","score_opus":0.03437848897085705,"score_gpt":0.29788852442819175,"score_spread":0.2635100354573347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393704048","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024931095,0.00040119726,0.004839874,0.0009993542,0.00046303382,0.001940994,0.97376364,0.0005840699,0.016758505],"genre_scores_gemma":[0.0006135069,0.000616664,0.00044349977,0.00025016352,0.00039469425,2.4458592e-7,0.9958787,0.001082253,0.0007202891],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973723,0.00039417687,0.0005629475,0.00047024523,0.00082036667,0.00037991971],"domain_scores_gemma":[0.99677545,0.0000618719,0.00043248368,0.0008252997,0.0017342407,0.00017066958],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001392541,0.00025236644,0.0003125657,0.00028319567,0.0019014548,0.00030934776,0.0010003991,0.00020576807,0.013533866],"category_scores_gemma":[0.0010996201,0.0002081968,0.00007249789,0.0006384254,0.0004295231,0.000121701756,0.0004955482,0.00046109894,0.002382139],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024541147,0.0001409738,3.834093e-7,0.00032100282,0.00013575939,0.0000065392146,0.0003142622,0.00009366275,0.00011986699,0.00002795411,0.99220544,0.006388723],"study_design_scores_gemma":[0.0008423461,0.00026474218,0.000020832058,0.00029533773,0.00005161606,0.000085776024,0.00009924725,0.00012881872,0.001166632,0.000022985436,0.9968202,0.00020145006],"about_ca_topic_score_codex":0.000007741793,"about_ca_topic_score_gemma":6.828546e-7,"teacher_disagreement_score":0.022115026,"about_ca_system_score_codex":0.00030033666,"about_ca_system_score_gemma":0.000051852407,"threshold_uncertainty_score":0.99939793},"labels":[],"label_agreement":null},{"id":"W4393873397","doi":"10.5281/zenodo.3382318","title":"Preliminary investigation of caspase6 cleavage of HTT and HTT-HAP40 2019/07/15","year":2019,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cleavage (geology); Geology; Paleontology","score_opus":0.04992357775856541,"score_gpt":0.28748609122215685,"score_spread":0.23756251346359145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393873397","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007594007,0.00082062493,0.000089234716,0.00058585865,0.00020778777,0.0012922658,0.98417807,0.00016226845,0.005069883],"genre_scores_gemma":[0.011448355,0.00147559,0.00015869937,0.00026065888,0.00021220667,1.3032738e-7,0.9847383,0.0009441022,0.0007619405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976023,0.00034689932,0.0005991271,0.00051531306,0.0006523374,0.00028401107],"domain_scores_gemma":[0.9975046,0.000065664135,0.0005466172,0.0009309592,0.00073155283,0.00022061571],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00066794973,0.0002586376,0.00051755866,0.000497333,0.0003291524,0.00008470931,0.00052883395,0.00024999512,0.007828109],"category_scores_gemma":[0.0004439,0.0002715211,0.000086914166,0.0004410555,0.0005093768,0.0001697777,0.0007014819,0.0005172511,0.0027690397],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005589933,0.00011783198,0.0000069437906,0.0013276247,0.00011404957,0.00001833893,0.00030725353,0.000005389154,0.005818524,0.000051448606,0.9890366,0.0026369812],"study_design_scores_gemma":[0.0015745587,0.0015960328,0.00092479074,0.0006464453,0.00013585121,0.00023156144,0.000108352826,0.000025259815,0.005795578,0.000054521784,0.9886879,0.00021918661],"about_ca_topic_score_codex":0.00007028604,"about_ca_topic_score_gemma":3.436735e-7,"teacher_disagreement_score":0.0050590695,"about_ca_system_score_codex":0.00015343129,"about_ca_system_score_gemma":0.00002959229,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W4393966947","doi":"10.5281/zenodo.1293892","title":"The Process Of Hdac11 Assay Development: Buffer Optimization Again","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Buffer (optical fiber); Process (computing); Computer science; Computational biology; Biology; Programming language","score_opus":0.03437848897085705,"score_gpt":0.29788852442819175,"score_spread":0.2635100354573347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393966947","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024931095,0.00040119726,0.004839874,0.0009993542,0.00046303382,0.001940994,0.97376364,0.0005840699,0.016758505],"genre_scores_gemma":[0.0006135069,0.000616664,0.00044349977,0.00025016352,0.00039469425,2.4458592e-7,0.9958787,0.001082253,0.0007202891],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973723,0.00039417687,0.0005629475,0.00047024523,0.00082036667,0.00037991971],"domain_scores_gemma":[0.99677545,0.0000618719,0.00043248368,0.0008252997,0.0017342407,0.00017066958],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001392541,0.00025236644,0.0003125657,0.00028319567,0.0019014548,0.00030934776,0.0010003991,0.00020576807,0.013533866],"category_scores_gemma":[0.0010996201,0.0002081968,0.00007249789,0.0006384254,0.0004295231,0.000121701756,0.0004955482,0.00046109894,0.002382139],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024541147,0.0001409738,3.834093e-7,0.00032100282,0.00013575939,0.0000065392146,0.0003142622,0.00009366275,0.00011986699,0.00002795411,0.99220544,0.006388723],"study_design_scores_gemma":[0.0008423461,0.00026474218,0.000020832058,0.00029533773,0.00005161606,0.000085776024,0.00009924725,0.00012881872,0.001166632,0.000022985436,0.9968202,0.00020145006],"about_ca_topic_score_codex":0.000007741793,"about_ca_topic_score_gemma":6.828546e-7,"teacher_disagreement_score":0.022115026,"about_ca_system_score_codex":0.00030033666,"about_ca_system_score_gemma":0.000051852407,"threshold_uncertainty_score":0.99939793},"labels":[],"label_agreement":null},{"id":"W4393983007","doi":"10.1158/1538-7445.am2024-ct203","title":"Abstract CT203: Multi-omic analysis of serial biopsies to inform biomarkers of sensitivity to olaparib and durvalumab in patients with metastatic <i>BRCA</i>-wildtype triple negative breast cancer (mTNBC)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Olaparib; Medicine; Breast cancer; Oncology; Atezolizumab; Biomarker; Internal medicine; PARP inhibitor; Cancer research; Triple-negative breast cancer; Cancer; Biology; Immunotherapy; Gene; Nivolumab; Genetics","score_opus":0.059833608512475246,"score_gpt":0.4129483053899583,"score_spread":0.35311469687748304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393983007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421394,0.0003630336,0.00004444606,0.0015637631,0.00014864159,0.001386674,0.0021829756,0.00002070147,0.00007584052],"genre_scores_gemma":[0.9987304,0.00018212116,0.00045704228,0.00013522104,0.000046012254,0.00026417538,0.00004168548,0.000033765245,0.00010953402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751866,0.0001541921,0.000494892,0.00048187436,0.0008988028,0.0004515775],"domain_scores_gemma":[0.998156,0.0003411176,0.000096614334,0.0003279367,0.0008120685,0.00026627904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011316708,0.00020790176,0.0007248524,0.001717176,0.00006463188,0.000039147322,0.00009804911,0.00007112221,0.00034953834],"category_scores_gemma":[0.00014779494,0.00016807254,0.00009500546,0.0048820274,0.00032629305,0.00019630756,0.00008341644,0.00031572676,0.0000064479136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055596422,0.0012319187,0.6093493,0.0032171954,0.014086979,0.0001240513,0.019098168,0.007954497,0.210453,0.000066899025,0.0040987595,0.074722774],"study_design_scores_gemma":[0.005526928,0.000497187,0.9550673,0.0011871998,0.0003775592,0.000002639303,0.00058749935,0.0008279082,0.035489094,0.000008409963,0.00021943083,0.00020886728],"about_ca_topic_score_codex":0.020900367,"about_ca_topic_score_gemma":0.012969637,"teacher_disagreement_score":0.34571794,"about_ca_system_score_codex":0.00082541467,"about_ca_system_score_gemma":0.0009073482,"threshold_uncertainty_score":0.98561954},"labels":[],"label_agreement":null},{"id":"W4393988984","doi":"10.1158/1538-7445.am2024-ct018","title":"Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Enzalutamide; Medicine; TMPRSS2; Placebo; Erg; Oncology; Internal medicine; Prostate cancer; Cancer; Alternative medicine; Pathology; Ophthalmology; Disease; Coronavirus disease 2019 (COVID-19); Androgen receptor","score_opus":0.06675336489293053,"score_gpt":0.4413804102331712,"score_spread":0.37462704534024066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832873,0.0027948015,0.000006279337,0.00081121194,0.00019889174,0.011094587,0.0016056732,0.00005054971,0.00015074018],"genre_scores_gemma":[0.98816216,0.0011387578,0.000048646183,0.000039388433,0.00009482372,0.009757521,0.00020558567,0.00010579751,0.00044732483],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956416,0.00024562422,0.00091073813,0.0010884507,0.0012444449,0.00086913473],"domain_scores_gemma":[0.99771357,0.00073923584,0.00020247482,0.00046944685,0.00052773254,0.00034754394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010534562,0.00047242915,0.00081948953,0.0009777996,0.00018311781,0.00011686616,0.00016388786,0.000108004744,0.00025852502],"category_scores_gemma":[0.00018332132,0.0003732274,0.00008813899,0.0013268165,0.00042221215,0.0003147005,0.000056508892,0.0005127617,0.000006891498],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53184557,0.03665383,0.19006996,0.007608549,0.00797103,0.0028971422,0.06886072,0.011072419,0.06573849,0.00014702762,0.002232656,0.0749026],"study_design_scores_gemma":[0.42801827,0.1270511,0.25934023,0.015543355,0.0014807641,0.0000628501,0.015628545,0.008107416,0.13314864,0.0004891351,0.008988079,0.0021416196],"about_ca_topic_score_codex":0.027791204,"about_ca_topic_score_gemma":0.027771724,"teacher_disagreement_score":0.10382731,"about_ca_system_score_codex":0.0029569769,"about_ca_system_score_gemma":0.002484016,"threshold_uncertainty_score":0.99987197},"labels":[],"label_agreement":null},{"id":"W4393989000","doi":"10.1158/1538-7445.am2024-ct169","title":"Abstract CT169: First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP inhibitor; Poly ADP ribose polymerase; Polymerase; Molecular biology; DNA; Chemistry; Biology; Biochemistry","score_opus":0.0650436417362831,"score_gpt":0.4188500716926601,"score_spread":0.353806429956377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393989000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98192537,0.0041967183,0.0000042181337,0.007983117,0.0002585601,0.0047730017,0.00035712984,0.00017107507,0.00033083514],"genre_scores_gemma":[0.9951861,0.00028590206,0.000025948437,0.00038512918,0.0011045068,0.0017917037,0.00012816043,0.00024594527,0.00084661855],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9921079,0.00067434396,0.0013910171,0.0015612235,0.002607335,0.0016581814],"domain_scores_gemma":[0.9962714,0.00061145186,0.00028626926,0.0016190135,0.00052170426,0.00069021014],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002030024,0.00077581214,0.0013900119,0.0015314685,0.00047299688,0.00020496867,0.0007526047,0.00024034006,0.0013253492],"category_scores_gemma":[0.00007954688,0.00047761406,0.0001397852,0.003644901,0.0013455554,0.00064859376,0.00017996998,0.0022368564,0.000026796248],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40798113,0.05329461,0.03407114,0.005613023,0.002667502,0.021207942,0.08743761,0.00048240574,0.3224053,0.00038621356,0.030007467,0.03444567],"study_design_scores_gemma":[0.13799758,0.060108382,0.018324096,0.017624084,0.0003421737,0.00031366234,0.03524341,0.0008393989,0.72315735,0.00008827125,0.0039385525,0.0020230364],"about_ca_topic_score_codex":0.014199639,"about_ca_topic_score_gemma":0.041245922,"teacher_disagreement_score":0.40075204,"about_ca_system_score_codex":0.0010472059,"about_ca_system_score_gemma":0.0024206457,"threshold_uncertainty_score":0.99976754},"labels":[],"label_agreement":null},{"id":"W4393989319","doi":"10.1158/1538-7445.am2024-lb181","title":"Abstract LB181: First disclosure of XRD-0394, a novel dual ATM/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PARP inhibitor; Cancer research; Topoisomerase; DNA; Dual (grammatical number); Chemistry; Poly ADP ribose polymerase; Pharmacology; Medicine; Polymerase; Biochemistry","score_opus":0.07114726092234676,"score_gpt":0.3767257946361513,"score_spread":0.30557853371380456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393989319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95435053,0.032169733,0.000014741936,0.011250701,0.0005877858,0.0007751141,0.00032437092,0.000105604515,0.0004214152],"genre_scores_gemma":[0.9891784,0.008463539,0.0001179014,0.00016850122,0.0010674011,0.0001505516,0.00004026952,0.00008774522,0.0007256617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967604,0.000085845895,0.0004934135,0.0007948426,0.0011629292,0.00070254656],"domain_scores_gemma":[0.9982477,0.00047549364,0.000087345434,0.00041691508,0.00033374992,0.00043884103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008737746,0.00033272733,0.00056375266,0.0005143141,0.00027789045,0.00018931211,0.00010631207,0.00023235052,0.00029260968],"category_scores_gemma":[0.000115693394,0.00027896088,0.00014588653,0.0006590637,0.0009977636,0.0003314026,0.00016563572,0.00085922715,0.000016817348],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015727523,0.00036592668,0.015154824,0.0037869792,0.00065510324,0.0008241942,0.0035160107,0.000020836123,0.92432266,0.00061783276,0.03473687,0.014426019],"study_design_scores_gemma":[0.008947133,0.0011611939,0.0992002,0.008825508,0.0002597073,0.0007358664,0.0031997536,0.0002786992,0.82415265,0.001122248,0.051174495,0.00094252505],"about_ca_topic_score_codex":0.0007762941,"about_ca_topic_score_gemma":0.00017275661,"teacher_disagreement_score":0.10016998,"about_ca_system_score_codex":0.00030893934,"about_ca_system_score_gemma":0.00045138772,"threshold_uncertainty_score":0.99996626},"labels":[],"label_agreement":null},{"id":"W4394037109","doi":"10.5281/zenodo.3560232","title":"ROS-Specific Huntingtin Interactions: Testing PARP activity in HD patient fibroblasts","year":2019,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Huntingtin; Poly ADP ribose polymerase; Chemistry; Molecular biology; Cell biology; Biology; Biochemistry; DNA; Polymerase; Gene","score_opus":0.12994473823670136,"score_gpt":0.34596076754958416,"score_spread":0.2160160293128828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394037109","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036448028,0.0003271373,2.6553712e-7,0.000094785406,0.00056773453,0.0009989848,0.99686944,0.00008180019,0.0006953466],"genre_scores_gemma":[0.0008103271,0.000028331304,0.000100009354,0.0004294153,0.00071531156,0.00067900715,0.9970026,0.00006150317,0.00017350887],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976973,0.000101250975,0.00054409326,0.0007114877,0.0004912078,0.0004546792],"domain_scores_gemma":[0.9973867,0.00072548626,0.00060372846,0.0009211353,0.00023188944,0.00013104903],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000075209755,0.00043580207,0.00064617867,0.00037540423,0.000072256815,0.000079644065,0.00022644816,0.0003422683,0.1652626],"category_scores_gemma":[0.0014595385,0.0004507336,0.00015843265,0.0005173533,0.000012191774,0.00020782738,0.00019210394,0.0013937487,0.010298838],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001294784,0.00020174481,0.000030492767,0.00095770997,0.000028306204,0.00008096285,0.000032673343,0.00003527523,0.00034123,4.3146954e-8,0.9931579,0.0050041457],"study_design_scores_gemma":[0.0009298498,0.00021825983,0.0012087811,0.026627373,0.000013795776,0.0000501584,0.000020842843,0.000049139137,0.0011637877,0.0000029624027,0.9693309,0.0003841503],"about_ca_topic_score_codex":0.00007093475,"about_ca_topic_score_gemma":0.000077888246,"teacher_disagreement_score":0.15496376,"about_ca_system_score_codex":0.00064167817,"about_ca_system_score_gemma":0.0002938043,"threshold_uncertainty_score":0.9997944},"labels":[],"label_agreement":null},{"id":"W4394059171","doi":"10.5281/zenodo.3560231","title":"ROS-Specific Huntingtin Interactions: Testing PARP activity in HD patient fibroblasts","year":2019,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Huntingtin; Poly ADP ribose polymerase; Chemistry; Molecular biology; Cell biology; Biology; Genetics; DNA; Polymerase; Gene","score_opus":0.08925077289686728,"score_gpt":0.30872418953653935,"score_spread":0.21947341663967207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394059171","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011291664,0.00022971685,0.00021314567,0.00076228654,0.00079987466,0.0021624654,0.9657814,0.0007006928,0.018058745],"genre_scores_gemma":[0.015391293,0.00033805138,0.00027336404,0.00031858854,0.0005255455,5.322982e-7,0.98109823,0.0016004576,0.00045391632],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691457,0.0004617946,0.00057414384,0.0008227342,0.0006817955,0.00054498133],"domain_scores_gemma":[0.9975072,0.00014765353,0.00044545782,0.0010287112,0.00066914223,0.00020180899],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00059208757,0.00034526637,0.00047708044,0.00071626523,0.00077582244,0.00048608985,0.00062130595,0.00019781287,0.017479902],"category_scores_gemma":[0.0010976222,0.00038035412,0.00010574385,0.0010182896,0.00014684984,0.000290398,0.0009147983,0.0013389623,0.015330505],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032887002,0.0003860207,0.0000051683737,0.00030602238,0.000045715686,0.00004733606,0.0001746466,0.000062026,0.0047431756,0.000007961957,0.9521826,0.04171044],"study_design_scores_gemma":[0.0012331867,0.000561801,0.0004981205,0.0009904096,0.000022218064,0.00024739798,0.000106607455,0.000100698926,0.00075865415,0.000014410532,0.9951421,0.00032436673],"about_ca_topic_score_codex":0.00007672745,"about_ca_topic_score_gemma":0.0000024101341,"teacher_disagreement_score":0.042959515,"about_ca_system_score_codex":0.0009147404,"about_ca_system_score_gemma":0.000022925587,"threshold_uncertainty_score":0.9998648},"labels":[],"label_agreement":null},{"id":"W4394109919","doi":"10.6084/m9.figshare.1591559.v11","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Environmental science; Computer science","score_opus":0.13559560655922193,"score_gpt":0.38115130862075386,"score_spread":0.24555570206153193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394109919","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.0511081e-7,0.0016195313,3.365809e-8,0.00019612795,0.00034407686,0.00037185513,0.99406385,0.00008709816,0.0033173005],"genre_scores_gemma":[5.620358e-7,0.000036290225,0.000017960057,0.0025581832,0.0020701324,0.00040416545,0.9932443,0.00003702758,0.0016314012],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998677,0.000027248494,0.00022363388,0.00031461052,0.00049842894,0.00025906283],"domain_scores_gemma":[0.99844086,0.000048389888,0.00016043137,0.00080320326,0.00027311506,0.00027399126],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004695807,0.0002574484,0.00039597455,0.000119779936,0.000031471034,0.000025712383,0.0002134016,0.00041750495,0.7889898],"category_scores_gemma":[0.0005633422,0.00023594209,0.00012548435,0.00014433925,0.000008264794,0.000054570915,0.000089042325,0.00053110864,0.07901725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038111415,0.0000437896,2.4765342e-7,0.0005357121,0.00004613926,0.0001193082,0.0000051457496,2.0866806e-7,0.0000016796862,9.389363e-8,0.9989925,0.00021706319],"study_design_scores_gemma":[0.0008750786,0.000107320884,0.000014565952,0.004634042,0.000045777684,0.00007482078,0.000002678699,7.4397786e-7,0.000068943875,0.000013285271,0.99393106,0.0002317159],"about_ca_topic_score_codex":0.0000132351615,"about_ca_topic_score_gemma":0.000008613641,"teacher_disagreement_score":0.70997256,"about_ca_system_score_codex":0.00023769258,"about_ca_system_score_gemma":0.00057344505,"threshold_uncertainty_score":0.96214396},"labels":[],"label_agreement":null},{"id":"W4394117085","doi":"10.6084/m9.figshare.21540411","title":"Additional file 15 of A comprehensive pan-cancer analysis of necroptosis molecules in four gynecologic cancers","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of Toronto","funders":"","keywords":"Necroptosis; Gynecologic cancer; Cancer; Medicine; Cancer research; Oncology; Internal medicine; Biology; Ovarian cancer; Apoptosis; Programmed cell death; Genetics","score_opus":0.060672209828437865,"score_gpt":0.32699459811043646,"score_spread":0.2663223882819986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394117085","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026497368,0.00075683894,4.121959e-8,0.000042198888,0.00006168575,0.00044939178,0.9984914,0.000015363788,0.00015659834],"genre_scores_gemma":[0.000022754079,0.00020246771,0.00007135136,0.00087028224,0.00008130906,0.0068920045,0.9917301,0.000024156663,0.000105560684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978751,0.00012359937,0.0006266963,0.00047168022,0.00063877524,0.0002641808],"domain_scores_gemma":[0.99646974,0.0016373777,0.0008891441,0.00053658674,0.000385458,0.000081709804],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000025558575,0.00030382184,0.0012025438,0.00095385977,0.000042293763,0.000006263555,0.00030591758,0.0002658164,0.999676],"category_scores_gemma":[0.00074593205,0.0003148951,0.00050170976,0.0018082717,0.000044339205,0.000039508584,0.00015918382,0.00053413626,0.00011478848],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012902616,0.00010036807,0.0000088325305,0.00073336175,0.0016710593,0.00006441214,0.000016028429,0.0011182663,0.000012984364,9.093128e-8,0.9958722,0.00027337024],"study_design_scores_gemma":[0.0006918168,0.00018817333,0.007855108,0.0025361266,0.0006214886,0.0000029976586,0.000073689815,0.000095892516,0.000055575805,0.000002845504,0.98763454,0.0002417585],"about_ca_topic_score_codex":0.000728291,"about_ca_topic_score_gemma":0.0013304901,"teacher_disagreement_score":0.9995612,"about_ca_system_score_codex":0.00081016176,"about_ca_system_score_gemma":0.0011664851,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W4394183905","doi":"10.6084/m9.figshare.1591559.v3","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.13559560655922193,"score_gpt":0.38115130862075386,"score_spread":0.24555570206153193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394183905","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.0511081e-7,0.0016195313,3.365809e-8,0.00019612795,0.00034407686,0.00037185513,0.99406385,0.00008709816,0.0033173005],"genre_scores_gemma":[5.620358e-7,0.000036290225,0.000017960057,0.0025581832,0.0020701324,0.00040416545,0.9932443,0.00003702758,0.0016314012],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998677,0.000027248494,0.00022363388,0.00031461052,0.00049842894,0.00025906283],"domain_scores_gemma":[0.99844086,0.000048389888,0.00016043137,0.00080320326,0.00027311506,0.00027399126],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004695807,0.0002574484,0.00039597455,0.000119779936,0.000031471034,0.000025712383,0.0002134016,0.00041750495,0.7889898],"category_scores_gemma":[0.0005633422,0.00023594209,0.00012548435,0.00014433925,0.000008264794,0.000054570915,0.000089042325,0.00053110864,0.07901725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038111415,0.0000437896,2.4765342e-7,0.0005357121,0.00004613926,0.0001193082,0.0000051457496,2.0866806e-7,0.0000016796862,9.389363e-8,0.9989925,0.00021706319],"study_design_scores_gemma":[0.0008750786,0.000107320884,0.000014565952,0.004634042,0.000045777684,0.00007482078,0.000002678699,7.4397786e-7,0.000068943875,0.000013285271,0.99393106,0.0002317159],"about_ca_topic_score_codex":0.0000132351615,"about_ca_topic_score_gemma":0.000008613641,"teacher_disagreement_score":0.70997256,"about_ca_system_score_codex":0.00023769258,"about_ca_system_score_gemma":0.00057344505,"threshold_uncertainty_score":0.96214396},"labels":[],"label_agreement":null},{"id":"W4394242887","doi":"10.6084/m9.figshare.1591559.v1","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.13559560655922193,"score_gpt":0.38115130862075386,"score_spread":0.24555570206153193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394242887","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.0511081e-7,0.0016195313,3.365809e-8,0.00019612795,0.00034407686,0.00037185513,0.99406385,0.00008709816,0.0033173005],"genre_scores_gemma":[5.620358e-7,0.000036290225,0.000017960057,0.0025581832,0.0020701324,0.00040416545,0.9932443,0.00003702758,0.0016314012],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998677,0.000027248494,0.00022363388,0.00031461052,0.00049842894,0.00025906283],"domain_scores_gemma":[0.99844086,0.000048389888,0.00016043137,0.00080320326,0.00027311506,0.00027399126],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004695807,0.0002574484,0.00039597455,0.000119779936,0.000031471034,0.000025712383,0.0002134016,0.00041750495,0.7889898],"category_scores_gemma":[0.0005633422,0.00023594209,0.00012548435,0.00014433925,0.000008264794,0.000054570915,0.000089042325,0.00053110864,0.07901725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038111415,0.0000437896,2.4765342e-7,0.0005357121,0.00004613926,0.0001193082,0.0000051457496,2.0866806e-7,0.0000016796862,9.389363e-8,0.9989925,0.00021706319],"study_design_scores_gemma":[0.0008750786,0.000107320884,0.000014565952,0.004634042,0.000045777684,0.00007482078,0.000002678699,7.4397786e-7,0.000068943875,0.000013285271,0.99393106,0.0002317159],"about_ca_topic_score_codex":0.0000132351615,"about_ca_topic_score_gemma":0.000008613641,"teacher_disagreement_score":0.70997256,"about_ca_system_score_codex":0.00023769258,"about_ca_system_score_gemma":0.00057344505,"threshold_uncertainty_score":0.96214396},"labels":[],"label_agreement":null},{"id":"W4394266738","doi":"10.6084/m9.figshare.21540405","title":"Additional file 13 of A comprehensive pan-cancer analysis of necroptosis molecules in four gynecologic cancers","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of Toronto","funders":"","keywords":"Necroptosis; Gynecologic cancer; Cancer; Medicine; Computational biology; Cancer research; Oncology; Internal medicine; Biology; Ovarian cancer; Programmed cell death; Genetics; Apoptosis","score_opus":0.05954861470911656,"score_gpt":0.3255412011157798,"score_spread":0.26599258640666323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394266738","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035097994,0.0006720001,3.9889255e-8,0.000043042022,0.00006219708,0.00045338296,0.9985574,0.000015406313,0.00016146972],"genre_scores_gemma":[0.000027729779,0.00021788942,0.00006042726,0.0008384669,0.000077070916,0.007183468,0.9914632,0.000024247098,0.00010749124],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788076,0.00012249529,0.000627438,0.00047212842,0.00063247065,0.0002647328],"domain_scores_gemma":[0.9964551,0.0016577992,0.00088791334,0.00053676555,0.00038147368,0.00008096296],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000025101093,0.00030442353,0.0012006836,0.00095207646,0.0000429833,0.0000063479615,0.00030633665,0.00025337664,0.99964607],"category_scores_gemma":[0.000730732,0.00031529323,0.00050507387,0.0017936254,0.00004449476,0.00003984974,0.00015887391,0.00050864584,0.000110492256],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001261604,0.00009909859,0.000010643918,0.0007395674,0.0016724102,0.00006276417,0.000016520687,0.0013578787,0.000012072412,8.0291535e-8,0.99562734,0.00027544235],"study_design_scores_gemma":[0.000697073,0.000185174,0.010134502,0.002542339,0.00061624765,0.0000029417654,0.00007285825,0.00010960457,0.000050378934,0.0000028126037,0.9853441,0.00024195891],"about_ca_topic_score_codex":0.0009934299,"about_ca_topic_score_gemma":0.0017667909,"teacher_disagreement_score":0.99953556,"about_ca_system_score_codex":0.0008058366,"about_ca_system_score_gemma":0.0011384621,"threshold_uncertainty_score":0.9999299},"labels":[],"label_agreement":null},{"id":"W4394345769","doi":"10.6084/m9.figshare.1591559.v6","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.13559560655922193,"score_gpt":0.38115130862075386,"score_spread":0.24555570206153193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394345769","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.0511081e-7,0.0016195313,3.365809e-8,0.00019612795,0.00034407686,0.00037185513,0.99406385,0.00008709816,0.0033173005],"genre_scores_gemma":[5.620358e-7,0.000036290225,0.000017960057,0.0025581832,0.0020701324,0.00040416545,0.9932443,0.00003702758,0.0016314012],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998677,0.000027248494,0.00022363388,0.00031461052,0.00049842894,0.00025906283],"domain_scores_gemma":[0.99844086,0.000048389888,0.00016043137,0.00080320326,0.00027311506,0.00027399126],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004695807,0.0002574484,0.00039597455,0.000119779936,0.000031471034,0.000025712383,0.0002134016,0.00041750495,0.7889898],"category_scores_gemma":[0.0005633422,0.00023594209,0.00012548435,0.00014433925,0.000008264794,0.000054570915,0.000089042325,0.00053110864,0.07901725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038111415,0.0000437896,2.4765342e-7,0.0005357121,0.00004613926,0.0001193082,0.0000051457496,2.0866806e-7,0.0000016796862,9.389363e-8,0.9989925,0.00021706319],"study_design_scores_gemma":[0.0008750786,0.000107320884,0.000014565952,0.004634042,0.000045777684,0.00007482078,0.000002678699,7.4397786e-7,0.000068943875,0.000013285271,0.99393106,0.0002317159],"about_ca_topic_score_codex":0.0000132351615,"about_ca_topic_score_gemma":0.000008613641,"teacher_disagreement_score":0.70997256,"about_ca_system_score_codex":0.00023769258,"about_ca_system_score_gemma":0.00057344505,"threshold_uncertainty_score":0.96214396},"labels":[],"label_agreement":null},{"id":"W4394384237","doi":"10.6084/m9.figshare.1591559.v4","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.13559560655922193,"score_gpt":0.38115130862075386,"score_spread":0.24555570206153193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394384237","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.0511081e-7,0.0016195313,3.365809e-8,0.00019612795,0.00034407686,0.00037185513,0.99406385,0.00008709816,0.0033173005],"genre_scores_gemma":[5.620358e-7,0.000036290225,0.000017960057,0.0025581832,0.0020701324,0.00040416545,0.9932443,0.00003702758,0.0016314012],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998677,0.000027248494,0.00022363388,0.00031461052,0.00049842894,0.00025906283],"domain_scores_gemma":[0.99844086,0.000048389888,0.00016043137,0.00080320326,0.00027311506,0.00027399126],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004695807,0.0002574484,0.00039597455,0.000119779936,0.000031471034,0.000025712383,0.0002134016,0.00041750495,0.7889898],"category_scores_gemma":[0.0005633422,0.00023594209,0.00012548435,0.00014433925,0.000008264794,0.000054570915,0.000089042325,0.00053110864,0.07901725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038111415,0.0000437896,2.4765342e-7,0.0005357121,0.00004613926,0.0001193082,0.0000051457496,2.0866806e-7,0.0000016796862,9.389363e-8,0.9989925,0.00021706319],"study_design_scores_gemma":[0.0008750786,0.000107320884,0.000014565952,0.004634042,0.000045777684,0.00007482078,0.000002678699,7.4397786e-7,0.000068943875,0.000013285271,0.99393106,0.0002317159],"about_ca_topic_score_codex":0.0000132351615,"about_ca_topic_score_gemma":0.000008613641,"teacher_disagreement_score":0.70997256,"about_ca_system_score_codex":0.00023769258,"about_ca_system_score_gemma":0.00057344505,"threshold_uncertainty_score":0.96214396},"labels":[],"label_agreement":null},{"id":"W4394510657","doi":"10.6084/m9.figshare.21540408","title":"Additional file 14 of A comprehensive pan-cancer analysis of necroptosis molecules in four gynecologic cancers","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of Toronto","funders":"","keywords":"Necroptosis; Gynecologic cancer; Cancer; Medicine; Cancer research; Oncology; Internal medicine; Biology; Programmed cell death; Apoptosis; Ovarian cancer; Genetics","score_opus":0.05971966217316705,"score_gpt":0.32627994009914685,"score_spread":0.2665602779259798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394510657","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002339048,0.000673397,4.401103e-8,0.000043962787,0.00006686203,0.00044786546,0.9985668,0.000015411819,0.00016225078],"genre_scores_gemma":[0.0000212556,0.0002135474,0.000071129136,0.00084498967,0.00007650965,0.0070150783,0.99161416,0.0000242462,0.00011910803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978618,0.00012454009,0.00062799704,0.00047284635,0.0006478068,0.00026499538],"domain_scores_gemma":[0.9964014,0.0016728592,0.00088995957,0.0005373008,0.00041756016,0.00008088847],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000026322045,0.00030420575,0.0012044909,0.0009513227,0.000043175143,0.000006271133,0.00030521915,0.00025904333,0.99963266],"category_scores_gemma":[0.00081416406,0.00031535566,0.0005062479,0.001791079,0.000044482502,0.00003910233,0.00015801912,0.00051994604,0.000107313346],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013049143,0.00009955132,0.0000082248125,0.00074557896,0.001667356,0.00006282886,0.0000156767,0.0011157024,0.000012205366,9.640871e-8,0.9958668,0.0002755274],"study_design_scores_gemma":[0.0007142742,0.00018656028,0.007279573,0.002557625,0.00062117196,0.0000029521161,0.00006211119,0.00009060208,0.000055431206,0.0000028428,0.9881847,0.00024215797],"about_ca_topic_score_codex":0.00065725675,"about_ca_topic_score_gemma":0.0012100018,"teacher_disagreement_score":0.9995253,"about_ca_system_score_codex":0.0008192594,"about_ca_system_score_gemma":0.0011324123,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W4395685966","doi":"10.51731/cjht.2024.876","title":"Olaparib (Lynparza)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Medicine; Computer science; Physics; Nuclear magnetic resonance","score_opus":0.041689355697901456,"score_gpt":0.34693427468736254,"score_spread":0.3052449189894611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395685966","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06560873,0.5816785,0.0017015889,0.3439282,0.0026466995,0.00035194398,0.000037270253,0.0005702446,0.0034768162],"genre_scores_gemma":[0.99569994,0.0015653244,0.0008838553,0.001545886,0.00004867048,0.0000053792196,0.000001734452,0.000018983104,0.00023021996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887925,0.00002435752,0.000463699,0.000115626164,0.00015569669,0.00036137848],"domain_scores_gemma":[0.99938434,0.000043355005,0.00012545219,0.00019797073,0.00011950813,0.00012936842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005248,0.000098806704,0.00030891973,0.00085130666,0.0001099688,0.000043297685,0.0001544566,0.00012671942,0.00013439056],"category_scores_gemma":[0.00018232656,0.00008035343,0.00009646107,0.00045007534,0.00020024895,0.000102061655,0.000006263591,0.0005924846,0.000042656447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002075815,0.000011364949,0.0015798623,0.00034437774,0.00009779446,0.001069901,0.00036469573,0.0000052617843,0.000302717,0.008180299,0.121116325,0.86690664],"study_design_scores_gemma":[0.0003788922,0.00047330395,0.0012609367,0.0011589745,0.000015206277,0.0021757723,0.00087196304,0.000019764808,0.0018476803,0.0073481975,0.9843676,0.00008167189],"about_ca_topic_score_codex":0.0007734823,"about_ca_topic_score_gemma":0.00052946515,"teacher_disagreement_score":0.9300912,"about_ca_system_score_codex":0.0007637004,"about_ca_system_score_gemma":0.0059393314,"threshold_uncertainty_score":0.9996961},"labels":[],"label_agreement":null},{"id":"W4395697371","doi":"10.1016/j.adro.2024.101528","title":"Concurrent Olaparib and Radiation Therapy for BRCA2-Mutated Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Advances in Radiation Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Olaparib; Medicine; Breast cancer; Radiation therapy; Oncology; Axilla; Internal medicine; Population; Ovarian cancer; Cancer","score_opus":0.019645734699918278,"score_gpt":0.4148843961869935,"score_spread":0.39523866148707526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395697371","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35439518,0.5788085,0.009641946,0.039210316,0.009621472,0.0042666756,0.0007151762,0.00049239857,0.002848353],"genre_scores_gemma":[0.8725489,0.12350796,0.00024267577,0.0017474443,0.00071540545,0.00092232553,0.00014498172,0.000030837455,0.0001394788],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888235,0.00007089146,0.00033976522,0.0003554914,0.00012248738,0.00022898742],"domain_scores_gemma":[0.99926543,0.0003709411,0.00010106741,0.000101046055,0.00007946912,0.00008206397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024042367,0.0001451053,0.00029527338,0.00022764227,0.000051651645,0.00002171981,0.00004370288,0.00013435104,0.00023031872],"category_scores_gemma":[0.000031448133,0.00013416108,0.000051105177,0.0003102611,0.000106094194,0.0003551735,0.000006652467,0.00017162463,0.000009189947],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003532649,0.000090628266,0.0088369,0.00010264972,0.000051385112,0.000009023115,0.0005977404,0.00031183593,0.0015755397,0.0023640755,0.0020594166,0.9836475],"study_design_scores_gemma":[0.008168993,0.00065484486,0.02983578,0.00014549747,0.000035467307,0.00011292169,0.00007629032,0.011004474,0.0021486613,0.001508608,0.9461201,0.0001884047],"about_ca_topic_score_codex":0.000028018027,"about_ca_topic_score_gemma":0.000053874883,"teacher_disagreement_score":0.9834591,"about_ca_system_score_codex":0.0007486348,"about_ca_system_score_gemma":0.0003764297,"threshold_uncertainty_score":0.54709303},"labels":[],"label_agreement":null},{"id":"W4396514095","doi":"10.51731/cjht.2024.879","title":"Niraparib and Abiraterone Acetate (Akeega)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Abiraterone acetate; Reimbursement; Medicine; Abiraterone; Prostate cancer; Asymptomatic; Internal medicine; Oncology; Chemotherapy; Cancer; Gynecology; Political science; Androgen deprivation therapy; Health care","score_opus":0.03726430238214361,"score_gpt":0.32689288200919125,"score_spread":0.28962857962704763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396514095","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30526718,0.4924323,0.00056570524,0.19977583,0.0009098756,0.00024471464,0.000026149288,0.0002603374,0.0005179172],"genre_scores_gemma":[0.9937544,0.004029912,0.00076818094,0.0012286934,0.00002845496,0.000004933899,0.0000013264453,0.000017751778,0.00016636039],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898595,0.000025122756,0.00042043987,0.00012602018,0.00011675827,0.00032573976],"domain_scores_gemma":[0.9994758,0.00003246783,0.0001209753,0.00015165968,0.000085910586,0.00013320835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004857211,0.000103479964,0.00032180414,0.0007022275,0.00011143949,0.00005449415,0.00009591186,0.00010923396,0.000044301043],"category_scores_gemma":[0.00009049045,0.00008317687,0.00004963451,0.00029701254,0.00028073776,0.000116784424,0.000008032921,0.00047918965,0.00001196142],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032238648,0.000008139172,0.002329145,0.0004971431,0.000106318934,0.0008586407,0.0006024425,0.0000033127653,0.0008267361,0.0030365326,0.02927177,0.96242756],"study_design_scores_gemma":[0.0009863364,0.0009826482,0.006075661,0.0017817568,0.000031132964,0.0042590387,0.0016076257,0.00003905575,0.0037047933,0.010295065,0.97008395,0.00015296023],"about_ca_topic_score_codex":0.00069012935,"about_ca_topic_score_gemma":0.00064418,"teacher_disagreement_score":0.9622746,"about_ca_system_score_codex":0.00038150643,"about_ca_system_score_gemma":0.002388537,"threshold_uncertainty_score":0.4237162},"labels":[],"label_agreement":null},{"id":"W4396544296","doi":"10.1038/s41598-024-60769-1","title":"Author Correction: Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer","year":2024,"lang":"en","type":"erratum","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Serous ovarian cancer; Poly ADP ribose polymerase; Polymerase; Nicotinamide adenine dinucleotide; Nicotinamide; Ovarian cancer; NAD+ kinase; Cancer research; Serous fluid; Chemistry; Molecular biology; Biochemistry; Biology; Medicine; Cancer; Enzyme; Genetics","score_opus":0.01445147011082678,"score_gpt":0.2764941567655626,"score_spread":0.26204268665473585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396544296","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41747838,0.04369489,0.00008806007,0.009130052,0.51981294,0.0031990597,0.0007689579,0.0006139244,0.0052137384],"genre_scores_gemma":[0.6138406,0.00052162836,0.00031887981,0.00043778957,0.004501642,0.00041094454,0.0017975867,0.0002733676,0.37789756],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925133,0.0002157307,0.0022701593,0.0024281964,0.0017423686,0.0008302283],"domain_scores_gemma":[0.9958124,0.00009593726,0.0016026434,0.0015905912,0.00047579937,0.00042260924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018469101,0.0007964394,0.0014388142,0.0015824798,0.00030729605,0.00037856345,0.00016047865,0.00078150263,0.00034967996],"category_scores_gemma":[0.00026902035,0.000797222,0.0003173227,0.002264035,0.0011481593,0.00039371126,0.0001805037,0.0012650915,0.000017944316],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004429622,0.00027291596,0.001084571,0.0016321079,0.00016168215,0.004247736,0.0013367105,0.000004921017,0.06207818,0.00009324211,0.9267734,0.0018715397],"study_design_scores_gemma":[0.0033613225,0.00035643135,0.007863647,0.028901596,0.00059921615,0.0017567527,0.0006090381,0.0001354315,0.16621141,0.003839435,0.7846578,0.0017079328],"about_ca_topic_score_codex":0.0014641392,"about_ca_topic_score_gemma":0.0030114313,"teacher_disagreement_score":0.5153113,"about_ca_system_score_codex":0.0016386126,"about_ca_system_score_gemma":0.0026085144,"threshold_uncertainty_score":0.9994479},"labels":[],"label_agreement":null},{"id":"W4396577124","doi":"10.1001/jamaoncol.2024.0851","title":"Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Genetic testing; Internal medicine; Homologous recombination; Cancer; Genetics; Gene","score_opus":0.048688765978499124,"score_gpt":0.370808606759038,"score_spread":0.32211984078053885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396577124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95728785,0.0038731932,0.00016212146,0.013678175,0.00021306216,0.00091297604,0.00003775959,0.00013231425,0.023702575],"genre_scores_gemma":[0.985923,0.00014992128,0.010751544,0.001154097,0.00023545774,0.0005805268,0.000009254043,0.000033947883,0.0011622877],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99893564,0.000081141574,0.00028847446,0.00027889843,0.00016903806,0.00024678148],"domain_scores_gemma":[0.99937755,0.0002616873,0.000058381753,0.00013206893,0.00009319423,0.00007711469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021372922,0.00012057546,0.00025745758,0.00015696883,0.000030832038,0.00003220648,0.000042234944,0.000057525485,0.00027318043],"category_scores_gemma":[0.00005181677,0.00009242788,0.000023974559,0.00047608238,0.000088256915,0.000079834754,0.000010630704,0.0002589451,0.000032900887],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048904275,0.00063398364,0.06817142,0.001768118,0.00072536356,0.016760916,0.00996265,0.0041028783,0.37791887,0.0014714805,0.024924172,0.48866972],"study_design_scores_gemma":[0.029582685,0.01120013,0.56395906,0.005149636,0.00087750674,0.0040451684,0.0029997663,0.034849036,0.016698118,0.004231401,0.32529414,0.0011133638],"about_ca_topic_score_codex":0.0006278349,"about_ca_topic_score_gemma":0.0010922977,"teacher_disagreement_score":0.49578765,"about_ca_system_score_codex":0.0006646207,"about_ca_system_score_gemma":0.0012866829,"threshold_uncertainty_score":0.37690994},"labels":[],"label_agreement":null},{"id":"W4396590738","doi":"10.1158/1538-7445.sabcs23-gs01-05","title":"Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Chemotherapy; Oncology; Olaparib; Internal medicine; Open label; Induction chemotherapy; Cancer; Randomized controlled trial; Immunotherapy; Polymerase","score_opus":0.14351004019557545,"score_gpt":0.4841436015656345,"score_spread":0.34063356137005907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396590738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9486466,0.010134999,0.0022385623,0.009477974,0.0013428979,0.026017765,0.00039593413,0.00045601762,0.001289221],"genre_scores_gemma":[0.94956845,0.0065542012,0.001086778,0.0017431541,0.0013447809,0.029624058,0.00017710536,0.0005154205,0.009386048],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990796,0.0009241332,0.0016104289,0.002243498,0.002489027,0.0019368776],"domain_scores_gemma":[0.994516,0.0011174727,0.00031521762,0.0015302846,0.0017485911,0.00077242736],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047854874,0.0010672904,0.0025354717,0.0011867369,0.00063932344,0.0011705244,0.0010239384,0.00032167742,0.0061934595],"category_scores_gemma":[0.00025897677,0.0007494802,0.00037019278,0.002255049,0.0009367738,0.0011240107,0.00018191467,0.0021296372,0.00014775773],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8703218,0.0066003585,0.000030730407,0.0016209133,0.0030129412,0.0006447957,0.0047458718,0.000050391256,0.009280318,0.00018724159,0.022198819,0.081305794],"study_design_scores_gemma":[0.88441575,0.017290052,0.00025517936,0.0032948372,0.0006968844,0.0004145768,0.0012841015,0.0027095194,0.01538417,0.00072963623,0.07226124,0.0012640539],"about_ca_topic_score_codex":0.0010542711,"about_ca_topic_score_gemma":0.0004322591,"teacher_disagreement_score":0.08004174,"about_ca_system_score_codex":0.0025479803,"about_ca_system_score_gemma":0.005292189,"threshold_uncertainty_score":0.99986637},"labels":[],"label_agreement":null},{"id":"W4396641051","doi":"10.1186/s13063-024-08142-5","title":"Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial","year":2024,"lang":"en","type":"article","venue":"Trials","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Taxane; Medicine; Debulking; Oncology; Ovarian cancer; Internal medicine; Chemotherapy; Docetaxel; Surgery; Cancer; Breast cancer","score_opus":0.13354845434484003,"score_gpt":0.4598511749932912,"score_spread":0.32630272064845117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396641051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5402889,0.000038879956,0.00006303142,0.00028304174,0.0008855842,0.45806012,0.00010021885,0.000042302498,0.00023788915],"genre_scores_gemma":[0.5007598,0.00001164367,0.00017176275,0.00007878956,0.00014881924,0.49834138,0.000055362434,0.00004550937,0.00038693807],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940304,0.0016051455,0.002531513,0.00070037076,0.0007201714,0.0004123701],"domain_scores_gemma":[0.99395907,0.0036449528,0.0013804446,0.00059368764,0.0003029808,0.0001188594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005414789,0.00049407815,0.0043566776,0.00026131596,0.00014967624,0.00017142975,0.00032365252,0.00012744247,0.0004820957],"category_scores_gemma":[0.00080293085,0.00026830248,0.00039770806,0.0004145081,0.00015494236,0.00014884619,0.000053930078,0.00021695449,0.0000027769354],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9698439,0.017662484,0.002525046,0.00007522285,0.0030791126,0.0000193704,0.0021123902,0.0002713096,0.00022869247,0.00012567209,0.00023967272,0.0038170796],"study_design_scores_gemma":[0.9757257,0.016726587,0.00041296487,0.0006667271,0.0011504377,7.8409784e-7,0.00021473113,0.0019423991,0.0018616423,0.000026969476,0.001007235,0.00026379555],"about_ca_topic_score_codex":0.0020865523,"about_ca_topic_score_gemma":0.0003037952,"teacher_disagreement_score":0.04028125,"about_ca_system_score_codex":0.0009039562,"about_ca_system_score_gemma":0.00082817505,"threshold_uncertainty_score":0.99997693},"labels":[],"label_agreement":null},{"id":"W4396669379","doi":"10.1016/j.dnarep.2024.103689","title":"DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors","year":2024,"lang":"en","type":"article","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Olaparib; Radiosensitizer; PARP inhibitor; Biology; Cancer research; Radioresistance; DNA repair; Radiosensitivity; DNA damage; Poly ADP ribose polymerase; Cancer cell; Cancer; Cell culture; Radiation therapy; DNA; Internal medicine; Medicine; Biochemistry; Genetics; Polymerase","score_opus":0.018501899627935726,"score_gpt":0.2893477540974099,"score_spread":0.2708458544694742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396669379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97887427,0.0039861538,0.000040537732,0.0085559245,0.0018600046,0.0011522012,0.00012942718,0.001248276,0.0041532344],"genre_scores_gemma":[0.9890017,0.0001744414,0.0005221339,0.0051529733,0.0013018281,0.00022878824,0.00012188146,0.00014949356,0.0033467738],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957658,0.0001179556,0.0010556695,0.0011838021,0.0010224129,0.0008543748],"domain_scores_gemma":[0.9981987,0.00012678023,0.00014663099,0.00093989464,0.00016082838,0.00042716248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007084327,0.00054466526,0.0008033908,0.0006296025,0.00011333891,0.00008951001,0.00014771246,0.00029525752,0.00051204755],"category_scores_gemma":[0.00009254925,0.0004921148,0.00062018645,0.001134519,0.0002578486,0.00021014827,0.00010056788,0.00072280393,0.0005165957],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017190464,0.0017942098,0.02794344,0.0016624571,0.0007833434,0.013500462,0.016392555,0.00007957191,0.19565795,0.0019309487,0.73163885,0.0068971477],"study_design_scores_gemma":[0.012078764,0.0016143176,0.061461754,0.0084943315,0.00046285312,0.0035795965,0.003783703,0.0091540525,0.42506132,0.0007413835,0.4712703,0.0022976361],"about_ca_topic_score_codex":0.00016634342,"about_ca_topic_score_gemma":0.000038871607,"teacher_disagreement_score":0.26036856,"about_ca_system_score_codex":0.0009924659,"about_ca_system_score_gemma":0.00057404017,"threshold_uncertainty_score":0.99975306},"labels":[],"label_agreement":null},{"id":"W4396864224","doi":"10.1038/s41467-024-48270-9","title":"Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","year":2024,"lang":"en","type":"erratum","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Senescence; Poly ADP ribose polymerase; Synthetic lethality; Cancer cell; Cancer; Computational biology; Cancer research; Biology; Chemistry; Cell biology; Genetics; DNA repair; DNA; Polymerase","score_opus":0.051417038738674,"score_gpt":0.37094956335246604,"score_spread":0.31953252461379206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396864224","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007262281,0.33803663,0.0020151187,0.14295037,0.15265813,0.0046323305,0.0027896238,0.0029956237,0.3466599],"genre_scores_gemma":[0.75117975,0.030524705,0.0016709488,0.001074599,0.004052181,0.0008701151,0.004062348,0.00022903497,0.20633629],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754727,0.00030840863,0.0006741897,0.0007186283,0.00039956413,0.00035193138],"domain_scores_gemma":[0.9963509,0.0005854459,0.00034887117,0.0019222762,0.0005662297,0.00022628678],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00032331047,0.00048101431,0.00066287385,0.00042537585,0.0005572033,0.00014130402,0.00043392173,0.0012286373,0.00045221412],"category_scores_gemma":[0.00027704446,0.0005028384,0.00024500585,0.0007631234,0.00028538436,0.00032773867,0.00046655996,0.00761656,0.00008980842],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034984616,0.00012349413,0.0002085737,0.0004916081,0.00024142805,0.000014775367,0.0011518755,0.0000021193698,0.001375655,0.00018360224,0.9928662,0.0033056673],"study_design_scores_gemma":[0.000548846,0.00010198526,0.00026820938,0.009700148,0.0010429376,0.0002738122,0.0016398433,0.0023036248,0.0014947924,0.00020010793,0.9818607,0.0005649731],"about_ca_topic_score_codex":0.0004528106,"about_ca_topic_score_gemma":0.0015080258,"teacher_disagreement_score":0.7439175,"about_ca_system_score_codex":0.0012143378,"about_ca_system_score_gemma":0.00063092395,"threshold_uncertainty_score":0.9997423},"labels":[],"label_agreement":null},{"id":"W4396939418","doi":"10.1016/j.isci.2024.109978","title":"CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"Cancer Council Queensland; Cancer Council NSW; National Health and Medical Research Council; Cancer Council South Australia; Medical Research Council; Cancer Council Tasmania; National Institutes of Health; Cooperative Research Centres, Australian Government Department of Industry; Cancer Council Victoria; Eisai; Australian Centre for Geomechanics; Sierra Oncology; University of Melbourne; Clovis Oncology; BeiGene; Australian Government; Medical Research and Materiel Command; Victorian Cancer Agency; University of Pennsylvania; Johns Hopkins University; AstraZeneca","keywords":"Ovarian cancer; PARP inhibitor; Cancer research; Chemistry; Medicine; Cancer; Poly ADP ribose polymerase; Internal medicine; DNA; Biochemistry; Polymerase","score_opus":0.032659306197201504,"score_gpt":0.3409201649224782,"score_spread":0.30826085872527664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396939418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96701026,0.007653509,0.0002537639,0.016741836,0.0014205251,0.000649739,0.00012371424,0.00016962577,0.005977001],"genre_scores_gemma":[0.9947446,0.0005401648,0.00034781639,0.0021284753,0.0005328152,0.00014766963,0.0000036544918,0.000025880687,0.0015289225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980299,0.000041048665,0.0003189634,0.0007053154,0.0004919857,0.00041278955],"domain_scores_gemma":[0.9992644,0.000103699975,0.000056526023,0.00029699222,0.000075255906,0.00020312799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035010243,0.00019876161,0.00027377793,0.00027687082,0.0001139885,0.00011757526,0.000121116114,0.000106402345,0.00037854712],"category_scores_gemma":[0.000060026676,0.0001686047,0.00005603589,0.0010064592,0.0003887511,0.00034559637,0.00006639502,0.00033961234,0.000052140167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013736938,0.00024158739,0.0062240567,0.00041642928,0.00007601585,0.0005216752,0.015217929,0.000014420821,0.83167356,0.0034924515,0.030995078,0.109753124],"study_design_scores_gemma":[0.004959813,0.0007267612,0.09819333,0.0045580785,0.00008391465,0.0001572061,0.0016612683,0.0014785249,0.6147012,0.0046489104,0.26790187,0.0009291008],"about_ca_topic_score_codex":0.00045128315,"about_ca_topic_score_gemma":0.00022442537,"teacher_disagreement_score":0.2369068,"about_ca_system_score_codex":0.0004151447,"about_ca_system_score_gemma":0.0005340516,"threshold_uncertainty_score":0.68755},"labels":[],"label_agreement":null},{"id":"W4397007301","doi":"10.1016/j.esmoop.2024.103220","title":"198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Japanese Society of Medical Oncology; Daewoong Pharmaceutical Company; Chugai Pharmaceutical; Seagen; Radius Health; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Immunotherapy; Cancer; Polymerase","score_opus":0.04492359654625794,"score_gpt":0.33558879898993604,"score_spread":0.2906652024436781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95125854,0.0029578565,0.009769526,0.011467115,0.0035009384,0.014580937,0.00073511107,0.0010094739,0.004720488],"genre_scores_gemma":[0.9596414,0.0010740486,0.008181576,0.008741322,0.0008756815,0.0065092063,0.0012426971,0.0006400651,0.013094005],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926797,0.00028438374,0.0019272451,0.0022339178,0.0014673065,0.0014074509],"domain_scores_gemma":[0.9957716,0.00041715582,0.000680502,0.0018291263,0.0006504454,0.0006511973],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006331427,0.0014040871,0.002497629,0.0005910351,0.00042652752,0.00091033423,0.00089611945,0.00047173162,0.006215059],"category_scores_gemma":[0.00012773919,0.0010365834,0.000574681,0.0011450456,0.00037162635,0.0013416819,0.00022568836,0.0011312678,0.00022043382],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61398643,0.003658763,0.003343382,0.0027497632,0.017201269,0.0036946756,0.034206174,0.001875063,0.002342561,0.00093007647,0.121770546,0.19424129],"study_design_scores_gemma":[0.30755496,0.015820848,0.025001802,0.0070127607,0.0033711244,0.0028238036,0.0027769636,0.019303298,0.0187287,0.0023494181,0.5898689,0.005387405],"about_ca_topic_score_codex":0.003446145,"about_ca_topic_score_gemma":0.0008229856,"teacher_disagreement_score":0.46809837,"about_ca_system_score_codex":0.003250182,"about_ca_system_score_gemma":0.004885531,"threshold_uncertainty_score":0.99987096},"labels":[],"label_agreement":null},{"id":"W4398174969","doi":"10.1101/2024.05.20.594972","title":"A PARP2-specific active site α-helix melts to permit DNA damage-induced enzymatic activation","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institutes of Health; University of Pennsylvania","keywords":"DNA damage; DNA; Helix (gastropod); Enzyme; Alpha (finance); Chemistry; Active site; Biophysics; Biochemistry; Biology","score_opus":0.0290935104986484,"score_gpt":0.2760991027193154,"score_spread":0.24700559222066704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398174969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887885,0.0005808805,0.00064331584,0.0031409634,0.0022305558,0.0028388477,0.00045184878,0.0010820241,0.00015270108],"genre_scores_gemma":[0.9917742,0.00019434452,0.0027625572,0.0015464982,0.0019834829,0.0012986996,0.0000037076145,0.0003815803,0.000054941283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99507356,0.0002149803,0.0009548011,0.0018811454,0.0010448371,0.0008306731],"domain_scores_gemma":[0.9954909,0.00015963918,0.0004881467,0.0022375819,0.00090952823,0.000714197],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006309223,0.0009975105,0.0011793262,0.0009828092,0.0001954797,0.00032992702,0.00045498702,0.00085379893,0.00042565184],"category_scores_gemma":[0.00026316862,0.0010567738,0.00037013547,0.0013823238,0.00010225947,0.00021245764,0.0006142267,0.0020115098,0.0016726529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040519956,0.00022826881,0.00024550312,0.0010813794,0.0004401796,0.00016126223,0.00023793844,0.000031256743,0.9925855,0.00046724416,0.0040922747,0.000023999726],"study_design_scores_gemma":[0.0014918564,0.00023149986,0.04600112,0.0045754816,0.0002894326,1.4024882e-7,0.00002409244,0.00020469596,0.9319422,0.000020943677,0.014099137,0.0011193873],"about_ca_topic_score_codex":0.000058078174,"about_ca_topic_score_gemma":0.000003632526,"teacher_disagreement_score":0.06064328,"about_ca_system_score_codex":0.0023025165,"about_ca_system_score_gemma":0.0013415805,"threshold_uncertainty_score":0.99918824},"labels":[],"label_agreement":null},{"id":"W4398175152","doi":"10.2139/ssrn.4834778","title":"A PARP2-Specific Active Site Α-Helix Melts to Permit DNA Damage-Induced Enzymatic Activation","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Helix (gastropod); DNA; Enzyme; DNA damage; Chemistry; Biophysics; Active site; Cell biology; Biochemistry; Biology","score_opus":0.027014359818847134,"score_gpt":0.31978015098823465,"score_spread":0.2927657911693875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398175152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745686,0.002956263,0.0033677178,0.0123547735,0.0016292369,0.0015971006,0.000053536736,0.00025072103,0.003222025],"genre_scores_gemma":[0.98749727,0.004044501,0.000293192,0.0009632895,0.0033220085,0.00024341948,0.00011728223,0.00021252793,0.0033065332],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9940785,0.0002618076,0.00093387114,0.0009647699,0.0011301608,0.0026309004],"domain_scores_gemma":[0.9975704,0.0001339976,0.00055234344,0.00085516565,0.0004610755,0.0004270251],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016229871,0.00071436464,0.0009529049,0.0009246905,0.00024583744,0.00024286266,0.00042655042,0.0005594189,0.00041991554],"category_scores_gemma":[0.00013189302,0.00066302746,0.00056205416,0.0006075491,0.00005570343,0.00017518664,0.0003511762,0.011273129,0.00085480546],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0071087996,0.001106525,0.0002396699,0.0014149667,0.007269375,0.0003834971,0.017977344,0.0007401301,0.7201848,0.0388056,0.016733637,0.18803565],"study_design_scores_gemma":[0.01019317,0.0045580994,0.0047286837,0.012392982,0.0016335445,0.0048200176,0.008491301,0.00073949853,0.19909921,0.72224337,0.027839674,0.003260463],"about_ca_topic_score_codex":0.00007768561,"about_ca_topic_score_gemma":0.00019070882,"teacher_disagreement_score":0.68343776,"about_ca_system_score_codex":0.011594189,"about_ca_system_score_gemma":0.008280271,"threshold_uncertainty_score":0.99992317},"labels":[],"label_agreement":null},{"id":"W4398188956","doi":"10.21037/tau-23-671","title":"Rucaparib monotherapy in the heavily pre-treated metastatic castrate-resistant prostate cancer setting: practical considerations and alternate treatment approaches","year":2024,"lang":"en","type":"editorial","venue":"Translational Andrology and Urology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Prostate cancer; Medicine; Oncology; Cancer; Gynecology; Internal medicine; Urology","score_opus":0.05990430698204948,"score_gpt":0.3624759638811003,"score_spread":0.30257165689905086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398188956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4847419,0.079690665,0.00027696532,0.31813464,0.10317096,0.0070694056,0.00523244,0.00024155104,0.0014414719],"genre_scores_gemma":[0.92542046,0.01024441,0.00093935925,0.0027654676,0.055660587,0.002367972,0.0018566161,0.00010309812,0.00064201496],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775153,0.00047932193,0.0005223147,0.00065036584,0.00025732015,0.00033913547],"domain_scores_gemma":[0.99769056,0.0018405464,0.00013679489,0.00016980882,0.00007494555,0.000087318185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000421464,0.00038589764,0.0006362534,0.00019133753,0.00015714385,0.00005345881,0.000036673595,0.00049474504,0.000119496406],"category_scores_gemma":[0.000037233665,0.0002586567,0.00008113658,0.00010964464,0.00055007363,0.00007543159,0.0000077316145,0.00083812536,0.0000040221516],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121716015,0.006330041,0.030374743,0.0033132033,0.018193392,0.014025635,0.06865591,0.0041211755,0.004818251,0.07617255,0.638259,0.014020089],"study_design_scores_gemma":[0.033357088,0.010592676,0.013033148,0.00026877454,0.0049751205,0.0057981447,0.00027346704,0.008118697,0.000245749,0.09650009,0.8255791,0.0012579109],"about_ca_topic_score_codex":0.00040962963,"about_ca_topic_score_gemma":0.0013446544,"teacher_disagreement_score":0.44067857,"about_ca_system_score_codex":0.000053837353,"about_ca_system_score_gemma":0.0007596132,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W4398782039","doi":"10.1007/s11239-024-02974-3","title":"Poly (ADP-ribose) Polymerase-1 modulations in the genesis of thrombosis","year":2024,"lang":"en","type":"review","venue":"Journal of Thrombosis and Thrombolysis","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Shastri Indo-Canadian Institute","keywords":"PARP1; Medicine; Immunology; Endothelial dysfunction; Cancer research; Pathogenesis; Endothelial activation; Inflammation; Platelet activation; Poly ADP ribose polymerase; Cell biology; Biology; Platelet; Internal medicine; Genetics; Polymerase","score_opus":0.12479942054944146,"score_gpt":0.4236530733260862,"score_spread":0.2988536527766448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398782039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043919,0.99150515,0.000068354195,0.002056473,0.0006809225,0.0006205298,0.00019681388,0.000020618754,0.00045923865],"genre_scores_gemma":[0.016331693,0.9814472,0.00064656086,0.00029710217,0.0010205983,0.000051945543,0.00003528789,0.000120614066,0.00004899124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99462676,0.00050875195,0.0027585588,0.00051642157,0.0011487675,0.00044071264],"domain_scores_gemma":[0.99621207,0.00056538486,0.0018762335,0.0008413324,0.00029585953,0.00020912178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014155973,0.00074399053,0.0048796306,0.0015116589,0.00013911293,0.00011649815,0.0005530077,0.0005087218,0.00035508003],"category_scores_gemma":[0.000091649265,0.00044345157,0.002345611,0.0021320288,0.0003615398,0.00026525886,0.00011202575,0.0011428803,0.000021355949],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012776347,0.0038436106,0.0030141491,0.055460483,0.030077573,0.00019750536,0.010125019,0.000013266612,0.0018040611,0.0028325312,0.03999703,0.852507],"study_design_scores_gemma":[0.0044058096,0.0023457217,0.026080493,0.115158126,0.094467595,0.002157604,0.003933301,0.00008828503,0.00040160897,0.0022273243,0.7465611,0.002172998],"about_ca_topic_score_codex":0.00022671495,"about_ca_topic_score_gemma":0.000015270516,"teacher_disagreement_score":0.850334,"about_ca_system_score_codex":0.00031099355,"about_ca_system_score_gemma":0.00068252726,"threshold_uncertainty_score":0.99980175},"labels":[],"label_agreement":null},{"id":"W4399072631","doi":"10.3390/cimb46060322","title":"Changing the Landscape of Solid Tumor Therapy from Apoptosis-Promoting to Apoptosis-Inhibiting Strategies","year":2024,"lang":"en","type":"review","venue":"Current Issues in Molecular Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cancer; Medicine; Clinical trial; Apoptosis; Cancer research; Oncology; Internal medicine; Biology; Genetics","score_opus":0.055893298451117825,"score_gpt":0.42729110599352166,"score_spread":0.3713978075424038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399072631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006024881,0.9890155,0.00086525606,0.0003517784,0.0015097333,0.0017166053,0.0002391334,0.000103457365,0.00017365644],"genre_scores_gemma":[0.0064210086,0.9904971,0.00052293204,0.00022017132,0.0010173799,0.000649546,0.0005202087,0.00013509377,0.000016565817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99633294,0.00053432584,0.0012376008,0.0009222016,0.00027920338,0.0006937203],"domain_scores_gemma":[0.99834406,0.00022216659,0.0004866955,0.00072510133,0.00010962471,0.000112343834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007081845,0.000702205,0.0023159992,0.0008122551,0.00007048295,0.000055405122,0.00050534814,0.000310584,0.00010493472],"category_scores_gemma":[0.00012405445,0.00045908405,0.0006548031,0.0012518296,0.00018034338,0.00004134183,0.00027023166,0.0010160457,0.00007653604],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060377966,0.00020848651,0.000021258633,0.011192312,0.0007386926,0.000029374318,0.0036905443,0.000008702538,0.0122830225,0.0015008862,0.0005241028,0.96974224],"study_design_scores_gemma":[0.0009888171,0.0005980848,9.3574266e-7,0.082100846,0.00088188547,0.00004336555,0.0013548731,0.00004586753,0.04152082,0.0019905868,0.8696117,0.0008622247],"about_ca_topic_score_codex":0.000022299575,"about_ca_topic_score_gemma":0.0000021145565,"teacher_disagreement_score":0.96888,"about_ca_system_score_codex":0.0001390402,"about_ca_system_score_gemma":0.0003480937,"threshold_uncertainty_score":0.9997861},"labels":[],"label_agreement":null},{"id":"W4399121924","doi":"10.1200/jco.2024.42.16_suppl.531","title":"PARPi eligibility amongst women with newly diagnosed invasive breast cancer enrolled in the GREAT universal genetic testing study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; St Mary's Hospital Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Genetic testing; Breast cancer; Oncology; Cancer; Internal medicine; Gynecology","score_opus":0.10453447063581303,"score_gpt":0.4549896726979898,"score_spread":0.35045520206217673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399121924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743784,0.0005461006,0.000033585573,0.009755453,0.0006613497,0.000629275,0.00000958568,0.000019122454,0.0009076821],"genre_scores_gemma":[0.99445444,0.00060916337,0.0005802793,0.0027471385,0.0014592712,0.00005969215,4.5459353e-7,0.000022028964,0.000067536545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960615,0.0010833528,0.0016976225,0.00031558823,0.0005222285,0.00031969653],"domain_scores_gemma":[0.98941606,0.008867878,0.0007326964,0.0002704438,0.00043803337,0.00027487267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040193005,0.00018205371,0.0011882886,0.00016683136,0.00005027954,0.000030474286,0.00025710842,0.00019723366,0.00030265737],"category_scores_gemma":[0.0015867378,0.00009982101,0.00017158013,0.0006127893,0.0003354126,0.00013253289,0.000036863763,0.0014155278,0.000009884677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009560622,0.0018263914,0.87760603,0.000050179857,0.00055987306,0.010306415,0.0032098042,0.00031964137,0.00010362198,0.000006834569,0.0018907156,0.09455989],"study_design_scores_gemma":[0.017780283,0.015785534,0.9576795,0.00043452735,0.00027816344,0.0011944465,0.003674602,0.00010582139,0.0000072734856,0.00025678662,0.0026914645,0.00011161006],"about_ca_topic_score_codex":0.0003360005,"about_ca_topic_score_gemma":0.0011092873,"teacher_disagreement_score":0.09444828,"about_ca_system_score_codex":0.0008734994,"about_ca_system_score_gemma":0.004703077,"threshold_uncertainty_score":0.83430564},"labels":[],"label_agreement":null},{"id":"W4399282503","doi":"10.1101/2024.05.31.596824","title":"The tumor-maintaining function of UTX/KDM6A in DNA replication and the PARP1-dependent repair pathway","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Replication (statistics); DNA replication; Function (biology); PARP1; DNA; Cell biology; Chemistry; Biology; Genetics; Poly ADP ribose polymerase; Virology; Polymerase","score_opus":0.014958921528741263,"score_gpt":0.24771327888328667,"score_spread":0.23275435735454542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399282503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829082,0.00944533,0.00035716023,0.0032402547,0.001342762,0.0020672171,0.00008610194,0.0004414522,0.00011155776],"genre_scores_gemma":[0.99649894,0.0011172502,0.00030662518,0.00052471866,0.0004824031,0.0009442108,4.682722e-7,0.000100309786,0.000025095276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968382,0.00033613024,0.0009206075,0.0010045252,0.00053095707,0.00036958366],"domain_scores_gemma":[0.9964475,0.00033885826,0.0005696158,0.0021472375,0.00037434307,0.00012243495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033537315,0.00038723194,0.00060381874,0.00023082696,0.00017300989,0.000106682,0.0002564455,0.00028130153,0.000020396665],"category_scores_gemma":[0.0005318906,0.00026595095,0.00021078691,0.00050201686,0.00042900577,0.000057505204,0.00039910313,0.0012048297,0.000018058647],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004483709,0.00035026163,0.01823207,0.002945913,0.0013171532,0.00020705862,0.00037079168,0.00017663896,0.89252037,0.07757452,0.0016351851,0.00018630523],"study_design_scores_gemma":[0.01171256,0.0006322586,0.23030123,0.008102466,0.0010321497,0.0000013939871,0.00026187155,0.005501025,0.6830653,0.001543839,0.056196574,0.0016493256],"about_ca_topic_score_codex":0.00008791499,"about_ca_topic_score_gemma":0.000011381186,"teacher_disagreement_score":0.21206917,"about_ca_system_score_codex":0.00047094174,"about_ca_system_score_gemma":0.00063610345,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W4399316087","doi":"10.1016/j.ygyno.2024.03.009","title":"Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; LEO Pharma; PharmaMar; European Society for Medical Oncology; Juno Therapeutics; Eisai; Seagen; Pfizer; Incyte; ANGLE; Mersana Therapeutics; Syndax Pharmaceuticals; Clovis Oncology; Ludwig Institute for Cancer Research; Fujirebio US; Teva Pharmaceutical Industries; Atara Biotherapeutics; Sanofi; Amgen; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Ovarian cancer; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.019324522038202896,"score_gpt":0.3192194002741925,"score_spread":0.2998948782359896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399316087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993224,0.0018286172,0.000019295869,0.004339938,0.0007256934,0.0019348592,0.00020758786,0.000055442626,0.0009563278],"genre_scores_gemma":[0.9959457,0.0016014933,0.0008352311,0.0010056233,0.00019781271,0.00019550174,0.0000846995,0.000021901453,0.00011205553],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99816686,0.00029446738,0.0005425254,0.0005090268,0.00019685955,0.0002902665],"domain_scores_gemma":[0.9973919,0.001988967,0.00018764217,0.00028522604,0.000058144113,0.00008816601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056308345,0.00018744785,0.0005810347,0.00009740345,0.0000611876,0.000014091166,0.00010209727,0.000253277,0.00019270819],"category_scores_gemma":[0.0003665451,0.00012387092,0.0000393999,0.00028933506,0.0003618777,0.00007253608,0.00006573402,0.00044500685,0.000004117084],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2975991,0.0015009369,0.060493626,0.00010819829,0.00057648844,0.00024567466,0.008572495,0.000103707374,0.0014687836,0.0005457718,0.0058806115,0.6229046],"study_design_scores_gemma":[0.16572161,0.004840259,0.8034177,0.00021613263,0.000113642614,0.000006158778,0.00015377124,0.000029687135,0.0001148909,0.00025046253,0.02499368,0.00014203937],"about_ca_topic_score_codex":0.00032530248,"about_ca_topic_score_gemma":0.0006872861,"teacher_disagreement_score":0.74292403,"about_ca_system_score_codex":0.00035544083,"about_ca_system_score_gemma":0.00041231886,"threshold_uncertainty_score":0.505131},"labels":[],"label_agreement":null},{"id":"W4399324904","doi":"10.1200/jco.2024.42.16_suppl.2013","title":"A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; Princess Margaret Cancer Centre","funders":"Fondation Brain Canada","keywords":"Medicine; Durvalumab; Olaparib; Oncology; Internal medicine; Cancer research; Cancer; Genetics; Gene; Immunotherapy; Poly ADP ribose polymerase; Nivolumab","score_opus":0.11197130207715664,"score_gpt":0.5119855964718868,"score_spread":0.40001429439473013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934104,0.00064619735,0.00003897514,0.002978505,0.0018645342,0.00037211334,0.000010780401,0.000007975871,0.00067051227],"genre_scores_gemma":[0.99789214,0.000495473,0.0005859838,0.0003657283,0.0005944615,0.0000059515883,0.0000045274014,0.0000138659625,0.000041886797],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99676526,0.0003401262,0.0021869792,0.00016869797,0.0003923817,0.00014655002],"domain_scores_gemma":[0.9974658,0.000996983,0.0008853811,0.00011162999,0.00033061538,0.00020960256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00234323,0.000107666056,0.0011723333,0.0002618497,0.000017110011,0.0000059175077,0.00006676475,0.00023074461,0.00009898598],"category_scores_gemma":[0.0010724537,0.00007029875,0.00018636089,0.00028982083,0.00023660106,0.00010194273,0.000026058511,0.0008532279,0.000002339597],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5280251,0.016396098,0.0062421104,0.00009322865,0.0004802218,0.0005526723,0.00035357184,0.0000032125208,0.00016148627,0.00009404032,0.0029244293,0.44467384],"study_design_scores_gemma":[0.6348906,0.2955498,0.021128694,0.001002211,0.00035033622,0.00013109644,0.000039880983,0.00014845912,0.00017019942,0.0004933603,0.045987636,0.000107714164],"about_ca_topic_score_codex":0.000006566968,"about_ca_topic_score_gemma":0.000012211947,"teacher_disagreement_score":0.44456613,"about_ca_system_score_codex":0.00015594624,"about_ca_system_score_gemma":0.0013907118,"threshold_uncertainty_score":0.3706898},"labels":[],"label_agreement":null},{"id":"W4399365134","doi":"10.1016/j.isci.2024.110180","title":"A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Structural Genomics Consortium; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Women's College Hospital","funders":"Canada Research Chairs; Human Frontier Science Program; Canada Foundation for Innovation; Cancer Prevention Initiative","keywords":"PARP inhibitor; Poly ADP ribose polymerase; Throughput; Sensitivity (control systems); Chemistry; High-throughput screening; Computational biology; Computer science; Biology; Biochemistry; DNA; Engineering; Polymerase; Telecommunications","score_opus":0.03343466005271373,"score_gpt":0.3697476581549479,"score_spread":0.3363129981022342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399365134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84872234,0.0004829514,0.13222705,0.008137834,0.0015936971,0.00076922687,0.00003512558,0.00042016822,0.007611615],"genre_scores_gemma":[0.9636503,0.0000067358083,0.028991614,0.004947485,0.00084760005,0.00009589717,0.000008335847,0.00003102377,0.0014210481],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99728495,0.0000810079,0.00035421934,0.0009576815,0.0008007875,0.0005213686],"domain_scores_gemma":[0.9987543,0.00015765357,0.00004853466,0.00053471397,0.00013876983,0.00036600957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010198922,0.00022646444,0.00033152866,0.00023065748,0.00021136833,0.00023951443,0.00016705976,0.000074093936,0.000045083205],"category_scores_gemma":[0.00015553509,0.00020645297,0.000093196366,0.0016527992,0.00020343145,0.0003490937,0.00015766852,0.0002605187,0.00055788254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059722544,0.0001159698,0.00016893276,0.00013116177,0.00001963239,0.000078794386,0.0026499166,0.0008535158,0.94378716,0.0015808248,0.03591807,0.014636304],"study_design_scores_gemma":[0.0007737556,0.0005554477,0.021608068,0.0017867049,0.000060479568,0.0006794926,0.00050495524,0.00902702,0.86935014,0.0011125639,0.09358631,0.00095509033],"about_ca_topic_score_codex":0.00013375263,"about_ca_topic_score_gemma":0.00001852754,"teacher_disagreement_score":0.11492793,"about_ca_system_score_codex":0.00036905066,"about_ca_system_score_gemma":0.00021937887,"threshold_uncertainty_score":0.84189075},"labels":[],"label_agreement":null},{"id":"W4399380532","doi":"10.1200/jco.2024.42.16_suppl.5599","title":"Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Durvalumab; Tolerability; Paclitaxel; Olaparib; Carboplatin; Endometrial cancer; Oncology; Internal medicine; Gynecology; Atezolizumab; Cancer; Urology; Chemotherapy; Cisplatin; Adverse effect; Immunotherapy; Nivolumab","score_opus":0.0789982247170708,"score_gpt":0.45499178659023803,"score_spread":0.37599356187316724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98596853,0.0030922485,0.00007070095,0.005030522,0.003381384,0.0019245913,0.00011406309,0.000012467911,0.00040552134],"genre_scores_gemma":[0.9936316,0.0040412694,0.0007004073,0.0007522601,0.00071234634,0.00006568351,0.000013662949,0.00003245557,0.000050293882],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99113435,0.002242037,0.0047588954,0.00048397598,0.0009873825,0.0003933596],"domain_scores_gemma":[0.9804773,0.016521702,0.0019064335,0.0003780205,0.00043894892,0.0002775925],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009086075,0.00030033945,0.002742306,0.00034819925,0.00004696889,0.00002275502,0.0002677565,0.0004633901,0.00025366817],"category_scores_gemma":[0.010855,0.000171879,0.00041813913,0.00095492153,0.0004187139,0.00025752248,0.00004122891,0.0019766632,0.000001651558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67519087,0.0057608443,0.10509248,0.00016778582,0.00048372374,0.00029128394,0.0012690772,0.00008706625,0.00007783556,0.000081221275,0.0030720425,0.2084258],"study_design_scores_gemma":[0.5916226,0.061745245,0.30614772,0.0014910741,0.0004953975,0.000041953725,0.000361542,0.00015420234,0.00005779266,0.0004946937,0.037074044,0.0003137487],"about_ca_topic_score_codex":0.00021487691,"about_ca_topic_score_gemma":0.0011987359,"teacher_disagreement_score":0.20811205,"about_ca_system_score_codex":0.00078579836,"about_ca_system_score_gemma":0.0033437766,"threshold_uncertainty_score":0.997477},"labels":[],"label_agreement":null},{"id":"W4399380599","doi":"10.1200/jco.2024.42.16_suppl.5554","title":"Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Placebo; Ovarian cancer; Double blind; Randomized controlled trial; Oncology; Internal medicine; Surgery; Cancer; Alternative medicine","score_opus":0.16616123566817184,"score_gpt":0.5008747153787974,"score_spread":0.3347134797106255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399380599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698541,0.0017321857,0.0012541189,0.0147209875,0.004152358,0.0066634174,0.0001657192,0.00004510387,0.0014119734],"genre_scores_gemma":[0.97800124,0.0054504387,0.0055010323,0.0027655936,0.0062302537,0.001086868,0.000086396976,0.00010368338,0.00077451265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98841786,0.0024472051,0.0066859713,0.0007715829,0.0010839413,0.0005934235],"domain_scores_gemma":[0.97635996,0.018291522,0.0035540408,0.0004929203,0.00070508313,0.0005964501],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010581246,0.0005385587,0.005331063,0.00038266936,0.000099844736,0.000070977934,0.00029137815,0.00064218894,0.0006760843],"category_scores_gemma":[0.0044080545,0.00032457945,0.0014029451,0.00040656,0.00040495227,0.00027684987,0.000028879427,0.001655151,0.000033571854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83645624,0.005359791,0.0006780923,0.000012024437,0.0028101394,0.0008529339,0.0011342879,0.00064033654,0.000020744905,0.00010831596,0.000864363,0.15106271],"study_design_scores_gemma":[0.9205303,0.05765567,0.0007609845,0.0011103123,0.0014982027,0.000037821726,0.00010463092,0.0032149132,0.000036063015,0.000714828,0.014044398,0.0002918479],"about_ca_topic_score_codex":0.0014027338,"about_ca_topic_score_gemma":0.0005102349,"teacher_disagreement_score":0.15077087,"about_ca_system_score_codex":0.0019790742,"about_ca_system_score_gemma":0.00804801,"threshold_uncertainty_score":0.9999206},"labels":[],"label_agreement":null},{"id":"W4399394481","doi":"10.1200/jco.2024.42.16_suppl.5023","title":"Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Placebo; Oncology; Internal medicine; Cancer; Pathology; Prostate cancer; Alternative medicine","score_opus":0.11996644588690984,"score_gpt":0.46293829670586434,"score_spread":0.3429718508189545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453914,0.0005075285,0.000055512744,0.0007122238,0.00039500633,0.0036791516,0.000054378455,0.0000091065995,0.00004795398],"genre_scores_gemma":[0.99855447,0.0002327385,0.00070042606,0.000095026124,0.000089720575,0.00023692872,0.000030198149,0.00003330766,0.000027158385],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99559826,0.00044035472,0.0028445052,0.0003726248,0.0004970136,0.00024723657],"domain_scores_gemma":[0.99431753,0.0029915576,0.0018777382,0.00015285425,0.0004648393,0.00019548844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017314536,0.00025035333,0.0014207117,0.00040985912,0.000041376763,0.000015975169,0.000072956085,0.00011558133,0.000035485537],"category_scores_gemma":[0.0010132934,0.00018230586,0.00017046841,0.0003920274,0.00019456964,0.00031521177,0.000020113028,0.00034789453,0.0000011595254],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35452607,0.081709996,0.44313633,0.0033974885,0.0030266563,0.0029592249,0.017353173,0.009473737,0.014716329,0.000063587955,0.00015707269,0.069480315],"study_design_scores_gemma":[0.41161653,0.40549463,0.1413197,0.005744624,0.0030052294,0.00016770612,0.008343201,0.009048276,0.013045202,0.00034737805,0.0013071921,0.0005603267],"about_ca_topic_score_codex":0.00032432622,"about_ca_topic_score_gemma":0.0007656235,"teacher_disagreement_score":0.32378465,"about_ca_system_score_codex":0.00063161616,"about_ca_system_score_gemma":0.0019138802,"threshold_uncertainty_score":0.7434217},"labels":[],"label_agreement":null},{"id":"W4399394861","doi":"10.1200/jco.2024.42.16_suppl.5063","title":"Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Enzalutamide; Eribulin; Abiraterone; Olaparib; Prostate cancer; Prednisone; CYP17A1; Internal medicine; Bicalutamide; Oncology; Prednisolone; Urology; Androgen receptor; Cancer; Metastatic breast cancer; Poly ADP ribose polymerase; Breast cancer","score_opus":0.1287155339789746,"score_gpt":0.4297501000838353,"score_spread":0.3010345661048607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909282,0.003020563,0.0007641161,0.0021888064,0.0011147115,0.0016549386,0.00023167153,0.000046205794,0.000050832805],"genre_scores_gemma":[0.990746,0.00198956,0.00651366,0.00020827807,0.00015159567,0.00016788633,0.000100130856,0.000052803753,0.00007005765],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9956362,0.0004502603,0.0026529306,0.00045846385,0.00045784822,0.00034429075],"domain_scores_gemma":[0.9940523,0.0030783575,0.0016927557,0.00021117851,0.0007114917,0.00025394655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020367089,0.00030916536,0.0018026554,0.00041871358,0.00012011256,0.00004117532,0.00009876709,0.00029779918,0.000035466357],"category_scores_gemma":[0.00053363177,0.00024060595,0.0002232912,0.00039146957,0.0004956081,0.0003384739,0.000034421308,0.00082865794,9.2138595e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5053562,0.013807483,0.2451418,0.0037995477,0.012717742,0.0013743993,0.02618224,0.022298811,0.004212267,0.0016494134,0.0038924608,0.15956767],"study_design_scores_gemma":[0.20399608,0.08738004,0.6826563,0.0023899488,0.0023007377,0.00029102986,0.0016749571,0.011048179,0.0013571596,0.0029061968,0.003283154,0.0007162125],"about_ca_topic_score_codex":0.00025533847,"about_ca_topic_score_gemma":0.001976484,"teacher_disagreement_score":0.4375145,"about_ca_system_score_codex":0.00072873826,"about_ca_system_score_gemma":0.0021067536,"threshold_uncertainty_score":0.9811626},"labels":[],"label_agreement":null},{"id":"W4399394934","doi":"10.1200/jco.2024.42.16_suppl.5020","title":"Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Placebo; Oncology; Internal medicine; Cancer; Alternative medicine; Prostate cancer; Pathology; Androgen receptor","score_opus":0.14268424787588121,"score_gpt":0.5026659190322387,"score_spread":0.3599816711563575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914181,0.0007506459,0.000035221507,0.0017750455,0.0005355974,0.005191912,0.00016562895,0.000013433822,0.0001143721],"genre_scores_gemma":[0.99818844,0.00024247015,0.0006167642,0.00012530833,0.00016203547,0.00047809308,0.000026530295,0.00004458399,0.00011578224],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99340206,0.0006931215,0.0042695976,0.000506274,0.0007383557,0.00039058318],"domain_scores_gemma":[0.9921927,0.0044547683,0.0020257735,0.00030770185,0.00072351395,0.00029552783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026713873,0.00035005496,0.0023404195,0.0004892307,0.000037506103,0.000016407153,0.00016037385,0.00020482992,0.00018919619],"category_scores_gemma":[0.002656129,0.00023960127,0.000373301,0.0006150501,0.00033243926,0.00018197211,0.000032622487,0.00057606364,0.0000032010041],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40896907,0.096273355,0.32543245,0.0012300886,0.003993557,0.0023186128,0.007321156,0.0011457305,0.0015346771,0.00003808496,0.0003510346,0.15139218],"study_design_scores_gemma":[0.28060156,0.275912,0.42451134,0.003252101,0.0025232425,0.00013885011,0.0015702574,0.0032519752,0.00179882,0.00036431913,0.005690816,0.000384755],"about_ca_topic_score_codex":0.000978796,"about_ca_topic_score_gemma":0.0034917102,"teacher_disagreement_score":0.17963862,"about_ca_system_score_codex":0.0006518489,"about_ca_system_score_gemma":0.004296744,"threshold_uncertainty_score":0.9770656},"labels":[],"label_agreement":null},{"id":"W4399394976","doi":"10.1200/jco.2024.42.16_suppl.5021","title":"Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Non-negative matrix factorization; Homologous recombination; Internal medicine; Matrix decomposition; Genetics; Cancer; Gene; Biology","score_opus":0.11696609909049363,"score_gpt":0.4567513490374288,"score_spread":0.33978524994693515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399394976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349695,0.0002812295,0.002238684,0.00083763653,0.00040863123,0.002583941,0.00012212177,0.00000894656,0.0000218813],"genre_scores_gemma":[0.9982889,0.0003968252,0.0008306105,0.000057300655,0.0000605126,0.00024803448,0.000055136818,0.000029887211,0.000032767326],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9953572,0.00044872102,0.0029240155,0.00040224916,0.0006371571,0.00023064046],"domain_scores_gemma":[0.99555737,0.0013973583,0.0021081918,0.00017585265,0.0006360136,0.00012521079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001490087,0.00027784894,0.0013983167,0.0006252758,0.00004123281,0.000027882941,0.000084074134,0.0001632033,0.000018483046],"category_scores_gemma":[0.00077357015,0.00020089776,0.00014422869,0.00069137826,0.00022337088,0.00063349894,0.000018100436,0.00045153187,5.628133e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22423306,0.13443233,0.49705148,0.0016540337,0.0015506195,0.00146576,0.02477452,0.053266216,0.016312456,0.00029444887,0.00004284459,0.04492224],"study_design_scores_gemma":[0.29856178,0.34332564,0.31072503,0.0041511767,0.0015881512,0.00009420439,0.0045758826,0.018077869,0.0172467,0.0010048925,0.00006825013,0.0005804232],"about_ca_topic_score_codex":0.0008164968,"about_ca_topic_score_gemma":0.003727007,"teacher_disagreement_score":0.2088933,"about_ca_system_score_codex":0.0013195681,"about_ca_system_score_gemma":0.0028517882,"threshold_uncertainty_score":0.8192373},"labels":[],"label_agreement":null},{"id":"W4399395213","doi":"10.1200/jco.2024.42.16_suppl.5595","title":"Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by <i>BRCA1</i>/<i>BRCA2</i> mutation (BRCAm) status.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Paclitaxel; Carboplatin; Olaparib; Endometrial cancer; Oncology; Gynecology; Cancer; Internal medicine; Urology; Chemotherapy; Cisplatin; Immunotherapy; Nivolumab","score_opus":0.12658107772163069,"score_gpt":0.4967792795174652,"score_spread":0.3701982017958345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399395213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9175386,0.028779183,0.0010749141,0.028986774,0.015842244,0.003898749,0.0027399838,0.000120523146,0.0010190596],"genre_scores_gemma":[0.9346081,0.050219174,0.003982505,0.00321964,0.003864127,0.00091740437,0.00060501485,0.00016962156,0.0024144077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900684,0.0009141674,0.0061671627,0.00093060057,0.0010299409,0.0008897782],"domain_scores_gemma":[0.9749347,0.020334926,0.002687621,0.00044286193,0.00072235224,0.00087752705],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004310841,0.0005866847,0.0031435455,0.00054062204,0.00012446802,0.00006534462,0.0002694303,0.00083722454,0.00040399985],"category_scores_gemma":[0.017480452,0.00043247658,0.001180897,0.001003557,0.00027996863,0.0004056857,0.000044507055,0.0014185188,0.000025504069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2356489,0.0069632237,0.0013885794,0.00025190684,0.0019735089,0.0019397553,0.0012700673,0.00078228366,0.0021193528,0.000087205364,0.22299503,0.5245802],"study_design_scores_gemma":[0.22908996,0.07342731,0.0010457843,0.0012730683,0.0010123178,0.00021806406,0.00023257452,0.0011203523,0.0020734551,0.0009326239,0.6890871,0.0004873807],"about_ca_topic_score_codex":0.00067228917,"about_ca_topic_score_gemma":0.0024094959,"teacher_disagreement_score":0.5240928,"about_ca_system_score_codex":0.0038043372,"about_ca_system_score_gemma":0.006584851,"threshold_uncertainty_score":0.9998127},"labels":[],"label_agreement":null},{"id":"W4399471862","doi":"10.1007/s00018-024-05292-2","title":"Poly (ADP-ribose) polymerase 1 promotes HuR/ELAVL1 cytoplasmic localization and inflammatory gene expression by regulating p38 MAPK activity","year":2024,"lang":"en","type":"article","venue":"Cellular and Molecular Life Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; People's Government of Jilin Province; Natural Science Foundation of Jilin Province; McGill University Health Centre; National Natural Science Foundation of China; McGill University","keywords":"Cell biology; p38 mitogen-activated protein kinases; Biology; Gene knockdown; Phosphorylation; PARP1; Messenger RNA; Molecular biology; Protein kinase A; Poly ADP ribose polymerase; Polymerase; Biochemistry; Gene","score_opus":0.012141445808864247,"score_gpt":0.26634204907602016,"score_spread":0.25420060326715593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399471862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9213437,0.03896202,0.037732363,0.0009692507,0.00020856259,0.00029147303,0.00001308751,0.00011107605,0.0003684897],"genre_scores_gemma":[0.9978831,0.00031422218,0.0009156983,0.0004889494,0.00014666472,0.000021155494,0.000022697688,0.000023634359,0.0001839258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984439,0.00009720757,0.00021675148,0.0005580041,0.00041694188,0.0002671964],"domain_scores_gemma":[0.99942744,0.000046297377,0.00007249635,0.00017892773,0.00003604769,0.0002388147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039661958,0.00019335642,0.00020553754,0.00015821455,0.0003029673,0.00013125947,0.00007432617,0.00010913976,0.00003984108],"category_scores_gemma":[0.000058167516,0.00016365648,0.00005271496,0.00031914026,0.0004660948,0.00026896645,0.000062853695,0.00013040175,0.000003992737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003270144,0.000025961808,0.00073093484,0.00015413768,0.00001846444,0.000046044377,0.00034565516,0.00000957672,0.9940071,0.0001509184,0.0005505658,0.0039279093],"study_design_scores_gemma":[0.00048040276,0.00014904415,0.00009934116,0.0003786208,0.0000367088,0.00005676374,0.00011067691,0.009089837,0.98711073,0.00025010036,0.0020480666,0.0001897082],"about_ca_topic_score_codex":0.00002218937,"about_ca_topic_score_gemma":7.296989e-7,"teacher_disagreement_score":0.076539375,"about_ca_system_score_codex":0.00003422597,"about_ca_system_score_gemma":0.00020372016,"threshold_uncertainty_score":0.6673718},"labels":[],"label_agreement":null},{"id":"W4399504653","doi":"10.1158/1538-8514.synthleth24-a019","title":"Abstract A019: Inhibition of nicotinamide adenine dinucleotide (NAD) production is a potent therapeutic strategy to inactivate homologous recombination in cancer cells","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"","keywords":"RAD51; Synthetic lethality; Olaparib; DNA repair; Homologous recombination; Genome instability; Biology; Poly ADP ribose polymerase; PALB2; NAD+ kinase; Cancer cell; DNA damage; Cancer research; PARP inhibitor; Nicotinamide phosphoribosyltransferase; Cancer; Cell biology; DNA; Mutation; Genetics; Biochemistry; Germline mutation; Enzyme; Polymerase; Gene","score_opus":0.03737261863275776,"score_gpt":0.3369266505763999,"score_spread":0.29955403194364216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97206664,0.0113489395,0.0016004753,0.01164327,0.0011688871,0.001499413,0.000090412934,0.00016089596,0.0004210414],"genre_scores_gemma":[0.99147844,0.0038046404,0.00026695995,0.0031727103,0.00019411977,0.0004588689,0.000031037744,0.00012707434,0.0004661393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972802,0.00011316017,0.0007416332,0.00076479325,0.0006060389,0.0004941788],"domain_scores_gemma":[0.998826,0.000043195367,0.00021236805,0.00047789622,0.00030247399,0.00013801565],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003507728,0.00040048605,0.0005168203,0.00059653365,0.000060189486,0.000057474208,0.0001356109,0.00022802108,0.00037094968],"category_scores_gemma":[0.000009093325,0.00039318769,0.0002025458,0.0012115896,0.00011807774,0.00020449697,0.000034304383,0.000575114,0.000027531694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005304798,0.00035277594,0.00045857756,0.00044468217,0.00032554823,0.00009566085,0.0010888488,0.0035125723,0.89328694,0.00027310077,0.0003370292,0.099293776],"study_design_scores_gemma":[0.0013769811,0.00066549674,0.007463553,0.0017288373,0.00022407166,0.00003668155,0.00017596784,0.0007907123,0.98198795,0.0023453422,0.0028039885,0.00040044205],"about_ca_topic_score_codex":0.00083111564,"about_ca_topic_score_gemma":0.00014716446,"teacher_disagreement_score":0.09889334,"about_ca_system_score_codex":0.001398995,"about_ca_system_score_gemma":0.0005346751,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W4399504666","doi":"10.1158/1538-8514.synthleth24-a004","title":"Abstract A004: Radiotherapy sensitizes preclinical models to DNA damage response agents","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Radiation therapy; In vivo; Cancer research; DNA damage; Pharmacology; Viability assay; Medicine; Cancer; In vitro; Biology; Internal medicine; DNA; Biochemistry","score_opus":0.10184426850061963,"score_gpt":0.40615270182311075,"score_spread":0.30430843332249113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9296116,0.016873933,0.025153227,0.023615016,0.0013411427,0.0011897113,0.00013664429,0.00057084835,0.0015078313],"genre_scores_gemma":[0.9575801,0.0019955274,0.0028907293,0.035499327,0.0005112894,0.00020457782,0.000023598343,0.00021303771,0.0010818461],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971567,0.00021739553,0.0005698269,0.0007693967,0.0007181208,0.0005685812],"domain_scores_gemma":[0.99833196,0.00022978084,0.000072746734,0.00083795656,0.00016688427,0.00036068045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000674524,0.0004171154,0.00051826175,0.000285837,0.000091929694,0.0001733695,0.00022164155,0.00026468857,0.0006706861],"category_scores_gemma":[0.000016238551,0.0003911634,0.0003638207,0.0005750241,0.00014116373,0.0001740278,0.000042195003,0.0005265581,0.00012350566],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005933381,0.00020488529,0.000060726717,0.00017032435,0.0012900509,0.0011639408,0.0023043635,0.004054113,0.9399519,0.00047678655,0.0042617507,0.040127754],"study_design_scores_gemma":[0.0058362847,0.0012473767,0.0053613684,0.0019050827,0.0006317793,0.00019569717,0.00022483688,0.027961273,0.40861207,0.0030819334,0.5436012,0.0013410756],"about_ca_topic_score_codex":0.000043166925,"about_ca_topic_score_gemma":0.00000837576,"teacher_disagreement_score":0.5393395,"about_ca_system_score_codex":0.0006342915,"about_ca_system_score_gemma":0.00060552306,"threshold_uncertainty_score":0.999854},"labels":[],"label_agreement":null},{"id":"W4399504926","doi":"10.1158/1538-8514.synthleth24-a018","title":"Abstract A018: STRIDE as a technology platform for accurate measurement of DNA breaks and breaks-associated repair proteins","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DNA repair; DNA damage; DNA; Synthetic lethality; Computational biology; Biology; Genetics","score_opus":0.05037764949518274,"score_gpt":0.3367402551636608,"score_spread":0.28636260566847804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94408596,0.03858323,0.0047385357,0.006859121,0.00046498634,0.0031829544,0.00030499394,0.00072811404,0.0010521295],"genre_scores_gemma":[0.99603164,0.0011791799,0.00069472875,0.001117821,0.00007888493,0.0006741089,0.000023073098,0.00009212514,0.00010841385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810547,0.000021645317,0.0004936824,0.00044776674,0.0005419295,0.0003895207],"domain_scores_gemma":[0.99883604,0.000048419977,0.00017813157,0.00040174922,0.00043945602,0.00009617843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004301911,0.00028615794,0.0004480427,0.00026583642,0.00007435112,0.000032593227,0.000120792596,0.0002998026,0.00006137344],"category_scores_gemma":[0.00004355779,0.00026132376,0.00022404408,0.0004775079,0.00017740706,0.00007802397,0.000033638706,0.00031772902,0.0000045716397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006180497,0.00020059674,0.0002495759,0.0006708643,0.0021427458,0.00007398556,0.00034535045,0.000023655775,0.94928676,0.001805245,0.00028367635,0.044299513],"study_design_scores_gemma":[0.004068531,0.0009614646,0.0014747782,0.0018045575,0.00069043605,0.000070641865,0.00016952776,0.0008685212,0.9278569,0.0059647635,0.055675864,0.00039397783],"about_ca_topic_score_codex":0.0001209386,"about_ca_topic_score_gemma":0.00007144824,"teacher_disagreement_score":0.055392187,"about_ca_system_score_codex":0.0005421587,"about_ca_system_score_gemma":0.0007036353,"threshold_uncertainty_score":0.9999839},"labels":[],"label_agreement":null},{"id":"W4399505079","doi":"10.1158/1538-8514.synthleth24-b023","title":"Abstract B023: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer; Cancer research; Medicine; Biology; Genetics; Gene; DNA repair","score_opus":0.0453209368628729,"score_gpt":0.36038447832171006,"score_spread":0.31506354145883714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92635924,0.0517683,0.0011527896,0.018567536,0.00045843355,0.0008697001,0.00008965772,0.00008481851,0.0006495069],"genre_scores_gemma":[0.9901328,0.0033317353,0.00013138028,0.0058322693,0.000114704104,0.0003087557,0.000006116644,0.00007272393,0.00006952557],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980606,0.00011262103,0.00050409755,0.0004822645,0.00042973174,0.00041069902],"domain_scores_gemma":[0.999103,0.00012825718,0.000094316914,0.00043034455,0.000115037285,0.00012906025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044954356,0.00028411005,0.0004408932,0.00020078114,0.00005851374,0.000046362915,0.00017007382,0.00015095511,0.00020585654],"category_scores_gemma":[0.000017107317,0.0002221606,0.00012498604,0.00070321216,0.0001977686,0.00006380782,0.00003977743,0.000492339,0.000006577251],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032824845,0.00011440692,0.0025927587,0.00053053343,0.0006221793,0.00015627092,0.004491612,0.0010218318,0.91380674,0.00041890208,0.00021375049,0.075702764],"study_design_scores_gemma":[0.0019973707,0.00019420365,0.045258705,0.0029517019,0.00041174208,0.00005832378,0.0005212409,0.0013182808,0.8973489,0.0017496159,0.04760543,0.000584485],"about_ca_topic_score_codex":0.0010722685,"about_ca_topic_score_gemma":0.00022634814,"teacher_disagreement_score":0.07511828,"about_ca_system_score_codex":0.00032941677,"about_ca_system_score_gemma":0.0004039035,"threshold_uncertainty_score":0.90594465},"labels":[],"label_agreement":null},{"id":"W4399505132","doi":"10.1158/1538-8514.synthleth24-pr002","title":"Abstract PR002: Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP1; Synthetic lethality; Olaparib; Cancer research; DNA damage; Biology; DNA ligase; DNA repair; Cancer; Chemistry; Poly ADP ribose polymerase; DNA; Genetics","score_opus":0.04460359950510362,"score_gpt":0.3589815907362381,"score_spread":0.31437799123113447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9264865,0.052172106,0.0011048461,0.018038139,0.0004297995,0.0009403805,0.00008779372,0.000084705855,0.00065573276],"genre_scores_gemma":[0.99075186,0.0031448312,0.0001371634,0.0053666565,0.00011259408,0.00033665268,0.0000059375857,0.0000722917,0.0000720393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998059,0.000113972776,0.00050464727,0.00048312722,0.0004307186,0.0004085377],"domain_scores_gemma":[0.99910593,0.00012521325,0.0000965259,0.0004278223,0.00011670876,0.00012782132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044782096,0.00028384794,0.0004378603,0.00019700966,0.00005776532,0.00004676708,0.00016836953,0.00015003968,0.00020343199],"category_scores_gemma":[0.000017669832,0.00022108894,0.00012201644,0.0006917209,0.00019635967,0.000065033455,0.00003944735,0.00048996555,0.0000061512774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003310679,0.00012116555,0.0024641748,0.0005692418,0.00062598963,0.00014864813,0.00473036,0.0009771772,0.90343297,0.00041472912,0.00020713478,0.08597736],"study_design_scores_gemma":[0.0019650157,0.00019966466,0.04860349,0.0030434078,0.00041202072,0.000058634585,0.00048309128,0.0013239946,0.89565253,0.0016044155,0.04608066,0.0005730976],"about_ca_topic_score_codex":0.0009321861,"about_ca_topic_score_gemma":0.00020692346,"teacher_disagreement_score":0.08540426,"about_ca_system_score_codex":0.0003281597,"about_ca_system_score_gemma":0.00036778126,"threshold_uncertainty_score":0.90157455},"labels":[],"label_agreement":null},{"id":"W4399505173","doi":"10.1158/1538-8514.synthleth24-ia009","title":"Abstract IA009: Single strand DNA GAP accumulation as a functional biomarker for DNA Repair Inhibitors","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; DNA repair; Cancer research; Homologous recombination; PARP1; Biology; Genome instability; DNA damage; Olaparib; Polymerase; Poly ADP ribose polymerase; Genetics; Gene; DNA","score_opus":0.11938644281047917,"score_gpt":0.37918037371034874,"score_spread":0.2597939308998696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9298529,0.02424855,0.024066746,0.008930087,0.0036402508,0.0022617376,0.0002540589,0.0011275032,0.00561814],"genre_scores_gemma":[0.9923831,0.00028357212,0.0006745366,0.0044875136,0.00074357947,0.00035898585,0.00018305785,0.00013999912,0.00074564666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979337,0.000040766605,0.00047212528,0.00058832543,0.0005613831,0.0004037419],"domain_scores_gemma":[0.9990139,0.000119568875,0.000100756675,0.00038477354,0.0002299362,0.0001510613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027087994,0.00032968813,0.00030560495,0.00022886494,0.00012430172,0.00010565895,0.00007964621,0.00024473976,0.00077446876],"category_scores_gemma":[0.000017111279,0.00031295046,0.00047481744,0.00041341726,0.000117319716,0.00016342408,0.000016530941,0.00024170418,0.00006688136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012144923,0.0002159618,0.0003882908,0.0003873625,0.0011425487,0.00007239824,0.00029609524,0.00024648666,0.9597186,0.00086569006,0.0038317111,0.0316204],"study_design_scores_gemma":[0.004332571,0.0005665971,0.005932539,0.00091782433,0.00071993243,0.00009247352,0.00009919598,0.0042550764,0.5746275,0.0048105605,0.4030192,0.0006265597],"about_ca_topic_score_codex":0.00003099241,"about_ca_topic_score_gemma":0.000011808128,"teacher_disagreement_score":0.39918748,"about_ca_system_score_codex":0.0005462262,"about_ca_system_score_gemma":0.00048736468,"threshold_uncertainty_score":0.9999322},"labels":[],"label_agreement":null},{"id":"W4399505261","doi":"10.1158/1538-8514.synthleth24-ia008","title":"Abstract IA008: Exploiting tumor selective vulnerabilities with structure based drug design","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DNA repair; Homologous recombination; Biology; DNA damage; Base excision repair; DNA replication; Genome instability; Cell biology; PARP1; Genetics; DNA; Poly ADP ribose polymerase; Polymerase","score_opus":0.032613292186137746,"score_gpt":0.3090953129435718,"score_spread":0.27648202075743405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8124334,0.025729632,0.14726292,0.007502759,0.0008036105,0.002328132,0.0002630679,0.0011914871,0.0024849826],"genre_scores_gemma":[0.985653,0.00008105074,0.0062126066,0.0070723593,0.00030041265,0.00028655154,0.000025218766,0.00016732706,0.00020146549],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979262,0.00011880556,0.00031378944,0.0005820942,0.00058626843,0.00047288425],"domain_scores_gemma":[0.9989632,0.00018185414,0.000088822875,0.00041277116,0.00021782989,0.00013553382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020463979,0.00039472175,0.00037595443,0.00018562717,0.00013457911,0.00012309621,0.00013460875,0.000096409225,0.00058979297],"category_scores_gemma":[0.0000093159,0.00031585284,0.00014657805,0.0005353647,0.00019132109,0.00012988002,0.000012865272,0.0006418233,0.000012316309],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022999074,0.0001951896,0.0016126051,0.0013101213,0.002021624,0.0013309685,0.0047946405,0.021638198,0.9378329,0.0009104612,0.0017083058,0.024345063],"study_design_scores_gemma":[0.0022277264,0.0003807707,0.00077977177,0.0015747729,0.0003791797,0.00012012317,0.00049595546,0.0065269847,0.97122365,0.0019890673,0.013712645,0.0005893375],"about_ca_topic_score_codex":0.000077991754,"about_ca_topic_score_gemma":0.00002235882,"teacher_disagreement_score":0.17321959,"about_ca_system_score_codex":0.00060112495,"about_ca_system_score_gemma":0.00095584145,"threshold_uncertainty_score":0.99992937},"labels":[],"label_agreement":null},{"id":"W4399505312","doi":"10.1158/1538-8514.synthleth24-b002","title":"Abstract B002: POLB knockout is synthetic lethal with PARP inhibition leading to complete and durable responses in BRCA-mutant tumor xenografts","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Synthetic lethality; Cancer; Mutant; Cancer research; Poly ADP ribose polymerase; Homologous recombination; PARP1; Mutation; Biology; Polymerase; Genetics; DNA; Gene","score_opus":0.04220035080186927,"score_gpt":0.3308149417042294,"score_spread":0.28861459090236014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974553,0.010408608,0.0014925832,0.011311189,0.00023761702,0.0007999936,0.00015080748,0.00015928964,0.00088693906],"genre_scores_gemma":[0.98854977,0.00055456423,0.00064816675,0.009541401,0.00013521803,0.00021042963,0.000012145088,0.0001187681,0.0002295472],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779636,0.00009190649,0.00041711572,0.00065908063,0.0004979936,0.0005375468],"domain_scores_gemma":[0.99911326,0.00011412847,0.00007579488,0.00039586003,0.00009877199,0.00020217575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002984608,0.00036262427,0.00045589742,0.00042469605,0.00009958547,0.00013479765,0.00008944223,0.00010821501,0.00023002457],"category_scores_gemma":[0.00001135867,0.00032050352,0.00009505128,0.0006788451,0.00017653254,0.000119375574,0.000034100325,0.00044677762,0.00005405747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015809127,0.000095878735,0.0011032826,0.00037203848,0.00027275534,0.0017300742,0.0023596243,0.00015903753,0.978822,0.00028311432,0.00019475444,0.01302654],"study_design_scores_gemma":[0.0035665382,0.0009233857,0.0075415145,0.0058548716,0.00033605561,0.0010214949,0.00043545655,0.00077618874,0.8943854,0.00063648645,0.083644345,0.00087824184],"about_ca_topic_score_codex":0.00018260498,"about_ca_topic_score_gemma":0.000094773226,"teacher_disagreement_score":0.084436566,"about_ca_system_score_codex":0.0004764107,"about_ca_system_score_gemma":0.00033302236,"threshold_uncertainty_score":0.9999247},"labels":[],"label_agreement":null},{"id":"W4399505374","doi":"10.1158/1538-8514.synthleth24-b005","title":"Abstract B005: Regulation of replication-induced PARP1/PARP2 activation by base excision repair: Implications for PARP and PARG inhibitor resistance","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"XRCC1; PARP1; Base excision repair; PARP inhibitor; Poly ADP ribose polymerase; Cancer research; DNA repair; DNA damage; Molecular biology; Polymerase; Biology; Chemistry; DNA; Genetics","score_opus":0.05036201442551773,"score_gpt":0.3601647727333316,"score_spread":0.30980275830781384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88418335,0.021654353,0.060508817,0.028403558,0.00039083578,0.0031020958,0.00046874053,0.00055164867,0.0007365766],"genre_scores_gemma":[0.9926844,0.0012853461,0.0029657993,0.001310906,0.00018752365,0.0008680295,0.00024959655,0.00008308617,0.0003652704],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812436,0.000047657886,0.0005885663,0.0006950972,0.00030101626,0.00024328078],"domain_scores_gemma":[0.9982379,0.00019493475,0.00023761562,0.0008697048,0.00035322027,0.00010661698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037717883,0.00023849795,0.00030668726,0.00014738078,0.00012343946,0.000043097894,0.00008841957,0.00019592732,0.00004952825],"category_scores_gemma":[0.00004945243,0.00023600832,0.00018497532,0.00042201445,0.000095858435,0.00017266301,0.000016981541,0.00017964243,0.0000026460104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044144638,0.0000947529,0.00051632937,0.00040255676,0.00021886322,8.777617e-7,0.0002007648,0.000017187358,0.9667247,0.0026926757,0.0052972212,0.023392629],"study_design_scores_gemma":[0.001410218,0.0001625463,0.014200033,0.0007741136,0.00024012594,0.0000047971794,0.000037392103,0.0008412437,0.8834471,0.0055236435,0.09308414,0.00027461545],"about_ca_topic_score_codex":0.000026499276,"about_ca_topic_score_gemma":0.00000837839,"teacher_disagreement_score":0.10850107,"about_ca_system_score_codex":0.00030789358,"about_ca_system_score_gemma":0.00026060862,"threshold_uncertainty_score":0.96241397},"labels":[],"label_agreement":null},{"id":"W4399614669","doi":"10.1177/17588359241255174","title":"PARP inhibitors in non-ovarian gynecologic cancers","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ovarian cancer; Context (archaeology); Olaparib; Oncology; PARP inhibitor; Endometrial cancer; Internal medicine; Poly ADP ribose polymerase; Cancer research; Cancer; Polymerase; Biology; Gene","score_opus":0.021426977265556247,"score_gpt":0.39641454717827285,"score_spread":0.3749875699127166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399614669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38020033,0.26033613,0.013744721,0.11585811,0.022316765,0.0045886184,0.00003226774,0.001079297,0.20184374],"genre_scores_gemma":[0.9684249,0.017396573,0.00076299417,0.011876685,0.00076616835,0.00042554148,0.000013869795,0.000046648012,0.00028661205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969808,0.000262633,0.00081455894,0.0006239339,0.00062744005,0.0006906221],"domain_scores_gemma":[0.9981844,0.0011065826,0.00008680132,0.0002917922,0.00003880988,0.0002916237],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013368351,0.00028181518,0.0007676254,0.00045701384,0.00003955574,0.000012611622,0.00025370475,0.00055357034,0.003381009],"category_scores_gemma":[0.00019843213,0.00023076725,0.000113288566,0.0010597776,0.00063464855,0.00021038172,0.000054879893,0.0013437646,0.00015462462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061013806,0.00032509805,0.007480028,0.00020645358,0.00006481138,0.0030141599,0.001054775,0.00018056869,0.0005674387,0.003346463,0.00068252685,0.98246753],"study_design_scores_gemma":[0.0072540897,0.0017738342,0.007938029,0.0013222962,0.000052674288,0.0004135005,0.00064114906,0.005960372,0.0005872607,0.01886968,0.9547783,0.0004087985],"about_ca_topic_score_codex":0.000102320904,"about_ca_topic_score_gemma":0.0010688012,"teacher_disagreement_score":0.98205876,"about_ca_system_score_codex":0.0025589971,"about_ca_system_score_gemma":0.0019436738,"threshold_uncertainty_score":0.99753004},"labels":[],"label_agreement":null},{"id":"W4399737405","doi":"10.1200/jco.2024.42.16_suppl.tps3174","title":"First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP inhibitor; Olaparib; Medicine; Poly ADP ribose polymerase; Cancer research; Synthetic lethality; Polymerase; Homologous recombination; DNA repair; PARP1; Pharmacology; DNA; Biology; Genetics","score_opus":0.07941985966849405,"score_gpt":0.45097663381761144,"score_spread":0.37155677414911736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399737405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787915,0.00169588,0.000041385916,0.01645983,0.0010160644,0.001664414,0.000051240713,0.000051089566,0.00022862999],"genre_scores_gemma":[0.994068,0.00022451716,0.00032853722,0.0023400385,0.0025679134,0.000083801155,0.00002028341,0.00011380503,0.0002530554],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9904132,0.0015410753,0.005236336,0.0007788932,0.0012758162,0.0007547072],"domain_scores_gemma":[0.99290335,0.0026217198,0.0024060358,0.00082251884,0.00049497955,0.0007514206],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0043356204,0.0006098261,0.0036497288,0.0007959333,0.00014978339,0.000053581953,0.0005655215,0.00047057276,0.0004211968],"category_scores_gemma":[0.00054958015,0.00032634343,0.00039099515,0.0012944046,0.0010870814,0.0005386709,0.00010303631,0.0027780018,0.000008905868],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6733917,0.12441416,0.06012056,0.00076974917,0.0033645288,0.04025568,0.017117392,0.0003093133,0.004802208,0.00024403166,0.012916943,0.062293734],"study_design_scores_gemma":[0.34429565,0.55798906,0.037868496,0.0082175,0.001778945,0.0033253087,0.014211709,0.001542659,0.018154759,0.0001822569,0.011200497,0.0012331989],"about_ca_topic_score_codex":0.00062760036,"about_ca_topic_score_gemma":0.009060413,"teacher_disagreement_score":0.4335749,"about_ca_system_score_codex":0.00042258293,"about_ca_system_score_gemma":0.0033935704,"threshold_uncertainty_score":0.9999189},"labels":[],"label_agreement":null},{"id":"W4399850714","doi":"10.1016/j.isci.2024.110333","title":"HTRF-based assay for detection of mono-ADP-ribosyl hydrolyzing macrodomains and inhibitor screening","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Kungliga Tekniska Högskolan; Volkswagen Foundation; Hessisches Ministerium für Wissenschaft und Kunst; European Federation of Pharmaceutical Industries and Associations; Fraunhofer-Gesellschaft; McGill University","keywords":"Chemistry; Computational biology; Biochemistry; Biology","score_opus":0.028199918135672717,"score_gpt":0.318488140006249,"score_spread":0.29028822187057624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399850714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64626193,0.0016436102,0.34993523,0.0010188965,0.00035982754,0.00034345483,0.000021523936,0.00010001974,0.00031548945],"genre_scores_gemma":[0.9925708,0.000019170027,0.00672438,0.0002827636,0.00019648825,0.00005092692,0.0000026636426,0.00001616542,0.00013660846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999014,0.000022897842,0.00019895687,0.00031615628,0.00025021913,0.00019777629],"domain_scores_gemma":[0.99943465,0.00021005713,0.00005324113,0.00015280448,0.00006527643,0.00008394273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006462362,0.00009642883,0.00015266844,0.00017394213,0.000112549176,0.00004108936,0.000057957946,0.000053089865,0.000014174115],"category_scores_gemma":[0.0001085419,0.00008588731,0.000065451466,0.00038945826,0.00020892345,0.00016125248,0.000017456126,0.000104589104,0.00000313428],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099401324,0.0000172407,0.0006914735,0.00015438828,0.000009190242,0.0000052839937,0.00019731087,0.00010940194,0.9278404,0.00010609433,0.00011801582,0.07065179],"study_design_scores_gemma":[0.0009367538,0.00032059813,0.0012935876,0.00052587886,0.000028653132,0.00002919474,0.0000656077,0.087085865,0.9001576,0.00029303375,0.009156943,0.000106303494],"about_ca_topic_score_codex":0.000014660874,"about_ca_topic_score_gemma":0.0000073233505,"teacher_disagreement_score":0.3463089,"about_ca_system_score_codex":0.000075130585,"about_ca_system_score_gemma":0.000113855574,"threshold_uncertainty_score":0.3502383},"labels":[],"label_agreement":null},{"id":"W4399878376","doi":"10.1139/cjc-2024-0047","title":"An optimized fluorescence assay for screening novel PARP-1 inhibitors","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Institute of Aging; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Research Manitoba","keywords":"Chemistry; Fluorescence; Poly ADP ribose polymerase; Combinatorial chemistry; Biochemistry; DNA; Polymerase","score_opus":0.02668238986995294,"score_gpt":0.29960397115161697,"score_spread":0.27292158128166405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399878376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.693523,0.017129181,0.24429356,0.029139446,0.004824882,0.0011223365,0.0008557028,0.00021481578,0.008897062],"genre_scores_gemma":[0.97115135,0.000026602385,0.025708966,0.00043061178,0.0021008519,0.000011384698,0.000029414206,0.000047239882,0.0004935563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989161,0.000010859017,0.00039354284,0.0001737514,0.00020542121,0.00030036518],"domain_scores_gemma":[0.99832433,0.0000864751,0.00011513637,0.00018381662,0.0002700383,0.0010202047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049928174,0.00013956462,0.0002635189,0.00011851008,0.00007153016,0.00009499454,0.00015348165,0.00013114438,0.0004222411],"category_scores_gemma":[0.0001687892,0.00013071863,0.00019428758,0.000170103,0.00010522755,0.00017385284,0.0000029787436,0.0003719042,0.0000025244158],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029671757,0.00003561523,0.00059802417,0.00041960104,0.00022334074,0.00051828584,0.00064850185,0.00039942257,0.9488073,0.000031294338,0.034462336,0.013559555],"study_design_scores_gemma":[0.0043859547,0.0002248267,0.00018705733,0.0028117485,0.00015569659,0.002504023,0.00060599507,0.0044118124,0.8752424,0.00017978795,0.10894455,0.00034615304],"about_ca_topic_score_codex":0.00013368536,"about_ca_topic_score_gemma":0.00004470332,"teacher_disagreement_score":0.27762836,"about_ca_system_score_codex":0.00031361604,"about_ca_system_score_gemma":0.0025889676,"threshold_uncertainty_score":0.53305507},"labels":[],"label_agreement":null},{"id":"W4399884665","doi":"10.3390/curroncol31060264","title":"Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Canadian Partnership Against Cancer; University of Calgary; Princess Margaret Cancer Centre; IGNIS Innovation (Canada); Simon Fraser University; Sunnybrook Health Science Centre; Canadian Agency for Drugs and Technologies in Health; Women's College Hospital; Alberta Health Services; Canadian Centre for Applied Research in Cancer Control; Public Health Ontario","funders":"","keywords":"Medicine; Ovarian cancer; Maintenance therapy; Oncology; Cancer research; Cancer; Gynecology; Internal medicine; Chemotherapy","score_opus":0.10192396136423887,"score_gpt":0.4379740286378051,"score_spread":0.33605006727356623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399884665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.822326,0.06465173,0.0038235765,0.0335167,0.027532019,0.007931897,0.006009513,0.00014947781,0.034059096],"genre_scores_gemma":[0.99017483,0.008028265,0.00026914227,0.00007300117,0.00027304987,0.0004636149,0.000052473817,0.000020153822,0.0006454964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893606,0.0000386606,0.0004673511,0.00022052975,0.00011520313,0.00022218797],"domain_scores_gemma":[0.9993331,0.00022270398,0.00011086761,0.00016892944,0.00009880742,0.00006559951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001107912,0.00011477434,0.000500257,0.00014513491,0.000011822263,0.0000011835574,0.000051244027,0.000042829965,0.00030652923],"category_scores_gemma":[0.000014119924,0.00009421945,0.000085352985,0.00028491314,0.00007250374,0.000019483608,0.000008078332,0.00008348119,9.0786244e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045395233,0.0011412561,0.12278058,0.0018428179,0.00045404432,0.00008872093,0.0016676597,0.000315562,0.0051363627,0.016802303,0.03731429,0.8079169],"study_design_scores_gemma":[0.00677069,0.0009681667,0.03656089,0.001041681,0.00012009284,0.000009808035,0.00012840565,0.0015541503,0.007433126,0.0004918217,0.9447992,0.00012196291],"about_ca_topic_score_codex":0.44471255,"about_ca_topic_score_gemma":0.8917699,"teacher_disagreement_score":0.9074849,"about_ca_system_score_codex":0.005241859,"about_ca_system_score_gemma":0.005390537,"threshold_uncertainty_score":0.9985768},"labels":[],"label_agreement":null},{"id":"W4399929192","doi":"10.1016/j.gore.2024.101439","title":"Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Discontinuation; Ovarian cancer; Oncology; Poly ADP ribose polymerase; Serous fluid; BRCA mutation; Internal medicine; Cancer; Polymerase","score_opus":0.09604871858255999,"score_gpt":0.3636607709334285,"score_spread":0.26761205235086855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399929192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547647,0.029006364,0.0000054829607,0.0034968636,0.0007156944,0.0011106364,0.000008016412,0.00018061505,0.010711607],"genre_scores_gemma":[0.9794469,0.01901216,0.00046827772,0.00032890207,0.00018569743,0.00042122626,0.000009848457,0.00004360816,0.000083399114],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9973261,0.00027818145,0.0008440295,0.0008915752,0.00022548607,0.0004346541],"domain_scores_gemma":[0.9981359,0.00066090754,0.00034563252,0.0005221774,0.0001613731,0.00017398187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013782316,0.0003314739,0.00093367475,0.00041499268,0.00006485442,0.000016693359,0.000063495936,0.0006097823,0.0002740928],"category_scores_gemma":[0.00017353351,0.00024741236,0.000094078,0.00038916667,0.0003279206,0.00017331867,0.000067918605,0.0006642731,0.000005781369],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015134547,0.0016769808,0.02929762,0.0007582814,0.0004953857,0.30522025,0.005102001,0.000003552321,0.009163204,0.0007038712,0.0011590018,0.6449064],"study_design_scores_gemma":[0.017107883,0.06477302,0.16977236,0.0032050984,0.00076039723,0.46456212,0.012585064,0.00026968223,0.063304745,0.009004666,0.19252557,0.0021294071],"about_ca_topic_score_codex":0.00015022667,"about_ca_topic_score_gemma":0.0016083743,"teacher_disagreement_score":0.642777,"about_ca_system_score_codex":0.00041649904,"about_ca_system_score_gemma":0.0007775972,"threshold_uncertainty_score":0.9999978},"labels":[],"label_agreement":null},{"id":"W4400248956","doi":"10.1038/s44321-024-00094-2","title":"FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer","year":2024,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Pershing Square Sohn Cancer Research Alliance; Memorial Sloan-Kettering Cancer Center; METAvivor; Irving Medical Center, Columbia University; National Cancer Institute; Emory University; Susan G. Komen; Monique Weill-Caulier Trust; Moffitt Cancer Center; American Cancer Society; Irma T. Hirschl Trust; U.S. Department of Defense","keywords":"Cancer research; Breast cancer; Medicine; Cancer; PARP inhibitor; Synthetic lethality; Biology; Internal medicine; DNA repair; Poly ADP ribose polymerase","score_opus":0.01591781675838453,"score_gpt":0.32424006646860537,"score_spread":0.3083222497102208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400248956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83437926,0.025445512,0.00072360644,0.13167973,0.0016072182,0.0014116402,0.0000614245,0.00022225249,0.004469331],"genre_scores_gemma":[0.9921064,0.0013523663,0.00029414066,0.0035239584,0.0010055081,0.0005688838,0.000037256617,0.000083288985,0.0010282211],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976293,0.00010515651,0.0005683141,0.0006318457,0.0006271584,0.0004382286],"domain_scores_gemma":[0.9990764,0.000084205196,0.00008783856,0.00047626832,0.00011395522,0.00016128195],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040728645,0.00029661486,0.0005202962,0.0005157091,0.000030340743,0.000018640761,0.00014604781,0.0001627072,0.0012087364],"category_scores_gemma":[0.00006485507,0.00024973878,0.00007447044,0.0012850445,0.00015957549,0.00014720054,0.000032686916,0.00054650794,0.000023254797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044889585,0.00013613305,0.0020527616,0.00072091643,0.00007198582,0.0005554393,0.0016081304,0.000059234833,0.9726489,0.00052368944,0.016828587,0.0043453006],"study_design_scores_gemma":[0.009380452,0.00028413953,0.038247824,0.032619134,0.00016093174,0.00005967407,0.00034650217,0.0009934575,0.8708382,0.0031768118,0.04314018,0.00075269],"about_ca_topic_score_codex":0.0011567217,"about_ca_topic_score_gemma":0.0005991283,"teacher_disagreement_score":0.15772709,"about_ca_system_score_codex":0.00092417334,"about_ca_system_score_gemma":0.00045139692,"threshold_uncertainty_score":0.99999547},"labels":[],"label_agreement":null},{"id":"W4400382949","doi":"10.14740/wjon1820","title":"Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Science and Higher Education of the Russian Federation","keywords":"Homologous recombination; Poly ADP ribose polymerase; Medicine; Polymerase; Mutation; Genetics; Computational biology; DNA; Gene; Biology","score_opus":0.11149024542431313,"score_gpt":0.432992976618258,"score_spread":0.32150273119394485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400382949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8584639,0.006637538,0.0010928764,0.11889314,0.0082909325,0.0005215261,0.00005494232,0.0001962664,0.0058489176],"genre_scores_gemma":[0.9887049,0.00065068685,0.0041777906,0.0011544697,0.0040920335,0.000010498207,0.0000308078,0.00004323712,0.0011355798],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963083,0.000877723,0.0017696902,0.00031827053,0.00045327737,0.00027272975],"domain_scores_gemma":[0.9950213,0.0029161314,0.0011367414,0.0002916157,0.00046974863,0.0001644956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002122914,0.00019587042,0.00072242203,0.00056349183,0.00012499047,0.000029629899,0.00018199372,0.00018262409,0.00034443958],"category_scores_gemma":[0.0007896116,0.00014678796,0.00046446593,0.0010067695,0.0003522682,0.00017908534,0.000050227827,0.0011800219,0.00002090696],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036683371,0.0013326287,0.018456312,0.00009801921,0.0012145325,0.0033475962,0.0012350255,0.00012709934,0.051899727,0.0015788216,0.049898807,0.8671431],"study_design_scores_gemma":[0.047062907,0.025100717,0.4659289,0.0096408995,0.0060802093,0.008419036,0.003758422,0.007992396,0.06670266,0.055125207,0.30263036,0.0015582959],"about_ca_topic_score_codex":0.00059100304,"about_ca_topic_score_gemma":0.00046978568,"teacher_disagreement_score":0.8655848,"about_ca_system_score_codex":0.0005544442,"about_ca_system_score_gemma":0.0013535923,"threshold_uncertainty_score":0.59858394},"labels":[],"label_agreement":null},{"id":"W4400571205","doi":"10.1016/j.ijrobp.2024.06.037","title":"Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors","year":2024,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Daiichi Sankyo Europe; National Cancer Institute; National Institutes of Health; Regeneron Pharmaceuticals; Merck; AstraZeneca; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Cisplatin; Clonogenic assay; RAD51; Breast cancer; Cancer research; Homologous recombination; Medicine; Radiation therapy; Cytotoxicity; Chemotherapy; Oncology; Cancer; Internal medicine; Cell culture; Biology; In vitro; Gene; Genetics","score_opus":0.021843823419345,"score_gpt":0.3342389538006516,"score_spread":0.3123951303813066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400571205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871927,0.0012690392,0.0036013424,0.002172247,0.0045381165,0.00040025287,0.00005799708,0.000056435238,0.000711881],"genre_scores_gemma":[0.9963169,0.0011345763,0.0007171795,0.000408036,0.0012475335,0.000029483963,0.000098871904,0.000034637378,0.000012765319],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975529,0.00035538818,0.0011524191,0.00028217598,0.00044041546,0.00021671294],"domain_scores_gemma":[0.9974119,0.0006166173,0.00092021615,0.00016722146,0.0007841219,0.00009994156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012369952,0.0002135651,0.0006004726,0.0005660643,0.000038314138,0.000028554081,0.00028547118,0.0002846171,0.00011586148],"category_scores_gemma":[0.00040221203,0.00019802504,0.00027408343,0.00047331458,0.00021561864,0.00028511407,0.000028161194,0.00056740246,0.00001792016],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005185038,0.0053834515,0.25193542,0.00014267142,0.0015286896,0.00039170485,0.0032135178,0.0025916577,0.20149359,0.122624926,0.00174543,0.4037639],"study_design_scores_gemma":[0.05650901,0.013188716,0.1647074,0.0017781449,0.00034520443,0.0015882052,0.00038243318,0.030938463,0.48569724,0.22808237,0.015767183,0.001015623],"about_ca_topic_score_codex":0.000055249213,"about_ca_topic_score_gemma":0.0000021633127,"teacher_disagreement_score":0.40274826,"about_ca_system_score_codex":0.0017978847,"about_ca_system_score_gemma":0.0010824288,"threshold_uncertainty_score":0.8075227},"labels":[],"label_agreement":null},{"id":"W4401182947","doi":"10.1101/2024.07.30.605465","title":"Intracellular accumulation of free cholesterol in macrophages triggers a PARP1 response to DNA damage and PARP1 impairs lipopolysaccharide-induced inflammatory response","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"PARP1; DNA damage; Lipopolysaccharide; Inflammation; Chemistry; Gene knockdown; Intracellular; Cell biology; Biochemistry; Biology; Apoptosis; Enzyme; Immunology; Poly ADP ribose polymerase; DNA","score_opus":0.028315574747499794,"score_gpt":0.29672681511114435,"score_spread":0.26841124036364455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401182947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188364,0.0013452969,0.00011905,0.002576399,0.0008155085,0.0025324207,0.0003267174,0.0003989184,0.0000020273417],"genre_scores_gemma":[0.99680924,0.00016228075,0.001344256,0.00047152347,0.00032555906,0.0006183744,7.4015793e-7,0.000255847,0.000012161678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99447316,0.0010503037,0.0014947448,0.0014751838,0.00079760683,0.0007089902],"domain_scores_gemma":[0.99544954,0.0005263103,0.0006029095,0.0023724,0.00044826185,0.0006006051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041978075,0.0008404454,0.001267825,0.0018531512,0.000089057845,0.00020937539,0.0005269852,0.00091796776,0.00006011811],"category_scores_gemma":[0.0013760334,0.00092033757,0.00024014508,0.00095725374,0.00021758374,0.0002294691,0.0008188972,0.0015563814,0.000046988796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013121413,0.00016653321,0.0051155644,0.0011874852,0.00022070127,0.0005441103,0.0003035666,0.00009029056,0.9789884,0.000047363123,0.00020332179,0.000011247005],"study_design_scores_gemma":[0.0032540427,0.00040090052,0.2145124,0.0030226735,0.00015540319,2.8331502e-7,0.000032609474,0.00030067045,0.7772393,0.00001522617,0.00042419642,0.0006422501],"about_ca_topic_score_codex":0.00010122375,"about_ca_topic_score_gemma":0.000011084377,"teacher_disagreement_score":0.20939684,"about_ca_system_score_codex":0.0010278361,"about_ca_system_score_gemma":0.0017029429,"threshold_uncertainty_score":0.99932474},"labels":[],"label_agreement":null},{"id":"W4401589313","doi":"10.1242/bio.061613","title":"Meeting proceedings of the 43rd Indian Association for Cancer Research (IACR)","year":2024,"lang":"en","type":"review","venue":"Biology Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Labex; Company of Biologists; Thermo Fisher Scientific; SCIEX","keywords":"Cancer; Subject (documents); Biology; Library science; Gerontology; Medicine; Genetics; Computer science","score_opus":0.324514509144551,"score_gpt":0.5751647572239271,"score_spread":0.25065024807937614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401589313","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000121091995,0.9809104,1.5645003e-7,0.0018722725,0.00068549224,0.0046827714,0.00034362788,0.000017215469,0.011366972],"genre_scores_gemma":[0.000047348192,0.9850917,0.00011078163,0.00015503974,0.00081969134,0.0033956748,0.000060582868,0.00004795925,0.010271254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984969,0.00011615809,0.00048467313,0.0003878524,0.00019500784,0.00031941774],"domain_scores_gemma":[0.9984954,0.0003520783,0.00046041008,0.00016839216,0.00047839383,0.00004534971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002842732,0.00017256897,0.0010498669,0.00017377092,0.00011925765,0.00004327342,0.0005866607,0.000550664,0.000069454945],"category_scores_gemma":[0.0005477591,0.00009907495,0.0002849831,0.0005894303,0.00011459934,0.000036465997,0.00033215014,0.00063489616,0.000032458192],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013422068,0.00011385032,0.0020476084,0.057018843,0.0022846754,0.0000016268699,0.0009665039,2.6081235e-8,0.00048543737,0.009884465,0.3655223,0.5615405],"study_design_scores_gemma":[0.00032389865,0.00010692873,0.000014887326,0.02307645,0.00045746486,0.000006252725,0.000047808935,2.0477042e-7,0.00013307676,0.0008149675,0.97492707,0.0000909956],"about_ca_topic_score_codex":0.00022532277,"about_ca_topic_score_gemma":0.00004177232,"teacher_disagreement_score":0.6094048,"about_ca_system_score_codex":0.0008813505,"about_ca_system_score_gemma":0.0012990618,"threshold_uncertainty_score":0.42472246},"labels":[],"label_agreement":null},{"id":"W4401595054","doi":"10.1080/14737140.2024.2393251","title":"Strategies for the prevention or reversal of PARP inhibitor resistance","year":2024,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; PARP inhibitor; Pharmacology; Oncology; Poly ADP ribose polymerase; Internal medicine; Cancer research; Intensive care medicine; Genetics","score_opus":0.12395268543175678,"score_gpt":0.4831962870911889,"score_spread":0.35924360165943214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401595054","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.1059118e-7,0.9899687,0.0007516024,0.0015498614,0.0010748929,0.005849711,0.00018394773,0.000053932094,0.0005669325],"genre_scores_gemma":[0.0000034454104,0.9908897,0.0017960309,0.0010860845,0.0013250521,0.0022898118,0.00007977045,0.0001371087,0.0023929859],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99631864,0.00023119796,0.0018726377,0.00059684174,0.00065444096,0.0003262224],"domain_scores_gemma":[0.9966799,0.00060247903,0.0011520083,0.0011108072,0.0003778249,0.000076988064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097517925,0.000610794,0.0034807078,0.00014504037,0.0000689569,0.000027913058,0.00043851096,0.00024242641,0.0006495358],"category_scores_gemma":[0.00009053211,0.0003044002,0.0018800715,0.00078127475,0.00039189408,0.00012057558,0.000036954225,0.0003780182,0.000013126462],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047226535,0.00012493863,9.563707e-8,0.2774587,0.0011135208,0.000004543167,0.00016334796,2.8459867e-8,0.000052706342,0.0013442681,0.1245686,0.594697],"study_design_scores_gemma":[0.00059125264,0.00037287537,1.5481334e-7,0.33295733,0.0010458216,0.000017719858,0.00006554632,6.6936593e-7,0.0001572575,0.00020203511,0.6643907,0.00019864838],"about_ca_topic_score_codex":0.000012190115,"about_ca_topic_score_gemma":0.000008686222,"teacher_disagreement_score":0.59449834,"about_ca_system_score_codex":0.00020009206,"about_ca_system_score_gemma":0.0024520345,"threshold_uncertainty_score":0.9999408},"labels":[],"label_agreement":null},{"id":"W4401812927","doi":"10.1042/bcj20230230","title":"Regulation of PARP1/2 and the tankyrases: emerging parallels","year":2024,"lang":"en","type":"review","venue":"Biochemical Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK; Wellcome Trust","keywords":"PARP1; Allosteric regulation; Biology; Effector; Poly ADP ribose polymerase; Function (biology); Parallels; Cell biology; DNA damage; Computational biology; Enzyme; Biochemistry; DNA","score_opus":0.05251421634566076,"score_gpt":0.3994840045239353,"score_spread":0.3469697881782745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401812927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006174484,0.9980313,0.00009514581,0.00072191167,0.00026471468,0.00035407065,0.000016255599,0.000016810898,0.00043802575],"genre_scores_gemma":[0.0003865241,0.99772304,0.0003168187,0.00011704216,0.0011252685,0.00002762679,0.000022815737,0.00003442136,0.00024646014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984403,0.000114172035,0.000764236,0.00019312541,0.0003337325,0.00015439604],"domain_scores_gemma":[0.99901193,0.00016488717,0.0004122018,0.00021011717,0.00008092747,0.00011992519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005163526,0.00022472304,0.00107047,0.00012396854,0.00004976339,0.00003666714,0.000109122855,0.00021100977,0.00016936324],"category_scores_gemma":[0.00010415854,0.00011528383,0.0005198472,0.00021818768,0.00029219413,0.000027426948,0.000043623808,0.00071446813,0.000013621152],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003789068,0.00007045272,0.0000033380097,0.023369057,0.0014650953,0.00006063294,0.00022622022,2.9426738e-7,0.0012156217,0.0015887595,0.093828,0.8777936],"study_design_scores_gemma":[0.0011990229,0.000039672428,0.0000015638547,0.03194017,0.0022185943,0.002976398,0.000018899455,0.000011084915,0.00026168025,0.0014677825,0.95973295,0.00013218234],"about_ca_topic_score_codex":0.0000011583901,"about_ca_topic_score_gemma":3.3458914e-8,"teacher_disagreement_score":0.87766147,"about_ca_system_score_codex":0.00010774295,"about_ca_system_score_gemma":0.0002474634,"threshold_uncertainty_score":0.4701138},"labels":[],"label_agreement":null},{"id":"W4401891802","doi":"10.21037/cco-24-82","title":"Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis","year":2024,"lang":"en","type":"review","venue":"Chinese Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Meta-analysis; Cancer; Prostate cancer; Oncology; Internal medicine","score_opus":0.2493478588089103,"score_gpt":0.5484438808299589,"score_spread":0.29909602202104857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401891802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008912792,0.9903353,0.000002362717,0.0015800693,0.00017495136,0.007599013,0.00012267908,0.000011093556,0.00008541285],"genre_scores_gemma":[0.00021256063,0.996234,0.000095696734,0.000664014,0.00021714962,0.0023666408,0.00006427507,0.00003237498,0.00011331711],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99168015,0.0026379116,0.0046405415,0.00058050925,0.0002491314,0.0002117719],"domain_scores_gemma":[0.98883647,0.008273279,0.0019417098,0.00073080946,0.000095419855,0.0001223005],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0034370173,0.00050490606,0.02073329,0.00021414309,0.000024465931,0.0000065054824,0.000153392,0.00039318553,0.00007004072],"category_scores_gemma":[0.00075815833,0.00020481611,0.0029162373,0.0016660187,0.00044289874,0.000017834851,0.00004635899,0.00047216823,0.0000038122066],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012228268,0.00082758436,0.00016796071,0.82749146,0.13195364,0.000055408207,0.0002729968,0.000002329967,1.4678899e-8,0.00003935352,0.00043213484,0.038634825],"study_design_scores_gemma":[0.0014048426,0.0019087391,0.00007817163,0.09595725,0.8069704,0.000058623526,0.000008730023,0.00000686242,1.4278989e-8,0.00008239993,0.093383804,0.00014013972],"about_ca_topic_score_codex":0.00004176711,"about_ca_topic_score_gemma":0.00012661623,"teacher_disagreement_score":0.73153424,"about_ca_system_score_codex":0.0002147293,"about_ca_system_score_gemma":0.00062794576,"threshold_uncertainty_score":0.99380493},"labels":[],"label_agreement":null},{"id":"W4401973294","doi":"10.3390/ijms25169032","title":"Leveraging PARP-1/2 to Target Distant Metastasis","year":2024,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Université de Montréal","keywords":"Poly ADP ribose polymerase; Metastasis; Computer science; Computational biology; Biology; Medicine; Cancer research; Internal medicine; Cancer; Genetics; DNA; Polymerase","score_opus":0.09546270611127548,"score_gpt":0.4461613400741298,"score_spread":0.3506986339628543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401973294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000066474844,0.9852083,0.007750251,0.0020966744,0.0032470028,0.00019882889,0.00003767796,0.000015350475,0.0013794622],"genre_scores_gemma":[0.0005280901,0.98585165,0.011823902,0.0009226065,0.00063522125,0.000014412701,0.000008639574,0.00003120675,0.00018428836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967032,0.00009987632,0.0009108455,0.00032643875,0.001752064,0.00020759515],"domain_scores_gemma":[0.9986,0.00007119567,0.0005218798,0.00015408147,0.00044169408,0.0002111697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010412078,0.00026445842,0.0009238233,0.0010483809,0.00004421086,0.00022375588,0.0008300076,0.000073222276,0.00020244023],"category_scores_gemma":[0.0001351424,0.00017355384,0.00082844385,0.00062723365,0.00014109084,0.0001274948,0.00011568787,0.0004229998,0.0000984854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004126192,0.00009383451,0.0000034360016,0.0011544464,0.0019806118,0.0065332227,0.0002675363,0.00008420566,0.00020198064,0.0014221821,0.006194225,0.98202306],"study_design_scores_gemma":[0.00018824208,0.00019267378,6.750505e-7,0.015308613,0.000684581,0.0047884737,0.000049938153,0.000009952497,0.0002918456,0.0010616586,0.97725886,0.00016446672],"about_ca_topic_score_codex":0.000004352009,"about_ca_topic_score_gemma":2.7626703e-7,"teacher_disagreement_score":0.9818586,"about_ca_system_score_codex":0.0004160526,"about_ca_system_score_gemma":0.0010636098,"threshold_uncertainty_score":0.70773196},"labels":[],"label_agreement":null},{"id":"W4402017500","doi":"10.1080/14737140.2024.2398494","title":"PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes","year":2024,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"PARP inhibitor; Medicine; Poly ADP ribose polymerase; Cancer research; Pharmacology; Genetics; DNA; Biology; Polymerase","score_opus":0.041042991253942805,"score_gpt":0.3953439882506444,"score_spread":0.3543009969967016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402017500","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000055455894,0.9902137,0.00025292728,0.00262934,0.0014319951,0.0044291574,0.00012893951,0.00023030513,0.00067808357],"genre_scores_gemma":[0.000013416103,0.985529,0.0049584573,0.0048658005,0.0017692863,0.0017264059,0.00011755211,0.0003329909,0.0006870671],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941758,0.0003980038,0.002244089,0.0014547993,0.0010183513,0.00070894917],"domain_scores_gemma":[0.99679446,0.00021419687,0.0010002984,0.0013083039,0.00034441153,0.00033831954],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008906012,0.0012914678,0.0052869227,0.0003677422,0.00013347197,0.00008629273,0.0004076921,0.00033534862,0.0005577899],"category_scores_gemma":[0.00009526275,0.0009065664,0.0013105613,0.00094243826,0.0005237955,0.00020523892,0.00013342069,0.0008430581,0.00007810653],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010476105,0.00020596769,0.0000016793153,0.2010307,0.0006869075,0.00008973419,0.00025751928,5.5043388e-9,0.0010013127,0.000588935,0.039648518,0.75638396],"study_design_scores_gemma":[0.0007466086,0.00013185748,8.415226e-7,0.35314476,0.00063695165,0.00011893031,0.00002126557,7.8389974e-7,0.0016214077,0.00024937422,0.642775,0.0005522215],"about_ca_topic_score_codex":0.00001524174,"about_ca_topic_score_gemma":0.0000034786788,"teacher_disagreement_score":0.7558317,"about_ca_system_score_codex":0.00041323795,"about_ca_system_score_gemma":0.0010635002,"threshold_uncertainty_score":0.9999837},"labels":[],"label_agreement":null},{"id":"W4402029898","doi":"10.1101/2024.08.29.24312245","title":"Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Olaparib; Durvalumab; Computational biology; Biology; Computer science; Poly ADP ribose polymerase; Genetics; Cancer; Gene","score_opus":0.06507049892282757,"score_gpt":0.3630245995252994,"score_spread":0.29795410060247185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402029898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98575455,0.00048799202,0.00028495165,0.007813542,0.0009517905,0.003422123,0.0011296995,0.00009692134,0.00005841466],"genre_scores_gemma":[0.99591535,0.00012442507,0.0009446387,0.00092221756,0.0004840351,0.0011613744,0.00008699789,0.000055938133,0.00030504243],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99507576,0.0017214185,0.0010889535,0.000988341,0.0007664848,0.00035905288],"domain_scores_gemma":[0.99717885,0.001119611,0.00027618682,0.0010032989,0.00021661211,0.00020546178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00457949,0.0004464168,0.001249724,0.0024192617,0.00006717725,0.00008079704,0.00025548213,0.00039542784,0.00008541935],"category_scores_gemma":[0.0018240617,0.0003460758,0.0003917504,0.0020306946,0.0002314874,0.00004352257,0.0004713855,0.0008552504,0.00002402763],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87249416,0.0005799551,0.010345175,0.00033721613,0.0024091478,0.0003013815,0.021479836,0.0022837117,0.086998366,0.00008774223,0.0019256041,0.00075769436],"study_design_scores_gemma":[0.08977141,0.009036455,0.81686807,0.0057404377,0.008781359,0.00008201171,0.004703,0.005785293,0.051997367,0.0011777566,0.0043921764,0.0016646466],"about_ca_topic_score_codex":0.00040786059,"about_ca_topic_score_gemma":0.00051552657,"teacher_disagreement_score":0.8065229,"about_ca_system_score_codex":0.00036907624,"about_ca_system_score_gemma":0.000597143,"threshold_uncertainty_score":0.99989915},"labels":[],"label_agreement":null},{"id":"W4402266317","doi":"10.1158/1538-7445.pediatric24-a007","title":"Abstract A007 DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"DNA damage; Neuroblastoma; Cancer research; Poly ADP ribose polymerase; Medicine; Biology; DNA; Genetics; Polymerase; Cell culture","score_opus":0.061881303580996604,"score_gpt":0.4477320316786257,"score_spread":0.3858507280976291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402266317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98499584,0.00208818,0.00010259578,0.0110324435,0.00018862424,0.00086473505,0.000036539055,0.00012140136,0.0005696097],"genre_scores_gemma":[0.99823606,0.0006455409,0.00008586872,0.00023339989,0.00017864621,0.00022616705,0.000010401581,0.000032775744,0.0003511212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770844,0.00037371193,0.00021574802,0.0005660063,0.0007407686,0.00039531983],"domain_scores_gemma":[0.9986127,0.0005982793,0.000031265252,0.00021627195,0.0002779902,0.00026347814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025385711,0.00014772598,0.00018656878,0.0004780487,0.00025020886,0.00016990164,0.000031698914,0.00009788974,0.00010249668],"category_scores_gemma":[0.00027328855,0.0001307158,0.000031113166,0.0007287165,0.0003332305,0.00026161093,0.0000919489,0.0005009338,0.00004124399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019392377,0.0000808391,0.00040274314,0.00043179537,0.0000100976,0.00032599698,0.0008932782,0.0000029300863,0.9650985,0.0002620887,0.0030902599,0.027462251],"study_design_scores_gemma":[0.0014880128,0.0015150055,0.2367975,0.0029958298,0.000018979475,0.0001726609,0.00029551837,0.0004154313,0.7449254,0.0005959052,0.010527082,0.00025266912],"about_ca_topic_score_codex":0.00006420953,"about_ca_topic_score_gemma":0.000056537625,"teacher_disagreement_score":0.23639476,"about_ca_system_score_codex":0.0002963568,"about_ca_system_score_gemma":0.00032495792,"threshold_uncertainty_score":0.53304356},"labels":[],"label_agreement":null},{"id":"W4402266520","doi":"10.1158/1538-7445.pediatric24-b004","title":"Abstract B004: Putting function back into paediatric cancer genomics – modelling the therapeutic implications of novel genomic features","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Genomics; Cancer; Function (biology); Computational biology; Medicine; Bioinformatics; Biology; Genome; Genetics; Internal medicine; Gene","score_opus":0.16794160001133024,"score_gpt":0.4390033547135228,"score_spread":0.27106175470219257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402266520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7463335,0.19429103,0.020874353,0.032076377,0.0013229762,0.0021744273,0.00032688046,0.00016212989,0.0024383743],"genre_scores_gemma":[0.9820842,0.013515052,0.00065924274,0.00046002545,0.0016902339,0.0006853783,0.000028855007,0.00008219324,0.00079479045],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980611,0.00006531177,0.00039384275,0.00047614172,0.00052670465,0.00047690712],"domain_scores_gemma":[0.99837786,0.00042580176,0.000087528795,0.0005284241,0.00045675947,0.00012360953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010281224,0.00017668377,0.00024016302,0.00034182135,0.0003008422,0.000100085774,0.0002825143,0.00013867325,0.00069144624],"category_scores_gemma":[0.000017260147,0.00013069423,0.00015519939,0.0010623464,0.00026201282,0.00012094205,0.000072538576,0.0009394775,0.00006206447],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037779566,0.0001156976,0.0007542551,0.00093651866,0.00046701584,0.000002570556,0.002238122,0.05053859,0.81999946,0.002691812,0.0110507645,0.110827416],"study_design_scores_gemma":[0.008415875,0.00093925494,0.06929862,0.003913634,0.0011504357,0.0001353431,0.0026800248,0.09881656,0.17251354,0.047381256,0.59312916,0.0016262847],"about_ca_topic_score_codex":0.0016814899,"about_ca_topic_score_gemma":0.00011547824,"teacher_disagreement_score":0.6474859,"about_ca_system_score_codex":0.0012765706,"about_ca_system_score_gemma":0.0014700326,"threshold_uncertainty_score":0.75708514},"labels":[],"label_agreement":null},{"id":"W4402413491","doi":"10.1038/s41467-024-51972-9","title":"Cation-induced intramolecular coil-to-globule transition in poly(ADP-ribose)","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Materials Research; National Institute of General Medical Sciences; Biological and Environmental Research; Natural Sciences and Engineering Research Council of Canada; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; Empire State Development Corporation; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; National Science Foundation; Brookhaven National Laboratory; U.S. Department of Energy","keywords":"Intramolecular force; Biophysics; Transition (genetics); Chemistry; Electromagnetic coil; Crystallography; Materials science; Stereochemistry; Biochemistry; Physics; Biology","score_opus":0.025943767690743177,"score_gpt":0.3679776530000493,"score_spread":0.3420338853093061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402413491","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36510307,0.0653628,0.01107994,0.5170283,0.0017547492,0.0030123761,0.0002273085,0.0011318434,0.03529965],"genre_scores_gemma":[0.98924136,0.0005020127,0.0041850666,0.0051344833,0.000185841,0.00024391939,0.0003597576,0.000037396225,0.00011014555],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988429,0.00012522431,0.0003077684,0.00027225653,0.0002497216,0.00020213159],"domain_scores_gemma":[0.9981526,0.00012763274,0.00002630401,0.0014144733,0.0001514913,0.00012750653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026076243,0.00014752502,0.00019399244,0.00038291374,0.00011294132,0.00005055957,0.00037419394,0.00030562704,0.000099682366],"category_scores_gemma":[0.000089083354,0.00015302676,0.000092474926,0.0012087076,0.000054791853,0.000120843884,0.000051311967,0.0012459311,0.00017460364],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005337625,0.0022712615,0.0013938375,0.0005256256,0.0006208873,0.00018839195,0.020514851,0.00039078481,0.65149367,0.18691999,0.06989336,0.06525358],"study_design_scores_gemma":[0.0054888884,0.0007057859,0.022655727,0.0036630474,0.00041613734,0.000487183,0.0015017254,0.045300756,0.06958624,0.0068229553,0.8419174,0.0014541484],"about_ca_topic_score_codex":0.0001098309,"about_ca_topic_score_gemma":0.00034751178,"teacher_disagreement_score":0.77202404,"about_ca_system_score_codex":0.00036531102,"about_ca_system_score_gemma":0.0002729411,"threshold_uncertainty_score":0.62402505},"labels":[],"label_agreement":null},{"id":"W4402510606","doi":"10.5194/egusphere-2024-1916-ac1","title":"Reply on RC1/RC2","year":2024,"lang":"en","type":"peer-review","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Computer science","score_opus":0.07207785681830353,"score_gpt":0.40708434350453054,"score_spread":0.335006486686227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402510606","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013083803,0.09050056,0.000015333315,0.4441721,0.0051635527,0.0005900712,0.00017529316,0.0003199452,0.45906183],"genre_scores_gemma":[0.0000066719485,0.022768669,0.00017247496,0.27278107,0.0024356677,0.00015378259,0.00073285477,0.00008330234,0.7008655],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785304,0.00003657445,0.00047868688,0.00065393193,0.00072485954,0.00025288414],"domain_scores_gemma":[0.998448,0.00008361756,0.000107224216,0.0010250533,0.00017770084,0.00015836641],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032712708,0.0003555606,0.0008236622,0.00018891919,0.00002461046,0.00002189449,0.00013153366,0.00023444074,0.03046756],"category_scores_gemma":[0.00010424998,0.00025890267,0.00039582903,0.00027069406,0.000052434803,0.000017045873,0.00003920181,0.0009413784,0.010496417],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003785955,0.000042236592,5.411629e-7,0.006838858,0.00015327333,0.00013866613,0.000009605495,8.567298e-8,0.000016104495,0.000506468,0.98415357,0.008102741],"study_design_scores_gemma":[0.00043320897,0.00028300812,0.0000032488047,0.03500183,0.00035317635,0.00012250799,0.0000025401653,0.000001937203,0.0003296967,0.00039505996,0.9628345,0.00023932652],"about_ca_topic_score_codex":0.00008087929,"about_ca_topic_score_gemma":0.0000093587305,"teacher_disagreement_score":0.24180366,"about_ca_system_score_codex":0.00033915436,"about_ca_system_score_gemma":0.0004243507,"threshold_uncertainty_score":0.9999863},"labels":[],"label_agreement":null},{"id":"W4402511951","doi":"10.1101/2024.09.09.612065","title":"DNA Damage Response Deficiency Enhances Neuroblastoma Progression and Sensitivity to Combination PARP and ATR Inhibition","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"DNA damage; Neuroblastoma; Poly ADP ribose polymerase; Sensitivity (control systems); Cancer research; DNA; Biology; Genetics; Polymerase; Cell culture; Engineering","score_opus":0.013055074316886416,"score_gpt":0.27149581309864057,"score_spread":0.25844073878175416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402511951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922348,0.0011290925,0.00045918478,0.0033102725,0.0007080636,0.0014943818,0.00015829263,0.00049190957,0.00001399338],"genre_scores_gemma":[0.9969499,0.00023572956,0.0016272634,0.00055871654,0.00024801522,0.00026032727,8.4590147e-7,0.00010966414,0.0000095246],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969443,0.00042808405,0.0004770507,0.001218001,0.0005272714,0.00040530958],"domain_scores_gemma":[0.9981134,0.0001842178,0.0002509094,0.0006619524,0.00040518408,0.00038436966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014390952,0.00050016044,0.00054237637,0.00053849205,0.00019285637,0.00024709952,0.00005997736,0.00039931978,0.000012789585],"category_scores_gemma":[0.00036631327,0.0005093472,0.00007970363,0.0005777095,0.00023605333,0.00014469183,0.00051350467,0.00079142005,0.00003818359],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008015269,0.00016097512,0.0009295461,0.0009625954,0.00003394952,0.00035059717,0.00006464166,0.0000043121354,0.99599963,0.00030865712,0.00036117277,0.000022382734],"study_design_scores_gemma":[0.0010809227,0.0005817156,0.23149818,0.0032721683,0.00013729552,0.0000010255103,0.000007021468,0.000443267,0.7614317,0.00002135066,0.0009925426,0.00053283834],"about_ca_topic_score_codex":0.000011255759,"about_ca_topic_score_gemma":0.0000031414208,"teacher_disagreement_score":0.23456797,"about_ca_system_score_codex":0.00030631133,"about_ca_system_score_gemma":0.0004370017,"threshold_uncertainty_score":0.99973583},"labels":[],"label_agreement":null},{"id":"W4402558349","doi":"10.1016/j.annonc.2024.08.1366","title":"1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"PARP inhibitor; Medicine; Homologous recombination; Cancer research; Poly ADP ribose polymerase; Olaparib; Phenotype; Lung cancer; Pathology; Genetics; Gene; Polymerase; Biology","score_opus":0.027569503970829617,"score_gpt":0.3603600992103541,"score_spread":0.3327905952395245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729568,0.011266977,0.0029532278,0.010034928,0.00081512623,0.0012681421,0.0002984499,0.000037321453,0.00036903072],"genre_scores_gemma":[0.9961866,0.0009787584,0.0006407018,0.001384908,0.00016549413,0.00021490143,0.00014275893,0.00003564304,0.00025019064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976891,0.00022763648,0.0008593976,0.00052023685,0.00036690483,0.00033667788],"domain_scores_gemma":[0.99745643,0.00038689433,0.00044878322,0.00043065686,0.0011520773,0.00012518217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000830943,0.00024550094,0.00078382343,0.001013019,0.00014220065,0.000031933396,0.00022701883,0.0002706841,0.0003752822],"category_scores_gemma":[0.00007281544,0.00020825976,0.0003255183,0.0015115885,0.00017985346,0.00012455307,0.00006960222,0.00032614835,0.000006171737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034998574,0.0027374418,0.0074656745,0.0017855347,0.00404793,0.00006280585,0.010603818,0.026608769,0.90109164,0.00039668757,0.024144618,0.017555244],"study_design_scores_gemma":[0.02217669,0.032523006,0.31689748,0.0029161444,0.025223969,0.000096288284,0.004031522,0.11379419,0.45343354,0.0011399792,0.02535437,0.0024128181],"about_ca_topic_score_codex":0.0009146002,"about_ca_topic_score_gemma":0.0013420957,"teacher_disagreement_score":0.44765806,"about_ca_system_score_codex":0.00022352257,"about_ca_system_score_gemma":0.0013930888,"threshold_uncertainty_score":0.84925866},"labels":[],"label_agreement":null},{"id":"W4402559864","doi":"10.1016/j.annonc.2024.08.812","title":"751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Bevacizumab; Carboplatin; Paclitaxel; Oncology; Internal medicine; Ovarian cancer; Chemotherapy; Cancer; Adverse effect; Cisplatin","score_opus":0.02996050006913973,"score_gpt":0.37450741893861755,"score_spread":0.3445469188694778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881659,0.0011092522,0.0003481787,0.005526539,0.00038348456,0.003143131,0.0003432069,0.000030634048,0.0009496791],"genre_scores_gemma":[0.997123,0.0005124565,0.0003267235,0.0011201854,0.000087843466,0.0005787707,0.00013135812,0.00004307111,0.00007660538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963011,0.00054237794,0.0014133737,0.0006881501,0.0005426135,0.0005123497],"domain_scores_gemma":[0.99756914,0.0008781431,0.0005835046,0.0004493733,0.0003880543,0.00013177386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001533289,0.00035389693,0.0013177012,0.00027497803,0.00006289064,0.000018049008,0.0001977036,0.00025701761,0.00009327617],"category_scores_gemma":[0.00047880507,0.00026596052,0.00014499763,0.0007538087,0.00039897897,0.00027344486,0.00004003585,0.00054003,0.0000015092851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7222874,0.010061695,0.033947356,0.001136544,0.00079608214,0.00055083405,0.02594181,0.0010449273,0.013797302,0.0009791916,0.0077615553,0.18169527],"study_design_scores_gemma":[0.84884465,0.034749374,0.09211045,0.0026468828,0.0003383106,0.000069026515,0.0022747773,0.0030371968,0.006589432,0.0018549983,0.0066964286,0.0007884745],"about_ca_topic_score_codex":0.0023757215,"about_ca_topic_score_gemma":0.002786439,"teacher_disagreement_score":0.18090679,"about_ca_system_score_codex":0.0005064347,"about_ca_system_score_gemma":0.0010832029,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W4402565436","doi":"10.1016/j.annonc.2024.08.2272","title":"LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Stand Up To Cancer; PharmaMar; Vifor Pharma; Eisai; Cancer Australia; European Commission; Canadian Cancer Society; Seagen; Aldeyra Therapeutics; MacroGenics; Veracyte; Austrian Science Fund; Amgen; Deciphera Pharmaceuticals; Clovis Oncology; Les Laboratories Pierre Fabre; National Health and Medical Research Council; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Mersana Therapeutics; Stryker; Pfizer; Incyte; EQRx; F. Hoffmann-La Roche; Verastem Oncology; Array BioPharma; Hexal AG; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Exelixis; Sanofi; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Medicine; Ovarian cancer; Oncology; Internal medicine; Randomized controlled trial; Maintenance therapy; Cancer; Chemotherapy","score_opus":0.04611177208356617,"score_gpt":0.40641699276092813,"score_spread":0.360305220677362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774116,0.00014376848,0.00073548954,0.015613496,0.0002835404,0.0054914956,0.00008823801,0.000038917326,0.00019345227],"genre_scores_gemma":[0.9923073,0.000064010615,0.00088095356,0.0058646174,0.00008175838,0.00058590533,0.000021555807,0.00005798012,0.00013589425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966433,0.0008429926,0.0008874798,0.0005800793,0.0006804462,0.00036568326],"domain_scores_gemma":[0.9958543,0.0027217371,0.00028340405,0.00037707426,0.0006090278,0.00015445657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030710122,0.0003371741,0.0013986798,0.00045801103,0.00006535227,0.000024917488,0.00018439561,0.0001051665,0.00015080921],"category_scores_gemma":[0.00053733226,0.00019082353,0.00014194688,0.0007740812,0.00026653666,0.000106082625,0.000033418626,0.00032344126,0.000002403328],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9480841,0.0027557882,0.0042027733,0.000022406562,0.0017508526,0.00016346341,0.018437868,0.0005054529,0.0068403194,0.000030343064,0.00058467087,0.016621934],"study_design_scores_gemma":[0.90013367,0.03085492,0.04933237,0.0016573442,0.0002267101,0.000016217627,0.0011951964,0.0011955138,0.012945382,0.000034612483,0.0020632467,0.00034480979],"about_ca_topic_score_codex":0.000387328,"about_ca_topic_score_gemma":0.0003269814,"teacher_disagreement_score":0.047950447,"about_ca_system_score_codex":0.0002077445,"about_ca_system_score_gemma":0.00096791936,"threshold_uncertainty_score":0.77815574},"labels":[],"label_agreement":null},{"id":"W4402565842","doi":"10.1016/j.annonc.2024.08.2269","title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Ovarian cancer; Maintenance therapy; Cancer; Chemotherapy; Immunotherapy","score_opus":0.06469292880486023,"score_gpt":0.40063125342927786,"score_spread":0.33593832462441764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402565842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97895604,0.0021843205,0.00050028757,0.008213368,0.0010559019,0.005692085,0.00004464049,0.00012569063,0.0032276826],"genre_scores_gemma":[0.98517215,0.0079821395,0.00028359197,0.0027996781,0.0003025136,0.0025355965,0.00012286927,0.00008539458,0.0007160497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964334,0.0005924436,0.0011927794,0.00068587845,0.0004900039,0.00060553825],"domain_scores_gemma":[0.9976056,0.00079172925,0.00054971786,0.00046733517,0.000390263,0.00019531375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093507115,0.000480217,0.0022407414,0.00051311863,0.00009347239,0.000044165958,0.00020004953,0.00028162674,0.000545465],"category_scores_gemma":[0.00008036766,0.0003594941,0.000393553,0.0005666529,0.00040194934,0.00022359665,0.000019605888,0.00035073937,0.000017970318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8712304,0.0073440475,0.0016204949,0.00004688776,0.0011310397,0.00013071034,0.004880616,0.00009390689,0.0004288376,0.0023269614,0.0024823511,0.108283706],"study_design_scores_gemma":[0.938386,0.026755435,0.0009084858,0.0006218937,0.00014110708,0.000015174024,0.00012989025,0.0017961843,0.0033051781,0.001772077,0.025830153,0.00033837755],"about_ca_topic_score_codex":0.004814446,"about_ca_topic_score_gemma":0.00061541464,"teacher_disagreement_score":0.10794533,"about_ca_system_score_codex":0.0009287415,"about_ca_system_score_gemma":0.0012668567,"threshold_uncertainty_score":0.9998857},"labels":[],"label_agreement":null},{"id":"W4402667247","doi":"10.1016/j.mbs.2024.109301","title":"A joint-threshold Filippov model describing the effect of intermittent androgen-deprivation therapy in controlling prostate cancer","year":2024,"lang":"en","type":"article","venue":"Mathematical Biosciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; National Natural Science Foundation of China","keywords":"Androgen deprivation therapy; Prostate cancer; Joint (building); Medicine; Cancer; Internal medicine; Oncology; Urology; Engineering","score_opus":0.0825050454956979,"score_gpt":0.3311779263676981,"score_spread":0.2486728808720002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402667247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982537,0.0022470313,0.0030470083,0.003198322,0.00013429925,0.0009169896,0.000009752065,0.000055996727,0.00056525157],"genre_scores_gemma":[0.998634,0.00033413156,0.0003604725,0.00027058762,0.00004163765,0.00025100028,0.0000011603727,0.000012582717,0.000094442614],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986036,0.000053838172,0.00042291445,0.00027391134,0.00041596737,0.0002297961],"domain_scores_gemma":[0.9993812,0.0002654317,0.00006936044,0.00019219305,0.00003903612,0.0000527892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011311352,0.0001422246,0.00032711204,0.0001455994,0.000058855465,0.00006677976,0.0001330913,0.00004885468,0.00007445458],"category_scores_gemma":[0.00011264761,0.00007193904,0.00011401043,0.00046817955,0.00032461958,0.00013261705,0.000027664422,0.00017078112,0.000008297175],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081549626,0.00024201877,0.010221946,0.001345989,0.00013973837,0.00003516832,0.009689747,0.0027102302,0.87351775,0.009781395,0.00029749202,0.09120301],"study_design_scores_gemma":[0.0016021479,0.0006411005,0.00031816607,0.002555527,0.000034350334,0.000023662376,0.00019739511,0.6757648,0.3087768,0.009905597,0.000047157442,0.00013329273],"about_ca_topic_score_codex":0.000011133217,"about_ca_topic_score_gemma":0.0000035405483,"teacher_disagreement_score":0.6730546,"about_ca_system_score_codex":0.00008319202,"about_ca_system_score_gemma":0.00010269828,"threshold_uncertainty_score":0.29335886},"labels":[],"label_agreement":null},{"id":"W4402704898","doi":"10.1016/j.annonc.2024.08.1707","title":"1626P Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Germline; Somatic cell; Incidence (geometry); Homologous recombination; Cancer research; Gene; Oncology; Genetics; Biology","score_opus":0.04936451172287829,"score_gpt":0.36329275357948987,"score_spread":0.31392824185661156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932184,0.0006466657,0.00019416363,0.0047152257,0.00025229526,0.0007920257,0.00003457904,0.000016384105,0.00013022427],"genre_scores_gemma":[0.9991022,0.0002379142,0.00027142998,0.00019768969,0.00005311114,0.000067157445,0.000028027232,0.0000074151067,0.00003508808],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983278,0.00040303293,0.00071805,0.00015552493,0.0002777008,0.000117921176],"domain_scores_gemma":[0.998326,0.0005039251,0.00065538555,0.00020864532,0.00029157253,0.000014458379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012757813,0.000099544806,0.0004471872,0.00017878108,0.00003906087,0.000005062511,0.000088304514,0.0001334694,0.000019275165],"category_scores_gemma":[0.00026344843,0.000056841654,0.00011075267,0.00037233828,0.00016689769,0.00008439742,0.00002273957,0.00014346212,2.7628826e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04583298,0.010875731,0.29386652,0.006171792,0.002264257,0.00012392637,0.057369974,0.007985932,0.4912469,0.052397925,0.00737201,0.02449204],"study_design_scores_gemma":[0.03489181,0.028318224,0.3909555,0.0025245268,0.00059313513,0.0006943305,0.0037955982,0.01476924,0.4846139,0.037974913,0.00042330337,0.00044551294],"about_ca_topic_score_codex":0.00017686076,"about_ca_topic_score_gemma":0.00009907024,"teacher_disagreement_score":0.097088985,"about_ca_system_score_codex":0.00010176534,"about_ca_system_score_gemma":0.00021220416,"threshold_uncertainty_score":0.23179355},"labels":[],"label_agreement":null},{"id":"W4402704941","doi":"10.1016/j.annonc.2024.08.1714","title":"1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Bavarian Nordic; Merck KGaA; Pfizer; CMC Microsystems; National Cancer Institute; National Institutes of Health","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Internal medicine; Cancer; Pathology; Alternative medicine; Androgen receptor","score_opus":0.056709507383788174,"score_gpt":0.4136443889298662,"score_spread":0.35693488154607805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402704941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986924,0.0011909417,0.000013771124,0.0019195135,0.00028601085,0.004995258,0.00043972436,0.00006162535,0.0012239474],"genre_scores_gemma":[0.9958949,0.0007978113,0.00013227024,0.0003331816,0.00008515317,0.0018120847,0.0002071322,0.000069081245,0.0006683911],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99648213,0.00026074186,0.001310475,0.00071992545,0.00069721317,0.0005295321],"domain_scores_gemma":[0.9980539,0.00027227763,0.00055580516,0.00049148616,0.0004124892,0.00021402678],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005872595,0.00046507956,0.0013907144,0.00047678404,0.00008442792,0.000020412033,0.00014322587,0.0001305769,0.0004490283],"category_scores_gemma":[0.00007111927,0.0003619623,0.00015229864,0.00069375767,0.00027660237,0.00021326954,0.000040868596,0.00029955484,0.0000133509375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27373272,0.12399195,0.33149648,0.0032024751,0.014518792,0.005337562,0.06313686,0.010130857,0.026286565,0.0007673361,0.0075466363,0.13985178],"study_design_scores_gemma":[0.26892954,0.36122513,0.23387557,0.0031392418,0.0031553584,0.0001979318,0.00406398,0.0017161652,0.08491526,0.0006534488,0.036612947,0.0015154207],"about_ca_topic_score_codex":0.0047615273,"about_ca_topic_score_gemma":0.007430956,"teacher_disagreement_score":0.23723318,"about_ca_system_score_codex":0.0006802953,"about_ca_system_score_gemma":0.0013409898,"threshold_uncertainty_score":0.99988323},"labels":[],"label_agreement":null},{"id":"W4402717809","doi":"10.1101/2024.09.18.613621","title":"Loss of PARP7 increases type I interferon signalling and prevents pancreatic tumour growth by enhancing immune cell infiltration","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Infiltration (HVAC); Interferon; Immune system; Signalling; Cancer research; Cell biology; Biology; Immunology; Materials science","score_opus":0.011208564327385406,"score_gpt":0.23880582300876405,"score_spread":0.22759725868137864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402717809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98367274,0.0134744225,0.00090325624,0.00010403321,0.0005313961,0.0008815575,0.00018892762,0.00022155498,0.000022122218],"genre_scores_gemma":[0.9955103,0.0023512545,0.0013937781,0.00010280821,0.00032993066,0.00014081887,0.0000037208154,0.0001500502,0.000017372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973076,0.00015310357,0.0009307885,0.0008021713,0.0004313469,0.0003750077],"domain_scores_gemma":[0.9980434,0.00012946862,0.00055895315,0.000541504,0.00049743545,0.00022920364],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005861541,0.0005301496,0.0008849766,0.0003045354,0.00007107231,0.00009818868,0.0002035138,0.000398664,0.00007573375],"category_scores_gemma":[0.00016513001,0.0005534429,0.00014264208,0.00042295706,0.0001446195,0.00011168782,0.00029668157,0.00083898276,0.000027535316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027812857,0.00021028118,0.004801756,0.004112499,0.00025306738,0.00003469269,0.000036801273,0.000009461876,0.99000305,0.00006845253,0.00019065045,0.0000011311287],"study_design_scores_gemma":[0.00093664293,0.00035454246,0.007241522,0.005954199,0.0004949988,1.4339697e-7,0.0000089403175,0.00018336724,0.9842619,0.000021570413,0.00008714398,0.00045508],"about_ca_topic_score_codex":0.00023590142,"about_ca_topic_score_gemma":0.0000016584215,"teacher_disagreement_score":0.011837537,"about_ca_system_score_codex":0.00033689986,"about_ca_system_score_gemma":0.0006624762,"threshold_uncertainty_score":0.9996917},"labels":[],"label_agreement":null},{"id":"W4402787403","doi":"10.2139/ssrn.4954552","title":"Adverse Events in the Placebo Arm of Solo2/Engot-Ov21 Maintenance Trial of Olaparib in Recurrent Ovarian Cancer","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Olaparib; Ovarian cancer; Placebo; Adverse effect; Medicine; Oncology; Internal medicine; Cancer; Alternative medicine; Biology; Pathology","score_opus":0.024350747634679853,"score_gpt":0.33752289403333846,"score_spread":0.3131721463986586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402787403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685055,0.016301634,0.0003670976,0.006696776,0.0035383997,0.0027238878,0.000094447554,0.000021339778,0.0017508965],"genre_scores_gemma":[0.9688798,0.029273959,0.00005977517,0.00014401018,0.0008655879,0.00029475635,0.00001830501,0.000049518883,0.0004142582],"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9952608,0.00049007765,0.0014033003,0.00046012172,0.00081935147,0.0015663897],"domain_scores_gemma":[0.9981866,0.00014360873,0.0008887595,0.00052834995,0.00017604836,0.00007662832],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005274722,0.0003706681,0.00094913883,0.0005574999,0.00003377492,0.000006733262,0.0005419135,0.00034536538,0.000120814206],"category_scores_gemma":[0.0001656226,0.00027266087,0.00045019423,0.00048511312,0.00011854051,0.00004673821,0.00016539135,0.008635786,0.000006587738],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6419015,0.011084427,0.014262772,0.005001857,0.007157691,0.00045753364,0.02476471,0.007942909,0.0044231573,0.14651984,0.0047692284,0.13171436],"study_design_scores_gemma":[0.23491141,0.005462649,0.0042964183,0.019247523,0.00086729747,0.0009421599,0.0054778955,0.00091509277,0.0014807029,0.721879,0.003550737,0.00096910214],"about_ca_topic_score_codex":0.0008955774,"about_ca_topic_score_gemma":0.0048370096,"teacher_disagreement_score":0.57535917,"about_ca_system_score_codex":0.004041866,"about_ca_system_score_gemma":0.01127203,"threshold_uncertainty_score":0.9999726},"labels":[],"label_agreement":null},{"id":"W4402939005","doi":"10.1073/pnas.2318098121","title":"Poly ADP-ribose signaling is dysregulated in Huntington disease","year":2024,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Structural Genomics Consortium; University of Toronto; McMaster University","funders":"National Institute of Neurological Disorders and Stroke; Medical Research Council; Canadian Institutes of Health Research; School of Medicine, Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Genentech; Medical Research Council Centre for Neurodevelopmental Disorders; Krembil Foundation; National Institute of General Medical Sciences; Ontario Genomics Institute; University of Toronto; University College London; European Federation of Pharmaceutical Industries and Associations; McMaster University; Merck KGaA; National Institutes of Health; Ontario Genomics; F. Hoffmann-La Roche; Genome Canada; University of California, Irvine; CHDI Foundation; McGill University; National Cancer Institute; Bayer; Johns Hopkins University; Pfizer; UK Research and Innovation; Bristol-Myers Squibb","keywords":"Huntington's disease; Cytosine; Guanine; Disease; Ribose; Cancer research; Genetics; Chemistry; Biology; Medicine; Biochemistry; DNA; Internal medicine; Nucleotide; Gene; Enzyme","score_opus":0.046191735055864255,"score_gpt":0.35334747175739595,"score_spread":0.3071557367015317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402939005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692114,0.0016674963,9.382241e-7,0.025126493,0.00004187321,0.00019634007,0.00002098437,0.000030845702,0.0037036412],"genre_scores_gemma":[0.9978282,0.000037811675,0.00045395194,0.0011216861,0.00018319325,0.000011818436,2.272983e-7,0.0000064136693,0.00035670376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815506,0.0000041692874,0.00033259092,0.00025553588,0.0011063186,0.00014633703],"domain_scores_gemma":[0.99952906,0.000086910215,0.00015114521,0.000007471373,0.00017040988,0.000055026132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096922944,0.00008625229,0.00014433294,0.00033155666,0.0000733896,0.000027348837,0.0002718643,0.00005964598,0.00009225387],"category_scores_gemma":[0.00023467584,0.000059486185,0.00008835113,0.0013565384,0.00050422223,0.0003434786,0.000049800557,0.00019416124,0.0000035923229],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014242424,0.00009407206,0.023480006,0.00052913564,0.000038146634,8.411836e-8,0.0008113387,0.000048343467,0.9406218,0.028627586,0.003603733,0.0020033428],"study_design_scores_gemma":[0.00042773387,0.000047310583,0.08521484,0.0018989285,0.000028641194,0.000006073916,0.00012779117,0.0041596415,0.85550404,0.051268823,0.0012164343,0.0000997418],"about_ca_topic_score_codex":0.000006326604,"about_ca_topic_score_gemma":1.5907393e-8,"teacher_disagreement_score":0.08511775,"about_ca_system_score_codex":0.00008240581,"about_ca_system_score_gemma":0.000114108145,"threshold_uncertainty_score":0.24257761},"labels":[],"label_agreement":null},{"id":"W4403089488","doi":"10.1200/jco.24.00683","title":"Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Olaparib; Medicine; Ovarian cancer; Refractory (planetary science); Oncology; Platinum; Internal medicine; Chemotherapy; Cancer; Poly ADP ribose polymerase","score_opus":0.10801391311127237,"score_gpt":0.4447158440343639,"score_spread":0.33670193092309153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96631116,0.002910007,0.0005576972,0.023629528,0.002651112,0.0011513211,0.000071352624,0.00010330417,0.00261452],"genre_scores_gemma":[0.97481984,0.006049335,0.006722253,0.008342573,0.0020688209,0.000056978697,0.000024469682,0.00010959332,0.0018061252],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377686,0.00060511584,0.0036458038,0.0005670746,0.00090456725,0.0005006027],"domain_scores_gemma":[0.99157417,0.0053740046,0.0017279505,0.0003179916,0.00046891242,0.00053695374],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003481626,0.0004246396,0.0027520754,0.00044344086,0.00009597611,0.00006628799,0.00025840264,0.00070017605,0.0015763681],"category_scores_gemma":[0.00095913786,0.00024738288,0.00023473088,0.000697107,0.0005177295,0.00044764217,0.000045672088,0.002162632,0.000010543963],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6268571,0.007878601,0.041090976,0.0016976793,0.0031920534,0.012908715,0.0036425567,0.00012814724,0.012481604,0.0006942223,0.051410474,0.23801789],"study_design_scores_gemma":[0.14858878,0.048831765,0.36909348,0.005477154,0.0008853069,0.0030820465,0.0006751547,0.0018114506,0.0007102893,0.0005682579,0.4194514,0.0008249354],"about_ca_topic_score_codex":0.00015679127,"about_ca_topic_score_gemma":0.0017175571,"teacher_disagreement_score":0.4782683,"about_ca_system_score_codex":0.0012132596,"about_ca_system_score_gemma":0.0076184855,"threshold_uncertainty_score":0.99999785},"labels":[],"label_agreement":null},{"id":"W4403089973","doi":"10.1101/2024.10.01.616136","title":"Targeting FEN1 to enhance efficacy of PARP inhibition in triple-negative breast cancer","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; PARP inhibitor; Cancer research; Oncology; Poly ADP ribose polymerase; Medicine; Internal medicine; Cancer; Biology; Genetics; DNA; Polymerase","score_opus":0.014615712320251988,"score_gpt":0.29350561115241197,"score_spread":0.27888989883216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403089973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98895663,0.0024930995,0.00042870277,0.00250818,0.0017383386,0.0022875103,0.0012319457,0.00032596244,0.000029615017],"genre_scores_gemma":[0.99380046,0.00067572005,0.0025809489,0.0006380668,0.0010707167,0.0010242541,0.000001221063,0.00019101426,0.000017618648],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99609745,0.00016496626,0.0011400499,0.0013233898,0.00064706325,0.00062710134],"domain_scores_gemma":[0.99732894,0.00014144975,0.0005252896,0.0009100371,0.00074592937,0.0003483664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077368453,0.0006411646,0.001096676,0.0007829185,0.00006288038,0.00007140923,0.0002030582,0.0005294657,0.00026403088],"category_scores_gemma":[0.00033547622,0.00068477634,0.00023533784,0.0015265471,0.0001553714,0.00010162453,0.0004021576,0.001430382,0.00010984439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007584745,0.0003508854,0.002739147,0.0017658089,0.00024017738,0.00015631733,0.0001493198,0.0005859606,0.99113166,0.00015386568,0.0019498181,0.000018580246],"study_design_scores_gemma":[0.0019448327,0.0001059161,0.07514127,0.010466644,0.00017025806,1.04135175e-7,0.000011806952,0.00023625907,0.91060364,0.000015373782,0.0005821138,0.0007217559],"about_ca_topic_score_codex":0.00044307433,"about_ca_topic_score_gemma":0.000014512179,"teacher_disagreement_score":0.080527976,"about_ca_system_score_codex":0.0014109013,"about_ca_system_score_gemma":0.0014569034,"threshold_uncertainty_score":0.99956036},"labels":[],"label_agreement":null},{"id":"W4403249848","doi":"10.1016/j.ygyno.2024.07.392","title":"Outcomes of niraparib first-line maintenance among patients with BRCA wild-type advanced ovarian cancer in a real-world clinical setting","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hôpital Maisonneuve-Rosemont; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Ovarian cancer; Internal medicine; Gynecology; Cancer","score_opus":0.03439876027864869,"score_gpt":0.39291256203307656,"score_spread":0.3585138017544279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403249848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839371,0.0002969533,0.00007635544,0.0058977418,0.0019540905,0.0011445297,0.00005843168,0.00016420688,0.006470632],"genre_scores_gemma":[0.9924224,0.0009631602,0.0024734288,0.001981531,0.00014835129,0.0002665594,0.00004667584,0.000044283548,0.0016536028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714774,0.000230673,0.0011197098,0.0006740582,0.00026865196,0.0005591892],"domain_scores_gemma":[0.99705935,0.0017304309,0.00039001735,0.00039210447,0.00027527116,0.00015284937],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000837955,0.00028764023,0.0011493285,0.0003163954,0.00005983131,0.00000977737,0.0001780889,0.0003263443,0.0009625812],"category_scores_gemma":[0.00062591373,0.00020728196,0.00014534913,0.00091090257,0.00045443946,0.00013281372,0.000078331555,0.0007219901,0.000023512133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012547319,0.00065674365,0.9463308,0.0001233832,0.0002226298,0.00022651276,0.00019826899,0.00043433232,0.000034109187,0.00032268692,0.0017095469,0.04848628],"study_design_scores_gemma":[0.008544556,0.003330133,0.96437716,0.00048106126,0.0001178195,0.000005104165,0.0000650326,0.0004278738,0.00005674421,0.00039243794,0.021983111,0.0002189434],"about_ca_topic_score_codex":0.0004644112,"about_ca_topic_score_gemma":0.013939405,"teacher_disagreement_score":0.04826734,"about_ca_system_score_codex":0.0010543739,"about_ca_system_score_gemma":0.0008106685,"threshold_uncertainty_score":0.99995065},"labels":[],"label_agreement":null},{"id":"W4403250000","doi":"10.1016/j.ygyno.2024.07.593","title":"Predictors for PARP inhibitor hematologic toxicity in ovarian cancer: Are patients with chemotherapy-induced toxicity at an increased risk?","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Toxicity; Ovarian cancer; Chemotherapy; Oncology; Internal medicine; PARP inhibitor; Pharmacology; Cancer; Poly ADP ribose polymerase; Genetics","score_opus":0.02311995834596108,"score_gpt":0.31787791736721444,"score_spread":0.29475795902125335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403250000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914749,0.00030935966,0.00016230925,0.0022461072,0.0010991105,0.0031718337,0.00042158942,0.00039698707,0.00071777205],"genre_scores_gemma":[0.9925548,0.0001795281,0.0012507786,0.003230774,0.00040765374,0.0020093734,0.00019363617,0.00007560545,0.00009787459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658024,0.0004380432,0.00072843645,0.0010862921,0.00034723838,0.0008197544],"domain_scores_gemma":[0.9974868,0.0010199905,0.00041027548,0.0005007285,0.00022776733,0.00035441],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078264426,0.000480609,0.0011355876,0.00032344164,0.00021836402,0.000031534495,0.00023433362,0.0007835997,0.001153167],"category_scores_gemma":[0.0004169679,0.000364043,0.00017205921,0.0005925951,0.00024742974,0.00020072487,0.000072340816,0.0006342999,0.00002834652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005506391,0.002572545,0.96617436,0.00028727832,0.00032704015,0.00021845469,0.000674038,0.000048591002,0.012625433,0.00016140853,0.0042743157,0.0071301367],"study_design_scores_gemma":[0.018707579,0.011814434,0.9198661,0.00028957214,0.00023746918,0.000052965148,0.00022184974,0.00063474075,0.032252483,0.00073785806,0.01457476,0.0006101911],"about_ca_topic_score_codex":0.00025997573,"about_ca_topic_score_gemma":0.0032909357,"teacher_disagreement_score":0.046308268,"about_ca_system_score_codex":0.0035599647,"about_ca_system_score_gemma":0.00084094825,"threshold_uncertainty_score":0.99988115},"labels":[],"label_agreement":null},{"id":"W4403250519","doi":"10.1016/j.ygyno.2024.07.441","title":"Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Context (archaeology); Quality of life (healthcare); Oncology; Ovarian cancer; Internal medicine; Cancer; Gynecology; Nursing","score_opus":0.055185630282282426,"score_gpt":0.34160691524997633,"score_spread":0.2864212849676939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403250519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855961,0.001268851,0.00009404246,0.0075448244,0.00032230053,0.0043632677,0.0003502941,0.00014516499,0.00031515697],"genre_scores_gemma":[0.9948831,0.001091818,0.00048750237,0.002442272,0.00006820006,0.00058944983,0.00022872476,0.000057168607,0.00015175769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958045,0.00071971613,0.0015124178,0.00093500555,0.0004070913,0.0006212847],"domain_scores_gemma":[0.99285775,0.0053171134,0.000854736,0.0005210369,0.00024200964,0.00020733813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013487113,0.0004726457,0.0016943867,0.00016196462,0.00018812114,0.000025401208,0.00019292977,0.00034985703,0.00021623836],"category_scores_gemma":[0.00071345083,0.00024420116,0.00006744596,0.00071459106,0.0007710493,0.00016317658,0.000044623594,0.0007624702,0.0000025093186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21655703,0.0010821902,0.7230048,0.00006517574,0.00082551513,0.00005607671,0.005105847,0.0003489437,0.000027046368,0.000077356606,0.00027111912,0.052578896],"study_design_scores_gemma":[0.22349192,0.013684153,0.7598332,0.0007504157,0.0000707225,0.0000037407945,0.00067078153,0.000055566696,0.000031106687,0.000020979218,0.001141596,0.0002457715],"about_ca_topic_score_codex":0.003996932,"about_ca_topic_score_gemma":0.0141309025,"teacher_disagreement_score":0.052333124,"about_ca_system_score_codex":0.00095000595,"about_ca_system_score_gemma":0.0010983917,"threshold_uncertainty_score":0.9958234},"labels":[],"label_agreement":null},{"id":"W4403250854","doi":"10.1016/j.ygyno.2024.07.237","title":"Characterization of epithelial ovarian cancer based on multigene tumor testing and homologous recombination deficiency (HRD) testing (COMBO)","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université Laval","funders":"","keywords":"Homologous recombination; Medicine; Ovarian cancer; Homologous chromosome; Epithelial ovarian cancer; Cancer research; Genetic testing; Oncology; Cancer; Internal medicine; Gene; Genetics; Biology","score_opus":0.055751893199495986,"score_gpt":0.3356247419975424,"score_spread":0.2798728487980464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403250854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093103,0.0001854138,0.00096648757,0.0019270001,0.0012310273,0.0007260774,0.000064821645,0.00023035378,0.0037377845],"genre_scores_gemma":[0.99043244,0.00004489908,0.007467773,0.001441973,0.0002011117,0.00024696626,0.000038442824,0.000028597187,0.00009778464],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983146,0.00024029436,0.00048824403,0.00047239522,0.00017498428,0.00030945623],"domain_scores_gemma":[0.99661726,0.002600465,0.0002591749,0.00018053532,0.00025624587,0.00008631723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080860226,0.00019362931,0.00043148434,0.00030078602,0.00012841752,0.000018356412,0.000081389284,0.00020634568,0.0003572834],"category_scores_gemma":[0.0023017477,0.00017007055,0.000049296337,0.0006125551,0.00018564811,0.000074877884,0.000031728243,0.00030164747,0.000017799317],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024309725,0.0005134721,0.018791117,0.0002801488,0.00002730698,0.00020183268,0.0001979786,0.00033378825,0.7247438,0.00024998083,0.000043096883,0.25437438],"study_design_scores_gemma":[0.0058750585,0.0101154465,0.78739095,0.00080766325,0.00022552481,0.00030463992,0.00007666054,0.12040035,0.06983101,0.0017176521,0.0027911917,0.0004638617],"about_ca_topic_score_codex":0.00011657643,"about_ca_topic_score_gemma":0.000022677068,"teacher_disagreement_score":0.7685998,"about_ca_system_score_codex":0.0005846401,"about_ca_system_score_gemma":0.00072712876,"threshold_uncertainty_score":0.6935275},"labels":[],"label_agreement":null},{"id":"W4403251129","doi":"10.1016/j.ygyno.2024.07.406","title":"Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Ovarian cancer; Oncology; Internal medicine; Cancer","score_opus":0.062247400791230645,"score_gpt":0.3838646518758335,"score_spread":0.3216172510846029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403251129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98615223,0.0020439166,0.000108712244,0.004136465,0.00073436263,0.0012127904,0.000041036277,0.00010655297,0.0054639475],"genre_scores_gemma":[0.9903202,0.0018919627,0.004584041,0.002250196,0.000045852183,0.00048313953,0.000022275397,0.000019663263,0.00038267957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980487,0.00023995298,0.00066624634,0.00046119277,0.00019246533,0.00039141282],"domain_scores_gemma":[0.9987497,0.00068084436,0.00018127864,0.00022481907,0.00005262035,0.00011076166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069264695,0.00019797684,0.0006280175,0.00036306688,0.000043339485,0.0000125890365,0.00008366079,0.00025942412,0.0008335645],"category_scores_gemma":[0.00015571815,0.00016596988,0.00008619336,0.00044406552,0.0002110612,0.00011461158,0.00011839989,0.00031327058,0.000020657437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036672985,0.0030626566,0.46108165,0.0032183842,0.0019543704,0.010575049,0.0057520526,0.0008438392,0.02327794,0.06997957,0.017769063,0.39881814],"study_design_scores_gemma":[0.020985333,0.0040986976,0.7376492,0.0018269295,0.00075377093,0.00038054373,0.0024114815,0.0020851244,0.0047579478,0.008396154,0.21584323,0.0008115847],"about_ca_topic_score_codex":0.0001975304,"about_ca_topic_score_gemma":0.00039719665,"teacher_disagreement_score":0.39800656,"about_ca_system_score_codex":0.0010219862,"about_ca_system_score_gemma":0.00025982966,"threshold_uncertainty_score":0.91269463},"labels":[],"label_agreement":null},{"id":"W4403251174","doi":"10.1016/j.ygyno.2024.07.025","title":"A phase II/III study of cediranib and olaparib combination compared to cediranib or olaparib alone or standard of care chemotherapy, in platinum-resistant ovarian cancer (NRG-GY005)","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Olaparib; Medicine; Ovarian cancer; Oncology; Chemotherapy; Standard of care; Internal medicine; Cancer research; Cancer","score_opus":0.043202448538459996,"score_gpt":0.39464880593340146,"score_spread":0.35144635739494146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403251174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896504,0.0012618811,0.000111594876,0.0030920461,0.00077563775,0.003640203,0.0003367751,0.000119849006,0.0010115736],"genre_scores_gemma":[0.99665517,0.00031055106,0.0009940482,0.0008150483,0.0001089714,0.0006262908,0.000058304493,0.000047564612,0.00038404917],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99671143,0.00030465878,0.0012786727,0.00071959716,0.000493655,0.0004919682],"domain_scores_gemma":[0.9977003,0.00093976175,0.00036291988,0.00039643256,0.00039357797,0.00020700583],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008029622,0.00037332732,0.0017796787,0.00054785394,0.000120814526,0.000018724295,0.00020616932,0.00035255574,0.0020404875],"category_scores_gemma":[0.0002762483,0.00028307643,0.00008177155,0.0010380377,0.0002489962,0.0001084081,0.00011284339,0.00042576328,0.0000028986715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3761105,0.03501531,0.017486855,0.0039797286,0.002424512,0.0027242221,0.1823723,0.00044885982,0.20619962,0.0017656329,0.017782768,0.1536897],"study_design_scores_gemma":[0.40405807,0.37787428,0.048915967,0.0023490102,0.0011986076,0.00018202394,0.050983768,0.0013916232,0.03220843,0.0006570678,0.07878866,0.0013925049],"about_ca_topic_score_codex":0.00081957167,"about_ca_topic_score_gemma":0.015416096,"teacher_disagreement_score":0.34285897,"about_ca_system_score_codex":0.0016096383,"about_ca_system_score_gemma":0.0015084689,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W4403410305","doi":"10.1016/j.jtho.2024.09.178","title":"MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Taiwan University; National Taiwan University Hospital; Saint Petersburg State University; University of Ulsan; Seoul National University Hospital; Moffitt Cancer Center; Seoul National University; Ankara Yıldırım Beyazıt Üniversitesi; McGill University","keywords":"Medicine; Pembrolizumab; Olaparib; Oncology; Internal medicine; Maintenance therapy; Cancer; Immunotherapy; Chemotherapy; Poly ADP ribose polymerase; Polymerase","score_opus":0.06445639390388534,"score_gpt":0.49051155205626484,"score_spread":0.4260551581523795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9158279,0.014619011,0.03056724,0.02731428,0.005262736,0.0036984426,0.000121687495,0.00015651828,0.0024322174],"genre_scores_gemma":[0.9864096,0.0014179327,0.0042982167,0.0024553237,0.0017523037,0.00024821193,0.000016930448,0.00010747749,0.0032939992],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965575,0.00034917588,0.0014404817,0.0004486191,0.0006194239,0.0005848253],"domain_scores_gemma":[0.9967828,0.0010118813,0.0007141491,0.0004240943,0.00071140006,0.00035569046],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020680558,0.0003937583,0.0013913296,0.0005745504,0.00016553904,0.00007476632,0.000335807,0.00018602524,0.0010274152],"category_scores_gemma":[0.00033084885,0.00029206538,0.0005703659,0.00046760074,0.00018723572,0.00027010535,0.00004067001,0.00090673834,0.00015621644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15095344,0.01490695,0.00019376999,0.001043974,0.0047753695,0.013592611,0.008006507,0.00073948904,0.0089221,0.0005728237,0.1028652,0.69342774],"study_design_scores_gemma":[0.07910844,0.09422105,0.00035330607,0.0013233367,0.0023504477,0.019213142,0.003020162,0.00454684,0.006524789,0.005793597,0.7828508,0.00069411634],"about_ca_topic_score_codex":0.000023876477,"about_ca_topic_score_gemma":0.000035185,"teacher_disagreement_score":0.69273365,"about_ca_system_score_codex":0.0014390053,"about_ca_system_score_gemma":0.0021213559,"threshold_uncertainty_score":0.99995315},"labels":[],"label_agreement":null},{"id":"W4403637538","doi":"10.1136/ijgc-2024-005976","title":"How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Duration (music); Ovarian cancer; Term (time); Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.09070783638145405,"score_gpt":0.36343949108522,"score_spread":0.2727316547037659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403637538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95298743,0.00023217,0.0011008637,0.043233752,0.0016650233,0.0004961915,0.00018639883,0.000015980724,0.000082164624],"genre_scores_gemma":[0.99561274,0.0017281644,0.0003205968,0.0017043031,0.0003652481,0.00011806776,0.000050997474,0.000026875137,0.000072977986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975558,0.0002721059,0.0006251741,0.00033447225,0.0010098756,0.00020259751],"domain_scores_gemma":[0.9959757,0.0013167462,0.0007256085,0.00014350955,0.0017360842,0.000102350205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081725663,0.00024312378,0.0003731584,0.0002814762,0.000064003725,0.00017467789,0.0002119082,0.00009051706,0.00026756583],"category_scores_gemma":[0.00053163804,0.00013642311,0.0000809314,0.00026741435,0.00012076656,0.0011039403,0.000036020796,0.00058556313,8.0675676e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007320169,0.00069200865,0.95114887,0.000015674872,0.001145911,0.00017789182,0.0013429003,0.00017966397,0.00007725831,0.00044469084,0.00019582821,0.03725912],"study_design_scores_gemma":[0.004352866,0.0015480275,0.9909251,0.0010661726,0.00005811108,0.000047782967,0.00017450111,0.00017031256,0.0009902258,0.000052422332,0.00044817818,0.00016633078],"about_ca_topic_score_codex":0.0001246434,"about_ca_topic_score_gemma":0.0008350941,"teacher_disagreement_score":0.04262531,"about_ca_system_score_codex":0.0009134162,"about_ca_system_score_gemma":0.00032014487,"threshold_uncertainty_score":0.5563173},"labels":[],"label_agreement":null},{"id":"W4403831142","doi":"10.3390/curroncol31110495","title":"Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Pusan National University Hospital; Pusan National University","keywords":"Ovarian cancer; Medicine; Poly ADP ribose polymerase; Polymerase; Maintenance therapy; Cancer; Internal medicine; Oncology; Cancer research; Bioinformatics; Enzyme; Biology; Biochemistry; Chemotherapy","score_opus":0.08510270949931435,"score_gpt":0.429801801892879,"score_spread":0.3446990923935646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403831142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876142,0.0047305264,0.00005721729,0.0046817767,0.0016832637,0.00079066755,0.000050263483,0.000020409889,0.0003716463],"genre_scores_gemma":[0.9979118,0.0009997479,0.000027402119,0.0005728327,0.00027120655,0.000120541175,0.000019078383,0.000025942192,0.000051421746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978321,0.00034693273,0.00085219706,0.00035143128,0.00033634074,0.00028098456],"domain_scores_gemma":[0.9988485,0.00035277285,0.00026500833,0.00034960735,0.00011485528,0.00006924205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005266208,0.00019612972,0.0006539455,0.0002634585,0.00001582315,0.000005774935,0.00016935688,0.00015256256,0.000081447244],"category_scores_gemma":[0.00006037706,0.000114878596,0.00015085399,0.00047779438,0.00036602956,0.00006493368,0.000026364196,0.0005152346,0.0000062221693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001999539,0.0012072559,0.8348044,0.00007432205,0.00007529097,0.000038395756,0.0023759012,0.0000017911757,0.000027193,0.00026123016,0.0004429089,0.15869173],"study_design_scores_gemma":[0.012227545,0.0025570772,0.97071356,0.0013693292,0.000048989677,0.000015722866,0.00054778816,0.000039867802,0.00026775213,0.00026307965,0.01179793,0.00015136428],"about_ca_topic_score_codex":0.00040831717,"about_ca_topic_score_gemma":0.00021513703,"teacher_disagreement_score":0.15854037,"about_ca_system_score_codex":0.0001694511,"about_ca_system_score_gemma":0.00054466096,"threshold_uncertainty_score":0.46846133},"labels":[],"label_agreement":null},{"id":"W4403847681","doi":"10.21037/actr-24-44","title":"Utilizing therapeutic response as a criterion for PARP inhibitor maintenance therapy in advanced triple negative breast cancer; promoting personalized medicine","year":2024,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Triple-negative breast cancer; PARP inhibitor; Breast cancer; Oncology; Medicine; Internal medicine; Cancer; Poly ADP ribose polymerase; Biology; Genetics","score_opus":0.317957896190338,"score_gpt":0.5660474151581424,"score_spread":0.2480895189678044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403847681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07230296,0.74155927,0.00049151166,0.16826329,0.0030017716,0.013625862,0.00024211005,0.00032689687,0.00018631424],"genre_scores_gemma":[0.19722183,0.763078,0.00081634603,0.031376638,0.002400586,0.004062589,0.00003847326,0.00014293916,0.0008626456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98913354,0.0048991395,0.0037580843,0.0010874132,0.0005347497,0.0005870497],"domain_scores_gemma":[0.9824282,0.015387708,0.0008698281,0.0005651984,0.00043680926,0.00031226533],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029538259,0.00048671203,0.0033649507,0.00020261115,0.00009683154,0.000043802786,0.00021593552,0.00024321633,0.0013957232],"category_scores_gemma":[0.02100881,0.00032323776,0.0010591868,0.0010201448,0.00047932073,0.00022465839,0.000032460695,0.00075147336,0.000044038643],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043160085,0.0003170637,0.00023043697,0.004674473,0.0004550016,0.00008734083,0.00091604167,4.051191e-7,0.015096165,0.00039625406,0.007415923,0.9272508],"study_design_scores_gemma":[0.058410197,0.007261502,0.0030339751,0.27643517,0.000964859,0.00036166495,0.0005555244,0.0007785256,0.002047757,0.0056664865,0.64355165,0.00093267986],"about_ca_topic_score_codex":0.000066208864,"about_ca_topic_score_gemma":0.000008683799,"teacher_disagreement_score":0.9263181,"about_ca_system_score_codex":0.00040885436,"about_ca_system_score_gemma":0.00096435077,"threshold_uncertainty_score":0.999922},"labels":[],"label_agreement":null},{"id":"W4403851416","doi":"10.3390/curroncol31110496","title":"Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Japan Agency for Medical Research and Development; Japan Science and Technology Agency; AstraZeneca","keywords":"Medicine; Tolerability; Olaparib; Ovarian cancer; Paclitaxel; Oncology; Internal medicine; Breast cancer; Cancer; Gynecology; Adverse effect; Genetics","score_opus":0.05102072510991683,"score_gpt":0.3732457410228598,"score_spread":0.32222501591294295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403851416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900631,0.0072569186,0.000028227238,0.0010190267,0.00048575367,0.00066612347,0.00032513117,0.000037254198,0.00011851916],"genre_scores_gemma":[0.99905676,0.00042352916,0.0000503756,0.0000754795,0.00012839717,0.00016121585,0.00006479325,0.00002142622,0.00001802779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872714,0.000107022825,0.0003059917,0.0003898302,0.00021598036,0.00025403177],"domain_scores_gemma":[0.99926734,0.0001830197,0.000112266694,0.0001415471,0.00016572456,0.00013007429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018902417,0.00017637317,0.0005135404,0.00014540559,0.000030178006,0.000009426451,0.000040854346,0.00010786668,0.000137806],"category_scores_gemma":[0.000030940235,0.0001281356,0.000018632683,0.00040932262,0.00030025674,0.00008524893,0.000028912862,0.00035813177,6.078579e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030150705,0.00074242265,0.9206443,0.00030930975,0.0001878182,0.000021659618,0.00080590684,0.000026892734,0.000038252074,0.0000277897,0.0006515136,0.073529094],"study_design_scores_gemma":[0.015562598,0.0015413379,0.979007,0.0016574009,0.00016768978,0.000029296029,0.000051846477,0.00028611562,0.000017401313,0.0000342493,0.0015093229,0.00013574208],"about_ca_topic_score_codex":0.00041066096,"about_ca_topic_score_gemma":0.0008521938,"teacher_disagreement_score":0.07339335,"about_ca_system_score_codex":0.00089241675,"about_ca_system_score_gemma":0.0007306293,"threshold_uncertainty_score":0.5225218},"labels":[],"label_agreement":null},{"id":"W4403904602","doi":"10.1016/j.jtho.2024.10.012","title":"Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Santé Montérégie","funders":"","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Lung cancer; Cancer; Immunotherapy; Polymerase; Poly ADP ribose polymerase","score_opus":0.06185208516748933,"score_gpt":0.4462156689385008,"score_spread":0.38436358377101143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403904602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7419662,0.0044333413,0.17635967,0.066283904,0.0032270271,0.0040881317,0.00013741391,0.00027285828,0.00323147],"genre_scores_gemma":[0.9511127,0.00040015485,0.032437183,0.005715871,0.0011155285,0.00021360788,0.000009825128,0.0001531395,0.008841988],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99693257,0.00020528631,0.0010109677,0.0004913512,0.0006895508,0.0006703052],"domain_scores_gemma":[0.9967111,0.0010260926,0.0006106117,0.0004579456,0.00070756424,0.0004866931],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013305057,0.00043436929,0.001550721,0.0007227251,0.00014626386,0.00008196007,0.00034428458,0.00021336661,0.0005455441],"category_scores_gemma":[0.00033583466,0.00027237294,0.00037592402,0.0006732287,0.00020994966,0.00028942732,0.00003566649,0.00074059697,0.00003917619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71217036,0.0012487475,0.00027579747,0.002149624,0.002201168,0.005525945,0.0062007094,0.0012254885,0.013015009,0.0006150485,0.05880611,0.19656597],"study_design_scores_gemma":[0.04591653,0.049976207,0.0009705753,0.00394719,0.0019025456,0.04168373,0.00125188,0.005316142,0.021871023,0.0017457796,0.82458216,0.0008362204],"about_ca_topic_score_codex":0.000012235376,"about_ca_topic_score_gemma":0.00014530156,"teacher_disagreement_score":0.7657761,"about_ca_system_score_codex":0.0019827527,"about_ca_system_score_gemma":0.0030133538,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4403977769","doi":"10.1007/s11523-024-01102-8","title":"Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Olaparib; Maximum tolerated dose; Open label; Refractory (planetary science); Oncology; Solid tumor; Internal medicine; Clinical trial; Cancer","score_opus":0.04736721586451495,"score_gpt":0.3932493215087382,"score_spread":0.3458821056442233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403977769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953721,0.00030812187,0.0000453358,0.0005598791,0.0003601155,0.0023884866,0.00002284123,0.000098394725,0.00084473286],"genre_scores_gemma":[0.99745667,0.000048651214,0.00092095934,0.00058769085,0.00011687832,0.00029427974,0.0004119539,0.00005870688,0.00010421091],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99782443,0.0002975633,0.0005493316,0.0006087988,0.0003353266,0.00038454434],"domain_scores_gemma":[0.99910504,0.00014146438,0.00017626765,0.00027944567,0.000120992736,0.00017678381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005576173,0.00025659293,0.0006612406,0.00052718155,0.00006859771,0.000054466294,0.00014430856,0.0002406728,0.00017432094],"category_scores_gemma":[0.00005644666,0.00020154657,0.000013195281,0.0006173435,0.00016313489,0.00057958515,0.000052258772,0.00060032896,0.000011480359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76151735,0.041037604,0.039665822,0.0003788258,0.00028975663,0.0017818453,0.010038875,0.00006630912,0.03827224,0.0010552111,0.0026963311,0.10319983],"study_design_scores_gemma":[0.7865131,0.13592742,0.06188533,0.0013718194,0.00011013673,0.000052524018,0.0004562224,0.0017609779,0.002260846,0.0004626954,0.00861908,0.0005798321],"about_ca_topic_score_codex":0.0002043127,"about_ca_topic_score_gemma":0.0005107737,"teacher_disagreement_score":0.10262,"about_ca_system_score_codex":0.0008688731,"about_ca_system_score_gemma":0.00081630563,"threshold_uncertainty_score":0.8218831},"labels":[],"label_agreement":null},{"id":"W4404039157","doi":"10.1038/s44319-024-00285-5","title":"PARP1 condensates differentially partition DNA repair proteins and enhance DNA ligation","year":2024,"lang":"en","type":"article","venue":"EMBO Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Basic Research Laboratory; National Institute of General Medical Sciences; National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Canadian Institutes of Health Research; Welch Foundation","keywords":"PARP1; XRCC1; DNA repair; DNA damage; DNA; Biology; DNA ligase; Cell biology; Poly ADP ribose polymerase; Polymerase; Chemistry; Molecular biology; Biochemistry; Gene","score_opus":0.015039607506710375,"score_gpt":0.30056793602563353,"score_spread":0.2855283285189232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404039157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913397,0.001614655,0.0007130077,0.0016850227,0.0006974474,0.00070995337,0.000005845438,0.0006358024,0.002598586],"genre_scores_gemma":[0.9953461,0.00012848881,0.00042960083,0.00029735678,0.00045781455,0.00024015758,0.00007688419,0.00003234647,0.0029912079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985393,0.000037844417,0.00045365404,0.000465804,0.00031334048,0.00019003435],"domain_scores_gemma":[0.99929744,0.000037103222,0.00013030798,0.00032652868,0.0000920698,0.000116525276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028995486,0.00015474232,0.00023028941,0.000085615146,0.00007492892,0.00006337383,0.000017734117,0.00009992613,0.0004108897],"category_scores_gemma":[0.000077132136,0.00013688799,0.00009777798,0.00014730146,0.00008923725,0.00016194572,0.000018387394,0.00015604646,0.000031704123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013054433,0.00015768636,0.009404396,0.00085969595,0.00024732173,0.0026752097,0.0011276385,0.0000027671583,0.9621488,0.0009682721,0.014706788,0.0075708795],"study_design_scores_gemma":[0.00037615164,0.00029172894,0.022984594,0.0013632581,0.00013074871,0.0016717948,0.000044270488,0.0003068806,0.9341088,0.0090169385,0.029446235,0.000258613],"about_ca_topic_score_codex":0.000016418833,"about_ca_topic_score_gemma":0.000012972234,"teacher_disagreement_score":0.028040016,"about_ca_system_score_codex":0.000093697636,"about_ca_system_score_gemma":0.00013375362,"threshold_uncertainty_score":0.55821306},"labels":[],"label_agreement":null},{"id":"W4404083849","doi":"10.4143/crt.2024.899","title":"Time-Trend Analysis and Risk Factors for Niraparib-Induced Nausea and Vomiting in Ovarian Cancer: A Prospective Study","year":2024,"lang":"en","type":"article","venue":"Cancer Research and Treatment","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Center; Ministry of Health and Welfare","keywords":"Medicine; Nausea; Vomiting; Ovarian cancer; Prospective cohort study; Oncology; Internal medicine; Gynecology; Cancer","score_opus":0.10263945405107198,"score_gpt":0.4521001129020116,"score_spread":0.3494606588509396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404083849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987223,0.009523594,0.00000983126,0.00047014566,0.000039745355,0.0021595035,0.00039844046,0.00003329128,0.00014239452],"genre_scores_gemma":[0.9897692,0.006896969,0.000039505256,0.000008874849,0.00013055129,0.0025677292,0.00002402385,0.000026065687,0.0005370639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983759,0.000107131986,0.00020431318,0.0006465083,0.0002687152,0.00039745643],"domain_scores_gemma":[0.99908954,0.00038818063,0.00003513596,0.00016947478,0.00008766213,0.00023001878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038695015,0.00019716924,0.00044029302,0.0006255876,0.00021816023,0.00011347548,0.00003072895,0.00006142574,0.00007188507],"category_scores_gemma":[0.000033769433,0.00014355003,0.00005925262,0.0008897636,0.0001475182,0.00009051375,0.00003280054,0.00021965842,9.2453104e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091894186,0.00035294358,0.96245605,0.00007500904,0.0038260608,0.00006040852,0.0074731107,0.000005510137,0.001082288,0.00003401397,0.00004953865,0.023666149],"study_design_scores_gemma":[0.012224614,0.0059397914,0.9620142,0.00035645554,0.0016043783,0.000006500979,0.0035542536,0.0017923833,0.011048074,0.00048135067,0.0007029455,0.00027506833],"about_ca_topic_score_codex":0.012194713,"about_ca_topic_score_gemma":0.014976509,"teacher_disagreement_score":0.023391081,"about_ca_system_score_codex":0.0009726117,"about_ca_system_score_gemma":0.00025652564,"threshold_uncertainty_score":0.99438316},"labels":[],"label_agreement":null},{"id":"W4404136502","doi":"10.1016/j.jtho.2024.10.026","title":"The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Santé Montérégie; McGill University; St Mary's Hospital Centre","funders":"Daiichi Sankyo Europe; EMD Serono; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; G1 Therapeutics; Pfizer; Coherus Biosciences; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Pemetrexed; Oncology; Maintenance therapy; Olaparib; Internal medicine; Lung cancer; Cancer; Chemotherapy; Immunotherapy; Polymerase; Cisplatin","score_opus":0.06874955987987083,"score_gpt":0.4853731063338285,"score_spread":0.4166235464539577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404136502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96047986,0.015673755,0.003924836,0.007925557,0.0063020946,0.0030260154,0.00007427239,0.000080868675,0.0025127504],"genre_scores_gemma":[0.9936911,0.0016748887,0.0012338659,0.0005094268,0.000958036,0.00023625247,0.00001034549,0.00009997465,0.0015861497],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99552715,0.00065918796,0.0017741016,0.0004464083,0.00092384376,0.0006692885],"domain_scores_gemma":[0.9938868,0.0029136888,0.0012319213,0.00061583536,0.0010502038,0.00030149272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023811585,0.00043201845,0.001551406,0.00057803787,0.00027433323,0.00008530201,0.0005640869,0.00019226904,0.0002515031],"category_scores_gemma":[0.0006694691,0.00027966098,0.0006698534,0.0007209768,0.00036876663,0.00024548548,0.00006278792,0.0009760945,0.000029851419],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48293552,0.00588885,0.000027973136,0.0005283436,0.005499627,0.002555674,0.008287445,0.0006561445,0.008717488,0.00097320415,0.041451354,0.44247836],"study_design_scores_gemma":[0.29914093,0.17141874,0.00034892463,0.0012353085,0.004606744,0.0090484535,0.021009086,0.008012732,0.011027592,0.0033304607,0.46991742,0.00090361736],"about_ca_topic_score_codex":0.000053752374,"about_ca_topic_score_gemma":0.0000819884,"teacher_disagreement_score":0.44157475,"about_ca_system_score_codex":0.0019828312,"about_ca_system_score_gemma":0.0036518485,"threshold_uncertainty_score":0.99996555},"labels":[],"label_agreement":null},{"id":"W4404260098","doi":"10.1038/s41573-024-01060-w","title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","year":2024,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"DNA damage; Genome instability; DNA repair; PARP inhibitor; Homologous recombination; Cancer research; Poly ADP ribose polymerase; Clinical trial; Synthetic lethality; Cancer; Biology; Medicine; Bioinformatics; Computational biology; DNA; Genetics; Polymerase","score_opus":0.06594507892205603,"score_gpt":0.44097843021533406,"score_spread":0.37503335129327803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404260098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033815115,0.97004724,0.0000016951786,0.019243853,0.0026364313,0.0044874675,0.0030529408,0.00007275599,0.00011945604],"genre_scores_gemma":[0.00003222213,0.98790056,0.000027996974,0.0015772793,0.0060794842,0.002908286,0.000886957,0.00017119048,0.00041601912],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948177,0.0014784184,0.0013934205,0.0012477904,0.00047531235,0.0005873809],"domain_scores_gemma":[0.99665445,0.0008294592,0.000681274,0.001525988,0.000080931764,0.0002279224],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001280185,0.0010104609,0.0028668817,0.000363584,0.00015270732,0.00024737688,0.0004421707,0.00074897235,0.000094251845],"category_scores_gemma":[0.00011866008,0.00054025964,0.0010530017,0.0016079658,0.00021376954,0.00028521617,0.00018718565,0.0047587156,0.000062872154],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012905835,0.000109599794,0.00011813939,0.0062126936,0.00019255768,0.000011109802,0.0003783102,5.3922403e-8,0.000007729888,0.0002750885,0.1278401,0.86472553],"study_design_scores_gemma":[0.0006034695,0.000024806413,0.0011296091,0.05969441,0.0010422687,0.000017807828,0.000053634896,2.1037914e-7,0.000002520919,0.00019706231,0.93675,0.00048419472],"about_ca_topic_score_codex":0.00007822268,"about_ca_topic_score_gemma":0.00018403576,"teacher_disagreement_score":0.86424136,"about_ca_system_score_codex":0.0010000985,"about_ca_system_score_gemma":0.0016677062,"threshold_uncertainty_score":0.9997049},"labels":[],"label_agreement":null},{"id":"W4404275877","doi":"10.1016/j.ygyno.2024.11.004","title":"Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Ovarian cancer; Placebo; Adverse effect; Oncology; Internal medicine; Gynecology; Cancer; Alternative medicine; Pathology","score_opus":0.04708799353265499,"score_gpt":0.38366285423559926,"score_spread":0.3365748607029443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404275877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744472,0.0010565462,0.000052181855,0.008055292,0.003236962,0.0022597467,0.00005108272,0.000034760076,0.010806247],"genre_scores_gemma":[0.99625903,0.0011441807,0.00029329088,0.0009135494,0.00020962114,0.0009044489,0.000014468906,0.00001458028,0.00024680258],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755985,0.00057151465,0.0008383326,0.00037623206,0.00025944092,0.00039460624],"domain_scores_gemma":[0.99794143,0.0013527278,0.0002555453,0.0003198181,0.00007854816,0.000051908155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018356909,0.00018192042,0.0007143813,0.0002887851,0.000021742208,0.0000015031005,0.00024532012,0.00031130516,0.0010188045],"category_scores_gemma":[0.00053825416,0.00012536903,0.00015002744,0.0006242612,0.00023028097,0.000053879547,0.00005264477,0.00060965936,0.00002103259],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37660012,0.024407405,0.088785216,0.0027200924,0.0012086122,0.0030453217,0.029243298,0.0020205916,0.015549779,0.038713202,0.048181824,0.36952454],"study_design_scores_gemma":[0.42429048,0.035319537,0.23789878,0.002877402,0.0004813199,0.0002620537,0.0053455336,0.0024709743,0.0035788007,0.020122154,0.26645842,0.00089454936],"about_ca_topic_score_codex":0.00029225342,"about_ca_topic_score_gemma":0.001885016,"teacher_disagreement_score":0.36863,"about_ca_system_score_codex":0.0009950906,"about_ca_system_score_gemma":0.0010614161,"threshold_uncertainty_score":0.9998944},"labels":[],"label_agreement":null},{"id":"W4404299430","doi":"10.1016/j.molcel.2024.10.024","title":"PARP enzyme de novo synthesis of protein-free poly(ADP-ribose)","year":2024,"lang":"en","type":"article","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; National Cancer Institute; National Institutes of Health; University of Oxford; Canada Foundation for Innovation; Canadian Institutes of Health Research; National Research Council; University of Saskatchewan; Canadian Light Source","keywords":"Biology; Poly ADP ribose polymerase; Enzyme; Ribose; Biochemistry; Molecular biology; Polymerase","score_opus":0.009381297734575283,"score_gpt":0.2587283121712924,"score_spread":0.2493470144367171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404299430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83081,0.035946243,0.02841138,0.009140952,0.00047634618,0.001440027,0.00014643901,0.00047883426,0.09314979],"genre_scores_gemma":[0.9930819,0.000069608395,0.003811024,0.0006747689,0.00018786466,0.00014839793,0.000007815804,0.00006609952,0.0019525156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987402,0.00006780497,0.00026225825,0.00029494992,0.00034550336,0.0002892764],"domain_scores_gemma":[0.9990666,0.000058236903,0.00005063689,0.00063270034,0.000058020305,0.00013381474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002107788,0.00016666918,0.00026160615,0.00014525141,0.000024473386,0.000018471104,0.00016982468,0.00011809014,0.0005374582],"category_scores_gemma":[0.00008299246,0.0001580447,0.00019279553,0.00027327499,0.00008374541,0.00003628439,0.000047467925,0.00019510432,0.00012516555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104827304,0.00012099664,0.000054180862,0.00060126145,0.0000918491,0.0007556571,0.00016524116,0.000008301022,0.98991346,0.0007208672,0.0031948215,0.004268519],"study_design_scores_gemma":[0.00079609395,0.00013107072,0.000037968686,0.0005153758,0.00009856763,0.00006004132,0.000026234644,0.00013160425,0.94608414,0.0009970581,0.05098175,0.00014009846],"about_ca_topic_score_codex":0.00004308028,"about_ca_topic_score_gemma":0.0000014260476,"teacher_disagreement_score":0.16227192,"about_ca_system_score_codex":0.0001333428,"about_ca_system_score_gemma":0.0002533613,"threshold_uncertainty_score":0.64448756},"labels":[],"label_agreement":null},{"id":"W4404815786","doi":"10.1093/emph/eoae029","title":"Towards a new therapeutic approach based on selection for function in tumors: response to Dr. Mesut Tez","year":2024,"lang":"en","type":"article","venue":"Evolution Medicine and Public Health","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"Centre National de la Recherche Scientifique; Agence Nationale de la Recherche","keywords":"Selection (genetic algorithm); Function (biology); Medicine; Computer science; Biology; Artificial intelligence; Genetics","score_opus":0.09716326348803332,"score_gpt":0.39059742393779673,"score_spread":0.2934341604497634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404815786","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016180983,0.0042736926,0.54094476,0.4346408,0.0005894774,0.0018987734,0.00001480803,0.00028875069,0.0011679342],"genre_scores_gemma":[0.95575595,0.00009477305,0.0016557624,0.039423868,0.0013936529,0.0003505476,0.000090066256,0.000042886204,0.0011925141],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780774,0.00031181134,0.0004849864,0.0004951222,0.00044613608,0.0004541802],"domain_scores_gemma":[0.99876505,0.00025363668,0.00006742264,0.00019911093,0.00014935486,0.00056542084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033625318,0.00019521387,0.0003790227,0.0011399329,0.00012337604,0.00003142316,0.000046743917,0.00011404034,0.00012353383],"category_scores_gemma":[0.0005315141,0.00015538793,0.00005710494,0.0014226529,0.000055400575,0.00013238355,0.000006421146,0.0003285927,0.000011504737],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022348816,0.0008708622,0.0045041237,0.0025675644,0.00016809649,0.000009057311,0.008682213,0.0004387369,0.00919545,0.028687198,0.5288096,0.39371824],"study_design_scores_gemma":[0.010295297,0.014663111,0.064411104,0.0021613115,0.000051589588,0.00010382687,0.0017488314,0.09493598,0.000058323792,0.003188656,0.8080413,0.00034069672],"about_ca_topic_score_codex":0.0008263475,"about_ca_topic_score_gemma":0.000051167597,"teacher_disagreement_score":0.93957496,"about_ca_system_score_codex":0.0012878015,"about_ca_system_score_gemma":0.0035381392,"threshold_uncertainty_score":0.6336536},"labels":[],"label_agreement":null},{"id":"W4404877801","doi":"10.1016/j.jconrel.2024.11.061","title":"Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Triple-negative breast cancer; Mutant; Cancer research; Breast cancer; DNA damage; Triple negative; DNA repair; Drug; Wild type; Cancer; DNA; Biology; Medicine; Pharmacology; Genetics; Gene","score_opus":0.008462827197743833,"score_gpt":0.2858685834992728,"score_spread":0.27740575630152897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404877801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831817,0.0091369115,0.000024028626,0.0063877217,0.00049335003,0.0005862194,0.000022575112,0.00003626342,0.00013123086],"genre_scores_gemma":[0.9956692,0.002960581,0.00009014051,0.0004717411,0.00023632907,0.000022721673,0.0000026087669,0.000026042771,0.00052064366],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99830246,0.00020818535,0.0007065543,0.00021712194,0.00037496694,0.00019073467],"domain_scores_gemma":[0.99874246,0.0002792304,0.00030800613,0.00011825654,0.00032293765,0.00022910329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006836217,0.00018318239,0.0006411026,0.00028602904,0.00006311259,0.000054252603,0.0000390248,0.00008925021,0.000095866366],"category_scores_gemma":[0.0002332898,0.00012882041,0.00013206189,0.00032498618,0.00009703768,0.0003384499,0.000021487489,0.00045502713,0.0000027493327],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071032114,0.00078424416,0.007719251,0.0006263339,0.00083812454,0.002471381,0.0041719554,0.00022873402,0.89058846,0.00039674077,0.013322073,0.007820558],"study_design_scores_gemma":[0.41261697,0.003595301,0.15725335,0.032605335,0.0022674375,0.0063711507,0.0019675465,0.07469944,0.29287055,0.0060304645,0.008339429,0.0013830299],"about_ca_topic_score_codex":0.000024708272,"about_ca_topic_score_gemma":0.000015037921,"teacher_disagreement_score":0.59771794,"about_ca_system_score_codex":0.00021187894,"about_ca_system_score_gemma":0.0003226724,"threshold_uncertainty_score":0.5253144},"labels":[],"label_agreement":null},{"id":"W4405114312","doi":"10.1038/s41467-024-54415-7","title":"Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université de Montréal","funders":"Canadian Institutes of Health Research; Science for Life Laboratory; Barncancerfonden; Novo Nordisk; Horizon 2020 Framework Programme; Stiftelsen Felix Mindus Bidrag till Leukemiforskningen; Novo Nordisk Fonden; Svenska Sällskapet för Medicinsk Forskning; Cancerfonden; Alfred Österlunds Stiftelse; European Commission; Pain Relief Foundation; Torsten Söderbergs Stiftelse; Michael Smith Health Research BC; Government of Canada; Karolinska Institutet; Loo och Hans Ostermans Stiftelse för Medicinsk Forskning","keywords":"PARP1; Drug discovery; Drug; Biology; Computational biology; Drug development; Target protein; Cell biology; Pharmacology; DNA; Polymerase; Poly ADP ribose polymerase; Biochemistry; Gene","score_opus":0.027112647200910497,"score_gpt":0.3666959977836419,"score_spread":0.3395833505827314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405114312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36858273,0.17181614,0.01385615,0.33689404,0.0040760357,0.005572177,0.00031189818,0.002661834,0.09622902],"genre_scores_gemma":[0.9763468,0.0009730257,0.017677946,0.0033371109,0.00027963685,0.00033664398,0.00018451986,0.000040681498,0.0008236592],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990115,0.000071171504,0.0002073526,0.00026442393,0.00022932778,0.00021618216],"domain_scores_gemma":[0.998264,0.00022064075,0.000030540104,0.0011702536,0.00016216072,0.00015238719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003331177,0.00015292162,0.00018981741,0.00020921239,0.00023297091,0.00003764487,0.00042990007,0.00013262832,0.0004177036],"category_scores_gemma":[0.000021662525,0.0001279418,0.00006619428,0.00058651547,0.00009303485,0.000068135574,0.0001485245,0.0014945125,0.0001919063],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005621283,0.0014303339,0.002963557,0.00042810576,0.0016657533,0.00016654504,0.0061916714,0.005962439,0.2799489,0.027922837,0.6683247,0.004433065],"study_design_scores_gemma":[0.0008742524,0.00013355247,0.00013007475,0.00028539693,0.0001820086,0.000030522424,0.0002822165,0.013526966,0.031649895,0.000096548996,0.95261794,0.00019062965],"about_ca_topic_score_codex":0.000011813746,"about_ca_topic_score_gemma":0.000030817733,"teacher_disagreement_score":0.60776407,"about_ca_system_score_codex":0.0002474901,"about_ca_system_score_gemma":0.00022436297,"threshold_uncertainty_score":0.6492996},"labels":[],"label_agreement":null},{"id":"W4405127888","doi":"10.57264/cer-2024-0133","title":"Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Neutropenia; Unit cost; Anemia; Internal medicine; Chemotherapy","score_opus":0.22567769074610858,"score_gpt":0.5142588447011285,"score_spread":0.28858115395501993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405127888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925807,0.0044212854,0.00087641977,0.00038517307,0.00018361783,0.0009881093,0.000014680307,0.000008025882,0.0005419631],"genre_scores_gemma":[0.99820626,0.0008786656,0.0006547637,0.000026292864,0.000060272283,0.000109807734,0.0000020457703,0.0000144826645,0.00004742261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963291,0.0015934963,0.00064271165,0.0002339965,0.00090269645,0.00029796053],"domain_scores_gemma":[0.9970715,0.0018840756,0.00019710879,0.00014706998,0.00056021404,0.00014004864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039303135,0.0001505349,0.0007114852,0.0010305818,0.000060913448,0.000043341206,0.00010230004,0.00006894626,0.00007772492],"category_scores_gemma":[0.00011047657,0.00011492242,0.000116093914,0.0009811355,0.00026043525,0.00030644157,0.00008215523,0.00073465693,0.000003929887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046684638,0.003247375,0.52395636,0.011660884,0.005974525,0.006365695,0.019250143,0.0069940304,0.29374573,0.039316643,0.003329106,0.039474834],"study_design_scores_gemma":[0.010956767,0.001973085,0.85631603,0.016300738,0.00014007885,0.00021138566,0.0018712005,0.0020807802,0.10363765,0.0032279275,0.0030455722,0.00023880595],"about_ca_topic_score_codex":0.00011214133,"about_ca_topic_score_gemma":0.000027665123,"teacher_disagreement_score":0.3323596,"about_ca_system_score_codex":0.0007910506,"about_ca_system_score_gemma":0.0003234611,"threshold_uncertainty_score":0.46864003},"labels":[],"label_agreement":null},{"id":"W4405181656","doi":"10.1158/1538-8514.cancerchem24-ia006","title":"Abstract IA006: Progress, pitfalls and promise: the journey to effective and well tolerated DNA damage response inhibitor combinations in the clinic","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PARP inhibitor; Tolerability; Medicine; Cancer; DNA damage; Poly ADP ribose polymerase; Pharmacology; Cancer research; Polymerase; DNA; Adverse effect; Internal medicine; Chemistry; Biochemistry","score_opus":0.032133666429144336,"score_gpt":0.368427072439368,"score_spread":0.33629340601022367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.932503,0.01778202,0.00009131256,0.046454795,0.00026037585,0.0024311128,0.000030396737,0.00006738253,0.00037959512],"genre_scores_gemma":[0.988748,0.000844093,0.00007687358,0.009151316,0.00011893489,0.00080721057,0.000008315569,0.000055398174,0.00018983586],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813163,0.00046046864,0.00034265735,0.00039799506,0.00037079022,0.00029644652],"domain_scores_gemma":[0.9988636,0.00046204563,0.00006946004,0.00038698578,0.00011496326,0.00010294092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012384612,0.00024729443,0.00025992547,0.00015968668,0.00015807389,0.00022983926,0.00015422428,0.00012395182,0.00006888986],"category_scores_gemma":[0.00003649045,0.00015471931,0.00007244474,0.00063867663,0.00030007266,0.0000835856,0.000043382195,0.00059502025,0.000020974967],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01344434,0.0018365853,0.009361027,0.0011700316,0.0022368808,0.001892948,0.057218183,0.00011076162,0.79131985,0.0031523525,0.011134782,0.107122235],"study_design_scores_gemma":[0.014641554,0.0032031015,0.45088953,0.0038586033,0.000977629,0.00035307716,0.0027327193,0.0019819355,0.15029967,0.003875708,0.36595666,0.0012298168],"about_ca_topic_score_codex":0.000022841052,"about_ca_topic_score_gemma":0.000030687,"teacher_disagreement_score":0.6410202,"about_ca_system_score_codex":0.00018228711,"about_ca_system_score_gemma":0.00026557085,"threshold_uncertainty_score":0.630927},"labels":[],"label_agreement":null},{"id":"W4405541073","doi":"10.1186/s13073-024-01413-5","title":"Patterns of genomic instability in &gt; 2000 patients with ovarian cancer across six clinical trials evaluating olaparib","year":2024,"lang":"en","type":"article","venue":"Genome Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; AstraZeneca","keywords":"Olaparib; Medicine; Oncology; Ovarian cancer; Interquartile range; Internal medicine; Cancer; PALB2; Cancer research; Gastroenterology; Germline mutation; Genetics; Mutation; Poly ADP ribose polymerase; Gene; Biology; Polymerase","score_opus":0.16688680550916507,"score_gpt":0.4903623368881579,"score_spread":0.3234755313789928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405541073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883881,0.0049007195,0.000269922,0.0026807804,0.0013358116,0.001585482,0.00037850396,0.00006439924,0.0003962677],"genre_scores_gemma":[0.99634707,0.00050684763,0.00029823266,0.0008270757,0.0012408646,0.00017775873,0.00016640798,0.000057340076,0.00037838198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995093,0.0007131098,0.0022548924,0.0006918698,0.00077692483,0.00047021275],"domain_scores_gemma":[0.997306,0.00096831686,0.0004162505,0.0007772552,0.0002926833,0.000239508],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009787404,0.00029074773,0.0015220672,0.00020624316,0.00004278453,0.000013751594,0.00021516158,0.0001785738,0.0029446096],"category_scores_gemma":[0.0012491748,0.0001975253,0.00015950197,0.00047855763,0.00028300186,0.000094049414,0.000079699705,0.0005770447,0.00002706544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029176567,0.00039333128,0.8996192,0.00077415636,0.00038764847,0.000040409548,0.007456652,0.00010206587,0.014164509,0.000023108592,0.00029820393,0.073823065],"study_design_scores_gemma":[0.018388754,0.0019307452,0.9683513,0.0019163169,0.00025810683,0.0000071213735,0.0003207373,0.00033463034,0.00016819462,0.000116097246,0.007991254,0.00021672336],"about_ca_topic_score_codex":0.00084318506,"about_ca_topic_score_gemma":0.00040921787,"teacher_disagreement_score":0.07360634,"about_ca_system_score_codex":0.0009267925,"about_ca_system_score_gemma":0.0011398165,"threshold_uncertainty_score":0.9979668},"labels":[],"label_agreement":null},{"id":"W4405696229","doi":"10.1080/14796694.2024.2442900","title":"Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"review","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Abiraterone acetate; PARP inhibitor; Androgen receptor; Enzalutamide; Oncology; Internal medicine; PARP1; Cancer research; Androgen deprivation therapy; Abiraterone; Cancer; Poly ADP ribose polymerase; Gene; Biology","score_opus":0.10008847965426025,"score_gpt":0.46419381523950315,"score_spread":0.3641053355852429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405696229","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003376701,0.98799044,0.000060969287,0.003231565,0.00313781,0.0040607606,0.00097584364,0.000089644745,0.00041922077],"genre_scores_gemma":[0.000034375564,0.988167,0.001256948,0.00049820245,0.0019470216,0.004447368,0.0011246313,0.00010880579,0.002415673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977997,0.00022178072,0.00082443666,0.00061856396,0.00019682517,0.00033870497],"domain_scores_gemma":[0.9987276,0.00020112637,0.0004594042,0.00027135672,0.0001941913,0.00014628634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043352722,0.00046017222,0.001972553,0.0002949776,0.000097304684,0.000051093353,0.000085436295,0.00039149323,0.00015233479],"category_scores_gemma":[0.000027434817,0.00034052483,0.00027738174,0.00028635564,0.00012816393,0.00006852622,0.000028053255,0.00051062705,0.00003383762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039974856,0.00017059577,0.0000010636469,0.048058152,0.0009806574,0.00007602579,0.00043377714,2.7093537e-7,0.000115954834,0.0024331724,0.0433319,0.9039987],"study_design_scores_gemma":[0.002719597,0.0013610659,0.0000069376483,0.006085121,0.0041523925,0.00026671655,0.00007985864,0.00001247256,0.0000134985185,0.000578687,0.98444647,0.00027720272],"about_ca_topic_score_codex":0.000025391626,"about_ca_topic_score_gemma":0.00017159783,"teacher_disagreement_score":0.94111454,"about_ca_system_score_codex":0.00088007475,"about_ca_system_score_gemma":0.0015644672,"threshold_uncertainty_score":0.9999047},"labels":[],"label_agreement":null},{"id":"W4405810367","doi":"10.3390/cancers17010040","title":"Cost-Effectiveness of PARP Inhibitors for Patients with BRCA1/2-Positive Metastatic Castration-Resistant Prostate Cancer—The Canadian Perspective","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Université de Montréal; McGill University Health Centre","funders":"Réseau Québécois de Recherche sur les Médicaments","keywords":"PARP inhibitor; Olaparib; Medicine; Prostate cancer; Oncology; Docetaxel; Clinical trial; Cost effectiveness; Internal medicine; Quality of life (healthcare); Cancer; Poly ADP ribose polymerase; Biology; Gene; Genetics","score_opus":0.031235089902514317,"score_gpt":0.34068715620709433,"score_spread":0.30945206630458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405810367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641203,0.005924872,0.0006916238,0.004046088,0.00178807,0.014419426,0.006704862,0.000105508145,0.0021992247],"genre_scores_gemma":[0.9971941,0.000060635102,0.00016127776,0.00025391244,0.00013784404,0.0018676182,0.00012507167,0.000054976113,0.00014454835],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99832344,0.00012586292,0.000302152,0.00044278023,0.0004392961,0.00036649316],"domain_scores_gemma":[0.9978364,0.00045513335,0.00013041208,0.0002491505,0.001105398,0.00022349691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003991204,0.00023021495,0.00036931277,0.00021303726,0.00020895331,0.00006557993,0.00009468843,0.00005296873,0.000056962293],"category_scores_gemma":[0.00008674486,0.00015714223,0.00012520317,0.0006135396,0.00034401118,0.00015250586,0.0000075311355,0.00020275298,0.0000032848548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.122379035,0.0014041031,0.16352987,0.020146342,0.03600997,0.0010351702,0.19527492,0.095905386,0.056791097,0.13346179,0.082796,0.091266334],"study_design_scores_gemma":[0.060472187,0.020644492,0.42548102,0.029818226,0.0067928783,0.00010508356,0.033740416,0.0060222307,0.30179504,0.017109154,0.09403538,0.0039838823],"about_ca_topic_score_codex":0.12840317,"about_ca_topic_score_gemma":0.16883989,"teacher_disagreement_score":0.26195115,"about_ca_system_score_codex":0.010727039,"about_ca_system_score_gemma":0.007813791,"threshold_uncertainty_score":0.99781096},"labels":[],"label_agreement":null},{"id":"W4405882965","doi":"10.5858/arpa.2024-0277-le","title":"Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine","year":2024,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Immunohistochemistry; Pathology; Medicine; Biology","score_opus":0.022793875742796725,"score_gpt":0.33650173171777875,"score_spread":0.313707855974982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405882965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96807045,0.009855525,0.017855799,0.0018755598,0.00066693797,0.00070880365,0.00021500324,0.000116467316,0.0006354414],"genre_scores_gemma":[0.9336579,0.00018368986,0.06461971,0.00047054654,0.00035194395,0.0001249855,0.00048323296,0.000054325592,0.000053689968],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981025,0.00015429892,0.00080761046,0.00040591133,0.00026785288,0.00026182542],"domain_scores_gemma":[0.9974404,0.0015018375,0.00017775131,0.00053787784,0.00018761925,0.00015449332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070564105,0.00022514777,0.00073012494,0.00032860544,0.000057160207,0.0000023098619,0.00020020155,0.00012070894,0.00012152831],"category_scores_gemma":[0.0008759641,0.00018627844,0.00008286185,0.0002887541,0.0011267408,0.000064061715,0.000044976296,0.00026238183,0.0000052288356],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052548386,0.00030833518,0.00035759018,0.0006900117,0.0001391762,0.00015264523,0.005316098,0.0000019576592,0.976528,0.0013590289,0.0012650243,0.013356631],"study_design_scores_gemma":[0.0126056215,0.0036817428,0.026107341,0.0053580734,0.00060526805,0.00040691835,0.0013215432,0.0009460887,0.89581084,0.0050177495,0.047610164,0.0005286271],"about_ca_topic_score_codex":0.0000037074362,"about_ca_topic_score_gemma":0.0000042613706,"teacher_disagreement_score":0.080717154,"about_ca_system_score_codex":0.000067726025,"about_ca_system_score_gemma":0.00061284134,"threshold_uncertainty_score":0.75962144},"labels":[],"label_agreement":null},{"id":"W4406407977","doi":"10.1111/cpr.13788","title":"Genome‐Wide Screening in Haploid Stem Cells Reveals Synthetic Lethality Targeting <scp> <i>MLH1</i> </scp> and <scp> <i>TP53</i> </scp> Deficient Tumours","year":2025,"lang":"en","type":"article","venue":"Cell Proliferation","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Azrieli Foundation; Israel Science Foundation","keywords":"Ploidy; Biology; Genome; Lethality; Synthetic lethality; Microbiology; Genetics; Gene","score_opus":0.016409069034183255,"score_gpt":0.2552971902097024,"score_spread":0.2388881211755191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406407977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96706754,0.0049367626,0.015678452,0.00058141205,0.00040736908,0.0019069233,0.000027773182,0.00020467571,0.009189067],"genre_scores_gemma":[0.9899876,0.00048083992,0.002038133,0.0029654764,0.00023642047,0.0002642002,0.00008512804,0.00007124918,0.003870932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961964,0.00043187564,0.0010787621,0.00094718253,0.00058542436,0.0007603437],"domain_scores_gemma":[0.99759334,0.00093222526,0.00039677208,0.0005387016,0.00028223242,0.00025675297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019959465,0.00045552215,0.0006934573,0.00044921637,0.0003545294,0.00018132453,0.00018952094,0.00029204926,0.000011808538],"category_scores_gemma":[0.0003859648,0.0004738189,0.00014121034,0.0007560692,0.00016640399,0.00028915747,0.00011325222,0.00067064073,0.000041360727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065868284,0.00046893518,0.14710614,0.0012097408,0.000058385674,0.000058148013,0.003551148,0.0024118745,0.834064,0.0002786256,0.009649204,0.0010779077],"study_design_scores_gemma":[0.004265165,0.0002640199,0.0199684,0.0010355223,0.00017558914,0.00003569212,0.0025249217,0.0026593718,0.9471312,0.0007357098,0.02102899,0.000175424],"about_ca_topic_score_codex":0.000038169364,"about_ca_topic_score_gemma":0.000012651304,"teacher_disagreement_score":0.12713775,"about_ca_system_score_codex":0.00032080477,"about_ca_system_score_gemma":0.00025730816,"threshold_uncertainty_score":0.99977136},"labels":[],"label_agreement":null},{"id":"W4406430419","doi":"10.1002/cncr.35707","title":"Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis","year":2025,"lang":"en","type":"article","venue":"Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center; AstraZeneca","keywords":"Olaparib; Medicine; Homologous recombination; BRCA mutation; Ovarian cancer; Oncology; Internal medicine; Cancer; Poly ADP ribose polymerase; Genetics; Gene","score_opus":0.03422678979343503,"score_gpt":0.3851186730661565,"score_spread":0.35089188327272147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406430419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864982,0.0019228702,0.0034680006,0.0037228493,0.0006008159,0.0018749088,0.00036950858,0.00006978571,0.0014730798],"genre_scores_gemma":[0.9919336,0.00043956743,0.0001477159,0.00064854854,0.00010109167,0.0013971479,0.00027257585,0.000021706306,0.005038039],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99846053,0.00011046667,0.00036843956,0.00056824775,0.0002280812,0.00026423423],"domain_scores_gemma":[0.9990288,0.00017506682,0.00019002536,0.00023392643,0.0002792866,0.000092904425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002194499,0.00024103362,0.0005276145,0.00030028253,0.00022124611,0.000040200455,0.000048360424,0.00011570249,0.000234231],"category_scores_gemma":[0.000054593642,0.00021991383,0.00013449708,0.0006471997,0.000060463626,0.0001064176,0.000012829029,0.000113456226,0.0000025550992],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04643099,0.0216897,0.14847253,0.00064021733,0.028322065,0.00056968955,0.049862504,0.004189863,0.10172443,0.007445649,0.05043348,0.5402189],"study_design_scores_gemma":[0.3906399,0.02864412,0.21784182,0.0011019524,0.033704154,0.00008746076,0.008786174,0.02846921,0.23813152,0.007760403,0.041910164,0.002923117],"about_ca_topic_score_codex":0.0021729534,"about_ca_topic_score_gemma":0.0010911432,"teacher_disagreement_score":0.53729576,"about_ca_system_score_codex":0.0012879289,"about_ca_system_score_gemma":0.000433317,"threshold_uncertainty_score":0.8967825},"labels":[],"label_agreement":null},{"id":"W4406821808","doi":"10.1038/s41467-025-56085-5","title":"CHD6 has poly(ADP-ribose)- and DNA-binding domains and regulates PARP1/2-trapping inhibitor sensitivity via abasic site repair","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Calgary","funders":"National Institute of Environmental Health Sciences; Canadian Institutes of Health Research; Canada Research Chairs; Government of Canada; National Institutes of Health; Natural Sciences and Engineering Research Council of Canada; Government of Alberta","keywords":"PARP1; Poly ADP ribose polymerase; Ribose; Chemistry; Trapping; PARP inhibitor; DNA repair; AP site; DNA; DNA damage; Sensitivity (control systems); Cell biology; Biophysics; Biochemistry; Biology; Enzyme; Polymerase","score_opus":0.021363413317152958,"score_gpt":0.316595786540859,"score_spread":0.29523237322370605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406821808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90942836,0.027234042,0.0005876785,0.05762147,0.00031808316,0.0008044819,0.00008655515,0.0005052137,0.0034141042],"genre_scores_gemma":[0.98989666,0.0014516445,0.0059617264,0.0019384387,0.00016527362,0.000056805562,0.00014508535,0.000027182836,0.00035717367],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856865,0.00024470477,0.00034358096,0.00038347492,0.0001931321,0.00026644737],"domain_scores_gemma":[0.99738485,0.00059170177,0.000119589065,0.0015857393,0.00018038329,0.00013773573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056250015,0.00023058156,0.00036635087,0.00029515073,0.0008389812,0.00007234833,0.00014910841,0.00038712643,0.000010526226],"category_scores_gemma":[0.00017422297,0.00023273211,0.000108841625,0.00058001117,0.000537828,0.00017793573,0.0003022584,0.0011443149,0.000005929897],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000508164,0.00076397933,0.061308276,0.0005613797,0.0010997142,0.00005640653,0.003979495,0.0000060489742,0.8586039,0.022579126,0.03359544,0.016938092],"study_design_scores_gemma":[0.013994672,0.0004447706,0.35006708,0.006096858,0.0013911637,0.0011909519,0.0019300003,0.026133474,0.14775594,0.005833555,0.4431499,0.0020116488],"about_ca_topic_score_codex":0.000055564255,"about_ca_topic_score_gemma":0.00039640992,"teacher_disagreement_score":0.710848,"about_ca_system_score_codex":0.00017963373,"about_ca_system_score_gemma":0.00013781176,"threshold_uncertainty_score":0.949054},"labels":[],"label_agreement":null},{"id":"W4406972424","doi":"10.1016/j.molcel.2025.01.004","title":"A PARP2 active site helix melts to permit DNA damage-induced enzymatic activation","year":2025,"lang":"en","type":"article","venue":"Molecular Cell","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institutes of Health; National Cancer Institute; University of Pennsylvania","keywords":"Biology; Helix (gastropod); DNA; Enzyme; DNA damage; Biophysics; Cell biology; Active site; Biochemistry; DNA Ligases; Genetics; DNA repair; Molecular biology; Ecology","score_opus":0.011912244729366563,"score_gpt":0.29764059049562624,"score_spread":0.28572834576625966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406972424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95103675,0.00006280574,0.0088227205,0.003709731,0.00016111087,0.0008523134,0.000009345976,0.00010110462,0.035244104],"genre_scores_gemma":[0.9872399,0.000006845959,0.0009096536,0.008723161,0.00006105781,0.00015725635,0.000047799735,0.000034191537,0.0028201297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986885,0.000091886985,0.00024888603,0.00038140942,0.0003161407,0.00027314946],"domain_scores_gemma":[0.9990618,0.000054723194,0.00007857738,0.00051248365,0.00014615284,0.00014621572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116827476,0.00020199564,0.0002821312,0.00025976257,0.00007618773,0.000028328217,0.00010439918,0.000117262134,0.00022164959],"category_scores_gemma":[0.00008015598,0.00020565392,0.00011756172,0.00056067837,0.000022240793,0.00007630242,0.000050541385,0.00021901166,0.00028259374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002832563,0.00013987748,0.00009798256,0.000116520496,0.00006386681,0.000052259744,0.0008556171,0.0000404656,0.9929377,0.00015156296,0.0021119101,0.0031490077],"study_design_scores_gemma":[0.002437328,0.0001868499,0.0027356779,0.00030104298,0.00007358887,0.000003112143,0.00017340356,0.00018153994,0.9852121,0.00026352218,0.00825595,0.0001758822],"about_ca_topic_score_codex":0.000046892226,"about_ca_topic_score_gemma":0.000006008368,"teacher_disagreement_score":0.03620314,"about_ca_system_score_codex":0.00033680117,"about_ca_system_score_gemma":0.00018510241,"threshold_uncertainty_score":0.83863235},"labels":[],"label_agreement":null},{"id":"W4407095946","doi":"10.1016/s1470-2045(24)00674-0","title":"Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Clovis Oncology","keywords":"Oncology; Ovarian cancer; Medicine; Open label; Internal medicine; Chemotherapy; BRCA mutation; Cancer; Randomized controlled trial","score_opus":0.17658309875335135,"score_gpt":0.48424069930187097,"score_spread":0.30765760054851965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407095946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96872044,0.00017353073,0.0015525685,0.018494124,0.0014755384,0.005150709,0.0005025481,0.000037381884,0.0038931933],"genre_scores_gemma":[0.9715672,0.0018157818,0.015003742,0.002942925,0.0015472012,0.0037040547,0.00055494375,0.000050278075,0.0028138377],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985305,0.00019907572,0.0005941774,0.00030104248,0.00016547753,0.00020974038],"domain_scores_gemma":[0.99791914,0.0007844887,0.00052352017,0.00045857238,0.0002663243,0.000047961963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005718761,0.00017214038,0.000900399,0.00009823893,0.00007387878,0.00001707869,0.000319715,0.00013016397,0.00015530003],"category_scores_gemma":[0.00014355806,0.000104726794,0.00006305886,0.00020451157,0.00021931126,0.00009676197,0.000018377545,0.00007913079,7.279074e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9122495,0.002435719,0.00000920366,0.00003626479,0.0009303228,0.000017825641,0.001285872,0.00004736979,0.008031915,0.00050830905,0.0023450642,0.0721026],"study_design_scores_gemma":[0.8595269,0.034776334,0.00005929843,0.0001076831,0.00030982797,0.000020953998,0.0001236186,0.0006564568,0.028028984,0.00020281768,0.07609541,0.00009173446],"about_ca_topic_score_codex":0.00045856505,"about_ca_topic_score_gemma":0.00061728834,"teacher_disagreement_score":0.07375035,"about_ca_system_score_codex":0.0005241951,"about_ca_system_score_gemma":0.0012704543,"threshold_uncertainty_score":0.42706347},"labels":[],"label_agreement":null},{"id":"W4407650966","doi":"10.1016/j.ijgc.2024.101073","title":"Real-World Experience Of Treating Ovarian Cancer With PARP Inhibitors","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Ovarian cancer; Oncology; Cancer; Gynecology; Internal medicine","score_opus":0.028574344574752466,"score_gpt":0.3878671504596491,"score_spread":0.35929280588489665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407650966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97636384,0.00070408336,0.0004801473,0.008097897,0.0015784614,0.00017781933,0.000024674178,0.000018822797,0.012554263],"genre_scores_gemma":[0.99359167,0.0012512893,0.0014445445,0.0015848163,0.00056063704,0.00007062063,0.0000021535277,0.000010700159,0.0014835673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824107,0.000051165505,0.00071136653,0.00018387365,0.00063666835,0.00017585033],"domain_scores_gemma":[0.99775785,0.00028013007,0.0006346923,0.000114450166,0.001110752,0.00010211236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002098669,0.00014881957,0.00042666143,0.00031498543,0.00004195255,0.000021042104,0.00025798523,0.00007829309,0.0025032577],"category_scores_gemma":[0.00015797671,0.00009969339,0.00015174817,0.00037595743,0.00020992456,0.00014945392,0.000040689352,0.0002950843,0.0000012579194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044947146,0.0005087872,0.90921926,0.000054626562,0.0010759886,0.0003123076,0.0008505836,0.0011753286,0.028028049,0.0031551374,0.0045398846,0.046585355],"study_design_scores_gemma":[0.010531135,0.0011924774,0.8097953,0.003162463,0.00026425006,0.00011606457,0.0006939005,0.00020103634,0.13692874,0.0013050644,0.03549649,0.00031308722],"about_ca_topic_score_codex":0.00059730205,"about_ca_topic_score_gemma":0.00043942084,"teacher_disagreement_score":0.108900696,"about_ca_system_score_codex":0.00084076065,"about_ca_system_score_gemma":0.00070745894,"threshold_uncertainty_score":0.9984086},"labels":[],"label_agreement":null},{"id":"W4407699835","doi":"10.1200/jco.2025.43.5_suppl.219","title":"Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROpel trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Olaparib; Prostate cancer; Abiraterone; Germline; Somatic cell; Germline mutation; PARP inhibitor; Oncology; Enzalutamide; Internal medicine; Placebo; Cancer; Mutation; Androgen receptor; Poly ADP ribose polymerase; Pathology; Genetics","score_opus":0.13235641196189069,"score_gpt":0.47395915832958185,"score_spread":0.34160274636769117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407699835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071574,0.00017979454,0.0001839143,0.0049416553,0.0006067041,0.0030202311,0.000015710766,0.000007879576,0.0003283795],"genre_scores_gemma":[0.9962131,0.00014803621,0.002219566,0.0008056465,0.0001765774,0.00021791377,0.000013384629,0.000023856419,0.00018192564],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940999,0.0011821125,0.003368344,0.00029363026,0.0007478923,0.0003081296],"domain_scores_gemma":[0.99254066,0.0037232444,0.0026566198,0.000286095,0.0006622381,0.00013112118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034532428,0.0002451595,0.0017583007,0.00034651998,0.00004761463,0.000022371876,0.00021818974,0.00017877547,0.00007844421],"category_scores_gemma":[0.0019785461,0.00012688748,0.00015292651,0.0007539962,0.00035320592,0.00020720174,0.000020134401,0.0009839743,0.0000024445194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9670758,0.004249311,0.004685185,0.0003034426,0.0006896625,0.0005617508,0.0020130635,0.0051163873,0.00014310761,0.00006012959,0.00029389627,0.014808245],"study_design_scores_gemma":[0.7865324,0.06318759,0.14353982,0.0021250497,0.0009728353,0.000059874736,0.0011545699,0.0010127897,0.00020272387,0.000106329746,0.0009064043,0.0001995883],"about_ca_topic_score_codex":0.00019606772,"about_ca_topic_score_gemma":0.0032682915,"teacher_disagreement_score":0.1805434,"about_ca_system_score_codex":0.001022311,"about_ca_system_score_gemma":0.008282797,"threshold_uncertainty_score":0.9973393},"labels":[],"label_agreement":null},{"id":"W4407720354","doi":"10.1093/nar/gkaf069","title":"Discovery of reversing enzymes for RNA ADP-ribosylation reveals a possible defence module against toxic attack","year":2025,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Biotechnology and Biological Sciences Research Council; Directorate for Biological Sciences; University of Oxford; Wellcome Trust; Ovarian Cancer Research Alliance; Cancer Research UK","keywords":"RNA; Biology; Biochemistry; ADP-ribosylation; Enzyme; Ribosomal RNA; Nucleic acid; NAD+ kinase; Gene","score_opus":0.09174375508304305,"score_gpt":0.42180667384995,"score_spread":0.33006291876690697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407720354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706586,0.0012322324,0.0064932774,0.0029589902,0.0002069249,0.001384057,0.00008517266,0.000054524582,0.016926235],"genre_scores_gemma":[0.9868055,0.00035148716,0.003915516,0.00032274006,0.00018538846,0.000120703684,0.00004143825,0.000031140495,0.008226058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977104,0.00017695609,0.00043969104,0.0004296179,0.00073551876,0.00050782214],"domain_scores_gemma":[0.99805236,0.0005003623,0.00010061572,0.00059354084,0.0006587316,0.00009436807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014616958,0.00014621226,0.00037144468,0.00052724394,0.00028906716,0.00005938528,0.00024420078,0.00016211724,0.00007285972],"category_scores_gemma":[0.00071984535,0.00013996742,0.00015808869,0.0010674393,0.00031091162,0.00035612928,0.00010450148,0.00037858504,0.00002204885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020517781,0.00031749654,0.0105424225,0.0013652752,0.00016080619,0.00001009065,0.0006358126,0.00018550575,0.9051995,0.0066356487,0.056798298,0.016097339],"study_design_scores_gemma":[0.0060278233,0.0009478665,0.01764596,0.00385716,0.00006064316,0.00000808596,0.0008983126,0.00564114,0.9432911,0.008497491,0.012809435,0.0003149533],"about_ca_topic_score_codex":0.00003035076,"about_ca_topic_score_gemma":0.0000056949316,"teacher_disagreement_score":0.04398886,"about_ca_system_score_codex":0.0004931298,"about_ca_system_score_gemma":0.00041487682,"threshold_uncertainty_score":0.57077056},"labels":[],"label_agreement":null},{"id":"W4407766018","doi":"10.1159/000544112","title":"Tumor Treating Fields gegen Krebs: Etabliert beim Glioblastom, neue Indikationen am Horizont?","year":2025,"lang":"de","type":"article","venue":"Kompass Onkologie","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.022568888855982416,"score_gpt":0.3213892499592475,"score_spread":0.2988203611032651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407766018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54476714,0.12779106,0.022987274,0.1508922,0.033063397,0.00669157,0.00092348934,0.0027627898,0.110121086],"genre_scores_gemma":[0.973989,0.0023980576,0.0015650012,0.007918161,0.0033318792,0.00051524566,0.00019135332,0.00009434849,0.009996955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99525493,0.0003785434,0.0012800874,0.0011563201,0.00068994693,0.0012401687],"domain_scores_gemma":[0.9964867,0.0009947463,0.00052578707,0.0012850768,0.00038795266,0.0003196999],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00075366074,0.0007424607,0.0012252132,0.0007614781,0.0005113663,0.00016930896,0.0006778958,0.00069411984,0.0017904355],"category_scores_gemma":[0.0008720014,0.00072929595,0.00040125297,0.0013158144,0.00040116353,0.0003158791,0.00025972733,0.0013086197,0.0014525137],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033535825,0.0021776468,0.081396006,0.0015948223,0.004944514,0.0010920726,0.0037200823,0.001338705,0.007565039,0.010922899,0.7488972,0.13299742],"study_design_scores_gemma":[0.014051507,0.003054192,0.042397156,0.0029948188,0.0021222152,0.000040122937,0.0018302114,0.00358601,0.051222693,0.008150824,0.8687964,0.0017538263],"about_ca_topic_score_codex":0.000599815,"about_ca_topic_score_gemma":0.00017833851,"teacher_disagreement_score":0.42922187,"about_ca_system_score_codex":0.0010328483,"about_ca_system_score_gemma":0.0011069629,"threshold_uncertainty_score":0.99951583},"labels":[],"label_agreement":null},{"id":"W4408200213","doi":"10.1016/j.tranon.2025.102337","title":"Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Translational Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Institut Du Cancer de Montréal; Université de Montréal","keywords":"Triple-negative breast cancer; Breast cancer; Cancer research; Medicine; Poly ADP ribose polymerase; PARP inhibitor; Oncology; Cancer; Internal medicine; Biology; DNA; Genetics; Polymerase","score_opus":0.020991044434454424,"score_gpt":0.3952706973243053,"score_spread":0.3742796528898509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408200213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9239499,0.00060341484,0.009715254,0.053745847,0.00051537395,0.0014512981,0.00023036604,0.000055824545,0.009732744],"genre_scores_gemma":[0.9940264,0.000074770054,0.0028656062,0.002280299,0.00016202823,0.00020139704,0.000053082815,0.000012134104,0.0003242871],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986196,0.000116119336,0.0005606747,0.00028501605,0.00020920968,0.0002093915],"domain_scores_gemma":[0.9990365,0.00046044614,0.00011942708,0.00010702125,0.0002093799,0.00006721592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002914016,0.00013043337,0.00040583147,0.00031585354,0.000040145107,0.000002938401,0.00004437027,0.00014138986,0.0007343628],"category_scores_gemma":[0.00006782054,0.0001334492,0.00007717703,0.00070133904,0.00010587842,0.00007607512,0.000008735228,0.00022438979,0.000016617296],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026758216,0.0031615554,0.0561974,0.00055898883,0.00050243735,0.0000958947,0.00963001,0.022697067,0.6950761,0.014480714,0.012643106,0.15819852],"study_design_scores_gemma":[0.023258844,0.00073305424,0.77609354,0.0016344236,0.0001428792,0.000037564347,0.00027296654,0.0011246587,0.1747859,0.006439092,0.0150536345,0.00042346062],"about_ca_topic_score_codex":0.00017080258,"about_ca_topic_score_gemma":0.00025492508,"teacher_disagreement_score":0.71989614,"about_ca_system_score_codex":0.0003749095,"about_ca_system_score_gemma":0.0007623115,"threshold_uncertainty_score":0.8040758},"labels":[],"label_agreement":null},{"id":"W4408220345","doi":"10.1016/j.esmoop.2025.104187","title":"29P BRCA1 reversion mutations confer a fitness benefit to PARP inhibitor-resistant subclones in high grade serous ovarian cancer models","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Reversion; PARP inhibitor; Serous ovarian cancer; Ovarian cancer; Serous fluid; Genetics; Biology; Cancer research; Mutation; Cancer; Medicine; Oncology; Internal medicine; Poly ADP ribose polymerase; DNA; Phenotype; Gene; Polymerase","score_opus":0.0445721061994778,"score_gpt":0.35147407901348515,"score_spread":0.30690197281400733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408220345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473854,0.00027815707,0.0012347784,0.041160922,0.0007721686,0.0024358297,0.00019912451,0.000084860265,0.006448764],"genre_scores_gemma":[0.98441285,0.00011451023,0.00153003,0.00503405,0.00013112948,0.0008581955,0.00012644906,0.00003510402,0.0077576684],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99826074,0.0000743652,0.00047088327,0.000534198,0.00030427793,0.00035552104],"domain_scores_gemma":[0.9989444,0.00008659751,0.00009318332,0.00050523225,0.0002017466,0.00016880906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002891357,0.00023099635,0.0004896952,0.0003077742,0.00016733655,0.00010056046,0.000338852,0.00015018637,0.0006335919],"category_scores_gemma":[0.00003346533,0.00022714125,0.000067878835,0.0008522353,0.00006226737,0.00032422904,0.00020065818,0.00024948016,0.00004074716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026686478,0.005184584,0.16818587,0.0019141051,0.0020533286,0.0017814407,0.024731645,0.0988703,0.08110379,0.35050124,0.20981216,0.02917505],"study_design_scores_gemma":[0.0441542,0.0008139838,0.6281673,0.00953792,0.00043863978,0.000052590458,0.0021586774,0.003516402,0.086924456,0.08743222,0.13488306,0.0019205929],"about_ca_topic_score_codex":0.037462004,"about_ca_topic_score_gemma":0.012085102,"teacher_disagreement_score":0.45998138,"about_ca_system_score_codex":0.0006008307,"about_ca_system_score_gemma":0.00050767337,"threshold_uncertainty_score":0.96894765},"labels":[],"label_agreement":null},{"id":"W4408220869","doi":"10.1371/journal.pone.0318267","title":"Intracellular accumulation of free cholesterol in macrophages triggers a PARP1 response to DNA damage and PARP1 impairs lipopolysaccharide-induced inflammatory response","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"PARP1; DNA damage; Inflammation; Lipopolysaccharide; Gene knockdown; Chemistry; Intracellular; Cell biology; Biochemistry; Biology; Apoptosis; Immunology; Enzyme; Poly ADP ribose polymerase; DNA","score_opus":0.0582871060609128,"score_gpt":0.32508872274353856,"score_spread":0.26680161668262575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408220869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180645,0.0002699525,0.00007789174,0.0062468755,0.00005853698,0.001362643,0.000031419295,0.000094976276,0.000051237723],"genre_scores_gemma":[0.99748814,0.00006084297,0.00086282706,0.00092294416,0.000056268782,0.00020063423,0.000007212545,0.000037655478,0.0003634661],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740165,0.0006391792,0.0007272824,0.0004393636,0.0004662392,0.00032625432],"domain_scores_gemma":[0.99790627,0.00072596356,0.00018689345,0.00082771754,0.00016049482,0.00019263956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018161135,0.00024522707,0.00060332956,0.0009073713,0.00006027019,0.00003443222,0.00018807105,0.00020149209,0.0000748896],"category_scores_gemma":[0.0015927164,0.000259697,0.00006928154,0.0005677735,0.00010623255,0.00021373821,0.000107560954,0.00033096992,0.0000134877755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03676228,0.00060819817,0.015811153,0.0002759909,0.00017124134,0.00006542133,0.0015961993,0.0000142699455,0.9439001,0.000024848576,0.00012949047,0.0006407746],"study_design_scores_gemma":[0.0061331773,0.00058548426,0.19028123,0.0014545295,0.000094543604,0.0000032866012,0.00028857426,0.0002337133,0.80054295,0.00014696408,0.00006941913,0.00016612398],"about_ca_topic_score_codex":0.00006391774,"about_ca_topic_score_gemma":0.00003680729,"teacher_disagreement_score":0.17447007,"about_ca_system_score_codex":0.00030507438,"about_ca_system_score_gemma":0.00032011754,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W4408253856","doi":"10.1093/narcan/zcaf007","title":"Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment","year":2025,"lang":"en","type":"article","venue":"NAR Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"DOD Prostate Cancer Research Program; Departament de Salut, Generalitat de Catalunya; European Regional Development Fund; Instituto de Salud Carlos III; Agència de Gestió d'Ajuts Universitaris i de Recerca; Generalitat de Catalunya; Agencia Estatal de Investigación; Ministerio de Ciencia, Innovación y Universidades; Albert Einstein Cancer Center; Centres de Recerca de Catalunya; U.S. Department of Defense","keywords":"PARP1; DNA repair; Effector; Biology; Poly ADP ribose polymerase; Cancer research; Homologous recombination; Oncogene; HIF1A; DNA damage; Cancer; PARP inhibitor; Cancer cell; Synthetic lethality; Promoter; Molecular biology; Polymerase; DNA; Gene; Cell biology; Cell cycle; Gene expression; Genetics; Angiogenesis","score_opus":0.04694264841448222,"score_gpt":0.37301251635112354,"score_spread":0.32606986793664133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408253856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.948689,0.008239129,0.010418105,0.015382301,0.002184063,0.0012457507,0.00046519368,0.00012379476,0.0132527],"genre_scores_gemma":[0.9912866,0.00058791664,0.00086715224,0.0014973704,0.00045861967,0.0005338224,0.000026675116,0.000018064546,0.004723832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896485,0.00003188102,0.00028415304,0.00026408373,0.00028802716,0.00016700411],"domain_scores_gemma":[0.999437,0.00003691101,0.00009430349,0.00016313892,0.00019613568,0.00007256006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008264779,0.0001374565,0.00027688418,0.00019386926,0.00006571586,0.000008860462,0.00005009179,0.00006235273,0.0016169712],"category_scores_gemma":[0.000010779396,0.00012283986,0.00009705358,0.00032376754,0.00005754328,0.000081007514,0.000007447603,0.00007765508,0.000004176299],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027226415,0.00029250866,0.044240654,0.00024077122,0.00087727694,0.000007154746,0.005011703,0.011572997,0.6564121,0.002970244,0.007410453,0.26824147],"study_design_scores_gemma":[0.009232597,0.0005311542,0.18298474,0.003449212,0.00036465676,0.0000062830172,0.00023991597,0.0032044924,0.61382496,0.0008420792,0.18504767,0.00027224724],"about_ca_topic_score_codex":0.0009985396,"about_ca_topic_score_gemma":0.00016856825,"teacher_disagreement_score":0.26796922,"about_ca_system_score_codex":0.0011363496,"about_ca_system_score_gemma":0.0005820168,"threshold_uncertainty_score":0.9992957},"labels":[],"label_agreement":null},{"id":"W4408519118","doi":"10.1038/s41416-025-02966-x","title":"Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status","year":2025,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck; AstraZeneca","keywords":"Olaparib; Medicine; BRCA mutation; Oncology; Ovarian cancer; Internal medicine; Germline mutation; Cohort; Cancer; Mutation; Biology; Genetics","score_opus":0.009865581849015198,"score_gpt":0.2956261631054802,"score_spread":0.285760581256465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408519118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98586845,0.007841884,0.0013506865,0.002826536,0.00064623007,0.0005158211,0.00013807151,0.00003911548,0.00077319087],"genre_scores_gemma":[0.9831585,0.011060056,0.0017562216,0.0014050006,0.00015375778,0.00007612424,0.000026445237,0.000034946574,0.0023288936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981003,0.00016694299,0.0007421019,0.0002736076,0.0003897627,0.0003272963],"domain_scores_gemma":[0.9983789,0.0001910687,0.0005530785,0.00011530966,0.0006360859,0.0001256053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048636156,0.00017929816,0.0005722376,0.00021408209,0.0000865387,0.000053428204,0.00005721418,0.00012653605,0.00019441219],"category_scores_gemma":[0.0002150655,0.00016806033,0.00007396397,0.00039673163,0.00013673838,0.00030388864,0.000014923782,0.0005101208,5.198934e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045880567,0.0019615449,0.20314267,0.0020452251,0.0034135876,0.016458876,0.005258516,0.0030663735,0.020420045,0.0010146104,0.08397623,0.6133618],"study_design_scores_gemma":[0.06693385,0.0019515451,0.87745047,0.021821521,0.0005337012,0.006897282,0.0010650442,0.0024442521,0.0071994094,0.0023913342,0.010596783,0.000714783],"about_ca_topic_score_codex":0.0034474465,"about_ca_topic_score_gemma":0.0071548196,"teacher_disagreement_score":0.6743078,"about_ca_system_score_codex":0.0010039127,"about_ca_system_score_gemma":0.0009989502,"threshold_uncertainty_score":0.68533015},"labels":[],"label_agreement":null},{"id":"W4408848600","doi":"10.3390/ijms26073034","title":"From DNA Repair to Redox Signaling: The Multifaceted Role of APEX1 (Apurinic/Apyrimidinic Endonuclease 1) in Cardiovascular Health and Disease","year":2025,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"AP site; DNA-(apurinic or apyrimidinic site) lyase; Endonuclease; Biology; DNA repair; DNA damage; Base excision repair; AP endonuclease; Cell biology; Cancer research; DNA; Genetics","score_opus":0.03701957199104864,"score_gpt":0.37736718389475427,"score_spread":0.3403476119037056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408848600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067807822,0.99002796,0.00019870666,0.0017845024,0.00049095973,0.00054261246,0.00007883717,0.00000998984,0.000085640175],"genre_scores_gemma":[0.014674544,0.9821863,0.0016455298,0.001165286,0.00025692204,0.000024717903,0.000013238311,0.00001709892,0.000016331313],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635863,0.00046148355,0.0011889738,0.00038464868,0.001416261,0.0001900201],"domain_scores_gemma":[0.9977984,0.00036678222,0.0007837043,0.00033692218,0.00034515292,0.00036908058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016133847,0.00023126818,0.0012161578,0.00070160674,0.000057482197,0.000048634385,0.0007358891,0.00007422251,0.000027974167],"category_scores_gemma":[0.0009959996,0.00015666612,0.0010645076,0.0005264523,0.00026357494,0.000090608555,0.00014081442,0.00035508297,0.0000022270333],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004924625,0.0003501721,0.00023406709,0.0019292153,0.003238177,0.0008138417,0.0013026361,0.0007765401,0.00052391953,0.00034917615,0.0005673983,0.9894224],"study_design_scores_gemma":[0.0031374071,0.0008542476,0.00020204086,0.082191296,0.0014125687,0.00039873805,0.0011789754,0.0002169445,0.00086325034,0.0021039362,0.9069585,0.00048204843],"about_ca_topic_score_codex":0.00011449118,"about_ca_topic_score_gemma":0.0000021032909,"teacher_disagreement_score":0.98894036,"about_ca_system_score_codex":0.00025435773,"about_ca_system_score_gemma":0.0032562383,"threshold_uncertainty_score":0.6388659},"labels":[],"label_agreement":null},{"id":"W4408851570","doi":"10.1016/j.ygyno.2025.03.018","title":"ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Nova (rocket); Oncology; Ovarian cancer; Term (time); Gynecology; Internal medicine; Cancer","score_opus":0.06785633356941483,"score_gpt":0.40835887318693526,"score_spread":0.3405025396175204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408851570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950563,0.0018371268,0.00017617398,0.008850152,0.004974256,0.0017020635,0.000030482031,0.000059715323,0.03180699],"genre_scores_gemma":[0.9939815,0.0035336618,0.0003477303,0.0010392793,0.0002530179,0.00026595904,0.000033416836,0.000012507379,0.0005329676],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978267,0.00038814498,0.0007827211,0.0004530034,0.00016563841,0.00038379326],"domain_scores_gemma":[0.9982185,0.0009951941,0.00025827438,0.00031091823,0.00012111279,0.00009600649],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009671767,0.00020613898,0.0009613004,0.000311373,0.000055447876,0.0000060376105,0.00014225557,0.00042383763,0.0013025363],"category_scores_gemma":[0.0004067294,0.00018518053,0.00009712939,0.00048840244,0.00032017988,0.00004424897,0.00009914217,0.0004512019,0.0000074221434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0966966,0.0028980917,0.36373648,0.00033941242,0.00039107658,0.00023333963,0.0005119093,0.000022655659,0.0028646023,0.009424574,0.0030677167,0.51981354],"study_design_scores_gemma":[0.16431986,0.0059692753,0.79212105,0.00023976843,0.00016308649,0.00002312399,0.00013721365,0.00003670776,0.00095022534,0.001424454,0.034373093,0.0002421435],"about_ca_topic_score_codex":0.0001773115,"about_ca_topic_score_gemma":0.0032219077,"teacher_disagreement_score":0.5195714,"about_ca_system_score_codex":0.00095129985,"about_ca_system_score_gemma":0.0010876274,"threshold_uncertainty_score":0.9996104},"labels":[],"label_agreement":null},{"id":"W4408919525","doi":"10.1101/2025.03.27.645734","title":"A large-scale method to measure the absolute stoichiometries of protein Poly-ADP-Ribosylation","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Measure (data warehouse); Stoichiometry; Scale (ratio); Absolute (philosophy); Chemistry; Chromatography; Physics; Computer science; Organic chemistry; Data mining; Philosophy; Quantum mechanics","score_opus":0.023652601558509942,"score_gpt":0.29181698092657343,"score_spread":0.2681643793680635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408919525","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4684942,0.01310005,0.49014276,0.011180143,0.0022845056,0.010401831,0.003132454,0.0009782139,0.00028582913],"genre_scores_gemma":[0.91049737,0.00009971817,0.08575455,0.0013270439,0.00068478636,0.0013571458,0.0000012558777,0.00012813899,0.00015002074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962652,0.00040487922,0.00086648413,0.0009510186,0.0009442923,0.00056812644],"domain_scores_gemma":[0.9957109,0.00015689743,0.00060057093,0.0019254221,0.0013358139,0.00027038335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023694774,0.0005566419,0.0009835031,0.0009020998,0.00020786632,0.00008563699,0.00054594944,0.00056785136,0.000111745045],"category_scores_gemma":[0.00051705213,0.0004809052,0.0003140807,0.0022949534,0.00012595314,0.0000943024,0.000427668,0.0010229979,0.00003230973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006086976,0.000343224,0.001922366,0.0013776737,0.0006300489,0.000012654718,0.00021503819,0.00009491644,0.99211425,0.0014214431,0.0012114615,0.00004823575],"study_design_scores_gemma":[0.0019698124,0.00019461886,0.046433993,0.0031873093,0.00039038443,4.053838e-8,0.000028661545,0.000409726,0.8981347,0.000019456682,0.048595812,0.0006355009],"about_ca_topic_score_codex":0.00008364529,"about_ca_topic_score_gemma":0.000010426556,"teacher_disagreement_score":0.44200313,"about_ca_system_score_codex":0.00049888523,"about_ca_system_score_gemma":0.0015544447,"threshold_uncertainty_score":0.99976426},"labels":[],"label_agreement":null},{"id":"W4408990988","doi":"10.1080/14796694.2025.2470106","title":"A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Internal medicine; Oncology; Cancer; Androgen deprivation therapy","score_opus":0.008952118645876158,"score_gpt":0.29775299261104465,"score_spread":0.2888008739651685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408990988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97937375,0.0011221367,0.000016038517,0.016100645,0.00010715749,0.0027192368,0.00043061914,0.000010265201,0.00012014955],"genre_scores_gemma":[0.99795705,0.00005583794,0.0005718508,0.00075178075,0.00005466186,0.00030993068,0.00004045602,0.000015479643,0.0002429796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998476,0.0005790909,0.0001950756,0.0003459867,0.0002259289,0.00017791237],"domain_scores_gemma":[0.9988763,0.00041584973,0.00026563444,0.0002695984,0.00013530187,0.00003733289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003708004,0.0001881015,0.00043994383,0.0000659483,0.00011106652,0.000045019897,0.00007288362,0.000061264574,0.0000051732363],"category_scores_gemma":[0.000048370337,0.00009257653,0.000017678178,0.00030284593,0.00025352262,0.00011330932,0.000042896256,0.00029065195,7.652658e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035951972,0.0011255323,0.86883444,0.00027710796,0.0013593326,0.00011717234,0.05739057,0.000035817342,0.0095199095,0.000019696377,0.0023209583,0.02304751],"study_design_scores_gemma":[0.026283432,0.0020502396,0.9562302,0.00056359364,0.00035105782,0.0000036442316,0.01235236,0.000021491718,0.0014346233,0.000015898253,0.0005941981,0.00009923448],"about_ca_topic_score_codex":0.0006928912,"about_ca_topic_score_gemma":0.011784139,"teacher_disagreement_score":0.08739581,"about_ca_system_score_codex":0.00018184532,"about_ca_system_score_gemma":0.00031042445,"threshold_uncertainty_score":0.65758264},"labels":[],"label_agreement":null},{"id":"W4409356929","doi":"10.1016/j.celrep.2025.115537","title":"DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition","year":2025,"lang":"en","type":"article","venue":"Cell Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; SickKids Foundation; Hospital for Sick Children","funders":"FDC Foundation; Garron Family Cancer Centre; Canadian Institutes of Health Research; Hospital for Sick Children; Centre for Applied Genomics; V Foundation for Cancer Research","keywords":"DNA damage; Poly ADP ribose polymerase; Neuroblastoma; Sensitivity (control systems); DNA; Cancer research; Biology; Genetics; Medicine; Polymerase; Cell culture","score_opus":0.008863277277109404,"score_gpt":0.2962314196613264,"score_spread":0.287368142384217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409356929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928781,0.0002468337,0.00074718567,0.0020825246,0.00022645426,0.00061632344,0.0000021120557,0.00008631523,0.003114181],"genre_scores_gemma":[0.9979623,0.000046678782,0.00033360627,0.00064898527,0.000026833057,0.00003986659,0.000010720945,0.000011528436,0.00091949414],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987402,0.00015986881,0.0002976967,0.00041587316,0.0002233806,0.00016301419],"domain_scores_gemma":[0.9992226,0.00014344743,0.00014828621,0.0002476393,0.00012249801,0.00011554354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079139974,0.00013083081,0.00019099652,0.00019100333,0.00014174165,0.000037184273,0.000008944325,0.0000755048,0.000010835164],"category_scores_gemma":[0.00022962879,0.00012321223,0.000026930864,0.00027885736,0.00010519337,0.00011047996,0.000052215386,0.00011532251,0.0000026994103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071556633,0.0001614652,0.005645823,0.00014393554,0.000003833068,0.0010011778,0.00030523012,0.0000025713505,0.9860828,0.000047455957,0.0014253063,0.0044648354],"study_design_scores_gemma":[0.0008179808,0.0004844013,0.21143346,0.0004645249,0.000029192224,0.0005675871,0.000070652786,0.00008371365,0.78214943,0.0004054654,0.0033699193,0.00012368734],"about_ca_topic_score_codex":0.0000064477904,"about_ca_topic_score_gemma":0.0000062512863,"teacher_disagreement_score":0.20578763,"about_ca_system_score_codex":0.00006842446,"about_ca_system_score_gemma":0.00010686802,"threshold_uncertainty_score":0.5024449},"labels":[],"label_agreement":null},{"id":"W4409627978","doi":"10.1158/1538-7445.am2025-6157","title":"Abstract 6157: PAR2 inhibitors reduce resistance to immunotherapy against cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Medicine; Cancer; Immunotherapy; Cancer immunotherapy; Resistance (ecology); Internal medicine; Pharmacology; Cancer research; Oncology; Biology","score_opus":0.08492788500421826,"score_gpt":0.4722232129293173,"score_spread":0.387295327925099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409627978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8660947,0.028650427,0.00006270149,0.0476623,0.0015385287,0.0019756225,0.00012645878,0.0001997551,0.053689472],"genre_scores_gemma":[0.9310193,0.011788512,0.0002770438,0.0068131383,0.0012857185,0.0030883155,0.00001809777,0.000093603405,0.04561629],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962316,0.00015566946,0.0005665099,0.0008362741,0.0011832984,0.0010266096],"domain_scores_gemma":[0.9973484,0.00024061766,0.00008589299,0.0009969932,0.00095955224,0.0003685194],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012085435,0.00029288023,0.0004917055,0.0007398729,0.0004045349,0.00010239223,0.0004477479,0.00020685414,0.0019337737],"category_scores_gemma":[0.0001666375,0.00027988254,0.00016175458,0.0023264368,0.00036527278,0.00014360539,0.00010160842,0.0010737285,0.00018032026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024932264,0.00013362747,0.0019519168,0.0002824563,0.00018738235,0.000041143492,0.00055056915,0.00007445838,0.5329389,0.0004249791,0.4083824,0.05253897],"study_design_scores_gemma":[0.00223796,0.00007025838,0.014455568,0.0024023796,0.000010534693,9.796221e-7,0.00021039874,0.0000029767734,0.37822464,0.00043518085,0.6017176,0.00023151524],"about_ca_topic_score_codex":0.000860141,"about_ca_topic_score_gemma":0.00068958063,"teacher_disagreement_score":0.19333522,"about_ca_system_score_codex":0.0024356814,"about_ca_system_score_gemma":0.0024826515,"threshold_uncertainty_score":0.9999653},"labels":[],"label_agreement":null},{"id":"W4409630653","doi":"10.1158/1538-7445.am2025-4186","title":"Abstract 4186: Discovery of novel PARP1-selective inhibitors for treatment of brain tumors using artificial intelligence","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Computational biology; Cancer research; Oncology; Biology","score_opus":0.2575320059382619,"score_gpt":0.5134667614376511,"score_spread":0.2559347554993892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409630653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98157334,0.0012023655,0.012885456,0.00160039,0.00026048566,0.0015783589,0.00024241798,0.00001540784,0.00064179994],"genre_scores_gemma":[0.99796104,0.00020285831,0.00068340177,0.000056192475,0.00029371493,0.00039966,0.000013023641,0.000023697658,0.000366429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982127,0.000050970815,0.0005331636,0.00035371428,0.00046080136,0.00038867528],"domain_scores_gemma":[0.99813974,0.00068727095,0.00013923156,0.0003003934,0.0006611709,0.000072192925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005551229,0.00014622814,0.0004492967,0.00045920492,0.000100257035,0.00001765564,0.000114321505,0.00009127779,0.000053026815],"category_scores_gemma":[0.0002395715,0.00012820656,0.00016826384,0.000901772,0.00045760814,0.000107789114,0.00002884611,0.0001456764,9.703984e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003080806,0.00094630156,0.001255855,0.00048974383,0.00021690705,0.0000039318666,0.00071958074,0.00059251115,0.96306896,0.0057423697,0.00065955747,0.023223503],"study_design_scores_gemma":[0.0010640181,0.0007948724,0.0012065948,0.00094470213,0.000027597609,0.0000018322634,0.0006895189,0.00047792948,0.99090445,0.0031482752,0.0006487773,0.000091433445],"about_ca_topic_score_codex":0.0012763175,"about_ca_topic_score_gemma":0.00013095049,"teacher_disagreement_score":0.027835516,"about_ca_system_score_codex":0.0012023568,"about_ca_system_score_gemma":0.0018434013,"threshold_uncertainty_score":0.5228112},"labels":[],"label_agreement":null},{"id":"W4409632101","doi":"10.1158/1538-7445.am2025-5722","title":"Abstract 5722: Gene expression analysis of different PARPi combination approaches with carboplatin at primary tumor and metastatic site in xenograft model of triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Carboplatin; Medicine; Triple negative; Breast cancer; Metastatic breast cancer; Cancer; Cancer research; Oncology; Primary tumor; Internal medicine; Metastasis; Chemotherapy; Cisplatin","score_opus":0.10453306443742745,"score_gpt":0.38728790887168596,"score_spread":0.2827548444342585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409632101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586123,0.0015758891,0.00025502063,0.00045932413,0.000020169186,0.0009081993,0.0005074034,0.000010010098,0.00040273924],"genre_scores_gemma":[0.9977352,0.0006793802,0.00039835146,0.000042334425,0.000013391112,0.0006892412,0.00008071431,0.000018827262,0.00034257665],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99786884,0.0001825119,0.00046445656,0.00041877432,0.00077189587,0.0002935118],"domain_scores_gemma":[0.99871373,0.00026886386,0.00020762847,0.00032410878,0.00038531327,0.000100374025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054762175,0.00017473612,0.0007279161,0.0011089091,0.00006968055,0.000011035546,0.000100084035,0.000054072854,0.00014936365],"category_scores_gemma":[0.000027738253,0.00013139057,0.00008184021,0.0016482002,0.00038320431,0.00009516364,0.0000854163,0.00032390826,2.079149e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062533887,0.00064280943,0.3769914,0.0014771764,0.0011876398,0.000009593737,0.0024643857,0.0110819535,0.59665143,0.00008208548,0.00022079711,0.002937357],"study_design_scores_gemma":[0.0050248,0.00011359017,0.6173941,0.0010447053,0.00037888304,0.0000013571481,0.0002733491,0.024297977,0.3511332,0.00021904345,0.0000023232221,0.00011666541],"about_ca_topic_score_codex":0.001741398,"about_ca_topic_score_gemma":0.0017397943,"teacher_disagreement_score":0.24551822,"about_ca_system_score_codex":0.00086694007,"about_ca_system_score_gemma":0.00050472456,"threshold_uncertainty_score":0.53579515},"labels":[],"label_agreement":null},{"id":"W4409690563","doi":"10.1158/1538-7445.am2025-38","title":"Abstract 38: Augmenting drug responses to PARP inhibitors in high grade serous cancer with inhibitors of the anti-apoptotic protein Bcl-XL","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Apoptosis; Poly ADP ribose polymerase; Cancer; Serous fluid; Drug; Cancer research; Serous ovarian cancer; Pharmacology; Biology; Internal medicine; Ovarian cancer; Enzyme; Biochemistry; Polymerase","score_opus":0.05261634181509617,"score_gpt":0.40690028335037987,"score_spread":0.3542839415352837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409690563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97379565,0.0018931788,0.0000055663513,0.020086393,0.00046188198,0.0030129587,0.000060052596,0.000053801938,0.00063050154],"genre_scores_gemma":[0.9920198,0.00028471902,0.0001050617,0.00042336676,0.0003480702,0.0019760465,0.0000040407813,0.000062511615,0.004776417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958215,0.0004171716,0.000698435,0.0006923742,0.0014599798,0.00091054366],"domain_scores_gemma":[0.9979463,0.00031496774,0.00018037186,0.00078838837,0.0005615839,0.00020837855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017223835,0.00029561846,0.00055973534,0.00086339656,0.00026736312,0.000059682447,0.0004403398,0.0001422687,0.0002654573],"category_scores_gemma":[0.0002984901,0.000212189,0.00011067343,0.003319564,0.00052269344,0.00014765217,0.00022308875,0.0011800921,0.000012264281],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034890936,0.00046322742,0.20036685,0.0013343199,0.000212359,0.00007318316,0.0024610576,0.00094287127,0.76949644,0.00026851948,0.015000596,0.0058914768],"study_design_scores_gemma":[0.0033949362,0.00015811187,0.16728517,0.009150491,0.000025750947,0.0000036337624,0.0008494258,0.000008594653,0.81273234,0.00020773818,0.0059535443,0.00023028527],"about_ca_topic_score_codex":0.009777792,"about_ca_topic_score_gemma":0.0022840907,"teacher_disagreement_score":0.043235864,"about_ca_system_score_codex":0.0015287879,"about_ca_system_score_gemma":0.0025541352,"threshold_uncertainty_score":0.99681616},"labels":[],"label_agreement":null},{"id":"W4409690809","doi":"10.1158/1538-7445.am2025-73","title":"Abstract 73: Molecular characterization of senescence induced by PARPi in preclinical xenograft mouse models of ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Ovarian cancer; Cancer; Senescence; Cancer research; Medicine; Biology; Oncology; Internal medicine","score_opus":0.1505554759126108,"score_gpt":0.4820722729312489,"score_spread":0.3315167970186381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409690809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416685,0.0010263782,0.00069609564,0.0021353178,0.00012029479,0.000858851,0.0001741015,0.000020486717,0.0008016188],"genre_scores_gemma":[0.99634165,0.0022734082,0.000072418035,0.00026172897,0.00005383456,0.0004775856,0.000048529775,0.000026902293,0.00044396374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763167,0.00018684416,0.0006701297,0.0004109848,0.00071019994,0.00039015344],"domain_scores_gemma":[0.9984779,0.00013520847,0.00015635464,0.0004811483,0.0006327145,0.00011669906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093740394,0.00014107751,0.00045402485,0.00041637686,0.000037239242,0.000012082706,0.00023401013,0.00021203456,0.00033343304],"category_scores_gemma":[0.000111174166,0.00014097756,0.0000801176,0.0011652575,0.00024467302,0.0001419551,0.000068344925,0.0006089443,0.0000021423054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009740873,0.00028499233,0.006339205,0.0004679745,0.00007461527,0.00000580258,0.0002735631,0.00012117335,0.9850826,0.00032364242,0.00034747334,0.005704828],"study_design_scores_gemma":[0.0024762542,0.0001114335,0.022529991,0.0013594893,0.000015517697,4.3375422e-7,0.00004612258,0.0005317958,0.9719272,0.0003728067,0.0005224754,0.000106456944],"about_ca_topic_score_codex":0.0023367477,"about_ca_topic_score_gemma":0.00011463542,"teacher_disagreement_score":0.016190786,"about_ca_system_score_codex":0.00039863968,"about_ca_system_score_gemma":0.0012987081,"threshold_uncertainty_score":0.5748898},"labels":[],"label_agreement":null},{"id":"W4409889205","doi":"10.1016/j.ygyno.2025.04.580","title":"Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck; AstraZeneca","keywords":"Olaparib; Medicine; Ovarian cancer; Germline; Oncology; Internal medicine; Germline mutation; BRCA mutation; Mutation; Cancer; Poly ADP ribose polymerase; Genetics; Gene; Biology","score_opus":0.038635838531484425,"score_gpt":0.3417833927683687,"score_spread":0.3031475542368843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409889205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97373605,0.00015143435,0.0004661411,0.018393246,0.0019492834,0.0026515329,0.00030859144,0.00007643707,0.0022673092],"genre_scores_gemma":[0.9865623,0.00035593772,0.0019761333,0.008719109,0.0004659822,0.00050247903,0.0003181661,0.000027101998,0.0010727512],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9971937,0.00060000777,0.0007717082,0.0007187404,0.00027895483,0.00043686776],"domain_scores_gemma":[0.9961444,0.0026433752,0.00045675828,0.00039387558,0.00027638202,0.00008520257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000731965,0.00031088688,0.00081336516,0.00012779028,0.0001694092,0.000026232432,0.00015293107,0.00038582712,0.00024449016],"category_scores_gemma":[0.00078800356,0.00019150885,0.00006859344,0.0003852798,0.00034981122,0.00010197638,0.00005449196,0.0006126023,0.0000068703653],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83758,0.0015040858,0.10044809,0.00002731529,0.00057968555,0.00021226199,0.0027519802,0.00037263334,0.00014129162,0.001034024,0.0074685807,0.047880054],"study_design_scores_gemma":[0.32644817,0.00554193,0.6509416,0.00026524212,0.0000705838,0.00000935963,0.00025082327,0.00044562327,0.000072559465,0.000845498,0.014882945,0.00022567171],"about_ca_topic_score_codex":0.001215935,"about_ca_topic_score_gemma":0.0038370697,"teacher_disagreement_score":0.55049354,"about_ca_system_score_codex":0.0009859877,"about_ca_system_score_gemma":0.0011619417,"threshold_uncertainty_score":0.7809504},"labels":[],"label_agreement":null},{"id":"W4410030770","doi":"10.1016/j.jconrel.2025.113812","title":"Radiation-guided nanoparticles enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors via immunotherapy","year":2025,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"H2020 European Research Council; Fundação para a Ciência e a Tecnologia; National Cancer Institute; European Research Council; Israel Cancer Research Fund; Israel Science Foundation; Egg Farmers of Canada; Tel Aviv University; Teva Pharmaceutical Industries","keywords":"Immunotherapy; Primary (astronomy); Medicine; Cancer research; Nanoparticle; Internal medicine; Nanotechnology; Cancer; Materials science","score_opus":0.008606387272397204,"score_gpt":0.2950125257560063,"score_spread":0.2864061384836091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410030770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701671,0.022455186,0.00084017654,0.0051914738,0.00025141897,0.00080922025,0.00000246468,0.000007864037,0.0002751223],"genre_scores_gemma":[0.99643767,0.0015434077,0.00025293152,0.0014979516,0.00008469878,0.00002956648,9.3877213e-7,0.000013912459,0.00013894636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975628,0.0003060725,0.0013840218,0.00013953313,0.00041352052,0.00019403742],"domain_scores_gemma":[0.9975652,0.0009977772,0.0008546708,0.00023508238,0.00026062064,0.00008662233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012692314,0.00016195652,0.0008811212,0.00034811665,0.000064726584,0.000020261235,0.000118672775,0.000043863867,0.000037853337],"category_scores_gemma":[0.0005079942,0.00010113307,0.00024918996,0.00044666347,0.00017200476,0.00010012364,0.000014337277,0.0002984282,0.0000015121822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032571983,0.0016382203,0.008360532,0.00022938334,0.001164571,0.00014601478,0.0016089402,0.0023107515,0.8629188,0.0005264855,0.0024318674,0.08609245],"study_design_scores_gemma":[0.30261984,0.0024389967,0.21167877,0.0038192747,0.0012107744,0.00055607205,0.0008227964,0.004551777,0.463836,0.0027730314,0.0051707975,0.00052185426],"about_ca_topic_score_codex":0.000023024799,"about_ca_topic_score_gemma":0.0000021877165,"teacher_disagreement_score":0.39908278,"about_ca_system_score_codex":0.00018556222,"about_ca_system_score_gemma":0.00053252524,"threshold_uncertainty_score":0.4124087},"labels":[],"label_agreement":null},{"id":"W4410569892","doi":"10.1007/s11523-025-01146-4","title":"Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation","year":2025,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Abiraterone; Prostate cancer; Oncology; PARP inhibitor; Internal medicine; Docetaxel; Cancer; BRCA mutation; Ovarian cancer; Poly ADP ribose polymerase; Androgen receptor","score_opus":0.04601313563003731,"score_gpt":0.3846335911876247,"score_spread":0.33862045555758735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410569892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00774233,0.97875667,0.00048296087,0.00041693298,0.00013432257,0.011713548,0.0007022199,0.000024576288,0.000026415579],"genre_scores_gemma":[0.0018827207,0.986869,0.0018592372,0.000110776156,0.00002712964,0.00795483,0.0008690401,0.000047265956,0.0003800399],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844104,0.0001891405,0.0006282583,0.00035010083,0.00017796761,0.00021351273],"domain_scores_gemma":[0.9981377,0.00069539493,0.00063448754,0.00020738589,0.00028019855,0.000044838824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014300231,0.00032903807,0.0014074497,0.00025913538,0.000068615824,0.0000121293015,0.000054201064,0.0001308659,0.000052124],"category_scores_gemma":[0.000017618062,0.00016314948,0.000072635754,0.00042932978,0.00015367453,0.0000575117,0.0000039070433,0.00011569383,4.1818114e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012573936,0.0016097197,0.00029076182,0.00761174,0.0012732038,0.000025777783,0.0016466839,0.000052294006,0.0000122075835,0.00008230214,0.00007844187,0.97474295],"study_design_scores_gemma":[0.08790901,0.058595046,0.004569127,0.014554626,0.0068056174,0.000038494174,0.00038427935,0.00021928218,0.00019324692,0.00017755467,0.82589626,0.0006574315],"about_ca_topic_score_codex":0.00026382538,"about_ca_topic_score_gemma":0.0020041612,"teacher_disagreement_score":0.9740855,"about_ca_system_score_codex":0.0010012008,"about_ca_system_score_gemma":0.0018897891,"threshold_uncertainty_score":0.6653043},"labels":[],"label_agreement":null},{"id":"W4410591558","doi":"10.1016/j.jbc.2025.110277","title":"Crystal structure and mutagenesis of a nucleic acid–binding BRCT domain in human PARP4","year":2025,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"University of Saskatchewan; Canadian Institutes of Health Research; Oregon Health and Science University","keywords":"Nucleic acid; Mutagenesis; Domain (mathematical analysis); Chemistry; Computational biology; Biochemistry; Biology; Biophysics; Mutation; Gene","score_opus":0.020502623524926215,"score_gpt":0.30700598950818025,"score_spread":0.28650336598325404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410591558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978068,0.0009572348,0.000035579484,0.00039514387,0.00003633328,0.000053948836,0.000016211523,0.0000056787085,0.00069309823],"genre_scores_gemma":[0.99897546,0.000114742135,0.0005903494,0.00012439446,0.00012650374,0.0000011674609,0.0000044079775,0.0000043306463,0.000058660204],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991342,0.00003136007,0.00046126556,0.00012259268,0.00012276394,0.00012782028],"domain_scores_gemma":[0.9994683,0.00005505751,0.00024766303,0.000093357754,0.00006368266,0.000071897106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021546426,0.00010390962,0.00038800584,0.000062861756,0.000028969598,0.0000070740234,0.000085702144,0.00019523897,0.00033991944],"category_scores_gemma":[0.000083464416,0.00007205362,0.00009634529,0.00016028901,0.00015338529,0.000025499794,0.000031386848,0.00030724803,1.2570298e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028164388,0.000048509482,0.05207355,0.00012390518,0.000049426337,0.000060776285,0.00004904251,0.000001658834,0.9466967,0.00001976077,0.000100442085,0.0004945741],"study_design_scores_gemma":[0.0023492577,0.00017042416,0.04212728,0.00041965765,0.000023125427,0.00027231313,0.0002508736,0.0000020395617,0.9520485,0.0017479141,0.00051718444,0.0000714457],"about_ca_topic_score_codex":0.0000015716669,"about_ca_topic_score_gemma":3.5490837e-7,"teacher_disagreement_score":0.009946266,"about_ca_system_score_codex":0.00009825832,"about_ca_system_score_gemma":0.00006191197,"threshold_uncertainty_score":0.37218794},"labels":[],"label_agreement":null},{"id":"W4410811534","doi":"10.1200/jco.2025.43.16_suppl.5060","title":"Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician’s choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Medicine; Prostate cancer; Germline; Somatic cell; Oncology; Internal medicine; BRCA mutation; Germline mutation; Cancer; Gynecology; Mutation; Ovarian cancer; Gene; Genetics","score_opus":0.08630820527101687,"score_gpt":0.49527910357005644,"score_spread":0.40897089829903954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959861,0.00011371118,0.000017275795,0.0021071471,0.00021370169,0.0013925264,0.000049768507,0.000002261062,0.000117515636],"genre_scores_gemma":[0.9989906,0.00007755126,0.000164312,0.0006040285,0.00009786756,0.000035262867,0.0000066069124,0.000010971622,0.000012779415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948208,0.0012624998,0.0029014838,0.00015042588,0.00067898113,0.0001858485],"domain_scores_gemma":[0.9870271,0.0079308655,0.0037991244,0.00028847886,0.0008846073,0.00006983749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021672582,0.00015683283,0.0014295562,0.00019923532,0.00003548281,0.000006092915,0.00019158765,0.0000744381,0.000034113513],"category_scores_gemma":[0.0021154566,0.00007496475,0.00028196012,0.0005582709,0.00025265213,0.00008675226,0.0000132490495,0.0006222034,3.9512517e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10194347,0.040803466,0.81227314,0.00035250495,0.0030541548,0.000070876806,0.006088618,0.0068892515,0.0013111512,0.00012724852,0.0009363215,0.02614978],"study_design_scores_gemma":[0.030853514,0.045656398,0.9206762,0.0005704517,0.0006341975,0.0000024561516,0.00093535875,0.00010793755,0.00026962892,0.00016692565,0.000074644246,0.000052331357],"about_ca_topic_score_codex":0.0005477305,"about_ca_topic_score_gemma":0.0005677025,"teacher_disagreement_score":0.108403005,"about_ca_system_score_codex":0.0002832771,"about_ca_system_score_gemma":0.002505511,"threshold_uncertainty_score":0.4444669},"labels":[],"label_agreement":null},{"id":"W4410811633","doi":"10.1200/jco.2025.43.16_suppl.11120","title":"Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Cancer; Androgen receptor; Alternative medicine; Pathology","score_opus":0.19123378402062463,"score_gpt":0.5290824125384349,"score_spread":0.3378486285178103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410811633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785504,0.00044250308,0.00008509861,0.014780579,0.0014159392,0.0036928905,0.00037292397,0.000027933596,0.0006317667],"genre_scores_gemma":[0.99404484,0.0002910854,0.0013223672,0.0024896436,0.00046134696,0.0006301632,0.0001070182,0.000035803045,0.0006177365],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9912339,0.0014046407,0.005625053,0.000575002,0.00067411875,0.00048732685],"domain_scores_gemma":[0.984272,0.010445504,0.003689805,0.00043632946,0.00088508154,0.00027126097],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037070166,0.0003960871,0.0022517133,0.00026613788,0.00018112201,0.00005161883,0.00022942074,0.00026083709,0.00012450943],"category_scores_gemma":[0.008603686,0.0002527153,0.00054254715,0.0004989778,0.0002514993,0.00020101224,0.0000427347,0.0009767348,0.00000370529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5906846,0.027630897,0.13096513,0.00007673627,0.008990842,0.004040884,0.009546409,0.0007637068,0.0056931153,0.00009844989,0.0110833645,0.21042585],"study_design_scores_gemma":[0.46097082,0.097689986,0.37649453,0.0012735493,0.0046406114,0.00022970348,0.005898887,0.0010775469,0.007189966,0.0026347945,0.041259624,0.0006399838],"about_ca_topic_score_codex":0.0014789907,"about_ca_topic_score_gemma":0.0035214236,"teacher_disagreement_score":0.24552941,"about_ca_system_score_codex":0.0012617565,"about_ca_system_score_gemma":0.0069893845,"threshold_uncertainty_score":0.9999925},"labels":[],"label_agreement":null},{"id":"W4410812834","doi":"10.1200/jco.2025.43.16_suppl.11121","title":"Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Homologous recombination; Oncology; Internal medicine; PARP inhibitor; Gene; Cancer; Poly ADP ribose polymerase; Androgen receptor; Genetics; Pathology; Biology; Polymerase","score_opus":0.1057754304687696,"score_gpt":0.4559922376212079,"score_spread":0.3502168071524383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884341,0.00031447763,0.000063182284,0.00802631,0.0002824205,0.0022954822,0.00001619599,0.000018635144,0.0005492158],"genre_scores_gemma":[0.99530953,0.00033505735,0.0023168344,0.0011260989,0.00009203129,0.0005725137,0.000013805576,0.00001995244,0.00021416992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946671,0.0013632765,0.0027451478,0.00040778177,0.00051458227,0.00030212317],"domain_scores_gemma":[0.99522585,0.0021508196,0.0017627749,0.0002808137,0.00045016574,0.0001295862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030019418,0.0002802972,0.0013811933,0.00038829487,0.00012970109,0.000042496224,0.00010427401,0.00014496897,0.000034488872],"category_scores_gemma":[0.00079171633,0.0001619801,0.00015145776,0.0005015158,0.00025689165,0.0002493762,0.000024438761,0.00077077514,5.6734143e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04097622,0.007966248,0.90614706,0.000060019906,0.0015739038,0.004783975,0.0058383425,0.0009162847,0.0004830338,0.000072175986,0.00032434595,0.030858373],"study_design_scores_gemma":[0.05556567,0.0463106,0.8897462,0.00046571856,0.0009539864,0.0008720683,0.003914055,0.0004371851,0.0004369676,0.0003501777,0.0007325893,0.00021481645],"about_ca_topic_score_codex":0.00051796,"about_ca_topic_score_gemma":0.008359156,"teacher_disagreement_score":0.038344353,"about_ca_system_score_codex":0.0008645222,"about_ca_system_score_gemma":0.0030769797,"threshold_uncertainty_score":0.6605357},"labels":[],"label_agreement":null},{"id":"W4410813020","doi":"10.1200/jco.2025.43.16_suppl.5561","title":"Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Internal medicine; Clinical trial; Poly ADP ribose polymerase; Cancer; Cancer research; Gynecology; Genetics; DNA; Biology; Polymerase","score_opus":0.10424352434215015,"score_gpt":0.5265013115800238,"score_spread":0.42225778723787366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410813020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700925,0.00033648207,0.00021076846,0.022893732,0.0009944728,0.0015812812,0.000020658112,0.000020386517,0.003849721],"genre_scores_gemma":[0.9570955,0.00073555746,0.037152685,0.002177546,0.0017312178,0.00019735517,0.0000051252105,0.000042177682,0.00086285704],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99258554,0.0010394469,0.00478639,0.0005059573,0.00059998693,0.00048269704],"domain_scores_gemma":[0.9926836,0.0021377061,0.0031156633,0.0004396164,0.0010644302,0.00055897847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00546706,0.0003074545,0.0031060288,0.00044207228,0.00009035192,0.000022132414,0.00021967817,0.00044196993,0.0003875667],"category_scores_gemma":[0.0009199801,0.00020198856,0.0003234244,0.0005855383,0.00038264767,0.00015377857,0.00006315433,0.0010009407,0.0000017550916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8439324,0.013413033,0.022340944,0.0000776904,0.0018864374,0.00090953964,0.00068703893,0.000101164085,0.0037339714,0.00004235723,0.0046344106,0.108241044],"study_design_scores_gemma":[0.55122334,0.26699826,0.13594352,0.003979663,0.00088105665,0.000040799685,0.00072898885,0.00021271368,0.00033383677,0.000119334116,0.039210793,0.000327706],"about_ca_topic_score_codex":0.000096287484,"about_ca_topic_score_gemma":0.00062711566,"teacher_disagreement_score":0.29270905,"about_ca_system_score_codex":0.0029833626,"about_ca_system_score_gemma":0.014969336,"threshold_uncertainty_score":0.9906149},"labels":[],"label_agreement":null},{"id":"W4410817483","doi":"10.1200/jco.2025.43.16_suppl.e15113","title":"Efficacy and safety data from Ph1b, dose optimization trial of two doses of TH1902 (sudocetaxel zendusortide), a novel SORT1-targeting peptide drug conjugate (PDC), administered weekly vs q3weekly in patients (pts) with advanced ovarian cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Conjugate; Pharmacology; Drug; Safety profile; Peptide; Clinical trial; Oncology; Internal medicine; Adverse effect","score_opus":0.10738001498988801,"score_gpt":0.46325764454127477,"score_spread":0.35587762955138674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410817483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98876035,0.0004516105,0.0031321181,0.0044963616,0.001265423,0.0010369199,0.00028500278,0.000011679322,0.0005605436],"genre_scores_gemma":[0.9660584,0.0016689436,0.030560076,0.00096806244,0.00051013654,0.00001404976,0.00011397497,0.000030147352,0.00007624638],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934704,0.00057874736,0.0046420186,0.00048810174,0.00053551624,0.00028523576],"domain_scores_gemma":[0.99031764,0.0033759943,0.004825669,0.0005269744,0.0007117714,0.0002419733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002740118,0.00026441982,0.0024429373,0.00027328887,0.000050852253,0.000012211402,0.00039445382,0.00026727884,0.00012802517],"category_scores_gemma":[0.0038848731,0.00020676585,0.00018919245,0.000403075,0.00041604173,0.0003363357,0.00016653033,0.0009311051,6.122792e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79889107,0.007895642,0.13824025,0.00015711288,0.0012686291,0.00006863445,0.0003598615,0.004952722,0.0017014651,0.000055621636,0.0014287006,0.044980276],"study_design_scores_gemma":[0.6917114,0.019334262,0.2768591,0.0027303651,0.0010527993,0.000012811324,0.00023512072,0.0027011218,0.000848935,0.00014174292,0.0040886328,0.0002837091],"about_ca_topic_score_codex":0.00034300025,"about_ca_topic_score_gemma":0.00038980154,"teacher_disagreement_score":0.13861886,"about_ca_system_score_codex":0.0002144452,"about_ca_system_score_gemma":0.0029635334,"threshold_uncertainty_score":0.8431667},"labels":[],"label_agreement":null},{"id":"W4410822217","doi":"10.1200/jco.2025.43.16_suppl.tps3174","title":"A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer research; Internal medicine; Oncology","score_opus":0.09521809611650829,"score_gpt":0.5079753282935783,"score_spread":0.41275723217707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99108267,0.0003239939,0.00010662688,0.005995743,0.0008642158,0.0011102464,0.000009357724,0.000009814463,0.00049731496],"genre_scores_gemma":[0.9960889,0.00015085752,0.0009800621,0.0022178125,0.00028044137,0.00003531586,0.000001929448,0.00001965708,0.00022497748],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99423265,0.001139353,0.0035377003,0.00027050145,0.00055689877,0.0002628917],"domain_scores_gemma":[0.9944787,0.0018428512,0.0026068753,0.0003906523,0.0004834069,0.00019750289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002516681,0.00021272556,0.001970974,0.00029747357,0.000053148276,0.000007845854,0.0002536032,0.00016300415,0.00012018666],"category_scores_gemma":[0.001861606,0.00011123865,0.00030549863,0.0007659319,0.0003314406,0.00017943725,0.000058577472,0.0010934584,0.0000020550835],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39021266,0.09392999,0.07156934,0.00030355802,0.0020245814,0.0017949851,0.003739452,0.0005319432,0.0063089593,0.00015858006,0.0026266496,0.42679933],"study_design_scores_gemma":[0.53119284,0.22194324,0.20997445,0.005348209,0.002039247,0.00064832356,0.0075378893,0.0012160321,0.012632667,0.0009821465,0.006030121,0.00045481598],"about_ca_topic_score_codex":0.00004235148,"about_ca_topic_score_gemma":0.0005500881,"teacher_disagreement_score":0.4263445,"about_ca_system_score_codex":0.0002305806,"about_ca_system_score_gemma":0.0029380529,"threshold_uncertainty_score":0.521198},"labels":[],"label_agreement":null},{"id":"W4410951548","doi":"10.3390/cells14110819","title":"A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance—A Role for Nicotinamide N-Methyltransferase","year":2025,"lang":"en","type":"article","venue":"Cells","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"Cancer Research UK; Prostate Cancer Canada; Canadian Institutes of Health Research; Sunnybrook Research Institute","keywords":"Radioresistance; Prostate cancer; Nicotinamide; Methyltransferase; Cancer research; Prostate; Cell culture; Radiation tolerance; Biology; Cancer; Chemistry; Medicine; Internal medicine; Oncology; Radiation therapy; Enzyme; Genetics; Biochemistry; DNA","score_opus":0.014219104833421526,"score_gpt":0.2829529162215231,"score_spread":0.26873381138810154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410951548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7385975,0.019216059,0.22965448,0.0022617627,0.00032466956,0.0030390732,0.0012267245,0.00009961549,0.0055801217],"genre_scores_gemma":[0.9238379,0.005610582,0.044773914,0.004057009,0.00011908607,0.0006458402,0.000079041296,0.00007339047,0.020803247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895906,0.00001329339,0.00035871402,0.00030006107,0.0001440587,0.00022478799],"domain_scores_gemma":[0.9993032,0.00010942026,0.00008207855,0.00024939995,0.00016593999,0.00008992683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017156276,0.00016334,0.0004321053,0.000106226755,0.0000439612,0.000008342871,0.00006706036,0.00008716397,0.000022358667],"category_scores_gemma":[0.000010088899,0.00015235438,0.00010017129,0.0001726808,0.00013506449,0.000045028013,0.000014572036,0.00011855819,7.9411353e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023245972,0.00024300902,0.00022074516,0.0015014105,0.00005981812,9.1680505e-7,0.00032301407,0.0024129234,0.98818064,0.00017885317,0.0017183418,0.0028357108],"study_design_scores_gemma":[0.010951538,0.0001521703,0.00009321858,0.00043196644,0.00016313915,0.0000010391494,0.000048794434,0.021463035,0.9592619,0.0009371429,0.006355534,0.00014053288],"about_ca_topic_score_codex":0.000055666722,"about_ca_topic_score_gemma":0.000013638938,"teacher_disagreement_score":0.18524039,"about_ca_system_score_codex":0.0001276579,"about_ca_system_score_gemma":0.00041614758,"threshold_uncertainty_score":0.6212831},"labels":[],"label_agreement":null},{"id":"W4410958737","doi":"10.1016/j.annonc.2025.05.009","title":"Dostarlimab and niraparib in primary advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"PharmaMar; Genesis Pharma; Astellas Pharma; Eisai; Seagen; Verastem Oncology; Pfizer; Incyte; Ipsen; Clovis Oncology; AstraZeneca; Novocure; Daiichi Sankyo Europe; Gilead Sciences; Intuitive Surgical; Regeneron Pharmaceuticals; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; GlaxoSmithKline; Amgen","keywords":"Medicine; Ovarian cancer; Oncology; Primary (astronomy); Gynecology; Internal medicine; Cancer","score_opus":0.05532924224225995,"score_gpt":0.4313976606856236,"score_spread":0.37606841844336364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410958737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85577416,0.007284055,0.000066604814,0.04972969,0.0002995029,0.00037993674,0.000020822936,0.00002418959,0.08642106],"genre_scores_gemma":[0.97125065,0.0061055254,0.0009380617,0.020794125,0.000049507118,0.00009792005,0.000010407807,0.000008782176,0.0007450387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921125,0.000051955638,0.0002841915,0.00018869454,0.000078869416,0.00018501037],"domain_scores_gemma":[0.9994833,0.00011605575,0.00008645771,0.0001563221,0.00011059212,0.000047256435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021467898,0.000084299034,0.0003902641,0.00019472073,0.000018520372,0.0000020661175,0.000049045182,0.00011851798,0.00012689136],"category_scores_gemma":[0.00004063403,0.00008158323,0.00003723913,0.00025129312,0.00013987091,0.000054007443,0.00003165582,0.00015251948,0.0000020083733],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004272039,0.00065218855,0.06684876,0.00035613382,0.00018424816,0.00007484587,0.00067751686,0.000034662913,0.05606237,0.004489439,0.018892854,0.84745497],"study_design_scores_gemma":[0.014010965,0.0016409897,0.46248683,0.00054599345,0.000041826308,0.000022734583,0.00016121872,0.000033590648,0.035170767,0.0047934004,0.48093426,0.00015742832],"about_ca_topic_score_codex":0.00016161514,"about_ca_topic_score_gemma":0.00013015192,"teacher_disagreement_score":0.8472975,"about_ca_system_score_codex":0.00010639403,"about_ca_system_score_gemma":0.0005370036,"threshold_uncertainty_score":0.33268675},"labels":[],"label_agreement":null},{"id":"W4411141961","doi":"10.1073/pnas.2426660122","title":"PARP12-mediated mono-ADP-ribosylation as a checkpoint for necroptosis and apoptosis","year":2025,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Necroptosis; RIPK1; Cell biology; Programmed cell death; Apoptosis; Kinase; Chemistry; Biology; FADD; Caspase 8; Cancer research; Caspase; Biochemistry","score_opus":0.04511146755693809,"score_gpt":0.35707300561662964,"score_spread":0.31196153805969157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411141961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683958,0.00032060433,0.000015313595,0.02127107,0.000028171442,0.0005636957,0.00002210893,0.00001963499,0.0093635805],"genre_scores_gemma":[0.99529946,0.00018017019,0.0027297758,0.0013557234,0.000053151187,0.00008345653,6.1269196e-7,0.000003999947,0.0002936754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987112,0.0000037723535,0.00033767315,0.00022983635,0.00059214566,0.0001253593],"domain_scores_gemma":[0.99903613,0.00019044458,0.00030344143,0.000008426272,0.00042472873,0.00003679757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008846868,0.0000887844,0.00018880943,0.00016447723,0.00016772814,0.000017557812,0.00019975138,0.000091087866,0.000020582956],"category_scores_gemma":[0.00083077926,0.00006255012,0.0000811467,0.0006668263,0.00054475083,0.0002703418,0.000052815423,0.00009229161,6.198008e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021174742,0.000077313176,0.017091371,0.00027605926,0.00006513009,9.0923835e-10,0.00026140845,0.000012085167,0.92563313,0.052323088,0.0025774983,0.0014711657],"study_design_scores_gemma":[0.0009251167,0.00011789478,0.043141168,0.00031630055,0.000043619388,0.000003166028,0.00024011028,0.0013891275,0.8930533,0.059152413,0.0015510086,0.00006677327],"about_ca_topic_score_codex":0.000013307801,"about_ca_topic_score_gemma":6.0038836e-8,"teacher_disagreement_score":0.032579828,"about_ca_system_score_codex":0.00008370634,"about_ca_system_score_gemma":0.00008028271,"threshold_uncertainty_score":0.25507197},"labels":[],"label_agreement":null},{"id":"W4411178697","doi":"10.1073/pnas.2424985122","title":"CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activity","year":2025,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; Biotechnology and Biological Sciences Research Council; Cancer Research UK; National Institutes of Health; UK Research and Innovation; Wellcome Trust","keywords":"Aryl hydrocarbon receptor; Proteome; Proteomics; CRISPR; Computational biology; Function (biology); Biology; Chemistry; Biochemistry; Cell biology; Gene","score_opus":0.07538694063742633,"score_gpt":0.37548924290980995,"score_spread":0.3001023022723836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411178697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770035,0.00017301545,0.000049258408,0.017406452,0.000030092871,0.0009847914,0.000022650327,0.000011112739,0.004319084],"genre_scores_gemma":[0.98586416,0.000096502095,0.01335939,0.00045463807,0.000044659188,0.000042099728,1.0233223e-7,0.000004983674,0.00013346015],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820143,0.000015800519,0.0003825244,0.00028400504,0.00097240024,0.00014382029],"domain_scores_gemma":[0.9987358,0.00014336308,0.0006307135,0.000021256104,0.00044463406,0.000024267374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011512059,0.00011610012,0.00027219704,0.000120854515,0.00021589498,0.000010838662,0.0004095616,0.00010471548,0.0000032767634],"category_scores_gemma":[0.00079810893,0.00007046678,0.00009470869,0.00095509656,0.0014582118,0.0003623265,0.00015268923,0.00030934002,1.705171e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020674102,0.00005645968,0.008476525,0.0002306421,0.000037777998,2.3006779e-9,0.00051998167,0.00011732739,0.9650348,0.02481655,0.000372565,0.00013066582],"study_design_scores_gemma":[0.00050607097,0.00010237268,0.039552517,0.0010774055,0.000031026862,0.0000043144537,0.00027197192,0.0033781612,0.89478385,0.06014845,0.0000759878,0.00006785006],"about_ca_topic_score_codex":0.00003417892,"about_ca_topic_score_gemma":2.0455275e-7,"teacher_disagreement_score":0.07025089,"about_ca_system_score_codex":0.00008738834,"about_ca_system_score_gemma":0.0001479971,"threshold_uncertainty_score":0.5372842},"labels":[],"label_agreement":null},{"id":"W4411241793","doi":"10.18192/osurj.v4i1.7309","title":"Flow Cytometry and Pharmacological Approaches Reveal Senescence Mechanisms in Breast Cancer","year":2025,"lang":"en","type":"article","venue":"University of Ottawa Science Undergraduate Research Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Flow cytometry; Senescence; Breast cancer; Cellular senescence; Biology; Computational biology; Cancer; Cancer research; Medicine; Internal medicine; Cell biology; Immunology; Genetics; Phenotype; Gene","score_opus":0.07690319259598392,"score_gpt":0.3750051008433844,"score_spread":0.29810190824740046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411241793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76095897,0.0010392906,0.035367884,0.18848446,0.00044046267,0.0008798838,0.000047069043,0.000050988496,0.012731014],"genre_scores_gemma":[0.9916437,0.0020833751,0.0053908653,0.00012482176,0.000033004835,6.156154e-7,4.9585765e-7,0.0000039614406,0.0007191168],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975815,0.0002388159,0.00019337134,0.00035840707,0.0010953784,0.00053253444],"domain_scores_gemma":[0.9987821,0.00013979149,0.000082936625,0.00013809085,0.00053641666,0.00032063664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034572952,0.000102985294,0.00024624533,0.0015789642,0.00062183454,0.000055016553,0.00041664785,0.0000713492,0.00010043338],"category_scores_gemma":[0.00008748603,0.00009522553,0.000055262804,0.0028729206,0.0022206015,0.00038252497,0.00020036128,0.0008505257,0.0000027711276],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019133042,0.0010321031,0.15679654,0.0003194088,0.00020266665,0.001070259,0.0008657773,0.00071418757,0.72229975,0.04201038,0.009619378,0.06315624],"study_design_scores_gemma":[0.027025307,0.0013846346,0.66714716,0.0044196574,0.00022407874,0.0042233155,0.015739612,0.07615163,0.104494706,0.094229005,0.003970503,0.0009903914],"about_ca_topic_score_codex":0.00013768992,"about_ca_topic_score_gemma":0.000034851106,"teacher_disagreement_score":0.61780506,"about_ca_system_score_codex":0.0008759077,"about_ca_system_score_gemma":0.0018208981,"threshold_uncertainty_score":0.81818986},"labels":[],"label_agreement":null},{"id":"W4411373157","doi":"10.1016/j.ejca.2025.115584","title":"Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Clovis Oncology","keywords":"Placebo; Medicine; Oncology; Internal medicine; Ovarian carcinoma; Ovarian cancer; Cancer; Pathology; Alternative medicine","score_opus":0.04079906210408889,"score_gpt":0.3484937278941718,"score_spread":0.3076946657900829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411373157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.915264,0.009137619,0.014755249,0.014211417,0.007961934,0.009591692,0.0008102372,0.000021331029,0.02824651],"genre_scores_gemma":[0.99452585,0.0005517964,0.00076848886,0.00024301332,0.00086617924,0.00007466283,0.000005584323,0.000024859954,0.0029395863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965576,0.00087098294,0.0017874425,0.00019554723,0.00037395867,0.00021449785],"domain_scores_gemma":[0.9958856,0.00087781966,0.0019807387,0.0003165256,0.000853505,0.00008580154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020709985,0.00022227073,0.0014678838,0.00017083494,0.00007202221,0.000011634999,0.00016244201,0.00003790583,0.00004435319],"category_scores_gemma":[0.0009770832,0.0001267048,0.000969249,0.00020148235,0.00028166804,0.000048037,0.000017864782,0.00019684414,6.32961e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96829104,0.00062512973,0.000024361096,0.000051742973,0.00097163965,0.00003644041,0.00091849366,0.0001465937,0.002763266,0.00035706745,0.007342096,0.018472143],"study_design_scores_gemma":[0.94967145,0.0035625182,0.00020900671,0.0010733092,0.0010622779,0.000031477277,0.00010741396,0.00033818773,0.023264546,0.00011553052,0.020471795,0.00009251451],"about_ca_topic_score_codex":0.000028317729,"about_ca_topic_score_gemma":0.00001066315,"teacher_disagreement_score":0.07926182,"about_ca_system_score_codex":0.000309907,"about_ca_system_score_gemma":0.0008634136,"threshold_uncertainty_score":0.5166872},"labels":[],"label_agreement":null},{"id":"W4412071623","doi":"10.1016/j.jbc.2025.110463","title":"Molecular determinants of nucleic acid recognition by an RNA-targeting ADP-ribosyltransferase toxin","year":2025,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Burroughs Wellcome Fund","keywords":"Nucleic acid; RNA; Toxin; Biology; Biochemistry; Chemistry; Gene","score_opus":0.026586026556972914,"score_gpt":0.31223403861410653,"score_spread":0.28564801205713364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412071623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669486,0.0012430539,0.0006355227,0.0003409645,0.00007594967,0.00007267893,0.000041493233,0.000014623969,0.000880821],"genre_scores_gemma":[0.99797666,0.0003734504,0.000860498,0.0006010278,0.0001203268,0.0000035673547,0.000030429665,0.000008083979,0.0000259628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987947,0.000056313635,0.000640646,0.00016021926,0.00017969524,0.00016842432],"domain_scores_gemma":[0.9991633,0.000054108496,0.00028370324,0.00012670866,0.00023376294,0.00013840813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033799425,0.00013365164,0.00040813483,0.00003790419,0.000031969426,0.0000083014265,0.00012962165,0.00022274912,0.0003824269],"category_scores_gemma":[0.00022391451,0.00010061287,0.00018628819,0.0001422433,0.00011183122,0.0000616564,0.000013540475,0.00033528436,0.0000017186904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000646589,0.0002606268,0.0033363688,0.00011428916,0.000046591464,0.000080777645,0.00001526938,0.0000015074021,0.98502,7.336408e-7,0.00049969193,0.009977598],"study_design_scores_gemma":[0.0017042728,0.00043189304,0.0005153159,0.00043638956,0.000050482573,0.00011246705,0.00008390056,0.000023998478,0.995641,0.00036816424,0.00053616904,0.00009595844],"about_ca_topic_score_codex":0.0000016778704,"about_ca_topic_score_gemma":8.028942e-8,"teacher_disagreement_score":0.010621031,"about_ca_system_score_codex":0.000077212186,"about_ca_system_score_gemma":0.00009175559,"threshold_uncertainty_score":0.41873065},"labels":[],"label_agreement":null},{"id":"W4412151132","doi":"10.1038/s41467-025-61297-w","title":"The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Oncolytics Biotech; National Institute for Health and Care Research; Cancer Research UK","keywords":"In vivo; PARP inhibitor; Cancer research; Poly ADP ribose polymerase; Cancer; Biology; Chemistry; Virology; Cell biology; Medicine; DNA; Biochemistry; Internal medicine; Polymerase","score_opus":0.02032030235593858,"score_gpt":0.33121527679635576,"score_spread":0.3108949744404172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412151132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8746108,0.03591521,0.00051558315,0.084034584,0.00015911506,0.001521908,0.00007817785,0.000079706595,0.0030849003],"genre_scores_gemma":[0.98906475,0.0048147487,0.00080612354,0.004129291,0.000036706817,0.00078007026,0.000006186564,0.000018827664,0.0003432965],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989236,0.0001514626,0.0003096936,0.00022372641,0.00016822174,0.0002233005],"domain_scores_gemma":[0.998226,0.0004543434,0.00006521785,0.0010164143,0.00016395544,0.000074073774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035853477,0.00014612831,0.00025788625,0.0002287163,0.00022785772,0.000041078045,0.00037839336,0.00018882049,0.0000043201853],"category_scores_gemma":[0.00010591853,0.00010694,0.00002695109,0.00071888027,0.00014067398,0.00010962712,0.00011276613,0.0011895573,0.0000010057814],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008327007,0.0022020454,0.20752189,0.00029598636,0.0008609219,0.000051719024,0.0120388325,0.037513644,0.5174544,0.17107557,0.030983321,0.0116746705],"study_design_scores_gemma":[0.071097024,0.0010714105,0.077258915,0.0147672575,0.0006821824,0.000106711545,0.010440696,0.29209808,0.14389178,0.015053711,0.37030298,0.0032292416],"about_ca_topic_score_codex":0.00059514464,"about_ca_topic_score_gemma":0.017738584,"teacher_disagreement_score":0.3735626,"about_ca_system_score_codex":0.0002938082,"about_ca_system_score_gemma":0.00029017348,"threshold_uncertainty_score":0.9898547},"labels":[],"label_agreement":null},{"id":"W4412163674","doi":"10.1158/1557-3265.aimachine-a026","title":"Abstract A026: GenAI and Physics Assisted Methods for the Design and Development of USP1 Inhibitors","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug development; Medicine; Medical physics; Physics; Pharmacology; Drug","score_opus":0.5759676318210664,"score_gpt":0.6597587551175987,"score_spread":0.08379112329653238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412163674","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28955004,0.03222675,0.6516203,0.017796168,0.0012176645,0.0061502256,0.00003476583,0.00007431176,0.0013297546],"genre_scores_gemma":[0.5832639,0.008318341,0.4025923,0.0016380815,0.0009542094,0.0019306525,0.000010048894,0.00006214111,0.0012303744],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99810284,0.000381571,0.0006017808,0.00033998446,0.00030061844,0.00027320147],"domain_scores_gemma":[0.9910905,0.007936045,0.00009628009,0.00027758558,0.00047582807,0.00012380164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007476146,0.00010591549,0.00035875264,0.00006402283,0.00022798564,0.000025666903,0.00011992818,0.0001312474,0.000050407456],"category_scores_gemma":[0.00094255165,0.00007128562,0.00007092002,0.00031325442,0.000720842,0.000036839647,0.00010391735,0.00051080895,0.0000013521045],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014698606,0.0001427281,0.0044575725,0.000458625,0.00027110518,9.842702e-7,0.00024432683,0.0000057369775,0.011617345,0.00022383338,0.0077170264,0.9733909],"study_design_scores_gemma":[0.011842327,0.0008529299,0.3751402,0.0018014273,0.0001826052,0.0000044576655,0.00063204794,0.0019362886,0.31284243,0.0065142997,0.28792027,0.0003307272],"about_ca_topic_score_codex":0.00003558542,"about_ca_topic_score_gemma":0.000008764858,"teacher_disagreement_score":0.97306013,"about_ca_system_score_codex":0.00012558978,"about_ca_system_score_gemma":0.0013142711,"threshold_uncertainty_score":0.29069433},"labels":[],"label_agreement":null},{"id":"W4412629665","doi":"10.1158/1078-0432.ccr-25-1248","title":"Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Astellas Pharma; Seagen; Eisai; MacroGenics; AstraZeneca; National Cancer Institute; Novocure; Revolution Medicines; Pfizer; Amgen","keywords":"Liquid biopsy; Population; Cancer research; DNA repair; Context (archaeology); Epigenomics; Medicine; Biology; Cancer; Internal medicine; Gene; DNA methylation; Genetics","score_opus":0.09597505638137298,"score_gpt":0.4711381872705757,"score_spread":0.3751631308892027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412629665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932286,0.0019063296,0.00001091929,0.0023688797,0.0001800149,0.0015907341,0.000180093,0.000053333602,0.0004810797],"genre_scores_gemma":[0.9974789,0.0005834338,0.0002867341,0.0005727093,0.000121055906,0.00033846646,0.00006168532,0.000042626874,0.0005143937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960893,0.00097387127,0.0008428198,0.0008718139,0.00059012504,0.0006320827],"domain_scores_gemma":[0.9969214,0.0016620876,0.00010895601,0.0006321448,0.00041848057,0.00025689145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002815992,0.0002187022,0.0006126329,0.00053702644,0.00016951692,0.000052725463,0.00022804666,0.00019644076,0.00018243652],"category_scores_gemma":[0.0007711578,0.00017905259,0.00007370725,0.0009504997,0.0008893161,0.00007453385,0.00020187478,0.0010913577,0.000027054033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06336034,0.00046394402,0.9097244,0.00009554736,0.000098604956,0.00005265391,0.0003680201,0.00002412436,0.023601333,0.000036697926,0.0003614587,0.0018128356],"study_design_scores_gemma":[0.008669337,0.0020586825,0.96966916,0.0011465268,0.00002762146,6.943924e-7,0.0002801873,0.00012732498,0.016406212,0.00013795696,0.0012997409,0.00017656153],"about_ca_topic_score_codex":0.0013519771,"about_ca_topic_score_gemma":0.0003665736,"teacher_disagreement_score":0.059944715,"about_ca_system_score_codex":0.0009086639,"about_ca_system_score_gemma":0.0016477744,"threshold_uncertainty_score":0.7301552},"labels":[],"label_agreement":null},{"id":"W4412790822","doi":"10.1101/2025.07.26.666954","title":"Rewiring DNA repair with PARP-based chemical inducers of proximity","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Donald E. and Delia B. Baxter Foundation","keywords":"Poly ADP ribose polymerase; DNA; Inducer; Computational biology; DNA repair; Genetics; Chemistry; Biology; Gene; Polymerase","score_opus":0.019421038118543232,"score_gpt":0.2549202066578404,"score_spread":0.23549916853929714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412790822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938304,0.0006411812,0.0013885819,0.00065674365,0.00051424355,0.0016880699,0.00025946533,0.00088988926,0.00013145382],"genre_scores_gemma":[0.9781441,0.000058954007,0.020135297,0.000699172,0.00034417212,0.0004957286,0.0000011119895,0.000109266985,0.000012202644],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966487,0.00011783933,0.0008018044,0.0011816836,0.00071398047,0.0005359795],"domain_scores_gemma":[0.9960411,0.000107184635,0.0006209145,0.0019949747,0.0009145124,0.00032129925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060775253,0.0006253059,0.0011011567,0.00041607913,0.00007505056,0.000035672503,0.00036055688,0.0007327274,0.00007712474],"category_scores_gemma":[0.00024818693,0.00060516375,0.0003270209,0.0008061631,0.00033682646,0.00009639221,0.00022186074,0.0012692695,0.000005793398],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010195506,0.0005044821,0.03346292,0.004237668,0.00072024483,0.000101908605,0.00001642226,0.000108388595,0.95866644,0.0003071384,0.0008520054,0.0000028123525],"study_design_scores_gemma":[0.0027292266,0.00015326797,0.018187333,0.005292831,0.0004164279,4.056009e-8,0.00000256082,0.00045246544,0.97020894,0.0000016362391,0.0019658545,0.0005894313],"about_ca_topic_score_codex":0.00004385655,"about_ca_topic_score_gemma":9.982953e-7,"teacher_disagreement_score":0.018746715,"about_ca_system_score_codex":0.00082378637,"about_ca_system_score_gemma":0.003518875,"threshold_uncertainty_score":0.99964},"labels":[],"label_agreement":null},{"id":"W4413147816","doi":"10.1016/j.drup.2025.101291","title":"Defining homologous recombination deficiency status in pancreatic ductal adenocarcinoma: Clinical implications for evaluating response to platinum chemotherapy","year":2025,"lang":"en","type":"article","venue":"Drug Resistance Updates","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Science and Technology Planning Project of Guangdong Province; Guangzhou Science and Technology Program key projects; National Natural Science Foundation of China","keywords":"Pancreatic ductal adenocarcinoma; Homologous recombination; Chemotherapy; Medicine; Oncology; Adenocarcinoma; Internal medicine; Pancreatic cancer; Biology; Genetics; Cancer; Gene","score_opus":0.03174208239471961,"score_gpt":0.40307234455219065,"score_spread":0.37133026215747106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413147816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635332,0.0037900314,0.0024699531,0.026892275,0.00025391037,0.0016244913,0.0000885309,0.00011706284,0.0012304956],"genre_scores_gemma":[0.96609795,0.00020490383,0.027577998,0.0021319666,0.000044714478,0.0009302756,0.00013165682,0.00003845622,0.002842067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973764,0.00030894123,0.00093534245,0.0006584081,0.00020781528,0.0005131304],"domain_scores_gemma":[0.99670386,0.002077501,0.0002226163,0.0005531258,0.00031582537,0.0001270703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002300104,0.00021937123,0.0004940726,0.00041000784,0.0002149451,0.00004321228,0.00017608672,0.000120970995,0.000046645724],"category_scores_gemma":[0.0023821187,0.00022910522,0.0001300022,0.00095295557,0.00011192946,0.00010754962,0.00003338604,0.00024399832,0.000018835013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018785525,0.00074164773,0.9011175,0.00029670534,0.00011244642,0.000011190621,0.0020442922,0.00009182449,0.022394016,0.021125287,0.02006494,0.013214626],"study_design_scores_gemma":[0.007209543,0.0003060477,0.9669879,0.0005674593,0.00007566225,0.0000081728185,0.00046127065,0.00024259255,0.0030173908,0.017496027,0.003362408,0.0002654914],"about_ca_topic_score_codex":0.000020635161,"about_ca_topic_score_gemma":0.0000950328,"teacher_disagreement_score":0.065870434,"about_ca_system_score_codex":0.0006036848,"about_ca_system_score_gemma":0.0006642674,"threshold_uncertainty_score":0.93426394},"labels":[],"label_agreement":null},{"id":"W4413376554","doi":"10.1101/2025.08.14.670376","title":"CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; Canada Research Chairs; University of Pennsylvania","keywords":"Vulnerability (computing); Breast cancer; Cancer; Medicine; Cancer research; Oncology; Internal medicine; Computer science; Computer security","score_opus":0.02021054994238718,"score_gpt":0.287986804563454,"score_spread":0.2677762546210668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413376554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809188,0.0024608558,0.00033278778,0.0083448645,0.00209089,0.0020479325,0.00315114,0.0005143536,0.00013833556],"genre_scores_gemma":[0.99348736,0.00081269874,0.0012894432,0.0021088202,0.0007512215,0.001378574,6.659011e-7,0.00011823267,0.000052979492],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99565053,0.0002780461,0.00094626815,0.0016878552,0.00065239944,0.00078489055],"domain_scores_gemma":[0.9962599,0.0001290709,0.00039966105,0.002152758,0.0006830378,0.00037553124],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073524175,0.0007734756,0.0012784683,0.00059190753,0.00011979753,0.00009310466,0.00051280507,0.0008839807,0.0010689255],"category_scores_gemma":[0.00014673192,0.000830174,0.00034218136,0.0009425158,0.0002959566,0.00011826862,0.00040890527,0.001912659,0.000071057984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014258764,0.002003842,0.41109252,0.00665411,0.0012020604,0.0005583539,0.00020992602,0.00061019365,0.56861144,0.0007422406,0.0068211444,0.000068316236],"study_design_scores_gemma":[0.0044532917,0.0000902743,0.7515737,0.009333323,0.00046129027,3.8238278e-7,0.000007680385,0.0013608327,0.22106537,0.00001561156,0.010043461,0.0015947734],"about_ca_topic_score_codex":0.00072855124,"about_ca_topic_score_gemma":0.000021651282,"teacher_disagreement_score":0.34754604,"about_ca_system_score_codex":0.0021092677,"about_ca_system_score_gemma":0.0029034712,"threshold_uncertainty_score":0.99984425},"labels":[],"label_agreement":null},{"id":"W4413453280","doi":"10.3802/jgo.2026.37.e9","title":"Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification","year":2025,"lang":"en","type":"article","venue":"Journal of Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Ministry of Health and Welfare","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Homologous recombination; Toxicity; Homologous chromosome; Oncology; Poly ADP ribose polymerase; Internal medicine; Cancer; Pharmacology; Genetics; DNA; Polymerase; Gene","score_opus":0.01131643990735361,"score_gpt":0.3096241683581557,"score_spread":0.2983077284508021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413453280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941912,0.0010880432,0.00012621241,0.0027173874,0.00036002483,0.0007798347,0.000009871867,0.000006303516,0.0007210941],"genre_scores_gemma":[0.9980772,0.0005844942,0.0009019298,0.00031616815,0.000025377622,0.000060877326,0.0000039711276,0.0000072663265,0.00002272639],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99831283,0.00026410358,0.0008449636,0.00017446991,0.00022549577,0.00017813417],"domain_scores_gemma":[0.9966682,0.0013796333,0.0011196659,0.00018582192,0.00058982224,0.00005685709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000620727,0.00013030654,0.00060947536,0.00029882736,0.000054619548,0.000004872921,0.00014651152,0.00017376013,0.0000561435],"category_scores_gemma":[0.0006907866,0.00008405009,0.00006229619,0.0004416732,0.00026028097,0.000082870465,0.000030072493,0.00033623894,3.3044802e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013032837,0.008685998,0.36966923,0.00015328918,0.00035982596,0.000054181382,0.0022532537,0.0035537404,0.047685504,0.0028225011,0.00054548716,0.5511842],"study_design_scores_gemma":[0.029801365,0.0113570895,0.93932927,0.00030400988,0.00015003124,0.00002044109,0.0005797789,0.00013671257,0.012576667,0.0045263697,0.0011152899,0.000102996586],"about_ca_topic_score_codex":0.000051667692,"about_ca_topic_score_gemma":0.00012556245,"teacher_disagreement_score":0.56966,"about_ca_system_score_codex":0.00054692547,"about_ca_system_score_gemma":0.0007840034,"threshold_uncertainty_score":0.34274632},"labels":[],"label_agreement":null},{"id":"W4413773813","doi":"10.1111/jcmm.70816","title":"Mechanisms of Resistance to <scp>PARPi</scp> in Pancreatic Ductal Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Cellular and Molecular Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Horizon 2020 Framework Programme","keywords":"Pancreatic ductal adenocarcinoma; Adenocarcinoma; Resistance (ecology); Cancer research; Medicine; Biology; Pancreatic cancer; Internal medicine; Cancer; Ecology","score_opus":0.009361074593105076,"score_gpt":0.26887149771732727,"score_spread":0.2595104231242222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413773813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8937027,0.028631043,0.06692409,0.005776092,0.00029902597,0.00031030911,0.0000023196942,0.000006789951,0.004347654],"genre_scores_gemma":[0.99304265,0.00048781387,0.0030601667,0.0022073633,0.00009103219,0.0000060283087,0.0000028684026,0.000017392013,0.0010846893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982708,0.00008873225,0.0007677921,0.00018075832,0.0004860588,0.00020586837],"domain_scores_gemma":[0.99883306,0.00012125925,0.00027661142,0.00030777935,0.00025677658,0.00020452173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006827937,0.00016265601,0.00071844785,0.0006015979,0.000022611734,0.0000047293124,0.00014932599,0.00008935979,0.000025504203],"category_scores_gemma":[0.00063146756,0.00013049165,0.00010205392,0.000524398,0.000116162366,0.000042189527,0.00003685314,0.00027395258,0.0000010861776],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002664961,0.00008159863,0.002328102,0.0002867951,0.00014165984,0.0011005247,0.0006382743,0.000007787431,0.9884514,0.0037435417,0.002812138,0.00014166864],"study_design_scores_gemma":[0.009387795,0.0016629082,0.022994839,0.004980816,0.00053251855,0.00040882718,0.0016105428,0.000026317692,0.9351729,0.015909707,0.007225346,0.00008746087],"about_ca_topic_score_codex":0.000014580006,"about_ca_topic_score_gemma":0.000004540497,"teacher_disagreement_score":0.09933997,"about_ca_system_score_codex":0.00008644415,"about_ca_system_score_gemma":0.00018285203,"threshold_uncertainty_score":0.5321295},"labels":[],"label_agreement":null},{"id":"W4414026833","doi":"10.3389/fcell.2025.1638964","title":"Interplay of replication stress response and immune microenvironment in high-grade serous ovarian cancer","year":2025,"lang":"en","type":"review","venue":"Frontiers in Cell and Developmental Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Serous ovarian cancer; Immune system; Tumor microenvironment; Ovarian cancer; Serous fluid; Replication (statistics); Biology; Fight-or-flight response; Medicine; Cancer; Immunology; Cancer research; Virology; Pathology; Genetics; Gene","score_opus":0.01441296681966797,"score_gpt":0.3102299847312858,"score_spread":0.29581701791161785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414026833","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016411262,0.9817851,0.00010689784,0.00013773936,0.00041198346,0.00079865614,0.0001883658,0.000007726081,0.0001522325],"genre_scores_gemma":[0.0025392745,0.9904396,0.0057462794,0.000104828934,0.000017012486,0.00029485757,0.0003073438,0.00001606093,0.0005347519],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982412,0.00024189988,0.0007085231,0.00054980104,0.000055931323,0.00020265748],"domain_scores_gemma":[0.9993675,0.00011700289,0.00023318706,0.00022449429,0.000009007588,0.00004883381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032784598,0.0002594961,0.0011971176,0.00046108328,0.000023303783,0.0000041654284,0.00009533425,0.00032948804,0.0000374094],"category_scores_gemma":[0.000022709262,0.00022626223,0.000053943113,0.00021409495,0.00020111121,0.000020859145,0.000112456364,0.0002737018,0.0000010810957],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012919548,0.00021628065,0.025607616,0.009753809,0.00017737308,0.000026231133,0.00057055673,3.501339e-7,0.0021519845,0.000013402674,0.0012680163,0.95892245],"study_design_scores_gemma":[0.0069271517,0.00040248595,0.0278809,0.035523903,0.00028321525,0.00011401921,0.00065211,0.00000433485,0.00964689,0.00026123985,0.9175254,0.0007783638],"about_ca_topic_score_codex":0.00018075824,"about_ca_topic_score_gemma":0.000022954759,"teacher_disagreement_score":0.95814407,"about_ca_system_score_codex":0.0006058279,"about_ca_system_score_gemma":0.0003289826,"threshold_uncertainty_score":0.9226706},"labels":[],"label_agreement":null},{"id":"W4414349897","doi":"10.1158/1538-7445.ovarian25-b046","title":"Abstract B046: Homologous recombination DNA repair dependent survival associations in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis consortium study","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; BC Cancer Agency; Vancouver General Hospital","funders":"","keywords":"Hazard ratio; Proportional hazards model; Serous fluid; Ovarian cancer; Ovarian carcinoma; Logistic regression; Homologous recombination; Confidence interval","score_opus":0.08076117053666851,"score_gpt":0.4354161229136033,"score_spread":0.3546549523769348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414349897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117947,0.00036397387,0.00009868934,0.0034194053,0.00062588346,0.0020414281,0.00017467627,0.00018398628,0.0019125055],"genre_scores_gemma":[0.99591565,0.000065517284,0.00013896564,0.00020015496,0.00022681674,0.0011320377,0.00021736707,0.000042507825,0.0020610099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948384,0.0012531567,0.0008336601,0.0009807344,0.0012942194,0.0007998252],"domain_scores_gemma":[0.99715835,0.0004861397,0.00018956195,0.0010162857,0.0008887658,0.000260902],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004047933,0.00026514506,0.0007863452,0.0019845734,0.0003970754,0.000109264976,0.00035732344,0.0002071106,0.0008643784],"category_scores_gemma":[0.00041272852,0.0002814737,0.00015604368,0.0042360574,0.00017100062,0.00022720043,0.000108419066,0.001152893,0.0000305068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006997913,0.0033763242,0.9759011,0.00010562625,0.0014818368,0.0008516475,0.0017110119,0.00042318227,0.011047449,0.0012886222,0.0013752265,0.0017381627],"study_design_scores_gemma":[0.0058883517,0.00050124724,0.98315084,0.00006369804,0.00035599203,0.0000061433957,0.001729404,0.00016835169,0.006754645,0.0008694842,0.00028113805,0.0002307162],"about_ca_topic_score_codex":0.038882915,"about_ca_topic_score_gemma":0.03574488,"teacher_disagreement_score":0.0072497088,"about_ca_system_score_codex":0.0035384458,"about_ca_system_score_gemma":0.0016103925,"threshold_uncertainty_score":0.99996376},"labels":[],"label_agreement":null},{"id":"W4414358574","doi":"10.3390/curroncol32090523","title":"Pulmonary Embolism Associated with Olaparib in BRCA2-Mutated Prostate Cancer: A Case Report","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Olaparib; Rivaroxaban; Pulmonary embolism; Prostate cancer; Chest pain; PARP inhibitor; Prostate","score_opus":0.0638244545062446,"score_gpt":0.4329810707004631,"score_spread":0.36915661619421847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414358574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97869277,0.004416142,0.00005417862,0.0046457127,0.0015689728,0.0011423728,0.000058176156,0.00016008687,0.009261608],"genre_scores_gemma":[0.99561656,0.00066942355,0.00004794063,0.00063316827,0.0001233773,0.0007792831,0.00022075312,0.000027861712,0.0018816362],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981175,0.00017416166,0.0005825789,0.00049330684,0.00019344974,0.00043899563],"domain_scores_gemma":[0.9988473,0.00014174957,0.0002777554,0.0003130954,0.00029217036,0.00012790905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040481225,0.00021994344,0.0006156193,0.00033077085,0.000078970916,0.000010857258,0.000074736745,0.00018615152,0.00015393758],"category_scores_gemma":[0.00016820905,0.00019263892,0.000063267486,0.0009236465,0.00019283318,0.00007169077,0.000043726643,0.0005835171,0.000008918144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032309236,0.003882721,0.41768828,0.00037283753,0.0005096663,0.36114806,0.0020584757,0.00012491648,0.0016494562,0.00036650666,0.01482516,0.19414298],"study_design_scores_gemma":[0.047306463,0.0020575307,0.25883457,0.006510069,0.00095774257,0.14247425,0.0013585374,0.003282307,0.0040827487,0.0018133237,0.53002924,0.0012932103],"about_ca_topic_score_codex":0.00029864354,"about_ca_topic_score_gemma":0.0007961,"teacher_disagreement_score":0.5152041,"about_ca_system_score_codex":0.0016522233,"about_ca_system_score_gemma":0.0017328559,"threshold_uncertainty_score":0.78555876},"labels":[],"label_agreement":null},{"id":"W4414379673","doi":"10.1093/oncolo/oyaf270","title":"Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec à Montréal","funders":"Genentech; Servier; European Society for Medical Oncology; Eisai; Verastem Oncology; Clovis Oncology; Astellas Pharma; Novocure; Regeneron Pharmaceuticals; Amgen; Mereo BioPharma; Pfizer; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Mersana Therapeutics; PTC Therapeutics; GlaxoSmithKline","keywords":"Clinical trial; Ovarian cancer; Immunotherapy; Bevacizumab; PARP inhibitor; Phases of clinical research; Poly ADP ribose polymerase","score_opus":0.2927783521745961,"score_gpt":0.5819201111673444,"score_spread":0.28914175899274835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414379673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85441405,0.028830525,0.02273687,0.07556572,0.004516409,0.010288778,0.001060291,0.00025019908,0.0023371866],"genre_scores_gemma":[0.9737952,0.006163277,0.0035112756,0.0044972966,0.0022051842,0.003578049,0.0002203735,0.00005800442,0.005971382],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964471,0.00077757944,0.0017274712,0.00043201252,0.00027221767,0.00034361408],"domain_scores_gemma":[0.9945984,0.0034539823,0.0009307582,0.0006426819,0.00028205005,0.00009216629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038697114,0.00029404924,0.0013651323,0.0001295232,0.00031809887,0.000025326617,0.00013646854,0.00021753536,0.00036443846],"category_scores_gemma":[0.0011264897,0.00018933784,0.00059957424,0.000347658,0.0005842538,0.0000654452,0.00002315341,0.00017346953,0.000005362629],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04050136,0.003477344,0.00021093956,0.0000971814,0.000850128,0.000008508394,0.00076865504,0.00026736804,0.08601316,0.00061018986,0.00307761,0.86411756],"study_design_scores_gemma":[0.4116598,0.045001753,0.0014689937,0.0016006834,0.002304196,0.00002645942,0.0009014685,0.0076925345,0.35567734,0.0051971637,0.16780798,0.0006616418],"about_ca_topic_score_codex":0.0004670417,"about_ca_topic_score_gemma":0.000157277,"teacher_disagreement_score":0.8634559,"about_ca_system_score_codex":0.00144925,"about_ca_system_score_gemma":0.002016494,"threshold_uncertainty_score":0.77209723},"labels":[],"label_agreement":null},{"id":"W4414445843","doi":"10.1101/2025.09.17.25335919","title":"Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i> -deficient tubo-ovarian high-grade serous carcinoma","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia; Foothills Medical Centre; BC Cancer Agency; Vancouver General Hospital; University of Calgary; University of Victoria","funders":"National Health and Medical Research Council; Medical Research Council; National Institutes of Health; Seagen; Verastem Oncology; Peter MacCallum Cancer Centre; F. Hoffmann-La Roche; Medical Research and Materiel Command; Mersana Therapeutics; AstraZeneca","keywords":"Context (archaeology); Serous fluid; Germline; Disease; Cohort; Immune system; Serous carcinoma; Overall survival","score_opus":0.015386642559989394,"score_gpt":0.27677254858732386,"score_spread":0.26138590602733447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414445843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99160963,0.001079308,0.00045125536,0.0006901706,0.0018396985,0.0017966576,0.00052770687,0.0000937303,0.0019118325],"genre_scores_gemma":[0.9972454,0.00015645212,0.0011417398,0.00074535963,0.00015135725,0.00013376285,0.00025987005,0.000075646276,0.00009043962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946746,0.0004683371,0.0015848485,0.0014083692,0.001249459,0.000614354],"domain_scores_gemma":[0.99703366,0.00024498388,0.0005855428,0.0013994013,0.00040663462,0.00032976203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011330815,0.000663334,0.0016668473,0.0005030847,0.000066278044,0.000032484008,0.000436487,0.0006457832,0.000032899974],"category_scores_gemma":[0.00016571755,0.0005805912,0.00024972582,0.0006725,0.00069328595,0.00005824683,0.00052243454,0.0014487373,0.000003612968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009862423,0.0012325149,0.9947276,0.0007408319,0.00017531653,0.00009861134,0.0003847796,0.00026332418,0.00021727386,0.000633549,0.00021060063,0.00032933033],"study_design_scores_gemma":[0.011436514,0.0010362265,0.98176885,0.0012180196,0.0003619372,0.000007712135,0.000060076123,0.00008776063,0.0025821351,0.000642052,0.00029352863,0.000505198],"about_ca_topic_score_codex":0.00040768148,"about_ca_topic_score_gemma":0.00007632451,"teacher_disagreement_score":0.012958785,"about_ca_system_score_codex":0.00021919321,"about_ca_system_score_gemma":0.000951216,"threshold_uncertainty_score":0.99966455},"labels":[],"label_agreement":null},{"id":"W4414517652","doi":"10.1021/acsomega.4c10672","title":"Identification of CYP2B6 as a Novel Biomarker of HRD in Colon Adenocarcinoma through WGCNA and Machine Learning","year":2025,"lang":"en","type":"article","venue":"ACS Omega","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Nomogram; Biomarker; Identification (biology); Personalized medicine; Gene expression profiling; Gene; Gene expression","score_opus":0.035720389839019734,"score_gpt":0.3338106201826997,"score_spread":0.29809023034368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414517652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258727,0.0026850996,0.00075584213,0.0012986646,0.00008357915,0.00027047936,0.000013479251,0.000016976206,0.0022886335],"genre_scores_gemma":[0.9980969,0.0002864556,0.00021962172,0.00020060994,0.000013018441,0.000024729994,0.000019260662,0.000009985745,0.0011294191],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991364,0.000036089827,0.00039067204,0.00018221696,0.00015084566,0.00010377462],"domain_scores_gemma":[0.9994268,0.000102023085,0.00016938474,0.00019113546,0.00008935758,0.00002130652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022156494,0.00008318158,0.00024538263,0.0001933158,0.000024377252,0.000005426942,0.000057544024,0.00007653293,0.000019445612],"category_scores_gemma":[0.00015686266,0.000082381026,0.00003229694,0.00046451634,0.00011328745,0.000082586215,0.000032762793,0.00012986962,0.0000031810116],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050221564,0.00015615237,0.15604341,0.00024878234,0.000065796776,0.0000047770213,0.00086585275,0.000009020819,0.83802253,0.0019670993,0.00019245943,0.0019219244],"study_design_scores_gemma":[0.005469399,0.00025523035,0.51033384,0.00051674363,0.00007181534,0.00003162737,0.000306919,0.00059797906,0.4777904,0.0014925993,0.0030244174,0.00010901974],"about_ca_topic_score_codex":0.00031466203,"about_ca_topic_score_gemma":0.000024554594,"teacher_disagreement_score":0.3602321,"about_ca_system_score_codex":0.00006126897,"about_ca_system_score_gemma":0.00007728043,"threshold_uncertainty_score":0.33594006},"labels":[],"label_agreement":null},{"id":"W4414649183","doi":"10.1016/j.ygyno.2025.04.243","title":"Assessing the relationship between KELIM score and response to niraparib first-line maintenance therapy in non-BRCA mutant advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Maintenance therapy; Mutant; Ovarian cancer; Cancer; Overall survival","score_opus":0.08085281568655181,"score_gpt":0.4215503135163501,"score_spread":0.3406974978297983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414649183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9060819,0.00068650703,0.0012910523,0.08744373,0.00056707056,0.0015717486,0.00001918973,0.000069892034,0.0022688915],"genre_scores_gemma":[0.9839448,0.0005600983,0.001411598,0.012056874,0.00014003196,0.0009535875,0.00001148304,0.000022627313,0.00089894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975573,0.0005405736,0.0006182388,0.0005776232,0.00017010055,0.000536169],"domain_scores_gemma":[0.9922685,0.006769912,0.00020935276,0.0004657243,0.00015656807,0.00012996072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018347759,0.00026024715,0.0006490421,0.00034425018,0.00033156443,0.000040016686,0.00019463668,0.00036135313,0.00016691681],"category_scores_gemma":[0.0024407867,0.00018509044,0.00007167207,0.0010279646,0.0003003537,0.00013503159,0.00009907459,0.0006834251,0.000013218747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035856925,0.00020399722,0.89877665,0.000040167342,0.000076823024,0.0001377007,0.0010022371,0.00039756473,0.0056572747,0.00069872756,0.0011581759,0.088264994],"study_design_scores_gemma":[0.007671444,0.0014709571,0.9513429,0.00032797016,0.000038419705,0.000022322889,0.00047485108,0.00009354417,0.00067077874,0.003416199,0.03429004,0.00018059998],"about_ca_topic_score_codex":0.00012733808,"about_ca_topic_score_gemma":0.0008277634,"teacher_disagreement_score":0.0880844,"about_ca_system_score_codex":0.001509556,"about_ca_system_score_gemma":0.0010248113,"threshold_uncertainty_score":0.7547769},"labels":[],"label_agreement":null},{"id":"W4414649823","doi":"10.1016/j.ygyno.2025.04.399","title":"Real-world experience with poly (ADP-ribose) polymerase inhibitors for the treatment of ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Olaparib; Ovarian cancer; Chemotherapy; Polymerase; Poly ADP ribose polymerase; Epithelial ovarian cancer","score_opus":0.0359723972299745,"score_gpt":0.39097497735633274,"score_spread":0.3550025801263582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414649823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90751094,0.0057335496,0.0012720117,0.050757065,0.0032922768,0.004422115,0.00013252332,0.00018678118,0.026692767],"genre_scores_gemma":[0.9798983,0.0021177079,0.0017528655,0.0034177636,0.00047206218,0.0040474217,0.000017632206,0.000021794505,0.00825445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855214,0.00009173884,0.0004301155,0.0003917654,0.00014032972,0.00039391706],"domain_scores_gemma":[0.9976719,0.0013947957,0.00024229584,0.00044468595,0.00015642423,0.000089873356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016021781,0.00022795523,0.00059943827,0.00018113852,0.00019393508,0.000007757406,0.00014809486,0.00016524622,0.00070352043],"category_scores_gemma":[0.000059105667,0.00013113671,0.00014143868,0.00051732105,0.00050706795,0.00004040334,0.0000211379,0.00011035084,0.0000040121035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015544224,0.006323082,0.2297543,0.00023163181,0.0021850828,0.00021770468,0.009014565,0.00016548306,0.04419309,0.016259523,0.029799541,0.64631176],"study_design_scores_gemma":[0.017864985,0.013412022,0.10354594,0.00013798125,0.00063563156,0.000025581907,0.0019708707,0.00015354449,0.15443777,0.0005442027,0.7069698,0.00030165268],"about_ca_topic_score_codex":0.0016671328,"about_ca_topic_score_gemma":0.002654857,"teacher_disagreement_score":0.6771703,"about_ca_system_score_codex":0.0012981689,"about_ca_system_score_gemma":0.0012104587,"threshold_uncertainty_score":0.7703055},"labels":[],"label_agreement":null},{"id":"W4414799446","doi":"10.21203/rs.3.rs-7572112/v1","title":"Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of Alberta; University of Calgary; University of British Columbia","funders":"Instituto de Salud Carlos III; National Health and Medical Research Council; Medical Research Council; Uniformed Services University of the Health Sciences; Medical Research and Materiel Command; Genentech; National Institutes of Health; BeiGene; Peter MacCallum Cancer Centre; Medizinische Abteilung der Margarete und Walter Lichtenstein-Stiftung; Ministerio de Ciencia e Innovación; Cancer Institute NSW; Agencia Estatal de Investigación; Marshfield Clinic Research Foundation; AstraZeneca; Ovarian Cancer Research Foundation; Ministerio de Ciencia, Innovación y Universidades; GlaxoSmithKline; European Regional Development Fund; U.S. Department of Defense","keywords":"Context (archaeology); Germline; Serous fluid; Serous carcinoma; Disease; Cohort; Immune system; Survival analysis","score_opus":0.04204219362471238,"score_gpt":0.38184615954699863,"score_spread":0.33980396592228623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414799446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914059,0.001221921,0.00016593737,0.00091713195,0.0005138638,0.0029072512,0.00082956214,0.000054342127,0.001984074],"genre_scores_gemma":[0.99815124,0.00022840592,0.0005548788,0.000098170676,0.00013947848,0.00021166146,0.00040774827,0.000059742422,0.00014865115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99283946,0.0011780281,0.0011229176,0.0013127718,0.0026829338,0.0008638725],"domain_scores_gemma":[0.99617827,0.0005755189,0.00024601773,0.0013722946,0.0012194677,0.00040845873],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026257834,0.0004391467,0.0012077031,0.0010961228,0.00011348882,0.00005546363,0.00045044092,0.00062758237,0.00007348886],"category_scores_gemma":[0.0005018782,0.0003822677,0.00019170648,0.0011065876,0.0009873444,0.00005589292,0.0008787092,0.0025666677,0.0000050495128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017271223,0.0015056022,0.99086994,0.0021458552,0.00014030315,0.00014264346,0.0006178609,0.00025434565,0.00007742945,0.0012906129,0.00040614593,0.0008221272],"study_design_scores_gemma":[0.009441494,0.0022124338,0.98273003,0.002749707,0.00008029324,0.0000040751524,0.0002790266,0.00015376486,0.0007844593,0.0010567012,0.00018954642,0.00031844512],"about_ca_topic_score_codex":0.0014239254,"about_ca_topic_score_gemma":0.0001477518,"teacher_disagreement_score":0.008139899,"about_ca_system_score_codex":0.00053466746,"about_ca_system_score_gemma":0.0022353588,"threshold_uncertainty_score":0.9998629},"labels":[],"label_agreement":null},{"id":"W4414889355","doi":"10.1016/j.dnarep.2025.103898","title":"PARP enzyme synthesis of protein-free poly(ADP-ribose): Implications for DNA damage signaling and repair","year":2025,"lang":"en","type":"article","venue":"DNA repair","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"DNA damage; Poly ADP ribose polymerase; PARP1; DNA repair; DNA; Context (archaeology); DNA replication; Enzyme","score_opus":0.021244598072996425,"score_gpt":0.30637696051121843,"score_spread":0.285132362438222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414889355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9455095,0.0050485455,0.0052893735,0.027005257,0.00025584863,0.004709993,0.00068936753,0.0016204745,0.00987165],"genre_scores_gemma":[0.97341275,0.0000779272,0.020731013,0.001192006,0.00025213687,0.0018129448,0.000038741524,0.000051510335,0.0024309729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985201,0.000066644534,0.00052401953,0.00045003212,0.0001629346,0.0002762729],"domain_scores_gemma":[0.99797606,0.00046388173,0.0001801862,0.0010444309,0.00022319621,0.000112237925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048174962,0.00019302873,0.00043569412,0.00020927747,0.00015152749,0.000011123697,0.0001505452,0.00013757295,0.000057634563],"category_scores_gemma":[0.0007661227,0.00018693921,0.00029971555,0.00034410317,0.00017215841,0.000084056475,0.00007151232,0.00012197452,0.000002890046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010045245,0.0004849252,0.00975302,0.0019132412,0.0007914027,0.00000913319,0.00034425402,0.000004971011,0.89992404,0.021911623,0.057007708,0.006851134],"study_design_scores_gemma":[0.00269595,0.00031292753,0.01643199,0.0011634476,0.00032863166,0.000015931022,0.00019917579,0.0003584967,0.89884573,0.0075019067,0.07187145,0.0002743294],"about_ca_topic_score_codex":0.000039484014,"about_ca_topic_score_gemma":0.000009212064,"teacher_disagreement_score":0.027903257,"about_ca_system_score_codex":0.00011762895,"about_ca_system_score_gemma":0.00022851561,"threshold_uncertainty_score":0.762316},"labels":[],"label_agreement":null},{"id":"W4415321365","doi":"10.1016/j.annonc.2025.10.007","title":"Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Clovis Oncology","keywords":"Interim; Ovarian cancer; Interim analysis; Olaparib; Maintenance therapy; Phases of clinical research","score_opus":0.07431117249813045,"score_gpt":0.43318192299261105,"score_spread":0.3588707504944806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415321365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740563,0.0030097843,0.0008623491,0.015112466,0.0017947532,0.0030716422,0.0009255998,0.000049900173,0.0011171843],"genre_scores_gemma":[0.9900003,0.0048302715,0.000933133,0.002414558,0.00020047031,0.000807232,0.00009182153,0.00004688945,0.0006752873],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719,0.0003682367,0.0009996477,0.0006037902,0.00036067844,0.00047762963],"domain_scores_gemma":[0.9950471,0.0026592296,0.0006798582,0.0009473345,0.00051929645,0.00014717906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011267619,0.00030820235,0.0013002318,0.0001190387,0.00014899505,0.0000125126,0.00048039874,0.00021470418,0.00024767802],"category_scores_gemma":[0.0009096546,0.0002448262,0.00024498167,0.00028372311,0.00045595347,0.000110268855,0.0003032496,0.00027224762,0.0000016325715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13490297,0.007497142,0.039030686,0.00038110587,0.0038799488,0.00012420825,0.012105292,0.00007258955,0.040159464,0.007328412,0.15508996,0.59942824],"study_design_scores_gemma":[0.34417745,0.02297666,0.13803044,0.0028678954,0.0009688906,0.00001215024,0.0062699644,0.00031588387,0.018233346,0.01594013,0.44929537,0.0009117834],"about_ca_topic_score_codex":0.0016222489,"about_ca_topic_score_gemma":0.0024477795,"teacher_disagreement_score":0.59851646,"about_ca_system_score_codex":0.0002083201,"about_ca_system_score_gemma":0.0006025928,"threshold_uncertainty_score":0.99837226},"labels":[],"label_agreement":null},{"id":"W4415641574","doi":"10.1016/j.drup.2025.101319","title":"ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Drug Resistance Updates","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China; Foundation for Innovative Research Groups of the National Natural Science Foundation of China; Foundation for Innovative Research Groups of Hubei Province of China; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Breast Cancer Research Foundation","keywords":"Synthetic lethality; Poly ADP ribose polymerase; PARP inhibitor; Ovarian cancer; DNA damage; DNA repair; Olaparib; Programmed cell death","score_opus":0.011116964085680128,"score_gpt":0.30246942756489226,"score_spread":0.2913524634792121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415641574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9545513,0.0024445495,0.00023490257,0.036231752,0.0004000402,0.0008419981,0.00017327604,0.00011473072,0.0050074914],"genre_scores_gemma":[0.99327356,0.0011951906,0.00027936068,0.002724718,0.00010160961,0.00030367705,0.0001202893,0.000025999698,0.0019756039],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810135,0.00016769636,0.00047189655,0.00058959477,0.00029377794,0.00037568194],"domain_scores_gemma":[0.9989924,0.0002204952,0.00010822407,0.0003666686,0.0001625034,0.00014973528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000546208,0.000236809,0.00042035023,0.00040461437,0.00013378091,0.000055698925,0.00006405922,0.0001292126,0.00028992372],"category_scores_gemma":[0.00021762509,0.00023741687,0.000052536994,0.0008207068,0.00020785166,0.00016290597,0.000040285453,0.00028011913,0.00001891426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012793118,0.00066578895,0.09133832,0.0022086112,0.0003755084,0.00028128072,0.004618005,0.00008528855,0.7916487,0.0117717,0.08019455,0.004019149],"study_design_scores_gemma":[0.007427068,0.000091937414,0.13916968,0.0041856263,0.00011553614,0.00001524176,0.0013311887,0.00010087749,0.73985577,0.004780767,0.10230867,0.0006176727],"about_ca_topic_score_codex":0.00064122176,"about_ca_topic_score_gemma":0.0045476407,"teacher_disagreement_score":0.05179294,"about_ca_system_score_codex":0.00050467986,"about_ca_system_score_gemma":0.00024096908,"threshold_uncertainty_score":0.96815795},"labels":[],"label_agreement":null},{"id":"W4415660146","doi":"10.1038/s41467-025-65315-9","title":"Regulation of ADP-ribosyltransferase activity by ART domain dimerization in PARP15","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke; Umeå Universitet; Karolinska Institutet; IngaBritt och Arne Lundbergs Forskningsstiftelse; Lunds Universitet; Crafoordska Stiftelsen; Cancerfonden; Science for Life Laboratory; Vetenskapsrådet; University of Lethbridge; VINNOVA; Swedish Cancer Foundation; Svenska Forskningsrådet Formas; U.S. Department of Health and Human Services","keywords":"Domain (mathematical analysis); Dimer; Mutant; Subcellular localization; Mechanism (biology); Transferase; Mutation; Protein domain; Protein structure","score_opus":0.013088067537464968,"score_gpt":0.3408750466531812,"score_spread":0.32778697911571625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415660146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84363276,0.008751133,0.030689418,0.06584626,0.0003339251,0.0017733104,0.0003059499,0.00019017754,0.048477065],"genre_scores_gemma":[0.99558735,0.00076284213,0.0019552968,0.00064278446,0.000011843555,0.00009058046,0.00053418876,0.00001040119,0.00040473993],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99915683,0.0001760376,0.00026430242,0.00014712875,0.00015396264,0.00010176336],"domain_scores_gemma":[0.9984684,0.00015935258,0.0000700909,0.0011309385,0.00013791403,0.000033279342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022587055,0.00009410107,0.00020286323,0.00020558914,0.00007674167,0.0000064756505,0.00022239062,0.00024738998,0.000055050983],"category_scores_gemma":[0.00008582655,0.000099393386,0.000056655117,0.0008193643,0.00011539168,0.00010431525,0.000037144946,0.0005923907,0.0000037020427],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040831638,0.0009934738,0.024989676,0.00008621356,0.000083168554,4.2323188e-7,0.000365576,0.000075533426,0.9165676,0.03181425,0.01997447,0.0046412586],"study_design_scores_gemma":[0.0097688865,0.00016878721,0.34383315,0.0013959111,0.00018992712,0.000009712839,0.0002530517,0.008995234,0.32021827,0.010321447,0.30433106,0.00051457237],"about_ca_topic_score_codex":0.000025472233,"about_ca_topic_score_gemma":0.00015931469,"teacher_disagreement_score":0.59634936,"about_ca_system_score_codex":0.00014843546,"about_ca_system_score_gemma":0.00012937892,"threshold_uncertainty_score":0.40531448},"labels":[],"label_agreement":null},{"id":"W4415665469","doi":"10.51731/cjht.2025.1274","title":"Mirvetuximab Soravtansine (Elahere)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fallopian tube; Cancer; Disease; Fallopian tube cancer; Primary care; Drug; First line","score_opus":0.028885706885149767,"score_gpt":0.3440581177649768,"score_spread":0.31517241087982706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415665469","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013539576,0.6408998,0.0026414082,0.33366495,0.0048238174,0.0006667139,0.00010618588,0.00014501979,0.0035125543],"genre_scores_gemma":[0.9779794,0.012461622,0.0011006339,0.006882795,0.00007982535,0.000010246544,0.000005062574,0.000045084224,0.0014353344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951721,0.00023661788,0.002386765,0.00038567904,0.00040316422,0.0014156834],"domain_scores_gemma":[0.9961999,0.00018244227,0.0014401209,0.0008550036,0.0009736961,0.00034883866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020216478,0.00045212827,0.0015248491,0.0032994214,0.0006622125,0.00010440166,0.0008704488,0.0007242947,0.0004887805],"category_scores_gemma":[0.0013545371,0.00043541356,0.0003266519,0.0020702116,0.0012625675,0.00022492715,0.0000413646,0.0021914735,0.000054258544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018954325,0.00010238393,0.004132659,0.00085281406,0.00048009946,0.0006744633,0.0005126016,0.00002438641,0.00014496311,0.008587321,0.12700477,0.85729396],"study_design_scores_gemma":[0.0050877086,0.0015997362,0.004811669,0.008455426,0.00014729638,0.00073279656,0.0071532535,0.000034896693,0.0028366658,0.01949068,0.9492883,0.0003615802],"about_ca_topic_score_codex":0.006565027,"about_ca_topic_score_gemma":0.0051049166,"teacher_disagreement_score":0.9644398,"about_ca_system_score_codex":0.003951386,"about_ca_system_score_gemma":0.03980915,"threshold_uncertainty_score":0.99987227},"labels":[],"label_agreement":null},{"id":"W4415689730","doi":"10.21203/rs.3.rs-7793649/v1","title":"Structural basis for selective remdesivir incorporation by SARS-CoV-2 polymerase, and S759A resistance","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; KU Leuven; Canada Excellence Research Chairs, Government of Canada; National Institutes of Health; University of Alberta","keywords":"Nucleotide; RNA; Nucleoside triphosphate; Nucleoside; DNA; Polymerase; Base pair; Primer (cosmetics); Mutant","score_opus":0.09075726185996913,"score_gpt":0.4482667897817922,"score_spread":0.35750952792182306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415689730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8558486,0.04000378,0.005909632,0.035059936,0.0012472625,0.020594727,0.014389976,0.0006398322,0.026306236],"genre_scores_gemma":[0.98314786,0.0012183425,0.0034461003,0.0006576066,0.0005941705,0.0020262587,0.0012926077,0.00007518452,0.0075418768],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965076,0.0004748632,0.00045389315,0.0009966455,0.0009813029,0.00058568903],"domain_scores_gemma":[0.99673504,0.0007487204,0.00019940677,0.0007000424,0.0014775901,0.00013920692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011184092,0.0003391715,0.0005949226,0.00056167156,0.00038378726,0.0001321097,0.0002153374,0.00048655237,0.000026875012],"category_scores_gemma":[0.00078667694,0.00033450752,0.00015605376,0.0006329578,0.00032533178,0.000117831485,0.00026206934,0.0013793699,0.0000045415995],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009366991,0.00019449595,0.005145454,0.010207193,0.00068546575,0.000037848702,0.0015670935,0.000009998204,0.24228822,0.0036949362,0.7161487,0.010653661],"study_design_scores_gemma":[0.004569355,0.0008344503,0.005703771,0.006384919,0.00012207057,0.000013518004,0.0003828331,0.00083098165,0.9134805,0.03326961,0.03369061,0.0007173505],"about_ca_topic_score_codex":0.00034335215,"about_ca_topic_score_gemma":0.00034049666,"teacher_disagreement_score":0.68245804,"about_ca_system_score_codex":0.0011635534,"about_ca_system_score_gemma":0.0015711215,"threshold_uncertainty_score":0.9999107},"labels":[],"label_agreement":null},{"id":"W4415707414","doi":"10.1126/science.adt1210","title":"FIGNL1 inhibits homologous recombination in BRCA2 deficient cells by dissociating RAD51 filaments","year":2025,"lang":"en","type":"article","venue":"Science","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"RAD51; Homologous recombination; Homologous chromosome; RAD52; BRCA2 Protein; DNA repair; Embryonic stem cell","score_opus":0.005017101347533156,"score_gpt":0.31583444058845855,"score_spread":0.3108173392409254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415707414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98575634,0.00033716366,0.0003025493,0.0017425283,0.0006570386,0.00033882508,0.000012326251,0.000050710896,0.010802494],"genre_scores_gemma":[0.99576247,0.00004622374,0.00060946675,0.0010540732,0.000010412496,0.00003362873,0.000008230604,0.000005300494,0.002470215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985923,0.0000379629,0.00025828715,0.00036990337,0.00041858284,0.00032291684],"domain_scores_gemma":[0.99947137,0.00007812838,0.0000938673,0.00020161411,0.000092249444,0.0000627584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084170524,0.000091694084,0.00014955437,0.00027055183,0.00019167739,0.00004169488,0.00016692355,0.000051704832,0.00006828036],"category_scores_gemma":[0.00022403114,0.00008993781,0.000029839106,0.0015083149,0.0002591255,0.00014674925,0.000057405516,0.00015820832,0.000028671448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003831563,0.00039405678,0.014472123,0.00004870139,0.000008194916,0.000009131059,0.0011132847,0.000106258325,0.9576117,0.0006821369,0.009126824,0.016389297],"study_design_scores_gemma":[0.002760057,0.00018111228,0.039147798,0.0006075653,0.000012740837,0.000007094481,0.00036859702,0.0019054614,0.9493088,0.0025708238,0.0029277515,0.00020219719],"about_ca_topic_score_codex":0.0000317074,"about_ca_topic_score_gemma":0.0000056568315,"teacher_disagreement_score":0.024675673,"about_ca_system_score_codex":0.0007928221,"about_ca_system_score_gemma":0.0003126585,"threshold_uncertainty_score":0.36675572},"labels":[],"label_agreement":null},{"id":"W4415918848","doi":"10.1038/s41467-025-64130-6","title":"Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Health and Medical Research Council; Genentech; Sierra Oncology; Cancer Council Victoria; Eisai; BeiGene; Clovis Oncology; University of Sydney; Australian Cancer Research Foundation; Pfizer; Australian Government; Gilead Sciences; RMIT University; Genomic Health; AstraZeneca; Eli Lilly and Company","keywords":"Olaparib; Clinical endpoint; Ovarian cancer; Homologous recombination; Priming (agriculture); PARP inhibitor","score_opus":0.016295990253787206,"score_gpt":0.3527248419449789,"score_spread":0.3364288516911917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415918848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72775465,0.15400402,0.00026695835,0.0982769,0.00070101564,0.010118466,0.00018455133,0.00017557171,0.008517842],"genre_scores_gemma":[0.98432124,0.010181313,0.0009793472,0.0029497137,0.00009499934,0.0011524637,0.00008348241,0.000019083021,0.0002183758],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981616,0.00065048767,0.00047375736,0.00030530276,0.00019401996,0.00021480052],"domain_scores_gemma":[0.99589634,0.0026156653,0.0001582829,0.001031304,0.00022219705,0.00007619991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009574919,0.00021684292,0.0006162676,0.00018537072,0.00036529984,0.00005780391,0.00028441707,0.00041574467,0.000019440371],"category_scores_gemma":[0.0014115699,0.00015784412,0.00009587792,0.0006522945,0.00059007393,0.00008422966,0.00018386588,0.0019637325,8.619066e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83902687,0.0037764877,0.0062855994,0.0002718368,0.0029059942,0.00005894861,0.009393425,0.00005483842,0.0065613473,0.10670403,0.0081578875,0.016802758],"study_design_scores_gemma":[0.9785692,0.00019473446,0.0021750475,0.00082799,0.0009829256,0.000047164238,0.00041581376,0.006160692,0.0006590992,0.0030235753,0.0066954093,0.0002483656],"about_ca_topic_score_codex":0.00019110482,"about_ca_topic_score_gemma":0.00086708885,"teacher_disagreement_score":0.25656655,"about_ca_system_score_codex":0.000089086774,"about_ca_system_score_gemma":0.00036615858,"threshold_uncertainty_score":0.853155},"labels":[],"label_agreement":null},{"id":"W4415939801","doi":"10.1016/j.annonc.2025.08.1862","title":"1227eP Real-world (rw) outcomes in patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib: Final results from the 1NSPIRE chart review study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada)","funders":"","keywords":"Epithelial ovarian cancer; Chemotherapy; Placebo; Chart; Ovarian cancer; Maintenance therapy","score_opus":0.10244560087867295,"score_gpt":0.41625983669040517,"score_spread":0.31381423581173223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7997537,0.0028651266,0.000014595108,0.18447699,0.0006871163,0.0032577247,0.00089974294,0.00005396626,0.0079909945],"genre_scores_gemma":[0.9178771,0.038182616,0.00016342165,0.03869491,0.0002825486,0.00067970075,0.00016605327,0.000041048,0.0039126193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99678993,0.0004509965,0.0012305978,0.00063127227,0.000425721,0.00047147775],"domain_scores_gemma":[0.99692327,0.00080220687,0.0006710936,0.00085833255,0.0006433613,0.00010170988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011383762,0.00033168786,0.0014122047,0.0001865605,0.00011611363,0.000008831437,0.00036458203,0.00014208014,0.00024377306],"category_scores_gemma":[0.0005552917,0.00021271277,0.0001540388,0.0007796337,0.00026479756,0.00009042748,0.00008858673,0.0005064835,0.00001644683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017847663,0.003727094,0.7540536,0.00030115887,0.00086416304,0.00009358872,0.0016780464,0.000059264265,0.00003729435,0.00014579369,0.14992124,0.071271114],"study_design_scores_gemma":[0.025364911,0.0038610022,0.8001111,0.005369522,0.00019553122,0.0000012040358,0.00012581627,0.000015752616,0.00023200297,0.00021877246,0.16430482,0.00019955472],"about_ca_topic_score_codex":0.010053714,"about_ca_topic_score_gemma":0.03131395,"teacher_disagreement_score":0.14578208,"about_ca_system_score_codex":0.00029314702,"about_ca_system_score_gemma":0.00066412747,"threshold_uncertainty_score":0.9965384},"labels":[],"label_agreement":null},{"id":"W4415939841","doi":"10.1016/j.annonc.2025.08.1740","title":"1102P Contribution of bevacizumab (bev) use to safety outcomes in FIRST/ENGOT-OV44","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Bevacizumab; Ovarian cancer; Chemotherapy; Stage (stratigraphy); Safety profile; MEDLINE","score_opus":0.07945393653273285,"score_gpt":0.43881939463913633,"score_spread":0.35936545810640347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337621,0.00031538933,0.000558008,0.059757236,0.00034541162,0.0006603269,0.00009336926,0.000025427255,0.004482753],"genre_scores_gemma":[0.9908544,0.00045621835,0.00042582353,0.007504983,0.00003278538,0.00005023994,0.000024870682,0.000008076472,0.0006426394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861914,0.00010692802,0.00066672155,0.00020400179,0.00015630873,0.0002468816],"domain_scores_gemma":[0.9984003,0.0006108784,0.00018089577,0.00030528492,0.00042751367,0.000075178934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046725431,0.000117962205,0.00074373046,0.00035108693,0.000026447191,0.0000023914108,0.00010057953,0.00019044675,0.000155417],"category_scores_gemma":[0.00082475215,0.00011063149,0.00012525229,0.00041523264,0.0001071991,0.00007017518,0.00004749312,0.00015496368,0.000014498749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01869828,0.003536478,0.7407133,0.000402024,0.0009103571,0.00011178225,0.001948186,0.00042546925,0.032152206,0.037973426,0.07153706,0.09159142],"study_design_scores_gemma":[0.010282408,0.0025164622,0.5608189,0.0003855249,0.000048842518,0.000009280128,0.000095370335,0.000027725233,0.066680305,0.0018338853,0.35717118,0.00013012593],"about_ca_topic_score_codex":0.0002845196,"about_ca_topic_score_gemma":0.0006058031,"teacher_disagreement_score":0.2856341,"about_ca_system_score_codex":0.0001997889,"about_ca_system_score_gemma":0.00031272287,"threshold_uncertainty_score":0.4511421},"labels":[],"label_agreement":null},{"id":"W4415940560","doi":"10.1016/j.annonc.2025.08.1739","title":"1101P FIRST/ENGOT-OV44 trial: Does the addition of dostarlimab (dost) impact niraparib (nira) tolerability, exposure, or dose modification?","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Bevacizumab; Ovarian cancer; Chemotherapy; Platelet; Cyclophosphamide","score_opus":0.15337787001863273,"score_gpt":0.48502219057507223,"score_spread":0.3316443205564395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.939986,0.0009570871,0.00017282733,0.047170922,0.00075883215,0.0020783145,0.0003889802,0.00007047352,0.008416589],"genre_scores_gemma":[0.99449897,0.0012402158,0.00022562504,0.0027300892,0.000246736,0.0003400516,0.000105954554,0.000019439898,0.00059292326],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756384,0.0003581364,0.0010561753,0.0003652348,0.00033333118,0.00032328736],"domain_scores_gemma":[0.99630374,0.0013935011,0.0005929492,0.00088647875,0.0007272756,0.00009604902],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011629686,0.00022363654,0.0008411528,0.00025178486,0.00011553938,0.000011550887,0.0002838104,0.00028030926,0.0014075444],"category_scores_gemma":[0.00069789554,0.00012777602,0.00034684272,0.0005950935,0.0005117295,0.00012817373,0.00006135824,0.000286364,0.000012786905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3491053,0.011221799,0.014370455,0.0011581818,0.0026630245,0.000042850614,0.005154892,0.00046580777,0.029131658,0.008471994,0.35109657,0.22711748],"study_design_scores_gemma":[0.15754756,0.039575055,0.16037944,0.0009847359,0.0006860094,0.000076574455,0.0015676949,0.000367154,0.17067182,0.025508372,0.44195876,0.00067681755],"about_ca_topic_score_codex":0.00027955,"about_ca_topic_score_gemma":0.00019770223,"teacher_disagreement_score":0.22644065,"about_ca_system_score_codex":0.00017900638,"about_ca_system_score_gemma":0.0010676752,"threshold_uncertainty_score":0.9995053},"labels":[],"label_agreement":null},{"id":"W4415940747","doi":"10.1016/j.annonc.2025.08.1727","title":"1089P Telling it as it is: Quality of life outcomes associated with maintenance olaparib and cediranib following a response to chemotherapy in relapsed platinum-sensitive ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; Stand Up To Cancer; Cancer Australia; Canadian Cancer Society","keywords":"Olaparib; Chemotherapy; Ovarian cancer; Quality of life (healthcare); Epithelial ovarian cancer; Chemotherapy regimen","score_opus":0.08929534852264863,"score_gpt":0.44509291900957476,"score_spread":0.3557975704869261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8727593,0.0001949639,0.00019139562,0.12304927,0.0001286409,0.00057879934,0.000048878275,0.000021467482,0.0030272983],"genre_scores_gemma":[0.9262816,0.00018527596,0.0005373364,0.071798295,0.000022644268,0.00006354937,0.000004578993,0.00002120716,0.0010855385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976384,0.00047214696,0.00086365826,0.00038444682,0.0002916793,0.00034963957],"domain_scores_gemma":[0.9968921,0.0018249057,0.00044950494,0.00027096405,0.00043707958,0.00012546947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022561282,0.00020938867,0.0011971341,0.00030687044,0.00004673191,0.000005753103,0.00009519844,0.00026059823,0.00007733186],"category_scores_gemma":[0.002126605,0.00018359034,0.0001338265,0.00062769,0.0001652778,0.000054916778,0.000029755336,0.0002847062,0.0000019567217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22973514,0.0022630785,0.4698674,0.000408388,0.005187236,0.0003143793,0.050644957,0.00042876313,0.19066934,0.0013034793,0.035342824,0.013835006],"study_design_scores_gemma":[0.05087068,0.007020635,0.83306116,0.0050548115,0.00016904203,0.00001061252,0.0063502956,0.00024013563,0.0775407,0.0012673497,0.01782776,0.0005868222],"about_ca_topic_score_codex":0.0010382544,"about_ca_topic_score_gemma":0.0009059162,"teacher_disagreement_score":0.36319375,"about_ca_system_score_codex":0.00023858385,"about_ca_system_score_gemma":0.0011299618,"threshold_uncertainty_score":0.7486597},"labels":[],"label_agreement":null},{"id":"W4415940758","doi":"10.1016/j.annonc.2025.08.1715","title":"1077P How long is long enough? An international GCIG collaboration investigating long term outcomes of exceptional responders with platinum sensitive recurrent ovarian cancer treated with PARP inhibitors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Syndax Pharmaceuticals","keywords":"Myeloid leukemia; Ovarian cancer; Disease; Myelodysplastic syndromes; Chemotherapy; Cancer","score_opus":0.08283893316557171,"score_gpt":0.4167267100380951,"score_spread":0.33388777687252336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96513,0.00010707734,0.00049840513,0.031940836,0.0002880262,0.00064031547,0.00017719062,0.000042676926,0.0011755077],"genre_scores_gemma":[0.9951834,0.00014414333,0.0010439442,0.002371565,0.00018996552,0.00009981397,0.00028536565,0.000027847142,0.0006539534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979521,0.00024316832,0.0005604351,0.00045056094,0.0005153571,0.0002784041],"domain_scores_gemma":[0.99704325,0.00025520645,0.0007209024,0.00027125847,0.0015728393,0.00013652256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037945123,0.00026894885,0.00066052366,0.00045622792,0.00009240546,0.000025163321,0.00011779562,0.00020890502,0.00014583801],"category_scores_gemma":[0.00012975546,0.00022017863,0.00007749932,0.00068729545,0.0005222621,0.00038813739,0.000034170745,0.00026623832,0.0000012025616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049714376,0.00048571374,0.9596353,0.00011987999,0.0011565072,0.00008969568,0.0032643576,0.00024418303,0.010232864,0.00034934387,0.0018709357,0.017579744],"study_design_scores_gemma":[0.005977131,0.003179927,0.8811811,0.0011535019,0.00016164439,0.000039833983,0.0011784678,0.00016269468,0.10614178,0.00006424337,0.00053445954,0.00022519105],"about_ca_topic_score_codex":0.00020155663,"about_ca_topic_score_gemma":0.0014308657,"teacher_disagreement_score":0.09590892,"about_ca_system_score_codex":0.00035004152,"about_ca_system_score_gemma":0.0014455628,"threshold_uncertainty_score":0.8978624},"labels":[],"label_agreement":null},{"id":"W4415942157","doi":"10.1016/j.annonc.2025.08.2890","title":"2274O Dissecting four decades of phase III randomised pharmacological interventions for primary cancer prevention to guide future developments: ESMO early detection and prevention task force","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Task force; Primary prevention; Psychological intervention; Cancer prevention; Phase (matter); Task (project management); MEDLINE","score_opus":0.10187781475284098,"score_gpt":0.49915074305878426,"score_spread":0.3972729283059433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9236939,0.0011694625,0.06911179,0.0022316016,0.00063286023,0.0023854685,0.00002702452,0.00003291915,0.00071501295],"genre_scores_gemma":[0.98902535,0.0009632977,0.005432932,0.0009460873,0.00023545428,0.001421412,0.000032954318,0.000014966182,0.0019275142],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831164,0.00019053515,0.0008550006,0.00029184687,0.000133939,0.00021703512],"domain_scores_gemma":[0.99848723,0.0002711536,0.00045355185,0.00010392281,0.0005976532,0.0000864922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010006671,0.00014666645,0.00058514444,0.0002939803,0.00010476738,0.0000068000995,0.000079567624,0.000186816,0.00007359511],"category_scores_gemma":[0.00026369016,0.00013796471,0.00028574603,0.00029727464,0.00007365312,0.00012484839,0.00004564165,0.00014071491,4.6800835e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030380443,0.00092103356,0.00086268544,0.0008077121,0.00093552086,0.0000026809714,0.00051452586,0.000018909122,0.39139578,0.00009174547,0.0029271678,0.5711418],"study_design_scores_gemma":[0.14772783,0.013988173,0.030526184,0.003473341,0.0013101657,0.000030195111,0.0007624762,0.00017472834,0.7619464,0.0035068812,0.0361915,0.00036211812],"about_ca_topic_score_codex":0.00003186822,"about_ca_topic_score_gemma":0.00009280506,"teacher_disagreement_score":0.5707797,"about_ca_system_score_codex":0.00018510451,"about_ca_system_score_gemma":0.00033836561,"threshold_uncertainty_score":0.5626038},"labels":[],"label_agreement":null},{"id":"W4415942701","doi":"10.1016/j.annonc.2025.08.1752","title":"1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Metastatic breast cancer; Endometrial cancer; Phases of clinical research; Clinical trial; Randomized controlled trial","score_opus":0.1684586252757167,"score_gpt":0.43680370448520456,"score_spread":0.26834507920948786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857443,0.003911107,0.0002009243,0.002776044,0.0005341191,0.005054414,0.00006472436,0.00007955075,0.0016347948],"genre_scores_gemma":[0.99408835,0.0013813035,0.00066311855,0.001611425,0.00014765952,0.0016898719,0.000026527541,0.000060542916,0.0003311802],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945441,0.0012161703,0.0015926376,0.00094660185,0.0007715624,0.0009289665],"domain_scores_gemma":[0.99622184,0.001420489,0.00080326415,0.00058164017,0.00060335046,0.0003693976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029381544,0.0006039913,0.003559028,0.0011545463,0.00022037844,0.00004146177,0.00027040183,0.00015896953,0.00040561048],"category_scores_gemma":[0.00067128043,0.000425936,0.00023495476,0.0015804714,0.0007617237,0.00021916452,0.00014660737,0.0006087374,0.0000030795056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9138292,0.016307585,0.004108572,0.0005243927,0.005288215,0.00037076275,0.013237812,0.0002708963,0.0030313146,0.000081482416,0.0012110617,0.041738674],"study_design_scores_gemma":[0.8955778,0.07832478,0.0016486411,0.0015732158,0.0019150901,0.00013238552,0.00895427,0.00079989317,0.0028543891,0.00009681595,0.0075184936,0.00060421746],"about_ca_topic_score_codex":0.0007869508,"about_ca_topic_score_gemma":0.0017849285,"teacher_disagreement_score":0.062017195,"about_ca_system_score_codex":0.0007985483,"about_ca_system_score_gemma":0.0014342476,"threshold_uncertainty_score":0.9998192},"labels":[],"label_agreement":null},{"id":"W4416084867","doi":"10.1093/neuonc/noaf201.0602","title":"DNAR-11. Differential DNA Damage and Repair burden in proliferating neural progenitor cells","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"DNA damage; DNA repair; Chromatin; Homologous recombination; RAD51; Neural stem cell; DNA; Progenitor cell","score_opus":0.018330492004844823,"score_gpt":0.3216161726590021,"score_spread":0.3032856806541573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416084867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874703,0.00011935573,0.000028530409,0.008104384,0.0011249186,0.0009908191,0.000008232756,0.00018058016,0.0019728553],"genre_scores_gemma":[0.994532,0.000043337153,0.00048655365,0.0036234187,0.00073522126,0.00022413088,0.000013053375,0.000028905219,0.00031337052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982707,0.00028364026,0.0004472653,0.00047953433,0.00016108878,0.00035777644],"domain_scores_gemma":[0.9991437,0.00027985199,0.00010425017,0.00028769622,0.00006708884,0.00011739792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016164286,0.0001992532,0.00046177043,0.00022067557,0.00008745467,0.000020765156,0.00009322965,0.00020735788,0.00011437607],"category_scores_gemma":[0.000120220626,0.00018861835,0.0000853492,0.0002457979,0.00015970488,0.000069545684,0.0001023607,0.00044980366,0.0000095817795],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056366005,0.00018133005,0.015640656,0.00013197173,0.000028084267,0.0003631651,0.00054390816,0.000010851917,0.97371936,0.00013651657,0.0039178315,0.0047626696],"study_design_scores_gemma":[0.021001806,0.0031980749,0.027913166,0.000283885,0.00023239819,0.00044811884,0.00057990226,0.014407146,0.6736019,0.00029890644,0.25749198,0.00054268533],"about_ca_topic_score_codex":0.000040733496,"about_ca_topic_score_gemma":0.00006706678,"teacher_disagreement_score":0.30011743,"about_ca_system_score_codex":0.0002125408,"about_ca_system_score_gemma":0.00027638744,"threshold_uncertainty_score":0.7691633},"labels":[],"label_agreement":null},{"id":"W4416141008","doi":"10.1093/neuonc/noaf201.0596","title":"DNAR-05. Discovery and development of a novel CNS-penetrating ATR inhibitor","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Variation Biotechnologies (Canada)","funders":"","keywords":"Drug discovery; Adept; In vivo; Kinase; Cancer therapy; Mechanism (biology); Cancer","score_opus":0.03693012742183182,"score_gpt":0.3397739218535768,"score_spread":0.302843794431745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364687,0.0003403968,0.003259522,0.003671982,0.00087333133,0.00044085408,0.000010692443,0.000049893013,0.0077064657],"genre_scores_gemma":[0.9804361,0.00006572461,0.013469196,0.0053650467,0.00020958207,0.000078021956,0.00001381807,0.00002091075,0.0003415875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99877733,0.00005311514,0.00048130905,0.00031287468,0.00015952089,0.00021587673],"domain_scores_gemma":[0.9991641,0.0003356426,0.0001550619,0.00019187083,0.00007871089,0.00007460088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019832153,0.00014479924,0.00038497202,0.00015860565,0.00007992703,0.000011215377,0.00006898068,0.0001390344,0.000036928526],"category_scores_gemma":[0.00013431096,0.00013555602,0.000044556506,0.00018972633,0.0001545881,0.00008452154,0.00008593607,0.00023920272,0.000004460056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003745636,0.0002822216,0.0052074757,0.00012620796,0.000053855423,0.000028519553,0.000677958,0.0000051607494,0.96238905,0.00045512477,0.0033102585,0.027089588],"study_design_scores_gemma":[0.010473749,0.0011735844,0.015006575,0.00035270012,0.000071874434,0.0002146602,0.00057257165,0.00011997871,0.6097637,0.00009454001,0.36193597,0.0002200965],"about_ca_topic_score_codex":0.000009998758,"about_ca_topic_score_gemma":0.000032741544,"teacher_disagreement_score":0.3586257,"about_ca_system_score_codex":0.00021697073,"about_ca_system_score_gemma":0.00095428363,"threshold_uncertainty_score":0.5527814},"labels":[],"label_agreement":null},{"id":"W4416141026","doi":"10.1093/neuonc/noaf201.0119","title":"BIOM-31. PLASMA CELL-FREE DNA METHYLOME PREDICTS RESPONSE TO COMBINED PARP AND IMMUNE CHECKPOINT INHIBITION IN IDH-MUTANT GLIOMA","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Olaparib; Immune checkpoint; DNA methylation; PARP inhibitor; Durvalumab; Glioma; Immune system; Biomarker; Epigenetics","score_opus":0.016935772640992556,"score_gpt":0.3065460026243378,"score_spread":0.28961022998334524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95071393,0.00028804716,0.00013921062,0.042609014,0.0009574514,0.0014938157,0.00006043974,0.00021024235,0.0035278685],"genre_scores_gemma":[0.9928464,0.0001542813,0.00065612147,0.0056271735,0.00011207385,0.00040249364,0.000028242908,0.000045928915,0.00012727913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967171,0.00070241524,0.00095813477,0.00071149686,0.0003155726,0.00059530506],"domain_scores_gemma":[0.99738044,0.0012443817,0.00021215178,0.00074075547,0.00014578222,0.00027652268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013625607,0.00032994043,0.00081417133,0.0010970915,0.00011303193,0.000025025818,0.00017103786,0.00040354402,0.0000770053],"category_scores_gemma":[0.0011689446,0.0003331625,0.00011061337,0.0012434211,0.00026080248,0.00010115456,0.00031812134,0.0005843862,0.0000554703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021939307,0.00053477,0.0002806891,0.00010457553,0.00003916663,0.0013495102,0.0008275747,0.0000139814365,0.96777076,0.00020551971,0.005306046,0.0016281164],"study_design_scores_gemma":[0.022422336,0.0045521962,0.005808679,0.0002270684,0.00006779093,0.00037112707,0.00023365012,0.00021356695,0.92135495,0.0010963506,0.043430947,0.00022131183],"about_ca_topic_score_codex":0.000055945056,"about_ca_topic_score_gemma":0.000051728675,"teacher_disagreement_score":0.04641577,"about_ca_system_score_codex":0.00093180814,"about_ca_system_score_gemma":0.00086022564,"threshold_uncertainty_score":0.999912},"labels":[],"label_agreement":null},{"id":"W4416141066","doi":"10.1093/neuonc/noaf201.0597","title":"DNAR-06. Discovery and development of novel CNS-penetrating PARP1-selective inhibitors","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"EMD Serono","keywords":"Drug discovery; PARP1; Poly ADP ribose polymerase; Drug development; Drug; Docking (animal); In vivo; Decoy","score_opus":0.03169128465356363,"score_gpt":0.33538403359929386,"score_spread":0.30369274894573023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799614,0.00035801475,0.002821075,0.0024430281,0.0006119929,0.0005644116,0.000010033474,0.00005707009,0.013172955],"genre_scores_gemma":[0.9896546,0.00007716186,0.0068675554,0.002929786,0.0001492595,0.00010024924,0.000015551921,0.00001998137,0.00018586322],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862653,0.00007639618,0.0005077319,0.00036480383,0.00017333582,0.000251221],"domain_scores_gemma":[0.998992,0.00044725114,0.00019085837,0.00017445516,0.00011752906,0.00007787547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022539035,0.00016788402,0.00042883086,0.00019576662,0.000101931706,0.000011271422,0.000069949274,0.00015876871,0.000018008725],"category_scores_gemma":[0.00018282286,0.00015884342,0.000047536403,0.00028881777,0.00018483704,0.00009934282,0.00007564779,0.0003079855,0.000004334929],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036336627,0.0003400354,0.012979959,0.00009479047,0.00008694525,0.000018137109,0.0012479754,0.0000078732055,0.9600408,0.00045282752,0.003487836,0.020879474],"study_design_scores_gemma":[0.0074791103,0.0010286235,0.025784474,0.00026037908,0.00007194121,0.00011917045,0.00068289455,0.00008720551,0.79157084,0.00016923428,0.17252746,0.00021863755],"about_ca_topic_score_codex":0.000016318088,"about_ca_topic_score_gemma":0.000044348428,"teacher_disagreement_score":0.16903964,"about_ca_system_score_codex":0.000330892,"about_ca_system_score_gemma":0.0011396272,"threshold_uncertainty_score":0.64774466},"labels":[],"label_agreement":null},{"id":"W4416202769","doi":"10.2196/72994","title":"Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"JMIR Medical Informatics","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ovarian cancer; Prospective cohort study; Adverse effect; Renal function; Cohort study; Risk factor; Creatinine","score_opus":0.01760685396451777,"score_gpt":0.3345136239345999,"score_spread":0.3169067699700821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416202769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98533225,0.00031680276,0.0039197206,0.001187614,0.00021767207,0.008049717,0.0001249991,0.00020108117,0.0006501291],"genre_scores_gemma":[0.9884695,0.00013816243,0.0026144248,0.0013808587,0.00013545404,0.0065787695,0.00008432368,0.00003799742,0.00056051835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966265,0.000067170484,0.0012921646,0.00036480668,0.0010270543,0.0006223017],"domain_scores_gemma":[0.9984466,0.00021448472,0.0003845792,0.00039926748,0.00017533547,0.00037974023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006068697,0.00042927254,0.0009496908,0.00032266852,0.00019766415,0.000018818928,0.00020021759,0.0003218415,0.00011257485],"category_scores_gemma":[0.00019171425,0.00031035996,0.000118056436,0.0007226448,0.00016662363,0.00036033295,0.00009159379,0.0005071019,0.0000054814464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011630455,0.0017861273,0.98211163,0.00028511797,0.0006065288,0.000033411212,0.010262947,0.00015348376,0.000011419914,0.00011460198,0.00018928619,0.0032823936],"study_design_scores_gemma":[0.06581281,0.003319317,0.7541817,0.005818218,0.0007510268,0.00012454159,0.0076923147,0.15870366,0.0020969156,0.0003500744,0.0003372368,0.0008122147],"about_ca_topic_score_codex":0.00016562463,"about_ca_topic_score_gemma":0.00022263048,"teacher_disagreement_score":0.22792996,"about_ca_system_score_codex":0.0010098423,"about_ca_system_score_gemma":0.0011908587,"threshold_uncertainty_score":0.99993485},"labels":[],"label_agreement":null},{"id":"W4416387684","doi":"10.1016/j.annonc.2025.09.054","title":"LBA42 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Institute of Cancer Research; Seoul St. Mary's Hospital, Catholic University of Korea; Instituto de Salud Carlos III; Amgen; lékařská fakulta Univerzity Karlovy; Yonsei University College of Medicine; Taipei Veterans General Hospital; Saitama Medical University; Catholic University of Korea; Yonsei University; Univerzita Karlova v Praze; Mersana Therapeutics; AstraZeneca; Merck; Daiichi-Sankyo","keywords":"Ovarian cancer; Phases of clinical research; Primary (astronomy); Cancer; Ovary","score_opus":0.04016149790392913,"score_gpt":0.37707460921462554,"score_spread":0.3369131113106964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845903,0.0004109039,0.0008370456,0.005027057,0.0002185791,0.00093991123,0.00028797705,0.000016916629,0.0076713264],"genre_scores_gemma":[0.9955983,0.00024384906,0.0014347085,0.0021250672,0.00003243049,0.00010524724,0.000117159965,0.000016761682,0.00032646063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978541,0.00023598524,0.0009688262,0.00031602447,0.00036847353,0.00025658766],"domain_scores_gemma":[0.9976643,0.00017121524,0.0008911827,0.0005056627,0.00070719275,0.000060451723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048733214,0.00018054587,0.000987739,0.0005932678,0.000063304935,0.0000028622198,0.00018653751,0.00017643133,0.0003339011],"category_scores_gemma":[0.00011481781,0.00013368082,0.0001630898,0.0018757791,0.00028466698,0.00007895256,0.00006677279,0.00019621252,2.455858e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08613835,0.02338477,0.4528469,0.0018179074,0.015565494,0.000039680635,0.0064138104,0.13064165,0.044051223,0.0043843356,0.017107375,0.2176085],"study_design_scores_gemma":[0.07475103,0.020577462,0.80565625,0.002703166,0.0051395604,0.0000038920125,0.00043023098,0.0068270825,0.05185408,0.00068104884,0.030765397,0.00061078515],"about_ca_topic_score_codex":0.00058658863,"about_ca_topic_score_gemma":0.00083128945,"teacher_disagreement_score":0.35280937,"about_ca_system_score_codex":0.00021646258,"about_ca_system_score_gemma":0.0010929331,"threshold_uncertainty_score":0.54513454},"labels":[],"label_agreement":null},{"id":"W4416387692","doi":"10.1016/j.annonc.2025.09.056","title":"LBA44 Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Defence and Security Accelerator; Humanitas University; Institute of Cancer Research; Yonsei University; University of Pittsburgh; Knight Cancer Institute, Oregon Health and Science University; Oregon Health and Science University; Università degli Studi di Milano; Debreceni Egyetem; AstraZeneca","keywords":"Bevacizumab; Durvalumab; Olaparib; Overall survival; Epithelial ovarian cancer; Survival analysis","score_opus":0.025898421506752027,"score_gpt":0.3407779570062561,"score_spread":0.3148795354995041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416387692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781634,0.001200955,0.00047017928,0.009795829,0.0012735389,0.0023451967,0.001477179,0.00014338038,0.005130294],"genre_scores_gemma":[0.98970443,0.0011444082,0.0016917061,0.00432974,0.00016488206,0.0006815106,0.00097518123,0.00011700705,0.0011911521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99370545,0.0006293315,0.0018518417,0.0014370593,0.0009929988,0.0013833125],"domain_scores_gemma":[0.995048,0.0012317002,0.0010557239,0.0011612059,0.0011152297,0.00038817103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007728552,0.0008564207,0.0024108165,0.00057169725,0.00019153324,0.000038876457,0.0005864957,0.00070251076,0.0006476375],"category_scores_gemma":[0.00066902477,0.0008185299,0.00035953752,0.0011990062,0.00047996303,0.0004066511,0.00016995025,0.001050366,0.000030516054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15022743,0.011544669,0.53326046,0.000768049,0.004422158,0.0011390614,0.004357556,0.0027409222,0.023022082,0.0015702866,0.10125029,0.16569705],"study_design_scores_gemma":[0.20003694,0.009599838,0.73287475,0.0029034787,0.0004252461,0.00000908071,0.0004646639,0.00082435226,0.012193134,0.0018630439,0.037426136,0.0013793261],"about_ca_topic_score_codex":0.0058289045,"about_ca_topic_score_gemma":0.0032870902,"teacher_disagreement_score":0.1996143,"about_ca_system_score_codex":0.0012632352,"about_ca_system_score_gemma":0.002312058,"threshold_uncertainty_score":0.99942654},"labels":[],"label_agreement":null},{"id":"W4416729538","doi":"10.1007/s10549-025-07861-w","title":"High PARP1 expression is associated with proliferative tumor biology in breast cancer","year":2025,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institutes of Health","keywords":"Breast cancer; PARP1; Biomarker; Gene expression; Human breast; Cancer; Gene","score_opus":0.04612059288081777,"score_gpt":0.4055971153934276,"score_spread":0.3594765225126098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416729538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690681,0.002220378,0.000009139959,0.025154421,0.00007453059,0.0013003427,0.0015553781,0.00004512419,0.0005725625],"genre_scores_gemma":[0.99179494,0.0022944964,0.000042378397,0.00068939733,0.00013573913,0.003364402,0.000060650542,0.000022770837,0.0015952064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980944,0.00019747364,0.0002314395,0.0005657072,0.0003215805,0.0005894234],"domain_scores_gemma":[0.9989766,0.00012144652,0.000063882406,0.000248992,0.00038496562,0.00020413543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019768714,0.00023992514,0.00045817913,0.0003307532,0.00018634628,0.00003425126,0.0000703256,0.000096626696,0.0007006899],"category_scores_gemma":[0.0000084913145,0.00015440819,0.00003977526,0.0006689814,0.0003315136,0.00008143404,0.00004498426,0.00027629655,0.0000057345933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014884499,0.0020450258,0.92577666,0.000091965034,0.00092415925,0.00025837042,0.0009203241,0.000013039476,0.012938053,0.0006223394,0.0049758204,0.036549754],"study_design_scores_gemma":[0.023603426,0.0015185733,0.91339034,0.0036279422,0.000082617196,0.00015439081,0.00031745774,0.00006292205,0.05382404,0.0011806075,0.0019466955,0.000290975],"about_ca_topic_score_codex":0.009243015,"about_ca_topic_score_gemma":0.0018441046,"teacher_disagreement_score":0.04088599,"about_ca_system_score_codex":0.0019685254,"about_ca_system_score_gemma":0.001200669,"threshold_uncertainty_score":0.9973545},"labels":[],"label_agreement":null},{"id":"W4416852973","doi":"10.1038/s44318-025-00656-1","title":"Ubiquitin pathway blockade reveals endogenous ADP-ribosylation marking PARP7 and AHR for degradation","year":2025,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Biotechnology and Biological Sciences Research Council; Cancer Research UK; Wellcome Trust","keywords":"Ubiquitin; Ubiquitin ligase; Aryl hydrocarbon receptor; Crosstalk; Protein degradation; Endogeny; Ubiquitin-conjugating enzyme; Signal transduction; Ubiquitin-Protein Ligases; F-box protein","score_opus":0.04920888236520157,"score_gpt":0.3159689192789767,"score_spread":0.26676003691377514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416852973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558109,0.0034557027,0.022047155,0.011763678,0.00062283373,0.0008064358,0.000021787258,0.000049938695,0.005421578],"genre_scores_gemma":[0.9939379,0.0005124455,0.001671435,0.0013468364,0.00080712454,0.000048985854,0.000015213395,0.000018414246,0.0016416261],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989712,0.00011575232,0.00035282763,0.00013885155,0.00020009441,0.00022124957],"domain_scores_gemma":[0.99912643,0.00027079356,0.00020395045,0.00016717415,0.00015883695,0.000072831215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010509788,0.00011662697,0.00019992785,0.000121621706,0.00042203625,0.000067752255,0.0000819407,0.00005585445,0.00008675116],"category_scores_gemma":[0.00014450753,0.00008311204,0.00008303192,0.00014691915,0.000053394575,0.00008850669,0.00001845358,0.00026570266,0.0000035690907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021195658,0.00017914585,0.01070533,0.00029750224,0.0005043027,0.00005163563,0.002582915,0.00011051066,0.73470116,0.007682389,0.01394401,0.22712152],"study_design_scores_gemma":[0.022377612,0.0014000874,0.035855822,0.0035027957,0.0010193719,0.008418882,0.0023819234,0.0033833117,0.59040076,0.14209801,0.1883579,0.0008035064],"about_ca_topic_score_codex":0.0000049462533,"about_ca_topic_score_gemma":0.000003629447,"teacher_disagreement_score":0.226318,"about_ca_system_score_codex":0.00014588381,"about_ca_system_score_gemma":0.00015737771,"threshold_uncertainty_score":0.33892107},"labels":[],"label_agreement":null},{"id":"W4417148749","doi":"10.1016/j.annonc.2025.11.020","title":"Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Bevacizumab; Durvalumab; Olaparib; Ovarian cancer; Prostate cancer; Cancer","score_opus":0.025408448384387324,"score_gpt":0.3711802441592098,"score_spread":0.3457717957748225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417148749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97974426,0.0025732988,0.00037027686,0.0110870125,0.00016688331,0.0018516955,0.00015225982,0.00007372044,0.003980626],"genre_scores_gemma":[0.9886373,0.0028759008,0.0024882338,0.0035695015,0.00004706671,0.00067185675,0.00005150798,0.00007065222,0.0015879568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686867,0.00022216744,0.0008342169,0.00091069005,0.00039471083,0.0007695226],"domain_scores_gemma":[0.99768424,0.000473613,0.0005003539,0.00053918455,0.00053020695,0.00027237798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005031846,0.0005187846,0.0016167646,0.00038876125,0.00013187173,0.000027049284,0.00017813723,0.0003466072,0.00010085059],"category_scores_gemma":[0.0002074405,0.00038868753,0.00007060354,0.0009181195,0.00072903343,0.00025631508,0.000076878954,0.0005337752,0.0000019325662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21622409,0.0033274044,0.45109716,0.001994087,0.003317726,0.002445299,0.009879314,0.00055249187,0.050303943,0.00091178966,0.028983023,0.23096366],"study_design_scores_gemma":[0.40741795,0.04658903,0.41044292,0.010382041,0.0013065797,0.0012614965,0.0061838077,0.0040768124,0.049793743,0.0011977605,0.05862909,0.0027187585],"about_ca_topic_score_codex":0.0023134847,"about_ca_topic_score_gemma":0.0073998114,"teacher_disagreement_score":0.22824492,"about_ca_system_score_codex":0.00036990838,"about_ca_system_score_gemma":0.001840591,"threshold_uncertainty_score":0.99985653},"labels":[],"label_agreement":null},{"id":"W4417199674","doi":"10.70829/ijrmcs.v03.i02.005","title":"Translating Histopathology-Based AI Models into Clinical Tools for Homologous Recombination Deficiency Detection","year":2025,"lang":"","type":"article","venue":"International journal of research in medical and clinical science.","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Ovarian cancer; Breast cancer; Homologous recombination; PARP inhibitor; Polymerase; Generalizability theory; Cancer; Poly ADP ribose polymerase","score_opus":0.20455969821697542,"score_gpt":0.5814969070314854,"score_spread":0.37693720881451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417199674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6068518,0.004323383,0.19555186,0.17327137,0.016395478,0.0011607637,0.000014559086,0.000021607018,0.0024091664],"genre_scores_gemma":[0.98707217,0.0051360237,0.0028177663,0.0034842317,0.0013468597,0.000040310653,0.000003631914,0.000012576017,0.00008642348],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.987875,0.0016852939,0.004161775,0.000855902,0.0046375617,0.0007844943],"domain_scores_gemma":[0.9797393,0.012894557,0.0007675123,0.00028376366,0.005400284,0.00091455696],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0806041,0.00022311267,0.00089018117,0.0020635128,0.0004386966,0.00027822753,0.0015662049,0.0007361607,0.00023023742],"category_scores_gemma":[0.04304729,0.00018466437,0.0005048123,0.0017708082,0.007491131,0.0009607476,0.00020840533,0.0039408323,0.000005550749],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004540807,0.0020995557,0.0106703155,0.00013267188,0.00006566102,0.00038341348,0.00018300298,0.00014364014,0.0004520638,0.003698302,0.0003096458,0.9773209],"study_design_scores_gemma":[0.04099949,0.013813641,0.058220226,0.00992637,0.00018486455,0.0005114235,0.0012962923,0.47029313,0.0011206773,0.39372066,0.009391262,0.0005219386],"about_ca_topic_score_codex":0.00008805136,"about_ca_topic_score_gemma":0.000093907285,"teacher_disagreement_score":0.976799,"about_ca_system_score_codex":0.0012387729,"about_ca_system_score_gemma":0.009745021,"threshold_uncertainty_score":0.9983571},"labels":[],"label_agreement":null},{"id":"W4417212566","doi":"10.1016/j.ygyno.2025.11.020","title":"Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health","keywords":"Food and drug administration; Gynecologic oncology; Clinical trial; Ovarian cancer; Clinical Practice; Drug; MEDLINE; Biomarker","score_opus":0.04627822145111066,"score_gpt":0.44785485950269105,"score_spread":0.4015766380515804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417212566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60978717,0.09689967,0.0003270864,0.27119622,0.003178865,0.009973641,0.00021361736,0.00013772403,0.008286022],"genre_scores_gemma":[0.8440734,0.071514785,0.020227473,0.05935039,0.00043627,0.0038600783,0.00013652875,0.00003848781,0.0003625862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99463254,0.0013636755,0.0022243839,0.00092962524,0.00020235228,0.0006474393],"domain_scores_gemma":[0.9899231,0.008009304,0.0011253702,0.00042393187,0.00033722993,0.00018101792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0051049115,0.00036871558,0.0019394285,0.00028244156,0.000100362304,0.000011775791,0.00022517562,0.00096863176,0.0002424203],"category_scores_gemma":[0.005218285,0.0003374915,0.00031459038,0.0008601522,0.000607468,0.00018989573,0.00014328198,0.00089582376,0.0000042039887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00773675,0.014808543,0.22940037,0.0066190693,0.0011858523,0.0003774368,0.0013194759,0.000020948728,0.0053058807,0.00550752,0.14679849,0.5809197],"study_design_scores_gemma":[0.03926078,0.024970625,0.095574565,0.0023709706,0.0011696949,0.00024733195,0.0025333536,0.00030167896,0.009128528,0.0043412247,0.819272,0.0008292632],"about_ca_topic_score_codex":0.0002369649,"about_ca_topic_score_gemma":0.0019125465,"teacher_disagreement_score":0.6724735,"about_ca_system_score_codex":0.0015004538,"about_ca_system_score_gemma":0.004445343,"threshold_uncertainty_score":0.99990773},"labels":[],"label_agreement":null},{"id":"W4417303129","doi":"10.1093/nar/gkaf1303","title":"PARP1 and PARylation facilitate transcription-coupled DNA repair by stabilizing the CSB–RNAPII complex","year":2025,"lang":"en","type":"article","venue":"Nucleic Acids Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université Laval","funders":"H2020 European Research Council; Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Canadian Institutes of Health Research; Université Laval","keywords":"DNA repair; Nucleotide excision repair; PARP1; DNA damage; Cockayne syndrome; Poly ADP ribose polymerase; Postreplication repair; Caenorhabditis elegans; Polymerase; DNA","score_opus":0.1179629883561099,"score_gpt":0.39170054849501934,"score_spread":0.27373756013890943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417303129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635892,0.0022776737,0.001026996,0.01756367,0.00012105625,0.0013247641,0.00006094682,0.0002291625,0.013806518],"genre_scores_gemma":[0.99350065,0.00071061985,0.00040286567,0.00081849337,0.0000813003,0.00018257176,0.000064810665,0.000025372981,0.004213306],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739885,0.0004078996,0.0003949493,0.0004688114,0.0008233325,0.0005061548],"domain_scores_gemma":[0.99836266,0.0004975113,0.000039053688,0.0005925678,0.00036428726,0.000143917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020358108,0.00016642868,0.00028051558,0.0002278299,0.0006078532,0.00007390836,0.00017840975,0.00012535704,0.00086170825],"category_scores_gemma":[0.00022988924,0.00012633711,0.00010979365,0.00076094497,0.00070141884,0.00015115479,0.00006394464,0.00065650867,0.00005823609],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011085267,0.00019353128,0.011726276,0.0003369778,0.0001994996,0.0000114521235,0.0032512776,0.000008396275,0.8666822,0.0023496726,0.10213505,0.011997168],"study_design_scores_gemma":[0.010307253,0.00112378,0.13736086,0.00065866276,0.000115419774,0.00004309897,0.007248799,0.031545013,0.032753393,0.009536217,0.7687771,0.0005304263],"about_ca_topic_score_codex":0.00019604551,"about_ca_topic_score_gemma":0.000030399317,"teacher_disagreement_score":0.83392876,"about_ca_system_score_codex":0.00028919592,"about_ca_system_score_gemma":0.00018515176,"threshold_uncertainty_score":0.94351006},"labels":[],"label_agreement":null},{"id":"W4417306596","doi":"10.1038/s41556-026-01961-5","title":"Nucleophagy removes cytotoxic trapped PARP1","year":2025,"lang":"en","type":"article","venue":"Nature Cell Biology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Ministry of Education - Singapore","keywords":"PARP1; Autophagy; DNA damage; Chromatin; Cytotoxicity; Homologous recombination; DNA repair; Programmed cell death","score_opus":0.007839766480626459,"score_gpt":0.3172593221444772,"score_spread":0.30941955566385076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417306596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75688344,0.016481569,0.00038615317,0.007631971,0.0021930817,0.00064428383,0.000037429378,0.0002908246,0.21545123],"genre_scores_gemma":[0.978084,0.0004889651,0.0008408081,0.0145973945,0.0002875617,0.000029574308,0.000063027626,0.000015665393,0.0055929767],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99898076,0.00007606528,0.00022663442,0.00036235465,0.000072874485,0.0002813371],"domain_scores_gemma":[0.9993078,0.00011778362,0.00006447214,0.00035828588,0.00007812491,0.00007349345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013052153,0.00016268063,0.00032140125,0.00017995754,0.00006186248,0.000006325842,0.00012871546,0.0007885837,0.0006023058],"category_scores_gemma":[0.000055298955,0.00013420249,0.00011984294,0.00033159813,0.00014553018,0.00002165447,0.000026665799,0.00075326156,0.0000758478],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047092664,0.00013226646,0.0026654436,0.00008126237,0.000074175674,0.000024352235,0.00005820228,7.959967e-7,0.9527975,0.0055176592,0.03136279,0.006814642],"study_design_scores_gemma":[0.0026630703,0.00020783396,0.0047666063,0.000059998656,0.00004033347,0.000016168264,0.000033008022,0.000021310743,0.50408536,0.0037598822,0.48421478,0.0001316474],"about_ca_topic_score_codex":0.0000052076734,"about_ca_topic_score_gemma":0.0000033065614,"teacher_disagreement_score":0.452852,"about_ca_system_score_codex":0.0000881594,"about_ca_system_score_gemma":0.00014385475,"threshold_uncertainty_score":0.65948266},"labels":[],"label_agreement":null},{"id":"W4417439405","doi":"10.1126/sciadv.adt7982","title":"SLFN14 functions as a P-TEFb inhibitor to modulate the transcription of HIV-1 and cellular genes","year":2025,"lang":"en","type":"article","venue":"Science Advances","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Key Research and Development Program of China","keywords":"Transcription factor; Transcription (linguistics); Gene; Function (biology); General transcription factor; Regulation of gene expression; Response element; Elongation factor","score_opus":0.0144985847987548,"score_gpt":0.3065721633940649,"score_spread":0.2920735785953101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417439405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97531134,0.005128441,0.00855546,0.007125533,0.0006444662,0.00037971957,0.0000110903675,0.00003398718,0.00280995],"genre_scores_gemma":[0.99564165,0.00018192537,0.000842677,0.0008933536,0.000074244344,0.00004479245,0.0000015415334,0.0000040748755,0.002315761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990844,0.000017341272,0.00017526942,0.00026538759,0.00029159183,0.00016600963],"domain_scores_gemma":[0.9994817,0.000033775912,0.000044184966,0.00023203129,0.00013844324,0.00006986655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003086393,0.000079768644,0.00012859431,0.00017959549,0.00024092334,0.00002196676,0.0001150207,0.00002135208,0.000038763694],"category_scores_gemma":[0.000050197472,0.000054767686,0.000035182326,0.0009905174,0.000656426,0.00028396136,0.000021602462,0.00006681672,0.000016675713],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000770021,0.000024722342,0.001033092,0.000029089972,0.000005785421,7.824252e-7,0.00037827616,0.0002801936,0.97154427,0.0008005316,0.0001890467,0.025637235],"study_design_scores_gemma":[0.00055093394,0.0002148486,0.003178767,0.00016439239,0.000028419112,0.000007556398,0.0009047596,0.00015045587,0.9321199,0.0022130867,0.060393028,0.00007385995],"about_ca_topic_score_codex":0.000015691447,"about_ca_topic_score_gemma":0.000009268849,"teacher_disagreement_score":0.060203984,"about_ca_system_score_codex":0.00004784755,"about_ca_system_score_gemma":0.0001718719,"threshold_uncertainty_score":0.24186291},"labels":[],"label_agreement":null},{"id":"W4417458323","doi":"10.1158/1078-0432.ccr-25-1818","title":"KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Olaparib; Chemotherapy; Breast cancer; Clinical endpoint; Immunotherapy","score_opus":0.18903189963681183,"score_gpt":0.5269343380585764,"score_spread":0.33790243842176454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417458323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92207295,0.01496405,0.00047373105,0.048633315,0.0036498434,0.0057383943,0.0019116944,0.00021621371,0.0023397906],"genre_scores_gemma":[0.9123474,0.055613622,0.00066021143,0.009192764,0.0025016046,0.0053402027,0.000127045,0.00019065333,0.014026533],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9879617,0.0017535742,0.0038775092,0.0024394726,0.0020711464,0.0018965817],"domain_scores_gemma":[0.98893416,0.005924986,0.00047147155,0.001738395,0.0018893866,0.0010416281],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0050902017,0.00081951113,0.0029288016,0.00079992984,0.00035335682,0.00019000094,0.0010433772,0.0008062124,0.018114911],"category_scores_gemma":[0.0019666601,0.00065588474,0.00078793115,0.0028470356,0.0017917359,0.00035973405,0.0004797196,0.005029121,0.0002483436],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.48688537,0.0053912825,0.12275611,0.0011875731,0.0028875633,0.00091893354,0.0017291455,0.0011845314,0.00007464894,0.00030645862,0.07388713,0.30279124],"study_design_scores_gemma":[0.26977447,0.0059861685,0.562625,0.01229666,0.00074965396,0.000067443296,0.0007488681,0.020498486,0.0010184136,0.0053768163,0.11887406,0.0019839704],"about_ca_topic_score_codex":0.013792678,"about_ca_topic_score_gemma":0.027891828,"teacher_disagreement_score":0.4398689,"about_ca_system_score_codex":0.004793116,"about_ca_system_score_gemma":0.010626177,"threshold_uncertainty_score":0.99958926},"labels":[],"label_agreement":null},{"id":"W48429485","doi":"10.1096/fasebj.24.1_supplement.485.9","title":"Proanthocyanidins (Vaccinium macrocarpon) induce apoptosis in DU145 human prostate cancer cells","year":2010,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Prince Edward Island","funders":"Cranberry Institute","keywords":"DU145; Apoptosis; Cytochrome c; Chemistry; FADD; Cell biology; Proanthocyanidin; Cancer cell; Molecular biology; Programmed cell death; Biochemistry; Biology; Cancer; Caspase; Polyphenol","score_opus":0.023563108687548323,"score_gpt":0.31621311037731825,"score_spread":0.29265000168976996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W48429485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047923,0.00019792603,0.00001187022,0.005110661,0.0012513347,0.0005338301,0.000024364857,0.00004170673,0.0023490654],"genre_scores_gemma":[0.99531406,0.00042503548,0.0002222423,0.0013404761,0.0012287879,0.00008394198,0.000004470251,0.00004908811,0.0013318957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827594,0.00011531586,0.0004771934,0.00023049538,0.00042246646,0.00047856668],"domain_scores_gemma":[0.99894387,0.00005094474,0.00026297476,0.00037286372,0.00014586274,0.00022347804],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008226986,0.00021577229,0.00030771285,0.00019290166,0.0003257812,0.00008378855,0.00027276028,0.0001261213,0.0014398727],"category_scores_gemma":[0.000024569219,0.00014496734,0.00012610835,0.00033566597,0.0001260144,0.00016594451,0.00004363321,0.0018823949,0.00007072254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002676413,0.00012664127,0.011200406,0.000021169208,0.000052099647,0.000038809903,0.0014820747,0.00001821311,0.9810221,0.00009377762,0.0034660243,0.0022110282],"study_design_scores_gemma":[0.0031944064,0.00016987903,0.010066373,0.00018994996,0.000054391607,0.0004255573,0.0003320737,0.000023411108,0.9805378,0.00046026873,0.0043611713,0.00018477527],"about_ca_topic_score_codex":0.00015235711,"about_ca_topic_score_gemma":0.00022024225,"teacher_disagreement_score":0.004834821,"about_ca_system_score_codex":0.00021775025,"about_ca_system_score_gemma":0.00036959333,"threshold_uncertainty_score":0.999473},"labels":[],"label_agreement":null},{"id":"W58280549","doi":"10.1023/a:1021645327079","title":"Single amino acid substitution enhances bacterial expression of PARP-1D214A","year":2003,"lang":"en","type":"article","venue":"Molecular and Cellular Biochemistry","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Substitution (logic); Amino acid substitution; Chemistry; Clinical chemistry; Biochemistry; Poly ADP ribose polymerase; Mutation; DNA; Philosophy; Gene","score_opus":0.009690877581571597,"score_gpt":0.23546947593259726,"score_spread":0.22577859835102565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W58280549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763716,0.002844819,0.005446909,0.00004202143,0.000114262155,0.00010735595,0.00000901479,0.000023000915,0.0037754653],"genre_scores_gemma":[0.9986006,0.000026423157,0.0009886824,0.00007729634,0.00006786299,0.000013447932,0.0000885343,0.000013941474,0.00012323211],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991295,0.00003645944,0.00021069535,0.00025416538,0.000192818,0.00017637224],"domain_scores_gemma":[0.99947447,0.0000076248753,0.0000920952,0.00025246953,0.000058635316,0.00011470777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096023,0.00013721631,0.00019546264,0.000026735983,0.000041035735,0.000011753258,0.000043653206,0.00014021111,0.00020370232],"category_scores_gemma":[0.000042487856,0.00013042557,0.000078862424,0.000082288956,0.0001496447,0.000026666634,0.000014713253,0.00008671245,0.0000031144345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010544398,0.00012148182,0.00023407578,0.00014643194,0.000017629362,0.000028965675,0.00002415218,3.4742354e-7,0.9989393,0.000129147,0.00006063958,0.00019243872],"study_design_scores_gemma":[0.0011367641,0.00009147725,0.000021017015,0.00015873197,0.000038199054,0.000042156462,0.00004906951,0.0000012369379,0.9963332,0.000115513154,0.001884622,0.00012804073],"about_ca_topic_score_codex":0.0000018504196,"about_ca_topic_score_gemma":5.9163973e-8,"teacher_disagreement_score":0.010963428,"about_ca_system_score_codex":0.00003888201,"about_ca_system_score_gemma":0.00006326923,"threshold_uncertainty_score":0.53186},"labels":[],"label_agreement":null},{"id":"W6893614791","doi":"10.5281/zenodo.2617678","title":"Dysregulation of poly ADP ribose signaling in HD and its potential as a therapeutic target","year":2019,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Huntingtin; DNA damage; DNA repair; DNA; Poly ADP ribose polymerase; Oxidative phosphorylation; Programmed cell death; Mitochondrion; Polymerase","score_opus":0.026797842409619858,"score_gpt":0.2725597315823472,"score_spread":0.24576188917272734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6893614791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97776556,0.00093141,0.0008489912,0.0011470712,0.000094542615,0.0007575784,0.000055580167,0.00019394245,0.01820532],"genre_scores_gemma":[0.99821806,0.00007099657,0.00015445572,0.00020350436,0.00009659012,4.757855e-8,0.0002663498,0.00042009182,0.0005698889],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877423,0.00017382036,0.00025745988,0.0002622187,0.00032960798,0.0002026614],"domain_scores_gemma":[0.99927807,0.000017118848,0.00010534217,0.00020994723,0.00029738844,0.00009211839],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00043302195,0.00009925541,0.00017902012,0.0002596392,0.00020235128,0.00007447583,0.0001611667,0.00006189072,0.011214056],"category_scores_gemma":[0.000093839306,0.00010320843,0.00003531091,0.00036518875,0.000063823034,0.00016680696,0.00014786716,0.00017134729,0.0011958624],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011106797,0.0002635683,0.00022450635,0.00026284708,0.00009094428,0.000021574524,0.0020888764,0.00031379284,0.9493538,0.0045815366,0.0020779793,0.039609864],"study_design_scores_gemma":[0.018522035,0.003986803,0.044752587,0.0010360595,0.00012493662,0.0009941298,0.00185856,0.016599545,0.26743853,0.004722448,0.6390501,0.00091422396],"about_ca_topic_score_codex":0.000011150591,"about_ca_topic_score_gemma":6.5665404e-8,"teacher_disagreement_score":0.6819153,"about_ca_system_score_codex":0.000100487705,"about_ca_system_score_gemma":0.000008677078,"threshold_uncertainty_score":0.9995818},"labels":[],"label_agreement":null},{"id":"W6902302403","doi":"10.6084/m9.figshare.25749987","title":"Additional file 1 of Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cohort; Chemotherapy; Stage (stratigraphy); Protocol (science); Cohort study; Neoadjuvant therapy","score_opus":0.0645270655847369,"score_gpt":0.3827441260852461,"score_spread":0.3182170605005092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902302403","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024671705,0.0000114234,0.0000011453179,0.000059019836,0.00014854631,0.36168364,0.6128656,0.000030049596,0.0005288635],"genre_scores_gemma":[0.050618783,6.938559e-7,0.00015468625,0.00005891536,0.00008122275,0.7699579,0.17856927,0.00004055379,0.0005179642],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974135,0.0002592755,0.001023901,0.00047174474,0.00056417345,0.0002673856],"domain_scores_gemma":[0.9951227,0.0032677199,0.0007655048,0.0003648843,0.00039963055,0.00007961062],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024299868,0.0003289985,0.0016089076,0.00016243212,0.00009653303,0.00006658396,0.00025018246,0.00009034203,0.58157825],"category_scores_gemma":[0.00083451223,0.00020075259,0.00022353935,0.0003157181,0.000052670257,0.00012452989,0.00005735203,0.00017464344,0.0000118899225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7951987,0.009657876,0.0000797335,0.00013149671,0.0010348369,0.0000124689195,0.0005632335,0.00011899673,0.0000065090953,0.0000052301552,0.19189326,0.001297684],"study_design_scores_gemma":[0.9544915,0.008404855,0.00050332956,0.0046385904,0.00016977178,6.990899e-7,0.000105132895,0.0030612578,0.00022057821,0.0000038221806,0.028213773,0.00018669247],"about_ca_topic_score_codex":0.00025533163,"about_ca_topic_score_gemma":0.0001578453,"teacher_disagreement_score":0.5815664,"about_ca_system_score_codex":0.00052711007,"about_ca_system_score_gemma":0.00080801186,"threshold_uncertainty_score":0.81864536},"labels":[],"label_agreement":null},{"id":"W6920674978","doi":"10.6084/m9.figshare.25750165","title":"Additional file 2 of Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cohort; Chemotherapy; Stage (stratigraphy); Protocol (science); Cohort study; Neoadjuvant therapy","score_opus":0.06290433605263106,"score_gpt":0.38223167923978724,"score_spread":0.31932734318715617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920674978","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02462753,0.000011607855,0.0000011295955,0.000058979007,0.00014974565,0.36264357,0.61193705,0.000030146884,0.000540251],"genre_scores_gemma":[0.050082985,7.0950585e-7,0.00015222582,0.00005901299,0.00008230955,0.7697199,0.17934212,0.000040574087,0.00052015873],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974137,0.00025920587,0.001024266,0.00047146424,0.00056406175,0.00026730754],"domain_scores_gemma":[0.99515986,0.0032309943,0.00076633174,0.0003643167,0.00039891253,0.00007959893],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024194439,0.0003289154,0.00160922,0.00016234764,0.00009653865,0.00006669874,0.00025007187,0.000090342444,0.57789636],"category_scores_gemma":[0.0008265068,0.00020070047,0.000223505,0.00031552312,0.00005266968,0.00012459767,0.000057345624,0.0001746115,0.000011789036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7967454,0.00967524,0.000077877725,0.00013271405,0.0010369667,0.000012765381,0.0005647665,0.00011969571,0.0000063423754,0.000005314014,0.19029379,0.001329095],"study_design_scores_gemma":[0.9537121,0.008409158,0.0004970777,0.004595049,0.00016934947,7.005959e-7,0.00010432036,0.00304622,0.00021957357,0.00000384784,0.029056162,0.00018645404],"about_ca_topic_score_codex":0.00025737315,"about_ca_topic_score_gemma":0.00015858689,"teacher_disagreement_score":0.57788455,"about_ca_system_score_codex":0.00052723,"about_ca_system_score_gemma":0.00080515613,"threshold_uncertainty_score":0.81843275},"labels":[],"label_agreement":null},{"id":"W6920774052","doi":"10.6084/m9.figshare.13265982.v1","title":"Additional file 2 of Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Primer (cosmetics); Serous ovarian cancer; Polymerase chain reaction; Polymerase; Ovarian cancer; Identification (biology); Real-time polymerase chain reaction; Olaparib","score_opus":0.034506491077435766,"score_gpt":0.27014322887075837,"score_spread":0.23563673779332261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920774052","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036632374,0.0002166364,0.000076057,0.0003508635,0.00006661562,0.00097478,0.9616517,0.000020542082,0.000010436293],"genre_scores_gemma":[0.39346546,0.0000037532052,0.0032485833,0.0002512974,0.00015063661,0.0022043765,0.60058457,0.00003279429,0.000058550697],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982047,0.0001027447,0.00074322894,0.0003074671,0.0004920142,0.00014984213],"domain_scores_gemma":[0.99737185,0.000850305,0.0006988643,0.00016072392,0.0007696892,0.00014858636],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000104543,0.00016900142,0.00036602857,0.00018644013,0.0000517325,0.000004276222,0.000081516046,0.000111826754,0.41386357],"category_scores_gemma":[0.0015231599,0.00016801106,0.000087225846,0.00040983144,0.00004338207,0.000094335504,0.000037251204,0.000073027986,0.000008657849],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011888346,0.00034032698,0.00018405126,0.00033448392,0.00038001273,6.1710006e-7,0.0010617628,0.000011667439,0.05803105,8.7790056e-7,0.92306554,0.00470129],"study_design_scores_gemma":[0.0058383774,0.0011884037,0.23950183,0.0030143894,0.000040828447,0.0000013982897,0.00014249011,0.00017973811,0.6726872,0.000012007371,0.077173516,0.00021982109],"about_ca_topic_score_codex":0.00002255937,"about_ca_topic_score_gemma":0.000004158589,"teacher_disagreement_score":0.845892,"about_ca_system_score_codex":0.00011733922,"about_ca_system_score_gemma":0.00078171905,"threshold_uncertainty_score":0.6851292},"labels":[],"label_agreement":null},{"id":"W6929316390","doi":"10.48524400/foo.bar","title":"[Pdf] Download Untethered Sky By Fonda Lee PDF Download","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Download; Popularity; Sky; Plot (graphics); Performance art; Canadian literature; Enhanced Data Rates for GSM Evolution; Closed captioning","score_opus":0.025479864017420504,"score_gpt":0.2758753231825708,"score_spread":0.25039545916515027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929316390","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008087803,0.003635186,0.0004874572,0.0021565915,0.00054973667,0.0011895605,0.0030495292,0.0026596987,0.98619133],"genre_scores_gemma":[0.0013439641,0.0022552568,0.0001537435,0.0011291761,0.0008991911,5.8576535e-7,0.012188424,0.00979184,0.9722378],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658555,0.00032181415,0.00049790705,0.0010408966,0.0008868504,0.00066697545],"domain_scores_gemma":[0.9978282,0.00002307273,0.0002566665,0.0010912535,0.00037475314,0.00042607743],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005103801,0.00050246634,0.00056341774,0.0007008959,0.0008193895,0.00050803606,0.00088717265,0.00041047437,0.56176907],"category_scores_gemma":[0.00022822732,0.00050075504,0.00021207028,0.0008562999,0.00038148824,0.00010507383,0.0008702829,0.0010155742,0.5161883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015784534,0.0001745816,7.4970404e-7,0.0004328388,0.00035286104,0.000086635875,0.0004146448,8.119167e-7,0.006066422,0.00024386123,0.9739667,0.01810202],"study_design_scores_gemma":[0.0018400896,0.00041016238,0.000004629072,0.0006737572,0.00010215573,0.0002857684,0.0001351884,0.0000110941555,0.0010356937,0.00012075828,0.99491376,0.00046692233],"about_ca_topic_score_codex":0.00007267805,"about_ca_topic_score_gemma":0.0000011626446,"teacher_disagreement_score":0.045580745,"about_ca_system_score_codex":0.00050472067,"about_ca_system_score_gemma":0.000023774068,"threshold_uncertainty_score":0.9997444},"labels":[],"label_agreement":null},{"id":"W6930255895","doi":"10.5281/zenodo.11591996","title":"Lucien Gélas (g2297)","year":2024,"lang":"de","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Guitar; Documentation; Period (music); Table (database)","score_opus":0.04454624002397951,"score_gpt":0.3008752051417194,"score_spread":0.2563289651177399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930255895","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001775084,0.0072721457,0.0003849286,0.0037757587,0.0026744301,0.0018388875,0.91639555,0.001988554,0.06549221],"genre_scores_gemma":[0.0012247331,0.0066906293,0.00009206394,0.0013238761,0.003839198,2.628295e-7,0.9753339,0.00600476,0.00549057],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99383396,0.0008076514,0.00096927007,0.001646068,0.001574572,0.001168503],"domain_scores_gemma":[0.99549377,0.00008477916,0.000367572,0.0020700453,0.0011967457,0.0007870808],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017082961,0.0007082419,0.0007500995,0.0010774872,0.0028899591,0.0021840974,0.0023375612,0.00052940013,0.24239784],"category_scores_gemma":[0.0010906425,0.00074906653,0.0003144328,0.0017735853,0.00074739853,0.0002609699,0.0027386446,0.0022049043,0.81253946],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032889246,0.0003755482,4.0396463e-7,0.0011592787,0.0006213443,0.0003807792,0.0006730062,0.000012703895,0.0008710079,0.00064719084,0.97194946,0.022980362],"study_design_scores_gemma":[0.0017174706,0.0009825662,0.000018446244,0.0012107084,0.0005052286,0.00046333176,0.0002641834,0.000113354516,0.0003071631,0.00026379255,0.99347144,0.0006823359],"about_ca_topic_score_codex":0.000030085734,"about_ca_topic_score_gemma":6.0589224e-7,"teacher_disagreement_score":0.5701416,"about_ca_system_score_codex":0.0012893856,"about_ca_system_score_gemma":0.000051063904,"threshold_uncertainty_score":0.99949604},"labels":[],"label_agreement":null},{"id":"W6930843769","doi":"10.5281/zenodo.12133623","title":"Lbs tarife 2022 pdf","year":2024,"lang":"de","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nucleofection; Netting; Population; Work (physics)","score_opus":0.034514248051976594,"score_gpt":0.2818204171777415,"score_spread":0.2473061691257649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930843769","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007078442,0.013624619,0.0011440688,0.0032292842,0.0021803705,0.0014432963,0.0014385212,0.0017112297,0.9751578],"genre_scores_gemma":[0.0026108462,0.0066645523,0.00018779268,0.0014640047,0.005384513,3.1593444e-7,0.009609746,0.022722276,0.95135593],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949252,0.0006890151,0.00074033526,0.0014168194,0.0012696167,0.0009589902],"domain_scores_gemma":[0.99683905,0.000039985673,0.00034364878,0.0014318791,0.00071722316,0.0006281993],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012010363,0.00062476203,0.0006711678,0.0010608158,0.0014344422,0.0012578005,0.0014597471,0.00050819735,0.8222722],"category_scores_gemma":[0.00060608966,0.0006732035,0.00028584944,0.0013884468,0.00057824695,0.00015526642,0.0015108709,0.001769673,0.8589625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022850728,0.00024899162,8.3939443e-7,0.0008372813,0.0007625527,0.000246065,0.0010080086,0.0000054627935,0.002041148,0.0032862874,0.9565933,0.034741607],"study_design_scores_gemma":[0.0016882643,0.00067346654,0.000020095904,0.0012807742,0.00032969416,0.00023665879,0.00030465834,0.000120348785,0.0003860796,0.00040765692,0.9939411,0.0006111524],"about_ca_topic_score_codex":0.00003358027,"about_ca_topic_score_gemma":6.085614e-7,"teacher_disagreement_score":0.0373479,"about_ca_system_score_codex":0.0009979678,"about_ca_system_score_gemma":0.000033976456,"threshold_uncertainty_score":0.99986553},"labels":[],"label_agreement":null},{"id":"W6931208431","doi":"10.5281/zenodo.4110403","title":"The Lethbridge Journal Incubator: A collaborative student-expert Open Access publishing model","year":2020,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Lethbridge","funders":"","keywords":"Publishing; Electronic publishing; Scholarly communication; Open research; Access to information","score_opus":0.1661730221976419,"score_gpt":0.402565475947282,"score_spread":0.23639245374964007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931208431","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04325785,0.0020238503,0.03266811,0.31323045,0.0006389526,0.004595194,0.0006953598,0.0016242939,0.6012659],"genre_scores_gemma":[0.97073543,0.0022490663,0.0010223602,0.0197033,0.0015819286,7.3491327e-7,0.000693085,0.0023603702,0.0016537277],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976984,0.00044272828,0.00036884905,0.00037149497,0.00075175,0.00036676522],"domain_scores_gemma":[0.9972679,0.000047993657,0.00021906963,0.00038918853,0.0016192547,0.00045660834],"candidate_categories":["sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012100203,0.00015365025,0.00021497824,0.00010732439,0.0038380781,0.015041973,0.0032097544,0.00006274129,0.0038260855],"category_scores_gemma":[0.0014514298,0.00012269488,0.000057302925,0.0009694942,0.00019703858,0.0024142247,0.0034553162,0.00069433457,0.00090766005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005915598,0.00011363715,0.000012686602,0.000017760052,0.00013098285,0.00003139019,0.006465694,0.0002168229,0.004187919,0.0029412806,0.95155007,0.03374021],"study_design_scores_gemma":[0.0022733426,0.0003291897,0.00019984544,0.000051223295,0.000015766682,0.00014670166,0.0017971606,0.0026079658,0.00096439983,0.00023629086,0.99123526,0.00014282884],"about_ca_topic_score_codex":0.0000089396635,"about_ca_topic_score_gemma":3.5737636e-7,"teacher_disagreement_score":0.9274776,"about_ca_system_score_codex":0.00037473952,"about_ca_system_score_gemma":0.000062255785,"threshold_uncertainty_score":0.99987024},"labels":[],"label_agreement":null},{"id":"W6931299092","doi":"10.5281/zenodo.7621486","title":"Eugenia cerrocacaoensis Barrie, Novon","year":2023,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mesoamerica; National park; Threatened species; Endangered species; Habitat; Occupancy; Altitude (triangle); Biome","score_opus":0.05984598860756893,"score_gpt":0.29831351085755897,"score_spread":0.23846752224999004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931299092","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35223472,0.00027510963,0.0030597113,0.01690273,0.0006811271,0.0017300815,0.0006562633,0.009612343,0.6148479],"genre_scores_gemma":[0.9862408,0.00033034533,0.00029599053,0.0013633091,0.0005300355,1.3532708e-7,0.0026675407,0.002277567,0.0062942673],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998274,0.00015700608,0.00025157965,0.00040819982,0.00048939703,0.00041976312],"domain_scores_gemma":[0.99860483,0.000024537756,0.000072056675,0.0005107398,0.0005152632,0.00027259075],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00054011145,0.00014401876,0.00018679774,0.00037942128,0.0012973088,0.00021849283,0.00037570376,0.00008021775,0.024623094],"category_scores_gemma":[0.0004259422,0.00015128961,0.00008104672,0.0013025064,0.00015492806,0.00014359743,0.00041526245,0.00028512115,0.041347142],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025935855,0.00009147315,0.000020386113,0.0000944554,0.00008545049,0.00008580017,0.0010019919,0.0000414761,0.058182653,0.0019340349,0.8824705,0.055732448],"study_design_scores_gemma":[0.0012560989,0.000263645,0.0022408878,0.000055000335,0.00002174194,0.00022739306,0.00022989926,0.00030389303,0.005209045,0.00020620898,0.98983216,0.00015400678],"about_ca_topic_score_codex":0.0000066295333,"about_ca_topic_score_gemma":1.4843978e-7,"teacher_disagreement_score":0.6340061,"about_ca_system_score_codex":0.0002091725,"about_ca_system_score_gemma":0.0000079685,"threshold_uncertainty_score":0.9977982},"labels":[],"label_agreement":null},{"id":"W6931713713","doi":"10.5683/sp3/zfdb45","title":"UNI-CEN Boundaries (CBF-Original Shorelines) - Census Subdivision (CSD) - 2001 - geojson format (WGS84 / EPSG:4326)","year":2023,"lang":"en","type":"dataset","venue":"Borealis","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Shapefile; North American Datum of 1927; File format; Census; Documentation; Boundary (topology); Data file; Geocoding","score_opus":0.05015864948492912,"score_gpt":0.35213584594335934,"score_spread":0.30197719645843024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931713713","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017013047,0.0012187023,0.00005543632,0.0025578493,0.0022653008,0.0010493022,0.99111724,0.00054955,0.001016508],"genre_scores_gemma":[0.0000144107225,0.008143094,0.0002668482,0.0020829502,0.003143929,0.00022336311,0.98475856,0.00019873858,0.0011681217],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947439,0.00015652845,0.0011964499,0.0010140522,0.0016020461,0.0012870439],"domain_scores_gemma":[0.9960817,0.00022030452,0.00057285605,0.0020163888,0.00048442435,0.0006243372],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078996515,0.0009695257,0.001377686,0.0007153666,0.00058670837,0.00037675144,0.00066727883,0.001005551,0.0007187368],"category_scores_gemma":[0.00030939217,0.00087274594,0.00044190141,0.00075600034,0.00066938496,0.00027691064,0.0002384761,0.0012791125,0.0012033859],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092413876,0.00020069531,0.00006208763,0.00060856796,0.00025389958,0.00064718694,0.00007652249,0.000004396908,0.000016218883,0.00016494063,0.9958716,0.0011697585],"study_design_scores_gemma":[0.0030802314,0.00048544144,0.0005047262,0.0011020789,0.00047686536,0.0003098131,0.000093243776,0.00007671949,0.00011881143,0.0004562594,0.99246454,0.00083123986],"about_ca_topic_score_codex":0.069229096,"about_ca_topic_score_gemma":0.012957783,"teacher_disagreement_score":0.056271315,"about_ca_system_score_codex":0.0008654596,"about_ca_system_score_gemma":0.0012671741,"threshold_uncertainty_score":0.9995743},"labels":[],"label_agreement":null},{"id":"W6931738350","doi":"10.5281/zenodo.6145526","title":"FIGURES 10–15 in The Californian clade of Cybaeus (Araneae: Cybaeidae) in the Nearctic: the septatus species group and three unplaced species","year":2022,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ImmunoPrecise (Canada)","funders":"","keywords":"Clade; Genus; Taxonomy (biology); Species complex; Group (periodic table)","score_opus":0.04477032109603521,"score_gpt":0.2667539024869264,"score_spread":0.22198358139089117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931738350","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003805278,0.0021181577,0.00005036803,0.008752623,0.00010344551,0.00202989,0.0008478864,0.00020541376,0.98208696],"genre_scores_gemma":[0.35041448,0.01150912,0.00034230048,0.008319449,0.0028752973,0.000008116603,0.008617975,0.013984427,0.6039288],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967212,0.0011160738,0.00040157064,0.00042495097,0.0009326694,0.00040352394],"domain_scores_gemma":[0.9985094,0.00019463465,0.00023842153,0.00089057814,0.000099785124,0.00006719935],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013479867,0.00026616774,0.0003529596,0.00039453054,0.0007363351,0.00029794112,0.0012482937,0.00012444775,0.10073876],"category_scores_gemma":[0.00041309133,0.00016354157,0.00009358505,0.0010086165,0.0007472647,0.00006072461,0.0005068559,0.0009620055,0.0006189377],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032379717,0.00018536476,0.00009378517,0.00021601994,0.000083384104,0.00006608767,0.0054836585,0.0000130333165,0.0006170151,0.0028978032,0.9860974,0.003922646],"study_design_scores_gemma":[0.0013955205,0.00029055699,0.007815888,0.0001566894,0.000038586266,0.00017800966,0.004220557,0.000030721778,0.000026848134,0.0001778987,0.98550564,0.00016310526],"about_ca_topic_score_codex":0.00017723559,"about_ca_topic_score_gemma":0.00008915908,"teacher_disagreement_score":0.37815812,"about_ca_system_score_codex":0.00020261646,"about_ca_system_score_gemma":0.000015831429,"threshold_uncertainty_score":0.9000833},"labels":[],"label_agreement":null},{"id":"W6931924914","doi":"10.5284/1002658","title":"SUY 076 Archaeological Monitoring Report: Land to the Rear of the Former Spread Eagle PH, Cross Street, Sudbury","year":2006,"lang":"en","type":"article","venue":"Archaeology Data Service","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Eagle; Sinkhole; Excavation; Prehistory; Dingo","score_opus":0.05065235236571713,"score_gpt":0.3461601654965945,"score_spread":0.2955078131308774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931924914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96752006,0.00047662016,0.00042959844,0.029198831,0.00058535713,0.00063536223,0.00043073468,0.000061835985,0.0006616082],"genre_scores_gemma":[0.99224585,0.00008739214,0.0018224511,0.0035420118,0.00097219116,0.00006886005,0.0004724533,0.000031092517,0.0007577057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766314,0.00018044977,0.00060804223,0.0006095756,0.00043175914,0.0005070122],"domain_scores_gemma":[0.99617183,0.00038901053,0.00025964103,0.0028246772,0.00024559372,0.00010926892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008243048,0.00022175835,0.00038614537,0.00006927889,0.00018784906,0.000007182302,0.001272136,0.00017492176,0.00013820834],"category_scores_gemma":[0.0002028032,0.00013077894,0.000080127764,0.00046250972,0.0008307667,0.0001481909,0.0018966147,0.00046302887,0.000051362877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004061067,0.00010292098,0.9902463,0.000074189986,0.0000835233,0.000156582,0.0011328801,0.00019409611,0.0034086707,0.00033370423,0.0032381436,0.0006229058],"study_design_scores_gemma":[0.0014519276,0.00017698377,0.857161,0.00015601731,0.00006891193,0.0008205232,0.00025819347,0.00014573745,0.012202578,0.0022466544,0.12512791,0.00018359123],"about_ca_topic_score_codex":0.017118512,"about_ca_topic_score_gemma":0.01280417,"teacher_disagreement_score":0.1330853,"about_ca_system_score_codex":0.000053598116,"about_ca_system_score_gemma":0.00014550396,"threshold_uncertainty_score":0.98942655},"labels":[],"label_agreement":null},{"id":"W6939483578","doi":"10.6084/m9.figshare.19695692","title":"Additional file 3 of Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chemotherapy; Mutation; Somatic cell; Ovarian carcinoma; Germline mutation; Serous fluid; Carcinoma","score_opus":0.02816034176825628,"score_gpt":0.2921409884059198,"score_spread":0.2639806466376635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939483578","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052167743,0.000033064996,2.3125507e-7,0.00008366877,0.000022325845,0.0003637882,0.9467249,0.000022597276,0.00058166636],"genre_scores_gemma":[0.42150235,5.4383025e-7,0.0001710085,0.00016579886,0.000044005665,0.0008229136,0.57717955,0.00001880722,0.00009500281],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998838,0.00006795865,0.00031653704,0.00017790309,0.00040583764,0.0001937404],"domain_scores_gemma":[0.998829,0.00052551035,0.00026944675,0.0002245654,0.00008254401,0.00006889788],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000027839538,0.00012529385,0.0002802015,0.00020770174,0.000037866477,0.0000037625598,0.00007711752,0.000044949073,0.991537],"category_scores_gemma":[0.00028762678,0.00012290079,0.00012571027,0.00035563068,0.000010473192,0.00005057388,0.000021244137,0.00018904608,0.0001135248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002910038,0.00028909123,0.00012308135,0.00012115526,0.000041053245,0.00004282412,0.00038168128,0.0006715328,0.00045694725,0.0000035136616,0.996129,0.0014491641],"study_design_scores_gemma":[0.011035628,0.0041477485,0.849141,0.0047760033,0.00001849568,0.00013401556,0.00039697034,0.0025867303,0.006560704,0.0005085765,0.12029983,0.00039430958],"about_ca_topic_score_codex":0.00012273983,"about_ca_topic_score_gemma":0.000007392675,"teacher_disagreement_score":0.9914234,"about_ca_system_score_codex":0.00048655953,"about_ca_system_score_gemma":0.00047289763,"threshold_uncertainty_score":0.50117487},"labels":[],"label_agreement":null},{"id":"W6949898688","doi":"10.5281/zenodo.2617679","title":"Dysregulation of poly ADP ribose signaling in HD and its potential as a therapeutic target","year":2019,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Huntingtin; DNA damage; DNA repair; DNA; Poly ADP ribose polymerase; Oxidative phosphorylation; Programmed cell death; Mitochondrion; Polymerase","score_opus":0.026797842409619858,"score_gpt":0.2725597315823472,"score_spread":0.24576188917272734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6949898688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97776556,0.00093141,0.0008489912,0.0011470712,0.000094542615,0.0007575784,0.000055580167,0.00019394245,0.01820532],"genre_scores_gemma":[0.99821806,0.00007099657,0.00015445572,0.00020350436,0.00009659012,4.757855e-8,0.0002663498,0.00042009182,0.0005698889],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877423,0.00017382036,0.00025745988,0.0002622187,0.00032960798,0.0002026614],"domain_scores_gemma":[0.99927807,0.000017118848,0.00010534217,0.00020994723,0.00029738844,0.00009211839],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00043302195,0.00009925541,0.00017902012,0.0002596392,0.00020235128,0.00007447583,0.0001611667,0.00006189072,0.011214056],"category_scores_gemma":[0.000093839306,0.00010320843,0.00003531091,0.00036518875,0.000063823034,0.00016680696,0.00014786716,0.00017134729,0.0011958624],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011106797,0.0002635683,0.00022450635,0.00026284708,0.00009094428,0.000021574524,0.0020888764,0.00031379284,0.9493538,0.0045815366,0.0020779793,0.039609864],"study_design_scores_gemma":[0.018522035,0.003986803,0.044752587,0.0010360595,0.00012493662,0.0009941298,0.00185856,0.016599545,0.26743853,0.004722448,0.6390501,0.00091422396],"about_ca_topic_score_codex":0.000011150591,"about_ca_topic_score_gemma":6.5665404e-8,"teacher_disagreement_score":0.6819153,"about_ca_system_score_codex":0.000100487705,"about_ca_system_score_gemma":0.000008677078,"threshold_uncertainty_score":0.9995818},"labels":[],"label_agreement":null},{"id":"W6955243534","doi":"10.58079/not8","title":"Noam Chomsky, Andre Vltchek, L’Occident terroriste. D’Hiroshima à la guerre des drones (On Western Terrorisme : from Hiroshima to Drone Warfare), Montréal, Écosociété, 2015 (édition originale 2013), 176 pages, 19 €.","year":2015,"lang":"fr","type":"article","venue":"OpenEdition (OpenEdition)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drone; Government (linguistics); Face (sociological concept); Terrorism","score_opus":0.05316420797035592,"score_gpt":0.3225894131061644,"score_spread":0.2694252051358085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6955243534","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23603617,0.074426904,0.016478868,0.57756734,0.039849143,0.009095428,0.022640768,0.0015038934,0.022401482],"genre_scores_gemma":[0.7628658,0.023843396,0.0068290033,0.085565075,0.029561283,0.0056519,0.025931885,0.00093701086,0.058814656],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9879617,0.0014400743,0.0024822566,0.002714399,0.0031484487,0.0022530833],"domain_scores_gemma":[0.99076486,0.0007566123,0.001324862,0.0022703595,0.001425303,0.0034579863],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0020693617,0.001983368,0.0021817344,0.000847131,0.0011798224,0.0010004748,0.0012252339,0.0014106225,0.008998854],"category_scores_gemma":[0.00051675574,0.002159271,0.0006713598,0.0012542392,0.0011615537,0.012435949,0.0004896143,0.0016709992,0.014664868],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003386553,0.0035216946,0.0027272187,0.0004769577,0.00074647093,0.001264773,0.0025816308,0.0015456087,0.0031912792,0.0023412667,0.95490694,0.023309577],"study_design_scores_gemma":[0.018657332,0.004225964,0.05366081,0.006404814,0.0013440351,0.0004701033,0.0048486325,0.0003739531,0.009735185,0.008978563,0.8883796,0.002921042],"about_ca_topic_score_codex":0.009338102,"about_ca_topic_score_gemma":0.015533834,"teacher_disagreement_score":0.5268296,"about_ca_system_score_codex":0.0046615982,"about_ca_system_score_gemma":0.0011678159,"threshold_uncertainty_score":0.99988574},"labels":[],"label_agreement":null},{"id":"W6957924070","doi":"10.6084/m9.figshare.19695692.v1","title":"Additional file 3 of Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chemotherapy; Mutation; Somatic cell; Ovarian carcinoma; Germline mutation; Serous fluid; Carcinoma","score_opus":0.02816034176825628,"score_gpt":0.2921409884059198,"score_spread":0.2639806466376635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957924070","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052167743,0.000033064996,2.3125507e-7,0.00008366877,0.000022325845,0.0003637882,0.9467249,0.000022597276,0.00058166636],"genre_scores_gemma":[0.42150235,5.4383025e-7,0.0001710085,0.00016579886,0.000044005665,0.0008229136,0.57717955,0.00001880722,0.00009500281],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998838,0.00006795865,0.00031653704,0.00017790309,0.00040583764,0.0001937404],"domain_scores_gemma":[0.998829,0.00052551035,0.00026944675,0.0002245654,0.00008254401,0.00006889788],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000027839538,0.00012529385,0.0002802015,0.00020770174,0.000037866477,0.0000037625598,0.00007711752,0.000044949073,0.991537],"category_scores_gemma":[0.00028762678,0.00012290079,0.00012571027,0.00035563068,0.000010473192,0.00005057388,0.000021244137,0.00018904608,0.0001135248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002910038,0.00028909123,0.00012308135,0.00012115526,0.000041053245,0.00004282412,0.00038168128,0.0006715328,0.00045694725,0.0000035136616,0.996129,0.0014491641],"study_design_scores_gemma":[0.011035628,0.0041477485,0.849141,0.0047760033,0.00001849568,0.00013401556,0.00039697034,0.0025867303,0.006560704,0.0005085765,0.12029983,0.00039430958],"about_ca_topic_score_codex":0.00012273983,"about_ca_topic_score_gemma":0.000007392675,"teacher_disagreement_score":0.9914234,"about_ca_system_score_codex":0.00048655953,"about_ca_system_score_gemma":0.00047289763,"threshold_uncertainty_score":0.50117487},"labels":[],"label_agreement":null},{"id":"W6958140263","doi":"10.6084/m9.figshare.19695695","title":"Additional file 4 of Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chemotherapy; Mutation; Somatic cell; Ovarian carcinoma; Germline mutation; Serous fluid; Carcinoma","score_opus":0.028392772654258693,"score_gpt":0.29259494968203675,"score_spread":0.26420217702777804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958140263","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051941194,0.00003320485,2.3289061e-7,0.000083534025,0.000022120952,0.00036424215,0.9469526,0.000022637276,0.0005802505],"genre_scores_gemma":[0.42387375,5.416792e-7,0.00017052781,0.0001653343,0.000043364274,0.00081972464,0.5748169,0.0000187279,0.00009114874],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988379,0.00006794921,0.00031665777,0.0001779221,0.00040581063,0.00019376387],"domain_scores_gemma":[0.9988294,0.0005265838,0.00026949315,0.00022469003,0.00008091219,0.00006890118],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000027863342,0.00012530314,0.00028027192,0.00020780461,0.00003788654,0.0000037646917,0.00007717792,0.000044953118,0.9913848],"category_scores_gemma":[0.00028334872,0.00012292564,0.00012572063,0.0003555823,0.000010475195,0.000050581748,0.000021252761,0.00018903984,0.000111059104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029469247,0.0002897043,0.00012356948,0.00012033513,0.000041119023,0.000043050757,0.00038269625,0.0006626189,0.00045021035,0.0000036558806,0.9961381,0.0014502574],"study_design_scores_gemma":[0.011008667,0.0042304564,0.85408616,0.0047966028,0.000018676892,0.00013573699,0.00039895947,0.0026008731,0.006428824,0.0005149842,0.11538493,0.0003950986],"about_ca_topic_score_codex":0.00012158011,"about_ca_topic_score_gemma":0.000007424969,"teacher_disagreement_score":0.99127376,"about_ca_system_score_codex":0.00048456743,"about_ca_system_score_gemma":0.00047101174,"threshold_uncertainty_score":0.50127625},"labels":[],"label_agreement":null},{"id":"W6958244048","doi":"10.60692/wsfgj-yvc78","title":"Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy","year":2020,"lang":"en","type":"article","venue":"Greater South Information System","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"","keywords":"Olaparib; Serous fluid; Ovarian cancer; Cytotoxicity; Targeted therapy; Poly ADP ribose polymerase; Cancer; Polymerase; Cytotoxic T cell","score_opus":0.03667870808536167,"score_gpt":0.24924433894820247,"score_spread":0.2125656308628408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958244048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95256937,0.000039306273,0.04323547,0.0003760349,0.00033047114,0.0016607946,0.0017234253,0.000054125638,0.000011023701],"genre_scores_gemma":[0.9962851,0.0000010321021,0.0027675268,0.0002250251,0.00008348551,0.00039745527,0.00020879181,0.000018677307,0.000012922854],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753326,0.00012796957,0.001423799,0.0002106363,0.00053436845,0.00016998725],"domain_scores_gemma":[0.99784976,0.000040151404,0.0010222554,0.00021029673,0.000712742,0.00016478104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006197231,0.00019729057,0.00043390505,0.00036939752,0.000079074074,0.000016781063,0.00007514745,0.00012222044,0.000022115628],"category_scores_gemma":[0.00008203834,0.00017507313,0.0000738708,0.00043266176,0.0000614881,0.00029930548,0.000028596321,0.000058845195,0.0000052331407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11902824,0.00018512046,0.33216587,0.0040739104,0.0024786072,0.0000013369062,0.42992923,0.00030569956,0.09576632,0.000064098655,0.0015606497,0.014440905],"study_design_scores_gemma":[0.010045647,0.00058465643,0.43287656,0.00046345912,0.00007399136,0.0000031403883,0.0042233435,0.0007642836,0.550493,7.1150583e-7,0.00028699715,0.00018423625],"about_ca_topic_score_codex":0.000033269615,"about_ca_topic_score_gemma":3.6379092e-7,"teacher_disagreement_score":0.45472667,"about_ca_system_score_codex":0.00022310224,"about_ca_system_score_gemma":0.00030496423,"threshold_uncertainty_score":0.71392757},"labels":[],"label_agreement":null},{"id":"W6958255677","doi":"10.6084/m9.figshare.28059501.v1","title":"Additional file 1 of Patterns of genomic instability in &gt; 2000 patients with ovarian cancer across six clinical trials evaluating olaparib","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Zygosity; Ovarian cancer; Germline; Clinical trial; Germline mutation; Cancer; Chemotherapy","score_opus":0.19971318138615599,"score_gpt":0.4670448457850503,"score_spread":0.26733166439889433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958255677","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11055455,0.00013265076,4.0167106e-7,0.000040419927,0.00008934477,0.00062686665,0.88816214,0.0000228612,0.00037074264],"genre_scores_gemma":[0.22242957,0.000003595664,0.00021474807,0.0001462635,0.00026481206,0.0016579297,0.77501196,0.000028786339,0.00024233638],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99763995,0.0003086041,0.0010799335,0.0003453295,0.00042452876,0.00020162147],"domain_scores_gemma":[0.99482083,0.004102678,0.00039221387,0.0002728739,0.0003273537,0.00008401868],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060233194,0.00014076504,0.00059875526,0.00006618143,0.000020783798,0.000013442932,0.00009424667,0.00013289473,0.9856157],"category_scores_gemma":[0.0052417815,0.00011425042,0.00017078711,0.00020516734,0.000029230414,0.00009703296,0.000046656,0.00028374075,0.00019678359],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064790907,0.0002638006,0.010050329,0.000731989,0.000123521,0.0000058261953,0.000384077,0.000035111927,0.00006493982,6.5773537e-7,0.9670245,0.020667322],"study_design_scores_gemma":[0.004134576,0.0004811047,0.6949297,0.019893935,0.000032423577,0.000001494281,0.00004523841,0.00050128193,0.00017983,0.000016945678,0.2796219,0.00016153872],"about_ca_topic_score_codex":0.000052532283,"about_ca_topic_score_gemma":0.00017002963,"teacher_disagreement_score":0.9854189,"about_ca_system_score_codex":0.00034149754,"about_ca_system_score_gemma":0.0015511912,"threshold_uncertainty_score":0.6275281},"labels":[],"label_agreement":null},{"id":"W6958301237","doi":"10.6084/m9.figshare.13265982","title":"Additional file 2 of Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Primer (cosmetics); Serous ovarian cancer; Polymerase chain reaction; Polymerase; Ovarian cancer; Identification (biology); Real-time polymerase chain reaction; Olaparib","score_opus":0.034506491077435766,"score_gpt":0.27014322887075837,"score_spread":0.23563673779332261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958301237","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036632374,0.0002166364,0.000076057,0.0003508635,0.00006661562,0.00097478,0.9616517,0.000020542082,0.000010436293],"genre_scores_gemma":[0.39346546,0.0000037532052,0.0032485833,0.0002512974,0.00015063661,0.0022043765,0.60058457,0.00003279429,0.000058550697],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982047,0.0001027447,0.00074322894,0.0003074671,0.0004920142,0.00014984213],"domain_scores_gemma":[0.99737185,0.000850305,0.0006988643,0.00016072392,0.0007696892,0.00014858636],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000104543,0.00016900142,0.00036602857,0.00018644013,0.0000517325,0.000004276222,0.000081516046,0.000111826754,0.41386357],"category_scores_gemma":[0.0015231599,0.00016801106,0.000087225846,0.00040983144,0.00004338207,0.000094335504,0.000037251204,0.000073027986,0.000008657849],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011888346,0.00034032698,0.00018405126,0.00033448392,0.00038001273,6.1710006e-7,0.0010617628,0.000011667439,0.05803105,8.7790056e-7,0.92306554,0.00470129],"study_design_scores_gemma":[0.0058383774,0.0011884037,0.23950183,0.0030143894,0.000040828447,0.0000013982897,0.00014249011,0.00017973811,0.6726872,0.000012007371,0.077173516,0.00021982109],"about_ca_topic_score_codex":0.00002255937,"about_ca_topic_score_gemma":0.000004158589,"teacher_disagreement_score":0.845892,"about_ca_system_score_codex":0.00011733922,"about_ca_system_score_gemma":0.00078171905,"threshold_uncertainty_score":0.6851292},"labels":[],"label_agreement":null},{"id":"W6958755302","doi":"10.6084/m9.figshare.28059501","title":"Additional file 1 of Patterns of genomic instability in &gt; 2000 patients with ovarian cancer across six clinical trials evaluating olaparib","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Zygosity; Ovarian cancer; Germline; Clinical trial; Germline mutation; Cancer; Chemotherapy","score_opus":0.19971318138615599,"score_gpt":0.4670448457850503,"score_spread":0.26733166439889433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958755302","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11055455,0.00013265076,4.0167106e-7,0.000040419927,0.00008934477,0.00062686665,0.88816214,0.0000228612,0.00037074264],"genre_scores_gemma":[0.22242957,0.000003595664,0.00021474807,0.0001462635,0.00026481206,0.0016579297,0.77501196,0.000028786339,0.00024233638],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99763995,0.0003086041,0.0010799335,0.0003453295,0.00042452876,0.00020162147],"domain_scores_gemma":[0.99482083,0.004102678,0.00039221387,0.0002728739,0.0003273537,0.00008401868],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060233194,0.00014076504,0.00059875526,0.00006618143,0.000020783798,0.000013442932,0.00009424667,0.00013289473,0.9856157],"category_scores_gemma":[0.0052417815,0.00011425042,0.00017078711,0.00020516734,0.000029230414,0.00009703296,0.000046656,0.00028374075,0.00019678359],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064790907,0.0002638006,0.010050329,0.000731989,0.000123521,0.0000058261953,0.000384077,0.000035111927,0.00006493982,6.5773537e-7,0.9670245,0.020667322],"study_design_scores_gemma":[0.004134576,0.0004811047,0.6949297,0.019893935,0.000032423577,0.000001494281,0.00004523841,0.00050128193,0.00017983,0.000016945678,0.2796219,0.00016153872],"about_ca_topic_score_codex":0.000052532283,"about_ca_topic_score_gemma":0.00017002963,"teacher_disagreement_score":0.9854189,"about_ca_system_score_codex":0.00034149754,"about_ca_system_score_gemma":0.0015511912,"threshold_uncertainty_score":0.6275281},"labels":[],"label_agreement":null},{"id":"W6976909158","doi":"10.6084/m9.figshare.25749987.v1","title":"Additional file 1 of Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cohort; Chemotherapy; Stage (stratigraphy); Protocol (science); Cohort study; Neoadjuvant therapy","score_opus":0.0645270655847369,"score_gpt":0.3827441260852461,"score_spread":0.3182170605005092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976909158","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024671705,0.0000114234,0.0000011453179,0.000059019836,0.00014854631,0.36168364,0.6128656,0.000030049596,0.0005288635],"genre_scores_gemma":[0.050618783,6.938559e-7,0.00015468625,0.00005891536,0.00008122275,0.7699579,0.17856927,0.00004055379,0.0005179642],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974135,0.0002592755,0.001023901,0.00047174474,0.00056417345,0.0002673856],"domain_scores_gemma":[0.9951227,0.0032677199,0.0007655048,0.0003648843,0.00039963055,0.00007961062],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024299868,0.0003289985,0.0016089076,0.00016243212,0.00009653303,0.00006658396,0.00025018246,0.00009034203,0.58157825],"category_scores_gemma":[0.00083451223,0.00020075259,0.00022353935,0.0003157181,0.000052670257,0.00012452989,0.00005735203,0.00017464344,0.0000118899225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7951987,0.009657876,0.0000797335,0.00013149671,0.0010348369,0.0000124689195,0.0005632335,0.00011899673,0.0000065090953,0.0000052301552,0.19189326,0.001297684],"study_design_scores_gemma":[0.9544915,0.008404855,0.00050332956,0.0046385904,0.00016977178,6.990899e-7,0.000105132895,0.0030612578,0.00022057821,0.0000038221806,0.028213773,0.00018669247],"about_ca_topic_score_codex":0.00025533163,"about_ca_topic_score_gemma":0.0001578453,"teacher_disagreement_score":0.5815664,"about_ca_system_score_codex":0.00052711007,"about_ca_system_score_gemma":0.00080801186,"threshold_uncertainty_score":0.81864536},"labels":[],"label_agreement":null},{"id":"W6976989526","doi":"10.6084/m9.figshare.13265979.v1","title":"Additional file 1 of Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Serous ovarian cancer; Immunohistochemistry; Antibody; Serous fluid; Ovarian cancer; Poly ADP ribose polymerase; Identification (biology); Olaparib; Real-time polymerase chain reaction","score_opus":0.03553428386707367,"score_gpt":0.27061586120110837,"score_spread":0.2350815773340347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976989526","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036814373,0.00021366414,0.000077416495,0.00035221357,0.000066257635,0.0009757411,0.9614696,0.000020535805,0.000010235629],"genre_scores_gemma":[0.39599705,0.0000036625308,0.003301012,0.0002506363,0.0001484042,0.0022346382,0.59797364,0.000032747983,0.00005823806],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982046,0.00010277395,0.0007429495,0.00030766067,0.00049211754,0.0001498885],"domain_scores_gemma":[0.9973607,0.0008605249,0.00069804926,0.00016098448,0.00077113294,0.00014860558],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000105024556,0.00016904654,0.00036595337,0.00018654266,0.00005172932,0.0000042684455,0.00008155416,0.000111826215,0.41774294],"category_scores_gemma":[0.0015387443,0.00016805717,0.00008724001,0.00041009902,0.000043382573,0.00009428127,0.000037255602,0.0000730421,0.000008736169],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011898486,0.0003391703,0.00018840354,0.00033074172,0.0003786145,6.010539e-7,0.0010571161,0.000011577904,0.059461445,8.6196064e-7,0.9217557,0.0045772907],"study_design_scores_gemma":[0.0057871914,0.0011845604,0.2416261,0.0030364995,0.000040826268,0.0000013913715,0.00014327792,0.00018019363,0.6731228,0.000011890786,0.074645706,0.00021952776],"about_ca_topic_score_codex":0.000022370261,"about_ca_topic_score_gemma":0.000004138037,"teacher_disagreement_score":0.84711,"about_ca_system_score_codex":0.000117311014,"about_ca_system_score_gemma":0.0007846496,"threshold_uncertainty_score":0.6853173},"labels":[],"label_agreement":null},{"id":"W6977200611","doi":"10.6084/m9.figshare.25750165.v1","title":"Additional file 2 of Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Cohort; Chemotherapy; Stage (stratigraphy); Protocol (science); Cohort study; Neoadjuvant therapy","score_opus":0.06290433605263106,"score_gpt":0.38223167923978724,"score_spread":0.31932734318715617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977200611","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02462753,0.000011607855,0.0000011295955,0.000058979007,0.00014974565,0.36264357,0.61193705,0.000030146884,0.000540251],"genre_scores_gemma":[0.050082985,7.0950585e-7,0.00015222582,0.00005901299,0.00008230955,0.7697199,0.17934212,0.000040574087,0.00052015873],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974137,0.00025920587,0.001024266,0.00047146424,0.00056406175,0.00026730754],"domain_scores_gemma":[0.99515986,0.0032309943,0.00076633174,0.0003643167,0.00039891253,0.00007959893],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024194439,0.0003289154,0.00160922,0.00016234764,0.00009653865,0.00006669874,0.00025007187,0.000090342444,0.57789636],"category_scores_gemma":[0.0008265068,0.00020070047,0.000223505,0.00031552312,0.00005266968,0.00012459767,0.000057345624,0.0001746115,0.000011789036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7967454,0.00967524,0.000077877725,0.00013271405,0.0010369667,0.000012765381,0.0005647665,0.00011969571,0.0000063423754,0.000005314014,0.19029379,0.001329095],"study_design_scores_gemma":[0.9537121,0.008409158,0.0004970777,0.004595049,0.00016934947,7.005959e-7,0.00010432036,0.00304622,0.00021957357,0.00000384784,0.029056162,0.00018645404],"about_ca_topic_score_codex":0.00025737315,"about_ca_topic_score_gemma":0.00015858689,"teacher_disagreement_score":0.57788455,"about_ca_system_score_codex":0.00052723,"about_ca_system_score_gemma":0.00080515613,"threshold_uncertainty_score":0.81843275},"labels":[],"label_agreement":null},{"id":"W6980765266","doi":"","title":"A cooperative game model for natural resource allocation: Canadian forest product case study","year":2019,"lang":"en","type":"other","venue":"Espace ÉTS (ETS)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product (mathematics); Game theory; Resource (disambiguation); Natural resource; Resource management (computing); Forest cover; Non-cooperative game","score_opus":0.02827167765244411,"score_gpt":0.3156957305956665,"score_spread":0.28742405294322243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6980765266","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.053969353,0.024091098,0.0052612,0.064034864,0.007114562,0.08604506,0.0034995351,0.0019980913,0.75398624],"genre_scores_gemma":[0.29263973,0.000020586433,0.00051720015,0.0013494897,0.0010929717,0.0007016451,0.00020721229,0.0004916894,0.7029795],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978837,0.00008707706,0.00028690806,0.0008545879,0.00036679694,0.0005209723],"domain_scores_gemma":[0.9980417,0.00006402056,0.00021736535,0.0010507023,0.00027627117,0.00034992848],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025227308,0.000487142,0.0006696903,0.000502689,0.00011368986,0.000052902753,0.000181779,0.00025476667,0.00037554884],"category_scores_gemma":[0.000110610745,0.00044193678,0.00012811723,0.00028540182,0.00010010865,0.000059782054,0.00002873788,0.0004960142,0.00020314586],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003379282,0.000195345,0.0004637656,0.0002023465,0.00042033824,0.0007154163,0.0061915023,0.0013300348,0.000033649885,0.00028068398,0.9893795,0.00044944504],"study_design_scores_gemma":[0.0053829015,0.00052264944,0.00006197673,0.000491709,0.00024545926,0.0009964666,0.0027587211,0.0142808035,0.000049697912,0.000009417398,0.9745581,0.000642061],"about_ca_topic_score_codex":0.03639347,"about_ca_topic_score_gemma":0.5218269,"teacher_disagreement_score":0.4854335,"about_ca_system_score_codex":0.0006753997,"about_ca_system_score_gemma":0.001877593,"threshold_uncertainty_score":0.99980325},"labels":[],"label_agreement":null},{"id":"W6982097556","doi":"","title":"Guidance Software to Announce 2012 Third Quarter Financial Results :: ITbriefing.net ::","year":2012,"lang":"en","type":"other","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Software; Quarter (Canadian coin); Work (physics); Financial Audit; Financial plan; Financial management","score_opus":0.021711989792188146,"score_gpt":0.29469193047840325,"score_spread":0.2729799406862151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6982097556","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013995773,0.0057940255,0.008923855,0.0060082637,0.0021921021,0.0011417979,0.0010136401,0.0009744205,0.9739379],"genre_scores_gemma":[0.000097903656,0.0002069146,0.019648958,0.018959122,0.0057821954,0.0001858964,0.0002987467,0.0004470124,0.95437324],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997184,0.00005915093,0.0006001684,0.0007448984,0.0006513615,0.0007604272],"domain_scores_gemma":[0.99784166,0.00007118402,0.00030901187,0.0011717192,0.00015581399,0.00045059828],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00033467915,0.0005573516,0.0007845546,0.0003208505,0.00006451942,0.00002970739,0.00026051907,0.00068015995,0.007446916],"category_scores_gemma":[0.00022831457,0.00049199944,0.00019011054,0.00036448502,0.000103412756,0.000109896755,0.000063098916,0.00047414104,0.005769296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049497717,0.00011239217,0.00020463901,0.0001367633,0.000057886242,0.000023172086,0.00020915174,7.4043754e-7,0.00015373976,0.00026889303,0.9960525,0.0022851608],"study_design_scores_gemma":[0.0023998227,0.00026552365,0.0011611544,0.0013219672,0.00005960126,0.0000437264,0.0000105994295,7.781061e-7,0.0003042913,0.000063371,0.99380136,0.0005678014],"about_ca_topic_score_codex":0.00028649857,"about_ca_topic_score_gemma":0.00030205495,"teacher_disagreement_score":0.01956465,"about_ca_system_score_codex":0.00021648976,"about_ca_system_score_gemma":0.00035293828,"threshold_uncertainty_score":0.9997532},"labels":[],"label_agreement":null},{"id":"W6995640100","doi":"","title":"Paysages interstitiels sous les autoroutes surélevées, trois études de cas canadiennes","year":2025,"lang":"fr","type":"other","venue":"Archipelago (University of Quebec in Montreal)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Disenchantment; Urbanism; Local Development","score_opus":0.012234531506154485,"score_gpt":0.22748893130099765,"score_spread":0.21525439979484318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995640100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6194582,0.013967808,0.0046478873,0.0050670947,0.0013227849,0.0014482215,0.001471085,0.00022005026,0.3523969],"genre_scores_gemma":[0.5727257,0.0036539333,0.00181792,0.00022297283,0.0003062914,0.000004199889,0.000114846946,0.00010716141,0.42104697],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99710315,0.00044977159,0.00044354633,0.0007322308,0.0003413232,0.00092997577],"domain_scores_gemma":[0.9976271,0.0007920825,0.00041225937,0.0006668144,0.00013833147,0.00036342716],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038719844,0.0005854926,0.0012182272,0.0010778235,0.00020081544,0.000021740092,0.00067237165,0.00058967905,0.00571446],"category_scores_gemma":[0.0001416041,0.00073633745,0.000399652,0.00041564583,0.0010779208,0.00014787033,0.0001969885,0.00077503186,0.000072562936],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012410862,0.0007005637,0.04493046,0.0020053152,0.0014958858,0.0029563904,0.10454409,0.00053592486,0.00061036035,0.03527081,0.018208247,0.78750086],"study_design_scores_gemma":[0.011037222,0.0009446648,0.67020446,0.018747205,0.0014818625,0.0001377842,0.1913061,0.0016361412,0.00041710012,0.014837828,0.08729787,0.0019517638],"about_ca_topic_score_codex":0.97720295,"about_ca_topic_score_gemma":0.9987673,"teacher_disagreement_score":0.7855491,"about_ca_system_score_codex":0.0022497384,"about_ca_system_score_gemma":0.0018152293,"threshold_uncertainty_score":0.99950874},"labels":[],"label_agreement":null},{"id":"W7000429195","doi":"","title":"Exploiting RAD54B-deficiency in colorectal cancer cells through synthetic lethal targeting of PARP1","year":2016,"lang":"en","type":"dissertation","venue":"Mspace (University of Manitoba)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; Research Manitoba","keywords":"Nucleofection; Proteogenomics; Gestational period; TSG101; Articular cartilage damage; Fusible alloy; Hyporeflexia; Diafiltration","score_opus":0.019868920981450277,"score_gpt":0.2587318247249617,"score_spread":0.23886290374351143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000429195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841144,0.0009842713,0.00016631465,0.00040322792,0.00057200226,0.0004641006,0.000087295055,0.000044685145,0.013163685],"genre_scores_gemma":[0.9969744,0.0011619517,0.0008727737,0.000018071842,0.00011171325,0.0000035635073,0.000079961785,0.000045702065,0.0007318358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983699,0.00009603983,0.00028006715,0.00042900033,0.00048583164,0.00033920872],"domain_scores_gemma":[0.99867827,0.0001426266,0.000662908,0.0002091139,0.0002410269,0.000066050205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021573743,0.0002627991,0.0006992665,0.000282181,0.00011712066,0.0000047428766,0.00023365993,0.0003117721,0.00017903234],"category_scores_gemma":[0.00003699949,0.00029938426,0.00021499512,0.00031588296,0.00018479375,0.00017946996,0.000039152736,0.00034288733,0.000020402254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023229092,0.00048210612,0.03913376,0.0025668715,0.00020035345,0.00021670072,0.009546377,0.00008859114,0.93946815,0.00032220734,0.0024757348,0.003176221],"study_design_scores_gemma":[0.006381723,0.0006234579,0.08397649,0.009807072,0.0004604857,0.000017159904,0.13850307,0.00012251193,0.756719,0.00031992854,0.0021538846,0.00091520685],"about_ca_topic_score_codex":0.0031011512,"about_ca_topic_score_gemma":0.026896333,"teacher_disagreement_score":0.18274915,"about_ca_system_score_codex":0.00044987455,"about_ca_system_score_gemma":0.00031360373,"threshold_uncertainty_score":0.9999458},"labels":[],"label_agreement":null},{"id":"W7027063691","doi":"","title":"Caractérisation moléculaire de la résistance aux inhibiteurs de PARP dans le cancer épithélial de l’ovaire par le biais de modèles cellulaires diversifiés","year":2023,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Institute of Cancer Research; Génome Québec; Ovarian Cancer Canada; Cancer Research Society","keywords":"Cancer; DNA laddering; Lymph node metastasis","score_opus":0.010214062832152338,"score_gpt":0.2268291921747552,"score_spread":0.21661512934260285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027063691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95456874,0.027199809,0.0045353486,0.0017080379,0.0017260513,0.00076536747,0.0004759275,0.0004211763,0.008599563],"genre_scores_gemma":[0.9683932,0.006584473,0.001145585,0.00033222674,0.0010657291,0.00024944602,0.0008939416,0.00016145808,0.021173961],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9947522,0.00084738806,0.000758515,0.0011346785,0.001105107,0.0014020767],"domain_scores_gemma":[0.99671847,0.0004368691,0.0007983264,0.00063030905,0.0005061747,0.0009098708],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0008364347,0.0008726036,0.0008413947,0.00056987425,0.009381077,0.0001378412,0.00061167014,0.001261468,0.0000605605],"category_scores_gemma":[0.00021311275,0.0011454538,0.00070046104,0.00085805834,0.0012509071,0.0006194354,0.0001522533,0.0011651779,0.000051232928],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003832595,0.00077208766,0.2855847,0.0012136527,0.0015122722,0.009431226,0.12692213,0.08931926,0.45252338,0.019574594,0.004636456,0.0046776556],"study_design_scores_gemma":[0.006480087,0.00022233676,0.48715004,0.0037922475,0.001576288,0.0014185383,0.1446866,0.018722242,0.31893083,0.0022936265,0.013104285,0.0016228813],"about_ca_topic_score_codex":0.4207935,"about_ca_topic_score_gemma":0.056637228,"teacher_disagreement_score":0.36415628,"about_ca_system_score_codex":0.031162001,"about_ca_system_score_gemma":0.024885973,"threshold_uncertainty_score":0.99909955},"labels":[],"label_agreement":null},{"id":"W7029718244","doi":"","title":"Le rôle de la sénescence cellulaire et des composantes de la réponse aux dommages à l’ADN dans le cancer de l’ovaire séreux de haut grade","year":2021,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"IRF1","score_opus":0.009603800641931313,"score_gpt":0.24463375044374158,"score_spread":0.23502994980181027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7029718244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8857404,0.07408426,0.00820195,0.0028973627,0.00083421724,0.00050626404,0.00027179043,0.00025383948,0.027209932],"genre_scores_gemma":[0.9624232,0.009722093,0.0047306237,0.00055914733,0.0004895011,0.00016848903,0.000537572,0.00011804809,0.021251332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9945883,0.0019225819,0.00062602595,0.00092926854,0.0007614768,0.001172313],"domain_scores_gemma":[0.9966181,0.00094509224,0.0005291729,0.0005987962,0.00046835153,0.0008404956],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0010708643,0.00077232794,0.0007980626,0.00035504904,0.007423444,0.00017811282,0.00064628257,0.0010412681,0.00009983288],"category_scores_gemma":[0.00027040995,0.0009929723,0.0005793486,0.0005971863,0.002253274,0.0005315644,0.00016705848,0.0014100515,0.00001526001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016779153,0.0010671465,0.114148214,0.000986672,0.00080653746,0.013372687,0.08089111,0.019444155,0.6861574,0.078472055,0.0016587989,0.0013172994],"study_design_scores_gemma":[0.0068237507,0.00021917679,0.24580343,0.0069541554,0.0011820971,0.010526458,0.1676871,0.008775747,0.5081302,0.0027940779,0.039583657,0.0015201492],"about_ca_topic_score_codex":0.20099847,"about_ca_topic_score_gemma":0.03358329,"teacher_disagreement_score":0.17802721,"about_ca_system_score_codex":0.015542535,"about_ca_system_score_gemma":0.03240215,"threshold_uncertainty_score":0.9992521},"labels":[],"label_agreement":null},{"id":"W7095100407","doi":"","title":"MKWEB.BCGSC.CA NOT NECESSARY","year":2016,"lang":"en","type":"article","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Visualization; Center (category theory); Object (grammar); Key (lock); Perspective (graphical)","score_opus":0.032976548595863034,"score_gpt":0.320125291204928,"score_spread":0.287148742609065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095100407","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31453145,0.00027172716,0.01019819,0.089236915,0.00078758126,0.00041965538,0.000034638342,0.00048815776,0.5840317],"genre_scores_gemma":[0.9270468,0.00014759155,0.0011206839,0.01122843,0.00043666616,0.000027380574,0.0000037796108,0.00001999267,0.059968673],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925804,0.00001621561,0.000156275,0.00018225645,0.00020606762,0.00018114907],"domain_scores_gemma":[0.9994239,0.000070838156,0.00003163287,0.0002951954,0.00005934197,0.00011904716],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009734517,0.00008898746,0.00014534425,0.00005596359,0.000030821506,0.0000058299847,0.00005779586,0.00005799884,0.016589943],"category_scores_gemma":[0.00002843906,0.000050158167,0.000061906416,0.000087488224,0.00006912268,0.00008875375,0.000016656224,0.000055839813,0.0025259636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005045472,0.00012414072,0.008992058,0.00003234895,0.00007150548,0.000048553968,0.00006635321,2.3385152e-7,0.5030679,0.0055859084,0.42962262,0.05188378],"study_design_scores_gemma":[0.005007985,0.00023926019,0.013837649,0.00019398183,0.000023312628,0.000087892084,0.000035602505,0.000012429422,0.4275095,0.001395332,0.5514711,0.00018592043],"about_ca_topic_score_codex":0.000016850341,"about_ca_topic_score_gemma":0.000004102747,"teacher_disagreement_score":0.61251533,"about_ca_system_score_codex":0.00007805037,"about_ca_system_score_gemma":0.00006801842,"threshold_uncertainty_score":0.99825066},"labels":[],"label_agreement":null},{"id":"W7099007207","doi":"","title":"Acquisitions and Acquisitions et Bibliographie Services services bibliographiques","year":2014,"lang":"en","type":"article","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Information system; Order (exchange); Reproduction; Electronic document; Work (physics)","score_opus":0.00932703940255538,"score_gpt":0.3002516158945993,"score_spread":0.29092457649204395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7099007207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.869258,0.0028094398,0.003028102,0.017222162,0.00023864947,0.0006726827,0.00015929983,0.0011942431,0.10541742],"genre_scores_gemma":[0.9519681,0.009339841,0.0040844795,0.033755064,0.00028089387,0.00011304156,0.0001697116,0.000042033917,0.00024685988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985031,0.00010109824,0.00032132122,0.00042634824,0.0003309724,0.00031719348],"domain_scores_gemma":[0.99873984,0.0001397124,0.00010124534,0.000476039,0.00024592385,0.00029724353],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034121462,0.00024754112,0.0003156581,0.010663165,0.00023829407,0.00017801007,0.00012948539,0.00014098812,0.0011808779],"category_scores_gemma":[0.0000026107334,0.00021268698,0.00016432015,0.010229181,0.00020152178,0.0005405014,0.000063445244,0.00017046263,0.00007122522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080846454,0.001816461,0.6372789,0.003318904,0.0014722958,0.000049569175,0.0032511717,0.000031260955,0.098797366,0.15416935,0.09130018,0.007706054],"study_design_scores_gemma":[0.0068684127,0.0013779629,0.6699934,0.0015125165,0.00049963675,0.00044143174,0.0016930407,0.0015041183,0.012781674,0.048991,0.25321537,0.0011214064],"about_ca_topic_score_codex":0.0004799013,"about_ca_topic_score_gemma":0.00037098373,"teacher_disagreement_score":0.1619152,"about_ca_system_score_codex":0.000010684713,"about_ca_system_score_gemma":0.000018694918,"threshold_uncertainty_score":0.9997322},"labels":[],"label_agreement":null},{"id":"W7104827558","doi":"10.71781/31346","title":"Inhibiteurs de PARP : leur rôle potentiel en monothérapie et en combinaison en cancer du sein triple-négatif","year":2020,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Carboplatin; Cancer; Breast cancer; Negative therapeutic reaction","score_opus":0.00878675496511932,"score_gpt":0.22530253920520102,"score_spread":0.2165157842400817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104827558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90095544,0.054628696,0.0038982008,0.010246054,0.0066183293,0.0019057362,0.0005893514,0.00043384268,0.02072438],"genre_scores_gemma":[0.938605,0.01267861,0.000989476,0.0017793175,0.0015838352,0.00026482888,0.001732799,0.00017200112,0.04219414],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940996,0.0011344465,0.0010121673,0.0013283894,0.0013580329,0.0010673692],"domain_scores_gemma":[0.99636555,0.0005982939,0.00086506305,0.0006354456,0.00050383864,0.0010318288],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00069197314,0.0010586962,0.0011877749,0.00056601875,0.0037141216,0.000111386,0.00071316015,0.0012802536,0.00038499903],"category_scores_gemma":[0.00029658154,0.0013030302,0.0007778447,0.0007984048,0.00040808,0.00068266754,0.0002351103,0.0018521831,0.00021412241],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012333511,0.0020999913,0.16082227,0.0023340452,0.004476704,0.01651828,0.3209041,0.017032556,0.35233468,0.07364293,0.01833863,0.019162297],"study_design_scores_gemma":[0.024955938,0.0014997238,0.20863436,0.006404074,0.0040879436,0.0036703611,0.12200942,0.024471786,0.15910995,0.0014672013,0.44007778,0.0036114608],"about_ca_topic_score_codex":0.057842653,"about_ca_topic_score_gemma":0.0052817287,"teacher_disagreement_score":0.42173916,"about_ca_system_score_codex":0.02091524,"about_ca_system_score_gemma":0.007734582,"threshold_uncertainty_score":0.99894196},"labels":[],"label_agreement":null},{"id":"W7104915816","doi":"10.71781/32299","title":"Le rôle de la sénescence cellulaire et des composantes de la réponse aux dommages à l’ADN dans le cancer de l’ovaire séreux de haut grade","year":2021,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"IRF1","score_opus":0.009603800641931313,"score_gpt":0.24463375044374158,"score_spread":0.23502994980181027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104915816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8857404,0.07408426,0.00820195,0.0028973627,0.00083421724,0.00050626404,0.00027179043,0.00025383948,0.027209932],"genre_scores_gemma":[0.9624232,0.009722093,0.0047306237,0.00055914733,0.0004895011,0.00016848903,0.000537572,0.00011804809,0.021251332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9945883,0.0019225819,0.00062602595,0.00092926854,0.0007614768,0.001172313],"domain_scores_gemma":[0.9966181,0.00094509224,0.0005291729,0.0005987962,0.00046835153,0.0008404956],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0010708643,0.00077232794,0.0007980626,0.00035504904,0.007423444,0.00017811282,0.00064628257,0.0010412681,0.00009983288],"category_scores_gemma":[0.00027040995,0.0009929723,0.0005793486,0.0005971863,0.002253274,0.0005315644,0.00016705848,0.0014100515,0.00001526001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016779153,0.0010671465,0.114148214,0.000986672,0.00080653746,0.013372687,0.08089111,0.019444155,0.6861574,0.078472055,0.0016587989,0.0013172994],"study_design_scores_gemma":[0.0068237507,0.00021917679,0.24580343,0.0069541554,0.0011820971,0.010526458,0.1676871,0.008775747,0.5081302,0.0027940779,0.039583657,0.0015201492],"about_ca_topic_score_codex":0.20099847,"about_ca_topic_score_gemma":0.03358329,"teacher_disagreement_score":0.17802721,"about_ca_system_score_codex":0.015542535,"about_ca_system_score_gemma":0.03240215,"threshold_uncertainty_score":0.9992521},"labels":[],"label_agreement":null},{"id":"W7104947231","doi":"10.71781/29877","title":"Comprendre la régulation de p21 indépendante de p53 durant la sénescence dans le cancer de l'ovaire","year":2023,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Tumor cells; Medical screening; Hereditary Cancer","score_opus":0.007936072348425194,"score_gpt":0.2232829682519133,"score_spread":0.2153468959034881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104947231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95435023,0.016567748,0.0043201246,0.0011916313,0.0021859305,0.00070944265,0.00033757192,0.00036614237,0.019971158],"genre_scores_gemma":[0.93781114,0.0045484,0.00092263304,0.00025213667,0.0007909625,0.0001645426,0.00083583314,0.0001230833,0.054551274],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99588126,0.0006551811,0.00066166715,0.00087001413,0.00092168775,0.0010102063],"domain_scores_gemma":[0.99739665,0.0004240858,0.00061573734,0.0005173854,0.0004015479,0.0006445692],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00066841114,0.0006753249,0.0006923787,0.000480767,0.005072414,0.00009307157,0.00050445966,0.0010165174,0.000119354874],"category_scores_gemma":[0.00011912793,0.00085195963,0.00046681688,0.00074276415,0.0007319148,0.000430068,0.000119480566,0.0011397185,0.00008870179],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0038220768,0.00069587,0.20461603,0.0014523974,0.0014318824,0.016948631,0.15818596,0.040260274,0.5283139,0.03136215,0.0023203017,0.010590531],"study_design_scores_gemma":[0.0057753073,0.00016905428,0.76768327,0.006007593,0.0010736964,0.0068133543,0.06278022,0.017855141,0.101692535,0.0008212208,0.02809765,0.0012309373],"about_ca_topic_score_codex":0.15108873,"about_ca_topic_score_gemma":0.029526033,"teacher_disagreement_score":0.56306726,"about_ca_system_score_codex":0.01997764,"about_ca_system_score_gemma":0.012036094,"threshold_uncertainty_score":0.9993931},"labels":[],"label_agreement":null},{"id":"W7108464563","doi":"10.1182/blood-2025-7390","title":"PARP inhibitors and the rising incidence of secondary myelodysplastic syndrome and acute myeloid leukemia: A comprehensive meta-analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incidence (geometry); Hazard ratio; Myelodysplastic syndromes; Myeloid leukemia; Cohort study; Cohort; Proportional hazards model; Confidence interval","score_opus":0.01997014474744769,"score_gpt":0.28439712214805485,"score_spread":0.26442697740060717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108464563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791509,0.017958509,0.00038171082,0.0013594321,0.00006187044,0.00040698738,0.00004915317,0.000030043104,0.0006014144],"genre_scores_gemma":[0.9972589,0.00070435455,0.00062684744,0.0010704579,0.000023392597,0.000057226247,0.000008541029,0.000011293683,0.00023895572],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9986273,0.00014421165,0.00045914124,0.0003369599,0.00025794294,0.00017444542],"domain_scores_gemma":[0.9984883,0.00071801926,0.0002041213,0.0003618459,0.00015211638,0.00007561935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002935495,0.00019642283,0.0011660397,0.00029009167,0.00012261506,0.000027547405,0.000084319945,0.00009451292,0.00008667116],"category_scores_gemma":[0.00006405651,0.000129525,0.00035283633,0.00074394094,0.0005817602,0.00008641457,0.00010222697,0.00028933826,0.000001924657],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024430803,0.0005177656,0.026663743,0.0015872504,0.8915266,0.00083817943,0.0046186456,0.00025830907,0.06434638,0.0035879049,0.0015479035,0.00206426],"study_design_scores_gemma":[0.024652557,0.0004469454,0.0975486,0.0002752826,0.81908166,0.001480761,0.00085947453,0.000535486,0.050664358,0.0031703429,0.0008321415,0.00045240548],"about_ca_topic_score_codex":0.00011701555,"about_ca_topic_score_gemma":0.000021346863,"teacher_disagreement_score":0.07244493,"about_ca_system_score_codex":0.000039570754,"about_ca_system_score_gemma":0.00019982614,"threshold_uncertainty_score":0.52818763},"labels":[],"label_agreement":null},{"id":"W7110017582","doi":"10.3390/curroncol32120690","title":"The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Renal cell carcinoma; Homologous recombination; Disease; Tyrosine kinase; Clinical significance; Immune checkpoint; DNA repair; Mechanism (biology); Immune system; Clear cell renal cell carcinoma","score_opus":0.08420431400621371,"score_gpt":0.38375051464937815,"score_spread":0.29954620064316445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110017582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90715325,0.07311078,0.00008652731,0.0026744267,0.0008149134,0.0004080673,0.000012781454,0.000020690195,0.015718581],"genre_scores_gemma":[0.99555075,0.0039918595,0.000046740293,0.00013937066,0.000027801549,0.00008480512,0.00002117727,0.0000064607575,0.00013101306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988897,0.00025526542,0.0003599779,0.0002089828,0.000068216745,0.00021788209],"domain_scores_gemma":[0.99914,0.00037292077,0.00014893939,0.0001927067,0.000106357984,0.00003906835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004838261,0.00011287234,0.00026177656,0.00025379844,0.00008806804,0.0000053874883,0.000107600215,0.00012988044,0.000029739038],"category_scores_gemma":[0.000040255403,0.000084748695,0.000046710236,0.00022724466,0.0005276781,0.000021300786,0.0000472169,0.00020564036,0.0000015943037],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005067435,0.0006131949,0.12939395,0.000104611,0.000033868415,0.000006721103,0.0005694908,7.9800867e-7,0.018654777,0.020256614,0.0008298921,0.8290293],"study_design_scores_gemma":[0.015999243,0.0051062834,0.2629723,0.0003885699,0.0002884889,0.00014387231,0.0074155508,0.0012668213,0.06542473,0.12627514,0.51423067,0.0004883036],"about_ca_topic_score_codex":0.000042433887,"about_ca_topic_score_gemma":0.000033903234,"teacher_disagreement_score":0.82854104,"about_ca_system_score_codex":0.0002106868,"about_ca_system_score_gemma":0.00041194246,"threshold_uncertainty_score":0.34559515},"labels":[],"label_agreement":null},{"id":"W7116881267","doi":"10.1016/j.annonc.2025.10.1207","title":"793P Real-world landscape of homologous recombination repair (HRR) gene alterations across solid tumors: Single-institution experience using comprehensive genomic profiling (CGP) from India","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Homologous recombination; Gene; Homologous chromosome; Profiling (computer programming); Genome; Gene deletion","score_opus":0.12288818312396775,"score_gpt":0.44734180711187016,"score_spread":0.3244536239879024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116881267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353874,0.00053469493,0.0011710083,0.0005767232,0.0005890624,0.00055432116,0.000105000625,0.000076647055,0.002853803],"genre_scores_gemma":[0.9910797,0.00030237148,0.007270784,0.0008540481,0.00016378034,0.00006361675,0.00017987598,0.000014658586,0.000071180526],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818075,0.00016767472,0.00084003137,0.00036674572,0.00016298547,0.0002818205],"domain_scores_gemma":[0.9981203,0.00021523591,0.00055904133,0.00035738826,0.000682548,0.00006547612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002465973,0.00016645476,0.000639766,0.00030772237,0.00015292548,0.000009839956,0.00011819783,0.00017068122,0.000055284963],"category_scores_gemma":[0.00010754168,0.00017799881,0.00014210197,0.00046284986,0.00034927204,0.00015142624,0.00006844232,0.00018697107,0.0000038096612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008261654,0.0007345239,0.03783052,0.00011940462,0.00023191044,0.000047614685,0.0037529457,0.0015153894,0.94898564,0.00092747196,0.00039660343,0.0046318113],"study_design_scores_gemma":[0.0028842855,0.0013322579,0.08717739,0.00046143107,0.00007288047,0.00004787807,0.0012742138,0.0025999043,0.9016901,0.0013368704,0.00093769416,0.00018508134],"about_ca_topic_score_codex":0.0005384432,"about_ca_topic_score_gemma":0.00013549728,"teacher_disagreement_score":0.049346868,"about_ca_system_score_codex":0.00026722453,"about_ca_system_score_gemma":0.00059387024,"threshold_uncertainty_score":0.7258581},"labels":[],"label_agreement":null},{"id":"W7117537090","doi":"10.20935/acadonco8089","title":"Targeting DNA repair in lung cancer with PARP inhibitors","year":2025,"lang":"en","type":"article","venue":"Academia oncology.","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Lung cancer; Context (archaeology); Treatment of lung cancer; PARP inhibitor; DNA repair; Poly ADP ribose polymerase; Synthetic lethality; DNA Damage Repair; Acquired resistance","score_opus":0.013611364587404003,"score_gpt":0.36856917046405474,"score_spread":0.3549578058766507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117537090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9360883,0.007873307,0.00012820575,0.036216494,0.00073895365,0.0009819012,0.000013975919,0.00036414902,0.017594708],"genre_scores_gemma":[0.96762395,0.0017916993,0.0019749168,0.023579393,0.0007087783,0.00073162204,0.000019022766,0.000041050153,0.003529565],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833465,0.00011220706,0.00048686104,0.00043057406,0.00021161784,0.00042406708],"domain_scores_gemma":[0.9992397,0.0002142401,0.00014471886,0.0002113862,0.00008424369,0.00010569954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055108906,0.00019204826,0.00045772153,0.00025903332,0.000076405886,0.0000036366687,0.00010849803,0.0007625363,0.00024064489],"category_scores_gemma":[0.00013039439,0.00016180446,0.00007324423,0.00073109474,0.00017345078,0.00010493581,0.000050035393,0.0016645192,0.00001217521],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010989973,0.00014235996,0.6410119,0.00023793436,0.00020644703,0.00017576478,0.00083563366,0.0002615742,0.017937833,0.0006123786,0.33184662,0.005632546],"study_design_scores_gemma":[0.012370274,0.00051084143,0.07837362,0.0023666262,0.00026078188,0.00004921053,0.0007168301,0.0015699078,0.031005796,0.00038107132,0.87193614,0.00045892698],"about_ca_topic_score_codex":0.00016164882,"about_ca_topic_score_gemma":0.00008190875,"teacher_disagreement_score":0.5626383,"about_ca_system_score_codex":0.0015723966,"about_ca_system_score_gemma":0.001089352,"threshold_uncertainty_score":0.72316},"labels":[],"label_agreement":null},{"id":"W7132896591","doi":"","title":"Mammary Lineage-dependent Homologous Recombination Repair and PARP Inhibitor Vulnerability","year":2020,"lang":"","type":"dissertation","venue":"TSpace","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Homologous recombination; DNA repair; PARP inhibitor; Germline; Poly ADP ribose polymerase; Breast cancer; Mammary gland; DNA damage; Mutation","score_opus":0.02938989010828229,"score_gpt":0.35656711093734655,"score_spread":0.32717722082906425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132896591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91250473,0.02400483,0.0026387007,0.017920755,0.011068161,0.006046415,0.00010785373,0.0018435133,0.02386502],"genre_scores_gemma":[0.9469659,0.008636331,0.0028104389,0.0019047507,0.0023402683,0.00066251867,0.0021307166,0.0002738888,0.034275226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9934432,0.00087856734,0.0015512662,0.0021837233,0.0011616974,0.0007815487],"domain_scores_gemma":[0.9955234,0.00055122847,0.0010840818,0.0013092981,0.00075954886,0.0007724616],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013626991,0.0010880745,0.0015908177,0.00037270092,0.00048442258,0.00014927672,0.00032719897,0.0013378527,0.0013720082],"category_scores_gemma":[0.0010793558,0.001205169,0.0004989163,0.0006801522,0.00028574746,0.00034853313,0.00015249678,0.0022720457,0.00027860954],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035941355,0.009785001,0.018802818,0.03626333,0.007217383,0.005603385,0.24376124,0.00017383824,0.31880513,0.009750675,0.11906804,0.1948278],"study_design_scores_gemma":[0.04667855,0.01502162,0.05601155,0.009321958,0.0043506227,0.0012007887,0.047377575,0.012355157,0.6873585,0.0055347383,0.106580265,0.008208704],"about_ca_topic_score_codex":0.00035346727,"about_ca_topic_score_gemma":0.00009351429,"teacher_disagreement_score":0.36855334,"about_ca_system_score_codex":0.00097227626,"about_ca_system_score_gemma":0.0010374932,"threshold_uncertainty_score":0.99995863},"labels":[],"label_agreement":null},{"id":"W7133058243","doi":"","title":"Combination Chemotherapy and In vivo Modeling of BRCA-deficient, High-grade Serous Ovarian Cancer","year":2020,"lang":"","type":"dissertation","venue":"TSpace","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Congressionally Directed Medical Research Programs; U.S. Department of Defense","keywords":"Ovarian cancer; Carboplatin; Olaparib; PARP inhibitor; Serous fluid; Synthetic lethality; In vivo; Cancer; BRCA mutation","score_opus":0.03338015695495077,"score_gpt":0.35685615705554635,"score_spread":0.3234760001005956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133058243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778552,0.0077490276,0.0023189492,0.007148923,0.0012799309,0.0016987018,0.00007031089,0.00007378971,0.0018051338],"genre_scores_gemma":[0.9830759,0.012784116,0.0005390856,0.00085840916,0.00029213508,0.00020601599,0.00026304612,0.00016011969,0.0018211493],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9964004,0.0001693906,0.0010876255,0.0009775743,0.0008292671,0.00053570006],"domain_scores_gemma":[0.99797446,0.00011017476,0.00081686216,0.00045885294,0.00038959173,0.00025008692],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036689942,0.0006631496,0.0013123711,0.00052844227,0.00012326633,0.00004608618,0.00021850661,0.0006138931,0.0011522362],"category_scores_gemma":[0.000060515493,0.0007619094,0.00015387469,0.0010319181,0.00012674913,0.00015041113,0.00002839128,0.0008251142,0.000008521006],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010267262,0.002005061,0.0056947875,0.0062779197,0.00083814067,0.00007423835,0.17889667,0.032359507,0.7499748,0.004928495,0.0010104246,0.0076726824],"study_design_scores_gemma":[0.049093176,0.0015014688,0.00678376,0.010838952,0.00079495576,0.000028207107,0.032770313,0.5030826,0.38875818,0.0021699776,0.0020216792,0.0021567733],"about_ca_topic_score_codex":0.0060453005,"about_ca_topic_score_gemma":0.00071947277,"teacher_disagreement_score":0.47072306,"about_ca_system_score_codex":0.0006323512,"about_ca_system_score_gemma":0.00067683175,"threshold_uncertainty_score":0.99976087},"labels":[],"label_agreement":null},{"id":"W841406333","doi":"10.1139/y08-033","title":"Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complicationsThis article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in Endothelin.","year":2008,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Oxidative stress; Downregulation and upregulation; Poly ADP ribose polymerase; Diabetes mellitus; Endocrinology; Streptozotocin; Internal medicine; PARP inhibitor; Biology; Kidney; Medicine; Polymerase; Biochemistry; Enzyme; Gene","score_opus":0.028079006886928947,"score_gpt":0.30580516148894227,"score_spread":0.27772615460201333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W841406333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973916,0.00035501702,0.000004725026,0.0015843614,0.00014909066,0.00026532696,0.000053457752,7.742255e-7,0.0001956799],"genre_scores_gemma":[0.9989981,0.00020871033,0.00003474019,0.0004040956,0.00031834838,0.000013123288,0.000007655092,0.0000063088373,0.000008927935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998592,0.00038005237,0.00062193413,0.00012500095,0.0001166267,0.00016435633],"domain_scores_gemma":[0.99900126,0.00018619269,0.00051337894,0.000091382506,0.00012852487,0.00007922882],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002988512,0.00008895302,0.00040911773,0.0004390466,0.000027824146,9.427415e-7,0.000096186566,0.00010449413,0.0028446452],"category_scores_gemma":[0.000033811433,0.00007529912,0.000047395653,0.00026324787,0.0002711175,0.00009312203,0.0000063548155,0.00029556215,4.280534e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008353449,0.0002530495,0.021097876,0.00006171407,0.000047568978,0.00000515393,0.0030442833,0.00021948903,0.97327906,0.00003983962,0.00045328992,0.00066331465],"study_design_scores_gemma":[0.0032323801,0.0008358456,0.17787546,0.00017286379,0.000022508924,0.000015530759,0.000190406,0.00007610217,0.8172331,0.00022166461,0.00008380468,0.00004035496],"about_ca_topic_score_codex":0.001350043,"about_ca_topic_score_gemma":0.0032401758,"teacher_disagreement_score":0.15677759,"about_ca_system_score_codex":0.00019107753,"about_ca_system_score_gemma":0.00071563746,"threshold_uncertainty_score":0.9980669},"labels":[],"label_agreement":null}]}